"","Proposal Number","Publication"
"1","MP980015","Murphy FG, et al. (1997): Health Values and Practices Among Seventh-Day Adventist. Am J Health Behav 21:43-50."
"2","MP980015","Murphy FG, Blumenthal DS, Dickson-Smith J, Peay RP (1990): The mortality profile of black Seventh-Day Adventists residing in metropolitan Atlanta: a pilot study. American Journal of Public Health 80:984-5."
"3","PC000011","Varghese S, Rabkin SD, Liu R, et al.  2006. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Therapy 13:253-265."
"4","PC000017","Bates PJ, Trent JO, Miller DM, et al.  2001.  Development of antiproliferative agents targeting nucleolin.  Clin Cancer Res 7(S):157."
"5","PC000017","Xu X, Hamhouyia F, Thomas SD, et al.  2001.  Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides.  J Biol Chem 276:43221-43230."
"6","PC000017","Dapic V, Bates PJ, Trent JO, et al.  2002.  Antiproliferative activity of G-quartet-forming oligonucleotides with backbone modifications.  Biochemistry 41:3676-3685."
"7","PC000017","Bates PJ, Kahlon JB, Thomas SD, et al.  1999.  Antiproliferative activity of G rich oligonucleotides correlates with protein binding.  J Biol Chem 274:26369-26377."
"8","PC000018","Doxsey S, 2002.  Duplicating dangerously:  Linking centrosome duplication and aneuploidy.  Molecular Cell 10:1-2.

"
"9","PC000018","Doxsey SJ, 2001.  Re-evaluating centrosome function.  Nature Reviews in Molecular Biology 2:688-699.

"
"10","PC000018","Pihan G, Y Zhou, J Wallace, et al.  2003. Centrosome abnormalities and genetic instability occur together in precancerous lesions.  Cancer Res 63:1398-404.
"
"11","PC000018","Doxsey SJ, 2001.  Centrosomes as command centers for cellular control.  Nat. Cell Biol. 3:E1-E3.
"
"12","PC000020","Perambakam S, Xie H, Edassery S, et al. 2010. Long-Term Follow-Up of HLA-A2+ Patients with High-Risk, Hormone- Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154). Clin Dev Immunol. doi: 10.1155/2010/473453. Epub 2011 Jan 5."
"13","PC000023","Thompson CJ, Tam NNC, Joyce JM, et al.  2002.  Gene expression profiling of changes associated with combined testosterone and estradiol-17beta-induced lateral prostate dysplasia in the noble rats and their response to the pure antiestrogen ICI 182,780.  Endocrinol 143:2093-2105."
"14","PC000023","Murphy LC, Leygue E, Niu Y, et al.  2002.  Relationship of co-regular and estrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer.  Brit J Cancer 87:1411-1416."
"15","PC000023","Leav I, Lau K-M, Adams JY, et al.  2001.  Comparative studies of estrogen receptor-beta, -alpha and androgen receptor in normal human prostate glands, dysplasia, and in primary and metastic carcinoma.  J Am Pathol 159:79-92."
"16","PC000023","Zhu X, Leav I, Leung YK, et al.  2004.  Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis.  Am J Pathol 164:2003-2012."
"17","PC000023","Mobley JA, L¿Esperance JO, Wu M, et al.  2004.  The novel estrogen 17alpha-20Z021-[(4-amino)phenyl]-19-norpregna-1,3,5(10),20-tetraene-3,17beta-diol induces apoptosis in prostate cancer cell lines at nonomolar concentrations in vitro.  Mol Cancer Ther 3:587-595."
"18","PC000023","Pais V, Leav I, Lau K-M, et al.  2003.  Estrogen receptor-beta expression in human testicular germ cell tumors.  Clin Cancer Res 9:4475-4482."
"19","PC000030","Pratap J, Javed A, Languino LR, et al.  2005.  The Runx2 osteogenic transcription factor regulates MMP9 in bone metastatic cancer cells and controls cell invasion.  Mol Cell Biol 25:8581-8591."
"20","PC000030","Goel HL, Breen M, Zhang J, et al.  2005.  Beta-1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts.  Cancer Res 65:6692-6700."
"21","PC000030","Goel HL, Fornaro M, Moro L, et al.  2004.  Selective modulation of type 1 insulin-like growth factor receptor signaling and functions by beta-1 integrins.  J Cell Biol 166:407-418."
"22","PC000030","Goel HL and Languino LR.  2004.  Integrin signaling in cancer.  Chapter 4.  Molecular Targeting and Signal Transduction (Kumar R, Ed.).  Kluwer Academic Publishers 119:15-33.

"
"23","PC000030","Languino LR.  2004.  Advances in prostate cancer research, Part III.  J Cell Biol 91:647-648."
"24","PC000030","Languino LR.  2004.  Advances in prostate cancer research, Part II.  J Cell Biol 91:431-432."
"25","PC000030","
Languino LR.  2004.  Advances in prostate cancer research, Part I.  J Cell Biol 91:1-2.
"
"26","PC000030","Moro L, Perlino E, Marra E, et al.  2004.  Regulation of beta-1C and beta-1A integrin expression in prostate carcinoma cells.  
J Biol Chem 279:1692-1702.
"
"27","PC000030","Fornaro M, Plescia J, Cheang S, et al.  2003.  Fibronectin protects prostate cancer cells from tumor necrosis factor alpha-induced apoptosis via the AKT/survivin pathway.  J Biol Chem 278:50402-50411."
"28","PC000030","Goel HL, Moro L, King M, et al.  2006.  The beta-1 integrins modulate cell adhesion by regulating IGF-II levels in the microenvironment.  Cancer Res 66:331-42."
"29","PC000030","Simon EL, Goel HL, Teider N, et al.  2005.  High dose fractionated ionizing radiation inhibits prostate cancer cell adhesion and beta-1 integrin expression.  Prostate 64:83-91."
"30","PC000030","Manes T, Zheng D-Q, Loftus J, et al.  2003.  Alpha-v-beta-3 integrin expression upregulates cdc2 which modulates cell migration.  J Cell Biol 164:817-826."
"31","PC001007","Khatri A, and Russell PJ.  2007.  Targeted gene directed enzyme prodrug therapies to tackle diversity and aggression of late stage prostate cancer.  Discov Med 7(37):39-45."
"32","PC001007","Khatri A, Husaini Y, Ow K, et al. 2009.  Cytosine Deaminase-Uracil Phosphoribosyltransferase and Interface Marked by Specific Modulation in Serum Cytokines Interleukin (IL)-12 and IL-18: A Multimodal Anticancer Interface Marked by Specific Modulation in Serum Cytokines.  Clin Cancer Res 15:2323-2334."
"33","PC001007","Khatri A, Russell PJ, Zhang B, et al.  2005.  Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in C57BL/6 mice.  J Gene Med 7(8):1129-1130."
"34","PC001007","Russell PJ, and Khatri A.  2006.  Novel gene-directed enzyme prodrug therapies against prostate cancer.  Expert Opin Investig Drugs 15(8):947-961."
"35","PC001007","Khatri A, Zhang B, Doherty E, et al.  2006.  Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against prostate cancer in C57BL/6 mice.  J Gene Med 8(9):1086-1096."
"36","PC001008","Tantivejkul K, Loberg RD, Mawocha SC, et al.  2005.  PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism.  J Cell Biochem 96(3):641-652."
"37","PC001019","hiomi N, Cui XM, Yamamoto T, Saito T, Shuler CF. 2006. Inhibition of SMAD2 expression prevents murine palatal fusion.  Dev Dyn 235:1785-93.

"
"38","PC001035","Williams K and Hayward SW (2003): Stem cells in glandular organs. In: Stem Cells Handbook. Sell S, ed. Humana Press."
"39","PC001035","Williams, K., Fernandez, S., Stien, X., Ishii, K., Love, H.D., Lau, Y.F., Roberts, R.L., Hayward, S.W. 2005. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype. Prostate. 63(4):369-384."
"40","PC001040","Ali JH, WB Wang, M Zevallos, and RR Alfano, 2004.  Near infrared spectroscopy and imaging to probe differences in water content in normal and cancer human prostate tissues.  TCRT (Technology in Cancer Research and Treatment) 3:491-498."
"41","PC001040","Pu Y, WB Wang, GC Tang, et al., 2005.  Spectral polarization imaging of human prostate cancer tissue using near-infrared receptor-targeted contrast agent.  TCRT (Technology in Cancer Research and Treatment) 4:429-436."
"42","PC001041","Khatri A, Zhang B, Doherty E, Chapman J, Ow K, Pwint H, Martiniello-Wilks R, Russell PJ. 2006. Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice.J Gene Med. 2006 Sep;8(9):1086-96"
"43","PC001052","Lu S, Hoestje SM, Choo EM, Epner DE (2002): Methionine restriction induces apoptosis of prostate cancer cells via the c-Jun N-terminal kinase-mediated signaling pathway. Cancer Lett 179:51-8."
"44","PC001052","Li M, Ittmann MM, Rowley DR, Knowlton AA, Vaid AK, Epner DE (2003): Glutathione S-transferase pi is upregulated in the stromal compartment of hormone independent prostate cancer. Prostate 56:98-105."
"45","PC001052","Lu S, Hoestje SM, Choo E, Epner DE (2003): Induction of caspase-dependent and -independent apoptosis in response to methionine restriction. Int J Oncol 22:415-20."
"46","PC001052","Lu S, Chen GL, Ren C, Kwabi-Addo B, Epner DE (2003): Methionine restriction selectively targets thymidylate synthase in prostate cancer cells. Biochem Pharmacol 66:791-800."
"47","PC001053","Shafer-Weaver KA1, Watkins SK, Anderson MJ, et al.  2009.  Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells.  Cancer Res 69(15):6256-6264."
"48","PC001053","Anderson MJ, Shafer-Weaver K, Greenberg NM, et al.  2007.  Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer.  J Immunol 178:1268-1276."
"49","PC001053","Watkins SK1, Zhu Z, Riboldi E, et al.  2011.  FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer.  J Clin Invest 121(4):1361-1372."
"50","PC001059","Zhao H, and BL Pagenkopf, 2003.  Stereospecific and efficient alkynylation at the more hindered carbon of trisubstituted epoxides.  Chem. Commun. :2592-3.

"
"51","PC001059","Yu M, and BL Pagenkopf, 2003.  Allylation of donor-acceptor cyclopropanes.  Org. Lett. 5:4639-40.

"
"52","PC001059","Gorman JST, ST Iacono, and BL Pagenkopf, 2004.  Selective oxidation of zirconocyclopentenes via organoboranes.  Org. Lett. 6:67-70."
"53","PC001059","Engers DW, MJ Bassindal, and BL Pagenkopf, 2004.  Synthesis of the C(1)-C(12) segment of peloruside A by an alpha-benzyloxymethyl ketone aldol strategy.  Org. Lett. 6:663-6."
"54","PC001059","Yu M, D Pantos, JL Sessler, and BL Pagenkopf, 2004.  Synthesis of 2,2'-bipyrroles and 2,2'-thienylpyrroles from donor-acceptor cyclopropanes and 2-cyanoheteroles.  Org. Lett. 6:1057-9.

"
"55","PC001059","Cong-Dung Le J, and BL Pagenkopf, 2004.  Asymmetric hydrogenation of Ortho-alkoxy substituted arylenamides.  J. Org. Chem. 69:4177-80."
"56","PC001059","Yu M, Pagenkopf BL (2002): The Regioselective Mono-deprotection of 1,3-Dioxa-2,2-(di-tert-butyl)-2- silacyclohexanes with BF(3).SMe(2). J Org Chem 67:4553-8."
"57","PC001059","Yu M, Pagenkopf BL (2003): Formal [3+2] cycloadditions of donor-acceptor cyclopropanes and nitriles. J Am Chem Soc 125:8122-3."
"58","PC001059","Reichwein JF, Pagenkopf BL (2003): A new Horner-Wadsworth-Emmons type coupling reaction between nonstabilized beta-hydroxy phosphonates and aldehydes or ketones. J Am Chem Soc 125:1821-4."
"59","PC001059","Reichwein JF, Pagenkopf BL (2003): New mixed phosphonate esters by transesterification of pinacol phosphonates and their use in aldehyde and ketone coupling reactions with nonstabilized phosphonates. J Org Chem 68:1459-63."
"60","PC001059","Yu M, and BL Pagenkppf, 2003.  A powerful new strategy for diversity-oriented synthesis of pyrroles from donor-acceptor cyclopropanes and nitriles.  Org. Lett. 5:5099-101.

"
"61","PC001076","Stephan DA, Howell GR, Teslovich TM, et al.  2002.  Physical and transcript map of the hereditary prostate cancer region at Xq27.  Genomics 79:41-50."
"62","PC001078","Siwoski A, Ishkanian A, Garnis C, et al.  2002.  An efficient method for the assessment of DNA quality of archival microdissected specimens. Mod Path 15:889-892."
"63","PC001082","Kaliberov SA, Buchsbaum DJ, Gillespie GY, et al. 2002. Adenovirus-mediated transfer of BAX by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells. Molecular Therapy, 6(2):190-198.
"
"64","PC001082","Arafat WO, Buchsbaum DJ, Gomez-Navarro J, et al. 2003. An adenovirus encoding proapoptotic Bax synergistically radiosensitizes malignant glioma. Int. J. Radiat. Oncol. Biol. Phys., 55(4):1037-50.
"
"65","PC001101","Yu X, Li P, Roeder RG, and Wang Z. 2001.  Inhibition of androgen receptor-mediated transcription by the amino-terminal enhancer of split, a Groucho/TLE family protein.  Mol Cell Biol 21:4614-4625."
"66","PC001101","Liu GZ, Wang H, Wang Z (2003): Identification of a highly conserved domain in the androgen receptor that suppresses the DNA-binding domain-DNA interactions. J Biol Chem 278:14956-60."
"67","PC001101","Li P, Yu X, Ge K, Melamed J, Roeder RG, Wang Z (2002): Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol 161:1467-74."
"68","PC001101","Gao S, Liu GZ, and Wang Z. 2004. Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells.  The Prostate 59:214-225."
"69","PC001101","Hosohata K, Li P, Hosohata Y, Qin J, Roeder RG, Wang Z (2003): Purification and identification of a novel complex which is involved in androgen receptor-dependent transcription. Mol Cell Biol 23:7019-29."
"70","PC001104","Lee SO, Lou W, Johnson CS, et al.  2004.  Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway.  Prostate 60:178-186.

"
"71","PC001104","Lee SO, Lou W, Qureshi KM, et al.  2004.  RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells.  Prostate 60(4):303-309."
"72","PC001104","Tan DF, Wu XX, Hou M, et al.  2005.  Interleukin-6 polymorphism is associated with recurrent prostate cancer.  J Urol 174:753-756."
"73","PC001104","Lee SO, Lou W, Nadiminty N, et al.  2005.  Requirement for NF-kappa-B in interleukin-4 induced androgen receptor activation in prostate cancer cells.  Prostate 64:160-167."
"74","PC001104","Lee SO, Nadiminty N, Wu XX, et al.  2005.  Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells.  Cancer Res 65:3487-3492."
"75","PC001104","Lee SO, Nadiminty N, Wu XX, et al.  2005.  Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells. Cancer Res 65(8):3487-3492."
"76","PC001104","DeMiguel F, Lee SO, Lou W, Xiao X, Pflug BR, Nelson JB, Gao AC (2002): Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice. Prostate 52:123-9."
"77","PC001104","Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC (2003): Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 9:370-6."
"78","PC001104","Leman ES, DeMiguel F, Gao AC, Getzenberg RH (2003): Regulation of androgen and vitamin d receptors by 1,25-dihydroxyvitamin D3 in human prostate epithelial and stromal cells. J Urol 170:235-40."
"79","PC001104","Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, Xie K (2003): Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22:319"
"80","PC001104","Lee SO, Lou W, Hou M, Onate SA, Gao AC (2003): Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene 22:7981-8."
"81","PC001104","Demiguel F, Lee SO, Onate AA, et al.  2003.  Stat3 enhances transactivation of steroid hormone receptors.  Biomed Central, Nuclear Receptor 1:3.
"
"82","PC001104","Nadiminty N, Lou W, Lee SO, et al.  2006.  Stat3 activation of NF-kB p100 processing involves CBP/p300 mediated acetylation. Proc Natl Acad Sci 103(19):7264-7269."
"83","PC001118","Singh S, Singh UP, Grizzle WE, and Lillard, Jr JW.  2004.  CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion.  Lab Invest 84:1666-76."
"84","PC001118","Singh S, Singh UP, Grizzle WE, and Lillard, Jr JW.  2004.  Expression and functional role of CCR9 in prostate cancer cell migration and invasion.  Clin. Cancer Res. 10:8743-50."
"85","PC001122","Grossmann ME, Madden BJ, Gao F, et al. 2004. Proteomics shows Hsp70 does not bind peptide sequences indiscriminately in vivo. Experimental Cell Research 297:108-117."
"86","PC001122","Wang MH, Grossmann ME, and Young CY. 2004. Forced expression of heat-shock protein 70 increases the secretion of Hsp70 and provides protection against tumour growth. British Journal of Cancer 90(4):926-931.

"
"87","PC001138","Cha TL, L Qiu, Y Wen, and MC Hung, 2005.  Emodin downregulates androgen receptor and inhibits prostate cancer cell growth.  Cancer Res. 65:2287-2295."
"88","PC001138","Wen Y, Giri D, Yan DH, et al.  2003.  Prostate specific antitumor activity by probasin promoter-directed p202 expression.  Mol Carcino 37:130-137."
"89","PC001142","Mamoune A, Luo JH, Lauffenburger DA, Wells A (2003): Calpain-2 as a target for limiting prostate cancer invasion. Cancer Res 63:4632-40."
"90","PC001142","Glading A, Lauffenburger DA, Wells A (2002): Cutting to the chase: calpain proteases in cell motility. Trends Cell Biol 12:46-54."
"91","PC001142","Wells A, and JR Grandis, 2003.  Phospholipase C-gammal in tumor progression.  Clin. & Exper. Metast. 20:285-290."
"92","PC001142","Wells A, Kassis J, Solava J, Turner T, Lauffenburger DA (2002): Growth factor-induced cell motility in tumor invasion. Acta Oncol 41:124-30."
"93","PC001147","Halpern EJ, JR Ramey, SE Strup, et al. 2005.  Detection of prostate cancer with contrast enhanced sonography using intermittent harmonic imaging.  Cancer, 104:2372-83.

"
"94","PC001149","Lotan TL, Lyon M, Huo D, et al.  2007.  Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression:  an important role for SAPK signaling in prostatic neoplasia.  Journal of Pathology 212:386-94.

"
"95","PC001156","Lassus P, Opitz-Araya X, Lazebnik Y (2002): Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 297:1352-4."
"96","PC001156","Lassus P, Rodriguez J, Lazebnik Y (2002): Confirming specificity of RNAi in mammalian cells. Sci STKE 2002:PL13."
"97","PC001172","Von Seggern DJ, HE Aguilar, K Kinder, et al., 2003.  In vivo transduction of photoreceptors or ciliary body by intravitreal injection of pseudotyped adenovirus vectors.  Molecular Therapy 7:27-34.

"
"98","PC001172","Wu E, SA Trauger, L Pache, et al., 2004.  Membrane cofactor protein Is a receptor for adenoviruses associated with epidemic keratoconjunctivitis.  Journal of Virology, 78:3897-905."
"99","PC001174","Guan Z Kukoyi B Feng P Kennedy MC Franklin RB Costello LC. (2003):  Kinetic identification of a mitochondrial zinc uptake transporter in prostate cells. J. Inorg. Biochem.  97:199-206."
"100","PC001174","Feng P, Li TL, Guan ZX, Franklin RB, Costello LC (2002): Direct effect of zinc on mitochondrial apoptogenesis in prostate cells. Prostate 52:311-8."
"101","PC001174","Franklin RB, Ma J, Zou J, et al.  2003.  HZIP1 is a major zinc uptake transporter for the accumulation of zinc in prostate cells.  J. of Inorganic Biochemistry, 96:435-442."
"102","PC001174","Feng P, Li TL, Guan ZX, et al.  2003.  Effect of zinc on prostatic tumorigenicity in nude mice.  Annals of the New York Academy of Sciences, 1010:316-320."
"103","PC001174","Costello LC, Guan ZX, Franklin RB et al.  2004.  Metallothionein can function as a chaperone for zinc uptake transport into prostate and liver mitochondria.  J. Inorganic Biochem. 98:664-666."
"104","PC001174","Costello LC, Feng P, Milon B, et al.  2004.  The role of zinc in the pathogenesis and treatment of prostate cancer:  critical issues to resolve.  Prostate Cancer and Prostatic Disease, 7:111-117.

"
"105","PC001186","Knowles LM, Axelrod F, Browne CD, et al.  2004.  A fatty acid synthase blockade induces tumor cell cycle arrest by down regulating Skp2.  J Biol Chem 279: 30540-30545."
"106","PC001186","Kridel SJ, Axelrod F, Rozenkrantz N, et al.  2004.  Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity.  Cancer Res 64:2070-2075."
"107","PC001193","Odedina FT, Scrivens J, Emanuel A., et. al. 2004.  A focus group study of factors influencing African- American men's prostate cancer screening behavior.  J. Natl. Med. Assoc., 96:780-8."
"108","PC001193","Odedina FT, Ogunbiyi F, and Ukoli F.  2006.  Prostate cancer burden in African Americans:  Can the origin be traced to ancestral African relatives?  J Natl Med Assoc 98(4):539-543."
"109","PC001193","Odedina FT, Scrivens J, Emanuel A, et al.  2005.  Gift of healthy life for the men in our life.  People in the Community:  Health. www.peopleinthecommunity.com."
"110","PC001193","Odedina FT, Warrick C, Vilme H, et al.  2008.  Pharmacist as health educators and risk communicators in the early detection of prostate cancer. J Soc Adm Pharm 4:59-66."
"111","PC001204","Sivashanmugam P, L Tang, and Y Daaka, 2004.  Interleukin 6 mediates the lysophosphatidic acid-regulated cross talk between stromal and epithelial prostate cancer cells.  J. Biol. Chem., 
279:21154-9"
"112","PC001204","Raj GV, JA Sekula, R Guo, et al., 2004.  Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-kappaB.  Prostate, 61:105-13.

"
"113","PC001204","Yowell CW, and Y Daaka, 2002.  G protein-coupled receptors provide survival signals in prostate cancer.  Clinical Prostate Cancer, 1:177-181.

"
"114","PC001204","Daaka Y, 2004.  G proteins in cancer:  The prostate cancer paradigm.  Sci. STKE (216) RE2.

"
"115","PC001204","Kasbohm EA, Guo R, Yowell CW, Bagchi G, Kelly P, Arora P, Casey PJ, Daaka Y. 2005. Androgen receptor activation by G(s) signaling in prostate cancer cells. J Biol Chem 280(12):11583-9."
"116","PC001204","Daaka Y (2002): Mitogenic action of LPA in prostate. Biochim Biophys Acta 1582:265-9."
"117","PC001204","Raj GV, Barki-Harrington L, Kue PF, Daaka Y (2002): Guanosine phosphate binding protein coupled receptors in prostate cancer: a review. J Urol 167:1458-63."
"118","PC001204","Kue PF TJHLPRUADY (2002): Lysophosphatidic acid-regulated mitogenic ERK signaling in androgen-insensitive prostate cancer PC-3 cells.  Intl. J. Cancer 102:572-9."
"119","PC001204","Guo R, Kasbohm EA, Arora P, Sample CJ, Baban B, Sud N, Sivashanmugam P, Moniri NH, Daaka Y. 2006. Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells. Endocrinology 147(10):4883-92."
"120","PC001204","Taub JS, R Guo, LM Leeb-Lundberg, et al., 2003.  Bradykinin receptor subtype 1 expression and function in prostate cancer. Cancer Res. 63:2037-2041."
"121","PC001209","Deroanne C, Vouret-Craviari V, Wang B, et al.  2003.  EphrinA1 inactivates integrin-mediated vascular smooth muscle cell spreading via the Rac/PAK pathway.  J Cell Sci 116:1367-1376."
"122","PC001209","Myshkin E and Wang B.  2003.  Chemometrical classification of ephrin ligands and Eph kinases using GRID/CPCA approach.  J Chem Inf Comput Sci 43:1004-1010."
"123","PC001209","Han DC, Shen TL, Miao H, et al.  2002.  EphB1 associate with Grb7 and regulate cell migration.  Journal of Biological Chemistry 277:45655-45661."
"124","PC001209","Zantek ND, Walker-Daniels J, Stewart J, et al.  2001.  MCF 10A NeoST:  A new cell system for studying cell-ECM and cell-cell interactions in breast cancer.  Clinical Cancer Research 7:3640-3648."
"125","PC001209","Guo H, Miao H, Gerber L, et al.  2006.  Disruption of EphA2 kinase led to increased susceptibility to skin carcinogenesis.  Cancer Research 66:7050-7058."
"126","PC001209","Lakhe-Reddy S, Khan S, Konieczkowski M, et al.  2006.  beta 8 integrin binds Rho GDP dissociation inhibitor-1 and activates Rac1 to inhibit mesangial cell myofibroblast differentiation.  J Biol Chem 281:19688-99."
"127","PC001209","Iida H, Honda M, Kawai HF, et al.  2005.  Ephrin-A1 expression contributes to the malignant characteristics of - fetoprotein-producing hepatocellular carcinoma.  Gut 54:843-851."
"128","PC001209","Miao H, Wei B-R, Peehl DM, et al.  2001.  EphA kinase activation inhibits Ras/MAPK pathway.  Nature Cell Biology 3:527-530."
"129","PC001209","Miao H, Burnett E, Kinch M, et al.  2000.  Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylatation.  Nature Cell Biology 2:62-69."
"130","PC001209","Jarad G, Wang B, Khan S, et al.  2002.  Fas activation induces renal tubular epithelial cell b8 integrin expression and function in the absence of apoptosis.  J Biol Chem 277:47826-33."
"131","PC001209","Miao H, Guan J-L, Shen TL, et al.  2005.  Inhibition of integrin-mediated cell adhesion and spreading, but not migration requires the catalytic activity of EphB3 kinase.  Journal of Biological Chemistry 280:923-932.  (Published online November 2004)."
"132","PC001209","Miao H, Nickel CH, Cantley LG, et al.  2003.  EphA kinase activation regulates HGF-induced epithelial branching morphogenesis.  J Cell Biol 162:1281-1292."
"133","PC001209","Khan S, Koepke A, Jarad G, et al.  2001.  Apoptosis and JNK activation are differentially regulated by Fas expression level in renal tubular epithelial cells.  Kidney International 60:65-76."
"134","PC001212","Glinsky GV, Glinskii AB, Stephenson AJ, et al.  2004.  Gene expression profiling predicts clinical outcome of prostate cancer.  J Clin Investig 113:913-923."
"135","PC001212","Yang M, Li L, Jiang P, et al.  2003.  Dual-color fluorescence imaging distinguishes tumor cells from induced host angiogenic vessels and stromal cells.  Proc Natl Acad Sci 100:14259-14262."
"136","PC001212","Yamamoto N, Jiang P, Yang M, et al.  2004.  Cellular dynamics visualized in live cells in vitro and in vivo by differential dual-color nuclear-cytoplasmic fluorescent-protein expression.  Cancer Res 64:4251-4256."
"137","PC001212","Glinskii AB, Smith BA, Jiang P, et al.  2003.  Viable circulating metastatic cells produced in orthotopic but not ectopic prostate cancer models.  Cancer Res 63:4239-4243."
"138","PC001212","Berezovskaya O, Schimmer AD, Glinskii AB, et al.  2005. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells.  Cancer Res 65(6):2378-2386."
"139","PC001212","Burton DW, Geller J, Yang M, et al.  2005.  Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. Prostate 62(3):275-281."
"140","PC001212","Yang M, Jiang P, Yamamoto N, et al.  2005.  Real-time whole-body imaging of an orthotopic metastatic prostate cancer model expressing red fluorescent protein. Prostate 62(4):374-379."
"141","PC001212","Deftos LJ, Barken I, Burton DW, et al.  2005. Direct evidence that PTHrP expression promotes prostate cancer progression in bone. Biochem Biophys Res Commun 327(2):468-472."
"142","PC001228","Poehlein CH, Ruttinger D, Ma J, et al.  2005.  Immunotherapy of melanoma: The good, the bad, and the future.  Curr Oncol Rep 7:383-392."
"143","PC001228","Fox BA.  2005.  Review of - Melanoma vaccines: What we know so far.  Oncology 19:112-115."
"144","PC001228","Jensen SM and Fox BA.  2005.  Adoptive cellular immunotherapy of cancer: A three-signal paradigm for translating recent developments into improved treatment strategies.  In: Tumor Immunology and Cancer Vaccines, (Khleif S, Ed.)."
"145","PC001228","Ma J, Poehlein CH, Jensen S, et al.  2004.  Manipulating the host response to autologous tumor vaccines.  Dev Biol Basel 116: 93-107."
"146","PC001229","Chowning SL, Susil RC, Krieger A, Fichtinger G, Whitcomb LL, Atalar E. 2006. A preliminary analysis and model of prostate injection distributions. Prostate. 66(4):344-357."
"147","PC001229","Krieger A, Susil RC, Ménard C, et al.  2005. Design of a novel MRI compatible manipulator for image guided prostate interventions. IEEE Trans Biomed Eng  52(2):306-313."
"148","PC001229","Susil RC, Ménard C, Krieger A, et al. 2006.  Transrectal prostate biopsy and fiducial marker placement in a standard 1.5T magnetic resonance imaging scanner. J Urol 175(1):113-120.  "
"149","PC001229","Ménard C, Susil RC, Choyke P,et al. 2005. An interventional magnetic resonance imaging technique for the molecular characterization of intraprostatic dynamic contrast enhancement.  Mol Imaging 4(1):63-66."
"150","PC001229","Atalar E, Ménard C.  2005. MR-guided interventions for prostate cancer. Magn Reson Imaging Clin N Am 13(3):491-504."
"151","PC001229","Susil RC Krieger A Derbyshire JA Tanacs A Whitcomb LL Fichtinger G Atalar E (2003): A system for MRI guided prostate interventions. Radiology 228:886-94."
"152","PC001229","Yung AC Oner AY Serfaty JM Feneley M Yang X Atalar E (2003): Phased-array MRI of canine prostate using endorectal and endourethral coils. Magn Reson Med.  49:710-5."
"153","PC001229","Yung C, Oner Y, Serfaty M, et.al.  2001.  Phased Array Coils for High Resolution Prostate MR Imaging.  IEEE EMBS, Istanbul, Turkey.
"
"154","PC001229","Susil R, Krieger J, Derbyshire A, et al.  2002.  A System for Guidance and Monitoring of Transrectal Prostate Biopsy in a 1.5 T Closed MR Scanner.  Published in Eur. Radiology vol: 12, page F3.
"
"155","PC001229","Susil R, Camphausen K, Choyke P, et al.  2004.   System for prostate brachytherapy and biopsy in a standard 1.5  T MRI scanner.  Mag Res Med, 52:683-7.
"
"156","PC001229","Menard C, Susil RC, Choyke P, et al.  2005.  An interventional MRI technique for the molecular characterization of intra-prostatic dynamic contrast enhancement.  Mol Imaging 4:63-6.

"
"157","PC001243","Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E, Yao TP (2001): p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 20:1331-40."
"158","PC001247","Lee LF Guan J Qiu Y Kung HJ (2001):  Neuropeptide-induced androgen independence in prostate cancer cells:  Roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol.  Cell.  Biol.  . 21:8385-8397."
"159","PC001263","Kim D-H, Hong YK, Egholm M and Strauss WM.  2001.  A non-disruptive PNA-FISH protocol for formalin-fixed and paraffin-embedded tissue sections.  BioTechniques 31(3):472, 475-6."
"160","PC001263","Hong YK, Ontiveros SD, Chen C and Strauss WM.  1999.  A new structure for the murine Xist gene and its relationship to chromosome choice/counting during X-chromosome inactivation. Proc Natl Acad Sci 96(12):6829-6834."
"161","PC001263","Memili E, Hong YK, Kim DH, et al.  2001.  Murine Xist RNA isoforms are different at their 3' ends: A role for differential polyadenylation.  Gene 266(1-2):131-7."
"162","PC001263","Hong YK, Ontiveros SD and Strauss WM.  2000.  A revision of the human XIST gene organization and structural comparison to mouse Xist.  Mammalian Genome 11:220-224."
"163","PC001263","Hong YK, Kim DH, Beletskii A, et al.  2001.  Development of two bacterial artificial chromosome shuttle vectors for a recombination-based cloning and regulated expression of large genes in mammalian cells.  Anal Biochem 291(1):142-148."
"164","PC001263","Ma, M and Strauss WM. 2005. Analysis of the Xist RNA isoforms suggests two distinctly different forms of regulation. Mamm. Genome. 16:391-404."
"165","PC001263","Beletskii A, Hong YK, Pehrson J, et al.  2001.  PNA interference mapping demonstrates functional domains in the noncoding RNA Xist.  Proc Natl Acad Sci 98(16):9215-20."
"166","PC001264","Yemelyanov A, Gasparian A, Lindholm P, et al.  2006.  Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells.  Oncogene 25(3):387-398."
"167","PC001264","Gasparian AV YYLJYALLSTBI (2002): Selenium compounds inhibit IkB kinase and transcriptional factor NF-kB in prostate cells. Mol Cancer Ther 1:1079-1087."
"168","PC001264","Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ, Budunova IV (2002): The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 115:141-51."
"169","PC001272","Cogan PS, Fowler CR, Post GC, and Koch TH. 2003. Doxsaliform: A novel N-Mannich base prodrug of doxorubicin formaldehyde conjugate.  Lett. Drug Design Dis. 1:247-255."
"170","PC001272","Burkhart DJ, Barthel BL, Post G, et al.  2006.  Design, synthesis and preliminary evaluation of Doxazolidine carbamates as prodrugs activated by carboxylesterases.  J Med Chem 49:7002-7012."
"171","PC001272","Cogan PS, Fowler CR, Post GC, et al.  2004.  Doxsaliform:  A novel N-Mannich base prodrug of a doxorubicin formaldehyde conjugate.  Letters in Drug Design and Discovery 1(3):247-255 (Betham Science Publishers)."
"172","PC001272","Post GC, Barthel BL, Burkhart DJ, et al.  2005.  Doxazolidine, a proposed active metabolite of doxorubicin that cross-links DNA.  J Med Chem 48:7648-7657."
"173","PC001272","Burkhart DJ, BT Kalet, MP Coleman, et al., 2004.  Doxorubicin-formaldehyde conjugates targeting alpha-v beta-3 integrin.  Mol. Cancer Therap. 4:1593-1604."
"174","PC001272","Cogan PS, and TH Koch, 2004.  Studies of targeting and intracellular trafficking of an anti-androgen-doxorubicin-formaldehyde conjugate in PC-3 prostate cancer cells bearing androgen receptor-GFP chimera.  J. Med. Chem. 47:5690-5699."
"175","PC001272","Cogan PS and Koch TH. 2003. Rational design and synthesis of androgen receptor targeted non-steroidal anti-androgen ligands for the tumor specific delivery of a doxorubicin-formaldehyde conjugate.  J. Med. Chem. 46:5258-5270"
"176","PC001276","Louie MC Yang HQ Ma AH Xu W Zou JX Kung HJ Chen HW. (2003):  Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex.  Proc. Natl. Acad. Sci. USA 100:2226-30."
"177","PC001280","Mehrian-Shai R and Reichardt JKV.  2004.  A renaissance of biomedical genetics?  SNPs, Haplotypes, Function and Complex Diseases.  Mol Genet Metabol 83:47-50."
"178","PC001280","Foti DM and Reichardt JK. 2004. YY1 binding within the human HSD3B2 gene intron 1 is required for maximal basal promoter activity: Identification of YY1 as the 3betal-A factor. J Mol Endocrinol 33:99-119."
"179","PC001283","Lee YJ, Song JJ, Kim JH, et al.  2004.  Low extracellular pH augments TRAIL-induced apoptotic death through the mitochindria-mediated caspase signal transduction pathway. Exp. Cell Res. 293:129-143."
"180","PC001288","Zhao JJ, Berger R, et. al 2003. Human mammaryu epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell 3:348-495."
"181","PC001288","Wei W JWCWHWSJ (2003): Abolition of cyclin-dependent kinase inhibitor p16Ink4a and p21Cip1/Waf1 functions permits ras-induced anchorage independent growth in telomerase-immortalized human fibroblasts. Mol. Cell. Biol. 23:2859-2870.  "
"182","PC001296","Davies B, Chen J, Modugno F, et al.  2005.  Contribution of the prostate limits the usefulness of survivin for the detection of bladder cancer.  J Urol 174:1767-1770."
"183","PC001302","Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nurmi M, Alanen K, Rui H, Nevalainen MT (2003): Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem 278:27287-92."
"184","PC001302","Ahonen TJ, Harkonen PL, Rui H, Nevalainen MT (2002): PRL signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro. Endocrinology 143:228-38."
"185","PC001302","Li H, TJ Ahonen, K Alanen, et al.  Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade.  Cancer Res., 64:4774-82."
"186","PC001325","Weinstein MH SSLM (2002): Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod. Pathol. 12:1302-1308."
"187","PC001325","Signoretti S DMLRARSIBRMMFLMPM (2002):  Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J. Clin. Invest. 110:633-641."
"188","PC001325","Lindeman N, Waltregny D, Signoretti S, Loda M (2002): Gene transcript quantitation by real-time rt-PCR in cells selected by immunohistochemistry-laser capture microdissection. Diagn Mol Pathol 11:187-92."
"189","PC001325","Garraway LA LDSSWDDJBNLM (2002): Intermediate basal cells of the prostate:  In vitro and in vivo characterization.  Prostate  15:206-218."
"190","PC001340","Nikrad M, Johnson T, Puthalalath H, et al.  2005.  The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.  Mol Cancer Ther 4:443-449."
"191","PC001340","Nesterov A, Lu X, Johnson M, et al.  2001.  Elevated Akt activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis.  J Biol Chem 276:10767-10774."
"192","PC001340","Nesterov A, M Nikrad, T Johnson, and AS Kraft.  Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis.  Cancer Research 64:3922-7."
"193","PC001340","Nesterov A Ivashchenko Y Kraft AS. (2002): Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells. Oncogene. 21:1135-1140."
"194","PC001340","Johnson TR Stone K Nikrad M Yeh T Zong WX Thompson CB Nesterov A Kraft AS (2003): The proteasome inhibitor PS-341 overcomes TRAIL resistance in bax and caspase 9 negative or bcl-xl overexpressing cells. Oncogene 22:4953-63."
"195","PC001347","Bupp K1, Sarangi A, Roth MJ.  2006.  Selection of feline leukemia virus envelope proteins from a library by functional association with a murine leukemia virus envelope. Virology 351(2):340-348."
"196","PC001347","Bupp K, Sarangi A, Roth MJ.  2005.  Probing sequence variation in the receptor-targeting domain of feline leukemia virus envelope proteins with peptide display libraries.  J Virol 79(3):1463-1469."
"197","PC001347","Bupp K and Roth MJ.  2003.  Targeting a retroviral vector in the absence of a known cell-targeting ligand.  Hum Gene Ther 14:1557-1564."
"198","PC001350","Zhao H1, Whitfield ML, Xu T,et al.  2004.  Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells.  Mol Biol Cell 15(2):506-519. "
"199","PC001350","Jones SB, DePrimo SE, Whitfield ML, et al.  2005. Resveratrol-induced gene expression profiles in human prostate cancer cells.  Cancer Epidemiol Biomarkers Prev 14(3):596-604."
"200","PC001354","Nguyen MM, Dincer Z, Wade JR, et al. 2009. Cytoplasmic localization of the androgen receptor is independent of calreticulin. Mol Cell Endocrinol 302(1):65-72."
"201","PC001354","Alur M, Nguyen MM, Eggener SE, et al. 2009. Suppressive roles of calreticulin in prostate cancer growth and metastasis. Am J Pathol 175(2):882-90."
"202","PC001364","Grzywacz MJ, Yang JM, Hait WN. 2004. Effect of the multidrug resistance protein on the transport of the antiandrogen flutamide. Cancer Res. 63(10):2492-2498."
"203","PC001366","Vijayakumar S, Garcia D, Hensel CH, et al.  2005. The human Y chromosome suppresses the tumorigenicity of PC-3, a human prostate cancer cell line, in athymic nude mice.  Genes Chromosomes Cancer. 44(4):365-372.

"
"204","PC001374","Devi GR, Oldenkamp JR, London CA, Iversen PL (2002): Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells. Prostate 53:200-10."
"205","PC001374","·London CA, Harmanjatinder SS, Arora V et al.  2003.  A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cell invasion and tumorigenecity.  Cancer Gene Therapy 10:823-32.
"
"206","PC001374","Devi GR, Sprenger CC, Plymate SR, Rosenfeld RG (2002): Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo. Prostate 51:141-52."
"207","PC001374","Devi GR (2002): Prostate cancer: status of current treatments and emerging antisense- based therapies. Curr Opin Mol Ther 4:138-48."
"208","PC001374","Iversen PL, Arora V and Devi, GR.  2004.  Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficiency and pharmacokinetics.  Curr Pharm Biotech 5:431-409.

"
"209","PC001375","Chiang GG, Abraham RT.  2004.  Determination of the catalytic activities of mTOR and other members of the phosphoinositide-3-kinase-related kinase family.  Methods Mol Biol 281:125-141."
"210","PC001375","Abraham RT.  2004.  mTOR as a positive regulator of tumor cell responses to hypoxia.  Curr Top Microbiol Immunol 279:299-319."
"211","PC001375","Hamad NM, Elconin JH, Karnoub AE, et al.  2002.  Distinct requirements for Ras oncogenesis in human versus mouse cells.  Genes Dev 16:2045-2057."
"212","PC001375","Hudson CC, Liu M, Chiang GG, et al.  2002.  Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.  Mol Cell Biol 22:7004-7014."
"213","PC001375","Abraham RT.  2002.  Identification of TOR signaling complexes: more TORC for the cell growth engine.  Cell 111:9-12. 

"
"214","PC001375","Edinger AL, CM Linardic, GG Chiang, et al.  Differential effects of rapamycin on mammalian target rapamycin signaling functions in mammalian cells.  Cancer Res., 63:8451-60.
"
"215","PC001384","Plowden KO.  2006.  To screen or not to screen: factors influencing the decision to participate in prostate cancer screening among urban African-American men.  Urol Nurs 26(6):477-482."
"216","PC001392","Ghilezan M, Yan D, Liang J, Jaffray D et al. 2004. Online image-guided intensity-modulated radiotherapy for prostate cancer: How much improvement can we expect? Int. J. Radiat. Oncol. Biol. Phys. 60(5):1602-1610."
"217","PC001392","Ghilezan MJ, Jaffray DA et al. 2005. Prostate gland motion assessed with cine-magnetic resonance imaging (cine-MRI). Int. J. Radiat. Oncol. Biol. Phys. 62(2):406-417."
"218","PC001403","Chang BL, Zheng SL, Isaacs SD, Turner A, Hawkins GA, Wiley KE, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J (2003): Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer. Br J Cancer 89:1524-9."
"219","PC001404","Wang L, Whitlatch LW, Flanagan JN, Holick MF, Chen TC (2003): Vitamin D autocrine system and prostate cancer. Recent Results Cancer Res 164:223-37."
"220","PC001404","Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, Lokeshwar BL, Rich ES, Holick MF, Chen TC (2002): 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Bioc"
"221","PC001404","Chen TC, Holick MF, Lokeshwar BL, Burnstein KL, Schwartz GG. 2003. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer. Recent Results Cancer Res. 164:273-287."
"222","PC001404","Wang L, Flanagan JN, Whitlatch LW, Jamieson DP, Holick MF, Chen TC. 2004. Regulation of 25-hydroxyvitamin D-1alpha-hydroxylase by epidermal growth factor in prostate cells. J. Steroid Biochem. Mol. Biol. 89-90:127-120."
"223","PC001404","Young MV, Schwartz GG, Wang L, Jamieson DP, Whitlatch LW, Flanagan JN, Lokeshwar BL, Holick MF, Chen TC. 2004. The prostate 25-hydroxyvitamin D-1alpha-hydroxylase is not influenced by parathyroid hormone and calcium: implication for prostate cancer chemoprevention by vitamin D. Carcinogenesis. 25(6):967-971."
"224","PC001404","Schwartz GG, Eads D, Rao A, Cramer SD, Willingham MC, Chen TC, Jamieson DP, Wang L, Burnstein KL, Holick MF, Koumenis C. 2004. Pancreatic cancer cells express 25-hydroxyvitamin D-1alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3. Carcinogenesis. 25(6):1015-1026."
"225","PC001404","Chen TC, Wang L, Whitlatch LW, Flanagan JN, Holick MF (2003): Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J Cell Biochem 88:315-22."
"226","PC001404","Chen TC and Holick MF. 2003. Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol. Metab. 14(9):423-430."
"227","PC001411","Nie D, Che M, Grignon D, Tang K, Honn KV (2001): Role of eicosanoids in prostate cancer progression. Cancer Metastasis Rev 20:195-206."
"228","PC001411","Nie D, Honn KV (2002): Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cell Mol Life Sci 59:799-807."
"229","PC001411","Nie D, Che M, Zacharek A, et al.  2004.  Thromboxane synthase expression in prostate cancer: Involvement in perineural invasion.  Am J Pathol 164:429-439."
"230","PC001411","Nie D, Honn KV.  2004.  Eicosanoid regulation of angiogenesis in tumors. Semin Thromb Hemost 30(1):119-125. "
"231","PC001411","Nie D, Che M, Zacharek A, et al.  2004. Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility. Am J Pathol 164(2):429-439."
"232","PC001416","Neuhausen SL, ML Slattery, CP Garner, et al., 2005.  Prostate cancer risk and IRS1, IRS2, IGFI, and INS polymorphisms:  Strong association of IRS1 G972R variant and cancer risk.  The Prostate 64:168-174."
"233","PC001420","Zerbini L, Y Wang, JY Cho, and T Libermann 2003.  Constitutive activation of nuclear factor &#61547;B p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.  Cancer Research 63:2206-2215."
"234","PC001420","Gu X, Zerbini LF, Otu HH, Bhasin M, Yang Q, Joseph MG, Grall F, Onatunde T, Correa RG, Libermann TA. 2007.  Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells. Cancer Research 67:4219-26.

"
"235","PC001420","Zhou JR, L Yu, L Zerbinin, et al., 2004.  Progression to androgen-independent LNCAP human prostate tumors:  Cellular and molecular alterations.  Int. J. Cancer 110:800-806."
"236","PC001426","Efstathiou E, Troncoso P, Wen S, et al.  2007.  Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer.  Clin Can Res 13:1224-31."
"237","PC001428","Xiao D, Qu X, Weber HC (2003): Activation of extracellular signal-regulated kinase mediates bombesin-induced mitogenic responses in prostate cancer cells. Cell Signal 15:945-53."
"238","PC001428","Xiao D, Chinnappan D, Pestell R, Albanese C, Weber HC. 2005. Bombesin regulates cyclin D1 expression through the early growth response protein Egr-1 in prostate cancer cells.Cancer Res.65(21):9934-42. 
"
"239","PC001428","Qu X, D Xiao, and HC Weber, 2004.  Transcriptional activation of the human gastrin-releasing peptide receptor gene in gastrointestinal and prostatic epithelial cancer cells.  J. Mol. Neuro. 22:75-82."
"240","PC001428","Xiao D, Qu X, Weber HC (2002): GRP receptor-mediated immediate early gene expression and transcription factor Elk-1 activation in prostate cancer cells. Regul Pept 109:141-8."
"241","PC001434","Tagliarino C, Pink JJ, Reinicke KE, Simmers SM, Wuerzberger-Davis SM, Boothman DA (2003): Mu-calpain activation in beta-lapachone-mediated apoptosis. Cancer Biol Ther 2:141-152."
"242","PC001434","Tagliarino C PJaBD (2001): Calpains and apoptosis. Korean J. Biol. Sci. 5:267-274."
"243","PC001434","Nasongkla N, Wiedmann A, Bruening A, et al.  2003.  Enhancement of solubility and bioavailability of beta-lapachone using cyclodextrin inclusion complexes.  J. Pharm. Research.  20:1626-33"
"244","PC001434","Planchon SM, Pink JJ, Tagliarino C, Bornmann WG, Varnes ME, Boothman DA (2001): beta-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3. Exp Cell Res 267:95-106."
"245","PC001434","Tagliarino C, Pink JJ, Reinicke K, et al.  2003. Mu-calpain activation in beta-lapachone-mediated apoptosis. Cancer Biology and Therapy 2(2):154-162."
"246","PC001434","Tagliarino C, Pink JJ, Dubyak GR, Nieminen AL, Boothman DA (2001): Calcium is a key signaling molecule in beta-lapachone-mediated cell death. J Biol Chem 276:19150-9."
"247","PC001446","·Walker-Daniels J, Hess AR, Hendrix MJC, and Kinch MS. 2003. Differential regulation of EphA2 in normal and malignant cells. Am. J. Pathol. 162:1037-1041."
"248","PC001446","·Kinch MS, Moore MB, and Harpole DH. 2003. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin. Cancer Res. 9:613-618."
"249","PC001446","·Kikawa KD, Vidale DR, Van Etten RI, and Kinch MS. 2002. Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. J. Biol. Chem. 277:39274 39279."
"250","PC001446","·Pratt R and Kinch MS. 2002. Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade. Oncogene 21:7690-7699."
"251","PC001446","·Coffman KT, Hu M, Carles-Kinch K, et al. 2003. Differential EphA2 epitope display on normal versus malignant cells. Cancer Res. In Press."
"252","PC001446","Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS (2002): Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 62:2840-7."
"253","PC001446","Kinch MS and Carles-Kinch K. 2003.  Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer.  Clin Exp Metastasis 20:59-68."
"254","PC001446","Pratt R and Kinch MS.  2003.  Ligand binding up-regulates EphA2 messenger RNA through the mitogen-activated protein/extracellular signal-regulated kinase pathway.  Mol Cancer Res 1:1070-1076.

"
"255","PC001446","Zabell KM, Laurence JS, Kinch MS, et al.  2006.  Expression and purification of the intact cytoplasmic domain of the human ephrin receptor A2 tyrosine kinase in Escherichia coli.
Protein Expr Purif 47:210-6."
"256","PC001446","·Walker-Daniels J, Riese DJ, and Kinch MS. 2002. cCbl-dependent EphA2 protein degradation is induced by ligand binding. Molecular Cancer Res. 1:79-87."
"257","PC001461","·Ma B, Bristow RG, et al.  2003.  Combined modality treatment of solid tumors using radiotherapy and molecular targeted agents.  Journal of Clinical Oncology, 21:2760-2776."
"258","PC001461","Bristow RG, Blussyen H, de Klein A, et al.  2001.  The PI3-kinase family as sensors and signals for DNA damage responses.  In: Trends in Molecular Biology (Gospodarowicz MK Ed.); Chapter 6, Wiley-Liss Inc., pp. 71-94, USA."
"259","PC001461","·Parker C, Milosevic M, et al.  2003.  A polarographic electrode study of tumor oxygenation in localized prostate cancer.  Int. J. Radiat. Oncol. Biol. Phys., 58:750-7."
"260","PC001461","Bromfield GP, Meng A, Warde P, Bristow RG (2003): Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. Prostate Cancer Prostatic Dis 6:73-85."
"261","PC001461","Bristow R on behalf of the CARO Task Force Members.  2004.  Recommendations for the future of translational radiobiology research:  A Canadian Perspective.  Radiotherapy and Oncology 70(2):159-164."
"262","PC001461","Cuddihy A and Bristow RG.  2004.  The p53 protein family and radiosensitivity: Yes or no?  Cancer Metastasis Reviews 
23(3-4):237-257.
"
"263","PC001461","Finlay M, Laperriere N, and Bristow R.  2004.  Radiotherapy and marfan syndrome: A report of two cases.  Clinical Oncology 17:54-6."
"264","PC001461","Catton C, Milosevic M, Warde P, et al.  2003.  Recurrent prostate cancer following external beam radiotherapy: Follow-up strategies and management.  Urol Clin North Am 
30(4):751-763.

"
"265","PC001461","Bindra R, Schaffer P, Meng A, et al.  2004.  Down-regulation of rad51 and decreased homologous recombination in hypoxic cancer cells.  Mol Cell Biol 24:8504-8518."
"266","PC001461","Fan R, Kumaravel TS, Jalali F, et al.  2004.  Defective DNA strand break repair following DNA damage in prostate cancer cells: Implications for genetic instability and prostate carcinogenesis.  Cancer Res 64:8526-8533."
"267","PC001461","Gospodarowicz, MK, O¿Sullivan B, and Bristow RG.  2001.  Host and tumor-related prognostic factors.  In: UICC Handbook of Prognostic Factors (Gospodarowicz MK Ed.), chapter 6, Wiley-Liss Inc., pp. 71-94, USA."
"268","PC001461","Catton C, Milosevic M, Warde Pet al.  2003.  Recurrent prostate cancer following external beam radiotherapy: follow-up strategies and management.  In: The Urologic Clinics of North America (Theodorescu D, Ed.), Vol 30 (4), pp. 751-763."
"269","PC001461","Bristow RG and Harrington L.  2005.  Genetic instability and DNA repair.  In: The Basic Science of Oncology, 4th Edition (Tannock IF, Hill RP, Harrington L, and Bristow RG, Eds.), chapter 5, McGraw-Hill Ltd., New York, pp. 77-99."
"270","PC001461","Bristow RG and Hill RP.  2005.  Molecular and cellular radiobiology.  In: The Basic Science of Oncology, 4th Edition (Tannock IF, Hill RP, Harrington L, and Bristow RG, Eds.), chapter 14, McGraw-Hill Ltd.; New York, pp. 261-288."
"271","PC001461","Hill RP and Bristow RG.  2005.  The scientific basis of clinical radiotherapy.  In: The Basic Science of Oncology, 4th Edition (Tannock IF, Hill RP, Harrington L, and Bristow RG, Eds.). chapter 15, McGraw-Hill Ltd., New York, pp. 289-321. 

"
"272","PC001461","Faulhaber O and Bristow RG.  2005.  Basis of cell kill following clinical radiotherapy.  In: Application of Apoptosis to Cancer Treatment (Sluyser M, Ed.), Kluwer-Springer Press, New York, VII, pp. 293-320."
"273","PC001461","West C, McKay M, Holscher T, et al.  2005.  Molecular markers predicting radiotherapy response: report and recommendations from an international atomic energy agency technical meeting. Int J Rad Oncol Biol Phys 62:1264-1273."
"274","PC001461","Nichol A, Lockwood G, Sweet J, et al.  2005.  A phase II study of localized prostate cancer treated to 75.6Gy with 3D conformal radiotherapy.  Radiother Oncol 76:11-17."
"275","PC001461","Horsburgh S, Matthew A, Bristow RG, et al.  2005.  Male BRCA1 and BRCA2 mutation carriers: A pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic.  The Prostate Journal 65:124-129."
"276","PC001461","Nichol A, Warde P, and Bristow RG.  2005.  Intermediate risk prostate cancer and radical radiotherapy: Clinical and translational issues.  Cancer 104:891-905."
"277","PC001461","Meng A, Jalali F, Cuddihy A, et al.  2005.  Hypoxia down-regulators DNA double strand break repair gene expression in prostate cancer cells.  Radiother Oncol 76:168-176."
"278","PC001461","Choudhury A, Cuddihy A, and Bristow RG.  2006.  Radiation and other new molecular-targeted agents, Part I: targeting ATM-ATR checkpoints, DNA repair and the proteasome.  Semin Radiat Oncol 16:51-58.

"
"279","PC001461","·Bayley AJ, Catton CN, et al.  2004.  A randomized trial of supine vs. prone positioning in patients undergoing escalated dose conformal radiotherapy for prostate cancer.  Radiotherapy and Oncology, 70:37-44."
"280","PC001472","Zhao D CACCHEMR (2003): Correlation of tumor oxygen dynamics with radiation response of the Dunning prostate R3327-H1 tumors. Radiat. Res. 159:621-631."
"281","PC001472","Zhao D, Constantinescu A, Hahn EW, Mason RP (2002): Differential oxygen dynamics in two diverse Dunning prostate R3327 rat tumor sublines (MAT-Lu and HI) with respect to growth and respiratory challenge. Int J Radiat Oncol Biol Phys 53:744-56."
"282","PC001472","Zhao D Ran S Constantinescu A Hahn EW Mason RP (2003): Tumor oxygen dynamics: correlation of in vivo MRI with histological findings.  Neoplasia. 5:308-18."
"283","PC001472","Culverhouse R, Lin J, Liu KY, Suarez BK (2001): Exploiting linkage disequilibrium in population isolates. Genet Epidemiol 21 Suppl 1:S429-34."
"284","PC001472","Reding DJ, Zhang KQ, Salzman SA, Thomalla JV, Riepe RE, Suarez BK, Catalona WJ, Burmester JK (2001): Identification of a gene frequently mutated in prostate tumors. Med Oncol 18:179-87."
"285","PC001472","Suarez BK, Gerhard DS, Lin J, Haberer B, Nguyen L, Kesterson NK, Catalona WJ (2001): Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls. Cancer Res 61:4982-4."
"286","PC001480","Yin D, He Y, Perera MA, Hong SS, Marhefka C, Stourman N, Kirkovsky L, Miller DD, Dalton JT (2003): Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol Pharmacol 63:211-23."
"287","PC001480","Yang J, Bohl CE, Nair VA, et al.  2006.  Preclinical pharmacology of a nonsteroidal ligand for androgen receptor mediated imaging of prostate cancer.  J Pharmacol Exp Ther 317:402-8."
"288","PC001481","Morgan TM, Lange PH, Vessella RL. 2007.  Detection and characterization of circulating and disseminated prostate cancer cells.  Front Biosci 12:3000-3009."
"289","PC001482","Mi Y, Thomas SD, Xu X, Casson LK, Miller DM, Bates PJ (2003): Apoptosis in leukemia cells is accompanied by alterations in the levels and localization of nucleolin. J Biol Chem 278:8572-9."
"290","PC001482","Xu X, Hamhouyia F, Thomas SD, Burke TJ, Girvan AC, McGregor WG, Trent JO, Miller DM, Bates PJ (2001): Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides. J Biol Chem 276:43221-30."
"291","PC001482","Dapic V, Bates PJ, Trent JO, Rodger A, Thomas SD, Miller DM (2002): Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications. Biochemistry 41:3676-85."
"292","PC001482","Girvan AC, Teng Y, Casson LK, et al.  2006.  AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin.  
Mol Cancer Ther 5(7):1790-1799."
"293","PC001482","Dapic V, Abdomerovic V, Marrington R, Peberdy J, Rodger A, Trent JO, Bates PJ (2003): Biophysical and biological properties of quadruplex oligodeoxyribonucleotides. Nucleic Acids Res 31:2097-107."
"294","PC001502","Ellerby HM Lee S Ellerby LM Chen S Kiyota T del Rio G Sugihara G Sun Y Bredesen DE Arap W Pasqualini R. (2003): An artificially designed pore-forming protein with anti-tumor effects.  J Biol Chem. 278:35311-6."
"295","PC001502","Arap W, Haedicke W, Bernasconi M, et al.  2002.  Targeting the prostate for destruction through a vascular address.  Proc Natl Acad Sci U S A 99(3):1527-1531."
"296","PC001525","Banerjee R, Li S, and Huang L.  Anisamide-targeted stealth liposomes:  A potent carrier for targeting doxorubicin to prostate cancer cells.  Int J Cancer, 112:693-700."
"297","PC001525","Yang L, Zhou W, and Li S.  2004.  Targeted delivery of antisense oligonucleotides to folate receptor-overexpressing tumor cells.  J Control Release 95:321-332."
"298","PC001525","Zhou W, Yuan X, Wilson A, et al.  2002.  Efficient intracellular delivery of oligonucleotides formulated in folate receptor-targeted lipid vesicles.  Bioconjug Chem 13:1220-1225."
"299","PC001527","Kwabi-Addo B, J Wang, H Erdem, et al., 2004.  The expression of sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer.  Cancer Res. 64:4728-4735."
"300","PC001532","Ghosh J. 2003. Inhibition of arachidonate 5-lipoxygenase triggers PC cell death through rapid activation of c-Jun N-terminal kinase.  Biochem. Biophys. Res. Commun. 307:342-349.  
"
"301","PC001532","Sundaram S, Ghosh J. 2006.  Expression of 5-oxoETE receptor in prostate cancer cells: Critical role in survival. Biochem Biophys Res Commun 339:93-98."
"302","PC001532","Ghosh J. 2004.  Rapid induction of apoptosis in prostate cancer cells by selenium: Reversal by metabolites of arachidonate 5-lipoxygenase.  Biochem Biophys Res Commun 315:624-635."
"303","PC001532","·Ghosh J and Myers CE. 2002. Molecular mechanisms of prostate cancer cell death triggered by inhibition of arachidonate 5-lipoxygenase: involvement of Fas death receptor-mediated signals.  Adv. Exp. Med. Biol. 507:415-420.
"
"304","PC001533","Clark JA, Talcott JA.  2006.  Confidence and uncertainty long after initial treatment for early prostate cancer: survivors' views of cancer control and the treatment decisions they made.  J Clin Oncol 24(27):4457-4463."
"305","PC001533","Clark JA, Bokhour BG, Inui TS, et al.  2003. Measuring patients' perceptions of the outcomes of treatment for early prostate cancer.
Med Care. 41(8):923-36"
"306","PC001533","Clark JA, Inui TS, Silliman RA, et al.  2003. Patients' perceptions of quality of life after treatment for early prostate cancer.
J Clin Oncol. 21(20):3777-84"
"307","PC001545","Davis SD, Ford ME.  2004.   A conceptual model of barriers to mental health services among African Americans.  African American Research Perspectives 10:44-54.
"
"308","PC001545","Ford ME, Randolph V, Hopkins-Johnson L, Eason SL, et al.  2004.  Design of a case management approach to enhance cancer screening trial retention among older African American men.  J Aging Health, 16:39S-57S.
"
"309","PC001545","Ford ME, Havstad SL, Davis SD.  2004.  A randomized trial of recuitment methods for older African American men in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.  Clinical Trials 1:343-351."
"310","PC001545","Ford ME, Vernon SW, Havstad MA, et al.  2006.  Factors influending behavioral intention regarding prostate cancer screening among older african-american men.  Journal Nat Med Assoc 98:505-514."
"311","PC001545","Ford ME, Havstad SL, Vernon SW, et al.  2006.  Enhancing adherence among older African American men enrolled in a longitudinal cancer screening trial.  Gerontologist 46:545-550."
"312","PC001545","Ford ME, Havstad SL, Tilley BC.  2003.  Recruiting older African American men to a cancer screening trial (the AAMEN Project).  The Gerontologist 43:27-35."
"313","PC001545","Ford ME, Havstad SL, Johnson CC.  Effects of false- positive prostate cancer screening results on subsequent prostate cancer screening behavior.  Cancer Epidemiol Biomarkers Prev, 14:190-4.
"
"314","PC001549","Coleman IM, Kiefer JA, Brown LG, et al. 2006. Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes. Neoplasia 8(10):862-78."
"315","PC001549","Lai JS, Brown LG, True LD, et al.  Metastases of prostate cancer express estrogen receptor beta.  Urology 64(4):814-20."
"316","PC001551","Gross M, Yang R, Top I, et al.  2004.  PIASy-mediated repression of the androgen receptor is independent of sumoylation.  Oncogene 23:3059-3066."
"317","PC001551","Liu B, Yang R, Wong KA, et al.  2005.   Negative regulation of NF-kappaB signaling by PIAS1. Mol Cell Biol 25:1113-23."
"318","PC001551","Shuai K.  2006.  Regulation of cytokine signaling pathways by PIAS proteins.  Cell Res 16:196-202."
"319","PC001551","Arora T, Liu B, He H, et al.  2003.  PIASx is a transcriptional co-repressor of signal transducer and activator of transcription 4.  J Biol Chem 278:21327-30."
"320","PC001551","Liu B, Mink S, Wong KA, et al.  2004.  PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity.  Nat Immunol 5:891-8."
"321","PC001557","Tong X and Li H. 2004. eNos protects prostate cancer cells from TRAIL-induced apoptosis.  Cancer Letters 210:63-71.
"
"322","PC001582","·Paddison PJ, Silva JM, Conklin DS, et al.  A resource for large-scale RNAi based screens in mammals.  Nature 428(6981)427-31."
"323","PC001583","Chan N, Milosevic M, and Bristow R.  2007.  Tumor hypoxia, DNA repair and prostate cancer progression: New targets and new therapies.  Future Oncol 3:329-341."
"324","PC001583","Milosevic M, Chung P, Parker C, et al.  2007.  Androgen withdrawal in patients with prostate cancer hypoxia:  Implications for disease progression and radiation response.  Cancer Res 67:6022-5."
"325","PC001583","Parker C, Milosevic M, Toi A, et al.  2004.  A polarographic electrode study of tumor oxygenation in localized prostate cancer.  Int J Radiat Oncol Biol Phys 58:750-757."
"326","PC001588","·Han K-R, Seligson DB, Liu X, et al. 2004. Prostate stem cell antigen (PSCA) expression is associated with Gleason score, seminal vesicle invasion, and capsular invasion in prostate cancer.  Journal of Urology 171:1117-21"
"327","PC001588","Han KR, DB Seligson, X Liu, et al., 2004.  PSCA expression is associated with Gleason score seminal vesicle invasion and capsular invasion in prostate cancer.  Journal of Urology 171:1117-1121.

"
"328","PC001590","Zhang X-k (2002): Vitamin A and apoptosis in prostate cancer. Endocrine-Related Cancer Volume 9:87-102."
"329","PC001590","Kolluri S, Cao X, Bruey-Sedano N, et al.  2003.  Mitogenic effect of orphan receptor TR3 and its regulation by MEKK1 in lung cancer cells.  Mol Cell Biol 23:8651-8667."
"330","PC001590","Lin B, Kolluri S, Cao X, et al.  2004.  Conversion of bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3.  Cell 116:1-20."
"331","PC001590","Dawson MI, Harris D, Liu G, et al.  2004.  Antagonist analogue of 6-[3'-(1-adamantyl)-4'-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN) family of apoptosis inducers that effectively blocks AHPN-induced apoptosis but not cell-cycle arrest.  J Med Chem 47:3518-36."
"332","PC001590","Dawson MI, Hobbs PD, Peterson VJ, Leid M, Lange CW, Feng KC, Chen Gq, Gu J, Li H, Kolluri SK, Zhang Xk, Zhang Y, Fontana JA (2001): Apoptosis induction in cancer cells by a novel analogue of 6-[3-(1- adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic aci"
"333","PC001595","Low J, Humes HD, Szczypka M, et al.  2004.  BKV and SV40 infection of human kidney tubular epithelial cells in vitro.  Virology 323:182-188."
"334","PC001595","Das D, Shah RB, and Imperiale MJ.  2004.  Detection and expression of human BK virus sequences in neoplastic prostate tissues.  Oncogene 23:7031-46."
"335","PC010016","Link KL, EP Williams, T Marshall, et al., 2005.  BAF57 governs androgen-receptor action and androgen-dependent proliferation through SWI/SNF.  Mol. Cell Biol. 25(6):2200-2215."
"336","PC010016","·Marshall TW, Link K, Weisman B, and Knudsen KE.  2003. Differential requirement of SWI/SNF for androgen receptor activity.  J Biol Chem 278:30605-30613."
"337","PC010017","Xu LL and Srivastava S.  2001.  Prostate Cancer-Associated Overexpression of PSGR.  Cancer Res Alert 120.

"
"338","PC010017","Xu LL, Sun C, Petrovics G, et al.  2006.  Quantitative Expression Profile of PSGR in Prostate Cancer.  Prostate Cancer and Prostatic Dis 9:56-61."
"339","PC010023","Wang Y, Raffoula JJ, Che M, et al.  2006.  Prostate cancer radiotherapy is enhanced by genistein in vitro and in vivo using a syngeneic orthotopic tumor model.  Radiat Res 166:73-80."
"340","PC010023","Krause M, Wohlfarth J, Georgi B, et al.  2005.  Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo.  Int J Radiat Biol 81:751-758."
"341","PC010023","Hillman GG, Wang Y, Kucuk O, et al.  2004.  Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model.  Mol Cancer Ther 3:1271-1279."
"342","PC010023","Krause M, Hessel F, Wohlfarth J, et al.  2003.  Ultrafractionation in A7 human malignant glioma in nude mice.  Int J Radiat Biol 79:377-383."
"343","PC010023","Krause M, Prager J, Wohlfarth J, et al.  2005.  Ultrafractionation does not improve the results of radiotherapy in radioresistant murine DDL1 lymphoma.  Strahlenther Onkol 181:540-544.
"
"344","PC010023","Harney J, Short S, Shah N, et al.  2004.  Low dose hyper-radiosensitivity in metastatic tumors.  Int J Radiat Oncol Biol Phys 59:1190-1195."
"345","PC010023","Harney J, Shah N, Short S, et al.  2004.  The evaluation of low dose hyper-radiosensitivity in normal human skin.  Radiother Oncol 70:319-329."
"346","PC010023","Joiner MC.  2004.  New frontiers or red herrings in radiation oncology research?  Lancet Oncol 5:10.

"
"347","PC010023","Chalmers A, Johnston P, Woodcock M, et al.  2004.  PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation.  Int. J. Radiat. Oncol. Biol. Phys. 58:410-419."
"348","PC010023","Marples B, Wouters BG, Collis SJ, et al.  2004.  Low-dose hyper-radiosensitivity:  A consequence of ineffective cell cycle arrest of radiation-damaged G2 phase cells.  Radiat. Res. 161:247-255."
"349","PC010023","Joiner MC and Marples B.  2006.  Response in vivo to high-LET radiation.  In: International Atomic Energy Agency Report.  Relative Biological Effectiveness and Dose Reporting in Proton and Heavier Ion Radiotherapy."
"350","PC010023","Krueger SA, Weinfeld M, Joiner MC,et al.  2007.  Role of apoptosis in low-dose hyper-radiosensitivity.  Radiat Res 167:260-7."
"351","PC010023","Krueger SA, Joiner MC, Weinfeld M, Piasentin E, Marples B.Role of apoptosis in low-dose hyper-radiosensitivity.Radiat Res. 2007 Mar;167(3):260-7"
"352","PC010023","Marples B Wouters BG and Joiner MC (2003): An association between the radiation-induced arrest of G2-phase cells and low-dose hyper-radiosensitivity: A plausible underlying mechanism?  Radiat. Res.  160:38-45."
"353","PC010023","Short SC, Woodcock M, Marples B, et al.  2003.  Effects of cell cycle phase on low-dose hyper-radiosensitivity.  Int J Radiat Biol 79:99-105."
"354","PC010030","Ritter MA, Gilchrist KW, Voytovich M, Chappell RJ, Verhoven BM (2002): The role of p53 in radiation therapy outcomes for favorable-to- intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 53:574-80."
"355","PC010039","Han B, Z Dong, JT Zhang, 2003.  Tight control of platelet-derived growth factor B/c-sis expression by interplay between the 5'-untranslated region sequence and the major upstream promoter.  J. Biol. Chem. 278:46983-93.

"
"356","PC010039","Han B  Zhang JT (2002): Regulation of gene expression by internal ribosome entry sites or cryptic promoters: the eIF4G story. Mol Cell Biol. 22 :7372-84."
"357","PC010039","Han B, Dong Z, Liu Y, et al.  2003.  Regulation of constitutive expression of mouse PTEN by the 5'-untranslated region.  Oncogene 22:5325-5337."
"358","PC010047","Shen H, Schuster R, Stringer KF, Waltz SE, Lentsch AB.2006. The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth.
FASEB J. 20(1):59-64."
"359","PC010047","Lentsch AB (2002): The Duffy antigen/receptor for chemokines (DARC) and prostate cancer. A role as clear as black and white? FASEB J 16:1093-5."
"360","PC010047","·Shen H, Lentsch AB.  2004.  Progressive dysregulation of transcription factors NF-kappa-B and STAT1 in prostate cancer cells causes proangiogenic production of CXC chemokines.  Am. J. Physiol. Cell Physiol. 286:C840-7."
"361","PC010055","·Dong Y, Lee SO, Zhang H, et al.  2004.  Prostate specific antigen (PSA) expression is down-regulated by selenium through disruption of androgen receptor signaling.  Cancer Research 64:19-22."
"362","PC010055","Zhang H, Dong Y, Marshall J, et al.  2005.  Microarray data mining of potential selenium targets in chemoprevention of prostate cancer.  Cancer Genomics and Proteomics 2:97-114.

"
"363","PC010055","Dong Y, Zhang H, Hawthorn L, Ganther HE, Ip C (2003): Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res 63:52-9."
"364","PC010058","Ahmed M, SD Cramer, and DS Lyles, 2004.  Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses.  Virology 330:34-49.

"
"365","PC010058","Ahmed M, McKenzie MO, Puckett S, Hojnacki M, Poliquin L, Lyles DS (2003): Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J Virol 77:4646-57."
"366","PC010058","Carey BL, Ahmed M, Puckett S, et al.  2008. Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus.  
J Viro l82(24):12104-12115."
"367","PC010062","·Lewis MR, Zhang J, and Jia F.  Biological comaparison of 149Pm, 166Ho, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-strepavidin fusion protein in xenograft bearing nude mice.  Nucl. Med. Biol. 31:213-23."
"368","PC010062","Miller WH, Hartmann-Siantar C, Fisher D, et al. 2005.  Evaluation of beta-absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides.  Cancer Biother Radiopharm 20:436-449.

"
"369","PC010062","Bryan JN, Jia F, Mohsin H, et al.  2005.  Comparative uptakes and biodistributions of internalizing vs. noninternalizing copper-64 radioimmunoconjugates in cell and animal models of colon cancer.  Nucl Med Biol 32:851-858."
"370","PC010062","Bryan JN, Lewis MR, Henry J, et al.  2004.  Development of a two-antibody model for the evaluation of copper-64 radioimmunotherapy.  Vet Comp Oncol 2:82-90."
"371","PC010062","·Miller WH, Hartmann-Siantar C, Descalle MA, et al.  2003.  Mouse organ absorbed dose fractions for beta emitters.  Trans. Am. Nucl. Soc. 89:689-692."
"372","PC010062","Mohsin H, Jia F, Lewis MR, et al.  2006.  Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: Biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177Lu.  Bioconjugate Chem. 17:485-92."
"373","PC010066","Niethammer AG Xiang R Becker JC Wodrich H Pertl U Karsten G Eliceiri BP Reisfeld RA (2002): A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 8:1369-75."
"374","PC010066","Zhou H, Luo Y, Mizutani M, Mizutani N, Reisfeld RA, Xiang R.  2005.  T cell-mediated suppression of angiogenesis results in tumor protective immunity.
Blood 106:2026-32.
"
"375","PC010066","Zhou H, Luo Y, Mizutani M, et al.  2004.  A novel transgenic mouse model for immunological evaluation of carcinoembryonic antigen-based DNA minigene vaccines.  J Clin Invest 113(12):1792-1798."
"376","PC010070","Park HI, Jin Y, Hurst DR, et al. 2003. The intermediate S1' pocket of the endometase/metrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling. J. Biol. Chem. 278:51646-51653."
"377","PC010070","Sang Q-X, Jin Y, Newcomer RG, et al.  2006.  Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. Curr Top Med Chem 6:289-316."
"378","PC010070","Park HI, Turk BE, Gerkema FE, Cantley LC, Sang QX (2002): Peptide substrate specificities and protein cleavage sites of human endometase/matrilysin-2/matrix metalloproteinase-26. J Biol Chem 277:35168-75."
"379","PC010070","·Hurst DR, Schwartz MA, Ghaffari MA, et al. 2004. Catalytic- and ecto- domains of membrane type 1-matrix metalloproteinase have similar inhibition profiles but distinct endopeptidase activities. Biochem J. 377:775-779."
"380","PC010070","Man Y-G, Shen T, Weisz J, et al.  2005.  A subset of in situ breast tumor cell clusters lacks expression of proliferation and progression related markers but shows signs of stromal and vascular invasion. Cancer Detect Prev 29:323-331."
"381","PC010070","Hurst DR, Schwartz MA, Jin Y, et al.  2005.  Inhibition of enzyme activity and cell-mediated substrate cleavage of membrane type 1-matrix metalloproteinase by newly developed mercaptosulfide inhibitors. Biochem J 392:527-536."
"382","PC010070","Qiu W, Bai S-X, Zhao M-R, et al.  2005.  Spatiotemporal expression of matrix metalloproteinase-26 in human placental trophoblasts and fetal red cells during normal placentation. Biol Reprod 72:954-959."
"383","PC010070","·Zhao YG, Xiao AZ, Park HI, et al. 2004. Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinases-2 and -4: A putative role in the initiation of breast cancer invasion. Cancer Research 64:590-598."
"384","PC010070","Sahab ZJ, Suh Y, and Sang Q-X.  2005.  Isoelectric point-based prefractionation of proteins from crude biological samples prior to two-dimensional gel electrophoresis. J Proteome Res 4:2266 2272."
"385","PC010070","Park HI, Jin Y, Hurst DR, et al. 2003.  The intermediate S1¿ pocket of the endometase/metrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling. J Biol Chem 278:51646-51653."
"386","PC010070","Liao X, Thrasher JB, Pelling J, et al.  2003.  Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 144:1656-1663."
"387","PC010070","Kang T-B, Zhao Y-G, Pei D, et al.  2002.  Intracellular activation of human Adamalysin 19/disintegrin and metalloproteinase 19 by furin occurs via one of the two consecutive recognition sites. J Biol Chem 277:25583-25591."
"388","PC010070","Lee S, Desai KK, Iczkowski KA, et al.  2006.  Coordinated peak expression of MMP-26 and TIMP-4 in preinvasive human prostate tumor.  Cell Res 16:750-8."
"389","PC010070","Kang T, Park HI, Suh Y, et al.  2002.  Autolytic processing at Glu(586)-Ser(587) within the cysteine-rich domain of human Adamalysin 19/disintegrin-metalloproteinase 19 is necessary for its proteolytic activity.  J Biol Chem 277:48514-48522.

"
"390","PC010070","Zhao YG, Xiao AZ, Newcomer RG, Park HI, Kang T, Chung LW, Swanson MG, Zhau HE, Kurhanewicz J, Sang QX (2003): Activation of pro-gelatinase B by endometase/matrilysin-2 promotes invasion of human prostate cancer cells. J Biol Chem 278:15056-64."
"391","PC010070","Man YG, Shen T, Zhao YG, et al.  2005.  Focal prostate basal cell layer disruptions and leukocyte infiltration are correlated events: A potential mechanism for basal cell layer disruptions and tumor invasion.  Cancer Detect Prev 29:161-9."
"392","PC010070","Qiu W, Bai SX, Zhao MR, et al.  2005.  Spatio-temporal expression of matrix metalloproteinase-26 in human placental trophoblasts and fetal red cells during normal placentation.  Biol Reprod 
72:954-959. 
"
"393","PC010070","Man YG and Sang QX.  2004.  The significance of focal myoepithelial cell layer disruptions in human breast tumor invasion: A paradigm shift from the 'proteasecentered' hypothesis.  Exp Cell Res 301:103-118."
"394","PC010070","Kang T, Tschesche H, and Sang QX.  2004.  Evidence for disulfide involvement in the regulation of intramolecular autolytic processing by human adamalysin19/ADAM19.  Exp Cell Res 298:285-295."
"395","PC010071","Ishii K and Hayward SW.  The history of tissue recombination technology: Current and future research. In: Challenges in Prostate Cancer II (Browsher W, Ed.) Blackwell, London."
"396","PC010075","Mincheff M, Zoubak S, Makogonenko Y. Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals.Cancer Gene Ther. 2006 Apr;13(4):436-44."
"397","PC010075","
Mincheff M, Makogonenko Y, and Zoubak S.  2005.  Immune responses against PSMA after gene-based vaccination for immunotherapy: A. Results from immunizations in animals.  Cancer Gene Ther 13:436-44.
"
"398","PC010075","Mincheff M, Zoubak S, Altankova I, et al.  2005.  Depletion of CD25+ cells from human T-cell enriched fraction eliminates immunodominance during priming and boosting with genetically modified dendritic cells.  Cancer Gene Ther 12:185-197.

"
"399","PC010075","Mincheff M, S Zoubak, I Altankova, et al., 2003.  Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes.  Cancer Gene Ther. 10(12):907-17.
"
"400","PC010077","Penington DJ, Bryant I, Riese DJ 2nd (2002): Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities. Cell Growth Differ 13:247-56."
"401","PC010077","Williams EE, Trout LJ, Gallo RM, Pitfield SE, Bryant I, Penington DJ, Riese DJ (2003): A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. Cancer Lett 192:67-74."
"402","PC010078","Thakore CT, BD Lehmann, JA McCubrey, and DM Terrian, 2005.  Intracellular Signaling in Cancer.  In Encyclopedia of Molecular Cell Biology and Molecular Medicine, Vol. 7, 2nd Ed., Meyers R.A. (ed.), Wiley VCH Verlay GmbH & Co., KGaA, Weinheim.

"
"403","PC010078","Thakore CT, Lehmann BD, McCubrey JA, et al.  2005.  Intracellular signaling in cancer.  In: Meyers RA (Ed.).  Encyclopedia of Molecular Cell Biology and Molecular Medicine, Wiley-VCH Verlag GmbH, Weinheim, pp. 1-28."
"404","PC010078","Wu D, Thakore C, Wescott G, et al.  2004.  Integrin signaling links protein kinase Ce to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells.  Oncogene, 23:8659-72.
"
"405","PC010078","Wu D, Terrian DM (2002): Regulation of caveolin-1 expression and secretion by a protein kinase cepsilon signaling pathway in human prostate cancer cells. J Biol Chem 277:40449-55."
"406","PC010078","Tachado SD, Mayhew MW, Wescott GG, Foreman TL, Goodwin CD, McJilton MA, Terrian DM (2002): Regulation of tumor invasion and metastasis in protein kinase C epsilon- transformed NIH3T3 fibroblasts. J Cell Biochem 85:785-97."
"407","PC010078","·McJilton MA, Sikes CV, Wescott GG, et al.  2003.  Protein kinase Ce interacts with Bax and promotes survival of human prostate cancer cells.  Oncogene 22:7958-7968."
"408","PC010078","Terrian DM (2003): Cancer Cell Signaling: Methods and Protocols (Methods in Molecular Biology . Humana Press. <20 Page(s)>."
"409","PC010078","Wu D WGaTD (2003): Manipulating expression of endogenous oncogenic proteins using an antisense oligonucleotide approach in prostate cancer cells. In: Cancer Cell Signaling: Methods and Protocols (Methods in Molecular Biology . Terrian DM, ed. Humana Press."
"410","PC010078","Wu D, Foreman TL, Gregory CW, McJilton MA, Wescott GG, Ford OH, Alvey RF, Mohler JL, Terrian DM (2002): Protein kinase cepsilon has the potential to advance the recurrence of human prostate cancer. Cancer Res 62:2423-9."
"411","PC010079","Perryman LA, Blair JM, Kingsley EA, Szymanska B, Ow KT, Wen VW, MacKenzie KL, Vermeulen PB, Jackson P, Russell PJ.
2006.  Over-expression of p53 mutants in LNCaP cells alters tumor growth and angiogenesis in vivo. Biochem Biophys Res Commun. 345(3):1207-1214.
"
"412","PC010083","Gu Z, Yamashiro J, Kono E, Reiter RE. 2005. Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanisim.  Cancer Res. 65(20):9495-500."
"413","PC010091","Nikitin AY, Liu CY, Flesken-Nikitin A, Chen CF, Chen PL, Lee WH (2002): Cell lineage-specific effects associated with multiple deficiencies of tumor susceptibility genes in Msh2(-/-)Rb(+/-) mice. Cancer Res 62:5134-8."
"414","PC010091","Tsai KY, MacPherson D, Rubinson DA, Nikitin AY, Bronson R, Mercer KL, Crowley D, Jacks T (2002): ARF mutation accelerates pituitary tumor development in Rb+/- mice. Proc Natl Acad Sci U S A 99:16865-70."
"415","PC010091","Sharp ZD, Lee WH, Nikitin AY, Flesken-Nikitin A, Ikeno Y, Reddick R, Richardson AG, Nelson JF (2003): Minimal effects of dietary restriction on neuroendocrine carcinogenesis in Rb+/- mice. Carcinogenesis 24:179-83."
"416","PC010091","Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ. 2006. Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate. 66(2):135-45."
"417","PC010091","Chen C, Sytkowski AJ. 2005. Apoptosis-linked gene-2 connects the Raf-1 and ASK1 signalings. Biochem. Biophys. Res. Commun. 333(1):51-7."
"418","PC010092","Panguluri RC, LO Long, W Chen, et al., 2004.  COX-2 gene promoter haplotypes and prostate cancer risk.  Carcinogenesis, 25:961-6."
"419","PC010092","Ukoli F, U Osime, F Akereyeni, et al., 2003.  Prevalence of elevated serum prostate specific antigen in rural Nigeria.  International Journal of Urology 10:315-322."
"420","PC010092","Kittles RA, W Chen, RK Pangulari, et al., 2002.  CYP3A-V4 and prostate cancer in African Americans:  Causal or confounding association because of population stratification.  Hum. Genet. 110:553-560.

"
"421","PC010092","Fowke JH, Signorello L, Chang S, et al.  2006.  Effects of obesity and height on PSA and percent free PSA levels among African-American and Caucasian Men.  Cancer 107:2361-7."
"422","PC010092","Fowke JH, Schlundt D, Signorello LB, et al.  2005.  Prostate cancer screening among low-income African-American and Caucasian men.  Urologic Oncology: Seminars and Original Investigation 23:333-340."
"423","PC010092","Ukoli FA, Egbagbe E, Akereyeni F, et al.  2006.  Response to prostate biopsy by nigerian men: community and hospital experience.  Proceedings of the UICC World Cancer Congress, Washington DC.  341-347.  Medimond International Proceedings."
"424","PC010092","Ukoli FA, Egbagbe E, Zhao BB.  2007.  Anthropometric body fat predictors of elevated prostate specific antigen among rural and urban Nigerians:  A Population-Based Study.  West Afr J Med 26:7-13."
"425","PC010092","Ukoli F, Lynch B, Adams-Campbell L, et al.  2006.  The effect of radical prostatectomy on patient quality of life in African Americans.  Ethn Dis 16:988-993."
"426","PC010092","Odedina FT, Ogunbiyi JO, Ukoli FA.  2006.  Roots of prostate cancer in African-American men.  J Natl Med Assoc 98(4):539-43."
"427","PC010092","Fowke JH, Signorello LB, Underwood W 3rd, et al.  2006.  Obesity and prostate cancer screening among African-American and Caucasian men.  Prostate 66:1371-80."
"428","PC010096","·Yeh IT, Luduena RF.  2004.  The betaII isotype of tubulin is present in the cell nuclei of a variety of cancers  Cell Motil. Cytoskeleton 57:96-106."
"429","PC010097","Sun J, Pons J, Craik CS (2003): Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies. Biochemistry 42:892-900."
"430","PC010110","Singh P, Mhaka AM, Christensen SB, et al.  2005.  Applying linear interaction energy method for rational design of non-competitive allosteric inhibitors of SERCA ATPase.  J Med Chem 48:3005-3014."
"431","PC010110","Mhaka A, Gady AM, Lo K-M, et al.  2004.  Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA).  Cancer Biol Ther 3:551-558."
"432","PC010110","Tombal B, Denmeade SR, Gillis JM, Isaacs JT (2002): A supramicromolar elevation of intracellular free calcium ([Ca(2+)](i)) is consistently required to induce the execution phase of apoptosis. Cell Death Differ 9:561-73."
"433","PC010110","Mhaka A, Denmeade SR, Yao W.  2002.  A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer.  Bioorg Medicinal Chemistry 12:2459-2461."
"434","PC010110","Mhaka A, Janssen S, Rosen M, et al.  2002.  Enzyme activation of prodrugs by prostate-specific membrane antigen.  European J Cancer 38(7):S36."
"435","PC010110","Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT (2003): Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 54:249-57."
"436","PC010110","Mhaka A, Denmeade SR, Yao W, Isaacs JT, Khan SR (2002): A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer. Bioorg Med Chem Lett 12:2459-61."
"437","PC010110","Denmeade SR, Jakobsen C, Janssen S, et al.  2003.  Prostate-specific antigen (PSA) activated thapsigargin prodrug as targeted therapy for prostate cancer.  J Natl Cancer Inst 95:990-1000. 

"
"438","PC010111","Stehr M, Adam RM, Khoury J, Zhuang L, Solomon KR, Peters CA, Freeman MR (2003): Platelet derived growth factor-BB is a potent mitogen for rat ureteral and human bladder smooth muscle cells: dependence in lipid rafts for cell signaling. J Urol 169:1165-70."
"439","PC010111","Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR (2002): Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res 62:2227-31."
"440","PC010111","Adam RM, Roth JA, Cheng HL, Rice DC, Khoury J, Bauer SB, Peters CA, Freeman MR (2003): Signaling Through PI3K/Akt Mediates Stretch and PDGF-BB-Dependent DNA Synthesis in Bladder Smooth Muscle Cells. J Urol 169:2388-2393."
"441","PC010112","Zhang Y, Lin J, and Pan D.  2007.  Synthesis of a technetium-99m labeled tricyclic ganciclovir analog for non-invasive reporter gene expression imaging.  Bioorganic & Medicinal Chemistry Letters 17:741-744."
"442","PC010112","Li H, Li J, Helm GA, et al.  2007.  Non-invasive imaging of firefly luciferase reporter gene expression using bioluminescence imaging in human prostate cancer models.  Biotechnol Appl Biochem 46:179-184."
"443","PC010112","Li H, Li J, Helm G, et al.  2005.  Highly specific expression of luciferase gene in lungs of naïve nude mice directed by prostate-specific antigen promoter.  Biochem Biophys Res Comm 334:1287-1291."
"444","PC010112","Zhang Y, Dai X, Kallmes D, et al.  2004.  Synthesis of a novel Tc-99m labeled TK report probe, 2¿-Deoxy-2¿fluoro-5-{3-oxo[N,N-bis(2-mercaptoethyl)ethylenediaminato][Tc-99m] technetium(V)-1(E)-propenyl}uridine.  Tetrahedron Letters 45:8673-8676."
"445","PC010114","Tseng P-H, Lin H-P, Chen J, et al.  2005.  Synergistic interactions between Imatinib and the novel phosphoinositide-dependent protein kinase-1 inhibitors OSU-03012 in overcoming Imatinib resistance.  Blood 105:4021-4027."
"446","PC010114","Zhu J, JW Huang, PH Tseng, et al., 2004.  From the cyclooxygenase-2 inhibitor celecoxib to a novel class of phosphoinositide-dependent protein kinase inhibitors.  Cancer Res. 64:4309-4318.

"
"447","PC010114","·Kulp SK, Yang YT, Hung CC, et al.  2004.  3-phosphoinositide-dependednt protein kinase 1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells.  Cancer Research 64:1444-51"
"448","PC010114","Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS (2002): Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst 94:1745-57."
"449","PC010131","·Tse, W. C., Boger, D. L.  2004.  A fluorescent intercalator displacement assay for establishing DNA binding selectivity and affinity.  Accounts of Chemical Research 37:61-9."
"450","PC010131","Boger DL.  2003.  Solution-phase synthesis of combinatorial libraries designed to modulate protein-protein or protein-DNA interactions. Bioorg Med Chem Lett 11:1607-1613."
"451","PC010131","Woods CR, Faucher N, Eschgfaller B, Bair KW, Boger DL (2002): Synthesis and DNA binding properties of saturated distamycin analogues. Bioorg Med Chem Lett 12:2647-50."
"452","PC010131","·Boger DL, et al.  2003.  Synthesis of isochrysohermidin-distamycin hybrids.  Journal Organic Chemistry 68:5249-5253."
"453","PC010131","·Boger DL, et al.  2003.  Solution-phase combinatorial libraries: Modulating cellular signaling by targeting protein-protein or protein-DNA interactions.  Angew. Chem. Int. Ed. 42:4138-4176."
"454","PC010131","Tse WC, Boger DL. 2004. A fluorescent intercalator displacement assay for establishing DNA binding selectivity and affinity. Acc Chem Res 37(1):61-69."
"455","PC010134","Tein AH, Xu L, and Helgason CD.  2005.  Altered immunity accompanies disease progression in a prostate cancer mouse model.  Cancer Res 65:2947-55."
"456","PC010137","Jayadevappa R, Bloom BS, Chhatre S, et al.  2005.  Health related quality of life and direct medical care cost in newly diagnosed younger men with prostate cancer.  J Urol 174:1059-1064."
"457","PC010137","Jayadevappa R, Chhatre S, Whittington R, et al.  2006. Health related quality of life and satisfaction with care among older men treated with radical prostatectomy or external beam radiation therapy.  BJU Int 97:955-62.
"
"458","PC010137","Jayadevappa R, Chhatre S, Weiner M, et al.  2005.   Medical care cost of patients with prostate cancer. Urol Oncol 23:155-62.

"
"459","PC010137","Jayadevappa R, Chhatre S, Rosner A, et al.  2004.  Quality of life of newly diagnosed prostate cancer patients in a public vs. private setting.  Value in Health 7(3):253."
"460","PC010146","·Lo J-F. Hayashi M, Kim SW, et al.  2004.  Tid1, a cochaperone of heat shock 70 protein and the mammalian counterpart of the drosphila tumor suppressor 1(2)Tid, is critical for early embryonic development and cell survival.  Mol. Cell Biol. 24:2226-2236."
"461","PC010148","Packianathan S, Mehta RG, Mehta RR, et al.  2004.  Designing a randomized phase I/II prostate cancer chemoprevention trial using 1alpha-hydroxy-24-ethyl-cholecalciferol, an analogue of vitamin D3.  Cancer J 10(6):357-67."
"462","PC010148","Vijayakumar S, Mehta RR, Boerner PS, et al.  2005.  Clinical trials involving vitamin D analogs in prostate cancer. Cancer Journal 11(5):362-373."
"463","PC010149","Lebedeva IV, Sarkar D, Su ZZ, Kitada S, Dent P, Stein CA, Reed JC, Fisher PB. 2003. Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene. 22(54):8758-73."
"464","PC010149","Lebedeva IV, Su ZZ, Sarkar D, Kitada S, et al. 2003. Melanoma differentiation associated gene-7, mda-7/interleukin-24, induces apoptosis in prostate cancer cells by promoting mitochondrial dysfunction and inducing reactive oxygen species. Cancer Res. 63(23):8138-44."
"465","PC010149","Sauane M, Lebedeva IV, Su ZZ, Choo HT et al. 2004. Melanoma differentiation associated gene-7/interleukin-24 promotes tumor cell-specific apoptosis through both secretory and nonsecretory products. Cancer Res. 64(9):2988-93."
"466","PC010152","Meigooni AS, H Zhang, JR Clark, 2004.  Dosimetric characteristics of the new RadioCoil(TM) 103Pd wire line source for use in permanent brachytherapy implants.  Med. Phys. 31(11):3095-3105.

"
"467","PC010155","Kimberly A. Kelly, Fred Reynolds, Ralph Weissleder, and Lee Josephson.   2004.  Fluorescein isothiocyanate¿hapten immunoassay for determination of peptide¿cell interactions.   Analytical Biochemistry 330:181¿185
"
"468","PC010155","'Xavier Montet, Ralph Weissleder, and Lee Josephson.  2006.  Imaging Pancreatic Cancer with a Peptide-Nanoparticle Conjugate Targeted to
Normal Pancreas.  Bioconjugate Chem. 17:905-911.'
"
"469","PC010155","Xavier Montet, Hushan Yuan, Ralph Weissleder and Lee Josephson.  2006.  Enzyme-based visualization of receptor¿ligand binding in tissues.  Lab Invest 1¿9.
"
"470","PC010159","Wadkins RM, Bearss D, Manikumar G, et al.  2004.  Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I.  Cancer Res 64:6679-6683.

"
"471","PC010159","Manikumar G, Wadkins RM, Bearss D, et al.  2004.  Camptothecin analogs with bulky, hydrophobic substituents at the 7-position via a Grignard reaction.  Bioorg Med Chem Lett 14:5377-5381.

"
"472","PC010159","Wadkins RM, Bearss D, Manikumar G, et al.  2004.  Topoisomerase I-DNA complex stability induced by camptothecins and its role in drug activity.  Curr Med Chem Anti-cancer Agents 4:327-334.

"
"473","PC010162","Lin X, Ryu KY, and Jhiang SM.  2004.  Cloning of the 5¿-flanking region of mouse sodium/iodide symporter and identification of a thyroid-specific and TSH-responsive enhancer.  Thyroid 14:19-27."
"474","PC010162","Knostman KA, Cho JY, Ryu KY, et al.  2004.  Signaling through 3',5'-cyclic adenosine monophosphate and phosphoinositide-3 kinase induces sodium/iodide symporter expression in breast cancer.  J Clin Endocrinol Metab 89:5196-5203.

"
"475","PC010162","·Marsee DK, Shen DHY, MacDonald LR, et al. 2004. Imaging of pulmonary tumors following NIS gene transfer using single photon emission computed tomography.  Gene Therapy 11:121-7
"
"476","PC010162","·Shen DHY, Marsee DK, Schaap J, et al. 2004. Effects of dose, intervention time and radionuclide on sodium iodide symporter (NIS) targeted radionuclide therapy.  Gene Therapy 11:161-169."
"477","PC010162","La Perle KM, Blomme EA, Capen CC, Jhiang SM (2003): Effect of Exogenous Human Sodium Iodide Symporter Expression on Growth of MATLyLu Cells. Thyroid 13:133-40."
"478","PC010162","La Perle KM, Shen D, Buckwalter TL, Williams B, Haynam A, Hinkle G, Pozderac R, Capen CC, Jhiang SM (2002): In vivo expression and function of the sodium iodide symporter following gene transfer in the MATLyLu rat model of metastatic prostate cancer. Prostate 50:170-8."
"479","PC010162","Lin X, Fischer AH, Ryu KY, et al.  2004.  Application of the Cre/loxP system to enhance thyroid-targeted expression of sodium/iodide symporter.  J Clin Endocrinol Metab 89:2344-2350."
"480","PC010174","Lyons LS, Rao S, Balkan W et. al. 2007. Ligand-Independent Activation of Androgen Receptors by Rho GTPase Signaling in Prostate Cancer. Mol Endocrinol 22(3):597-608."
"481","PC010174","Yang ES, Maiorino CA, Roos BA, et al.  2002.  Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer.  Mol Cell Endocrinol 186:69-79."
"482","PC010174","Knight SR, Welsh CF, Liu YQ, et al.  2004.  Deregulation of the Rho GTPase, Rac1, suppresses cyclin dependent kinase inhibitor p21cip in androgen independent human prostate cancer cells.  Oncogene 23:5513-22."
"483","PC010174","Burnstein KL.  2005.  Regulation of androgen receptor levels: implications for prostate cancer progression and therapy.  J Cell Biochem 95:657-69."
"484","PC010174","Lyons LS  Burnstein KL.  2006.  Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity.  Mol Endocrinol 20:1061-72."
"485","PC010174","Yang ES, Burnstein, KL.  2003.  Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm.  J Biol Chem 278:46862-8."
"486","PC010180","Semmes OJ, Feng Z, Adam BL, et al.  2005.  Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.  Clin Chem 51:102-112."
"487","PC010180","Malik G, Ward MD, Gupta SK, et al.  2005.  Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer.  Clin Cancer Res 11:1073-1085."
"488","PC010180","Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr (2002): Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62:3609-14."
"489","PC010180","Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, Feng Z, Semmes OJ, Wright GL Jr (2002): Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 48:1835-43."
"490","PC010180","·Qu Y, Adam BL, Thornquist M, et al.  2003.  Data reduction using discrete wavelet transform in discriminant analysis with very high dimension.  Biometrics 59:143-151."
"491","PC010180","·Yasui Y, Pepe M, Thompson ML, et al.  2003.  A data-analytic strategy for protein biomarker discovery: Profiling of high-dimensional proteomic data for cancer detection.  Biostatistics 4:449-463."
"492","PC010180","·Banez LL, Prasanna P, Sun L, et al.  2003.  Diagnostic potential of serum proteomic patterns in prostate cancer. J. Urol. 170:442-446."
"493","PC010180","·Yasui Y, McLerran D, Adam BL, et al.  2003.  An automated peak identification/calibration procedure for high-dimensional protein measures from mass spectrometers.  J. Biomed. Biotechnol. 4:242-248."
"494","PC010180","Wagner M, Naik DN, Pothen A, et al.  2004.  Computational protein biomarker prediction: a case study for prostate cancer.  BMC Bioinfomatics 11:26."
"495","PC010180","Yasui Y, Pepe M, Hsu L, et al.  2004.  Supervised learning using an EM-boosting algorithm.  Biometrics 60:199-206."
"496","PC010186","·Zurita AJ, Troncoso P, Cardo-Vila M, et al.  2004. Combinatorial screenings in patients: The interleulin-11 receptor alpha as a candidate target in the progression of human prostate cancer.  Cancer Research 64:435-439.

"
"497","PC010186","Arap MA, Lahdenranta J, Mintz PJ, et al.  Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands.  Cancer Cell 6:275-284."
"498","PC010201","Hodge JC, Bub J, Kaul S, Kajdacsy-Balla A, Lindholm PF (2003): Requirement of RhoA activity for increased nuclear factor kappaB activity and PC-3 human prostate cancer cell invasion. Cancer Res 63:1359-64."
"499","PC010201","Nithipatikom K, Isbell MA, Lindholm PF, Kajdacsy-Balla A, Kaul S, Campell WB (2002): Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion. Clin Exp Metastasis 19:593-601."
"500","PC010201","Hwang YS, Hodge JC, Sivapurapu N, et al. 2006. Lysophosphatidic acid stimulates PC-3 prostate cancer cell Matrigel invasion through activation of RhoA and NF-kappa B activity.  Mol Carcinog 45:518-29.
"
"501","PC010201","Yemelyanov A, Gasparian A, Lindholm PF, et al.  2005.  Effects of IKK inhibitor PS1145 on NF-kappa B function, proliferation, apoptosis and invasion activity in prostate carcinoma cells.  Oncogene advanced online publication: doi:10.1038/sj.onc.1209066."
"502","PC010201","Nithipatikom K, Borscheid CL, Kajdacsy-Balla A, et al.  2002.  Determination of cyclooxygenase and arachidonic acid metabolites in invasive human prostate cancer cells.  Adv Exp Med Biol 507:269-274."
"503","PC010211","Jones GB, Xie L, El-Shafey A, et al.  2004.  Image contrast agents activated by prostate specific antigen (PSA).  Bioorg Med Chem Lett 14:3081-3084."
"504","PC010211","Jones GB, Crasto CF, Mathews JE, et al.  2006.  An image contrast agent selectively activated by prostate specific antigen. Bioorg Med Chem 14(2):418-425."
"505","PC010217","Markushin Y, Gaikwad N, Zhang H, et al.  2006.  Potential biomarker for early risk assessment of prostate cancer.  Prostate 66(14):1565-1571."
"506","PC010219","·Kittles R and Weiss K.  2003.  Race, ancestry and genes: Implications for defining disease risk.  Annual Review of Genomics and Human Genetics 4:33-67."
"507","PC010219","Panguluri RC, Chen W, Wang S, et al. 2004. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis, 25(6):961-966."
"508","PC010219","·Hoggart C, Parra E, Shriver M, et al.  2003.  Control of confounding of genetic associations in stratified populations. American Journal of Human Genetics 72:1492-1504."
"509","PC010219","·Ukoli F, Akereyeni F, Okunzuwa O, et al.  2003.  Prevalence of elevated serum prostate specific antigen in rural Nigeria. International Journal of Urology 10:315-322."
"510","PC010219","·Shriver MD, Parra EJ, Dios C, et al.  2003.  Skin pigmentation, biogeographical ancestry and admixture mapping. Human Genetics 112:387-399."
"511","PC010219","·Collins-Schramm H, Kittles R, Operario D, et al.  2002. Markers that discriminate between European and African Ancestry show limited variation within Africa.  Human Genetics 111:566-569."
"512","PC010219","·Kittles RA, Chen W, Panguluri RK, et al.  2002.  CYP3A4-V and prostate cancer in African American: casual or confounding association because of population stratification?  Human Genetics 110:553-560."
"513","PC010219","·Pfaff C, Kittles R, and Shriver M.  2002.  Adjusting population structure in admixed populations.  Genetic Epidemiology 22:196-201."
"514","PC010219","Bonilla C, Mason T, Long L, et al. 2006. E-cadherin polymorphisms and haplotypes influence risk for prostate cancer. Prostate. 66:546-556."
"515","PC010219","Kittles RA, Boffoe-Bonnie A, Moses T, et al. 2006. A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J. Med. Genetics 43:507-11."
"516","PC010225","Krishnan AV, XY Zhao, S Swami, et al., 2002.  A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity:  Therapeutic implications for androgen-independent prostate cancer.  Encocrinology 143:1109-1900."
"517","PC010225","Krishnan AV, R Shinghal, N Raghavachari, et al., 2004.  Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays.  Prostate 59:243-251."
"518","PC010225","Peng L, Malloy PJ, Wang J, et al.  2006.  Growth inhibitory concentrations of androgens up- regulate insulin-like growth factor binding protein-3 (IGFBP-3) expression via an androgen response element in LNCaP human prostate cancer cells.  Endocrinology 147:4599-607."
"519","PC010225","Peng L, Malloy PJ, and Feldman D. 2004. Identification of a functional Vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Molecular Endocrinology. 18(5):1109-1119."
"520","PC010227","Parrish AR, Sallam K, Nyman DW, Orozco J, Cress AE, Dalkin BL, Nagle RB, Gandolfi AJ (2002): Culturing precision-cut human prostate slices as an in vitro model of prostate pathobiology. Cell Biol Toxicol 18:205-19."
"521","PC010231","Ye X1, Han SJ, Tsai SY, et al.  2005.  Roles of steroid receptor coactivator (SRC)-1 and transcriptional intermediary factor (TIF) 2 in androgen receptor activity in mice.  Proc Natl Acad Sci U S A 102(27):9487-9492."
"522","PC010237","Kiviharju-af Hällström TM, Jäämaa S, Mönkkönen M, et al. 2007. Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc Natl Acad Sci U S A 104:7211¿7216.
"
"523","PC010239","Tang Y, Borgstrom P, Maynard J, et al. Mapping of angiogenic markers for targeting of vectors to tumor vascular endothelial cells. Cancer Gene Ther 14(4):346-353."
"524","PC010240","Ressom H, Varghese RS, Orvisky E, et al.  2005.  Analysis of MALDI-TOF serum profiles for biomarker selection and sample classification.  Proceedings of the IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology, La Jolla, California, 378-384."
"525","PC010240","Ressom H, Varghese RS, Saha D, et al.  2005.  Particle swarm optimization for analysis of mass spectral serum profiles.  Genetic and Evolutionary Computation Conference, Washington, DC. (Beyer HG, et al. Eds.) 1:431-438."
"526","PC010240","Ressom H, Varghese RS, Abdel-Hamid M, et al.  2005.  Analysis of mass spectral serum profiles for biomarker selection.  Bioinformatics 21:4039-4045."
"527","PC010240","Orvisky E, Drake SK, Martin BM, et al.  2006.  Enrichment of low molecular weight fraction of serum for mass spectrometric analysis of peptides associated with hepatocellular carcinoma.  Proteomics 6:2895-2902."
"528","PC010242","Gabaglia CR, DeLaney A, Gee J, et al.  2010. Treatment combining RU486 and Ad5IL-12 vector attenuates the growth of experimentally formed prostate tumors and induces changes in the sentinel lymph nodes of mice. J Transl Med 8:98"
"529","PC010242","Raja Gabaglia C, Diaz de Durana Y, Graham FL, et al.  Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.  Cancer Res 67(5):2290-2297."
"530","PC010267","Ludewig G, Esch H, and Robertson LW.  2007.  Polyhalogenierte Bi- und Terphenyle.  In: (Dunkelberg H., Gebel T, Hartwig A, Eds.).  Handbuch der Lebensmitteltoxikologie, Wiley-VCH Weinheim, 1031-1094 (Chapter 20)."
"531","PC010267","Lehmann L, Esch HL, Kirby PA, et al.  2007.  4-Monochlorobiphenyl (PCB3) induces mutations in the livers of transgenic Fisher 344 rats.  Carcinogenesis 28:471-478."
"532","PC010267","Ptak A, Ludewig G, Kapiszewska M, et al.  2006.  Induction of cytochromes P450, caspase-3 and DNA damage by PCB3 and its hydroxylated metabolites in porcine ovary.  Toxicol Lett 166:200-211."
"533","PC010267","Vyas S, Parkin S, Robertson LW, et al.  2006.  2,5-Dichloro- 4'-methoxybiphenyl.  Acta Crystallogr Section E: Structure Reports Online E62(9):o4162-o4163."
"534","PC010267","Liu Y, Apak TI, Lehmler H-J, et al.  2006.  Hydroxylated polychlorinated biphenyls are substrates and inhibitors of human hydroxysteroid sulfotransferase SULT2A1.  Chem Res Toxicol 19:1420-1425."
"535","PC010267","Strathmann J, Schwarz M, Tharappel JC, et al.  2006.  PCB 153, a nondioxin-like tumor promoter, selects for beta-Catenin (Catnb) mutated mouse liver tumors.  Toxicol Sci 93:34-40."
"536","PC010267","Bender RP, Lehmler H-J, Robertson LW, et al.  2006.  Polychlorinated biphenyl quinone metabolites poison human topoisomerase II(alpha): Altering enzyme function by blocking the N-terminal protein gate.  Biochemistry 45:10140-10152."
"537","PC010267","Kania-Korwel I, Garrison AW, Avants JK, et al.  2006.  Distribution of chiral PCBs in selected tissues in the laboratory rat.  Environ Sci Technol 40:3704-3710."
"538","PC010267","Luthe G, Leonards PEG, Reijerink GS, et al. 2006.  Monofluorinated analogues of polybrominated diphenyl ethers (F-PBDEs) as analytical standards: Synthesis, NMR and GC-MS characterization and molecular orbital studies.  Environ Sci Technol 40:3023-3029."
"539","PC010267","Kunz S, Schmitz H-J, Buchmann A, et al.  2006.  Tumor promoting potency of PCBs 28 and 101 in rat liver.  Toxicol Lett 164:133-143."
"540","PC010267","Ptak A, Ludewig G, Robertson LW, et al.  2006.  In vitro exposure of porcine prepubertal follicles to 4-chlorobiphenyl (PCB3) and its hydroxylated metabolites: Effects on sex hormone levels and aromatase activity.  Toxicol Lett 164:113-122."
"541","PC010267","Wang L-Q, Lehmler H-J, Robertson LW, et al.  2006.  Polychlorobiphenylols are selective inhibitors of human phenol sulfotransferase 1A1 with 4-nitrophenol as a substrate.  Chem Biol Interact 159:235-246."
"542","PC010267","Suh Y, Buettner GR, Venkataraman S, et al.  2009.  UVA/B-induced formation of free radicals from decabromodiphenyl ether (Deca-BDE).  Environ Sci Technol 43(7):2581-2588."
"543","PC010267","
Luthe G, Boy RG, Jacobus J, et al.  2008.  Xenobiotic geometry and media pH determine cytotoxicity through solubility.  Chem Res Toxicol 21:1017-1027.  PMID: 18402468.
"
"544","PC010267","Robertson LW, Sulkowski W, and Hennig B.  2008.  Focus on PCBs: Recent advances in environmental distribution and health effects.  Environ Toxicol Pharmacol 25:2-127."
"545","PC010267","Luthe G, Jacobus JA, and Robertson LW.  2008.  Receptor interactions by polybrominated diphenyl ethers versus polychlorinated biphenyls: A theoretical structure-activity assessment.  Environ Toxicol Pharmacol 25(2):202-210."
"546","PC010267","Ludewig G, Lehmann L, Esch H, et al.  2008.  Metabolic activation of PCBs to carcinogens in vivo--A review.  Environ Toxicol Pharmacol 25(2):241-246.  PMID:  18452002; PMCID: PMC2364599."
"547","PC010267","Glauert HP, Tharappel JC, Lu Z, et al.  2008.  Role of oxidative stress in the promoting activities of PCBs.  Environ Toxicol Pharmacol 25(2):247-250.  NIHMSID #74041."
"548","PC010267","Jacobus JA, Flor S, Klingelhutz AJ, et al.  2008.  2-(4-chlorophenyl)-1,4-benzoquinone increases the frequency of micronuclei and shortens telomeres.  Environ Toxicol Pharmacol 25(2):267-272.  PMID: 18438462; PMCID: PMC2346440."
"549","PC010267","Ravoori S, Ayotte P, Srinivasan C, et al.  2008.  DNA damage associated with PCBs in the whole blood cells of Inuit.  Environ Toxicol Pharmacol 25(2):273-276."
"550","PC010267","Liu Y, Smart JT, Song Y, et al.  2009.  Structure-activity relationships for hydroxylated polychlorinated biphenyls as substrates and inhibitors of rat sulfotransferases and modification of these relationships by changes in thiol status.  Drug Metab Dispos 37(5):1065-1072."
"551","PC010267","Klosener J, Peters TM, Adamcakova-Dodd A, et al.  2009.  Innovative application of fluoro-tagging to trace airborne particulate and gas-phase polybrominated diphenyl ether exposures.  Chem Res Toxicol 22(1):179-186."
"552","PC010267","Pessah I, Lehmler H-J, Robertson LW, et al.  2009.  Enantiomeric specificity of (-)-2,2',3,3',6,6'-hexachlorobiphenyl ((-) - PCB 136) towards ryanodine receptor Types 1 and 2.  Chem Res Toxicol 22:201-207."
"553","PC010267","Li X, Parkin S, Robertson LW, et al.  2008.  4'-chlorobiphenyl-4- yl 2,2,2-trichloroethyl sulfate.  Acta Cryst.  E64 o246."
"554","PC010267","Song Y, Buettner G, Parkin S, et al.  2008.  Chlorination increases the persistence of semiquinone free radicals derived from polychlorinated biphenyl hydroquinones and quinones.  J Org Chem 73:8296-8304."
"555","PC010267","Tharappel JC, Lehmler H-J, Srinivasan C, et al.  2008.  Effect of antioxidant phytochemicals on the hepatic tumor promoting activity of 3,3',4,4'-tetrachlorobiphenyl (PCB-77).  Food Chem Toxicol 46:3467-3474.  PMID: 18796325; PMCID:  PMC2597727.

"
"556","PC010267","Venkatasubbaiah VA, Venkataraman S, Sarsour EH, et al.  2008.  Catalase ameliorates polychlorinated biphenyl-induced cytotoxicity in non-malignant human breast epithelial cells.  Free Radic Biol Med 45:1094-1102.  PMID: 18691649.

"
"557","PC010267","Glauert HP, Tharappel JC, Banerjee S, et al.  2008.  Inhibition of the promotion of hepatocarcinogenesis by 2,2',4,4',5,5'-hexachlorobiphenyl (PCB-153) by the deletion of the p50 subunit of NF-kB in mice.  Toxicol Appl Pharmacol 232:302-308 doi: 10.1016/j.taap.2008.06.013; PMID: 18644402; PMCID: PMC2583134."
"558","PC010267","Kania-Korwel I, Xie W, Hornbuckle KC, et al.  2008.  Enantiomeric enrichment of 2,2',3,3',6,6'-hexachlorobiphenyl (PCB 136) in mice after induction of CYP enzymes.  Arch Environ Contam Toxicol 55:510-517, DOI 10.1007/s00244-007-9111-4.  PMID: 18437444."
"559","PC010267","Telu S, Parkin S, Robertson LW, et al.  2008.  1,3,5-trichloro-2-methoxybenzene.  Acta Crystallographica Section E Structure Reports Online.  Acta Cryst E64, o424."
"560","PC010267","Hennig B, M Toborek, P Ramadass, et al.  Polychlorinated biphenyls, oxidative stress and diet.  Reviews in Food and Nutrition Toxicity 3:93-128."
"561","PC010267","Wangpradit O, Mariappan SV, Teesch LM, Michael et al.  2009.  Oxidation of 4-chlorobiphenyl metabolites to electrophilic species by prostaglandin H synthase.  Chem Res Toxicol 22:64-71."
"562","PC010267","Klosener J, Swenson DC, Robertson LW, et al.  2008.  Effects of fluoro substitution on 4-bromodiphenyl ether (PBDE 3).  Acta Cryst  B64, 108-119.  PMID: 18204217.
"
"563","PC010267","Sacco JC, Lehmler H-J, Robertson LW, et al.  2008.  Glucuronidation of polychlorinated biphenylols and UDPGA concentration in channel catfish liver and intestine.  Drug Metab Dispos 36:623-630.  PMID: 18180271."
"564","PC010267","Stemm DN, Tharappel JC, Lehmler H-J, et al.  2008.  Effect of dietary selenium on the promotion of hepatocarcinogenesis by 3,3',4,4'-tetrachlorobiphenyl and 2,2',4,4',5,5'-hexachlorobiphenyl.  Exp Biol Med 233:366-376.  PMID: 18296742."
"565","PC010267","Kania-Korwel I, Hornbuckle KC, Robertson LW, et al.  2008.  Influence of dietary fat on the enantioselective disposition of 2,2',3,3',6,6'-hexachlorobiphenyl (PCB 136) in female mice.  Food Chem Toxicol 46:637-644.  PMID: 17950514. NIHMSID # 40694."
"566","PC010267","Kania-Korwel I, Hornbuckle K, Robertson L, et al.  2008.  Dose-dependent enantiomeric enrichment of 2,2',3,3',6,6'-hexachlorobiphenyl in female mice.  Environ Toxicol Chem 27:299-305.  PMID: 18348647.

"
"567","PC010267","
Robertson LW, Berberian I, Borges T, et al.  2007.  Suppression of peroxisomal enzyme activities and cytochrome P-4504A isozyme expression by congeneric polybrominated and polychlorinated biphenyls.  PPAR Research 2007, 15481:5, 10.1155/2007/15481; PMID: 18274624; PMCID: PMC2220027.
"
"568","PC010267","
Zettner M, Flor S, Ludewig G, et al.  2007.  Quinoid metabolites of 4-monochlorobiphenyl (PCB3) induce gene mutations in cultured Chinese hamster V79 cells.  Toxicol Sci 100:88-98.
"
"569","PC010267","Bunaciu RP, Tharappel JC, Lehmler H-J, et al.  2007.  The effect of dietary glycine on the hepatic tumor promoting activity of polychlorinated biphenyls (PCBs) in rats.  Toxicology 239:147-155.  PMID: 17703865; PMCID: PMC2063585."
"570","PC010267","Sadeghi-aliabadi H, Chan K, Lehmler H-J, et al.  2007.  Molecular cytotoxic mechanisms of catecholic polychlorinated biphenyl metabolites in isolated rat hepatocytes.  Chem Biol Interact 167:184-192.  PMID: 17408604."
"571","PC010267","Luthe G, Swenson DC, and Robertson LW.  2007.  Influence of fluoro-substitution on the planarity of 4-chlorobiphenyl (PCB 3), Acta Crystallographica, Section B: Structural Science 63:319-327.  PMID: 17374943."
"572","PC010267","Ludewig G, Esch H, and Robertson LW.  2007.  Polyhalogenierte Bi- und terphenyle, chapter 20, In: Handbuch der Lebensmitteltoxikologie, (Dunkelberg H, Gebel T, and Hartwig A, Eds.).  Wiley-VCH Weinheim, pp 1031-1094."
"573","PC010267","Kania-Korwel I, Shaikh NS, Hornbuckle KC, et al.  2007.  Enantioselective disposition of PCB 136 (2,2',3,3',6,6'-hexachlorobiphenyl) in C57BL/6 mice after oral and intraperitoneal administration.  Chirality 19:56-66."
"574","PC010267","Lehmann L, Esch HL, Kirby PA, et al.  2007.  4-monochlorobiphenyl (PCB3) induces mutations in the livers of transgenic Fisher 344 rats.  Carcinogenesis 28:471-478."
"575","PC010267","Tampal NM, LW Robertson, C Srinivasan, and G Ludewig, 2003.  Polychlorinated biphenyls are not substrates for the multidrug resistance transporter-1.  Toxicol. Appl. Pharmacol. 187:168-177."
"576","PC010267","Hennig B, Reiterer G, Toborek M, et al.  2005.  Dietary fat interacts with PCBs to induce changes in lipid metabolism in mice deficient in low-density lipoprotein receptor.  Environ. Health Perspect. 113:83-87."
"577","PC010267","Glauert HP, Lu Z, Kumar A, et al.  2005.  Dietary vitamin E does not inhibit the promotion of liver carcinogenesis by polychlorinated biphenyls in rats.  Journal of Nutrition 135:283-286."
"578","PC010267","Hennig B, Toborek M, Ramadass P, et al.  2005.  Polychlorinated biphenyls, oxidative stress, and diet.  Reviews in Food and Nutrition Toxicity 3:93-128.

"
"579","PC010267","Ritchie JM, Via SL, Fuortes LJ, et al.  2005.  Comparison of proposed frameworks for grouping polychlorinated biphenyl congener data applied to a case-control pilot study of prostate cancer.  Environmental Research 98:104-113."
"580","PC010267","Hansen L, Machala M, Fischer L, et al.  2005.  Research needs identified at the Second PCB Workshop in Brno, Czech Republic, May 7-11, 2002.  Toxicological & Environmental Chemistry 87(3), 261¿265."
"581","PC010267","Ludewig G, Esch H, and Robertson LW.  2006.  Polyhalogenierte bi- und terphenyle.  
Handbuch der Lebensmitteltoxikologie, Wiley-VCH Weinheim.
"
"582","PC010267","Luthe G, Leonards PEG, Reijerink GS, et al.  Monofluorinated analogues of polybrominated diphenyl ethers (F-PBDEs) as analytical standards: Synthesis, NMR, and GC-MS characterization and molecular orbital studies.  Environ Sci Technol 40:3023-9."
"583","PC010267","Wang L-Q, Lehmler H-J, Robertson LW, et al.  2006.  Polychlorobiphenylols are selective inhibitors of human phenol sulfotransferase 1A1 with 4-nitrophenol as a substrate.  Chem.-Biol. Interactions 159:235-246."
"584","PC010267","Kodavanti PRS, Ward TR, Ludewig G, et al.  2005.  Polybrominated diphenyl ether (PBDE) effects in rat neuronal cultures: 14CPBDE accumulation, biological effects, and structure-activity relationships.  Toxicological Sciences 88:181¿192."
"585","PC010267","Kania-Korwel I, Hornbuckle KC, Peck A, et al.  2005.  Congener specific tissue distribution of Aroclor 1254 and a highly chlorinated environmental PCB mixture in rats.  Environmental Science & Technology 39:3513-3520."
"586","PC010267","Wang L-Q, Lehmler H-J, Robertson LW, et al.  2005.  In vitro inhibition of human hepatic and cDNA-expressed sulfotransferase activity with 3-Hydroxybenzo[a]pyrene by polychlorobiphenylols.  Environmental Health Perspectives 113:680-687."
"587","PC010267","Ptak A, Ludewig G, Lehmler H-J, et al.  2005.  Comparison of the actions of 4-chlorobiphenyl and its hydroxylated metabolites on estradiol secretion by ovarian follicles in primary cells in culture.  Reproductive Toxicology 20:57-64."
"588","PC010267","Esch H, Lehmann L, Robertson LW, Ludewig G.  2006.  4-Monochlorobiphenyl is mutagenic in the liver of transgenic BigBlue® rats. Naunyn-Schmiedeberg's Arch.  Pharmacol. 372:106."
"589","PC010267","Vyas SM, Parkin S, Robertson LW, et al.  2006.  4 -Chloro- 2¿,3¿-dimethoxybiphenyl.  Acta Crystallogr Section E: Structure Reports Online E62(9):o3639-o3640."
"590","PC010267","Kania-Korwel I, Shaikh NS, Hornbuckle KC, et al.  2007.  Enantioselective disposition of PCB 136 (2,2¿,3,3¿,6,6¿-hexachlorobiphenyl) in C57BL/6 mice after oral and intraperitoneal administration.  Chirality 19:56-66."
"591","PC010267","Sadeghi-Aliabadi H, Chan K, Lehmler HJ, et al.  2007.  Molecular cytotoxic mechanisms of catecholic polychlorinated biphenyl metabolites in isolated rat hepatocytes.  Chem Biol Interact 167:184-192."
"592","PC010267","Luthe G, Swenson DC, and Robertson LW.  2007.  Influence of fluoro-substitution on the planarity of 4-chlorobiphenyl (PCB 3).  Acta Crystallographica Section B 63:319-327."
"593","PC010269","Foos G, and CA Hauser, 2004.  The role of Ets transcription factors in mediating cellular transformation.  In:  Handbook of Experimental Pharmacology 166:259-75, Springer, Heidelberg and New York, in press."
"594","PC010270","Lee YJ Song YK Song JJ Siervo-Sassi RR Kim HR Li L Spitz DR Lokshin A Kim JH (2003): Reconstitution of galectin-3 alters blutahione content and potentiates TRAIL-induced cytotoxicity by dephosphorylation of Akt. Exp Cell Res.  288:21-34."
"595","PC010270","Lee, Y. J.,Song, J. J., Kim, J. H., Kim, H. R., Song, Y. K. 2003.  Low extracellular pH augments TRAIL-induced apoptotic cell death through the mitochondria-mediated caspase signal transduction pathway.  Experimental Cell Research 293:129-143."
"596","PC010273","Werner H and Roberts CT.  2003.  The IGF-I receptor gene: a molecular target for disrupted transcription factors.  Genes Chromosomes Cancer 36:113-120."
"597","PC010273","Wadsworth TL, Carroll JM, Roberts CT, et al.  2004.  Saw palmetto extract suppresses IGF-I signaling and induces SAPK/JNK phosphorylation in human prostate epithelial cells. Endocrinol 145:3205-3214."
"598","PC010273","Plymate SR, Tennant MK, Culp SH, et al.  2004.  Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF on proliferation and AR activity between localized and metastatic tumors. Prostate 61:276-290."
"599","PC010273","Pandini G, Mineo R, Frasca F, et al.  2005.  Androgens up-regulate the IGF-I receptor in prostate cancer cells.  Cancer Res 65:1849-1857."
"600","PC010281","Bowen C, Stuart A, Ju JH et al. 2007.  NKX3.1 homeodomain protein binds to topoisomerase I and enhances its activity. Cancer Res. Jan 15;67(2):455-64."
"601","PC010286","Elmore LW, Forsythe R, Forsythe H, et al.  2008.  Overexpression of telomerase-associated chaperone proteins in prostatic intraepithelial neoplasia and carcinomas. Oncol Rep 20(3):613-617."
"602","PC010286","Harvey SA, Jensen KO, Elmore LW, Holt SE (2002): Pharmacological approaches to defining the role of chaperones in aging and prostate cancer progression. Cell Stress Chaperones 7:230-4."
"603","PC010286","Compton SA, Elmore LW, Haydu K, et al.  2006.  Induction of NOS dependent telomere shortening after functional inhibition of Hsp90 in human tumor cells.  Mol Cell Biol 26:1452-1462."
"604","PC010300","Safavy A, Bonner JA, Waksal HW, Buchsbaum DJ, Gillespie GY, Khazaeli MB, Arani R, Chen DT, Carpenter M, Raisch KP (2003): Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjug Chem 14:302-10."
"605","PC010300","Safavy A, George GI, Vander Velde D, et al.  2004.  Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure. Bioconjugate Chem 15:1264-1274."
"606","PC010300","Safavy A, Khazaeli MB, Safavy K, et al.   2003.  Biodistribution and in vitro drug release kinetics of a radiolabeled paclitaxel-monoclonal antibody conjugate. Clin Cancer Res 9:6194s.

"
"607","PC010300","Safavy A, Raisch KP, Safavy K, et al.  2002.  Taxanemonoclonal
antibody covalent conjugates for targeted chemotherapy of cancer. Eur J Cancer 38:S128.
"
"608","PC010300","Safavy A, George GI, Vander Velde D, et al.  2004.  Drug release studies with site-specifically radioiodinated antibody conjugates. World J Nucl Med 3:236."
"609","PC010304","Qian DZ, Ren M, Wei Y, et al.  2005.  In vivo imaging of retinoic acid receptor beta-2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.  Prostate 64:20-8.

"
"610","PC010308","Hanisch L and Coyne J.  2006.  Validation of sternal conductance for detection of hot flashes in prostate cancer survivors.  Psychophysiology 44:189-93."
"611","PC010308","Hanisch L, Mao J, Kodransky M, et al.  2006.  Endogenous opioids and hot flashes still hypothetical.  Lancet 367(9505):92-93."
"612","PC010324","Haelens A, Tanner T, Denayer S, et al. 2007. The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. Cancer Res 67(9):4514-23."
"613","PC010324","Claessens F, Verrijdt G, Haelens A, et al.  2006.  Molecular biology of the androgen responses.  Andrologie 37:209-210."
"614","PC010324","Tanner T, Claessens F, and Haelens A.  2004.  The hinge region of the androgen receptor plays a role in proteasome-mediated transcriptional activation.  Ann N Y Acad Sci 1030:586-590."
"615","PC010324","Claessens F and Gewirth D.  2004.  DNA recognition by nuclear receptors.  Essays Biochem 40:59-72."
"616","PC010324","Callewaert L, Verrijdt G, Haelens A, et al.  2003.  Differential effect of small ubiquitin-like modifier: SUMO-ylation of the androgen receptor in the control of cooperativity on selective versus canonical response elements.  Mol Endocrinol 18:1438-1449."
"617","PC010324","Callewaert L, Verrijdt G, Haelens A, et al.  2004.  Differential effect of sumoylation of the androgen receptor in the control of cooperativity on selective versus canonical response element.  Mol. Endocrinol. 18:1438-49."
"618","PC010324","Shaffer P, Jivan A, Dollins DE, et al.  2004.  Structural basis of androgen receptor binding to selective androgen response elements.  Proc. Natl. Acad. Sci. USA 101:4758-4763."
"619","PC010324","Callewaert L, Van Tilborgh N, and Claessens F.  2006.  Interplay between two hormone-independent activation domains in the androgen receptor.  Cancer Res 66:543-553."
"620","PC010325","Saleh K and Smith NB.  2005.  A 63 element 1.75 dimensional ultrasound phased array for the treatment of benign prostatic hyperplasia.  BioMedical Engineering On-Line 4:39."
"621","PC010325","Sun L, Collins CM, Schiano J, et al.  2005.  Adaptive control for MRI-guided ultrasound hyperthermia treatment for prostate disease: in vivo and ex vivo results.  Mag Res Engineering 27B:51-63."
"622","PC010325","Saleh K and Smith NB.  2004.  Design and evaluation of a 3 x 21 element 1.75 dimensional tapered ultrasound phased array for the treatment of prostate disease.  Materials Research Innovation 8:121-124."
"623","PC010325","·Saleh K and Smith NB.  2004.  Two-dimensional ultrasound phased array design for tissue ablation for treatment of benign prostatic hyperplasia.  Inter. J. Hyperthermia 1:7-31."
"624","PC010325","Saleh K and Smith NB.  2004.  Two dimensional array design for tissue ablation for treatment of benign prosthetic hyperplasia.  Inter J Hyperthermia 20:7-31. 

"
"625","PC010326","Ma Q, Fu W, Li P, et al. 2009. FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment. Mol Endocrinol 23(2):213-25."
"626","PC010326","Li P, Lee H, Guo S, Unterman TG, Jenster G, Bai W (2003): AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol 23:104-18."
"627","PC010326","Yang Y, Hou L, Haller E, et al.  2005.  Suppression of activity of FOXO1 by FHL2 through SIRT1 mediated deacetylation.  EMBO J 24:1021-32."
"628","PC010326","Fu W, Ma Q, Chen L, et al. 2009. MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation. J Biol Chem 284(21):13987-4000."
"629","PC010333","Cui Y, Kelleher E, Straley E, et al.  2003. Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells.
Nature Medicine 9:952-958 "
"630","PC010338","Maceyka M, Nava V, Milstein S, and Spiegel S.  Aminoacylase 1 is a sphingosine kinase 1 interacting protein.  FEBS Lett. 568:30-4."
"631","PC010340","Titus MA, Gregory CW, Ford OH III, et al.  2005.  Steroid 5a-reductase isozymes I and II in recurrent prostate cancer.  Clin Cancer Res 11:4365-4371."
"632","PC010340","Titus MA, Schell MJ, Tomer KB, et al.  2005.  Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.  Clin Cancer Res 11:4653-4657."
"633","PC010340","Singh S, Kim D, Mohler JL.  2005.  Java web start based software for automated quantitative nuclear analysis of prostate cancer and benign prostate hyperplasia.  Bio Med Eng Online 4:31."
"634","PC010340","Singh SS, Kim D, Ford OH, and Mohler JL.  2005.  Automated nuclear analysis of prostate cancer and benign prostate hyperplasia.  Proceeding of Biomedical Engineering, IASTED International Conference on Software Engineering, p 95-98, Innsbruck, Austria, ACTA Press."
"635","PC010342","·Flesken-Nikitin A, Choi KC, and Eng JP.  2003.  Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium.  Cancer Res. 63:3459-3463."
"636","PC010342","Flesken-Nikitin A, Williams RM, Zipfel WR, et al.  2004.  Use of multiphoton imaging for studying cell migration in the mouse. In: (Guan J-L, Ed.). Methods in Molecular Biology, vol. 294: Cell Migration: Developmental Methods and Protocols. Totowa, New Jersey: Humana Press, Inc. 335-344."
"637","PC010342","Sharp DZ, Lee W-H, Nikitin AY, et al.  2002.  Minimal effects of dietary restriction on neuroendocrine carcinogenesis in Rb[+/-] mice.  Carcinogenesis 24:179-183."
"638","PC010342","Tsai KY, MacPherson D, Rubinson DA, et al.  2002.  ARF mutation accelerates pituitary tumor development in Rb[+/-] mice.  Proc Natl Acad Sci USA 99:16865-16870."
"639","PC010342","Nikitin AY, Liu CY, Fleskin-Nikitin A, et al.  2002.  Cell lineage-specific effects associated with multiple deficiencies of tumor susceptibility genes in Msh2(-/-)RB(+/-) mice.  Cancer Res 62:5134-5138."
"640","PC010342","·Zipfel WR, Williams RM, and Christie R.  2003.  Live tissue intrinsic emission microscopy using multiphoton-excited native fluorescence and second harmonic generation.  Proc. Natl. Acad. Sci. USA 100:7075-7080."
"641","PC010343","Sastry KS, Karpova Y, Kulik G. 2006. Epidermal growth factor protects prostate cancer cells from apoptosis by inducing BAD phosphorylation via redundant signaling pathways. J Biol Chem. 281(37):27367-77.
"
"642","PC010343","Sastry KS, Smith AJ, Karpova Y, Datta SR, Kulik G. 2006. Diverse antiapoptotic signaling pathways activated by vasoactive intestinal polypeptide, epidermal growth factor, and phosphatidylinositol 3-kinase in prostate cancer cells converge on BAD. J Biol Chem. 281(30):20891-901."
"643","PC010347","Huang X, T Raskovalova, A Lokshin, et al. 2005. Combined antiangiogenic and immune therapy of prostate cancer.  Angiogenesis 8:13-23.

"
"644","PC010350","Hui, Seng, Li, Xin, et. al. 2003.'Syntaxin 2 and Endobrevin ar Required for the Terminal Step of Ctyokinesis in Mammalian Cells.' Developmental Cell 4: 753-759."
"645","PC010350","Li X, Low SH, Miura M, Weimbs T (2002): SNARE expression and localization in renal epithelial cells suggest mechanism for variability of trafficking phenotypes. Am J Physiol Renal Physiol 283:F1111-22."
"646","PC010350","Kreitzer G, Schmoranzer J, Low SH, Li X, Gan Y, Weimbs T, Simon SM, Rodriguez-Boulan E (2003): Three-dimensional analysis of post-Golgi carrier exocytosis in epithelial cells. Nat Cell Biol 5:126-36."
"647","PC010350","Low SH, Marmorstein LY, Miura M, Li X, Kudo N, Marmorstein AD, Weimbs T (2002): Retinal pigment epithelial cells exhibit unique expression and localization of plasma membrane syntaxins which may contribute to their trafficking phenotype. J Cell Sci 115:4545-53."
"648","PC010352","Trendel JA1, Ellis N, Sarver JG,et al.  2008.  Catalytically active peptidylglycine alpha-amidating monooxygenase in the media of androgen-independent prostate cancer cell lines.  J Biomol Screen 13(8):804-809."
"649","PC010353","Freeman MR, Cinar B, and Lu ML.  2005.  Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer.  Trends Endocrinol Metab 16:273-9."
"650","PC010353","Cinar B, De Benedetti A, and Freeman MR.  2005.  Post-transcriptional regulation of the androgen receptor by the mammalian target of rapamycin.  Cancer Res 65:2547-
2553.
"
"651","PC010353","Zhuang L, Kim J, Adam RM, et al.  2005.  Cholesterol
targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts.  J Clin Invest 115:959-968.
"
"652","PC010353","·Cinar B, Yeung F, Konaka H, et al. 2004. Identification of a negative regulatory cis-element in the enhancer core region of prostate specific antigen (PSA) promoter: Implications for intersection of androgen receptor and NF-kappaB signaling in prostate cancer cells. Biochemical Journal 379:421-31.

"
"653","PC010353","·Freeman MR and Solomon KR. 2004. Cholesterol and prostate cancer. Journal of Cellular Biochemistry 91:54-69"
"654","PC010353","Zhuang L, Peng JB, Tou L, Takanaga H, Adam RM, Hediger MA, Freeman MR (2002): Calcium-selective ion channel, CaT1, is apically localized in gastrointestinal tract epithelia and is aberrantly expressed in human malignancies. Lab Invest 82:1755-64."
"655","PC010358","Meade-Tollin, L. C., Wijeratne, E. M., Cooper, D.  et al.  2003.  Ponicidin and oridonin are responsible for the antiangiogenic activity of Rabdosia rubescent, a constituent of the herbal supplement PC SPES. Journal of Natural Products 67:2-4."
"656","PC010375","Lim JTE and Weinstein IB.  2004.  Overexpression of CDK6 in LNCaP prostate cancer cells increases cell growth, colony formation and prostate specific antigen (PSA) expression and secretin.  Proc Am Assoc Cancer Res 45:445."
"657","PC010375","Lim JTE and Weinstein IB.  2003.  A novel role of CDK6 in androgen receptor signaling pathways.  Proc Am Assoc Cancer Res 44:818."
"658","PC010375","Lim JTE, M Mansukhani, and IB Weinstein, 2005.  Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity.  Proc. Natl. Acad. Sci., 102:5156-61."
"659","PC010381","Eggener SE, Stern JA, Jain PM, et al.  2006.  Enhancement of intermittent androgen ablation by off-cycle maintenance with finasteride in LNCaP prostate cancer xenograft model.  Prostate 66:495-502."
"660","PC010381","Wang Y, Gupta S, Hua V, et al.  2010.  Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor model.  Prostate 70(2):147-154."
"661","PC010383","·Wang S, Gao J, Lei Q, et al.  2003.  Prostate-specific deletion of the murine PTEN tumor suppressor gene leads to metastatic prostate cancer.  Cancer Cell 4:209-221."
"662","PC010383","Thomas GV and Sawyers CL.  Chapter 22.  Mechanistic concepts in the progression from androgen dependent to androgen independent prostate cancer.  In: Hormones and Cancer, 1st edition       [B. Henderson and R. Ross, Eds] Oxford University Press."
"663","PC010383","·Ellwood- Yen K, Graber TG, Wongvipat J, et al.  2003.  Myc-derived murine prostate cancer shares molecular features with human prostate tumors.  Cancer Cell 4:223-238."
"664","PC010384","Fornaro M, Manes T, Languino LR (2001): Integrins and prostate cancer metastases. Cancer Metastasis Rev 20:321-31."
"665","PC010384","Manes T, Zheng DQ, Tognin S, Woodard AS, Marchisio PC, Languino LR (2003): Alpha(v)beta3 integrin expression up-regulates cdc2, which modulates cell migration. J Cell Biol 161:817-26."
"666","PC010392","Bektas M, Payne S, Liu G, et al.  2005.  A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells. J Cell Biol 169: 801-811."
"667","PC010392","Spiegel S. and Milstien, S.  2005.  Critical role of acylglycerol kinase in epidermal growth factor-induced mitogenesis of prostate cancer cells. Biochem Soc Trans 33:1362-1365."
"668","PC010392","·Maceyka M and Spiegel S.   2003.  Sphingosine-1-phosphate receptors.  In: Handbook of Cell Signaling, Elsevier Science, 247-251."
"669","PC010392","·Spiegel S and Milstien S.  2003.  Sphingosine-1-phosphate: An enigmatic signaling lipid.  Nature Rev. Mol. Cell Biology    4:397-407."
"670","PC010392","·Spiegel S and Milstien S.  2003.  Exogenous and intracellularly generated sphingosine 1-phosphate can regulate cellular processes by divergent pathways. Biochem. Soc. Tran. 31:1216-1219."
"671","PC010392","·Watterson K, Sankala H, Milstien S, et al.  2003.  Pleiotropic actions of sphingosine 1- phosphate.  Prog. Lipid Res 42:344-357."
"672","PC010392","·Bektas M and Spiegel S.  2004.  Glycosphingolipids and cell death.  Glycoconj. Journal 20:39-47.

"
"673","PC010392","Payne SG, Milstien S, and Barbour SE.  2004.  Modulation of adaptive immune responses by sphingosine-1-phosphate.  Semin Cell Dev Biol 15:521-527."
"674","PC010392","Payne SG, Milstien S, Spiegel S (2002): Sphingosine-1-phosphate: dual messenger functions. FEBS Lett 531:54-7."
"675","PC010392","Spiegel S, Milstien S (2002): Sphingosine 1-phosphate, a key cell signaling molecule. J Biol Chem 277:25851-4."
"676","PC010392","Spiegel S, English D, Milstien S (2002): Sphingosine 1-phosphate signaling: providing cells with a sense of direction. Trends Cell Biol 12:236-42."
"677","PC010392","Maceyka M, Payne SG, Milstien S, Spiegel S (2002): Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. Biochim Biophys Acta 1585:193-201."
"678","PC010392","Bektas M. and Spiegel S.  2004.  Glycosphingolipids and cell death. Glycoconj J 20:39-47."
"679","PC010394","Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, Qian C, Marks AF, Slager SL, Peterson BJ, Smith DI, Cheville JC, Blute ML, Jacobsen SJ, Schaid DJ, Tindall DJ, Thibodeau SN, Liu W (2003): Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 72:270-80."
"680","PC010395","Shankar S, Chen X, and Srivastava RK.  2005.  Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo.  Prostate 62:165-186."
"681","PC010395","·Shankar S, Singh TR, and Srivastava RK. 2004. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. Prostate, 61(1):35-49."
"682","PC010395","Shankar S and Srivastava RK.  2004.  Enhancement of therapeutic potential of TRAIL in cancer by chemotherapy and irradiation: Mechanisms and clinical implications.  Drug Research Update 7:139-156."
"683","PC010401","Jung M, Y Zhang, A Dimtchev, et al., 2004.  Interstitial gene delivery in human xenograft prostate tumors using titanium metal seeds.  Molecular Cancer Therapeutics 3:655-59."
"684","PC010403","Zaveri NT, Sato BG, Jiang F, et al.  2009.  A novel peroxisome proliferator-activated receptor delta antagonist, SR13904, has anti-proliferative activity in human cancer cells.  Cancer Biol Ther 8(13):1252-1261."
"685","PC010404","Huber JS DSQJea (2001): Conceptual design of a compact positron tomograph for prostate imaging.  IEEE Trans. Nucl. Sci 48:1506-1511."
"686","PC010406","Takanaga H, B Mackenzie, Y Suzuki, and MA Hediger, 2005.  Identification of mammalian praline transporter, SITI (SLC6A20) with characteristics of classical system imino.  J. Biol. Chem. 280(10):8974-84."
"687","PC010424","Fowke JH, Motley SS, Wills M, et al.  2007. Prostate volume modifies the association between obesity and prostate cancer or high-grade prostatic intraepithelial neoplasia.  Cancer Causes Control 18(4):375-384."
"688","PC010424","Fowke JH, Motley SS, Cookson MS, et al.  2007.  The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis 10(2):137-142."
"689","PC010427","Wu TG1, Perdigão JR, Umhoefer TK, et al.  2009.   Heterogeneous interleukin-15 inducibilities in murine B16 melanoma and RM-1 prostate carcinoma by interferon-alpha treatment.  J Interferon Cytokine Res 29(11):719-728."
"690","PC010427","Wu TG, Rose WA II, Albrecht TB, et al.  2007.  IFN-alpha-induced murine B16 melanoma cancer vaccine cells:  induction and accumulation of cell-associated IL-15.  J Interferon Cytokine Res 27:13-22."
"691","PC010427","Fleischmann WR, Jr., and TG Wu, 2005.  Development of an Interferon-based Cancer Vaccine Protocol:  Applications to Several Types of Murine Cancers.  In DJJ Carr, ed., Interferon Methods and Protocols, Totowa:  Humana Press.

"
"692","PC010427","Fleischmann WR, Jr., and TG Wu, 2004.  Development of a vaccine against cancers.  Medicinski Razgledi 43(suppl. 5):51-61."
"693","PC010431","Gududuru V, Hurh E, Dalton JT, et al.  2005.  Discovery of 
2-arylthiazolidine-4-carboxylic acid amides as a new class of cytotoxic agents for prostate cancer.  J Med Chem 48:2584-2588.
"
"694","PC010431","Gududuru V, Hurh E, Sullivan J, et al.  2005.  SAR studies of 2 arylthiazolidine-4-carboxylic acid amides:  A novel class of cytotoxic agents for prostate cancer.  Bioorg Med Chem Lett 15:4010-4013."
"695","PC010435","Simpson MA, Reiland J, Burger SR, et al.  2001.  Hyaluronan synthase elevation in metastatic prostate carcinoma cells correlates with hyaluronan surface retention, a prerequisite for rapid adhesion to bone marrow endothelial cells.  J Biol Chem 276:17949-17957."
"696","PC010435","·Simpson MA WCaMJ (2002): Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am. J. Pathol.  161:849-857."
"697","PC010435","Bullard KM, Kim HR, Wheeler MA, et al.  Hyaluronan synthase-3 is upregulated in metastatic colon carcinoma cells and manipulation of expression alters matrix retention and cellular growth.  Int J Cancer 107:739-746"
"698","PC010435","McCarthy JB and Simpson MA.  2003.  Hyaluronan in prostate cancer progression.  Glycoforum.  (Web based- http://www.glycoforum.gr.jp/)."
"699","PC010435","Simpson MA, Wilson CM, Furcht LT, et al.  2002.  Manipulation of hyaluronan synthase expression in prostate adenocarcinoma cells alters pericellular matrix retention and adhesion to bone marrow endothelial cells.  J Biol Chem 277:10050-10057."
"700","PC010436","·Posey JT, Soloway MS, Ekici S, et al.  2003.  Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer.  Cancer Res. 63(10): 2638-2644."
"701","PC010436","Isoyama T, Thwaites D, Selzer MG, et al.  2006.  Differential selectivity of hyaluronidase inhibitors toward acidic and basic hyaluronidases.  Glycobiology 16:11-21."
"702","PC010436","Cohen BL, Gomez P, Omori Y, et al.  2006.  Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence.  Int J Cancer 119:1082-7."
"703","PC010436","Lokeshwar VB, Cerwinka WH, Lokeshwar BL.  2005.  HYAL1 hyaluronidase: A molecular determinant of bladder cancer growth and invasion.  Cancer Res 65:2243-50.

"
"704","PC010436","Franzmann E, Schroeder GL, Goodwin GJ, et al.  2003.  Expression of tumor markers, hyaluronic acid and hyaluronidase, in head and neck tumors.  Int J Cancer 106:438-445."
"705","PC010436","Ekici S, Cerwinka WH, Duncan RC, et al.   2004.  Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL1), CD44v6 and microvessel density for prostate cancer.  
Int J Cancer 112:121-129.
"
"706","PC010436","Dandekar DS, Lokeshwar VB, Cevallos-Ariello E, et al.  2003.  An orally active Amazonian plant extract (birm) inhibits prostate cancer growth and metastasis.  Cancer Chemother Pharmalcol 52:59-66."
"707","PC010436","Lokeshwar VB, Cerwinka WH, and Lokeshwar BL.  HYAL1 hyaluronidase in prostate cancer: A tumor promoter and a suppressor.  Cancer Res 65:7782-7789."
"708","PC010436","Lokeshwar VB, Schroeder GL, Carey RI, Soloway MS, Iida N (2002): Regulation of hyaluronidase activity by alternative mRNA splicing. J Biol Chem 277:33654-63."
"709","PC010448","Fei B, Wang H, Muzic RF, et al. (2006). Deformable and rigid registration of MRI and microPET images for photodynamic therapy of cancer in mice, Medical Physics, 33:753-60.

"
"710","PC010448","Fei B, Duerk D, Sodee D, et al.  2005.  Semiautomatic nonrigid registration for the prostate and pelvic MR volumes.  Acad Radiol, 12:815-24.
"
"711","PC010448","Fei B, Lee Z, Duerk J, et al.  2003.  Slice to volume registration and its potential application to interventional MRI guided radiofrequency thermal ablation of prostate cancer.  IEEE Transactions on Medical Imaging 22:515-525.
"
"712","PC010448","·Fei BW, Lee Z, Boll DT, et al.  2003.  Image registration and fusion for interventional MRI guided thermal ablation of prostate cancer.  Lecture Notes in Computer Science   2879:364-372."
"713","PC010448","·Fei BW, Lee Z, Duerk JL, et al.  2003.  Image registration for interventional MRI guided procedures: similarity measurements, interpolation methods, and applications to the prostate. Lecture Notes in Computer Science 2717:221-229."
"714","PC010448","Fei BW, Lee Z, Duerk JL, et al.  2004.  Registration and fusion of SPECT, high resolution MRI and interventional MRI for thermal ablation of prostate cancer.  IEEE Transductions on Nuclear Science 51:177-183."
"715","PC010448","Fei B, Duerk JL, Wilson DL (2002): Automatic 3D registration for interventional MRI-guided treatment of prostate cancer. Comput Aided Surg 7:257-67."
"716","PC010448","Fei B, Kemper C, Wilson DL (2003): A comparative study of warping and rigid body registration for the prostate and pelvic MR volumes. Comput Med Imaging Graph 27:267-81."
"717","PC010449","·Mohler JL, Gregory CW, Ford OH, et al.  2004.  The androgen axis in recurrent prostate cancer.  Clin. Cancer Res.    10:440-448."
"718","PC010449","·Ford OH, Gregory CW, Collins Q, et al.  2003.  Androgen receptor gene amplification and protein expression in recurrent prostate cancer.  J. Urology 170:1817-1821."
"719","PC010449","·Calvo BF, Levine AM, Marcos M, et al.  2003.  Human epidermal receptor-2 expression in prostate cancer.  Clin. Cancer Res. 9:1087-1097."
"720","PC010449","·Gregory CW, Fei X, Pontuta LA, et al.  2004.  Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer.  J. Biol. Chem. 279:7119-7130."
"721","PC010449","Gregory CW, Whang YE, McCall W, et al.  2005.  Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.  Clin Cancer Res 11:1704-12."
"722","PC010449","He B, Gampe RT, Kole AJ, et al.  2004.  Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance.  Mol Cell 16:425-438."
"723","PC010449","Bai S, He B, and Wilson EM.  2005.  Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction.  Mol Cell Biol 25:1238-1257."
"724","PC010449","He B, Bai S, Hnat AT, et al.  2004.  An androgen receptor NH2-terminal signature motif interacts with carboxyl terminus of Hsp70-interacting protein CHIP.  J Biol Chem 279:30643-30653."
"725","PC010449","He B, Gampe RT, Hnat AT, et al.  2006.  Probing the functional link between androgen receptor coactivator and ligand binding sites in prostate cancer and androgen insensitivity.  J Biol Chem 281:6648-6663."
"726","PC010458","Freedland SJ PAPSZAGTEDMWNDTCBAS (2003): Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system. Prostate 55:299-307."
"727","PC010458","Freedland SJ SDLAPAPSHSWJZANDTCPABAS (2003): Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate 55:71-80."
"728","PC010458","·Singh S, Sadacharan S, Su S, et al. (2003)  Overexpression of vimentin: Role in the invasive phenotype in an androgen-independent model of prostate cancer.  Cancer Research 63:2306-2311.

"
"729","PC010458","·An S, Sun YP, Adams J, et al. (2003)  Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha and TNF-related apoptosis-inducing ligand in prostate cancer.  Clinical Cancer Research 9:4537-4545."
"730","PC010458","Liu AY, Brubaker KD, Goo YA, et al.  2004.  Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines.  Prostate 60:98-108."
"731","PC010459","·Lee ECY, Packman K, and Tenniswood M.  2003.  Antiandrogen induced cell death in LNCaP human prostate cancer cells.  Cell Death Differentiation 10:761-771."
"732","PC010459","·Lee ECY and Tenniswood M.  2004.  Programmed cell death and survival pathways in prostate cancer cells.  Arch. Androl 50:27-32."
"733","PC010459","·Lee ECY and Tenniswood M.  2004.  Emergence of metastatic hormone refractory disease in prostate cancer after anti-androgen therapy. Journal of Cellular Biochemistry 91:662-70."
"734","PC010459","Lee EC, Tenniswood MP. 2004.  Emergence of metastatic hormone-refractory disease in prostate cancer after anti-androgen therapy.  J Cell Biochem 91(4):662-670."
"735","PC010459","Tenniswood M, Lee EC. 2004.  On the trail of cell death pathways in prostate cancer. Cancer Biol Ther 3(8):769-771."
"736","PC010459","Zhan P, Lee EC, Packman K, Tenniswood M (2002): Induction of invasive phenotype by Casodex in hormone-sensitive prostate cancer cells. J Steroid Biochem Mol Biol 83:101-11."
"737","PC010461","Anilkumar G, Rajasekaran SA, Wang S, Hankinson O, Bander NH, Rajasekaran AK (2003): Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. Cancer Res 63:2645-8."
"738","PC010461","Christiansen JJ, Rajasekaran SA, Moy P, Butch A, Goodglick L, Gu Z, Reiter RE, Bander NH, Rajasekaran AK (2003): Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured"
"739","PC010461","·Rajasekaran SA, Anilkumar E, Oshima E, et al.  2003.  A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen.  Mol. Biol. Cell.   14:4835-4845. 

"
"740","PC010461","Rajasekaran AK, G Anilkumar, and J Christiansen.  Is prostate specific membrane antigen a multifunctional protein?  Amer. J. Phys., Cell Phys., 288:C975-81."
"741","PC010461","Christiansen JJ, S Rajasekaran, L chung, et al.  N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen:  Implications for immunotherapy.  Mol. Cancer Ther., 4:704-14.

"
"742","PC010461","Christiansen J, Rajasekaran S, Inge L, et al.  2005.  N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy.  Mol Cancer Ther 4(5):704-14.
"
"743","PC010461","Rajasekaran AK, Anilkumar G, and Christiansen J.  2005.  Is prostate-specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol 288:C975-C981.

"
"744","PC010463","Hanks BA, Jiang J, Singh R, et al.  2005.  Re-engineered CD40 receptor enables potent pharmacological activation of dendritic cell cancer vaccines in vivo.  Nature Med 11:130-7.
 
"
"745","PC010468","Saika T1, Kusaka N, Mouraviev V, et al.  2006.  Therapeutic effects of adoptive splenocyte transfer following in situ AdIL-12 gene therapy in a mouse prostate cancer model.  Cancer Gene Ther 13(1):91-98."
"746","PC010468","Saika T, Kusaka N, Mouraviev V, et al.  2006.  Therapeutic effects of adoptive splenocyte transfer following in situ AdIL-12 gene therapy in a mouse prostate cancer model.  Cancer Gene Ther 13:91-8."
"747","PC010468","·Satoh T, Saika T, Ebara S, et al.  2003.  Macrophages transduced with adenoviral vectors to express IL-12 suppress tumor growth and metastasis in pre-clinical models of prostate cancer.  Cancer Research 63:7853-7860."
"748","PC010468","Saika T, Satoh T, Kusaka N, et al.  Route of administration influences the anti-tumor effects of bone marrow derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model. Cancer Gene Therapy 11:317-24."
"749","PC010476","Schwarze SR, Fu VX, Desotelle JA, Kenowski ML, Jarrard DF. 2005. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. Neoplasia. 7(9):816-823."
"750","PC010476","Faith D, Han S, Lee DK, Friedl A, Hicks JL, De Marzo AM, Jarrard DF. 2005. p16 is upresgulated in proliferative inflammatory atrophy of the prostate. Prostate. 65(1):73-82."
"751","PC010476","Schwarze SR, Luo J, Isaacs WB, Jarrard DF. 2005. Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate. 64(1):67-74."
"752","PC010476","Atwood CS, Barzilai N, Brown-Borg HM, et al.  2003.  Pennington Scientific Symposium on Mechanisms and Retardation of Aging.  Exp Gerontol 38:1217-1226."
"753","PC010476","Fu VX, Schwarze SR, Grabert L, et al.  2004.  A loss of IGF2 imprinting in modulated by CTCF downregulation at senescence in human epithelial cells.  J Biol Chem 279:52218-52226."
"754","PC010477","Claessens F and Gewirth DT.  2004.  DNA recognition by nuclear receptors.  Essays Biochem 40:59-72."
"755","PC010480","Thompson TA, and G Wilding, 2003.  Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells.  Mol. Cancer Therap. 2:797-803."
"756","PC010480","Church DR, E Lee, TA Thompson, et al., 2004.  Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells.  Prostate 63:155-68."
"757","PC010480","Mehraein-Ghomi F, Lee E, Church DR, et al.  2008.  JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells.  Prostate 68(9):924-934. "
"758","PC010482","·Schwarze SR, Fu VX, and Jarrard FD.  2003.  Cdc37 enhances proliferation and is necessary for normal human prostate epithelial cell survival. Cancer Res. 63:4614-4619."
"759","PC010488","Gully J, Arlen Ph, Bastian A, et al.  2005.  Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer.  Clin Cancer Res 11:3353-62.
"
"760","PC010489","Chen M, Fu YY, Lin CY, et al. 2007 Prostasin induces protease-dependent and independent molecular changes in the
human prostate carcinoma cell line PC-3. Biochim Biophys Acta 1773(7):1133-1140."
"761","PC010489","Lin HY, Zhang H, Yang Q, et al.  2006.  Expression of prostasin and protease nexin-1 in rhesus monkey (Macaca mulatta) endometrium and placenta during early pregnancy.  J Histochem Cytochem 54:1139-47."
"762","PC010489","Chen LM, Wang C, Chen MQ, et al.  2006.  Prostasin attenuates inducible nitric oxide synthase expression in lipopolysaccharide-induced urinary bladder inflammation.  Am J Physiol Renal Physiol 291:F567-77."
"763","PC010489","Chen MQ, Chen LM, and Chai KX.  2006.  Androgen regulation of prostasin gene expression is mediated by sterol-response element-binding proteins and SLUG.  Prostate 66:911-20."
"764","PC010489","Narikiyo T, Kitamura K, Adachi M, Miyoshi T, Iwashita K, Shiraishi N, Nonoguchi H, Chen LM, Chai KX, Chao J, Tomita K (2002): Regulation of prostasin by aldosterone in the kidney. J Clin Invest 109:401-8."
"765","PC010489","Chen, L. M., Zhang, X., Chai, K. X.  2004.  Regulation of prostasin expression and function in the prostate 59:1-12."
"766","PC010489","Chen MQ, Chen LM, and Chai KX.  2006.  Mechanisms of sterol regulatory element binding 
protein-2 (SREBP-2) regulation of human prostasin gene expression.  Biochem Biophys Res Commun 346:1245-53."
"767","PC010490","Hamilton-Reeves JM, Rebello SA, Thomas W, et al.  2007.  Soy protein isolate increases urinary estrogens and the ratio of 2:16alpha-hydroxyestrone in men at high risk of prostate cancer. J Nutr  137:2258-2263."
"768","PC010490","Hamilton-Reeves JM, Rebello SA, Thomas W, et al.  2007.  Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor beta expression or serum hormonal profiles in men at high risk of prostate cancer.  J Nutr 137(7):1769-1775."
"769","PC010490","Hamilton-Reeves J and Kurzer MS.  2003.  Effects of soy isoflavone consumption on reproductive hormones in males.  Soy Connection 11(4):3-5."
"770","PC010496","Weng J, Ma W, Mitchell D, Zhang J, Liu M. 2005. Regulation of human prostate-specific G-protein-coupled receptor, PSGR, by two distinct promoters and growth factors. J. Cell Biochem. 96(5):1034-1048."
"771","PC010496","Guo X, Stafford LJ, Bryan B, Xia C, Ma W, Wu X, Liu D, Songyang Z, Liu M (2003): A Rac/Cdc42-specific exchange factor, GEFT, induces cell proliferation, transformation, and migration. J Biol Chem 278:13207-15."
"772","PC010496","Weng J, J Wang, Y Cai, et al., 2005.  Increased expression of prostate-specific G-protein coupled receptor (PSGR) in human prostate intraepithelial neoplasia (PIN) and prostate cancers.  Int. J. Cancer 113(5):811-8."
"773","PC010496","Weng J, Wang J, Hu X, Wang F, Ittman M, Liu M. 2006. PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer. Int. J. Cancer. 118(6):1471-1480."
"774","PC010497","Chirgwin JM, Mohammad KS, and Guise TA.  2004.  Tumor-bone cellular interactions in skeletal metastases.  J Musculoskelet Neuronal Interact 4:308-318."
"775","PC010497","Clines GR, Chirgwin JM, and Guise TA.  2004.  Skeletal complications of malignancy: Central role of the osteoblast.  
In: Topics in Bone Biology Vol 2."
"776","PC010497","Guise TA and Chirgwin JM.  2004.  Biology of bone metastases.  In: Diseases of the Breast 3rd Edition.  Harris, Lippman, Morrow, and Osborne (eds).  Lippincott Williams & Wilkins, 1285-1296.

"
"777","PC010497","Graham Solomons JT, Burns S, Wessner L, et al.  2004.  The crystal structure of mouse phosphoglucose isomerase* at 1.6 &#506; resolution and its complex with glucose 6-phosphate reveals the mechanism of sugar ring opening.  J Mol Biol 342:847-860. (*Phosphoglucose isomerase is identical to tumor autocrine motility factor, which plays an established role in tumor progression, including prostate cancer)."
"778","PC010497","Guise TA, Kozlow WM, Heras-Herzig A, et al.  2004.  Molecular mechanisms of breast cancer metastases to bone.  Clin Breast Cancer 5:S46-53.

"
"779","PC010499","Sardar VM, Bautista DL, Fischer DJ, et al. 2002. Molecular basis for lysophosphatidic acid receptor antagonist selectivity.  Biochemica et Biophysica Acta. 1582:309-317.
 
"
"780","PC010499","Parrill AL, Sardar VM, and Yaun H. 2004. Sphingosine 1-phosphate and lysophosphatidic acid receptors: Agonist and antagonist binding and progress towards development of receptor-specific ligands. Sem Cell Dev Biol. 15:467-76."
"781","PC010499","Virag T, Elrod DB, Liliom K, Sardar VM, Parrill AL, Yokoyama K, Durgam G, Deng W, Miller DD, Tigyi G (2003): Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol Pharmacol 63:1032-42."
"782","PC010501","Ghosh J.  2004.  Rapid induction of apoptosis in prostate cancer cells by selenium: Reversal by metabolites of arachidonate 5-lipoxygenase.  Biochem Biophys Res Commun 315:624-635.

"
"783","PC010501","·Ghosh J and Myers CE.  2002.  Molecular mechanisms of prostate cancer cell death triggered by inhibition of arachidonate     5-lipoxygenase: Involvement of Fas death receptor-mediated signals.  Adv. Exp. Med. Biol. 507:415-420."
"784","PC010501","Sarveswaran S, Thamilselvan V, Brodie C, et al.  2011. Inhibition of 5-lipoxygenase triggers apoptosis in prostate cancer cells via down-regulation of protein kinase C-epsilon. 
Biochim Biophys Acta 1813(12):2108-2117."
"785","PC010501","Sarveswaran S, Myers CE, Ghosh J. 2010. MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 3'-kinase.  Cancer Lett 291(2):167-176."
"786","PC010501","·Ghosh J.  2003.  Inhibition of arachidonate 5-lipoxygenase triggers prostate cancer cell death through rapid activation of c-Jun N-terminal kinase.  Biochem. Biophys. Res. Commun. 307:342-349."
"787","PC010501","Sundaram S and Ghosh J.  2006.  Expression of 5-oxoETE receptor in prostate cancer cells: Critical role in survival.  Biochem Biophys Res Commun 339:93-98."
"788","PC010503","Korokhov N1, Mikheeva G, Krendelshchikov A,et al.  2003,Targeting of adenovirus via genetic modification of the viral  capsid combined with a protein bridge. J Virol 77(24):12931-12940. "
"789","PC010505","Fan X, Du W, MacEneaney P, Zamora M, Karczmar G (2002): Structure of the water resonance in small voxels in rat brain detected with high spectral and spatial resolution MRI. J Magn Reson Imaging 16:547-52."
"790","PC010505","Fan X, Medved M, River J, et al.  2004.  A new model for analysis of dynamic contrast enhanced MRI data distinguishes metastatic from non-metastatic rodent prostate tumors.  Magn Reson Med 51(3):487-94."
"791","PC010505","Medved M, Karczmar G, Dignam J, et al.  2004.  Semi-quantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time.  Magn Reson Imaging 20:122-8."
"792","PC010505","Medved M, Newstead G, Fan X, et al.  2004.  Fourier components of inhomogeneously broadened water resonances in breast a new source of contrast.  Magn Reson Med 52(1):193-6.

"
"793","PC010505","Du W, Fan X, Foxley S, et al.  2005.  Comparison of high resolution echo-planar spectroscopic imaging with conventional MR imaging of prostate tumors in mice.  NMR Biomed 18:285-292."
"794","PC010505","Fan X, Medved M, Foxley S, et al.  2006.  Multi-slice dynamic contrast-enhanced MRI using P760 distinguishes between metastatic and non-metastatic rodent prostate tumors.  MAGMA 19:15-21."
"795","PC010505","Karczmar GS, Fan X, Al-Hallaq H, River JN, Tarlo K, Kellar KE, Zamora M, Rinker-Schaeffer C, Lipton MJ (2002): Functional and anatomic imaging of tumor vasculature: high-resolution MR spectroscopic imaging combined with a superparamagnetic contrast agent."
"796","PC010505","Du W, Karczmar GS, Uftring S, Du YP, et al.  2005.  Anatomic and functional brain imaging using high resolution echo-planar spectroscopic imaging at 1.5 Tesla.  NMR Biomed 18:235-241."
"797","PC010505","Du W, Du YP, Fan X, Zamora MA, Karczmar GS (2003): Reduction of spectral ghost artifacts in high-resolution echo-planar spectroscopic imaging of water and fat resonances. Magn Reson Med 49:1113-20."
"798","PC010505","Du W, Karczmar GS, Pan X (2002): Effects of constant frequency noise in magnetic resonance imaging with nonuniform k-space sampling. Med Phys 29:1832-8."
"799","PC010507","Patri AK, Kukowska-Latallo JF, Baker JR, et al.  2005.  Targeted drug delivery with dendrimers: Comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Del Rev (57)2203-2214.

"
"800","PC010507","Patri AK, Myc A, Beals J, et al.  2004.  Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjugate Chem (15)1174-1181."
"801","PC010507","Patri AK, Myc A, Beals J, et al.  2004.  Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjugate Chem 15:1174-1181. 

"
"802","PC010513","·Markiewicz MA and Kast WM. 2003. Advances in immunotherapy for prostate cancer. Advances in Cancer Research.87:159-94."
"803","PC010513","·Poole CL, Bommiasamy H, and Kast WM. 2003. Recent progress in tumor vaccine development. Expert Opinion Investigating Drugs 12(6):971-981.

"
"804","PC010516","Zhu YS, Cai LQ, Huang Y, et al.  2005.  Receptor isoform and ligand specific modulation of DHT-induced PSA gene expression and prostate tumor cell growth by estrogens.  (Editorial Commentary: Dehm, SM, Tindall DJ.)  J Androl 26:509¿510."
"805","PC010516","Zhu YS and Sung GF.  2005.  5alpha-reductase isozymes in the prostate.  J Med Sci 25:1-11."
"806","PC010516","Cai LQ, Cai J, Wu W, et al. 2011. 17¿-Estradiol and genistein inhibit high fat diet induced prostate gene expression and prostate growth in the rat. J Urol 186(4):1489-96."
"807","PC010516","Cai LQ, Imperato-McGinley J, and Zhu YS.  2006.  Regulation of prostate 5alpha-reductase-2 gene expression and prostate weight by dietary fat and caloric intake in the rat.  Prostate, 66:738-748."
"808","PC010516","Zhu YS, Cai LQ, Huang Y, et al.  2005.  Receptor isoform and ligand specific modulation of DHT-induced PSA gene expression and prostate tumor cell growth by estrogens.  J Androl 26:500-508."
"809","PC010520","·Louie MC, Yang HQ, Ma AH, et al.  2003.  Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex.  Proc. Natl. Acad. Sci. 100:2226-2230."
"810","PC010520","Chen KY, Huang LM, Kung HJ, et al.  2003.  The role of tyrosine kinase Etk/Bmx in EGF-induced apoptosis of MDA-MB-468 breast cancer cells.  Oncogene 23(10):1854-1862.

"
"811","PC010520","Jiang T, Guo Z, Dai B, et al.  2004.  Bi-directional regulation between tyrosine kinase Etk/BMX and tumor suppressor p53 in response to DNA damage.  J Biol Chem 279:50181."
"812","PC010520","Mayeur GL, Kung WJ, Martinez A, et al.  2005.  Ku is a novel transcriptional recycling coactivator of the androgen receptor in prostate cancer cells.  J Biol Chem 280:11:10827-33."
"813","PC010520","Xia L, Robinson D, Ma AH, Chen HC, Wu F, Qiu Y, Kung HJ (2002): Identification of human male germ cell-associated kinase, a kinase transcriptionally activated by androgen in prostate cancer cells. J Biol Chem 277:35422-33."
"814","PC010520","Lee LF, Guan JL, Qia Y, et al.  2001.  Neuropeptide-induced androgen independence in prostate cancer cells: The roles of non-receptor tyrosine kinases Etk/Bmx, Src and FAK.  Mol Cell Biol 21:8385-8397."
"815","PC010520","·Lee LF, Louie MC, Desai SJ, et al.  2004.  Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.  Oncogene 23:2197-205."
"816","PC010522","Safe S, McDougal A (2002): Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers (Review). Int J Oncol 20:1123-8."
"817","PC010522","·Morrow D, Qin C, Smith III, R, et al.  2004.  Aryl hydrocarbon receptor-mediated inhibition of LNCaP prostate cancer cell growth and hormone-induced transactivation.  J. Steroid Biochem. Mol. Biol. 88:27-36."
"818","PC010523","Yano S, Macleod RJ, Chattopadhyay N, et al.  2004.   Calcium Sensing Receptor Activation Stimulates Parathyroid Hormone Related Protein Secretion in Prostate Cancer Cells: Role of Epidermal Growth Factor Receptor Transactivation.  Bone 35:664-672."
"819","PC010523","Sanders JL, Chattopadhyay N, Kifor O, Yamaguchi T, Brown EM (2001): Ca(2+)-sensing receptor expression and PTHrP secretion in PC-3 human prostate cancer cells. Am J Physiol Endocrinol Metab 281:E1267-74."
"820","PC010531","·Onuma M, Bub JD, Rummel TL, et al.  2003.  Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase.  J. Biol. Chem. 278:42660-42667."
"821","PC010531","Miyazaki T, Bub JD, Iwamoto Y.  2008. c-Jun NH(2)-terminal kinase mediates leptin-stimulated androgen-independent prostate cancer cell proliferation via signal transducer and activator of transcription 3 and Akt. Biochim Biophys Acta 1782(10):593-604."
"822","PC010531","Miyazaki T, Bub JD, Uzuki M, et al.  2005.  Adiponectin activates c-Jun NH2-terminal kinase and inhibits signal transducer and activator of transcription 3. Biochem Biophys Res Commun 333(1):79-87."
"823","PC010531","Nithipatikom K, Endsley MP, Isbell MA, et al.  2004.  
2-Arachidonoylglycerol inhibits invasion of androgen-independent prostate cancer cells.  Cancer Res 64:8826-8830.
"
"824","PC010531","Zhang G, Chen F, Xu Y, et al.  2004.  Autocrine overexpression of fibronectin by human transitional carcinoma cells impairs bacillus Calmette-Guerin adherence and signaling.  J Urol 172:1496-1500."
"825","PC010531","·Chen F, Zhang G, Iwamoto Y, et al.  2003.  Bacillus Calmette-Guerin initiates intracellular signaling in a transitional carcinoma cell line by cross linking a5b1 integrin.  J. Urol. 170:605-610."
"826","PC010531","Welte T, Zhang SS, Wang T, Zhang Z, Hesslein DG, Yin Z, Kano A, Iwamoto Y, Li E, Craft JE, Bothwell AL, Fikrig E, Koni PA, Flavell RA, Fu XY (2003): STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci U S A 100:1879-84."
"827","PC010531","Chen FH, Crist SA, Zhang GJ, Iwamoto Y, See WA (2002): Interleukin-6 production by human bladder tumor cell lines is up- regulated by bacillus Calmette-Guerin through nuclear factor-kappaB and Ap-1 via an immediate early pathway. J Urol 168:786-97."
"828","PC010531","Bub JD, Miyazaki T, Iwamoto Y. 2006. Adiponectin as a growth inhibitor in prostate cancer cells.  Biochem Biophys Res Commun 340(4):1158-1166."
"829","PC010531","·Kano A, Wolfgang MJ, Gao Q.  2003.  Endothelial cells require STAT3 for protection against endotoxin-induced inflammation.  J. Exp. Med. 198:1517-1525.

"
"830","PC010531","·Chen F, Langenstrort P, Zhang G, et al.  2003.  Androgen dependent regulation of bacillus Calmette-Gurin-induced IL-6 expression in human transitional carcinoma cell lines.       J. Urol. 170:2009-2013."
"831","PC010531","Jacoby JJ, Kalinowski A, Liu M, et al.  2003.  Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age.  Proc. Natl. Acad. Sci. USA 100:12929-12934."
"832","PC010536","Hongo F, Huerta-Yepez S, Vega M, et al.  2005.  Inhibition of the transcription factor Yin Yang 1 (YY1) activity by S-nitrosation.  Biochem Biophys Res Commun 336:692-701.

"
"833","PC010536","Jazirehi AR, Vega M, Odabaei G, et al.  2004.  Rituximab-mediated inhibition of the Raf-1-MEK1/2-ERK1/2 signaling pathway and chemosensitization of non-hodgkin¿s lymphoma B-cells: Involvement of Raf-1 kinase inhibitor protein (RKIP) and Bcl-[xL] expression.  Cancer Res 64:7117-7126."
"834","PC010536","Ng CP, Bonavida B (2002): X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Mol Cancer Ther 1:1051-8."
"835","PC010536","Ng CP, Bonavida B (2002): A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross- resistance. Adv Cancer Res 85:145-74."
"836","PC010536","Ng CP, Zisman A, Bonavida B (2002): Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate 53:286-99."
"837","PC010536","Huerta-Yepez S, Vega M, Jazirehi A, et al.  2004.  Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappaB and inhibition of Bcl-xL expression.  Oncogene 23:4993-5003."
"838","PC010536","Gordon S, Akopyan G, Garban H, et al.  2006.  Transcription factor YY1: Structure, function, and therapeutic implications in cancer.  Oncogene 25:1125-42."
"839","PC010536","Bonavida B, Huerta-Yepez S, Goodglick L, et al.  2005.  Can we develop biomarkers that predict response of cancer patients to immunotherapy?  Biomarkers 10(1):69-76."
"840","PC010536","Bonavida B.  2006.  Principles of tumor immunology.  In: Nutritional Oncology (Herber D, Ed.)."
"841","PC010536","Seligson D, Horvath S, Huerta-Yepez S, et al.  2005.  Expression of transcription factor Yin Yang 1 in prostate cancer.  Int J Oncol 27(1):131-141."
"842","PC010536","Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T (2003): Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 169:1670-5."
"843","PC010536","Mizutani Y, Matsubara H, Yamamoto K, et al.  2004.  Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.  Cancer 101(8):1794-1802.

"
"844","PC010536","Odabaei G, Chatterjee D, Jazirehi AR, et al.  2004.  Raf-1 kinase inhibitor protein (PKIP): Structure, function, regulation of cell signaling and pivotal role in apoptosis.  Adv Cancer Res 91:169-200."
"845","PC010536","Jazirehi AR, Gan X-H, De Vos S, et al.  2003.  Rituximab (anti-CD20) selectively down-regulates Bcl-[xL] and up-regulates Apaf-1 in non-hodgkin¿s lymphoma (NHL) b-cells: Complementation with paclitaxel results in synergy in apoptosis.  Mol Cancer Ther 2:1183-1193."
"846","PC010536","Hansch C, Jazirehi A, Medapati SB, et al.  2003.  QSAR of apoptosis induction in various cancer cells.  Bioorg Med Chem 11:3015:3019."
"847","PC010536","Frost B, Caliliw R, Belldegrun A, et al.  2003.  Immunosensitzation of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes (TIL).  Int J Oncol 22(2):431-437."
"848","PC010537","Dwivedi PP, PH Anderson, JL Omdahl, et al., 2005.  Identification of growth factor independent-1 (GFI1) as a repressor of 25-hydroxyvitamin D 1-alpha hydroxylase (CYP27B1) gene expression in human prostate cancer cells.  Endocrine Related Cancer 12:1-15."
"849","PC010538","·Chandra D and Tang DG.  2003.  Mitochondrially-localized active caspase-9 and caspase-3 results mostly from translocation from cytosol and partly from caspase-mediated activation in the organelle: Lack of evidence for         Apaf-1-mediated procaspase-9 activation in the mitochondria.        J. Biol. Chem. 278:17408-17420."
"850","PC010538","Chandra D, Choy G, Tang DG.  2007.  Cytosolic accumulation of HSP60 during apoptosis with or without apparent mitochondrial release: evidence that its pro-apoptotic or pro-survival functions involve differential interactions with caspase-3.  J Biol Chem 282(43):31289-31301."
"851","PC010538","Chandra D, Liu JW, Tang DG. 2002. Early mitochondrial activation and cytochrome c up-regulation during apoptosis. J Biol Chem. 277(52):50842-54."
"852","PC010538","Chandra D, Choy G, Deng X, et al. 2004. Association of active caspase 8 with the mitochondrial membrane during apoptosis: potential roles in cleaving BAP31 and caspase 3 and mediating mitochondrion-endoplasmic reticulum cross talk in etoposide-induced cell death. Mol Cell Biol. 24(15):6592-607."
"853","PC010541","Buchsbaum DJ, Chaudhuri TF, Yamamoto M, Zinn KR. 2004. Gene expression imaging with radiolabeled peptides. Ann. Nucl. Med. 18(4):275-283."
"854","PC010541","Kaliberov SA, Kaliberova LN, Stockard CR, Grizzle WE, Buchsbaum DJ. 2004. Adenovirus-mediated FLT1-targeted proapototic gene therapy of human prostate cancer. Mol. Ther. 10(6):1059-1070."
"855","PC010541","Buchsbaum DJ, Chaudhuri TR, Zinn KR. 2005. Radiotargeted gene therapy. J. Nucl. Med. 46 Suppl 1:179S-186S."
"856","PC010551","Emelianov SY, Hamilton MF, Ilinskii YU A, et al.  2004.  Nonlinear dynamics of a gas bubble in an incompressible elastic medium.  J Acoust Soc Am 115:581-588."
"857","PC010555","Lin HK, YC Hu, L Yang, et al., 2003.  Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers.  J. Biol. Chem. 278:50902-50907."
"858","PC010555","Lin HK, YC Hu, DK Lee, and C Chang, 2004.  Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells.  Mol. Endoocrinol. 18:2409-2423."
"859","PC010555","Lin HK, Hu YC, Yang L, et al. 2003.  Suppression versus induction of androgen receptor funtions by the phosphatidyinositol3-kinase/Akt pathway in PC LNCaP cells with different passage numbers. JBiol Chem.  278(51):50902-50907"
"860","PC010562","Ramaswamy S, Nakamura N, Sansal I, Bergeron L, Sellers WR (2002): A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell 2:81-91."
"861","PC010562","Sansal I and Sellers WR.  2004.  The biology and clinical relevance of the PTEN tumor suppressor pathway.  J Clin Oncol 22:2954-2963."
"862","PC010563","Knudsen BS and Edlund M.  2004.  Prostate cancer and the Met hepatocyte growth factor receptor.  Adv Cancer Res 91:32-67."
"863","PC010566","Britt DE, DF Yang, DQ Yang, et al., 2004.  Identification of a novel protein, LYRIC, localized to tight junctions of polarized epithelial cells.  Exp. Cell Res. 300:134-148."
"864","PC010575","Gery S, and HP Koeffler, 2003.  Repression of the TMEFF2 promoter by c-Myc.  J. Mol. Biol. 328:977-83."
"865","PC010575","Gery S, D Yin, D Xie, et al., 2003.  TMEFF1 and brain tumors. Oncogene 22:2723-7."
"866","PC010577","Okazaki T and Sakamuro D.  2007.  Induction of Fas (CD95/APO-1) ligand is essential for p53-dependent apoptosis in an in vitro renal carcinoma model system.  J Cancer Res Clin Oncol 133:581-588."
"867","PC010577","Pyndiah S, Tanida S, Ahmed KM, et al.  2011.  c-MYC suppresses BIN1 to release poly(ADP--ribose) polymerase 1: A mechanism by which cancer cells acquire cisplatin resistance.  Sci Signal 4(166):ra19."
"868","PC010577","Kumari A, Iwasaki T, Pyndiah S, Cassimere EK, Palani CD, Sakamuro D. 2015. Regulation of E2F1-induced apoptosis by poly(ADP-ribosyl)ation. Cell Death Differ. 22(2):311-22."
"869","PC010577","Cassimere EK, Pyndiah S, and Sakamuro D.  2009.  The c-MYC-interacting proapoptotic tumor suppressor BIN1 is a transcriptional target for E2F1 in response to DNA damage.  Cell Death & Diff 16:1641-1653."
"870","PC010577","Kinney EL, Tanida S, Rodrigue AA, et al.  2008.  Adenovirus E1A oncoprotein liberates c-Myc activity to promote cell proliferation through abating Bin1 expression via an Rb/E2F1-dependent mechanism.  J Cell Physiol 216:621-631."
"871","PC010582","Zhou L, Civitello ER, Gupta N, et al.  2005.  Endowning RNas H-inactive antisense with catalytic activity: 2-5A-Morphants.  Bioconjug Chem 16(2):383-390."
"872","PC010582","
Torrence PF, Civitello E, Powell L, et al.  2003.  Harnessing the 2-5A system: A new therapeutic approach to prostate cancer.  Recent Research Developments in Nucleosides and Nucleotides 1:49-58.
"
"873","PC010583","Mazzone M, Baldassarre M, Beznoussenko G, et al.  2004.  Intracellular processing and activation of membrane type 1 matrix metalloprotease depends on its partitioning into lipid domains.  J Cell Sci 117:6275-6287."
"874","PC010583","Pavlaki, M., Cao, J., Hymowitz, M., Chen, W. T., Bahou, W., Zucker, S  2002.  A conserved sequence within the propeptide domain of membrane type 1 matrix metalloproteinase is critical for function as an intra-molecular chaperone. Journal of Biochemistry 277(4):2740-2749."
"875","PC010583","Zucker, S., Hymowitz, M., Conner, C., DeClerck, Y., Cao, J.   2004.  TIMP-2 is released as an intact molecule following binding to MT1-MMP on the cell surface. Experimental Cell Research 293:164-74"
"876","PC010583","Jiang C, Wang Z, Ganther H, Lu J (2002): Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther 1:1059-66."
"877","PC010583","Zucker S, Doshi K, and Cao J.  2004.  Measurement of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMP) in blood and urine: Potential clinical applications.  Adv Clin Chem 38:37-85."
"878","PC010583","Zucker, S., Pei, D. , Cao, J. , Lopez-Otin, C. .  2003.  Membrane type-matrix metalloproteinases (MT-MMP). Current Top Development Biology 54:1-74."
"879","PC010583","Chandra D, Liu JW, Tang DG (2002): Early mitochondrial activation and cytochrome c up-regulation during apoptosis. J Biol Chem 277:50842-54."
"880","PC010583","Caudroy, S. , Polette, M., Nawrocki-Raby, B., Cao, J., Toole, B. P., Zucker, S., Birembaut, P.   2002.  EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clinical Experimental Metastasis 19(8):697-702."
"881","PC010591","Brewer CF, Miceli MC, Baum LG (2002): Clusters, bundles, arrays and lattices: novel mechanisms for lectin- saccharide-mediated cellular interactions. Curr Opin Struct Biol 12:616-23."
"882","PC010591","·He J and Baum LG.  2004.  Presentation of galectin-1 by extracellular matrix triggers T cells death.  J. Biol. Chem. 2004 Feb 6: 279 (6): 4705-12.

"
"883","PC010599","·Kemp TJ, Elzey BD, Griffith TS.  2003.  Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation.  J. Immunol. 171:212-218."
"884","PC010599","Ludwig AT, Moore JM, Luo Y, et al.  2004.  TNF-related apoptosis inducing ligand (TRAIL/Apo-2L): A novel mechanism for BCG-induced anti-tumor activity. Cancer Res 64:3386-3390."
"885","PC010599","Kemp TJ, Moore IM, and Griffith TS.  2004.  Human B cells express functional TRAIL/Apo-2L after CpG ODN stimulation. J Immunol 173:892-899.

"
"886","PC010599","VanOosten RL, Moore IM, Ludwig AT, et al.  Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.  Mol Ther 11:542-552."
"887","PC010599","·Kemp TJ, Kim JS, Crist SA, et al.  2003.  Induction of necrotic tumor cell death by TRAIL/Apo-2L.  Apoptosis 8:587-899."
"888","PC010599","·Griffith TS and Kemp TJ.  2003.  The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.  Cancer Chemother. Pharmacol. 52:175-184"
"889","PC010614","Hernandez J, Balic I, Johnson-Pais TL, et al. 2006.  Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men.
J Urol.175(2):523-7.
"
"890","PC010614","Verheul HM, Qian DZ, Carducci MA, et al. 2007. Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. Cancer Chemother Pharmacol. 60(3):329-339."
"891","PC010614","Hall DC, Johnson-Pais TL, Grubbs B, et al. 2008. Maspin reduces prostate cancer metastasis to bone. Urol Oncol 26(6):652-658."
"892","PC010614","Vijayakumar S, Hall DC, Reveles XT, et al. 2006.  Detection of recurrent copy number loss at Yp11.2 involving TSPY gene cluster in prostate cancer using array-based comparative genomic hybridization. Cancer Res.66(8):4055-64.  
"
"893","PC010614","·Padalecki SS, KS Weldon, XT Reveles, et al.  2003.  Chromosome 18 suppresses prostate cancer metastases.  Urologic Oncology 21: 366-373."
"894","PC010614","Schwartz Z, Graham EJ, Wang L, J Cell Physiol. 2005.  Phospholipase A2 activating protein (PLAA) is required for 1alpha,25(OH)2D3 signaling in growth plate chondrocytes. J Cell Physiol. 2005 Apr;203(1):54-70.
"
"895","PC010617","Sun YX, Schneider A, Jung Y, et al.  2005.  Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.  J Bone Miner Res 20:318-329."
"896","PC010617","Zhou H, Wu T, Wu X, et al.  2004.  Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4 chemokine receptor.  Cancer Res 64:4302-4308."
"897","PC010617","Cooper CR, Sikes RA, Nicholson BE, et al.  2004.  Cancer cells homing to bone: the significance of chemotaxis and cell adhesion. Cancer Treat Res 118:291-309."
"898","PC010617","Havens A, Wang J, Sun YX, et al.  2003.  The role of CD164 in metastatic cancer.  University of Michigan Undergraduate Research Opportunity Program Book."
"899","PC010633","Heltemes LM, Hagan CR, Mitrofanova EE, Panchal RG, Guo J, Link CJ (2003): The rat sodium iodide symporter gene permits more effective radioisotope concentration than the human sodium iodide symporter gene in human and rodent cancer cells. Cancer Gene Ther 10:14-22."
"900","PC010633","·Mitrofanova E, Hagan C, Qi J, et al.  2003.  Sodium iodide symporter/radioactive iodine system has a more efficient antitumor effect in a three dimensional structure.  Anticancer Research 23:2397-2404."
"901","PC010633","Mitrofanova E, Unfer R, Vahanian N, et al.  2004.  Rat sodium iodide symporter (rNIS) for radioiodide therapy of cancer.  Clin Cancer Res 10:6969-6976."
"902","PC010633","Mitrofanova E, Unfer R, Vahanian N, et al.  2005.  Effective growth arrest of a human colon cancer in mice, using rNIS and radioiodine therapy. Human Gene Ther 16:1333-1337.

"
"903","PC010633","Mitrofanova E, Unfer R, Vahanian N, et al.  2006.  Rat sodium iodide symporter allows using
lower dose of 131I for cancer therapy. Gene Ther 13:1052-6.

"
"904","PC010634","·Kurizaki T, Abe M, Sanderson SD, et al.  2004.  Role of polymorphonuclear leukocytes, nitric oxide synthase, and cyclooxygenase in vascular permeability changes induced by C5a agonist peptides.  Mol. Cancer Ther. 3:1-7."
"905","PC010634","Kurizaki T, Okazaki S, Sanderson SD, et al.  2002.  Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a. J Nucl Med 43:957-967."
"906","PC010634","Wittel UA, Jain M, Goel A, et al.  2005.  Engineering and characterization of a divalent single-chain Fv angiotensin II fusion construct of the monoclonal antibody CC49.  Biochem Biophys Res Commun 329:168-176."
"907","PC010645","·Crespo, CJ, and Arbesman J.  2003, Review.  Obesity in the United States: A worrisome epidemic.  The Physician and Sports Medicine 31:23-28."
"908","PC010645","·Crespo CJ and Smit E.  2003.  Prevelence of overweight and obesity in the United States.  In: Obesity: Etiology, Assessment, Treatment and Prevention (Andersen, RE, Ed.). Human Kinetics Publishers, Inc., Champaign, IL."
"909","PC010645","Garcia-Palmieri MR, Crespo C, McGee D, et al.  2005.  Wide pulse pressure is an independent predictor of cardiovascular mortality in Puerto Rican men.  Nutr Metab Cardiovasc Dis 15:71-8."
"910","PC010645","Garcia-Palmieri Mr, Crespo CJ, et al.  2005.  Wild pulse pressure as a risk factor for cardiovascular mortality: Results from the Puerto Rico Heart Health Program.  Nutrition Metabolism and Cardiovascular Disease 15:71-78."
"911","PC010645","Rohrman S, Giovanucci E, Smit E, et al.  2005.  Association of cigarette smoking, alcohol consumption, and physical activity with lower urinary tract symptoms in older U.S. men in the third national health and nutrition examination survey (NHANESA III).  Br J Urol 96:77-82."
"912","PC010645","Borrell L, Crespo CJ, and Garcia-Palmieri MR.  2007.  Skin color and mortality risk among men: The Puerto Rico Heart Health Program.  Ann Epidemiol 17:335-41."
"913","PC010645","Crespo CJ.  2005.  Physical activity in minority populations: Overcoming a public health challenge.  President¿s Council on Physical Fitness and Sports.  Research Digest."
"914","PC010645","Smit E, Garcia-Palmieri MR, Figueros NR, et al.  2007.  Protein and legume intake and prostate cancer mortality in Puerto Rican men.  Nutr Cancer 58:146-52."
"915","PC010651","·Huang Q, Zhang X, Wang H, et al.  2004.  A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells.  Clinical Cancer Res 10:1439-1445."
"916","PC010651","Liu S, Wang H, Yang Z, et al.  2005.  Enhancement of cancer radiation therapy by use of adenovirus-mediated secretable glucose-regulated protein 94/gp96 expression.  Adv Cancer Res 65(20):9126-9131.

"
"917","PC010654","Li Y, Malaeb BS, Li ZZ, et al.  2010.  Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer. Prostate 70(6):616-629."
"918","PC010654","Canales BK, Li Y, Thompson MG, et al. 2006.  Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model.  Urologic Oncology: Seminars and Original Investigations, 24:141-151."
"919","PC010654","·Chen Z, Koeneman KS and Corey DR.  2003.  Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells.  Cancer Research 63:5917-5925.

"
"920","PC010659","O'Mahony OA, Steinkamp MP, Albertelli MA, et al. 2008. Profiling human androgen receptor mutations reveals treatment effects in a mouse model of prostate cancer. Mol Cancer Res 6(11):1691-701."
"921","PC010659","Simanainen U, Brogley M, Gao YR, et al. 2011. Length of the human androgen receptor glutamine tract determines androgen sensitivity in vivo. Mol Cell Endocrinol 342(1-2):81-6."
"922","PC010659","Robins DM, Albertelli MA, and O'Mahony OA. 2008. Androgen receptor variants and prostate cancer in humanized AR mice. J Steroid Biochem Mol Biol 108(3-5):230-6."
"923","PC010659","Albertelli MA, O'Mahony OA, Brogley M, et al. 2008. Glutamine tract length of human androgen receptors affects hormone-dependent and -independent prostate cancer in mice. Hum Mol Genet 17(1):98-110."
"924","PC010659","Albertelli MA, Scheller A, Brogley M, et al. 2006. Replacing the mouse androgen receptor with human alleles demonstrates glutamine tract length-dependent effects on physiology and tumorigenesis in mice. Mol Endocrinol 20(6):1248-60."
"925","PC010659","Steinkamp MP, O'Mahony OA, Brogley M, et al. 2009. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 69(10):4434-42."
"926","PC010659","Yu Z, Dadgar N, Albertelli M, et al.  2006.  Abnormalities of germ cell maturation and Sertoli cell cytoskeleton in androgen receptor113 CAG knock-in mice reveal toxic effects of the mutant protein.  Am J Pathol, 168:195-204.

"
"927","PC010660","Kasai M, Guerrero-Santoro J, Friedman R, Leman ES, et al. 2003. The Group 3 LIM Domain protein paxillin potentiates androgen receptor transactivation in prostate cancer cell lines. Cancer Research 63:4927-4935."
"928","PC010661","Carmody J, Olendzki B, Reed G, et al.  2008. A dietary intervention for recurrent prostate cancer after definitive primary treatment: Results of a randomized pilot trial.  Urology 72:1324-8."
"929","PC010665","Connell PP, Siddiqui N, Hoffman S, et al.  2004.  A hot spot for RAD51C interactions revealed by a peptide that sensitizes cells to cisplatin.  Cancer Res 1;64(9):3002-3005."
"930","PC010671","Minev BR, Guo F, Gueorguieva I, Kaiser HE (2002): Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects. In Vivo 16:405-15."
"931","PC010674","Bonfil RD, Sabbota A, Nabha S, et al. 2006.  Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor.  Int J Cancer 118:2721-6.

"
"932","PC010674","Bianco FJ, Wood DP, Cher ML, et al.  2003. Ten-year survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate cancer. Clin Prostate Cancer 1:242-7."
"933","PC010674","Chinni SR, Sivalogan S, Dong Z, et al.  CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12.  Prostate 66:32-48."
"934","PC010674","Deng X, Bhagat S, Filetti LC, et al.  2003.  Genetic modification of human bone with TIMP-1 and -2 adenoviral vectors to create a hostile microenvironment for prostate cancer metastasis.  Proc AACR 44:3337A."
"935","PC010674","Deng X, Bhagat S, Dong Z, et al.  2006.  Tissue inhibitor of metalloproteinase-3 induces apoptosis in prostate cancer cells and confers increased sensitivity to paclitaxel.  Eur J Cancer  42:3267-73."
"936","PC010674","Podgorski I, Linebaugh BE, Sameni M, et al.  2005. Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer.  Neoplasia 7:207-23."
"937","PC010674","Li Y, Kucuk O, Hussain M, et al.  Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer.  Cancer Res 66:4816-25."
"938","PC010674","Dong Z, Bonfil RD, Chinni, S, et al.  2005.  Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol 166:1173-86."
"939","PC010677","Gonzalez JR, Pena EA, and Slate EH.  2005.  Modeling intervention effects after cancer relapses.  Statistics in Medicine 24:3959-3975."
"940","PC010677","Pena EA and Slate EH.  2006.  Global validation of linear model assumptions.  Journal of the American Statistical Association 101(473):341-353."
"941","PC010677","Inoue LYT, Etzioni R, Slate E, et al. 2004.  Combining longitudinal studies of PSA.  Biostatistics 5(3):483-500."
"942","PC010687","·Chen L, Smith L, Wang Z, et al.  2003.  Preservation of caspase-3 subunits from degradation contributes to apoptosis evoked by lactacystin: any single lysine or lysine pair of the small subunit is sufficient for ubiquitination.  Molecular Pharmacology 64:334-345."
"943","PC010690","·Schrantz N, da Silva Correia J, Fowler B, et al.  2003.  Mechanism of p21-activated kinase 6-mediated inhibition of androgen receptor signaling.  Journal of Biological Chemistry 279:1922-1931."
"944","PC010690","Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z (2002): Linking beta-catenin to androgen-signaling pathway. J Biol Chem 277:11336-44."
"945","PC010690","Sharma M, Chuang WW, Sun Z (2002): Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J Biol Chem 277:30935-41."
"946","PC010690","Sharma M, Li X, Wang YZ, et al.  2003.  HZimp10 is an androgen receptor coactivator and forms a complex with SUMO-1 at replication foci.  The EMBO Journal 22:6101-6114."
"947","PC010690","Verras M, Brown J, Li XM, Nusse R, Sun ZJ. 2004. Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. Cancer Res. 64:8860-8866."
"948","PC010693","Tantivejkul K, Kalikin LM, and Pienta KJ.  2004.  Dynamic process of prostate cancer metastasis to bone.  J Cell Biochem 91:706-717."
"949","PC010693","Shah MD, Mehta R, Chinnaiyan A., et al. 2004.  Androgen independent prostate cancer is a heterogenous group of diseases: lessons from a rapid autopsy program.  Cancer Res 64:9209-15.

"
"950","PC010693","Chay CH, Cooper CR, Gendernalik JD, Dhanasekaran SM, Chinnaiyan AM, Rubin MA, Schmaier AH, Pienta KJ (2002): A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology 60:760-5."
"951","PC010693","·Kalikin LM, Schneider A, Thakur MA, et al.  2003.  In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice.  Cancer Biology and Therapy 2:17-21.
"
"952","PC010693","Lee HL PKKWCC (2003): The effect of bone associated growth factors and cytokines on the growth of prostate cancer cells derived from soft tissue versus bone metastases in vitro. Int J Oncol. 22:921-6."
"953","PC010696","Elas M, Ahn KH, Parasca A, et al.  2006.  Electron paramagnetic resonance oxygen images correlate spatially and quantitatively with oxylite oxygen measurements.  Clin Cancer Res 12(14 Pt 1):4209-4217."
"954","PC010696","Haney CR, Parasca AD, Ichikawa K, et al.  2006.  Reduction of image artifacts in mice by bladder flushing with a novel double-lumen urethral catheter.  Mol Imaging 5(3):175-179."
"955","PC010698","Tsui BMW and Frey EC.  2005.  Analytic image reconstruction methods.  In: Quantitative Analysis of Nuclear Medicine Images (Zaidi H, Ed.).  Kluwer Academic/Plenum Publishers."
"956","PC010698","·Sayeram S, Tsui BMW, Zhao XD, and Frey EC. 2003. Performance evaluation of 3 different SPECT systems used in In-111 ProstaScint SPECT Imaging. Conference Record of the 2003 IEEE Nuclear Science Symposium and Medical Imaging Conference.

"
"957","PC010698","·Garrity J, Segars WP, and Tsui BMW. 2003. Development of a dynamic model for the lung lobes and airway tree in the NCAT phantom. IEEE TNS, 50:378-383."
"958","PC010698","Frey EC and Tsui BMW.  2005.  Correction for collimator response function in SPECT.  In: Quantitative Analysis of Nuclear Medicine Images (Zaidi H, Ed.).  Kluwer Academic/Plenum Publishers."
"959","PC010699","Lu J, Jiang C.  2005.  Selenium and cancer chemoprevention:  Hypotheses integrating the actions of selenoproteins and selenium metabolites in epithelial and non-epithelial target cells.  Antioxid Redox Signal 7:1715-1727."
"960","PC010699","Hu H, Jiang C, Schuster T, et al.  2006.  Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway.  Mol Cancer Ther 5(7):1873-1882."
"961","PC010699","Li GX, Hu H, Jiang C, et al.  2007.  Differential involvement of reactive oxygen species in apoptosis induced by two classes of selenium compounds in human prostate cancer cells.  Int J Cancer (Epub ahead of print)."
"962","PC010699","Hongbo Hu, Guang-xun Li, Lei Wang, et al.  2008.  Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down regulates anti-apoptotic proteins Bcl-XL and survivin.  Clinical Cancer Res 14:1150-8.

"
"963","PC010699","Wang Z, Jiang C, Lu J (2002): Induction of caspase-mediated apoptosis and cell-cycle G1 arrest by selenium metabolite methylselenol. Mol Carcinog 34:113-20."
"964","PC010699","·Jiang C, Wang Z, Ganther H, et al.  Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells.  Molecular Cancer Therapeutics 1:1059-66."
"965","PC010699","Jiang C, Hu H, Malewicz B, et al.  2004.  Selenite-induced p53 Ser-15 phosphorylation and caspase-mediated apoptosis in LNCaP human prostate cancer cells.  Mol Cancer Ther 3(7):877-884."
"966","PC010699","Cho SD, Jiang C, Malewicz B, et al.  2004.  Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription.  Mol Cancer Ther 3(5):604-611."
"967","PC010699","Hu H, Jiang C, Ip C, et al.  2005.  Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in DU145 prostate cancer cells primarily through enhancing JNK-dependent caspase activation.  Clin Cancer Res 11:2379-88."
"968","PC010699","Hu Hongbo, C Jiang, G Li, and J Lu, 2005.  PKB/AKT and ERK regulation of caspase-mediated apoptosis by methylseleninic acid in LNCaP prostate cancer cells.  Carcinogenesis 26(8):1374-1381.

"
"969","PC010717","Reddi AH RDFCaMS (2003): Mechanisms of tumor metastasis to the bone: challenges and opportunities. J Bone Miner Res 18:190-194."
"970","PC010717","Moseley TA HDRLRA (2003):  Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 14:155-174."
"971","PC010717","Haudenschild D, Palmer S, Moseley TA, et. al.  2004.  Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist Noggin in prostate cancer.  Cancer Res 64:8276-8284."
"972","PC010718","Sweeney C, L Li, R Shanmugam, et al., 2004.  Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate.  Clin. Cancer Res. 10:5501-5507."
"973","PC010718","Shanmugam R, Jayaprakasan V, Gokmen-Polar Y,et al.  2006.  Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. Prostate 66(14):1498-1511."
"974","PC010731","Xie X, Eberding A, Madera C, et al.  2006.  Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models.  J Urol 175(5):1926-1931."
"975","PC011004","Freedman ML, Haiman CA, Patterson N, et al. 2006. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. PNAS 103(38):14068-73."
"976","PC011004","Cheng I, Stram DO, Penney KL, et al.  2006. Common genetic variation in IGF1 and prostate cancer risk in the multiethnic cohort.  J Natl Cancer Inst 98(2), 123-134."
"977","PC011004","Freedman ML, Pearce CL, Penney KL, et al.  2005.  Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study. Am J Hum Genet 76:82-90."
"978","PC011004","Freedman ML, D Reich, KL Penney, et al., 2004.  Assessing the impact of population stratification on genetic association studies.  Nat. Genet. 36(4):388-93."
"979","PC011008","Bowen A, Khan S, Berghman L, et al.  2006.  Immunization of pigs against chicken gonadotropin-releasing hormone-II and lamprey gonadotropin-releasing hormone-III: Effects on gonadotropin secretion and testicular function.  J Anim Sci 84:2990-2999."
"980","PC011008","Hendry WJ III, Weaver BP, Naccarato TR, et al.  2006.  Differential progression of neonatal diethylstilbestrol-induced disruption of the hamster testis and seminal vesicle.  Reprod Toxicol 21:225-240."
"981","PC011008","McDonald CA, Millena AC, Reddy S, et al.  2006.  Follicle-stimulating hormone-induced aromatase in immature rat Sertoli cells requires an active phosphatidylinositol 3-kinase pathway and is inhibited via the mitogen-activated protein kinase signaling pathway.  Mol Endocrinol 20:608-618."
"982","PC011008","Jo Y, King SR, Khan SA, et al.  2005.  Involvement of protein kinase C and cyclic adenosine 3¿,5¿-monophosphate-dependent kinase in steroidogenic acute regulatory protein expression and steroid biosynthesis in Leydig cells.  Biol Reprod 73:244-255."
"983","PC011011","Chi KN, Eisenhauer E, Siu L, et al.  2008.  A Phase 1 study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCIC CTG IND 154.  Clinical Cancer Research 14:833-839."
"984","PC011011","Chi KN, Zoubeidi A, and Gleave ME.  2008.  Custirsen (OGX-011): A second-generation antisense inhibitor of clusterin for the treatment of cancer.  Expert Opin Investig Drugs 17:1955-62."
"985","PC011011","Sonpavde G, Chi KN, Powles T, et al.  2007.  Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer.  Cancer 110:2628-39."
"986","PC011011","Gleave M, Miyake H, and Chi K.  2005.  Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer.  Cancer Chemother Pharmacol 56:47-57."
"987","PC011011","Gleave M and Chi KN.  2005.  Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers.  Ann N Y Acad Sci 1058:1-15."
"988","PC011011","Chi KN, Eisenhauer E, Fazli L, et al.  2005.  A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97:1287-1296."
"989","PC011011","Chi KN, and ME Gleave, 2004.  Antisense approaches in prostate cancer.  Expert Opinion on Biologic Therapy 4(6):927-36."
"990","PC011015","Sokoloff MH, Rinker-Schaeffer C, Chung W, et al.  2004.  Adjunctive therapy f or men with high risk localized and locally-advanced prostate cancer:  Targeting disseminated tumor cells. 
J Urol 172(6, Part 2of 2):2539-2544.
"
"991","PC011020","Roth TJ, Sheinin Y, Lohse CM, et al.  2007.  B7-H3 Ligand Expression by Prostate Cancer: A Novel Marker of
Prognosis and Potential Target for Therapy.  Cancer Res 2007; 67:7893-7900."
"992","PC011023","Franklin RB, Feng P, Milon B, et al.  hZIP1 zinc uptake transporter down regulation and zinc in rostate cancer.  Mol Cancer 4:32."
"993","PC011023","Bagasra O, and KR Prilliman.  2004.  RNA interference:  the molecular immune system.  J Mol Histol, 35:545-53."
"994","PC011023","Costello LC, Franklin RB, Feng P, et al.  2005.  Zinc and prostate cancer:  A critical scientific medical and public interest debate.  Cancer Causes and Control 16:901-915.

"
"995","PC011023","Rishi I, H Baidouri, JA Abbasi, et al., 2003.  Prostate cancer in African American men is associated with downregulation of Zinc transporters.  Applied Immunohistochemistry & Molecular Morphology 11(3):253-60."
"996","PC011023","Alhatou MI, T Sladky, O Bagasra, and D Glass.  Mitochondrial abnormalities in dermatomyositis:  Characteristic pattern of neuropathology.  J Mol Histol, 35:615-9."
"997","PC011023","Bagasra O.  2004.  Citrate sours the malignant intent of prostate epithelia.  Mitochondria 4:339-341."
"998","PC011030","Powel L and Clark JA.  2005.  The value of the marginalia as an adjunct to structured questionnaires: Men¿s experiences after prostate cancer surgery.  Qual Life Res 14:827-835.

"
"999","PC020012","Newton JR, Kelly KA, Mahmood U, et al.  2006.  In vivo selection of phage for the optical imaging of human prostate carcinoma in mice.  Neoplasia 8:772-780."
"1000","PC020012","Fish R, and Deutscher SL.  2006.  In vivo molecular imaging of cancer growth using luciferase-tagged carcinoma cells.  Life Sciences Week."
"1001","PC020012","Newton JR, and Deutscher SL.  2007.  Phage in molecular imaging for 'Handbook of Experimental Pharmacology'.  Springer-Verlag)."
"1002","PC020012","Landon LA, Harden W, Illy C, et al.  2004.  High throughput fluorescence spectroscopic analysis of binding affinity of ligands displayed on bacteriophage.  Anal Biochem 331:60-67."
"1003","PC020012","Landon LA and Deutscher SL.  2004.  Is phage display technology on target for developing peptide-based cancer drugs?  Current Drug Discovery Technol 1:113-32."
"1004","PC020012","Zou J, Dickerson MT, Owen NK, et al.  2004.  Biodistribution of filamentous phage peptide libraries in mice.  Molecular Biology Reports.  31(2):121-129."
"1005","PC020017","Gray MJ, Zhang J, Ellis LM, et al.  2005.  HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas.  Oncogene 24:3110-3120."
"1006","PC020035","·Jing L, Liu L, Yu YP, et al.  2004.  Expression of myopodin induces suppression of tumor growth and metastasis.  American Journal of Pathology, 2004, 164: 1799-1806."
"1007","PC020035","Mamoune A, Luo JH, Lauffenburger, et al.  2003. Calpain-2 as a target for limiting prostate cancer invasion. Cancer Res 63:4632-40"
"1008","PC020035","Yu YP, Paranjpe S, Nelson, J, et al.  2005. High throughput screening of methylation status of genes in prostate cancer using an oligonucleotide methylation array.  Carcinogenesis 26:471-9."
"1009","PC020035","Yu YP, Landsittel D, Jing L, et al.  2004.  Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy.  J Clin Oncol 22:2790-9."
"1010","PC020035","Ren B, Yu G, Tseng GC, et al.  2006. MCM7 amplification and overexpression are associated with prostate cancer progression.  Oncogene 25:1090-8."
"1011","PC020039","Tavano R, Gri G, Molon B, et al.  2004.  CD28 and lipid rafts coordinate recruitment of Lck to the immunological synapse of human T lymphocytes.  J Immunol 173:5392-5397."
"1012","PC020039","Molon B, Gri G, Betella M, et al.  2005.  T cell costimulation by chemokine receptors.  Nat Immunol 6:465-471.

"
"1013","PC020039","Gri G, Molon B, Manes S, et al.  2004.  The inner side of T cell lipid rafts.  Immunology Letters 94:247-52.
"
"1014","PC020039","Zambello R, Cabrelle A, Trentin L, et al.  2004.  The rafts marker GM1 identifies functional subsets of granular lymphocytes in patients with CD3+ lymphoproliferative disease of granular lymphocytes.  Leukemia 18:771-776."
"1015","PC020039","Bronte V, Kasic T, Gri G, et al.  2005.  Boosting anti-tumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 201:1257-1268."
"1016","PC020039","Manes S and Viola A.  2006.  Lipid rafts in lymphocyte activation and migration.  Mol Membr Biol 23:59-69."
"1017","PC020039","Kasic T and Viola A.  2005.  Prostate cancer-induced immunodysfunction: A lesson from organ cultures.  Immunol Lett 100:98-102."
"1018","PC020043","Bruxvoort KJ, Charbonneau HM, Giambernardi TA, et al. 2007. Inactivation of Apc in the mouse prostate causes prostate carcinoma. Cancer Res 67(6):2490-6."
"1019","PC020052","Liu Z, Eltoum IE, Guo B, et al. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer. 
J Immunol 180(9):6044-6053."
"1020","PC020052","Guo BL, Liu Z, Aldrich WA, Lopez RD. 2005. Innate anti-breast cancer immunity of apoptosis-resistant human gammadelta-T cells.  Breast Cancer Res Treat. 93(2):169-75."
"1021","PC020052","Liu Z, BL Guo, BC Gehrs, L Nan, and RD Lopez, 2005.  Ex-vivo expanded human Vgamma9Vdelta2+gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro.  J. Urol. 173:1552-1556."
"1022","PC020062","Straathof K, M Pule, P Yotnda, et al.  An inducible caspase 9 safety switch for cell therapy.  Blood, 105:4247-54."
"1023","PC020062","Seethammagari M, Xie X, Greenberg NM, et al.  2006.  EZC2-Prostate offer both high-sensitivity and specificity for non-invasive imaging of prostate cancer progression and androgen receptor action. Cancer Res 66:6199-209.

"
"1024","PC020062","Nikitina EY, Desai SA, X Zhao, et al.  Versatile prostate cancer treatment with inducible caspase, and interleukin-12.  Cancer Res 65:4309-19."
"1025","PC020068","Tutar IB, Gong L, Narayanan S, et al.  2008.  Seed-based transrectal ultrasound-fluoroscopy registration method for intraoperative dosimetry analysis of prostate brachytherapy.  Med Phys 35:840-8."
"1026","PC020068","Orio PF, Tutar IB, Narayanan S, et al.  2007.  Intraoperative ultrasound-fluoroscopy fusion can enhance prostate brachytherapy quality.  Int J Radiat Oncol Biol Phys 69:302-7."
"1027","PC020068","Tutar IB, Pathak SD, Gong L, et al.  2006.  Semi-automatic 3D prostate segmentation from TRUS images using spherical harmonics.  IEEE Trans Med Imaging 25:1645-1654."
"1028","PC020068","Narayanan S and Cho PS.  2006.  A perspective matrix-based seed reconstruction algorithm with
applications to C-arm based intra-operative dosimetry. Proc SPIE Med Imag 2006: Visualization, Image-Guided Procedures, and Display Vol 6141(61411I):1-11.
"
"1029","PC020068","Reed DR, Wallner KE, Narayanan S, et al.  2005.  Intraoperative fluoroscopic dose assessment in prostate brachytherapy patients. Int J Rad Oncol Biol Phys 63:301-307."
"1030","PC020068","Lam ST, PS Cho, RJ Marks II, and S Narayanan, 2005.  Detection and correction of patient motion in prostate brachytherapy seed reconstruction.  Phys. Med. Biol. 50:2071-2087."
"1031","PC020068","Cho SP, Narayanan S, Lam ST, et al. 2004. Dynamic brachytherapy: Intra-operative dose optimization using dual-modality imaging. In: Proceeding of the 14th International Conference on Computers in Radiotherapy (Yi B, Ahn S, Choi E and Ha S, Eds.). Jeong Publishing, Seoul 10-13."
"1032","PC020068","Lam ST, Cho PS, Marks II RJ, and Narayanan S. 2004. Three-dimensional seed construction for prostate brachytherapy using Hough trajectory. Phys Med Biol 49: 557-569."
"1033","PC020094","Poehlein CH, Ruttinger D, Ma J, et al.  2005.  Immunotherapy for melanoma: the good, the bad, and the future.  Curr Oncol Rep 7:383-392."
"1034","PC020094","Fox BA.  2005.   Review of - melanoma vaccines: what we know so far.  Oncology 19:112-5."
"1035","PC020094","Jensen SM and Fox BA.  2005.  Adoptive cellular immunotherapy of cancer: A three-signal paradigm for translating recent developments into improved treatment strategies, in Tumor Immunology and Cancer Vaccines.  Ed. Khleif S."
"1036","PC020094","van den Engel NK, Winter H, Ruttinger D, et al.  2006.  Characterization of immune responses in gastric cancer patients: A possible impact of H. pylori to polarize a tumorspecific type 1 response?  Clin Immunol 120(3):285-296."
"1037","PC020094","Wang LX, LI R, Yang G, et al.  2005.  IL-7 dependent expansion and persistence of adoptively transferred T cells in lymphodepleted mice after vaccination leads to tumor regression and editing.  Cancer Research 65:10569-10577."
"1038","PC020094","Ruttinger D, van den Engel NK Winter H, et al.  2007.  Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: First clinical experience and evidence of an immune response.  J Transl Med 5:43."
"1039","PC020094","Ruttinger D, Winter H, van den Engel NK, et al.  2006.  Immunotherapy of lung cancer: An update.  Onkologie 29(1-2):33-38."
"1040","PC020094","He H, Wisner P, Yang G, et al.  2006.  Combined IL-21 and low-dose IL-2 therapy induces antitumor immunity and long-term curative effects in a murine melanoma tumor model.  J Transl Med 4(1):24."
"1041","PC020094","Sakamoto N, Tsuji K, Muul LM, et al.  2007.  Bovine apolipoprotein B-100 is a dominant immunogen in the therapeutic cell populations cultured in FCS in mice and humans.  Blood 110:501-508."
"1042","PC020094","Meijer SL, Dols A, Jensen SM, et al.  2007.  Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100109-2M peptide.  J Immunother 30:533-543."
"1043","PC020094","RÃ¼ttinger D, Hatz RA, Jauch KW, et al.  2007.  Current immunotherapeutic strategies in lung cancer.  Surg Oncol Clin N Am 16(4):901-918."
"1044","PC020094","Nemunaitis J, Jahan T, Ross H, et al.  2006.  Phase 1/2 trail of autologous tumor mixed with an allogeneic GVAX® vaccine in advanced-stage non-small-cell lung cancer.  Cancer Gene Therapy 13(6):555-562."
"1045","PC020102","Keller ET and Brown J.  2004.  Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.  J Cell Biochem 91:718-729."
"1046","PC020102","Keller ET.  2004.  Mechanisms of bone resorption in prostate cancer skeletal metastases.  In:  Progress in Prostate Cancer Research (Columbus F, Ed.). Nova Publishers."
"1047","PC020102","·Zhang J, Lu Y, Dai J, et al.  In vivo real-time imaging of  TGF-beta;-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer.  The Prostate, 58(4):360-9."
"1048","PC020102","·Zhang J, Dai J, Yao Z, et al.  2003.  Soluble receptor activator of nuclear factor KB Fc diminishes prostate cancer progression in bone.  Cancer Research 63:7883-7890."
"1049","PC020104","Zheng X, Yin L, Liu Y, et al.  2004.  Hematopoietic peripheral antigen-expressing cells impose activation-induced cell death of autoreactive T cells in the secondary lymphoid organs.  Eur J Immunol 34:3126-3134"
"1050","PC020104","Zheng X, Gao JX, Chang X, et al.  2004.  B7-CD28 Interaction Promotes Proliferation and Survival but Suppresses Differentiation of CD4-CD8- T Cells in the Thymus. J Immunol. 173:2253-2261."
"1051","PC020121","·Jin C, McKeehan K, Guo W, Ittmann MM, et al.  2003. Cooperation between ectopic FGFR1 and depression of FGFR2 signaling in induction of prostatic intraepithelial neoplasia in mouse prostate.  Cancer Research 63:8784-8790.

"
"1052","PC020121","·Jin C, McKeehan K, Wang F.  2003.  Transgenic mouse with high Cre recombinase activity in all prostate lobes, seminal vesicle, and ductus deferens.  The Prostate 57:160-164."
"1053","PC020121","Zhang Y, Y Lin, C Bowles, and F Wang, 2004.  Direct cell cycle regulation by the fibroblast growth factor receptor (FGFR) kinase through phosphorylation-dependent release of Cks1 from FGFR substrate 2.  J. Biol. Chem. 279:55348-55354."
"1054","PC020121","Lin Y, Liu G, Wang F, et al.   2006.  Generation of an Fgf9 conditional null allele.  Genesis 44:150-154."
"1055","PC020121","Guo C, Wu G, Taylor SS, et al.  2006.  Bub1 up-regulation and hyperphosphorylation are major features promoting prostate cancer transformation in SV40 tag -induced transgenic mouse models.  Mol Cancer Res 4:957-69."
"1056","PC020128","Nakamori M, X Fu, CA Pettaway, and X Zhang, 2004.  Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer.  Prostate 60(1):53-60."
"1057","PC020129","Valzasina B, Guiducci C, Dislich H, et al.  2005.  Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity:  A novel regulatory role for OX40 and its comparison with GITR.  Blood 105:2845."
"1058","PC020129","Weinberg AD, Evans DE, and Hurwitz.  2004.  Accentuating tumor immunity through costimulation.  In: Cancer Immunotherapy at the Crossroads, How Tumors Evade Immunity and What Can Be Done- (Finke JH and Bukwoski RM, Eds.). Humana Publishing, 173-194."
"1059","PC020129","Weinberg AD, Evans DE, Thalhofer C, et al.  2004.  The generation of T cell memory: A review describing the molecular and cellular events following OX40 (CD134) engagement.  Journal of Leukocyte Biology 75:962-72."
"1060","PC020129","·Prell RA, Evans DE, Thalhofer C, et al.  2003.  OX40-mediated memory T cell generation is TNF receptor-associated factor 2 dependent.  Journal of Immunology 171:5997-6005."
"1061","PC020129","Huddleston CA, Weinberg AD, and Parker DC.  2006.  OX40 engagement drives differentiation of CD4 T cells to effector cells.  Eur J Immunol 36:1093-103."
"1062","PC020138","Wang JQ, Zheng QH, Fei X, et al. 2004. An improved total synthesis of PET HSV-tk gene expression imaging agent 9-[3-[18F]fluoro-1-hydroxy-2-propoxy)methyl]guanine ([18F]FHPG). Syn Commun 34(5):917-932."
"1063","PC020138","Zheng QH, Gardner TA, Raikwar SP, et al. 2004. [11C]Choline as a PET biomarker for assessment of prostate cancer tumor models. Bioorg Med Chem 12:2887-2893."
"1064","PC020138","Zheng QH, Wang JQ, Liu X, et al. 2004. An improved total synthesis of Pet HSV-tk gene reporter probe 9-(4-[18F]fluoro-3-hydroxmethylbutyl)guanine ([18F]FHBG). Syn Commun 34(4):689-704."
"1065","PC020138","Wang J, Xiangshu F, Gardner TA, et al.  2004.  Synthesis of 2-amino-6-(4-11Cmethoxyphenylothio)-9-2-(phosphonomethoxy)ethylpurine bis (2,2,,2-trifluoriethyl)ester as a novel potential PET gene reporter probe for HBV and HSV-tk in cancers.  Bio Med Chem 13:549-556.
"
"1066","PC020146","Finlay JC, Zhu TC, Dimofte A, et al.  2005.  In vivo measurement of fluorescence emission in the human prostate during photodynamic therapy.  Proc SPIE 5689:299-310."
"1067","PC020146","Altschuler MD, Zhu TC, Jun Li, et al.  2005.  Optimization of light sources for prostate photodynamic therapy.  Proc SPIE 5689:186-197."
"1068","PC020146","Zhu TC, Dimofte A, Finlay JC, Get al.  2005.  Detector calibration factor for interstitial in vivo light dosimetry using isotropic detectors with scattering tip.  Proc SPIE 5689:174-185."
"1069","PC020146","Zhu TC, Dimofte A, Finlay JC, et al.  2005.  Optical properties of human prostate at 732nm measured in vivo during motexafin lutetium-mediated photodynamic therapy.  Photochem Photobiol 81:96-105."
"1070","PC020146","Zhu TC and Finlay JC.  2006.  Prostate PDT dosimetry.  Photodiagnosis and Photodynamic Therapy 3, Elsevier Publishers."
"1071","PC020146","Altschuler MD, Zhu TC, Jun Li, et al.  2005.  Optimized interstitial PDT prostate treatment planning with the cimmino feasibility algorithm.  Med Phys 32: 3524-3536."
"1072","PC020146","Finlay J, Zhu T, Dimofte A, et al.  2006.  Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy.  Photochem Photobiol 82: available on line, PMID: 16808592."
"1073","PC020146","Finlay JC, Zhu TC, Dimofte A, et al.  2006. Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy. Photochem Photobiol 82(5):1270-1278."
"1074","PC020146","Zhu TC, Finlay JF, and Hahn SM.  2005.  Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in vivo in human prostate during motexafin
lutetium-mediated photodynamic therapy.  J Photochem Photobiol B 79:231-241.
"
"1075","PC020146","Zhu TC, Dimofte A, Finlay JC, et al. 2004. Light dosimetry at tissue surfaces for oblique circular fields. Proc SPIE 5315:113-124."
"1076","PC020146","Finlay JC, Zhu TC, Dimofte A, et al. 2004. In vivo determination of the absorption and scattering spectra of the human prostate during photodynamic therapy. Proc SPIE 5315:132-142."
"1077","PC020146","Dimofte A, Finlay JC, and Zhu TC.  2005.  A method for determination of the absorption and scattering properties interstitially in turbid media.  Phys Med Biol 50:2291-2311."
"1078","PC020147","·Dudkin VY, Miller JS, and Danishefsky SJ.  2003.  A concise route to the core pentasaccharide of N-linked glycoproteins.  Tetrahedron Lett.  44:1791-1793."
"1079","PC020147","·Dudkin VY, Miller JS, and Danishefsky SJ, et al.  2004.  Chemical synthesis of normal and transformed PSA glycopeptides.  J. Am. Chem. Soc. 126:736-738."
"1080","PC020147","Ragupathi G, Koide F, Livingston PO, et al.  2006.  Preparation and Evaluation of Unimolecular Pentavalent and Hexavalent Antigenic Constructs Targeting Prostate and Breast Cancer: A Synthetic Route to Anticancer Vaccine Candidates.  J Am Chem Soc 128:2715-2725."
"1081","PC020147","Wan Q, Cho YS, Lambert TH, et al.  2005.  Olefin Cross-Metathesis: A Powerful Tool for Constructing Vaccines Composed of Multimeric Antigens.  Carbohydrate Chem 24:425."
"1082","PC020147","·Miller JS, Dudkin VY, Lyon GJ, et al.  2003.  Toward fully synthetic N-linked glycoproteins.  Angew. Chem. Int. Ed.  42:431-434."
"1083","PC020169","Jiang T, Guo Z, Dai B, et al.  2004.  Bi-directional regulation between tyrosine kinase Etk/BMX and tumor suppressor p53 in response to DNA damage.  J Biol Chem 279:50181-50189."
"1084","PC020169","Xie Y, Xu K, Qiu Y, et al.  2006.  The 44 kd Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs.  Oncogene 25:70-78."
"1085","PC020169","·Kim O, Jiang T, Xie Y, et al.  2004.  Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells.  Oncogene 23:1838-1844."
"1086","PC020171","Raina K, Blouin MJ, Singh RP, et al.  2007. Cancer Res. 2007 Nov 15;67(22):11083-91. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.Cancer Res 67(22):11083-11091."
"1087","PC020171","Singh RP, Deep G, Blouin MJ,et al.  Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft. Carcinogenesis 28(12):2567-2574."
"1088","PC020176","·Boucher K, Asselain B, Tsodikov A, et al.  2004.  Semiparametric versus parametric regression analysis based on the bounded cumulative hazard model: An application to breast cancer recurrence.  In Semiparametric Models in Survival Analysis, Quality of Life and Reliability."
"1089","PC020176","·Tsodikov A, Ibrahim JG, and Yakolev AY.  2003.  Estimating cure rates from survival data: An alternative to two- component mixture models.  Journal of the American Statistical Association 98:1063-1078."
"1090","PC020176","Broet P, Tsodikov A, De Rycke Y, et al.  2004.  Two-sample statistics for testing the equality of survival functions against improper semi-parametric accelerated failure time alternatives: An application to the analysis of a breast cancer clinical trial.  Lifetime Data Anal l(10):103-120."
"1091","PC020176","Tsodikov A, Szabo A, and Wegelin J.  2006.  A population model of prostate cancer incidence, Stat Med 25:2846-66."
"1092","PC020176","·Tsodikov A.  2003.  Semiparametric models: A generalized self-consistency approach.  Journal of the Royal Statistical Society, Series B 65:759-774."
"1093","PC020176","Wendland MM, Tsodikov A, Glenn MJ, et al.  2004.  Time interval to the development of breast cancer following treatment for Hodgkins Disease. Cancer 101:1275-1282.

"
"1094","PC020177","Ray S, Paulmurugan R, and Hildebrandt I, et al.  2004.  Novel bidirectional vector strategy for amplification of therapeutic and reporter gene expression.  Hum Gene Ther 15:681-690."
"1095","PC020177","Iyer M, Salazar FB, and Lewis Z, et al.  2004.  Noninvasive imaging of enhanced prostate-specific gene expression using a two-step transcriptional amplification-based lentivirus vector.  Mol Ther 10:545-552.

"
"1096","PC020177","·Zhang L, Johnson M, Le K, et al.  2003.  Interrogating androgen receptor function in recurrent prostate cancer. Cancer Research 63:4552-4560.
"
"1097","PC020177","·Sato M, Johnson M, Zhang L, et al.  Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy.  Molecular Therapy. 8:726-37
"
"1098","PC020177","Sato M, Johnson M, Zhang L, et al.  2005.  Functionally of androgen receptor-based gene expression imaging in hormone refractory prostate cancer.  Clin Cancer Res 11:3743-3749."
"1099","PC020177","Iyer M, Bergara F, Lewis X, et al.  2005.  Noninvasive imaging of a transgenic mouse model using a two-step transcriptional amplification strategy.  Transgenic Res 14:47-55."
"1100","PC020177","Ilagan R, Zhang L, Pottratz J, et al.  2005.  Imaging androgen receptor function during flutamide treatment in a prostate cancer xenograft.  Mol Can Ther 4:1662-9."
"1101","PC020189","Tekant Y, Davydova J, Ramirez PJ, et al.  2005.  Oncolytic adenoviral therapy in gallbladder carcinoma.  SURGERY 137(5):527-35."
"1102","PC020189","Ono HA, Le LP, Davydova JG, et al.  2005.  Non-invasive visualization of adenovirus republication with a fluorescent reporter in the E3 region.  Cancer Res 65(22):10154-8."
"1103","PC020189","Davydova J, Le LP, Gavrokova T, et al.  2004.  Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal andenocarcinoma.  Cancer Res 15:64:4319-4327."
"1104","PC020189","Yamamoto M.  2004.  Conditionally replicative adenovirus for gastrointestinal cancers.  Expert Opinion on Biology Therapy 4(8):1241-1250.

"
"1105","PC020189","Liang Q, Yamamoto M, Curiel DT, et al.  2004.  Noninvasive imaging of transcriptionally restricted transgene expression following intratumoral injection of an adenovirus in which the COX-2 promoter drives a reporter gene.  Mol Imaging Biol 6(6):395-404."
"1106","PC020189","Ono HA, Davydova JG, Adachi Y, et al.  2005.  Promoter-controlled infectivity enhanced conditionally replicative adenoviral vectors for the treatment of gastric cancer.  
J Gastroenterol 40:31-42.
"
"1107","PC020189","·Yamamoto M, Davydova D, Wang M, et al.  2003.  Cyclooxygenase-2 promoter based conditionally replicative adenovirus for pancreatic cancer.  Gastroenterology 125:1209-1218.

"
"1108","PC020189","Le LP, Le HN, Dmitriev IP, et al.  2006.  Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling.  J Natl Cancer Inst 98(3):203-14."
"1109","PC020189","·Yamamoto M and Curiel DT.  2004.  Nonreplicating viral vectors for suicide gene therapy: the adenoviral vectors.  Methods Mol. Med. 90:61-70."
"1110","PC020205","Yi Y, Nandana S, Case T, et al.  2009. Candidate metastasis suppressor genes uncovered by array comparative genomic
hybridization in a mouse allograft model of prostate cancer.  Mol Cytogenet. Sep 26;2:18. 
"
"1111","PC020205","Masumori N, Tsuchiya K, Tu WH, et al.  2004.  An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line.  J Urology 171:439-442."
"1112","PC020206","Bandyopadhyay A and Sun L-Z.  2007.  Soluble TGF-beta type III receptor suppresses malignant progression of human cancer cells.  In ¿Transforming Growth Factor-beta in Cancer Therapy, Vol. 2¿ S.B. Jakowlew, ed., The Humana Press, Inc., Totowa, New Jersey"
"1113","PC020206","Verona EV, Elkahloun A, Yang J, et al.  2007.  TGF-beta signaling in prostate stromal cells supports prostate carcinoma growth by upregulating stromal genes related to tissue remodeling.  Cancer Res 67:5737-5746."
"1114","PC020206","Bandyopadhyay A, Wang L, Lopez-Casillas F, et al.  2005.  Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer.  The Prostate 63:81-90."
"1115","PC020206","Bandyopadhyay A and Sun, LZ.  Soluble TGF-beta type III receptor suppresses malignant progression of human cancer cells.  Transforming Growth Factor-beta in Cancer Therapy, Vol. 2 Jakowlew, SB (Ed.). The Humana Press, Inc., Totowa, New Jersey"
"1116","PC020213","Pevsner A, Davis B, Joshi S, et al.  2006.  Evaluation of an automated deformable image matching method for quantifying lung motion in respiration-correlated CT images.  Med Phys 33(2):369-376."
"1117","PC020213","Foskey M, Davis B, Goyal L, et al.  2005.  Large deformation three-dimensional image registration in image-guided radiation therapy.  Phys Med Biol 50(24):5869-5892.

"
"1118","PC020222","Bisanz K, Yu J, Edlund M, et al.  2005.  Targeting ECM/integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in bone in a xenograft imaging model.  Mol Ther 12:634-643."
"1119","PC020222","Hsieh CL, Xie Z, Yeung F, et al.  2005.  Luciferase transgenic mouse model: Visualization of prostate development and its androgen responsiveness in live animals.  J Mol Endocrinol 35:293-304."
"1120","PC020222","Jin F, Xie Z, Kuo CJ, et al.  2005.  Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy.  Cancer Gene Ther 12:257-267."
"1121","PC020228","Srivastava M, L Bubendorf, M Raffeld, et al., 2004.  Prognostic impact of ANX7-GTPase in metastatic and HER2 negative breast cancer patients.  Clin. Can. Res. 10:2344-50."
"1122","PC020228","Leighton X, V Srikantan, HB Pollard, et al., 2004.  Significant allelic loss of ANX7 region (10q21) in hormone receptor negative breast carcinomas.  Cancer Lett. 210(2):239-44."
"1123","PC020228","Torosyan Y, Simakova O, Naga S, et al.  2009.  Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells.  Int J Cancer 125(11):2528-2539."
"1124","PC020237","Nigavekar SS, Sung LY, Llanes M, et al.  3H dendrimer nanoparticle organ/tumor distribution.  Pharm Res 21(3):476-483."
"1125","PC020237","Khan MK, Minc LD, Nigavekar S, et al.  2008.  Fabrication of radioactive gold/dendrimer composite nanodevices and their use for nanobrachytherapy.  Nanomedicine 4:57¿69."
"1126","PC020237","Balogh L, Nigavekar SS, Nair BM, et al.  2007.  Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models.  Nanomedicine 3:281-296."
"1127","PC020237","Lesniak WG, Kariapper MST, Nair BM, et al.  2007. Synthesis and characterization of PAMAM dendrimer-based multifunctional nanodevices for targeting avb3 integrins.  Bioconjug Chem 18:1148-1154."
"1128","PC020237","Khan MK, Nigavekar SS, Minc KD, et al.  2005.  In vivo biodistribution of dendrimers and dendrimer nanocomposites - Implication for cancer imaging and therapy.  Technology in Cancer Research and Treatment 4(6):603-613."
"1129","PC020248","Yang Y and Xing L. 2005. Towards biologically conformal radiation therapy (BCRT): selective IMRT dose escalation under the guidance of spatial biology distribution. 32(6):1473-1484."
"1130","PC020248","Yang Y and Xing L. 2005. Optimization of radiotherapy dose-time fractionation with consideration of tumor specific biology. Med. Phys. 32(12):3666-3677."
"1131","PC020248","Lian J and Xing L.  2004.  Incorporating model parameter uncertainty into inverse treatment planning.  Med Phys 31:2711-2720."
"1132","PC020248","Yan Y and Xing L.  2004.  Clinical knowledge-based inverse treatment planning.  Phys Med Biol 49:5101-5117."
"1133","PC020248","Lian J, Cotrutz C, and Xing L.  2003.  Therapeutic treatment plan optimization with probability density-based dose prescription.  Med Phys 30:655-666."
"1134","PC020254","Karseladze AI, Rytin IIe, and Budunova IV.  2004.  Immunohistochemical study of the prostate-specific antigen in prostate cancer.  Arkh Patol 6(2):3-7.

"
"1135","PC020254","Yemelyanov A, Czwornog J, Chebotaev D, et al.  2004.  New methods for gene transfer: Advantages of lentivirus-mediated gene transduction.  R. Lurie Comprehensive Cancer Center Journal 10:21-26."
"1136","PC020254","Yemelyanov A, Gasparian A, Lindholm P, et al.  2006.  Effect of IKK specific inhibitor PS1145 on NF-kappaB activity, proliferation and apoptosis in prostate carcinoma cell lines.  Oncogene 25:387-98."
"1137","PC020254","Yemelyanov A, Czwornog J, Chebotaev D, et al.  2005.  New methods for gene transfer: Advantages of lentivirus-mediated gene transduction.  The Journal of the R Lurie Comprehensive Cancer Center of Northwestern University X(1):21-26."
"1138","PC020254","Yemelyanov A, Czwornog J, Chebotaev D, et al.  2007.  Tumor suppressor effect of glucocorticoid receptor in prostate.  Oncogene 26:1885-96."
"1139","PC020254","Nelius T, Filleur S, Yemeyanov A, et al.  2007.  Volpert Androgen receptor targets NFkB and TSP1 to suppress prostate tumor growth in vivo.  Int J Cancer 121(5):999-1008."
"1140","PC020260","T. C. Sroka, J. Marik, M. E. Pennington, K. S. Lam, and A. E. Cress. The minimum element of a synthetic peptide required to block prostate tumor cell migration. Cancer Biology and Therapy, 5:1556 1562, 2006.
"
"1141","PC020271","Wang LG, Liu XM, and Chiao JW.  2006.  Repression of androgen receptor cancer cells by phenethyl isothiocyanate.  Carcinogenesis 27:2124-32."
"1142","PC020271","Ma X, Fang Y, Beklemisheva A, et al.  2006.  Phenylhexyl isothiocyanate inhibits histone deactylases and remodels chromatins to induce growth arrest in human leukemia cells.  Int J Oncology 28:1287."
"1143","PC020271","Lu L, Liu D, Ma X, et al.  2006.  The phenylhexyl isothiocyanate induces apoptosis and inhibits leukemia cell growth in vivo.  Oncology Reports 16:1363."
"1144","PC020271","Beklemisheva A, Feng J, Yeh YA, et al.  2007.  Modulating testosterone stimulated prostate growth by phenethyl isothiocyanate via Sp1 and androgen receptor down-regulation.  The Prostate 67:863."
"1145","PC020271","Wang LG, Beklemisheva A, Liu XM, et al.  2007.  Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer.  Mol Carcinogenesis 46:24."
"1146","PC020271","Wang LG, Beklemisheva A, Liu XM, et al.  2006.  Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer.  Mol Carcinogenesis 46:24-31."
"1147","PC020271","Beklemisheva A, Feng A, Yeh J, Wang YA, et al. 2007. Modulating testosterone stimulated prostate growth by phenethyl isothiocyanate via Sp1 and androgen receptor down-regulation. Prostate 67:863-70."
"1148","PC020271","Beklemisheva A, Fang Y, Feng J, et al.  2006.  Epigenetic mechanism of growth inhibition induced by phenelhexyl isothiocyanate in prostate cancer cells.  Anticanc Res 26:1225."
"1149","PC020271","Chiao JW, Beklemisheva A, Yang J, et al.  2006.  Transcriptional activation of p21 by phenethyl isothiochanate via chromatin remodeling and c-myc de-repression in prostate cancer cells.  Am Assoc Canc Res 47:1314."
"1150","PC020271","Wang LG, Beklemisheva A, Liu XM, et al.  2007.  Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer.  Mol Carcinog 46:24."
"1151","PC020271","Wang LG, Chiao JW.  2010.  Prostate cancer chemopreventive activity of phenethyl isothiocyanate through epigenetic regulation (review).  Int J Oncol 37(3):533-539."
"1152","PC020271","Wang LG, Liu XM, Fang Y, et al.  2008. De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc.   Int J Oncol 33(2):375-380."
"1153","PC020271","Chiao JW, Wu H, Ramaswamy G, et al.  2004.  Ingestion of an isothiocyanate metabolite from cruciferous vegetables inhibits growth of human prostate cancer cell xenografts by apoptosis and cell cycle arrest.  Carcinogenesis 25:1403-1408."
"1154","PC020286","Barranco WT and Eckhert CD.  2006.  Cellular changes in boric acid-treated DU-145 prostate cancer cells.  Brit J Cancer 94:884-890."
"1155","PC020286","Barranco WT and Eckhert CD.  2004.  Boric acid inhibits human prostate cancer cell proliferation.  Cancer Lett 216:21-29."
"1156","PC020286","Kim DH, Faull KF, Norris AJ, et al.  2004.  Borate-nucleotide complex formation depends on charge and phosphorylation state.  J Mass Spectrom 39:743-751."
"1157","PC020286","Barranco WT and Eckhert CD.  2004.  Boric acid acts as a cADPR / RyR antagonist during inhibition of human prostate cancer cell proliferation.  FASEB J 18:A351.2-352.2."
"1158","PC020286","Kim DH, Faull KF, Eckhert CD.  2004.  Determination of borate complex with cyclic ADP-ribose (cADPR) by electrospray ionization mass spectrometry (ESI-MS) FASEB J 18:A351.4 (351.4)."
"1159","PC020286","Eckhert CD.  2004.  Concentration and variation of boron, selenium and elements associated with cancer risk in non-tumor human prostate tissue. FASEB J 18:A351.3 (351.3)."
"1160","PC020286","Que HS, Norris A, Faull KF, Eckhert CD, et al.  2006.  Boric acid inhibits adenosine diphosphate-ribosyl cyclase non-competitively.  J Chromatography A 1115:246-252."
"1161","PC020286","Barranco WT, Hudak PF, Eckhert CD, et al.  2007.  Evaluation of ecological and in vitro effects of boron on prostate cancer risk.  Cancer Causes Control 18:71-7."
"1162","PC020286","Barranco WT, Hudak PF, and Eckhert CD.  2007.  Evaluation of ecological and in vitro effects of boron on prostate cancer risk.  Cancer Causes Control 18:71-77."
"1163","PC020286","Barranco WT, Hudak PF, and Eckhert CD.  2007.  Erratum to: Evaluation of ecological and in vitro effects of boron on prostate cancer risk.  Cancer Causes Control 18:71-77 (published online: http://dx.doi.org/10.1007/s10552-007-0077-8)."
"1164","PC020287","Vazquez F, Matsuoka S, Sellers WR, et al.  2006.  Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane.  Proc Natl Acad Sci USA 103:3633-3638."
"1165","PC020287","Vazquez F and Devreotes P.  2006.  Regulation of PTEN as PIP3 gatekeeper through membrane interaction.  Cell Cycle 5(14):1523-1527."
"1166","PC020287","Janetopoulos C, J Borleis, F Vazquez, et al., 2005.  Temporal and spatial regulation of phosphoinositide signaling mediates cytokinesis.  Dev. Cell 8:467-477."
"1167","PC020304","·Chen Z, Koeneman KS, Corey DR. 2003. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells. Cancer Research 63(18):5917-25."
"1168","PC020315","Zhang X, Jin TG, Yang H, et al.  2004.  Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer.  Cancer Res 64:7086-91."
"1169","PC020315","Zhang X, Zhang L, Yang H, et al.  2007.  C-FOS as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells.  Cancer Res 67(19):9425-9434."
"1170","PC020320","Wang HY, McNight NC, Zhang T, et al.  2007.  SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells.  Cancer Res 67:528-536.

"
"1171","PC020322","Mathew JP, Taylor BS, Bader GD, Pyarajan S, Antoniotti M, Chinnaiyan AM, Sander C, Burakoff SJ, Mishra B. Related Articles, Links  
 From bytes to bedside: data integration and computational biology for translational cancer research. PLoS Comput Biol. 2007 Feb 23;3(2):e12.
"
"1172","PC020322","Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM, Shah RB. Related Articles, Links   Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.
Mod Pathol. 2007 Mar 2;"
"1173","PC020322","Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, Varambally S, Ghosh D, Chinnaiyan AM.  Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007 Feb;9(2):166-80."
"1174","PC020322","Rhodes DR, Yu J, Shanker K, et al.  2004.  ONCOMINE: A cancer microarray database and integrated data-mining platform.  Neoplasia 6(1):1-6."
"1175","PC020322","Kumar-Sinha C and Chinnaiyan AM.  2003.  Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer.  Urology 62 (Suppl 1):19-35."
"1176","PC020322","Hanauer DA, Rhodes DR, Sinha-Kumar C, Chinnaiyan AM. Related Articles, Links  
 Bioinformatics approaches in the study of cancer.
Curr Mol Med. 2007 Feb;7(1):133-41."
"1177","PC020322","Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE, Rubin MA. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007 Jan 22"
"1178","PC020322","Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005 Oct 28;310(5748):644-8.
"
"1179","PC020322","Wang R, Asangani IA, Chakravarthi BV, et al.  2012.  Role of transcriptional corepressor CtBP1 in prostate cancer progression. Neoplasia 14(10):905-914."
"1180","PC020322","Ghosh D, Chinnaiyan AM.   Empirical Bayes identication of tumor progression genes from microarray data. Biom J. 2007 Feb;49(1):68-77. 
"
"1181","PC020325","Zeleniuch-Jacquotte A, Ludin E, Micheli A, et al.  2006.  Circulating enterolactone and risk of endometrial cancer.  Int J Cancer 119(10):2376-2381."
"1182","PC020325","Akl E, Barba M, Rohilla S, et al.  2008.  Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer.  Cochrane Database Syst Rev 16(2)CD006650.

"
"1183","PC020325","Nie J, Beyea J, Bonne MR, et al.  2007.  Exposure to traffic emissions throughout life and risk of breast cancer: The Western New York exposures and breast cancer (WEB) study.  Cancer Causes Control 18(9):947-955."
"1184","PC020325","Schunemann HJ, Castell M, and Muti P.  2007.  Systematic reviews for the Journal of Experimental and Clinical Cancer Research: Going where the science takes us.  J Exp Cli Cancer Res 26(2):169-174."
"1185","PC020325","Sant M, Allemani C, Sieri S, et al.  2007.  Salad vegetables dietary pattern protects against HER-2-positive breast cancer: A prospective Italian study.  Int J Cancer 121(4):911-914.

"
"1186","PC020325","Barba M, Terrenato I, Schünemann H, et al. 2008. Indicators of sexual and somatic development and adolescent body size in relation to prostate cancer risk: Results form a case control study.  Urology 72(1):183-187."
"1187","PC020325","Sieri S, Pala V, Muti P, et al.  2008.  Dietary glycemic index, glycemic load and risk of breast cancer in the ORDET cohort.  Am J Clin Nutr 87(6):1793-801."
"1188","PC020325","Cavalieri E, Chakravarti D, Guttenplan J, et al.  2006.  Catechol estrogen quinones as initiators of breast and other human cancers: Implications for biomarkers of susceptibility and cancer prevention.  BBA-Reviews 1766(1):63-78.

"
"1189","PC020325","McCann SE, Kulkarni S, Trevisan M, et al.  2006.  Dietary lignan intakes and risk of breast cancer by tumour estrogen receptor status.  Breast Cancer Res Treat 99(3):309-311."
"1190","PC020325","Barba M, McCann S, Nie J, et al.  2006.  Perinatal exposures and breast cancer risk in the Western New York exposures and breast cancer (WEB) study.  Cancer Causes Control 17(4):395-401."
"1191","PC020325","Barba M, Terrenato I, SchÃ¼nemann H, et al.  2008.  Indicators of sexual and somatic development and adolescent body size in relation to prostate cancer risk: Results form a case control study.  Urology  72:183-7."
"1192","PC020325","Akl EA, Rohilla S, Barba M, et al.  2008.  Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.  Cochrane Database Syst Rev 23;(1):CD006649. Review, PMID: 18254108."
"1193","PC020325","Capurso G, Schünemann HJ, Terrenato I, et al.  2007.  Meta-analysis: The use of non-steroidal anti-inflammatory drugs and pancreatic cancer risk for different exposure categories.  Aliment Pharm & Therapy 26(8):1089-1099."
"1194","PC020325","Fuhrman BJ, Teter BE, Barba M, et al.  2008.  Equol status modifies the association of soy intake and mammographic density in a sample of postmenopausal women.  Cancer Epidemiol, Biomarkers and Prev 17(1):33-42."
"1195","PC020325","Schernhammer E, Berrino F, Krogh V, et al.  2008.  Urinary 6 Sulphatoxymelatonin level and risk of breast cancer in postmenopausal women: The ORDET cohort.  JNCI 100(12):898-905."
"1196","PC020325","Quick SK, Shields P, Nie J, et al.  2008.  Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk.  Cancer Epidemiol Biomarkers Prev 7(5)."
"1197","PC020325","Micheli A, Secreto G, Meneghini E, et al.  2007.  Endogenous steroid hormone concentrations and risk of breast cancer among pre-menopausal women.  JNCI 7;99(5):408-409."
"1198","PC020325","Han D, Nie J, Bonner MR, et al.  2006.  Lifetime adult weight gain, central adiposity and the risk of pre- and postmenopausal breast cancer in the Western New York exposures and breast cancer study.  Int J Cancer 119(12):2931-2937.

"
"1199","PC020325","Barba M, Cavalleri A, Schünemann HJ, et al.  2006.  Reliability of urinary 6-sulfatoxymelatonin as a biomarker in breast cancer.  Int J Biol Markers 21(4):242-245."
"1200","PC020325","Muti P, Rogan E, and Cavalieri E.  2006.  Androgens and estrogens in the etiology and prevention of breast cancer.  Nutr Cancer 56(2):247-252.

"
"1201","PC020325","Barba M, Fuhrman B, and Muti P.  2006.  Cancer epidemiology.  In:  Fundamentals of Medical Oncology.  Cavalli F, Cognetti F, Costa A, et al, Eds.  Milan: Elsevier."
"1202","PC020325","McCann SE, Wactawski-Wende J, Olson J, et al.  2007.  Changes in 2-hydroxyestrone and 16alpha-hydroxyestrone metabolism with flaxseed consumption: Modification by COMT and CYP1B1 genotype.  Cancer Epidemiol Biomarkers Prev 16(2):256-262."
"1203","PC020325","McCann SE, McCann WE, Hong C, et al.  2007.  Dietary patterns related to glycemic index and load and risk of pre- and postmenopausal breast cancer in the Western New York exposure and breast cancer study.  Am J Clin Nutr 86(2):465-471."
"1204","PC020325","Browne R, Koury S, Marion S, et al.  2007.  Accuracy and biological variation of human serum paraoxonase 1 activity and polymorphism (Q192R) by kinetic enzyme assay.  Clin Chem 53(2):310-317."
"1205","PC020325","Sant M, Allemani C, Sieri S, et al.  2007.  Salad vegetables dietary pattern protects against HER-2-positive breast cancer: A prospective Italian study.  Int J Cancer 121(4):911-914."
"1206","PC020325","Gaikwad NW, Yang L, Muti P, et al.  2008.  The molecular etiology of breast cancer: Evidence from biomarkers of risk.  Int J Cancer122(9):1949-1957.

"
"1207","PC020325","Kunz R, Djulbegovic B, Schunemann HJ, et al.  2008.  Misconceptions, challenges, uncertainty and progress in guideline recommendations.  Semin Hematol 45:167-175."
"1208","PC020325","Strano S, Barba M, and Muti P.  2007.  Geni, ambiente e longevità.  In: Il manifesto della Lunga Vita.  Marandola P and Marotta F, Eds.  Sperling & Kupfer S.P.A, 32-36."
"1209","PC020325","Muti P and Grazzini G.  2008.  Il rischio tumori nelle donne.  Notiziario Inca Welfare di genere: Tra passato e futuro.  INCA N 31-32."
"1210","PC020325","Akl EA, Terrenato I, Barba M, et al. 2008.  Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: A systematic review and a meta-analysis.  Arch Intern Med 168:1261-9."
"1211","PC020325","Akl EA, Rohilla S, Barba M, et al.  2008.  Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review.  Cancer 113:1685-94."
"1212","PC020332","Lockett J, Yin S, Li X, Meng Y, Sheng S. 2006. Tumor suppressive maspin and epithelial homeostasis. 97(4):651-660."
"1213","PC020332","Yin S, Li X, Meng Y, Finley RL, Sakr W, Yang H, Reddy N, Sheng S. 2005. Tumor-suppressive maspin regulates cell response to oxidative stress by direct interaction with glutathione S-transferase. J. Biol. Chem. 280(41):34985-96."
"1214","PC020332","Liu J, Yin S, Reddy N, et al. 2004.  Bax Mediates the Apoptosis-Sensitizing Effect of Maspin.  Cancer Research 64:1703-1711"
"1215","PC020332","Yin S, Lockett J, Meng Y, et al.  2006.  Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator system. Cancer Res  66(8):4173-4181."
"1216","PC020345","Botchkina G, Kim R, Botchkina I, et al.  2005.  Noninvasive detection of prostate cancer by quantitative analysis of telomerase activity.  Clin Cancer Res.  11(9):3243-49.
"
"1217","PC020345","Botchkina GI, Kim RH, Botchkina IL, et al.  2005.  Noninvasive detection of prostate cancer by quantitative analysis of telomerase activity.  Clin Cancer Res 11:3243-3249."
"1218","PC020345","Kabotyanski EA, Botchkina GI, Kosobokova O, et al.  2006.  Highly sensitive revealing of PCR products with capillary eletrophoresis based on single photon detection.  Biosens Bioelectron 21:1924-31."
"1219","PC020372","Ponnazhagan S, Mahendra G, Kumar S, et al. 2004. Adeno-associated virus 2-mediated anti-angiogenic cancer gene therapy: Long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Research, 64: 1781-1787."
"1220","PC020372","Isayeva T, Ren C, and Ponnazhagan S.  2007.  Intraperitoneal gene therapy by rAAV provides long-term survial against epithelial ovarian cancer independently of survivin pathway.  Gene Ther 14:138-46."
"1221","PC020372","Ponnazhagan S. Parvovirus vectors for cancer gene therapy. Expert. Opin Biol Ther, 4:53-64."
"1222","PC020372","Ponnazhagan S and Hoover F. 2004. Delivery of DNA to tumor cells in vivo using adeno-associated virus. Meth Mol Biol, 246:237-243."
"1223","PC020372","Isayeva T, and S Ponnazhagan, 2004.  Anti-angiogenic gene therapy for cancer.  Int. J. Oncol. 25:335-343."
"1224","PC020372","Mahendra G, P Mahasreshti, DT Curiel, et al., 2005.  Anti-angiogenic gene therapy through adeno-associated virus 2-mediated stable expression of soluble Flt-1 receptor.  Cancer Gene Ther. 12:26-34."
"1225","PC020372","Isayeva T, C Ren, and S Ponnazhagan, 2005.  Recombinant adeno-associated virus 2-mediated anti-angiogenic prevention in a mouse model of intraperitoneal ovarian cancer.  Clin. Cancer Res. 11:1342-1347."
"1226","PC020373","Sim HG, Kliot M, Lange PH, Ellis WJ, Takayama TK, Yang CC.  2006. Two-year outcome of unilateral sural nerve interposition graft after radical prostatectomy. Urology 68(6):1290-4."
"1227","PC020392","Ugel S1, Zoso A, De Santo C,et al.  2009.  In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.  Cancer Res 69(24):9376-9384."
"1228","PC020401","Drivdahl R, Tennant MK, Sprenger CT, et al.  2004.  Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9.  Oncogene 23(26):4584-93."
"1229","PC020401","Plymate SR, CT Roberts, Jr., MK Tennant, et al., 2004.  IGF-IR regulation of androgen receptor signaling in progression to metastatic prostate cancer.  Prostate 61:276-284."
"1230","PC020401","Bavik C, Coleman I, Dean J, et al.  2006.  The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms.  2006 Cancer Research 66:794-802."
"1231","PC020401","Reed MJ, Karres N, Eyman D, et al.  2007.  The effects of aging on tumor growth and angiogenesis are tumor-cell dependent.  Int J Cancer.  120:753-60."
"1232","PC020401","Wu JD, Haugk K, Woodke L, et al.  2006.  Interaction of IGF signaling and the androgen receptor in prostate cancer progression.  J Cell Biochem 99:392-401."
"1233","PC020405","Sarkar K, Shi WT, Chatterjee, et al.  2005.  Characterization of ultrasound contrast misrobubbles using in vitro experiments and viscous and viscoelastic interface models for incapsulation.  J Acoust Soc Am 118:539-50."
"1234","PC020406","Zlotocha S, Staab MJ, Horvath D, et al.  2005.  A phase I study of a DNA vaccine
targeting prostatic acid phosphatase (PAP) in patients with stage D0 prostate cancer.  
Clin. Genitourinary Cancer 4:215-218.
"
"1235","PC020406","Johnson LE, Zhang G, Wolff JA, et al.  2003.  Intraarterial delivery of a DNA-based vaccine elicits high levels of antigen expression and antigen-specific immunity.  Proc. Amer. Assn. Cancer Res 44:886."
"1236","PC020406","
Johnson LE, Frye TP, Arnot AR, et al.  2006.  Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).  Vaccine 24:293-303.
"
"1237","PC020406","McNeel DG.  2005.  Prostate cancer antigens and vaccines, preclinical developments.  
Cancer Chemotherapy and Biological Response Modifiers 247-261.
"
"1238","PC020406","McNeel DG and Malkovsky M.  2005.  Immune-based therapies for prostate cancer. Immunol 96:3-9."
"1239","PC020406","McNeel DG and Malkovsky M.  2005.  Immune-based therapies for prostate cancer.  Immunol Lett 96:3-9."
"1240","PC020407","Shao H, Xu X, Jing N, et al.  2006.  Structure requirements for signal transducer and activator of transcription (STAT) 3 binding to granulocyte colony-stimulating factor receptor (G-CSFR)
phosphotyrosine ligands 704 and 744.  J Immunol 176(5):2933-2941.
"
"1241","PC020407","Jing N, Zhu Q, Yuan P, et al.  2006.  Targeting Stat3 with G-quartet oligonucleotides: A potential novel therapy for head and neck cancer.  Mol Cancer Ther 5(2):279-286."
"1242","PC020407","·Jing N, Li Y, Xu X, et al.  2003.  Targeting Stat3 with G-quartet oligodeoxynucleotides in human cancer cells.  DNA and Cell Biology 22:685-696."
"1243","PC020407","Jing N, Li Y, Xu X, et al.  2004.  G-quartet oligonucleotides: A new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis.  Cancer Res 64:6003-6009.

"
"1244","PC020407","Jing N, Sha W, Li Y, et al.  Rational drug design of G-quartet DNA an anti-cancer agents.  Curr Pharm Des 11:2841-54."
"1245","PC020407","Jing N and Tweardy DJ.  Targeting Stat3 in cancer therapy.  Anti-Cancer Drugs 16:601-7."
"1246","PC020413","Sunami E, Shinozaki M, Higano CS, Wollman R, Dorff TB, Tucker SJ, Martinez SR, Mizuno R, Singer FR, Hoon DS. Multimarker circulating DNA assay for assessing blood of prostate cancer patients.Clin Chem. 2009 Mar;55(3):559- 67. Epub 2009 Jan 8.Erratum in: Clin Chem. 2009 Jun;55(6):1258. Mizuno, Ryuich [added]."
"1247","PC020415","Jagadeesh S, Banerjee PP.  2006.  Inositol hexaphosphate represses telomerase activity and translocates TERT from the nucleus in mouse and human prostate cancer cells via the deactivation of Akt and PKCalpha.  Biochem Biophys Res Commun 349(4):1361-1367."
"1248","PC020427","Nguyen KH, Hachem P, Khor L-Y, et al.  2005.  Adenoviral-E2F-1 radiosensitizes p53 (wild-type) and p53 (null) human prostate cancer cells.  Int J Radiat Oncol Biol Phys 63:238-246."
"1249","PC020427","Stoyanova R, Hachem P, Hensley H, et al. Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo.  Int J Radiat Oncol Biol Phys 68(4):1151-1160."
"1250","PC020427","Udayakumar TS, Hachem P, Ahmed MM,  2008.  Antisense MDM2 enhances E2F1-induced apoptosis and the combination sensitizes androgen-sensitive [corrected] and androgen-insensitive [corrected] prostate cancer cells to radiation. Mol Cancer Res 6(11):1742-1754."
"1251","PC020427","Hanlon AL, Horwitz EM, Hanks GE, et al.  2004.  Short term androgen deprivation and PS doubling time: Their association and relationship to disease progression after radiation therapy for prostate cancer.  Intl J Radiat Oncol Biol Phys 58:43-52."
"1252","PC020427","Pollack A, DeSilvio M, Khor LY, et al.  2004.  Ki-67 staining is a strong predictor of distant metastasis and mortality of men with prostate cancer treated with radiotherapy plus androgen deprivation: an analysis of RTOG 92-02.  J Clin Oncol 22:2133-2140."
"1253","PC020427","Li R, Heydon K, Hammond ME, et al.  2004.  Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: An analysis of patients in RTOG protocol 8610.  Clin Cancer Res 10:4118-4124.

"
"1254","PC020427","Mu Z, Hachem P, Agrawal S, et al.  2004.  Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation and the combination.  Int. J. Radiat. Oncol. Biol. Phys. 58:336-343."
"1255","PC020427","Khor L, DeSilvio ML, Al Saleem T, et al.  2005.  MDM2 as a predictor for prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610.  Cancer 104:962-7."
"1256","PC020427","Mu Z, Hachem P, Hensley H, et al.  2008. Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo.  Prostate 68(6):599-609."
"1257","PC020439","Thorburn J, F Moore, A Rao, et al., 2005.  Selective inactivation of a Fas-associated death domain protein (FADD)-dependent apoptosis and autophagy pathway in immortal epithelial cells.  Mol. Biol. Cell. 16:1189-1199.

"
"1258","PC020441","Liu J-W, Chandra D, Rudd MD, et al.  2005.  Induction of pro-survival molecules by apoptotic stimuli: Involvement of FOXO3a and ROS.  Oncogene 24:2020-2031."
"1259","PC020441","Chandra D, Choy G, Daniel PT, et al.  Bax-dependent regulation of Bak by voltage-dependent anion channel 2.  J Biol Chem 280:19051-19061."
"1260","PC020441","Bhatia B, Multani AS, Patrawala L, et al.  2008.  Evidence that senescent human prostate epithelial cells enhance tumorigenicity: cell fusion as a potential mechanism and inhibition by p16INK4a and hTERT.  Int J Cancer 1483-95."
"1261","PC020441","Patrawala L, Calhoun T, Schneider-Broussard R, et al.  2005.  Side population (SP) is enriched in tumorigenic, stem-like cancer cells whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic.  Cancer Res 65:6207-6219."
"1262","PC020441","Bhatia B, Maldonado C, Tang S-H, et al. 2003.  Subcellular localization and tumor-suppressive functions of 15-lipoxygenase 2 (15-LOX2) and its splice variants. J. Biol. Chem. 278:25091-25100."
"1263","PC020441","Tang S, Bhatia B, Zhou J, et al.  2004.  Evidence that Sp1 positively and Sp3 negatively regulate and androgen does not directly regulate functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) gene expression in normal human prostate epithelial cells.  Oncogene 23:6942-6953."
"1264","PC020441","Bhatia B, Tang S, Yang P, et al.  2005.  Cell autonomous induction of functional tumor suppressor I5-lipoxygenase 2 (15-LOX2) contributes to replicative senescence of human prostate progenitor cells.  Oncogene 24:3583-95."
"1265","PC020441","Patrawala L, Calhoun T, Schneider-Broussard R, et al.  2006.  Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells.  Oncogene 25:1696-1708."
"1266","PC020441","Tang DG, Patrawala L, Calhoun T, et al.  2007.  Prostate cancer stem/progenitor cells: Identification, characterization, and implications.  Mol Carcinog 46:1-14."
"1267","PC020441","Chandra D, Choy G, Deng X, et al.  2004.  Active caspase-8 on the outer mitochondrial membrane cleaves BAP31 and caspase-3 and mediates mitochondria ¿ ER crosstalk in etoposide-induced apoptosis.  Mol Cell Biol 24:6592-6607."
"1268","PC020449","Sarkar S, Abujamra AL, Loew JE, et al.  2011.  Histone Deacetylase Inhibitors Reverse CpG Methylation by Regulating DNMT1 through ERK Signaling.  Anticancer Res 31(9):2723-2732."
"1269","PC020449","Mork CA, Spanjaard RA, and Faller DV.  2005.  A mechanistic approach to anticancer therapy; Targeting the cell cycle with histone deacetylase inhibitors.  Current Reviews in Pharmacology 11:1091-104."
"1270","PC020455","Gomez LA, de las Pozas A, Reiner T, et al.  2007.  Increased expression of Cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy.  Molecular Cancer Therapeutics 6:1534-1543.

"
"1271","PC020455","Perez-Stable CM.  2005.  2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells.  Cancer Letters 231:49-64."
"1272","PC020455","Perez-Stable CM.  2006.  2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells.  Cancer Letters 231:49-64.

"
"1273","PC020455","Gomez A, de las Pozas A, Perez-Stable C.  2006.  Sequential combination of flavopiridol and docetaxel reduces the levels of XIAP and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells.  Mol Cancer Ther 5:1216-26."
"1274","PC020455","Reiner T, de las Pozas A, Perez-Stable C.  2006.  Sequential combinations of flavopiridol and docetaxel inhibit prostate tumors, induce apoptosis, and decreases angiogenesis in the G&#947;/T-15 transgenic mouse model of prostate cancer.  The Prostate 66:1487-1497."
"1275","PC020455","Brown JW, Cappell S, Perez-Stable C et al.  2004.  Extracts from two marine sponges lower cyclin B1 levels, cause a G2/M cell cycle block and trigger apoptosis in SW-13 human adrenal carcinoma cells.  Toxicon 43(7):841-6."
"1276","PC020456","Shapiro PJ, Coyne JC, Kruus LK, et al.  2004.  Interest in services among prostate cancer patients receiving androgen deprivation therapy.  Psycho-Oncology 13(8):512-25."
"1277","PC020456","Coyne JC, Palmer SC, and Shapiro PJ.  2004.  Prescribing antidepressants to advanced cancer patients with mild depressive symptoms is not justified: Response to Fisch et al.  J. Clin. Oncology 22:205-206.

"
"1278","PC020458","Chinni SR, Sivalogan S, Dong Z, et al.  2006.  CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: The role of bone microenvironment-associated CXCL12.  The Prostate. 66(1):32-48."
"1279","PC020458","Chinni, S.R., Dong Z, Hamilto Y, Bonfil RD and Cher ML. CXCL12/CXCR4 trans-activates HER2 in lipid rafts of PC cells and promotes in vivo intra-osseous tumor growth.  Molecular Cancer Research.  6(3):446-457, 2008."
"1280","PC020459","Siemens DR, Hu N, Sheikhi AK,et al.  2008.  Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: role of nitric oxide. Cancer Res 68(12):4746-4753."
"1281","PC020459","Frederiksen LJ, Sullivan R, Maxwell LR, et al.  2007.  Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling.  Clin Cancer Res 13(7):2199-2206."
"1282","PC020459","Postovit LM, Sullivan R, Adams MA, et al. 2005.  Nitric oxide signaling and cellular adaptations to changes in oxygenation.  Toxicol 208:235-238."
"1283","PC020459","·Frederiksen LJ, Siemens DR, Heaton JP, et al. 2003. Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate. Journal of Urology, 170: 1003-1007."
"1284","PC020463","Ozen M, Medrano EE, Ittmann M.  2004. Inhibition of proliferation and survival of melanoma cells by adenoviral-mediated expression of dominant negative fibroblast growth factor receptor. Melanoma Res.14(1):13-21.


"
"1285","PC020463","Ozen M, and M Ittmann.  2005. Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer, Clin. Cancer Res., 11:4701-6."
"1286","PC020464","Watson PA, Ellwood-Yen K, King JC, Wongvipat J, Lebeau MM, Sawyers CL. 2005. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res. 65(24):11565-11571."
"1287","PC020469","Nie J, D Pei, 2004.  Rapid inactivation of alpha-1-proteinase inhibitor by neutrophil specific leukolysin/membrane-type matrix metalloproteinase 6.  Exp. Cell Res. 296:145-150.

"
"1288","PC020469","·Wang X, Ma D, Keski-Oja J, et al.  2004.  Co-recycling of MT1-MMP and Mt3-MMP through the trans-golgi network: Identification of DKV582 as a recycling signal.  J. Biol. Chem. 279:9331-6."
"1289","PC020469","·Nie J and Pei D.  2003.  Direct activation of proMMP-2 by leukolysin/MT6-MMP at the Asn109-Tyr bond.  Cancer Res.  63:6758-6762."
"1290","PC020469","Wang P, M Tortorella, K England, et al., 2004.  Proprotein Convertase Furin interacts with and cleaves pro-ADAMTS4 (aggrecanase-1) in the trans-Golgi network.  J. Biol. Chem. 279:15434-40."
"1291","PC020469","·Jiang A and Pei D.  2003.  Distinct roles of catalytic and pexin-like domains in MT-MMP mediated proMMP-2 activation and collagenolysis.  J. Biol. Chem. 278:38765-38771."
"1292","PC020469","·Wang P, Wang X, and Pei D.  2004.  Mint-3 regulates the retrieval of internalized MT5-MMP to plasma membrane by binding to its carboxyl end motif EWV.  J. Biol. Chem. 279(19):20461-70."
"1293","PC020469","Nie J, Pei J, Blumenthal M, et al.  2007.  Complete restoration of cell surface activity of transmembrane-truncated MT1-MMP by a glycosylphosphatidylinositol anchor: IMPLICATIONS for MT1-MMP-Mediated Prommp2 activation and collagenolysis in three-dimensions.  J Biol Chem 282:6438-6443"
"1294","PC020469","Liu B, Wang J, Chan KM, et al.  2005.  Genomic instability in laminopathy-based premature aging.  Nat Med. 11:780-5."
"1295","PC020469","Pei D.  2005.  Matrix metalloproteases target protease-activated receptors during tumor Progression. Cancer Cell 7:207-208."
"1296","PC020469","Cha T, A Guo, Y Jun, et al., 2004.  Immobilization of oriented protein molecules on poly(ethylene glycol)-coated Si(111)(pNA). Proteomics 4:1965-76."
"1297","PC020469","Ma D, WQ Xie, B Zou, et al.  An efficient and tunable route to AG7088, a rhinovirus protease inhibitor.  Tetrahedron Lett. 45:8103-5."
"1298","PC020469","Wang P, J Nie, and D Pei, 2004.  The hemopexin domain of MT1-MMP is not required for its activation of proMMP2 on cell surface, but essential for MT1-MMP mediated invasion in 3-D type I collagen.  J. Biol. Chem. 279:51148-55."
"1299","PC020469","Pan G. B Qin, N Liu, et al., 2004.  Identification of a nuclear localization signal in Oct4 and generation of a dominant negative mutant by its ablation.  J. Biol. Chem. 279:37013-20."
"1300","PC020469","Cui P, B Qin, G Pan, et al., 2004.  Nuclear localization of the phosphatidylserine receptor protein via multiple nuclear localization signals.  Exp. Cell Res. 293:154-63."
"1301","PC020469","
Iida J, KL Whilhelmson, MA Price, et al., 2004.  Membrane-type-1-matrix metalloproteinase (MT1-MMP) promotes human melanoma invasion and growth.  J. Inv. Derm. 122:167-76.
"
"1302","PC020469","Wilson MJ, A Jiang, C Wiehr, et al., 2004.  Limited processing of pro-matrix metalloprotease-2 (Gelatinase A) overpexpressed by transfection in PC-3 human prostate tumor cells:  Association with restricted cell surface localization of membrane-type matrix metalloproteinase-1.  J. Androl. 25:274-85."
"1303","PC020469","Zhao H, MM Bernardo, P Osenkowski, et al., 2004.  Differential inhibition of MT3-MMP and MT1-MMP by TIMP-2 and TIMP-3 regulates pro-MMP-2 activation.  J. Biol. Chem. 279:8592-601."
"1304","PC020469","Pan G and Pei D.  2005.  The stem cell pluripotency factor nanog activates transcription with two unusually potent subdomains at its C-terminus. J Biol Chem. 280:1401-1407."
"1305","PC020470","Chao WR, Yean D, Amin A, et al.  2007.  Computer-Aided (SR13668) Designed to Mimic the Unique Anticancer Mechanisms of Dietary Indole-3-Carbinol to Block Akt Signaling.  J. Med. Chem. 50:3412-3415."
"1306","PC020470","Jong L.  2006.  Computer-Aided Rational Drug Design:  A Novel Agent (SR13688) Designed to Mimic the Unique Anticancer Mechanisms of Dietary Indole-3-Carbinol to Block Akt Pathway.  J Med
Chem 1-4."
"1307","PC020476","Hayakawa J, Mittal S, Wang Y, et al.  2004.  Identification of genes bound and regulated by c-Jun and ATF2 transcription factors in vivo following DNA damage using promoter arrays.  
Mol Cell 16:521-535.
"
"1308","PC020476","·Adamson E, Belle ID, Mittal S, et al. 2003. Egr1 signaling in prostate cancer. Cancer Biology & Therapy 2:6, 617-622."
"1309","PC020476","Xia X, McClelland M, and Yipeng WY.  2005.  WebArray: An online platform for microarray data analysis.  BMC Bioinformatics 6:306."
"1310","PC020476","Wang Y, Yu Q, Cho A, et al.  2005.  Survey of differentially methylated promoters in prostate cancer cell lines.  Neoplasia 7:748-760."
"1311","PC020493","Kim C-Y, Jeong M, Kim B-M, et al.  2006.  Adenoviral delivery of the gene encoding secretable trimeric TRAIL suppresses tumor growth in vitro and in vivo via apoptosis induction.  Gene Ther 13:330-338."
"1312","PC020502","Sytkowski AJ.  2004.  Erythropoietin: Blood Brain and Beyond. Wiley-VCH, Weinheim, Germany.

"
"1313","PC020502","Chen C, Sytkowski AJ.  2004.  Erythropoietin regulation of Raf-1 and Mek: evidence for a Ras-independent mechanism.  Blood 104:73-80."
"1314","PC020502","Jeong JY, Hoxhaj G, Socha AL, et al. 2009. An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells. Mol Cancer Res 7(7):1150-7."
"1315","PC020502","Debeljak N, Feldman L, Davis KL, et al.  2006.  Variability in the immunodetection of his-tagged recombinant proteins.  Anal Biochem 359:216-223."
"1316","PC020502","Feldman L, Wang Y, Rhim JS, et al.  2006.  Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells.  Prostate 66:135-145."
"1317","PC020515","Wang J, Eltoum IE, and Lamartiniere CA. 2007. Genistein chemoprevention of prostate
cancer in TRAMP mice. J Carcinog 16(6)3."
"1318","PC020515","Harper CE, Patel BB, Wang J, et al. 2007.
Resveratrol suppresses prostate cancer progression in transgenic mice.  Carcinogenesis 28(9):1946-1953."
"1319","PC020520","Guan B, Pungaliya P, Li X, et al. 2008. Ubiquitination by TOPORS regulates the prostate tumor suppressor NKX3.1. J Biol Chem 283(8):4834-4840."
"1320","PC020520","Khalili M, Mutton LN, Gurel B, et al.  2010. Loss of Nkx3.1 expression in bacterial prostatitis: a potential link between inflammation and neoplasia. 
Am J Pathol 176(5):2259-2268.






























"
"1321","PC020520","Li X, Guan B, Srivastava MK, Padmanabhan A, et al.  2007.  The reverse in-gel kinase assay to profile physiological kinase substrates. Nat Methods 4(11):957-62. 

"
"1322","PC020520","Bethel CR, Bieberich CJ.  2007.  Loss of Nkx3.1 expression in the transgenic adenocarcinoma of mouse prostate model. Prostate 67(16):1740-50."
"1323","PC020520","Li X, Guan B, Maghami, S, et al.  2006.  NKX-3.1 is regulated by protein kinase.
CK2 in prostate tumor cells.  Mol Cellular Biol 8:3008-3017.
"
"1324","PC020526","Kazansky AV, Spencer DM, and Greenberg NM.  2003.  Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: Evidence from a transgenic adenocarcinoma of the mouse prostate system.  Cancer Res. 63:8757-8762.

"
"1325","PC020530","Song JJ, An JY, Kwon YT, et al.  2007.  Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance.  Involvement of Bcl-xL.  J Biol Chem 282:319-328."
"1326","PC020530","Kim YH and Lee YJ.  2007.  TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation.  J Cell Biochem 100:998-1009.

"
"1327","PC020530","Kim KM and Lee YJ.  2005.  Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the PI3-Akt pathway.  Oncogene 24:355-366."
"1328","PC020530","Lee YJ, Moon MS, Kwon SJ, et al.  2005.  Hypoxia and low glucose differentially augment TRAIL-induced apoptotic death.  Mol Cell Biochem 270:89-97."
"1329","PC020530","Kim KM, Lee YK.  2005.  The role of HER-2/neu signaling in sensitivity to tumor necrosis factor-related apoptosis-inducing ligand: amiloride enhances TRAIL cytotoxicity by inhibiting HER-2/neu-associated antiapoptotic signals.  J Cell Biochem 96:376-89."
"1330","PC020530","Kim YH and Lee YJ.  2006.  Time sequence of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin treatment is responsible for a complex pattern of synergistic cytotoxicity.  J Cell Biochem 98(5):1284-1295."
"1331","PC020531","·Wu L and Sato M.  2003.  Integrated, molecular engineering approaches to develop prostate cancer gene therapy.  Current Gene Therapy 3:452-467.  

"
"1332","PC020531","Sato M, Johnson M, Zhang L, et al.  2005.  Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer.  Clin Cancer Res 11:3743-9."
"1333","PC020531","Iyer M, Sato M, Johnson M, et al.  2005.  Applications of molecular imaging in cancer gene therapy.  Curr Gene Ther 5:607-618."
"1334","PC020531","Figueiredo M, Sato M, Johnson M, et al.  2006.  Specific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification system.  Future Oncol 2:391-406."
"1335","PC020531","Sato M, Johnson M, Burton J, et al.  2005.  In vivo molecular imaging to monitor prostate cancer-directed suicide gene therapy.  Mol Imaging 4(4):463-472."
"1336","PC020531","·Sato M, Johnson M, Zhang L, et al.  2003.  Optimization of adenoviral vectors to direct highly amplified prostate-specific gene expression for imagining and gene therapy.   Mol. Ther. 8:726-737."
"1337","PC020531","Johnson M, Huyn S, Burton J, et al.  2006.  Differential biodistribution of adenoviral vector in vivo as monitored by bioluminescence imaging and quantitative polymerase reaction.  Hum Gene Ther 17(12):1262-1269."
"1338","PC020531","Lee NV, Sato M, Annis DS, et al.  2006.  ADAMTS1 mediates the release of antiangiogenic polypeptide from TSP1 and 2.  EMBO J 25(22):5270-5283."
"1339","PC020532","·Zheng SL, Augustsson-Balter K, Chang BL, et al.  2004.  Sequence variants of TLR4 are associated with prostate caner risk: Results from the CAPS study. Cancer Res. 64(8):2918-22."
"1340","PC020532","Chang B, Zheng SL, Isaacs DS, et al.  2003.  Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk.  Intl J Cancer 106:375-378.

"
"1341","PC020532","Xu J, Gillanders EM, Isaacs SD, et al.  2003.  Genome-wide scan for prostate cancer susceptibility genes in the Johns Hopkins hereditary prostate cancer families.  Prostate 57:320-325.

"
"1342","PC020532","Chang BL, Zheng SL, Isaacs SD, et al.  2004.  The polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer.  Cancer Res 64:1997-1999."
"1343","PC020532","Cramer SD, Chang B, Rao A, et al.  2003.  Genetic polymorphism in the far upstream region of the PSA gene contributes to individual variation in serum PSA levels.  J Natl Cancer Inst 95:1044-1053."
"1344","PC020532","Chang B, Zheng SL, Isaacs SD, et al.  2003.  Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer.  Br J Cancer 89:1524-1529."
"1345","PC020532","Friedrichsen DM, Stanford JL, Isaacs SD, et al.  2004.  Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families.  Proc Natl Acad Sci USA 101:1939-1944."
"1346","PC020532","Gillanders EM, Xu J, Chang BL, et al.  2004.  Combined genome-wide scan for prostate cancer susceptibility genes: Evidence of linkage at 17Q22.  J Natl Cancer Inst 96:1240-1247."
"1347","PC020532","Hawkins GA, Chang BL, Zheng SL, et al.  2004.  Mutational analysis of PinX1 in hereditary prostate cancer.  Prostate 60:298-302."
"1348","PC020532","Lindmark F, Zheng SL, Wiklund F, et al.  2004.  The H6D polymorphism in the macrophage inhibitory cytokine gene 1 (MIC-1) is associated with prostate cancer.  J Natl Cancer Inst 96:1248-1254."
"1349","PC020532","Brown WM, Lange EM, Chen H, et al.  2004.  Hereditary prostate cancer in African American families: Linkage analysis using markers that map to five candidate susceptibility loci.  Br J Cancer 90:510-514.

"
"1350","PC020532","Xu J, Lagefeld CD, Zheng SL, et al.  2004.  Interaction effect of PTEN and CDKN1B chromosomal regions on prostate cancer linkage.  Hum Genet 115:255-262."
"1351","PC020532","Schaid DJ and Chang BL.  2004.  The international consortium for prostate cancer genetics description of the international consortium for prostate cancer genetics, and failure to replicate linkage of hereditary prostate cancer to 20q13.  Prostate 63:276-290."
"1352","PC020532","·Zheng SL, Zheng W, Chang BL, et al.  2003.  Joint effect of estrogen receptor beta sequence variants and endogenous estrogen exposure on breast cancer risk in Chinese women.  Cancer Res. 63:7624-7629."
"1353","PC020532","Chang BL, Gillanders EM, Isaacs SD, et al.  2005.  Evidence for a general cancer susceptibility locus at 3p24 in families with hereditary prostate cancer.  Cancer Lett 219:177-182."
"1354","PC020536","Sato M, M Johnson, L Zhang, et al., 2005.  Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer.  Clin. Cancer Res 11:3743-9."
"1355","PC020536","Ray S, R Paulmurugan, I Hildebrandt, et al., 2004.  Novel bidirectional vector strategy for amplification of therapeutic and reporter gene expression.  Hum. Gene Ther. 15:681-90.

"
"1356","PC020536","·Wu L and Sato.  2003.  Integrated, molecular engineering approaches to develop prostate cancer gene therapy.  Current Gene Therapy 3:452-467."
"1357","PC020536","·Sato M, Johnson M, Zhang L, et al.  2003.  Optimization of adenoviral vectors to direct highly amplified prostate-specific gene expression for imaging and gene therapy.     Mol. Ther. 8:726-737."
"1358","PC020536","·Wu L, Johnson M, Sato M.  2003.  Transcriptionally-targeted gene therapy to detect and treat cancer.  Trends in Molecular Medicine 9:421-429.

"
"1359","PC020536","Bao Y, Peng W, Verbitsky A, et al.  2005.  Human coxsackie adenovirus receptor (CAR) expression in transgenic mouse prostate tumors enhances adenoviral delivery of genes.  Prostate 64:401-7."
"1360","PC020536","Sato M, Figueiredo ML, Burton JB, et al.  2008.  Configurations of a two-tiered amplified gene expression system in adenoviral vectors designed to improve the specificity of in vivo prostate cancer imaging.  Gene Ther 15:583-93."
"1361","PC020536","Brakenhielm E, Burton JB, Johnson M, et al.  2007.  Modulating metastasis by a lymphangiogenic switch in prostate cancer.  Int J Can 121:2153-2161.

"
"1362","PC020536","Bjornadahl MA, Cao R, Burton JB, et al.  2005.  Vascular endothelial growth factor A promotes tumoral lymphangiogenesis and lymphatic metastasis.  Can Res 65:9261-8.  

"
"1363","PC020536","Johnson M, Sato M, Burton J, et al.  2005.  MicroPET/CT monitoring of hoerpes thymidine kinase suicide gene therapy in a prostate cancer xenograft:  the advantage of cell-specific transcriptional targeting approach. Mol Imaaging 4:463-72."
"1364","PC020536","Burton JB, Johnson M, Sato M, et al.  2008.  Adenovirus mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer.  Nat Med 14:882-8."
"1365","PC020544","Zhang X, Cai W, Cao F, et al. 2006.  18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.  J Nucl Med 47:492-501."
"1366","PC020544","Yang Y-S, Zhang X, Xiong Z, et al.  2006.  MicroPET imaging of gastrin-releasing peptide receptor expression with 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma.  Nucl Med Biol 33:371-380."
"1367","PC020544","·Chen X, Park R, Hou Y, et al.  2004.  MicroPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA- Lys3-bombesin in human prostate adenocarcinoma xenografts. J. Nucl. Med. 45(8):1390-0397."
"1368","PC020557","Hillier SM, Marquis JC, Zayas B, et al.  2006.  DNA adducts formed by a novel antitumor agent 11 beta-dichloro in vitro and in vivo.  Mol Cancer Ther.  5:977-84."
"1369","PC020557","Marquis JC, Hillier SM, Dinaut AN, et al.  2005.  Disruption of gene expression and
induction of apoptosis in prostate cancer cells by a bis-alkylating DNA damaging
agent tethered to an androgen receptor ligand. Chem Biol 12:779-787.
"
"1370","PC020558","Bradley SV, Oravacz-Wilson KI, Bougeard G, et al.  2005.  Serim antibodies to huntingtin interacting protein-1: A new blood test for prostate cancer.  Cancer Res 15:4126-4133."
"1371","PC020558","Wang X, Yu, J, Sreekumar A, et al.  2005.  Antibody signatures in prostate cancer.  N Engl J Med 353:1224-35."
"1372","PC020558","Sreekumar A, Laxman B, Rhodes DR,et  al.  2004. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst. 96(11):834-843."
"1373","PC020558","Sreekumar A, Laxman B, Rhodes DR, et al.  Protein microarray analysis reveals that prostate cancer patients elicit a humoral immune response to a-Methylacyl-CoA racemase.  JNCI 96(10):834-843."
"1374","PC020558","Yan F, Sreekumar A, Laxman B, et al.  2003.  Protein micorarrays using liquid phase fractionation of cell lysates.  Proteomics 3(7):1228-1235."
"1375","PC020586","Varkarakis IM, Inagaki T, Allaf ME, et al.  2005.  Comparison of
Erbium:YAG and Holmium:YAG lasers for incision of the urethra and bladder neck in a chronic porcine model. Urology 65(1):191-195.
"
"1376","PC020586","Fried NM, Yang Y, Chaney CA, et al.  2004.  Transmission of Q-switched Erbium:YSGG and Erbium:YAG laser radiation through germanium oxide and sapphire optical fibers at high pulse energies. Lasers in Med Sci 19(3):155-160."
"1377","PC020586","Levin K, Tran D, Tchapijnikov A, et al.  2004.  Specialty fiber expands infrared laser applications.  Biophotonics Intl 11(4):
41-43. 
"
"1378","PC020586","·Chaney CS, Yang Y, and Fried NM.  2004.  Hybrid germanium/ silica optical fibers for endoscopic delivery of Erbium:YAG laser radiation. Lasers in Surgery and Medicine 34:5-11."
"1379","PC020586","·Fried NM, Tesfaye Z, Ong AM, et al.  2003.  Optimization of the Erbium:YAG laser for precise incision of urethral tissues: in vitro and in vivo results.  Lasers in Surgery and Medicine    33:108-114."
"1380","PC020586","Chaney CA, Yang Y, Fried NM. 2004. Assembly and testing of germanium / silica optical fibers for flexible endoscopic delivery of Erbium:YAG laser radiation. Proc. SPIE: Optical Fibers and Sensors for Medical Applications 4 5317:1-8."
"1381","PC020586","Varkarakis IM, Inagaki T, Allaf ME, Chan TY, Rogers CG, Wright EJ, Fried NM. 2005. Erbium vs. Holmium laser incision of urethra and bladder neck. Proc. SPIE: Photonic Therapeutics and
Diagnostics 5686:171-175."
"1382","PC020586","Ngo AK, Fried NM. 2007. Delivery of Erbium:YAG laser radiation through side-firing germanium oxide fibers. Proc. SPIE."
"1383","PC020586","Ngo AK, Fried NM.  2006.  Side-firing germanium oxide optical fibers for use with erbium:YAG laser. J Endourol. 20(7):475-8.




"
"1384","PC020586","Fried NM, Tesfaye Z, Ong AM, Rha KH, Hejazi P. 2004.  Variable pulsewidth Erbium:YAG laser ablation of the ureter and urethra in vitro and in vivo: optimization of the laser fluence, pulse
duration, and pulse repetition rate. Proc. SPIE: Lasers in Surgery 14 5312:105-111."
"1385","PC020586","Fried NM, Yang Y, Lee K, Tafti HA. 2005.Transmission of free-running and Q-switched Er:YAG laser energy through germanium / silica fibers. Proc. SPIE: Optical Fibers and Sensors for Medical
Applications 5 5691:155-119."
"1386","PC020586","Varkarakis IM, Inagaki T, Allaf ME, Chan TY, Rogers CG, Wright EJ, Fried NM. 2005.  Comparison of Erbium:YAG and Holmium:YAG lasers for incision of the urethra and bladder neck in a chronic
porcine model. Urology 65(1):191-195."
"1387","PC020590","Yang G, TL Timme, TM Wheeler, and TC Thompson, 2005.  Combined c-Myc and caveolin-1 expression in human prostate cancer predicts prostate cancer progression.  Cancer 103(6):1188-1194.

"
"1388","PC020591","Zhou Y, Gu X, Ashayeri E, et al.  2007. Nicotine decreases the cytotoxicity of doxorubicin towards MCF-7 and KB-3.1 human cancer cells in culture.  J Natl Med Assoc 99:319-27.

"
"1389","PC020591","Gu X, Schwartz JL, Zhou Y, et al.  2005.  Cytotoxicity of liposomal alpha-tocopheryl succinate towards hamster cheek pouch carcinoma (HCPC-1) cells in culture.  Cancer Ltrs."
"1390","PC020591","Sridhar R.  2005.  RNA processing in health and disease: A brief review.  J Clin Ligand Assay 28(2):61-67."
"1391","PC020591","
Velan SS, Durst CL, Lemieux SK, et al.  2007.  Investigation of muscle lipid metabolism by localized one- and two-dimensional MRS techniques using a clinical 3T MRI/MRS scanner.  J Magn Reson Imaging 25:192-199.
"
"1392","PC020591","Velan SS, Lemieux SK, Raylman RR, et al.  2007. Detection of cerebral metabolites by single-voxel based PRESS and COSY techniques at 3T.  J Magn Reson Imaging 26:405-9."
"1393","PC020591","Velan SS, Durst CL, Lemieux SK, et al.  2007.  Investigation of muscle lipid metabolism by localized one-and two-dimensional MRS techniques using a clinical 3T MRI-MRS scanner.  J Magn Reson Imaging 25:192-199."
"1394","PC020591","Bratasz A, Weir NM, Parinandi NL, et al.  2006.  Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro-derivative of aspirin.  Proc Natl Acad Sci USA 103:3914-3918."
"1395","PC020591","Gu X, Schwartz JL, Zhou Y, et al.  2006.  Cytotoxicity of liposomal alpha-tocoperheryl succinate towards hamster cheek pouch carcinoma (HCPC-1) cells in culture.  Cancer Lett 239:281-291."
"1396","PC020591","Zhou Y, Gu X, Ashayeri E, et al.  2007.  Nicotine decreases the cytotoxicity of doxorubicin towards MCF-7 and KB-3.1 human cancer cells in culture.  J Natl Med Assoc 99:319-327."
"1397","PC020591","Shan L, Wang S, Sridhar R, et al. 2007.  A dual probe with fluorescent and magnetic properties for imaging solid tumor xenografts.  Mol Imaging 6:85-95."
"1398","PC020604","Yong Y and Xing L. 2004. Inverse treatment planning with adaptively evolving voxel-dependent penalty scheme. Med Phys. 31:2839-44."
"1399","PC020604","Schreibmann E and Xing L.  2005.  Dose-volume based ranking of incident beam directions and its utility in facilitating IMRT beam placement.  International Journal of Radiation Oncology, Biology, Physics 63:584-593.
"
"1400","PC020604","Schreibmann E, and L Xing, 2005.  Narrow band deformable registration of prostate MRI/MRSI and CT studies.  Int. J. Radiat. Oncol., Biol., Phys. 62:595-605."
"1401","PC020604","Lian J, S Hunjan, B Daniel, et al., 2004.  Mapping of the prostate in endorectal coil-based MRI/MRSI and CT:  A deformable registration and validation study.  Medical Physics 31:2711-20.

"
"1402","PC020604","Yang Y, and L Xing, 2004.  Inverse planning with adaptively evolving voxel-dependent penalty scheme.  Medical Physics 31:2819-25."
"1403","PC020604","Xing L, Q Wu, Y Yang, and AL Boyer, 2005.  Physics of IMRT and inverse treatment planning, in intensity modulated radiation therapy:  A clinical perspective, AF Mundt, and JC Roeske, eds., pages 20-51, BC Decker, Inc., publisher, Hamilton, Canada."
"1404","PC020604","Xing L, Y Yang, and D Spielman.  Molecular/functional image-guided radiation therapy, T Bortfetld, R Schmidt-Ullrich and W de Neve, eds., Springer-Verlag Heidelberg, Berlin, Germany."
"1405","PC020604","Yang Y, and L Xing, 2005.  Towards biologically conformal radiation therapy (BCRT):  Selective IMRT dose escalation under the guidance of spatial biology distribution.  Medical Physics 32:1473-84.

"
"1406","PC020604","Xia P, N Yu, L Xing, et al., 2005.  Investigation of a new objective function for inverse planning optimization.  Medical Physics 32:920-7."
"1407","PC020604","Paquin D, Levy D, Schreibmann E, et al.  2006.  Multistage image registration.  Mathematical Biosciences and Engineering 3:389-418."
"1408","PC020604","Loo B, Draney MT, Sivanadan R, et al.  2006.  Indirect MR lymphangiography using conventional gadolinium contrast.  Int J Radiat Oncol Biol Phys 66:462-8."
"1409","PC020604","Xing L, Thorndyke B, Schreibmann E, et al.  2006.  Overview of image guided radiation therapy (IGRT).  Medical Dosimetry 31:91-122.

"
"1410","PC020604","Thorndyke B, Schreibmann E, Koong A, et al.  2006.  Enhancing the performance of 4D PET imaging by retrospective stacking.  Med Phys 33:2632-41."
"1411","PC020604","Li J and Xing L.  Radiation dose planning, computer-aided.  In: Encyclopedia of Medical Devices and Instrumentation (Webster JG Ed.)   John Wiley & Sons."
"1412","PC020604","Pawlicki T, Kim G, Hsu A, et al.  2006.  Investigation of Linac based Image-guided Hypofractionated Prostate Radiotherapy.  Medical Dosimetry 31:91-122."
"1413","PC020604","Schreibmann E, Chen G, and Xing L.  2006.  Image interpolation in 4D CT.  International Journal of Radiation Oncology, Biology, Physics 64:1537-1550."
"1414","PC020604","Schreibmann E and Xing L.  2006.  Image registration with auto-mapped control volumes.  Medical Physics 33:1165-1179."
"1415","PC020604","Lian J, Hunjan S, Daniel B, et al. 2004. Mapping of the   prostate in endorectal coil-based MRI/MRSI and CT: A deformable registration and validation study. Med Phys. 31:3087-94."
"1416","PC020604","Schreibmann E and L Xing, 2004.  Beam orientation class-solutions for IMRT prostate cancer treatment.  Medical Physics 31:2863-70."
"1417","PC020604","Yang Y, and L Xing, 2004.  Clinical knowledge-based inverse treatment planning.  Physics in Biology and Medicine 49:5101-17."
"1418","PC020604","Kim D, D Mayer, L Xing, et al., 2005.  In vivo detection of citrate for prostate cancer at 3 Tesla.  Magnetic Resonance Imaging in Medicine 53:1177-82."
"1419","PC020606","Johansson M, McKay JD, Stattin P, et al.  2007.  Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer.  Int J Cancer 120:539-542."
"1420","PC020606","Canzian F, McKay JD, Cleveland RJ, et al.  2006.  Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: Results from the EPIC study.  Br J Cancer 94(2):299-307."
"1421","PC020606","Al-Zahrani A, Sandhu MS, Luben RN, et al.  2006.  IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer.  Hum Mol Genet 16:1-10."
"1422","PC020606","Johansson M, McKay JD, Wiklund F, et al.  2007.  Genetic variation in the IGF1 gene - in relation to circulating levels of IGF1 - Implications for prostate cancer.  J Clin Endocrinol Metab 92:4820-4826."
"1423","PC020606","McKay JD, Kaaks R, Johansson M, et al.  2007.  Haplotype-based analysis of common variation in the growth hormone receptor gene and prostate cancer risk.  Cancer Epidemiol Biomarkers Prev 16:169-173."
"1424","PC020611","Kuzmichev A, Margueron R, Vaquero A, et al.  2005.  Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci USA 102:1859-1864."
"1425","PC020611","Gao H, Ouyang X, Banach-Petrosky W, et al.  2004.  A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis.  Proc Natl Acad Sci USA 101:1720417209."
"1426","PC020611","Ouyang X, DeWeese TL, Nelson WG, Abate-Shen C. 2005. Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res. 65(15):6773-6779."
"1427","PC020616","Sikes RA, Cooper CR, Beck GL, et al.  2005.  Bone stromal cells as therapeutics targets in osseous metastasis.  In: Cancer Growth and Progression, Integration/Interaction of Oncologic Growth.  (Meadows G, Ed, Kaiser H, Series Ed).  Kluwer Academic Publishers, Boston, Massachusetts."
"1428","PC020620","¿Chendil D, Ranga RS, Meigooni D, et al.  2004.  Curcumin confers radio-sensitizing effect in prostate cancer cell line PC-3.  Oncogene 23:1599-1707.

"
"1429","PC020630","Elzey BD, Tian J, Jensen RJ, et al.  2003.  Platelet-mediated modulation of adaptive immunity: A communication link between innate and adaptive immune compartments.  Immunity 19:9-19."
"1430","PC020630","Elzey BD, Grant JF, Sinn HW, et al.  2005.  Cooperation between platelet-derived CD154 and CD4+ T cells for enhanced germinal center formation.  J Leukoc Biol 78:80-84.

"
"1431","PC020638","Tucker JM, Murphy JT, Kisiel N et al.  2005.  Potent modulation of intestinal tumorigenesis in Apc min/+ mice by the polyamine catabolic enzyme spermidine/spermind N1-acetyltransferase.  Cancer Res 65:5390-5398."
"1432","PC020638","Hector S, Porter CW, Kramer DL, et al.  2004.  Polyamine catabolism in platinum drug action: Interactions between oxaliplatin and the polyamine analogue N1, N11-diethylnorspermine at the level of spermidine/spermine N1-acetyltransferase.  Mol Cancer Ther 3:813-822."
"1433","PC020638","·Kee K, Vujcic S, Kisiel N, et al.  2003.  Activation of polyamine catabolism as a novel strategy for treating and/or preventing prostate cancer.  Proc. Am. Assoc. Cancer Res.   44:1277."
"1434","PC020638","Kee K, Vujcic S, Merali S, et al.  2004.  Metabolic and antiproliferative consequences of activated polyamine catabolism in LNCaP prostate carcinoma cells.  J Biol Chem 279:27050-27058."
"1435","PC020638","Kee K, Foster BA, Merali S, et al.  2004.  Activated polyamine catabolism depletes acetyl-CoA and suppresses prostate tumor growth in the TRAMP mouse.  J Biol Chem 279:40076-40083.

"
"1436","PC020646","Frost GI, Lustgarten J, Dudouet B, et al.  2005.  Novel syngeneic pseudo-orthotopic prostate cancer model: Vascular, mitotic and apoptotic responses to castration.  Microvasc Res 69(1-2):1-9."
"1437","PC020653","Wang Z, Zhai W, Richardson JA, et al.  2004.  Polybromo protein BAF180 functions in mammalian cardiac chamber maturation.  Genes Dev 18:3106-3116."
"1438","PC020655","Dhanasekaran SM, A Dash, J Yu, et al., 2005.  Molecular profiling of human prostate tissue:  Insights into gene expression patterns of prostate development during puberty.  FASEB J. 19:243-245."
"1439","PC020674","Domarkas J, Dudouit F, Williams C, et al.  2006.  The combi-concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR).  J.Med Chem 49:3544-3552."
"1440","PC020680","Larson GP, Ding Y, Cheng LS, et al.  2005.  Genetic linkage of prostate cancer risk to the chromosome 3 region bearing FHIT.  Cancer Res 65:805-814."
"1441","PC020695","Song XT, Evel-Kabler K, Rollins L, et al.  2006.  An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells.PLoS Med 3(1):e11.Shen L, Evel K, Strube R, et al.  2004.  Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigenspecific anti-tumor immunity.  Nat Biotechnol 22:1546-1553."
"1442","PC020695","Shen L, Evel K, Strube R, et al.  2004.  Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific antitumor immunity.  Nature Biotechnology 22:1546-1553."
"1443","PC020695","Schroers R, Shen L, Rollins L, et al.  2003.  Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.  Clinical Cancer Research    9:3260-3271."
"1444","PC020695","Evel-Kabler K, Song XT, Aldrich M, et al.  2006.  SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling.  J Clin Invest 116(1):90-100."
"1445","PC020718","Singh RP, Dhanalakshmi S, Agarwal C, et al.  2005.  Silibinin strongly inhibits growth and survival of endothelial cells via cell cycle arrest and down-regulation of survivin, Akt and NF-kappa B: Implications for angioprevention and antiangiogenic therapy.  Oncogene 24:1188-1202."
"1446","PC020718","Singh RP and Agarwal R.  2004.  A cancer chemopreventive agent silibinin, targets mitogenic and cell survival signaling in prostate cancer. Mutat Res 555:21-32."
"1447","PC020722","Miller DC, Zheng SL, Dunn RL, et al.  2003.  Germ-line mutations of the macrophage scavenger receptor 1 gene: Association with
prostate cancer risk in African American men.  Cancer Res 63:3486-3489.
"
"1448","PC020722","Claeys GB, Sarma AV, Dunn RL, et al.  2005.  INS Pst1 polymorphism and prostate cancer in African American men.  The Prostate 65:83-87."
"1449","PC020722","Beebe-Dimmer J, Lange LA, Cain JE, et al.  2006.  Polymorphisms in the prostate-specific antigen gene promoter do not predict serum prostate-specific antigen levels in African American men.  Prost Cancer Prostat Dis 9:50-55."
"1450","PC020722","Amundadottir LT, Sulem P, Gudmundsson J, et al.  2006.  A common variant associated with prostate cancer in European and African populations.  Nat Genet Adv Online Publication, 1-7."
"1451","PC020722","Amundadottir LT, Sulem P, Gudmundsson J, et al.  2006.  A common variant associated with prostate cancer in European and African populations.  Nat Genet 38(6):652-658."
"1452","PC020733","Taylor RA, Cowin PA, Cunha GR, et al.  2006.  Formation of human prostate tissue from embryonic stem cells.  Nat Meth 3(3):179-181."
"1453","PC020735","Li YM, Vilain E, Conte F, et al.  2007.  TSPY is expressed in early and late stages of gonadoblastoma and testicular carcinoma-in-situ.  Urol Oncol 25:141-146."
"1454","PC020735","Li YM, Tabatabi ZL, Lee T-L, et al.  2007.  The Y-encoded TSPY protein: A significant marker potentially plays a role in the pathogenesis of testicular germ cell tumors.  Hum Pathol 38:1470-81."
"1455","PC020735","Lau Y-FC, Kido T and Li YM.  2007.  Chapter 4: The TSPY gene family.  In:  Y Chromosome and Male Germ Cell Biology (Lau Y-FC and Chan WY, eds.).  World Scientific Press, Singapore, pp 73-90."
"1456","PC020735","Kido T and Lau Y-FC.  2006.  The rat Tspy is preferentially expressed in elongated spermatids and interacts with the core histones.  Biochem Biophys Res Commun 350:56-67."
"1457","PC020735","Oram SW, Liu XX, Lee T-L, et al.  2006.  TSPY potentiates cell proliferation and tumorigenesis by promoting cell cycle progression in HeLa and NIH3T3 cells.  BMC Cancer 6:154."
"1458","PC020735","Hoei-Hansen C, Sehested A, Juhler M, et al.  2006.  New evidence for origin of intracranial germ cell tumors from primordial germ cells: Analysis of c-Kit, Oct-3/4, AP-2-gamma, TSPY, and others.  J Path 209:25-33."
"1459","PC020735","Honecker F, Stoop H, Mayer F, et al.  2006.  Germ cell lineage differentiation in non-seminomatous germ cell tumours. J Pathol 208:395-400."
"1460","PC020735","Cools M, Honecker F, Stoop H, et al.  2006.  Maturation delay of germ cells in fetuses with trisomy 21 results in increased risk for the development of testicular germ cell tumors.  Hum Pathol 37:101-111."
"1461","PC020735","Kersemaekers AM, Honecker F, Stoop H, et al.  2005.  Identification of germ cells at risk for neoplastic transformation in gonadoblastoma: An immunohistochemical study for OCT3/4 and TSPY.  Hum Pathol 36:512-521."
"1462","PC020735","Williams K, Fernandex S, Stien X, et al.  2005.  Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype.  Prostate 63:369-384.

"
"1463","PC020735","Lau Y-FC, Lau HW, Komuves LG. 2003. Expression pattern of a gonadoblastoma candidate gene suggests a role of the Y chromosome in prostate cancer. Cytogenet Genome Research 101:250-260 

"
"1464","PC020735","Kido T and Lau Y-FC.  2005.  A Cre gene directed by a human TSPY promoter is specific for germ cells and neurons.  Genesis 42:263-275."
"1465","PC020761","Teixeira MS, Camacho-Vanegas O, Fernandez Y, et al.  2007.  KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma.  Int J Cancer 121:1976-83."
"1466","PC020761","DiFeo A, Narla G, and Martignetti JA.  2007.  Alternative splicing of KLF6 and KLF6-SV1 in human cancer.  Beyond Guilt by Association.  In: Alternative Splicing in Human Cancer.  Ed J.P. Venables."
"1467","PC020761","DiFeo A, Narla G, Hirshfeld J, et al.  2006.  Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination.  Clin Cancer Res 12:3730-9."
"1468","PC020761","Camacho-Vanegas O, Narla G, Teixeira MS, et al.  2007.  Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma.  Int J Cancer 121:1390-5.

"
"1469","PC020761","DiFeo A, Narla G, and Martignetti JA.  Alternative splicing of KLF6 and KLF6-SV1 in human cancer.  Beyond guilt by association.  In: Alternative Splicing in Human Cancer (Venables JP, Ed.)

"
"1470","PC020761","Reeves HL, Narla G, Ogunbiyi O, et al.  2004.  The tumor suppressor gene kruppel-like factor 6 (KLF6) is inactivated in a majority of colorectal cancers.  Gastroenterology 126:1090-1103."
"1471","PC020761","Kremer-Tal S, Reeves HL, Narla G, et al.  2004.  Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma.  Hepatology 40:1047-1052.

"
"1472","PC020761","Narla G, Martignetti JA, et al.  2005.  A germline DNA polymorphism associated with increased prostate cancer risk enhances alternative splicing of the KLF6 tumor suppressor gene.  Cancer Res 65:1213-1222."
"1473","PC020761","Narla G, Martignetti JA, et al.  2005.  Targeted inhibition of the KLF6 splice variant KLF6 SV1 suppresses prostate cancer cell growth and spread.  Cancer Res 65:5761-5768."
"1474","PC020761","Kirschenbaum A, Liu XH, Yao S, et al.  2006.  Sex steroids have differential effects on growth and gene expression in primary human prostatic epithelial cell cultures derived from the peripheral vs. transition zones.  Carcinogenesis 27:216-624."
"1475","PC020761","Park JH, Eliyahu E, Narla G, et al.  2005.  Promoter analysis of the murine acid ceramidase gene: The role of KLF6 in the regulation of acid ceramidase gene expression.  Biochim Biophys Acta 1732:82-87."
"1476","PC020761","DiFeo A, Narla G, Hirshfeld J, et al.  2006.  Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination.  Clin Cancer Res 12:3730 3739."
"1477","PC020761","DiFeo A, Narla G, Camacho-Vanegas O, et al.  2006.  E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor.  Oncogene 25:6026-31."
"1478","PC020761","Narla G, DiFeo A, Reeves H, et al.  2005.  A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk.  Cancer Res 65(4):1213-22.
"
"1479","PC020763","Li TH, Zhao H, Peng Y, et al.  2007.  A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells.  Nucleic Acids Res 35(8):2767-2776 (http://nar.oxfordjournals.org/cgi/content/full/35/8/2767)."
"1480","PC020763","Verras M and Sun Z.  2005.  beta-catenin is involved in insulin-like growth factor 1-mediated transactivation of the androgen receptor.  Mol Endocrinol 19:391-398."
"1481","PC020763","Verras M, Brown J, Li X, et al.  2004.  Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells.  Cancer Res 64:8860-8866."
"1482","PC020763","Beliakoff J and Sun ZJ.  2006.  Zimp7 and Zimp10, two novel pias-like proteins, function as
androgen receptor co-regulators.  Nucl Recept Signal 4:e017 (http://www.nursa.org/article.cfm?doi=10.1621/nrs.04017).
"
"1483","PC020763","Li X, Thyssen G, Beliakoff J, et al.  2006.  The novel PIAS-like protein, hZimp10, enhances
Smad transcriptional activity.  J Biol Chem 281:23748-23756 (http://www.jbc.org/cgi/content/full/281/33/23748).
"
"1484","PC020763","Verras M and Sun ZJ.  2006.  Roles and regulation of Wnt signaling and beta-catenin in prostate cancer.  Cancer Lett 237:22-32.

"
"1485","PC020770","Li D, Yea S, Cooreman MP, et al.  2005.  KLF6 promotes preadipocyte differentiation through histone deacetylase 3 (HDAC3)-dependent repression of Dlk.  J Biol Chem 280(29):26941-26952."
"1486","PC020770","Kremer-Tal S, Reeves HL, Narla G, et al.  2004.  Frequent inactivation of the tumor suppressor Kruppel like factor 6 (KLF6) in hepatocellular carcinoma.  Hepatology 40:1047-1052."
"1487","PC020770","Li D, Yea S, Martiginetti J., et al.  2005.  Regulation of Kruppel-like Factor 6 Tumor Suppressor Activity by Acetylation.  Cancer Res 65:9216-9225.
"
"1488","PC020782","Sarkar FH and Li Y.  2006.  Plant derived antioxidants.  In:  Singh KK, ed. Oxidative Stress, Disease and Cancer.  London:  Imperial College Press."
"1489","PC020782","·Rahman KM, Li Y, and Sarkar FH. 2004. Inactivation of Akt and NF-kappaB play important roles during Indole-3-Carbinol-induced apoptosis in breast cancer cells. Nutr Cancer 48:84-94."
"1490","PC020782","Li Y, X Li, and FH Sarkar, 2003.  Gene expression profiles of I3C- and DIM-treated PC3 human prostate cancer cells determined by cDNA microarray analysis.  Amer. Soc. For Nutritional Sci. 133(4):1011-9."
"1491","PC020782","Li Y, Wang Z, Kong D, et al.  2007.  Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3¿-diindolylmethane (DIM) contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells.  JBC 2007."
"1492","PC020782","Li Y, X Li, and FH Sarkar, 2003.  Gene expression profiles of I3C and DIM-treated PC3 human prostate cancer cells by cDNA microarray analysis.  J Nutr., 133:1011-9."
"1493","PC020782","Sarkar FH, and Y Li, 2003.  Significance of indole-3-carbinol and its metabolite in human cancers.  Evidence-Based Integrative Medicine 1:33-41."
"1494","PC020782","Li Y, SR Chinni, and FH Sarkar. 2005. Selective growth regulatory and pro-apoptotic effects of DIM is mediated by Akt and NF-kappaB pathways in prostate cancer cells.  Front Biosci, 10:236-43."
"1495","PC020782","Sarkar FH and Li Y.  2006.  Using chemopreventative agents to enhance the efficacy of cancer therapy.  Cancer Res 66(7):3347-3350.

"
"1496","PC020782","Bhuiyan MM, Li Y, Banerjee S, et al.  2006.  Down-regulation of androgen receptor by 3,3¿-diidolylmethane contributes to inhibition of  cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer c ells.  Cancer Res 66:10064-72."
"1497","PC020782","Li Y, Wang Z, and Sarker FH.  2007.  Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3¿-diindolylmethane (DIM) contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells.  Proc Am Assoc Cancer Res 48:3370."
"1498","PC020782","Kong D, Li Y, Wang Z, et al.  2007.  Inhibition of angiogenesis and invasion by 3, 3'-diindolylmethane is mediated by NF-kappa(B) downsream target genes MMP-9 and uPA regulated bioavailability of VEGF in prostate cancer.  Cancer Res 67:3310-9."
"1499","PC020791","Nie D and Honn KV. 2004. Eicosanoid regulation of angiogenesis in tumors. Semin Thromb Hemost 30(1):119-125."
"1500","PC020791","Pidgeon GP, Tang K, Rice RL, et al. 2003. Overexpression of leukocyte type 12-lipoxygenase promotes W256 tumor cell survival by enhancing a Vbeta5 expression. Intl J Cancer 105:459-471."
"1501","PC020791","Pidgeon GP, Tang K, Cai YL, et al. 2003. Overexpression of platelet type 12-lipoxygenase promotes tumor cell survival by enhancing a Vbeta3 and a Vbeta5 integrin expression. Cancer Res 63:4258-4267."
"1502","PC020791","Kandouz M, Nie D, Pidgeon GP, et al. 2003. Platelet-type 12-lipoxygenase activates NF-kappaB in prostate cancer cells. Prostaglandins Other Lipid Mediat 71(3-4):189-204."
"1503","PC020791","Nie D, Nemeth J, Qiao Y, et al. 2003. Increased metastatic potential in human prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase. Clin Exp Metastasis 20(7):657-663."
"1504","PC020791","Nie D, Che M, Grignon D, et al. 2001. Role of eicosanoids in prostate cancer progression. Cancer and Metastasis Review 20:195-206.

"
"1505","PC020802","Halabi S, Vogelzang NJ, Ou SS, et al.  2006. Clinical outcomes by age in men with hormone refractory prostate cancer:  A pooled analysis of eight Cancer and Leukemia Group B (CALGB) Studies.  J  Urol 176:81-6."
"1506","PC020802","Halabi S, Vogelzang NJ, Ou SS, et al.  2007.  The impact of prior radical prostatectomy in men with metastatic castration-recurrent prostate cancer: A pooled analysis of nine CALGB trials.  Journal of Urology 177:531-534."
"1507","PC020802","Halabi S, Vogelzang NJ, Kornblith AB, et al.  2008.  Pain interference predicts overall survival in men with metastatic castration refractory prostate cancer (CRPC).  J Clin Oncol 26:2544-9.
"
"1508","PC020802","Halabi S, Ou SS, Vogelzang NJ, et al.  2007.  Inverse relationship between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer.  Cancer 110:1478-1484.
"
"1509","PC020802","Halabi S.  2008.  Statistical considerations for the design and analysis of phase III clinical trials in Prostate cancer.  Urol Oncol 26:300-7."
"1510","PC020809","Gromley A, Yeaman C, Rosa J, et al.  2005.  Centriolin anchoring of exocyst and SNARE complexes at the midbody is required for secretory-vesicle-mediated abscission.  Cell 123:1-13.

"
"1511","PC020809","Chien Y, Kim S, Bumeister R, et al.  2006.  RalB GTPase-mediated activation of the IkB family kinase TBK1 couples innate immune signaling to tumor cell survival.  Cell 127:157-170."
"1512","PC020822","Ozerdem U, Hargens AR.  2005.  A simple method for measuring interstitial fluid pressure in cancer tissues.  Microvas Res 70:116-120."
"1513","PC020822","Ozerdem U, Alitalo K, Salven P, et al.  2005.  Contribution of bone marrow-derived pericyte precursor cells to corneal vasculogenesis.  IOVS 46(10)3502-3506."
"1514","PC020822","Ozerdem U.  2006.  Targeting of pericytes diminishes neovascularization and lymphangiogenesis in prostate cancer.  The Prostate 66:294:304."
"1515","PC020822","Ozerdem U and Stallcup WB.  2004.  Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan.  Angiogenesis 7:269-276."
"1516","PC020822","Ozerdem U and Stallcup WB.  2003.  Early contribution of pericytes to angiogenic sprouting and tube formation.  Angiogenesis 6:241-249."
"1517","PC020827","Liu J-W, Chandra D, Rudd MD, et al.  2005.  Induction of pro-survival molecules by apoptotic stimuli: Involvement of FOXO3a and ROS. Oncogene 24:2020-2031."
"1518","PC020829","Kodibagkar VD, Cui W, Merritt M, et al.  2006.  Novel 1H NMR approach to quantitative tissue oximetry using hexamethyldisiloxane.  Magn Reson Med 55:743-748."
"1519","PC020834","Sato S, Kwon Y, Kamisuki S, Srivastava N, Mao Q, Kawazoe Y, Uesugi M.  2007. Polyproline-rod approach to isolating protein targets of bioactive small molecules: isolation of a new target of indomethacin. J Am Chem Soc. 31;129(4):873-80"
"1520","PC020834","Choi Y, Kawazoe Y, Murakami K, et al.  2003.  Identification of bioactive molecules by adipogenesis profiling of organic compounds.  J. Biol. Chem. 278:7320-7324."
"1521","PC020850","Jia L, Noker PE, Piazza GA,et al. 2008.  Pharmacokinetics and pharmacodynamics of Phor21-betaCG(ala), a lytic peptide conjugate.  J Pharm Pharmacol 60(11):1441-1448."
"1522","PC020850","Hansel W, Leuschner C, and Enright F.  2007.  Destruction of breast cancers and their metastases by lytic peptide conjugates in vito and in vivo.  Mol Cell Endocrinol 2:260-262:183-9."
"1523","PC020850","Hansel W, Leuschner C, and Enright F. 2007.  Conjugates of lytic peptides and LHRH or betaCG target and cause necrosis of prostate cancers and metastases.  Mol Cell Endocrinol 269(1-2):26-33."
"1524","PC020866","Adamson ED, Yu J, Mustelin T.  2005.  Co-factors p300 and CBP catch Egr1 in their network.  Prostate 63:407-410."
"1525","PC020866","Yu J, deBelle I, Liang H, et al.  2004.  Coactivating factors p300 and CBP are transcriptionally crossregulated by Egr1 in prostate cells, leading to divergent responses.  Mol Cell 
15:83-94.
"
"1526","PC020873","Daugherty SE, Hayes RB, Yeager M, et al. 2007.  RNASEL Arg462Gln polymorphism and prostate cancer in PLCO.  Prostate 67:849-54."
"1527","PC020873","Michaud DS, Daugherty SE, Berndt SI, et al.  2006.  Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer.  Cancer Res 66:4525-4530."
"1528","PC020884","Kim J, Sun P, Lam YW, et al.  2005.  Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer.  Cancer Epidemiol Biomarkers Prev 14:1697-702."
"1529","PC020884","Lam YW, Mobley JA, Evans JE, et al.  2005.  Mass profiling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer.  Proteomics 5:2927-2938."
"1530","PC020886","Yamane K, Toumazou C, Tsukada YI, et al.  2006.  JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor.  Cell 125:483-495."
"1531","PC020886","Li J, Fu J, Toumazou C, et al.  2006.  A role of the amino-terminal (N) and carboxyl-terminal (C)   interaction in binding of androgen receptor to chromatin.  Mol Endocrinol 20 :776-785."
"1532","PC020886","Yoon HG and Wong J.  2006.  The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor.  Mol Endocrinol 20:148-160."
"1533","PC020888","·Vukovic B, Park P, Al-Maghrabi J, et al. 2003. Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma. Oncogene 22(13):1978-1987."
"1534","PC020888","Hughes S, Arneson SN, Done S, and Squire JA. 2004. The use of whole genome amplification in the study of human diseases. Prog Biophys Mol Biol. 88:173-89."
"1535","PC020888","·Hughes S, Lim G, Beheshti B, et al. 2004. Use of whole genomic amplification and comparative genomic hybridization to detect chromosomal copy number alterations in cell line and patient material. Cytogenetic and Genome Research 105:18-24."
"1536","PC020888","Hughes S, Lim G, Beheshti B, et al. 2004. Use of whole genomic amplification and comparative genomic hybridization to detect chromosomal copy number alterations in cell line and patient material. Cytogenet Genome Res 105:18-24."
"1537","PC021004","Freeman MR and Solomon K.  2004.  Cholesterol and prostate cancer.  J Cell Biochem 91:54-69."
"1538","PC021004","Trindade Filho JC, Bonfil RD, Osenkowski P, et al.  2005.  MT1-MMP expression in LNCaP human prostate cancer cells promotes tumor growth and bone degradation in a bone metastasis model.  Proc Amer Assoc Cancer Res 46:1028 (Abs. # 4350)."
"1539","PC021004","Dong Z, Bonfil RD, Trindade Filho, et al.  2005.  Specific MT1-MMP silencing reduces prostate cancer cell proliferation and bone matrix degradation.  Proc Amer Assoc Cancer Res 46:687 (Abs. # 2926)."
"1540","PC021004","Dong Z, Bonfil RD, Trindade Filho JC, et al.  2005.  Prostate cancer cell-associated MT1-MMP modulates tumor growth in bone and bone degradation.  Skeletal Complications of Malignancy IV, organized by The Paget Foundation, Bethesda, Maryland."
"1541","PC021004","Guise TA.  2006.  Bone loss and fracture risk associated with cancer therapy.  Oncologist 11(10):1121-1131."
"1542","PC021004","Lai JS, Corey E, Brown LG, et al.  2006.  Evaluation of the effects of prostate specific antigen (PSA) on prostate cancer bone metastasis.  Proc Amer Assoc Cancer Res 47:1026-4371."
"1543","PC021004","Allsbrook WC, Jr., Mangold KA, Johnson MH, et al.  2001.  Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists.  Hum Pathol 32(1):74-80."
"1544","PC021004","Chen C, Hyytinen ER, Sun X, et al.  2003.  Deletion, mutation, and loss of expression of KLF6 in human prostate cancer.  Am J Pathol 162(4):1349-1354."
"1545","PC021004","Jimenez RE, Fischer AH, Petros JA, et al.  2000.  Glutathione S-transferase pi gene methylation: The search for a molecular marker of prostatic adenocarcinoma.  Adv Anat Pathol 7(6):382-389."
"1546","PC021004","Lim SD, Sun C, Lambeth JD, et al.  2005.  Increased Nox1 and hydrogen peroxide in prostate cancer.  Prostate 62(2):200-207."
"1547","PC021004","Liu FS, Dong JT, Chen JT, et al.  2003.  KAI1 metastasis suppressor protein is down-regulated during the progression of human endometrial cancer.  Clin Cancer Res 9(4):1393-1398."
"1548","PC021004","Nassar A, Amin MB, Sexton DG, et al.  2005.  Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic 132 immunohistochemical marker for cancer.  Appl Immunohistochem Mol Morphol  13(3):252-5."
"1549","PC021004","Rubin MA, Bismar TA, Andren O, et al.  2005.  Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death.  Cancer Epidemiol Biomarkers Prev 14(6):1424-1432."
"1550","PC021004","Sanchez P, Hernandez AM, Stecca B, et al.  2004.  Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling.  Proc Natl Acad Sci USA 101(34):12561-12566."
"1551","PC021004","Srigley J, Amin M, Boccon-Gibod L, et al.  2005.  Prognostic and predictive factors in prostate cancer: Historical perspectives and recent international consensus initiatives.  Scand J Urol Nephrol Suppl (216):8-19."
"1552","PC021004","True L, Coleman I, Hawley S, et al.  2006.  A molecular correlate to the Gleason grading system for prostate adenocarcinoma.  Proc Natl Acad Sci USA 103(29):10991-10996."
"1553","PC021004","Andren O, Fall K, Franzen L, et al.  2006.  How well does the Gleason score predict prostate cancer death?  A133 20-year followup of a population based cohort in Sweden.  J Urol 175(4):1337-1340."
"1554","PC021004","Dhanasekaran SM, Dash A, Yu J, et al.  2005.  Molecular profiling of human prostate tissues: Insights into gene expression patterns of prostate development during puberty.  Faseb J 19(2):243-245."
"1555","PC021004","Paris PL, Hofer MD, Albo G, et al.  2006.  Genomic profiling of hormonenaive lymph node metastases in patients with prostate cancer.  Neoplasia 8(12):1083-1089."
"1556","PC021004","Rubin MA.  2004.  Using molecular markers to predict outcome.  J Urol 172(5 Pt 2):S18-21 discussion S21-2."
"1557","PC021004","Rubin MA, Bismar TA, Curtis S, et al.  2004.  Prostate needle biopsy reporting: How are the surgical members of the Society of Urologic Oncology using pathology reports to guide treatment of prostate cancer patients?  Am J Surg Pathol 28(7):946-952."
"1558","PC021004","Mohammad KS, Chen CG, Balooch G, et al.  2009.  Pharmacologic inhibition of the tgf-beta type I receptor kinase has anabolic and anti-catabolic effects on bone.  PLoS ONE 4(4):e5275."
"1559","PC021004","Brown SA and Guise TA.  2009.  Cancer treatment-related bone disease.  Crit Rev Eukaryot Gene Expr 19(1):47-60."
"1560","PC021004","Guise TA.  2008.  Antitumor effects of bisphosphonates: Promising preclinical evidence.  Cancer Treat Rev 34(1):S19-24."
"1561","PC021004","Clines GA and Guise TA.  2008.  Molecular mechanisms and treatment of bone metastasis.  Expert Rev Mol Med 6;10:e7."
"1562","PC021004","Mohammad KS, Chirgwin JM, and Guise TA.  2008.  Assessing new bone formation in neonatal calvarial organ cultures.  Methods Mol Biol 455:37-50."
"1563","PC021004","Chen Z, Koeneman K, and Corey DR.  2003.  Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells.  Cancer Res 63:5917-5925."
"1564","PC021004","Collins SJ, Swartz MJ, Nelson WG, et al.  2003.  Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors.  Cancer Res 63:1550-1554."
"1565","PC021004","Lupold SE and Rodriguez R.  2004.  Disulfide-constrained peptides that bind to the extracellular portion of the prostate specific membrane antigen.  Molecular Cancer Ther.  4(5):597-603."
"1566","PC021004","Books
Rubin 2004.  Co-author on prostate cancer chapters of Eble JN, Sauter G, Epstein JI, Sesterhenn IAE.  World Health Organization Classification of Tumours.  Pathology and Genetics of Tumours of the Male Urinary System and Male Genital Organs.  Volume 1.  Lyon: IARC Press. 
"
"1567","PC021004","Rubin MA, Varambally S, Beroukhim R, et al.  2004. Overexpression, amplification and androgen-regulation of TPD52 in prostate cancer.  Cancer Res 64(11):3814-22."
"1568","PC021004","Rubin MA and DeMarzo AM.  2004.  Molecular genetics of human prostate cancer.  Mod Pathol. 17:380-388."
"1569","PC021004","Rubin MA, Zerkowski MP, Camp RL, et al.  2004.  Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): A novel paradigm for automated and continuous biomarker measurements.  Am J Pathol 164:831-840."
"1570","PC021004","Kumar-Sinha C, Shah RB, Laxman B, et al.  2004.  Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer.  Am J Pathol 164:787-793."
"1571","PC021004","Hofer MD, Kuefer R, Varambally S, et al.  2004.  The role of metastasis-associated protein 1 in prostate cancer progression.  Cancer Res 64:825-829."
"1572","PC021004","Chen C, Zhou Y, Zhou Z, et al.  2004.  Regulation of KLF5 involves the Sp1 transcription factor in human epithelial cells.  Gene 330:133-142."
"1573","PC021004","Chen CD, Welsbie DS, Tran C, et al.  2004.  Molecular determinants of resistance to antiandrogen therapy.       (Epub December 21, 2003).  Nat Med 10(1):33-39."
"1574","PC021004","Kim J, Adam RM, Solomon KR, et al.  2004.  Involvement of cholesterol-rich lipid rafts in interleukin-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells. Endocrinology 145:613-619."
"1575","PC021004","Cinar B, Yeung F, Konaka H, et al.  2004.  Identification of a negative regulatory cis-element in the enhancer core region of the prostate specific antigen (PSA) promoter: Implications for intersection of androgren receptor and NK-kappaB signaling in prostate cancer cells.  Biochem J 379:421-431."
"1576","PC021004","Wang RX, Xu JC, Saramaki O, et al.  2004.  PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8Q21.1 and overexpressed in human prostate cancer.  Cancer Res 64:1589-1594."
"1577","PC021004","Sreekumar A, Laxman B, Rhodes DR, et al.  2004.  Humoral immune responses to alpha-methylacyl-CoA  racemase and prostate cancer. J Natl Cancer Inst 96(11):834-843."
"1578","PC021004","Amin MB, Grignon D, Humphrey PH, et al.  2004.  Gleason grading of prostate cancer: A contemporary approach.  Lippincott Williams and Wilkins, Philadelphia, Pennsylvania."
"1579","PC021004","Schlicht M, Matysiak B, Brodzeller T, et al.  2004.  Cross-species global and subset gene expression profiling identifies genes involved in prostate cancer response to selenium.  BMC Genomics 5:58."
"1580","PC021004","Melamed J, Datta MW, Becich MJ, et al.  2004.  The cooperative prostate cancer tissue resource: A specimen and data resource for cancer researchers.  Clin Cancer Res 10:4614-4621."
"1581","PC021004","Zhuang L, Kim J, Adam RM, et al.  2005.  Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts.   J Clin Invest 115:959-968."
"1582","PC021004","Freeman MR.  2004.  HER2/HER3 heterodimers in prostate cancer: Whither HER1/EGFR?  Cancer Cell 6:427-428."
"1583","PC021004","Freeman MR, Cinar B, and Lu ML.  2005.  Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer.  Trends Endocrinol Metab 16:273-9."
"1584","PC021004","Etim A, Zhou G, Wen X, et al.  2004.  ChromSorter PC: A database of chromosomal regions associated with human prostate cancer.  BMC Genomics 5:27."
"1585","PC021004","Berman JJ, Datta M, Kajdacsy-Balla A, et al.  2004.  The tissue microarray data exchange specification: Implementation by the Cooperative Prostate Cancer Tissue Resource.  BMC Bioinformatics 5:19."
"1586","PC021004","Matysiak BE, Brodzeller T, Buck S, et al.  2003.  Simple, inexpensive method for automating tissue microarray production provides enhanced microarray reproducibility.  Appl Immunohistochem Mol Morphol 11:269-273."
"1587","PC021004","Cinar B, De Benedetti A, and Freeman MR.  2005.  Post-transcriptional regulation of the androgen receptor by Mammalian target of rapamycin.  Cancer Res 65:2547-2553."
"1588","PC021004","Moore S, Knudsen B, True LD, et al.  2005.  Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma.  Int J Cancer 114:563-571."
"1589","PC021004","Clegg N, Abbott D, Ferguson C, et al.  2004.  Characterization and comparative analyses of transcriptomes from the normal and neoplastic human prostate.  Prostate 60:227-239."
"1590","PC021004","Sebat J, Lakshmi B, Troge J, et al.  2004.  Large-scale copy number polymorphism in the human genome.  Science 305:525-528."
"1591","PC021004","Paris PL, Andaya A, Fridlyand J, et al.  2004.  Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors.  Hum Mol Genet 13:1303-1313.

"
"1592","PC021004","Kuefer R, Hofer MD, Gschwend JE, et al.  2003.  The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer.  Clin Cancer Res 9:6447-6452."
"1593","PC021004","Patel AA, Kajdacsy-Balla A, Berman JJ, et al.  2005.  The development of common data elements for a multi-institute prostate cancer tissue bank: The cooperative prostate cancer tissue resource (CPCTR) experience.  BMC Cancer 5(1):108 (Epub ahead of print)."
"1594","PC021004","Zhou J, Hernandez G, Tu S, et al.  2005.  The mechanism of antiandrogen effect of DOC-2/DAB2 on androgen receptor-mediated cell growth in androgen independent prostate cancer.  Cancer Res 65:9906-9913."
"1595","PC021004","Amin MB, Grignon D, Humphrey PH, et al.  2004.  Contemporary approach to gleason grading.  Lippincott Williams & Wilkins, Philadelphia, Pennsylvania."
"1596","PC021004","Kiang Z, Wu CL, Wada BA, et al.  2004.  Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker.  Histopathology 45:218-225.

"
"1597","PC021004","Datta MW, Kahler A, Macias V, et al.  2005.  A simple inexpensive method for the production of tissue microarrays from needle biopsy specimens: Examples with prostate cancer.  Appl Immunohistochem Mol Morphol (1):96-103."
"1598","PC021004","Liu P, Ramachandran S, Ali Seyed M, et al.  2006.  Sex-determining region y box 4 is a transforming oncogene in human prostate cancer cells.  Cancer Res 66(8):4011-4019."
"1599","PC021004","Datta MW, Hernandez AM, Schlicht MJ, et al.  2006.  Perlecan, a candidate gene for the CAPB locus, regulates prostate cancer cell growth via the Sonic Hedgehog pathway.  Mol Cancer 5:9."
"1600","PC021004","Datta S and Datta MW.  2006.  Sonic hedgehog signaling in advanced prostate cancer.  Cell Mol Life Sci 63(4):435-448."
"1601","PC021004","Patel AA, Kajdacsy-Balla A, Berman JJ, et al.  2005.  The development of common data elements for a multi-institute prostate cancer tissue bank: The cooperative prostate cancer tissue resource (CPCTR) experience.  BMC Cancer 5:108."
"1602","PC021004","Chen C, Sun X, Ran Q, et al.  2005.  Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells.  Oncogene 24:3319-3327."
"1603","PC021004","Chen Q, Watson JT, Marengo SR, et al.  2006.  Gene expression in the LNCaP human prostate cancer progression model: Progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.  Cancer Lett 244:274-88."
"1604","PC021004","Nelson PS and Montgomery B.  2006.  Cell type-specific analyses for identifying prostate cancer biomarkers.  Curr Urol Rep 7(1):57-63."
"1605","PC021004","York TP, Plymate SR, Nelson PS, et al.  2005.  cDNA microarray analysis identifies genes induced in common by peptide growth factors and androgen in human prostate epithelial cells.  Mol Carcinog 44(4):242-251."
"1606","PC021004","Nelson PS.  2004.  Predicting prostate cancer behavior using transcript profiles.  J Urol 172(5 Pt 2): S28-32; discussion S33."
"1607","PC021004","Eble JN, Sauter G, Epstein JI, et al.  2004.  World health organization classification of tumours.  Pathology and Genetics of Tumours of the Male Urinary System and Male Genital Organs 1:Lyon:IARC Press."
"1608","PC021004","Sreekumar A, Laxman B, Rhodes DR, et al.  2004.  Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.  J Natl Cancer Inst 96:834-43."
"1609","PC021004","Shappell SB, Thomas GV, Roberts RL, et al.  2004.  Prostate pathology of genetically engineered mice: Definitions and classification.  The consensus report from the Bar Harbor Meeting of the mouse models of human cancer consortium prostate pathology committee.  Cancer Res 64:2270-2305."
"1610","PC021004","Rubin MA and Kantoff PW.  2004.  Effect of finasteride on risk of prostate cancer: How little we really know.  J Cell Biochem 91:478-482."
"1611","PC021004","Hofer MD, Kuefer R, Varambally S, et al. 2004.  The role of metastasis-associated protein 1 in prostate cancer progression.  Cancer Res 64: 825-829."
"1612","PC021004","Tomlins SA, Mehra R, Rhodes DR, et al.  2006.  Whole transcriptome amplification for gene expression profiling and development of molecular archives.  Neoplasia (2):153-162."
"1613","PC021004","Bismar TA, Demichelis F, Riva A, et al.  2006.  Defining aggressive prostate cancer using a 12-gene model.  Neoplasia 8(1):59-68."
"1614","PC021004","Stanbrough M, Bubley GJ, Ross K, et al.  2006.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.  Cancer Res 66(5):2815-2825."
"1615","PC021004","Kim R, Demichelis F, Tang J, et al.  2005.  Internet-based Profiler system as integrative framework to support translational research.  BMC Bioinformatics 6:304.

"
"1616","PC021004","Varambally S, Yu J, Laxman B, et al.  2005.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.  Cancer Cell 8(5):393-406."
"1617","PC021004","Hofer MD, Browne TJ, He L, et al.  2005.  Identification of two molecular groups of seminomas by using expression and tissue microarrays.  Clin Cancer Res 11(16):5722-5729."
"1618","PC021004","Sun X, Frierson HF, Chen C, et al.  2005.  Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer.  Nat Genet 37:407-412."
"1619","PC021004","Zhang Z, Karam J, Frenkel EP, et al.  2006.  The potential application of epigenetic modifiers in the treatment of prostate and bladder cancer.  Urologic Oncol 24:152-160."
"1620","PC021004","Epstein JI, Amin M, Boccon-Gibod L, et al.  2005.  Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens.  Scand J Urol Nephrol Suppl (216): 34-63."
"1621","PC021004","Epstein JI, Allsbrook WC, Jr., Amin MB, et al.  2006.  Update on the Gleason grading system for prostate cancer: Results of an international consensus conference of urologic pathologists.  Adv Anat Pathol 13(1):57-59."
"1622","PC021004","Yamamoto H, Bonfil RD, Wiesner C, et al.  2007.  Quantitative assessment of small intraosseous prostate cancer burden in SCID mice using fluorescence imaging.  Prostate 67:107-114."
"1623","PC021004","Bonfil RD, Dong Z, Trindade Filho JC, et al.  2007.  Prostate cancer-associated membrane type 1-matrix metalloproteinase: Its pivotal role in bone response and intraosseous tumor growth.  Am J Pathol 170:2100-11."
"1624","PC021004","Wiesner C, Bonfil RD, Dong Z, Yamamoto et al.  2007.  Heterogeneous activation Of Mmp-9 due to prostate cancer-bone interaction.  Urology 69:795-9."
"1625","PC021004","Chirgwin JM and Guise TA.  2003.  Interactions between tumor and bone alter the phenotypes of both.  J Musculoskelet Neuronal Interact 3:278-281."
"1626","PC021004","De la Taille A, Viellefond A, Berger N, et al.  2003.  Evaluation of the interobserver reproducibility of Gleason grading of prostatic adenocarcinoma using tissue microarrays.  Hum Pathol 34:444-449."
"1627","PC021004","Gao AC, Lou W, Dong JT, et al.  2003.  Defining regulatory elements in the human KAI1 (CD 82) metastasis suppressor gene.  Prostate 57:256-260."
"1628","PC021004","Jiang Z, Wu CL, Woda BA, et al.  2004.  Alpha-methylacyl-CoA racemase: A multi-institutional study of a new prostate cancer marker.  Histopathology 45:218-225."
"1629","PC021004","Zhou W, Goodman M, Lyles RH, et al.  2004.  Surgical margin and Gleason score as predictors of postoperative recurrence in prostate cancer with or without chromosome 8p allelic imbalance.  Prostate 61:81-91."
"1630","PC021004","Skinnider BF, Oliva E, Young RH, et al.  2004.  Expression of alpha-methylacyl-CoA racemase (P504S) in nephrogenic adenoma: A significant immunohistochemical pitfall compounding the differential diagnosis with prostatic adenocarcinoma.  Am J Surg Pathol 28:701-705."
"1631","PC021004","Gao X, Cui Y, Levenson RM, et al.  2004.  In vivo cancer targeting and imaging with semiconductor quantum dots.  Nat Biotechnol 22:969-976."
"1632","PC021004","Diamond TH, Higano CS, Smith MR, et al.  2004.  Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: Recommendations for diagnosis and therapies.  Cancer 100:892-899."
"1633","PC021004","Malaeb B, Gardener TA, Margulis V, et al.  2005.  Elevated activated partial thromboplastin time during administration of first generation adenoviral vectors from gene therapy of prostate cancer: Identification of lupus anticoagulants (LAC).  Urol 66:830-4."
"1634","PC021004","Cui W, Otten P, Li Y, et al.  2004.  Novel NMR approach to assessing gene transfection: 4-fluoro-2-nitrophenyl-beta-D-galactopyranoside as a prototype reporter molecule for beta-galactosidase.  Magn Reson Med 51:616-620."
"1635","PC021004","Karam J, Benaim E, Chen H, et al.  2004.  Epigenetics in prostate cancer.  In: Prostate Cancer: Mechanisms, Prevention, and Hormone Therapy (Chang C, editor).

"
"1636","PC021004","Freeman MR and Solomon KR.  2004.  Choleserol and prostate cancer.  J Cell Biochem 91:54-69."
"1637","PC021004","O'Keefe RJ and Guise TA.  2003.  Molecular mechanisms of bone metastasis and therapeutic implications.  Clin Orthop Relat Res. 415:S100-104."
"1638","PC021004","Mohammad KS and Guise TA.  2003.  Mechanisms of osteoblastic metastases: role of endothelin-1.  Clin Orthop Relat Res 415:S67-74."
"1639","PC021004","Guise TA and Chirgwin JM.  2003.  Transforming growth factor-beta in osteolytic breast cancer bone metastases.  Clin Orthop Relat Res 415:S32-38."
"1640","PC021004","Guise TA and Chirgwin JM.  2003.  Role of bisphosphonates in prostate cancer bone metastases.  Semin Oncol 30:717-723."
"1641","PC021004","Yin JJ, Mohammad KS, Kakonen SM, et al.  2003.  A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases.  Proc Natl Acad Sci SA 100:10954-10959."
"1642","PC021004","Guise TA and Mohammad KS.  2004.  Endothelins in bone cancer metastases.  Cancer Treat Res 118:197-212."
"1643","PC021004","Titus B, Frierson HF Jr, Conaway M, et al.  2005.  Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2.  Cancer Res 65:7320-7327."
"1644","PC021004","Canales BK, Li Y, Thompson MG, et al.  2006.  Telomerase inhibition in combination with cytolytic therapy in an in-vitro androgen independent prostate cancer model.  Urol Oncol 24(2):141-151."
"1645","PC021004","Koeneman KS.  2006.  Prostate cancer stem cells, telomerase biology, epigenetic modifiers, and molecular systemic therapy for the androgen independent lethal phenotype.  Urol Oncol 24(2):119-121."
"1646","PC021004","Zongbing Y, Xu-Bao S, Grayson D, et al.  2005.  Interleukin-17 Receptor-like gene is a novel anti-apoptotic gene highly expressed in androgen independent prostate cancer.  Cancer Res 66:175-183."
"1647","PC021004","Huang CL, Cheng JC, Liao CH, et al.  2004.  Disabled-2 is a negative regulator of integrin aIIb_3-mediated fibronogen adhesion and cell signaling.  J Biol Chem 279:4279-4289."
"1648","PC021004","Zhou J, Tu S, Hernandez G, et al.  2005.  Synergistic induction of DOC-2/DAB2 gene expression in transitional carcinoma cells in the presence of GATA6 and histone deacetylase inhibitor.  Cancer Res 65: 6089-6096."
"1649","PC021004","Nassar A, Amin MB, Sexton DG, et al.  2005.  Utility of alpha-methylacyl coenzyme A racemase (P504S Antibody) as a diagnostic immunohistochemical marker for cancer.  Appl Immunohistochem Mol Morphol 13(3):252-255."
"1650","PC021004","Petros JA, Baumann AK, Ruiz-Pesini E, et al. 2005.  mtDNA mutations increase tumorigenicity in prostate cancer.  Proc Natl Acad Sci USA.  18:102(3):719-724 (Epub 2005)."
"1651","PC021004","Ramachandran S, Liu P, Young AN, et al.  2005.  Loss of HOXC6 expression induces apoptosis in prostate cancer cells.  Oncogene 24(1):188-198."
"1652","PC021004","Pritchard C, Coil D, Hawley S, et al.  2006.  The contributions of normal variation and genetic background to mammalian gene expression.  Genome Biol 7(3):R26 (Epub 2006).

"
"1653","PC021004","Lu W, Zhou D, Glusman G, et al.  2006.  KLK31P is a novel androgen regulated and transcribed pseudogene of kallikreins that is expressed at lower levels in prostate cancer cells than in normal prostate cells.  Prostate 66:936-44."
"1654","PC021004","Narla G, Difeo A, Reeves HL, et al.  2005.  A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk.  Cancer Res 65(4):1213-1222."
"1655","PC021004","Melamed J, Datta MW, Becich MJ, et al. 2004.  The cooperative prostate cancer tissue resource: A specimen and data resource for cancer researchers.  Clin Cancer Res 10(14):4614-4621."
"1656","PC021004","Epstein JI, Allsbrook WC Jr, Amin MB, Egevad et al.  2005.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.  Am J Surg Pathol (9):1228-1242."
"1657","PC021004","Chirgwin JM and Guise TA.  2006.  Does prostate-specific antigen contribute to bone metastases?  Clin Cancer Res 12(5):1395-1397."
"1658","PC021004","Bartholin L, Wessner LL, Chirgwin JM, et al.  2007.  The human Cyr61 gene is a transcriptional target of transforming growth factor beta in cancer cells.  Cancer Lett 246(1-2):230-236."
"1659","PC021004","Clines GA, Mohammad KS, Bao Y, et al.  2007.  Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation.  Mol Endocrinol 21(2):486-498."
"1660","PC021004","Guise TA, Mohammad KS, Clines G, et al.  2006.  Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.  Clin Cancer Res 12(20 Pt 2):6213s-6216s."
"1661","PC021004","Lai JS, Corey E, Brown LG, et al.  2005.  Does the human kallikrein prostate specific antigen (PSA) contribute to the prostate cancer osteoblastic response?  J Bone Miner Res 20(1):S216-#SU118."
"1662","PC021004","Lipton A, Berenson JR, Body JJ, et al.  2006.  Advances in treating metastatic bone cancer: summary statement for the first cambridge conference.  Clin Cancer Res 20:6209s-6212s."
"1663","PC021004","Guise TA, Mohammad KS, Clines G, et al.  2006.  Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.  Clin Cancer Res 20:6213s-6216s."
"1664","PC021004","Vessella RL and Corey E.  2006.  Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastases.  Clin Cancer Res 20:6285s-6290s."
"1665","PC021004","Huang CL, Cheng JC, Ster A, et al.  2006.  Disabled-2 is a novel integrin _IIb-binding protein that negatively regulate plateletfibrinogen interaction and platelet aggregation.  J Cell Sci 119:4420-4430."
"1666","PC021004","Hager M, Solomon KR, and Freeman MR.  2006.  The role of cholesterol in prostate cancer. Current Op. Clin. Nutrition Metabol.  Care 9:379-385."
"1667","PC021004","Freeman MR, Solomon KR, and Moyad M.  2006.  Statins and the risk of cancer.  JAMA 295:2720-2721."
"1668","PC021004","Freeman MR, Cinar B, Kim J, et al.  2007.  Transit of hormonal and EGF receptor-dependent signals through cholesterol-rich membranes.  Steroids 72:210-217."
"1669","PC021004","Adam RM, Mukhopadhyay NK, Kim J, et al.  2007.  Cholesterol sensitivity of endogenous and myristoylated Akt.  Cancer Res 67:6238-46."
"1670","PC021004","Amin ML, Boccon-Gibod, and Egevad L, et al.  2005.  Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens.  Scand J Urol Nephrol Suppl (216):20-33."
"1671","PC021004","Beach R, AM Gown, De Peralta-Venturina MN, et al.  2002.  P504S immunohistochemical detection in 405 prostatic specimens including 376 18- gauge needle biopsies.  Am J Surg Pathol 26(12):1588-1596."
"1672","PC021004","Chen C, Bhalala H, Vessella RL, et al.  2003.  KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer.  Prostate 55(2):81-88."
"1673","PC021004","Chen C, Sun X, Guo P, et al.  2005.  Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells.  J Biol Chem 280(50):41553-41661."
"1674","PC021004","Donald CD, Sun CQ, Lim SD, et al.  2003.  Cancer-specific loss of betadefensin 1 in renal and prostatic carcinomas.  Lab Invest 83(4): 501-505."
"1675","PC021004","Dong JT.  2006.  Prevalent mutations in prostate cancer.  J Cell Biochem 97(3):433-447."
"1676","PC021004","Lin DW, Coleman IM, Hawley S, et al.  2006.  Influence of surgical manipulation on prostate gene expression: Implications for molecular correlates of treatment effects and disease prognosis.  J Clin Oncol 24(23):3763-3770."
"1677","PC021004","Wu GJ, Varma VA, Wu MW, et al.  2001.  Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues.  Prostate 48(4):305-15."
"1678","PC021004","Wu GJ, Wu MW, Wang SW, et al.  2001.  Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 overexpression in prostate cancer cell lines and tissues with malignant progression.  Gene. 279(1):17-31."
"1679","PC021004","Descazeaud A, de la Taille A, Allory Y, et al.  2006.  Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system.  Prostate 66(10):1037-1043."
"1680","PC021004","Febbo PG, Thorner A, Rubin MA, et al.  2006.  Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer.   Clin Cancer Res 12(1):152-158."
"1681","PC021004","Paris PL, Weinberg V, Simko J, et al.  2005.  Preliminary evaluation of prostate cancer metastatic risk biomarkers.  Int J Biol Markers 20(3):141-145."
"1682","PC021004","Fournier PG, Chirgwin JM, and Guise TA.  2006.  New insights into the role of T cells in the vicious cycle of bone metastases.  Curr Opin Rheumatol 18(4):396-404."
"1683","PC021004","Guise TA.  2006.  Do markers of bone turnover predict clinical outcome in patients with bone metastases?  Nat Clin Pract Endocrinol Metab 2(5):258-259."
"1684","PC021004","Lipton A, Berenson JR, Body JJ, et al.  2006.  Advances in treating metastatic bone cancer: Summary statement for the First Cambridge Conference.  Clin Cancer Res 12(20 Pt 2):6209s-6212s."
"1685","PC021004","Haudenschild DR, Curtiss SB, Moseley TA, et al.  2006.  Generation of interleukin-17 receptor-like protein (IL-17RL) in prostate by alternative splicing of RNA.  Prostate 66:1268-1274."
"1686","PC021004","Wu JD, Haugk K, Coleman I, et al.  2006.  Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors.  Clin Cancer Res 20:6153-6160."
"1687","PC021004","Zhou J, Fan J, and Hsieh J.  2006.  Inhibition of mitogens-elicited signal transduction and growth in prostate cancer with a small peptide derived from the functional domain of DOC-2/DAB2 delivered by a unique vehicle.  Cancer Res 66:8954-8958."
"1688","PC021004","Hsieh CL, Gardner TA, Miao L, et al.  2004.  Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells. Cancer Gene Ther 11:148-155."
"1689","PC021004","Wang R, Xu J, Saramaki O, et al.  2004.  PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer.  Cancer Res 64:1589-1594."
"1690","PC021005","Singh SS, Kim D, and Mohler JL.  2005.  Java Web Start based software for automated nuclear analysis of prostatic carcinoma and benign prostatic hyperplasia. Biomed Eng Online 4:31-40.

"
"1691","PC021005","Singh SS, Qaqish B, Johnson JL, et al.  2004.  Sampling strategy for prostate tissue microarrays for Ki-67 and androgen receptor biomarkers.  Anal Quant Cytol Histol 26:194-200.

"
"1692","PC021005","Schroeder JC, Bensen JT, Su LJ, et al.  2006.  The North Carolina ¿ Louisiana Prostate Cancer Project (PCaP): Methods and design of a multidisciplinary population-based cohort study of racial differences in prostate cancer outcomes.  Prostate 66:1162-1176"
"1693","PC021005","Bensen JT, Xu Z, McKeigue PM, et al.  2014.  Admixture mapping of prostate cancer in African Americans participating in the North Carolina-Louisiana Prostate Cancer Project (PCaP). Prostate 74(1):1-9."
"1694","PC021005","Carpenter WR, Godley PA, Clark JA, et al.  2009.  Racial differences in trust and regular source of patient care and the implications for prostate cancer screening use.  Cancer 115(21):5048-5059."
"1695","PC021005","Song L, Weaver MA, Chen RC,et al.  2014. Associations between patient-provider communication and
socio-cultural factors in prostate cancer patients: A cross-sectional evaluation 
of racial differences. Patient Educ Couns pii:
S0738-3991(14)00368-1."
"1696","PC021005","Arab L, Su J, Steck S, et al.  2013.  Adherence to world cancer research fund/American Institute for cancer research lifestyle recommendations reduces prostate cancer aggressiveness among African and Caucasian Americans.  Nutrition and Cancer 65(5):633-643."
"1697","PC021005","Singh SS, Mehedint DC, Ford OH, et al.  2009.  Comparison of ACINUS, caspase-3, and TUNEL as apoptotic markers in determination of tumor growth rates of clinically localized prostate cancer using image analysis.  Prostate 69(15):1603-1610."
"1698","PC030008","Kahn SM, Hryb DJ, Nakhla AM, Romas NA, Rosner W.  2005.  Immunohistochemical and in situ detection of sex hormone-binding globulin (SHBG) expression in breast and prostate cancer: Implications for hormone regulation.  Hormonal Carcinogenesis 4: 508-514."
"1699","PC030012","Fang P, Hwa V, Rosenfeld, RG.  2004.  IGFBPs and Cancer (review).  In:  Norvatis Foundation Symposium Number 262: Biology of IGF-1: It¿s Interaction with Insulin in Health and Malignant States (Bock G and Goode J, Eds.).  John Wiley & Sons Ltd., Chichester, United Kingdom, pp. 215-234."
"1700","PC030012","Fang P, Hwa V, and Rosenfeld RG.  2006.  Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway.  Exp Cell Res 312:1229-39."
"1701","PC030012","Fang P, Hwa V, and Rosenfeld RG.  2006.  Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway.  Exp Cell Res 312:1229-1239."
"1702","PC030018","Rees I, Lee S, Kim H, et al.  2006.  The E3 ubiquitin ligase CHIP binds the androgen receptor in a phosphorylation-dependent manner.  Biochim Biophys Acta 1764:1073-1079."
"1703","PC030018","Haslberger T, Weibezahn J, Zahn R, et al.  2007.  M Domains couple the ClpB threading motor with the DnaK chaperone activity.  Mol Cell 25:247-260."
"1704","PC030018","Lee S, Choi J-M, Tsai FTF, et al.  2007.  Visualizing the ATPase cycle in a protein disaggregating machine:  Structural basis for substrate binding by ClpB.  Mol Cell 25:261-271."
"1705","PC030018","Weibezahn J, Tessarz P, Schlieker C, et al. 2004. Thermotolerance requires refolding of aggregated proteins by substrate translocation through the central pore of ClpB.
Cell 119:653-665.
"
"1706","PC030018","Lee S and Tsai FTF.  2007.  Crystallization and preliminary x-ray crystallographic analysis of a 40 kDa N-terminal fragment of the yeast prion-remodeling factor, Hsp104.  Acta Crystallogr F 63:784-786."
"1707","PC030019","Bakin RE and Jung MO.  2004.  Cytoplasmic sequestration of HDAC7 from mitochondrial and nuclear compartments upon initiation of apoptosis.  J Biol Chem 279:51218-51225."
"1708","PC030021","Maroto R, Raso A, Wood TG, et al.  TRPC1 forms the stretch-activated cation channel in vertebrate cells.  Nat Cell Biol 7:1442-1446"
"1709","PC030031","Gonzales de Mejia EG, Vasconez M, de Lumen BO, et al.  2004.  Lunasin concentration in soybean genotypes, commercial soy protein and isoflavone products.  J Agric Food Chem 
52:5882-5887.
"
"1710","PC030031","de Lumen BO.  Lunasin, a cancer preventive soy peptide.  
Nutr Rev 63:16-21.
"
"1711","PC030031","Park JH, Jeong HJ, de Lumen BO, et al. 
Contents and bioactivities of lunasin, bowman-birk inhibitor, and isoflavones in soybean seed. J Agric Food Chem 53(20):7686-7690."
"1712","PC030031","Jeong HJ, Jeong JB, Kim DS, et al.  2007.  Inhibition of core histone acetylation by the cancer preventive peptide lunasin. J Agric Food Chem 55(3):632-637."
"1713","PC030037","Du KL, Mick R, Busch TM, et al.  2006.  Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer.  Lasers Surg Med 38(5):427-434."
"1714","PC030037","Yu G, Durduran T, Wang HW, et al.  2005.  Noninvasive monitoring of murine tumor blood flow during and after photodynamic therapy provides early assessment of therapeutic efficacy.  Clin Cancer Res 11:3543-3552.
"
"1715","PC030037","Yu G, Durduran T, Zhou C, et al.  2006.  Real-time in situ monitoring of human prostate photodynamic therapy with diffuse light.  Photochem Photobiol 82:1279-1284."
"1716","PC030038","Zhang Q, Yang X, Pins M, et al.  2005.  Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: Eradication of autologous mouse prostate cancer.  Cancer Res 65(5):1761-1769.

"
"1717","PC030038","Zhang Q, Jang TL, Yang X, et al.  2005.  Infiltration of tumors specific transforming growth factor-beta insensitive CD8+ T cells into tumor parenchyma is associated with apoptosis in tumor cells.  Prostate 66:235-247."
"1718","PC030061","Krishnan K, Stone WL, Campbell S, et al.  2005.  More optimal forms of vitamin E.  J Am Diet Assoc 105(2):204-205"
"1719","PC030061","Campbell SE, Stone WL, Lee S, et al.  2006.  Comparative effects of alpha- and gamma-tocopherol on proliferation and apoptosis in human colon cancer cell lines.  BMC Cancer 6:13."
"1720","PC030061","Krishnan K, Campbell SC, Stone WL, et al.  2004.  Overview of tocopherols and tocotrienols in cancer chemoprevention. Encyclopedia of Vitamin E."
"1721","PC030061","Stone WL and Smith M.  2004.  Therapeutic uses of antioxidant liposomes.  Mol Biotechnol 27(3):217-230."
"1722","PC030061","Stone WL, Krishnan K, Campbell SE, et al.  2004.  Tocopherols and the treatment of colon cancer.  Ann N Y Acad Sci 1031:223-233."
"1723","PC030076","Ivanov I, Lo KC, Hawthorn L, et al.  2007.  Identifying candidate colon cancer tumor suppressor genes using inhibition of nonsense-mediated mRNA decay in colon cancer cells.  Oncogene 26:2873-2884."
"1724","PC030076","Rossi MR, Hawthorn L, Platt J, et al.  Identification of inactivating mutations in the JAK1, SYNJ2 and CLPTM1 genes in prostate cancer cells using inhibition of nonsense mediated decay and microarray analysis.  Cancer Genet Cytogenet 161:97-103."
"1725","PC030076","Kunnev D, Ivanov I, Ionov Y. 2009. Par-3 partitioning defective 3 homolog (C. elegans) and androgen-induced prostate proliferative shutoff associated protein genes are mutationally inactivated in prostate cancer cells. BMC Cancer 9:318."
"1726","PC030092","Kelavkar UP, Harya NS, Hutzley J, et al.  2007.  DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.  Prostaglandins Other Lipid Mediat 82(1-4):185-197."
"1727","PC030092","Collard RL, Harya NS, and Monzon FA.  2006.  Methylation of the ASC gene promoter is associated with aggressive prostate cancer.  Prostate 66(7):687-695."
"1728","PC030092","Collard RL, Harya NS, Monzon FA, et al.  2006.  Methylation of the ASC gene promoter is associated with aggressive prostate cancer.  Prostate 15:66(7):687-695."
"1729","PC030095","Li H, Stampfer MJ, Giovannucci EL, et al.  2007.  Prediagnostic plasma vitamin D levels, vitamin D receptor gene polymorphisms, and susceptibility to prostate cancer.  PLoS Med 4(3):e103."
"1730","PC030095","Giovannucci E, Liu Y, Stampfer M, et al.  2006.  A prospective study of calcium intake and incident and fatal prostate cancer.  Cancer Epidemiol Biomarkers Prev 15(2):203-210."
"1731","PC030095","Li H, Stampfer MJ, Mucci L, et al. 2010. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate
cancer risk and survival. Clin Chem 56(1):34-43."
"1732","PC030097","Taylor RA, Cowin PA, Cunha GR, et al.  2006.  Formation of human prostate tissue from embryonic stem cells.  Nature Methods 3(3):179-181."
"1733","PC030098","Zhao H, Lai F, Nonn L, et al.  2004.  Molecular targets of doxazosin in human prostatic stromal cells.  Prostate 62:400-10.
"
"1734","PC030098","Zhao H, Whitfield ML, Xu T, et al.  2004.  Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells.  Mol Biol Cell 15(2):506-519."
"1735","PC030098","Zhao H, Kim Y, Wang P, et al.  2004.  Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines.  Prostate
[E-published ahead of print].
"
"1736","PC030104","Lopez GI, Figueroa M, Maliski S, et al. 2008. Translation Barriers in conducting Qualitative Research with Spanish Speakers. Qual Health Res 18(12):1729-1737."
"1737","PC030122","Srinivas S, Krishnan AV, Colocci N, et al.  2006.  Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer.  Urology 67(5):1001-1006."
"1738","PC030130","Li Y and Cozzi PJ.  2007.  MUC1 is a promising therapeutic target for prostate cancer therapy. Curr Cancer Drug Targets 7:191-201."
"1739","PC030130","Wang L, Ma J, Liu FH, et al.  2007.  Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance.  Gynecol Oncol 105:695-702."
"1740","PC030130","Wang J, Rizvi SMA, Madigan MC, et al.  2006.  Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted &#945; radioimmunoconjugates.  Prostate 66:1753-1767."
"1741","PC030130","Cozzi PJ, Wang J, Delprado W, et al.  2006.  Evaluation of urokinase plasminogen activator (uPA) and its receptor (uPAR) in different grades of human prostate cancer.  Hum Pathol 37:1442-1445."
"1742","PC030134","Girvan AC, Teng Y, Casson LK, et al.  2006. AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin.  Mol Cancer Ther 5(7):1790-1799."
"1743","PC030136","Smith AB III, Mesaros EF, and Meyer EA.  2005.  Total synthesis of (¿)kendomycin exploiting a Petasis-Ferrier rearrangement/ring-closing olefin metathesis synthetic strategy.  J Am Chem Soc 127:6948."
"1744","PC030136","Smith AB III and Xian M.  2006.  Anion relay chemistry:  An effective tactic for diversity oriented synthesis.  J Am Chem Soc 128:66."
"1745","PC030147","Xu M, Lu X, Kallinteris NL, et al.  2004.  Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules.  Curr Opin Mol Ther 6:160-165."
"1746","PC030147","Wang Y, Xu M, Che M, et al.  2005.  Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii protein.  Hum Gene Ther 16:187-199."
"1747","PC030147","Lu X, Wu S, Blackwell CE, et al.  2007.  Suppression of major histocompatibility complex class II-associated invariant chain enhances the potency of an HIV gp120 DNA vaccine.  Immunology 120:207-216 (2007).  [Epub Nov 2006]."
"1748","PC030147","Wang Y, Xu M, Che M, et al.  2005.  Curative anti-tumor immune response is optimal with tumor irradiation followed by genetic induction of MHC class I and Class II molecules and suppression of Ii protein.  Hum Gene Ther 16:187-199."
"1749","PC030147","Hillman GG, Kallinteris NL, Lu X, et al.  2004.  Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: Immuno-curing and immuno-consolidation.  Cancer Treat Rev 30:281-290."
"1750","PC030166","Lashinger L, Zhu K, Williams S, et al.  2005.  Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res 65(11):4902-4908."
"1751","PC030171","Liu S, Zhang H, Zhu L, et al.  2008.  KLF4 is a novel mediator of selenium in growth inhibition.  Molecular Cancer Research, 6:306¿313.

"
"1752","PC030171","Lee SO, Chun JY, Nadiminity N, et al.  2006.  Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).  Prostate 66:1070-1075."
"1753","PC030171","Zhang H, Wu Y, Malewicz B, et al.  2006.  Augmented suppression of androgen receptor signaling by a combination of &#61537;-Tocopheryl succinate and methyseleninic acid.  Cancer 107:2942-2948."
"1754","PC030171","Dong Y, Zhang H, Gao AC, et al.  2005.  Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers.  Molecular Cancer Therapeutics 4:1047-1055."
"1755","PC030173","Pandori MW, and Sano T.  2005.  Chemically inactivated adenoviral vectors that can efficiently transduce target cells when delivered in the form of virus-microbead conjugates.  Gene Therapy 12:521-533."
"1756","PC030191","Jia L and Coetzee GA.  2005.  AR-dependent PSA expression in androgen-independent prostate cancer does not involve AR occupancy of the PSA locus.  Cancer Res 65:8003-8008."
"1757","PC030191","Shen HC and Coetzee GA.  2005.  The androgen receptor: Unlocking the secrets of its unique transactivation domain.  Vitam Horm 71:301-319"
"1758","PC030191","Shen HC, Buchanan G, Butler LM, et al.  2005.  GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor.  Biol Chem 386:69-74."
"1759","PC030191","Kim J, Jia L, Stallcup MR, et al.  2005.  The role of protein kinase A pathway and cAMP responsive element-binding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus.  J Mol Endocrinol 34:107-118."
"1760","PC030191","Kim J and Coetzee GA.  2004.  Prostate specific antigen gene regulation by androgen receptor.  J Cell Biochem 93:233-241."
"1761","PC030191","Prescott J and Coetzee GA.  2006.  Molecular chaperones throughout the life cycle of the androgen receptor.  Cancer Lett 231:12-19."
"1762","PC030191","Jia L, Shen HC, Wantroba M, et al.  2006.  Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells.  Mol Cell Biol 26:7331-41."
"1763","PC030214","Hofer MD, Kuefer R, Huang W, et al.  2006. Prognostic factors in lymph node positive prostate cancer. Urol 67:1016-21."
"1764","PC030214","Hofer MD, Tapia C, Browne TJ, et al.  2006. Comprehensive analysis of the expression of the metastasis-associated gene 1 (MTA1) in human neoplastic tissue.  Archives Pathol Lab Med 130:989-96."
"1765","PC030214","Hofer MD, Browne TJ, He L, et al.  2005.  Identification of two molecular groups of seminomas using expression and tissue microarrays.  Clin Cancer Res 15:11(16): 5722-5729."
"1766","PC030214","Hofer MD, Kuefer R, Varambally S, et al.  2004.  The role of metastasis-associated protein 1 in prostate cancer progression.  Cancer Res 64(3):825-829."
"1767","PC030214","Hofer MD, Fecko A, Shen R, et al.  2004.  Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors.  Neoplasia 6(5):503-512."
"1768","PC030224","Jayadevappa R, Chhatre S, Weiner M et al. 2005.  Medical care cost of patients with prostate cancer.  Urologic Oncol 23:155-62."
"1769","PC030224","Jayadevappa R, Bloom BS, Chhatre S et al.  Health-related quality of life and direct medical cost in newly diagnosed younger men with prostate cancer.  J Urol 174:1059-64."
"1770","PC030224","Jayadevappa R, Chhatre S, Whittington R, et al. 2006.  Health related quality of life and satisfaction with care among older men treated with radical prostatectomy or external beam radiation therapy.  BJU International 97:955-62."
"1771","PC030224","Jayadevappa R, Chhatre S, Bloom BS, et al.  2007.  Ethnic Differences in health related quality of life and satisfaction with care among older men with prostate cancer.  Cancer 109:2229-2238."
"1772","PC030239","Steven N. Quayle, Nasrin R. Mawji, Jun Wang, and Marianne D. Sadar, 2007.  Androgen receptor decoy molecules block the growth of prostate cancer.  PNAS  104:1331¿1336.
"
"1773","PC030242","Doxsee DW, Gout PW, Kurita T, et al.  2007.  Sulfasalazine-induced cystine starvation: Potential use for prostate cancer therapy.  Prostate 67(2):162-171."
"1774","PC030242","Ricke WA, Ishii K, Ricke EA, et al.  2006.  Steroid hormones stimulate human prostate cancer progression and metastasis.  Int J Cancer 118:2123-2131."
"1775","PC030242","Wang YZ, Revelo MP, Sudilovsky D, et al.  2005.  Development and characterization of efficient xenograft models for benign and malignant human prostate tissue.  Prostate.

"
"1776","PC030242","Wang Y, Xue H, Cutz J-C, et al.  2005.   An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line.  Lab Invest 85:1392-1404.

"
"1777","PC030254","Yi Y, Mirosevich J, Shyr Y, et al.  2005.  Coupled analysis of gene expression and chromosomal location.  Genomics 85:401-412."
"1778","PC030254","Nam S, Kim D, Cheng JQ, et al.  2005.  Action of the Src family kinase inhibitor, Dasatinib (BMS-354825), on human prostate cancer cells.  Cancer Res 65:9185-9189."
"1779","PC030254","Mirosevich J, Gao N, Gupta A, et al.  2006.   Expression and role of Foxa proteins in prostate cancer.  Prostate 66:1013-28."
"1780","PC030254","Gao N, Ishii K, Mirosevich J, et al.  2005.  Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation.  Development 132:3431:3443."
"1781","PC030254","Mirosevich J, Gao N, and Matusik RJ.  2004.  Expression of Foxa transcription factors in the developing and adult murine prostate.  Prostate 62:339-352."
"1782","PC030254","Klezovitch O, Chevillet J, Mirosevich J, et al.  2004.  A casual role for hepsin in prostate cancer metastasis.  Cancer Cell 6:185-195."
"1783","PC030271","Kovar JL, Johnson MA, Volcheck WM, et al.  2006.  Hyaluronidase induces prostate tumor metastasis in an orthotopic mouse model.  Amer J Pathol 169(4):1415-1426."
"1784","PC030271","Kovar JL, Volcheck WM, Chen J, et al.  2007.  Purification method directly influences effectiveness of an epidermal growth factor-coupled targeting agent for noninvasive tumor detection in mice.  Anal Biochem 361(1):47-54."
"1785","PC030271","Simpson MA.  2006.  Concurrent expression of hyaluronan biosynthesis and processing enzymes promotes growth and vascularization of prostate tumors in mice.  Am J Pathol 169:247-57."
"1786","PC030273","Chen B, Pogue BW, and Hasan T.  2005.  Liposomal delivery of photosensitizing agents.  Expert Opin Drug Deliv 2:477-487."
"1787","PC030273","Chen B, BW Pogue, PJ Hoopes, and T Hasan.  Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy.  Int. J. Radiat. Oncol. Biol. Phys., 61:1216-26.

"
"1788","PC030273","Chen B, BW Pogue, X Zhou, et al.  Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model.  Clin. Cancer Res., 11:720-7."
"1789","PC030274","Pettaway CA, Song R, Wang X, et al.  2008.  The ratio of matrix metalloproteinase to E-cadherin expression level: Prognostic significance of mRNA and protein expression among African
American prostate cancer patients. Prostate 68(13):1467-1476."
"1790","PC030290","Hyer ML, Croxton R, Krajewska M, et al.  2005.  Synthetic triterpenoids cooperate with TRAIL to induce apoptosis of breast cancer cells both in vitro and in vivo.  Cancer Res 65:4799-808.

"
"1791","PC030297","Kawaguchi Y, Ito A, Appella E, et al.  2006.  Charge modification at multiple C-terminal lysine residues regulates p53 oligomerization and its nucleus-cytoplasm trafficking.  J Biol Chem 281:1394-400."
"1792","PC030301","Dote H, Toyooka S, Tsukuda K, et al.  2004.  Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer.  Clin Cancer Res 10:2082-2089."
"1793","PC030301","Xie D, Gore C, Zhou J, et al. 2009.  DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis.  Proc Natl Acad Sci U S A. 106(47):19878-19883."
"1794","PC030301","Xie D, Gore C, Liu J, et al.  2010.  Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci U S A 107(6):2485-2490."
"1795","PC030301","Hsieh JT, Karam JA and Min W.  2007.  The link of genetic and biologic evidence from DAB2IP gene with aggressive prostate cancer.  J Natl Cancer Inst 99:1823-1824."
"1796","PC030301","Zhou J, Tu S, Hernandez G, et al.  2005.  Synergistic induction of DOC-2/DAB2 gene expression in transitional carcinoma cells in the presence of GATA6 and histone deacetylase inhibitor.  Cancer Res 65:6089-6096."
"1797","PC030301","Chen H and Hsieh JT.  2005.  Down regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.  J. Biol Chem 280:22437-22444."
"1798","PC030301","Chen H, Karam JA, Schultz R, et al.  2006.  Cloning of mDAB21P gene, a novel member of the RasGTPase-activating protein family and characterization of its regulatory region.  DNA Cell Biol 25:232-245.

"
"1799","PC030301","Karam J, Benaim E, Chen H, et al.  2005.  Epigenetics in prostate cancer.  In Prostate Cancer: Mechanisms, Prevention, and Hormone Therapy (Chang C, ed) World Scientific 213-228."
"1800","PC030305","Liao YP, CC Wang, LH Butterfield, et al., 2004.  Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells.  J. Immunol. 173:2462-2469."
"1801","PC030305","Oh YT, WC Chen, GJ Dougherty, and WH McBride,m 2004.  Adenoviral interleukin-3 gene-radiation therapy in a mouse prostate cancer model.  Int. J. Radiat. Oncol. Biol. Phys. 59:579-583."
"1802","PC030305","McBride WH, CS Chiang, JL Olson, et al., 2004.  A sense of danger from radiation.  Radiat. Res. 162:1-19."
"1803","PC030305","Pajonk F, and WH McBride, 2004.  The proteasome in cancer biology and therapy.  Cancer Drug Discovery and Development:  Proteasome Inhibitors in Cancer Therapy, New Jersey."
"1804","PC030305","Tsai CH, Hong JH, Hsieh KF, et al.  2006.  Tetracycline-regulated intratumoral expression of interleukin-3 enhances the efficacy of radiation therapy for murine prostate cancer.  Cancer Gene
Therapy 13:1082-1092.
"
"1805","PC030310","Dennis LK, Coughlin JA, McKinnon BC, et al. 2009.  Sexually Transmitted Infections and Prostate Cancer among Men in the U.S. Military.  Cancer Epid Bio 18:2665-71."
"1806","PC030320","Barwe SP, Anilkumar G, Moon SY, et al.  2005.  Novel role for NA, K-ATPase in phosphatidylinositol 3-kinase signaling and suppression of cell motility.  Mol Biol Cell 16(3):1082-1094."
"1807","PC030320","Anilkumar G, Barwe SP, Christiansen JJ, et al.  2006.  Association of prostate specific membrane antigen with caveolin-1 and its caveolae-dependent internalization in microvascular endothelial cells: Implications for targeting to tumor vasculature.  Microvasc Res 72:54-61."
"1808","PC030320","Barwe SP, Maul RS, Christiansen JJ, et al.  2007.  Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix.  International Journal of Oncol 30:899-904."
"1809","PC030320","Christiansen JJ, Rajasekaran SA, Inge L, et. al.  2005.  N-glycosylation and microtubule integrity are involved in apical targeting of prostate specific membrane antigen: Implications for immunotherapy.  Mol Cancer Ther 4:704-14.

"
"1810","PC030323","McGary JE and Teh BS.  2004.  Real time tumor localization using an inductively coupled transmitter and a superconducting quantum interference devise (SQUID) magnetometer system.  Cancer J 10:56."
"1811","PC030323","McGary JE.  2004.  Theoretical foundation for real-time prostate localization using an inductively coupled transmitter and a superconducting quantum interference devise (SQUID) magnetometer system.  J Appl Clin Med Phys 5:4."
"1812","PC030325","Sloane BF, Yan S, Podgorski I, et al.  2005.  Cathepsin B and tumor proteolysis: Contribution of the tumor microenvironment.  Semin Cancer Biol 15(2):149-157.

"
"1813","PC030325","Podgorski I, Linebaugh BE, Sameni M, et al.  2005.  Bone Microenvironment Modulates Expression and Activity of Cathepsin B in Prostate Cancer.  Neoplasia, 7(3):207-23.

"
"1814","PC030325","Sloane BF, Sameni M, Podgorski I, et al.  2006.  Functional imaging of tumor proteolysis.  Ann Rev Pharmacol 46:301-315."
"1815","PC030328","Tehrani OS, Muzik O, Heilbrun LK, et al.  2007.  Tumor imaging using [F-18]1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-thymine and (PET).  J Nucl Med. 48:1436-1441."
"1816","PC030328","Bading JR and Shields AF.  2008.  Imaging cell proliferation: Status and prospects.  J Nucl Med 49 Suppl 2:64S-80S."
"1817","PC030328","Sun H, Sloan A, Mangner TJ, et al.  2005.  Imaging DNA synthesis with [F-18]FMAU and positron emission tomography in patients with cancer.  Eur J Nuc Med 32:15-22."
"1818","PC030328","Shields AF.  2006.  Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology.  Mol Imag Biol 8:141-50."
"1819","PC030328","Tehrani OS, Douglas KA, Lawhorn-Crews JM, et al.  2008.  Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2.  Eur J Nucl Med Mol Imaging 35:1480-8."
"1820","PC030328","Peng F, Lu X, Janisse J, et al.  2006.  PET of human prostate cancer xenografts in mice with increased uptake of 64CuCl2.  J Nucl Med 47:1649-1652."
"1821","PC030328","Shields AF.  2006.  Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology.  Mol Imaging Biol 8:141-150."
"1822","PC030328","Sun H, Mangner TJ, Collins JM, et al.  2005.  Imaging DNA synthesis in vivo with 18F-FMAU and PET.  J Nucl Med 46:292-296."
"1823","PC030329","Liang Q, Dmitriev I, Kashentseva E, et al.  2004.  Noninvasive of adenovirus tumor retargeting in living subjects by a soluble adenovirus receptor-epidermal growth factor (sCAR-EGF) fusion protein.  Mol Imaging Biol 6:385-394.

"
"1824","PC030329","Le LP, Everts M, Dmitriev IP, et al.  2004.  Fluorescently labeled adenovirus with pIX-EGFP for vector detection.  Mol Imaging 3:105-116.

"
"1825","PC030329","Liang Q, Yamamoto M, Curiel DT, et al.  2004.  Noninvasive imaging of transcriptionally restricted transgene expression following intratumoral injection of an adenovirus in which the COX-2 promoter drives a reporter gene.  Mol Imaging Biol 6:395-404."
"1826","PC030329","Li J, Le L, Sibley DA, et al.  2005.  Genetic incorporation of HSV-1 thymidine kinase into the adenovirus protein IX for functional display on the virion.  Virol 338(2):247-258.

"
"1827","PC030329","Le LP, Rivera AA, Glasgow JN, et al.  2006.  Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells.  Gene Ther 13(5):389-399.

"
"1828","PC030329","Hakkarainen T, Hemminki A, Curiel DT, et al. 2006.  A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy.  Int J Mol Med 18(4):751-759."
"1829","PC030335","Ghosh R, Schoolfield J, Yeh I-Tien, et al.  2009.  Loss of NADPH quinone oxidoreductase (NQO1) in the prostate and enhanced serum levels of cytokine-induced neutrophil chemoattractant- 2alpha in hormone stimulated Noble rats: potential role in prostatic intraepithelial neoplasia development.  Transl Oncol 2(2):65-72."
"1830","PC030338","Rohan JN, and Weigel NL.  2009.  1,25(OH)2D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology 150(5):2046-2054.

"
"1831","PC030340","Wang X, Taniguchi K, Seelan RS, et al.  2006.  Germline p53AIP1 mutations disrupting DNA damage-induced apoptosis are associated with sporadic prostate cancer.  Cancer Res 66:10302-10307."
"1832","PC030340","Zheng L, Wang F, Neumann RM, et al.  2006.  Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines.  Hum Mut 27:1062-1063."
"1833","PC030348","Mei X and Pang G.  2005.  Development of high quantum efficiency, flat panel, thick detectors for megavoltage x-ray imaging: An experimental study of a single-pixel prototype.  Med Phys 32:3379-3388."
"1834","PC030348","Pang G and Rowlands JA.  2004.  Development of a new generation of area detectors for a portal imaging: High quantum efficiency direct-conversion flat panel images.  Physics of Medical Imaging.  Proc. SPIE 5368:119-126."
"1835","PC030348","Pang G and Rowlands JA.  2004.  Development of high quantum efficiency, flat panel, thick detectors for megavoltage x-ray imaging: A novel direct-conversion design and its feasibility. Med Phys 31:3004-3016."
"1836","PC030351","Kawakubo H, Carey JL, Brachtel E, et al.  2004.  Expression of the NF-kappaB-responsive gene BTG2 is aberrantly regulated in breast cancer.  Oncogene 23:8310-8319.

"
"1837","PC030351","Kawakubo H, Brachtel E, Hayashida T, et al.  2006.  Loss of B-cell translocation gene-2 in estrogen receptor-positive breast carcinoma is associated with tumor grade and overexpression of cyclin D1 protein.  Cancer Res 66:7075-7082."
"1838","PC030362","Thakur CS, Xu Z, Wang Z, et al.  2005.  A convenient and sensitive fluorescence resonance energy transfer assay for RNASEL and 2',5' oligoadenylates.  Methods Mol Med 116:103-113."
"1839","PC030368","Eeles RA, Kote-Jarai Z, Giles G, et al.  2008.  Multiple newly identified loci associated with prostate cancer susceptibility.  Nature Genet 40:316-321."
"1840","PC030368","Kote-Jarai, et al.  2008.  Multiple novel prostate cancer predisposition loci confirmed by an international study: The PRACTICAL Consortium.  Cancer Epidemiol Biomarkers Prev 17:2052-61."
"1841","PC030370","Atashbar MZ, Bejcek B, Vijh A, et al.  2005.  QCM Biosensor with ultra thin polymer film.  Sensor and Actuators B, 107:2, 945-951."
"1842","PC030370","Atashbar MZ, Bejcek B, and Singamameni S.  2006.  Carbon nanotube network-based biomolecule detection.  IEEE Sens J 6:(3)524-528."
"1843","PC030370","Atashbar MZ, Bejeck B, Singamaneni S, et al.  2005.  SWNT Network for biomolecule detection in functional carbon nanotubes.  Mater Res Soc Symp Proc Mater Res Soc. 858E, HH14.8.1-HH14.8.6."
"1844","PC030377","Kline EE, Treat EG, Averna TA, et.al.  2006.  Citrate Concentrations in Human Seminal Fluid and Expressed Prostatic Fluid Determined via 1H Nuclear Magnetic Resonance Spectroscopy Outperform Prostate Specific Antigen in Prostate Cancer Detection.  Urology 176:2274-2279."
"1845","PC030377","Averana TA, Kline EE, Smith AY, et. al.  2005.  A Decrease in 1H Nuclear Magnetic Resonance Spectroscopically  Determined Citrate in Human Seminal Fluid Accompanies the Development of Prostate Adenocarcinoma.  Urology 173:433-438."
"1846","PC030388","Cao X, Liu W, Lin F, et al.  2004.  Retinoid X receptor regulates Nur77/TR3-dependent apoptosis by modulating its nuclear export and mitochondrial targeting.  Mol Cell Biol 24:9705-9725."
"1847","PC030388","Dawson MI, Ye M, Cao X,et al.  2009.  Derivation of a retinoid X receptor scaffold from peroxisome proliferator-activated receptor gamma ligand 1-Di(1H-indol-3-yl)methyl-4-trifluoromethylbenzene.  ChemMedChem 4(7):1106-1119."
"1848","PC030390","Gioeli D.  2005.  Signal Transduction in Prostate Cancer Progression.  Clinical Science.

"
"1849","PC030390","Gioeli D, Black B, Gordon V, et al.  2006.  Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization.  Mol Endocrinol 20:503-15."
"1850","PC030390","Gioeli D, Kraus S, Weber MJ, et al.  2007. Signal transduction by the RAS MAP kinase pathway in prostate cancer progression.  Prostate Cancer Signaling Networks; Humana Press."
"1851","PC030390","Kraus S, Gioeli D, Vomastek T, et al.  2006.  RACK1 and Src regulate the tyrosine phosphorylation and function of the androgen receptor.  Cancer Res 66(22):11047-11054."
"1852","PC030390","Wu Z, Conaway M, Gioeli D, et al.  2006.  Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells.  Prostate 66(10):1114-1123."
"1853","PC030390","Lange CA, Gioeli D, Hammes SR, et al.  2007.  Integration of rapid signaling events with steroid hormone receptor action in breast and prostate cancer.  Annual Review Physiology, 69:17.1¿17.29.

"
"1854","PC030391","Wang Z, Prins GS, Coschigano KT, et al.  2005.   Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/Tag mouse.  Endocrinology 146:5188-5196.

"
"1855","PC030402","Patil AV and Hossack JA.  2007.  3D prostate elastography: algorithm, simulations and experiments.  Phys Med Biol (52):3643--3663."
"1856","PC030402","Tay PC, Acton ST, and Hossack JA.  2006.  Ultrasound despeckling using an adaptive window stochastic approach.  Proceedings, IEEE International Conference on Image Processing 2549-2552."
"1857","PC030402","
Tay PC, Acton ST, and Hossack J.  2006.  A stochastic approach to ultrasound despeckling.  Proceedings, 2006 IEEE International Symposium for Biomedical Imaging:  From Nano to Macro 221-224.
"
"1858","PC030402","
Patil A, Garson CD, Oberhardt MA, et al.  2006.  Multi-resolution hybrid strain estimator for elastography.  Proceedings, 2006 IEEE International Ultrasonics Symposium 1258-1261.
"
"1859","PC030402","Hossack J.  2006.  Simulations and Experiments.  Proceedings, 2006 IEEE International Ultrasonics Symposium 1230-1233."
"1860","PC030402","Li B and Acton ST.  2008.  Automatic active model initialization via Poisson inverse gradient.  IEEE Trans on Image Processing 17(8):1406-1420."
"1861","PC030407","Litovchick L, Chestukhin A, and DeCaprio J.  2004.  Glycogen synthase kinase 3 phosphorylates RBL2/p130 during quiescence.  Mol Cell Biol 24:8970-8980."
"1862","PC030410","Sun H, Nikolovska-Coleska Z, Yang CY, et al.  2008.  Design of small-molecule peptidic and nonpeptidic Smac mimetics.  Acc Chem Res 41(10):1264-1277."
"1863","PC030410","Chen J, Nikolovska-Coleska Z, Wang G, et al.  2006.  Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein.  Bioorg Med Chem Lett 16(22):5805-5808."
"1864","PC030410","Sun H, Nikolvska-Coleska A, Lu J et al. 2007. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc 129(49):15279-94."
"1865","PC030410","Nikolovska-Coleska Z, Meagher JL, Jiang S, et al.  2008.  Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 domains. Anal Biochem 374(1):87-98."
"1866","PC030429","Tang WW, Stelter AA, French S, et al.  2007.  Loss of cell-adhesion molecule complexes in solid pseudopapillary tumor of pancreas.  Mod Pathol 20(5):509-513."
"1867","PC030429","Bian Y, Huang S, Yang L, et al.  2007.  The sonic hedgehog-Gli1 pathway in colorectal adenocarcinomas.  World J Gastroenterol 13(11):1659-1665."
"1868","PC030429","Ma X, Sheng T, Zhang Y, et al.  2006.  Hedgehog signaling is activated in subsets of esophageal cancers.  Int J Cancer 118(1):139-148."
"1869","PC030429","Huang S, He J, Zhang X, et al.  2006.  Activation of the hedgehog pathway in human hepatocellular carcinomas.  Carcinogenesis 27(7):1334-1340."
"1870","PC030429","Sheng T, Chi S, Zhang X, et al.  2006.  Regulation of Gli1 localization by the cAMP/protein kinase A signaling axis through a site near the nuclear localization signal.  J Biol Chem 281(1): 9-12."
"1871","PC030429","Xie J.  2008.  Implications of hedgehog signaling antagonists for cancer therapy.  Acta Biochimica et Biophysica Sinica (Shanghai) 40(7):670-680."
"1872","PC030429","Ma X, Chen K, Huang S, et al.  2005.  Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas.  Carcinogen 26(10):1698-1705. 

"
"1873","PC030429","Sheng T, Li C, Zhang X, et al.  2004.  Activation of the hedgehog pathway in advanced prostate cancer.  Mol Cancer 3:29."
"1874","PC030429","Sumin C, Shuhong H, Chengxin L, et al.  2006.  Activation of the hedgehog pathway in a subset of lung cancers.  Cancer Lett 244:53-60."
"1875","PC030462","Ragin CC, Taioli E, McFarlane-Anderson N, et al.  2007.  African-Caribbean cancer consortium for the study of viral, genetic, and environmental cancer risk factors.  Infect Agent Cancer 2:17.

"
"1876","PC030462","Odedina FT, Scrivens J, Emanuel A, et al.  2004.  A naturalistic study of factors influencing African American menâ¿¿s prostate cancer screening behavior.  J Natl Med Assoc 96(6):780-8."
"1877","PC030462","Odedina FT, Warrick C, Vilme H, et al.  2008.  Pharmacistsâ¿¿ role in prostate cancer screening and advocacy.  J Soc Adm Pharm 4(1):59-66."
"1878","PC030462","Odedina FT, Campbell E, Scrivens J.  2008.  Personal Factors Affecting African American menâ¿¿s prostate cancer screening behavior.  J Natl Med Assoc 100(6):724-733."
"1879","PC030462","Dahan K, Fennal M and Kumar NB.  2008.  Lycopene in the prevention of prostate cancer.  J Soc Integr Oncol 6(1):29-36."
"1880","PC030462","Odedina FT, Thorpe Y and Odedina AO.  2008.  Comparability of the prostate cancer burden in Nigeria to other countries:  An investigation of the cancer registration system used for assessment.  Eur J Cancer Prev."
"1881","PC030462","Odedina FT, Campbell E, Scrivens J, et al.  2008.  Personal factors affecting African American men's prostate cancer screening behavior.  J Natl Med Assoc 100:724-33."
"1882","PC030462","Dahan K, Fennal M, and Kumar NB.  2008.  Lycopene in the prevention of prostate cancer.  J Soc Integr Oncol 6(1):29-36."
"1883","PC030462","Odedina FT, Ogunbiyi F and Ukoli F.  2006.  Prostate cancer burden in African-Americans:  Can the origin be traced to Ancestral African relatives?  J Natl Med Assoc 98(4):539-543."
"1884","PC030462","Xiao H, Gwede CK, Kiros GE, et al.  2007.  Analysis of prostate cancer incidence in the state of Florida using GIS and multilevel modeling.  J Natl Med Assoc 99(3):218-225."
"1885","PC030462","Ragin CC, Taioli E, McFarlane-Anderson N, et al.  2007.  African- Caribbean cancer consortium for the study of viral, genetic and environmental cancer risk factors.  Infect Agent Cancer 24(2):17."
"1886","PC030462","Odedina FT, Ogunbiyi F, and Ukoli F.  2005.  Prostate cancer burden in African-Americans: Can the origin be traced to ancestral African relatives?  J Natl Med Assoc 98(4):1-5."
"1887","PC030462","Odedina FT, Kumar N, Scrivens J, et al.  2006.  Prostate cancer communication module: The dos and don¿ts of communicating with African American men.  Resource guide for health care providers, health educators and researchers."
"1888","PC030471","Bakin R and Jung M.  2004.  Cytoplasmic sequestration of HDAC7 from mitochondria and nuclear compartment upon initiation of apoptosis.  J Biol Chem 279:51218-51225."
"1889","PC030471","Zhang Y, Jung M, Dritschilo A, et al.  2004.  Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors.  Radiat Res 161:667-674."
"1890","PC030471","Chen B, Petukhov PA, Jung M, et al.  2005.  Chemistry and biology of mercaptoacetamides as novel histone histone deacetylase inhibitors.  Bioorg Med Chem Lett 15:1389-1392."
"1891","PC030471","Jung M, Velena A, Chen B, et al.  2005.  Novel HDAC inhibitors with radiosensitizing properties.  Radiat Res 163:488-493."
"1892","PC030471","Jung M, Kozikowski A, Dritschilo A, et al.  2005.  Rational design and development of radiation-sensitizing histone deacetylase inhibitors.  Chem Biodivers 2:1452-1461."
"1893","PC030478","Norris AM, Woodruff RD, D¿Agostino RB Jr., et al.  2007.  Elevated levels of the mismatch repair protein PMS2 are associated with prostrate cancer.  Prostate 67:214-225."
"1894","PC030480","Coleman IM, Kiefer JA, Brown LG, et al.  2006.  Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes.  Neoplasia 8:862-78.
"
"1895","PC030481","Luo J-L, Tan W, Ricono JM, et al.  2007.  Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin.  Nature 446:690-4.
"
"1896","PC030481","Ammirante M, Luo JL, Grivennikov S, et. al. 2010.  B-Cell-Derived Lymphotoxin Promotes Castration-Resistant Prostate Cancer.  Nature 464:302-06."
"1897","PC030482","Yang. J-M, O¿Neill P, Jin W, et al.  2006.  Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to anoikis through inhibition of Bim.  J Biol Chem 281: 9719-9727."
"1898","PC030482","Foty RA and Steinberg MS.  2005.  Cadherin-mediated cell-cell adhesion and tissue segregation in relation to malignancy.  Int J Dev Biol 48:397-409."
"1899","PC030482","Winters BS, Shepard SR, and Foty RA.  2005.  Biophysical measurement of brain tumor cohesion.  Int J Cancer 114:371-379."
"1900","PC030482","Foty RA and Steinberg MS.  2005.  The differential adhesion hypothesis: A direct evaluation.  Dev Biol 278(1):255-263."
"1901","PC030482","Winters BS, Raj M, Robinson EE, et al.  2006.  Three-dimensional culture regulates Raf-1 expression to modulate fibronectin matrix assembly.  Mol Bio Cell 17:3386-3396."
"1902","PC030511","Clark DE, Errington TM, Smith JA, et al.  2005.  Identification of the first specific inhibitor of p90 ribosomal s6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation.  Cancer Res 65:1027-34."
"1903","PC030511","Clark DE, Errington TM, Smith JA, et al.  2005.  The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation.  Cancer Res 65(8):3108-3116."
"1904","PC030511","Hilinski MK, Mrozowski RM, Clark DE, et al. 2012.  Analogs of the RSK inhibitor SL0101: optimization of in vitro biological stability.  Bioorg Med Chem Lett 22(9):3244-7."
"1905","PC030511","Mrozowski RM, Vemula R, Wu B, et al. 2012.  Improving the affinity of SL0101 for RSK using structure-based design. ACS Med Chem Lett 4(2):175-179."
"1906","PC030512","Rajasekaran AL, Anilkumar G and Christiansen J.  2005.  Is prostate specific membrane antigen a multifunctional protein? 
Am J Phys 288:C975-81.
"
"1907","PC030512","Inge LJ, Rajasekaran SA, Ryazantsev S, et al.  2008.  Alpha-catenin overrides Src-dependent activation of beta-catenin oncogenic signaling.  Mol Cancer Ther 7(6):1386-1397."
"1908","PC030512","Goodman OB Jr, Barwe SP, McPherson P, et al.  2007.  Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2.  Int J Oncol 5:1199-2003."
"1909","PC030512","Olson WC, Heston WD, and Rajasekaran AK.  2007.  Clinical trials of cancer therapies targeting prostate-specific membrane antigen.  RRCT 2:182-190.

"
"1910","PC030512","Rajasekaran S, Christiansen JJ, Schmid I, et al.  2008.  Prostate specific membrane antigen associates with anaphase promoting complex and induces chromosomal instability.  Mol Cancer Ther 7(7):2142-2151."
"1911","PC030512","Barwe SP, Maul RS, Christiansen JJ, et al.  2007.  Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix.  Int J Oncol 30:899-904."
"1912","PC030512","Christiansen JJ, Weimbs, Bander N, et al.  2006.  Differing effects of microtubule depolymerizing and stabilizing chemotherapeutic agents in t-SNARE mediated apical targeting of Prostate Specific Membrane Antigen.  Mol Cancer Ther 5:2468-2473."
"1913","PC030512","Anilkumar G, Barwe SP, Christiansen JJ, et al.  2006. Association of prostate specific membrane antigen with caveolin-1 and its caveolae-dependent internalization in microvascular endothelial cells: implications for targeting to tumor vasculature.  Microvasc Res 72:54-61."
"1914","PC030512","Christiansen JJ and Rajasekaran AK.  2006.  Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 66:8319-8326."
"1915","PC030515","Kim O, Jiang T, Xie Y, et al.  2004.  Synergism of cytoplasmic kinases in IL6-induced ligand independent activation of androgen receptor in prostate cancer cells.  Oncogene 23:1838-1844."
"1916","PC030515","Jiang T, Guo Z, Dai B, et al.  2004.  Bi-directional regulation between tyrosine kinase Etk/BMX and tumor suppressor p53 in response to DNA damage.  J Biol Chem 279:50181-50189.

"
"1917","PC030515","Kim O, Jiang T, Xie Y, et al.  2004.  Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells. Oncogene 23:1838-1844."
"1918","PC030515","Xie Y, Xu K, Dai B, et al.  2006.  The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene 25(1):70-78."
"1919","PC030519","He Q, Luo X, Jin W, et al.  2008.  Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP.  Oncogene 27:2656-60."
"1920","PC030524","Diefenbach MA.  2005.  Multimedia technology for cancer patients.  Hospital Pharmacy Europe, 42-43."
"1921","PC030524","Diefenbach MA and Butz BP.  2004.  A multimedia interactive education system for prostate cancer patients: development and preliminary evaluation.  J Med Internet Res 6:e3.

"
"1922","PC030525","Wu JD, LM Higgins, A Steinle, D Cosman, et al., 2004.  Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer.  Journal of Clinical Investigation 114:560-568."
"1923","PC030525","Page ST, Plymate SR, Bremmer WJ, et al.  2006.  Effect of medical castration on CD4+CD25+ T cells, CD8+ T cell IFN-&#61543; expression, and NK cells:  a physiological role for testosterone and/or its metabolites.  Am J Physiol Endocrinol Metab 290:E856-E863."
"1924","PC030528","Bisson WH, Cheltsov AV, Bruey-Sedano N, et al. 2007. Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A 104(29):11927-11932."
"1925","PC030529","Gao K, Henning SM, Youssefian AA, et al.  2006.  The citrus flavonoid naringenin stimulates DNA repair in prostate cancer cells.  J Nutr Biochem 17:89-95.
"
"1926","PC030529","Gao K, Xu A, Krul C, et al.  2006.  Of the major phenolic acids formed during human microbial fermentation of tea, citrus, and soy flavonoid supplements only 3,4-dihydroxy phenylacetic acid has antiproliferative activity.  J Nutr 136:52-7."
"1927","PC030529","Henning SM, Gao K, Xu A, et al.  2005.  The citrus flavonoid naringenin stimulates DNA repair in prostate cancer cells.  FASEB J 19(4):A1475.

"
"1928","PC030538","Buchanan G, Yang M, Cheong A, et al.  2004.  Structural and functional consequences of glutamine tract variations in the androgen receptor.  Hum Mol Genet 13:1677-1692."
"1929","PC030538","Buchanan G, Craft PS, Yang M, et al.  2004.  PC-3 cells with enhanced androgen receptor signaling: A model for clonal selection in prostate cancer.  Prostate 60:352-366.

"
"1930","PC030538","Shen HC, Buchanan G, Butler LM, et al.  2005.  GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor.  Biol Chem 386:69-74."
"1931","PC030538","Scher HI, Buchanan G, Gerald W, et al.  2004.  Targeting the androgen recptor: Improving outcomes for castration resistant prostate cancer.  Endocr Relat Cancer 11:459-476.

"
"1932","PC030538","Buchanan G, Birrell SN, Ramsay K, et al.  2005.  Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate.  Cancer Res 65:8487-8496."
"1933","PC030538","Han G, Buchanan G, Harris JM, et al.  2005.  Mutation of the androgen receptor causes oncogenic transformation of the prostate.  Proc Natl Acad Sci USA 102:1151-1156."
"1934","PC030538","Makridakis NM, Buchanan G, Tilley WD, et al.  2005.  Androgen metabolic genes in prostate cancer predisposition and progression.  Frontiers in Bioscience 10:2892-2903."
"1935","PC030538","Beekman KW, Buchanan G, Tilley WD, et al.  Anti-androgen withdrawal syndromes: Pathophysiology and clinical implications.  In: Prostate Cancer: Principles and Practice (Partin AW Ed.), Lippincott, Philadelphia, Pennsylvania."
"1936","PC030538","Beekman KW, Buchanan G, Tilley, WD, et al.  2005.  Beyond first line hormones: Options for castration-resistant disease.  In: Comprehensive Textbook of Genitourinary Oncology Third Edition (Vogelzang NJ, Scardino PT, Shipley WU, et al. Eds.), Wiley and Williams, Lippincott, Philadelphia, Pennsylvania pp 330-340."
"1937","PC030538","Butler LM, Centenera MM, Neufing PJ, et al.  2006.  Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant.  Mol Endocrinol 20:1009-24.

"
"1938","PC030538","Ricciardelli C, Choong CS, Buchanan G, et al.  2004.  Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease.  Prostate 63:19-28."
"1939","PC030550","Fukuhara H, Ino Y, Kuroda T, et al.  2005.  Triple gene-deleted oncolytic herpes
simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by
bacterial artificial chromosome-mediated system. Cancer Res 65:10663-10668.
"
"1940","PC030550","Kuroda T, Martuza RL, Todo T, et al.  2006.  Flip-flop HSV-BAC: Bacterial artificial chromosome based system chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases.  BMC Biotechnology 6:40.

"
"1941","PC030550","Varghese S, Rabkin S, Nielson GP, et al.  2007.  Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses.  Cancer Res 67:9371-9379."
"1942","PC030550","Fukuhara H, Martuza RL, Rabkin SD, et al.  2005. Oncolytic herpes simplex virus vector
g47delta in combination with androgen ablation for the treatment of human prostate
adenocarcinoma. Clin Cancer Res 11:7886-7890.

"
"1943","PC030556","Davis MI, Bennett MJ, Thomas LM, et al.  2005.  Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase.  Proc Natl Acad Sci USA 102:5981-5986."
"1944","PC030562","Mahmud S, Franco E, and Aprikian A.  2004.  Prostate cancer and use of nonsteroidal anti-inflammatory drugs: Systematic review and meta-analysis.  Br J Cancer 12:90(1)."
"1945","PC030562","Mahmud SM, Tanguay S, Begin LR, et al.  2006.  Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population.  Eur J Cancer Prev 15:158-164."
"1946","PC030562","Dasgupta K, Di Cesar D, Ghosn J, et al.  2006.  Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence.  Cancer J 12:130-135."
"1947","PC030575","Dunphy EJ, Johnson LE, Olson BM, et al. 2006.  New approaches to identification of antigenic candidates for future prostate cancer immunotherapy.  Cancer chemotherapy and biological response modifiers Annual 23.

"
"1948","PC030575","Johnson LE, Frye TP, Arnot AR, et al.  2006.  Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).  Vaccine 24:293-303."
"1949","PC030595","Leung YK, Mak P, Hassan S, et al.  2006.  Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling.  Proc Natl Acad Sci USA 103(35):13162-13167."
"1950","PC030595","
Mak P, Leung YK, Tang WY, et al.  2006.  Apigenin suppresses cancer cell growth through ERbeta.  Neoplasia 8(11):896-904.
"
"1951","PC030595","Leung YK, Gao Y, Lau KM, et al.  2006.  ICI 182,780-regulated gene expression in DU145 prostate cancer cells is mediated by estrogen receptor-beta/NFkappaB crosstalk.  Neoplasia 8(4):242-249."
"1952","PC030595","Leung YK, Gao Y, Lau KM, et al.  2006.  ICI 182,780-regulated gene expression in DU145 prostate cancer cells is mediated by estrogen receptor-beta/NFkappaB crosstalk.  Neoplasia 4:242-249."
"1953","PC030595","Zhu X, Leav I, Leung YK, et al.  2004.  Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis.  Am J Path 164:2003-2012."
"1954","PC030595","Zhang X, Leung YK, and Ho SM.  2007.  AP-2 regulates the transcription of estrogen receptor (ER)-beta by acting through a methylation hotspot of the ON promoter in prostate cancer cells.  Oncogene 26:7346-7354."
"1955","PC030595","Ho SM, Leung YK, and Chung I.  2006.  Estrogens and antiestrogens as etiological factors and therapeutics for prostate cancer.  Ann NY Acad Sci 1089:177-193."
"1956","PC030601","Husbeck B, Peehl DM, and Knox SJ.  2005.  Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing.  Free Rad Biol Med 38:50-57.

"
"1957","PC030601","Husbeck B, Nonn L, Peehl DM, et al.  2006.  Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells.  Prostate 66:218-225."
"1958","PC030601","Husbeck B, Bhattacharyya RS, Feldman D, et al.  2006.  Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: Two distinct mechanisms of action.  Mol Cancer Ther 5(8):2078-2085."
"1959","PC030601","Bhattacharyya RS, Husbeck B, Feldman D, et al.  2008.  Selenite treatment inhibits LAPC-4 tumor growth and PSA secretion in a human prostate cancer xenograft model.  Int J Radiat Oncol Biol Phys 72(3):935-940."
"1960","PC030607","Estebanez-Perpina E, Moore JM, Mar E, et al.  2004.  The molecular mechanisms of coactivator utilization in ligand dependent transactivation by the androgen receptor.  J Biol Chem 280:8060-8."
"1961","PC030614","Burger PE, Xiong X, Coetzee S, et al.  2005.  Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with a high capacity to reconstitute prostatic tissue.  Proc Natl Acad Sci USA 102:7180-7185."
"1962","PC030614","Goto K, Salm SN, Coetzee S, et al.  2006.  Proximal prostatic stem cells are programmed to regenerate a proximal-distal ductal axis.  Stem Cells 24:1859-1868."
"1963","PC030618","Cinar B, Fang PK, Lutchman M, et. al. 2007.  The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1.  EMBO J 26(21):4523-34."
"1964","PC030618","Cinar B, Mukhopadhyay NK, Meng G 2007.  Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains.  J Biol Chem 282(40):29584-93."
"1965","PC030618","Freeman RM, B Cinar, and ML Lu, 2005.  Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer.  Trends in Endocrinol. Metabol., 16:273-9."
"1966","PC030618","Cinar B, A de Benedetti, and MR Freeman, 2005.  Post-translational modification of androgen receptor by mammalian target of rapamycin.  Cancer Res 65:2547-53."
"1967","PC030621","Wang Q, Zheng JY, Kreth J, et al.  2009.  Regulation of prostate-specific antigen expression by the junctional adhesion molecule A.  Urology 73(5):1119-25."
"1968","PC030621","Wang Q, Wang W, Zheng J, et al.  2007.  Paradoxical effects of two theta-defensins on HIV type 1 Infection.  AIDS Res Hum Retroviruses 23:508-14."
"1969","PC030625","Li X, Wang Y, Sharif-Afshar A-R, et al.  2009.  Urothelial transdifferentiation to prostate epithelia is mediated by paracrine TGF-beta signaling.  Differentiation 77(1):95-102."
"1970","PC030625","Placencio VR, Sharif-Afshar A-R, Li X, et al.  2008.  Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activityTGF-beta responsiveness of the stroma dictates prostatic sensitivity to androgen ablation.  Cancer Res 68:4709-4718."
"1971","PC030625","Li X, Placencio V, Iturregui JM, et al.  2008.  Prostate tumor progression is mediated by paraacrine TGF-beta/Wnt3 a signaling axis. Oncogene 27:7118-30."
"1972","PC030628","Lin B, White JT, Lu W, et al.  2005.  Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses:  A systems approach to disease.  Cancer Res 65(8):3081-3091."
"1973","PC030653","Hwang C, Giri VN, Wilkinson JC, et al.  2008.  EZH2 regulates the transcription of estrogen-responsive genes through association with REA, and estrogen receptor corepressor.  Breast Cancer Res Treat 107:235-42.

"
"1974","PC030659","Kuefer R, Day KC, Kleer CG, et al.  2006.  ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease.  Neoplasia 8:319-329."
"1975","PC030659","Najy AJ, Day KC, and Day ML.  2008.  ADAM15 supports prostate cancer metastasis by modulating tumor cell¿endothelial cell interaction.  Cancer Res 68:1092-1099."
"1976","PC030666","Freedland SJ and Isaacs WB.  2005.  Explaining racial differences in prostate cancer in the United States: Sociology or biology?  Prostate 62:243.

"
"1977","PC030666","Mavropoulos J, Isaacs WB, Pizzo S, et al.  2005.  Is there a role for a low-carbohydrate ketogenic diet in the management of prostate cancer?  Urology 68:15-8."
"1978","PC030669","Nie D.  2007.  Cyclooxygenases and lipoxygenases in prostate and breast cancer.  Front Biosci 12:1574-1585."
"1979","PC030669","Wang MT, Honn KV, and Nie D.  2007.  Cyclooxygenases, prostanoids, and tumor progressions.  Cancer Metastasis Rev 26:525-534."
"1980","PC030669","Nie D and Honn KV.  2004.  Eicosanoid regulation of angiogenesis in tumors.  Semin Thromb Hemost 30:119-25"
"1981","PC030669","Nie D, Guo Y, Yang D, et al.  2008.  Thromboxane A2 receptors in prostate carcinoma:  expression and its role in regulating cell motility via small GTPase Rho.  Cancer Res 68:115-121."
"1982","PC030669","Nie D, Krishnamoorth S, Jin R, et al., 2006.  Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells.  J Biol Chem 281: 18601-18609."
"1983","PC030669","Tang Y, Olefumi L, Wang M, et al.  2008.  Role of Rho GTPases in breast cancer.  Front Biosci 13:759-776."
"1984","PC030669","Chen Y, Tang Y, Zeng S, et al.  2007.  Human pregnane X receptor and resistance to chemotherapy in prostate cancer.  Cancer Res 67:10361-10367."
"1985","PC030669","Pidgeon GP, Lysaght J, Krishnamoorthy S, et al.  2007.  Lipoxygenase metabolism:  Roles in tumor progression and survival.  Cancer Metastasis Rev 26:503-524."
"1986","PC030677","Lipinski RJ, Gipp J, Zhang J, et al.  Individual and Cooperative Activities of the Gli Transcription Factors in Hedgehog Signaling.  Experimental Cell Research."
"1987","PC030677","Zhang J, Lipinski RJ, Shaw A, et al.  2007. Lack of demonstrable autocrine hedgehog signaling in human prostate cancer cell lines.  J Urol 177:1179-85."
"1988","PC030680","Reed BC, Cefalu BC, Bellaire C, et al.  2005. GLUT1CBP (TIP2/GIPC1) interactions with GLUT1 and Myosin VI: Evidence supporting an adapter function for GLUT1CBP.  Mol Biol Cell 16:4183-4201."
"1989","PC030685","Li X, Zhang Y, Kim HS, et al.  2005.  Gene therapy for prostate cancer by controlling adenovirus E1A and E4 gene expression with PSES enhancer.  Cancer Res 65:1941-51."
"1990","PC030685","Li X, Raikwar SP, Liu YH, et al.  2006.  Combination therapy of androgen-independent prostate cancer using a prostate restricted replicative adenovirus and a replication-defective adenovirus encoding human endostatin-angiostatin fusion gene.  Mol Cancer Ther 5(3):676-684."
"1991","PC030685","Li X, Liu YH, Lee SJ, et al.  2008.  Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy.  Clin Cancer Res 14(1):291-299."
"1992","PC030694","Gu Y, Kim KH, Ko D, et al.  2005.  Androgen and androgen receptor antagonist responsive primary African American benign prostate epithelial cell line.  Anticancer Res 25:1-8."
"1993","PC030694","Timofeeva, Zhang, Ressom, et al. 2009. Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men. Int J Oncol. 35: 751-760."
"1994","PC030695","Sridhar SC and Miranti CK  2006.  Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene 25:2367-78.
"
"1995","PC030695","Sridhar SC and Miranti CK.  2005.  Tumor metastasis suppressor KAI1/CD82 is a tetraspanin.  In:  Contemporary Cancer Research: Metastasis."
"1996","PC030695","Knudsen BS and Miranti CK  2006.  The impact of cell adhesion changes on proliferation and survival during prostate cancer development and progression. J Cell Biochem 99:345-61."
"1997","PC030695","Edick MJ, Tesfay L, Lamb LE, et al.  2007.  Inhibition of integrin-mediated crosstalk with EGFR/Erk or Src signaling pathways in autophagic prostate epithelial cells induces caspase-independent death.  Mol Biol Cell 18:2481¿2490."
"1998","PC030704","Minea R et al.  2005.  Development of a novel recombinant disintegrin, contortrostatin as an effective anti-tumor and anti-angiogenic agent.  Pathophysiol Haemost Thromb 34(4-5):177-183."
"1999","PC030708","Larina IV, Evers BM, and Esenaliev RO.  2005.  Optimal drug and gene delivery in cancer cells by ultrasound-induced cavitation.  Anticancer Res 25(1A):149-156. 

"
"2000","PC030708","Chumakova OV, Liopo AV, Andreev VG, et al.  2008.  Composition of PLGA and PEI/DNA nanoparticles improves ultrasound-mediated gene delivery in solid tumors in vivo.  Cancer Lett 261:215¿225."
"2001","PC030711","Huss WJ, Gray DR, Greenberg NM, et al.  2005.  BCRP/ABCG2-mediated efflux of androgen in putative benign and malignant prostate stem cells.  Cancer Res, 65:6640-50."
"2002","PC030740","Bentle MS, Bey EA, Dong Y, et al.  2006.  New tricks for old drugs: The anticarcinogenic potential of DNA repair inhibitors.  J Mol Histol 37:203-18."
"2003","PC030740","Blanco E, Bey EA, Dong Y, et al. 2007. Betalapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells. J Control Release 122(3):365-374. [Epub 2007 Apr 29]."
"2004","PC030740","Choi EK, Terai K, Ji I-M, et al.  2007.  Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells.  Neoplasia 9:634-42."
"2005","PC030740","Reinicke K, Bey E, Pink JJ, et al.  2005.  Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:Quinone oxidoreductase 1 levels. Clin Cancer Res 11:3055-64."
"2006","PC030740","Park HJ, Ahn KJ, Ahn SD, et al.  2005.  Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation.  Int J Radiat Oncol Biol Phys 61:212-219."
"2007","PC030740","Bentle M, Reinicke K, Bey E, et al.  2006.  Calcium regulation of PARP-1 hyperactivation for altered cellular metabolism and inhibition of DNA repair.  J Biol Chem 281(44):33684-33696."
"2008","PC030740","Wang F, Blanco E, Ai H, et al.  2006.  Modulating beta-lapachone release from polymer millirods through cyclodextrin complexation.  J Pharm Sci 95(10):2309-2319."
"2009","PC030740","Ai H, Pink JJ, Shuai X, et al.  2005.  Interactions between self-assembled polyelectrolyte shells and tumor cells.  J Biomed Mat Res 73(3):303-312."
"2010","PC030740","Ough M, Lewis A, Bey E, et al.  2005.  Efficacy of beta-lapachone in pancreatic cancer treatment: Exploiting the novel, therapeutic target NQO1.  Cancer Biol Ther 4(1):54-61."
"2011","PC030740","Nasongkla N, Shuai X, H Ai, et al.  2004.  cRGD-functionalized polymer micelles for targeted doxorubicin or beta-lapachone delivery.  Angew Chem Int Ed Eng 43(46):6323-6327."
"2012","PC030740","Park HJ, Ahn K-J, Ahn SD, et al.  2005.  Radiation increases the sensitivity of cancer cells to beta-lapachone.  Int J Rad Oncol Biol & Phys 61(1):212-219."
"2013","PC030740","Park HJ, Choi EK, Choi J, et al.  2005.  Heat-induced up-regulation of NAD(P)H:quinone oxidoreductase potentiates anticancer effects of beta-lapachone.  Clin Cancer Res 11(24):8866-8871."
"2014","PC030740","Bianco E, Wang F, Ai H, et al.  2006.  Modulating beta-lapachone release from polymer millirods through cyclodextrin complexation.  J Pharm Res 95:2309-19."
"2015","PC030752","Shaw A, Papadopoulas J, Johnson C, et al.  2005.  Isolation and characterization of an immortalized mouse urogenital sinus mesenchyme cell line.  Prostate 
9999:1-12.
"
"2016","PC030752","Shaw A, Papadopoulos J, Johnson C, et al.  2006.  Isolation and characterization of an immortalized mouse urogenital sinus mesenchyme cell line.  The Prostate 66:1347-1358."
"2017","PC030752","Zhang J, Lipinski R, Shaw A, et al.  2007.  Lack of demonstrable autocrine hedgehog signaling in human prostate cancer cell lines.  The Journal of Urology 177:1179-1185."
"2018","PC030753","Xu L, Yang D, Wang S, et al.  2005.  (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer.  Mol Cancer Ther 4(2):197-205."
"2019","PC030760","Pan W, Esfandyari T, Farassati F, et al.  2007.  13-signal smart oncolytic herpes virus: The first transcriptionally targeted mutant herpes virus against pro-oncogenic signaling pathways.  Mol Ther 15(Supplement 1):S270."
"2020","PC030782","Adegbola O and Pasternack GR.  2005.  Phosphorylated retinoblastoma complexes with pp32 and inhibits pp32-mediated apoptosis.  J Biol Chem 280:15497-15502."
"2021","PC030782","Adegbola O and Pasternack GR.  2005.  A pp32-retinoblastoma protein complex modulates androgen receptorâ¿mediated transcription and associates with components of the splicing machinery.  Biochem Biophys Res Commun 334:702-708."
"2022","PC030800","Wang L, Feigenberg S, Chen L, et al.  2006.  Benefit of 3D image-guided stereotactic localization in the hypofractionated treatment of lung cancer.  Int J Rad Oncol Bio Phys 66:738-747."
"2023","PC030800","Michael B, Miyuki B, Butts K, et al.  2007.  MRI guided thermal ablation therapy: model and parameter estimates to predict cell death from MR thermometry images.  Ann Biomed Eng 35(8)1391-1403."
"2024","PC030800","
Luo W, Li JS, Price RA, et al.  2006.  Monte Carlo based IMRT QA using MLC log files and R/V outputs.  Med Phys 33:2557-2564.
"
"2025","PC030800","Fan J, Li L, Chen L, et al.  2006.  Practical Monte Carlo MU verification tool for IMRT quality assurance.  Phys Med Biol 51:2503-2515."
"2026","PC030800","Chen L, Nguyen T-B, Jones E, et al.  2007.  Magnetic resonance-based treatment planning for prostate intensity-modulated radiotherapy: creation of digitally reconstructed radiographs. Int J Radiat Oncol Biol Phys 68:903-11."
"2027","PC030800","Wang L, Li J, Paskalev K, et al.  2006.  Commissioning and quality assurance of a commercial stereotactic treatment planning system for extracranial IMRT.  Journal of Clinic Appl Med Phys 7:21-34."
"2028","PC030800","Chen Z, Ma C-M, Paskalev K, et al.  2006.  Investigation of MR image distortion for radiotherapy treatment planning of prostate cancer Phys Med Bio 51:1393-403."
"2029","PC030800","Chen L.  2004.  Magnetic resonance has proven useful in radiation therapy simulation and treatment planning for prostate intensity-modulated radiation therapy.  Advance for Imaging and Oncology 14:57-58."
"2030","PC030800","Yang J, Li J, Chen L, et al.  2005. Dosimetric verification of IMRT treatment planning using Monte Carlo simulations for prostate cancer. Phys Med Biol 50:869-78.

"
"2031","PC030800","Yuh EL, Shulman SG, Mehta SA, et al.  2005.  Delivery of a systemic chemotherapeutic agent to tumors using focused ultrasound: A study in a murine model.  Radiol 234:431-7.

"
"2032","PC030800","Xiong W, Li J, Chen L, et al.  2004.  Optimization of combined electron and photon beams for breast cancer.  Phys Med Biol 49:1973-1989."
"2033","PC030800","Wang L, Hoban P, Paskalev K, et al.  2005.  Dosimetric advantage and clinical implication of a micro-multileaf collimator in the treatment of prostate with intensity modulated radiotherapy.  Med  Dosim. 30:97-103.
"
"2034","PC030800","Wang L, Movsas B, Jacob R, et al.  2004.  Stereotactic IMRT for prostate cancer: Dosimetric impact of multileaf collimator leaf width in the treatment of prostate cancer with IMRT.  J Appl Clin Med Phys 5:29-41."
"2035","PC030800","Wang L, Jacob R, Chen L, et al.  2004.  Stereotactic IMRT for prostate cancer: Setup accuracy of a new stereotactic body localization system.  J Appl Clin Med Phys 5:18-28."
"2036","PC030800","Ma CM, Price Jr RA, Li JS, et al.  2004.  Monitor unit calculation for Monte Carlo treatment planning.  Phys Med Biol 49:1671-1687."
"2037","PC030800","Li JS, Freedman GM, Price R, et al.  2004.  Clinical implementation of intensity-modulated tangential beam irradiation for breast cancer.  Med Phys 31(5):1023-1031."
"2038","PC030800","Chen L, Price Jr RA, Wang L, et al.  2004.  MRI-based treatment planning for radiotherapy: Dosimetric verification for prostate IMRT.  Int J Rad Oncol Biol Phys 60(2):636-647."
"2039","PC030800","Qin L, Li JS, Price RA, et al.  2004.  A Monte Carlo based treatment optimization tool for modulated electron radiation therapy.  Proc of the XIVth International Conference on the Use of Computers in Radiation Therapy 527-530."
"2040","PC030800","Chen L, Price Jr RA, Wang L, et al.  2004.  Dosimetric evaluation of MRI-based treatment planning for prostate cancer.  Phys Med Biol 49:5157-5170."
"2041","PC030800","Chen Z, Ma C-M, Yang J, et al.  2007a.  Monte Carlo dose verification of MR image based IMRT treatment planning for prostate cancer.  In:  Proceedings of the 15th International Conference on the Use of Computer in Radiation Therapy (ICCR).  Jean-Pierre B, ed.  Novel Digital Publishing, Oakville, Volume II: 267-271."
"2042","PC030817","Yang F, Strand DW, and Rowley DR.  2008.  Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.  Oncogene 27:450-459."
"2043","PC030817","Rowley DR.  2008.  Reactive stroma and evolution of tumors:  Integration of transforming growth factor-beta, connective tissue growth factor, and fibroblast growth factor-2 activities.  In:  Transforming Growth Factor-beta in Cancer Therapy (Jakowlew S, Ed) Towta, New Jersey."
"2044","PC030817","Yang F, Tuxhorn JA, Ressler SJ, et al.  2005.  Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis.  Cancer Res 65:8887-8895."
"2045","PC030828","Friedrichsen DM, Stanford JL, Isaacs SD, et al.  2004.  Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families.  PNAS 101:1939-1944."
"2046","PC030840","Burns MA, Taylor JL, Wu CL, et al.  2005.  Reduction of spinning sidebands in proton NMR of human prostate tissue with slow high resolution magic angle spinning.  Magn Reson Med 54:34-42."
"2047","PC030840","Jordan K, He W, Halpern E, et al.  2007.  Evaluation of tissue metabolites with high resolution magic angle spinning MR spectroscopy human prostate samples after three-year storage at -80C.  Biomarker Insights 2:147-154."
"2048","PC030840","Cheng LL and Pohl U.  2007.  The role of NMR-based metabolomics in cancer.  In: Handbook of Metabonomics and Metabolomics (Lindon JC, Nicholson J, and Holmes E, Eds.).  Elsevier, Amsterdam."
"2049","PC030840","Burns MA, Taylor JL, Wu CL, et al.  2005.  Reduction of spinning sidebands in proton NMR of human prostate tissue with slow high resolution magic angle spinning. Magn Reson Med 54:34-42."
"2050","PC030840","Cheng LL, Pohl U. 2006.  Disease studies  cancer. In: Metabolomins. (Lindon JC, Nicholson J, Holmes E, Eds), Elsevier."
"2051","PC030840","Cheng LL, Burns MA, Lean CL.  2006.  High resolution magic angle spinning (HRMAS) proton MRS of surgical specimens. In: (Webb G, Ed), Mod Magnetic Resonance, Vol II Medical Uses, Springer."
"2052","PC030840","Lentz MR, Taylor JL, Feldman DA, et al.  2005.  Current clinical applications of in vivo magnetic resonance spectroscopy and spectroscopic imaging.  Curr Med Imag Rev 1:271-302.

"
"2053","PC030840","Loening NM, Chamberlin AM, Zepeda AG, et al.  2005.  Quantification of phosphocholine and glycerophosphocholine with 31P edited 1H NMR spectroscopy.  NMR Biomed 18:413-420."
"2054","PC030840","Cheng LL, Burns MA, Taylor JL, et al. 2005.  Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy.  Cancer Res 65:3030-4."
"2055","PC030840","Jordan KW and Cheng LL.  Metabolic characterization of prostate cancer: magnetic resonance spectroscopy.  In: Cancer Imaging Volume II (Hayat MA, Ed.).  Elsevier."
"2056","PC030840","Taylor JL, Wu CL, Cory D, et al.  2003.  High-resolution magic angle spinning proton NMR analysis of human prostate tissue with slow spinning rates.  Magn Reson Med 50:627-632."
"2057","PC030840","Burns MA, He W, Wu CL, et al.  2004.  Quantitative pathology in tissue MR spectroscopy based human prostate metabolomics.  Tech Cancer Res Treat 3:591-598."
"2058","PC030840","Wu CL, Taylor JL, He WL, et al.  2003.  Proton high resolution magic angle spinning nmr analysis of fresh and previously frozen tissue of human prostate.  Magn Reson Med 50:1307-1311."
"2059","PC030840","Jordan KW and Cheng LL.  2007.  NMR-based metabolomics approach to target biomarkers for human prostate cancer.  Expert Rev Proteomics 4:389-400."
"2060","PC030849","Puc J, Keniry M, Li HS, et al.  2005.  Lack of PTEN inhibits CHK1 and initiates genetic instability. Cancer Cell 7:193-204."
"2061","PC030867","Bemis L, Chan DA, Finkielstein CV, et al.  2004.  Distinct aerobic and hypoxic mechanisms of HIF-1 regulation by CSN5.  Genes Dev (7):739-44.
 
"
"2062","PC030867","
Richardson K and Zundel W.  2005.  The emerging role of the COP9 signalosome in tumor progression.  Mol Cancer Res 3(12).
"
"2063","PC030867","Mikus P and Zundel W.  2005.  COPing with hypoxia.  Semin Cell Dev Biol 16(4-5):462-73."
"2064","PC030897","Luduena RF and Banerjee A.  2005.  The post-translational modifications of tubulin.  In: Microtubules (Fojo T, Ed.). Humana Press."
"2065","PC030897","Luduena RF and Banerjee, A.  2005.  The isotypes of tubulin: Distribution and functional significance.  In: Microtubules (Fojo T, Ed.).  Humana Press.

"
"2066","PC030897","Luduena RF and Banerjee A.  2005.  The tubulin superfamily. In: Microtubules (Fojo T, Ed.).  Humana Press.
"
"2067","PC030898","Mistry SJ and Atweh GF.  2006.  Therapeutic interaction between stathmin inhibition and chemotherapeutic agents in prostate cancer.  Mol Cancer Ther 5(12):3248-3257."
"2068","PC030898","Mistry SJ, Bank A, and Atweh GF. 2007. Synergistic antiangiogenic effects of stathmin inhibition and taxol exposure.  Mol Cancer Res 5(8)773-782."
"2069","PC030898","Atweh G.  2005.  The effects of the anti-stathmin adenovirus in prostate cancer cell line.  Mol Cancer Ther 4(12):1821-1829."
"2070","PC030903","Zhu T, Guo J, Collins L, et al.  2007.  Phellinus linteus activates different pathways to induce apoptosis in prostate cancer cells.  Br J Cancer 96(4):583-590."
"2071","PC030903","Qiu W, Zhang Y, Chen CY, et al.  2008.  Retinoblastoma protein modulates MDM2-gankyrin in regulation of p53 stability and chemosensitivity.  Oncogene 27(29):4034-4043."
"2072","PC030903","Chang DL, Ying H, Zhang Y, et al.  2007.  ARF promotes accumulation of retinoblastoma protein through inhibition of MDM2.  Oncogene 26:4627-34."
"2073","PC030903","Collins L, Zhu T, Guo J, et al.  2006.  Pillinus linteus sensitizes apoptosis induced by doxorubicin in prostate cancer.  Br J Cancer 95(3):282-288."
"2074","PC030903","Guo J, Zhu T, Xiao ZX and Chen CY 2007. Modulation of Intracellular Signaling Pathways to Induce Apoptosis in Prostate Cancer Cells. JBC,282"
"2075","PC030903","Chu M, Guo J, and Chen C-Y.  2005.  Persistent exposure to nicotine, via Ras pathway, induces cyclin D1 to stimulate G1 cell cycle transition.  J Biol Chem 280:6369-6379."
"2076","PC030903","Guo J, Zhu T, Collins L, et al.  2007.  Modulation of lung cancer growth arrest and apoptosis by Phellinus linteus.  Mol Carcinog 46(2):144-154."
"2077","PC030909","Pouliot J, Kim Y, Lessard E, et al.  2004.  Inverse planning for HDR prostate brachytherapy use to boost dominant intra-prostatic lesion defined by magnetic-resonance spectroscopy imaging.  Oncology Biol Phys 59(4)1196-1207.

"
"2078","PC030909","Kim Y, Hsu I, and Poulio J.  2007.  Measurement of cranio-caudal catheter displacement between fractions in CTBased HDR brachytherapy of prostate cancer.  Journal of Applied Clinical Med. Phys 8 (4):1-13."
"2079","PC030909","Alterovitz R, Goldberg K, Pouliot J, et al.  2006.  Registration of MR prostate images with biomechanical modeling and nonlinear parameter estimation.  J Med Phys 33(2)446-454."
"2080","PC030909","Reed G, Cunha JA, Noworolski SM, et al.  2011.  Interactive, multi-modality image registrations for combined MRI/MRSI-planned HDR prostate brachytherapy.  J Contem Brachytherapy (3)1:26-31."
"2081","PC030909","Kim Y, Noworolski SM, Pouliot J, et al.  2005.  Endorectal and rigid coils for prostate MRI: Impact on prostate distortion and rigid image registration.  Med Phys 32(12):3569-3578."
"2082","PC030909","Kim Y, Hsu IC, Lessard E, et al.  2008.  Class solution in inverse planned HDR prostate brachytherapy for dose escalation of DIL defined by combined MRI/MRSI.  Radiat Oncol 88(1):148-155."
"2083","PC030914","Kau TR, Schroeder F, Ramaswamy S, et al.  2003.  A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells.  Cancer Cell 4:463-476."
"2084","PC030914","Majumder PK and Sellers WR.  2005.  Akt-regulated pathways in prostate cancer.  Oncogene 24(50):7465-7474."
"2085","PC030914","Kau TR, Way JC, and Silver PA.  2004.  Nuclear transport and cancer: From mechanism to intervention.  Nat Rev Cancer 4(2):106-117."
"2086","PC030914","Sansal I and Sellers WR.  2004.  The biology and clinical relevance of the PTEN tumor suppressor pathway.  J Clin Oncol 22:2954-2963."
"2087","PC030914","Schroeder FC, Kau TR, Silver PA, et al.  2005.  The psammaplysenes, specific inhibitors of FOXO1a nuclear export.  J Nat Prod 68(4):574-576."
"2088","PC030922","Kim TH, Xiong H, Zhang Z, et al.  2005.  beta-catenin activates the growth factor endothelin-1 in colon cancer cells.  Oncogene 24:597-604."
"2089","PC030922","Sun P, Xiong H, Kim TH, et al.  2006.  Positive inter-regulation between Beta-catenin/ T cell factor-4 signaling and endothelin-1 signaling potentiates proliferation and survival of prostate cancer cells.  Mol Pharmacol 69:520-531."
"2090","PC030923","Adhami VM, Aziz MH, Reagan-Shaw SR, et al.  2004.  Sanguinarine causes cell cycle blockade and apoptosis of human prostate carcinoma cells via modulation of cyclin kinase inhibitor-cyclin-cyclin-dependent kinase machinery.  Molecular Cancer Therapy 3(8):933-940."
"2091","PC030923","Reagan-Shaw S and Ahmad N.  2005.  Silencing of polo-like kinase (Plk) via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: Implications for the treatment of prostate cancer.  FASEB J 

"
"2092","PC030923","Aziz MH, Siddiqui IA, Ahsan H, et al.  2005.  Preclinical evaluation of plant alkaloid sanguinarine against prostate cancer development in a nude mice xenograft model.  Proc Amer Assoc Cancer Res 46:1012-1013."
"2093","PC030923","Reagan-Shaw S, Breur J, and Ahmad N.  2006.  Enhancement of UVB radiation-mediated apoptosis by sanguinarine in HaCaT human immortalized keratinocytes.  Mol Cancer Ther 5:418-29."
"2094","PC030923","Reagan-Shaw S and Ahmad N.  2005.  Silencing of polo like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis-machinery in human prostate cancer cells: Implications for the treatment of prostate cancer.  FASEB J 19:611-613. 

"
"2095","PC030931","Doxsey S, Zimmerman W, and Mikule K.  2005.  Centrosome control of the cell cycle.  Trends Cell Biol 15:303-311."
"2096","PC030931","Doxsey S, McCollum D, and Theurkauf W.  2005.  Centrosomes in cellular regulation.  Annu Rev Cell Biol 21:411-434."
"2097","PC030931","Gromley A, Yeaman C, Redick S, et al. 2005. Centriolin-anchoring of exocyst and SNARE complexes at the midbody is required for secretory-vesicle-mediated abscission.  Cell 123:75-87."
"2098","PC030931","Jurczyk A, Gromley A, Redick A, et al.  2004.  Pericentrin is required for primary cilia assembly and anchoring intraflagellar transport proteins at basal bodies.  J Cell Biol 166:637-643."
"2099","PC030931","Rosa J, Islam A, Altieri D, et al. 2006. Survivin  modulates microtubule dynamics and nucleation throughout the cell cycle. Mol Biol Cell 17:1483-93."
"2100","PC030931","Mikule K, Delaval B, Kaldis P, et al.  2007.  Loss of centrosome integrity induces p38/p53/p21-dependent G1/S arrest.  Nat Cell Biol 9(2):160-170."
"2101","PC030931","Rosa J, Canovas P, Islam A, et al.  2006.  Survivin modulates microtubule dynamics and nucleation throughout the cell cycle.  Mol Biol Cell 17(3):1483-1493.

"
"2102","PC030931","Pihan G, Zhou Y, Wallace J, et al.  2003.  Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas.  Cancer Res 63:1398-1404."
"2103","PC030931","Chen D, Purohit A, Halilovic E, et al.  2004.  Centrosomal anchoring of protein kinase C beta II by pericentrin controls microtubule organization, spindle function, and cytokinesis.  J Biol Chem 279:4829-4839."
"2104","PC030931","Zimmerman W, Sillibourne J, Rosa J, et al.  2004.  Mitosis-specific anchoring of gamma tubulin complexes by pericentrin controls spindle organization and mitotic entry.  Mol Biol Cell 15:3642-3657."
"2105","PC030943","Sarfaraz S, Afaq F, Adhami V, et al.  2005.  Cannabinoid receptor as a novel target for the treatment of prostate cancer.  Cancer Research 65:1635-41."
"2106","PC030943","Sarfaraz S, Afaq F, Adhami VM, et al.  2006.  Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest.  J Biol Chem 281(51):39480-39491."
"2107","PC030943","Sarfaraz S, Adhami VM, Syed DN, et al.  2008.  Cannabinoids for cancer treatment: Progress and promise.  Cancer Research (68):2:339-342."
"2108","PC030945","Zhu N, Tran P, Bell N, et al.  2007.  Tyrphostin tumor growth inhibitors of EGFR and ErbB2 tyrosine kinase.  J Chemical Crystallography 37:679-683."
"2109","PC030958","Valdespino V, Tsagkozis P, and Pisa P. 2007. Current perspectives in the treatment of advanced prostate cancer.  Med Oncol 24:273-86."
"2110","PC030958","Miller AM and Pisa P.  2007.  Tumor escape mechanisms in prostate cancer.  Cancer Immunol Immunother 56:81-7.
"
"2111","PC030958","Pavlenko M, Leder C, Moreno S, et al.  2007.  Priming of CD8+ T cell responses after DNA immunization is impaired in TLR9- and MyD88-deficient mice.  Vaccine 25(34):6341-6347."
"2112","PC030958","Roos A-K, King A, and Pisa P.  2008.  DNA vaccination for prostate cancer.  In: Electroporation Protocols: Experimental and Clinical Medicine (Li S, Ed).  Humana Press.  Methods Mol Biol 423:463-472."
"2113","PC030958","Valdespino V, Tsagkozis P, and Pisa P.  2007.  Outlooks in advanced prostate cancer.  Med Oncol 24(3):273-286."
"2114","PC030958","Roos A-K, King A and Pisa P.  2008.  Electroporation protocols:  Experimental and clinical medicine, DNA vaccination for prostate cancer.  Methods Mol Biol 423:463-472."
"2115","PC030958","Culp WD, Tsagozis P, Burgio M, et al.  2007.  Interference of macrophage migration inhibitory factor expression in a mouse melanoma inhibits tumor establishment by up-regulating thrombospondin-1.  Mol Cancer Res 5(12):1225-1231."
"2116","PC030958","Lundberg K, Roos AK, Pavlenko M, et al.  2009.  An optimized epitope identified for generation and monitoring of PSA-specific T-cells in patients on early phases of PSA-based immunotherapeutic protocols.  Vaccine 27:1557-1565."
"2117","PC030958","Roos AK, Eriksson F, Pisa P, et al.  2009.  Optimization of skin electroporation to increase tolerability of DNA vaccine delivery to patients.  Mol Ther 17(9):1637-42."
"2118","PC030958","Jonmarker S, Glaessgen A, Culp WD, et al.  2008.  Expression of PDX-1 in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic tissue.  APMIS 116(6):491-498."
"2119","PC030958","Tsagozis P, Eriksson F and Pisa P.  2008.  Zoledronic acid modulates antitumoral responses of prostate cancer tumor associated macrophages.  Cancer Immunol Immunother 57:1451-1459."
"2120","PC030958","Miller AM, Lundberg K, Ozenci O, et al.  2006.  CD4 +CD25[high] regulatory T cells are enriched in the peripheral blood and tumor tissue of patients with prostrate cancer.  J Immunol 177:7398-7405."
"2121","PC030958","Roos A-K, Moreno S, Leder C, et al.  2006.  Electroporation enhances intradermal vaccination with naked DNA coding for PSA.  Mol Ther 13:320-327."
"2122","PC030958","Mill AM, Ozenci V, Kiessling R, et al.  2005.  Immune monitoring in a phase I trial of a PSA DNA vaccine in patients with prostate cancer.  J Immunother 28:389-395."
"2123","PC030958","Roos A-K, King A, and Pisa P.  2007. DNA vaccination for prostate cancer.  In:  Molecular Biology Series, Electroporation Protocols:  Experimental and Clinical Medicine, (Li S, Ed.).  Humana Press, Totowa, New Jersey.

"
"2124","PC030958","Miller AM and Pisa P.  Tumor escape mechanisms in prostate cancer.  Cancer Immunol Immunother 56:81-87."
"2125","PC030958","Lundquist A, Palmborg A, Pavlenko M, et al.  2005.  Mature dendritic cells induce tumor specific Type 1 regulatory T cells.  J Immunother 28:229-35."
"2126","PC030958","Roos A-K, Moreno S, Leder C, et al.  2006. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation.   Mol Ther 13:320-7.
"
"2127","PC030958","Ozenci V, Miller AM, Palmborg A, et al.  2005.  The presence and specificity of tumor associated lymphocytes from ascites fluid in prostate cancer.  Prostate 65:20-6."
"2128","PC030958","Pavlenko M, Leder C, Roos AK, et al.  2005.  Identification of an immunodominant H-2Db-restricted CTL epitope of human prostate specific antigen.  Prostate."
"2129","PC030970","Liu WM and Zhang XA.  2006.  KAI1/CD82, a tumor metastasis suppressor.  Cancer Lett 240:183-94."
"2130","PC030970","He B, Liu L, Cook GA, et al.  2005.  Tetraspanin CD82 attenuates cellular morphogenesis through down-regulating integrin alpha-6-mediated cell adhesion.  J Biol Chem 280:3346-3354."
"2131","PC030970","Zhou B, Liu L, Reddivari M, et al.  2004.  The palmitoylation of metastasis suppressor KAI1/CD82 is important for its motility- and invasiveness-inhibitory activities.  Cancer Res 64:7455-7463."
"2132","PC030970","Zhang XA and Bari R.  2007.  KAI1/CD82 metastasis suppressor.  Encyclopedia of Cancer, 2nd Edition, edited by M. Schwab."
"2133","PC030970","Jiang J-C, Ning Y-C, Chen C, et al.  2007.  Cytochrome P450 epoxygenase promotes human cancer metastasis. Cancer Res 67:6665-6674."
"2134","PC030977","Follis AV, Hammoudeh DI, Wang H, et al.  2008. Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chem Biol 15(11):1149-1155."
"2135","PC030977","Wang H, Hammoudeh DI, Viacava Follis A, et al.  2007.  Improved low molecular weight Myc-Max inhibitors.  Mol Cancer Ther 6:2399-2408.

"
"2136","PC030977","Guo J, Parise RA, Joseph E, et al.  2009.  Efficacy, pharmacokinetics, tissue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 .  Cancer Chemother and Pharmacol 63:615-25."
"2137","PC030999","Baraz B, Haupt Y, Elkin M, et al.  2006.  Tumor suppressor p53 regulates heparanase gene expression.  Oncogene 25:3939-47.
"
"2138","PC030999","Edovitsky E, Lerner E, Zcharia E, et al.  2005.  Role of endothelial heparanase in delayed-type hypersensitivity.  Blood (Epub ahead of print Dec 29, 2005)."
"2139","PC030999","Lerner I, Pikarsky E, Baraz L, et al.  2008.  Function of heparanase in prostate tumorigenesis: potential for therapy. Cancer Res 14:668-76."
"2140","PC031027","Higa LA, Banks D, Wu, M, et al.  2006.  L2DTL/CDT2 interacts with the CUL4/DDB1 complex and PCNA and regulates CDT1 proteolysis in response to DNA damage.  Cell Cycle 5:1675-1680."
"2141","PC031027","Higa LA, Wu M, Ye T, et al.  2006. CUL4/DDB1 ubiquitin ligase interacts with multiple WD40-repeat proteins and regulates histone methylation.  Nat Cell Biol 8:1277-1283."
"2142","PC031027","Banks D, Wu M, Higa LA, et al.  2006.  L2DTL/CDT2 and PCNA interact with p53 and regulate p53 polyubiquitination and protein stability through MDM2 and CUL4A/DDB1 complexes.  Cell Cycle 5:1719-1729."
"2143","PC031034","Lapteva N, Aldrich M, Ren W, et al.  2009.  Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity.  Mol Ther 17(9):1626-36.

"
"2144","PC031034","Lapteva N, Aldrich M, Weksberg D, et al.  2009.  Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent anti-tumor immunity. J Immunother 32:145-156.

"
"2145","PC031038","Bandyopadhyay S, Zhan R, Chaudhuri M, et al.  2006.  Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression.  Nat Med 12:933-938."
"2146","PC031038","
Iiizumi M, Mohinta S, Bandyopadhyay S, et al.  2007.  Tumor ¿ endothelial cell interactions: Therapeutic potential.  Microvasc Res 74:114-120.
"
"2147","PC031038","Iiizumi M, Bandyopadhyay S, and Watabe K.  2007.  Interaction of Duffy antigen receptor for chemokines and KAI1: A critical step in metastasis suppression.  Cancer Res 67:1411-4."
"2148","PC031038","Bandyopadhyay S and Watabe K.  2007.  The tumor metastasis suppressor gene drg-1 in cancer progression and metastasis.  In: Developments in Metastasis Suppressors.  Nova Publishers.

"
"2149","PC031042","Zhang B, Arola DD, Roys S, et al.  2011.  Three-dimensional elastic image registration based on strain energy minimization: application to prostate magnetic resonance imaging.  J Digit Imaging 24(4):573-585."
"2150","PC031045","Karanikolas BD, Figueiredo ML, Wu L. 2009. Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Mol Cancer Res 7(9):1456-1465.
"
"2151","PC031045","Karanikolas BD, Figueiredo ML, Wu L. 2010.  Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. Prostate70(6):675-688."
"2152","PC031071","Tanaka Y, Sasaki M, Shiina H, et al.  2004.  Polymorphisms of cytochrome P450 1B1 are risk factors for prostate cancer.  J Urol 171(Suppl. 4):111."
"2153","PC031075","Yu J, Liu L, Kodibagkar V, et al.  2006.  Synthesis and evaluation of novel enhanced gene reporter molecules:  Detection of Beta-galactosidase activity using 19F NMR of Trifluoromethylated Aryl Beta-D-Galactopyranosides, Bioorg Med Chem 14(2):326-333."
"2154","PC031075","Liu L, Kodibagkar V, Yu J, et al.  2007.  19F-NMR detection of lacZ gene expression via the enzymic hydrolysis of 2-fluoro-4-nitrophenyl Beta-galactopyranoside in vivo in PC3 prostate tumor xenografts in the mouse.  FASEB J 21."
"2155","PC031075","Yu J, Ma Z, Li Y, et al.  2005.  Synthesis and evaluation of a novel gene reporter molecule: Detection of beta-galactosidase activity using 19F NMR of a fluorinated vitamin B6 conjugate.  Med Chem 1:255-62."
"2156","PC031075","Kodibagkar V, Yu J, Liu L, et al.  2006.  Imaging Beta-galactosidase activity using 19F chemical shift imaging of LacZ gene-reporter molecule 2-fluoro-4-nitrophenol-Beta-d-galactopyranoside, Magn Reson Imaging 24:959-962."
"2157","PC031075","Yu J, Otten P, Ma Z, et al.  2004.  Novel NMR platform for detecting gene transfection: synthesis and evaluation of fluorinated phenyl beta-D-galactosides with potential application for assessing lacZ gene expression.  Bioconj Chem 15:1334-1341."
"2158","PC031091","Sinha AA, Morgan JL, Wood N, et al.  2007.  Heterogeneity of cathepsin B and stefin A expression in Gleason pattern 3+3 (score 6) prostate cancer needle biopsies.  Anticancer Res 27:1407-1414."
"2159","PC031091","Sinha AA, Morgan JL, Buus RJ.  2007.  Cathepsin B expression is similar in African-American and Caucasian prostate cancer patients.  Anticancer Res 7960-S (in press)."
"2160","PC031120","Liao X, Tang S, Thrasher JB, et al.  2005.  Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer.  Mol Cancer Ther 4:505-15."
"2161","PC031120","Li B and Brantley J.  2006.  Thrasher nano-scaled techniques in prostate cancer management: from basic research to clinic settings.  Cancer Nanotechnology 1¿13."
"2162","PC031120","Shanmugam I, Cheng G, Terranova PF, et al.  2007.  Serum/glucocorticoid-induced protein kinase-1 facilitates androgen receptor-dependent cell survival.  Cell Death Differ 14(2):2085-2094."
"2163","PC031120","Zhu Q, Tang J, Youn H, et al.  2008.  Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers.  Oncogene 27:4569-79."
"2164","PC031120","Li B and Thrasher JB. Androgen receptor and cellular survival in prostate cancer.  Recent Research Developments in Cancer.  Transworld Research Network, Kerala, India."
"2165","PC031120","Sun A, Tang J, Hong Y, et al.  2008.  Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.  The Prostate 68(4):453-461."
"2166","PC031130","Stiles B, Groszer M, Wang S, et al.  2004.  PTENless means more. Devel Biol 273:175-184."
"2167","PC031130","Chang C-J, Freeman D and Wu H.  2004.  PTEN regulates Mdm2 expression through the P1 promoter.  J Biol Chem 279:29841-29848."
"2168","PC031130","Roy-Burman P, Wu H, Powell WC, et al.  2004.  Genetically defined mouse models that mimic natural aspects of human prostate cancer development.  Endocrine-Related Cancer 11:225-254."
"2169","PC031130","Stiles B, Wang Y, Stahl A, et al.  2004.  Liver specific deletion of Pten results in fatty liver and insulin hypersensitivity.  Proc Natl Acad Sci USA 101:2082-2087."
"2170","PC031130","Wang S, Gao J, Lei Q-Y, et al.  2003.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.  Cancer Cell 4:209-221."
"2171","PC031130","Sundaresan G, Paulmurugan R, Berger F, et al.  2004.  MicroPET imaging of Cre-loxP mediated conditional activation of a herpes simplex virus type 1 thymidine kinase reporter gene.  Gene Ther 7:609-618.

"
"2172","PC031130","Chang CJ, Mulholland DJ, Valamehr B, et al.  2008. PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Mol Cell Biol 28(10):3281-3289."
"2173","PC031130","Jiao J, Wang S, Qiao R, et al.  Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res 67(13):6083-6091."
"2174","PC031130","Groszer M, Erickson R, Scripture-Adams D, et al.  2006.  PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry.  Proc Natl Acad. Sci USA 103:111-116."
"2175","PC031130","Stanger BZ, Stiles B, Lauwers G, et al.  2005.  Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 8:172-185."
"2176","PC031130","Nakano I, Paucar AA, Bajpai R, et al.  2005.  Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation. J Cell Biol 170:413-427."
"2177","PC031130","Yue Q, Groszer M, Gil JS, et al.  2005.  PTEN deletion in Bergmann glia leads to premature differentiation and affects laminar organization.  Development 132:3151-3326."
"2178","PC031130","Wu H, Khodavirdi A, and Roy-Burman P.  2004.  Capturing signal anomalies of human prostate cancer into mouse models. In: Prostate Cancer: Basic Mechanisms and Therapeutic Approaches.
"
"2179","PC031130","Lim MA, Moon SY, Zheng Y, et al.  2004.  Roles of PDK-1 and PKN in regulating cell migration and cortical actin formation in PTEN-deficient cells.  Oncogene 23:9348-58."
"2180","PC031130","Kurlawalla-Martinez C, Stiles B, Wang Y, et al.  2004.  Insulin hypersensitivity and resistance to streptozotocin induced diabetes in mice lacking Pten in adipose tissue.  Mol Cell Biol 25:2498-510.
"
"2181","PC031130","Wang S, Garcia A, Wu M, et al.  2006.  Pten deletion leads to the expansion of prostatic stem/progenitor cell subpopulation and tumor initiation.  Proc Natl Acad Sci USA 103:1480-1485."
"2182","PC031130","Tsai P, Ohab J, Kertesz N, et al.  2006.  A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery.  J Neurosci 26:1269-1274."
"2183","PC031130","Mulholland DJ, Dedhar S, Wu H, et al.  2006.  PTEN and GSK3&#946;:  Key regulators of progression to androgen independent prostate cancer.  Oncogene 25(3):329-337."
"2184","PC031130","Yao D, Alexander CL, Quinn JA, et al.  2006.  PTEN loss promotes rasHa-mediated papillomatogenesis via dual up-regulation of AKT activity and cell cycle deregulation, but malignant conversion proceeds via PTEN-associated pathways.  Cancer Res 66(3):1302-1312."
"2185","PC031130","Yoo LI, Liu DW, Vu SL, et al.  2006.  Pten deficiency activates distinct downstream signaling pathways in a tissue specific manner. Cancer Res 66(4):1929-1939."
"2186","PC031130","Khodavirdi A, Song Z, Yang S, et al.  2006.  Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res 66:883-8."
"2187","PC031130","Guo W, Lasky J, and Wu H.  2006.  Cancer stem cells.  Pediatr Res 59:59R-64R."
"2188","PC031130","Li G, Hu Y, Liu M, et al.  2006.  PTEN deletion leads to up-regulation of a secreted growth factor pleiotrophin.  J Biol Chem 281:10663-8."
"2189","PC031130","Lei Q, Jiao J, Xin L, et al.  2006.  NKX3.1 stabilizes p53, inhibits AKT activation and delays prostate cancer initiation caused by PTEN loss.  Cancer Cell 9:367-78."
"2190","PC031130","Liu B, Yang R, Wong KA, et al.  2005.  PIAS1 participates in the negative regulation of NF-kB signaling.  Mol Cell Biol 25:1113-1123."
"2191","PC031130","Lasky J. and Wu H.  2005.  Notch signaling, brain development and human disease. Pediatr Res 57:104R-109R."
"2192","PC031130","Sanchez T, Thangada S, Wu MT, et al.  2005.  PTEN as an effector in the signaling of anti-migratory G protein-coupled receptor.  Proc Natl Acad Sci USA 102:4312-4317."
"2193","PC031130","Shi Y, Sharma A, Wu H, et al.  2005.  Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway.  J Biol Chem 280:10964-10973."
"2194","PC031137","Ghosh Roy DN, Roberts J, Schabel M, et al.  2007.  Noise propagation in linear and nonlinear inverse scattering.  J Acous Soc Am Volume 125."
"2195","PC031149","Wu C-T, Altuwaijri S, Ricke WA, et al.  2007.  Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor.  PNAS 104(31):12679-12684."
"2196","PC031159","Mellinghoff IK.  2007.  Why do cancer cells become 'addicted' to oncogenic epidermal growth factor receptor? PLoS Medicine 4 (10):e321.

"
"2197","PC031159","Xin L, Teitell MA, Lawson DA, et al.  2006.  Progression of prostate cancer by synergy of Akt with genotropic and nongenotropic actions of the androgen receptor.  Proc Natl Acad Sci USA 103:7789-7794."
"2198","PC031159","Mellinghoff IK.  2006.  Novel approaches to androgen receptor blockade.  In:  Prostate Cancer:  Translational and Emerging Therapies (Dawson NA, Kelly WK, Eds.).  Taylor and Francis Publishing Group.

"
"2199","PC031159","Mellinghoff IK, Vivanco I, Kwon A, et al.  2004.  Her-2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.  Cancer Cell 
6:427-428.
"
"2200","PC031159","Vivanco I, Rohle D, Versele M, et al.  2010.  The phosphatase and tensin homolog regulates epidermal growth factor receptor inhibitor response by targeting EGFR for degradation.  Proc Natl Acad Sci U S A 107(14):6459-6464."
"2201","PC031161","Shinohara E, K Niermann, C Cao, et al.  2005. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 24:5414-22."
"2202","PC031161","Li HC, ET Shinohara, and B Lu.  Plasminogen activator inhibitor-1(PAI-1) promoter polymorphism is not associated with prognosis in prostate cancer.  Clin. Oncol., 18:333-7."
"2203","PC031161","Shinohara E, Niermann K, Cao C, et al.  2005.  mTOR inhibitors as a potential anti-angiogenesis agent enhanced efficacy of radiotherapy. 24:5414-5422."
"2204","PC031161","Li HC, Shinohara E and Lu B.  2006. Plasminogen activator inhibitor-1(PAI-1) promoter polymorphism is not associated with prognosis in prostate cancer.  Clin Oncol 18:333-7."
"2205","PC031161","Cao C, Subhawong T, Albert JM, et al.  2006.  Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells.  Cancer Res 15;66(20):10040-10047."
"2206","PC031161","Kim KW, Mutter RW, Cao C, et al.  2006.  Autophagy for cancer therapy through inhibition of proapoptotic proteins and mTOR signaling.  J Biol Chem 1;281(48):36883-36890.

"
"2207","PC031161","Browning RL, Li H, Shinohara ET, et al.  2006.  ATM polymorphism IVS62+60G>A is not associated with aggressiveness of disease in prostate cancer.  Urology 67(6):1320-1323."
"2208","PC031161","Shinohara E, Niermann K, Cao C, et al.  2005.  mTOR inhibitors as a potential anti-angiogenesis agent enhanced efficacy of radiotherapy.  Oncogene 24:5414-5422.
"
"2209","PC031161","Jaboin J, Hwang M, and Lu B.  2009.  2011.  No evidence for association of the MDM2 -309 T/G promotor polymorphism with prostate cancer outcomes.  Urol Oncol 29(3):319-323."
"2210","PC031161","Moretti L, Kim KW, and Lu B.  2007.  Crosstalk between Bak/Bax and mTOR signaling regulates radiation-induced autophagy.  Autophagy 3(2):142-144."
"2211","PC031161","Moretti L, Yang ES, Kim KW, et al.  2007.  Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy.  Drug Resist Updat 10(4-5):135-143."
"2212","PC031161","Jaboin JJ, Hwang M, Lopater Z, Chen H, et al.  2011.  The matrix metalloproteinase-7 polymorphism Rs10895304 is associated with increased recurrence risk in patients with clinically localized prostate cancer.  Int J Radiat Oncol Biol Phys 79(5):1330-1335."
"2213","PC031161","Li HC, Albert JM, Shinohara ET, et al.  2006.  E-cadherin promoter polymorphisms are not associated with the aggressiveness of prostate cancer in Caucasian patients. Urol Oncol  24(6):496-502."
"2214","PC031161","Moretti L, Niermann K, Schleicher S, et al.  2011.  MLN8054, a small molecule inhibitor of aurora kinase a, sensitizes androgen-resistant prostate cancer to radiation.  Int J Radiat Oncol Biol Phys 80(4):1189-1197."
"2215","PC031161","Perez CA, Chen H, Shyr Y, et al.  2010.  The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer.  J Urol 183(5):2062-2069."
"2216","PC031161","Niermann KJ, Moretti L, Giacalone NJ, et al.  2011.  Enhanced radiosensitivity of androgen-resistant prostate cancer: AZD1152-mediated Aurora kinase B inhibition. 
Radiat Res 175(4):444-451."
"2217","PC031161","Li HC, Shinohara E, and Lu B.  2005.  Endostatin polymorphism 4349G/A(D104N) is not associated with aggressiveness of disease in prostate cancer. Dis Markers 21(1)."
"2218","PC031163","Cesaretti JA, Stock RG, Lehrer S, et al.  2005.  ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer.  Int J Radiat Oncol Biol Phys 61(1):196-202."
"2219","PC031163","Andreassen CN, Overgaard J, Alsner J, et al.  2006.  ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy.  Int J Radiat Oncol Biol Phys 64(3):776-83."
"2220","PC031163","Cesaretti J, Pennather A, Rosenstein B, et al.  2008.  Radiosurgery for thoracic malignancies.  Ann Thorac Surg 85(2):S785-91."
"2221","PC031163","Kao J, Stone NN, Lavaf A, et al.  2008.  (125)I monotherapy using D90 implant doses of 180 Gy or greater.  Int J Radiat Oncol Biol Phys 70(1):96-101."
"2222","PC031163","Stock RG, Cesaretti JA, and Stone NN.  2006.  Disease-specific survival following the brachytherapy management of prostate cancer.  Int J Radiat Oncol Biol Phys 1:64(3):810-816."
"2223","PC031163","Stock RG, Stone NN, Cesaretti JA, et al.  2006.  Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results.  Int J Radiat Oncol Biol Phys 1:64(2):527-533."
"2224","PC031163","Kollmeier MA, Stock RG, Cesaretti J, et al.  2005.  Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy.  J Urol 173(3):808-812."
"2225","PC031163","Schiff JD, Bar-Chama N, Cesaretti J, et al.  2006.  Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function.  BJU Int 98(6):1255-1258."
"2226","PC031163","Lehrer S, Cesaretti J, Stone NN, et al.  2006.  Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.  BJU Int 98(5):979-981."
"2227","PC031163","Stock RG, Ho A, Cesaretti JA, et al.  2006.  Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control.  Int J Radiat Oncol Bio Phys 66(2):389-394."
"2228","PC031163","Peters CA, Cesaretti JA, Stone NN, et al.  2006.  Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease.  Int J Radiat Oncol Biol Phys 66(2):424-429."
"2229","PC031163","Ho AY, Atencio DP, Peters S, et al.  2006.  Genetic predictors of adverse radiotherapy effects:  The Gene-PARE project.  Int J Radiat Oncol Biol Phys 65(3):646-655."
"2230","PC031163","Zagar TM, Stock RG, Cesaretti JA, et al.  2007.  Assessment of postbrachytherapy sexual function:  A comparison of the IIEF-5 and the MSEFS.  Brachytherapy 6(1):26-33."
"2231","PC031163","Ho AY, Burri RJ, Jennings GT, et al.  2007.  Is seminal vesicle implantation with permanent sources possible?  A dose-volume histogram analysis in patients undergoing combined 103Pd implantation and external beam radiation for T3c prostate cancer.  Brachytherapy 6(1):38-43."
"2232","PC031163","Cesaretti JA, Stock RG, Atencio DP, et al.  2007.  A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy.  Int J Radiat Oncol Biol Phys 68:1410-6."
"2233","PC031163","Cesaretti JA, Kao J, Stone NN, et al.  2007.  Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: Analysis at >/= 7 years of follow-up.  BJU Int 100(2):362-367."
"2234","PC031163","Peters CA, Stock RG, Cesaretti JA, et al.  2008.  TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy.  Int J Radiat Oncol Biol Phys 70:752-9."
"2235","PC031163","Cesaretti JA, Stone NN, Skouteris BM, et al.  2007.  Brachytherapy for prostate cancer.  Cancer J 13(5):302-312."
"2236","PC031175","Ross JS, Gray KE, Webb I, et al.  2005.  Antibody-based therapeutics: Focus on prostate cancer. Cancer Metast Rev 224:517-533."
"2237","PC031178","Garg M, Shah SJ, Deb NJ, et al.  2005.  Targeting the tie2 receptor tyrosine kinase pathway for radiosensitization of prostate cancer.  Int J Radiat Oncol Biol Phys 63(Supplement 1):S145-S146."
"2238","PC031178","Deb NJ, Garg MK, Kawashita Y, et al.  2001.  A novel antiangiogenic therapy with soluble tek (Tie2) receptor tyrosine kinase alone or in combination with fractionated irradiation in a murine model of lung cancer.  Int J Radiat Oncol Biol Phys 51(Issue 3; Supplement 1):154-155."
"2239","PC040002","Zhou XE, Suino-Powell K, Ludidi PL, McDonnell DP, Xu HE.  Expression, purification and primary crystallographic study of human androgen receptor in complex with DNA and coactivator motifs.  2010. Protein Expr Purif. 2010 May;71(1):21-7


"
"2240","PC040002","Zhou XE, Suino-Powell KM, Li J, et al. 2010. Identification of SRC3/AIB1 as a Preferred Coactivator for Hormone-activated Androgen Receptor. J Biol Chem 285: 9161-9171. (PMID: 20086010)."
"2241","PC040002","Sierra ML, Beneton V, Boullay AB, et al.  2007.  Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.  J Med Chem 22;50(4):685-695 (PMID: 17243659)."
"2242","PC040002","Tolbert WD, Daugherty J, Gao C, et al.  2007.  A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist.  Proc Natl Acad Sci U S A 11;104(37):14592-14597 (PMID:17804794)."
"2243","PC040002","Guo D, Sarkar J, Suino-Powell K, et al.  2007.  Induction of nuclear translocation of CAR by PPARalpha synthetic ligands in mouse liver.  J Biol Chem 25;PMID:17962186."
"2244","PC040002","Li Y, Suino K, Daugherty J, et al.  2005.  Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor.  Mol Cell 19:367-380."
"2245","PC040009","Pelletier CL, Maggi LB, Brady SN, et al.  2007. TSC1 sets the rate of ribosome export and protein synthesis through increased nucleophosmin translation.  Cancer Res 67:1609-17."
"2246","PC040009","Yu Y, Maggi LB, Brady SN, et al.  2006.  Nucleophosmin is essential for ribosomal protein L5 nuclear export.  Mol Cell Biol 26:3798-2809."
"2247","PC040013","Jain A, McKnight DA, Fisher LW, et al. 2009. Small integrin-binding proteins as serum markers for prostate cancer detection. Clin Cancer Res 15(16):5199-5207."
"2248","PC040013","Hoffman WH, Jain A, Chen H, et al.  2008.  Matrix extracellular phosphoglycoprotein (MEPE) but not FGF-23, correlates with serum phosphorus prior to and during octreotide treatment and following excisional surgey in hypophosphatemic linear nevus sebaceous syndrome.  Am J Med Genet 146A(16):2164-2168."
"2249","PC040013","Fisher LW, Jain A, Tayback M, et al.  2004.  Small integrin binding ligand N-linked glycoprotein (SIBLING) gene family expression in different cancers.  Clin Cancer Res 10(24):10:8501-8511.

"
"2250","PC040013","Jain A, Karadag A, Fisher LW, et al.  2008.  Structural requirements for bone sialoprotein-binding and modulation of matrix metalloproteinase-2.  Biochemistry 47(38):10162-10170."
"2251","PC040013","BellahcÃ¨ne A, Castronovo V, Ogbureke KUE, et al.  Small integrin-binding ligand N-linked glycoproteins (SIBLINGs):  Multifunctional proteins in cancer.  Nat Rev Cancer 8:212-226."
"2252","PC040013","Jain A, Fisher LW and Fedarko NS.  2008.  Bone sialoprotein alters MMP-2 affinity for natural and synthetic inhibitors.  Biochemistry 47(22):5986-5995."
"2253","PC040013","Jain A, Fisher LW, Fedarko NS.  2008. Bone sialoprotein binding to matrix metalloproteinase-2 alters enzyme inhibition kinetics.  Biochemistry. 47(22):5986-95. 

  

"
"2254","PC040020","Wang Q, Carroll JS, and Brown M.  2005.  Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking.  Mol Cell 19:631-642."
"2255","PC040021","Douglas DA, Zhong H, Ro JY, et al.  2006.  Novel mutations of epidermal growth factor receptor in localized prostate cancer.  Front Biosci 11:2518-2525."
"2256","PC040021","Berger AD, Satagopan JM, Lee P, et al. 2006.  Differences in the clinicopathological features of prostate cancer between African American and white patients treated in the 1990's and 2000's.  Urology 67:120-4."
"2257","PC040021","Wang G, Firoz EF, Rose A, et.al. 2009.  MDM2 expression and regulation in prostate cancer racial disparity.  Int J Clin Exp Pathol 2:353-60.
 

"
"2258","PC040021","2006.  Loss of neutral endopeptidase and activation of protein Kinase B (Akt) is associated with prostate cancer progression.  Cancer 107(11):2628-36."
"2259","PC040021","Dasha A, Leeb P, Zhouc Q, et al.  2008.  The impact of socioeconomic factors on prostate cancer outcomes in black patients treated with surgery.  Urology 72(3):641-6."
"2260","PC040021","2008.  Epidermal growth factor receptor (EGFR) activation in prostate cancer by three novel missense mutations.  Oncogene 27(22):3201-10."
"2261","PC040055","Zeigler-Johnson CM, Spangler E, Jalloh M, et al.  2008.  Genetic susceptibility to prostrate cancer in men of African descent: Implications for global disparities in incidence and outcomes.  Can J Urol 15:3872-3882."
"2262","PC040055","Zeigler-Johnson CM, Rennert H, Mittal RD, et al.  2008.  Evaluation of prostate cancer characteristics in four populations worldwide.  Can J Urol 15:4056-4064."
"2263","PC040055","Rennert H, Zeigler-Johnson CM, Addya K, et al.  2005.  Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men.  Cancer Epidemiol Biomarkers Prev 14(4):949-957."
"2264","PC040055","Rebbeck RT, Rennert H, Walker AH, et al.  2008.  Joint effects on inflammation and androgen metabolism on prostrate cancer severity.  Int J Can 123:1385-1389. 

"
"2265","PC040055","Rennert H, Zeigler-Johnson CM, Tan YC, et al.  2008.  Analysis of the RNASEL/HPC1 and macrophage scavenger receptor-1 in Asian-Indian advanced prostrate cancer.  Urology 72:456-460."
"2266","PC040089","Douglas J.  2007.  Adenoviral vectors for gene therapy.  Mol Biotechnol 36:71-80."
"2267","PC040089","Kim M, Bodenstine TM, Sumerel LA, et al.  2006.  Tissue inhibitor of metalloproteinases-2 improves antitumor efficacy of a replicating adenovirus in vivo.  Cancer Biol Ther 5."
"2268","PC040107","Williams SA, Singh P, Isaacs JT, et al.  2007.  Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer?  Prostate 15:67(3):312-329."
"2269","PC040117","Daniels NA, Ewing SK, Zmuda JM, et al. for the Osteoporotic Fractures in Men (MrOS) Research Group.  2005.  Prevalence and correlates of prostatitis in a large community-based cohort of older men.  Urology 66:964-970."
"2270","PC040117","Daniels NA, Link CL, Barry MJ, McKinlay JB for the BACH Survey Investigators.  2007.  Are past urinary tract infections associated with current symptoms of chronic prostatitis/chronic pelvic pain syndrome:  Results from the Boston Area Community Health (BACH) Survey.  J Natl Med Assoc 99:509-516."
"2271","PC040117","Daniels NA, Chen YH and Bent S.  2009.  Antibiotic and anti-inflammatory use and the risk of prostate cancer:  A Pilot Study.  BMC Research Notes, 2009, 2:57."
"2272","PC040118","Schmelz M, and Prasad A.  2006.  Cytokeratin 6 expression in prostate stem cells.  In: Adhesion and cytoskeletal molecules in metastasis.  Cress AE and Nagle RB (Eds).  Springer Science and Business Media, Dordrecht, The Netherlands."
"2273","PC040118","Schmelz M and Prasad A.  2006.  Cytokeratin 6 expression in prostate stem cells.  In Cancer Metastasis ¿ Biology and Treatment, Springer Publishing, 9:103-122."
"2274","PC040120","Moreno J, Krishnan AV, and Feldman D.  2006.  Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: Inhibition of the prostaglandin pathway.  Anticancer Res 26(4A):2525-2530."
"2275","PC040120","Moreno J, Krishnan AV, Swami S et al.  2005.  Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells.  Cancer Res 65:7917-7925.

"
"2276","PC040120","Moreno J, Krishnan AV, and Feldman D.  2005.  Molecular mechanisms mediating the anti-proliferative effects of vitamin D in prostate cancer.  J Steroid Biochem Mol Biol, 97:31-6."
"2277","PC040120","Krishnan AV, Moreno J, Nonn L, et al. 2007.  Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: Role of anti-inflammatory activity.  J Bone Mineral Res 22 Suppl 2:V74-80."
"2278","PC040121","Cheng J, Kang X, Zhang S, et al.  2007.  SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia.  Cell 131:584-595."
"2279","PC040121","Bawa-Khalfe T, Cheng J, Wang Z, et al.  2007.  Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells.  J Biol Chem 282(52):37341-37349 (Epub 2007)."
"2280","PC040121","Cheng J, Wang D, Wang Z, et al.  2004.  SENP1 enhances androgen receptor-dependent transcription through desumoylation of HDAC-1.  Molecular and Cellular.  Biology 24:6021-6028."
"2281","PC040121","Bawa-Khalfe T, Cheng J, Wang Z, et al.  2007.  Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells.  J Biol Chem 282(52):37341-37349."
"2282","PC040121","Cheng J, Bawa T, Lee P, et al.  2006.  Role of desumoylation in the development of prostate cancer.  Neoplasia 8(8):667-676."
"2283","PC040121","Cheng J, Perkins ND, and Yeh ETH.  2005.  Differential regulation of c-Jun-dependent transcription by SUMO specific Proteases.  J Biol Chem 280:14492-14498."
"2284","PC040130","Kwee SA, Turner H, Lim J, et al.  2006.  Dimethylaminoethanol reduces 18F-Fluoroethylcholine uptake in prostate cancer cells.  J Nucl Med 47:425P."
"2285","PC040130","Kwee S, Wei H, Sesterhenn IA, et al.  2006.  Intensity modulated radiation therapy for prostate cancer with radiation dose augmentation guided by 18F-FCH PET Imaging.  J Nucl Med 47:457P."
"2286","PC040130","Kwee SA, Thibault G, Stack R, et al.  2006.  Cancer localization in the prostate with 18F-Fluorocholine PET: Initial results from a whole prostate histopathologic correlation study.  J Nucl Med 47:459P."
"2287","PC040130","Kwee SA, DeGrado TR, Talbot JN, et al.  2007.  Cancer imaging with fluorine-18 labeled choline derivatives.  Semin Nucl Med 37:420-428."
"2288","PC040130","DeGrado TR, Kwee SA, Coel MN, et al.  2007.  The impact of urinary excretion of 18F-labeled choline analogs.  J Nucl Med 48:1225."
"2289","PC040130","Kwee SA, Thibault G, Stack R, et al.  2008.  Use of step-section histopathology to evaluate 18F-fluorocholine PET sextant localization of prostate cancer.  Mol Imaging 7(1):12-20."
"2290","PC040130","Kwee SA and Degrado T.  2008.  Prostate biopsy guided by 18F-fluorocholine PET in men with persistently elevated PSA levels.  Eur J Nucl Med Mol Imaging 35(8):1567-1569."
"2291","PC040130","Kwee SA, Coel MN, and Ly BH.  2009.  18F-choline PET/CT imaging of RECIST measurable lesions in androgen insensitive prostate cancer.  Ann Nucl Med 23(6):541-548."
"2292","PC040130","Kohli V, Kwee SA, and Coel MN.  2006.  Comparison between 2D and 3D Prostate PET imaging.  J Nucl Med 47:370P.

"
"2293","PC040130","Kwee S, Wei H, Sesterhenn IA, et al.  2006.  Intensity modulated radiation therapy for prostate cancer with radiation dose augmentation guided by 18F-FCH PET imaging.  J Nucl Med 47:457P.

"
"2294","PC040130","Lim J, Kwee S, Cabral C, et al.  2006.  Automated synthesis and in vitro uptake of [18F] fluoroethylcholine in prostate cancer.  Mol Imaging 5(3)."
"2295","PC040130","Kwee SA, et al.  2007.  Oncologic imaging with fluorine-18 labeled choline derivatives.  Seminars in Nuclear Medicine."
"2296","PC040130","Kwee SA, Wei H, Yun D, et al. 2006.  Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET.  J Nucl Med 47:262-269."
"2297","PC040144","Goun E, Shinde R, Dehnert K, et al.  2005.  Intracellular cargo delivery by an octaarginine transporter adapted to target prostate cancer cells through cell surface protease activation intracellular drug delivery targeting membrane-associated proteases.  Bioconjugate Chemistry 17:3, 787-96."
"2298","PC040158","Solban N, Sznycer-Taub N, Benavides JM, et al.  The need for optical imaging in the understanding and optimization of photodynamic therapy.  In: Genetically Engineered and Optical Probes for Biomedical Applications III. (Bornhop DJ, Achilefu SI, Raghavachari R, Savitsky AP, Eds).  Proc. SPIE 5704:1-9."
"2299","PC040158","Solban N, Ortel B, Pogue B, et al.  2005.  Targeted optical imaging and photodynamic therapy.  In: Molecular Imaging: An Essential Tool in Preclinical Research, Diagnostic Imaging, and Therapy. (Bogdanov AA, Jr. and Licha K, Eds.).  Springer-Verlag Heidelberg, Germany 229-258."
"2300","PC040158","Kosharskyy B, Solban N, Chang SK, et al.  2006.  A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer.  Cancer Res 66(22):10953-10958."
"2301","PC040158","Hasan T, Ortel B, Solban N, et al.  2005.  Photodynamic therapy of cancer.  In:  DW Kufe and RR Weichselbaum, editors, Cancer Medicine.  BC Decker Inc.  Chapter 35a."
"2302","PC040158","Chen B, Pogue BW, Zhou X, et al.  2005.  Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model.  Clin Cancer Res 11:720-727"
"2303","PC040158","Solban N, Rizvi I, Hasan T, et al.  2006.  Targeted photodynamic therapy.  Lasers Surg Med 38:522-531"
"2304","PC040158","Solban N, Selbo PK, Sinha AK, et al.  2006.  Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer.  Cancer Res 66:5633-5640."
"2305","PC040160","Jia L, Berman BP, Jariwala U, et al.  2008.  Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity.  PLoS ONE 3(11):e3645."
"2306","PC040160","Jia L, Shen HC, Wantroba M, et al.  2006.  Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Mol Cell Biol 26:7331-7341."
"2307","PC040160","Jia L and Coetzee GA.  2005.  Androgen receptor-dependent PSA expression in androgen-independent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus.  Cancer Res 65:17."
"2308","PC040160","Shen HC, Buchanan G, Butler LM, et al.  2005.  GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor.  Biol Chem 386:69-74."
"2309","PC040160","Kim J, Jia L, Stallcup MR, et al.  2005.  The role of protein kinase A pathway and cAMP responsive element-binding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus.  J Mol Endocrinol 34:107-118.

"
"2310","PC040160","Prescott J and Coetzee GA.  2006.  Molecular chaperones throughout the life cycle of the androgen receptor.  Cancer Lett. 231:12-9.

"
"2311","PC040160","Shen HC and Coetzee GA.  2005.  The androgen receptor: Unlocking the secrets of its unique transactivation domain.  Vitamins and Hormones 71:301-19."
"2312","PC040160","Mulholland DJ, Dedhar S, Coetzee GA, et al.  2005.  Interaction of nuclear receptors with Wnt/beta-catenin/Tcf signaling: Wnt you like to know?  Endocrine Reviews.

"
"2313","PC040161","Kung H-J and Evans CP.  2009.  Oncogenic activation of androgen receptor.  Urol Oncol 27(1):48-52."
"2314","PC040161","Evans CP.  2008.  Editorial comment on: Barriers to the practice of evidence-based urology.  J Urol 179:2350."
"2315","PC040161","Chang Y-M, Bai L, Yang JC, et al.  2008.  Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.  Oncogene 27(49):6365-6375."
"2316","PC040161","Gautschi O, Tepper CG, Purnell PR, et al.  2008.  Regulation of Id1 expression by Src in cancer: implications for targeting of the bone morphogenetic protein pathway.  Cancer Res 68:2250-2258."
"2317","PC040161","Ramirez ML, Nelson EC, and Evans CP.  2008.  Beyond prostate-specific antigen: Alternate serum markers.  Prostate Cancer Prostatic Dis 11:216-29."
"2318","PC040161","Nelson EC, Rodriguez RL, Dawson K, et al.  2008.  The interaction of genetic polymorphisms with lifestyle factors: Implications for the dietary prevention of prostate cancer.  Nutr Cancer 60:301-312."
"2319","PC040161","Evans CP.  2008.  Editorial comment on: Tumor characteristics of carriers and noncarriers of the decode 8q24 prostate cancer susceptibility alleles.  J Urol 179:2202."
"2320","PC040161","Ramirez ML, Nelson EC, de Vere White RW, et al.  2008.  Current applications for prostate-specific antigen doubling time.  Eur Urol 11(3):216-229."
"2321","PC040161","Nelson EC, Evans CP, and Lara PN.  2007.  Renal cell carcinoma: Current status and emerging therapies.  Cancer Treat Rev 33:299-313."
"2322","PC040161","Evans CP.  2007.  Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder cancer.  Eur Urol. 52:1129-30."
"2323","PC040161","Nelson EC, Evans CP, Pan CX, et al.  2007.  Prostate cancer and markers of bone metabolism: Diagnostic, prognostic, and therapeutic implications.  World J Urol 25:393-9."
"2324","PC040161","Nelson EC, Evans CP, Mack PC, et al.  2007.  Inhibition of Akt pathways in the treatment of prostate cancer.  Prostate Cancer Prostatic Dis 10:331-9."
"2325","PC040161","Cambio AJ, Ellison LM, Chamie K, et al.  2007.  Cost-benefit and outcome analysis: Effect of prostate biopsy under-grading.  Urology 69:1152-6."
"2326","PC040161","Chang Y-M, Kung H-J, and Evans CP.  2007.  Non-receptor tyrosine kinases in prostate cancer.  Neoplasia 9:90-100."
"2327","PC040161","Nelson EC, Cambio AJ, Yang JC, et al.  2007.  Clinical implications of neuroendocrine differentiation in prostate cancer.   Prostate Cancer Prostatic Dis 10:6-14."
"2328","PC040161","Cambio AJ and Evans CP.  2006.  Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH).  Therapeutics and Clinical Risk Management."
"2329","PC040161","Evans CP.  2006.  Editorial comment on penis conserving treatment for T1 and T2 penile carcinoma:  Clinical implications of a local recurrence.  J Urol 176:580."
"2330","PC040161","Cambio AJ and Evans CP.  2006.  Minimizing incontinence during radical prostatectomy: Considerations and evidence.  Eur Urol 50:903-913."
"2331","PC040161","Cambio AJ and Evans CP.  2006.  Management approaches to the small renal tumor.  BJU Int 97:456-60.

"
"2332","PC040161","McGahan JP, Mee RK, Evans CP, et al.  2006.  Efficacy of transhepatic radiofrequency ablation of renal cell carcinoma.  Am J Radiol 186:S311-5."
"2333","PC040161","Ok J, Cambio A, Lara PN, et al.  2005.  Is the use of anything but MVAC justified in the evidence-based medicine era?  Curr Opin Urol 15:312-4."
"2334","PC040161","Ok J, Meyers FJ, Evans CP.  2005.  Medical and surgical palliative care of patients with urological malignancies.  J Urol 174:1177-82."
"2335","PC040161","Evans CP, Fleshner N, Fitzpatrick J, et al.  2005.  An evidence based approach to understanding pharmacological class effect in the management of prostatic diseases.  BJU Int 95:743-749."
"2336","PC040161","Chang SS, Benson MC, Campbell S, et al.  2005.  Society of Urologic Oncology position statement:  Redefining the management of hormone-refractory prostate carcinoma.  Cancer 103:11-21."
"2337","PC040161","Nelson EC, Cambio AJ, Yang JC, et al.  2007.  Biologic agents as adjunctive therapy for prostate cancer: A rationale for use with androgen deprivation.  Nature Clinical Practice Urology 4:82-94."
"2338","PC040167","Fung CH, Spencer B, Eslami MS, et al.  2007.  Quality indicators for the screening and care of urinary incontinence in vulnerable elders.  J Am Geriatr Soc 55(2):S443-S449."
"2339","PC040167","Wong T and Spencer BA.  2011.  Medical indicators of quality.  In: Quality and Safety in Radiotherapy (Pawlicki T, Dunscombe P, Mundt A, et al., Eds.).  CRC Press, Taylor and Francis Group, Boca Raton, Florida, Page 643."
"2340","PC040167","Spencer BA, Miller DC, Litwin MS, et al.  2008.  Variations in quality of care for men with early-stage prostate cancer.  Journal of Clinical Oncology 26:(22)14-21."
"2341","PC040167","Miller DC, Spencer BA, Shah RB, et al.  2007.  The quality of surgical pathology care for men undergoing radical prostatectomy in the U.S.  Cancer 109(12):2445-2453."
"2342","PC040167","Miller DC, Spencer BA, Ritchey J, et al.  2007.  Treatment choice and quality of care for men with localized prostate cancer.  Med Care 45(5):401-409."
"2343","PC040185","Chinnaiyan P, Varambally S, Tomlins SA, et al.  2005.  Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition.  Int J Cancer.  Sep 8; [Epub ahead of print]"
"2344","PC040185","Chinnaiyan P, Varambally S, Tomlins SA, et al.  2006.  Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition.  Int J Cancer 118(4):1041-1050."
"2345","PC040198","Author name not provided.  2007.  Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.  Prostate 67:685-691.

"
"2346","PC040203","Denberg TD, Kim FJ, Flanigan RC, et al.  2006.  The influence of patient race andsocial vulnerability on urologist treatment recommendations in localized prostate carcinoma.  Medical Care 44(12)."
"2347","PC040203","Denberg TD, Beaty BL, Kim FJ, et al.  2005.  Marriage and ethnicity predict treatment in localized prostate carcinoma.  Cancer 103(9):1819-1825."
"2348","PC040203","Denberg TD, Melhado TV, and Steiner JS.  2006.  Patient treatment preferences in localized prostate carcinoma.  Cancer 107(3):620-630."
"2349","PC040203","Denberg T, Brenda B, Michael GL, et al.  2006.  Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma.  Br J Urol 98(2):335-340."
"2350","PC040203","Denberg T, Robert F, Fernando K, et al.  2007.  Self-reported radical prostatectomy volume among urologists in the USA.  British Journal of Urology International 99(2):339-343."
"2351","PC040203","Hoffman R, Denberg T, Hunt W, et al.  2007.  Prostate Cancer testing following a negative prostate biopsy: Over testing in the elderly.  J Gen Intern Med 22(8):1139-1143."
"2352","PC040204","Richman EL, Carroll PR, and Chan JM.  2012.  Vegetable and fruit intake after diagnosis and risk of prostate cancer progression. Int J Cancer  131(1):201-210."
"2353","PC040204","Richman EL, Stampfer MJ, Paciorek A, et al. 2010. Intakes of meat, fish, poultry, and eggs and risk of prostate cancer progression. Am J Clin Nutr 91: 712-721."
"2354","PC040204","Richman EL, Kenfield SA, Stampfer MJ, et al.  2011. Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res 71(11):3889-3895.
"
"2355","PC040215","Wilkinson JC, Wilkinson AS, Csomos RA, et al.  2008.  AIF is a target for ubiquitination through interaction with XIAP.  Mol Cell Biol 28:237-247."
"2356","PC040215","Hwang C, Giri, VN, Wilkinson JC, et al.  2008.  EZH2 regulates the transcription of estrogen-responsive genes through association with REA, and estrogen receptor corepressor.  Breast Cancer Res Treat 107:235-242."
"2357","PC040215","Hwang C, Oetjen KA, Kosoff D, et al.  2008.  X-linked inhibitor of apoptosis deficiency in the TRAMP mouse prostate cancer model.  Cell Death Diff 208:1-10."
"2358","PC040215","Mufti AR, Burstein E, Csomos RA, et al.  2006. XIAP is a copper binding protein deregulated in Wilson's disease and other copper toxicosis disorders.  Mol Cell 21:775-85."
"2359","PC040215","Wright CW and Duckett CS.  2005.  Re-awakening the cellular death program in neoplasia through the therapeutic blockade of IAP function.  J Clin Invest 115:2673-2678.

"
"2360","PC040215","Duckett CS.  2005.  IAP proteins: Sticking it to Smac.  Biochem J 385:e1-e2."
"2361","PC040215","Burstein E, Hoberg JE, Wilkinson AS, et al.  2005.  COMMD proteins:  A novel family of structural and functional homologs of MURR1.  J Biol Chem 280:22222-22232."
"2362","PC040215","Xia Y, Novak LJ, Duckett CS, et al.  2006.  Xaf1 can cooperate with TNF-a in the induction of apoptosis, independently of interaction with XIAP.  Mol Cell Biochem 286:67-76."
"2363","PC040221","Goel HL, Li J, Kogan S, et al.  2008.  Integrins in prostate cancer progression.  Endocrine-Related Cancer 3:657-664.

"
"2364","PC040221","Vaira V, Lee CW, Goel HL, et al.  2007.  Regulation of survivin expression by IGF-1/mTOR signaling.  Oncogene 26(19):2678-2684."
"2365","PC040221","De Clerck YA, Weissman BE, Yu D, et al.  2006.  Tumor progression and metastasis from genetic to microenvironmental determinants: A workshop of the tumor progression and metastasis NIH study section.  Cancer Biol Ther 5:1588-1599."
"2366","PC040221","Languino LR and Rangnekar VM.  2007.  'D' approach to prevent metastasis.  Cancer Biol Ther 6:110-1."
"2367","PC040221","Alam N, Goel HL, Zarif MJ, et al.  2007.  The integrin-growth factor receptor duet.  J Cell Physiol 213:649-653."
"2368","PC040221","FitzGerald TJ, Wang T, Goel HL, et al.  2008.  Prostate carcinoma and radiation therapy: Therapeutic treatment resistance and strategies for targeted therapeutic intervention.  Expert Rev Anticancer Ther 8:967:974."
"2369","PC040221","Languino LR and Ho S-M.  2006.  Androgen Action Series.  J Cell Biochem 99:331-332."
"2370","PC040221","Goel HL, Moro L, King M, et al.  2006.  The beta1 integrins modulate cell adhesion by regulating IGF-II levels in the microenvironment.  Cancer Res 66:331-342."
"2371","PC040221","Pratap J, Javed A, Languino LR, et al.  2005.  The Runx2 osteogenic transcription factor regulates MMP9 in bone metastatic cancer cells and controls cell invasion.  Mol Cell Biol 25:8581-8591."
"2372","PC040221","Goel HL, Breen M, Zhang J, et al.  2005.  Beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts.  Cancer Res 65:6692-6700.

"
"2373","PC040221","Vaira V, Lee CW, Goel HL, et al.  2007.  Regulation of surviving expression by IGF-1/mTOR signaling.  Oncogene 26(19):2678-2684."
"2374","PC040221","Wang T, Alavian M, Goel HL, et al.  2008.  Bicalutamide inhibits androgen promotion of prostate cancer cell adhesion when exposed to ionizing radiation.  Prostate 68:1734-1742."
"2375","PC040221","Simon EL, Goel HL, Teider N, et al.  2005.  Dose fractionated ionizing radiation inhibits prostate cancer cell adhesion and beta1 integrin expression.  The Prostate 64:83-91."
"2376","PC040221","Goel HL, Bre en M, Zhang J, et al.  2005.  Beta-1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts.  Cancer Res 65:6692-6700."
"2377","PC040238","Muindi JR, Yu W-D, Engler K, et al.  2006.  Inhibitors of 24-hydroxylase activity enhance systemic calcitriol exposure in preclinical animal models.  Proc Amer Assoc Cancer Res 47:2153."
"2378","PC040238","Alagbala AA, Moser MT, Johnson CS, et al.  2006.  Mechanisms of vitamin D insensitivity in prostate cancer using TRAMP.  Proc Amer Assoc Cancer Res 47:3930."
"2379","PC040238","Trump DL, Chadha M, Sunga AY, et al.  2009.  Vitamin D deficiency and insufficiency among patients with prostate cancer.  British J Urol 104(7):909-914."
"2380","PC040238","Morrison CD, Cheney RT, Johnson CS, et al.  2009.  Central quadrant procurement of radical prostatectomy specimens.  Prostate 69:770-773."
"2381","PC040238","Johnson CS, Chung I, and Trump DL.  2010.  Epigenetic silencing of CYP24 in the tumor microenvironment.  J Steroid Biochem Mol Biol 121(1-2):338-342.

"
"2382","PC040238","Hidalgo AA, Mazzilli SA, Trump DL, et al.  2010.  Glucocorticoid regulation of the vitamin D receptor.  J Steroid Biochem Mol Biol 121(1-2):372-375.
"
"2383","PC040238","Chadha MK, Tian L, Mashtare T, et al.  2010.  Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (Calcitriol) in combination with dexamethasone for castration-resistant prostate cancer.  Cancer 116(9):2132-2139."
"2384","PC040238","Alagbala AA, Johnson CS, Trump DL, et al.  2006.  Antitumor effects of two less-calcemic vitamin D analogs (paricalcitol and QW-1624F2-2) in squamous cell carcinoma (SCC) cells.  Oncology 70:483-492."
"2385","PC040238","Chung I, Yu WD, Karpf AR, et al.  2007.  Anti-proliferative effects of calcitriol on endothelial cells derived from two different microenvironments.  J Steroid Biochem Mol Bio 103(3-5):768-770."
"2386","PC040238","Muindi JR, Johnson CS, Trump OL, et al.  2009.  A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors.  Cancer Chemother Pharmacol 65(1):33-40."
"2387","PC040238","Chung I, Han G, Seshadri M, et al.  2009.  Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo.  Cancer Res 69(3):967-975."
"2388","PC040238","Rassnick KM, Muindi JR, Johnson CS, et al.  2008.  In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors.  Cancer Chemother Pharmacol 62(5):881-891."
"2389","PC040238","Ma Y, Yu WD, Hershberger PA, et al.  2008.  1 alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma modeL.  Mol Cancer Ther 7(9):3047-3055."
"2390","PC040238","Beer TM, Javle MM, Ryan CW, et al.  2007.  Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer.  Cancer Chemother Pharamacol 59(5):581-587."
"2391","PC040238","Hidalgo AA, Paredes R, Garcia VM, et al.  2007.  Altered VDR-mediated transcriptional activity in prostate cancer stroma.  J Ster Biochem Mol Biol 103:731-736."
"2392","PC040238","Fakih MG, Trump DL, Muindi JR, et al.  2007.  A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors.  Clin Cancer Res 13(4):1216-1223."
"2393","PC040238","
Deeb KK, Johnson CS, and Trump DL.  2007.  Vitamin D signaling pathways in cancer: Potential for anticancer therapeutics.  Nature Rev Cancer 7:684-700.
"
"2394","PC040238","Chung I, Karpf AR, Muindi JR, et al.  2007.  Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol.  J Biol Chem 282(12):8704-8714."
"2395","PC040238","Muindi JR, Peng Y, Wilson JW, et al.  2007.  Monocyte fructose 1,6-bisphosphatase activity: A sensitive measure of calcitriol status and effects in cancer patients.  Cancer Chemother Pharmacol 59(1):97-104."
"2396","PC040238","Muindi J, Nganga A, Engler K, et al.  2007.  CYP24 splicing variants are associated with different patterns constitutive and calcitriol-inducible CYP24 activity in human prostate cancer cell lines.  J Steroid Biochem Mol Biol 103:334-337.

"
"2397","PC040238","Ma Y, Yu WD, Kong RX, et al.  2006.    Role of nongenomic activation of phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase ½ pathway in 1,25D3-medicated apoptosis in squamous cell carcinoma cells.  Cancer Res 66(16):8131-8138.
"
"2398","PC040238","Flynn G, Chung I, Yu WD, et al.  2006.  Calcitriol (1,25-dihydroxycholecalciferol) selectively inhibits proliferation of freshly isolated tumor-derived endothelial cells and induces apoptosis.  Oncology 70:447-57.

"
"2399","PC040238","Chung I, Wong MK, Flynn G, et al.  2006.  Differential anti-proliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells.  Cancer Res 66:8565-73."
"2400","PC040238","Muindi JR, Peng Y, Wilson JW, et al.  2006.  Monocyte fructose 1,6-bisphosphatase activity:  A sensitive measure of calcitriol status and effects in cancer patients.  Cancer Chemother Pharmacol 59:97-104."
"2401","PC040238","Trump DL, Potter DM, Muindi J, et al.  2006.  Phase II trial of high dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) + dexamethasone in androgen independent prostate cancer.  Cancer 106(10): 2136-2142.

"
"2402","PC040238","Trump DL, Muindi J, Fakih M, et al.  2006.  Vitamin D compounds:  Clinical development as cancer therapy and prevention agents.  Anticancer Res 26:2551-2556."
"2403","PC040238","Johnson CS, Muindi JR, Hershberger PA, et al.  2006.  The antitumor efficacy of calcitriol:  Preclinical studies.  Anticancer Res 26:2543-2550."
"2404","PC040238","Alagbala AA, Johnson CS, Trump DL, et al.  2007.  Characterization of vitamin D insensitive prostate cancer cells.  J Steroid Biochem Mol Bio 103(3-5):712-716."
"2405","PC040246","Hodgson MC, Astapova I, Hollenberg AN, et al.  2007.  Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.  Cancer Res 67(17):8388-8395."
"2406","PC040246","Hodgson MC, Astapova I, Hollenberg AN, et al.  2007.  Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR.  Cancer Res 67:8388-8395."
"2407","PC040246","Hodgson MC, Astapova I, Cheng S, et al.  2005.  The androgen receptor recruits nuclear receptor corepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists.  
J Biol Chem 280(8):6511-6519.
"
"2408","PC040247","Garcia-Bassets I, Kwon YS, Telese F, et al.  2007.  Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors.  Cell 128:505-518."
"2409","PC040256","Liu Y, Gao L, and Gelman IH.  2006.  SSeCKS/Gravin/AKAP12 attenuates expression of proliferative and angiogenic genes during suppression of v-Src-induced oncogenesis.  BMC Cancer 6:105."
"2410","PC040256","Bu Y and Gelman IH.  2007.  v-Src-mediated down-regulation of SSeCKS metastasis Suppressor gene promoter by the recruitment of HDAC1 into a USF1-Sp1-Sp3 complex.  J Biol Chem  282:26725-26739."
"2411","PC040256","Su B, Zheng Q, Vaughan MM, et al.  2006.  SSeCKS metastasis-suppressing activity in MatLyLu prostate cancer cells correlates with vascular endothelial growth factor inhibition.   Cancer Res 66:5599-5607."
"2412","PC040256","Gelman IH and Gao L.  2006.  SSeCKS/Gravin/AKAP12 metastasis suppressor inhibits podosome formation via RhoA- and Cdc42-dependent pathways.  Mol Cancer Res 4:151-158."
"2413","PC040260","Chung LW, Huang WC, Sung, SY, et al.  Stromal-epithelial interaction in prostate cancer progression.  Clinical Genitourinary Cancer 5(2):162-170."
"2414","PC040260","Gao X, Chung LW, and Nie S.  2007.  Quantum dots for in vivo molecular and cellular imaging.  Methods Mol Biol 374:135-146."
"2415","PC040260","Xu J, Wang R, Xie ZH, et al.  2006.  Prostate cancer metastasis: Role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. The Prostate 66:1664-73."
"2416","PC040260","Xing Y, Chaudry Q, Shen C, et al. 2007.  Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry.  Nat Protoc 2(5):1152-1165."
"2417","PC040277","Li H, Bubley GJ, Balk SP, et al. 2007. Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. Prostate 67:1354-1361.
"
"2418","PC040282","Li J and Xing L.  Radiation dose planning, computer-aided. 
In: Encyclopedia of Medical Devices and Instrumentation (Webster JG, Ed.).  John Wiley & Sons.
"
"2419","PC040282","Song Y, Boyer A, Ma C, et al.  2005.  Modulated electron beam therapy.  In: Intensity Modulated Radiation Therapy: A Clinical Perspective (Mundt AF and Roeske JC, Eds.).  BC Decker, Inc., Publisher, Hamilton, Canada 327-336.

"
"2420","PC040282","Xing L.  2008.  Quality assuraqnce of PET/CT for radiation therapy.  Int J Radiat Oncol Biol Phys 71:38-41."
"2421","PC040282","Xing L, Lee L, and Timmerman R.  2009 (in press).  Image guided adaptive radiation therapy.  In: Image Guided and Adaptive Radiation Therapy (Timmerman R and Xing L, Eds.).  Lippincott, Williams, and Wilkins Publishing, Baltimore."
"2422","PC040282","Xie Y, Djajaputra D, King C, et al.  2008.  Intrafraction motion of prostate in hypofractionated radiation therapy. Int J Radiat Oncol Biol Phys 72:236-246."
"2423","PC040282","Paquin D, Levy D, Schreibmann E, et al.  2006, Multistage image registration.  Mathematical Biosciences and Engineering 3:389-418."
"2424","PC040282","Xie Y, Xing L, Paquin D, et al.  2007.  Deformable image registration with inclusion of auto-detected homologous tissue features.  Int J Radiat Oncol Biol Phys 69:S646-S647."
"2425","PC040282","Keall P and Xing L.  2008.  Image guided and adaptive therapy.  In:  The Textbook of Radiation Oncology.  Phillips T and Leibel S, Eds.  Saunders."
"2426","PC040282","Yang Y, Schreibmann E, Li T, et al.  2007.  Evaluation of dosimetric accuracy of kV cone beam CT-based dose calculation.  Phys Med Biol 52:685-705."
"2427","PC040282","Timmerman RD, Kavanagh BD, Cho LC, et al.  2007.  Stereotactic body radiation therapy in multiple organ sites.  J Clin Oncol 25:947-952."
"2428","PC040282","
Chao M, Schreibamnn E, Li T, et al.  2007.  Automated contour mapping using sparse volume sampling for 4D radiation therapy.  Med Phys 34:4023-4029.
"
"2429","PC040282","de la Zerda A, Armbruster B, and Xing L.  2007.  Formulating adaptive radiation therapy (ART) treatment planning into a closed-loop control framework.  Phys Med Biol 52:4137-4153."
"2430","PC040282","Mao W, Li T, and Xing L.  2007.  Image registration in sinogram space.  Med Phys 34:3596-3602."
"2431","PC040282","Wiersma R and Xing L.  2007.  Geometric and dosimetric accuracies of gated IMRT.  Med Phys 34:3962-3970.

"
"2432","PC040282","Li T, Koogn A, and Xing L.  2007.  Enhanced 4D cone-beam computed tomography using an on-board imager.  Med Phys 34:3688-3695 (figures featured in the cover of the issue of the journal)."
"2433","PC040282","Xing L, Siebers J, and Keall P.  2007.  Software solutions for real-time adaptive image-guided radiotherapy.  Seminar in Radiation Oncology 17:245-257."
"2434","PC040282","Paquin D, Levy D, and Xing L.  2007.  Hybrid multistage landmark and deformable image registration.  Math Biosciences Eng 4:711-737."
"2435","PC040282","Lee L, Le Q, and Xing L. 2008.  Retrospective IMRT dose reconstruction based on cone-beam CT and MLC log-file.  Int J Radiat Oncol Biol Phys 70:634-44."
"2436","PC040282","Chao M, Schreibamnn E, Li T, et al. 2008.   Automated contour mapping with a regional deformable model.  Int J Radiat Oncol Biol Phys 70:599-608."
"2437","PC040282","Xing L.  2008.  Image guided intensity modulated radiation therapy.  In:  Mathematical Methods in Biomedical Imaging and IMRT.  Censor Y, Jiang M, and Louis AK, Eds.  Springer-Verlag."
"2438","PC040282","Lee L, Le Q, La T, et al.  2007.  IMRT dose reconstruction on CBCT:  A platform for head-and-neck adaptive therapy.  Int J Radiat Oncol Biol Phys 69:S412."
"2439","PC040282","Wang J, Chao M and Xing L.  2007.  Toward clinical implementation of adaptive treatment planning: Auto-propagation of contours from planning CT to CBCT.  Int J Radiat Oncol Biol Phys 69:S43."
"2440","PC040282","Wiersma RD and Xing L.  2007.  Dosimetric consequences of electronic delay on gated radiation therapy.  Int J Radiat Oncol Biol Phys 69(3):S131-S132."
"2441","PC040282","Mao W and Xing L.  2007.  Design of multi-purpose phantom and automated software analysis tool for quality assurance of onboard kV/MV imaging system.  Int J Radiat Oncol Biol Phys 69(3):S666."
"2442","PC040282","Lee L, Mao W, and Xing L.  2008.  The use of EPID-measured leaf sequence files for IMRT dose reconstruction in adaptive radiation therapy.  Med Phys 35:5019-5029."
"2443","PC040282","Xie Y, Chao M, Lee P, et al.  2008.  Feature-based rectal contour propagation from planning CT to cone beam CT.  Med Phys 35:4450-4459."
"2444","PC040282","Zhu L, Lee L, Ma Y, et al.  2008.  Using total-variation regularization for inverse planning with field specific numbers of segments.  Phys Med Biol 53:6653Ã¢-6672."
"2445","PC040282","Paquin D, Levy D, Xing L. 2009.  Multiscale registration of planning CT and daily cone beam CT images for adaptive radiation therapy. Med Phys 36(1):4-11."
"2446","PC040282","Lee L, Ma Y, Ye Y, Xing L. 2009.  Conceptual formulation on four-dimensional inverse planning for intensity modulated radiation therapy. Phys Med Biol 54(13):N255-266."
"2447","PC040282","Zhu L, Xing L. 2009.  Search for IMRT inverse plans with piecewise constant fluence maps using compressed sensing techniques.  Med Phys 36(5):1895-1905."
"2448","PC040282","Ma Y, Lee L, Keshet O, et al.  2009. Four-dimensional inverse treatment planning with inclusion of implanted fiducials in IMRT segmented fields. Med Phys 36(6):2215-2221."
"2449","PC040282","Xia P, Almos H, and Xing L.  2008.  Intensity modulated radiation therapy.  In: The Textbook of Radiation Oncology (Phillips T and Leibel S, Eds.).  Saunders (Elsevier) Publishing, Philadelphia.

"
"2450","PC040282","Wu QW, Xing L, Ezzel G, et al.  2005.  Inverse treatment planning.  In: Modern Technology of Radiation Oncology II 
(Van Dyk J, Ed.).  Medical Physics Publishing, Madison, Wisconsin. 

"
"2451","PC040282","Xing L, Wu Q, Yong Y, et al.  2005.  Physics of IMRT and inverse treatment planning.  In: Intensity Modulated Radiation Therapy: A Clinical Perspective (Mundt AF and Roeske JC, Eds.). 
BC Decker, Inc., Publisher, Hamilton, Canada 20-51.
"
"2452","PC040282","Xing L, Yang Y, and Spielman D.  Molecular/functional image-guided radiation therapy (Bortfetld T, Schmidt-Ullrich R, and de Neve W, Eds.).  Springer-Verlag, Heidelberg, Berlin.

"
"2453","PC040282","Xia P, Yu N, Xing L, et al.  2005.  Investigation of a new objective function for inverse planning optimization.  Med Phys 32:920-927."
"2454","PC040282","Xing L, Thorndyke B, Schreibmann E, et al.  2006.  Overview of image guided radiation therapy (IGRT).  Med Dosim 31:91-112."
"2455","PC040282","Wiersma R and Xing L.  2008.  Real-time monitoring of implanted fiducials using onboard kV and treatment MV beams.  Med Phys 35:1191-1198."
"2456","PC040282","Liu W, Wiersma R, Mao W, et al.  2008.  Real-time 3D internal marker tracking during arc radiotherapy by use of combined MV-kV imaging.  Phys Med Biol 53:7197-7213."
"2457","PC040282","Mao W, Lee L, and Xing L.  2008.  Design of multi-purpose phantom and automated software analysis tool for quality assurance of onboard kV/MV imaging system.  Med Phys 35:1497-1506."
"2458","PC040282","Mao W, Riaz N, Lee L, et al.  2008.  A fiducial detection algorithm for real-time image guided IMRT based on simultaneous MV and kV imaging.  Med Phys 35:3554-3564.

"
"2459","PC040282","Mao W, Wiersma R, and Xing L.  2008.  Fast fiducial detection algorithm for onboard MV and kV imaging systems.  Med Phys 35:1942-1949."
"2460","PC040282","Schreibmann E, Thorndyke B, and Xing L.  2008.  4D-4D Image registration for image guided radiation therapy (IGRT).  Int J Radiat Oncol Biol Phys 71:578-586 (highlighted article of the issue)."
"2461","PC040282","Thornydy B, Koong A, and Xing L.  2008.  Reducing respiratory motion artifacts in radionuclide imaging through retrospective stacking: A simulation study.  Linear Algebra Appl 428:1325-1344."
"2462","PC040282","Chao M, Schreibamnn E, Li T, et al.  2008.  Contour propagation from planning CT to cone beam CT (CBCT).  Phys Med Biol 53:4533-4542."
"2463","PC040282","Wang C, Chao M, Lee L, et al.  2008.  MRI-based treatment planning with electron density information mapped from CT images: A preliminary study.  Technol Cancer Res Treat 7:341-348."
"2464","PC040282","Wang J, Li T, Liang Z, et al.  2008.  Dose reduction in kV cone beam CT for radiation therapy.  Phys Med Biol 53:897-909."
"2465","PC040285","Chen G, Wang X, Yu J, et al.  2007.  Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma.  Cancer Res. 67(7):3461-3467."
"2466","PC040285","Bradford TJ, Tomlins SA, Wang X, and Chinnaiyan AM.  Molecular markers of prostate cancer.  Urol Oncol 24:538-51."
"2467","PC040285","Bradford T, Wang X, Chinnaiyan AM.  2006.  Cancer immunomics: Using autoantibody signatures in the early detection of prostate cancer.  Urol Oncol 24(3):237-242."
"2468","PC040285","Wang X, Yu J, Sreekumar A, et al.  2005.  Autoantibody signatures in prostate cancer.  N Engl J Med 353:1224-1235.

"
"2469","PC040286","Karl E, Zhang Z, Dong Z, et al. 2007.  Unidirectional crosstalk between Bcl-xL and Bcl-2 enhances the angiogenic phenotype of endothelial cells. Cell Death Differ 14(9):1657-1666."
"2470","PC040286","Zeitlin BD, Joo E, Dong Z, et al. 2006.Antiangiogenic Effect of TW37, a Small-Molecule Inhibitor of Bcl-2. Cancer Res. 2006 Sep 1;66(17):8698-8706"
"2471","PC040286","Karl E, Warner K, Zeitlin B, et al.  2005.  Bcl-2 acts in a pro-angiogenic signaling pathway through NF-kB and CXC chemokines.  Cancer Res. 65:5063-5069 (Appendix A)."
"2472","PC040298","Fu XS, Hu C-AA, Chen J, et al.  2006.  Cancer genomics, proteomics, and clinical applications.  In: Genomic Signal Processing and Statistics (Dougherty ER, Shmulevich I, Chen J, et al., Eds.)."
"2473","PC040299","Hernandez M, Shao Q, Yang XJ, et al.  2006.  A histone deacetylation-dependent mechanism for transcriptional repression of the gap junction gene cx43 in prostate cancer cells.  Prostate 66(11):1151-1161."
"2474","PC040299","Behmoaram E, Bijian K, Bismar TA, et al.  2008. Early stage cancer cell invasion: From cell signaling to biomarkers and therapeutic targeting.  Front Biosci 13:6314-6325."
"2475","PC040299","Alaoui-Jamali MA.  2006.  Protein tyrosine kinase signaling diversity and susceptibility to targeted kinase inhibitors.  Biomed Pharmacother 60(9):629-32."
"2476","PC040299","Alaoui-Jamali MA and Xu Y.  2006.  Proteomic technology for biomarker profiling in cancer: An update.  J Zhejiang Univ Sci B 7(6):411-420."
"2477","PC040299","Luh S-P and Alaoui-Jamali MA.  2007.  New targets, new agents, and the evolving phenomena of drug resistance.  Current Cancer Therapy Reviews."
"2478","PC040299","Alaoui-Jamali MA and Pinto D.  2008.  Proteomic profiling of tyrosine kinases as pharmacological endpoints for clinical response to targeted therapy.  Cancer drug discovery and development - Cancer proteomics.  Bench to Bedside.  Humana Press 59-77."
"2479","PC040299","Darnel AD, Behmoaram E, Vollmer RT, et al.  2009.  Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer.  Clinical Cancer Res 15:1376-1383."
"2480","PC040299","Alaoui-Jamali MA and Pinto D.  2007.  Proteomic profiling of tyrosine kinases as pharmacological endpoints for clinical response to targeted therapy.  Daoud S, Ed.  Washington State University, Humana Press, NJ (published).
Alaoui-Jamali MA.  2006.  Protein tyrosine kinase signaling diversity and susceptibility to targeted kinase inhibitors.  Biomed Pharmacother 60(9):629-632.
"
"2481","PC040311","Jin S, DiPaola RS, Mathew R, et al.  2007.  Metabolic catastrophe: A means to cancer cell death.  J Cell Science 120:379-383."
"2482","PC040311","Stein M, Lin H, Jeyamohan C, et al.  2010. Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies.  Prostate 70(13):1388-1394."
"2483","PC040311","DiPaola RS, Dvorzhinski D, Thalasila A, et al.  2008.  Therapeutic starvation and autophagy in prostate cancer:  A new paradigm for targeting metabolism in cancer therapy.  The Prostate 68:1743-1752."
"2484","PC040312","Chen W, Dang T, Blind R, et al.  2008.  Glucocorticoid receptor phosphorylation differentially affects target gene expression.  Molecular Endocrinology 22(8):1754-1766."
"2485","PC040312","Taneja SS, Ha S, Swenson NK, et al.  2005.  Cell specific regulation of androgen receptor phosphorylation in vivo.  J Biol Chem 280:40916-24."
"2486","PC040312","Li W, Cavasotto CN, Cardozo T, et al.  2005.  An androgen receptor mutation identified in prostate cancer displays aberrant ART-27 coactivator function.  Mol Endocrinol 19:2273-82."
"2487","PC040312","Taneja S, Ha S, Swenson N, et al.  2004.  Androgen receptor coactivator, ART-27, in androgen-mediated cell growth, cancer and development.  J Biol Chem 279:13944."
"2488","PC040312","Nwachukwu JC, Li W, Huang HY, et al.  2007.  Transcriptional regulation of the androgen receptor cofactor, ART-27.  Mol Endocrinol 21:2864-76."
"2489","PC040315","Morikawa A, Varma V, Gillespie TW, et al.  2008.  Counting alleles in single lesions of prostate tumors from ethnically diverse patients.    Prostate 68(3):231-240."
"2490","PC040315","Zhong D, Morikawa A, Guo L, et al.  2006.  Homozygous deletion of SMAD4 in breast cancer cell lines and invasive ductal carcinomas.  Cancer Biol Ther (6):601-607."
"2491","PC040321","Sunduram S and Ghosh J.  2006.  Expression of 5-oxoETE receptor in prostate cancer cells: Critical role in survival.  Biochem Biophys Res Commun 339:93-98."
"2492","PC040321","Ghosh J.  2004.  Rapid induction of apoptosis in prostate cancer cells by selenium: Reversal by metabolites of arachidonate 
5-lipoxygenase.  Biochem Biophys Res Commun 315:624-635. 
"
"2493","PC040321","Sarveswaran S, Liroff J, Zhou Z, et al.  Selenite triggers rapid transcriptional activation of p53, and p53-mediated apoptosis in prostate cancer cells: Implication for the treatment of early-stage prostate cancer.  Int J Oncol 36(6):1419-428."
"2494","PC040322","Jariwala U, Prescott J, Jia L, et al.  2007.  Identification of novel androgen receptor target genes in prostate Cancer.  Mol Cancer 6:39."
"2495","PC040322","Barski A, Pregizer S, and Frenkel B.  2008.  Identification of transcription factor target genes by ChIP display.  Methods Mol Cell Biol 455:177-190."
"2496","PC040322","Prescott J, Jariwala U, Jia L, et al.  2007.  Androgen receptor-mediated repression of novel target genes.  Prostate 67:1371-1383."
"2497","PC040322","Jariwala U, Prescott J, Jia L, et al.  2007.  Identification of novel androgen receptor target genes in prostate cancer.  Mol Cancer 6:39."
"2498","PC040322","Khalid O, Baniwal SK, Purcell DJ, et al.  2008.  Modulation of Runx2 activity by estrogen receptor alpha:  Implications for osteoporosis and breast cancer.  Endocrinology 149:5984â¿¿5995."
"2499","PC040322","Jia L, Frenkel B, and Coetzee GA.  2008.  Chromatin remodeling and androgen receptor-mediated transcription.  Androgen action in prostate cancer.  Springer, New York, New York."
"2500","PC040322","Jia L, Berman B, Jariwala U, et al.  2008.  Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS ONE 3:e3645."
"2501","PC040322","Jariwala U, Cogan JP, Jia L, et al.  2009.  Inhibition of AR-mediated transcription by binding of Oct1 to a motif enriched in AR-occupied regions.  Prostate 69:392-400."
"2502","PC040323","Vieweg J, Su Z, Dahm P, et al.  2007.  Reversal of tumor-mediated immunosuppression.  Clin Cancer Res 13:727s-732s."
"2503","PC040323","Vieweg J.  2007.  Immunotherapy for advanced prostate cancer.  Rev Urol 9(Supp 1):S29-S38."
"2504","PC040323","Dannull J, Kusmartsev S, Su Z, et al.  2008.  Reversal of myeloid CD33+ cell-mediated immunosuppression in patients with metastatic renal cell carcinoma.  Clin Cancer Res 14(24):8270-8278.

"
"2505","PC040326","Wang J, Luo H, Thompson B, et al.  2006.  Sprouty4 is a suppressor of tumor cell motility that is methylated in human prostate cancer.  Prostate 1:66(6):613-624."
"2506","PC040326","Kwabi-Addo B, Wang J, Erdem H, et al.  2004.  Sprouty1, an inhibitor of fibroblast growth factors is down-regulated in prostate cancer.  Cancer Res 64(14):4728-4735."
"2507","PC040326","Kwabi-Addo B, Ozen M, and Ittmann M.  2004.  The role of fibroblast growth factors and their receptors in prostate cancer.  Endocr Relat Cancer 11(4):709-724."
"2508","PC040326","Kwabi-Addo B, Chung W, Shen L, et al.  2007.  Age-related DNA methylation changes in normal human prostate tissues.  Clin Cancer Res Jul 1:13(13):3796-3802."
"2509","PC040341","Lipton A, Berenson JR, Body JJ, et al.  2006.  Advances in treating metastatic bone cancer: Summary statement for the First Cambridge Conference.  Clin Cancer Res 12(20):6209s-6212s."
"2510","PC040341","Coleman RE, Guise TA, Lipton A, et al.  2008.  Advancing treatment for metastastic bone cancer: Consensus recommendations from the Second Cambridge Conference.  Clin Cancer Res 14(20):6387-6395."
"2511","PC040341","Hadji P, Body JJ, Aapro MS, et al.  2008.  Practical guidance for the management of aromatase inhibitor-associated bone loss.  Ann Oncol Apr 19(8):1407-1416.

"
"2512","PC040341","Mohammad KS, Chen CG, Balooch G, et al.  2009.  Pharmacologic inhibition of TGF-beta type 1 receptor kinase has anabolic and anti-catabolic effects on bone.  PloS ONE 4(4):e5275."
"2513","PC040341","Bendre MS, Margulies AG, Walser B, et al.  2005.  Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.  Cancer Res 65(23):11001-11009."
"2514","PC040341","Guise TA and Mohammad KS.  2004.  Endothelins in bone cancer metastases.  Cancer Treat Res 118:197-212."
"2515","PC040341","Heras-Herzig A and Guise TA.  2004.  Effects of drug treatment for malignancy on skeletal health of cancer survivors.  Clin Rev Bone Min Metab 2(2):103-114."
"2516","PC040341","Clines GA and Guise TA.  2004.  Mechanisms and treatment for bone metastases.  Clin Adv Hematol Oncol 2(5):295-301."
"2517","PC040341","Guise TA.  2005.  Thromboembolism to metastasis: The platelet-lysophosphatidic acid connection.  Bonekey Osteovision10.1138/20050154."
"2518","PC040341","Clines GA, Chirgwin JM and Guise TA.  2005.  Skeletal complications of malignancy: Central role for the osteoclast.  In: Engineering of Functional Skeletal Tissues (Topics in Bone Biology), Volume 2.  (Bronner, Rubin, Farach-Carson, et al., Eds.) Springer Publishing, New York, New York 151-174."
"2519","PC040341","Aris RM and Guise TA.  2005.  Cystic fibrosis and bone disease: Are we missing a genetic link? Eur Respir J 25(1):9-11."
"2520","PC040341","Titus B, Frierson HF Jr, Conaway M, et al.  2005.  Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2.  Cancer Res 65(16):7320-7327."
"2521","PC040341","Clines GA and Guise TA.  2005.  Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone.  Endocr Relat Cancer 12(3):549-583."
"2522","PC040341","Kingsley LA, Fournier PG, Chirgwin JM, et al.  2007.  Molecular biology of bone metastasis.  Mol Cancer Ther 6(10):2609-2617."
"2523","PC040341","Brown SA and Guise TA.  2007.  Cancer-associated bone disease.  Curr Osteoporos Rep 5(3):120-127."
"2524","PC040341","Kingsley LA, Chirgwin JM, and Guise TA.  2007.  Breaking new ground to build bone.  Proc Natl Acad Sci USA 104(26):10753-10754."
"2525","PC040341","Siclari VA, Guise TA, and Chirgwin JM.  2006.  Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases.  Cancer Metastasis Rev 25(4):621-633."
"2526","PC040341","Bartholin L and Guise TA.  2007.  TGFbeta in breast cancer osteolysis.  In:  TGFbeta in Health and Disease (S Jakalew, Ed.) Chapter 7."
"2527","PC040341","Fournier PGJ and Guise TA.  2007.  BMP7: A new bone metastases prevention?  Am J Pathol 171(3):739-743."
"2528","PC040341","Khosla S, Burr D, Cauley J, et al.  2007.  Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research.  J Bone Miner Res 22(10):1479-1491."
"2529","PC040341","Guise TA.  2006.  Bone loss and fracture risk associated with cancer therapy.  Oncologist 11(10):1121-1131."
"2530","PC040341","Javelaud D, Mohammad KS, McKenna CR, et al.  2007.  Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis.  Cancer Res 67(5):2317-2324."
"2531","PC040341","Brown SA and Guise TA.  2007.  Drug insight: The use of bisphosphonates for the prevention and treatment of osteoporosis in men.  Nat Clin Pract Urol 4(6):310-320."
"2532","PC040341","Heras-Herzig A and Guise TA.  2008.  Disorders of calcium metabolism.  In: Therapy of Renal Diseases and Related Disorders.  Suki WN and Massry SG, Eds.  Kluwer Academic Publishers, Chapter 5, Fourth edition."
"2533","PC040341","Heras-Herzig A, Kozlow W, Brown S, et al.  2008.  Osteoporosis associated with cancer and cancer treatment.  In: Osteoporosis.  Marcus R, Feldman D, Nelson DA, et al, Eds.  Academic Press, Third Edition, Volume II, 54:1337-1374, Boston."
"2534","PC040341","Clines GA, Mohammad KS, Bao Y, et al.  2007.  Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation.  Mol Endocrinol 21(2):486-498."
"2535","PC040341","Guise TA, Mohammad KS, Clines G, et al.  2006.  Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.  Clin Cancer Res 12(20):6213s-6216s."
"2536","PC040341","Brown SA and Guise TA.  2009.  Cancer treatment-related bone disease.  Crit Rev Eukaryot Gene Expr 19(1):47-60."
"2537","PC040341","Guise TA.  2008.  Antitumor effects of bisphosphonates: Promising preclinical evidence.  Cancer Treat Rev 34S1:S19-S24."
"2538","PC040341","Mohammad KS, Chirgwin JM, and Guise TA.  2008.  Assessing new bone formation in neonatal calvarial organ cultures.  Methods Mol Biol 455:37-50."
"2539","PC040341","Seth P, Wang ZG, Pister A, et al.  2006.  Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy.  Hum Gene Ther 17(11):1152-1160."
"2540","PC040358","Song H, Hollstein M, Xu Y.  2007.  p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.  Nat Cell Biol 9:573-80."
"2541","PC040358","Song H and Xu Y.  2007.  Gain of function of p53 cancer mutants in disrupting critical DNA damage response pathways.  Cell Cycle 6:1570-1573."
"2542","PC040358","Xu Y. 2008. Induction of genetic instability by p53 cancer mutants.  Oncogene 27:3501-7."
"2543","PC040364","Wu J, Haugk K, Woodke L, et al.  2006.  Interaction of IGF signaling and the androgen receptor in prostate cancer progression.  J Cell Biochem 99:392-401."
"2544","PC040364","Wu J, Corey E, Haugk K, et al.  2006.  Targeting the type 1 insulin-like growth factor receptor with a monoclonal antibody enhances the activity of docetaxel against androgen-independent and osseous human prostate cancer in vivo.  Clinical Cancer Res 12:6153-6160."
"2545","PC040364","Xu C, Graf LF, Fazli L, et al.  2008.  Regulation of global gene expression in the bone marrow microenvironment by androgen: Androgen ablation increases insulin-like growth factor binding protein - 5 expression.  Prostate 67:1621-1629.

"
"2546","PC040364","Bentov I, Narla G, Schayek H, et al.  2008.  Insulinlike growth factor-1 regulates Kruppel-like factor-6 gene expression in a p53-dependent manner.  Endocrinology 149(4):1890-1897."
"2547","PC040364","Schayek H, Haugk K, Sun S, et al.  2009.  Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor-I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner.  Clin Cancer Res 15(5):1558-1565.  
"
"2548","PC040364","Sprenger CCT, Haugk K, Sun S, et al.  2009.  Transforming growth factor-beta-stimulated clone-22 (TSC-22) is an androgen regulated tumor suppressor gene in prostate cancer that enhances apoptosis when the insulin-like growth factor-1 receptor inhibition.  Clin Cancer Res 15(24):7634-7641."
"2549","PC040364","Xu C, Graf LF, Coleman I, et al.  2007.  Prostate regulation of global gene expression in the bone marrow microenvironment by androgen: Androgen ablation increases insulin-like growth factor binding protein-5 expression.  Prostate 67:1621-1629."
"2550","PC040366","Fukuda MN and Sugihara K.  2008.  An integrated view of L-selectin and trophinin function in human embryo implantation.  J Ob Gy Res 34:129-136."
"2551","PC040366","Fukuda MN, Sugihara K, and Nakayama J. 2008.  Trophinin: What embryo implantation teaches us about human cancer.  Cancer Bio Ther 7:1165."
"2552","PC040366","Kabir-Salmani M and Fukuda MN.  2008.  Cell adhesion molecules for uterine receptivity to human embryo implantation.  In: New Cell Adhesion Research.  Columbus F, Ed."
"2553","PC040366","Hatakeyama S, Sugihara K, Lee S-H, et al.  2008.  Enhancement of human sperm motility by trophinin-binding peptide.  J Urology 180:767-771."
"2554","PC040366","Fukuda MN, Miyoshi M, and Nadano D.  2008.  The role of bystin in embryo implantation and in ribosomal biogenesis.  Cell Mol Life Sci 65:92-99."
"2555","PC040366","Kabir-Salmani K, Fukuda MN, Kanai-Azuma M, et al.  2008.  The membrane-spanning domain of CD98hc promotes avb3 integrin signals in human extravillous trophoblasts.  Mol Endocrin 22:707-715."
"2556","PC040366","Yang S, Liu X, Yin Y, et al.  2008.  Tastin is required for bipolar spindle assembly and centrosome integrity during mitosis.  FASEB J 22:1960-1972."
"2557","PC040366","Aoki R, Suzuki N, Paria BC, et al.  2006.  The bysl gene product, bystin, is essential for survival of mouse embryos.  FEBS Lett 580:6062-6068."
"2558","PC040366","Sugihara K, Kabir-Salmani M, Byrne J, et al.  2008.  Induction of trophinin in human endometrial surface epithelia by CGb and IL-1b.  FEBS Lett 582:197-202."
"2559","PC040366","Aoyama J, Akazawa Y, Kasahara K, et al.  2008.  Nuclear localization of magphinins, alternative splicing products of the human trophinin gene.  J Cell Biochem 103:765-77."
"2560","PC040366","Baba T, Mori S, Matsumura N, et al.  2007.  Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity.  Biochem Biophys Res Commun 360:363-369."
"2561","PC040366","Tamura N1, Sugihara K, Akama TO, et al.  2011.  Trophinin-mediated cell adhesion induces apoptosis of human endometrial epithelial cells through PKC-delta.  Cell Cycle 10(1):135-143."
"2562","PC040366","Harada O, Suga T, Suzuki T, et al.  2007.  The role of trophinin, an adhesion molecule unique to human trophoblasts, in progression of colorectal cancer.  Int J Cancer 121:1072-1078."
"2563","PC040366","Fukuda MN and Sugihara K.  2007.  Signal transduction in human embryo implantation.  Cell Cycle 6:1153-1156."
"2564","PC040366","Sugihara K, Sugiyama D, Byrne J, et al.  2007.  Trophoblastic cell activation by trophinin ligation is implicated in human embryo implantation.  Proc Natl Acad Sci USA 104:3799-3804."
"2565","PC040366","Aoyama J, Nakayama Y, Sugiyama D, et al.  2005.  Apical cell adhesion molecule, trophinin, localizes to the nuclear envelope.  FEBS Lett, 579:6326-32.
"
"2566","PC040366","Miyoshi M, Okajima T, Matsuda T, et al.  2007.  Bystin in human cancer cells: Intracellular localization and function in ribosome biogenesis.  Biochem J 404:373-381."
"2567","PC040371","Keating GA, Bogen K, Chan J.  2007.  Development of a meat frequency questionnaire for use in diet and cancer studies.  J Am Diet Assoc (in press).  107:1356-62."
"2568","PC040371","Louis ED, Zheng W, Jiang W, et al.  2007.  Quantification of the neurotoxic beta-carboline harmane in barbecued/grilled meat samples and correlation with level of doneness.  J Toxicol Environ Health A 70:1014-9."
"2569","PC040371","Bogen KT.  2006.  PSA-based screening outcomes, dietary heterocyclic amine exposure, and prostate cancer risk in African Americans:  Annual Report (Year 1 of 3).  UCRL-TR-218258. Lawrence Livermore National Laboratory, Livermore, California."
"2570","PC040371","Bogen KT, Keating II GA, Chan JM, et al.  2007.  Highly elevated PSA and dietary PhIP intake in a prospective clinic-based study among African Americans.  Prostate Cancer Prostatic Dis 10:261-9."
"2571","PC040371","Louis ED, Keating GA, Bogen KT, et al.  2008.  Dietary epidemiology of essential tremor: Meat consumption and meat cooking practices.  Neuroepidemiology 30(3):161."
"2572","PC040371","Bogen KT, Keating GA II, Chan JM, et al.  2007.  Highly elevated PSA and dietary PhIP intake in a prospective clinic-based study among African Americans.  Prostate Cancer and Prostatic Diseases 1-9."
"2573","PC040372","Rai R and Kashina A.  2005.  Identification of mammalian arginine transferases that modify a specific subset of protein substrates.  Proc Natl Acad Sci USA 102:10123-10128."
"2574","PC040372","Sorokina I and Kashina A.  2005.  Archived gels as a tool for identification of protein complexes: POLO kinase cofractionates with Drosophila 205 kDa MAP and ncd in mitotic embryonic extracts.  Anal Biochem 344:55-157.

"
"2575","PC040372","Karakozova M, Kozak M, Wong CCL, et al.  2006.  Arginylation of beta actin regulates actin cytoskeleton and cell motility.  Sci 313:192-196."
"2576","PC040372","Rai R, Mushegian A, Makarova K, Kashina A, et al.  2006.  Molecular dissection of arginyltransferase guided by similarity to bacteria peptidoglycan synthases.  EMBO Rep. 7,8 800-805."
"2577","PC040372","Kashina AS.  2006.  Differential arginylation of actin isoforms: The mystery of the actin N-terminus.  Trends Cell Biol 16:610-5."
"2578","PC040372","Wong CLC,  Xu T,  Rai R, et al.  2007.  Global analysis of posttranslational protein arginylation. PLoS Biol 5:e258."
"2579","PC040380","Robins DM, Albertelli MA, and O¿Mahony OA.  2008.  Androgen receptor variants and prostate cancer in humanized AR mice.  J Steroid Biochem Mol Biol 108:230-236."
"2580","PC040380","Albertelli MA, O¿Mahony OA, Brogley M, et al.  2008.  Glutamine tract length of human androgen receptors affects hormone dependent and independent prostate cancer in mice.  Hum Mol Genet 17: 98-110."
"2581","PC040393","Burstein E, Hoberg JE, Wilkinson AS, et al.  2005.  COMMD proteins:  A novel family of structural and functional homologs of MURR1.  J Biol Chem 280:22222-22232."
"2582","PC040413","Powell M, Lisanti M, Nevalainen MT, et al.  2008.  Androgen receptor epigenetic modification and acetylation regulate prostate cellular growth.  In: Prostate Cancer: Signaling Networks, Genetics and New Treatment Strategies (Nevalainen MT and Pestell R, Eds.).  Springer Humana Press, New York."
"2583","PC040413","Tan S and Nevalainen MT.  2008.  Transcription factor Stat5 in breast and prostate cancer. Endocr Relat Cancer 15:367-390."
"2584","PC040413","Dagvadorj A, Kirken RA, Karras J, et al.  2008.  Transcription factor Stat5 promotes growth of human prostate cancer cells in vivo.  Clin Cancer Res 14:1317-1324 (featured article)."
"2585","PC040413","Culig Z, Pestell RP, and Nevalainen M.  2008.  Transcription factors Stat5 and Stat3: Key survival factors for prostate cancer cells.  In: Prostate Cancer: Signaling Networks, Genetics and New Treatment Strategies (Nevalainen MT and Pestell R, Eds.).  Springer Humana Press, New York."
"2586","PC040413","Nevalainen M and Culig Z.  2007.  Transcription factors Stat5 and Stat3: Key survival factors for prostate cancer cells.  In: Prostate Cancer:  Signaling Networks, Genetics and New Treatment Strategies (Nevalainen MT and Pestell R, Eds) Humana Press."
"2587","PC040413","Li H, Zhang Y, Glass A, et al.  2005.  Activation of signal transducer and activator of transcription-5 (Stat5) in prostate cancer predicts early recurrence.  Clin Cancer Res 11:5863-5868."
"2588","PC040413","Powell M, Lisanti M, Nevalainen MT, et al.  2007.  Androgen receptor epigenetic modification and acetylation regulate prostate cellular growth.  In:  Prostate cancer: Signaling networks, genetics and new treatment strategies (Nevalainen MT and Pestell R, Eds) Humana Press."
"2589","PC040413","Li H, Ahonen TJ, Alanen K, et al.  2004.  Activation of signal transducer and activator of transcription 5 (Stat5) in human prostate cancer is associated with high histological grade. Cancer Res 64:4774-4782."
"2590","PC040413","Popov VM, Wang C, Shirley LA, et al.  2007.  The functional significance of nuclear receptor acetylation.  Steroids 72:221-230."
"2591","PC040413","LeBaron MJ, Ahonen TJ, Nevalainen MT, et al.  2007.  In vivo response-based identification of direct hormone target cell populations using high-density tissue arrays.  Endocrinology 148:989-1008."
"2592","PC040413","Tan S-H, Dagvadorj A, Shen F, et al.  2008.  Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells.  Cancer Res 68:1-13."
"2593","PC040413","Dagvadorj A, Collins S, Jomain, J, et al.  2007.  Autocrine prolactin promotes prostate cancer cell growth via Jak2-Stat5 signaling pathway.  Endocrinology 148:3089-3101."
"2594","PC040420","Swami S, Krishnan AV, Peehl DM, et al.  2005.  Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: Role of the direct inhibition of CYP24 enzyme activity.  Mol Cell Endocrin 241:49-61."
"2595","PC040420","Vaday GG, Peehl DM, Kadam PA, et al.  2006.  Expression of CCL5 (RANTES) and CCR5 in prostate cancer.  Prostate 66:124-134."
"2596","PC040420","Chen N, Szentirmay MN, Pawar SA, et al.  2006.  Tumor suppression function of transcription factor USF2 in prostate carcinogenesis.  Oncogene 25:579-587."
"2597","PC040420","Bauman DR, Steckelbroeck S, Williams MV, et al.  2006.  Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha, 17beta-diol to 5alpha-dihydrotestosterone: A potential therapeutic target for androgen dependent disease.  Mol Endocrin 20:444-458."
"2598","PC040420","San Francisco IF, DeWolf WC, Peehl DM, et al.  2004.  Expression of transforming growth factor beta1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts.  Int J Cancer 112:213-218."
"2599","PC040420","iviharju-af Hällström TM, Jäämaa S, Mönkkönen M, et al. 2007. Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc Natl Acad Sci U S A 104:7211¿7216.
"
"2600","PC040420","Khanim FL, Gommersall LM, Wood VHJ, et al.  2004.  Altered SMRT levels disrupt vitamin D3 receptor signaling in prostate cancer cells.  Oncogene 23:6712-6725."
"2601","PC040420","Vaday GG, Hua SB, Peehl DM, et al.  2004.  CXCR4 and CXCL12 (SDF-1) in prostate cancer: Inhibitory effects of human single chain Fv antibodies.  Clin Cancer Res 10:5630-5639."
"2602","PC040420","Moreno J, Krishan AV, Swami S, et al., 2005.  Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells.  Cancer Res 65:7917-7925."
"2603","PC040420","Penning TM, Steckelbroeck S, Bauman DR, et al.  2006.  Aldo-keto reductase (AKR) 1C3: Role in prostate disease and the development of specific inhibitors.  Mol Cell Endocrin 248:182-191."
"2604","PC040420","Gommersall LM, Khanim FL, Peehl DM, et al.  2004.  Epigenetic repression of transcription, by the vitamin D3 receptor in prostate cancer cells.  J Biochem Mol Biol 89-90:251-256."
"2605","PC040425","Jason Reed, BudMishra, Bede Pittenger, et al.  2007.  Single molecule transcription profiling with AFM.  Nanotechnology 18:044032 (15pp)."
"2606","PC040425","Iuliana Ionita, Raoul-Sam Daruwala, and Bud Mishra.  2006. Mapping Tumor-Suppressor Genes with Multipoint Statistics from Copy-Number¿Variation Data.  Am. J. Hum. Genet. 2006;79:13¿22."
"2607","PC040429","Wang X, Julio MK, Economides KD, et al. 2009. A luminal epithelial stem cell that is a cell of origin for prostate cancer.   Nature 461(7263):495-500."
"2608","PC040435","Vavere AL, Kridel SJ, Wheeler FB, et al.2008.  1-11C-Acetate as a PET Radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer.  J Nucl Med 49:327-334."
"2609","PC040435","Vavere AL, Lewis JS.  2005.  Correlation of [1-11C] acetate uptake to fatty acid synthase expression in prostate tumors.  J Label Compd Radiopharm 48:S1-S341."
"2610","PC040436","Hall CL, Dubyk CW, Riesenberger TA, et al.  2008.  Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase.  Neoplasia 10:797-803."
"2611","PC040436","Sequeira L, Dubyk CW, Riesenberger TA, et al.  2008.  Rho GTPases in PC-3 prostate cancer cell morphology, invasion and tumor cell diapedesis.  Clin Exp Metastasis 25:569-579.

"
"2612","PC040452","Qunying L, Jiao J, Xin L, et al.  2006.  NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss.   Cancer Cell 9(5):367-378."
"2613","PC040455","Han B, Xie H, Chen Q, et al.  2006.  Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3sigma&#61486;  Mol Cancer Therap 5:903-912."
"2614","PC040458","Roy Chowdhury SK, Gemin A, and Singh G.  2005.  High activity of mitochondrial glycerophosphate dehydrogenase and glycerophosphate-dependent ROS production in prostate cancer lines.  Biochem Biophys Res Commun 333:1139-1145."
"2615","PC040460","Williams K, Fernandez S, Stien X, et al.  2005.  Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype. Prostate 63:369-384."
"2616","PC040460","Jin RJ, Lho Y, Wang Y, et al.  2008.  Down regulation of p57Kip2 induces prostate cancer in the mouse.  Cancer Res 68:3601-3608."
"2617","PC040484","Smith DJ, M Jaggi, W Zhang, et al.  2006.  Metallothioneins and resistance to cisplatin and radiation in prostate cancer.  Urology 67(6):1341-47."
"2618","PC040484","Narassa N and Balaji K.  2008.  Metallothioneins and prostate cancer: Metallothioneins in biochemistry and pathology.  World Scientific Publishing Company, Singapore."
"2619","PC040486","Wang J, Cai Y, Penland R, et al.  2006.  Increased expression of the metastasis-associated gene Ehm2 in prostate cancer.  The Prostate 66:1641-1652."
"2620","PC040493","Mimeault M, Venkatraman G, Johansson SL, et al.  2006.  Novel combination therapy against metastatic and androgen-independent prostate cancer by using a combination of gefitinib, tamoxifen and etoposide.  Int J Cancer 120:160-9."
"2621","PC040493","Mimeault M, Moore E, Moniaux N, et al.  2006.  Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells.  Int J Cancer 118:1022-1031."
"2622","PC040493","Mimeault M, Batra SK. Functions of tumorigenic and migrating cancer progenitor cells in cancer progression and metastasis and their therapeutic implications.Cancer Metastasis Rev. 2007 Mar;26(1):203-14. Review."
"2623","PC040493","Mimeault M, Moore E, Moniaux N, et al.  2005.  Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors in prostate cancer cells.  Intl J Cancer Aug 17; (EPub ahead of print) PMID:16195239."
"2624","PC040493","Mimeault M and Batra SK.  2006.  Recent advance on the significance of stem cells in tissue regeneration and cancer therapies.  Stem Cells 24:2319-2345."
"2625","PC040493","Mimeault M, Johansson SL, Vankatraman G, Moore E, Henichart JP, Depreux P, Lin MF, Batra SK. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.Mol Cancer Ther. 2007 Mar;6(3):967-78."
"2626","PC040493","Mimeault M, Venkatraman G, Johansson SL, Moore E, Henichart JP, Depreux P, Lin MF, Batra SK. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.Int J Cancer. 2007 Jan 1;120(1):160-9."
"2627","PC040493","Mimeault M and Batra SK.  2006.  Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies.  Carcinogenesis 27:1-22.

"
"2628","PC040499","Chen SY, Wulf G, Zhou XZ, et al.  Activation of beta-catenin signaling in prostate cancer by peptidyl-prolyl isomerase Pin1-mediated abrogation of the androgen receptor-beta-catenin interaction.  Mol Cell Biol 26:929-39."
"2629","PC040500","Yang J, Wei S, Wang D-S, et al.  2008.  Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents.  J Med Chem 51:2100-7.
"
"2630","PC040500","Wei S, Lin L-F, Yang C-C, et al.  2007.  Thiazolidineiones modulate the expression of beta-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of SCF E3 ubiquitin ligase independently of PPARgamma.  Mol Pharmacol 72:725-733."
"2631","PC040500","Garrison JB, Shaw YJ, Chen CS, et al. 2007. Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity. Cancer Res 67(23):11344-11352."
"2632","PC040500","Weng JR, Chen CDY, Pinzone JJ, et al.  2006.  Beyond peroxisome proliferator-activated receptor gamma signaling: The multi-facets of the antitumor effect of thiazolidinediones. Endocr Relat Cancer 13:401-13."
"2633","PC040500","Chen CS, Yang C-C, Wang Y-C, Wei S, et al.  2007.  Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res 67:5318-27."
"2634","PC040500","Shiau C-W, Huang J-W, Wang D-S, et al.  2006.  &#61537;-Tocopheryl succinate induces apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 function.  J Biol Chem 281:11819-11825."
"2635","PC040500","Huang J-W, Shiau C-W, Yang Y-T, et al.  2005.  Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidenediones and their derivatives in breast cancer cells.  Mol Pharmacol 67:1342-1348."
"2636","PC040500","Yang C-C, Wang Y-C, Wei S, et al.  2007.  Peroxisome Proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone: Mechanism and pharmacological exploitation.  Cancer Res 67:3229-3238."
"2637","PC040502","Senapati S, Singh AP, and Batra SK.  2008.  GDF15 (growth differentiation factor 15).  Atlas Genet Cytogenet Oncol Haematol.  http://AtlasGeneticsOncology.org/Genes/GDF15ID40701ch19p13.html"
"2638","PC040502","Singh AP, Bafna S, Chaudhary K, et al.  2008.  Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells.  Cancer Lett 259(1):28-38."
"2639","PC040502","Mimeault M, Mehta PP, Hauke R, et al.  2008.  Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies.  Endocrine Reviews 29(2):234-252."
"2640","PC040502","Singh AP, Chauhan SC, Bafna S, et al.  2005.  Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas.  Prostate 

"
"2641","PC040502","Mimeault M and Batra SK.  2005.  Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies.  Carcinogenesis"
"2642","PC040502","Mimeault M and Batra SK.  2006.  Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies.  Carcinog 27:1-22."
"2643","PC040502","Singh AP, Chauhan SC, Bafna S, et al.  2006.  Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas.  Prostate 66:421-429."
"2644","PC040502","Mimeault M and Batra SK.  2006.  Recent advances on the functions of stem cells in tissue regeneration and cancer therapy.  Stem Cells 24(11):2319-2345."
"2645","PC040502","Chen SJ, Karan D, Johansson SL, et al.  2007.  Prostate-derived factor as a paracrine and autocrine factor for the proliferation of androgen receptor-positive human prostate cancer cells. Prostate 67:557-71.
"
"2646","PC040502","Mimeault M, Moore E, Moniaux N, et al.  2006.  Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells. Intl J Cancer 118(4):1022-1031."
"2647","PC040502","Mimeault M, Venkatraman G, Johansson S, et al.  2007.  Novel combination therapy against metastatic and androgen-independent prostate cancer by using a combination of gefitinib, tamoxifen and etoposide. Intl J Cancer 120(1):160-169."
"2648","PC040502","Mimeault M. and Batra SK.  2007.  Functions of tumorigenic and migrating cancer progenitor cells in cancer progression and metastasis and their therapeutic implications.  Cancer Metastasis Reviews 26: 203-214,"
"2649","PC040502","Mimeault M and Batra SK.  2007.  Interplay of distinct growth factors during epithelialmesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies.  Ann Oncol 18(10):1605-19.

"
"2650","PC040502","Mimeault M, Hauke R and Batra S.  2007.  K A Stem cells -- A revolution in therapeutics. Clinical Pharmacology and Therapeutics 82(3)252-264."
"2651","PC040502","Mimeault M, Hauke R, Mehta PP, et al.  2007.  Recent advances in cancer stem/progenitor cell research:  Therapeutic implications for overcoming resistance to the most aggressive cancers.  Journal Cell Mol Med 11981-1011."
"2652","PC040506","Wagner M, Loos J, Weksler N, et al.  2005.  Resistance of prostate cancer cell lines to COX-2 inhibitor treatment.  Biochem Biophys Res Commun 332(3):800-807."
"2653","PC040517","Mehra R, Tomlins SA, Shen R, et al.  2007.  Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.  Mod Pathol 20(5):538-544."
"2654","PC040517","Yu J, Yu J, Rhodes DR, et al.  2007.  A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.  Cancer Res 67:(22)."
"2655","PC040517","Mehra R, Tomlins SA, Yu J, et al.  2008.  Characterization of TMPRSS2-ETS gene aberrations in Androgen-independent metastatic prostate cancer.  Cancer Res. 68(10):3584-3590."
"2656","PC040517","Yu J, Cao Q, Mehra R, et al.  2007.  Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer.  Cancer Cell 12(5):419-431."
"2657","PC040517","Mehra R, Han B, Tomlins SA, et al.  2007.  Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma:  Molecular evidence for an independent group of diseases.  Cancer Res 67(17):7991-7995.

"
"2658","PC040517","Kim JH, Dhanasekaran SM, Mehra R, et al.  2007.  Integrative analysis of genomic aberrations associated with prostate cancer progression.  Cancer Res 67(17):8229-8239."
"2659","PC040517","Tomlins SA, Mehra R, Rhodes DR, et al.  2007.  Integrative molecular concept modeling of prostate cancer progression.  Nat Genet 39(1):41-51."
"2660","PC040517","Yu J, Rhodes DR, Tomlins SA, et al.  2007.  A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.  Cancer Res 67(22):10657-10663."
"2661","PC040517","Helgeson BE, Tomlins SA, Shah N, et al.  2008.  Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.  Cancer Res 68(1):73-80."
"2662","PC040517","Laxman B, Morris DS, Yu J, et al.  2008.  A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.  Cancer Res 68(3):645-649.

"
"2663","PC040517","Tomlins SA, Laxman B, Varambally S, et al.  2008.  Role of the TMPRSS2-ERG gene fusion in prostate cancer.  Neoplasia 10(2):177-188."
"2664","PC040517","Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005 Oct 28;310(5748):644-8.
"
"2665","PC040517","Laxman B, Tomlins SA, Mehra R, et al.  2006.  Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.  Neoplasia 8(10):885-888."
"2666","PC040517","Morris DS, Tomlins SA, Rhodes DR, et al.  2007.  Integrating biomedical knowledge to model pathways of prostate cancer progression.  Cell Cycle 6(10):1177-1187."
"2667","PC040517","Tomlins SA, Laxman B, Dhanasekaran SM, et al.  2007.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.  Nature 2:448(7153):595-599."
"2668","PC040520","Zhu P, Baek SH, Ohgi KA, et al.  2006.  Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway.  Cell 124(3):615-629."
"2669","PC040520","Baek SH, Ohgi KA, Nelson CA, et al.  2006.  Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells.  Proc National Academy of Science, USA 11:04-51."
"2670","PC040520","Zhou W, Zhu P, Wang J, et al.  2007.  Histone H2A monoubiquitination represses transcription by inhibiting RNA polymerase II transcriptional elongation.  Mol Cell 27:609-621."
"2671","PC040520","Kim J-H, Kim B, Cai L, et al.  2005.  Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes.  Nature 434:921-926."
"2672","PC040520","Perissi V, Scafoglio C, Zhang J, et al.  2008.  TBL1 and TBLR1 phosphorylation on regulated gene promoters overcomes a dual CtBP and NCoR.SMRT transcription repression checkpoint.  Mol Cell 29:755-66."
"2673","PC040545","Heaphy CM, Hines WC, Butler KS, et al.  2007.  Assessment of the frequency of allelic imbalance in human tissue using a multiplex polymerase chain reaction system.  J Mol Diagn 9:266-71."
"2674","PC040568","Zhang Z, Wang H, Li M, et al.  2005.  Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway.  Oncogene 48:7238-47."
"2675","PC040568","Zhang Z and Zhang R.  2005.  Activities of MDM2 and their relevance to cancer therapy.  Curr Cancer Drug Targets 5:9-20."
"2676","PC040568","Zhang Z, Li M, Rayburn ER, et al.  2005.  Oncogenes as novel targets for cancer therapy (Part I): Growth factors and protein tyrosine kinases.  Am J Pharmacogenomics 5:173-190."
"2677","PC040568","Zhang Z, Li M, Rayburn ER, et al.  2005.  Oncogenes as novel targets for cancer therapy (Part II): Intermediate signaling molecules.  Am J Pharmacogenomics 5:247-257."
"2678","PC040568","Zhang Z, Li M, Rayburn ER, et al.  2005.  Oncogenes as novel targets for cancer therapy (Part III): Transcription factors.  Am J Pharmacogenomics 5:327-338."
"2679","PC040568","Zhang Z, Li M, Rayburn ER, et al.  2005.  Oncogenes as novel targets for cancer therapy (Part IV): Regulators of the cell cycle, DNA damage repair and apoptosis.  Am J Pharmacogenomics (in press)."
"2680","PC040568","Zhang Z, Wang H, Li M, et al.  2005.  Novel MDM2 p53-independent functions identified through RNA silencing technologies.  
Ann N Y Acad Sci 1058:205-14.
"
"2681","PC040568","Li M, Zhang Z, Hill D, et al.  2005.  Genistein, a diet isoflavone, down-regulates the MDM2 oncogene at both transcriptional and post-translational levels.  Cancer Res 65:8200-8208."
"2682","PC040568","Rayburn ER, Wang W, Zhang Z, et al.  2006.  Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation and potentiation of chemotherapy.  Prostate 66(15):1653-1663."
"2683","PC040568","Li M, Zhang Z, Hill DL, Wang H, Zhang R. 2007.  Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 67:1988-1996."
"2684","PC040568","Zhang Z, Zhang R.  2008.  Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBO J. 27(6):852-64. Epub 2008 Feb 28."
"2685","PC040569","Wang T, Chen YH, Zeng Y, et al.  2009.  Increased nucleotide polymorphic changes in the 5'-untranslated region of delta-catenin (CTNND2) gene in prostate cancer.  Oncogene 28:555-64."
"2686","PC040569","Lu Q, Dobbs LJ, Christopher WG, et al.  2005.  Increased expression of delta-catenin/neural plakophilin-related armadillo protein (NPRAP) is associated with the downregulation and redistribution of Ecadherin and p120ctn in human prostate cancer.  Human Pathology 36:cover illustration."
"2687","PC040569","Kim K, Oh M, Ki H, et al.  2008.  Identification of E2F1 as a positive transcriptional regulator for delta-catenin.  Biochem Biophys Res Commun 369(2):414-420."
"2688","PC040569","Bareiss SK and Lu Q.  2008.  Delta-catenin: A new member of the GSK-3b signaling complex that promotes beta-catenin turnover.  FASEB J 22:lb25."
"2689","PC040569","Lu Q, Dobbs LJ, Christopher WG, et al.  2005.  Increased expression of delta-catenin/neural plakophilin-related armadillo protein (NPRAP) is associated with the downregulation and redistribution of E-cadherin and p120ctn in human prostate cancer.  Human Pathology 36:1037-1048.

"
"2690","PC040570","Li J, Wang E, Rinaldo F, et al.  2005.  Up-regulation of VEGF-C by androgen depletion: The involvement of ICF-IR-FOXO pathway.  Oncogene 24(35):5510-5520."
"2691","PC040570","Rinaldo F, Li J, Wang E, et al.  2007.  RalA regulates vascular endothelial growth factor-C (VEGF-C) synthesis in prostate cancer cell during androgen ablation.  Oncogene 26:1731-8."
"2692","PC040578","Zhang H, Wang J, Pang B, et al.  2007.  PC-1/PrLZ contributes to malignant progression in prostate cancer.  Cancer Res 67:8906-8913.

"
"2693","PC040578","Wang RX, Xu JC, Mabjeesh N, et al.  2007.  PrLZ is expressed in normal prostate development and in human prostate cancer progression.  Clin Cancer Res 13:6040-6048."
"2694","PC040587","Veeramani S, Igawa T, Yuan TC, et al.  2005.  Expression of p66Shc protein correlates with proliferation of human prostate cancer cells.  Oncogene 24:7203-7212."
"2695","PC040607","Fukushima T, Zapata JM, Singha NC, et al.  2006.  Critical function for SIP, a ubiquitin E3ligase component of the beta-catenin degradation pathway, for thymocyte development and G1 checkpoint.  Immunity 24:29-39.

"
"2696","PC040616","Nonn L, Duong DT, and Peehl DM. 2007.  Chemopreventive anti-inflammatory properties of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells.  Carcinogenesis 28:1188-96."
"2697","PC040616","Moreno J, Krishan AV, Swami S, et al.  2005.  Regulation of prostaglandin metabolism by calcitriol (vitamin D) attenuates growth stimulation in prostate cancer cells. Cancer Res 65(17):7917-7925."
"2698","PC040616","Ma J, Nonn L, Campbell M, et al.  2004.  Mechanisms of decreased vitamin D 1-alpha-hydroxylase activity in prostate cancer cells.  Mol Cell Endocrinology 221:67-74."
"2699","PC040616","Peehl DM, Shighal R, Nonn L, et al.  2004.  Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis.  J Steroid Biochem Mol Bio 92:131-141."
"2700","PC040616","Husbeck B, Nonn L, Peehl DM, et al.  2006.  Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells.  Prostate 66:218-225."
"2701","PC040616","Krishnan AV, Moreno J, Nonn L, et al.  2007.  Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer.  J Steroid Biochem Mol Biol 103:694-702."
"2702","PC040616","Nonn L, Peng LH, Feldman D, et al.  2006.  Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via MAP kinase phosphatase 5: Implications for prostate cancer prevention by vitamin D.  Cancer Res 66:4516-4524."
"2703","PC040619","Hill R, Song Y, Cardiff RD, et al.  2005.  Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model.  Cancer Res 65(22):10243-10254."
"2704","PC040619","Hill R, Song Y, Cardiff RD, et al.  2005.  Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis.  Cell 123(6):1-11."
"2705","PC040626","Forootan SS, Foster CS, Aachi VR, et al.  2005.  Prognostic significance of osteopontin expression in human prostate cancer.  Int J Cancer"
"2706","PC040630","Lee Y-F, Cai Y, Li G, et al.  2008.  A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.  Int J Cancer 123(1):195-201."
"2707","PC040630","Ting HJ, Hsu J, Bao BY.  2007.  Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1alpha,25-dihydroxyvitamin D(3).  Cancer Lett 247:122-129 (Epub 2006)."
"2708","PC040630","Ting H-J, Bao B-Y, and Lee Y-F.  2005.  Androgen receptor coregulators mediate the suppressive effect of androgen signals on vitamin D receptor activity.  Endocrine 26:1-10."
"2709","PC040630","Bao B-Y, Yeh S-D, and Lee Y-F.  2006.  1alpha, 25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective protease.  Carcinogenesis 27:32-42."
"2710","PC040635","Holder SL, Lilly MB, and Brown ML. 2007. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.  Bioorg Med Chem 15:6463-73."
"2711","PC040635","Zemskova M, Sahakian E, Bashkirova S, et al.  2008.  The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells.  J Biol Chem 283(30):20635-20644."
"2712","PC040635","Holder SL, Lilly MB, and Brown ML.  2007.  Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 Kinase.  Bioorg Med Chem 15:6463-73."
"2713","PC040635","Holder SL, Zemskova M, Bremmer R, et al.  2007.  Identification of specific, cell-permeable small molecule inhibitor of the PIM1 kinase.  Mol Cancer Therapeutics 6:163-72."
"2714","PC040638","Beroukhim R, Lin M, Park Y, et al.  2006.  Inferring loss-of-heterozygosity from unpaired tumors using high-density oliogonucleotide SNP arrays.  PLoS Comput Biol 2:e41."
"2715","PC040638","Perner S, Demichelis F, Beroukhim R, et al.  2006.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.  Cancer Res 66:8337."
"2716","PC040641","Cariveau M, Tang J, Cui X, et al.  2007.  Conserved NBS1 C-terminal small peptides can inhibit the ATM-mediated DNA damage response and enhance radiation sensitivity.  Mol Pharmacol 72: 320-326."
"2717","PC040641","Tang X, Hui Z-G, Cui X-L, et al.  2008.  A novel ATM-dependent pathway regulates Protein Phosphatase 1 and histone H3 phosphorylation in response to DNA damage.  Mol Cell Biol 28:2559-2566."
"2718","PC040641","Gasior SL, Wakeman T, Xu B, et al.  2006.  The human LINE-1 retrotransposon creates DNA DSBs.  J Mol Biol 357(5):1383-1393."
"2719","PC040655","HONGJUAN ZHAO, CRISTIANE F. RAMOS, JAMES D. BROOKS,
DONNA M. PEEHL.  2007.  Distinctive Gene Expression of Prostatic Stromal Cells Cultured From Diseased Versus Normal Tissues.  J CELL PHYSIOL 210:111¿121."
"2720","PC040655","David R. Bauman, Stephan Steckelbroeck, Donna M. Peehl, Trevor M. Penning.  2006.  Transcript Profiling of the Androgen Signal in Normal Prostate, Benign Prostatic Hyperplasia, and
Prostate Cancer.  Endocrinology 147(12):5806¿5816."
"2721","PC040684","Chandra D, Choy G, Deng X, et al.  2004.  Association of active caspase 8 with the mitochondrial membrane during apoptosis: Potential roles in cleaving BAP31 and caspase 3 and mediating mitochondrion-endoplasmic reticulum cross talk in etoposide-induced cell death.  Mol Cell Biol 24:6592-6607."
"2722","PC040684","Chandra D, Choy G, Daniel PT, et al.  2005.  Bax-dependent regulation of Bak by voltage-dependent anoin channel 2.  J Biol Chem 280:19051-19061."
"2723","PC040684","Choy G, Li JW, Chandra D, et al.  2005.  Cell survival signaling during apoptosis: implications in drug resistance and anti-cancer therapeutic development.  Prog Drug Res 63:116-145."
"2724","PC040685","Yao V and Bacich DJ.  2006.  Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro.  Prostate 66:867-875."
"2725","PC040685","Yao V et al 2008. Moderate Expression of Prostate-Specific Membrane Antigen, a Tissue Differentiation Antigen and Folate Hydrolase, Facilitates Prostate Carcinogenesis. Cancer Res 68(21):9070-7."
"2726","PC040685","Yao V, Berkman CE, Choi JK, et al.  2010.  Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate 70(3):305-316."
"2727","PC040697","Mattie MD, Benz CC, Bowers J, et al.  2006.  Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies.  Mol Cancer 5:24. 
"
"2728","PC040715","Beroukhim R, Getz G, Nghiemphu L, et al.  2007.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma.  Proc Natl Acad Sci USA 104:20007-20012."
"2729","PC040715","Demichelis F, Setlur SR, Beroukhim R, et al.  2009.  Distinct genomic aberrations associated with ERG rearranged prostate cancer.  Genes Chromosomes Cancer 48(4):366-380."
"2730","PC040735","Taylor TR, Makambi K, Sween J, et al. 2011. The effect of a supervised exercise trial on exercise adherence among African American Men: a pilot study. J Natl Med Assoc 103(6):488-91."
"2731","PC040737","Fenton BM and SF Paoni.  2007.  The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature.  Cancer Res 67(20):9921-8."
"2732","PC040737","Conover D, Ning R, Paoni S, et al.  2006.  Proceedings of SPIE 6143: 61433G1-6, Cone beam computer tomography angiogenesis imaging: Preliminary studies."
"2733","PC040737","Fenton BM and SF Paoni. 2009. Alterations in daily sequencing of axitinib and fractionated radiotherapy do not affect tumor growth inhibition or pathophysiological response. Radiat Res 171(5):606-14."
"2734","PC040747","Dunn T, Chen S, Faith D, et al.  2006.  A novel role of myosin VI in human prostate cancer.  Am J Pathol 169:1843-54.

"
"2735","PC040758","Goodman OB Jr, Febbraio M, Simantov R, et al.  2006.  Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2.  J Biol Chem 281:33597-33605. 

"
"2736","PC040758","Horiguchi A, Chen DY, Goodman OB Jr, et al.  2008.  Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis.  Prostate Cancer Prostatic Dis 11(1):79-87."
"2737","PC040768","Andersen RJ, Mawji NR, Wang J, et al. 2010. Regression of castrate-recurrent prostate cancer by a small molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell, 10: 535-546."
"2738","PC040777","Kofoed EM, Guerbadot M, Schaufele F. 2008.  
Dimerization between aequorea fluorescent proteins does not affect interaction between tagged estrogen receptors in living cells.  J Biomed Opt. 13(3):031207."
"2739","PC040777","Schaufele F, Carbonell X, Guerbadot M, et al.  2005.  The structural basis of androgen receptor activation: intramolecular and intermolecular amino¿carboxy interactions.  Proc Natl Acad Sci USA, 102:9802-9807."
"2740","PC040777","Kofoed EM, Guerbadot M, Schaufele F. 2010.  Structure, affinity, and availability of estrogen receptor complexes in the cellular environment. J Biol Chem 285(4):2428-2437."
"2741","PC040780","Landers KA, Samaratunga H, Teng L, et al.  2008.  Identification of metastatic markers for prostate cancer.  BJ Cancer 99:491-501."
"2742","PC040790","Sobol P, Mossman KL.  2006.  ICPO prevents RNase L-independent rRNA cleavage in herpes simplex virus type 1-infected cells.  J Virol 80(1):218-225."
"2743","PC040796","Latini DM, Hart SL, Knight SJ, et al.  2006.  Cancer anxiety predicts time to active treatment for men with localized prostate cancer on active surveillance: Data from CaPSUREâ¿¢.  Ann Behav Med 31:C132."
"2744","PC040796","Latini DM, Hart SL, Knight SJ, et al. 2007.  The relationship between anxiety and time to treatment for prostate cancer patients on surveillance.  J Urol 178:821-827."
"2745","PC040802","Shankar S, and Srivastava RK.  2007.  Involvement of Bcl-2 family memebers, phosphatidylinositol 3¿-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer.  Int J Oncol 30:905-918."
"2746","PC040802","Shankar S, and Srivastava RK.  2007.  Bax and bax genes are essential for maximum apoptotic response by curcumin (diferulolylmethane), a polyphenolic compound and cancer chemopreventive agent derived from turmeric.  Carcinogenesis 28:1277-1286."
"2747","PC040806","Li W, Zhang X and Olumi A. 2007. MG-132 Sensitizes TRAIL-Resistant Prostate Cancer Cells by Activating c-Fos/cJun Heterodimers and Repressing c-FLIP(L). Cancer Res 67(5):2247."
"2748","PC040806","Zhang L, Zhang X, Garrisford G and Olumi A. 2007. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Let 251(1):146-157."
"2749","PC040806","Zhang X, Li W, and Olumi AF.  2007.  Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells.  Clin Cancer Res 13(23):7."
"2750","PC040806","Huang X, Zhang X, Farahvash B and Olumi A. 2007. Novel Targeted Pro-Apoptotic Agents for the Treatment of Prostate Cancer. J Urology 178(5):1846-1854"
"2751","PC040806","Zhang X, Zhang L, Yang H, Huang X, Otu H, Libermann T, DeWolf W, Khosravi-Far R and Olumi A. 2007. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res 67(19):9425-9434."
"2752","PC040833","Kim KM and Lee YJ.  2005.  Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathway.  Oncogene 24:355-366."
"2753","PC040833","Kim YH and Lee YJ.  2007.  TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation.  J Cell Biochem 100:998-1009."
"2754","PC040833","Kim KM and Lee YJ.  2005.  Role of HER-2/neu signaling in sensitivity to tumor necrosis factor related apoptosis-inducing ligand: enhancement of TRAIL-mediated apoptosis by amiloride.  J Cell Biochem 96:376-389."
"2755","PC040833","Kim YH and Lee YJ.  2006.  Time sequence of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin treatment is responsible for a complex pattern of synergistic cytotoxicity.  J Cell Biochem 98:1284-1295."
"2756","PC040835","Bai F, Pei XH, Pandolfi PP, et al.  2006.  p18Ink4c and Pten constrain a positive regulatory loop between cell growth and cell cycle control.  Mol Cell Biol 26:4564-4576."
"2757","PC040836","Thomas MA, Lange T, Velan SS, et al.  2008.  Two-dimensional MR spectroscopy of healthy and cancerous prostates in vivo.  MAGMA 21(6):443-458.

"
"2758","PC040836","Nagarajan R, Gomez AM, Raman S, et al.  2010.  Correlation of endorectal 2D JPRESS findings with pathological Gleason scores in prostate cancer patients.  NMR Biomed 23(3):257-261.

"
"2759","PC040836","Gomez AM, Raman SS, Margolis DJ, et al.  2008.  State of the art imaging of prostate cancer. In:  Contemporary Diagnostic Radiology, A Biweekly Review of Clinical Radiologic Practice 31(26):1-6, Lippincott, Williams & Wilkins (Campbell RE, Ed.).

"
"2760","PC040844","Grishina IB, Kim SY, Ferrara C, et al.  2005.  BMP7 inhibits morphogenesis in the prostate gland and interferes with notch signaling.  Dev Biol 288:334-347."
"2761","PC040845","Ma AH, Xia L, Desai S, et al.  2006.  Male germ cell-associated kinase, a male-specific kinase regulated by androgen, is a co-activator of androgen receptor in prostate cancer cells.  Cancer Res 66:8439-8447."
"2762","PC040845","Mayeur GL, Kung WJ, Martinez A, et al. Ku is a novel transcriptional recycling coactivator of the androgen receptor in prostate cancer cells. J Biol Chem 280(11):10827-10833."
"2763","PC040861","Chen L, Meng S, Bali P, et al.  2005.  Chemical ablation of androgen receptor in prostate cancer cells with the histone deacetylase inhibitor LAQ824.  American Association for Cancer Research Annual Meeting, Anaheim, California.

"
"2764","PC040861","Chen L, Meng S, Wang H, et al.  2005.  Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.  Mol Cancer Ther 4:1311-1319.

"
"2765","PC040907","Howard DL, Taylor YJ, and Ross LE.  2008.  Differences in lower urinary tract symptoms, treatment and mortality among African-American and White elderly men.  J Natl Med Assoc 100(10):1146-1152."
"2766","PC040907","Ross LE, Meade SA, Powe BD, et al.  2009.  Prostate-specific antigen test use and digital rectal examinations among African American men, 2002-2006.  J Natl Black Nurses Assoc 20(1):52-58."
"2767","PC040907","Ross LE, Berkowitz Z, and Ekwueme DU.  2008.  Use of the prostate-specific antigen test among U.S. men:  Findings from the 2005 national health interview survey.  Cancer Epidemiol Biomarkers Prev 17(3)."
"2768","PC040907","Gooden KM, Howard DL, Carpenter WR, et al.  2008.  The effect of hospital and surgeon volume on racial differences in survival following radical prostatectomy.  Med Care 46(11):170--1176."
"2769","PC040907","
Ross LE, Taylor YJ, Richardson LC, et al.  2009.  Patterns in prostate-specific antigen test use and digital rectal examinations in the behavioral risk factor surveillance system, 2002-2006. J Natl Med Assoc; 101(4): 316-324.
"
"2770","PC040907","Ross LE, Powe BD, Yhenneko J, et al.  2008.  Physician-patient discussions with African American men about prostate cancer screening.  Am J Mens Health 2:2."
"2771","PC040907","Ross LE, Hall IJ, Fairley TL, et al.  2008.  Prayer and self-reported health among cancer survivors in the United States, National Health Interview Survey, 2002.  J Altern Complement Med 14(8):931-938.

"
"2772","PC040912","Silha JV, Sheppard PC, Mishra S, et al.  2006.  Insulin-like growth factor (IGF) binding protein-3 attenuates prostate tumor growth by IGF-dependent and IGF-independent mechanisms.  Endocrinology 147:2112-2121.

"
"2773","PC040931","Dai J, Fishback JA, Zhou Y-D, et al.  2006.  Sodwanone and yardenone triterpenes from a South African species of the marine sponge Axinella inhibit hypoxia-inducible factor-1 (HIF-1) activation in both breast and prostate tumor cells.  J Nat Prod 69:1715-20."
"2774","PC040931","Nagle DG and Zhou Y-D.  2006.  Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1).  Current Drug Targets 7:355-69."
"2775","PC040931","Dai J, Liu Y, Zhou Y-D, et al.  2007.  Hypoxia-selective antitumor agents: Norsesterterpene peroxides from the marine sponge Diacarnus levii preferentially suppress the growth of tumor cells under hypoxic conditions.  J Nat Prod 70:130-3."
"2776","PC040931","Nagle DG and Zhou Y-D.  2006.  Natural product-derived small molecule activators of hypoxia-inducible factor-1 (HIF-1).  Curr Pharm Des 12:2673-2688."
"2777","PC040931","Nagle DG, Ferreira D, Zhou Y-D.  2006.  Molecules of interest: Epigallocatechin-3-gallate (EGCG): Chemical and biomedical perspectives.  Phytochemistry 67:1849-1855."
"2778","PC040947","Borowsky AD, Dingley K, Ubick E, et al.  2006.  Inflammation and atrophy precede prostate neoplasia in PhIP induced rat model.  Neoplasia 8:708-715."
"2779","PC040961","Liu XH, Kirschenbaum A, Yao S, et al.  2007.  Androgens promote preosteoblast differentiation via activation of the canonical Wnt signaling pathway.  Ann N Y Acad Sci 1116:423-431."
"2780","PC040961","Liu XH, Kirschenbaum A, Yao S, et al.  2007.  Androgen-induced Wnt signaling activation in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells.  Cancer Res 67(12):5747-5753."
"2781","PC040961","Liu XH, Kirschenbaum A, Yao S, et al.  2006.  Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system.  Ann N Y Acad Sci 1068:225-233."
"2782","PC040961","Liu XH, Kirschenbaum A, Yao S, et al.  The role of interleukin-6/GP-130 signaling pathway in bone metabolism.  Vitam Horm 74 (14):341-355."
"2783","PC040971","Jogie-Brahim S, et al.  2005.  Proteomic approach for investigation of IGF-independent actions of IGFBPs in cancer.  Expert Rev Proteomics 2:71-86.

"
"2784","PC040971","Kwee SA, DeGrado TR, Talbot JN, et al.  2007.  Cancer imaging with fluorine-18 labeled choline derivatives.  Semin Nucl Med 37:420-428."
"2785","PC040971","DeGrado TR, Kwee SA, Coel MN, et al.  2007.  The impact of urinary excretion of 18F-labeled choline analogs.  J Nucl Med 48:1225."
"2786","PC040972","Schütz C, Fleck M, Mackensen A, et al.  2008.  Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells.  Blood 111(7):3546-3552."
"2787","PC040985","Varghese S, Rabkin SD, Liu R, et al.  2006.  Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.  Cancer Gene Ther 13:253-265."
"2788","PC040985","Varghese S, Rabkin SD, Nielsen PG, et al.  2006.  Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung.  Clin Cancer Res 12:2919-2927."
"2789","PC040985","Varghese S, Rabkin SD, Nielsen GP et al. 2007. Systemic thereapy of spontaneous prostate cancer in transgenic mice iwth oncolytic herpes simplex viruses. Cancer Res 67:9371-9379."
"2790","PC041004","Murthy S and Reddy GP.  2006.  Replitase: complete machinery for DNA synthesis.  J Cell Physiol 209:711-717."
"2791","PC041004","Reddy GP, Barrack ER, Dou QP, et al.  2006.  Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone refractory prostate cancer.  J Cell Biochem 98:1408-1423."
"2792","PC041004","Sivanandam A, Murthy S, Chinnakannu K, et al.  2011. Calmodulin protects androgen receptor from calpain-mediated breakdown in prostate cancer cells. J Cell Physiol 226:1889-96."
"2793","PC041004","Wang A, Li CJ, Reddy GPV, et al.  2005.  Cancer chemotherapy by deoxynucleotide depletion and E2F-1 elevation.  Cancer Res 65:7809-7814."
"2794","PC041004","Li X, Chen D, Yin S, et al.  2007.  Maspin augments proteasome inhibitor, induced apoptosis in prostate cancer cells.  J Cell Physiol 212(2):298-306."
"2795","PC041004","Yang H, Murhty S, Sarkar FH, et al.  2008.  Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells.  J Cell Physiol 217:569-576."
"2796","PC041004","Bai VU, Kaseb A, Tejwani S, et al.  2007.  Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine.  Proc Natl Acad Sci USA 13;104(7):2343-2348 (Epub 2007 Feb 5)."
"2797","PC041004","Kaseb AO, Chinnakannu K, Chen D, et al.  2007.  Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer.  Cancer Res 15;67(16):7782-7788."
"2798","PC041004","Bai VU, Cifuentes, E, Menon M, et al.  2005.  Androgen receptor regulates Cdc6 in synchronized LNCaP cells progressing from G1 to S Phase.  J Cell Physiol l 204:381-387."
"2799","PC041004","Pelley RP, Chinnakannu K, Murthy S, et al.  2006.  Calmodulin-androgen receptor interaction: calcium-dependent, calpain-mediated breakdown of androgen receptor in LNCaP prostate cancer cells.  Cancer Res 66:11754-62."
"2800","PC041004","Murthy S, Wu M, Bai VU, et al.  2013. Role of androgen receptor in progression of LNCaP prostate cancer cells from G1 to S phase. PLoS One 8:e56692."
"2801","PC041039","Ma J, Arnold HK, Lilly MB, et al.  2007.  Negative regulation of Pim-1 protein kinase levels by the B56 beta subunit of PP2A.  Oncogene 26:5145-53."
"2802","PC041039","Chen WW, Chan DC, Donald C, et al.  2005.  Pim family kinases enhance tumor growth of prostate cancer cells.  Mol Cancer Res 3:443-551.

"
"2803","PC041048","Chakrabarti R, Jones JL, and Oelschlager DK.  2007.  Phosphorylated LIM kinases colocalize with gamma-tubulin in centrosomes during early stages of mitosis.  Cell Cycle 6:23 2944-2952."
"2804","PC041048","Davila M,  Jhala D, Ghosh D, et al.  2007.  Upregulation of LIM kinase 1 is associated with reversible G1/S arrest and chromosomal instability in prostate epithelial cells.  Mol Cancer 6:40-51."
"2805","PC041053","Liu C, Dickinson C, Shobe J, et al.  2004.  A hybrid fibronectin motif protein as an integrin targeting selective tumor vascular thrombogen.  Mol Cancer Ther 3:793-801."
"2806","PC041053","Wu W, Sun C, Luo Y, et al.  2006.  Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates drug resistant neoplasms.  Cancer Res. 66:970-80."
"2807","PC041053","Luo Y, Zhou H, Krueger J, et al.  2006.  Targeting tumor-associated macrophages as a novel strategy against breast cancer.  J Clin Invest 116(8):2132-2141."
"2808","PC041067","Wang F, Blanco E, Ai H, et al.  2006.  Modulating beta-lapachone release from polymer millirods through cyclodextrin complexation.  J Pharm Sci 95(10):2309-2319."
"2809","PC041075","Kuo L and Yang LX.  2008.  Gamma-H2AX - A novel biomarker for DNA double-strand breaks.  In Vivo 22(3):305-310."
"2810","PC041075","Lieu T and Yang LX.  2008.  Design, synthesis and development of novel camptothecin drugs.  Curr Pharm Des 14:1078-1097."
"2811","PC041075","Legarza K and Yang L-X.  2005.  Novel camptothecin derivatives.  In Vivo 19:283-292."
"2812","PC041075","Legarza K and Yang LX.  2006.  New molecular mechanisms of action of camptothecin-type drugs.  Anticancer Research 26:3301-3305."
"2813","PC041075","Yount G, Yang Y, Wong B, et al.  2007.  A Novel camptothecin analog with enhanced antitumor activity.  Anticancer Res 27:3173-8."
"2814","PC041086","Piironen T, Haese A, Huland H, et al.  2006.  Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clin Chem 52:838-844."
"2815","PC041086","Ressine A, Finnskog D, Malm J, et al.  2005.  Macro/nano-structured silicon as solid support for antibody arrays: Surface design, reproducibility, and assay characteristics enabling discovery of kallikrein gene products for prostate disease diagnostics.  Nanobiotech 1:93-104.

"
"2816","PC041086","Ekström S, Wallman L, Malm J, et al.  2004.  Integrated selective enrichment target ¿ A microtechnology platform for matrix-assisted laser desorption/ionization-mass spectrometry applied on protein biomarkers in prostate diseases. Electrophoresis 25:3769-3777."
"2817","PC041086","Finnskog D, Järås K, Ressine A, et al. 2006.  High-speed biomarker identification utilizing porous silicon nanovial arrays and MALDI-TOF mass spectrometry. Electrophor 27:1093-1103."
"2818","PC041115","Yaligar J, Thakur SB, Bokacheva L, et al. 2012. Lactate MRSI and DCE MRI as surrogate markers of prostate tumor aggressiveness. NMR Biomed. 25(1):113-122."
"2819","PC041115","Thakur SB, Yaligar J, and Koutcher JA.  2009.  In-vivo lactate signal enhancement using binomial spectral-selective pulses in SELective MQ coherence (SS-SelMQC) spectroscopy.  Magnetic Resonance in Medicine 62(3):591-598."
"2820","PC041122","
Pemble CW, Johnson LC, Kridel SJ, et al.  2007.  Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat.  Nature Structural and Molecular Biology 14(8):704-709. 
"
"2821","PC041122","Weiling Z, Kridel SJ, Thornburn A, et al.  2006.  Fatty acid synthase: A novel target for anti-glioma therapy.  British Journal of Cancer 95(7):869-878."
"2822","PC041122","Zhao W, Kridel S, Thorburn A, et al.  2006.  Fatty acid synthase: A novel target for antiglioma therapy.  British Journal of Cancer 95:869-878."
"2823","PC041122","Chen YQ, Edwards IJ, Kridel SJ, et al.  2007.  Dietary fat-gene interactions in cancer.  Cancer and Metastasis Reviews DOI 10.1007/s10555-007-9075-x."
"2824","PC041122","Kridel SJ, Lowther WT, and Pemble CW.  2007.  Fatty acid synthase inhibitors: New directions for oncology.  Expert Opinion on Investigational Drugs 16(11):1817-1829."
"2825","PC041122","Little JL, Wheeler F, Fels DR, et al.  2007.  Inhibition of fatty acid synthase inhibitors induce endoplasmic reticulum stress in tumor cells.  Cancer Research 67:1262-9."
"2826","PC041123","Gudmundsson J, Sulem P, Manolscu A, et al. 2007. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 39:631-7.
"
"2827","PC041126","Guerrero C, Milenkovic T, Przulj N, et al.  2008.  Characterization of the proteasome interaction network by QTAX-based tag-team strategy and protein interaction network analysis.  Proc Natl Acad Sci U S A. 105(36):13333-13338."
"2828","PC041126","Wang X, Guerrero C, Kaiser P, et al.  2007.  Proteomics analysis of ubiquitin-proteasome degradation pathways.  Expert Rev Proteomics 4(5):649-665."
"2829","PC041126","Jones JJ, Yang Y, Wu K, et al.  2008.  A targeted proteomic analysis of the ubiquitin-like modifier nedd8 and associated proteins.  J Proteome Res 7(3):1274-1287.

"
"2830","PC041126","Wang X and Huang L.  2008.  Identifying dynamic interactors of protein complexes by quantitative mass spectrometry.  Mol Cell Proteomics 7(1):46-57."
"2831","PC041126","Meierhofer M, Wang X, Huang L, et al.  2008.  Quantitative analysis of global ubiquitination in HeLa cells by mass spectrometry.  J Proteome Res 7(10):4566-4576.

"
"2832","PC041126","Fang L, Wang X, Yamoah K, et al.  2008.  Characterization of human COP9 signalosome complex using affinity purification and mass spectrometry.  J Proteome Res 7:4914-25."
"2833","PC041126","Wang X, Chen CF, Baker PR, et al.  2007.  Mass spectrometric characterization of the affinity purified human 26S proteasome complex.  Biochemistry 46(11):3553-3565."
"2834","PC041144","Guo S, Tschammer N, Mohammed S, et al.   2005.  Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA.  Hum Gene Ther 16:1097-1109."
"2835","PC041144","Khaled A, Guo S, Li F, et al.  2005.  Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology.  Nano Lts 5:1797-1808."
"2836","PC041158","Chen Q, Watson JT, Marengo SR, et al.  2006.  Gene expression in the LNCaP human prostate cancer progression model: Progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.  Cancer Lett 244:274-288."
"2837","PC041158","He Y, Franco OE, Jiang M, et al.  2007.  Tissue-specific consequences of cyclin D1 overexpression in prostate cancer progression.  Cancer Res 67:8188-8197."
"2838","PC041158","
True L, Coleman I, Gifford D, et al.  2006.  A molecular correlate to the Gleason grading system for prostate cancer.  Proc Natl Acad Sci USA 103:10991-10996.
"
"2839","PC041158","Khodavirdi AC, Song Z, Nelson PS, et al. 2006. Increased expression of osteopontin contributes to the progression of prostate cancer.  Cancer Res 66:883-8."
"2840","PC041158","Bianchi-Frias D, Pritchard C, Mecham BH, et al.  2007.  Genetic background influences murine prostate gene expression: Implications for cancer phenotypes.  Genome Biol 8(6):R117."
"2841","PC041176","
Lyles B, Akinyeke TO and Moss PE.  2009.  Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPAR gammadependent and PPAR gamma-independent pathways.  Cell Cycle 8 268-277.
"
"2842","PC041176","Ukoli FA, Taher K, Egbagbe E, et al.  2009.  Association of self-reported consumption of cooked meat, fish, seafood and eggs with prostate cancer risk among Nigerians.  Infect Agent Cancer 4(Suppl 1):S1-S6."
"2843","PC041176","Akinyeke T and Stewart LV.  2011.  Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARg-independent mechanism.  Cancer Biol Ther 11(12):1046-1058."
"2844","PC041176","Patel K, Kenerson D, Wang H, et al.  2010.  Factors influencing prostate cancer screening in low-income African Americans in Tennessee.  JHCPU 21:114-126."
"2845","PC041176","Moss PE, Lyles BE, and Stewart LV.  2010.  The PPARgamma ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgenindependent human prostate cancer cells.  Exp Cell Res 316:3478-3488."
"2846","PC041176","Ukoli FA, Egbagbe E, Zhao BB, et al.  2011.  Anthropometric body fat predictors of elevated prostate specific antigen among rural and urban Nigerians:  A population-based study.  West Afr J Med 26(1):7-13."
"2847","PC041176","Ukoli FA, Egbagbe E, Akereyeni F, et al.  2006.  Response to prostate biopsy by Nigerian men:  Community and hospital experience.  Proceedings of the UICC World Cancer Congress, Washington, DC.  Medimond. International Proceedings 341-347."
"2848","PC041176","
Ukoli F, Taher K, Lomotey M, et al.  2009.  The association of self-reported cooked meat, fish, seafood and egg intake with prostate cancer risk among Nigerians.  Infect Agent Cancer 4(S1): 1-5.
"
"2849","PC041176","Ukoli FA, Akumabor PN, Oguike TC, et al.  2009.  The association of plasma fatty acids with prostate cancer risk in Nigerians.  Ethn Dis 19:454-461."
"2850","PC041176","Ukoli F, Fowke J, Akumabor P, et al.  2010.  The association of plasma fatty acids with prostate cancer risk in African Americans and Africans.  J Health Care Poor Underserved (21):127-147.

"
"2851","PC041176","Ukoli FA, Lynch B, and Adams-Campbell L.  2006.  The effect of radical prostatectomy on patient quality of life in African Americans.  Ethn Dis 16:988-993."
"2852","PC041176","Fowke JH, Signorello LB, Underwood W III, et al.  2006.  Obesity and prostate cancer screening among African-American and Caucasian men.  Prostate 66(13):1371-1380."
"2853","PC041176","Ukoli FA, Egbagbe E, Zhao BB, et al.  2007.  Anthropometric body fat predictors of elevated prostate specific antigen among rural and urban Nigerians: A population-based study.  West African J Med 26:7-13."
"2854","PC041176","Odedina FT, Ogunbiyi JO, and Ukoli FA.  2006.  Roots of prostate cancer in African-American men.  J Natl Med Assoc 98(4):539-543."
"2855","PC041176","Fowke JH, Signorello L, Chang S, et al.  2006.  Effects of obesity and height on PSA and percent free PSA levels among African-American and Caucasian men.  Cancer 107(10):2361-2367."
"2856","PC041199","Tang Y, Akbulut H, Maynard J, et al.  2006.  Vector prime/protein boost vaccine that overcomes defects acquired during aging and cancer.  J Immunology 177:5697¿5707."
"2857","PC041199","Tang Y, Zhang L, Yuan J, et al.  2004.  Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens.  Blood  104:2704-2713."
"2858","PC041201","McNeel DG.  2005.  Prostate cancer antigens and vaccines, preclinical developments.  In: Cancer Chemotherapy and Biological Response Modifiers, Annual 22 (Giaccone G, Schilsky R, Sondel P., Eds.).  Oxford: Elsevier Limited 247-261.

"
"2859","PC041201","McNeel DG and Malkovsky M.  2005.  Immune-based therapies for prostate cancer.  Immunol Lett 96:3-9."
"2860","PC041206","Cesaretti JA, Kao J, Stone NN, et al.  2007.  Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: Analysis at >/= 7 years of follow-up.  BJU International 10:362-267.

"
"2861","PC041206","Burri RJ, Rangaswamy B, Kostakoglu L, et al.  2008.  Correlation of PET standard uptake value and pathological specimen size in cancer of the head and neck.  International Journal of Radiation Oncology Biology and Physics 71:682-688."
"2862","PC041206","Hou YN, Lavaf A, Huang D, et al.  2009.  Development of an automated gamma-H2AX immunocytochemistry assay.  Radiation Research 171:360."
"2863","PC041206","Lavaf A, Fu S, Peters S, et al.  2009.  Serine 1981 ATM phosphorylation as a molecular reporter of cellular radiosensitivity.  Journal of Cancer Molecules 5:9-14."
"2864","PC041206","Kao J, Vu HL, Genden EM, et al.  2009.  Diagnostic and prognostic utility of PET/CT for detection of recurrent head and neck cancer following radiotherapy.  Cancer 115:4586-4594."
"2865","PC041206","Kao J, Sikora A, and Fu S.  2009.  Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma.  Current Cancer Drug Targets 9:931-937."
"2866","PC041206","Kao J, Conzen SD, Jaskoviak NT, et al.  2005.  Concomitant Radiation therapy and paclitaxel for unresectable locally advanced breast cancer: Results from two consecutive phase I/II trials.  International Journal of Radiation Oncology Biology and Physics 61:1045-1053."
"2867","PC041206","Salama JK, Heimann R, Lin F, et al.  2005.  Does the number of lymph nodes examined in node negative breast cancer have prognostic significance?  Cancer 103:664-671."
"2868","PC041206","Vu HL, Sikora A, Fu S, et al.  2010.  HPV-induced oropharyngeal cancer, immune response and response to therapy.  Cancer Letters 28:149."
"2869","PC041206","Kao J, Ko EC, Eisenstein S, et al.  2011.  Targeting immune suppressing myeloid-derived suppressor cells in oncology.  Crit Rev Oncol Hematol 77(1):12-19."
"2870","PC041206","Jani AB, Kao J, Heimann R, et al.  2005.  Hormone therapy and radiation therapy for early prostate cancer: A utility-adjusted number needed to treat analysis.  International Journal of Radiation Oncology Biology and Physics 61:687-694."
"2871","PC041206","Kao J, Rosenstein BS, Peters S, et al.  2005.  Cellular response to DNA damage.
Annl NY Acad Sci 1066:243-258."
"2872","PC041206","Kao J, Milano MT, Javaheri A, et al.  2006.  &#947;-H2AX as a therapeutic target for improving the efficacy of radiotherapy.  Curr Cancer Drug Targets 6:197-205."
"2873","PC041206","Milano MT, Vokes EE, Kao J, et al.  2006.  Intensity modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: Preliminary experience and future directions.  Int J Oncol 28:1141-1151."
"2874","PC041206","Salama JK, Vokes EE, Chmura SJ, et al.  2006.  Long term outcome of concurrent chemotherapy and re-irradiation for recurrent head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 64:382-391."
"2875","PC041206","Cesaretti JA, Stone NN, Kao J, et al.  2006.  Brachytherapy for prostate cancer.  In: Prostate Cancer: Principles and Practice (Kirby RS, Partin AW, Feneley M, et al., Eds.).  Taylor and Francis Medical Books, Abdington, United Kingdom 817-835."
"2876","PC041206","Lavaf A, Genden EM, Cesaretti JA, et al.  2008.  Adjuvant radiotherapy improves overall survival for node positive head and neck squamous cell carcinoma.  Cancer 112:535-543."
"2877","PC041206","Kao J, Lavaf A, Teng MS, et al.  2008.  Adjuvant radiotherapy and survival for patients with node positive head and neck cancer: An Analysis by primary site and nodal stage.  Int J Radiat Oncol Biol Phys 71:362-370."
"2878","PC041206","Kao J, Stone NN, Lavaf A, et al.  2008.  Dose escalation using I-125 monotherapy: An analysis of prostate implants with a minimum D90 of 180 Gy.  Int J Radiat Oncol Biol Phys 70:96-101."
"2879","PC041206","Ozao-Choy J, Ma G, Kao J, et al.  2009.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppresion and modulation of tumor microenvironment for immune-based cancer therapies.  Cancer Res 69:2514-2522."
"2880","PC041206","Kao J, Packer S, Sung M, et al.  2009.  Phase I study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response.  Cancer  115:3571-80."
"2881","PC041206","Kao J, Sung M, Schwartz M, et al.  2008.  Phase I study of concurrent sunitinib and hypofractionated image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases.  Int J Radiat Oncol Biol Phys 72(Suppl):142."
"2882","PC041206","Jani AB and Kao J.  2005.  Post-prostatectomy adjuvant versus salvage radiotherapy: A utility-adjusted number needed to treat (NNT) analysis.  Cancer 103:1833."
"2883","PC041206","
Milano MT, Vokes EE, Salama JK, et al.  2005.  Twice-daily re-irradiation of recurrent and second primary head and neck cancer with gemcitabine, paclitaxel, and fluorouracil chemoradiotherapy.  International Journal of Radiation Oncology Biology and Physics 61:1096-1106.
"
"2884","PC041206","Kao J, Conzen S, Fleming G, et al.  2006.  In Response to Dr. Formenti, et al. (Int J Radiat Oncol Biol Phys 63:1275-1276, 2005).  International Journal of Radiation Oncology Biology and Physics 64:658."
"2885","PC041210","Ligr M, Li Y, Zou X, Daniels et al.  2010.  Tumor suppressor function of androgen receptor coactivator ARA70alpha in prostate cancer.  Am J Pathol 176(4):1891-1900 [Epub 2010 Feb 18]."
"2886","PC041210","Peng Y, Li C, Chen F, et al.  2008.  Stimulation of prostate growth and invasion by androgen receptor cofactor ARA70(beta).  Am J Pathol 172(1):225-35."
"2887","PC041210","Peng Y, Chiriboga L, Pei Z, et al.  2008.  Androgen receptor coactivator ARA70a and ARA70b isoform-specific antibodies:  New tools for studies of expression and immunohisto-chemical localization.  Appl Immunohistochem Mol Morphol 16(1):7-12."
"2888","PC041214","Markushin Y, Gaikwad N, Zhang H, et al.  2006.  Potential biomarker for early risk assessment of prostate cancer.  Prostate 66(14):1565-7151."
"2889","PC041214","Fujita K, Pavlovich CP, Netto GJ, et al.  2009.  Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology.  Hum Pathol 40:924-33."
"2890","PC041214","Fujita K, Ewing CM, Getzenberg RH, et al.  2010.  Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia.  Prostate 70(5):473-481."
"2891","PC041214","Fujita K, Ewing CM, Sokoll LJ, et al.  2008.  Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation.  Prostate 68(8):872-882."
"2892","PC041214","Fujita K, Ewing CM, Chan DYS, et al.  2009.  Endoglin (CD105) as a urinary and serum marker of prostate cancer.  Int J Cancer 124(3):664-669."
"2893","PC041214","Rogers CG, Gonzalgo ML, Yan G, et al.  High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection.  J Urol 176(5):2280-2284."
"2894","PC041214","Fujita K, Pavlovich CP, Netto GJ, et al.  2008.  Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology.  Hum Pathol 872-882."
"2895","PC041214","Fujita K, Ewing CM, Isaacs WB, et al.  2011.  Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status.  Int J Cancer 29 (2): 424-432."
"2896","PC041220","Garcia JA, Rosenberg JE, Weinberg V, et al.  2007.  Evaluation and significance of circulating epithelial cells in hormone refractory prostate cancer patients.  British Journal of Urology 99:519-24."
"2897","PC041220","Rosenberg JE, Weinberg VK, Kelly WK, et al.  2007.  Activity of second-line chemotherapy in docetaxel-refractory hormone refractory prostate cancer patients: Randomized phase II study of ixabepilone or mitoxantrone and prednisone.  Cancer 110(3): 556-563."
"2898","PC041220","Paris PL, Kobayashi Y, Zhao Q, et al.  2009.  Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer.  Cancer Lett 277:164-73."
"2899","PC041223","Thompson IM, Bermejo C, Hernandez J, et al.  2005.  Screening for prostate cancer: Opportunities and challenges.  Surg Oncol Clin N Am 14(4):747-760."
"2900","PC041223","Schraudenbach P and Bermejo CE.  2007.  Management of the complications of radical prostatectomy.  Curr Urol Rep 8(3):197-202."
"2901","PC041225","Banck M.S, Beaven SW, Narla G, et al.  2006.  KLF6 degradation after apoptotic DNA damage. FEBS Lett 580(30):6981-6986."
"2902","PC041225","Banck MS, Li S, Nishio H, et al.  2009.  The ZNF217 oncogene is a candidate organizer of repressive histone modifiers.  Epigenetics 4(2):100-106."
"2903","PC041225","Barradas M, Anderton E, Acosta1 JC, et al.  2009.  Histone demethylase KDM6B/JMJD3 mediates epigenetic control of INK4a/ARF by oncogenic RAS.  Genes Dev 23(10):1177-1182."
"2904","PC041225","Kremer-Tal S, Narla G, Chen Y, et al.  2007.  Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation.  J Hepatol 46(4):645-654.

"
"2905","PC050010","Michaelson MD, Regan MM, Oh WK, et al.  2009.  Phase II study of sunitinib in men with advanced prostate cancer.  Annals of Oncology 20:913-920.

"
"2906","PC050010","Saylor PJ, Mahmood U, Kunawudhi A, et al.  2012.  Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer.  J Nucl Med. 53(11):1670-1675."
"2907","PC050014","Beaudoin EL and Junghans RP.  2008.  Sorting vector producer cells for high transgene expression increase retroviral titer.  J Virol Methods 148:253-259."
"2908","PC050037","Johnson LE and McNeel DG. 2012. Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted t-cell epitopes. Prostate 72(7):730-740."
"2909","PC050037","Olson BM, Johnson LE, and McNeel DG. 2013. The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunol Immunother 62(3):585-596."
"2910","PC050037","McNeel DG, Dunphy EJ, Davies JG, et al.  2009.  Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with stage D0 prostate cancer.  J Clin Oncol27(25):4047-54"
"2911","PC050037","Zlotocha S, Staab MJ, Horvath D, et al.  2005.  A phase I study of a DNA vaccine targeting prostatic acid phosphatase (PAP) in patients with stage D0 prostate cancer.  Clin Genitourinary Cancer 4:215-218."
"2912","PC050037","Dunphy EJ, Staab MJ, Horvath D, et al.  2007.  Phase I study of a DNA-based vaccine targeting prostatic acid phosphatase (PAP) in patients with clinical stage D0 prostate cancer.  Proc Amer Assn Cancer Res 48:1858."
"2913","PC050037","Olson BM, Jankowska-Gan E, Becker JT, et al. Human Prostate Tumor Antigen-Specific CD8+ Regulatory T Cells Are Inhibited by CTLA-4 or IL-35 Blockade. Journal Immunol 189(12):5590-5601."
"2914","PC050037","Becker JT, Olson BM, Johnson LE, et al. 2010. DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) Elicits Long-term T-cell Responses in Patients With Recurrent Prostate Cancer. J Immunother 33(6): 639-647."
"2915","PC050042","Lee J, Kuo N, Deguet A, et al. 2011. Intraoperative 3-D Reconstruction of Prostate Brachytherapy Implants with Automatic Pose Correction. Phys Med Biol 56(15):5011-5027."
"2916","PC050042","Song DY, Jain AK, Zhang Z, et al. Dynamic intraoperative dosimetry for prostate brachytherapy using a nonisocentric C-arm. Brachytherapy 10(2):98-106."
"2917","PC050042","Lee J, Labat C, Jain AK, et al. 2009. Optimal Matching for Prostate Brachytherapy Seed Localization with Dimension Reduction. Med Image Comput Comput Assist Interv. 12(Pt 1):59-66."
"2918","PC050042","Kuo N, Deguet A, Song DY, et al. 2012. Automatic segmentation of radiographic fiducial and seeds from X-ray images in prostate brachytherapy. Med Eng Phys 34(1):64-77."
"2919","PC050042","Lee J, Labat C, Jain AK, et al. 2011. REDMAPS: Reduced-Dimensionality Matching for Prostate Brachytherapy Seed Reconstruction. IEEE Trans Med Imaging 30(1):38-51."
"2920","PC050042","Song DY, Burdette EC, Fiene J, et al. 2011. Robotic needle guide for prostate brachytherapy: Clinical testing of feasibility and performance. Brachytherapy 10(1):57-63."
"2921","PC050042","Jain A, Deguet A, Iordachita I, et al.  2007.  Intra-operative 3D guidance in prostate brachytherapy using a non-isocentric Carm.  Med Image Comput Comput Assist Interv Int Conf Med Image Comput Comput Assist Interv 10(Pt 2):9-17."
"2922","PC050042","Lee J, Liu X, Prince JL, et al.  2008.  Prostate brachytherapy seed localization with Gaussian blurring and camera self-calibration.  Eleventh International Conference on Medical Image Computing and Computer-Assisted Intervention.  Proceedings in Lecture Notes in Computer Science 5242:636-643, Springer."
"2923","PC050042","Liu X, Jain AK, and Fichtinger G.  2007.  Prostate implant reconstruction with discrete tomography.  Tenth International Conference on Medical Image Computing and Computer-Assisted Intervention.  Proceedings in Lecture Notes in Computer Science 4791:734-741, Springer."
"2924","PC050042","Lee J, Liu X, Jain AK, Song DY, Burdette EC, Prince JL, Fichtinger G. 2009.  Prostate Brachytherapy Seed Localization with Gaussian Blurring and optimal coverage cost. IEEE Trans Med Imaging, 28:1955-69."
"2925","PC050042","Hefny M, Karimaghaloo Z, Gobbi D, et al.  2008.  Quantification of edematic effects in prostate brachytherapy interventions.  Eleventh International Conference on Medical Image Computing and Computer-Assisted Intervention.  Proceedings in Lecture Notes in Computer Science 5242:493-500, Springer."
"2926","PC050059","AO M, Williams K, Bhowmick N, et al.  2006.  TGF-beta promotes invasion in tumorigenic but not in non-tumorigenic human prostatic epithelial cells.  Cancer Res 66:8007-16."
"2927","PC050059","Ao M, Franco OE, Park D, et al.  2007.  Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium.  Cancer Res 67:4244-4253."
"2928","PC050074","Malloy PJ, Peng L, Wang J, et al.  2009.  Interaction of the vitamin D receptor with a vitamin D response element in the Mullerian inhibiting substance (MIS) promoter: Regulation of MIS expression by calcitriol in prostate cancer cells.  Endocrinology 150(4):1580-1587."
"2929","PC050074","Krishnan AV, Moreno J, Nonn L, et al.  2007.  Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer.  J Steroid Biochem Mol Biol 103:694-702."
"2930","PC050074","Malloy PJ, Peng L, Wang J, et al.  2009.  Interaction of the vitamin D receptor with a vitamin D response element in the Mullerian- inhibiting substance (MIS) promoter: Regulation of MIS expression by calcitriol in prostate cancer cells.  Endocrinology 150:1580-7."
"2931","PC050111","You Z, Shi XB, DuRaine G, et al.  2006.  Interleukin-17 receptor-like gene is a novel anti-apoptotic gene highly expressed in androgen independent prostate cancer.  Cancer Res 66(1):175-183."
"2932","PC050111","You Z, Dong Y, Kong X, et al.  2007.  Differential expression of IL-17RC isoforms in androgen-dependent and androgen-independent prostate cancer.  Neoplasia 9(6):464-470."
"2933","PC050111","You Z, Dong Y, Kong X, et al.  2008.  Midkine is a NF-kappaB-inducible gene that supports prostate cancer cell survival.  BMC Medical Genomics 1:6."
"2934","PC050111","Ge D and You Z.  2008.  Expression of interleukin-17RC protein in normal human tissues. Int Arch Med 1:19."
"2935","PC050114","Lee YS and Dutta A.  2009.  MicroRNAs in cancer.  Annu Rev Pathol 4:199-227."
"2936","PC050119","Gao Y, Hubbert C, Lu J, et al.  2007.  Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis.  Mol Biol Cell 27:8637-47."
"2937","PC050127","Park SY, Kim YJ, Gao AC, et al.  2006.  Hypoxia increases androgen receptor activity in prostate cancer cells.  Cancer Res 66(10):5121-5129."
"2938","PC050127","Kim Y-J, Ahn J-Y, Liang P, et al.  2007.  Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: Implication to tumor biology.  Cancer Res 67:546-554."
"2939","PC050127","
Kim Y-J, Baek S-H, Bogner PN, et al.  2007.  Targeting the Nrf2-Prx1 pathway with selenium to enhance the efficacy and selectivity of cancer therapy.  J Cancer Mol 3(2):37-43.

"
"2940","PC050127","Park S-Y, Yu X, Ip C, et al.  2007.  Peroxiredoxin 1 interact with androgen receptor and enhances its transactivation.  Cancer Res 67:9294-303."
"2941","PC050127","Lee WS, Choi K-S, Riddell J, et al.  2007.  Human Prx1 and Prx2 are not duplicate proteins: The unique presence of Cys83 in Prx1 underscores the structural and functional differences between Prx1 and Prx2.  J of Biol Chem 282(30):22011-22022."
"2942","PC050136","Wallace KL, Furner SE, Freeman VF, et al.  2006.  Racial trends in prostate cancer incidence in Illinois and the United States 1986-2000.  Journal of Registry Management 33(4):108-110."
"2943","PC050156","Bentle M, Reinicke K, Bey E, et al.  2006.  Calcium regulation of PARP-1 hyperactivation for altered cellular metabolism and inhibition of DNA repair.  J Biological Chemistry 281(44):33684-33696."
"2944","PC050156","Ying D, Chin S-F, Blanco E, et al.  2009.  Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy.  Clinical Cancer Res 15(1):131-139."
"2945","PC050156","Blanco E, Bey EA, Dong Y, et al.  2007.  Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells.  J Control Release 122(3):365-374."
"2946","PC050156","Bentle MS, Reinicke KE, Dong Y, et al.  2007.  Non-homologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone.  Cancer Research 67(14):6936-45."
"2947","PC050156","Choi EK, Terai K, Ji I-M, et al.  2007.  Upregulation of NAD (P) H: quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells.  Neoplasia 9(8):634-642."
"2948","PC050168","Frohlich DA, McCabe MT, Arnold, R, et al.  2008. The Role of Nrf2 in increased reactive oxygen species (ROS) and DNA damage in prostate tumorigenesis. Oncogene  27:4353-62."
"2949","PC050170","Zhou Y, Jain A, Chirikjian GS, et al.  2006.  Incorporating seed orientation in brachytherapy implant reconstruction.  SPIE Medical Imaging:  Visualization, Image-Guided Procedures, and Display.  6141:438-452."
"2950","PC050170","Jain A and Fichtinger G.  2006.  C-arm tracking and reconstruction without an external tracker.  Ninth International Conference on Medical Image Computing and Computer-Assisted Intervention, Computer Science 419:494-502."
"2951","PC050170","Vikal S, Jain A, Deguet A, et al.  2006.  Seed segmentation in C-arm fluoroscopy for brachtherapy implant reconstruction.  Conference of American Association of Physicists in Medicine, Journal of Medical Physics 33(6):2229."
"2952","PC050170","Vikal S, Jain A, Deguet A, et al.  2006.  Automated segmentation of radiographic fiducials for C-arm tracking, Conference of American Association of Physicists in Medicine, Journal of Medical Physics 33(6):2208."
"2953","PC050170","Lee J, Liu X, Jain A, et al.  2008.  Tomosynthesis-based radioactive seed localization in prostate brachytherapy using modified distance map images.  Proc IEEE Int Symp Biomed Imaging 14:680-683."
"2954","PC050182","Li ZG, Yang J, Vazquez ES, et al.  2008.  Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone.  Oncogene 27:596-603."
"2955","PC050199","Chen B, Pogue BW, Luna J, et al.  2006.  Tumor vascular permeabilization by vasculartargeting photosensitization: effects, mechanism and therapeutic implications.  Clin Cancer Res 10: 917-23."
"2956","PC050199","Chen B, He C, de Witte P, et al.  2008.  Vascular targeting in photodynamic therapy.  In: Advances in Photodynamic Therapy: Basic, Translational and Clinical (Chapter 9).  Hamblin MR and Mroz P, Eds.  Artech House, Inc., Norwood, Massachusetts, pp.179-191."
"2957","PC050199","Chen B, Crane C, He C, et al.  2008.  Disparity in vascular response to verteporfin-mediated vascular-targeting therapy between prostate tumor interior versus peripheral vasculature.  Int J Cancer 123:695-701."
"2958","PC050199","He C, Fateye B, and Chen B.  2009.  Combination of vascular targeting PDT with combretastatin A4 phosphate.  Proc of SPIE 7380:7380321-7380326.

"
"2959","PC050199","Chen B, Pogue BW, Hoopes PJ, et al.  2006.  Vascular and cellular targeting for photodynamic therapy.  Crit Rev Eukaryot Gene Expr 16: 279-306."
"2960","PC050199","He C, Agharkar P, and Chen B.  2009.  Intravital microscopic analysis of vascular perfusion and macromolecule extravasation after verteporfin-mediated photodynamic therapy.  Pharm Res 25:1873-1880."
"2961","PC050202","Beer TM, Javle MM, Ryan CW, et al.  2007.  Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer, Cancer Chemother Pharmacol 59:581-587.

"
"2962","PC050202","Chung I, Karpf AR, Muindi JR, et al.  2007.  Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol, J Biol Chem 282:8704-8714."
"2963","PC050202","Fakih MG, Trump DL, Muindi JR, et al.,  2007.  A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors, Clin Cancer Res 13:1216-1223."
"2964","PC050202","Chung I, Wong MK, Flynn G, et al.  2006.  Differential anti-proliferative effects of calcitriol on tumor derived, and matrigel-derived endothelial cells.  Cancer Res 66(17):8565-8573."
"2965","PC050202","Flynn G, Chung I, Yu WD, et al.  2006.. Calcitriol (1,25-dihydroxycholecalciferol) selectively inhibits proliferation of freshly isolated tumor-derived endothelial cells and induces apoptosis.  Oncology 70:447-457."
"2966","PC050202","Ma Y, Yu WD, Kong RX, et al.  2006.  Role of nongenomic activation of phosphatidylinositol 3-kinase/Akt, and mitogen activated protein kinase/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase 1/2 Pathway in 1,25D3-mediated apoptosis in squamous cell carcinoma cells.  Cancer Res 66(16):8131-8138.

"
"2967","PC050204","Ménard C and Crook J.  2008.  The use of Image-Guidance in prostate brachytherapy.  In: Image-Guided Therapy of Prostate Cancer (Valicenti R, Dicker AP, Jaffray DA, Eds.).  New York, NY: Informa Healthcare, Chapter 15:167-181."
"2968","PC050204","Chopra S, Toi A, Taback N, et al. 2012. Pathological Predictors for Site of Local Recurrence After Radiotherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 82(3):e441-e448."
"2969","PC050207","Kimple ME, Joseph JW, Bailey CL, et al.  2008.  Galphaz negatively regulates insulin secretion and glucose clearance.  J Biol Chem 283(8):4560-4567."
"2970","PC050209","Zhang X, Leung YK, and Ho SM.  2007.  AP-2 regulates the transcription of estrogen receptor (ER)-beta by acting through a methylation hotspot of the 0N promoter in prostate cancer cells.  Oncogene 26(52):7346-54."
"2971","PC050209","Bakshi S, Zhang X, Godoy-Tundidor S, et al.  2008.  Transcriptome analyses in normal prostate epithelial cells exposed to low-dose cadmium:  Oncogenic and immunomodulations involving the action of tumor necrosis factor environ health perspect doi:10.1289/ehp.11215."
"2972","PC050249","Banach-Petrosky W, Jessen WJ, Ouyang X, et al.  2007.  Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice, Cancer Res 67:9089-9096."
"2973","PC050249","Ouyang X, Jessen WJ, Al-Ahmadie H, et al.  2008.  Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer.  Cancer Res 68:2132-2144.

"
"2974","PC050249","Shen MM and Abate-Shen C.  2007.  Pten inactivation and the emergence of androgen-independent prostate cancer.  Cancer Res 67:6535-6538."
"2975","PC050252","Shurin MR, Shurin GV, Lokshin A, et al.  2006.  Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: Friends or enemies?  Cancer Metastasis Rev 25:333-356."
"2976","PC050252","Aalamian-Matheis M, Chatta GS, Shurin MR, et al.  2007.  Inhibition of dendritic cell generation and function by serum from prostate cancer patients: Correlations with serum free PSA.  Adv Exp Med Biol 601:173-182."
"2977","PC050252","Zhong H, Shurin MR, Han B.  2007.  Optimizing dendritic cell-based immunotherapy for cancer. Expert Rev Vaccines 6(3):333-345."
"2978","PC050266","Migita T, Ruiz S, Fornari A, et al.  2009.  Fatty acid synthase: A metabolic enzyme and candidate oncogene in prostate cancer.  J Natl Cancer Inst 101(7):519-532.

"
"2979","PC050266","Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S,
Loda M, Roberts TM, and Zhao JJ. Kinase-dependent and -independent roles of PI3K-p110Î² in cell growth, metabolism and tumorigenesis. Nature.
2008;454(7205):776-9.

"
"2980","PC050266","Sabbisetti S, Di Napoli A, Seeley A, et al.  2009.  p63 promotes cell survival through fatty acid synthase.  PLoS ONE 4(6):e5877."
"2981","PC050266","Grisanzio C and Signoretti S.  2009.  Adult prostate epithelium renewal, stem cells and cancer.  In: Stem Cells and Cancer.  Bagley RG and Teicher BA, Eds."
"2982","PC050266","Majumder P, Grisanzio C, Oâ¿¿Connell F, et al.  2008.  A prostatic intraepithelial neoplasia-dependent p27kip1 checkpoint induces senescence, inhibits cell proliferation and cancer progression.  Cancer Cell 14(2):146-155."
"2983","PC050266","Grisanzio C and Signoretti S.  2008.  p63 in prostate biology and pathology.  J Cell Biochem 103:1354-68."
"2984","PC050266","Signoretti S and Loda M.  2006.  Prostate stem cells:  from development to cancer.  Semin Cancer Biol. 17:219-24."
"2985","PC050266","Berger R, Lin DI, Nieto, et al.  2006.  Androgen-dependent regulation of Her-2/neu in prostate cancer cells.  Cancer Res 66:5723-8."
"2986","PC050266","Signoretti S and Loda M.  2006.  Defining stem cells in the prostate epithelium.  Cell Cycle 5:138-41."
"2987","PC050269","Comer SB, Vielhauer GA, Manthe CA, et al. 2010. Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. Prostate 70(1):27-36."
"2988","PC050269","Donnelly AC, Mays JR, Burlison JA, et al.  2008.  The design, synthesis, and evaluation of coumarin ring derivative of the novobiocin scaffold that exhibit antiproliferative activity.  J Org Chem73(22):8901-8920."
"2989","PC050269","Yu XM, Shen G, Neckers L, et al.  2005.  Hsp90 inhibitors identified from a library of novobiocin analogues.  J Am Chem Soc 127(37):12778-12779."
"2990","PC050269","Goetzl M, Blagg BS, Cronk B, et al.  2006.  Modulation of heat shock protein 90 (Hsp90) client protein expression in prostate cancer cells by a novel novobiocin analog.  J Urol 751(4):140.

"
"2991","PC050277","Maricque BB, Eickhoff JC, and McNeel DG. 2011. Antibody Responses to Prostate-Associated Antigens in Patients with Prostatitis and Prostate Cancer. Prostate 71(2):134-146."
"2992","PC050277","Morse MD and McNeel DG. 2010. Prostate Cancer Patients Treated with Androgen Deprivation Therapy Develop Persistent Changes in Adaptive Immune Responses. Hum Immunol 71(5):496-504."
"2993","PC050277","Morse MD and McNeel DG.  2008.  Androgen deprivation elicits an adaptive immune response to prostate tissue antigens in patients with prostate cancer.  Proc Amer Assn Cancer Res 49:2088."
"2994","PC050277","Morse MD and McNeel DG. 2012. T cells localized to the androgen-deprived prostate are TH1 and TH17 biased. Prostate 72(11):1239-1247."
"2995","PC050277","Smith HA, Maricque BB, Eberhardt J, et al. 2011. IgG Responses to Tissue-Associated Antigens as Biomarkers of Immunological Treatment Efficacy. J Biomed Biotechnol 2011:454861."
"2996","PC050284","Grossman ME, Mizuno NK, Bonorden MJ, et al.  2009.  Role of the adiponectin leptin ratio in prostate cancer.  Oncology Research 18:269-277.

"
"2997","PC050286","Tan S and Nevalainen MT.  2008.  Transcription factor Stat5 in breast and prostate cancer.  Endocr Relat Cancer 15:367-390."
"2998","PC050286","Abdulghani J, Gu L, Dagvadorj A, et al.  2008.  Transcription factor Stat3 promotes metastatic behavior of prostate cancer.  Am J Pathol 172:1717-1728 (Featured in Uro.Today and ScienceNews.com)."
"2999","PC050286","Culig Z, Pestell RG, and Nevalainen M.  2008.  Transcription factors Stat5 and Stat3: Key survival factors for prostate cancer cells.  In: Prostate Cancer: Signaling Networks, Genetics and New Treatment Strategies.  Nevalainen MT and Pestell R, Eds.  Humana Press."
"3000","PC050286","Gu L, Dagvadorj A, Lutz J, et al.  2010.  Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo while Stat5 has a preferential role in the promotion of prostate cancer cell viability and tumor growth.  American Journal of Pathology 176(4):1959-72.
"
"3001","PC050286","Abdulghani J, Gu L, Dagvadorj A, et al.  2008.  Transcription factor Stat3 promotes metastatic behavior of prostate cancer.  American Journal Pathology 172:1717-1728.

"
"3002","PC050286","Powell M, Lisanti M, Nevalainen MT, et al.  2008.  Androgen receptor epigenetic modification and acetylation regulate prostate cellular growth.  In: Prostate Cancer: Signaling Networks, Genetics and New Treatment Strategies.  Nevalainen MT and Pestell R, Eds.  Humana Press."
"3003","PC050288","Zhu K, Chan W, Heymach J, et al.  2009.  Control of HIF-1alpha expression by eIF2alpha phosphorylation mediated translational repression.  Cancer Res 69(5):1836-1843."
"3004","PC050304","Alagbala AA, Moser MT, Johnson CS, et al. 2007.  Characterization of vitamin D insensitive prostate cancer cells.  J Steroid Biochem Mol Bio 103:712-716."
"3005","PC050304","Alagbala AA, Johnson CS, Trump DL, et al.  2007.  Antitumor effects of two less-calcemic vitamin D analogs (paricalcitol and QW-1624F2-2) in squamous cell carcinoma (SCC) cells. Oncology 70:483-492."
"3006","PC050304","Alagbala AA, McRiner AJ, Borstnik K, et al.  2006.  Biological mechanisms of action of novel C-10 non-acetal trioxane dimers in prostate cancer cell lines.  J Med Chem 49:7836-7842."
"3007","PC050304","Alagbala AA and Foster BA.  2007.  Animal models of prostate cancer.  In:  Sourcebook of Models for Biomedical Research.  Conn M, Ed.  Humana Press Inc, pp639-650."
"3008","PC050313","Zhou T, Jepsen K, Solum D, et al.  2007.  SMRT-mediated repression of an H3K27 demethylase in progression from neural stem cell to neuron.  Nature 450:415-419."
"3009","PC050337","Yang W and Freeman MR.  2008.  Proteomics approaches to the analysis of multiprotein signaling complexes.  Proteomics 8:832-851."
"3010","PC050337","Di Vizio D, Solomon KR and Freeman MR.  2008.  Cholesterol and cholesterol-rich membranes in prostate cancer:  An update.  Tumori 94:633-639."
"3011","PC050337","Freeman MR, Cinar B, Kim J, et al.  2007.  Transit of hormonal and EGF receptor-dependent signals through cholesterol-rich membranes.  Steroids 72(2):210-217.

"
"3012","PC050337","Hager M, Solomon KR, and Freeman MR.  2006.  The role of cholesterol in prostate cancer.  Curr Opin Clin Nutr Metab Care 9(4):379-385."
"3013","PC050337","Di Vizio D, Kim J, Hager MH, et al.  2009.  Oncosome formation in prostate cancer: Association with a region of frequent chromosomal deletion in metastatic disease.  Cancer Research 69:5601-5609."
"3014","PC050337","Lutchman M, Solomon KR, and Freeman MR.  2007.  Cholesterol, cell signaling and prostate cancer.  In:  Prostate Cancer:  Novel Biology, Genetics and Therapy.  Second edition, Humana Press, Totowa, New Jersey."
"3015","PC050337","Solomon KR and Freeman MR.  2008.  Do the cholesterol-lowering properties of statins affect cancer risk?  Trends Endocrinol Metab 19:113-121."
"3016","PC050337","Hager MH, Morley S, Bielenberg DR, et al.  2012. DIAPH3 governs the cellular transition to the amoeboid tumour phenotype. EMBO Mol Med 4(8):743-760."
"3017","PC050337","Qi M, Liu Y, Freeman MR, et al.  2009.  Cholesterol-regulated stress fiber formation.  J Cell Biochem 106:1031-1040."
"3018","PC050342","Yaspan BL, RcReynold KM, Elmore JB, et. al.  2008.  A haplotype at chromosome Xq27.2 confers susceptibility to prostate cancer.  Hum Genet 123:379-86."
"3019","PC050349","Swami S, Krishnan AV, Moreno J, et al.  2007.  Calcitriol and genistein actions to inhibit the prostaglandin pathway: Potential combination therapy to treat prostate cancer.  J Nutr 1 (Suppl):205S-210S."
"3020","PC050349","Bhattacharyya RS, Krishnan AV, Swami S, et al.  2006.  Fulvestrant (ICI 182,780) downregulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells.  Mol Cancer Ther 5(6):1539-1549."
"3021","PC050349","Husbeck B, Bhattacharyya RS, Feldman D, et al.  2006.  Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: Two distinct mechanisms of action.  Mol Cancer Ther 5(8):2078-2085."
"3022","PC050351","Segala J, Engelman DM, Reshetnyak YK, et al.  2009.  Accurate analysis of tumor margins using a fluorescent pH low insertion peptide (pHLIP).  International Journal of Molecular Sciences 10:3478-3487."
"3023","PC050351","Vavere AL, Biddlecombe GB, Spees WM, et al.  2009.  A novel technology for the imaging of acidic prostate tumors by positron emission tomography.  Cancer Research 69(10):4510-4516."
"3024","PC050351","Reshetnyak YK, Andreev O, Segala M, et al.  2008.  Energetics of peptide (pHLIP) binding to and folding across a lipid bilayer membrane.  Proced Natl Acad Sci U.S.A. 105(40):15340-15345."
"3025","PC050351","Zoonens MA, Reshetnyak YK, and Engelman DM.  2008.  Bilayer interactions of pHLIP, a peptide that can deliver drugs and target tumors.  Biophys J 95:225-235.

"
"3026","PC050351","Andreev OA, Dupuy AD, Segala M, et al.  2007.  Mechanism and uses of a peptide that targets tumors and other acidic tissue in vivo.  Proced Natl Acad Sci USA 104(19):7893-7898."
"3027","PC050351","Reshetnyak YK, Segala M, Andreev OA, et al.  2007.  A monomeric membrane peptide that lives in three worlds: in solution, attached to and inserted across lipid bilayers.  Biophys J 93:2363-72."
"3028","PC050351","Andreev OA, Sandugu S, Engelman DM, et al.  2006.  Injection of molecules into cells using a pH-triggered molecular nanosyringe.  Technical Proceedings of the 2006 Nanotech Conference 2:57-60."
"3029","PC050351","Reshetnyak YK, Andreev OA, Lehnert U, et al.  2006.  Translocation of molecules into cells by pH-dependent insertion of a transmembrane helix.  Proc Natl Acad Sci U S A 103(17):6460-6465."
"3030","PC050351","Andreev OA, Engelman DM, and Reshetnyak YK.  2009.  Targeting acidic diseased tissue.  New technology based on use of the pH (Low) insertion peptide (pHLIP).  Chemistry Today 27:10-13."
"3031","PC050353","Simms-Waldrip T, Rodriguez-Gonzalez A, Lin T, et al. 2008. The aggresome pathway as a target for therapy in hematologic malignancies. Mol Genet Metab 94:283-6.
"
"3032","PC050353","Rodriguez-Gonzalez A, Lin T, Ikeda AK, et al. 2008. Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. Cancer Res 68:2557-60.
"
"3033","PC050353","Rodriguez-Gonzalez A, Cyrus K, Salcius M, et al. 2008. Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer. Oncogene [Epub ahead of print].
"
"3034","PC050353","Rodriguez-Gonzalez A and Sakamoto KM.  2008.  Proteolysis targeting chimeric molecules: Recruiting cancer-causing proteins for ubiquitination and degradation.  In:  Modulation of Protein Stability in Cancer Therapy (Sakamoto KM and Rubin E, Eds.).  Springer Publishing, Secaucus, New Jersey.

"
"3035","PC050355","Mucci L, Pawitan Y, Demichelis F, et al.  2008.  Testing a multigene signature of prostate cancer death in the swedish watchful waiting cohort.  Cancer Epi Biom Prev 17:1682-8."
"3036","PC050355","Andrén O, Fall K, Andersson SO, et al.  2007.  MUC-1 gene is associated with prostate cancer death ¿ a 20 year follow-up of a population-based study in Sweden.  Br J Cancer 97(6):730-734."
"3037","PC050355","Mucci L, Pawitan Y, Demichelis F, et al.  2008.  Nine-gene molecular signature in tumors does not predict prostate cancer death.  Cancer Epi Biom Prev17(1):249-251."
"3038","PC050355","Demichelis F, Fall K, Perner S, et al.  2007.  TMPRSS2: ERG gene fusion associated with prostate cancer-specific death.  Oncogene 26(31):4596-4599."
"3039","PC050355","Setlur S, Mertz KD, Hoshida Y, et al.  2008.  Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.  J Natl Cancer Inst 100:815-25."
"3040","PC050364","Hamilton-Reeves JM, Rebello SA, Thomas W, et al.  2007.  Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor beta expression or serum hormonal profiles in men at high risk of prostate cancer.  J Nutr 137:1769-1775."
"3041","PC050364","Hamilton-Reeves JM, Rebello SA, Thomas W, et al.  2008.  Effects of soy protein isolate consumption on prostate cancer biomarkers in men at high risk of prostate cancer.  Nutr Cancer 60(1):7-13."
"3042","PC050364","Hamilton-Reeves JM, Rebello SA, Thomas W, et al.  2007.  Soy protein isolate increases urinary estrogens and the ratio of 2:16&#945;-hydroxyestrone in men at high risk of prostate cancer.  J Nutr 137:2258-2263."
"3043","PC050390","Moss PE, Lyles BE,and Stewart LV.  2010. The PPAR¿ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells.  Exp Cell Res 316(20):3478-3488."
"3044","PC050402","Chen M, Tanner M, Levine A, et al.  2009.  Androgenic regulation of hedgehog signaling pathway components in prostate cancer cells.  Cell Cycle 8:149-157."
"3045","PC050402","Terry S, Queires L, Gil-Diez-de-Median S, et al.  2006.  Protocadherin-PC promotes androgen-independent prostate cancer cell growth.  Prostate 66:1100-1113."
"3046","PC050402","Chen M, Feurstein MA, Levina E, et al.  2010.  Hedgehog / Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells.  Mol Cancer 9:89-101."
"3047","PC050402","Yang X, Chen M.-W, Terry S, et al.  2006.  Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells.  Oncogene 25:3436-3444."
"3048","PC050404","Zhang H, Wu Y, Malewicz B, et al.  Augmented suppression of androgen receptor signaling by a combination of alpha-tocopheryl succinate and methylseleninic acid.  Cancer 107:2942-8."
"3049","PC050404","Zhang H, Fang J, Yao D, et al.  2010.  Activation of FOXO1 is critical for the anticancer effect of selenium in prostate cancer cells.  The Prostate 70(12):1265-73."
"3050","PC050420","Chandrasekaran EV, Xia J, Xue J, et al.  2008. Reversible sialylation: Synthesis of Cytidine 5'-Monophospho-N-acetlneuraminic Acid from Cytidine 5'-Monophosphate with alpha2,3-Sialyl 0-Glycan-, Glycolipid-, and Macromolecule-Based Donors Yields Diverse Sialylated Products (dagger).  Biochemistry 47:320-30."
"3051","PC050440","Chao M, Li T, Schreibmann E, et al.  2008.  Automated contour mapping with a regional deformable model.  Int J Radiat Oncol Biol Phys 70:599-608."
"3052","PC050440","Chao M, Schreibmann E, Li T, et al.  2007.  Automated contour mapping using sparse volume sampling for 4D radiation therapy.  Med Phys 34:4023-4029."
"3053","PC050440","Li T, Koong A, and Xing L.  2007.  Enhanced 4D cone-beam CT with inter-phase motion model.  Med Phys 34:3688-3695."
"3054","PC050440","Li T and Xing L  2007.  Optimizing 4D cone-beam CT acquisition protocol for external beam radiotherapy.  Int J Radiat Oncol Biol Phys 67:1211-9."
"3055","PC050440","Wink N, Chao M, Antony J, et al.  2008.  Individualize treatment margin in respiration-gated radiation therapy.  Phys Med Biol 53:165-175."
"3056","PC050440","Chao M, Xie Y, and Xing L.  2008.  Auto-propagation of contours for adaptive prostate radiation therapy.  Physics in Medicine and Biology 53:4533-4542.

"
"3057","PC050440","Chao M, Xie Y, and Xing L.  2008.  Auto-propagation of contours for adaptive prostate radiation therapy.  Physics in Medicine and Biology 53(17):4533-4542."
"3058","PC050440","Xie Y, Chao M, Lee P, et al.  2008.  Feature-based rectal contour propagation from planning CT to cone beam CT for adaptive radiotherapy.  Medical Physics 35:4474-4487."
"3059","PC050442","Ozawa MG, CardÃ³-Vila M, Mintz PJ, et al.  2010.  Cracking the code for compartment-specific dual functionality proteins in cancer: the case for CRKL.  Cell Cycle 9(1):8-9."
"3060","PC050442","Mintz PJ et al.  2009.  An unrecognized extracellular function for an intracellular adapter protein released from the cytoplasm into the tumor microenvironment.  Proc Natl Acad Sci U S A 106:2182-7."
"3061","PC050457","De Marzo AM, Platz EA, Sutcliffe S, et al.  2007.  Inflammation in prostate carcinogenesis.  Nat Rev Cancer 7:256-269."
"3062","PC050457","Nakai Y, Nelson WG and De Marzo AM.  2007.  The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo [4,5-]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate.  Cancer Res 67(3):1378-1384."
"3063","PC050462","Zhao Y, Wang W, Han L, et al.  2007.  Isolation, structural determination, and evaluation of the biological activity of 20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol [20(S)-25-OCH3-PPD], a novel natural product from Panax notoginseng.  Med Chem 3:51-60."
"3064","PC050462","Wang W, Rayburn ER, Hao M, et al.  2008.  Prostate experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides.  Prostate 68:809-819."
"3065","PC050462","Wang W, Wang H, Rayburn ER, et al.  2008.  20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: Activity in vitro and in vivo and mechanisms of action.  Br J Cancer 98:792-802."
"3066","PC050462","Rayburn ER, Wang W, Zhang Z, et al.  2006.  Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy.  Prostate 66:1653-1663."
"3067","PC050462","Rayburn ER, Wang H, Zhang R, et al.  2006.  Antisense-based cancer therapeutics: are we there yet?  Expert Opinion in Emerging Drugs 11:337-352."
"3068","PC050462","Wang H, Rayburn E, Zhang R, et al.  2005.  Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics.  Current Pharmaceutical Design 11:2889-2907."
"3069","PC050462","Rayburn EER, Wang W, Zhang R, et al.  2007.  Experimental therapy for colon cancer: Anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53.  Int J Oncol 1511-1519."
"3070","PC050462","Wang W, Zhao Y, Rayburn ER, et al.  2007.  In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng.  Cancer Chemother Pharmacol 59:589-601

"
"3071","PC050485","Cobb LJ, Liu B, Lee KW, et al.  2006.  Phosphorylation by DNA-dependent protein kinase is critical for apoptosis induction by insulin-like growth factor binding protein-3.  Cancer Res 66:10878-10884."
"3072","PC050485","Cohen P.  2006.  Insulin-like growth factor binding protein-3:  Insulin-like growth factor independence comes of age.  Endocrinology 147:2109-2111."
"3073","PC050485","Liu B, Lee KW, Anzo M, et al.  2007.  IGFBP-3 inhibition of prostate cancer growth involves suppression of angiogenesis.  Oncogene 26:1811-1819.

"
"3074","PC050485","Heber D and Cohen P.  2006.  Endocrine and paracrine factors in carcinogenesis.  In: Nutritional Oncology, 2nd Edition (Heber D, Blackburn G, Go V, et al., Eds.).  Academic Press, Elsevier, Amsterdam, The Netherlands."
"3075","PC050485","Colon E, Strand ML, Carlsson-Skwirut C, et al.  2006.  Anti-apoptotic factor humanin is expressed in the testis and prevents cell-death in leydig cells during the first wave of spermatogenesis.  J Cell Physiol 208:373-85."
"3076","PC050485","Anzo M, Cobb LJL, Hwang DL, et al.  2008.  Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulation IGF axis but does not reduce tumor progression.  Cancer Res 68:3342-9."
"3077","PC050485","Kobayashi N, Barnard RJ, Said J, et al.  2008.  Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model.  Cancer Res 68:3066-3073."
"3078","PC050485","Lee KW, Cobb L, Ma L, et al.  2007.  Contribution of the orphan nuclear receptor Nur77 to the apoptotic action of IGFBP-3.  Carcinogenesis 28:1653-1658."
"3079","PC050485","
Raina K, Blouin MJ, Singh RP, et al.  2007.  Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.  Cancer Res 67:11083-11091.

"
"3080","PC050489","Huang C-Y, Beer TM, Higano CS, et al.  2007.  Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: Identification of a cytoprotective mechanism involving growth differentiation factor 15.  Clin Cancer Res 13 5825-33."
"3081","PC050497","Markowski MC, Bowen C, and Gelmann EP.  2008.  Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1.  Cancer Res 68:(17)."
"3082","PC050506","Wang X, Yin L, Rao P, et al.  2007.  Targeted treatment of prostate cancer, J Cell Biochem 
102:571-9."
"3083","PC050506","Jayaprakash S, Wang X, Kozikowski AP, et al.  2006.  Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy.  Chem Med Chem 1(1):299-302."
"3084","PC050513","McLerran D, Grizzle WE, Feng Z, et al.  2007.  SELDITOF-MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer.  Clin Chem 54(1):53-60."
"3085","PC050513","McLerran D, Grizzle WE, Feng Z, et al.  2008.  SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer.  Clin Chem 54:53-60."
"3086","PC050513","McLerran D, Grizzle WE, Feng Z, et al.  2008.  Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: Sources of sample bias.  Clin Chem 54:44-52. 

"
"3087","PC050513","Drake RR, Schwegler EE, Malik G, et al.  2006.  Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers.  Mol Cell Proteomics 5:1957-1967."
"3088","PC050513","Semmes OJ, Malik G, and Ward M.  2006.  Application of mass spectrometry to the discovery of biomarkers for detection of prostate cancer.  J Cell Biochem 98:496-503."
"3089","PC050513","Malik G, Rojahn E, Ward MD, et al.  2007.  SELDI protein profiling of dunning R3327 derived cell lines: Identification of molecular markers of prostate cancer progression.  The Prostate 67(14):1565-1575."
"3090","PC050513","McLerran D, Grizzle WE, Feng Z, et al.  2007.  Analytical validation of protein expression profiling for diagnosis of PCa: Sources of sample bias.  Clin Chem 54(1):44-52."
"3091","PC050513","Malik G, Rojahn E, Ward MD, et al.  2007.  SELDI protein profiling of Dunning R-3327 derived cell lines: Identification of molecular markers of prostate cancer progression.  Prostate 67:1565-1575."
"3092","PC050531","Yoshimoto M, Joshua AM, Ludkovski O, et al.  2008.  Absence of TMPRSS2:ERG gene rearrangement and PTEN losses in prostate cancer is associated with a favourable outcome.  Mod Pathol 23."
"3093","PC050531","Joshua AM, Evans A, Van der Kwast T, et al.  2008.  Prostatic preneoplasia and beyond. Biochim Biophys Acta 1785(2):156-181"
"3094","PC050531","Yoshimoto M, Cutz JC, Nuin PA, et al.  2006.  Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias.  Cancer Genetics Cytogenetics 169(2):128-137."
"3095","PC050531","Yoshimoto M, Joshua AM, Chilton-Macneill S, et al.  2006.  Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.  Neoplasia 8(6):465-469."
"3096","PC050531","Joshua AM, Vukovic B, Braude I, et al.  2007.  Telomere length analysis of high-grade prostatic intraepithelial Neoplasia and surrounding stroma predicts outcome to prostate cancer and provides evidence of field carcinogenesis.  Neoplasia 9(1):81-89."
"3097","PC050535","Sarma K, Margueron R, Ivanov A, et al.  2008.  Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo.  Mol Cell Biol 28:2718-2731."
"3098","PC050535","Margueron R, Li G, Sarma K, et al.  2008.  Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms.  Mol Cell 32:503-18."
"3099","PC050541","Park ER, Eblen ST and Catling AD.  2007.  MEK Activation by PAK:  A novel mechanism.  Cell Signal 191488-1496."
"3100","PC050549","Mao X, Gluck N, Li D, et al.  2009.  GCN5 is required cofactor for a ubiquintin ligase that targets NF kappa B/RelA.  Genes Dev (7):849-861."
"3101","PC050549","Ramsey CS, Yeung F, and Stoddard PB, et al.  2008.  Copine-I represses NF-kappaB transcription by endoproteolysis of p65.  Oncogene 27:3516-26."
"3102","PC050554","Miles FL, Pruitt FL, van Golen KL, et al.  2008.  Stepping out of the flow: Capillary extravasation in cancer metastasis.  Clin Exp Metastasis 25:305-324."
"3103","PC050571","Nwachukwu JC, Li W, Huang HY, et al.  2007.  Transcriptional regulation of the androgen receptor cofactor, ART-27.  Mol Endocrinol (12):2864-76."
"3104","PC050571","Taneja SS, Ha S, Swenson NK, et al.  2005.  Cell specific regulation of androgen receptor phosphorylation in vivo.  J Biol Chem 280:40916-24."
"3105","PC050571","Shapiro E, Huang HY, Ruoff R, et al.  2008.  The heterochromatin protein 1 family is regulated in prostate development and cancer.  J Urol 179:2435-9.
"
"3106","PC050571","Chen W, Dang T, Blind R, et al.  2008.  Glucocorticoid receptor phosphorylation differentially affects target gene expression.  Mol Endocrinol 22(8):1754-1766."
"3107","PC050608","Wang GG, Cai L, Pasillas MP, et al.  2007.  NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis.  Nat Cell Biol 9(7):804-812."
"3108","PC050608","Kim JH, Kim B, Cai L, et al.  2005.  Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes.  Nature 434(7035):921-926."
"3109","PC050608","Wang J, Scully K, Zhu X, et al.  2007.  Opposing LSD1 complexes function in developmental gene activation and repression programmes.  Nature 446:882-887."
"3110","PC050617","Rahrmann EP, Collier LS, Knutson TP, et al.  2009.  Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon based somatic mutagenesis screen.  Cancer Res 69:4388-97."
"3111","PC050649","Dai B, Kim O, Xie Y, et al.  2006.  Tyrosine Kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse.  Cancer Res 66: 8058-8064."
"3112","PC050649","Xie Y, Xu K, Dai B, et al.  2006.  The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs.  Oncogene 25:70-78."
"3113","PC050649","Guo Z, Dai B, Jiang T, et al.  2006.  Regulation of androgen receptor activity by tyrosine phosphorylation.  Cancer Cell, 10:309-319."
"3114","PC050649","Xu K, Shimelis H, Linn DE, et al.  2009.  Regulation of androgen receptor transcriptional activity and specificity by RNF6.  Cancer Cell 15:270-282."
"3115","PC050653","Ricke WA, McPherson SJ, Bianco JJ, et al.  2008.  Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha-signaling.  FASEB J 22:1512-20."
"3116","PC050656","Heaphy CM, Hines WC, Butler KS, et al.  2007.  Assessment of the frequency of allelic imbalance in human tissue using a multiplex polymerase chain reaction system. J Mol Diagn 9:266-71."
"3117","PC050656","Heaphy CM, Hines WC, Butler KS, et al. 2007.   Measurement of genome-wide allelic imbalance in human tissue using a multiplex PCR system.  J Mol Diagn 9(2):266-271."
"3118","PC050656","Heaphy CM, Bisoffi M, Fordyce CA, et al.  2006.  Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors.  Int J Cancer 119:108-116 (Appendix B)."
"3119","PC050667","Xu J, Humphrey PA, Kibel AS, et al.  2009.  Magnetic resonance diffusion characteristics of histologically defined prostate cancer in humans.  Magn Reson Med 61:842-50.
"
"3120","PC050680","Rankin AM1, Forman L, Sarkar S, et al.  2013.  Enhanced cytotoxicity from deoxyguanosine-enriched T-oligo in prostate cancer cells.  Nucleic Acid Ther 23(5):311-321."
"3121","PC050680","Longe HO, Romesser PB, Faller DV, et al.  2008.  Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: Mechanism and therapeutic potential.  Int J Cancer 124(2):473-482."
"3122","PC050680","Rankin A, Spanjaard RA, and Faller DV.  2008.  Telomerase inhibitors versus T-Oligo; Contrasting mechanisms of cytotoxicity in cancer.  Anti-Cancer Drugs 19:329-338."
"3123","PC050682","Meng Y, Tang W, Dai Y, et al.  2008.  Natural BH3-mimetic chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.  Mol Cancer Ther 7(7):2192-2202."
"3124","PC050682","Dai Y, Lawrence TS and Xu L.  2009.  Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B.  Am J Transl Res 1(1):4-18."
"3125","PC050682","Dai Y, Liu M, Tang W, et al.  2008.  Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis.  Clin Cancer Res 14:7701-10."
"3126","PC050682","Dai Y, DeSano TJ, Meng Y, et al.  2009.  Celastrol potentiates radiation therapy via impairment of DNA damage processing in human prostate cancer.  Int J Radiat Oncol Biol Phys 74(4):1217-1225."
"3127","PC050682","Dai Y, Liu M, Tang W, et al.  2009.  A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.  BMC Cancer  9:392."
"3128","PC050682","Dai Y, Desano J, Tang W, et al.  2010. Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB. PLoS One 5(12):e14153."
"3129","PC050682","Dai Y, Desano J, Qu Y, et al.  2011.  Natural IAP inhibitor Embelin enhances therapeutic efficacy of ionizing radiation in prostate cancer. Am J Cancer Res 1(2):128-143.
"
"3130","PC050684","Tsukano C, Siegel DR, and Danishefsky SJ.  2007.  Differentiation of nonconventional 'carbanions'- the total synthesis of nemorosone and clusianone.  Angew Chem Int Ed Engl 46:8840-4."
"3131","PC050690","Ewald JA, Desotelle JA, Almassi N, et al.  2008.  Drug-induced senescent prostate cancer induces proliferation in vitro but not in vivo.  Br J Cancer 98:1244-1249."
"3132","PC050690","Ewald JA, Desotelle JA, Laurila T, et al.  2009.  A novel high-throughput screen to identfy senescence-inducing compounds.  J Biomol Screen 14(7):853-858."
"3133","PC050691","Ghosh R, Gu G, Tillman E, et al.  2007.  Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression.  Prostate 67(10):1038-1052.  PMID:17455228."
"3134","PC050691","Williams K, Ghosh R, Giridhar PV, et al.  2012.  Inhibition of Stathmin1 accelerates the metastatic process. Can Res 72(20):5407-5417."
"3135","PC050698","Zhang J, Lipinski R, Shaw A, et al.  2007.  Lack of demonstrable autocrine hedgehog signaling in human prostate cancer cell lines.  J Urol 177:1179-85."
"3136","PC050698","Shaw A and Bushman W.  2006.  Isolation and characterization of an immortalized mouse urogenital sinus mesenchyme cell line.  Prostate 66:1347-58."
"3137","PC050698","Shaw A and Bushman W.  2007.  Hedgehog signaling in the prostate.  J Urol 177:832-8."
"3138","PC050698","Cook C, Vezina CM, Hicks SM, et al.  2007.  Noggin is required for normal lobe patterning and ductal budding in the mouse prostate.  Dev Biol 312(1)217:230."
"3139","PC050707","Xiao M, Nyagilo1 J, Arora V, et. al.  2010. Gold Nanotags for Combined
Multi-Colored Raman Spectroscopy and X-Ray Computed Tomography. Nanotechnology, 21(3): 1-8."
"3140","PC050707","Zhou Y, Gulaka P, Zhou J, et. al. 2008. Preparation and Evaluation of a Radioisotope-incorporated Iron Oxide Core/Au Shell Nanoplatform for Dual
Modality Imaging. J. Biomed. Nanotechnol.4:474-481"
"3141","PC050720","Haiyang H, Morely JE, Silva-Lopez E, et al.  2009.  Synthesis and characterization of nonsteroidal-linked M(CO)3+ (M = 99mTc, Re) compounds based on the androgen receptor targeting molecule flutamide.  Bioconjug Chem 20:78-86."
"3142","PC050720","Benny Paul D, Fugate FA, Barden AO, et al.  2008.  Metal-assisted in situ formation of a tridentate acetylacetone ligand for complexation of fac-Re(CO)3+ for radiopharmaceutical applications.  Inorg Chem 47(7):2240-2242."
"3143","PC050720","Moore AL, Bu[bad character(269)]arb D-K, MacGillivray LR, et al.  2010.  'Click' labeling strategy for M(CO)3 (M= Re, 99mTc) prostate cancer targeted flutamide agents.  Dalton Trans.  RSC Publishing, Cambridge, United Kingdom."
"3144","PC050720","Benny PD, Fugate GA, Morley JE, et al.  2009.  Synthesis and characterization of 2,5-bis(benzyl thio)-1,3,4-thiadiazole complexes with fac-ReBr3(CO) 32-.  Inorganica Chim Acta 362:1289-1294."
"3145","PC050720","Benny PD, He H, and Morley J.  2009.  Functionalized cysteine derivatives for labeling Tc(CO)3.  J Radiolabeled Compounds S442."
"3146","PC050720","He H, Morley JE, Twamley B, et al.  2009.  Investigation of the coordination interactions of S-(Pyridin-2-ylmethyl)-L-Cysteine Ligands with M(CO)3 + (M = Re, 99mTc).  Inorg Chem 48(22):10625-10634."
"3147","PC050733","Podder TK, Sherman J, Rubens D, et al.  2008.  Methods for prostate stabilization during transperineal LDR brachytherapy.  The International Journal of Physics in Medicine and Biology 53:1563-1579."
"3148","PC050733","Yan K, Podder T, Buzurovic I, Y. et al.  2008.  Investigation of radioactive seed immobilization techniques for interstitial brachytherapy procedure:  Preliminary study.  International Journal of Computer Assisted Radiology and Surgery 3-1:S335-S336.

"
"3149","PC050733","Podder TK, Buzurovic I, Huang K, et al.  2011.  Reliability of EUCLIDIAN: an autonomous robotic system for image-guided prostate brachytherapy. Med Phys 38(1):96-106."
"3150","PC050733","Podder TK, Ng WS, and Yu Y.  2007.  Multichannel robotic system for prostate brachytherapy. The 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) 1233-1236, Lyon, France."
"3151","PC050733","Podder TK, Sherman J, Li L, et al.  2007.  Mechanical properties of human prostate tissue in the context of surgical needle insertion.  International Journal of Computer Assisted Radiology and Surgery 2:S106-108."
"3152","PC050733","Yan K, Podder T, Sherman J, et al.  2008.  A novel method for estimating needle insertion force using patient-specific factors.  International Journal of Computer Assisted Radiology and Surgery 3-1:S302-S303."
"3153","PC050734","Tyner A and Brauer P.  2008.  FRK.  Targeted Proteins Database 1:[22045],10.2970/tpdb.2008.177."
"3154","PC050738","Senoo M, Pinto F, Crum CP, et al.  2007.  p63 is essential for the proliferative potential of stem cells of stratified epithelia.  Cell 129:523-36."
"3155","PC050738","Yang A, Zhu Z, Kapranov P, et al.  2006.  Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. Molecular Cell 24:593-602."
"3156","PC050754","Lee KW, Cobb LJ, Paharkova-Vatchkova V, et al.  2007.  Contribution of the orphan nuclear receptor Nur77 to the apoptotic action of IGFBP-3.  Carcinogenesis 28:1653-1658."
"3157","PC050754","Cobb LJ, Liu B, Lee K-W, et al.  2006.  Phosphorylation by DNA-dependent protein kinase is critical for apoptosis induction by insulin-like growth binding protein 3.  Cancer Res 66:10878-10884."
"3158","PC050754","Cobb LJ, Liu B, Lee KW, et al.  2006.  Phosphorylation by DNA-dependent protein kinase is critical for apoptosis induction by insulin-like growth factor binding protein-3.  Cancer Res 66:10878-10884."
"3159","PC050766","Yu JX, Cui W, Zhao D, et al.  2008.  Non-invasive physiology and pharmacology using 19F magnetic resonance.  In:  Fluorine and Health (Tressaud A and Haufe G, Eds.), Elsevier B.V. (Chapter 5)."
"3160","PC050766","Jennewein M, Lewis MA, Zhao D, et al.  2008.  Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine.  Clin Cancer Res 14:1377-85."
"3161","PC050766","Kodibagkar VD, Wang X, Mason RP.  2008.  Physical principles of quantitative nuclear magnetic resonance oximetry.  Front Biosci 13:1371-1384."
"3162","PC050766","Kodibagkar VD, Wang X, Pacheco-Torres J, et al.  2008.  Proton imaging of siloxanes to map tissue oxygenation levels (PISTOL):  A tool for quantitative tissue oximetry.  NMR Biomed 21:899-907."
"3163","PC050769","Alam SM, Rajendran M, Ouyang S, et al.  2008.  A novel of role of Shc adaptor proteins in steroid hormone-regulated cancers.  Endocr Relat Cancer (Epub-PMID: 19001530)."
"3164","PC050769","Yuan TC, Veeramani S, Lin FF, et al.  2007.  Neuroendocrine-like prostate cancer cells: Neuroendocrine transdifferentiation of prostate adenocarcinoma cells.  Endocr-Relat Cancer 14:531-547 [PMID: 17904087].

"
"3165","PC050769","Veeramani S, Igawa T, Yuan TC, et al.  2005.  Expression of p66Shc protein correlates with proliferation of human prostate cancer cells.  Oncogene 24:7203-7212"
"3166","PC050769","Veeramani S, Yuan TC, Lin FF, et al.  2008.  Mitochondrial redox signaling by p66Shc is involved in regulating androgenic growth stimulation of human prostate cancer cells.  Oncogene 27:5057-5068."
"3167","PC050769","
Rajendran M, Thomes P, Zhang L, et al.  2010.  p66Shc - A longevity redox protein in human prostate cancer progression and metastasis.  Cancer Metastasis Rev 29(1):207-222.
"
"3168","PC050769","Zhang L, Davis JS, Zelivianski S, et al.  2009.  Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by Gemcitabine in an androgen-reduced environment.  Cancer Lett 285:58-65 [PMID: 19467571]."
"3169","PC050769","Chen SJ, Karan D, Johansson SL, et al.  2007.  Prostate-derived factor as a paracrine and autocrine factor for the proliferation of androgen receptor-positive human prostate cancer cells. The Prostate 67:557-571 [PMID: 17221842]."
"3170","PC050769","Yuan TC, Lin FF, Veeramani S, et al.  2007.  ErbB-2 via PYK2 up-regulates the adhesive ability of androgen receptor-positive human prostate cancer cells.  Oncogene 26:7552-7559.

"
"3171","PC050769","Yuan TC, Veeramani S, Lin FF, et al.  2006.  Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.  Endocr-Relat Cancer 13:151-167 [PMID: 16601285]."
"3172","PC050773","Chen CT and Doxsey S.  2009.  A last-minute rescue of trapped chromatin.  Cell 136:397-399."
"3173","PC050782","Jeter C, Badeaux M, Choy G, et al.  2009.  Functional evidence that the self-renewal gene NANOG regulates human tumor development.  Stem Cells 27(5):993-1005."
"3174","PC050782","Patrawala L, Calhoun T, Schneider-Broussard R, et al.  2005.  Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2-cancer cells are similarly tumorigenic.  Cancer Res 65:6207-6219."
"3175","PC050782","Tang DG, Patrawala L, Calhoun T, et al.  2007.  Prostate cancer stem/progenitor cells: Identification, characterization, and implications.  Mol Carcinogenesis 46:1-14."
"3176","PC050782","Li HW, Jiang M, Honorio S, et al.  2009.  Methodologies in assaying prostate cancer stem cells.  Methods Mol Biol 568:85-138."
"3177","PC050782","Patrawala L, Calhoun T, Schneider-Broussard R, et al.  2006.  Highly purified CD44+ prostate cancer cells from xenograt human tumors are enriched in tumorigenic and metastatic progenitor cells.  Oncogene 25 1696-1708."
"3178","PC050782","Patrawala L and Tang DG.  2008.  CD44 as a functional caner stem cell marker and therapeutic target.  Progress in Gene Therapy:  Autologous and Cancer Stem Cell Gene Therapy.  World Scientific Publishers 3:317-334."
"3179","PC050782","Bhatia B, Multani AS, Patrawala L, et al.  2008.  Evidence that senescent human prostate epithelial cells enhance tumorigenicity:  Cell fusion as a potential mechanism and inhibition by p161NK4a and hTERT.  Int J Cancer 122:1483-1495."
"3180","PC050782","Bhatia B, Jiang M, Suraneni M, et al.  2008.  Critical and distinct roles of p16 and telomerase in regulating the proliferative lifespan of normal human prostate epithelial progenitor cells.  J Biol Chem 283:27959-27972."
"3181","PC050782","Patrawala L, Calhoun-Davis T, Schneider-Broussard R, et al.  2007.  Hierarchical organization of prostate cancer cells in xenograft tumors:  The CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells.  Cancer Res 67:6796-6805."
"3182","PC050785","Freedland SJ, Mavropoulos J, Wang A, et al.  2008.  Carbohydrate restriction and prostate cancer growth.  Prostate 2008 68:11-19."
"3183","PC050790","Suh M-J, Tang X-H, and Gudas LJ.  2006.  Structure elucidation of retinol metabolites in biological samples using PSD LDI mass spectrometry after HPLC separation.  Anal Chem 78:5719-5728."
"3184","PC050790","Tang X-H, Suh M-J, Li R, et al.  2007.  Cell proliferation inhibition and alterations of retinol esterification induced by phytanic acid and docosahexaenoic acid in normal human prostate epithelial cells and in prostate cancer cells: Identification of novel retinyl esters by mass spectrometry.  J Lipid Res 48:165-176."
"3185","PC050812","Prins GS, Tang WY, Belmonte J, et al.  2008.  Developmental exposure to bisphenol A increases prostate cancer susceptibility in adult rats: Epigenetic mode of action is implicated.  Fertil Steri 89(2 Suppl):e41."
"3186","PC050812","Prins GS, Birch L, Tang WY, et al.  2007.  Developmental estrogen exposures predispose to prostate carcinogenesis with aging.  Reprod Toxicol 23(3):374-382."
"3187","PC050812","Prins GS, Tang WY, Belmonte J, et al.  2007.  Perinatal exposure to estradiol and bisphenol A alters the prostate epigenome and increases susceptibility to carcinogenesis.  Basic Clin Pharmacol Toxicol 102(2):134-138."
"3188","PC050812","Tang WY and Ho S.  2007.  Epigenetic reprogramming and imprinting in origins of disease.  Reviews in Endocrine and Metabolic Disorder 8(2):173-182."
"3189","PC050812","Ho S and Tang WY.  2007.  Techniques used in studies of epigenome dysregulation due to aberrant DNA methylation: An emphasis on fetal-based adult diseases.  Reprod Toxicol 23:267-82."
"3190","PC050812","Ho S, Tang WY, Belmonte J, et al.  2006.  Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4.  Cancer Research 66(11):5624-5632."
"3191","PC050812","Prins GS, Birch L, Tang WY, et al.  2006.  Developmental estrogen exposures predispose to prostate carcinogenesis with aging.  Reprod Toxicol 23:374-82."
"3192","PC050817","Srinivasan R, Mager GM, Ward RM, et al.  2006.  The NAB2 corepressor interacts with the CHD4 subunit of the NuRD complex.  J Biol Chem 281:15129-15137."
"3193","PC050818","Kawai T, Hiroi S, Nakanishi K, et al.  2007.  Telomere length and telomerase expression in atypical adenomatous hyperplasia and small bronchioloalveolar carcinoma of the lung.  Am J Clin Pathol 127:254-262."
"3194","PC050818","Bechan GI, Meeker AK, Marzo AM, et al.  2008.  Telomere length shortening in Langerhans cell histiocytosis.  Br J Haematol 140(4):420-428.

"
"3195","PC050818","Cummings SD, Ryu B, Samuels MA, et al.  2008.  Id1 delays senescence of primary human melanocytes.  Mol Carcinog 47:653-659.
"
"3196","PC050818","Stewénius Y, Jin Y, Øra I, et al.  2007.  Defective chromosome segregation and telomere dysfunction in aggressive Wilms' tumors.  Clin Cancer Res 13:6593-6602."
"3197","PC050818","Iwata T, Meeker AK, Smearman E, et al.  2008.  The telomere shortening in prostatic atrophy lesions.  Lab Invest 88:162A-162A 738."
"3198","PC050818","Hansel DE, Meeker AK, Hicks J, et al.  2006.  Telomere length variation in biliary tract metaplasia, dysplasia, and carcinoma.  Mod Pathol 19:772-779."
"3199","PC050818","Palapattu GS, Meeker AK, Harris T, et al.  2006.  Epithelial architectural destruction is necessary for bone marrow derived cell contribution to regenerating prostate epithelium.  J Urol 176:813-818."
"3200","PC050820","Kim SY and Hahn WC.  2007.  Cancer genomics: Integrating form and function.  Carcinogenesis 28(7):1387-92."
"3201","PC050820","Boehm J, Zhao J, Yao J, et al.  2007.  Integrative genomic approaches identify IKBKE as a breast cancer oncogene.  Cell 129(6):1065-79."
"3202","PC050825","Mease RC, Dusich CL, Foss CA, et al.  2008.  N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: A new imaging probe for prostate cancer.  Clin Cancer Res 14:3036-43"
"3203","PC050830","Hillier SM, Marquis JC, Zayas B, et al.  2006.  DNA adducts formed by a novel antitumor agent 11&#946;-dichloro in vitro and in vivo.  Mol Cancer Ther 5(4);977-984."
"3204","PC050850","Guo Y, Zhang W, Giroux C, Cai, et al.  2011.  Identification of the orphan G protein-coupled receptor GPR31 as a receptor for 12-(S)-hydroxyeicosatetraenoic acid.  J Biol Chem 286(39):33832-33840.  "
"3205","PC050873","Dybiec M, Chornokur G, Ostapenko S, et al.  2007.  Photoluminescence spectroscopy of bioconjugated CdSe/ZnS quantum dots.  Appl Phys Lett 90:263112-263115 (Appendix 8)."
"3206","PC050873","Torchynska TV, Diaz Cano A, Dybiec M, et al.  2007.  Raman scattering and SEM study of bio-conjugated core-shell CdSe/ZnS quantum dots. Phys Status Solidi (c) 4(2):241-243 (Appendix 7)."
"3207","PC050873","Chornokur G, Ostapenko S, Oleynik E, et al.  2008.  Scanning photoluminescent spectroscopy of bioconjugated quantum dots.  Superlattices and Microstructures 45(4-5):240-248."
"3208","PC050873","Chornokur G, Ostapenko S, Emirov Y, et al.  2008.  Biologically engineered quantum dots for biomedical applications.  MRS Proceedings 1095E:1095-EE08-05."
"3209","PC050873","Chornokur G, Ostapenko S, Emirov Y, et al.  2008.  Spectroscopic behavior of bioconjugated quantum dots.  Semicond Sci Technol 23."
"3210","PC050899","Zhao H, Ramos CF, Brooks JD, et al.  2007.  Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues.  J Cell Physiol 210:111-121."
"3211","PC050906","Wang X, Lundgren AD, Singh P, et al.  2009.  An six-amino acid motif in the alpha3 domain of MICA is the cancer therapeutic target to inhibit shedding.  Biochem Biophys Res Commun 387(3):476-481."
"3212","PC050906","Wu JD, Atteridge CL, Wang X, et al.  2009.  Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation.  Clin Cancer Res 15(2):632-640."
"3213","PC050918","Xie Y, Xu K, Dai B, et al.  2006.  The 44 kd Pim-1 kinase directly interacts with tyrosine Kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs.  Oncogene 25:70-78."
"3214","PC050918","Xie Y, Xu K, Linn D, et al.  2008.  The 44 kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and promotes its drug resistant activity in human prostate caner cells.  J Biol Chem 283:3349-3356."
"3215","PC050918","Xu K, Shimelis H, Linn DE, et al.  2009.  Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination.  Cancer Cell 15:270-82."
"3216","PC050938","Birnie R, Bryce SD, Roome C, et al.  2008.  Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions.  Genome Biology 9:R83."
"3217","PC050938","Maitland NJ and Collins AT.  2008.  Prostate cancer stem cells: A new target for therapy.  Journal of Clinical Oncology 26(17):2862-2870."
"3218","PC050938","Maitland NJ and Collins AT.  2008.  Inflammation as the primary aetiological agent of human prostate cancer: A stem cell connection?  J Cellular Biochem 105:931-939."
"3219","PC050938","Keith WN, Thomson CM, Howcroft J, et al.  2007.  Seeding drug discovery: Integrating telomerase cancer biology and cellular senescence to uncover new therapeutic opportunities in targeting cancer stem cells.  Drug Discov Today 12(15-16):611-621 [Epub 2007 Jul 27, Review].

"
"3220","PC050938","Maitland NJ, Bryce SD, Stower MJ, et al.  2006.  Prostate cancer stem cells: A target for new therapies.  Ernst Schering Found Symp Proc 5:155-9 (Review)."
"3221","PC050938","Maitland MJ, Bryce S, Stower M, et al.  Prostate cancer stem cells: A target for new therapies.  Schering Foundation Symposium Series, Springer Verlag, Berlin."
"3222","PC050938","Collins AT and Maitland NJ.  2006.  Prostate cancer stem cells.  European J Cancer 42:1213-1218."
"3223","PC050938","Maitland NJ and Collins AT.  2006.  Prostate cancer: New designs in treatment development.  Oncology News 1:5-7."
"3224","PC050942","Voloshyna I, Besana A, Castillo M, et al.  2008.  TREK-1 is a novel molecular target in prostate cancer.  Cancer Res 68:1197-203."
"3225","PC050945","Noberini R, Koolpe M, Peddibhotla S, et al.  2008.  Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.  J Biol Chem 283:29461-29472."
"3226","PC050945","Pasquale EB.  2007.  Eph receptors and ephrins.  In:  Modern Concepts in Angiogenesis (Simons M and Rubanyi G, Eds.)  Imperial College Press, London.  Chapter 18, pp 27-66."
"3227","PC050945","Noren NK and Pasquale EB.  2007.  Paradoxes of the EphB4 receptor in cancer.  Cancer Res 67:3994-3997.

"
"3228","PC050945","Pasquale EB.  2008.  Eph-ephrin bidirectional signaling in physiology and disease.  Cell 133:38-52."
"3229","PC050949","Chanda D, Isayeva T, Kumar S, et al.  2009.  Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostrate cancer bone metastasis.  Clin Cancer Res 15(23):7175-85."
"3230","PC050949","Kumar S, Wan C, Ramaswamy G, et al.  2010.  Modified mesenchymal stem cells producing osteogenic and angiogenic factors enhance bone regeneration in a mouse model of segmental bone defect.  Mol Ther 18:1026-1034."
"3231","PC050949","Isayeva T, Moore LD, Chanda D, et al.  2009.  Tumoristatic effects of endostatin in prostate cancer is dependent on androgen receptor status.  The Prostate 69:1055-1066."
"3232","PC050949","Chanda D, Isayeva T, Kumar S, et al.  2008.  Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis.  Mol Ther 16:871-878."
"3233","PC050949","Ren C, Kumar S, Chanda D, et al.  2008.  Anti-tumor activity of mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model.  Gene Ther 15:1446-53."
"3234","PC050949","Chanda D, Kumar S, and Ponnazhagan S.  2010.  Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton.  J Cell Biochem 111(2):249-57."
"3235","PC050949","Isayeva I, Chanda D, Eltoum IE, et al.  2007.  Effects of sustained anti-angiogenic therapy in multi-stage prostate cancer in TRAP mice.  Cancer Res 67:5789-97."
"3236","PC050949","Kumar S and Ponnoazhaan S.  2007.  Bone homing of  mesenchymal stem cells by ectopic (alpha) 4 integrin expression.  FASEB J 21:3917-27."
"3237","PC050959","Hamilton SR, Fard SF, Paiwand FF, et al.  2007.  The hyaluronan receptors CD44 and RHAMM (CD168) form complexes with ERK1, 2 that sustain high basal motility in breast cancer cells.  J Biol Chem 282:16667-16680.

"
"3238","PC050959","Tolg C, Hamilton SR, Nakrieko KA, et al.  2006.  RHAMM-/- fibroblasts are defective in CD44-mediated ERK1, 2 motogenic signaling, leading to defective skin wound repair.  J Cell Biol 175:1017-1028."
"3239","PC050965","Setlur SR, Mertz KD, Hoshida Y, et al. 2008. Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer. J Natl Cancer Inst 100:815-25."
"3240","PC050965","Setlur SR, Royce TE, Sboner A, et al.  2007.  Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer.  Cancer Res 67:10296-10303."
"3241","PC050965","Demichelis F, Fall K, Perner S, et al. 2007. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 26(31):4596-9."
"3242","PC050976","Ibaragi S, Yoshioka N, Kishikawa H, et al.  2009.  Angiogenin-stimulated ribosomal RNA transcription is essential for initiation and survival of AKT-induced prostate intraepithelial neoplasia.  Molecular Cancer Research 7(3):415-424."
"3243","PC050976","Yoshioka N, Wang L, Tsuji T, et al.  2006.  A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation.  Proceed Natl Acad Sci USA 103(39):14519-14524."
"3244","PC050976","Ibaragi S, Yoshioka N, Li S, et al.  2009.  Neamine inhibits prostate cancer growth by suppressing angiogenin-mediated ribosomal RNA transcription.  Clinical Cancer Research 15(6):1981-1988 (in press)."
"3245","PC050986","Wang K, Chen K, Kassis AI, et al.  2006.  Crystal structure of 2-(2¿-hydroxyphenyl)-6-tributylstanny1-4-(3H)-quinazolinone and 2-2(2¿-hydroxphenyl)-6-iodo-4-(3H)-quinazolinone.  Cryst Res Technol 41:622-627 (Appendix-I)."
"3246","PC050986","Pospisil P, Iyer LK, Adelstein SJ, et al.  2006.  A combined approach to data mining of textual and structured data to identify cancer-related targets.  BMC Bioinformatics 7:354."
"3247","PC050986","Pospisil P, Wang K, Al Aowad AF, et al.  2007.  Computational modeling and experimental evaluation of a novel prodrug for targeting the extracellular space of prostate tumors.  Cancer Res 67:2197-2205.

"
"3248","PC050986","Wang K, Adelstein SJ, and Kassis AI.  2008.  DMSO increases radioiodination yield of radiopharmaceuticals.  Appl Radiat Isotopes 66:50-59."
"3249","PC050990","Ahn M, Lee S-J, Li X, et al.  2009.  Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter.  Cancer Gene Ther 16:73-82."
"3250","PC050990","Ahn M, Li X, Lee S-J, et al.   Tumor-specific suicide gene therapy for prostate cancer using m6 promoter-driven herpes simplex virus thymidine kinase and ganciclovir.  Cancer Gene Ther. 4-18."
"3251","PC051037","Cockburn M, Mills P, Zhang X, et al. 2011. Prostate cancer and ambient pesticide exposure in agriculturally intensive areas in California.  Am J Epidemiol 173(11):1280-8."
"3252","PC051037","Costello S, Cockburn MG, Zhang X, et al.  2009.  Parkinson disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California.  Am J Epidemiol 169(8):919-926."
"3253","PC051037","Goldberg D, Wilson J, Knoblock C, et al.  2008.  An effective and efficient approach for manually improving geocodes.  Int J Health Geographics 7:60-79."
"3254","PC051049","Libertini S, Tepper CG, Rodriguez V, et al.  2007.  Evidence for calpain mediated androgen receptor cleavage as a mechanism of androgen independence and potential therapeutic target in prostate tumors.  Cancer Research 69:9001-9005."
"3255","PC051049","Bedolla RG, Wang Y, Asuncion A, et al.  2009.  Nuclear versus cytoplasmic localization of filamin A in prostate cancer:  Immunohistochemical correlation with metastases.  Clin Cancer Res 15(3):788-796."
"3256","PC051049","Chen H, Libertini SJ, Wang Y, et al.  2010.  Erk regulates calpain 2 induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines.  J Biol Chem 285(4):2368-2374."
"3257","PC051049","Devlin H-L and Mudryj M.  2009.  Progression of prostate cancer:  Multiple pathways to androgen independence.  Cancer Lett 274 (2):177-186.

"
"3258","PC051049","Chen H, Libertini SJ, George M, et al. 2010. Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines. Endocr Relat Cancer. 17(4):857-73."
"3259","PC051060","Wu LY, Do JC, Kazak M,et al.  2008.  Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen.  Bioorg Med Chem Lett 18(1):281-284."
"3260","PC051060","Liu T, Wu LY, Kazak M, et al.  2008. Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen.  Prostate 68(9):955-964."
"3261","PC051060","Liu T, Toriyabe Y, and Berkman CE.  2006.  Purification of prostate-specific membrane antigen with conformational epitope-specific antibody-affinity chromatography.  Prot Exp Purif 49:251 (in press)."
"3262","PC051060","Liu T, Toriyabe Y, Kazak M, et al.  2008.  Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics.  Biochemistry 47(48):12658-12660."
"3263","PC051072","Gray MA, Centeno JA, Slaney DP, et al.  2005.  Environmental exposure to trace elements and prostate cancer in three New Zealand ethnic groups.  Int J Environ Res Public Health 2:374-384."
"3264","PC051072","Sarafanov A, Todorov T, Kajdacsy-Balla A, et al.  2008  Analysis of iron, zinc, selenium and cadmium in paraffin-embedded prostate tissue specimens using inductively coupled plasma mass-spectrometry.  J Trace Elem Med Biol 22:305-14."
"3265","PC051072","Van der Voet GB, Sarafanov AG, Todorov TI, et al.  2008.  Clinical and analytical toxicology of dietary supplements: a case study and a review of the literature.  Biol Trace Elem Res 125:1-12."
"3266","PC051081","Taylor BS, Varambally S, and Chinnaiyan AM.  2006.  A systems approach to model metastatic progression.  Cancer Research 66(11):5537-5539."
"3267","PC051081","Tomlins SA, Laxman B, Varambally S, Cao et al.  2008.  Role of the TMPRSS2-ERG gene fusion in prostate cancer.  Neoplasia 10(2):177-188."
"3268","PC051081","Taylor BS, Varambally S, and Chinnaiyan AM.  2006.  Differential proteomic alterations between localized and metastatic prostate cancer.  Br J Cancer 95(4):425-430."
"3269","PC051081","Yu J, Cao Q, Mehra R, et al.  2007.  Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer.  Cancer Cell 12(5):419-431."
"3270","PC051081","Yu J, Yu J, Rhodes DR, et al.  2007.  A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.  Cancer Res 15; 67(22):10657-10663."
"3271","PC051081","Varambally S, Laxman B, Mehra R, et al.  2008.  Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer.  Neoplasia 10(11):1285-1294."
"3272","PC051081","Cao Q, Yu J, Dhanasekaran SM, et al.  2008.  Repression of E-cadherin by the polycomb group protein EZH2 in cancer.  Oncogene 27(58):7274-7284."
"3273","PC051081","Varambally S, Cao Q, Mani RS, et al.  2008.  Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.  Science 322(5908):1695-1699."
"3274","PC051099","Liu W, Chang B, Li T, et al.  2007.  Germline copy number polymorphisms involving larger than 100 kb are uncommon in normal subjects.  Prostate 67(3):227-233."
"3275","PC051100","Davis K, Haisfield L, Dorfman C, et al.  2011. Physicians' attitudes about the shared decision making process for prostate cancer screening.  Fam Med 43(4):260-266."
"3276","PC051100","Dorfman C, Williams RM, Kassan EC, et al.  2010.  The development of a web- and a print-based decision aid for prostate cancer screening.  BMC Med Inform Decis Mak 10:12."
"3277","PC051106","Kasper JS, Liu Y and Giovannucci E.  2009.  Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study.  Int J Cancer 124:1398-403."
"3278","PC051106","Kasper JS, Liu Y, Pollak MN, et al.  2008.  Hormonal profile of diabetic men and the potential link to prostate cancer.  Cancer Causes Control 19:703-10-9-14.

"
"3279","PC051110","Ouyang B, Leung YK, Wang V, et al. 2011. ethylacyl-CoA racemase spliced variants and their expression in normal and malignant prostate tissues.  Urology 77(1):249.e1-249.e7."
"3280","PC051110","Ouyang B, Bracken B, Burk B, et al. 2009.  A duplex qPCR assay based on quantification of alpha-methylacyl-coa racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer.  J Urology 181:2508-13."
"3281","PC051110","Ouyang B, Bracken B, Burke B, et al.  2009.  A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer.  J Urol 181(6):2508-2513."
"3282","PC051131","Chun JY, Hu Y, Pinder E, et al.  2007.  Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter.  Mol Cancer Ther 6(9):2572-2580.

"
"3283","PC051131","Namidity N and Gao AC.  2008.  Mechanisms of selenium chemoprevention and therapy in prostate cancer.  Mol Nutr Food Res 52(11):1247-60."
"3284","PC051131","Nadiminty N and Gao AC.  2009.  Selenium and androgen receptor signaling in prostate cancer.  In: Androgen Action in Prostate Cancer (Tindall D and Mohler J, Eds.).  Springer Science + Business Media.  ISBN: 978-0-387-69177-0."
"3285","PC051131","Dong Y, Zhang HT, Gao AC, et al.  2005.  Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers.  Molecular Cancer Therapeutics 4:1047-1055."
"3286","PC051131","Lee So, Chun JY, Nadiminty N, et al.  2006.  Monomethylated selenium inhibits the growth of LNCaP human prostate cancer xenograft accompanied by decrease in the expression of androgen receptor and prostate-specific antigen.  Prostate 66:1070-1075.

"
"3287","PC051131","Zhang H, Dong Y, Zhao HJ, et al.  2005.  Microarray data mining for potential selenium targets in chemoprevention of prostate cancer.  Cancer Genomics & Proteomics 2:97-114."
"3288","PC051131","Chun JY, Nadiminty N, Lee SO, et al.  2006.  Mechanisms of selenium down regulation of androgen receptor signaling in prostate cancer.  Mol Cancer Ther 5(4):913-918."
"3289","PC051131","Dong Y, Lee SO, Zhang H, et al.  2004.  Prostate specific antigen (PSA) expression is down-regulated by selenium through disruption of androgen receptor signaling.  Cancer Res 64(1):19-22."
"3290","PC051136","Lambert JR, Eddy VJ, Young CD, et al.  2010.  A vitamin D receptor-alkylating derivative of 1¿,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth.  Cancer Prev Res (Phila) 3(12):1596-1607."
"3291","PC051136","Ray R, Lambert JR.  2011.  1¿,25-Dihydroxyvitamin D3-3¿-bromoacetate, a potential cancer therapeutic agent: synthesis and molecular mechanism of action. Bioorg Med Chem Lett 21(8):2537-2540."
"3292","PC051136","Persons KS, Eddy VJ, Chadid S, et al.  Anti-growth effect of 1,25-dihydroxyvitamin D3-3-bromoacetate alone or in combination with 5-amino-imidazole-4-carboxamide-1-beta-4-ribofuranoside in pancreatic cancer cells. Anticancer Res 30(6):1875-1880."
"3293","PC051136","Kaya T, Swamy N, Persons KS, et al.  2009.  Covalent labeling of nuclear vitamin D receptor with affinity labeling reagents containing a cross-linking probe at three different positions of the parent ligand: Structural and biochemical implications.  Bioorg Chem 37:57-63."
"3294","PC051136","Ray A, Swamy N, and Ray R.  2008.  Cross-talk among structural domains of human DBP upon binding 25-hydroxyvitamin D.  Biochem Biophys Res Comm 365:746-750."
"3295","PC051136","Swamy N and Ray R.  2008.  Fatty acid-binding site environment of serum vitamin D-binding protein and albumin are different.  Bioorg Chem 36:165-168."
"3296","PC051136","Lambert J, Young C, Persons K, et al.  2007.  Mechanistic and pharmacodynamic studies of 25-dihydroxyvitamin D3 derivative in prostate cancer cells.  Biochemical and Biophysical Research Communication 361:189-195."
"3297","PC051153","Powell IJ, Dyson G, Land S, et al. 2013.  Genes associated with prostate cancer are differentially expressed in African American and European American men. Cancer Epidemiol Biomarkers Prev 22(5):891-897."
"3298","PC051156","Cheng J, Teply BA, Sherifi I, et al.  2007.  Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery.  Biomaterials 28:869-876."
"3299","PC051156","Teply BA, Rocha FG, Levy-Nissenbaum E, et al.  2006.  Nanoparticle-aptamer bioconjugates for targeted antineoplastic drug delivery.  Am J Drug Delivery 4:123-130."
"3300","PC051157","Estebanez-Perpina E and Fletterick RJ.  2008.  The androgen receptor coactivator binding interface.  In: Springer Science."
"3301","PC051157","Estébanez-Perpiñá E, Arnold LA, Jouravel N, et al.  2007.  Structural insight into the mode of action of a direct inhibitor of coregulator binding to the thyroid hormone receptor.  Mol Endocrinol 21(Issue 12):2919-2928."
"3302","PC051157","Estebanez-Perpina E, Arnold LA, Mar E, et al.  2007.  Inhibitors of androgen receptor-coregulators assembly.  Proc Natl Acad Sci U S A (PNAS), 104(41):16074-9."
"3303","PC051157","Arnold LA, Estebanez-Perpina E, Togashi M, et al.  2006.  A high-throughput screening method to identify small molecule inhibitors of thyroid hormone receptor coactivator binding. Sci STKE  341:13."
"3304","PC051157","Arnold LA, Estebanez-Perpina E, Togashi M, et al.  2005.  Discovery of small molecule inhibitors of the interaction of thyroid hormone receptor with transcriptional coregulators. JBiol Chem 280(52):43048-43055."
"3305","PC051157","Estebanez-Perpina E, Moore JM, Mar E, et al.  2005.  The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor. J Biol Chem 280:8060 8068."
"3306","PC051157","Estébanez-Perpiñá E and Fletterick RJ.  2009.  The androgen receptor coactivator binding interface.  In: Androgen Action in Prostate Cancer (Tindall D and Mohler J, Eds.).  Springer First Edition 297-314."
"3307","PC051157","Estebanez-Perpina E, Jouravel N, and Fletterick RJ.  2007.  Perspectives on designs of anti-androgens for prostate cancer.  Expert Opinion in Drug Discovery 2(10):1341-1355."
"3308","PC051157","Jouravel N, Sablin E, Arnold LA, et al.  2007.  Interaction between the androgen receptor and a segment of its corepressor SHP.  Acta Crystallogr D Biol Crystallogr 63(Pt 11):1198-1200."
"3309","PC051173","Xu C Graf LF, Fazli L, et al.  2007.  Regulation of global gene expression in the bone marrow microenvironment by androgen: Androgen ablation increased insulin-like growth factor binding protein-5 expression.  Prostate 67(15):1621-1629."
"3310","PC051194","Siclari VA, Guise TA and Chirgwin JM.  2006.  Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases.  Cancer Metastasis Rev 25:621-633.

"
"3311","PC051194","Guise TA, Kozlow WM, Heras-Herzig A, et al.  2005.  Molecular mechanisms of breast cancer metastases to bone.  Clin Breast Cancer 2:S46-53."
"3312","PC051194","Bendre MS, Margulies AG, Walser B, et al.  2005.  Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.  Cancer Res 65:11001-11009."
"3313","PC051194","Chirgwin JM and Guise TA.  2007.  Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment.  J Cell Biochem 102(6):1333-1342."
"3314","PC051194","Bartholin L, Wessner LL, Chirgwin JM, et al.  2007.  The human Cyr61 gene is a transcriptional target of transforming growth factor beta in cancer cells.  Cancer Lett 246:230-6."
"3315","PC051194","Fournier PG, Chirgwin JM, and Guise TA.  2006.  New insights into the role of T cells in the vicious cycle of bone metastases.  Curr Opin Rheumatol 18:396-404."
"3316","PC051194","Guise TA, Mohammad KS, Clines G, et al.  2006.  Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.  Clin Cancer Res 12:6213s-6216s."
"3317","PC051194","Chirgwin JM and Guise TA.  2006.  Does prostate-specific antigen contribute to bone metastases?  Clin Cancer Res 12:1395-1397."
"3318","PC051194","Kingsley LA, Fournier PF, Chirgwin JM, et al.  2007.  Molecular biology of bone metastasis ¿ the bone microenvironment changes the phenotype of tumor metastases to the skeleton.  Mol Cancer Ther 6:2609-2617."
"3319","PC051194","Sackett DL, Ozbun L, Zudaire E, et al.  2008.  Intracellular proadrenomedullin-derived peptides decorate the microtubules and contribute to cytoskeleton function.  Endocrinology 149:2888-98.

"
"3320","PC051194","Mohammad KS, Chirgwin JM, and Guise TA.  2008.  Assessing new bone formation in neonatal calvarial organ cultures.  Methods Mol Biol 455:37-50."
"3321","PC051194","Kingsley LA, Chirgwin JM and Guise TA.  2007.  Breaking new ground to build bone.  Proc Natl Acad Sci U S A 104(26):10753-10754."
"3322","PC051194","Titus B, Frierson HF Jr., Conaway M, et al.  2005.  Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2.  Cancer Res 65:7320-7327."
"3323","PC051194","Clines GA, Mohammad KS, Bao Y, et al.  2007.  Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation.  Mol Endocrinol 21:486-98."
"3324","PC051202","Carraway RE, Hassan S, and Dobner PR.  2008.  Protein kinase C inhibitors alter neurotensin receptor binding and function in prostate cancer PC3 cells.  Regul Pept 147:96-109."
"3325","PC051202","Hassan S and Carraway RE.  2006.  Involvement of arachidonic acid metabolism and EGF receptor in neurotensin-induced prostate cancer PC3 cell growth.  Regul Pept 133:105-114."
"3326","PC051202","Carraway RE, Hassan S and Cochrane DE.  2006.  Regulation of neurotensin receptor function by the arachidonic acid-lipoxygenase pathway in prostate cancer PC3 cells.  Prostaglandins Leukot Essent Fatty Acids 74:93-107."
"3327","PC051202","Carraway RE and Hassan S.  2007.  Neurotensin receptor binding and neurotensin-induced growth signaling in prostate cancer PC3 cells are sensitive to metabolic stress.  Regul Pept 141:140-153."
"3328","PC051202","Carraway RE and Plona AM.  2006.  Involvement of neurotensin in cancer growth:  Evidence, mechanisms and development of diagnostic tools.  Peptides 27:2445-2460.

"
"3329","PC051217","Zerbini LF, Czibere A, Wang Y, et al.  2006.  A novel pathway involving MDA-7/IL-24 mediates NSAID induced apoptosis of cancer cells.  Cancer Research 66:11922-11931."
"3330","PC051217","Gu X, Zerbini LF, Otu H, et al.  2007.  Reduced PDEF expression leads to an increase in cell motility, invasion and expression of mesenchymal genes in prostate cancer cells.  Cancer Res 67:4219-4226."
"3331","PC051227","Mendonca MS1, Chin-Sinex H, Gomez-Millan J, et al.  2007.  Parthenolide sensitizes cells to X-ray-induced cell killing through inhibition of NF-kappaB and split-dose repair.  Radiat Res 168(6):689-697."
"3332","PC051227","Shanmugam R, Kusumanchi P, Cheng L, et.al.  2010.  A Water-Soluble Parthenolide Analogue Suppresses in Vivo Prostate Cancer Growth by Targeting NFkB and Genrating Reactive Oxygen Species.  Prostate DOI 10.1002/pros.21141."
"3333","PC051247","Tahir SA, Park S, and Thompson TC.  2009.  Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cells.  Cancer Biol Ther 8(23):78-88."
"3334","PC051247","Li L, et al.  2009.  Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells.  Mol Cancer Res 7(11):1781-1791."
"3335","PC051247","Thompson TC, Tahir SA, Li L, et al.  2010.  The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis 13(1):6-11."
"3336","PC051247","Watanabe M, et al.  2009.  Functional analysis of secreted caveolin-1 in mouse models of prostate cancer progression.  Mol Cancer Res 7(9):1446-1455."
"3337","PC051247","Yang G, Timme TL, Naruishi K, et al.  2008.  Mice with cav-1 gene disruption have benign stromal lesions and compromised epithelial differentiation.  Exp Mol Pathol 84:131-140."
"3338","PC051247","Yang G, Addai J, Wheeler TM, et al.  2007.  Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis.  Hum Pathol 38(11):1688-1695.

"
"3339","PC051247","Tahir SA, Yang G, Goltsov AA, et al.  2008.  Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer.  Cancer Res 68(3):731-739."
"3340","PC051247","Tahir ST, Frolov A, Hayes TG, et al.  2006.  Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.  Clin Can Res 12(16):4872-4875."
"3341","PC051248","Arrach N, Zhao M, Porwollik S, et al.  2008.  Salmonella promoters preferentially activated inside tumors.  Cancer Res 68:4827-4832."
"3342","PC051248","Zhao M., Geller J, Ma H, et al.  2007.  Monotherapy with a tumor targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer.  Proc Natl Acad Sci USA 104:10170-10174."
"3343","PC051248","Yam C, Zhao M, Hayashi K, et al.  2010.  Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer. J Surg Res 164(2):248-255."
"3344","PC051259","Mori R, Wang Q, Xiong S, et al.  2010.  The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes.  Prostate 70(15):1692-1700."
"3345","PC051259","Mori R, Wang Q, Quek ML, et al.  2008.  Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer.  Anticancer Res 28(1B):425-430."
"3346","PC051259","Daneshmand S, Quek ML, Lin E, et al.  2007.  Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival.  Hum Pathol 38:1547-1552."
"3347","PC051264","Chang BL, Liu W, Sun J, et al.  2007.  Integration of somatic deletion analysis of prostate cancers and germline linkage analysis of prostate cancer families reveals two small consensus regions for prostate cancer genes at 8p.  Cancer Res 67(9):4098-103."
"3348","PC051264","Sun J, Liu W, Adams TS, et al.  2007.  DNA copy number alterations in prostate cancers: A combined analysis of published CGH studies.  Prostate 67(7):692-700."
"3349","PC051264","Kim JW, Kim ST, Turner AR, et al.  2012.  Identification of new differentially methylated genes that have potential functional consequences in prostate cancer. PLoS One 7(10):e48455."
"3350","PC051264","Liu W, Chang B, Sauvageot J, et al.  2006.  Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array.  Genes Chromosomes Cancer 45(11):1018-32."
"3351","PC051264","Liu W, Chang B, Li T, et al.  2007.  Germline copy number polymorphisms involving larger than 100 kb are uncommon in normal subjects.  Prostate 67(3):227-33."
"3352","PC051264","Zheng SL, Sun J, Cheng Y, et al.  2007.  Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans.  J Natl Cancer Inst 99(20):1525-33."
"3353","PC051264","Liu W, Chang BL, Cramer S, et al.  2007.  Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers.  Clin Cancer Res 13(17):5028-33."
"3354","PC051264","
Liu W, Ewing CM, Chang BL, et al.  2007.  Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers.  Genes Chromosomes Cancer 46(11):972-80.
"
"3355","PC051264","Xu J, Zheng S, Isaacsc SD, et. al. 2009. Inherited genetic variant predisposes to aggressive
but not indolent prostate.  cancer.www.pnas.org/cgi/doi/10.1073/pnas.0914061107"
"3356","PC051271","Priolo C, Agostini M, Vena N, et.al.  2010.  Establishment and Genomic Characterizatin of Mouse Xenografts of Human Primary Prostate Cancer.  Tumor Neo Prog 176(4):1901-13."
"3357","PC051290","Singh S, Singh R, Singh UP, et al.  2009.  Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines.  Intl J Cancer 125:2288-2295."
"3358","PC051290","VanCleave TT, Moore JH, Benford ML, et al.  2010.  Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk.  The Prostate 70:341-352."
"3359","PC051290","El-Haibi CP, Sharma P, Johnson PR, et al.  2010.  PI3Kp110-, Src, and FAK-dependent and DOCK2-independent migration and invasion by CXCL13-stimulated prostate cancer cells.  Mol Cancer 9:85."
"3360","PC051290","El-Haibi CP, Singh R, Sharma P, et al.  2012.  Antibody microarray analysis of signaling networks regulated by CXCL13 and CXCR5 in prostate cancer.  Protemics Clin Appl 5(8):177-184."
"3361","PC051290","Singh S, Singh R, Sharma P, et al.  2009.  Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion.  Cancer Lett 283:29-35."
"3362","PC051307","Yue Q, Groszer M, Gil JS, et al.  2005.  PTEN deletion in Bergmann glia leads to premature differentiation and affects laminar organization.  Development 132:3151-3326."
"3363","PC051307","Tahk S, Liu B, Chenishof V, et al.  2007.  Control of specificity and magnitude of NF-kB and STAT1-mediated gene activation through PIASy and PIAS1 co-operation.  Proc Natl Acad Sci USA 104:11643-8."
"3364","PC051307","Majumder P, Grisanzio C, Fedele G, et al.  2008.  A prostatic intraepithelial neoplasia-dependent p27kip1 checkpoint induces senescence, inhibits cell proliferation and cancer progression.  Cancer Cell 14(2):146-155."
"3365","PC051307","Mulholland DJ, Jiao J, and Wu H.  2008.  Hormone refractory prostate cancer: Lesions leaned from the PTEN prostate cancer model.  Adv Exp Med Biol 617:87-95."
"3366","PC051307","Li G, Hu Y, Liu M, et al.  2006.  PTEN deletion leads to up-regulation of a secreted growth factor pleiotrophin.  J Biol Chem 281:10663-10668."
"3367","PC051307","Yao D, Alexander CL, Quinn JA, et al.  2006.  PTEN loss promotes rasHa-mediated papillomatogenesis via dual up-regulation of AKT activity and cell cycle deregulation, but malignant conversion proceeds via PTEN-associated pathways.  Cancer Res 66(3):1302-1312."
"3368","PC051307","Degtyarev M, De MaziÃ¨re A, Orr C, et al.  2008.  Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to late-stage autophagy inhibition.  J Cell Biol 183(1):101-116."
"3369","PC051307","Yoo LI, Liu DW, Vu SL, et al.  2006.  Pten deficiency activates distinct downstream signaling pathways in a tissue specific manner.  Cancer Res 66(4):1929-1939."
"3370","PC051307","Wang S, Garcia A, Wu M, et al.  2006.  Pten deletion leads to the expansion of prostatic stem/progenitor cell subpopulation and tumor initiation.  Proc Natl Acad Sci USA 103:1480-1485."
"3371","PC051307","Berquin I, Min Y, Wu R, et al.  2006.  Expression signature of the mouse prostate.  J Biol Chem 280:36442-36451."
"3372","PC051307","Sanchez T, Thangada S, Wu MT, et al.  2005.  PTEN as an effector in the signaling of anti-migratory G protein-coupled receptor.  Proc Natl Acad Sci USA 102:4312-4317."
"3373","PC051307","Shen WH, Balajee AS, Wang J, et al.  2007.  Essential role for nuclear PTEN in maintaining chromosomal integrity.  Cell 128:157-170."
"3374","PC051307","He X, Zhang J, Grindley JC, et al.  2007.  Inactivation of PTEN leads to enhanced activation of intestinal stem cells and biasing on lineage fate determination.  Nature Genetics 39:189-198."
"3375","PC051307","Vivanco I, Palaskas N, Tran C, et al.  2007.  Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN.  Cancer Cell 11:555-69."
"3376","PC051307","Jiao J, Wang S, Qiao R, et al.  2007.  Murine cell lines derived from Pten null prostate cancer demonstrate the critical role of PTEN in hormone refractory prostate cancer development.  Cancer Res 67:6083-91."
"3377","PC051307","Berquin IM, Min Y, Wu R, et al.  2007.  Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids.  J Clinic Invest 117:1866-75."
"3378","PC051308","Man YG, Zhao CQ, Wang J, et al.  2006.  A subset of prostate basal cells lacks corresponding phenotypic markers.  Pathology-Research & Practice 202(9):651-662."
"3379","PC051308","Man YG and Gardner WA.  2008.  Focal basal cell degeneration and the resultant auto-immunoreactions: A potential mechanism for prostate tumor progression and invasion.  Med Hypotheses 70(2):387-408."
"3380","PC051342","Gao H, Wu B, Giese R, et al.  2008.  Hom-1 inhibits tumor growth in both p53 sufficient and deficient colon cancer cells.  Gastroenterology 134 (4):A744-1."
"3381","PC051342","Wu X, Gao H, Ke W, et al.  2011.  VentX trans-activates p53 and p16ink4a to regulate cellular senescence.  J Biol Chem 286:12693-12701."
"3382","PC051342","Gao H, Le Y, Wu X, et al.  2010.  VentX, a novel lymphoid-enhancing factor/T-cell factor-associated transcription repressor, is a putative tumor suppressor.  Cancer Res 70(1):202-210."
"3383","PC051342","Wu X, Gao H, Ke W, et al.  2011.  Human homeobox gene VentX controls macrophages terminal differentiation and activation.  J Clin Invest 121(7):2599-2613."
"3384","PC051346","Hatcher D, Daniels G, Osman I, et al.  2009.  Molecular mechanisms involving prostate cancer racial disparity.  Am J Transl Res 1(3):235-248."
"3385","PC051346","Li Y, Li CX, and Chen F.  2008.  Decrease in stromal androgen receptor associates with androgen-independent disease and promotes prostate cancer cell proliferation and invasion.  J Cell Mol Med 12(6b):2790-2798."
"3386","PC051346","Ye H, Li Y, Melamed J, et al.  2009.  Stromal anti-apoptotic androgen receptor target gene c-FLIP in prostate cancer.  J Urol 181(2):872-877."
"3387","PC051353","Scher HI, Halabi S, Tannock I, et al.  2008.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group.  J Clin Oncol 26(7):1148-1159."
"3388","PC051353","Ross RW, Beer TM, Jacobus S, et al.  2008.  A phase II study of carboplatin plus docetaxel in men with metastatic hormone refractory prostate cancer who are refractory to docetaxel.  Cancer 112(3):521-526."
"3389","PC051353","Basch EM, Somerfield MR, Beer TM, et al.  2007.  Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.  J Clin Oncol 25(33):5313-5318."
"3390","PC051353","Ross RW, Beer TM, Jacobus S, et al.  2007.  A phase II study of carboplatin plus docetaxel in men with metastatic hormone refractory prostate cancer who are refractory to docetaxel.  Cancer 112(3):521-526 (Epub ahead of print)."
"3391","PC051353","Morris MJ, Basch EM, Wilding G, et al.  2009.  Department of Defense prostate cancer clinical trials consortium: A new instrument for prostate cancer clinical research.  Clinical GU Cancer 7:51-7."
"3392","PC051354","Tanaka H, Kono E, Tran CP, et al. 2010.  Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance.  Nature Medicine 16(12):1414-1420."
"3393","PC051358","Scales, C. D., Jr., Norris, R. D., Keitz, S. A. et al. 2007. A critical assessment of the quality of reporting of randomized, controlled trials in the urology literature.  J Urol, 177: 1090
"
"3394","PC051358","Tseng, T. Y., Dahm, P., Poolman, R. W., Preminger, G. M., Canales, B. J., Montori, V. M. 2008. How to use a systematic literature review and meta-analysis.  J Urol, 180: 1249.

"
"3395","PC051358","Scales, C. D., Jr., Norris, R. D., Preminger, G. M., Vieweg, J., Peterson, B. L., Dahm, P. 2008. Evaluating the evidence: statistical methods in randomized controlled trials in the urological literature.  J Urol, 180: 1463.

"
"3396","PC051358","Scales, C. D., Jr., Dahm, P. 2008.  The critical use of population-based medical databases for prostate cancer research.  Curr Opin Urol, 18: 320

"
"3397","PC051358","Tseng, T. Y., Breau, R. H., Fesperman, S. F., Vieweg, J., Dahm, P. 2009. Evaluating the evidence: the methodological and reporting quality of comparative observational studies of surgical interventions in urological publications.  BJU Int 103(8):1026-31.

"
"3398","PC051358","Dahm, P., Preminger, G. M. 2007. A Users' Guide to the Urological Literature: Introducing a Series of Evidence Based Medicine Review Articles.  Journal of Urology, 178: 1149

"
"3399","PC051358","Kusmartsev, S., Eruslanov, E., Kubler, H. et al. 2008. Oxidative Stress Regulates Expression of VEGFR1 in Myeloid Cells: Link to Tumor-Induced Immune Suppression in Renal Cell Carcinoma.  J Immunol, 181: 346

"
"3400","PC051358","Vieweg, J., Su, Z., Dahm, P. et al.2007.  Reversal of tumor-mediated immunosuppression.  Clin Cancer Res, 13: 727s.

"
"3401","PC051358","Krupski, T. L., Dahm, P., Fesperman, S. F. et al. 2008. How to perform a literature search. J Urol 179(4):1264-70.
"
"3402","PC051358","Dahm, P., Yeung, L. L., Chang, S. S. et al. 2008. A Critical Review of Clinical Practice Guidelines for the Management of Clinically Localized Prostate Cancer. J Urol 180(2):451-9.
"
"3403","PC051358","Tseng, T., Dahm, P., Poolman, R. W., Preminger, G. M., Canales, B. J., Montori, V. M. 2008. Users' Guide to the Urological Literature: How to Use a Systematic Literature Review and Meta-Analysis.  Journal of Urology, 180: 1249.
"
"3404","PC051358","Bajammal, S., Dahm, P., Scarpero, H. M., Orovan, W., Bhandari, M. 2008. How to use an article about therapy.   J Urol, 180: 1904.

"
"3405","PC051358","Scales, C. D., Jr., Norris, R. D., Keitz, S. A., Peterson, B. L., Preminger, G. M., Vieweg, J. et al.   2007. A critical assessment of the quality of reporting of randomized, controlled trials in the urology literature.  
J Urol, 177: 1090
"
"3406","PC051358","Scales, C. D., Jr., Preminger, G. M., Keitz, S. A., Dahm, P. 2007. Evidence Based Clinical Practice: A Primer for Urologists.  J Urol 178(3 Pt 1):775-82.

"
"3407","PC051358","Scales, C. D., Jr., Preminger, G. M., Keitz, S. A. et al. 2007. Evidence Based Clinical Practice:  A Primer for Urologists.  
"
"3408","PC051358","Scales, C. D., Jr., Voils, C. I., Fesperman, S. F. et al. 2008. Barriers to the Practice of Evidence-Based Urology. J Urol 179(6):2345-9.
"
"3409","PC051363","Morris MJ, Basch EM, Wilding G, et al.  2009.  Department of defense prostate cancer clinical trials consortium: A new instrument for prostate cancer clinical research.  Clin Genitourin Cancer 7(1):51-57."
"3410","PC051363","Rathkopf D, Carducci MA, Morris M, et al.  2008.  A phase II trial of decetaxel with rapid androgen cycling as a treatment for patients with prostate cancer.  J Clin Oncol 26:2959-2965."
"3411","PC051369","Lloyd JC, Antonelli J, Masko EM, et al.  2010.  Effect of isocaloric low-fat diet on prostate cancer xenograft progression in a hormone-deprivation model.  J Urol 183:1619-1624."
"3412","PC051369","Bañez LL, Klink J, Jayachandran J, et al.  2010.  Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy.  Cancer Epi Bio Prev 19:722-728."
"3413","PC051369","Bañez LL, Loftis RM, Freedland SJ, et al.  2010.  The influence of hepatic dysfunction on prostate cancer outcomes following radical prostatectomy.  Prost Cancer Prost Dis 13:173-177."
"3414","PC051369","Buschemeyer WC, Klink J, Mavropoulos JC, et al.  2010.  Effect of intermittent caloric restriction on prostate cancer growth and survival in SCID mice.  Prostate 70:1037-1043."
"3415","PC051369","Moreira DM, Presti JC, Aronson WJ, et al.  2010.  Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: Results from the SEARCH database.  BJU Intl 105:1541-1547."
"3416","PC051369","Teeter AE, Sun L, Moul JW, et al.  2010.  External validation of the SEARCH model for predicting aggressive recurrence after radical prostatectomy: Results from the Duke Prostate Center database.  BJU Intl 106:796-800."
"3417","PC051369","Hamilton RJ, Banez LL, Aronson WJ, et al.  2010.  Statin medication use and the risk of biochemical recurrence following radical prostatectomy: Results from the SEARCH database.  Cancer 116:3389-3398."
"3418","PC051369","Tang P, Sun L, Uhlman M, et al.  Baseline PSA as a predictor of prostate cancer specific mortality over the past 2 decades: Duke University experience.  Cancer 116:4711-4717."
"3419","PC051369","Kim H, Presti JC Jr, Aronson WJ, et al.  2010.  Glycemic control and prostate cancer progression: Results from the SEARCH database.  Prostate 70:1540-1546."
"3420","PC051369","Masko EM, Thomas JA, Antonelli JA, et al.  2010.  Low-carbohydrate diets and prostate cancer: How low is 'low-enough'?  Cancer Prev Res 3:1124-1131."
"3421","PC051369","Thomas JA II, Antonelli JA, Lloyd JC, et al.  2010.  Effect of intermittent fasting on prostate cancer tumor growth in a mouse model.  Pros Can Pros Dis 13:350-355."
"3422","PC051369","Moreira DM, Presti JC Jr, Aronson WJ, et al.  2010.  Postoperative PSA nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the SEARCH database.  Int J Urol 17:914-922."
"3423","PC051369","Andriole GL, Bostwick D, Brawley OW, et al.  2011.  The effect of dutasteride on the utility of PSA for the diagnosis of high-grade and clinically relevant prostate cancer in men with a previous negative biopsy: Results from the REDUCE study.  J Urol 185:126-131."
"3424","PC051369","Teeter AE, Presti JC Jr, Aronson WJ, et al.  2011.  Does PSADT after radical prostatectomy correlate with overall survival and prostate cancer-specific mortality?  A Report from the SEARCH database group.  Urol 77:149-153."
"3425","PC051369","Thomas JA and Freedland SJ.  2011.  Obesity and prostate cancer: Collateral damage in the battle of the bulge.  Front Biosciences 3:594-605."
"3426","PC051369","Kopp RP, Han M, Partin AW, et al.  2011.  Obesity and prostate enlargement in men with localized prostate cancer.  BJU Intl 108(11):1750-1705."
"3427","PC051369","De Nunzio C, Freedland SJ, Miano R, et al.  2011.  Metabolic syndrome is associated with high grade Gleason score when prostate cancer is diagnosed on biopsy.  Prostate doi:1002/pros.21364."
"3428","PC051369","Moreira DM, Anderson T, Gerber L, et al.  2011.  The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series.  Cancer Causes Control 22(7):977-983."
"3429","PC051369","Moreira DM, Antonelli JA, Presti JC Jr, et al.  2010.  Association of cigarette smoking with time to biochemical recurrence after radical prostatectomy: Results from the SEARCH database.  Urology 76:1218-1223."
"3430","PC051369","Williams CD, Whitley BM, Hoyo C, et al.  2011.  A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased prostate cancer risk.  Nutrition Research 31:1-8."
"3431","PC051369","Joshu CE, Mondul AM, Menke A, et al.  2011.  Weight gain is associated with an increased risk of prostate cancer recurrence in the PSA era.  Cancer Prev Res 4:544-551."
"3432","PC051369","Freedland SJ.  2011.  Screening, risk assessment, and the approach to therapy in patients with prostate cancer.  Cancer 117:1123-1135."
"3433","PC051369","Stewart SB and Freedland SJ.  2011.  Influence of obesity on the incidence and treatment of genitourinary malignancies.  Urol Oncol 29(5):476-486."
"3434","PC051369","Kim H, Moreira DM, Smith MR, et al.  2011.  A natural history of weight change in men with prostate cancer on androgen deprivation therapy: Results from the SEARCH database.  BJU Intl 107:924-928."
"3435","PC051369","Armstrong AJ, Freedland SJ, and Garcia-Blacno M.  2011.  Epithelial-mesenchymal transition in prostate cancer: Providing new targets for therapy.  Asian J Andr 13:179-180."
"3436","PC051369","Banez LL, Hamilton RJ, Partin AW, et al.  2007.  Obesity-related plasma hemodilution and psa concentration among men with prostate cancer.  JAMA 298:2275-2280."
"3437","PC051369","King CR, Freedland SJ, Terris MK, et al.  2007.  Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: A report by the SEARCH database study group.  Urol 69:921-926."
"3438","PC051369","Buschemyer WC and Freedland SJ.  207.  Obesity and prostate cancer: Epidemiology and clinical implications.  Eur Urol 52:331-343."
"3439","PC051369","Freedland SJ.  Obesity and prostate cancer: Importance of race and state of disease.  J Urol 178:1842-1843."
"3440","PC051369","Freedland SJ, Mavropoulos J, Wang J, et al.  2008.  Carbohydrate restriction and prostate cancer growth.   Prostate 68:11-19."
"3441","PC051369","
Hamilton RJ and Freedland SJ.  2008.  Rationale for statins in the chemoprevention of prostate cancer.  Curr Urol Rep 9:189-196.
"
"3442","PC051369","Freedland SJ and Moul JW.  2007.  PSA recurrence after definitive therapy.  J Urol 177:1985:1991.

"
"3443","PC051369","Schroeck FR, Sun L, Freedland SJ, et al.  2008.  Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy.  Prostate Cancer Prostatic Dis 11:371-376."
"3444","PC051369","Price MM, Hamilton RJ, Robertson CN, et al.  2008.  Body mass index, PSA, and digital rectal examination findings among participants in a prostate cancer screening clinic.  Urol 71:787-791."
"3445","PC051369","Jayachandran J, Banez LL, Levy D, et al.  2008.  Risk stratification for biochemical recurrence among men with positive surgical margins or extracapsular disease after radical prostatectomy: Results from the SEARCH database.  J Urol 179:1791-1796."
"3446","PC051369","Arlen PM, Bianco F, Dahut WL, et al.  2008.  Prostate-specific antigen working groupâ¿¿s guidelines on PSA doubling time.  J Urol 179:2181-2185."
"3447","PC051369","Hamilton RJ and Freedland SJ.  2008.  Review of recent evidence in support of a role for statins in the prevention of prostate cancer.  Curr Opin Urol 18:333-339."
"3448","PC051369","Schroeck FR, Sun L, Freedland SJ, et al.  2008.  Comparison of PSA recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic prostatectomy or robot-assisted laparoscopic radical prostatectomy.  BJU Intl 102:28-32."
"3449","PC051369","Rampersaud E, Sun L, Moul JW, et al.  2008.  Percent tumor involvement and risk of biochemical progression after radical prostatectomy.  J Urol 180:571-576."
"3450","PC051369","Trock BJ, Han M, Freedland SJ, et al.  2008.  Prostate cancer-specific survival in men with biochemical recurrence after radical prostatectomy: impact of salvage radiation therapy vs. observation.  JAMA 299:2760-2769."
"3451","PC051369","Jayachandran J and Freedland SJ.  2008.  Prevention of prostate cancer:  What we know and where we are going.  Amer J Mens Health 2:178-189."
"3452","PC051369","Jayachandran J, Aronson WJ, Terris MK, et al.  2008.  Obesity and positive surgical margins by anatomic location after radical prostatectomy:  Results from the SEARCH database.  BJU Intl 102:964-968."
"3453","PC051369","Freedland SJ, Wen J, Wuerstle M, et al.  2008.  Obesity is a significant risk factor for prostate cancer at the time of biopsy.  Urol 72:1102-1105."
"3454","PC051369","Hamilton RJ, Amling CL, Kane CJ, et al.  2008.  Limitations of PSADT following biochemical recurrence after radical prostatectomy: results from the SEARCH database.  J Urol 179:1785-1789."
"3455","PC051369","Freedland SJ, Sun L, Kane CJ, et al.  2008.  Obesity and oncological outcome after radical prostatectomy: Impact of PSA-based prostate cancer screening: Results from the SEARCH and Duke Prostate Center databases.  BJU Intl 102:969-974."
"3456","PC051369","Turley RS, Terris MK, Kane CJ, et al.  2008.  The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained: results from the SEARCH database.  BJU Intl 102:1980-1984."
"3457","PC051369","Teeter AE, BaÃ±ez LL, Aronson WJ, et al.  2008.  What are the factors associated with a short PSA doubling time?  Report from the SEARCH database group.  J Urol 180:1511-1518."
"3458","PC051369","Freedland SJ.  2009.  Editorial comment.  Urology 74:516."
"3459","PC051369","Freedland SJ, Banez LL, Sun L, et al.  2009.  Obese men have higher-grade and larger tumors: An analysis of the Duke Prostate Center Database.  Pros Can Pros Dis 12:259-263."
"3460","PC051369","Freedland SJ and Aronson WJ.  2009.  Words of wisdom: Weight Loss with a low-carbohydrate, Mediterranean, or low-fat diet.  Eur Urol 55:249-250."
"3461","PC051369","Jones LW, Eves ND, Haykowsky M, et al.  2009.  Physiologic and molecular mechanisms of exercise intolerance in cancer and role of aerobic training to mitigate dysfunction.  Lancet Onc 10:598-605."
"3462","PC051369","Freedland SJ and Aronson WJ.  2009.  Dietary intervention strategies to modulate prostate cancer risk and prognosis.  Curr Opin Urol 19:263-267."
"3463","PC051369","Antonelli J, Freedland SJ, and Jones LW.  2009.  Exercise therapy across the prostate cancer continuum.  Pros Can Pros Dis 12:110-115."
"3464","PC051369","Moreira DM, Presti JC, Aronson WJ, et al.  2009.  Natural history of patients with persistently elevated PSA after radical prostatectomy: Results from the SEARCH Database.  J Urol 182:2250-2256."
"3465","PC051369","Moul JW, Sun L, and Freedland SJ.  2009.  Clinical and pathological characteristics of prostate cancer: Analysis of the Duke Prostate Center (DPC) and SEARCH Databases grand rounds.  Urol 8:6-9."
"3466","PC051369","Teeter AE, Presti JC Jr., Aronson WJ, et al.  2009.  Does early PSADT, calculated starting at the first detectable PSA after radical prostatectomy, correlate with standard PSADT?-A report from the SEARCH database group.  BJU Intl 104:1604-1609."
"3467","PC051369","Bañez LL, Sun L, Trock BJ, et al.  2009.  Body mass index and prostate specific antigen as a predictor of adverse pathology of prostate cancer and biochemical recurrence following radical prostatectomy.  J Urology 182:491-496."
"3468","PC051369","Lyman GH, Kuderer NM, and Freedland SJ.  2009.  Does treatment intensity matter in superficial bladder cancer? Consensus, clinical practice, and confounding.  J Natl Cancer Inst 101:543-545."
"3469","PC051369","Aronson WJ, Barnard RJ, Freedland SJ, et al.  2010.  Growth inhibitory effect of a low-fat diet on prostate cancer cells: Results of a prospective randomized dietary intervention trial in men with prostate cancer.  J Urol 183:345-350.
"
"3470","PC051369","Jayachandran J, Aronson WJ, Terris MK, et al.  2010.  Diabetes and outcomes after radical prostatectomy -- Are results affected by obesity and race?  Results from the SEARCH database.  Can Epi Bio Prev 19:9-17.

"
"3471","PC051369","Jayachandran J, Schroeck F, Sun L, et al.  2010.  The shared equal access regional cancer hospital (SEARCH) nomogram for risk stratification in intermediate risk group of men with prostate cancer: Validation in the Duke prostate center (DPC) database.  BJU Intl 105:180-184."
"3472","PC051369","Lloyd JC, Bañez LL, Aronson WJ, et al.  2010.  Estimated blood loss as a predictor of PSA recurrence: Results from the SEARCH database.  BJU Intl 105:347-351."
"3473","PC051369","Chang SL, Freedland SJ, Terris MK, et al.  2010.  Freedom from a detectable ultrasensitive PSA at two years after radical prostatectomy predicts a favorable clinical outcome: Analysis of the SEARCH database.  Urol 2:439-444."
"3474","PC051369","Moreira DM, Banez LL, Presti JC, et al.  2010.  Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: Results from the SEARCH database.  BJU Intl 105:28-33."
"3475","PC051369","Moreira DM, Presti JC Jr, Aronson WJ, et al.  2010.  The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.  Prost Can Pros Dis 13:87-93."
"3476","PC051369","Chu DI and Freedland SJ.  2011.  Metabolic risk factors in prostate cancer.  Cancer 117(10):2020-2023."
"3477","PC051369","Kane CJ, Im R, Amling CL, et al.  2010.  Outcomes after radical prostatectomy among men who are candidates for active surveillance: Results from the SEARCH database.  Urol 76:695-700."
"3478","PC051369","Hamilton RJ, Goldberg KC, Platz EA, et al.  2008.  The influence of statin medications on prostate specific antigen levels in healthy men.  J Natl Cancer Inst 100:1511-1518."
"3479","PC051369","Freedland SJ.  2008.  PSA kinetics and surrogacy: Ready for prime time?  Lancet Onc 9:1025-1026."
"3480","PC051369","Schroeck FR, Aronson WJ, Presti JC Jr., et al.  2009.  Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone?  BJU Intl 103:603-608."
"3481","PC051369","Wong Y, Freedland SJ, Hudes G, et al.  2009.  The role of androgen deprivation therapy in node positive prostate cancer.  J Clin Onc 27:100-105."
"3482","PC051369","Jayachandran J, Aronson WJ, Terris MK, et al.  2010.  Diabetes and outcomes after radical prostatectomy -- Are results affected by obesity and race? Results from the SEARCH database. Cancer Epi Bio Prev 19:9-17."
"3483","PC051369","Jayachandran J, Banez LL, Levy D, et al.  2009.  Obesity as a predictor of adverse outcome across black and white race: Results from the shared equal access regional cancer hospital (SEARCH) database.  Cancer 115:5263-5371."
"3484","PC051369","Wong YN, Freedland SJ, Egleston B, et al.  2009.  The role of primary androgen deprivation therapy in localized prostate cancer.  Eur Urol 56:609-616."
"3485","PC051369","Antonelli J, Jones LW, Banez LL, et al.  2009.  Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy.  J Urol 182:2226-2231."
"3486","PC051369","Donovan MJ, Khan FM, Fernandez G, et al.  2009.  Personalized prediction of tumor response and cancer progression on prostate needle biopsy.  J Urol 182:125-132."
"3487","PC051369","Roobol MJ, Schröder FH, Crawford ED, et al.  2009.  A framework for the identification of men at increased risk of developing prostate cancer.  J Urol 182:2112-2122."
"3488","PC051369","Aronson WJ, Barnard RJ, Freedland SJ, et al.  2010.  Growth inhibitory effect of a low-fat diet on prostate cancer cells: Results of a prospective randomized dietary intervention trial in men with prostate cancer.  J Urol 183:345-350."
"3489","PC051369","Freedland SJ, William CD, and Masko EM.  2010. Adiponectin and prostate cancer mortality: To be or not to be skinny? Clin Chem 56:1-3."
"3490","PC051369","Keating NL, O'Malley AJ, Freedland SJ, et al.  2010.  Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.  J Natl Cancer Inst 102:39-46."
"3491","PC051369","Mavropoulos JC, Buschemeyer WC, Tewari AK, et al.  2009.  The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Can Prev Res 2:557-565."
"3492","PC051369","Banez LL, Aronson WJ, Presti JC Jr., et al.  2009.  Race and time from diagnosis to radical prostatectomy: Does equal-access mean equal timely access to the operating room? - Results from the SEARCH database.  Cancer Epi Biomarkers Prev 18:1208-1212."
"3493","PC051369","Gross M, Nepomuceno E, Luthringer D, et al.  2009.  Androgen receptor and estrogen receptor beta associates with Gleason score, but not obesity, in prostate cancer.  Prostate 69:520-527."
"3494","PC051369","Freedland SJ and Aronson WJ.  2009.  LUTS and inflammation: Weighing the evidence.  Am J Epi 169:1291-1293."
"3495","PC051369","Lloyd JC, Banez LL, Aronson WJ, et al.  2009.  Preoperative predictors of blood loss at the time of radical prostatectomy: Results from the SEARCH database.  Pros Can Pros Dis 12:264-268."
"3496","PC051369","Moreira DM, Jayachandran J, Presti JC, et al.  2009.  Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: Results from the SEARCH Database.  BJU Intl 104:1452-1456."
"3497","PC051369","Hamilton RJ, Platz EA, and Freedland SJ.  2009.  Prostate-specific antigen: A misused and maligned prostate cancer biomarker.  J Natl Can Inst 101:611-612."
"3498","PC051369","Freedland SJ, Eastham J, and Shore N.  2009.  Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer.  Pros Can Pros Dis 12:333-338."
"3499","PC051373","Reyes-Ortiz CA, Ju H, Eschbach K, et al.  2009.  Neighborhood ethnic composition and diet among Mexican-Americans.  Public Health Nutr 12(12):2293-2301 (Epub 2009 Mar 2)."
"3500","PC051373","Reyes-Ortiz CA, Ju H, Inniss A, et al.  2009.  Acculturation and serum nutrients thought to be involved with cancer prevention among Mexican American men in the United States.  Cancer Control 16(2):169-175."
"3501","PC051373","Reyes-Ortiz CA, Eschbach K, Zhang DD, et al.  2008.  Neighborhood composition and cancer among Hispanics: Tumor stage and size at time of diagnosis.  Cancer Epidemiol Biomarkers Prev 17(11):2931-2936."
"3502","PC051375","Harzstark AL, Weinberg VK, Sharib J, et al.  2009.  A phase I trial of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration resistant prostate cancer resistant to docetaxel-based therapy: A study of the department of defense prostate cancer clinical trials consortium.  J Clin Oncol 27:2772-8."
"3503","PC051375","Scher HI, Halabi S, Tannock I, et al.  2008.  Design and endpoints of phase 2 Trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group (PCWG2).  Journal of Clinical Oncology 26(7):1148-1159."
"3504","PC051375","Beekman KW, Colevas AD, Cooney K, et al.  2006.  Phase II evaluations of EMD121974 (NSC 707544, cilengitide) in asymptomatic patients with androgen independent prostate cancer: Scientific rational and study design.  Clinical Genitourinary Cancer 4(4):299-302."
"3505","PC051380","Urba WJ, Nemunaitis J, Marshall F, et al.  2008.  Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic cellular immunotherapy.  J Urol 180(5):2011-2017."
"3506","PC051380","Ryan CJ, Zavodovskaya M, Kerner J, et al.  2008.  Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF- 1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells.  Prostate 68(11):1232-1240."
"3507","PC051380","Rosenberg J, Ryan CJ, Weinberg VK, et al.  2008.  A phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration resistant prostate cancer refractory to docetaxel-based therapy: A study of the Department of Defense Prostate Cancer Clinical Trials Consortium.  J Clin Oncol 27:2772-8.

"
"3508","PC051380","
Kavanagh B, O'Brien S, Lee D, et al.  2008.  CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.  Blood 112(4):1175-1183.
"
"3509","PC051380","Fong L and Small ES.  2008.  Anti-CTLA4 antibody: The first in an emerging class of immunomodulatory antibodies for cancer treatment.  J Clin Oncol 26:5275-83."
"3510","PC051380","Higano CS, Corman JM, Smith DC, et al.  2008.  Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113(5):975-984."
"3511","PC051380","Ryan C, Smith MR, Rosenberg JE, et al.  2008.  Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17-alpha hydroxylase C17,20-lyase inhibitor in castration resistant prostate cancer.  Proc Am Soc Clin Oncol 26:254s."
"3512","PC051380","Ryan CJ, Harzstark AH, Rosenberg JE, et al.  2008.  A pilot dose escalation study of the effects of nordihydroguareacetic acid (NDGA) on hormone levels and prostate specific antigen in patients with relapsed prostate cancer.  BJU Int 101(4):436-439."
"3513","PC051380","Lin AM, Ryan CJ, and Small EJ.  2007.  Intermittent chemotherapy for metastatic hormone refractory prostate cancer.  Crit Rev Oncol Hematol 61:243-54."
"3514","PC051382","Netto G, Armstrong A, Wood D, et al.  2009.  Pharmacodynamic (PD) study of pre-prostatectomy rapamycin in men with advanced localized prostate cancer (PC): A DOD prostate cancer clinical trials consortium trial.  J Clin Oncol 27(15s):5001."
"3515","PC051382","Rathkopf DE, Carducci MA, Morris M, et al.  2008.  A phase II trial of docetaxel with rapid androgen cycling as a treatment for patients with prostate cancer.  J Clin Oncol 26:2959--2965."
"3516","PC051382","Oh WK, Manola J, Ross RW, et al.  2006.  A phase II study of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy: Preliminary results.  Proc Am Soc Clin Onc 24:14533."
"3517","PC051382","Ross RW, Beer TM, Jacobus S, et al.  2008.  A phase II study of carboplatin plus docetaxel in men with metastatic hormone refractory prostate cancer who are refractory to docetaxel.  Cancer 112:521--526."
"3518","PC051382","Manola J, Ross RW, Berkowitz A, et al.  2006.  A phase II study of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy:  Preliminary results.  Proc Am Soc Clin Onc 24 (18S):639."
"3519","PC051382","Danila DC, Rathkopf DE, Morris MJ, et al.  2008.  Abiraterone acetate and prednisone in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy.  J Clin Oncol 26:5019.

"
"3520","PC051382","Scher HI, Beer TM, Higano CS, et al.  2008.  Phase I/II study of MDV3100 in patients (pts) with progressive castration-resistant prostate cancer (CRPC).  J Clin Oncol 26:5006."
"3521","PC051382","
Higano CS, Corman JM, Smith DC, et al.  2008.  Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113:975-984.
"
"3522","PC051382","Yu EY, Wilding G, Posadas E, et al.  2008.  Dasatinib in patients with hormone-refractory progressive prostate cancer: A phase II study.  J Clin Oncol 26:5156."
"3523","PC051382","Ryan CJ, Smith MR, Rosenberg JE, et al.  2008.  Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17-alpha hydroxylase C17,20-lyase inhibitor in castration resistant prostate cancer.  J Clin Oncol 26:5018."
"3524","PC051382","Zurita AJ, Shore ND, Kozloff MF, et al.  2007.  A phase I/II study of sunitinib in combination with docetaxel (dcx) and prednisone (pdn) in patients with metastatic castrate-resistant prostate cancer (mCRPC).  Eur J Cancer 5:287."
"3525","PC051382","Bradley DA, Dunn R, Rathkopf D, et al.  2008.  Vorinostat in hormone refractory prostate cancer (HRPC):  Trial results and IL-6 analysis (NSC 701852): NCI 6862.  J Clin Oncol 26:211."
"3526","PC051382","Beekman KW, Colevas AD, Cooney K, et al.  2006.  Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: Scientific rationale and study design.  Clin Genitourin Cancer 4:299-302.

"
"3527","PC051382","Basch EM, Somerfield MR, Beer TM, et al.  2007.  American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.  J Clin Oncol 25:5313-8."
"3528","PC051382","Scher HI, Halabi S, Tannock I, et al.  2008.  Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone:  Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-59."
"3529","PC051382","Bradley DA, Dunn R, Ryan C, et al.  2007.  EMD121974 (NSC 707544, Cilengitide) in asymptomatic metastatic androgen independent prostate cancer (AIPCa) patients (pts):  A randomized trial by the PCCTC (NCI 6372).  J Clin Oncol 25:5137."
"3530","PC051382","Bradley DA, Daignault S, Ryan C, et al.  2008.  Celingitide in asymptomatic metastatic androgen-independent prostate cancer patients: A randomized phase II trial.  J Clin Oncol 26:5144.

"
"3531","PC051382","Rathkopf DE, Carducci MA, Morris M, et al.  2008.  A phase II trial of docetaxel with rapid androgen cycling as a treatment for patients with prostate cancer.  J Clin Oncol 26:2959-65.

"
"3532","PC051382","Taplin ME, Ko Y, Regan M, et al.  2008.  Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC).  J Clin Oncol 26:5068."
"3533","PC051382","Hussain M, Dunn R, Rathkopf D, et al.  2007.  Suberoylanilide hydroxamic acid (vorinostat) post chemotherapy in hormone refractory prostate cancer (HRPC) patients (pts): A phase II trial by the Prostate Cancer Clinical Trials Consortium (NCI 6862).  J Clin Oncol 25:5132."
"3534","PC051382","Zurita AJ, Shore ND, Kozoloff MF, et al.  2007.  Distinct patterns of PSA modulation by single-agent sunitinib before combination with docetaxel and prednisone in patients with metastatic castrate-resistant prostate cancer (CRPCa).  J Clin Oncol 25:5134."
"3535","PC051382","Zurita AJ, Shore N, Kozloff M, et al.  2007.  Phase I study of sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone refractory prostate cancer (mHRPC).  J Clin Oncol 25:230.

"
"3536","PC051382","George DJ, Liu G, Wilding G, et al.  2008.  Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer (mHRPC) - preliminary results.  J Clin Oncol 26:5131."
"3537","PC051382","Beer TM, Slovin SF, Higano CS, et al.  2008.  Prostate Cancer Clinical Trials Consortium.  Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC).  J Clin Oncol 26:5004."
"3538","PC051382","Graff J, Smith DC, Neerukonda L, et al.  2008.  Phase II study of sagopilone (ZK-EPO) plus prednisone as first-line chemotherapy in patients with metastatic androgen-independent prostate cancer (AIPC).  J Clin Oncol 26:5141."
"3539","PC051382","Harrison MR, Hahn N, Pili R, et al.  2008.  Phase II study of 2-methoxyestradiol (2ME2) NanoCrystalÂ® Dispersion (NCD) in patients with taxane-refractory, metastatic hormone-refractory prostate cancer (HRPC).  J Clin Oncol 26:5173."
"3540","PC051382","Rathkopf DE, Wong BY, Ross RW, et al.  2008.  A phase I dose escalation study of oral panobinostat (LBH589) alone and in combination with IV docetaxel (Doc) and oral prednisone in castration-resistant prostate cancer (CRPC).  J Clin Oncol 26:5152."
"3541","PC051382","Morris MJ, Basch EM, Wilding G, et al.  2009.  Department of Defense Prostate Cancer Clinical Trials Consortium: a new instrument for prostate cancer clinical research.  Clin Genitourin Cancer 7:51-7."
"3542","PC051382","Ross RW, Manola J, Oh WK, et al.  2008.  Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity.  J Clin Oncol 26:5069."
"3543","PC051382","Lin AM, Ryan CJ, and Small EJ.  2007.  Intermittent chemotherapy for metastatic hormone refractory prostate cancer.  Crit Rev Oncol Hematol 61(3):243-254."
"3544","PC051382","Ross RW, Beet TM, Jacobus S, et al.  2008.  A phase II study of carboplatin plus docetaxel in men with metastatic hormone refractory prostate cancer who are refractory to docetaxel.  Cancer 112:521-6."
"3545","PC051382","Harzstark AL, Weinberg VK, Sharib J, et al.  2008.  Second-line combination chemotherapy: A phase I trial of ixabepilone, mitoxantrone, and prednisone in patients with metastatic hormone refractory prostate cancer (HRPC) previously treated with chemotherapy.  J Clin Oncol 26:5151."
"3546","PC051382","
Taplin ME, Ko Y, Regan M, et al.  2008.  Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC).  J Clin Oncol 26:5068.
"
"3547","PC051382","Rathkopf DE, Chi KN, Vaishampayan U, et al.  2009.  Phase Ib dose finding trial of intravenous (i.v.) panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC).  J Clin Oncol 27(15s):5064.

"
"3548","PC051382","Tran C, Ouk S, Clegg NJ, et al.  2009.  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.  Science 324(5928):787-90."
"3549","PC051382","
Scher HI, Beer TM, Higano CS, et al.  2009.  Antitumor activity of MDV3100 in a phase 1-2 study of castration-resistant prostate cancer (CRPC).  J Clin Oncol 27(15s):5011.
"
"3550","PC051382","Hotte SJ, Yu EY, Hirte HW, et al.  2009.  OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO) against HSP27: Results of a first-in human trial.  J Clin Oncol 27(15s):3506.

"
"3551","PC051382","Higano C, Alumkal J, Ryan CJ, et al.  2009.  A phase 2 study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody (MAb) against the insulinlike growth factor-I receptor (IGF-IR), as monotherapy in patients with metastastic, asymptomatic castrate resistant prostate cancer (CRPC).  J Clin Oncol 27(15s):5142."
"3552","PC051382","Oh WK, Febbo PG, Richie JP, et al.  2009.  A phase II study of neoadjuvant chemotherapy with docetaxel and bevacizumab in patients (pts) with high-risk localized prostate cancer: A prostate cancer clinical trials consortium trial.  J Clin Oncol 27(15s):5060."
"3553","PC051382","Yu EY, Massard C, Gross M, et al.  2009.  A phase 2 study of once-daily dasatinib for patients with castration-resistant prostate cancer (CRPC) (CA180085).  J Clin Oncol 27(15s):5147."
"3554","PC051382","Beer TM, Smith DC, Hussain A, et al.  2009.  Phase II study of first-line sagopilone combined with prednisone in patients with metastatic castration-resistant prostate cancer (CRPC).  J Clin Oncol 27(15s):5059.

"
"3555","PC051382","Yuan J, Orlandi F, Jefferson M, et al.  2009.  Cytokine changes in castrate metastatic prostate cancer (CPMC) patients (pts) treated with Ipilimumab (Ipi).  J Clin Oncol 27:e16149.

"
"3556","PC051382","Slovin SF, Beer TM, Higano CS, et al.  2009.  Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC).  J Clin Oncol 27(15s):5138."
"3557","PC051382","Lin J, Beer TM, Ryan CJ, et al.  2009.  A randomized, phase II study of ATN-224 in patients with biochemically relapsed, hormone-naïve prostate cancer: A DOD/PCF prostate cancer clinical trials consortium trial.  J Clin Oncol 27(15s):5135."
"3558","PC051382","Zurita AJ, Liu G, Hutson T, et al.  2009.  Sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone-refractory prostate cancer (mHRPC).  J Clin Oncol 27(15s):5166."
"3559","PC051382","Rosenberg JE, Ryan CJ, Weinberg VK, et al.  2009.  Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration- resistant prostate cancer previously treated with docetaxel-based therapy: A study of the department of defense prostate cancer clinical trials consortium.  J Clin Oncol 27:2772.

"
"3560","PC051382","Small EJ, Harzstark AL, Weinberg VK, et al.  2009.  Ixabepilone, mitoxantrone, and prednisone in patients with metastatic castrate-resistant prostate cancer (CRPC) refractory to docetaxel-based therapy: A phase 2 study of the DOD prostate cancer clinical trials consortium.  J Clin Oncol 27(15s):5058.

"
"3561","PC051382","Sinibaldi VJ, Carducci MA, Moore-Cooper S, et al.  2009.  A randomized double blind phase I-II study to determine the tolerability/efficacy of 2 different doses of lenalidomide (L), CC-5013, in biochemically relapsed (BR) prostate cancer (PC) patients (pts), (M0) after local treatment (LT). J Clin Oncol 27(15s):5130.

"
"3562","PC051387","Yu EY, Wilding G, Posadas E,et al.  2009.  Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.  Clin Cancer Res 15(23):7421-7428."
"3563","PC051387","Scher HI, Halabi S, Tannock I, et al.  2008.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.  J Clin Oncol 8:26:1148-1159."
"3564","PC051387","
Morris MJ, Basch EM, Wilding G, et al.  2009.  Department of Defense prostate cancer clinical trials consortium: A new instrument for prostate cancer clinical research.  Clinical Genitourin Cancer 7(1):51-57.
"
"3565","PC051387","Liu G, Wilding G, Somer B, et al.  2009.  An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer.  Clin Cancer Res 15:3172-6."
"3566","PC051391","Morris MJ, Basch EM, Wilding G, et al.  2009.  Department of Defense Prostate Cancer Clinical Trials Consortium: A new instrument for prostate cancer clinical research.  Clin Genitourin Cancer 7(1):51-57."
"3567","PC051391","Ross RW, Beer TM, Jacobus S, et al.  2008.  A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.  Cancer 112:521-526."
"3568","PC051392","Rosenberg JE, Ryan CJ, Weinberg V, et al.  2009.  A phase I study of ixabepilone, mitoxantrone and prednisone in patients with metastatic castration resistant prostate cancer treated with docetaxelbased therapy: A study of the Department of Defense Prostate Cancer Clinical Trials Consortium. J Clin Oncol 27:2772-8."
"3569","PC051399","Fesinmeyer MD, Gulati R, Zeliadt S, et.al.  2009.  Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States.  Cancer Epidemiol Biomarkers Prev 18(3):808-815."
"3570","PC051407","Lu y, Wang J, Xu Y, et. al. (2008) CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro. Mol Cancer Res,6,546-54."
"3571","PC051407","Mishra A, Shiozawa Y, Pienta KJ, et al.  2011.  Homing of cancer cells to the bone.  Cancer Microenviron 4(3):221-235."
"3572","PC051407","Shiozawa Y, Pienta KJ, and Taichman RS.  2011.  Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors.  Clin Cancer Res 17(17):5553-5558."
"3573","PC051407","Wang J, Lu Y, Wang J, Koch AE, Zhang J, Taichman RS. 2008. CXCR6 induced prostate cancer progression by the AKT/mTOR signaling pathway. Cancer Res 68(24):10367-76."
"3574","PC060006","Chakroborty D, Sarkar C, Basu B, et al.  2009.  Catecholamines regulate tumor angiogenesis.  Cancer Res 69:3727-3730."
"3575","PC060010","Dong J-T and Chen C.  2009.  Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases.  Cell Mol Life Sci 66(16):2691-2706 (Review).
"
"3576","PC060010","Liu R, Zhou Z, Huang J, et al.  2011.  PEMPA1 promotes androgen receptor negative prostate cell proliferation through suppressing the Smad3/4-c-Myc-p21Cip1 signaling pathway.  J Pathology 223(5):683-694."
"3577","PC060010","Liu R, Zhou Z, Huang J, et al.  2011.  PEMPA1 promotes androgen receptor negative prostate cell proliferation through suppressing the Smad3/4-c-Myc-p21Cip1 signaling pathway.  J Pathol 223(5):683-694."
"3578","PC060010","Zhao D, Zheng H, Zhou Z, et al.  2010.  The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation.  Cancer Res 70(11):4728-4738."
"3579","PC060010","Liu R, Zheng H, Zhou Z, et al.  2009.  KLF5 promotes breast cell survival partially through FGF-BP-pERK-mediated MKP-1 protein phosphorylation and stabilization.  J Biol Chem 284:16791-8.

"
"3580","PC060010","Li Y, Zhou Z, Alimandi M, et al.  2009.  WW domain containing E3 ubiquitin protein ligase 1 targets the full length ErbB4 for ubiquitin-mediated degradation in breast cancer.  Oncogene 28:2948-58."
"3581","PC060010","Chen C, Zhou Z, Sheehan CE, et al.  2009.  Overexpression of WWP1 is associated with estrogen receptor and insulin-like growth factor receptor 1 in breast carcinoma.  Int J Cancer 124(12):2829."
"3582","PC060010","Li Y, Zhou Z, and Chen C.  2008.  WW domain containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis.  Cell Death and Differentiation 15:1941-1951."
"3583","PC060010","Chen C, Li Y, Zhou Z, et al.  2008.  The WW domain containing E3 ubiquitin protein ligase 1 upregulates ErbB2 and EGFR through RING finger protein 11.  Oncogene 27:6845-6855."
"3584","PC060010","Chen C.  2008.  WWP1 (WW domain containing E3 ubiquitin protein ligase 1).  Atlas Genet Cytogenet Oncol Haematol http://AtlasGeneticsOncology.org/Genes/WWP1ID42993ch8q21.html."
"3585","PC060010","Chen C and Matesic LE.  2007.  The Nedd4-like family of E3 ubiquitin ligases and cancer.  Cancer Metastasis Rev 26:587-604.

"
"3586","PC060018","Lin Q, Zhu F, Yang W. 2010.  Coupling cellular mitogenesis to apoptosis by designed biomolecules.  Cell Signal 22(2):190-196."
"3587","PC060032","Dafni H, Larson PEZ, Yoshihara H, et al.  2010.  Hyperpolarized 13C spectroscopic imaging informs on hypoxia inducible factor 1 and Myc activity downstream of platelet derived growth factor receptor.  Cancer Res 70(19):7400-7410."
"3588","PC060032","Dafni H and Ronen SM.  2010.  Dynamic nuclear polarization in metabolic imaging of metastasis: common sense, hypersense and compressed sensing.  Cancer Biomark 7(4):189-199."
"3589","PC060032","Dafni H, Burghardt AJ, Majumdar S,et al.  2012.  Vascular patterning and permeability in prostate cancer models with differing osteogenic properties. NMR Biomed 25(6):843-851."
"3590","PC060032","2008.  Contrast-enhanced (DCE)-MRI detects reduced vascular permeability in a prostate cancer bone metastasis model following anti-platelet-derived growth factor receptor (PDGFR) therapy, indicating a drop in vascular endothelial growth factor receptor (VEGFR) activation.  Magn Reson Med 60(4):822-833."
"3591","PC060042","Norris AM, Woodruff RD, Dâ¿¿Agostino Jr. RB, et al.  2007.  Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer.  Prostate 67:214-225.

"
"3592","PC060044","Hong MY, Henning S, Moro A, et al. 2011.  Chinese red yeast rice inhibition of prostate tumor growth in SCID mice. Cancer Prev Res 4(4):608-615."
"3593","PC060044","Hong MY, Seeram NP, Zhang Y, et al.  2008.  Chinese red yeast rice vs. lovastatin effects on prostate cancer cells with and without androgen receptor overexpression.  J Med Food 11:657-666."
"3594","PC060095","Huber JS, Peng Q, and Moses WW.  2009.  Multi-modality phantom development.  IEEE Trans Nucl Sci NS 56:2722-2727."
"3595","PC060095","Huber JS, Peng Q, Moses WW, et al.  2011.  Development of a PET-transrectal ultrasound prostate imaging system.  IEEE Trans Nucl Sci NS-58:674-681."
"3596","PC060112","Balanathan P, Williams ED, Wang H, Pedersen et al.  2009.  Elevated level of inhibin-alpha subunit is protumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer.  Br J Cancer 100:1784-1793.

"
"3597","PC060114","McCabe CD, Spyropoulos DD, Martin D, et. al.  2008.  Genome-wide analysis of the homebox C6 transcriptional network in prostate cancer.  Cancer Res 68(6):1988-96."
"3598","PC060114","Scharer CD, McCabe Cd, Ali-Seyed M, et. al.  2009.  Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells.  Cancer Res 69(2):709-17."
"3599","PC060145","Scharer CD, McCabe CD, Ali-Seyed M, et al.  2009.  Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells.  Cancer Res 69:709-717."
"3600","PC060156","Rahman KM, Banerjee S, Ali S, et al.  2009.  3,3'-Diindolylmethane Enhances Taxotere-Induced Apoptosis in
Hormone-Refractory Prostate Cancer Cells through Survivin
Down-regulation.  Cancer Res 69:4468-75."
"3601","PC060158","Tu T, Thotala D, Geng L, et al.  2008.  Bmx is activated by ionizing radiation and is a molecular target for development for radiosensitizing drugs.  Cancer Research 68(8):2861-2869."
"3602","PC060159","Hanhn s, Nesslinger N, Drapala R, et al.  2009.  Castration induces autoantibody and T cell responses that correlate with inferior outcomes in an androgen-dependent murine tumor model.  Int J Cancer.  125(12):2871-8."
"3603","PC060159","Nesslinger NJ, Ng A, Tsang K-Y, et al.  2010.  A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self proteins in prostate cancer patients. Clin Cancer Res 16(15):4046-56.  Epub 2010 Jun 18. PMID: 20562209."
"3604","PC060159","Nesslinger NJ, Pai HH, Ludgate CM, et al.  2008.  Exploring the effects of standard treatments on the immune response to prostate cancer.  In:  Methods of Cancer Diagnosis, Therapy, and Prognosis (Editor not named).  Springer Vol. 2."
"3605","PC060159","Nesslinger NJ, Pai HH, Ludgate CM, et al.  2008.  Exploring the effects of standard treatments on the immune response to prostate cancer. Methods of cancer diagnosis, therapy, and prognosis.  Springer Vol. 2.  

"
"3606","PC060159","Nielsen JS, Wick DA, Tran E, et al.  2010.  An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and influenza for use as a functional control in human immune monitoring studies.  J Immunol Methods 360(1-2):149-156.  Epub 2010 Jul. PMID: 20637775."
"3607","PC060162","Lazebnik Y.  2010.  What are the hallmarks of cancer?  Nat Rev Cancer 10:232-233."
"3608","PC060162","Gottesman A, Milazzo J, and Lazebnik Y.  2010.  V-fusion: A convenient, nontoxic method for cell fusion.  Biotechniques 49:747-750."
"3609","PC060162","Duelli DM, Padilla-Nash HM, Berman D, et al.  2007.  A virus causes cancer by inducing massive chromosomal instability through cell fusion.  Curr Biol 17:431-437."
"3610","PC060162","Duelli D and Lazebnik Y.  2007.  Cell-to-cell fusion as a link between viruses and cancer.  Nature 7:968-976."
"3611","PC060207","Zeng Y, Sankala H, Zhang X, et al.  2008.  Phosphorylation of argonaute2 at serine 387 facilitates its localization to processing bodies.  Biochem J 413:429-436."
"3612","PC060207","Kalscheuer S, Zhang X, Zeng Y, et al.  2008.  Differential expression of microRNAs in early stage neoplastic transformation in the lungs of F344 rats  chronically treated with the tobacco  carcinogen 4-(methylnitrosamino)-1-(3-pyridy1)-1-butanone.  Carcinogenesis doi:  10.1093/carcin/bgn209."
"3613","PC060214","Yang J, Xie S-X, Huang Y, et al.  2012.  Prostate-targeted loaded with androgen receptor silencing constructs eradiate xenograft tumors in mice.  Nanomedicine 7(9):1297-1309."
"3614","PC060224","Ross LE, Powe BD, Taylor YJ, et al.  2008.  Physician-patient discussions with African American men about prostate cancer screening.  Am J Mens Health 2(2)."
"3615","PC060224","Ross LE, Berkowitz Z, and Ekwueme DU.  2008.  Use of the prostate-specific antigen test among U.S. men: Findings from the 2005 national health interview survey.  Cancer Epidemiol Biomarkers Prev 17(3)."
"3616","PC060233","Livingston J, Smith MA, Mills C, et al.  2009.  Theater as a tool to educate African Americans about cancer.  Journal of Cancer Education 24:297-300."
"3617","PC060233","Moreira DM, Anderson T, Gerber L, et al.  2011.  The association of diabetes mellitus and high-grade prostate cancer in multiethnic biopsy series.  Cancer Causes Control 22(7):977-983."
"3618","PC060233","Williams CD, Whitely B, Hoyo B, et al.  2011.  A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased risk of prostate cancer.  Nutrition Res 31(1):1-8.

"
"3619","PC060233","Grant DJ, Moorman PG, Akushevich L, et al.  2010.  Primary peritoneal and serous ovarian cancer: An epidemiological comparative analysis.  Cancer Causes Control 21:991-998.


"
"3620","PC060233","Antonelli J, Jones LW, Banez LL, et al.  2009.  Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy.  J Urology 182:2101-2."
"3621","PC060233","Grant DJ, Hoyo C, Oliver SD,et al.  2013. Association of uridine diphosphate-glucuronosyltransferase 2B gene variants with serum glucuronide levels and prostate cancer risk.  Genet Test Mol Biomarkers 17(1):3-9."
"3622","PC060266","Cao Q, Yu J, Tomlins SA, et al.  2008.  Repression of E_cadherin by the polycomb group protein EZH2 in cancer.  Oncogene 27:7274-7284."
"3623","PC060266","Varambally S, Cao Q, Mani RS, et al.  2008.  Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.  Science 322:1695-1699.

"
"3624","PC060266","Yu JJ, Yu J, Corder KE, et al.  2008.  A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival.  Neoplasia 10(1):79-88."
"3625","PC060266","Yu J, Yu J, Almal AA, et al.  2007.  Feature selection and molecular classification of cancer using genetic programming.  Neoplasia 9:292-303."
"3626","PC060266","Yu J, Cao Q, Mehra R, et al.  2007.  Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer.  Cancer Cell 12:9-21."
"3627","PC060266","Yu J, Yu JJ, Rhodes DR, et al.  2007.  A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.  Cancer Res 67:10657-10663."
"3628","PC060271","Lucas D and Frenette PS.  2008.  Osteoblasta:  Yes, they can.  Blood 112(3):455."
"3629","PC060271","Hidalgo A and Frenette PS.  2009.  When integrins fail to integrate.  Nat Med 15(3):249-50."
"3630","PC060271","Mendez-Ferrer S, Chow A, Merad M, et al.  2009.  Circadian rhythms influence hematopoietic stem cells.  Curr Opin Hamatol 16:235-42"
"3631","PC060271","Mendez-Ferrer S and Frenette PS.  2009.  Galpha(s)uncouples hematopoietic stem cell homing and mobilization.  Cell Stem Cell 4:379-80."
"3632","PC060271","Magnon C and Frenette PS.  2008.  Hematopoietic stem cell trafficking.  The Stem Cell Research Community.  StemBook doi/10.3824/stembook.1.8.1."
"3633","PC060271","MÃ©ndez-Gerrer S, Lucas D, Battista M, et al.  2008.  Haematopoietic stem cell release is regulated by circadian oscillations.  Nature 452(7186):442-447."
"3634","PC060276","Cai Y, Wang J, Li R, et al.  2009.  GGAP2/PIKE-A directly activates both the Akt and nuclear factor-KB pathways and promotes prostate cancer progression.  Cancer Res 1;69(3):819-827.

"
"3635","PC060283","Wang Q, Li W, Liu XS, et al.  2007.  A hierarchical network of transcription factors governs androgen receptor dependent prostate cancer growth.  Mol Cell 27(3):380-392."
"3636","PC060283","Wang Q, Li W, Zhang Y, et al.  2009.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.  Cell 138(2):245-256."
"3637","PC060283","He HH, Meyer CA, Shin H, et al.  2010.  Nucleosome dynamics defines transcriptional Enhancers.  Nat Genet 42(4):343-347."
"3638","PC060283","Zhang Y, Liu T, Meyer CA, et al.  2008.  Model-based analysis of ChIP-Seq (MACS).  Genome Biol 9(9):R137."
"3639","PC060283","Zhang Y, Shin H, Song JS, et al.  2008.  Identifying positioned nucleosomes with epigenetic marks in human from ChIP-Seq.  BMC Genomics 9:537."
"3640","PC060283","Lupien M, Eeckhoute J, Meyer CA, et al. 2008. FoxA1 translates epigenetic signatures into enhancer driven lineage-specific transcription.  Cell 132:958-70."
"3641","PC060286","Junkui Ai, Wang Y, Dar JA, et al.  2009.  HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer.  Molecular Endocrinology 23:1963-1972."
"3642","PC060303","Lin SL, Chang D, Chiang A,et al.  2008.  Androgen receptor regulates CD168 expression and signaling in prostate cancer. Carcinogenesis 29(2):282-290."
"3643","PC060331","Jin Z, Mashuta M, Stolowich N, et al.  2012.  Physangulidines A, B and C: Three new antiproliferative withanolides from Physalis angulata L.  Org. Lett 14:1230-1233."
"3644","PC060331","Aponte JC, Jin Z, Vaisberg AJ, et al.  2011.  Cytotoxic and anti-infective phenolic compounds isolated from Mikania decora (compositae) and Cremastosperma microcarpum (annonaceae).  Planta Medica 77:1597-1599."
"3645","PC060331","Aponte JC, Vaisberg AJ, Castillo D, et al.  2010.  Trypanoside, anti-tuberculosis, leishmanicidal and cytotoxic activities of tetrahydrobenzothienopyrimidines.  Bioorg Med Chem 18:2880-2886."
"3646","PC060331","Reyes-Reyes EM, Jin Z, Vaisberg AJ, et al.  2013. Physangulidine A, a withanolide from Physalis angulata, perturbs the cell cycle and induces cell death by apoptosis in prostate cancer cells. J Nat Prod 76(1):2-7."
"3647","PC060331","Aponte JC, Yang H, Vaisberg AJ, et al.  2010.  Cytotoxic and anti-infective sesquiterpenes present in plagiochila disticha (Plagiochilaceae) and ambrosia peruviana (Asteraceae).  Planta Med 76:705-707."
"3648","PC060331","Aponte JC, VerÃ¿Â¡stegui M, MÃ¿Â¡laga E, et al.  2008.  Synthesis, cytototoxic and anti-Trypanosoma cruzi activity of new chalcones.  J Med Chem 51:6230-6234."
"3649","PC060331","Aponte JC, Vaisberg AJ, Rojas R, et al.  2009.  A multipronged approach to the study of Peruvian ethnomedicinal plants.  A legacy of the ICBG-Peru project.  J Nat Prod 72:524-526."
"3650","PC060340","Kasic T, Colombo P, Soldani C,, et al.  2011. Modulation of human T-cell functions by reactive nitrogen species. Eur J Immunol 41(7):1843-1849."
"3651","PC060340","Molon B, Ugel S, Del Pozzo F, et al.  2011. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 208(10):1949-1962."
"3652","PC060340","Viola A and Bronte V.  2007.  Metabolic mechanisms of cancer-induced inhibition of immune responses.  Semin Cancer Biol 17:309-316."
"3653","PC060344","Féau C, Arnold LA, Kosinski A, et al.  2011.  Ligand competition binding assay for the androgen receptor.  Methods Mol Biol 776:59-68."
"3654","PC060344","De Leon JT, Iwai A, Feau C, et al.  2011. Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells.  Proc Natl Acad Sci U S A 108(29):11878-11883."
"3655","PC060344","Féau C, Arnold LA, Kosinski A, et al.  2009.  Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription. ACS Chem Biol 4(10):834-843."
"3656","PC060344","Feau C, Arnold LA, Kosinski A, et al. 2009. A high-throughput ligand competition binding assay for the androgen receptor and other nuclear receptors.  J Biomol Screen 14:43-8."
"3657","PC060344","Jones JO, Bonton EC, Huang Y, et al.  2009.  Non-Competitive androgen receptor inhibition in vitro and in vivo.  PNAS 106(17):7233-8."
"3658","PC060350","Aziz Moammir H, Manoharan HT, Church R, et al.  2007.  Protein kinase C-epsilon interacts with Stat3, phosphorylates Stat3Ser727 and regulates its constitutive activation in prostate cancer.  Cancer Res 67:8828-8838."
"3659","PC060354","Mavis C, Morey Kinney SR, Foster BA, et al.  2009.  Expression level and DNA methylation status of glutathione-S-transferase genes in normal murine prostate and TRAMP tumors.  Prostate 69:1312-1324."
"3660","PC060354","Morey SR, Smiraglia DJ, James SR, et al.  2006.  DNA methylation pathway alterations in an autochthonous murine model of prostate cancer.  Cancer Research 66:11659-11667."
"3661","PC060354","Morey Kinney SR, Zhang W, Gillard B, et al.  2009.  Lack of evidence for green tea polyphenols as a DNA methylation inhibitor in mice.  Cancer Prev Res 2(12):1065-75.

"
"3662","PC060354","Morey Kinney SR, Smiraglia DJ, Karpf AR, et al.  2008.  Stage-specific alterations of DNA Methyltransferase expression, DNA hypermethylation, and DNA hypomethylation during prostate cancer progression in the Transgenic Adenocarcinoma of Mouse Prostate model.  Mol Cancer Res 6:1365-74."
"3663","PC060354","Camoriano M, Morey Kinney S, Moser M et. al. 2008 Phenotype-specific CpG Island Methylation Events in a Murine Model of Prostate Cancer. Cancer Res 68:4173-82."
"3664","PC060377","Cowin PA, Foster P, Pedersen J, et al.  2008.  Early onset endocrine disruptor-induced prostatitis in the rate.  Environ Health Perspect 116:923-9."
"3665","PC060385","Silverman RH, Nguyen C, Weight CJ, et al.  2010.  The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome.  Nat Rev Urol 7:392-402."
"3666","PC060385","Qiu X, Swanson P, Luk K-C, et al.  2010.  Characterization of antibodies elicited by XMRV infection and development of immunoassays useful for epidemiologic studies.  Retrovirology 7:68."
"3667","PC060385","Onlamoon N, Das Gupta J, Sharma P, et al.  Infection, viral dissemination and antibody responses of rhesus macaques exposed to the human gammaretrovirus XMRV.  J Virol online:201."
"3668","PC060385","Lombardi VC, Ruscetti FW, Das Gupta J, et al.  2009.  Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome.  Science 23;326(5952):585-589."
"3669","PC060385","Kim S, Rusmevichientong A, Dong B, et al.  2010.  Fidelity of target site duplication and sequence preference during integration of xenotropic murine leukemia virus-related virus.  PLoS One 20;5(4):e10255."
"3670","PC060385","Kim S, Kim N, Dong B, et al.  2008.  Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer.  J Virol 20:9964-9977.

"
"3671","PC060385","Hong S, Klein EA, Das Gupta J, et al.  2009.  Fibrils of prostatic acid phosphatase fragments boost infections by XMRV, a human retrovirus associated with prostate cancer.  J Virol 83:6995-7003."
"3672","PC060387","Xiao L, Eto M, Kazanietz MG. 2009.  ROCK mediates phorbol ester-induced apoptosis in prostate cancer cells via p21Cip1 up-regulation and JNK.  J Biol Chem 284(43):29365-75."
"3673","PC060387","Xiao L, Caino MC, von Burstin VA, et al.  2008.  Phorbol ester-induced apoptosis and senescence in cancer cell models.  Methods Enzymol 446:123-39."
"3674","PC060389","Penney KL, Sinnott JA, Fall K, et al.  2011.  An mRNA expression signature of Gleason grade predicts lethal prostate cancer.  J Clin Oncol 29(17):2391-2396."
"3675","PC060389","Stark JR, Judson G, Alderete JF, et al.  2009. Trichomonas vaginalis infection and prostate cancer incidence and mortality: a prospective study in the Physicians' Health Study.  J Natl Cancer Inst 101(20):1406-11."
"3676","PC060389","Meyer MS, Penney KL, Stark JR, et al.  2010.  Genetivariation in RNASEL associated with prostate cancer risk and progression.  Carcinogenesis 31(9):1597-1603."
"3677","PC060403","Schaue D, Comin-Anduix B, Ribas A, et al.  2008.  T-Cell responses to survivin in cancer patients undergoing radiation therapy.  Clin Cancer Res 14:4883-4890."
"3678","PC060409","Quann EJ, Khwaja F, and Djakiew D.  2007.  The p38 MAPK pathway mediates aryl propionic acid-induced messenger RNA stability of p75NTR in prostate cancer cells.  Cancer Res 67:11402-11410."
"3679","PC060409","Khwaja FS, Quann EJ, Pattabiraman N, et al.  2008.  Carprofen induction of p75NTR â¿¿dependent apoptosis via the p38 mitogen-activated protein kinase pathway in prostate cancer cells.  Mol Cancer Ther 7(11):3539-45."
"3680","PC060409","Quann EJ, Khwaja F, Zavitz KH, et al.  2007.  The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells.  Cancer Res 67:3254-3262."
"3681","PC060420","Dan HC, Cooper MJ, Cotgswell PC, et al.  2008.  Akt-dependent regulation of NFkappaBeta in prostate cancer is controlled in mTOR and Raptor in association with IKK.  Genes Dev 22(11):1490-1500."
"3682","PC060420","Dan HC and Baldwin AS.  2008.  Differential involvement of IKKalpha and IKKbeta I cytokine- and insulin-induced mammalian target of rapamycin (mTOR) activation determined by Akt. J Immununol 180(11):7583-7589."
"3683","PC060420","Dan HC, Adli M and Baldwin AS.   2007.  Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha.  Cancer Res 67(13):6263-6269."
"3684","PC060429","Hsu MJ, Eghtedari M, Goodwin AP, et al.  2011.  Characterization of individual ultrasound microbubble dynamics with a light-scattering system.  J Biomed Opt 16(6):067002."
"3685","PC060429","Hall DJ, Hsu M, Esener S, et al.  2009.  Detection of ultrasound-modulated photons and enhancement with ultrasound microbubbles.  Proc Soc Photo Opt Instrum Eng 7177:71771L.

"
"3686","PC060429","Hall DJ, Sunar U and Farshchi-Heydari S.  2008.  Quadrature detection of ultrasound-modulated photons with a gain-modulated, image-intensified, CCD camera.  Open Optics 2:75-78.

"
"3687","PC060433","Rodriguez JJ and Goff SP.  2010.  Xenotropic murine leukemia virus-related virus establishes an efficient spreading infection and exhibits enhanced transcriptional activity in prostate carcinoma cells.  J Virol 84(5):2556-2562."
"3688","PC060433","Schlaberg R, Choe DJ, Brown KR, et al. 2009.  XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors.  Proc Natl Acad Sci U S A. 22;106(38):16351-16356."
"3689","PC060436","Aldrich MB, Sanders D, Lapteva N, et al. 2008. SOCS1 downregulation in dendritic cells promotes memory T cell responses.  Vaccine 26:1128-35."
"3690","PC060436","Lapteva N, Seethammagari MR, Hanks B, et al.  2007.  Enhanced activation of human dendritic cells by inducible CD40 and TLR4 ligation.  Cancer Res 67(21):10528-10537."
"3691","PC060436","Lapteva N.  2010.  Enhanced migration of human dendritic cells expressing inducible CD40.  Methods Mol Biol 651:79-87.
"
"3692","PC060436","Lapteva N, Aldrich MB, Weksberg D, et al.  2009.  Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent anti-tumor immunity.  J Immunother 32:145-56."
"3693","PC060443","Buchanan G, Need EF, Bianco-Miotto T, et al.  2009.  Insights from AR gene mutations.  In: Androgen Action in Prostate Cancer (Tindall D and Mohler J, Eds).  Springer."
"3694","PC060443","Chiam K, Tilley WD, Butler LM, et al.  2009.  The dynamic and static modulation of the epigenome by hormones: A role in the developmental origin of hormone related cancer.  Biochimica et Biophysica Acta 1795:104-109."
"3695","PC060443","Bianco-Miotto T, Chiam K, Buchanan G, et al.  2010.  Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development.  Cancer Epidemiology, Biomarkers and Prevention 19(10):2611-2622."
"3696","PC060447","Torkko KC, van Bokhoven A, Mai P, et al.  2008.  VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in non-Hispanic white and Hispanic white men.  Clin Cancer Res  14:3223-3229."
"3697","PC060451","Andersen RJ, Mawji NR, Wang J, et al.  2010.  Regression of castrate-recurrent prostate cancer by a small molecule inhibitor of the amino-terminus domain of the androgen receptor.  Cancer Cell 17(6):535-46."
"3698","PC060451","Sadar MD.  2011.  Small molecultes targeting the 'Achilles' heel of androgen receptor activity.  Cancer Res 71:1208-1213."
"3699","PC060451","Sadar MD, Williams DE, et al. (2008) Sintokamides A to E, Chlorinated Peptides from the Sponge Dysidea sp. that Inhibit Transactivation of the N-Terminus of the Androgen Receptor in Prostate Cancer Cells. Org. Lett., 10(21):4947-50.
"
"3700","PC060483","Hong S, Yoon S, Moelling C, et al.  2009.  Non-catalytic function of extracellular signal-regulated kinase 1/2 (ERK1/2) can promote Raf/MEK/ERK-mediated growth arrest signaling.  J Biol Chem 284(48):33006-33018."
"3701","PC060483","Arthan D and Hong S, Park JI.  2010.  Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells.  Cancer Lett 297(1):31-41."
"3702","PC060492","Baena E, Shao Z, Linn DE,et al.  2013. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev 27(6):683-698."
"3703","PC060504","Lyons L, Rao S, Balkan W, et al.  2008.  Molecular endocrinol ligand-independent activation of androgen receptors Rho GTPase signaling in prostate cancer.  Mol Endocrinol 3:597-608."
"3704","PC060508","Chen H, Libertini SJ, Wang Y, et al.  2010.  ERK regulates calpain 2 induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines.  J Biol Chem 285(4):2368-2374."
"3705","PC060508","Guo Z, Yang X, Sun F, et al.  2009.  A novel androgen receptor splice variant promotes androgen-independent growth by regulating a unique set of target genes in human prostate cancer cells.  Cancer Res 69(6):2305-2313."
"3706","PC060508","Kung HJ and Evans CP.  2009.  Oncogenic activation of androgen receptor.  Urol Oncol 27(1):48-52."
"3707","PC060513","Halter RJ, Schned A, Heaney J, et al.  2009.  Electrical properties of prostatic tissues: I. Single frequency admittance properties.  J Urol 182(4):1600-7."
"3708","PC060513","Halter RJ, Schned AR, Heaney JA, et. al. 2008. Electrical impedance spectroscopy of benign and malignant prostatic tissues.  J Urol 179:1580-6."
"3709","PC060513","Halter RJ, Schned A, Heaney J, et al.  2009.  Electrical properties of prostatic tissues: II. Spectral admittance properties.  J Urol 182(4):1608-13."
"3710","PC060513","Halter RJ, Hartov A, Paulsen KD, et al.  2008.  Genetic and least squares algorithms for estimating spectral EIS parameters of prostatic tissues.  Physiol Meas 29:S111-S123.

"
"3711","PC060513","Halter RJ, Schned A, Heaney J, et. al.  2007.  Electrical impedance spectroscopy of human prostate.  Proceedings of the 13th International Conference on Electrical Bioimpedance, International Federation for Medical and Biological Engineering Proceedings 17:126-129."
"3712","PC060521","Cai Y, Wang J, Li R, et al.  2009.  GGAP2/PIKE-A directly activates both the Akt and Nuclear Factor-KB pathways and promotes prostate cancer progression.  Cancer Res 69:(3)."
"3713","PC060521","Cai Y, Wang J, Ren C, and Ittmann M. 2012. Frequent heterogeneous missense mutations of GGAP2 in prostate cancer: implications for tumor biology, clonality and mutation  analysis. PLoS One. 7(2):e32708.
"
"3714","PC060524","Scott KEN, Wheeler F, Thomas M, et al.  2012.  Metabolic regulation of podosomes and invasion by acetyl-CoA carboxylase and de novo lipogenesis.  PLoS One 7(1):e29761."
"3715","PC060524","Vavere AL, Kridel SJ, Wheeler FB, et al.  2008.  1-11C-Acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer.  J Nucl Med 49:327-334."
"3716","PC060524","Little JL, Wheeler F, Koumenis C, et al.  2007.  Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells.  Cancer Res 67(3):1262-1269."
"3717","PC060524","Pemble CW, Johnson LC, Kridel SJ, et al.  2007.  Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat.  Nat Struct Mol Biol 14(8):704-709."
"3718","PC060524","Chen YQ, Edwards IJ, Kridel SJ, et al.  2007.  Dietary fat-gene interactions in cancer.  Cancer Metastasis Rev 26(3-4):535-551."
"3719","PC060524","Kridel SJ, Lowther WT, and Pemble CW.  2007.  Fatty acid synthase inhibitors: New directions for oncology.  Expert Opin Investig Drugs 16(11):1817-1829."
"3720","PC060524","Fels DR, Ye J, Segan AT, et al.  2008.  Preferential cytotoxicity of bortezomib towards hypoxic cells via over activation of ER stress pathways.  Cancer Res 68(22):9323-9330."
"3721","PC060524","Little JL and Kridel SJ.  2008.  Fatty acid synthase activity in tumor cells.  In:  Lipids in Health and Disease: Subcellular Biochemistry (Quinn PJ and Wang X, Eds.).  Springer Netherlands 49:169-194."
"3722","PC060524","Little JL, Wheeler FB, Koumenis C, et al.  2008.  Disruption of crosstalk between the fatty acid synthesis and proteasome pathways enhances unfolded protein response signaling and cell death.  Mol Cancer Ther 7(12):3816-3824."
"3723","PC060565","Qin J and Tang DG.  2010.  Prostate cancer stem cells.  In:  Cancer Stem Cells (Guan XY, Ed). Transworld Research Network 37-56."
"3724","PC060565","Jeter CR and Tang DG.  2010.  Prostate cancer stem cells.  In:  Cancer Stem Cells (Farrar W, Ed).  Cambridge University Press 15-30."
"3725","PC060565","Suraneni M, Schneider-Brousaard R, Moore JR, et al.  2010.  Transgenic expression of 15-lipoxygenase 2 (15-LOX2) in mouse prostate leads to hyperplasia and cell senescence.  Oncogene 29:4261-4275."
"3726","PC060565","Li HW, Jiang M, Honorio S, et al.  2009.  Methodologies in assaying prostate cancer stem cells.  Methods Mol Biol 569:85-138."
"3727","PC060565","Chandra D and Tang DG.  2009.  Detection of apoptosis in cell-free systems.  Methods Mol Biol 559:65-75."
"3728","PC060565","Chen X, Schneider-Broussard R, Hollowell D, et al.  2009.  Abnormal differentiation, hyperplasia and embryonic/perinatal lethality in BK5-T/t transgenic mice.  Differentiation 77:324-334."
"3729","PC060565","Yan H, Qin J, and Tang DG.  2009.  Cancer stem cells: Potential mediators of therapeutic resistance and novel targets of anti-cancer treatments.  In: Pharmaceutical Perspectives of Cancer Therapeutics. (Liu Y and Mahato RI, Eds.)  AAPS-Springer Pages 559-579."
"3730","PC060565","Jeter C, Badeaux M, Choy G, et al.  2009.  Functional evidence that the self-renewal gene NANOG regulates human tumor development.  Stem Cells 27:993-1005."
"3731","PC060565","
Li HW and Tang DG.  2009.  Prostate cancer stem cells and their involvement in metastasis.  In: Current Clinical Oncology: From Local Invasion to Metastatic Cancer (Leong S PL, Ed.). Humana Press, New York 455-461.
"
"3732","PC060565","Patrawala L and Tang DG.  2008.  CD44 as a functional cancer stem cell marker and therapeutic target.  In:  Progress in Gene Therapy:  Autologous and cancer stem cell gene therapy.  (Bertolotti R, Ozawka K, eds).  World Scientific Publishers 3:317-334."
"3733","PC060565","Bhatia B, Jiang M, and Suraneni M.  2008.  Critical and distinct roles of p16 and telomerase in regulating the proliferative lifespan of normal human prostate epithelial progenitor cells.  J Biol Chem 283:27957-72."
"3734","PC060565","Chandra D, Choy G, and Tang DG.  2007.  Cytosolic accumulation of HSP60 during apoptosis with or without apparent mitochondrial release â¿¿ evidence that its pro-apoptotic or pro-survival functions involve differential interactions with caspase-3.  J Biol Chem 282:31289-31301.

"
"3735","PC060565","Li HW, Chen X and Calhoun-Davis T, et al.  2008.  PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells.  Cancer Res 68:1820-1825."
"3736","PC060565","Bhatia B, Multani AS, Patrawala L, et al.  2008.  Evidence that senescent human prostate epithelial cells enhance tumorigenicity:  Cell fusion as a potential mechanism and inhibition by p16INK4a and hTERT.  Int J Cancer 122:1483-1495."
"3737","PC060565","Honorio S, Li H, and Tang DG.  2009.  Prostate cancer stem/progenitor cells.  In: Cancer Drug Discovery and Development: Stem Cells and Cancer. (Bagley RG and Teicher BA, Eds.)  Humana Press Pages 217-230."
"3738","PC060566","Huang WC, Wu D, Xie Z, et al.  2006.  beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis.  Cancer Res 66:9108-9116."
"3739","PC060566","Seo S, Gera L, Zhau HE, et al.  2008.  BKM1740, an acyl-tyrosine bisphosphonate amide derivative, inhibits the bone metastatic growth of human prostate cancer cells by inducing apoptosis.  Clin Cancer Res 14:6198-6206."
"3740","PC060566","Wu D, Zhau HE, Huang W-C, et al.  2007.  cAMP-response element-binding protein regulates vascular endothelial growth factor expression: Implication in human prostate cancer bone metastasis.  Oncogene 26:5070-5077."
"3741","PC060566","Sung SY, Hsieh CL, Wu D, et al.  2007.  Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance.  Curr Probl Cancer 31:36-100."
"3742","PC060566","Zhang S, Zhau HE, Osunkoya AO, et al.  2010.  Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells.  Mol Cancer 9:9.

"
"3743","PC060566","Nomura T, Huang WC, Zhau HE, et al.  2006.  Beta2-microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis.  Clin Cancer Res 12:7294-7305.

"
"3744","PC060566","Zhang S, Zhau HE, Wang X, et al.  2011.  EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis.  Oncogene 30(50):4941-4952."
"3745","PC060574","
Qin J and Tang DG.  2008.  Cancer stem cells: A definition.  In: Cancer and Stem Cells (Dittmar T and Zanker KS, Eds.).  Nova Science Publishers, Inc, Hauppauge, New York.  ISBN: 978-1-60456-478-5.
"
"3746","PC060574","Yan H, Qin J, and Tang DG.  2009.  Cancer stem cells: Potential mediators of therapeutic resistance and novel targets of anti-cancer treatments.  In: Pharmaceutical Perspectives of Cancer Therapeutics (Liu Y and Mahato RI, Eds.).  AAPS-Springer."
"3747","PC060577","Li H and Tang DG.  2009.  Prostate cancer stem cells and their involvement in metastasis.  In: Current Clinical Oncology:  From Local Invasion to Metastatic Cancer (Leong SPL, Ed).  Humana Press, New York 455-461."
"3748","PC060577","Li H, Honorio S, Patrawala L, et al.  2009.  Methodologies in assaying prostate cancer stem cells.  Methods Mol Biol 568:85-138.
"
"3749","PC060577","Li H, Chen X, Calhoun-Davis T, et al.  2008.  PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells.  Cancer Res 15;68(6):1820-1825."
"3750","PC060577","Honorio S, Li H, and Tang DG.  2009.  Prostate cancer stem/progenitor cells.  Stem Cells and Cancer.  In: Cancer Drug Discovery and Development serial (Bagley RG & Teicher BA, Ed.) Humana/Springer Press 217-230."
"3751","PC060595","Lucas J, True L, Hawley S, et al.  2008.  The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mis-localized in prostate adenocarcinoma.  J Pathol 215:118-25."
"3752","PC060595","Pritchard C, Mecham B, Dumpit R, et al.  2009.  Conserved gene expression programs integrate mammalian prostate development and tumorigenesis.  Cancer Research 69(5):1739-1747."
"3753","PC060595","Datta MW, True LD, Nelson PS, et al.  2007.  The role of tissue microarrays in prostate cancer biomarker discovery.  Adv Anat Pathol 14(6):408-418."
"3754","PC060599","Pajonk F, Vlashi E, and McBride WH.  2010.  Radiation resistance of cancer stem cells - the 4Rs of radiobiology revisited.  Stem Cells 28(4):639-648."
"3755","PC060599","Vlashi E, Kim K, Lagadec C, et al.  2009.  In-vivo imaging, tracking, and targeting of cancer stem cells.  J Natl Cancer Inst 101:350-9."
"3756","PC060599","Vlashi E, McBride WH, and Pajonk F.  2009.  Radiation responses of cancer stem cells.  J Cell Biochem 108:339-342."
"3757","PC060599","Donna LD, Lagadec C, and Pajonk F.  2012.  Radioresistance of prostate cancer cells with low proteasome activity.  Prostate 72(8):868-874."
"3758","PC060599","Lagadec C, Vlashi E, Della DL, et al.  2012.  Radiation-induced reprogramming of breast cancer cells.  Stem Cells 30(5):833-844."
"3759","PC060610","Hirak S. Basu1, Todd A. et al. 2009.  A small molecule polyamine oxidase inhibitor blocks androgen-induced oxidative stress and delays prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Res 69(19):7689-95.
"
"3760","PC060612","Maliski S, Rivera S, Connor S, et.al. 2008.  Renegotiating Masculine Identity After Prostate Cancer Treatment.  Qual Health Res e-pub."
"3761","PC060613","(Author not provided.)  2007.  Tissue-specific consequences of cyclin D1 overexpression in prostate cancer progression.  Cancer Res 67:8188-8197."
"3762","PC060628","Ponguta LA, Gregory CW, French FS, et al.  2008.  Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer.  J Biol Chem 283:20989-201001."
"3763","PC060644","Edwards CL and Campbell LC.  2008.  The burden of prostate cancer among black men: A health crisis.  Journal of Minority Issues and Economic Development: Special Issue on Men."
"3764","PC060644","Campbell LC. Andrews N, Scipio C, et al.  2009.  Pain coping in Latino populations.  J Pain 10(10:1012-9."
"3765","PC060662","Zhang Y and Hamburger AW.  2010.  Androgen receptor coregulators as therapeutics targets in prostate cancer.  Current Cancer Therapy Reviews 6(2)"
"3766","PC060662","Zhang Y, Ali TZ, Zhou H, et al.  2010.  ErbB3 binding protein 1 represses metastasis-promoting gene anterior gradient protein 2 in prostate cancer.  Cancer Research 70(1):240-248."
"3767","PC060662","Zhou J, Mazan-Mamczarz K, Martindale JL, et al.  2010.  Post-transcriptional regulation of androgen receptor mRNA by an ErbB3 binding protein 1 in prostate cancer.  Nucleic Acids Research 38(11):3619-3631."
"3768","PC060662","Zhang Y, Lu Y, Zhou H, et al.  2008.  Dwarfism and iImpaired mammary development in ErbB3 binding protein -1 (Ebp1) deficient mice.  BMC Cell Biol 9:69.

"
"3769","PC060662","Zhang Y, Linn D , Liu Z , et al.  2008.  EBp1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance.  Mol Cancer Ther 7(10):3176-3186.

"
"3770","PC060671","Robbins EW, Travanty EA, Yang K, et al.  2008.  MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells.  BioMed Central Cancer 8:260."
"3771","PC060671","Handorean AM, Yang K, Flaig T, et al.  2009.  Silibinin suppresses CD44 expression in prostate cancer cells.  Am J Transl Res 1:80-87."
"3772","PC060671","Yang K, Handorean AM, and Iczkowski KA.  2009.  MicroRNA 373 and 520c are downregulated in prostate cancer, suppress CD44 translation, and modulate prostate cancer cell invasion.  Int J Clin Exp Pathol 2:361-369."
"3773","PC060695","Lynch CC and Matrisian LM.  2008.  Matrix metalloproteinases as key regulators of tumor-bone interaction.  In:  The Cancer Degradome, Proteases and Cancer Biology (Edwards DR, Hoyer-Hansen G, Blasi F, et al. Eds).  Springer, New York, Chapter 27, Pages 541-566."
"3774","PC060695","Bruni-Cardoso A, Johnson LC, Peterson TE, et al.  2010.  Osteoclast MMP-9 directly affects angiogenesis in the prostate tumor-bone microenvironment.  Mol Cancer Res 8(4):459-70."
"3775","PC060695","Fingleton B and Lynch CC.  2009.  Cancer in context: The importance of the tumor microenvironment.  In:  Cell-Extracellular Matrix Interactions in Cancer (Zent R and Pozzi A, Eds).  Springer, NT, Chapter 3, Pages 75-100."
"3776","PC060695","Mundy GR, Edwards CM, Edwards JR, et al.  2008.  Localized osteolysis.  In:  Principals of Bone Biology 3rd Edition (Biezikian J, Craig Z, and Martin TJ, Eds).  Academic Press, Inc., San Diego, California, Chapter 64, Pages 1391-1413."
"3777","PC060695","Fowler JA, Mundy GR, Lwin ST, et al.  2009.  A murine model of myeloma that allows genetic manipulation of the host microenvironment.  Disease Models and Mechanisms 2(11-12):604-611.  PMCID:  PMC2776114."
"3778","PC060695","Thiolloy S, Halpern JL, Holt GE, et al.  2009.  Host derived MMP-7, but not MMP-9 impacts mammary tumor induced osteolysis.  Cancer Res 69:6747-6755."
"3779","PC060695","Lynch CC, Vargo-Gogola T, Matrisian LM,et al.  2010.  Cleavage of E-Cadherin by Matrix Metalloproteinase-7 Promotes Cellular Proliferation in Nontransformed Cell Lines via Activation of RhoA.  J Oncol 22010:530745."
"3780","PC060695","Lynch CC.  2011.  MMPs as master regulators of the vicious cycle of bone metastasis.  Bone 48:44-53.

"
"3781","PC060710","Sullivan S, Wagner J, Resnick NM, et al.  2011. Vertebral fractures and the misclassification of osteoporosis in men with prostate cancer. J Clin Densitom 14(3):348-353."
"3782","PC060716","Jiang M, Strand DW, Fernandez S, et al.  2010.  Functional remodeling of benign human prostatic tissues in vivo by spontaneously immortalized progenitor and intermediate cells.  Stem Cells 28:344-356."
"3783","PC060716","Jiang M, Fernandez S, Jerome WG, et al.  2010.  Disruption of PPAR-gamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy.  Cell Death  Differ 17(3):469-81."
"3784","PC060716","Strand DW, Franco OE, Basanta D, et al.  2010.  Perspectives on tissue interactions in development and disease.  Curr Mol Med 10:95-112.
"
"3785","PC060716","Jiang M.  2010.  Beyond the Abstract -- Functional remodeling of benign human prostatic tissues in vivo by spontaneously immortalized progenitor and intermediate cells.  UroToday 3345."
"3786","PC060716","Jiang M, Jerome WG and Hayward SW.  2010.  Autophagy in nuclear receptor PPARgamma-deficient mouse prostatic carcinogenesis.  Autophagy 6:175-176."
"3787","PC060726","Nandana S, Ellwood-Yen K, Sawyers CL, et al.  2009.  Hepsin cooperates with myc in the progression of adenocarcinoma in a prostate cancer mouse model.  Prostate 70(6):591-600.

"
"3788","PC060726","Tripathi M, Nandana S, Yamashita H, et al.  2008.  Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.  J Biol Chem 283:30576-30584."
"3789","PC060727","Rekoske BT, Smith HA, Olson BM, et al. 2015. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. Cancer Immunol Res 3:946-55."
"3790","PC060727","Olson B and McNeel D.  2009.  Methods for constructing and evaluating anti-tumor DNA vaccines.  Methods in Mol. Bio 542:211-243."
"3791","PC060727","Olson B and McNeel D.  2008.  Methods for constructing and evaluating anti-tumor DNA vaccines.  In Cancer Gene Ther (Ed. Walther W, Stein U).  Humana Press, Totowa, New Jersey.

"
"3792","PC060727","Olson B and McNeel D.  2007.  Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer.  Prostate 67:1729-1739.

"
"3793","PC060727","Dunphy E, Johnson L, Olson B, et al.  2006.  New approaches to identification of antigenic candidates for future prostate cancer immunotherapy.  Update Cancer Ther 1:273-284.

"
"3794","PC060734","Sprenger CC, Plymate SR, and Reed MJ.  2008.  Extracellular influences on tumour angiogenesis in the aged host.  Br J Cancer 98(2):250-255."
"3795","PC060746","Wang X, Yin L, Rao P, et al.  2007.  WDW: Targeted therapy of prostate cancer.  J Cell Biochem 102:571-579."
"3796","PC060746","Cramer H, Okicki JR, Rho T, et al.  2007.  2-5A ligands- a new concept for the treatment of prostate cancer.  Nucleosides Nucleotides and Nucleic Acids 26:1471-1477."
"3797","PC060754","Bianchi-Frias D, Vakar-Lopez F, Coleman IM, et al.  2010.  The effects of aging on the molecular and cellular composition of the prostate microenvironment.  PLoS ONE 5(9):pii: e12501."
"3798","PC060798","Rege K, Patel SJ, Megeed Z, et al.  2007.  Amphipathic peptide-based fusion peptides and immunoconjugates for the targeted ablation of prostate cancer cells.  Cancer Res 67:(13)."
"3799","PC060802","Nock NL, Tang D, Rundle A, et al.  2007.  Associations between smoking, polymorphisms in polycyclic aromatic hydrocarbon (PAH) metabolism and conjugation genes and PAH-DNA adducts in prostate tumors differ by race.  Cancer Epidemiol Biomarkers Prev 16(6):1236-1245."
"3800","PC060802","Yan Y, Signorello LB, Strom SS,et al.  2015.  Generalizability of established prostate cancer risks variants in men of African ancestry.  Int J Cancer 136(5):1210-1217."
"3801","PC060802","Neslund-Dudas C, Levin AM, et al.  2014.  Case-only gene-environment interaction between ALAD tag SNPs and occupational lead exposure in prostate cancer.  Prostate 74(6):637-646."
"3802","PC060802","Neslund-Dudas C, Levin AM, Beebe-Dimmer JL, et al.  2014.  Gene-environment interactions between JAZF1 and occupational and household led exposure in propostate cancer among African American men.  Cancer Causes Control 25(7):869-879."
"3803","PC060802","Rybicki BA, Neslund-Dudas C, Bock CH, et al.  2008.  Polycyclic aromatic hydrocarbon-DNA adducts in prostate and biochemical recurrence after prostatectomy.  Clin Cancer Res 1:14(3):750-757."
"3804","PC060802","Neslund-Dudas C, Bock CH, Monaghan K, et al.  2007.  SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.  Prostate 67(15):1654-1663."
"3805","PC060802","Neslund-Dudas, Kandegedara A, Kryvenko ON, et al.  2014.  Prostate tissue metal levels and prostate cancer recurrence in smokers.  Biol Trace Elem Res 157(2):107-112."
"3806","PC060802","Tang D, Liu JJ, Bock CH, et al.  2007.  Racial differences in clinical and pathological associations with PhIP-DNA adducts in prostate.  Int J Cancer 15:121(6):1319-1324."
"3807","PC060802","Tang D, Liu JJ, Rundle A, et al.  2007.  Grilled meat consumption and PhIP-DNA adducts in prostate carcinogenesis.  Cancer Epidemiol Biomarkers Prev 16(4):803-808."
"3808","PC060807","Cai C, He HH, Chen S., et al.  2011. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 20:457-471.  
"
"3809","PC060807","Cai C, Wang H, Xu Y, et al.  2009.  Reactivation of androgen receptor regulated TMPRSS2:ERG gene expression in castration resistant prostate cancer.  Cancer Res 69:6027-32."
"3810","PC060807","Taplin ME, Manola J, Oh WK, et al.  2008.  A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int 101:1084-1089."
"3811","PC060807","Bao BY, Chuang BF, Wang Q, et al.  2008.  Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes.  Prostate 68:839-848."
"3812","PC060814","Jiang Z, Holyoak GR, Ritchey JW,et al.  2011.  Different optical spectral characteristics in a necrotic transmissible venereal tumor and a cystic lesion in the same canine prostate observed by triple-band transrectal optical tomography under transrectal ultrasound guidance.  Proceedings of SPIE, Paper 7892-7924.
"
"3813","PC060814","Xu G, Piao D, Dehghani H.  2011. The Utility of direct-current as compared to frequency domain measurements in spectrally-constrained diffuse optical tomography toward cancer imaging.  Technol Cancer Res Treat 10: 403-416. "
"3814","PC060814","Jiang Z, Piao D, Bartels KD, et al. 2011.  Transrectal ultrasound-integrated spectral optical tomography of hypoxic progression of a regressing tumor in a canine prostate. Technol Cancer Res Treat 10:519-531."
"3815","PC060814","Jiang Z, Piao D, Holyoak GR, et al.  2011.  Trans-rectal ultrasound-coupled spectral optical tomography of total hemoglobin concentration enhances assessment of the laterality and progression of a transmissible venereal tumor in canine prostate.  Urology  77(1):237-242."
"3816","PC060814","Piao D.  2008.  Diffuse optical techniques: Instrumentation.  In:  Translational Multimodality Optical Imaging.  (Azar FS and Intes X, Eds.)  Artech House."
"3817","PC060814","Jiang Z, Piao D, Xu G, et al.  2008.  Trans-rectal ultrasound-coupled near-infrared optical tomography of the prostate part II: Experimental demonstration.  Optics Express 16(22):17505-17520."
"3818","PC060814","Jiang Z, Ritchey JW, Holyoak GR, Bartels et al.  2009.  In vivo trans-rectal ultrasound coupled trans-rectal near-infrared optical tomography of canine prostate bearing transmissible venereal tumor.  Proceedings of SPIE Volume 7174, Paper Number 71741U."
"3819","PC060814","Xu G, Bunting CF, Dehghani H, et al.  2009.  A hierarchical spatial prior approach for prostate image reconstruction in trans-rectal optical tomography.  Proceedings of SPIE Volume 7171, Paper Number 71710S."
"3820","PC060814","Jiang Z, Piao D, and Krasinski JS.  2009.  Development of a continuous-wave dual-band trans-rectal optical tomography system for concurrent sagittal imaging with trans-rectal ultrasound.  Proceedings of SPIE Volume 7171, Paper Number 71710G."
"3821","PC060814","Xu G, Piao D, Musgrove CH, et al.  2008.  Trans-rectal ultrasound-coupled near-infrared optical tomography of the prostate part I: Simulation.  Optics Express 16(22):17484-17504."
"3822","PC060814","Zhang A, Piao D, Bunting CF, et al.  2010.  Photon diffusion in a homogeneous medium bounded externally or internally by an infinitely long circular cylindrical applicator ---- Part I: Steady-state theory.  J Opt Soc Am A 27(3):648-662."
"3823","PC060814","Piao D, Bartels KE, Jiang Z, et al.  2010.  Alternative trans-rectal prostate imaging: A diffuse optical tomography method.  IEEE Journal of Selected Topics in Quantum Electronics, 'Biophotonics 2' (Special Issue).

"
"3824","PC060814","Piao D, Jiang Z, Bartels KE, et al.  2009.  In vivo trans-rectal ultrasound-coupled near-infrared optical tomography of intact normal canine prostate.  J Innov Opt Health Sci 2(3):215-225.

"
"3825","PC060814","Jiang Z, Holyoak GR, Bartels KE, et al.  2009.  In vivo trans-rectal ultrasound coupled near-infrared optical tomography of a transmissible venereal tumor model in the canine pelvic canal.  J Biomedical Optics Letters 14(3):030506."
"3826","PC060814","Piao D, Jiang Z, Bartels KE, et al.  2011.  Optical biopsy of the prostate: can we TRUST (trans-rectal ultrasound-coupled spectral tomography)?  Proceedings of SPIE, Paper 7895-18 (invited paper)."
"3827","PC060814","Xu G, Piao D, Dehghani H.  2011.  Spectral a priori to spatial a posteriori in continuous-wave image reconstruction in near-infrared optical tomography.  Proceedings of SPIE, Paper 7892-7912."
"3828","PC060814","Xu G, Piao D.  2011.  Feasibility of rapid near-infrared diffuse optical tomography by swept-spectral-encoded sequential light delivery.  Proceedings of SPIE, Paper 7896-7931."
"3829","PC060821","Thobe MN and Waltz SE.  2008.  The Ron receptor and cancer.  In: Encyclopedia of Cancer (Schwab M, Ed.)  2nd edition, Springer, New York.

"
"3830","PC060821","
Leonis MA, Thobe MN, and Waltz SE.  2007.  Ron-receptor tyrosine kinase in tumorigenesis and metastasis.  Future Oncol 3(4):441-448.

"
"3831","PC060821","Thobe MN, Gurusamy D and Waltz SE.  2010.  The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells.  Oncogene 29(2):214-226."
"3832","PC060842","Liu GL, Anwar MS, Bouchard L-S, et al.  2009.  Cobalt nanowonton for picomolar sensitivity dual modality imaging of T2 MRI and photoacoustic tomography.  Proc Natl Acad Sci U S A 106:4085-4089."
"3833","PC060842","Chamberland DL, Taurog JD, Richardson JA, et al.  2009. Photoacoustic tomography - A new imaging technology for inflammatory arthritis-as applied to B27 rat joints.  Clin Exp Rheumatol 27:387-8."
"3834","PC060842","Rajian JR, Carson PL, and Wang X.  2009.  Quantitative evaluation of tissue optical absorption spectrum by novel spectroscopic photoacoustic aided by an optical contrast agent.  Optics Express 17(6):4879-4889.

"
"3835","PC060842","Wang X, Fowlkes JB, Carson PL, et al.  2010.  A high-speed photoacoustic tomography system based on a commercial ultrasound and a custom transducer array.  Proc SPIE 7564:756424."
"3836","PC060842","Wang X, Roberts WW, Carson PL, et al.  2010. Photoacoustic tomography: a potential new tool for prostate cancer. Biomed Opt Express 1(4):1117-1126."
"3837","PC060842","Wang X, Fowlkes JB, Cannata JM, et al.  2011. Photoacoustic imaging with a commercial ultrasound system and a custom probe.  Ultrasound Med Biol 37(3):484-492."
"3838","PC060842","Rajian JR, Carson PL, Fowlkes JB, et al.  2010.  Quantitative photoacoustic measurement of blood oxygen saturation in vivo aided by an optical contrast agent.  Proc SPIE 7564:756412."
"3839","PC060843","Vander Griend DJ, Karthaus WL, Dalrymple S, et al.  2008.  The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells.  Cancer Res 68:(23)."
"3840","PC060855","Elankumaran S, Chavan V, Qiao D, et al.  2010.  Type I interferon-sensitive recombinant Newcastle disease virus for oncolytic virotherapy.  J of Virology 84(8):3835-3844."
"3841","PC060857","Coleman RE, Guise TA, Lipton A, et al.  2008.  Advancing treatment for metastatic bone cancer, consensus recommendations from the second Cambridge conference.  Clin Cancer Res 14:6387-6395."
"3842","PC060857","Shiozawa Y, Havens AM, Pienta KJ, et al.  2008.  The bone marrow niche:  Habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites.  Leukemia 22:941-50."
"3843","PC060857","Wang J, Wang J, Dai J, et al.  2007.  A glycolytic mechanism regulating an angiogenic switch, Cancer Res 67(1):149-159."
"3844","PC060857","Havens AM, Pederson EA, Shiozawa Y, et al.  2008.  An in vivo mouse model for human prostate cancer metastasis.  Neoplasia 10(4):371-380."
"3845","PC060857","Keller ET, Dai J, Escara-Wilke J, et al.  2007.  New trends in the treatment of bone metastasis.  J Cell Biochemy 102(5):1095-1102.

"
"3846","PC060857","Jung Y, Shiozawa Y, Wang J, et. al. 2009. Expression of PGK1 by Prostate Cancer Cells
Induces Bone Formation. Mol Cancer Res 7(10)."
"3847","PC060857","Wang J, Ying G, Wang J, et al.  2010.  Characterization of PGK1 expression by stromal cells derived from the tumor microenvironment in prostate cancer progression.  Cancer Res 70(2):471-480."
"3848","PC060857","Taichman RS, Loberg R, Mehra R, et al.  2007.  The biology and treatment of localized and metastatic prostate cancer.  J Clin Invest 117(9):2351-2361."
"3849","PC060857","Mizutani K, Taichman RS, and Pienta KJ.  Year of publication not specified.  Prostate cancer metastasis: Thoughts on biology and therapeutics.  In:  Cancer Metastasis: Biologic Basis and Therapeutics (Welch D and Lyden D, Eds.).  Cambridge University Press."
"3850","PC060865","Schilling SH, Hjelmeland AB, Radiloff DR, et al.  2009.  NDRG4 is required for cell cycle progression and cell survival in glioblastoma.  Journal of Biological Chemistry 284:25160-25169."
"3851","PC060865","Radiloff DR, Wakeman TP, Feng J, et al.  2011.  Trefoil factor 1 acts to suppress senescence induced by oncogene-activation during the cellular transformation process.  Proc Natl Acad Sci U S A 108(16):6591-6596."
"3852","PC060866","Huang W-C, Havel JJ, Zhau HE, et al.  2008.  Beta2-Microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells.  Clin Cancer Res 14:5341-7.

"
"3853","PC060866","Seo SI, Gera L, Zhau HE, et al.  2008.  BKM1740, an acyl-tyrosine bisphosphonate amide derivative, inhibits the bone metastatic growth of human prostate cancer cells by inducing apoptosis.  Clin Cancer Res 14:6198-206."
"3854","PC060866","Zhau HE, Odero-Marah V, Lue HW, et al.  2008.  Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model.  Clin Exp Metastasis 25(6):601-610."
"3855","PC060866","Odero-Marah V, Wang R, Chu G, et al.  2008.  Receptor activator of NFkB ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res 18(8):858-870."
"3856","PC060866","Josson S, Nomura T and Lin JT.  2011.  Beta2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells.  Cancer Res 71(7):2600-2610."
"3857","PC060866","Huang WC, Zhau HE and Chung LW.  2010.  Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a mitogen-activated protein kinase/lipogenic pathway in human prostate cancer cells.  J Chem Biol 285(11):7947-7956.
"
"3858","PC060866","Zhang S, Wang X, Osunkoya AO, et al.  2011.  EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis.  Oncogene 30(50):4941-4952."
"3859","PC060879","Oltean S, Febbo PG and Garcia-Blanco MA.  2008.  Dunning rat prostate adenocarcinomas and alternative splicing reporters: Powerful tools to study epithelial plasticity in prostate tumors in vivo.  Clin Exp Metastasis 25(6):611-619."
"3860","PC060886","Schaue D, Koya RC, Liao Y-P, et al.  2010.  Immune rejection in a humanized model of murine prostate cancer.  Anticancer Res 30:409-414."
"3861","PC060886","Schaue D and McBride WH.  2010.  Links between innate immunity and normal tissue radiobiology.  Radiat Res 173:406-417."
"3862","PC060886","Brush JM, Kim K, Sayre JW, et al.  2009.  Imaging of radiation effects on cellular 26S proteasome function in situ.  Int J Radiat Biol 85:483-94.
"
"3863","PC060886","Kim K, Brush JM, Watson PA, et al.  2008.  EGFRvIII expression in U87 glioblastoma cells alters their proteasome composition, function, and response to irradiation.  Mol Cancer Res 6(3):426-434."
"3864","PC060886","Schaue D, Comin-Anduix B, Ribas A, et al.  2008.  T-Cell responses to survivin in cancer patients undergoing radiation therapy.  Clin Cancer Res 14:4883-4890."
"3865","PC060886","Liao Y-P, Wang C-C, Schaue D, et al.  2009.  Local irradiation of murine melanoma affects the development of tumor-specific immunity.  Immunol 128:1-e797-804."
"3866","PC060911","Carson AP, Howard DL, Carpenter WR, et al.  2010.  Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer.  J Pain Symptom Manage 39:872-881."
"3867","PC060913","Yang F, Strand DW, and Rowley DR.  2008.  Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.  Oncogene 27:450-9."
"3868","PC060932","Bawa-Khalfe T, Cheng J, Lin SH, et al.  2010.  SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms.  J Biol Chem 285(33):25859-25866."
"3869","PC060951","Baniwal SK, Khalid O and Sir D.  2009.  Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its binding to DNA.  Mol Endo 23:1203-1214.
"
"3870","PC060951","Khalid O, Baniwal Sk and Purcell D.  2008.  Modulation of Runx2 activity by estrogen receptor alpha: Implications for osteoporosis and breast cancer.  Endocrinology 149:5984-5995."
"3871","PC060960","DaSilva J, Gioeli D, Weber M, et. al.  2009.  The Neuroendocrine-Derived Peptide Parathyroid Hormone-Related Protein Promotes Prostate Cancer Cell Growth by Stabilizing the Androgen Receptor.  Can Res 69:(18) 4687 OF1-10."
"3872","PC061027","Ramachandran IR, Song W, Lapteva N, et al. 2011. The Phosphatase Src Homology Region 2 Domain-Containing Phosphatase-1 Is an Intrinsic Central Regulator of Dendritic Cell Function. J Immunol 186(7):3934-3945."
"3873","PC061038","Chang BL, Spangler E, Gallagher S, et al.  2011.  Validation of genome-wide prostate cancer associations in men of African descent.  Cancer Epidemiol Biomarkers Prev 20(10):23-32."
"3874","PC061038","Strom SS, Yamamura Y, Forman MR, et al.  2008.  Saturated fat intake predicts biochemical failure after prostatectomy.  Int J Cancer 122(11):2581-2585."
"3875","PC061038","Hinch AG, Tandon A, Patterson N, et al.  2011.  The landscape of recombination in African Americans.  Nature 20;476(7359):170-175."
"3876","PC061038","Haiman CA, Chen GK, Blot WJ, et al.  2011.  Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21.  Nat Genet 43(6):570-573."
"3877","PC061051","Jee-Yeong Jeong, Gerta Hoxhaj, Amanda L. Socha, Arthur J. Sytkowski, and Laurie Feldman. 2009.  An Erythropoietin Autocrine/Paracrine Axis Modulates the Growth and Survival of Human Prostate Cancer Cells, Mol Cancer Res, 7:1150-1157"
"3878","PC061051","Jeong JY, Feldman L, Solar P, et al.  2008.  Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells.  Int J Cancer 122(2):274-280."
"3879","PC061051","Solar P, Feldman L, Jeong JY, et al.  2008.  Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype.  Int J Cancer 122(2):281-288."
"3880","PC061051","Jeong JY, Wang Y, and Sytkowski AJ.  2009.  Human selenium binding protein-1 (hSP56) interacts with VDU1 in a selenium-dependent manner.  Biochem Biophys Res Commun 379(2):583-588."
"3881","PC061052","Menon T, Yates JA and Bochar DA.  2010.  Regulation of androgen-responsive transcription by the chromatin remodeling factor CHD8.  Mol Endocrinol 24(6):1165-74."
"3882","PC061053","Schulmerich MV, Kodali AK, Reddy RK, et al.  2010.  Dark field Raman microscopy.  Anal Chem 82:6273-6280."
"3883","PC061053","Book Chapter
Walsh MJ and Bhargava R.  2010.  Infrared spectroscopic imaging: An integrative approach to pathology.  In: Nanobiophotonics (Popescu G, Ed.).  McGraw-Hill Professional, New York.
"
"3884","PC061053","Kwak JT, Hewitt SM, Sinha S,et al.  2011. Multimodal microscopy for automated histologic analysis of prostate cancer.  BMC Cancer 11:62."
"3885","PC061053","Bhargava R.  2007.  Practical FTIR chemical imaging for cancer pathology.  Anal Bioanal Chem 389:1155-1169."
"3886","PC061053","Srinivasan G and Bhargava R.  (Year not provided.)  Fourier transform infrared spectroscopic imaging: The emerging evolution from a microscopy tool to a cancer imaging modality.  Spectroscopy 22:40-51."
"3887","PC061053","Bhargava R and Levin IW.  (Anticipated 2008 publication.)  Prostate cancer diagnosis by FTIR imaging.  (Diem M, Griffiths PR, and Chalmers J, Eds.)"
"3888","PC061053","Llora X, Priya A, and Bhargava R.  2009.  Observer-invariant histopathology using genetics-based machine learning.  Nat Computing 8:101-120.

"
"3889","PC061053","Bhargava R and Levin IW.  2008.  Prostate cancer diagnosis by FTIR imaging.  (Diem M, Griffiths PR, and Chalmers J, Eds.)

"
"3890","PC061053","Bhargava R and Davis BJ.  2010.  Histologic models for optical tomography and spectroscopy of tissues.  Proc SPIE 7174:71742H."
"3891","PC061053","Davis BJ, Carney PS and Bhargava R.  2010.  Theory of mid-infrared absorption microspectroscopy.  I. Homogeneous samples.  Anal Chem 82:3474--3486."
"3892","PC061053","Davis BJ, Carney PS and Bhargava R.  2010.  Theory of mid-infrared absorption microspectroscopy.  II. Heterogeneous samples.  Anal. Chem 82:3487--3499."
"3893","PC061053","Kodali AK, Bhargava R.  2010.  Nanostructured probes to enhance optical and vibrational spectroscopic imaging for biomedical applications.  In:  The Oxford handbook of Nanoscience and Technology:  Vol. III (Fu YY and Narlikar A, Eds.).  Oxford University Press, Oxford, United Kingdom."
"3894","PC061053","Reddy RK and Bhargava R.  2010.  Chemometric methods for biomedical Raman spectroscopy and imaging.  In:  Emerging Raman Applications and Techniques in Biomedical and Pharmaceutical Fields (Morris MD, Matousek P, Eds.).  Springer-Verlag, Berlin, Heidelberg.

"
"3895","PC061053","Walsh MJ, Nasse MJ, Pounder FN, et al.  2009.  Synchrotron FTIR imaging for the identification of cell types within human tissues AIP Conference.  Proc SPIE 1214:105-107."
"3896","PC061053","Pounder FN, Reddy RK, Walsh MJ, et al.  2009.  Validating the cancer diagnosis potential of mid-infrared spectroscopic imaging.  Proc SPIE 7186:71860f."
"3897","PC061053","Davis BJ, Carney PS, and Bhargava R.  2011.  Infrared microspectroscopy of intact fibers.  Anal Chem 83:525-532."
"3898","PC061053","
Kodali AK, Schulmerich MV, Palekar R, et al.  2010.  Optimized nanospherical layered alternating metal-dielectric probes for optical sensing.  Opt Exp 18:23302-23313.
"
"3899","PC061053","Davis BJ, Carney PS, and Bhargava R.  2010.  Theory of mid-infrared absorption microspectroscopy. I. Homogeneous samples.  Anal Chem 82:3474-3486.

"
"3900","PC061053","Nasse MJ, Walsh MJ, Mattson EC, et al.  2011.  High-resolution fourier transform infrared chemical imaging with multiple synchrotron beams.  Nat Methods 8:413-416.

"
"3901","PC061053","Moreno-Torres JG, Llora X, Goldberg DE, et al.  2011.  Repairing fractures between data using genetic programming-based feature extraction: A case study in cancer diagnosis.  In:  Information Sciences & Informatics and Computer Science Intelligent Systems Applications (An International Journal) (Pedrycz W, Ed.).  Elsevier Publishing."
"3902","PC061053","Kwon B, Wang C, Park K, et al.  2011.  Themomechanical sensitivity of microcantilevers in the mid-infrared spectral region.  Nano Micro Thermophys Eng 15: 16-28."
"3903","PC061053","Reddy RK and Bhargava R.  2010.  Automated noise reduction for accurate classification of tissue from low signal-to-noise ratio imaging data.  Analyst 135:2818-2825."
"3904","PC061053","Moreno-Torres JG, Llora X, Goldberg DE, et al.  2010.  On the homogenization of data from two laboratories using genetic programming.  Lect Notes Comput Sci 6471:185-197.

"
"3905","PC061053","Kong R, Reddy RK, and Bhargava R.  2010.  Characterization of tumor progression in engineered tissue using infrared spectroscopic imaging.  Analyst 135:1569-1578."
"3906","PC061053","Kodali AK, Schulmerich MV, Ip J, et al.  2010.  Narrowband midinfrared reflectance filters using guided mode resonance.  Anal Chem 82:5697-5706."
"3907","PC061053","Kwak JT, Hewitt SM, Sinha S, et al.  2011.  Multimodal microscopy for automated histologic analysis of prostate cancer.  BMC Cancer 11:62."
"3908","PC061053","Holton SE, Walsh MJ, and Bhargava R.  2011.  Localizing subcellular biochemical transformations in cancer-activated fibroblasts using high-resolution infrared spectroscopic imaging.  Analyst 136:2953-2958."
"3909","PC061053","Kong R and Bhargava R.  2011.  Characterization of porcine skin as a model for human transdermal diffusion.  Analyst 136: 2359-2366."
"3910","PC061067","Jin G, Sun J, Liu W, et al. 2011. Genome-wide copy-number variation analysis identifies common genetic variants at 20p13 associated with aggressiveness of prostate cancer. Carcinogenesis 32(7):1057-1062."
"3911","PC061067","Jin G, Sun J, Isaacs SD, et al. 2011. Human polymorphisms at long non-coding RNAs (lncRNAs) and association with prostate cancer risk. Carcinogenesis 32(11):1655-1659."
"3912","PC061077","Lee KW, Ma L, Cobb L, et al.  2007.  Contribution of the orphan nuclear receptor Nur77 to the apoptotic action of IGFBP-3.  Carcinogenesis 28:1653-1658."
"3913","PC061077","Lue Y, Swerdloff R, Liu Q, et al.  2010.  Opposing roles of insulin-like growth factor binding protein 3 and humanin in the regulation of testicular germ cell apoptosis.  Endocrinology 151:350-357."
"3914","PC061077","Paharkova-Vatchkova V and Lee KW.  2010.  Nuclear export and mitochondrial and ER-targeting of IGFBP-3 regulates its apoptotic properties.  Endocrine-Related Cancer 17(2):293-302. 

"
"3915","PC061077","Yamada PM and Lee KW.  2009.  Perspectives in mammalian IGFBP-3 biology: Local vs. systemic action.  Am J Physiol Cell Physiol 296(5):C954-C976."
"3916","PC061077","Jia Y, Lee KW, Swerdloff RS, et al.  2010.  The interaction of insulin-like growth factor binding protein-3 and bax in mitochondria promotes male germ cell apoptosis.  J Biol Chem 285(3):1726-32."
"3917","PC061077","Paharkova-Vatchkova V and Lee KW.  2010.  Nuclear export and mitochondrial and ER-targeting of IGFBP-3 regulates its apoptotic properties.  Endocr Relat Cancer 17(2):293-302."
"3918","PC061077","Kim H, Ali O, Shim M, Lee KW et. al. 2007. Insulin-Like Growth Factor Binding Protein-3 Induces Insulin Resistance in Adipocytes In Vitro and in Rats In Vivo. Pediatric Res 61(2):159-164"
"3919","PC061077","Liu B, Lee KW, Anzo M, et al.  2007.  IGFBP-3 inhibition of prostate cancer progression involves suppression of angiogenesis. Oncogene 26:1811-9."
"3920","PC061094","Reams RR, Agrawal D, Davis MB, et al.  2009.  Micro array comparison of prostate tumor gene expression African American and Caucasian males: A pilot project study.  Infectious Agents and Cancer 4(1):S3"
"3921","PC061094","Odedina FT, Dagne G, Pressey S, et al.  2011. Prostate cancer health and cultural beliefs of black
men: The Florida Prostate Cancer Disparity Project. Infect Agent Cancer 23;6 Suppl 2:S10."
"3922","PC061094","Odedina FT, Akinremi TO, Chinegwundoh F, et al.  2009.  Does the prostate cancer disparities seen in US Black men follow the path of the transatlantic slave trade?  Infectious Agents and Cancer 4(1):S2."
"3923","PC061094","Odedina FT, Campbell E, LaRose-Pierre M, et al.  2008.  Personal factors affecting African American men¿s prostate cancer screening behavior.  J Natl Med Assoc 100(6):724-733."
"3924","PC061094","Kumar NB, Yu D, Akinremi TO, et al.  2009.  Comparing dietary and other lifestyle factors among immigrant Nigerian men living in the US and indigenous from Nigeria:  Potential implications for prostate cancer risk reduction.  J Immigr Minor Health 11(5):391-9."
"3925","PC061094","Odedina FT, Yu D, Akinremi TO, et al.  2008.  Prostate cancer cognitive-behavioral factors in a West African population.  J Immigr Minor Health 11:258-67."
"3926","PC061094","Ragin CC, Taioli E, McFarlane-Anderson N, et al.  2007.  African-Caribbean cancer consortium for the study of viral, genetic and environmental cancer risk factors.  Infect Agent Cancer 2:17."
"3927","PC061106","Wang H and Yan C.  2011.  A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells.  Neoplasia 13(7):611-619."
"3928","PC061106","Mo P, Wang H, Lu H, et al.  2010.  MDM2 mediates ubiquitination and degradation of activating transcription factor 3.  J Biol Chem 285(35):26908-26915."
"3929","PC061106","Nair RR, Avila H, Ma X, et al.  2008.  A novel high-throughput screening system identifies a small molecule repressive for matrix metalloproteinase-9 expression.  Mol Pharmacol 73(3):919-929."
"3930","PC061106","Wang H, Mo P, Ren S, et al.  2010.  Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6.  J Biol Chem 285(17):13201-13210. "
"3931","PC061106","Wang H, Ma X, Ren S, et al.  2011.  A small-molecule inhibitor of MDMX activates p53 and induces apoptosis in cancer cells.  Mol Cancer Ther 10(1):69-79."
"3932","PC061114","Brakenhielm E, Burton JB, Johnson M, et al.  2007.  Modulating metastasis by a lymphangiogenic switch in prostate cancer.  Int J Cancer 121(10)2153-61.

"
"3933","PC061114","Burton JB, Priceman SJ, Sung JL, et al.  2008.  Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis.  Cancer Res 68:7828-37.
"
"3934","PC061114","Burton JB, Johnson M, Sato M, et al.  2008. Adenovirus mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer.  Nat Med 14(8) 882-8."
"3935","PC061118","Fischer GS, Iordachita I, Csoma C, et al.  2008.  MRI-Compatible pneumatic robot for transperineal prostate needle placement.  IEE 13(3):295-305.

"
"3936","PC061118","Tokuda J, Fischer GS, Csoma C, et al.  2008.  Software strategy for robotic transperineal prostate therapy in closed-bore MRI.  Lect Notes Comput Sci 5242:701-709 (Springer)."
"3937","PC061118","Fischer GS, Krieger A, Iordachita I, et al.  2008.  MRI compatibility of robot actuation techniques â¿¿ A comparative study.  Lect Notes Comput Sci 5242:509-517 (Springer)."
"3938","PC061127","Sun Q, Yu X, DeGraff DJ, et al.  2009.  Upstream stimulatory factor 2, a novel FoxA1-interacting protein, is involved in prostate-specific gene expression.  Mol Endocrinol 23(12):2038-2047.

"
"3939","PC061127","Zhang J-F, Gao N, DeGraff DJ, et al.  2010.  Characterization of cis elements of the probasin promoter necessary for prostate-specific gene expression.  Prostate 70(9):934-51."
"3940","PC061134","Gudmundsson J, Sulem P, Manolescu A, et al.  2007.  Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24.  Nat Genet 39(5):631-637 [Epub 2007 Apr 1]."
"3941","PC061134","Haiman CA, Chen GK, Blot WJ et al.  2011.  Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans.  PLoS Genet 7(5):e1001387."
"3942","PC061134","Xu J, Kibel AS, Hu JJ, et al.  2009.  Prostate cancer risk associated loci in African Americans.  Cancer Epidemiol Biomarkers Prev 18(7):2145-2149."
"3943","PC061134","Sun J, Purcell L, Gao Z, et al.  2008.  Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans.  Prostate 15;68(7):691-697."
"3944","PC061134","Haiman CA, Chen GK, Blot WJ, et al. 2011. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21, Nat Genet 43(6):570-573."
"3945","PC061139","Liao Z, Lutz J, and Nevalainen MT.  2010.  Transcription factor Stat5a/b as a therapeutic target protein for prostate cancer.  Int J Biochem Cell Biol 42:186-192."
"3946","PC061139","Reddy A, Huang C, Liu H, et al.  2010.  Robust network analysis reveals alteration of the Stat5a network as a hallmark of prostate cancer. Genome Inform 24:139-153."
"3947","PC061139","Gu L, Zhu XH, Visakorpi T, et al.  2010.  Activating mutation (V617F) in the tyrosine kinase Jak2 is absent in locally-confined or castration-resistant prostate cancer.  Cellular Oncology 33(2):55-59."
"3948","PC061139","Dagvadorj A, Tan S, Xie J, et al.  2010.  N-Terminal truncation of Stat5a/b circumvents PIAS3-mediated inhibition of Stat5 in prostate cancer cells.  Int J Biochem Cell Biol 42(12):2037-2046."
"3949","PC061139","Gupta S, Vogiatzi P, and Nevalainen MT.  2010.  Jak2/Stat5 signaling axis and novel therapeutic strategies in prostate cancer. In: Cutting Edge Therapies for Cancer in 21st Century (Claudio PP Ed.)  Bentham Science Publishers, Ltd."
"3950","PC061139","Gupta S, Liao Z, and Nevalainen MT.  2010.  Jak2-Stat5 pathway in prostate cancer.  In: The Encyclopedia of Cancer Targets (Marshall JL, Weiner L, Gelmann E, et al., Eds).  Springer Verlag."
"3951","PC061139","Powell M, Lisanti M, Nevalainen MT, et al.  2008.  Androgen receptor epigenetic modification and acetylation regulate prostate cellular growth.  In: Prostate Cancer: Signaling Networks, Genetics and New Treatment Strategies.  Nevalainen MT and Pestell R (Eds).  Humana Press."
"3952","PC061139","Dagvadorj A, Tan ST, Cavalli L, et al.  2008.  Androgen-dependent and highly tumorigenic human prostate cancer cell line established from a transplantable primary CWR22 tumor. Clin Cancer Res 14: 6062-6072."
"3953","PC061139","Gu L, Dagvadorj A, Lutz J, et al.  2010.  Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5 has a preferential role in the promotion of prostate cancer cell viability and tumor growth.  Am J Pathol 176(4):1959-1972."
"3954","PC061139","Gu L, Vogiatzi PV, Puhr M, et al.  2010.  Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo.  Endocr Related Cancer 18:481-493."
"3955","PC061139","Abdulghani J, Gu L, Dagvadorj A, et al.  2008.  Transcription factor stat3 promotes metastatic behavior of prostate cancer.  Am J Pathol 172:1717-1728.

"
"3956","PC061139","Culig Z, Pestell RP, and Nevalainen M.  2008.  Transcription factors stat5 and Stat3: Key survival factors for prostate cancer cells.  In: Prostate Cancer: Signaling Networks, Genetics and New Treatment Strategies.  Nevalainen MT and Pestell R (Eds).  Humana Press."
"3957","PC061139","Tan S and Nevalainen MT.  2008.  Transcription factor stat5 in breast and prostate cancer.  Endocr Relat Cancer 15:367-390."
"3958","PC061139","Tan S-H, Dagvadorj A, Shen F, et al.  2008.  Transcription factor stat5 synergizes with androgen receptor in prostate cancer cells.  Cancer Res 68:1-13."
"3959","PC061139","Dagvadorj A, Kirken RA, Karras J, et al.  2008.  Transcription factor stat5 promotes growth of human prostate cancer cells in vivo.  Clin Cancer Res 14:1317-1324"
"3960","PC061145","Mukhopadhyay N, Kim J, Cinar B, et al.  2009.  Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation.  Cancer Res 69:(6):2210-2218.

"
"3961","PC061145","Di Vizio D, Kim J, Hager MH, et al.  2009.  Oncosome formation in prostate cancer: Association with a region of frequent chromosomal deletion in metastatic disease.  Cancer Res 69(13):5601-5609."
"3962","PC061151","Ingermann AR, Yang Y-F, Han J, et al.  2010.  Identification of a novel cell death receptor mediating IGFBP-3-induced antitumor effects in breast and prostate cancer.  Journal of Biological Chemistry 230(39):30233-30246."
"3963","PC061151","Jogie-Brahim S, Feldman D, and Oh Y.  2009.  Unraveling IGFBP-3: IGF-independent actions in human disease.  Endocrine Reviews 30(5):417-437."
"3964","PC061157","Xie Y, Wolff DW, Lin MF, et al.  2007.  Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.  Mol Pharmacol 72:73-85."
"3965","PC061157","Wong CY, Wuriyanghan H, Xie Y, et al. 2011. Epigenetic regulation of phosphatidylinositol 3,4,5-triphosphate-dependent Rac exchanger 1 gene expression in prostate cancer cells.  J Biol Chem 286(29):25813-25822."
"3966","PC061157","Qin J, Xie Y, Wang B, et al.  2009.  Upregulation of PIP3-dependent Rac exchanger promote prostate cancer metastasis.  Oncogene 28:1853-63."
"3967","PC061157","Wolff DW, Xie Y, Deng C, et al. 2012. Epigenetic repression of regulator of G-protein signaling 2 promotes androgen-independent prostate cancer cell growth. Int J Cancer. 130(7):1521-31."
"3968","PC061165","Kobayashi T, Tsang WY, Li J, et al.  2011.  Centriolar kinesin Kif24 interacts with CP110 to remodel microtubules and regulate ciliogenesis.  Cell 145(6):914-925."
"3969","PC061165","Tsang WY, Spektor A, Vijayakumar S, et al.  2009.  Cep76, a centrosomal protein that specifically restrains centriole reduplication.  Dev Cell 16(5):649-660."
"3970","PC061165","Spektor A, Tsang WY, Khoo D, et al.  2007.  Cep97 and CP110 suppress a cilia assembly program.  Cell 130:678-690."
"3971","PC061185","Kingsley LA, Fournier PG, Chirgwin JM, et al.  2007.  Molecular biology of bone metastasis.  Mol Cancer Ther 6(10):2609-2617."
"3972","PC061185","Fournier PG and Guise TA.  2007.  BMP7: A new bone metastases prevention? Am J Pathol 171(3):1047-1057."
"3973","PC061187","Bañez LL, Terris MK, Aronson WJ, et al.  2009.  Race and time from diagnosis to radical prostatectomy: Does equal-access mean equal timely access to the operating room? Results from the SEARCH database.  Cancer Epidemiol Biomarkers Prev 18(4):1208-1212."
"3974","PC061187","Hamilton RJ, Goldberg KC, Platz EA, et al.  2008.  The influence of statin medications on prostate specific antigen levels in healthy men.  J Natl Cancer Inst 100(21):1511-1518."
"3975","PC061187","Bañez LL, Klink JC, Jayachandran J, et al.  2010.  Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy.   Cancer Epidemiol Biomarkers Prev 19(3):722-728."
"3976","PC061187","Hamilton RJ, Banez LL, Aronson WJ, et al.  2010.  Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 116(14):3389-3398."
"3977","PC061187","Hamilton RJ, Aronson WJ, Presti JC Jr., et al.  2007.  Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy:  Results from the SEARCH database.  Cancer 110(10):2202-2209."
"3978","PC061208","Elkahwaji JE, Zhong W, Hopkins WJ, et al.  2007.  Chronic bacterial infection and inflammation incite reactive hyperplasia in a mouse model of chronic prostatitis.  Prostate 67(1):14-21."
"3979","PC061209","Kim L, DeCesare S, Zhang T, et al.  2008.  Effect of lumpectomy cavity volume change on the CTV for accelerated partial breast irradiation: A deformable registration study.  International Journal of Radiation Oncology, Biology and Physics 72(1) Supp. 1:S511-S512."
"3980","PC061209","Xu X, Kim J, Laganis P, et al.  (2011)  Development of a tetrahedron beam computed tomography benchtop system with a multiple pixel field emission X-ray tube.  Med Phys 38(10):5500-5508."
"3981","PC061209","Schulze D, Liang J,Zhang T, et al.  2009.  Comparison of various online IGRT strategies: The benefits of online treatment plan re-optimization.  Radiother Oncol 90:367-76"
"3982","PC061209","Zhang T, Chi Y, Meldolesi E, et al.  2007.  Automatic delineation of online head-and-neck computed tomography images:  Toward online adaptive radiotherapy.  Int J Radiat Oncol Biol Phys 68(2):522-530.

"
"3983","PC061209","DeCesare S, Kim L, Zhang T, et al.  2008.  Is the lumpectomy cavity the gold standard for image guidance in accelerated partial breast irradiation?'  International Journal of Radiation Oncology, Biology and Physics 72(1) Supp. 1:S509-S510."
"3984","PC061209","Zhang T and Schulze D.  2009.  Tetrahedron beam computed tomography (TBCT): A new online imaging system for image guided radiotherapy.  Physics in Medicine and Biology 54(11):3365-3378."
"3985","PC061209","Hugo GD, Campbell J, Zhang T, et al.  2009.  Cumulative lung dose for several motion management strategies as a function of pretreatment patient parameters.  International Journal of Radiation Oncology, Biology and Physics 74(2):593-601."
"3986","PC061210","Xia D, Cho S, and Pan X.  2007.  Extended reconstructible volume in reduced saddle scan.  IEEE Medical Imaging Conference M04-5.

"
"3987","PC061210","Zhao X, Bian J, Sidky EY, et al.  2007.  GPU-based 3D cone-beam CT image reconstruction: Application to Micro-CT.  IEEE Medical Imaging Conference M19-287."
"3988","PC061210","Cho S, Xia D, Pelizzari CA, et al.  2010.  A BPF-FBP tandem algorithm for image reconstruction in reverse helical cone-beam computed tomography.  Med Phys 37:32-39."
"3989","PC061210","Xia D, Cho S, and Pan X.  2009.  Image reconstruction in reduced circular sinusoidal cone-beam CT.  J X-ray Sci Tech 17:189-205."
"3990","PC061210","Cho S, Pearson E, Pelizzari CA, et al.  2009.  Region-of-interest imaging with intensity-weighting in circular cone-beam CT for image-guided radiation therapy.  Med Phys 36:1184-1192."
"3991","PC061210","Han X, Cho S, Bian J, et al.  2009.  Low-dose kilovoltage cone-beam CT imaging for image-guided radiation therapy: A feasibility study.  Proc of 2009 International Meeting on Fully 3D Image Reconstruction in Radiology and Nuclear Medicine 389-393.

"
"3992","PC061210","Cho S, Pearson E, Sidky E, et al.  2009.  Prior-image-based few-view cone-beam C for applications to daily scans in image-guided radiation therapy: Preliminary study.  Proc SPIE 7258:7258-7265."
"3993","PC061210","Xia D, Cho S, and Pan X.  2007.  Image noise properties in circular sinusoid cone-beam CT.  IEEE Medical Imaging Conference M13-285."
"3994","PC061210","Cho S, Sidky EY, Bian J, et al.  2010.  Dual-energy technique at low tube voltages for small animal imaging.  Tsinghua Sci Technol 15(1):79-86."
"3995","PC061210","Xia D, Cho S, and Pan X.  2009.  Backprojection filotration algorithm with improved noise property for a circular cone beam CT.  Proc of 2009 International Meeting on Fully 3D Image Reconstruction in Radiology and Nuclear Medicine 170-173."
"3996","PC061210","Cho S, Xia D, Pearson E, et al.  2009.  Half-fan-based region-of-interest imaging in circular cone-beam CT for radiation therapy.  Proc of 2009 International Meeting on Fully 3D Image Reconstruction in Radiology and Nuclear Medicine 385-388."
"3997","PC061210","Cho S, Bian J, Pelizzari CA, et al.  2007.  Region-of-interest image reconstruction in circular cone-beam microCT.  Med Phys 34:4923-4933."
"3998","PC061210","Xia D, Cho S, Bian J, et al.  2008.  Tomosynthesis with source distributions over a surface.  Proc SPIE 6913-69132A."
"3999","PC061210","Cho S, Pearson E, Xia D, et al.  2008.  A preliminary study of intensity-weighted ROI imaging in cone-beam CT.  Proc SPIE 6913-691325."
"4000","PC061210","Cho S, Sidky E, Pelizzari CA, et al.  2008.  A preliminary investigation of using prior information for potentially improving image reconstruction in few-view CT.  Proc SPIE 6913-69132C."
"4001","PC061210","Cho S, Xia D, Pelizzari CA, et al.  2008.  Exact reconstruction of volumetric images in reverse helical cone-beam CT.  Med Phys 35:3030-3040."
"4002","PC061210","Cho S, Bian J, Pelizzari CA, et al.  2007.  Region of interest image reconstruction in circular cone-beam microCT.  Med Phys 34:4923-4933."
"4003","PC061210","Xia D, Cho S, and Pan X.  2010.  Backprojection-filtration reconstruction without invoking a spatially varying weighting factor.  Med Phys 37(3):1201-9."
"4004","PC061231","Lu Y, Chen QY, Corey E, et al.  2009.  Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone.  Clin Exp Metastasis 26(2):161-169.

"
"4005","PC061231","Zhang J, Lu Y, and Pienta KJ.  2010.  Multiple roles of CC chemokine ligand 2 (CCL2) in promoting prostate cancer growth.  J Natl Cancer Inst 102(8):522-528."
"4006","PC061231","Lu Y, Wang J, Xu Y, et al.  2008.  CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro.  Mol Cancer Res 6(4):546-554.

"
"4007","PC061231","Lu Y, Cai Z, Xiao G, et al.  2007.  Monocyte chemotactic protein-1 (MCP-1) mediates prostate cancer-induced bone resorption.  Cancer Res 67:3646-3653."
"4008","PC061231","Lu Y, Nie DB, Witt WT, et al.  2008.  Expression of the fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3-beta phosphorylation.  Mol Cancer Ther 7(10):3203-3211.
"
"4009","PC061231","Lu Y, Xiao G, Galson DL, et al.  2007.  PTHrP-induced MCP-1 production by human bone marrow endothelial cells promotes osteosteoclastast differentiation and prostate cancer cell proliferation and invasion in vitro.  Int J Cancer 121:724-733."
"4010","PC061231","Cai Z, Chen QY, Chen J, et al.  2009.  MCP-1 promotes lung cancer-induced bone resorptive lesions in vivo.  Neoplasia 11(3):228-236."
"4011","PC061244","Zheng X, Zhang H, Yin L, et al.  Modulation of NKT cell development by B7-CD28 Interaction: An expanding horizon for co-stimulation.  PLoS ONE 3(7):e2703 (Appendix 2)."
"4012","PC061244","Zhou P, Zheng X, Zhang H, et al.  2009.  B7 Blockade re-balances regulatory T cells and tumor-reactive T cells for prevention and therapy of prostate cancer.  Clin Cancer Res 15:960-970."
"4013","PC061244","Zhou P, Fang X, McNally BA, Yu P, Zhu M, Fu YX, Wang L, Liu Y, Zheng P. 2009.  Targeting lymphotoxin-mediated negative selection to prevent prostate cancer in mice with genetic predisposition.  PNAS 106:17134-9."
"4014","PC061256","Furuta E, Pai S, Zhan R, et al.  2008.  Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and SREBP.  Cancer Res 68:1003."
"4015","PC061256","Iiizumi M, Bandyopadhyay S, Pai SK, et al.  2008.  RhoC promtes metastasis via activation of Pyk2 pathway in prostate cancer.  Cancer Res 68(18):7613-7620."
"4016","PC061256","Iiizumi M, Liu W, and Watabe K.  2008.  Drug development against metastasis-related gene and their pathways: A rational for cancer therapy.  Biochim Biophys Acta Cancer Reviews 1786:87-104.

"
"4017","PC061256","Liu W, Iiizumi-Gairani M, Okuda H, et al.  2011.  KAI1 is engaged in NDRG1-mediated metastasis suppression in human prostate cancer.  J Biol Chem 286(21):18949-18959."
"4018","PC061256","Furuta E, Okuda H, Kobayashi A, et al.  2010.  Metabolic genes in cancer: Their roles in tumor progression and clinical implications.  Biochim Biophys Acta 1805:141-152.
"
"4019","PC061272","Begley LA, Kasina S, Mehra R, et al.  2008.  CXCL5 promotes prostate cancer progression.  Neoplasia 10(3):244-254."
"4020","PC061279","Lin SH, Cheng CJ, Lee YC, et al.  2008.  A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation.  Oncogene 4:27(39):5195-5203."
"4021","PC061279","Chu K, Cheng CJ, Ye X, et al.  2008.  Cadherin-11 promotes the metastasis of prostate cancer cells to bone.  Mol Cancer Res 6(8):1259-1267.

"
"4022","PC061279","Ye XC, Choueiri M, Tu SM, et al.  2007.  Biology and clinical management of prostate cancer bone metastasis.  Front Biosci 1(12):3273-3286."
"4023","PC061279","Cheng CJ, Ye XC, Vakar-Lopez F, et al.  2007.  Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells.  Mol Cancer Res 5(7):675-684."
"4024","PC061279","Chen N, Ye XC, Chu K, et al.  2007.  A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells.  Cancer Res 15:67(14):6544-6548."
"4025","PC061289","Kolonin MG, Sergeeva A, Molldrem J, et al.  2006.  Display technologies: application for the discovery of drug and gene delivery agents.  Adv Drug Deliv Rev 58:1622-1654."
"4026","PC061289","Ji Y, Yuin G, Tsui K, et al.  2007.  Bayesian mixture models for complex high-dimensional count data in phage display experiments.  J R Stat Soc Ser C Appl Stat 56(2):139-152.

"
"4027","PC061289","Traktuev D, Merfeld-Clauss S, Li J, et al.  2008.  A population of CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a perivascular niche, and stabilize endothelial networks.  Circ Res 102:77-85."
"4028","PC061289","Cardo-Vila M, Zurita AJ, Giordano RJ, et al.  2008.  A ligand peptide motif selected from a cancer patient is a receptor-interacting site within human interleukin-11.  PLoS ONE 3 (10) 3452-2460."
"4029","PC061289","Nie J, Chang B, Traktuev D, et al.  2008.  Integrin Î±5/beta 1 is a receptor for the matricellular protein SPARC on adipose stromal cells and a prospective therapeutic target.  Stem Cells 26 (10)-2735-2745."
"4030","PC061300","Rambhatla A, Kovanecz I, Ferrini M, et al.  2008.  Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: experimental and clinical review.  Int J Impot Res 20(1):30-34."
"4031","PC061300","Kovanecz I, Rambhatla A, Ferrini M, et al.  2008.  Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats.  Int J Impot Res (2):202-212."
"4032","PC061300","Kovanecz I, Rambhatla A, Ferrini MG, et al.  2008.  Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection.  BJU Int 101(2):203-210."
"4033","PC061300","Ferrini MG, Moon J, Rivera S, et al.  2010.  The genetic inactivation of inducible nitric oxide synthase (iNOS) intensifies fibrosis and oxidative stress in the penile corpora cavernosa in type 1 diabetes.  J Sex Med 7(9):3033-3044.
"
"4034","PC061300","Gonzalez-Cadavid NF and Rajfer J.  2010.  Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy.  Nat Rev Urol (4):215-221.  Epub PubMed PMID:  20212516."
"4035","PC061300","Gonzalez-Cadavid NF.  2009.  Mechanisms of penile fibrosis.  J Sex Med 6(3):353-362."
"4036","PC061300","Ferrini MG, Kovanecz I, Sanchez S, et al.  2009.  Fibrosis and loss of smooth muscle in the corpora cavernosa precede corporal veno-occlusive dysfunction (CVOD) induced by experimental cavernosal nerve damage in the rat.  J Sex Med 6(2):415-428."
"4037","PC061300","Gonzalez-Cadavid NF and Rajfer J.  2009.  Experimental models of Peyronie's disease:  Implications for new therapies.  J Sex Med 6(2):303-313."
"4038","PC061307","Lin B, Wang J, and Cheng Y.  2008.  Recent patents and advances in the next-generation sequencing technologies.  Recent Patents on Biochemical Engineering 1:60-67."
"4039","PC061307","Lin B, Utleg AG, Gravdal K, et al.  2008.  WDR19 expression is increased in prostate cancer compared to normal cells, but low intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence.  Clin Cancer Res 14(5):1397-1406."
"4040","PC061307","Biaoyang L, Wechsler J, and Hood L.  2008.  Signal sequencing for gene expression profiling.  In:  Molecular Biology in Cancer Research, Springer."
"4041","PC061307","Li R. Guo Y, Han B, et al.  2008.  Integrated proteomics analysis of human expressed prostatic secretions reveals rich source of biomarker candidates.  Proteomics Clin Appl 2(4):543-555."
"4042","PC061307","Lin B, Wang J, Hong X, et al.  2009.  Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor.  PLoS One 4(8):e6589.

"
"4043","PC061307","Lin B, White JT, Wu J, et al.  2009.  Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer.  Proteomics Clin Appl 3(7):853-861."
"4044","PC061307","Li R, Guo Y, Han BM, et al.  2008.  Proteomics cataloging analysis of human expressed prostatic secretions reveals rich source of biomarker candidates.  Proteomics Clin Appl 2(4):543-555."
"4045","PC061328","Xiao L, Caino MC, von Burstin VA, et al.  2008.  Phorbol ester-induced apoptosis and senescence in cancer cell models.  Methods Enzymol 446:123-139."
"4046","PC061328","Xiao L, Gonzalez-Guerrico A, and Kazanietz MG.  2008.  PKC-mediated secretion of death factors in LNCaP prostate cancer cells is regulated by androgens.  Mol Carcinog 48(3):187-195 [Epub ahead of print]."
"4047","PC061337","Salk JJ, Fox EJ, and Loeb LA.  2010.  Mutational heterogeneity in human cancers: Origin and consequences.  Annu Rev Pathol 5:51-75."
"4048","PC061337","Loeb LA and Harris CC.  2008.  Advances in chemical carcinogenesis: A historical review and prospective.  Cancer Res 68:6863-6872."
"4049","PC061345","Zrazhevskiy P and Gao X.  Molecular profiling of cancer cells and tissues using multicolor quantum dots.  In Encyclopedia of Inorganic Chemistry (Lukehart CM and Scott RA, Eds)."
"4050","PC061345","Zrazhevskiy P and Gao X.  2008.  Bioconjugated quantum dots for tumor molecular imaging and profiling.  In: Oxford Handbook of Nanoscience and Technology: Frontiers and Advances (Narlikar A and Fu Y, Eds.)  Oxford University Press, United Kingdom."
"4051","PC061368","Tomaszewski JJ, Cummings JL, Parwani AV, et al.  2011.  Increased cancer cell proliferation in prostate cancer patients with high levels of serum folate.  Prostate 71(12):1287-1293."
"4052","PC061368","Yao V, Berkman CE, Choi JK, et al.  2010.  Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid.  Prostate 15;70(3):305-316."
"4053","PC061368","Yao V, Parwani A, Maier C, et al.  2008.  Moderate expression of prostate specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis.  Cancer Res 68(21):9070-9077.

"
"4054","PC061377","Sunami E, Shinozaki M, Higano CS, et al.  2009.  Multimarker circulating DNA assay for assessing blood of prostate cancer patients.  Clin Chem 55:559-567."
"4055","PC061377","Lessard L, Sunami E, and Hoon DSB.  2011.  Circulating tumor-related DNA alterations as prostate cancer biomarkers.  In: Circulating Nucleic Acids in Plasma and Serum (Gahan P, Ed.)  Springer, pp 21-27."
"4056","PC061396","Qi B, Newcomer RG, and Sang Q-X.  2009.  ADAM19/adamalysin 19 structure, function, and role as a putative target in tumors and inflammatory diseases.  Curr Pharm Des 15:2336-48."
"4057","PC061396","Sahab ZJ, Iczkowski KA, and Sang QXA.  2007.  Anion exchange fractionation of serum proteins versus albumin elimination.  Anal Biochem 368:24-32."
"4058","PC061396","Roycik MD, Fang X, and Sang Q-X.  2009.  A fresh prospect of extracellular matrix hydrolytic enzymes and their substrates.  Curr Pharm Design 15:1295-308."
"4059","PC061396","Khamis Z, Iczkowski K, Sahab Z, et al.  2010.  Protein Profiling of Isolated Leukocytes, Myofibroblasts, epithelial, Basal, and Endothelial Cells from Normal, Hyperplastic, Cancerous, and Inflammatory Human Prostate Tissues.  Journal of Cancer 1:70-79."
"4060","PC061397","Haiman CA, Chen GK, Blot WJ, et al. 2011. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21, Nat Genet 43(6):570-573."
"4061","PC061397","Lavender NA, Benford ML, Vancleave TT, et al.  2009.  Examination of polymorphic glutathione S-transferase (GST) genes, tobacco smoking and prostate cancer risk among men of African descent: A case-control study.  BMC Cancer 9:397."
"4062","PC061397","Kosoy R, Nassir R, Tian C, et al.  2009.  Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America.  Hum Mutat 30:69-78."
"4063","PC061397","Giri VN, Egleston B, Ruth K, et al.  2009.  Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high risk men.  Cancer Prev Res 2:244-250."
"4064","PC061397","Ukoli FA, Fowke JH, Akumabor P, et al.  2010.  The association of plasma fatty acids with prostate cancer risk in African Americans and Africans.  J Health Care Poor Underserved 21(1Suppl):127-147."
"4065","PC061397","Mason TE, Ricks-Santi L, Chen W, et al.  2010.  Association of CD14 variant with prostate cancer in African American men.  Prostate 70:262-269."
"4066","PC061397","Lavender NA, Komolafe OO, Benford M, et al.  2010.  No association between variant DNA repair genes and prostate cancer risk among men of African descent.  Prostate 70:113-119."
"4067","PC061397","Hooker S, Hernandez W, Chen H, et al.  2010.  Replication of prostate cancer risk loci on 8q24, 11q13, 17q12, 19q33, and Xp11 in African Americans.  Prostate 70:270-275."
"4068","PC061397","Chen H, Liu W, Roberts W, et al.  2010.  8q24 allelic imbalance and MYC gene copy number in primary prostate cancer.  Prostate Cancer Prostatic Dis 13(3):238-243."
"4069","PC061397","Robbins CM, Hooker S, Kittles RA, et al.  2011.  EphB2 SNPs and sporadic prostate cancer risk in African American men.  PLoS ONE 6(5):e19494."
"4070","PC061397","Bonilla C, Hooker S, Mason T, et al.  2011.  Prostate cancer susceptibility loci identified on chromosome 12 in African Americans.  PLoS One 16;6(2):e16044."
"4071","PC061397","Kosoy R, Nassir R, Tian C, et al.  2009.  Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America.  Hum Mutat 30(1):69-78."
"4072","PC061397","Giri VN, Egleston B, Ruth K, et al.  2009.  Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men.  Cancer Prev Res 2(3):244-250."
"4073","PC061397","Bock CH, Schwartz AG, Ruterbusch JJ, et al. 2009.  Results from a prostate cancer admixture mapping study in African American men.  Hum Genet 126(5):637-42."
"4074","PC061397","Robbins CM, Hernandez W, Ahaghotu C, et al.  2008.  Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases.  Prostate 68:1790-7."
"4075","PC061397","Haiman CA, Chen GK, Blot WJ, et al. 2011. Characterizing Genetic Risk at Known Prostate Cancer Susceptibility Loci in African Americans. PLoS Genet 7(5): e1001387."
"4076","PC061397","Hooker S, Bonilla C, Akereyeni F, et al.  2008.  NAT2 and NER genetic variants and sporadic prostate cancer susceptibility in African Americans.  Prostate Cancer Prostatic Dis 11:349-56."
"4077","PC061397","Robbins C, Benn Torres J, Hooker S, et al.  2007.  Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus.  Genome Research 17(12):1717-1722."
"4078","PC061397","Hernandez W, Grenade C, Santos ER, et al.  2007.  IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African Americans.  Carcinogenesis 28(10):2154-2159."
"4079","PC061397","Benn Torres J and Kittles R.  2007.  The relationship between â¿¿raceâ¿ and genetics in biomedical research.  Current Hypertension Reports 9:196-201."
"4080","PC061397","Kittles R, Santos ER, Oji-Njideka N, et al.  2007.  Race, skin color and genetic ancestry: Implications for biomedical research on health disparities.  Californian Journal of Health Promotion 5:9-23."
"4081","PC061410","Kriedt CL, Baldassare J, Shah M, et al.  2010.  Zinc functions as a cytotoxic agent for prostate cancer cells independent of culture and growth conditions.  J Exp Ther Oncol 8(4):287-295.

"
"4082","PC061410","Shah MR, Kriedt CL, Lents NH, et al.  2009.  Direct intra-tumoral injection of zinc-acetate halts tumor growth in a xenograft model of prostate cancer.  J Exp Clin Cancer Res 28:84.

"
"4083","PC061440","Corso CD, Dickherber A, and Hunt WD.  2007.  Lateral field excitation of thickness shear mode waves in a thin film ZnO solidly mounted resonator.  Journal of Applied Physics 101:054514.

"
"4084","PC061440","Dickherber A, Corso CD, and Hunt WD.  2008.  Optimization of the thickness shear mode in ZnO solidly mounted resonators.  Sensors & Actuators A: Physics 144(1):7-12.

"
"4085","PC061440","Corso CD, Dickherber A, and Hunt WD.  2008.  A comparison of antibody immobilization methods employing organosilanes and phosphonic acids on planar crystalline ZnO surfaces.  Biosensors & Bioelectronics 24(4):811-817."
"4086","PC061441","Aggarwal S, Brennen WN, Kole TP, et al.  2008.  Fibroblast activation protein (FAP) peptide substrates identified from human collagen I-derived gelatin cleavage sites.  Biochemistry 47:1076-86."
"4087","PC061441","Lebeau A, Brennen WN, Aggarwal S, et al.  2009.  Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin.  Mol Cancer Ther 8(5):1378-1386."
"4088","PC061444","Hamill OP and Maroto R.  2009.  Mechanically-ignited Ca2+ flickers: Reemergence of an old role in mechanosensitive regulation of cell migration and the discovery of a new role in chemotaxis.  Cell Science Reviews 6(2)."
"4089","PC061444","Gottlieb P, Folgering J, Maroto R, et al.  2008.  Revisiting TRPC1 and TRPC6 mechanosensitivity.  Pflugers Arch 455(6):1097-1103."
"4090","PC061444","Maroto R and Hamill OP.  2007.  MscCa regulation of tumor cell migration and metastasis.  Curr Tops Membr 59:485-509."
"4091","PC061444","Hamill O and Maroto P.  2007.  TRPCs as MS channels, and MscCa regulation of tumor cell migration and metastastis.  Current Topics in Membrane Transport 59."
"4092","PC061444","Hamill OP and Maroto R.  2007.  TRPC family of ion channels and mechanotransduction.  In:  Sensing with Ion channel (Martinac B, Ed), pp 121-160."
"4093","PC061445","Kwon EM, Salinas CA, Kolb S, et al.  2011.  Genetic polymorphisms in inflammation pathway genes and prostate cancer risk.  Cancer Epidemiol Biomarkers Prev 20(5):923-933."
"4094","PC061445","Fitzgerald LM, Kwon EM, Koopmeiners JS, et al.  2009.  Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features.  Clin Cancer Res 15:3231-7."
"4095","PC061445","Penney KL, Salinas CA, Pomerantz M, et al.  2009.  Evaluation of 8q24 and 17q risk loci and prostate cancer mortality.  Clin Cancer Res.  PMID: 19366828."
"4096","PC061445","Agalliu I, Salinas CA, Hansten PD, et al.  2008.  Statin use and risk of prostate cancer: Results from a population-based epidemiologic study.  Am J Epidemiol 168(3):250-260.  PMID: 18556686."
"4097","PC061445","Salinas CA, E Kwon, CS Carlson, et al.  2008.  Multiple independent genetic variants in the 8q24 region are associated with prostate cancer risk.  Cancer Epidemiol Biomarkers Prev 17(5):1203-1213.  PMID:18483343"
"4098","PC061445","Kote-Jarai Z, Easton DF, Stanford JL, et al.  2008.  PRACTICAL Consortium, Eeles RA.  Multiple novel prostate cancer predisposition loci confirmed by an international study: The PRACTICAL Consortium.  Cancer Epidemiol Biomarkers Prev 17(8):2052-2061.  PMID: 18708398."
"4099","PC061445","Salinas CA, Koopmeiners JS, Kwon EM, et al.  2009.  Clinical utility of five genetic variants for predicting prostate cancer risk and mortality.  Prostate 69(4):363-372.  PMID: 19058137.

"
"4100","PC061445","Holt SK, Salinas CA and Stanford JL.  2008.  Vasectomy and the risk of prostate cancer.  J Urol 180(6):2565-2567.  PMID: 18930503."
"4101","PC061456","Memarzadeh S, Cai H, Janzen DM, et al. 2011. Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal. Proc Natl Acad Sci U S A. 108(19):962-7967."
"4102","PC061456","Silvers CR, Williams K, Salamone L, et al. 2010. A novel in vitro assay of tumor-initiating cells in xenograft prostate tumors. Prostate 70(13):1379-1387."
"4103","PC061456","Goldstein AS, Huang J, Guo C, et al. 2010. Identification of a Cell of Origin for Human Prostate Cancer. Science 329(5991):568-571."
"4104","PC061456","Huang J, Wu C, di Sant'Agnese PA, et al.  2007.  Function and molecular mechanisms of neuroendocrine cells in prostate cancer.  Anal Quanti Cytol Histol 29:128-138."
"4105","PC061456","Podder TK, Sherman J, Li L, et al.  2007.  Mechanical properties of human prostate tissue in the context of surgical needle insertion.  Int J Comput Assist Radiol Surg 2(Suppl I):S106-S108."
"4106","PC061456","Wu C, Chen G, Na Y, et al.  2007.  The function of Interleukin-8 in prostate cancer.  In: Progress in Chemokine Research.  (Linkes WP, Ed.)  Nova Science Publishers, Inc., New York, pp 149-156."
"4107","PC061456","Oh WK, Tay MH, and Huang J.  2007.  Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?  Cancer 109(3):477-486."
"4108","PC061456","Deng X, Liu H, Huang J, et al.  2008.  Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: Implications for disease progression. Cancer Res 68:9663-9670."
"4109","PC061456","Ross RW, Beer TM, Jacobus S, et al.  2008.  For the prostate cancer clinical trials consortium (PCCTC).  A phase II study of carboplatin plus docetaxel in men with metastatic hormone refractory prostate cancer who are refractory to docetaxel.  Cancer 112:521-526."
"4110","PC061456","Yao JL, Huang J and di Sant'Agnese PA.  2008.  Small cell carcinoma of the prostate.  Diagn Histopathol 14/3:117-121."
"4111","PC061456","Sun Y, Niu J and Huang J.  2009.  Neuroendocrine differentiation in prostate cancer.  Am J Transl Res 1:148-162."
"4112","PC061456","Palapattu GS, Wu C, Silvers CR, et al.  2009.  Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer.  Prostate 15;69:787-798."
"4113","PC061456","Brick A, Niu J, Huang J, et al.  2010.  Possibility for platinum chemotherapy treatment for HRPC patients?  In: Drug Management of Prostate Cancer.  (Figg WD, Chau CH, Small EJ, Eds.)  Humana Press, NJ, Chapter 14."
"4114","PC061456","Silvers CR, Williams K, Salamone L, et al.  2010.  A novel in vitro assay of human prostate cancer tumor initiation.  Prostate (in press)."
"4115","PC061456","Lawson DA, Zong Z, Memarzadeh S, et al.  2010.  Basal epithelial stem cells are efficient targets for prostate cancer initiation.  Proc Natl Acad Sci U S A 9;107:2610-2618."
"4116","PC061456","Huang J and Witte ON.  2010.  A seminal finding for prostate cancer?  N Eng J Med 362:175-176."
"4117","PC061456","Goldstein AS, Huang J, Guo C, et al.  2010.  Identification of a cell of origin for human prostate cancer.  Science 329(5991):568-571."
"4118","PC061456","Simon RA, di Sant'Agnese PA, Huang L-S, et al.  2009.  CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers.  Hum Pathol 40:252-258."
"4119","PC061456","Palapattu GS, Wu C, Silvers CR, et al.  2009.  Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer.  Prostate 69:787-98."
"4120","PC061456","Wu C, Huang J.  2007.  Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer.  J Biol Chem 282(6):3571-3583."
"4121","PC061456","Cai Y, Lee Y-F, Li G, et al.  2008.  A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.  Int J Can 123:195-201."
"4122","PC061474","Mosquera J-M, Mehra R, Regan MM, et al.  2009.  Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.  Clin Cancer Res 15(14):4706-11.

"
"4123","PC061474","Barry M, Perner S, Demichelis F, et al.  2007.  TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer:  Clinical and biologic implications.  Urology 70 (4):630-33.
"
"4124","PC061486","Rao V, Guan B, Mutton LN, et al. 2012. Proline-mediated proteasomal degradation of the prostate-specific tumor suppressor NKX3.1. J Biol Chem 287:36331-36340."
"4125","PC061486","Guan B, Pungaliya P, Li X, et al.  2008.   Ubiquitination by TOPORS regulates the prostate tumor suppressor NKX3.1.  J Biol Chem 283:4834-440."
"4126","PC061498","Lucas N, Najy AN and Day M.  2009.  Therapeutic potential of ADAM15.  Curr Pharm Des 15:2311-8."
"4127","PC061498","Lucas N and Day M.  2009.  The role of the disintegrin metalloproteinase ADAM15 in prostate cancer progression.  J Cell Biochem 106:967-974."
"4128","PC061498","Najy A, Day KC and Day ML.  2008.  ADAM15 supports prostate cancer metastasis by modulating tumor cell-endothelial cell interaction.  Cancer Res 15:68(4):1092-1099."
"4129","PC061524","Shimazu T, Degenhardt K, Nur-E-Kamal A, et al.  2007.  NBK/BIK antagonizes MCL-1 and BCL-XL and activates BAK-mediated apoptosis in response to protein synthesis inhibition.  Genes Dev 15;21(8):929-941(40)."
"4130","PC061532","Muhlbradt E, Asatiani E, Ortner E, et al.  2009.  NKX3.1 activates expression of IGFBP-3 to mediate IGF-I signaling and cell proliferation.  Cancer Res 69:2615-2622."
"4131","PC061612","Choi H, Zhou X, Ma J.  2008.  Use of perfluorocarbon compound in the endorectal coil to improve magnetic resonance spectroscopy of the prostate.  Amer J Roentgenol 190:1055-9."
"4132","PC061612","Boonsirikamchai P, Kaur H, Kuban DA, et al.  2012.  Use of maximum slope images generated from dynamic contrast-enhanced MRI to detect locally recurrent prostate carcinoma after prostatectomy: A practical approach. AJR Am J Roentgenol 198(3):W228-36.

"
"4133","PC061612","Boonsirikamchai P, Choi S, Frank SJ, et al.  2013.  MRI of the prostate cancer in radiation oncology: What radiologists need to know.  Radiographics 33(3):741."
"4134","PC061641","Basch E, Somerfield M, Beer T, et al.  2007.  American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on non-hormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.  J Clin Oncol 25(33):5313-5318."
"4135","PC061641","Graff J, Smith DC, Neerukonda L, et al.  2006.  Prostate cancer clinical trials consortium.  Phase II study of sagopilone (ZK-EPO) plus prednisone as first-line chemotherapy in patients with metastatic androgen-independent prostate cancer (AIPC).  J Clin Oncol 26:2008-5141."
"4136","PC061641","Morris MJ, Basch EM, Wilding G, et al.  2008.  Department of Defense prostate cancer clinical trial consortium: A new instrument for prostate cancer clinical research.  Clin Genitourin Cancer 7(1):51-57."
"4137","PC061641","Scher HI, Halabi S, Tannock I, et al.  2008.  Design and endpoints of Phase 2 trials for patients with progressive prostate cancer and castrate levels of testosterone.  Recommendation of the Prostate Cancer Trials Working Group (PCWG2).  J Clin Oncol  26(7):1148-1159.

"
"4138","PC061643","Dean JP and Nelson PS.  2008.  Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis.  Br J Cancer 29:98(2):245-249."
"4139","PC061643","Dean JP and Higano CS.  2009.  Does chemotherapy have a role before hormone-resistant disease develops?  Curr Urol Rep 10(3):226-235."
"4140","PC061655","Mitra R, Chao OS, Nanus DM, et al. 2013. Negative Regulation of NEP Expression by Hypoxia. Prostate 73(7):706-714."
"4141","PC061661","Tsivian M, Wright T, Price M, et al.  2012.  111-in-capromab pendetide imaging using hybrid gamma camera-computer tomography technology is not reliable in detecting seminal vesicle invasion in patients with prostate cancer.  Urol Oncol 30(2):150-154."
"4142","PC061664","Ross RW, Galsky MD, Febbo PG, et al.  2012.  In press.  Phase II study of neoadjuvant chemotherapy with docetaxel and bevacizumab in patients with high-risk localized prostate cancer: A prostate cancer clinical trials consortium trial.  Cancer 118(19):4777-4784."
"4143","PC061664","Kim MK, Osada T, Barry WT, et al.  2012.  Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer.  Mol Cancer Ther 11(7):1500-1509."
"4144","PC061664","Hsu DS, Kim MK, Balakumaran BS, et al.  2010.  Immune signatures predict prognosis in localized cancer.  Cancer Invest 28(7):765-773."
"4145","PC061664","Febbo PG.  2009.  Genomic approaches to outcome prediction in prostate cancer.  Cancer 115(13):3046-3057."
"4146","PC061664","Febbo PG.  2009.  Epigenetic events highlight the challenge of validating prognostic biomarkers during the clinical and biological evolution of prostate cancer.  JCO 27(19):3088."
"4147","PC061664","Foye A and Febbo PG.  2010.  Cancer gene profiling.  In: Methods in Molecular Medicine.  (Pilarsky C and Grutzmann R, Eds.)  Humana Press."
"4148","PC061664","Febbo PG and Blobe G.  2009.  Molecular biology of cancer.  In: Oxford Handbook of Oncology.  Oxford University Press, New York, New York."
"4149","PC061664","Foye A and Febbo PG.  2010.  Cancer gene profiling in prostate cancer.  Methods Mol Biol 576:293-326."
"4150","PC061664","Pei Y, Moore C, Wang J, et al.  2012.  An animal model of MYC-driven medulloblastoma.  Cancer Cell 21(2):155-167."
"4151","PC061664","Stewart SB, Bañez LL, Robertson CN, et al.  2011.  Utilization trends at a multidisciplinary prostate cancer clinic: Initial 5-year experience from the Duke Prostate Center.  J Urol 187(1):103-108.  "
"4152","PC061664","Armstrong AJ, Netto GJ, Rudek MA, et al.  2010.  A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.  Clin Cancer Res 16(11):3057-3066."
"4153","PC061664","Balakumaran B, Herbert JT, and Febbo PG.  2010.  MYC activity mitigates response to rapamycin in prostate cancer through 4EBP1-mediated inhibition of autophagy.  Autophagy 6(2):281-282."
"4154","PC061667","Lubaroff DM.  2012.  Prostate cancer vaccines in clinical trials.  Expert Rev Vaccines 11:857-568."
"4155","PC061667","Geary SM, Lemke CD, Lubaroff DM, et al.  2013.  Proposed mechanisms of action for prostate cancer vaccines.  Nature Reviews Urology 10:149-160."
"4156","PC073009","Miranti CK.  2009.  Controlling cell surface dynamics and signaling: How CD82/KAI1 suppresses metastasis.  Cell Signal 21:196-211."
"4157","PC073019","Dillard PR, Lin MF, and Khan SA.  Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol.  Mol Cell Endocrinol 295:115-1208."
"4158","PC073073","Garraway IP, Sun W, Tran CP, et al.  2009.  Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo.  The Prostate PROS 09-224.R1."
"4159","PC073073","Peek EM, Li DR, Zhang H, et al.  2012.  Stromal modulation of bladder cancer-initiating cells in a subcutaneous tumor model.  Am J Cancer Res 2(6):745-751."
"4160","PC073073","Mulholland DJ, Tran LM, Li Y, et al.  2011.  Cell autonomous role of PTEN regulating castrate-resistant prostate cancer growth.  Cancer Cell 19(6):792-804."
"4161","PC073073","Klatte T, Seligson DB, Rao JY, et al.  2010.  Absent CD44v6 expression is an independent predictor of poor outcome for patients with urothelial bladder cancer.  J Urology 183(6):2403-2408."
"4162","PC073073","Garraway IP, Sun W, Tran CP, et al.  2010.  Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo.  Prostate 70(5):491-501. "
"4163","PC073073","Garraway IP.  2012.  Will identification of a prostate cancer stem cell lead to its cure?  Urol Oncol 30(4):351-352."
"4164","PC073073","Jing J, Hindoyan A, Goldstein A, et al.  2012.  Identification of CD166 as a marker for enriching prostate tumor initiating cells.  PLoS One 7(8):e42564. "
"4165","PC073073","Garraway IP.  2013.  Targeting the RANKL pathway: Putting the brakes on prostate cancer progression in bone.  J Clin Oncology 31(30):3838-3840."
"4166","PC073073","Goldstein AS, Huang J, Guo C, et al.  2010.  Identification of a cell of origin for human prostate cancer.  Science 329(5991):568-571."
"4167","PC073073","Guo C, Liu H, Zhang B, et al.  2012.  Epcam, CD44, and CD49f distinguish sphere-forming human prostate basal cells from a subpopulation with increased tubule initiation capability.  PLoS One 7(4):e34219."
"4168","PC073073","Hance MW, Dole K, Fopal U, et al.  2012.  Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer.  J Biol Chem 287(45):37732-37744."
"4169","PC073085","Li X, Koh AJ, Wang Z, et al.  2011.  Inhibitory effects of megakaryocytic cells in prostate cancer skeletal metastasis.  J Bone Miner Res 26(1):125-134."
"4170","PC073093","Young LA, Neiss MB, Samuels MH,et al.  2010.  Cognition is not modified by large but temporary changes in sex hormones in men.  J Clin Endocrinol Metab 95(1):280-288."
"4171","PC073095","Altman MB, Stinauer MA, Javier D, et al.  2009.  Validation of temporal optimization for a single fraction of radiation in vitro.  Int J Rad Onc Biol Phys 75(4):1240-1246."
"4172","PC073095","Altman MB, Vesper BJ, Smith BD, et al.  2009.  Characterization of a novel phantom for three-dimensional in vitro cell experiments.  Phys Med Biol 54(5):N75-N82."
"4173","PC073097","Czarnota GJ, Karshafian R, Burns PN, et al. 2012. Tumor radiation response enhancement by acoustical stimulation of the vasculature. Proc Natl Acad Sci U S A. 109(30):E2033-E2041."
"4174","PC073097","Strohm E, Czarnota GJ, Kolios M.  2010.  Quantitative measurements of apoptotic cell properties using acoustic microscopy.  IEEE Trans Ultrason Ferroelectr Freq Control 57(10):2293-2304."
"4175","PC073097","Vlad RM, Kolios MC, Moseley JL, et al.  2010.  Evaluating the extent of cell death in 3D high frequency ultrasound by registration with whole-mount tumor histopathology.  Med Phys 37:4288."
"4176","PC073104","Aneja R, et al.  2010.  A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells.  Eur J Cancer 46(9):1668-78."
"4177","PC073104","Pannu V, Karna P, Sajja HK, et al.  2011.  Synergistic antimicrotubule therapy for prostate cancer.  Bio Pharm 81:478-487."
"4178","PC073121","Palapattu GS, Wu G, Silvers C, et al.  2009.  Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer.  Prostate 15;69(7):787-798.

"
"4179","PC073121","Silvers CR, Williams K, Salamone L, et al.  2010.  A novel in vitro assay of tumor-initiating cells in xenograft prostate tumors.  Prostate 70(13):1379-1387."
"4180","PC073121","Lin K, Huang J, Ivanov I, et al.  2012.  The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration.  Cell Stem Cell 10(5):556-569."
"4181","PC073127","Chen L, Mu Z and Hachem P.  2010.  MR guided focused ultrasound:  Enhancement of intratumoral uptake of [3H]-Docetaxel in vivo.  Phys Med Biol 55(24):7399-7410."
"4182","PC073144","Burger KL, Learman BS, Boucherle AK, et al. 2014. Src-dependent Tks5 phosphorylation regulates invadopodia-associated invasion in prostate cancer cells. 2014 Feb;74(2):134-48. doi: 10.1002/pros.22735. Epub 2013 Oct 30."
"4183","PC073167","Brady GF, Galbán S, Liu X, et al.  2010.  Regulation of the copper chaperone Ccs by XIAP-mediated ubiquitination.  Mol Cell Biol 30(8):1923-1936."
"4184","PC073168","Krishnamoorthya S, Jina R, Caia Y, et al.  2010.  12-Lipoxygenase and the regulation of hypoxia-inducible factor in prostate cancer cells.  Exp Cell Res 316:1706-1715."
"4185","PC073201","Xu K, Shimelis H, Linn DE, et al.  2009.  Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination.  Cancer Cell 15:270-82."
"4186","PC073201","Guo Z, Yang X, Sun F, et al.  2009.  A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.  Cancer Res, 69(6):2305-2313.

"
"4187","PC073208","Davis JS, Nastiuk KL, and Krolewski JJ.  2011.  TNF is necessary for castration-induced prostate regression, whereas TRAIL and FasL are dispensable.  Mol Endocrinol 25(4):611-620."
"4188","PC073210","Lee CY, Rennie PS, and Jia WW.  2009.  MicroRNA regulation of oncolytic herpes simplex virus type 1 for selective killing of prostate cancer cells.  Clin Cancer Res 15(16):5126-5135."
"4189","PC073211","Wan X, Liu J, Lu JF, et al.  2012.  Activation of beta-catenin signaling in androgen receptor-negative prostate cancer cells.  Clin Cancer Res 18(3):726-736. "
"4190","PC073217","Su YA, Wu J, Zhang L, et al.  2008.  Dysregulated mitochondrial genes and networks with drug targets in postmortem brain of patients with posttraumatic stress disorder (PTSD) revealed by human mitochondria-focused cDNA microarrays.  Int J Biol Sci 5;4(4):223-235."
"4191","PC073217","Kino T, Takatori H, Manoli I, et al.  2009.  Guanine nucleotide exchange factor Brx mediates leukocyte adaptive response to osmotic stress: Intracellular signaling pathways linking extracellular hyperosmosis and immune activation.  Sci Signal 2:1-15."
"4192","PC073217","Kino T, Su YA, and Chrousos GP.  2009.  Human glucocorticoid receptor (GR) isoform [bad character(946)]: recent understanding of its potential implications in physiology and pathophysiology.  Cell Mol Life Sci 66:3435--3448."
"4193","PC073217","Kelkar S, Manoli I, Wang Y, et al.  2009.  Human glucocorticoid receptor (GR) isoform beta has intrinsic, GRalpha-independent transcriptional activity.  Biochem Biophys Res Commun 381:671-675."
"4194","PC073217","Johnston DS, Su YA, and Alesci S.  2009.  Mitocohondrial gene profiling: Translational perspectives.  Pharmocogenomics 10:1245-1255.

"
"4195","PC073229","Rekoske BT, Smith HA, Olson BM, et al. 2015. PD-1 or PD-L1 Blockade
Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine
Immunization. Cancer Immunol Res 3:946-55."
"4196","PC073229","Alam S and McNeel DG.  2010.  DNA vaccines for the treatment of prostate cancer.  Exp Rev Vaccines 9:731-745."
"4197","PC073229","Olson BM and McNeel DG.  2011.  CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells.  Cancer Immunol Immunoth 60:781-792.
"
"4198","PC073229","Smith HA and McNeel DG.  2010.  The SSX family of cancer-testis antigens as target proteins for tumor therapy.  Clin Dev Immunol 2010:150591. "
"4199","PC073229","Smith HA and McNeel DG.  2011.  Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.  J Immunotherapy (in press).

"
"4200","PC073229","Olson BM, Frye TP, Johnson LD, et al.  2010.  HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.  Cancer Immunol Immunother 59:943-953.

"
"4201","PC073242","Xie R, Nguyen S, McKeehan WL, et al.  2010.  Acetylated microtubules are required for fusion of autophagosomes with lysosomes.  BMC Cell Biology 11:89."
"4202","PC073242","Liu L, Xie R, Yang C, et al.  2009.  Dual function microtubule- and mitochondria-associated proteins mediate mitotic cell death.  Cell Oncol 31(5)."
"4203","PC073242","Liu L, Xie R, Nguyen S, et al.  2009.  Robust autophagy/mitophagy persists during mitosis.  Cell Cycle 8 1616-1620."
"4204","PC073242","Xie R, Nguyen S, McKeehan K, et al.  2011.  Microtubule-associated protein 1s (MAP1S) bridges autophagic components with microtubules and mitochondria to affect autophagosomal biogenesis and degradation.  J Biol Chem 286:10367-10377."
"4205","PC073242","Xie R, Wang F, McKeehan WL, et al. 2011. Autophagy Enhanced by Microtubule and Mitochondrion-associated MAP1S Suppresses Genome Instability and Hepatocarcinogenesis. Cancer Res 71(24):7537-7546."
"4206","PC073242","Liu L, McKeehan WL, Wang F, et al. 2012. MAP1S enhances autophagy to suppress tumorigenesis. Autophagy 8(2):278-280."
"4207","PC073246","Lamb LE, Knudsen BS, and Miranti CK.  2010.  E-cadherin-mediated survival of androgen receptor expressing secretory prostate epithelial cells derived from a stratified in vitro differentiation model.  J Cell Sci 123:266-276."
"4208","PC073261","Yu H-Y, Hevelone ND, Lipsitz S, et al.  2012.  Hospital volume, utilization, costs and outcomes of robot-assisted laparoscopic radical prostatectomy.  J Urol 187:1632-1638."
"4209","PC073261","Kowalczyk KJ, Levy JM, Caplan CF, et al.  2012.  Temporal national trends of minimally invasive and retropubic radical prostatectomy outcomes from 2003 to 2007: Results from the 100% Medicare sample.  Eur Urol 61(4):803-809."
"4210","PC073261","Ulmer WD, Prasad SM, Kowalczyk KJ, et al.  2012.  Factors associated with the adoption of minimally invasive radical prostatectomy in the United States.  J Urol 188(3):775-780."
"4211","PC073261","Williams SB, Prasad SM, Weinberg AC, et al.  2011.  Trends in the care of radical prostatectomy in the United States from 2003 to 2006.  BJU 108(1):49-55."
"4212","PC073261","Williams SB, Gu X, Lipsitz SR, et al.  2011.  Utilization and expense of adjuvant cancer therapies following radical prostatectomy.  Cancer 117(21):4846-4854.

"
"4213","PC073261","Williams SB, D'Amico AV, Weinberg AC, et al.  2011.  Population-based determinants of radical prostatectomy surgical margin positivity.  BJU 107:1734-1740."
"4214","PC073261","Prasad SM, Gu X, Nguyen PL, et al.  2011.  Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States.  Cancer 118(5):1260-1267."
"4215","PC073261","Prasad SM, Gu X, Lavelle R, et al.  2011.  Comparative effectiveness of perineal versus retropubic and minimally invasive radical prostatectomy.  J Urology 185:111-511."
"4216","PC073261","Nguyen PL, Gu X, Lipsitz SR, et al.  2011.  Cost implications of the rapid adoption of newer technologies for treating prostate cancer.  J Clin Oncol 29:1517-1524."
"4217","PC073261","Kowalczy KJ, Weinburg AC, Gu X, et al.  2011.  Comparison of outpatient narcotic prescribing patterns after minimally invasive vs. retropubic and perineal radical prostatectomy.  J Urology 186(5):1843-1848."
"4218","PC073261","Ju JC, Gu X, Lipsitz SR, et al.  2009.  Comparative Effectiveness of Minimally Invasive vs. Open Radical Prostatectomy.  JAMA 302(14)1557-64."
"4219","PC073261","Choi WW, Williams SB, Gu X, et al.  2011.  Overuse of imaging for staging low risk prostate cancer.  J Urology 185:1645-1649."
"4220","PC073281","Di Vizio D, Kim J, Hager MH, et al.  2009.  Oncosome formation in prostate cancer: Association with a region of frequent chromosomal deletion in metastatic disease.  Cancer Res 69:5601-5609"
"4221","PC073281","Yang W, Di Vizio D, Kirchner M, et al.  2010.  Proteome scale characterization of human S-acylated proteins in lipid raft-enriched and non-raft membrane domains.  Mol Cell Proteomics 9:54-70."
"4222","PC073284","Vasudevan KM, Barbie DA, DaviesMA, et al.  2009.  AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.  Cancer Cell 16 (1):21-32."
"4223","PC073287","Link KA, Balasubramaniam S, Sharma A, et al.  2008.  Targeting the BAF57 SWI/SNF subunit in prostate cancer: A novel platform to control AR activity.  Cancer Res 15;68(12):4551-4558."
"4224","PC073287","Shen H, Powers N, Saini N, et al.  2008.  The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer.  Cancer Res 15;68(24):10154-10162."
"4225","PC073289","Yu M, Gipp J and Yoon JW et al.  2009.  Sonic hedgehog-responsive genes in the fetal prostate.  J Biol Chem 284(9):5620-5629."
"4226","PC073293","Hao G, Zhou J, Guo Y, et al.  2011.  A cell permeable peptide analog as a potential-specific PET imaging probe for prostate cancer detection.  Amino Acids 41(5):1093-1101."
"4227","PC073293","Singh AN, Liu W, Hao G, et al.  2011.  Multivalent bifunctional chelator scaffolds for Gallium-68 based positron emission tomography imaging probe design: signal amplification via multivalency.  Bioconjugate Chem 22(8):1650-1662."
"4228","PC073293","Zhou J, Liu W, Pong RC, et al.  2012.  Analysis of oligo-arginine cell¿permeable peptides uptake by prostate cells.  Amino Acids 42(4): 1253-1260."
"4229","PC073293","Liu W, Hao Gg, Long MA, et al.  2009.  Imparting multivalency to a bifunctional chelator: A scaffold design for targeted PET imaging probes.  Angew Chem Int Ed 48:7346-7349."
"4230","PC073297","Simanainen U, Brogley M, Gao YR, et al.  2011.  Length of the human androgen receptor glutamine tract determines androgen sensitivity in vivo.  Mol Cell Endocrinol 342(1-2):81-86."
"4231","PC073297","Robins DM.  2012.  Androgen receptor gene polymorphisms and alterations in prostate cancer: Of humanized mice and men.  Mol Cell Endocrinol 352(1-2):26-33. "
"4232","PC073297","Higgins J, Brogley M, Palanisamy N, et al. 2015. Interaction of the androgen receptor, ETV1, and PTEN pathways in mouse prostate varies with pathological stage and predicts cancer progression. Hormones & Cancer 2015 Jun;6(2-3):67-86. doi: 10.1007/s12672-014-0215-9. Epub 2015 Jan 29."
"4233","PC073297","Robins DM.  2009.  The role of the androgen receptor polyglutamine tract in prostate cancer: In mice and men.  In: Androgen Action in Prostate Cancer (Tindall D and Mohler J, Eds).  Springer, New York, New York 269-295."
"4234","PC073297","Grivas PD, Robins DM, and Hussain M.  2013.  Predicting response to hormonal therapy and survival in men with metastatic prostate cancer.  Crit Rev Oncol Hematol 85(1):82-93."
"4235","PC073298","Valdez CD, Davis JN, Odeh HM, et al.  2011.  Repression of androgen receptor transcription through the E2F1/DNMT1 Axis.  PLoS One 6(9):e25187."
"4236","PC073307","Ellem SJ, Wang H, Poutanen M, et al.  2009.  Increased endogenous estrogen synthesis leads to sequential induction of prostatic inflammation and prostatic pre-malignancy.  Am J Pathal 175(3):1187-1199."
"4237","PC073309","Zhu B, Li X, Zhang Y, et al.  2013.  Cross-talk of alpha tocopherol-associated protein and JNK controls the oxidative stress-induced apoptosis in prostate cancer cells.  Int J Cancer 132(10):2270-2282."
"4238","PC073314","Christian PA, Thorpe JA, and Schwarze SR.  2009.  Velcade sensitizes prostate cancer cells to TRAIL induced apoptosis and suppresses tumor growth in vivo.  Cancer Biol Ther 8:69-76."
"4239","PC073325","Axanova L, Chen Y, Sui G, et al.  2010.  1,25-dihydroxyvitamin D3 and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells.  Prostate 70:1658-1671."
"4240","PC073341","Kowalik CG, Gerling GJ, Lee AJ,et al.  2012. Construct validity in a high-fidelity prostate exam simulator.  Prostate Cancer Prostatic Dis 15(1):63-69."
"4241","PC073341","Carson WC, Gerling GJ, Krupski TL, et al.  2011.  Material characterization of ex vivo prostate tissue via spherical indentation in the clinic.  Med Eng Phys 33(3):302-309."
"4242","PC073341","Wang N, Gerling GJ, Moyer Childress R, et al.  2010.  Using a prostate exam simulator to decipher palpation techniques that facilitate abnormality detection near clinical limits.  Simulation in Healthcare: The Journal of the Society for Simulation in Healthcare 5(3):152-160."
"4243","PC073341","Wang N, Gerling GJ, Moyer Childress R, et al.  2010.  Quantifying palpation techniques in relation to performance in a clinical prostate exam.  IEEE Transactions Inf Technol Biomed 14(4):1088-1097.
"
"4244","PC073341","Baumgart LA, Gerling GJ, and Bass EJ.  2010.  Characterizing the range of simulated prostate abnormalities palpable by digital rectal examination.  Cancer Epidemiology 34 (1):79-84."
"4245","PC073349","Ferjami S, Huang G, Shang QY, et al.  2013.  Alignment focus of daily image guidance for concurrent treatment of prostate and pelvic lymph nodes.  Int J Radiat Oncol Biol Phys 87(2):383-389."
"4246","PC073349","Curtis W, Khan M, Magnelli A, et al.  2013.  Relationship of imaging frequency and planning margin to account for intrafraction prostate motion:  Analysis based on real-time monitoring data.  Int J Radiat Oncol Biol Phys 85(3):700-706.

"
"4247","PC073349","Pejavar S, Yom SS, Hwang A, et al.  2013.  Computer-assisted, atlas-based segmentation for target volume delineation in whole pelvic IMRT for prostate cancer.  Technol Cancer Res Treat 12:199."
"4248","PC073349","Shang QY, Sheplan LJ, Stephans KL, et al.  2013.  Prostate rotation detected from implanted markers can affect dose coverage and cannot be simply dismissed.  J App Clin Med Phys 14(3):4262."
"4249","PC073349","Shang QY, Qi P, Ferjami S, et al.  2013.  Effect of MLC leaf width on treatment adaptation and accuracy for concurrent irradiation of prostate and pelvic lymph nodes.  Med Phys 6:061701."
"4250","PC073349","Xia P, Qi P, Hwang A, et al.  2010.  Comparison of three strategies in management of independent movement of the prostate and pelvic lymph nodes.  Med Phys 37(7):5006-5013."
"4251","PC073356","Huang W-C, Zhau HE, and Chung LWK.  2010.  Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/Lipogenic pathway in human prostate cancer cells.  The Journal of Biological Chemistry 285(11):7947-7956."
"4252","PC073356","Huang W-C, Havel JJ, Zhau HE, et al.  2008.  B2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells.  Clin Cancer Res 14(17)."
"4253","PC073356","Josson S, Nomura T, Lin J-T, et al.  2011.  Beta-2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells Cancer Res 71: 2600-2610."
"4254","PC073358","Hossain S, Dubielecka PM, Sikorski AF, et al.  2012.  Crk and Abi1: Binary molecular switches that regulate Abl tyrosine kinase and signaling to the cytoskeleton. Genes Cancer 3(5-6):402-413."
"4255","PC073358","Kotula, L. 2012.  Abi1, a critical molecule coordinating actin cytoskeleton reorganization with PI-3 kinase and growth signaling. Special Issue of FEBS Letters on Modular Protein Domains.  FEBS Lett. 586:2790-2794."
"4256","PC073358","Xiong X, Chorzalska, A, Dubielecka PM,  et al.  2012.  Disruption of Abi1/Hssh3bp1 expression induces prostatic epithelial neoplasia in the conditional Abi1/Hssh3bp1 KO mice. Oncogenesis 1:e26."
"4257","PC073358","Dubielecka PM, Cui P, Xiong X, et al.  2010.  Differential regulation of macropinocytosis by abi1/hssh3bp1 isoforms.  PLoS One 5(5):e10430."
"4258","PC073358","Dubielecka PM, Ladwein K, Xiong X, et al.  2011.  Essential role for Abi1 in embryonic survival and WAVE2 complex integrity.  Proc Natl Acad Sci USA 108:7022-7027."
"4259","PC073358","Dubielecka PM, Machida K, Xiong X, et al.  2010.  Abi1/Hssh3bp1 pY213 links Abl kinase signaling to p85 regulatory subunit of PI-3 kinase in regulation of macropinocytosis in LNCaP cells.  FEBS Lett 584(15):3279-3286.

"
"4260","PC073367","Wang J, Cai Y, Wendogn Y, et al.  2008.  Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts.  Cancer Res 68:20."
"4261","PC073367","Wang J, Cai Y, Shao LJ, et al.  2011.  Activation of NF-kappaB by TMPRSS2/ERG fusion isoforms through toll-like receptor-4.  Cancer Res 71(4):1325-1333.

"
"4262","PC073375","CaiC, Portnoy DC, Wang,H, et al.  2009.  Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2.  Cancer Res 69:5202-5209."
"4263","PC073375","HurW, VelentzaQ, Kim S, et al.  2008.  Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.  Bioorg Med Chem Lett 18:5916-5919."
"4264","PC073392","Chen GY, Tang J, Zheng P, et al.  2009.  CD24 and Siglect-10 selectively repress tissue damage induced immune responses.  Science 323:1722."
"4265","PC073405","McKeithen D, Graham T, Chung LWK, et al.  2010.  Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells.  Prostate 70(9)982-92."
"4266","PC073406","Moussavi M, Fazli L, Tearle H, et al.  2010.  Oncolysis of prostate cancers induced by vesicular stomatitis virus in PTEN knockout mice.  Cancer Res 15;70(4):1367-1376."
"4267","PC073412","Silberstein J and Parsons JK.  2008.  Current concepts in diet and prostate cancer.  Aging Health 4:495-450."
"4268","PC073412","Parsons JK, Newman V, Mohler JL, et al.  2009.  Dietary intervention after definitive therapy for localized prostate cancer: Results from a pilot study.  Can J Urol 16(3):4648-4654."
"4269","PC073416","Farwell WR, Lourenco C, Holmberg E, et al.  2011.  The association between height and prostate cancer grade in the early stage prostate cancer cohort study.  Cancer Causes Control 22(10):1453-1459."
"4270","PC073416","Farwell WR, D'Avolio LWD, Scranton RE, et al.  2011.  Statins and prostate cancer diagnosis and grade in a veterans population.  J Natl Cancer Inst 103(11):885-892."
"4271","PC073417","Gray A, de la Luz Garcia-Hernandez M, van West M, et al.  2009.  Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages.  Vaccine 27(6):G52-G59."
"4272","PC073417","Koh YT, Gray A, Higgins SA, Hubby B, Kast WM. Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate 2009 May 1;69(6):571-84"
"4273","PC073417","Gray A, Yan L, and Kast WM.  2010.  Prevention is better than cure: The case for clinical trials of therapeutic cancer vaccines in the prophylactic setting.  Mol Interv 10(4):197-203."
"4274","PC073419","Kim RH, Coates JM, Bowles TL, et al.  2009.  Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.  Cancer Res 15;69(2):700-708."
"4275","PC073419","Kim RH, Bold RJ, and Kung HJ.  2009.  ADI, autophagy, and apoptosis: Metabolic stress as a therapeutic option for prostate cancer.  Autophagy 5(4):567-568."
"4276","PC073420","Kim RH, Coates JM, Bowles TL, et al.  2009.  Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.  Cancer Res 69(2):700-708."
"4277","PC073420","Kim RH, Bold RJ, and Kung H-J.  2009.  ADI, autophagy and apoptosis: Metabolic stress as a therapeutic option for prostate cancer.  Autophagy 5(4):567-568."
"4278","PC073444","Yao M, Taylor RA, Richards MG, et al.  2010.  Prostate regenerating capacity of cultured human adult prostate epithelial cells.  Cells Tissues Organs 191(3):203-212 (IF 2.6).
"
"4279","PC073444","Risbridger GP and Taylor RA.  2011.  The complexities of identifying a cell of origin for human prostate cancer.  Asian J Androl 13(1):118-119."
"4280","PC073444","Risbridger GP, Davis ID, Birrell SN and Tilley WD Breast and prostate cancer: more similar than different Nature Reviews Cancer online 2-11-2010"
"4281","PC073444","Taylor RA, Toivanen R, and Risbridger GP.  2010.  Stem cells in prostate cancer -- Treating the root of the problem.  Endocr Relat Cancer 17(4):R273-85 (IF 5.683)."
"4282","PC073470","Taylor, et al.  2010.  Integrative genomic profiling of human prostate cancer.  Cancer Cell 18(1):11-22."
"4283","PC073480","Barron DA, Strand DW, Ressler SJ, et al.  2010.  TGF-beta-1 induces an age-dependent inflammation of nerve ganglia and fibroplasia in the prostate gland stroma of a novel transgenic mouse.  PLoS One 5(10):e13751.

"
"4284","PC073480","Barron DA and Rowley DR.  2012.  The reactive stroma microenvironment and prostate cancer progression.  Endocr Relat Cancer 19(6):R187-204."
"4285","PC073488","Siddique HR and Saleem M.  2012.  Concise review: Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: Preclinical and clinical evidences.  Stem Cells 30:372-378."
"4286","PC073488","Siddique HR, Parray A, Tarapore RS, et al.  2013.  BMI1 polycomb group protein acts as a master switch for growth and death of tumor cells:  Regulates TCF4-transcriptional factor-induced BCL2 signaling.  PLoS One 8(5):e60664."
"4287","PC073529","Wang J, Li T, Liang Z, et al.  2008.  Dose reduction for kilovoltage cone-beam computed tomography in radiation therapy.  Physics in Medicine and Biology 53:2897-2909.

"
"4288","PC073529","Wang J, Zhu L, and Xing L.  2009.  Noise reduction in low-dose X-ray fluoroscopy for image guided radiation therapy.  Int J Radiat Oncol Biol Phys 74:637-43
"
"4289","PC073529","Wang J, Li T, and Xing L.  2009.  Iterative image reconstruction for CBCT using edge-preserving prior.  Medical Physics 36:252-260."
"4290","PC073529","Zhu L, Wang J, and Xing L.  2009.  Noise suppression in scatter correction for cone-beam CT.  Medical Physics 36:741-752."
"4291","PC073529","Zhu L, Xie Y, Wang J, et al.  2009. 
Scatter correction for cone-beam CT in radiation therapy.  Med Phys 36(6):2258-2268."
"4292","PC073533","Yegnasubramanian S, Wu, Haffner MC, et al. 2011. Chromosome-wide mapping of DNA methylation patterns in normal and malignant prostate cells reveals pervasive methylation of gene-associated and conserved intergenic sequences. BMC Genomics 12: 313."
"4293","PC073533","Liu W, Laitinen S, Khan S, et al.  2009.  Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.  Nat Med 15:559-65.

"
"4294","PC073533","Aryee MJ, Wu Z, Ladd-Acosta C, et al. 2011. Accurate genome-scale percentage DNA methylation estimates from microarray data. Biostatistics 12(2):197-210."
"4295","PC073536","Jackson RS, Franco OE, and Bhowmick NA.  2088.  Gene targeting to the stroma of the prostate and bone.  Differentiation 76(6):606-623."
"4296","PC073540","Saito YD.  2010.  Fyn:  A novel molecular target in cancer.  Cancer 116(7):1629-1637."
"4297","PC073540","Posadas EM.  2009.  FYN is overexpressed in human prostate cancer.  BJU Int 103(2): 171-177."
"4298","PC073540","Jensen AR.  2011.  Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells.  Clin Cancer Res 17(10):3112-3122."
"4299","PC073547","Haga K, Tomioka A, Liao C-P, et al.  2009.  PTEN-knockout prostate cancer as a model for experimental immunotherapy.  J Urol 181:354-362."
"4300","PC073548","Smith AJ, Karpova Y, D'Agostino Jr R, et al.  2009.  Expression of the Bcl-2 protein BAD promotes prostate cancer growth.  PLoS One 4(7):e6224."
"4301","PC073548","Hassan S, Karpova Y, Baiz D, et al. 2013. Behavioral stress accelerates prostate cancer development in mice. J Clin Invest:123(2):874–886."
"4302","PC073548","Hassan S, Flores A, Karpova Y, and Kulik G. 2013. Surgical stress delays prostate cancer regression. PLoS One: 8(11) e78175."
"4303","PC073549","Niu G and Chen X.  2008.  Has molecular and cellular imaging enhanced drug discovery?  Drugs R&D 9(6):351-368."
"4304","PC073549","Niu G and Chen X.  2009.  PET imaging of angiogenesis.  PET Clinics 4(1):17-38."
"4305","PC073549","Niu G and Chen X.  2009.  From protein-protein interaction to therapy response: Molecular imaging of heat shock proteins.  Eur J Radiol 70(2):294-304.

"
"4306","PC073549","Niu G, Li ZB, Cao Q, et al.  2009.  Monitor therapeutic response of human ovarian cancer to 17-DMAG by non-invasive PET imaging with 64Cu-trastuzumab.  Eur J Nucl Med Mol Imaging 36(9):1510-1519."
"4307","PC073549","Niu G, Cai W, Chen K, et al.  2008.  Non-invasive PET imaging of EGFR degradation induced by a heat shock protein 90 inhibitor.  Mol Imaging Biol 10(2):99-106."
"4308","PC073549","Niu G, Li ZB, Xie J, et al.  2009.  Imaging antibody delivery with microPET in EGFR positive head-neck squamous cell carcinoma models.  J Nucl Med 50(7):1116-1123."
"4309","PC073563","McCauley PS and Gallick GE.  2010.  Pre-clinical mouse models of prostate cancer.  Curr Protoc Pharmacol Chapter 14:Unite 14.15."
"4310","PC073572","Wang Z, Li Y, and Sarkar FH.  2010.  Signaling mechanism(S) of reactive oxygen species in epithelial-mesenchymal transition reminiscent of cancer stem cells in tumor progression.  Current Stem Cell Research & Therapy 5(1):74-80."
"4311","PC073572","Wang Z, Li Y, Kong D, et al.  2010.  The role of notch signaling pathway in epithelial mesenchymal transition (EMT) during development and tumor aggressiveness.  Curr Drug Targets 11(6):745-51."
"4312","PC073572","Wang Z, Li Y, Banerjee S, Kong D, et al.  2010.  Downregulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappa-B signaling pathways.  J Cell Biochem 109(4):726-736."
"4313","PC073572","Wang Z, Li Y, Banerjee S, et al.  2009.  Emerging role of notch in stem cells and cancer.  Cancer Letter 279(1):8-12.

"
"4314","PC073572","Wang Z, Li Y, and Sarkar FH.  2010.  Notch signaling proteins: Legitimate targets for cancer therapy.  Curr Protein Pept Sci 11(6):398-408."
"4315","PC073572","Wang Z, Li Y, Ahmad A, et al.  2011.  Down-regulation of notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells.  J Cell Biochem 112:78--88."
"4316","PC073572","Wang Z, Li Y, Banerjee S, et al.  2008.  Exploitation of the notch signaling pathway as a novel target for cancer therapy.  Anticancer Res 28:3621-3630."
"4317","PC073572","Wang Z, Ahmad A, Li Y, et al.  2010.  Emerging roles of PDGF-D signaling pathway in tumor development and progression.  Biochim Biophys Acta 1806:3621-3630."
"4318","PC073572","Wang Z, Li Y, Ahmad A, et al.  2010.  Targeting notch signaling pathway to overcome drug resistance for cancer therapy.  Biochim Biophys Acta 1806:258-267."
"4319","PC073572","Wang Z, Li Y, Kong D, et al.  2010.  Cross-talk between miRNA and notch signaling pathways in tumor development and progression.  Cancer Lett 292:141-148."
"4320","PC073585","Bright RK, and Mamula MJ.  2015.  Regulation of adaptive immune responses to self-antigens in cancer and autoimmunity.  Cur Trends Immunology 15:47-57."
"4321","PC073585","Bright JD, Aldrich JF, Byre JA, et al.  2014.  Vaccination with the prostate cancer over-expressed tumor self-protein TPD52 elicits protective tumor immunity and a potentially unique subset of CD8+T cells.  Austin J Clin Immunol 1(2):1-13."
"4322","PC073586","Askew EB, Minges JT, Hnat AT, et al. 2012. Structural features discriminate androgen receptor N/C terminal and coactivator interactions. Mol Cell Endocrinol 348(2):403-410."
"4323","PC073586","Askew EB, Gampe RT Jr, Stanley TB, et al.  2007.  Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone.  J Biol Chem 282:25801-25816."
"4324","PC073586","Askew EB, Bai S, Blackwelder AJ, et al.  2010.  Transcriptional synergy between melanoma antigen protein-A11 (MAGE-11) and p300 in androgen receptor signaling.  J Biol Chem 285(28):21824-21836."
"4325","PC073586","Askew EB, Bai S, Hnat AT, et al.  2009.  Androgen receptor coregulator MAGE-11 is an F-box protein that interacts with TIF2.  J Biol Chem 284: 34793-34808.
"
"4326","PC073594","Tschöp K, Conery AR, Litovchick L, et al.  2011.  A kinase shRNA screen links LATS2 and the pRb tumor suppressor.  Genes Dev 25: 814-830."
"4327","PC073594","Litovchick L, Florens LA, Swanson SK, et al.  2011.  DYRK1A Protein kinase promotes quiescence and senescence through the DREAM complex assembly.  Genes Dev 25: 801-813.

"
"4328","PC073598","Shin S, Kim T-D, Jin F, et al.  2009.  Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81.  Cancer Res 69:8102-8110."
"4329","PC073604","Zuo X, Xia F, Xiao Y, et al.  2010.  A sensitive and selective, amplified fluorescent DNA detection based on exonuclease III aided target recycling.  J Am Chem Soc 132:1816-1818."
"4330","PC073604","Xiao Y, Dane K, Uzawa T, et al.  2010.  Detection of telomerase activity in high concentration of cell lysates using primer-modified gold nanoparticles.  J Am Chem Soc 132:15299-15307."
"4331","PC073604","Patterson A, Caprio F, Vallee-Belisle A, et al.  2010.  Using triplex-forming oligonucleotide probes for the reagentless, electrochemical detection of double-stranded DNA.  Anal Chem 82(21):9109-9115."
"4332","PC073614","He J, Schepmoes AA, Shi T, et al. 2015. Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods. Journal of Translational Medicine 13: 54. doi: 10.1186/s12967-015-0418-z."
"4333","PC073614","Rastogi A, Tan SH, Mohamed AA, et al. 2014. Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer. Genes & Cancer 5, 273-284."
"4334","PC073614","Gsponer JR, Braun M, Scheble VJ, et al. 2014. Analysis of the ERG rearrangement and protein expression in the progression from hormone-naïve to castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases 17, 126-131."
"4335","PC073614","Thangapazham R, Saenz F, Mohamed AA, et al. 2014. NKX3.1 is a negative regulator of TMPRSS2-ERG fusions in prostate cancer. BMC Cancer 14:16."
"4336","PC073614","Braun M, Goltz D, Shaikhibrahim Z, et al.  2012.  ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer - a comparative study of two monoclonal antibodies.  Prostate Cancer and Prostatic Diseases 15:165-169."
"4337","PC073614","Rosen P, Sesterhenn IA, Brassell S, et al.  2012.  Clinical potential of the ERG oncoprotein in prostate cancer.  Nature Reviews Urology 9:131-137."
"4338","PC073614","Mohamed AA, Tan SH, Mikhalkevich N, et al.  2010.  Ets family protein, erg expression in developing and adult mouse tissues by a highly specific monoclonal antibody.  J Cancer 1:197-208."
"4339","PC073614","Furusato B, Tan SH, Young D, et al.  2010.  ERG oncoprotein expression in prostate cancer: Clonal progression of ERG positive tumor cells and potential for ERG based stratification.  Prostate Cancer and Prostatic Diseases 13:228-237."
"4340","PC073614","Hu Y, Dobi A, Sreenath T, et al.  2008.  Delineation of TMPRSS2-ERG Splice variants in prostate cancer.  Clin Cancer Res 14(15) 4719-4725."
"4341","PC073615","Wang D, Garcia-Bassets I, Benner C, et al.  2011.  Reprogramming transcription via distinct classes of enhancers functionally defined by eRNA.  Nature 474(7351):390-394."
"4342","PC073615","Lin C, Yang L, Tanasa B, et.al. 2009.  Nuclear Receptor-Induced Chromosomal Proximity and DNA Breaks Underlie Specific Translocations in Cancer.  Cell 139:1-15."
"4343","PC073618","Dhillon PK, Penney KL, Schumacher F, et al.  2011.  Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer.  Cancer Epidemiol Biomarkers Prev 20(12):2618-2627."
"4344","PC073618","Penney KL, Schumacher FR, Li H, et al.  2010.  A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival.  Cancer Prev Res 3(5):604-610.  PMCID:  PMC2865569"
"4345","PC073618","Cao Y, Kenfield S, Song Y, et al.  2011.  Cigarette smoking cessation and total and cause-specific mortality:  A 22-year follow-up study among US male physicians.  Arch Intern Med 171(21):1956-1959. "
"4346","PC073624","Peng J, Hartley RM, Fest GA, et al.  2012.  Amyrisins A-C,O-prenylated flavonoids from Amyris madresis.  J Nat Prod 75: 494-496.

"
"4347","PC073624","Hartley RM, Peng J, Fest GA, et al.  2012.  Polygamain, a new microtubule depolymerizing agent that occupies a unique pharmacophore in the colchicine site.  Mol Pharmacol 81:431-439."
"4348","PC073640","Furuta E, Pai SK, Zhan R, et al. 2008. Fatty Acid Synthase Gene Is Up-regulated by Hypoxia via Activation of Akt and Sterol Regulatory Element Binding Protein-1. Cancer Res 68:1003-1011."
"4349","PC073643","Jaggi M, Chauhan SC, Du C, et al.  2008.  Bryostatin modulates beta-catenin subcellular localization and transcription activity through protein kinase D1 activation.  Mol Cancer Ther 7(9):2703-2712.
 

"
"4350","PC073643","Chauhan SC, Vannatta K, Ebeling MC, et al.  2009.  Expression and in vitro functions of transmembrane mucin MUC13 in ovarian cancer.  Cancer Res 69(3):765-774.

"
"4351","PC073643","Chauhan SC, Kumar D, and Jaggi M.  2009.  Mucins in ovarian cancer diagnosis and therapy.  J Ovarian Res 2(1):21."
"4352","PC073643","Paul M, Jaggi M, Viqar S, et al.  2008.  Protein kinase D1 (PKD1) influences androgen receptor (AR) function in prostate cancer cells.  Biochem Biophys Res Commun 73:618-623."
"4353","PC073643","Yallapu MM, Maher DM, Sundram V, et al. 2010. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth.  J Ovarian Res 3:11."
"4354","PC073643","Yallapu MM, Jaggi M, and Chauhan SC.  2010.  Beta-cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells.  Colloids Surf B Biointerfaces 79(1):113-125."
"4355","PC073643","Du C, Jaggi M, Zhang C, et al.  2009.  Protein kinase D1 (PKD1) mediated phosphorylation and subcellular localization of beta-catenin.  Cancer Res 69(3):1117-1124."
"4356","PC073643","Sundram V, Chauhan SC, Ebeling M, et al.  2012.  Curcumin attenuates beta-catenin signaling in prostate cancer cells through activation of protein kinase D1.  PLoS One 7(4):e35368.

"
"4357","PC073643","Yallapu MM, Jaggi M, and Shauhan SC.  Poly (beta-cyclodextrin)/curcumin self-assembly: A novel approach to improve curcumin delivery and its therapeutic efficacy in prostate cancer cells.  Macromol Biosci 10(10):1141-1151."
"4358","PC073645","Dong Y, Bey EA, Li LS, et al.  2010.  Prostate cancer radiosensitization through PARP-1 hyperactivation.  Cancer Res 70(20): 8088-8096."
"4359","PC073645","Li LS, Bey EA, Dong Y, et al.  2011.  Modulating endogenous NQO1 levels identifies key regulatory mechanism of action of beta-lapachone for pancreatic cancer therapy.  Clin Cancer Res 17(2):275-285."
"4360","PC073645","Dong Y, Chin SF, Blanco E, et al.  2009.  Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy.  Clinical Cancer Research 15(1):131-139."
"4361","PC073646","Vora SR, Palamakumbura AH, Mitsi M, et al.  2010.  Lysyl oxidase propeptide inhibits FGF-2-induced signaling and proliferation of osteoblasts.  J Biol Chem 285:2384-2393.

"
"4362","PC073646","Palamakumbura AH, Vora SR, Nugent MA, et al. 2009. Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling. Oncogene 28:3390-400."
"4363","PC073646","Vora SR, Guo Y, Stephens DN, et al.  2010.  Characterization of recombinant lysyl oxidase propeptide.  Biochemistry 49:2962-2972.

"
"4364","PC073690","Wiersma RD, Riaz N, Dieterich S, et al.  2009.  Use of MV and kV imager correlation for maintaining continuous real-time 3D internal marker tracking during beam interruptions.  Phys Med Biol 54(1):89-103."
"4365","PC073690","Wiersma RD, Mao W, and Xing L.  2008.  Combined kV and MV imaging for realtime tracking of implanted fiducial markers.  Med Phys 35(4):1191-1198."
"4366","PC073690","Mao W, Wiersma RD, and Xing L.  2008.  Fast internal marker tracking algorithm for onboard MV and kV imaging systems.  Med Phys 35(5):1942-1949.

"
"4367","PC073690","Mao W, Riaz N, Lee L, et al.  2008.  A fiducial detection algorithm for real-time image guided IMRT based on simultaneous MV and kV imaging.  Med Phys 35(8):3554-3564."
"4368","PC073690","Liu W, Wiersma RD, Mao W, et al.  2008.  Real-time 3D internal marker tracking during arc radiotherapy by the use of combined MV-kV imaging.  Phys Med Biol 53(24):7197-7213."
"4369","PC073698","Zhai L, Polascik TJ, Foo WC, et al.  2012.  Acoustic radiation force impulse imaging of human prostates: Initial in vivo feasibility demonstration.  Ultrasound Med Biol 38(1):50-61."
"4370","PC073698","Zhai L, Madden J, Foo WC, et al.  2010.  Acoustic radiation force impulse imaging of human prostates ex vivo.  Ultrasound Med Biol 36: 576-588."
"4371","PC073698","Zhai L, Madden J, Foo WC, et al.  2010.  Characterizing prostatic tissue with acoustic radiation force.  Ultrasonic Imaging 32:201-213."
"4372","PC073700","Choi EW, Nayak LV and Bates PJ.  2010.  Cancer-selective antiproliferative activity is a general
property of some G-rich oligodeoxynucleotides.  Nucleic Acids Res 38:1623-1635.
"
"4373","PC073709","Rais-Bahrami S, Levinson AW, Fried NM, et al.  2008.  Optical coherence tomography of cavernous nerves:  a step toward real-time intraoperative imaging during nerve-sparing radical prostatectomy.  Urology 72(1):198-204."
"4374","PC073709","Chitchian S, Fiddy MA, and Fried NM.  2009.  Denoising during optical coherence tomography of the prostate nerves via wavelet shrinkage using dual-tree complex wavelet transform.  J Biomed Opt 14(1):014-031."
"4375","PC073709","Chitchian S, Weldon TP, and Fried NM.  2009.  Sementation of optical coherence tomography images for differentiation of the cavernous nerves from the prostate gland.  Journal of Biomedical Optics 14(4):044033.

"
"4376","PC073709","Chitchian S, Weldon TP, and Fried NM.  2009.  OCT image segmentation of the prostate nerves.  Proc SPIE 7443:74431D, San Diego, California."
"4377","PC073709","Chitchian S and Fried NM.  2010.  Near-IR optical properties of canine prostate tissue using oblique incidence reflectometry.  Proc SPIE, San Francisco, California."
"4378","PC073709","Tozburun S, Lagoda GA, Mayeh M, et al.  2010.  Incorporation of fiber optic beam shaping into a laparoscopic probe for laser stimulation of the cavernous nerves.  Proc SPIE, San Francisco, California."
"4379","PC073709","Tozburun S, Lagoda GA, Burnett AL, et al.  2010.  Gaussian versus flat-top spatial beam profiles for optical stimulation of the prostate nerves.  Proc SPIE, San Francisco, California."
"4380","PC073709","Chitchian S, Weldon TP, Fiddy MA, Fried NM.  2010.  Combined image processing algorithms for improved optical coherence tomography of the prostate nerves. Journal of Biomedical Optics 15(4):046014."
"4381","PC073709","Tozburun S, Cilip CM, Lagoda GA, et al.  2010.  Continuous-wave infrared optical nerve stimulation for potential diagnostic applications. Journal of Biomedical Optics 15(5):055012."
"4382","PC073709","Tozburun S, Lagoda GA, Burnett AL, et al. 2012. Subsurface near-infrared laser stimulation of the periprostatic cavernous nerves. J Biophotonics. 5(10):793-800."
"4383","PC073709","Tozburun S, Lagoda GA, Burnett AL, et al. 2011. Continuous-wave laser stimulation of the rat prostate cavernous nerves using a compact and inexpensive all single mode optical fiber system. J Endourol 25(11):1727-1731."
"4384","PC073710","Ateeq B, Tomlins SA, Laxman B, et al.  2011.   Therapeutic targeting of SPINK1-positive prostate cancer.  Sci Transl Med 3(72):72ra17."
"4385","PC073710","Han B, Mehra R, Lonigro RJ, et al.  2009.  Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.  Mod Pathol 22(8):1083-1093."
"4386","PC073710","Han B, Mehra R, Suleman K, et al.  2009.  Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.  Mod Pathol 22(9):1176-1185."
"4387","PC073716","Shen MM and Abate-Shen C.  2010.  Molecular genetics of prostate cancer:  New prospects for old challenges.  Genes Dev 24:1967:2000."
"4388","PC073716","Kinkade CW, Castillo-Martin M, Puzio-Kuter A, et al.  2008.  Targeting Akt/TOR and Erk MAPK signaling inhibits hormone-refractory prostate cancer in a pre-clinical mouse model.  J Clin Invest 118:3051-3064."
"4389","PC073739","Zhang F, Zaidi S, Haney KM, et al.  2011.  Regio- and stereo-selective syntheses of the natural product CCR5 antagonist anibamine and its three olefin isomers.  J Org Chem 76(19):7945-7952.

"
"4390","PC073739","Zhang Y.  2010.  Book Review in: Chemokine Receptors in Cancer.  (Fulton AM, Ed).  Humana Press.  Chem Med Chem 477."
"4391","PC073739","Haney KM, Zhang F, Arnatt CK, et al.  2011.  The natural product CCR5 antagonist anibamine and its analogs as anti prostate cancer agents.  Bioorg Med Chem Lett 21:5159-5163."
"4392","PC073739","Zhang X, Haney KM, Richardson AC, et al.  2010.  Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti prostate cancer agents.  Bioorg Med Chem Lett 20(15):4627-4630."
"4393","PC073739","Guo Li, Haney KM, Kellogg GE, et al.  2009.  A comparative docking study of Anibamine as the first natural product CCR5 antagonist in CCR5 homology models.  J Chem Inf Model 49(1):120-32.

"
"4394","PC073745","Ribas J and Lupold SE.  2010.  The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer.  Cell Cycle 9(5):923-929."
"4395","PC073745","Ribas J, Ni X, Haffner M, et al.  2009.  miR-21: An androgen receptor regulated microRNA which promotes hormone dependent and independent prostate cancer growth.  Cancer Res [Priority Report] 69(18):7165-7169.

"
"4396","PC073761","Montecinos VP, Godoy A, Hinklin J, et al.  2012.  Primary xenografts of human prostate tissue as a model to study angiogenesis induced by reactive stroma.  PLoS One 7(1):e29623. 
"
"4397","PC073761","Godoy A, Kawinsky E, Li Y, et al.  2011.  5alpha-reductase type 3 expression in human benign and malignant tissues: A comparative analysis during prostate cancer progression.  Prostate 71(10):1033-1046."
"4398","PC073761","Godoy A, Salazar K, Peruzzo B, et al.  2009.  Nutritional channels in breast cancer.  J Cell Mol Med 13:3973-3984."
"4399","PC073761","Mathew G, Timm E Jr., Sotomayor P, et al.  2009.  ABCG2-Mediated dyecycle violet efflux defined side population in benign and malignant prostate.  Cell Cycle 8:1-93."
"4400","PC073761","Godoy A, Montecinos V, Gray D, et al.  2011.  Androgen deprivation induces rapid vascular involution and recovery in the short-term prostate primary xenograft model.  Am J Physiol Endocrinol Metab 300:E263-75."
"4401","PC073761","Sotomayor P, Godoy A, Smith G, et al.  2009.  Oct4A is expressed by a subpopulation of prostate neuroendocrine cells.  Prostate 69:401-410."
"4402","PC073761","Tanner MJ, Welliver C Jr, Chen M, et al.  2011.  Effects of androgen receptor and androgen on gene expression in prostate stromal fibroblast and paracrine signaling to prostate cancer.  PLoS One 6:e16027."
"4403","PC073761","Godoy A, Watts A, Sotomayor P, et al.  2008.  Androgen receptor is causally involved in the homeostasis of the human prostate endothelial cell.  Endocrinology 149:2959-2969."
"4404","PC073761","Chadha K, Nair B, Chakravarthi S, et al.  2011.  Enzymatic activity of free-prostate-specific antigen (F-PSA) is not required for some of its physiological activities. Prostate 71(15):1680-1690."
"4405","PC073761","Reinicke K, Sotomayor P, Cisterna P, et al.  2012.  Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue.
J Cell Biochem 113(2):553-62.
"
"4406","PC073761","Mohler JL, Titus M., Godoy A, et al.  2011.  Intracrine synthesis of androgen by prostate cancer in response to androgen deprivation therapy.  In: Recent Advances in Prostate Cancer: Basic Science Discoveries and Clinical Advance.  (Tindall DJ, and Scardino PT, Ed.).  World Scientific Publishing Company, USA, Chapter 8."
"4407","PC073763","Honorio S, Li H, and Tang DG.  2009.  Prostate cancer stem/progenitor cells.  In: Stem Cells and Cancer.  Bagley RG and Teicher BA, Eds.  Humana Press, New York, New York."
"4408","PC073763","Li HW, Jiang M, Honorio S, et al.  2009.  Methodologies in assaying prostate cancer stem cells.  In: Methods Mol. Biol.  Yu JS, Ed.  Humana Press, New York, New York.  

"
"4409","PC073769","Freeman MR, Kim J, Lisanti MP, et al.  2011.  A metabolic perturbation by U0126 identifies a role for glutamine in resveratrol-induced cell death.  Cancer Biology and Therapy 12(11):966-977."
"4410","PC073769","Di Vizio D, Morello M, Sotgia F, et al.  2009.  An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation.  Cell Cycle 8:2420-2424.  "
"4411","PC073769","Cinar B, Collak FK, Lopez D, et al.  2011.  MST1 is a multifunctional caspase-independent inhibitor of androgenic signaling.  Cancer Research 71:4303-4313.  "
"4412","PC073769","Solomon KR and Freeman MR.  2011.  The complex interplay between cholesterol and prostate malignancy.  Urologic Clinics of North America 38:243-259.  "
"4413","PC073769","Mostaghel EA, Solomon KR, Pelton K, et al.  2012.  Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors.  PLoS One 7(1):e30062. "
"4414","PC073769","Mukhopadhyay M, Kim J, Cinar B, et al.  2009.  Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation.  Cancer Res 69:2210-2218."
"4415","PC073769","Di Vizio D, Kim J, Hager, MH, et al.  2009.  Oncosome formation in prostate cancer: Association with a region of frequent chromosomal deletion in metastatic disease.  Cancer Res 69:5601-5609."
"4416","PC073769","Freeman MR, Di Vizio D and Solomon KR.  2010.  The rafts of the Medusa:  Cholesterol targeting in cancer therapy.  Oncogene 29:3745-3747."
"4417","PC073779","Jiang X, Chen S, Asara JM, et al.  2010.  Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.  J Biol Chem 285(20):14980-14989."
"4418","PC073779","Cai C, Portnoy DC, Wang H, et al.  2009.  Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2.  Cancer Res 69:5202-5209."
"4419","PC073790","Wang J, Place RF, Huang V, et al.  2010.  Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration.  Cancer Res 70:10182-10191."
"4420","PC073790","Portnoy V, Huang V, Place RF et al.  2011.  Small RNA and transcriptional upregulation.  Wiley Interdiscip Rev RNA 2(5):748-760."
"4421","PC073790","Huang V, Qin Y, Wang J, et al.  2010.  RNAa is conserved in mammalian cells.  PLoS One.  5(1):e8848."
"4422","PC073813","Guo P, Zhao KW, Dong XY, et al.  2009.  Acetylation of KLF5 alters the assembly of P15 transcription factors in TGFbeta-mediated induction in epithelial cells.  J Biol Chem 284:18184-93."
"4423","PC073813","Guo P, Dong XY, Zhao KW, et al.  2009.  Opposing effects of KLF5 on the transcription of Myc in epithelial proliferation in the context of TGFbeta.  J Biol Chem 284(41):28243-28252.

"
"4424","PC073813","Guo P, Dong XY, Zhang X, et al.  2009.  Pro-proliferative factor KLF5 becomes anti-proliferative in epithelial homeostasis upon signaling-mediated modification.  J Biol Chem 284(10):6071-6078."
"4425","PC073828","Kwabi-Add B, Wang S, Chung W, et al.  2010.  Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men.  Clin Cancer Res 16(14):3539-3547."
"4426","PC073829","Liu S, Qi Y, Ge Y, et al.  2010.  Telomerase as an important target of androgen signaling blockade for prostate cancer treatment.  Mol Cancer Ther 9(7):2016-25."
"4427","PC073831","Nam C, Case AJ, Hostager BS, et al.  2009.  The role of vasoactive intestinal peptide (VIP) in megakaryocyte proliferation.  J Mol Neurosci 37(2):160-167."
"4428","PC073831","Place TL, Fitzgerald MP, Venkataraman S, et al.   2011.  Aberrant promoter CpG methylation is a mechanism for impaired PHD3 expression in a diverse set of malignant cells.  PLoS One 6(1):e14617."
"4429","PC073831","Case AJ and Domann FE.  2009.  Hypoxia-induced gene regulation through hypoxia inducible factor-1 alpha.  In: Redox Signaling and Regulation in Biology and Medicine.  Jacob C and Winyard P, et al, Eds.  Wiley-VCH."
"4430","PC073831","Case AJ, McGill JL, Tygrett LT, et al.  2011.  Elevated mitochondrial superoxide disrupts normal T cell development, impairing adaptive immune responses to an influenza challenge.  Free Radic Biol Med 50(3):448-458."
"4431","PC073847","Kolluri S, Zhu X, Zhou X, et al.  2008.  A short Nur77-derived peptide converts Bcl-2 from a protector to a killer.  Cancer Cell 14:285-298."
"4432","PC073847","Han YH, Zhou H, Kim JH, et al.  2009.  A unique cytoplasmic localization of RARgamma and its regulations.  J Biol Chem 284:18503-18514."
"4433","PC073847","Zhou H, Liu W, Su Y, et al.  2010.  NSAID sulindac and its analogs bind RXRalpha and inhibit RXRalpha-dependent AKT signaling.  Cancer Cell 17:560-573."
"4434","PC073847","Yan TD, Wu H, Zhang HP, et al.  2010.  Oncogenic potential of retinoic acid receptor-gamma in hepatocellular carcinoma.  Cancer Res 70:2285-2295.
"
"4435","PC073847","Sun Z, Cao X, Jiang M-M, et al.  2012.  Inhibition of beta-catenin signaling by nongenomic action of orphan nuclear receptor Nur77.  Oncogene 31(21):2653-2667."
"4436","PC073847","Liu J, Zhou W, Li SS, et al.  2008.  Modulation of orphan nuclear receptor Nur77-mediated apoptotic pathway by acetylshikonin and analogues.  Cancer Res 68:8871-8880."
"4437","PC073847","Wu H, Lin Y, Li W, et al.  2010.  Regulation of Nur77 expression by beta-catenin and its mitogenic effect in colon cancer cells.  FASEB J 25:192-205.  "
"4438","PC073851","Y Pu, Wang WB, Achilefu S, et al.  2011.  Study of rotational dynamics of receptor-targeted contrast agents in cancerous and normal prostate tissues using time-resolved picosecond emission spectroscopy.  Appl Opt 50(7):1312-1322.

"
"4439","PC073851","Xu M, Pu Y, and Wang WB.  2011.  Clean image synthesis and target numerical marching for optical imaging with backscattering light.  Biomed Opt Express 2(4):850-857."
"4440","PC073851","Pu Y, Wang WB, Xu M, et al.  2011.  Near infrared photonic finger imager for prostate cancer screening.  Technol Cancer Res Treat 10(6):507-517."
"4441","PC073851","Pu Y, Wang WB and Tang GC.  2010.  Changes of collagen and NADH contents in human cancerous and normal prostate tissues studied using fluorescence spectroscopy with selective excitation wavelength.  J Biomed Optics 15:047008."
"4442","PC073851","Pu Y, Wang WB, Das BB, et al.  2009.  Time-resolved spectral wing emission kinetics and optical imaging of human cancerous and normal prostate tissues.  Optics Communications 282:4308-4314."
"4443","PC073851","Pu Y, Wang WB, Tang GC, et al.  2013.  Near infrared spectral polarization imaging of prostate cancer tissue using Cybesin: A receptor-targeted contrast agent.  Proceedings of SPIE 8565:85651G-1-9."
"4444","PC073851","Pu Y, Wang WB, Das BB, et al.  2009.  Time-resolved near infrared wing emission of human native cancerous and normal prostate tissues.  Proceedings of SPIE 7174:71741W-1-6."
"4445","PC073851","Pu Y, Tang R, Xue J, et al.  2013.  Synthesize dye-bioconjugates to visualize cancer cells using fluorescence microscopy.  Proceedings of SPIE 8587:85871Z-1-8.

"
"4446","PC073851","Pu Y, Wang W, Yang Y, et al.  2013.  The efficacy of stokes shift spectroscopy for detecting prostate and breast cancer tissue.  Proceedings of SPIE 8577:857702-1-9."
"4447","PC073851","Jeyasingh E, Pu Y, Liu CH, et al.  2011.  Diagnostic potential of Stokes shift spectroscopy of breast and prostate tissues -- a preliminary pilot study.  Technol Cancer Res Treat 10(2):153-162."
"4448","PC073851","Pu Y, Wang W, Yang Y, et al.  2012.  Stokes shift spectroscopy highlights differences of cancerous and normal human tissues.  Optics Lett 37(16)3360-3362."
"4449","PC073851","Pu Y, Tang GC, Wang WB, et al.  2011.  Native fluorescence spectroscopic evaluation of chemotherapeutic effects on malignant cells using nonnegative matrix factorization analysis.  Technol Cancer Res Treat 10(2)113-120."
"4450","PC073851","Pu Y, Wang WB, Das BB, et al.  2012.  A mini-review of ultrafast fluorescence polarization spectroscopy.  Appl Opt 52(5):917-929."
"4451","PC073851","
Pu Y, Wang W, Xu M, et al.  2012.  Characterization and three-dimensional localization of cancerous prostate tissue using backscattering scanning polarization imaging and independent component analysis.  J Biomed Opt 17(8):081419-1-8.
"
"4452","PC073851","Jeyasingh E, Yang P, Wang WB, et al.  2012.  Stokes shift spectroscopy pilot study for cancerous and normal prostate tissues.  Appl Optics 51(16):3642-3649."
"4453","PC073851","Pu Y, Wang W, Al-Rubaiee M, et al.  2012.  Determination of optical coefficients and fractal dimensional parameters of cancerous and normal prostate tissues.  Appl Spectrosc 66(7)828-834."
"4454","PC073851","Pu Y, Wang WB, Tang GC, et al.  2010.  Changes of collagen and NADH contents in human cancerous and normal prostate tissues studied using fluorescence spectroscopy with selective excitation wavelength.  J Biomed Opt 15:047008-1-5."
"4455","PC073851","Pu Y, Tang R, Xue J, et al.  2013.  Synthesize dyebioconjugates to visualize cancer cells using fluorescence microscopy.  2013 International Biomedical Optics Symposium (BIOS), SPIE Photonics West 2013, Conference 8587: 'Imaging, Manipilation, and Analysis of Biomolecules, Cells, and Tissues XI,' San Francisco, California, Technical Program, 8587-73, p 152."
"4456","PC073851","Pu Y, Wang W, Yang Y, et al.  2013.  Stokes shift spectroscopic analysis of multi-fluorophores for human cancer detection in breast and prostate tissues.  Journal of Biomedical Optics 18(1):017005-1-8."
"4457","PC073851","Pu Y, Wang W, Yang Y, et al.  2012.  Cancer detection using stokes shift spectroscopy.  BioOptics World 5(6):35-43."
"4458","PC073851","Jeyasingh E, Pu Y, Liu CH, et al.  2011.  Stokes-shift spectroscopy for breast and prostate cancer detection.  Technol Cancer Res Treat 10(2):153-162.

"
"4459","PC073851","Pu Y, Xue J, Xu B, et al.  2013.  Investigation of native fluorescence spectral difference among prostate cancer cell lines with different risk levels.  Proceedings of SPIE 8577:85770X-1-8."
"4460","PC073877","Hannon GJ, Rivas FV, Murchison EP, et al.  2006.  The expanding universe of noncoding RNAs. Cold Spring Harbor Symp Quant Biol 71:551-564."
"4461","PC073877","Zou JX, Guo L, Revenko AS, et al.  2009.  Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer.  Cancer Res 15:69 (8):3339-3346. "
"4462","PC073877","Yang P, Guo L, Duan ZJ, et al.  2012.  Histone methyltransferase NSD2/MMSET mediates constitutive NF-kappaB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.  Mol Cell Biol 32(15):3121-3131.  "
"4463","PC073887","Yallapu MM, Jaggi M, and Chauhan SC.  2010.  Scope of nanotechnology in ovarian cancer therapeutics.  J Ovarian Res 6:3:19."
"4464","PC073887","Yallapu MM, Gupta B, Jaggi M et al.  2010.  Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells.  J Colloid Interface Sci 351(1):19-29."
"4465","PC073887","Yallapu MM, Jaggi M, and Chauhan SC.  2010.  Poly(beta-cyclodextrin)-curcumin self-assembly: A novel approach to improve curcumin delivery and its therapeutic efficacy in prostate cancer cells.  Macromol Biosci 10(10):1141-1151."
"4466","PC073887","Yallapu MM., Jaggi M, and Chauhan SC.  2011.  Design and engineering of nanogels for cancer treatment.  Drug Discov Today 16(9-10):457-63."
"4467","PC073887","Sundram V, Chauhan SC, and Jaggi M.  2012.  Curcumin attenuates beta-catenin signaling in prostate cancer cells through activation of protein kinase D1.  PLoS One 7(4):e35368."
"4468","PC073887","Yallapu MM, Othman SF, Curtis ET, et al.  2012.  Curcumin loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications.  Int J Nanomedicine 7:1761-1779.

"
"4469","PC073887","Yallapu MM, Othman SF, Curtis ET, et al.  2011.  Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy.  Biomaterials 32(7):1890-1905."
"4470","PC073887","Yallapu MM, Ebeling MC, Chauhan N, et al.  2011.  Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes.  Internat J Nanotech 6:2779-2790."
"4471","PC073887","Yallapu MM, Doberphool M, Maher DM, et al.  2012.  Design of curcumin loaded cellulose nanoparticles for prostate cancer.  Curr Drug Metab 13(1):120-128."
"4472","PC073887","Yallapu MM, Jaggi M, and Chauhan SC.  2012.  Curcumin nanoformulations: A future nanomedicine for cancer.  Drug Discovery Today 17(1-2):71-80."
"4473","PC073887","Yallapu MM, Jaggi M, and Chauhan SC.  2010.  Poly(beta-cyclodextrin)-curcumin self-assembly : A novel approach to improve curcumin delivery and its therapeutic efficacy in prostate cancer cells.  Macromol Biosci 10(10):1141-1151."
"4474","PC073887","Chauhan SC, Jaggi M, Bell MC, et al.  2009.  Epidemiology of human papilloma virus (HPV) in cervical mucosa.  Methods Mol Biol 471:439-456.  PMID: 19109793."
"4475","PC073887","Yallapu MM, Jaggi M, and Chauhan SC. 2010. Beta-cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells.  Colloids Surf B: Biointerfaces 79(1):113-25."
"4476","PC073887","Chauhan SC, Kumar D, and Jaggi M.  2009.  Mucins in ovarian cancer diagnosis and therapy.  J Ovarian Res 2(1):21.  PMID: 20034397."
"4477","PC073887","Yallapu MM, Maher DM, Sundram V, et al.  2010. Curcumin induces chemo/radiosensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth.  J Ovarian Res 29:3-11."
"4478","PC073887","Bell MC, Schmidt-Grimminger D, Jacobsen C, et al.  2011.  Risk factors for HPV infection among American Indian and white women in the northern plains.  Gynecol Oncol 121(3):532-536.

"
"4479","PC073887","Yallapu MM, Othman SF, Curtis ET, et al.  2011.  Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy.  Biomaterials 32(7):1890-1905."
"4480","PC073912","Guo Z, Yang X, Sun F, et al.  2009.  A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.  Cancer Res 69:2305-2313."
"4481","PC073917","Linn DE, Yang X, Sun F, et al.  A role of OCT4 for tumor initiation of drug resistant prostate cancer cells.  Genes & Cancer 1:908-916."
"4482","PC073917","Dai B, Chen H, Guo S, et al.  Compensatory up-regulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells.  Cancer Research 70:5587-5596."
"4483","PC073945","Cai H, Babic I, Wei X, et al.  2011.  Invasive prostate carcinoma driven by c-Src and androgen receptor synergy.  Cancer Res 71(3):862-872."
"4484","PC073945","Memarzadeh S, Cai H, Janzen D, et al.  2011.  Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal.  Proc Natl Acad Sci U S A 108(19):7962-7967."
"4485","PC073945","Cai H, Smith DA, Memarzadeh S, et al.  2011.  Differential transformation capacity of Src family kinases during the initiation of prostate cancer.  Proc Natl Acad Sci U S A 103(16):6579-6584."
"4486","PC073951","Zhao H, Lo Y-H, Ho P-H, et al.  2012.  Interaction of proliferation cell nuclear antigen (PCNA) with the non-receptor tyrosine kinase c-Abl in cell proliferation and response to DNA damages in breast cancer cells.  PLoS ONE 7(1):e29416.  "
"4487","PC073951","Lo Y-H, Ho P-C, and Wang S-C. 2012. Epidermal Growth Factor Receptor Protects Proliferating Cell Nuclear Antigen from Cullin 4A Protein-mediated Proteolysis J Biol Chem 287:27148-27157."
"4488","PC073951","Zhao H, Lo Y-H, Ma L, et al.  2011.  Targeting tyrosine phosphorylation of PCNA inhibits prostate cancer growth.  Mol Cancer Therap 10:29-36."
"4489","PC073952","Shiozawa Y, Pienta KJ, Taichman RS.  2011.  Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors.  Clin Cancer Res 17(17):5553-5558."
"4490","PC073952","Shiozawa Y, Pedersen EA, Havens AM, et al.  2011.  Metastases target the hematopoietic stem cell niche to establish footholds in bone.  J Clin Invest 121(4):1298-1312.

"
"4491","PC073952","Y Shiozawa, EA Pedersen, AM Havens, et al.  2011. Metastases target the hematopoietic stem
cell niche to establish footholds in bone.  J Clin Invest 121(4):1298-1312."
"4492","PC073952","Pedersen EA, Shiozawa Y, Taichman RS.  2010.  Meeting report from the IX international meeting on cancer induced bone disease.  IBMS 7(1):32-46.

"
"4493","PC073969","Barron D, Ressler SD, Dang SJ, et al.  2010.  TGF-beta1 induces an age-dependent Inflammation of nerve ganglia and fibroplasia in the prostate gland stroma of a novel transgenic mouse.  PLoS ONE 5(10): e13751."
"4494","PC073976","Conway RE, Joiner K, Patterson A, et al. 2013. Prostate specific membrane antigen produces pro-angiogenic laminin peptides downstream of matrix metalloprotease-2. Angiogenesis 16(4):847-60."
"4495","PC073976","Grant CL, Caromile LA, Rahman MM, et al.  2012.  Prostate specific membrane antigen (PSMA) regulates angiogenesis independently of VEGF during ocular neovascularization.  PLoS One 7(7):e41285."
"4496","PC073977","Yates C.  2011.  Prostate tumor cell plasticity: A consequence of the microenvironment.  Adv Exp Med Biol 720:81-90. "
"4497","PC073977","Josson S, Sharp S, Sung S-Y, et al.  2010.  Tumor-stromal interactions influence radiation sensitivity in epithelial- versus mesenchymal-like prostate cancer cells.  Journal of Oncology, Volume 2010, Article ID 232831, 10 pages."
"4498","PC073977","Josson S, Anderson CS, Sung S-Y, et al.  2011.  Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy.  Prostate 71(3):232-240."
"4499","PC073977","Zhou J, Wang H, Cannon V, et al.  2011.  Side population rather than CD133+ cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cell.  Molecular Cancer 10(1):112.  "
"4500","PC073981","Deng X, Liu H, Huang J, et al.  2008.  Ionizing radiation induces prostate cancer cell neuroendocrine differentiation through interplay of CREB and ATF2: Implications for disease progression.  Cancer Res 68:9663-9670."
"4501","PC073981","Hu CD, Choo R, and Huang J. 2015. Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure. Front Oncol 5:90. doi: 10.3389/fonc.2015.00090. eCollection 2015."
"4502","PC073981","Deng X, Elzey BD, Poulson JM, et al.  2011.  Ionizing radiation induces neuroendocrine differentiation in vitro, in vivo and in human prostate cancer patients.  Am J Cancer Res 1:834:844."
"4503","PC073981","Deng X, Liu H, Huang J, et al.  2008.  Ionizing radiation induces prostate cancer cell neuroendocrine differentiation through interplay of CREB and ATF2: Implications for disease progression.  Cancer Res 68:9663-9670.

"
"4504","PC073981","Hsu C and Hu CD.  2012.  Critical role of an N-terminal end nuclear export signal in regulation of ATF2 subcellular localization and transcriptional activity.  J Biol Chem 287:8621-8632."
"4505","PC073988","Gong Y, Li Y, Lu Y, et al.  2011.  Bioactive tanshinones in salvia miltiorrhiza inhibit the growth of prostate cancer cells in vitro and in mice.  Int J Cancer 129:1042-1052."
"4506","PC073988","Li Y, Gong Y, Li L, et al. 2013. Bioactive tanshinone I inhibits the growth of lung cancer in part via downregulation of Aurora A function.  Mol Carcinog 52(7):535-543."
"4507","PC073988","Gong Y, Li Y, Abdolmaleky HM, et al.  2012. Tanshinones inhibit the growth of breast cancer cells through epigenetic modification of Aurora A expression and function.  PLoS One 7(4):e33656."
"4508","PC073989","Levina E, Chen M, Carkner R, et al.  2012.  Paracrine hedgehog increases the steroidogenic potential of prostate stromal cells in a Gli-dependent manner.  Prostate 72(8):817-824.

"
"4509","PC073989","Shtutman M, Baig M, Levina E, et al.  2011.  Tumor-specific silencing of COPZ2 gene encoding coatomer protein complex subunit {zeta}2 renders tumor cells dependent on its paralogous gene COPZ1.  Proc Natl Acad Sci U S A.  108(30):12449-12454"
"4510","PC073989","Chen M, Feuerstein MA, Levina E, et al.  2010.  Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells.  Mol Cancer 9:89."
"4511","PC073989","Shtutman M, Maliyekkel A and Yu S.  2010.  Function-based gene identification using enzymatically generated normalized shRNA library and massive parallel sequencing. Proc Natl Acad Sci U S A 107(16):7377-82.
"
"4512","PC073989","Shtutman M and Roninson IB.  2011.  A subunit of coatomer protein complex offers a novel tumor-specific target through a surprising mechanism.  Autophagy 7(12).

"
"4513","PC073990","Kashyap V and Gudas LJ.  Epigenetic regulatory mechanisms distinguish retinoic acid-mediated transcriptional responses in stem cells and fibroblasts.  J Biol Chem 285(19):14534-14548."
"4514","PC073991","Cyrus K, Wehenkel M, Choi EY, et al.  2010.  Two-headed PROTAC: An effective new tool for targeted protein degradation.  ChemBioChem 11:1531-1534."
"4515","PC073991","Cyrus K, Wehenkel M, Choi EY, et al.  2010.  Jostling for position: Optimizing linker location in the design of estrogen receptor-targeting PROTACs.  ChemMedChem 5:979-985."
"4516","PC073991","Jang ER, Lee W, and Kim KB.  2010.  Targeted degradation of proteins by PROTAC (PROteolysis TArgeting Chimeric molecules).  Curr Protoc Chem Biol 2:71-87."
"4517","PC073991","Lee S, Sielaff B, Lee J, et al.  2010.  CryoEM structure of Hsp104 and its mechanistic implication for protein disaggregation.  Proc Natl Acad Sci U S A 107(18):8135-40."
"4518","PC073991","Sielaff B, Lee KS, and Tsai FTF.  2010.  Crystallization and preliminary X-ray crystallographic analysis of a GroEL1 fragment from mycobacterium tuberculosis H37Rv.  Acta Crystallogr F66:418-420.
"
"4519","PC073991","Cyrus K, Wehenkel M, Choi EY, et al.  2011.  Impact of linker length on the activity of PROTACs.  Mol BioSyst 7:359-364."
"4520","PC074000","Cai C, Wang H, Xu Y, et al.  2009.  Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.  Cancer Res 1;69(15):6027-6032.

"
"4521","PC074012","Pritchard CC, Kroh EM, Wood B, et al.  2012.  Blood cell origin of circulating microRNAs: A cautionary note for cancer biomarker studies.  Cancer Prev Res 5(3):492-497."
"4522","PC074012","Kroh EM, Parkin RP, Mitchell PS, et al.  2010.  Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR).  Methods 50(4):298-301."
"4523","PC074016","Yip KW, Cuddy M, Pinilla C, et al.  2011.  A high-content screening (HCS) Assay for the identification of chemical inducers of PML oncogenic domains (PODs).  J Biomolecular Screening 16:251-258."
"4524","PC074021","Zhou H, Liu W, Su Y, et al.  2010.  NSAID sulindac and its analog bind RXRa and inhibit RXRa-dependent AKT signaling.  Cancer Cell 17(6):560-573."
"4525","PC074022","Yu X, Wang Y, DeGraff D, et al.  2011.  Wnt/beta-Catenin activation promotes prostate tumor progression in a mouse model.  Oncogene 30(16):1868-1879."
"4526","PC074031","Podgorski I.  2009.  Future of anticathepsin k drugs: Dual therapy for skeletal disease and atherosclerosis? Future Medicinal Chemistry 1(1):21-34."
"4527","PC074031","Podgorski I, Linebaugh BE, Koblinski et al.  2009.  Bone marrow- derived cathepsin K cleaves SPARC in bone metastasis.  Am J Pathol 175(3):1255-1269."
"4528","PC074038","Joshi MD, Ahmad R, Raina D, et al.  2009.  MUC1 oncoprotein is a druggable target in human prostate cancer cells.  Mol Cancer Ther 8:3056-3065."
"4529","PC074038","Rajabi H, Joshi MD, Jin C, et al.  2011.  Androgen receptor regulates expression of the MUC1-C oncoprotein in human prostate cancer cells.  Prostate 71(12):1299-1308."
"4530","PC074041","Zhaorigetu S, Wan G, Kaini R, et al.  2008.  ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death.  Autophagy 4(8):1079-82.

"
"4531","PC074041","Kaini RR, and Hu C-A.  2012.  Synergistic killing effect of chloroquine and androgen deprivation in LNCaP cells. Biochem Biophys Res Communications 425:150-156."
"4532","PC074041","Wan G, Zhaorigetu S, Liu Z, et al.  2008.  Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death.  J Biol Chem 283(31):21540-21549.

"
"4533","PC074048","Min J, Zaslavsky A, Fedele G, et al.  2010.  An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB.  Nat Med 16(3):286-294."
"4534","PC074075","Viswanath S, Palumbo D, Chappelow J, et al.  2011.  Empirical evaluation of bias field correction algorithms for computer-aided detection of prostate cancer on T2w MRI.  SPIE Medical Imaging 7963."
"4535","PC074075","Chappelow J, and Madabhushi A.  2011.  HistoStitcher©:  An interactive program for accurate and rapid reconstruction of digitized whole histological sections from tissue fragments.  Comput Med Imaging Graph 35(7-8):557-567."
"4536","PC074075","Xiao G, Bloch BN, Chappelow J, et al.  2010.  A structural-functional MRI-based disease atlas: Application to computer-aided-diagnosis of prostate cancer.  SPIE Medical Imaging 7623."
"4537","PC074075","Sparks R, Toth R, Chappelow J, et al.  2010.  An integrated framework for analyzing three-dimensional shape differences:  Evaluating prostate morphometry.  Proc IEEE Int Symp Biomed Imaging.  IEEE International Symposium on (ISBI) 1081-1084."
"4538","PC074075","Chappelow J, Both S, Viswanath S, et al.  2010.  Computer-assisted targeted therapy (CATT) for prostate radiotherapy planning by fusion of CT and MRI.  SPIE Medical Imaging 7625."
"4539","PC074075","Chappelow J and Madabhushi A.  2010.  Multi-attribute combined mutual information (MACMI):  An image registration framework for leveraging multiple data channels.  Proc IEEE Int Symp Biomed Imaging.  IEEE International Symposium on (ISBI)376-379."
"4540","PC074075","Viswanath S, Chappelow J, Patel P, et al.  2011.  Enhanced multi-protocol analysis via intelligent supervised embedding (EMPrAvISE):  Detecting prostate cancer on multi-parametric MRI.  SPIE Medical Imaging 7963.

"
"4541","PC074075","Chappelow J, Bloch N, Rofsky N, et al.  2011.  Elastic registration of multimodal prostate MRI and histology via multi-attribute combined mutual information.  Med Phys 38(4):2005-2018."
"4542","PC074075","Chowdhury N, Chappelow J, Toth R, et al.  2011.  Novel approach for building linked statistical shape models for multimodal prostate radiotherapy planning.  SPIE Medical Imaging 7963."
"4543","PC074077","Fortson WS, Kayarthodi S, Fujimura Y, et al.  2011.  Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in TMPRSS2-ERG positive prostate cancer cells.  Intl J of Oncology 39(1):111-119.

"
"4544","PC074101","Facompre ND, El-Bayoumy K, Sun YW, et al.  2010.  R. 1,4- phenylenebis (methylene) selenocyanate but not selenomethionine inhibits androgen receptor and Akt signaling in human prostate cancer cells.  Cancer Prev Res 3(8):975-984."
"4545","PC074103","Vinall RL, Mahaffey CM, Davis RR, et al.  2011.  Dual blockade of PKA and NF-kappaB Inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis.  Horm Cancer 2(4):224-238."
"4546","PC074104","Ko S, Shi L, Kim S, et al.  2008.  Interplay of NF-kappaB and B-myb in the negative regulation of androgen receptor expression by TNF alpha.  Mol Endocrinol 22(2):273-286.

"
"4547","PC074116","Caire AA, Sun L, Ode O, et al.  2009.  Delayed prostate-specific antigen recurrence after radical prostatectomy: How to identify and what are their clinical outcomes?  Urology 74(3):643-647."
"4548","PC074116","Stackhouse DA, Sun L, Schroeck FR, et al.  2009.  Factors predicting prostatic biopsy Gleason sum under grading.  J Urol 182(1):118-122."
"4549","PC074117","Radhakrishnan P, Lin M-F, and Cheng P-W.  2009.  Elevated expression of L-selectin ligand in lymph node-derived human prostate cancer cells correlates with increased tumorigenicity.  Glycoconj J 26(1):75-81."
"4550","PC074119","Li C-W, Ai N, Dinh GK, et al.  2010.  Human ADA3 regulates RAR-alpha transcriptional activity through direct contact between LxxLL motifs and the receptor coactivator pocket.  Nucl Acid Res 38:5291-5303."
"4551","PC074126","Leyton JV, Olafsen T, Lefin EJ, et al.  2008.  Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors.  Clin Cancer Res 14(22):7488-7496.

"
"4552","PC074126","
Leyton JV, Olafsen T, Sherman MA, et al.  2009.  Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors.  Protein Eng Des Sel 22(3):209-216.
"
"4553","PC074126","Lepin EJ, Leyton JV, Zhou Y, et. al.  2010.  An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors.  Eur J Nucl Med Mol Imaging 37(8):1529-1538."
"4554","PC074126","Knowles SM, Zettitz KA, Tavare R, et al.  2014.  Quantitiative immunoPET of prostate cancer xenografts with 89Zr- and 124l-labled anti-PSCA A11 minibody.  J Nucl Med 55(3):452-459."
"4555","PC074128","Marian CO, Yang L, Zhou Y, et al.  2011.  Evidence of epithelial to mesenchymal transition associated with increased tumorigenic potential in an immortalized normal prostate epithelial cell line.  Prostate 71:626-636."
"4556","PC074128","Marian CO, Wright WE, and Shay JW.  2010.  The effects of telomerase inhibition on prostate tumor-initiating cells.  Int J Cancer 127:321-331."
"4557","PC074128","Marian CO and Shay JW.  2009.  Prostate tumor-initiating cells: A new target for telomerase inhibition therapy? Biochim Biophys Acta 1792:289-296."
"4558","PC074133","Haga K, Tomioka A, Liao C-P, et al.  2009.  PTEN-knockout prostate cancer as a model for experimental immunotherapy.  J Urol 181:354-362."
"4559","PC074151","Sargeant AM, Rengel RC, Kulp SK, et al. 2008.  OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 68:399-4009."
"4560","PC074151","Berman-Booty LD, Sargeant AM, Rosol TJ, et al.  2012.  A review of the existing grading schemes and a proposal for a modified grading scheme for prostatic lesions in TRAMP mice.  Toxicol Pahtol 40:5-17."
"4561","PC074151","Weng J-R, Tsai C-H, Omar H, et al.  2009.  OSU-A9, a potent indole-3-carbinol derivative, suppresses breast tumor growth by targeting the Akt-NF-kB pathway and stress response signaling.  Carcinogenesis 30:1702-1709."
"4562","PC074151","Omar HA, Sargeant AM, Weng J-R, et al.  2009.  Targeting of the Akt-NF-kB signaling network by OSU-A9, a novel indole-3-carbinol derivative, in a mouse model of hepatocellular carcinoma.  Mol Pharmacol 76:957-968."
"4563","PC074171","Zhang C, Kallakury BV, Ross JS, et al.  2012.  The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence.  Int J Cancer 133(1):31-42. "
"4564","PC074201","Kerns SL, Stone NN, Stock RG, et al. 2013.  A Two-Stage Genome-Wide Association Study to Identify Single Nucleotide Polymorphisms Associated with Development of Urinary Symptoms Following Radiotherapy for Prostate Cancer. J Urol: 90(1):102-8."
"4565","PC074201","Kerns SL, Stock RG, Stone NN, et al. 2013. Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer. Radiother Oncol: 107(3):372-6."
"4566","PC074201","Rosenstein BS, Capala J, Efstathiou JA, et al. 2015. How Will Big Data Improve Clinical and Basic Research in Radiation Therapy? Int J Radiat Oncol Biol Phys. 95(3):895-904."
"4567","PC074201","Kerns S, Stock R, Stone N, et al.  2013.  A two-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of erectile dysfunction following radiotherapy for prostate cancer.  Int J Radiat Oncol Biol Phys 85(1):e21-28."
"4568","PC074201P1","Kerns SL, Ostrer H, Stock R, et al.  2010.  Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer.  Int J Radiat Oncol Biol Phys.  78(5):1292-1300.  "
"4569","PC074228","Gelman IH, Peresie J, Eng KH, et al. 2014. Differential requirement for Src family tyrosine kinases in the initiation, progression, and metastasis of prostate cancer. Mol Cancer Res.(10):1470-9. doi: 10.1158/1541-7786.MCR-13-0490-T. Epub 2014 Jul 22."
"4570","PC074228","Su B, Gillard B, Gao L, et al. 2013. Src controls castration recurrence of CWR22 prostate cancer xenografts. Cancer Med. (6):784-92. doi: 10.1002/cam4.144. Epub 2013 Oct 11."
"4571","PC074228","Gelman IH. 2014. Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases. Int J Biol Sci. 2014 Jun 5;10(6):620-6. doi: 10.7150/ijbs.8264. eCollection 2014."
"4572","PC074228","Gelman IH. 2016. How the TRAMP Model Revolutionized the Study of Prostate Cancer Progression. Cancer Res. 76(21):6137-6139."
"4573","PC074253","Putzke AP, Ventura AP, Bailey AM, et al.  2011.  Metastatic progression of prostate cancer and E-cadherin regulation by ZEB1 and SRC family kinases.  Am J Pathol 179(1):400-410."
"4574","PC074262","Badaan S and Stoianovici D.  2011.  Robotic system: Past, present and future.  In: Robotics in Genitourinary Surgery (Hemal AK and Menon M, Eds.)  Springer (1st Edition), pp 655-665."
"4575","PC074262","Stoianovici D, Kim C, Srimathveeravalli G, et al. 2013.  MRI-Safe robot for endorectal prostate biopsy. IEEE/ASME Transactions on Mechatronics 99:1-11."
"4576","PC074262","Macura KJ and Stoianovici D.  2009.  Advancements in magnetic resonance guided robotic interventions in the prostate.  Topics in Magnetic Resonance Imaging 19(6)."
"4577","PC074262","Mozer P, Troccaz J, and Stoianovici D.  2011.  Robotics in urology: Past, preset, and future.  In: Atlas of Robotic Urologic Surgery Volume 1 (Su LM, Ed.)  New York Springer, ISBN 978-1-60761-025-0;  pp 3-13."
"4578","PC074262","Huang CM, Kim C, Petrisor D, et al.  2010.  Partial volume artifact on prostate ultrasound imaging.  Journal of Endourology 24:2093-2157."
"4579","PC074262","Mozer P, Troccaz J, Stoianovici D.  2009.  Urologic robots and future directions.  Curr Opin Urol 19(1):114-119."
"4580","PC074262P1","Macura KJ, and Stoianovici D.  2008.  Advancements in magnetic resonance-guided robotic interventions in the prostate.  Top Magn Reson Imaging 19(6):297-304."
"4581","PC074262P1","Mozer P, Troccaz J, and Stoianovici D.  2011.  Robotics in urology: Past, preset, and future.  In: Atlas of Robotic Urologic Surgery, Volume 1 (Su LM, Ed.).  New York Springer ISBN 978-1-60761-025-0; Pages 3-13."
"4582","PC074262P1","Stoianovici D, Kim C, Srimathveeravalli G, et al.  2013.  MRI-safe robot for transrectal prostate biopsy.  IEEE/ASME Transactions on Mechatronics."
"4583","PC074262P1","Mozer P, Troccaz J and Stoianovici D.  2009.  Urologic robots and future directions.  Curr Opin Urol 19(1):114-119."
"4584","PC074262P1","Badaan S and Stoianovici D.  2011.  Robotic system: Past, present and future.  In: Robotics in Genitourinary Surgery, 1st Edition (Hemal AK and Menon M, Eds.).  Springer ISBN 978-1-84882-113-2, Pages 655-665."
"4585","PC074289","Chou Y-W, Chaturvedi NK, Ouyang S, et al.  2011.  Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells.  Cancer Lett 311(2):177-186."
"4586","PC074289","Zhang, L, Davis, JS, Zelivianski, S. et al. 2009. Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by Gemcitabine in an androgen-reduced environment. Cancer Letters 285, 58-65."
"4587","PC074289","Chuang T-D, Chen S-J, Lin F-F, et al.  2010.  Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth.  J Biol Chem 285(31):23598--23606."
"4588","PC074289","Veeramani S, Chou Y-W, Lin FC, et al.  2012.  Reactive oxygen species induced by p66Shc longevity protein mediate nongenomic androgen action via tyrosine phosphorylation signaling to enhance tumorigenicity of prostate cancer cells.  Free Radical Biology and Medicine 53:95-108."
"4589","PC074289P1","Mimeault M and Batra S.  2011.  Animal models relevant to human prostate carcinogenesis underlining the critical implication of prostatic stem/progenitor cells.  Biochimica et Biophysica Acta 1816:25-37."
"4590","PC074289P1","Chuang T-D, Chen S-J, Lin F-F, et al.  2010.  Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth.  J Biol Chem 285(31):23598--23606.

"
"4591","PC074289P1","Mimeault M and Batra SK.  2011.  Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies.  Mol Med 17:949-964."
"4592","PC074289P1","Mimeault M, Johansson SL, Henichart J-P, et al.  2010.  Cytotoxic effects induced by docetaxel, gefitinib and cyclopamine on side population and non-side population cell fractions from human invasive prostate cancer cells.  Mol Cancer Ther 9(3):617-630."
"4593","PC074307","Johnson LA, Kanak MA and Kajdacsy-Balla.  2010.  Differential zinc accumulation and expression of human zinc transporter 1 (hZIP1) in prostate glands.  Methods 52(4):316-321."
"4594","PC074307P1","Sarafanov AJ, Todorov TI, Centeno JA, et al.  2011.  Prostate cancer outcome and tissue levels of metal ions.  Prostate 71:1231-1238.

"
"4595","PC074307P1","Costello L Levy B, Desouki M, et al.  2011.  Decreased zinc and downregulation of ZIP3 zinc uptake transporter in the development of pancreatic adenocarcinoma.  Cancer Biol Ther 12:297-303."
"4596","PC074307P1","Johnson LA, Kanak M, Kajdacsy-Balla A, et al.  2010.  Differential zinc accumulation and expression of human zinc transporter 1 (hZIP1) in prostate glands.  Methods 52:316-321."
"4597","PC074307P1","Mihelich BL, Khramtsova EA, Arva N, et al.  2011.  miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells.  J Biol Chem 286(52):44503-44511."
"4598","PC074307P1","Franklin RB, Levy BA, Zou J, et al. 2012.  ZIP14 zinc transporter downregulation and zinc depletion in the development and progression of hepatocellular cancer.  J Gastrointest Cancer 43:249-257."
"4599","PC074317","Tang X, Gal J, Kyprianou N et al.  2011.  Detection of microRNAs in prostate cancer cells by microRNA array.  Methods in Molecular Biology: MicroRNAs in Development 732:69-88."
"4600","PC074317","Zhu H, Zhao J, Zhu B et al.  2012.  EMMPRIN regulates cytoskeleton reorganization and prostate cancer cell invasion.  Prostate 72(1):72-81."
"4601","PC074317","Martin SK, Vaughan TB, Atkinson T, et al.  2012.  Prostate cancer biomarker update.  Oncology Reports 28:409-417."
"4602","PC074317P1","Zhu H, Zhao J, Zhu B, et al.  2012.  EMMPRIN regulates cytoskeleton reorganization and prostate cancer cell invasion. Prostate 72(1):72-81. "
"4603","PC074317P1","Martin SK, Vaughan TB, Atkinson T, et al.  2012.  Emerging biomarkers of prostate cancer. Oncology Reports 28:409-417."
"4604","PC074317P1","Desiniotis A and Kyprianou N.  2011.  Significance of talin in cancer progression and metastasis.  Int Rev Cell Mol Biol 4(289):117-147. "
"4605","PC074317P1","Tang X, Tang X, Gal J, et al.  2011.  Detection of microRNAs in prostate cancer cells by microRNA array.  Methods Mol Biol 732:69-88.  "
"4606","PC074348","Hannan R, Tumati V, Xie XJ, et al. 2016. Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial. Eur J Cancer. 2016 May;59:142-51."
"4607","PC074348","Kim DN, Straka C, Cho LC, et al. 2017. Early and multiple PSA bounces can occur following high-dose prostate stereotactic body radiation therapy: Subset analysis of a phase 1/2 trial. Pract Radiat Oncol. 2017 Jan - Feb;7(1):e43-e49."
"4608","PC074348","Kim DW, Cho LC, Straka C, et al. 2014. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):509-17."
"4609","PC074348","Kim DW, Straka C, Cho LC, et al. 2014. Stereotactic Body Radiation Therapy for Prostate Cancer: Review of Experience of a Multicenter Phase I/II Dose-Escalation Study. Front Oncol. Nov 26;4:319."
"4610","PC074348","Jones BL, Gan G, Diot Q, et al. 2012. Dosimetric and deformation effects of image-guided interventions during stereotactic body radiation therapy of the prostate using an endorectal balloon. Med Phys. 2012 Jun;39(6):3080-8."
"4611","PC074348","Boike TP, Lotan Y, Cho LC, et al.  2011.  Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer.  J Clin Oncol 29:2020-2026."
"4612","PC080010","Wei J, Wu X, Peng Y, et al.  2011.  Regulation of HMGA1 expression by microRNA296 affects prostate cancer growth and invasion.  Clin Cancer Res 17(6):1297-1305."
"4613","PC080010","Koscuiszka M, Hatcher D, Christos PJ et al.  2012.  Impact of race on survival in patients with clinically nonmetastatic prostate cancer who deferred primary treatment.  Cancer 118(2):3145-3152."
"4614","PC080010","Daniels G, Jha R, Logan S, et al.  2014.  Androgen receptor coactivators that inhibit prostate cancer.  Am J Clin Experimental Urology 6(4):329-339."
"4615","PC080010","Daniels G, Pei Z, Logan S, et al.  2014.  Androgen receptor phosphorylation in prostsate cancer.  Am J Clin Experimental Urology 1(1):25-29."
"4616","PC080010","Singh M, Jia R, Melamed J, et al.  2014.  Stromal androgen receptor in prostate development and cancer.  Am J Path 184(10):2598-2607."
"4617","PC080010","Daniels G, Gellert LL, Zhou A, et al.  2014.  TBLR1 as an AR coactivator selectively activates AR target genes tso inhibit prostate cancer growth.  Endocrine Related Cancer 21(1):127-142."
"4618","PC080010","Singh M, Daniels D, Li Y, et al.  2013.  Expression and function of stromal androgen receptor in prostate cancer.  In: Advances in Prostate Cancer (Hamilton G, Ed.).  InTech Publishers, first edition. doi: 10.5772/45948.  Chapter 19."
"4619","PC080010","Wu X, Gong S, Roy-Burman P, et al.  2013.  Current animal and cell models in prostate cancer research.  Endocrine Related Cancer 20(4):R155-70."
"4620","PC080010","Li Y, Tian L, Ligr M, et al.  2013.  Functional domains of androgen receptor coactivator p44/Mep50/WDR77 and its interaction with Smad1.  PLoS One 8(5):e64663."
"4621","PC080010","Li Y, Zhang DY, Ren Q, et al.  2012.  Regulation of a novel androgen receptor target gene, the cyclin B1 gene, through androgen-dependent E2F family member switching.  Mol Cell Biol 32(13):2454-2466."
"4622","PC080010","Daniels G, Gellert LL, Melamed M, et al.  2014.  Decreased stromal estrogen receptor alpha and beta in prostate cancer.  Am J Trans Res 6(2):140-146."
"4623","PC080024","Sun T, Lee GS, Oh WK, et al.  2011.  Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort.  Clin Cancer Res 17:1546-1552."
"4624","PC080038","Cole G, Harrington K, Su H, et al.  2011.  Closed-loop actuated surgical system utilizing real-time in-situ MRI guidance.  In:  Springer Tracts in Advanced Robotics (Khatib O, Kumar V, Sukhatme G, Springer-Verlag, Eds.)."
"4625","PC080038","Su H, Camilo A, Cole GA, et al.  2011.  High-field MRI compatible needle placement robot for prostate interventions.  Stud Health Technol Inform 623-629."
"4626","PC080038","Su H and Fischer GS.  2012.  High-field MRI-compatible needle placement robots for prostate interventions:  In:  Pneumatic and Piezoelectric Approaches (Gulrez T and Hassanien A, Eds.). Advances in Robotics and Virtual Reality, Springer-Verlag, Intelligent Systems Reference Library 26:3-32.

"
"4627","PC080038","Tokuda J, Fischer GS, DiMaio SP, et al.  2010.  Integrated navigation and control software system for MRI-guided robotic prostate interventions.  Comput Med Imaging Graph 34(1):3-8."
"4628","PC080038","Tokuda J, Fischer GS, Papademetris X, et al.  2009.  OpenIGTLink: An open network protocol for image-guided therapy environment.  Int J Med Robot 5(4):423-434. "
"4629","PC080062","Ozawa MG, CardÃ³-Vila M, Mintz PJ, et al.  2010.  Cracking the code for compartment-specific dual functionality proteins in cancer: the case of CRKL.  Cell Cycle 9:8-9."
"4630","PC080074","Xu S and Zhang W.  2011.  Loss of EGFR autophagy sensitizes hormone refractory prostate cancer cells to adriamycin.  The Prostate 71:1216-1224."
"4631","PC080074","Bollu RL, Ren J, Chen J, et al.  2012.  Epidermal growth factor receptor in prostate cancer cells.  In Detection, Growth and Treatment of Prostate Cancer.  Nova Publishers pp 147-160."
"4632","PC080074","Blessing A, Xu L, Gao G, et al.  2012.  Sodium/glucose co-transporter 1 expression increases in human diseased prostate.  J Cancer Sci Ther 4:306-312."
"4633","PC080074","Ren J, Bollu LR, Su F, et al.  2013.  EGFR- SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors.  Prostate 73(13):1453-1461."
"4634","PC080117","Oliver JS, Worley C, DeCoster J, et al.  2012. Disparities in colorectal cancer screening behaviors: Implications for African American men.  Gastroenterol Nurs 35(2):93-98.

"
"4635","PC080117","Pisu M, Oliver JS, Kim Y-I, et al.  2010.  Treatment for older prostate cancer patients: Disparities in a southern state.  Med Care 48(10):915-922."
"4636","PC080135","Rodriguez,E, Aburjania N, Priedigkeit,NM, et al.  2010.  Nucleo-cytoplasmic localization domains regulate krÃ¼ppel-like factor 6 (KLF6) protein stability and tumor suppressor function. PLoS ONE 5(9)."
"4637","PC080135","Rodríguez E and Martignetti JA.  2009.  The Krüppel traffic report: Cooperative signals direct KLF8 nuclear transport.  Cell Res 19(9):1041-1043."
"4638","PC080147","Dhillon PK, Kenfield SA, Stampfer MJ, et al.  2011.  Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006.  Int J Cancer 128(10):2444-2452."
"4639","PC080147","Nimptsch K, Kenfield SA, Jensen MK, et al.  2011.  Dietary glycemic index, glycemic load, insulin index, fiber and whole-grain intake in relation to risk of prostate cancer.  Cancer Causes Control 22(1):51-61."
"4640","PC080147","Wilson KM, Kasperzyk JL, Rider JR, et al.  2011.  Coffee consumption and prostate cancer risk and progression in the health professionals follow-up study.  J Natl Cancer Inst 103(11):876-884."
"4641","PC080147","Kasperzyk JL, Shappley WV 3rd, Kenfield SA, et al.  2011.  Watchful waiting and quality of life among prostate cancer survivors in the physicians' health study.  J Urol 186(5):1862-1867.

"
"4642","PC080147","Kenfield SA, Stampfer MJ, Giovannucci E, et al.  2011.  Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study.  J Clin Oncol 29(6):726-732."
"4643","PC080147","Platz EA, Yegnasubramanian S, Liu JO, et al.  2011.  A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment.  Cancer Discovery 1(1):68-77.

"
"4644","PC080147","Richman EL, Kenfield SA, Stampfer MJ, et al.  2011.  Physical activity after diagnosis and risk of prostate cancer progression: Data from the cancer of the prostate strategic urologic research endeavor.  Cancer Res 71(11):3889-3895."
"4645","PC080147","Kenfield SA, Stampfer MJ, Chan JM, et al.  2011.  Smoking and prostate cancer survival and recurrence.  JAMA 305(24):2548-2555.

"
"4646","PC080154","Nakabayashi M, Hayes JH, Taplin ME, et al.  2013.  Clinical predictors of survival in men with castration-resistant prostate cancer: Evidence that gleason score 6 cancer can evolve to lethal disease.  Cancer 119(16):2990-2998."
"4647","PC080154","Hayes JH, Barry MJ, and McMahon PM.  2013.  Observation versus initial treatment for prostate cancer.  Ann Intern Med 159(8):574."
"4648","PC080154","Hayes JH, Ollendorf DA, Pearson SD, et al.  2013.  Observation versus initial treatment for men with localized, low-risk prostate cancer: A cost-effectiveness analysis.  Ann Intern Med 158(12):853-860."
"4649","PC080154","Hayes JH, Ollendorf DA, Pearson SD, et al.  2010.  Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.  JAMA 304 (21):2373-2380.

"
"4650","PC080160","Jiang M, Strand DW, Fernandez S, et al.  2010.  Functional remodeling of benign human prostatic tissues in vivo by spontaneously immortalized progenitor and intermediate cells.
Stem Cells 28(2):344-356.
"
"4651","PC080160","Barron D, Strand D, Ressler SJ, et al.  2010.  TGF-beta1 induces an age-dependent inflammation of nerve ganglia and fibroplasia in the prostate gland stroma of a novel transgenic mouse.  PLoS One 5(10):e13751.

"
"4652","PC080160","Jiang M, Min YF, DeBusk L, et al.  2010.  Spontaneous immortalization of human dermal microvascular endothelial cells.  World J Stem Cells 2(5):114-120."
"4653","PC080160","Franco OE, Jiang M, Strand DW, et al.  2011.  Altered TGF-beta signaling in a subpopulation of stromal cells promotes prostate carcinogenesis.  Cancer Res 71(4):1272-1281."
"4654","PC080160","Jiang M, Strand DW, Franco OE, et al.  2011.  PPAR Gamma: A molecular link between systemic metabolic disease and benign prostate hyperplasia.  Differentiation 82(4-5):220-236."
"4655","PC080160","Strand DW and Hayward SW.  2010.  Modeling stromal-epithelial interactions in disease progression.  Discov Med 9(49):504-511.
"
"4656","PC080160","Strand DW, Basanta D, Franco OE, et al.  2010.  Perspectives on tissue interactions in development and disease.  Curr Mol Med 10(1):95-112."
"4657","PC080160","Franco OE, Shaw AK, Strand DW, et al.  2010.  Cancer associated fibroblasts in cancer pathogenesis.  Semin Cell Dev Biol 21(1):33-39."
"4658","PC080174","Priceman SJ, Sung JL, Shaposhnik Z, et al.  2010.  Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: Combating tumor evasion of anti-angiogenic therapy.  Blood 115(7):1461-1471."
"4659","PC080176","Manning ML, Kostova M, Williams SA, et al.  2012.  Trypsin-like proteolytic contamination of commercially available PSA purified from human seminal fluid.  Prostate 72(11):1233-1238."
"4660","PC080184","Mack JT, Helke KL, Normand G, et al.  2011.  ABCA2 transporter deficiency reduces incidence of TRAMP prostate tumor metastasis and cellular chemotactic migration.  Cancer Lett 300(2):154-61."
"4661","PC080184","Norell H, Martins da Palma T, Lesher A, et al.  2009.  Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1 (27-35)-reactive T cells from activation-induced cell death.  Cancer Res 69(15):6282-6289."
"4662","PC080184","Ford ME, Wahlquist AH, Blake R, et al.  2012.  Assessing an intervention to improve clinical trial perceptions among predominantly African American communities in South Carolina.  Progress in Community Health Partnerships: Research Education and Action 6:249-263."
"4663","PC080189","Antonarakisa ES, Heath EI, Smith DC, et al.  2013.  Repurposing itraconazole as a treatment for advanced prostate cancer: A noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer.  The Oncologist 18:163-173."
"4664","PC080189","Harzstark AL, Rosenberg JE, Weinberg VK, et al.  2011.  Ixabepilone, mitoxantrone, and prednisone for metastatic castration resistant prostate cancer after docetaxel-based therapy: A phase 2 study of the Department of Defense Prostate Cancer Clinical Trials Consortium.  Cancer 117(11):2419-2425."
"4665","PC080189","Ward JE, Karrison T, Chatta G, et al.  2012.  A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: A University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.  Prostate Cancer Prostatic Dis 15:87-92."
"4666","PC080189","Alva A, Slovin S, Carducci M, et al.  2012.  Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study DOD/PCF prostate cancer clinical trials consortium.  Invest New Drugs 30(2):749-757."
"4667","PC080189","Bradley DA, Daignault S, Ruan CJ, et al.  2010.  Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.  Invest New Drugs (c05-010).

"
"4668","PC080189","Rosenberg J, Ryan C, Weinberg VK, et al.  2009.  Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy:  A study of the Department of Defense prostate cancer clinical trials consortium.  J Clin Oncol 2772-2778 (c05-008)."
"4669","PC080189","Smith DC, Smith MR, Sweeney C, et al.  2013.  Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.  J Clin Oncol 31(4):412-419."
"4670","PC080189","Bradley D, Rathkoppf D, Dunn R, et al.  2009.  Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): Trial results and interleukin-6 analysis:  A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium.  Cancer 115(23):5541-5549 
(c05-009).
"
"4671","PC080189","Dreicer R, Garcia J, Hussain M, et al.  2010.  Oral enzastaurin in prostate cancer: A two cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based therapy.  Invest New Drugs (c07-009).
"
"4672","PC080193","Evaul K, Li R, Papari-Zareei M, et al.  2010.  3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer.  Endocrinology 151(8):3514-3520."
"4673","PC080193","Sharifi N, McPhaul MJ, and Auchus RJ.  2010.  'Getting from here to there' - Mechanisms and limitations to the activation of the androgen receptor in castration-resistant prostate cancer.  J Investig Med 58(8):938-944."
"4674","PC080193","Chang K-H, Li R, Papari-Zareei M, et al.  2011.  Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer.  Proc Natl Acad Sci U S A.  108(33):13728-13733."
"4675","PC080193","Li R, Evaul K, Sharma KK, et al.  2012.  Abiraterone inhibits 3b-hydroxysteroid dehydrogenase: A rationale for increasing drug exposure in castration-resistant prostate cancer.  Clin Cancer Res 18(13):3571-3579."
"4676","PC080193","Chang KH, Li R, Kuri B, et al.  2013.  A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer.  Cell 154(5):1074-1084."
"4677","PC080193","Thomas R and Sharifi N.  2012.  SOD mimetics: A novel class of adrogen receptor inhibitors that suppresses castration-resistant growth of prostate cancer.  Mol Cancer Ther 11(1):87-97."
"4678","PC080196","Yong T, Sun A, Henry MD, et al.  2011.  Down regulation of CSL activity inhibits cell proliferation in prostate and breast cancer cells.  J Cell Biochem 112:2340-2351."
"4679","PC080196","Davis JN, Rogers D, Adams L, et al.  2010.  Association of core binding factor-beta with the malignant phenotype of prostate and ovarian cancer cells.  J Cell Physiol 225(3):875-87."
"4680","PC080203","Chou CK, Schietinger A, Liggitt HD, et al.  2012.  Cell-Intrinsic abrogation of TGF-beta signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T Cells in a murine model of autochthonous prostate cancer.  J Immunol 189:3936-3946."
"4681","PC080209","Lee GT, Kwon SJ, Lee J-H, et al.  2011.  Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6-IL6 loop.  Prostate 71:1525-1537."
"4682","PC080209","Lee GT, Kwon SJ, Lee J-H, et al.  2010.  Induction of IL-6 expression by BMP-6 in macrophages requires both Smad and p38 signaling pathways.  J Biol Chem 285:39401-39408."
"4683","PC080214","Szmulewitz RZ, Clark R, Lotan T, et al.  2012.  MKK4 suppresses metastatic colonization by multiple highly metastatic prostate cancer cell lines through a transient impairment in cell cycle progression.  Int J Cancer 130(3):509-520."
"4684","PC080258","Schaufele F.  2014.  Maximizing the quantitative accuracy and reproducibility of Förster resonance energy transfer measurement for screening by high throughput widefield microscopy.  Methods 66(2):188-199."
"4685","PC080258","Krylova I, Kumar RR, Kofoed EM, et al.  2013.  A versatile, bar-coded nuclear marker/reporter for live cell fluorescent and multiplexed high content imaging.  PLoS One  8(5):e63286"
"4686","PC080262","Lee C, Zhang Q, Kozlowski J, et al.  2013.  Natural products and transforming growth factor-beta (TGF-beta) signaling in cancer development and progression.  Curr Cancer Drug Targets 13(5):500-505."
"4687","PC080262","Zhang Q, Helfand BT, Jang TL, et al.  2009.  NF-kB-Mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.  Clin Cancer Res 19:128-139."
"4688","PC080262","Principe DR, Doll JA, Bauer J, et al.  2014.  TGF-beta: Duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst 106(2):djt369."
"4689","PC080262","Yu N, Kozlowski JM, Park II, et al.  2010.  Over-expression of transforming growth factor beta-1 in malignant prostate cells is partly caused by a runaway of TGF-beta-1 auto-induction mediated through a defective recruitment of protein phosphatase 2A by TGF-beta type I receptor.  Urology 76(6):1519.e8-13."
"4690","PC080262","Zhang Q, Chen L, Helfand BT, et al.  2011.  Transforming growth factor-beta-induced DNA methyltransferase contributes to aggressive prostate cancer phenotypes and predicts biochemical recurrence after radical prostatectomy.  PLoS ONE 6(9): e25168."
"4691","PC080275","Tai W, Shukla RS, Qin B, et al.  2011.  Development of a peptide-drug conjugate for prostate cancer therapy.  Mol Pharm 8(3):901-912."
"4692","PC080275","Zhao Y, Duan S, Zeng X, et al.  2012.  Pro-drug strategy for PSMA targeted delivery of TGX-221 to prostate cancer cells.  Mol Pharm 9(6):1705-1716."
"4693","PC080285","Williams AB, Weiser PT, Hanson RN et al.  2009.  Synthesis of biphenyl proteomimetics as estrogen receptor-alpha coactivator binding inhibitors.  Org Lett 11(23):5370-5373."
"4694","PC080315","Chinni S, Singareddy R, Semaan L, et al.  2013.  Transcriptional regulation of CXCR4 in prostate tumor cells: Significance of TMPRSS2-ERG fusions.  Mol Cancer Res 11(11):1349-1361."
"4695","PC080315","St. John J, Powell K, Conley-LaComb M, et al.  2012.  TMPRSS2-ERG fusion gene expression in prostate tumor cells and its clinical and biological significance in prostate cancer progression.  J Cancer Sci Ther 4(4):94-101."
"4696","PC080315","Cai J, Kandagatla P, Singareddy R, et al.  2010.  Androgens induce functional CXCR4 via ERG factor expression in TMPRSS2-ERG fusion positive prostate cancer cells.  Transl Oncol 3(3):195-203.


"
"4697","PC080315","Conley-LaComb MK, Saliganan A, Kandagatla P, et al.  2013.  PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.  Mol Cancer 12(1):85."
"4698","PC080318","Shi Y-K, Yu YP, Tseng GC, et al.  2010.  Inhibition of prostate cancer growth and metastasis using small interference RNA specific for minichromosome complex maintenance component 7.   Cancer Gene Ther 17(10):694-699.

"
"4699","PC080321","Studen A, Brzezinski K, Chesi E, et al.  2013.  Silicon detectors for combined MR-PET and MR-SPECT imaging.  Nucl Ins Meth Phys Res A 702:88-90."
"4700","PC080321P1","Lacasta C, Clinthorne NH, and Llosa G.  2011.  The PET Magnifier Probe.  In:  Radiation Physics for Nuclear Medicine (Cantone MC, and Hoeschen C, Eds.).  Springer, Chapter 11."
"4701","PC080321P1","Clinthorne N, Cochran E, Chesi E, et al.  2012.  A high-resolution PET demonstrator using a silicon 'magnifying glass'.  Physics Procedia 37:1488-1496."
"4702","PC080321P1","Studen A, Brzezinski K, Chesi E, et al.  2013.  Silicon detectors for combined MR-PET and MR-SPECT imaging.  Nucl Instrum Methods Phys Res A 702:88-90."
"4703","PC080321P1","Clinthorne N, Brzenzinski K, Chesi E, et al.  2013.  Silicon as an unconventional detector in positron emission tomography.  Nucl Ins Meth Phys Res A 699:216-220."
"4704","PC080349","Hsia DA, Tepper CG, Pochampalli MR, et al.  2010.  KDM8, a H3K36me2 histone demethylase that acts in the cyclin A1 coding region to regulate cancer cell proliferation.  Proc Natl Acad Sci U S A 107(21):9671-9676."
"4705","PC080355","Jayachandran J, Aronson WJ, Terris MK et al.  2010.  Diabetes and outcomes after radical prostatectomy -- Are results affected by obesity and race? Results from the SEARCH database.  Can Epi Bio Prev 19:9-17."
"4706","PC080355","Keto CJ, Aronsno WJ, Terris MK, et al.  2012.  Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: Results from the SEARCH database.  BJU Int 110(4):492-498."
"4707","PC080363","Lu B, Asara JM, Sanda MG, et al.  2011.  The role of the transcription factor SIM2 in prostate cancer.  PLoS One 6(12):e28837. "
"4708","PC080363","Kissick HT, Sanda MG, Dunn LK, et al.  2014. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response. PLoS One. 9(4):e93231."
"4709","PC080363","Arredouani MS, Tseng-Rogenski SS, Hollenbeck BK, et al.  2010.  Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice.  Prostate 70(9):1002-1011.

"
"4710","PC080363","Arredouani MS, Lu B, Bhasin M, et al. 2009.  Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer.  Clin Cancer Res 15(18):5794-5802.
"
"4711","PC080377","Wang Z, Fukushima H, Gao D, et al.  2011.  The two faces of Fbw7 in cancer drug resistance.  BioEssays 33(11):851-859."
"4712","PC080377","Wang Z, Gao D, Fukushima H, et al.  2011.  Skp2: A novel potential therapeutic target for prostate cancer.  Biochim Biophys Acta 1825(1):11-17.

"
"4713","PC080377","Wan L, Zou W, Gao D, et al.  2011.  Cdh1 regulates osteoblast function through an APC/C-independent modulation of Smurf1.  Mol Cell 44(5):721-733."
"4714","PC080377","Gao D, Inuzuka H, Tan M, et al.  2011.  mTOR drives its own activation via SCFb- TRCP-dependent degradation of the mTOR inhibitor DEPTOR.  Mol Cell 44(2):290-303."
"4715","PC080377","Shaik S, Nucera C, Inuzuka H, et al.  2012.  SCF-beta-TRCP suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF-Receptor-2.  J Experimental Med 209(7):1289-1307."
"4716","PC080377","Wang Z, Inuzuka H, Fukushima H, et al.  2011.  The emerging function of the Fbw7 tumor suppressor in stem cell differentiation.  EMBO Report 13:36-43."
"4717","PC080377","Inuzuka H, Gao D, Finley L, et al.  2012.  Acetylation-dependent regulation of Skp2 function.  Cell 150(1):179-193."
"4718","PC080377","Wang G, Wang Z, Sarkar FH, et al.  2012.  Targeting prostate cancer stem cells for cancer therapy.  Discovery Medicine 13:135-142 "
"4719","PC080377","Inuzuka H, Shaik S, Onoyama I, et al.  2011.  SCFFbw7 regulates cellular apoptosis by targeting the Mcl-1 oncoprotein for ubiquitination and destruction.  Nature 471:104-109."
"4720","PC080400","Chiam K, Ryan NK, Ricciardelli C, et al.  2013.  Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers.  Prostate 73(2):182-193.

"
"4721","PC080400","Philp LK, Butler MS, Hickey TE, et al.  2013.  SGTA: A new player in the molecular co-chaperone game.  Horm Cancer 4(6):343-357."
"4722","PC080400","Day TK, Chiam K, and Bianco-Miotto T.  2013.  Recent updates on epigenetic biomarkers for prostate cancer.  In: Epigenetics and Cancer (Sarkar F, Ed.)."
"4723","PC080400","Day TK and Bianco-Miotto T.  2013.  Common gene pathways and families altered by DNA methylation in breast and prostate cancer.  Endocr Relat Cancer 20(5):R215-32."
"4724","PC080412","Song JH and Kraft AS.  2012.  Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737.  Cancer Res 72: 294-303."
"4725","PC080412","Beharry Z, Mahajan S, Zemskova M, et al.  2011.  The Pim protein kinases regulate energy metabolism and cell growth.  PNAS 108:528-533."
"4726","PC080412","Cen B, Sandeep M, Zemskova M, et al.  2010.  Regulation of SKP2 levels by the PIM-1 Protein Kinase.  J Biol Chem 285:29128-29137."
"4727","PC080421","Higano CS, Beer TM, Taplin ME, eet al.  2015.  Long-term safety and antitumor activity in the Phase 1-2 study of enzalutamide in pre- and postdocetaxel castration-resistant prostate cancer.  Eur Urol 68(5):795-801."
"4728","PC080421","Anand A, Scher HI, Beer TM, et al.  2010.  Circulating tumor cells and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer treated with MDV3100.  J Clin Oncol 28:7s."
"4729","PC080421","Scher HI, Beer TM, Higano CS, et al.  2010.  Antitumour activity of MDV3100 in castration-resistant prostate cancer.  Lancet 24;375(9724):1437-1446."
"4730","PC080421","Ryan CJ, Smith MR, Logothetis C, et al.  2010.  Median time to progression in chemotherapy (chemo)-naive patients with castration-resistant prostate cancer treated with abiraterone acetate and low-dose prednisone (Pred).  J Clin Oncol 28:7s."
"4731","PC080421","Lin J, Zahurak M, Beer TM, et al.  2011.  A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.  Urol Oncol 31(5):581-588."
"4732","PC080421","Ryan CJ, Shah SK, Efstathiou E, et al.  2011. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.  Clin Cancer Res 17(14):4854-4861."
"4733","PC080421","Zurita AJ, George DJ, Shore ND, et al.  2012.  Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: A phase 1/2 clinical trial.  Ann Oncol 23(3):688-694.

"
"4734","PC080421","Araujo JC, Mathew P, Armstrong AJ, et al.  2012.  Dasatinib combined with docetaxel for castration-resistant prostate cancer: Results from a phase 1-2 study.  Cancer 118(1):63-71."
"4735","PC080421","Smith MR, Sweeney CJ, Corn PG, et al.  2014.  Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: Results of a phase II nonrandomized expansion study.  J Clin Oncol 32(30):3391-3399."
"4736","PC080421","Hussain M, Corn PG, Michaelson MD, et al.  2014.  Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen.  Clin Cancer Res 20(16):4218-4227."
"4737","PC080421","Morris MJ, Molina A, Small EJ, et al.  2015.  Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.  J Clin Oncol 33(12):1356-1363."
"4738","PC080421","Corn PG, Song DY, Heath E, et al.  2013.  Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study.  Int J Radiat Oncol Biol Phys 86(3):540-545."
"4739","PC080421","Smith DC, Smith MR, Sweeney C, et al.  2013.  Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial.  J Clin Oncol 31(4):412-419."
"4740","PC080429","Casavant BP, Guckenberger DJ, Berry SM, et al.  2013.  The VerIFAST: An integrated method for cell isolation and extracellular/intracellular staining.   Lab on a Chip 13(3):391-396."
"4741","PC080429","Warrick J, Casavant B, Frisk M, et al.  2010.  A microfluidic cell concentrator.  Anal Chem 82(19):8320-8326."
"4742","PC080429","Casavant BP, Mosher R, Warrick JW, et al.  2013.  A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells.  Methods 64(2):137-143.

"
"4743","PC080429","Bischel L, Casavant B, Young P, et al. 2014.  A combined microfluidic coculture and multiphoton FAD analysis assay enables insight into the influence of the bone microenvironment on prostate cancer cells.  Integrative Biol (Camb) 6(6):627-635."
"4744","PC080439","Ni L, Yang CS, Gioeli D, et al.  2010.  FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells.  Mol Cell Biol (5):1243-1253."
"4745","PC080441","Fernandez-Marcos PJ, Abu-Baker S, Joshi J, et al.  2009.  Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF-B activation and invasive prostate carcinoma.  Proc Natl Acad Sci U S A 106:12962-12967.  "
"4746","PC080441","Diaz-Meco MT, and Moscat J.  2012.  The atypical PKCs in Inflammation: NF-kappaB and beyond (Review).  Immunol Rev 246(1):154-167.

"
"4747","PC080441","Moscat J, Diaz-Meco MT, and Wooten MW.  2009.  Of the atypical PKCs, Par-4 and p62: Recent understandings of the biology and pathology of a PB1-dominated complex.  Cell Death Differ 16(11):1426-1437."
"4748","PC080441","Diaz-Meco MT and Abu-Baker S.  2009.  The Par-4/PTEN connection in tumor suppression.  Cell Cycle 8(16):2518-2522.

"
"4749","PC080441","Kim JY, Valencia T, Abu-Baker S, et al. 2013. c-Myc Phosphorylation by PKC Represses Prostate Tumorigenesis.  Proc Natl Acad Sci USA 110(16):6418-23.  doi:  10.1073/pnas.1221799110."
"4750","PC080443","Petrylak DP, Gandhi JG, Clark WR, et al.  2012.  Phase I results from a phase I/II study of orteronel, and oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone in metastatic castration-resistant prostate cancer.  J Clin Oncol 30 (suppl; abstr 4656)."
"4751","PC080443","Yu EY, Wilding G, Posadas E, et al.  2009.  Phase II study of Dasatinib in patients with metastatic castration-resistant prostate cancer.  Clin Cancer Res 1;15(23):7421-7428."
"4752","PC080443","Rathkopf DE, Shore N, Antonarakis ES, et al.  2012.  A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer.  J Clin Oncol 30 (suppl; abstr TPS4607)."
"4753","PC080443","Antonarakis ES, Heath El, Posadas EM, et al.  2012.  A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.  Cancer Chemother Pharmacol 71(4):883-892."
"4754","PC080443","Rathkopf D, Picus J, Hussain A, et al.  2013.  A phase II study of I.V. panobinostat in patients with metastatic hormone refractory prostate cancer.  Cancer Chemother Pharmacology (in press)."
"4755","PC080443","Heath EI, Stein MN, Vaishampayan UN, et al.  2013.  Phase II trial of single-agent ganetespib (STA-9090), a heat shock protein 90 (Hsp90) inhibitor in heavily pretreated patients with metastatic castration-resistant prostate cancer post docetaxel-based chemotherapy: Results of a prostate cancer clinical trials consortium (PCCTC) study.  J Clin Oncol 31 (suppl; abstr 5085)."
"4756","PC080443","Heath EI, Mannuel HD, Liu G, et al.  2013.  Randomized phase II trial of docetaxel and prednisone with or without AZD2171 (Cediranib), in chemotherapy-naïve, metastatic castration-resistant prostate cancer.  J Clin Oncol 31 (suppl 6; abstr 38)."
"4757","PC080443","Smith MR, Antonarakis ES, Ryan CJ, et al.  2013.  ARN-509 in men with high-risk nonmetastatic castration-resistant prostate cancer.  J Clin Oncol 31 (suppl 6; abstr 7)."
"4758","PC080443","Petrylak D, Gandhi JG, Clark WR, et al.  2013.  A phase I/II study of safety and efficacy of oteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone in metastatic castration-resistant prostate cancer: Updated phase II results.  J Clin Oncol 31 (suppl 6, abstr 59)."
"4759","PC080443","McNeel DM, Becker JT, Eickhoff JC, et al.  2013.  Long-term immune response elicited by a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with non-metastatic castrate-resistant prostate cancer.  J Clin Oncol 31 (suppl 6; abstr 135)."
"4760","PC080443","Morisson C, Jeraj R, and Liu G.  2013.  Imaging of castration-resistant prostate cancer development of imaging response biomarkers.  Curr Opin Urol 23(3):230-236."
"4761","PC080443","Harrison MR, Hahn NM, Pili R, et al.  2011.  A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal(R) dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).  Invest New Drugs 29(6):1465-1474."
"4762","PC080443","Liu G, Kelly WK, Wilding G, et al.  2009.  An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer.  Clin Cancer Res 15(9):PMID 19366825."
"4763","PC080446","Ho E, Clarke JD, and Dashwood RH.  2009.  Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention.  J Nutr 139:2393-2396."
"4764","PC080446","Clarke JD, Yu Z and Ho E.  2010.  Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal and prostate cancer cells.  FASEB J  24:107.5."
"4765","PC080446","Clarke, JD, Hsu A, Yu Z, et al.  2011.  Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells.  Mol Nutr Food Res 55(7):999-1009."
"4766","PC080453","Grubisha MJ, Cifuentes ME, Hammes SR, et al.  2012.  A local paracrine and endocrine network involving TGFbeta, Cox-2, ROS, and estrogen receptor beta influences reactive stromal cell regulation of prostate cancer cell motility.  Mol Endocrinol 26(6):940-954."
"4767","PC080474","Lessard L, Labbé DP, Deblois G, et al.  2012.  PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer.  Cancer Res 72(6):1529-1537.
"
"4768","PC080474","Labbé DP, Hardy S, and Tremblay ML.  2012.  Protein tyrosine phosphatases in cancer: Friends and foes!  Prog Mol Biol Transl Sci 106:253-306."
"4769","PC080474","David P. Labbé, Noriko Uetani, Valérie Vinette, Laurent Lessard, Isabelle Aubry, Eva Migon, Jacinthe
Sirois, Jody J. Haigh, Louis R. Bégin, Lloyd C. Trotman, Marilène Paquet, and Michel L. Tremblay

PTP1B deficiency enables the ability of a high fat diet to drive the invasive character of 
PTEN-deficient prostate cancers

Cancer Res. 2016 Jun 1; 76(11): 3130–3135.
Published online 2016 Mar 28. doi:  10.1158/0008-5472.CAN-15-1501"
"4770","PC080488","Shi XB, Xue L, Ma AH, et al.  2011.  miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes.  Prostate 71:538-549."
"4771","PC080488","Shi XB, Xue L, Ma AH, et al.  2013.  Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells.  Oncogene 32(35):4130-4108."
"4772","PC080496","Bhardwaj A, Singh S, Srivastava SK, et al.  2011.  Moduation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications.  Mol Cancer Ther 10(5):720-731."
"4773","PC080496","Bhardwaj A, Singh S, Srivastava SK, et al.  2014.  Restoration of PPP2CA expression reverses epithelial to mesenchymal transition and suppresses prostate tumor growth and metastasis in an orthotopic mouse model.  Brit J Cancer 110(8):2000-2010."
"4774","PC080513","Yang NY, Fernandez C, Richter M et al.  2011.  Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells.  Cell Signal 23:201-212."
"4775","PC080522","Hughes L, Ruth K, Rebbeck TR, et al.  2013.  Genetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African American men.  Prostate Cancer Prostatic Dis 16(4):308-314."
"4776","PC080522","Chang BL, Hughes L, Chen DYT, et al.  2014.  Validation of association of genetic variants at 10q with PSA levels in men at high risk for prostate cancer.  BJU Int 113(5b):E150-6."
"4777","PC080522","Fleisher L, Davis SN, Gross L, et al.  2016.  Lessons learned from implementing a prostate cancer risk assessment program for underserved high-risk men in the community: The Prostate REACH project.  J Cancer Educ 31(1):191-197."
"4778","PC080522","Handorf E, Crumpler N Gross L, et al.  2014.  Prevalence of the HOXB13 G84E mutation among unaffected men with a family history of prostate cancer.  J Genetic Counseling 23(3):371-376."
"4779","PC080522","Chang BL, Hughes L, Chen DY, et al.  2013.  Validation of association of genetic variants at 10q with PSA levels in men at high risk for prostate cancer.  BJU Int 113(5b):E150-6."
"4780","PC080522","Hall MJ, Ruth K, and Giri VN.  2012.  Rates and predictors of colorectal cancer screening by race among motivated men participating in a prostate cancer risk assessment program.  Cancer 118 (2):478-484."
"4781","PC080522","Ishak M and Giri VN.  2011.  A systematic review of replication studies of prostate cancer susceptibility genetic variants in high-risk men originally identified from genome-wide association studies.  Cancer Epidemiol Biomarkers Prev 20(8):1599-1610."
"4782","PC080538","Nadiminty N, Chun JY, Lou W, et al.  2009.  NF-kappaB2/p52 enhances androgen- independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen deprivation.  Prostate 68(16):1725-1733."
"4783","PC080538","Nadiminty N, Lou W, Sun M, et al.  2010.  Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells.  Cancer Res 70(8):3309-3319.
"
"4784","PC080538","Nadiminty N, Dutt S, Tepper C, et al.  2010.  Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells.  Prostate 70(3):276-287."
"4785","PC080542","Lerner M, D'Souza J, Pazina T, et al.  2012.  Hybrids of a genetically engineered antibody and a carbon nanotube transistor for detection of prostate cancer biomarkers.  ACS Nano 6(6):5143-5149."
"4786","PC080542","Lerner MB, Dailey J, Goldsmith BR, et al.  2013.  Detecting Lyme disease using antibody-functionalized single-walled carbon nanotube transistors.  Biosensors and Bioelectronics 45:163-167."
"4787","PC080542","Goldsmith BR, Mitala JJ, Josue J, et al.  2011.  Biomimetic chemical sensors using nanoelectronic readout of olfactory receptor proteins.  ACS Nano 5(7):5408-5416."
"4788","PC080542","Lerner MB, Resczenski JM, Amin A, et al.  2012.  Toward quantifying the electrostatic transduction mechanism in carbon nanotube molecular sensors.  J Am Chem Soc 134(35):14318-14321."
"4789","PC080542P1","Lerner MB, Resczenski JM, Amin A, et al.  Toward quantifying the electrostatic transduction mechanism in carbon nanotube molecular sensors.  J Am Chem Soc 134(35):14318-14321."
"4790","PC080542P1","Lerner M, D'Souza J, Pazina T, et al.  2012.  Hybrids of a genetically engineered antibody and a carbon nanotube transistor for detection of prostate cancer biomarkers.  ACS Nano 6(6):5143-5149."
"4791","PC080542P1","Goldsmith BR, Mitala JJ, Josue J, et al.  2011.  Biomimetic chemical sensors using nanoelectronic readout of olfactory receptor proteins.  ACS Nano 5(7):5408-5416."
"4792","PC080542P1","Lerner MB, Dailey J, Goldsmith BR, et al.  2013.  Detecting Lyme disease using antibody-functionalized single-walled carbon nanotube transistors.  Biosens Bioelectron 45:163-167."
"4793","PC080550","Tripathi M, Nandana S, Yamashita H, et al.  2008.  Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.  J Biol Chem 283(45):30576-30584."
"4794","PC080550","Tripathi M, Potdar A, Yamashita H, et al.  2011.  Laminin-332 cleavage by Matriptase alters motility parameters of prostate cancer cells.  Prostate 71(2):184-196."
"4795","PC080571","Na IK.  2010.  Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivo.  Blood 116(11):e18-e25.

"
"4796","PC080571","Lu SX.  2011.  Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.  PLoS One 6:e21611."
"4797","PC080571","Dudakov J.  2012.  Interleukin-22 drives endogenous thymic regeneration in Mice.  Science 336:391."
"4798","PC080571","Jenq RR.  2012.  Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation.  J Exp Med. 209(5):903-911. "
"4799","PC080571","Jenq RR.  2012.  Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer.  PLoS ONE 7: 4-e3522."
"4800","PC080571","Lu SX.  2010.  Absence of P-selectin in recipients of allogeneic bone marrow transplantation ameliorates experimental graft-versus-host disease.  J Immunol 185:1912."
"4801","PC080571","Penack O.  2010.  Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth.  J Natl Cancer Inst 102:894."
"4802","PC080591","Gan L, Chen S, Wang Y, et al.  2009.  Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.  Cancer Res 69(21):8386-8394. "
"4803","PC080591","Bohrer LR, Liu P, Zhong J, et al.  2013.  FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants.  Prostate 73(10):1017-1027."
"4804","PC080617","Stott SL, Hsu C-H and Tsukrov DI.  2010.  Isolation of circulating tumor cells using a microvortex-generating herringbone-chip.  Proc Natl Acad Sci USA 107:18392-18397.

"
"4805","PC080617","Lee RJ, Saylor PJ, MMichaelson MD, et al.  2013.  A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.  Clin Cancer Res 19(11):3088-3094."
"4806","PC080617","Ozkumur E, Shah AM, Ciciliano JC, et al.  2013.  Inertial focusing for tumor antigen-dependent and ¿independent sorting of rare circulating tumor cells.  Sci Transl Med 5(179):179ra47."
"4807","PC080617","Miyamoto DT, Lee RJ, Stott SL et al.  2012.  Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.  Cancer Discov 2(11):995-1003."
"4808","PC080617","Stott SL, Lee RJ, et al.  2010.  Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.  Sci Transl Med 25ra23."
"4809","PC080637","Chang J, Varghese DS, Gillam MC, et al.  2012.  Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.  Br Cancer 106(1):116-125. 

"
"4810","PC080659","Boyce M, Carrico IS, Ganguli AS, et al.  2011.  Metabolic cross-talk allows labeling of O-linked beta-N-acetylglucosamine-modified proteins via the N-acetylgalactosamine salvage pathway.  Proc Natl Acad Sci U S A 108:3141-3146."
"4811","PC080659","Hubbard SC, Boyce M, and McVaugh CT, et al.  2011.  Cell surface glycoproteomic analysis of prostate cancer-derived PC-3 cells.  Bioorg Med Chem Lett 21:4945-4950."
"4812","PC080663","Rodriguez AR, Choe U-J, Kamei DT, et al.  2012.  Fine tuning of vesicle assembly and properties using dual hydrophilic triblock copolypeptides.  Macromol Biosci 12:805-811."
"4813","PC080663","Zhao K, Choe U-J, Kamei DT, et al.  2012.  Enhanced activity of cyclic transporter sequences driven by phase behavior of peptide¿lipid complexes.  Soft Matter 8:6430-6433."
"4814","PC080663","Mosley GL, Yamanishi CD and Kamei DT.  2013.  Mathematical modeling of vesicle drug delivery systems: 1.  Vesicle formation and stability along with drug loading and release.  J Lab Autom 18:34-45."
"4815","PC080663","Choe U-J, Rodriguez AR, Li Z, et al.  2013.  Characterization and minimization of block copolypeptide vesicle cytotoxicity using different hydrophobic chain lengths.  Macromol Chem Physic 214:994-999."
"4816","PC080663","Kramer JR, Rodriguez AR, Choe U-J, et al.  2013.  Glycopeptide conformations in bioactive block copolymer assemblies influence their nanoscale morphology.  Soft Matter 9:3389-3395."
"4817","PC080663","Sun VZ, Choe U-J, Rodriguez AR, et al.  2013.  Transfection of mammalian cells using block copolypeptide vesicles.  Macromol Biosci 13:539-550."
"4818","PC080663","Ying CT, Wang J, Lamm RJ, et al.  2013.  Mathematical modeling of vesicle drug delivery systems: 2.  Targeted vesicle interactions with cells, tumors, and the body.  J Lab Autom 18:46-62."
"4819","PC080663","Choe U-J, Rodriguez AR, Lee BS, et al.  2013.  Endocytosis and intracellular trafficking properties of transferrin-conjugated block copolypeptide vesicles.  Biomacromolecules 14:1458-1464."
"4820","PC080663","Sun VZ, Li Z, Deming TJ, et al.  2011.  Intracellular fates of cell-penetrating block copolypeptide vesicles.  Biomacromolecules 12:10-13."
"4821","PC080663","Choe UJ, Sun VZ, Tan JK, et al.  2012.  Self-assembled polypeptide and polypeptide hybrid vesicles: from synthesis to application.  Top Curr Chem 310:117-134."
"4822","PC080663","Choe U-J, Sun VZ, Tan JK, et al.  2012.  Self-assembled polypeptide and polypeptide hybrid vesicles:  from synthesis to application.  Top Curr Chem 310:117-134."
"4823","PC080665","Maher CA, Palanisamy N, Brenner JC, et al.  2009.  Chimeric transcript discovery by paired-end transcriptome sequencing.  Proc Natl Acad Sci U S A 106(30):12353-12358."
"4824","PC080665","Cao Q, Mani RS, Ateeq B, et al.  2011.  Coordinated regulation of polycomb group complexes through microRNAs in cancer.  Cancer Cell 20(2):187-199."
"4825","PC080665","Kappes F, Waldmann T, Mathew V, et al.  2011.  The DEK oncoprotein is a Su (var) that is essential to heterochromatin integrity.  Genes Dev 25(7):673-678.

"
"4826","PC080665","Yu J, Cao Q, Yu J, et al.  2010.  The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer.  Oncogene 29(39):5370-5380."
"4827","PC080665","Zhao JC, Yu J, Runkle C, et al.  2012.  Cooperation between polycomb and androgen receptor during oncogenic transformation.  Genome Res 22(2):322-331."
"4828","PC080665","Zhao B, Li L, Wang L, et al.  2012.  Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis.  Genes Dev 26(1):54-68.

"
"4829","PC080665","Kim JH, Dhanasekaran SM, Prensner JR, et al.  2011.  Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer.  Genome Research 21(7):1028-1041."
"4830","PC080665","Brenner JC, Ateeq B, Li Y, et al.  2011.  Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.  Cancer Cell 19(5):664-678. PMID:  21575865."
"4831","PC080665","Rickman DS, Chen YB, Banerjee S, et al.  2010.  ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.  Neoplasia 12(12):1031-1040 PMID:  21170267."
"4832","PC080665","Wang Q, Li W, Zhang Y, et al.  2009.  Reprogrammed androgen receptor function in androgen-independent prostate cancer.  Cell 138(2):245-256.  PMID: 19632176."
"4833","PC080665","Yu J, Cao Q, Yu J, et al.  2010.  The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer.  Oncogene 29(39):5370-5380."
"4834","PC080665","Qin ZS, Yu J, Shen J, et al.  2010.  HPeak: an HMM-based algorithm for defining readenriched regions in ChIP-Seq data.  BMC Bioinformatics 11(1):369."
"4835","PC080665","Lian I, Kim J, Okazawa H, et al.  2010.  The role of YAP transcription co-activator in regulating stem cells self-renewal and differentiation.  Genes Dev 24(11):1106-1118."
"4836","PC080665","Vellaichamy A, Sreekumar A, Strahler JR, et al.  2009.  Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases.  PLoS One 4(9):e7075."
"4837","PC080665","Hu M, Yu J, Taylor JM, et al.  2010.  On the detection and refinement of transcription factor binding sites using ChIP-Seq data.  Nucleic Acids Res 38(7):2154-2167."
"4838","PC080665","Yu J, Yu J, Mani RS, et al.  2010.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.  Cancer Cell 17(5):443-454."
"4839","PC080673","Izumi K, Zheng Y, Hsu J-W, et al.  2013.  Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: A potential mechanism of androgen-induced bladder carcinogenesis.  Mol Carcinogen 52(2):94-102."
"4840","PC080673","Kawahara T, Kashiwagi E, Ide H, et al.  2015.  The role of NFATc1 in prostate cancer progression: Cyclosporine A and tacrolimus inhibit cell proliferation, migration, and invasion.  Prostate 75(6):573-584."
"4841","PC080673","Canacci AM, Izumi K, Zheng Y, et al.  2011.  Expression of semenogelins I and II and its prognostic significance in human prostate cancer.  Prostate 71(10):1108-1114."
"4842","PC080673","Izumi K, Li Y, Zheng Y, et al.  2012.  Seminal plasma proteins in prostatic carcinoma: Increased nuclear semenogelin I expression is a predictor of biochemical recurrence after radical prostatectomy.  Hum Pathol 43(11):1991-2000."
"4843","PC080673","Li Y, Zheng Y, Izumi K, et al.  2013.  Androgen activates beta-catenin signaling in bladder cancer cells.  Endocr Relat Cancer 20(3):293-304."
"4844","PC080673","Zheng Y, Izumi K, Yao JL, et al.  2011.  Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Endocr-Relat Cancer 18(4): 451-464."
"4845","PC080673","Izumi K, Zheng Y and Miyamoto H.  2011.  Eppin expression in prostate cancer.  Eur Urol 59(6):1071-1072."
"4846","PC080673","Izumi K, Li Y, Ishiguro H, et al.  2014.  Expression of UDP-glucuronosyltransferase 1A in bladder cancer:  Association with prognosis and regulation by estrogen.  Mol Carcinog 53(4):314-324."
"4847","PC080673","Zheng Y, Izumi K, Li Y, et al.  2012.  Contrary regulation of bladder cancer cell proliferation and invasion by dexamethasone-mediated glucocorticoid receptor signals.  Mol Cancer Ther 11:2621-2632."
"4848","PC080673","Li Y, Izumi K, and Miyamoto H.  2012.  The role of the androgen receptor in the development and progression of bladder cancer.  Jpn J Clin Oncol 42(7):569-577."
"4849","PC080673","Izumi K, Zheng Y, Li Y, et al.  2012.  Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor.  Int J Oncol 41(5):1587-1592."
"4850","PC080673","Kawahara T, Miyamoto H.  2014.  Androgen receptor antagonists in the treatment of prostate cancer.  Clin Immunol Endocr Metab Drugs 1(1):11-19."
"4851","PC080697","Shah S, Prasad S, and Knudsen K.  2012.  Targeting pioneering factor and hormone receptor cooperative pathways to suppress tumor progression.  Cancer Res 72:1248-1259.

"
"4852","PC080702","Harui A, Kiertscher SM, and Roth MD.  2011.  Reconstitution of huPBL-NSG mice with donor-matched dendritic cells enables antigen-specific T-cell activation.  J Neuroimmune Pharmacol 6(1):148-57."
"4853","PC080729","Mishra V, Schned A, Hartov, et al. 2013. Electrical property sensing biopsy needle for prostate tissue assessment. The Prostate, 73(15): 1603-1613."
"4854","PC080729","Halter RJ, Schned AR, Heaney JA, et al.  2009.  Electrical properties of prostatic tissues: I. Single frequency admittivity properties.  J Urol 182:1600-1607.

"
"4855","PC080729","Mishra V, Bouyad H, Schned A, et al.  2012.  A real-time electrical impedance sensing biopsy needle.  IEEE Transactions Biomed Eng 59(12):3327-3336."
"4856","PC080729","Halter RJ, Milone M, Schned A, et al.  2010.  Relationship between electrical admittivity and quantitative histopathology in human prostate.  J Phys Conf Ser 224:012113."
"4857","PC080729","Fortson WS, Kayarthodi S, Fujimura Y, et al.  2011.  Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in TMPRSS2-ERG positive prostate cancer cells.  Intl J of Oncology 39(1):111-119."
"4858","PC080729","Halter RJ, Schned AR, Heaney JA, et al.  2009.  Electrical properties of prostatic tissues: II. Spectral admittivity properties.  J Urol 182:1608-1613."
"4859","PC080729","Halter RJ, Schned AR, Heaney JA, et al.  2011.  Passive bioelectrical properties for assessing high- and low-grade prostate adenocarcinoma.  Prostate 71(16):1759-1767."
"4860","PC080729","Halter RJ, Mishra V, Bouayad H, et al.  2011.  Electrical property-based biopsy for prostate cancer detection and assessment.  Proceedings of SPIE Photonics West."
"4861","PC080753","Cherian MT, Wilson EM, and Shapiro DJ.  2012.  A competitive inhibitor that reduces recruitment of androgen receptor to androgen responsive genes.  J Biol Chem 287(28):23368-23380."
"4862","PC080784","Mahajan K, Coppola D, Challa S, et al.  2010.  Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activity.  PLoS One 5(3):e9646.
"
"4863","PC080811","Abd Elmageed ZY, Yang Y, Thomas R, et l. 2014. Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes. Stem Cells 32(4):983-97. PMID: 24715691."
"4864","PC080813","Rico-Bautisa E, Yang C-C, Lu L, et al.  2010.  Chemical genetics approach to restoring the tumor suppressor p27Kip in cancer cells.  BMC Biology 8:153."
"4865","PC080847","Wu CF, Wang R, Liang Q, et al.  2010.  Dissecting the M phase-specific phosphorylation of serine-proline or threonine-proline motifs.  Mol Biol Cell 21:1470-1481."
"4866","PC080847","Wang R, Jung SY, Wu CF, et al.  2010.  Direct roles of the signaling kinase RSK2 in Cdc25 activation during Xenopus oocyte maturation.  Proc Natl Acad Sci USA 107:19885-19890."
"4867","PC080847P1","Wu CF, Wang R, Liang Q, et al.  2010.  Dissecting the M phase-specific phosphorylation of serine-proline or threonine-proline motifs.  Mol Biol Cell 21:1470-1481."
"4868","PC080847P1","Wang R, Jung SY, Wu CF, et al.  2010.  Direct roles of the signaling kinase RSK2 in Cdc25C activation during xenopus oocyte maturation.  PNAS U S A 107(46):19885-19890."
"4869","PC080859","Guo W, Liu R, Ono Y, et al.  2012. Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs. Mol Pharmacol 82(5):938-947."
"4870","PC080883","Yang CC and Wolf DA.  2009.  Inflamed snail speeds metastasis.  Cancer Cell 15(5):355-357."
"4871","PC080920","Koppolu B, Rahimi M and Nattama S.  2010.  Development of multiple-layer polymeric particles for targeted and controlled drug delivery.  Nanomedicine 6:355-361."
"4872","PC080920","Rahimi M, Meletis EI and You S, et al.  2010.  Formulation and characterization of novel temperature sensitive polymeric coated magnetic nanoparticles.  J Nanosci Nanotechnol 10:6072-6081."
"4873","PC080920","Koppolu B, Bhavsar Z, Wadajkar AS, et al.  2012.  Temperature-sensitive polymer-coated magnetic nanoparticles as a potential drug delivery system for targeted therapy of thyroid cancer. J Biomed Nanotechnol 8(6):983-990."
"4874","PC080920","Wadajkar AS, Menon JU, Tsai YS, et al.  2013.  Prostate cancer-specific thermo-responsive polymercoated iron oxide nanoparticles.  Biomaterials 34(14):3618-3625."
"4875","PC080920","Wadajkar AS, Menon JU, Kadapure T, et al.  2013.  Design and application of magnetic-based theranostic nanoparticle system.  Recent Pat Biomed Eng 6(1):47-57.

"
"4876","PC080920","Menon JU, Jadeja P, Tambe P, et al.  2013.  Nanomaterials for photo-based diagnostic and therapeutic applications.  Theranostics 3(3):152-166."
"4877","PC080920","Wadajkar AS, Kadapure T, Zhang Y, et al.  2012.  Dual-imaging enabled cancer targeting nanoparticles.  Adv Healthc Mater 1(4):450-456.

"
"4878","PC080920","Chastek TT, Wadajkar A, Nguyen KT, et al.  2010.  Polyglycol-templated synthesis of poly(N-isopropyl acrylamide) microgels with improved biocompatibility.  Colloid Polym Sci 288:105-114."
"4879","PC080920","Rahimi M, Youself M, Cheng Y, et al.  2009.  Formulation and characterization of covalently coated magnetic nanogel.  J Nanosci Nanotechnol 9: 4128-4134."
"4880","PC080920","Wadajkar AS, Bhavsar Z, Ko CY, et al.  2012.  Multifunctional nanoparticles for melanoma-targeted drug delivery.  Acta Biomater 8(8):2996-3004."
"4881","PC080920","Alsmadi NZ, Wadajkar AS, Cui W, et al.  2011.  Effects of surfactants on properties of polymer-coated magnetic nanoparticles for drug delivery application.  Journal of Nanoparticle Research 13(12):7177-7186."
"4882","PC080920","Rahimi M, Wadajkar A and Subramanian K.  2010.  In vitro evaluation of novel polymer-coated magnetic nanoparticles for controlled drug delivery.  Nanomedicine 6(5)672-80."
"4883","PC080941","Qian J, Lee L, Ma Y, et al.  2009.  Geometric and dosimetric quality assurance in volumetric modulated arc therapy (VMAT).  Int J Radiat Oncol Biol Phys 75:S639."
"4884","PC080941","Liu W, Qian J, Hancock S, et al.  2010.  Clinical development of a failure detection-based online repositioning strategy for prostate IMRT ¿ Experiments, simulation, and dosimetry study.  Med Physics 37:5287-5297."
"4885","PC080941","Qian J, Lee L and Xing L.  2009.  Verification of geometric parameters in volumetric modulated arc therapy (VMAT).  Med Phys 36:2572."
"4886","PC080941","Xing L, Qian J, Choi K, et al.  2010.  Chapter 2. Three- and four-dimensional morphological imaging for adaptive radiation therapy planning.  In: Adaptive Radiation Therapy (Li A, Taylor and Francis, Eds.).

"
"4887","PC080941","Lee L, Qian J, Xing L, R, et al.  2009.  Retrospective RapidArc dose reconstruction based on MLC dynamic and delivery log files recorded during treatment.  Med Phy 36:2693-2694."
"4888","PC080941","Ma Y, Qian J and Xing L.  2009.  Incorporating prior knowledge into aperture modulated arc therapy inverse planning.  Int J Radiat Oncol Biol Phys 75:S720.
"
"4889","PC080941","Qian J, Lee L, Liu W, et al.  2010.  Dose reconstruction for volumetric modulated arc therapy (VMAT) using cone-beam CT and dynamic log-files.  Physics Med Biol 55:3597-3610."
"4890","PC080943","Ramachandran IR, Song W, Lapteva N, et al.  2011.  The phosphatase SRC homology region 2 domain-containing phosphatase-1 is an intrinsic central regulator of dendritic cell function.  J Immunol 186(7):3934-3945."
"4891","PC080963","Sprenger C, Plymate S, and Reed M.  2010.  Aging-related alterations in the extracellular matrix modulate the microenvironment and influence tumor progression.  Int J Cancer 127(12):2739-48."
"4892","PC080987","Russell MR, Liu Q, and Fatatis A.  2010.  Targeting the alpha receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis.  Clinical Cancer Research 16:5002-5010."
"4893","PC080987","Liu Q, Jernigan D, Zhanh Y, et al.  2011.  Implication of platelet-derived growth factor receptor alpha in prostate cancer skeletal metastasis.  Chinese J. Cancer 30:612-619."
"4894","PC080987","Russell MR, Liu Q, Lei H, et al.  2010.  The alpha receptor for platelet derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-independent mechanisms.  Cancer Research 70:4195-4203."
"4895","PC081001","Klokov D, Leskov K, Araki S, et al.  2013.  Low dose IR-induced IGF-1-sCLU expression:  A p53-repressed expression cascade that interferes with TGFbeta1 signaling to confer a pro-survival bystander effect. Oncogene 32(4):479-490."
"4896","PC081001","Goetz EM, Shankar B, Zou Y, et al.  2011.  ATM-dependent IGF-1 induction regulates secretory clusterin expression after DNA damage and in genetic instability.  Oncogene 30:3745-3754."
"4897","PC081012","Chen Y, Tang Y, Robbins G, et al.  2010.  Camptothecin attenuates cytochrome P450 3A4 induction by the antagonism of human pregnane X receptor.  J Pharmacol Exp Ther 334(3):999-1008."
"4898","PC081013","Ward JE, Karrison T and Chatta G.  2012.  A randomized phase II study of pazopanib in castrate-sensitive prostate cancer:  A University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.  Prostate Cancer Prostatic Dis 15:87-92."
"4899","PC081025","Blackburn A, Wilson D, Gelfond J, et al.  2013.  Validation of copy number variants associated with prostate cancer risk and prognosis.  Urol Oncol 1439(13)00253-00256."
"4900","PC081025","Blackburn A, Göring HHH, Dean A, et al.  2013.  Utilization of extended pedigree information for discovery and confirmation of copy number variable regions among Mexican Americans.  Eur J Hum Genet 21(4):404-409."
"4901","PC081032","Mudryj M and Tepper CG.  2013.  On the origins of the androgen receptor low molecular weight species.  Horm Cancer 4(5):259-269."
"4902","PC081042","Liu W, Wiersma RD, and Xing L.  2010.  Optimized hybrid megavoltage-kilovoltage imaging protocol for volumetric prostate arc therapy.  Int J Radiat Oncol Biol Phys 78(2):595-604."
"4903","PC081042","Qian J.  2010.  Dose reconstruction for volumetric modulated arc therapy (VMAT) using cone-beam CT and dynamic log files.  Phys Med Biol 55(13):3597-3610."
"4904","PC081042","Liu W.  2010.  Clinical development of a failure detection-based online repositioning strategy for prostate IMRT-Experiments, simulation, and dosimetry study.  Med Phys 37(10):5287-5297."
"4905","PC081042","Liu W, Wiersma RD, and Xing L.  2010.  Optimized hybrid MV-kV imaging protocol for volumetric prostate arc therapy.  Int J Radiat Oncol Biol Phys 78(3)904-11."
"4906","PC081042","
Liu W, et al.  2009.  Real-time motion detection of prostate target during volumetric arc therapy using onboard imaging devices.  Med Phys 36:2800-2801.
"
"4907","PC081042","Liu W, et al.  2009.  Intrafraction prostate motion monitoring with cine-MV and minimal as-needed onboard KV imaging.  Med Phys 36:2724."
"4908","PC081042","Liu W, Luxton G, and Xing L.  2009.  Optimized hybrid MV-kV imaging protocol for volumetric prostate arc therapy.  Int J Radiat Oncol Biol Phys 75(3):S570-S571."
"4909","PC081044","Salari K, Tibshirani R, and Pollack JR.  2010.  DR-Integrator: A new analytic tool for integrating DNA copy number and gene expression data.  Bioinformatics 1;26(3):414-416."
"4910","PC081044","Holcomb IN, Young JM, Coleman I, et al.  2009.  Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer.  Cancer Res 1;69(19):7793-7802 [Epub 2009 Sep 22]."
"4911","PC081044","Kao J, Salari K, Bocanegra M, et al.  2009.  Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.  PLoS One 3;4(7):e6146."
"4912","PC081048","Li W, Wang L, Katoh H, et al.  2011.  Identification of a tumor suppressor relay between the FOXP3 and the HIPPO pathways in breast and prostate cancers.  Cancer Res 71:2162-2171."
"4913","PC081048","Katoh H, Qin ZS, Liu R, et al.  2011.  FOXP3 orchestrates H4K16 acetylation and H3K4 tri-methylation for gene activation through recruiting MOF and causing displacement of PLU-1.  Molecular Cell 44(5):770-784."
"4914","PC081048","Wang L, Liu R, Li W, et al.  2009.  Somatic single-hits inactivate the X-linked tumor suppressor FOXP3 in the prostate.  Cancer Cell 16(4):336-346."
"4915","PC081048","Katoh H, Zheng P, and Liu Y.  2010.  Signaling networks in focus.  Signaling through FOXP3 as an X-linked tumor suppressor.  Int J Biochem Cell Biol 42(11):1784-1787.

"
"4916","PC081048","Liu Y, Wang and Zheng P.  2010.  X-linked tumor suppressor genes: Perplexing inheritance and a unique therapeutic opportunity.  Trends Genet 26(6):260-265. 

"
"4917","PC081050","Danila DC, Fleisher M, and Scher HI.  2011.  Circulating tumor cells as biomarkers in prostate cancer.  Clin Cancer Res 17(12):3903-3912. "
"4918","PC081050","Danila DC, Anand A, Sung CC, et al.  2011.  TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.  Eur Urol 60(5):897-904."
"4919","PC081050","Mitsiades N, Sung C, Schultz N, et al.  2012.  Distinct patterns of dysregulated expression of enzymes involved in androgen metabolism in situ in metastatic prostate cancer.  Cancer Res 72(23):6142-6152."
"4920","PC081050","Danila DC.  2011.  Circulating tumors cells as biomarkers in prostate cancer progress toward biomarker qualification.  Cancer J 17:438-450."
"4921","PC081072","Washington MN and Weigel NL.  2010.  1 alpha,25-Dihyroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. Endocrinology 151:1409-1417."
"4922","PC081072","Kim JS, Roberts JM, Bingman WE 3rd, et al. 2014. The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling. Endocrinology 155(9):3262-73. doi: 10.1210/en.2013-2019. Epub 2014 Jun 13. PubMed PMID: 24926821; PubMed Central PMCID: PMC5377584."
"4923","PC081089","He Y, Xu Y, Zhang C, et al.  2011.  Identification of a lysosomal pathway that modulates glucocorticoid signaling and the inflammatory response.  Sci Signal 4(180):ra44."
"4924","PC081089","Martin KR, Xu Y, Looyenga BD, et al.  2011.  Identification of PTPsigma as an autophagic phosphatase.  J Cell Sci Mar 124(5):812-819."
"4925","PC081089","Looyenga BD, and Mackeigan JP.  2012.  Characterization of differential protein tethering at the plasma membrane in response to epidermal growth factor signaling.  J Proteome Res 11(6):3101-3111."
"4926","PC081089","Martin KR, Narang P, Xu Y, et al.  2012.  Identification of small molecule inhibitors of PTPsigma through an integrative virtual and biochemical approach.  PLoS One 7(11):e50217."
"4927","PC081107","Exley MA, and Nakayama T.  2011. NKT-cell-based immunotherapies in clinical trails.  Clin Immunol 140:117-118."
"4928","PC081107","Nowak M, Arredouani MS, Tun-Kyi A, et al.  2010.  Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with alphagalactosylceramide.  PLoS One 5:e11311.

"
"4929","PC081107","Yue SC, Nowak M, Shaulov-Kask A, et al.  2010.  Direct CD1d-mediated stimulation of APC IL-12 production and protective immune response to virus infection in vivo.  J Immunol 184:268-276."
"4930","PC081107","Exley MA, Lynch L, Varghese B, et al.  2011.  Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: Reversing tumor-induced defects.  Clin Immunol 140:184-195."
"4931","PC081107","Hogan AE, O'Reilly V, Dunne MR, et al.  2011.  Activation of human invariant natural killer T cells with a thioglycoside analogue of alpha-galactosylceramide.  Clin Immunol 140:196-207."
"4932","PC081107","Nowak M, Lynch L, Yue S, et al.  2010.  The A2aR adenosine receptor controls cytokine production in iNKT cells.  European J Immunol 40(682-687."
"4933","PC081107","Arredouani MS, Tseng-Rogenski SS, Hollenbeck BK, et al.  2010.  Androgen Ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic Mice.  Prostate 20:1002-1011."
"4934","PC081107","Nowak M, Arredouani MS, Tun-Kyi A, et al.  2010.  Defective NKT cell activation by CD1d+ tramp prostate tumor cells is corrected by interleukin-12 with alpha-galactosylceramide.  Plos One 5(6):e11311."
"4935","PC081107","Kissick HT, Sanda MG, Dunn LK, et al.  2014. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response. PLoS One. 9(4):e93231."
"4936","PC081115","Cai C, Portnoy CD, and Wang H.  2009.  Androgen receptor expression in prostate cancer is suppressed by activation of EGFR and ErbB2.  Cancer Res 69(12):5186-5193.

"
"4937","PC081115","Cai C, Wang H, and Xu Y.  2009.  Reactivation of androgen receptor regulated TMPRSS2:ERG gene expression in castration resistant prostate cancer.  Cancer Res 69(15):6027-6032."
"4938","PC081116","Lee Y, Chen Y, Tarasova NI, et al.  2011.  The structure of monomeric components of self-assembling CXCR4 antagonists determines the architecture of resulting nanostructures.  Nanotechnology 22:505101."
"4939","PC081116","Tarasov SG, Gaponenko V, Howard OM, et al.  2011.  Structural plasticity of a transmembrane peptide allows self-assembly into biologically active nanoparticles.  Proc Natl Acad Sci 108 (24):9798-9803."
"4940","PC081116","Tarasova SG, Gaponenko V, Howard OMZ, et al.  2011.  Structural plasticity of a transmembrane peptide allows self-assembly into biologically active nanoparticles.  Biophysical J 101(11):2731-2739."
"4941","PC081119","Cai C, Wang H, He HH, et al. 2013. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest 123(3):1109-1122."
"4942","PC081147","Anderson PD, McKissic SA, Logan M, et al.  2012.  Nkx3.1 and c-Myc cross-regulate shared target genes in mouse and human prostate tumorigenesis.  J Clin Invest 122(5):1907-1919. "
"4943","PC081176","Li J, Huang J, Jeong JH, Park SJ, et al. 2014. Selective TBK1/IKKi dual inhibitors with anticancer potency. Int J Cancer 134(8):1972-80."
"4944","PC081177","Chen L, Siddiqui S, Bose S, et al.  2010.  Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.  Cancer Res 70:5994-6003."
"4945","PC081177","Chen L, Mooso BA, Jathal MK, et al.  2011.  Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3.  Clin Cancer Res 17(19):6218-6228.
"
"4946","PC081177","Chen H, Libertini SJ, George M, et al.  Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines.  Endocrine Relat Cancer 17(4):857-873.  "
"4947","PC081198","Chakraborty S, Mitra S, Falk M, et al.  2010.  E-cadherin differentially regulates the assembly of connexin43 and connexin32 into gap junctions in human squamous carcinoma cells.  J Biol Chem 285:10761-10776.

"
"4948","PC081198","Govindarajan R, Chakraborty S, Johnson KE, et al.  2010.  Assembly of connexin43 is differentially regulated by E-cadherin and N-cadherin in rat liver epithelial cells.  Mol Biol Cell 21:4089-4107."
"4949","PC081198","Kelsey L, Katoch P, Johnson KE; et al.  2012.  Retinoids regulate the formation and degradation of gap junctions in androgen-responsive human prostate cancer cells.  PLoS One 7:e32846."
"4950","PC081198","Johnson KJ, Mitra S, Katoch P, et al.  2013.  Phosphorylation on serines 279 and 282 of connexin43 regulates endocytosis and gap junction assembly in pancreatic cancer cells.  Mol Biol Cell 24:715-733."
"4951","PC081246","Placencio VR, Li X and Sherrill TP.  et al.  2010.  Bone marrow derived mesenchymal stem cells incorporate into the prostate during regrowth.  PLoS One 5(9):e12920.
 

"
"4952","PC081249","Tanaka H, Kono E, Tran CP, et al.  2010.  Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, invasion, metastasis and castration resistance.  Nat Med 16(12):1414-20."
"4953","PC081249P1","Tanaka H, Kono E, Tran CP, et al.  2010.  E. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, invasion, metastasis and castration resistance.  Nat Med 16(12):1414-20."
"4954","PC081264","Cai QY, Yu P, Besch-Williford C, et al.  2013.  Near-infrared fluorescence imaging of gastrin releasing peptide receptor targeting in prostate cancer lymph node metastases.  The Prostate 73:842-854.

"
"4955","PC081264","Ma L, Zhang M, and Yu P.  2011.  Imaging site-specific peptide-targeting in tumor tissues using spectral-domain optical coherence tomography.  Proceedings of SPIE Vol. 78900V (p.1- p.8), doi:10.1117/12.874079."
"4956","PC081264","Goswami LN, Ma L, Cai Q, et al.  2013.  cRGD peptide-conjugated icosahedral closo-B12(2-) core carrying multiple Gd(3+)-DOTA chelates for alpha-v-beta-3 integrin-targeted tumor imaging (MRI).  Inorganic Chemistry 52(4):1701-1709."
"4957","PC081282","Dasgupta S, Wasson LM and Rauniyar N et al.  2009.  Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells.  Oncogene 28:2860-2872."
"4958","PC081292","Lin HK, Wang G, Chen Z, et al.  2009.  Phosphorylation-dependent regulation of the SCF complex formation and Skp2 oncogenic function by Akt/PKB.  Nat Cell Biol 11:420-432.

"
"4959","PC081292","Lin HK, Chen Z, Wang G, et al.  2010.  Skp2 targeting suppresses tumorigenesis by Arf-p53-indepedent cellular senescence.  Nature (Article) 464:374-379.

"
"4960","PC081292","Chan CH, Li CF, Yang WL et al.  2012.  The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis.  Cell 149:1098-1111."
"4961","PC081299","Daniel M-C, Grow ME, Pan H, et al.  Gold nanoparticle-cored poly(propyleneimine) dendrimers as new platform for multifunctional drug delivery systems.  N J Chem 35(10):2366-2374."
"4962","PC081299","Pan H and Daniel MC.  2010.  Gadolinium-labeled dendronized gold nanoparticles as new targeted MRI contrast agent.  Proc. SPIE 7674, (Smart Biomedical and Physiological Sensor Technology VII), 767404/1-767404/10."
"4963","PC081299","Pan H and Daniel MC.  2011.  Studies of MRI relaxivities of gadolinium-labeled dendrons.  Proc. SPIE 8025 (Smart Biomedical and Physiological Sensor Technology VIII), 80250F/1- 80250F/9."
"4964","PC081329","Fortson WS, Kayathodo S, Fujimura Y, et al.  2011.  Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in TMPRSS2-ERG positive prostate cancer cells.  Int J Oncol 39(1):111-119."
"4965","PC081336","Fudala R, Ranjan AP, Mukerjee A, et al.  2011.  Fluorescence detection of MMP-9. I. MMP-9 selectively cleaves Lys-Gly-Pro-Arg-Ser-Leu-Ser-Gly-Lys peptide.  Curr Pharm Biotechnol 12:834-838."
"4966","PC081336","Luchowski R, Shtoyko T, Apicella E, et al.  2011.  Fractal-like silver aggregates enhance the brightness and stability of single-molecule fluorescence.  Appl Spectrosc 65(2):174-180.

"
"4967","PC081336","Raut S, Heck A, Vishwanatha J, et al.  2011.  Fluorescent properties of antioxidant cysteine ABZ analogue.  J Photochem Photobiol B 102:241-245."
"4968","PC081336","Sharma V, He J, Narvenkar S, et al.  2011.  Quantification of light reflectance spectroscopy and its application: Determination of hemodynamics on the rat spinal cord and brain induced by electrical stimulation.  NeuroImage 56:1316-1328."
"4969","PC081336","Sharma V, Patel N, Shen J, et al.  2011.  A dual-modality optical biopsy approach for in vivo detection of prostate cancer in rat model.  J Innov Opt Health Sci 4(3):269-277.

"
"4970","PC081336","Kim SB, Temiyasathit C, Bensalah K, et al.  2010.  An efficient procedure for classification of prostate cancer in optical spectra.  Expert Syst Appl 37(5):3863-3869."
"4971","PC081336","Mukerjee A, Luchowski R, Ranjan AP, et al.  2010.  Enhanced fluorescence of curcumin on plasmonic platforms.  Curr Pharm Biotechnol 11:223-228."
"4972","PC081336","Mukerjee A, Sorensen TJ, Ranjan AP, et al.  2010.  Spectroscopic properties of curcumin: orientation of transition moments.  J Phys Chem B 114:12679-12684."
"4973","PC081336","Sharma V, Kashyap D, Mathker A, et al.  2009.  Optical reflectance spectroscopy for detection of human prostate cancer.  31st Annual International Conference of the IEEE EMBS, Conf Proc IEEE Eng Med Biol Soc 118-121."
"4974","PC081336","Patel RH, Wadajkar AS, Patel NL, et al.  2012.  Multifunctionality of indocyanine green-loaded biodegradable nanoparticles for enhanced optical imaging and hyperthermia intervention of cancer.  J Biomed Opt 17(4):046003."
"4975","PC081336","Sharma V, Shivalingaiah S, Peng Y, et al.  2012.  Autofluorescence lifetime and light reflectance spectroscopy for breast cancer diagnosis: Potential tools for intra-operative margin detection.  Biomed Opt Express 3(8):1826-1840."
"4976","PC081337","Rickman DS, Soong TD, Moss B, et al.  2012.  Oncogene-mediated alterations in chromatin conformation.  Proc Natl Acad Sci USA 109(23):9083-9088."
"4977","PC081337","Elemento O, Rubin MA and Rickman DS.  2012.  Oncogenic transcription factors as master regulators of chromatin topology:  A new role for ERG in prostate cancer.  Cell Cycle 11(18):3380-3383."
"4978","PC081337","Rickman DS, Chen YB, Banerjee S, et al.  2010.  ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.  Neoplasia 12(12):1031-1040."
"4979","PC081337","Pflueger D, Rickman DS, Sboner A, et al.  2009.  N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.  Neoplasia 11(8):804-811."
"4980","PC081337","Rickman DS, Pflueger D, Moss B, et al.  2009.  SLC45A3-ELK4 is a novel and frequent ETS fusion transcript in prostate cancer.  Cancer Research 69(7):2734-2738."
"4981","PC081386","Li, Y, Tian Y., Rezai T, et al.  2011.  Simultaneous analysis of glycosylated and sialylated PSA reveals differential distribution of glycosylation PSA isoforms in prostate cancer tissues.  Anal Chem 83(1):240-245."
"4982","PC081393","Pollock JA, Wardell SE, Parent AA, Stagg DB, Ellison SJ, Alley HM, Chao CA, Lawrence SA, Stice JP, Spasojevic I, Baker JG, Kim SH, McDonnell DP, Katzenellenbogen JA,  and Norris JD.  2016.   Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer. Nat Chem Biol 12(10):795-801."
"4983","PC081400","Mahapatra S, Klee EW, Young CYF, et al.  2012.  Global methylation profiling for risk prediction of prostate cancer.  Clin Cancer Res 18: 2882-2895."
"4984","PC081400","Sun Z, Chai1 HS, Wu Y, et al.  2011.   Batch effect correction for genome-wide methylation data with Illumina Infinium platform.  BMC Med Genomics 4(1):84."
"4985","PC081400","Mahapatra S, Karnes RJ, Young CYF, et al.  2012.  Antiangiogenic effects and therapeutic targets of azadirachta indica leaf extract in endothelial cells.  Evid Based Complement Alternat Med 12: 303019."
"4986","PC081400","Young CYF, Donkena KV, Yuan HQ, et al.  2012.  Carotenoids that are involved in prostate cancer risk.  Med Chem 8(5):529-537."
"4987","PC081400","Donkena KV, and Young CYF.  2011.  Vitamin D, sunlight and prostate cancer risk.  Adv Prev Med 281863."
"4988","PC081400","Mahapatra S, Karnes RJ, Young CYF, et al.  2011.  Novel molecular targets of azadirachta indica associated with inhibition of tumor growth in prostate cancer.  AAPS J 13:365-377."
"4989","PC081409","Senapati S., Das S. and Batra S.K.  2010.  Mucin-interacting proteins: from function to therapeutics.  Trends in Biochemical Science 35(4):236-245."
"4990","PC081416","Wang D, Chu P-C, Yang CN, et al.  2012.  Development of a novel class of glucose transporter inhibitors.  J Med Chem 55:3827-3836.  "
"4991","PC081416","Chen CH, Huang PH, Chu PC, et al.  2010.  Epigenetic activation of KLF6 tumor suppressor gene expression by energy restriction in prostate cancer cells, in part, through histone modifications.  J Bio Chem 286:9968-9976."
"4992","PC081416","Berman-Booty LD, Chu PC, Thomas-Ahner JM, et al.  2013.  Suppression of prostate epithelial proliferation and intraprostatic pro-growth and survival signaling in transgenic mice by a novel energy restriction-mimetic agent.  Cancer Prev Res 6:232-241."
"4993","PC081416","Huang PH, Wang D, Chuang HC, et al.  2009.  alpha-Tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis. Carcinogenesis 30(7):1125-1131."
"4994","PC081416","Lin H-Y, Kuo Y-C, Weng Y-I, et al.  2012.  Activation of silenced tumor suppressor genes in prostate cancer cells by a novel glucose transporter inhibitor.  Prostate 72:1767-1778."
"4995","PC081421","Cook CC, and Higuchi M.  2012.  The awakening of an advanced malignant cancer: an insult to the mitochondrial genome.  Biochim Biophys Acta 1820(5):552-562."
"4996","PC081421","Cook CC, Kim A, Terao S et al.  2012.  Consumption of oxygen: a mitochondrial-generated progression signal of advanced cancer.  Cell Death Dis 3:e258."
"4997","PC081460","Kemnade JO, Seethammagari M, Narayanan P, et al.  2012.  Off-the-shelf adenoviral mediated immunotherapy via bicistronic expression of tumor antigen and iMyD88/CD40 adjuvant.  Mol Ther 20(7):1462-1471."
"4998","PC081477","Zammarchi F, Boutsalis G, and Cartegni L.  2013.  5' UTR control of native ERG and of Tmprss2:  ERG variants activity in prostate cancer.  PLoS ONE 8(3):e49721."
"4999","PC081540","Bajjuri KM, Liu Y, Liu C, et al.  2011.  The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity.  Chem Med Chem 6:54-59."
"5000","PC081540","Goswami RK, Liu Y, Liu C, et al.  2013.  Synthesis and evaluation of the aldolase antibody-derived chemical-antibodies targeting alpha5Beta1 integrin.  Mol Pharmaceutics 10:538-543."
"5001","PC081540","Liu Y, Bajjuri KM, Liu C, et al.  2012.  Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug.  Mol Pharm 168-175.

"
"5002","PC081540","Goswami RK, Bajjuri KM, Forsyth JS, et al.  2011.  Chemically programmed antibodies targeting multiple alpha(v) integrins and their effects on tumor-related functions in vitro. Bioconjugate Chem 22:1535-1544."
"5003","PC081559","Xiong Q, Oviedo HV, Trotman LC, et al.  2012.  PTEN regulation of local and long-range connections in mouse auditory cortex.  J Neurosci 32(5):1643-1652."
"5004","PC081559","Cho H, Herzka T, Zheng W, et al.  2014.  Rapid CaP, a novel Gem model for analysis and therapy of metastatic prostate cancer reveals Myc as a driver of Pten-mutant metastasis.  Cancer Discov 4(3):318-333."
"5005","PC081559","Lessard L, Labbé DP, Debloisa G, et al.  2012.  PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer.  Cancer Res 72(6):1529-1537."
"5006","PC081559","Howitt J, Lackovic J, Low LH, et al.  2012.  Ndfip1 regulates nuclear Pten import in vivo to promote neuronal survival following cerebral ischemia.  J Cell Biol 196(1):29-36."
"5007","PC081559","Trotman LC.  2011.  Calling on the cancer sleuths:  How cell biologists will do the detective legwork of the postcancer genome era.  Mol Biol Cell 22(6):715.PMID:  21406578."
"5008","PC081559","Chen M, Pratt CP, Zeeman ME, et al.  2011.  Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression.  Cancer Cell 20(2):173-186."
"5009","PC081559","Alimonti A, Carracedo A, Clohessy JG, et al.  2010.  Subtle variations in Pten dose determine cancer susceptibility.  Nat Genet 42(5):454-458."
"5010","PC081559","Schreiber SL, Shamji AF, Clemons PA, et al.  2010.  Towards patient-based cancer therapeutics.  The Cancer Target Discovery and Development Network.  Nat Biotechnol 28(9):904-906.  
"
"5011","PC081559","Trotman L and Powers S.  2010.  New views into the prostate cancer genome.  Cancer Cell 18(1):1-2."
"5012","PC081560","Tao S, Wang Z, Feng J, et al.  2012.  A genome-side search for loci interacting with known prostate cancer risk-associated genetic variants.  Carcinogenesis 33(3):598-603."
"5013","PC081560","Tao S, Feng J, Webster T, et al.  2012.  Genome-wide two-locus epistasis scans in prostate cancer using two European populations.  Hum Genet 131(7):1225-1234."
"5014","PC081560","Xu J, Zheng S, Isaacsc SD, et. al. 2009. Inherited genetic variant predisposes to aggressive but not indolent prostate. cancer.www.pnas.org/cgi/doi/10.1073/pnas.0914061107."
"5015","PC081594","Abdel-Mageed AB, Moroz K, Srivastav SK, et al.  2013.  High circulating estrogens and selective expression of ER-beta in prostate tumors of Americans:  Implications for racial disparity of prostate cancer.  Carcinogenesis 34(9):2017-2023."
"5016","PC081609","Mazumder R, Morampudi KS, Motwani M, et al.   2012.  Proteome-wide analysis of single-nucleotide variations in the N-glycosylation sequon of human genes.  PLoS One 7(5):e36212.  "
"5017","PC081609","Leymarie N, Griffin PJ, Jonscher, et al.  2013.  Interlaboratory study on differential analysis of protein glycosylation by mass spectrometry: The ABRF glycoprotein research multi-institutional study 2012.  Mol Cell Proteomics 12(10):2935-2951."
"5018","PC081609","Chandler K and Goldman R.  2013.  Glycoprotein disease markers and single protein-omics.  Mol Cell Proteomics 12(4):836-845.  "
"5019","PC081609","Bekesova S.  2012.  N glycans in liver secreted and immunoglobulin-derived protein fractions.  J Proteomics 75(7):2216-2224."
"5020","PC081609","Kosti O, Xu X, Veenstra TD, et al.  2011.  Urinary estrogen metabolites and prostate cancer risk: A pilot Study.  Prostate 71(5):507-516.  

"
"5021","PC081610","Liu G, Perlman S, Perk T, et al.  2015.  Quantitative total bone imaging in patients with metastatic castration-resistant prostate cancer using NaF PET/CT.  J Clin Oncol 33 (e16016)."
"5022","PC081610","Goodin S, Stein MN, Shih W, et al.  2012.  A phase II study of atorvastatin and celecoxib in patients with rising PSA following local therapy for prostate cancer (PC).  J Clin Oncol 30(5):89.

"
"5023","PC081610","Morris MJ, Bruce JY, Reyno LM, et al.  2012.  Phase I trial of ASG-5ME in metastatic castration-resistant prostate cancer (CRPC).  J Clin Oncol 30:4568.

"
"5024","PC081610","Morris MJ, Hammers HJ, Sweeney C, et al.  2012.  A phase I/IIa study of the safety and efficacy of radium-223 chloride (Ra- 223) with docetaxel (D) for castration-resistant prostate cancer (CRPC) patients with bone metastases.  J Clin Oncol 30:TPS4694."
"5025","PC081610","Ryan CJ, Rosenthal M, Ng S, et al.  2012.  A multicenter, randomized phase II study of rilotumumab (R) (AMG 102) or placebo (Pbo) plus mitoxantrone (M) and prednisone (P) in patients (pts) with previously treated castrate-resistant prostate cancer (CRPC).  J Clin Oncol 30(115).

"
"5026","PC081610","Smith MR, Sweeney C, Rathkopf DE, et al.  2012.  Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC):  Results from a phase II nonrandomized expansion cohort (NRE).  J Clin Oncol 30:4513."
"5027","PC081610","Taplin ME, Montgomery RB, Logothetis C, et al.  2012.  Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC):  Results of a randomized phase II study.  J Clin Oncol 30(4521)."
"5028","PC081610","Hussain M, Smith MR, Sweeney C, et al.  2011.  Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC):  Results from a phase II randomized discontinuation trial.  J Clin Oncol 29:4516."
"5029","PC081610","Morris MJ, Farrelly JS, Fox JJ, et al.  2011.  The prostate cancer clinical trials consortium (PCCTC) bone scan data capture tool for clinical trials using Prostate Cancer Working Group 2 (PCWG2) criteria:  Effect on data accuracy and workload.  J Clin Oncol 29(7):121.

"
"5030","PC081610","Petrylak DP, Kantoff PW, Frank RC, et al.  2011.  Prostate-specific membrane antigen antibody¿drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer.  J Clin Oncol 29:4650."
"5031","PC081610","Rathkopf DE, Danila DC, Slovin SF, et al.  2011.  A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC).  J Clin Oncol 29:TPS190."
"5032","PC081610","Smith DC, Smith MR, Small EJ, et al.  2011.  Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease.  J Clin Oncol 29(7):127."
"5033","PC081610","Danila DC, Anand A, Yao J, et al.  2012.  Predictive biomarkers in circulating tumor cells (CTC) from patients with castration-resistant prostate cancer (CRPC) through genomic analysis.  J Clin Oncol 30:4562."
"5034","PC081610","Dennis ER, Jia X, Mezheritskiy IS, et al.  2012.  Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.  J Clin Oncol 10:30(5):519-524."
"5035","PC081610","Antonarakis ES, Heath EI, Posadas EM, et al.  2012.  Prostate cancer clinical trials consortium (PCCTC).  A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer (CRPC):  A PCCTC trial.  J Clin Oncol 30(4654)."
"5036","PC081610","Petrylak DP, Gandhi JG, Clark WR, et al.  2012.  Phase I results from a phase I/II study of orteronel, an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC).  J Clin Oncol 30:4656.

"
"5037","PC081610","Rathkopf DE, Danila DC, Morris MJ, et al.  2012.  Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a prostate cancer clinical trials consortium study.  J Clin Oncol 30(5):43.

"
"5038","PC081610","Rathkopf DE, Shore N, Antonarakis ES, et al.  2012.  A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC).  J Clin Oncol 30:TPS4697."
"5039","PC081610","
Ward JE, Karrison T, Chatta G, et al.  2012.  A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.  Prostate Cancer Prostatic Dis 15(1):87-92.
"
"5040","PC081610","Danila DC, Anand A, Yao J, et al.  2011.  Genomic analysis of circulating tumor cells to evaluate predictive biomarkers.  J Clin Oncol 29:7-38."
"5041","PC081610","Dennis ER, Fox JJ, Larson SM, et al.  2011.  The PCCTC imaging data capture toolset:  An analysis of its impact on prostate cancer clinical trial accuracy and workload.  J Clin Oncol 29:4635."
"5042","PC081610","Palmbos PL, Feng FYC, Tomlins SA, et al.  2015.  A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer.  J Clin Oncol 33(TPS5074)."
"5043","PC081610","Friedlander TW, Graff JN, Zhang L, et al.  2015.  Initial results from a phase II study of increased-dose abiraterone acetate in patients with castration resistant prostate cancer (CRPC).  J Clin Oncol 33(7):188."
"5044","PC081610","Morris MJ, Molina A, Small EJ, et al.  2015.  Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer.  COU-AA-302 Results.  J Clin Oncol 33(12):1356-1363."
"5045","PC081610","Scher HI, Morris MJ, Stadler WM, et al.  2015.  The prostate cancer working group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC).  J Clin Oncol 33(5000)."
"5046","PC081610","Scher HI, Heller G, Molina A, et al.  2015.  Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.  J Clin Oncol 33(12):1348-1355."
"5047","PC081610","Touijer KA, Chen Y, Carver BS, et al.  2014.  Establishing a neoadjuvant platform for developing targeted agents:  Degarelix prior to prostatectomy for patients with intermediate- and high-risk prostate cancer.  J Clin Oncol 32:5s(TPS5105)."
"5048","PC081610","Quinn DI, Vaishampayan U, Higano CS, et al.  2014.  Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.  Expert Rev Anticancer Ther 14(1):51-61."
"5049","PC081610","Armstrong AJ, Halabi S, Healy P, et al.  2015.  A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy (RT) in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).  J Clin Oncol 33:7-35."
"5050","PC081610","Beer TM, Hotte SJ, De Bono JS, et al.  2014.  Pain palliation as an oncology label indication: Lessons learned in custirsen phase III development.  J Clin Oncol 32:4-222."
"5051","PC081610","Hussain M, Miller K, Rybicka I, et al.  2014.  Primary outcomes of the placebo-controlled phase 2 study PERSEUS (NCT01360840) investigating two dose regimens of abituzumab (DI17E6, EMD 525797) in the treatment of chemotherapy-naive patients (pts) with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC).  J Clin Oncol 32:5s(5030)."
"5052","PC081610","Aggarwal RR, Bryce AH, Weinberg VK, et al.  2015.  A multicenter phase I study of cabazitaxel (Cbz), mitoxantrone (Mito), and prednisone (Pred) (CAMP) for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC).  J Clin Oncol 33(7):238."
"5053","PC081610","Hussain M, Carducci MA, Slovin S, et al.  2014.  Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.  Invest New Drugs 32(5):904-912."
"5054","PC081610","Hussain M, Corn PG, Michaelson MD, et al.  2014.  Prostate Cancer Clinical Trials Consortium, A Program of the Department of Defense Prostate Cancer Research Program and the Prostate Cancer Foundation.  Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen.  Clin Cancer Res 20(16):4218-4227."
"5055","PC081610","Smith MR, Sweeney CJ, Corn PG, et al.  2014.  Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: Results of a Phase II nonrandomized expansion study.  J Clin Oncol 32(30):3391-3399."
"5056","PC081610","Antonarakis ES, Heath EI, Smith DC, et al.  2013.  Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer.  Oncologist.  18(2):163-173."
"5057","PC081610","Antonarakis ES, Heath EI, Posadas EM, et al.  2013.  A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.  Cancer Chemother Pharmacol 71(4):883-892."
"5058","PC081610","Bianchini D, Omlin A, Pezaro C, et al.  2013.  First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castrationresistant prostate cancer.  Br J Cancer 109(10):2579-2586."
"5059","PC081610","Corn PG, Song DY, Heath E, et al.  2013.  Plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: Results from a multi-institutional Phase 1 study.  Int J Radiat Oncol Biol Phys 86(3):540-545."
"5060","PC081610","Freedland SJ, Carducci MA, Kroeger N, et al.  2013.  A double-blind, randomized, neoadjuvant study of the tissue effects of Pomx pills in men with prostate cancer prior to radical prostatectomy.  Cancer Prev Res (Phila) 6(10):1120-1127."
"5061","PC081610","Lin J, Zahurak M, Beer TM, et al.  2013.  A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.  Urol Oncol 31(5):581-588."
"5062","PC081610","Paller CJ, Ye X, Wozniak PJ, et al.  2013.  A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer.  Prostate Cancer Prostatic Dis 16(1):50-55."
"5063","PC081610","Rathkopf DE, Morris MJ, Fox JJ, et al.  2013.  Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.  J Clin Oncol 31(28):3525-3350."
"5064","PC081610","Rathkopf DE, Picus J, Hussain A, et al.  2013.  A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer.  Cancer Chemother Pharmacol 72(3):537-544."
"5065","PC081610","Scher HI, Morris MJ, Larson S, et al.  2013.  Validation and clinical utility of prostate cancer biomarkers.  Nat Rev Clin Oncol 10(4):225-234."
"5066","PC081610","Slovin SF, Higano CS, Hamid O, et al.  2013.  Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.  Ann Oncol 24(7):1813-1821."
"5067","PC081610","Smith DC, Smith MR, Sweeney C, et al.  2013.  Cabozantinib in patients with advanced prostate cancer: results of a Phase II randomized discontinuation trial.  J Clin Oncol 31(4):412-419."
"5068","PC081610","Antonarakis ES, Kibel AS, Adams GW, et al.  2015.  Antigen-specific immune responses through 24 months in the STAND trial:  A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC).  J Clin Oncol 33(7):171."
"5069","PC081610","Petrylak DP, Smith DC, Appleman LJ, et al.  2014.  A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxanerefractory metastatic castration-resistant prostate cancer (mCRPC).  J Clin Oncol 32 (4):83."
"5070","PC081610","Taplin ME and Montgomery RB.  2014.  ARMOR2 Group.  ARMOR2: Galeterone in progressive CRPC patients who have failed oral therapy.  J Clin Oncol 32 (4):71."
"5071","PC081610","Montgomery RB, Eisenberger MA, Heath EI, et al.  2014.  Galeterone in men with CRPC: Results in four distinct patient populations from the ARMOR2 study.  J Clin Oncol 32:5s(5029)."
"5072","PC081610","Basch E, Autio KA, Smith MR, et al.  2015.  Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.  Eur Urol 67(2):310-318."
"5073","PC081610","Palmbos PL, Feng FYC, Tomlins SA, et al.  2015.  A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer.  J Clin Oncol 33(TPS5074)."
"5074","PC081610","Courtney KD, Manola JB, Elfiky AA, et al.  2015.  A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.  Clin Genitourin Cancer 13(2):113-123."
"5075","PC081610","McKay RR, Werner L, Zukotynski KA, et al.  2014.  Results of a phase II trial of abiraterone acetate (AA) combined with dutasteride (DUT) for men with metastatic castration resistant prostate cancer (mCRPC).  J Clin Oncol 32(4):126."
"5076","PC081610","Siegel AP, Bryce AH, Lin AM, et al.  2014.  Results of a multicenter phase I/II trial of abiraterone acetate plus BEZ235 in metastatic, castration-resistant prostate cancer (mCRPC).  J Clin Oncol 32(e16042)."
"5077","PC081610","Petrylak DP, Gandhi JG, Clark WR, et al.  2015.  Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castrationresistant prostate cancer.  Invest New Drugs 33(2):397-408."
"5078","PC081610","Rathkopf RE, Carver BS, Chen Y, et al.  2014.  Targeting reciprocal feedback inhibition in the clinic:  ARN509 and PI3K pathway inhibition in patients with metastatic castration-resistant prostate cancer (mCRPC).  J Clin Oncol 32:5s(TPS5106)."
"5079","PC081610","Rathkopf DE, Antonarakis ES, Shore ND, et al.  2014.  ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment.  J Clin Oncol 32:5s(5026)."
"5080","PC081610","Danila DC, Szmulewitz RZ, Baron AD, et al.  2014.  A phase I study of DSTP3086S, an antibody-drug conjugate (ADC) targeting STEAP-1, in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).  J Clin Oncol 32:5s(5024)."
"5081","PC081610","Aggarwal RR, Weinberg VK, Ryan CJ, et al.  2014.  A multicenter phase I study of cabazitaxel (Cbz), mitoxantrone (Mito), and prednisone (Pred) (CAMP) for chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC).  J Clin Oncol 32(4):243."
"5082","PC081610","Aggarwal RR, Weinberg VK, Ryan CJ, et al.  2014.  A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naive patients with metastatic castration-resistant prostate cancer.  J Clin Oncol 32(16060)."
"5083","PC081610","Monk P, Liu G, Stadler WM, et al.  2015.  Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC).  J Clin Oncol 33(7):146."
"5084","PC081610","Corn PG, Tu SM, Zurita AJ, et al.  2014.  A randomized phase I/II study to examine the contribution of carboplatin to cabazitaxel for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) with and without anaplastic features.  J Clin Oncol 32(4):148."
"5085","PC081610","Corn PG, Tu SM, Zurita AJ, et al.  2015.  A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC).  J Clin Oncol 33(5010)."
"5086","PC081610","Rathkopf D, Wong BY, Ross RW, et al.  2010.  A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.  Cancer Chemother Pharmacol 66(1):181-189."
"5087","PC081610","Anand A, Scher HI, Beer TM, et al.  2010.  Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100.  J Clin Oncol 28(7s) [abstract 4546]."
"5088","PC081610","Carducci MA, Eisenberger MA, Denmeade SR, et al.  2010.  Phase I dose-escalation study of AGS-1C4D4, an anti-PSCA human antibody in castration-resistant prostate cancer (CRPC).  J Clin Oncol 28(7s) [abstract 4669]."
"5089","PC081610","Scher HI, Beer TM, Higano CS, et al.  2010.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study.  Lancet 24;375(9724):1437-1446.

"
"5090","PC081610","Danila DC, Morris MJ, de Bono JS, et al.  2010.  Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.  J Clin Oncol 28(9):1496-501."
"5091","PC081610","Reid AH, Attard G, Danila DC, et al.  2010.  Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.  J Clin Oncol 28(9):1489-95."
"5092","PC081610","Rathkopf D, Liu G, Carducci MA, et al.  2011.  Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer.  Clin Cancer Res 17(4):880-887."
"5093","PC081610","Ryan CJ, Shah SK, Efstathiou E, et al.  2011.  Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.  Clin Cancer Res 17(14):4854-4861."
"5094","PC081610","Yu EY, Massard C, Gross ME, et al.  2011.  Once-daily dasatinib: Expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration resistant prostate cancer.  Urology 77(5):1166-1171."
"5095","PC081610","Araujo J and Logothetis C.  2010.  Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.  Cancer Treat Rev 36(6):492-500."
"5096","PC081610","Armstrong AJ, Netto GJ, Rudek MA, et al.  2010.  A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.  Clin Cancer Res 1;16(11):3057-3066."
"5097","PC081610","Beer TM, Ryan C, Alumkal J, et al.  2010.  A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.  Anticancer Drugs 21(4):433-438."
"5098","PC081610","Dreicer R, Garcia J, Hussain M, et al.  2010.  Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease.  Invest New Drugs. "
"5099","PC081610","Garzotto M, Higano CS, O'Brien C, et al.  2010.  Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.  Cancer 116(7):1699-1708."
"5100","PC081610","Keizman D, Zahurak M, Sinibaldi V, et al.  2010.  Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: Results of a phase I/II double-blinded, randomized study.  Clin Cancer Res 1;16(21):5269-5276."
"5101","PC081610","Lilja H and Scher HI.  2010.  Detection of androgen receptor mutations in circulating tumor cells: Highlights of the long road to clinical qualification.  Clin Chem 56(9):1375-1377."
"5102","PC081610","Bradley DA, Rathkopf D, Dunn R, et al.  2009.  Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (NCI Trial 6862): Trial results and IL-6 analysis.  A study by the Department of Defense prostate cancer clinical trial consortium and University of Chicago phase II consortium.  Cancer 115(23):5541-5549.

"
"5103","PC081610","Bradley D, Rathkopf D, Dunn R, et al.  2009.  Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): Trial results and interleukin-6 analysis: A study by the Department of Defense prostate cancer clinical trial consortium and University of Chicago phase 2 consortium.  Cancer 115(23):5541-5549."
"5104","PC081610","Ryan CJ, Smith MR, Fong L, et al.  2009.  Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.  J Clin Oncol 20;28(9):1481-1488."
"5105","PC081610","Taplin ME, Regan MM, Ko YJ, et al.  2009.  Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.  Clin Cancer Res 15;15(22):7099-7105."
"5106","PC081610","Tran C, Ouk S, Clegg NJ, et al.  2009.  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.  Science 324(5928):787-790."
"5107","PC081610","Yu EY, Wilding G, Posadas E, et al.  2009.  Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.  Clin Cancer Res 15(23):7421-7428."
"5108","PC081610","Higano CS, Corman JM, Smith DC, et al.  2008.  Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer.  Cancer 113:975-984."
"5109","PC081610","Shah S and Ryan C.  2010.  Abiraterone acetate for castration resistant prostate cancer.  Expert Opin Investig Drugs (4):563-570.

"
"5110","PC081610","Liu G, Kelly WK, Wilding G, et al.  2009.  An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer.  Clin Cancer Res 15(9):3172-3176.

"
"5111","PC081610","Morris MJ, Basch EM, Wilding G, et al.  2009.  Department of Defense prostate cancer clinical trials consortium: A new instrument for prostate cancer clinical research.  Clin GU Cancer 7;51-57."
"5112","PC081610","Rosenberg JE, Ryan CJ, Weinberg VK, et al.  2009.  Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: A study of the Department of Defense prostate cancer clinical trials consortium.  J Clin Oncol 27:2772-2778."
"5113","PC081610","Scher HI, Halabi S, Tannock I, et al.  2008.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group.  J Clin Oncol 26:1148-1159."
"5114","PC081610","Basch EM, Somerfield MR, Beer TM, et al.  2007.  American society of clinical oncology endorsement of the cancer care Ontario practice guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration resistant) prostate cancer.  J Clin Oncol 25:5313-5318."
"5115","PC081610","Rathkopf DE, Carducci MA, Morris M, et al.  2008.  A phase II trial of docetaxel with rapid androgen cycling as a treatment for patients with prostate cancer.  J Clin Oncol 26:2959-2965."
"5116","PC081610","Lin AM, Ryan CJ, and Small EJ.  2007.  Intermittent chemotherapy for metastatic hormone refractory prostate cancer.  Crit Rev Oncol Hematol 61:243-254.

"
"5117","PC081610","Beekman KW, Colevas AD, Cooney K, et al.  2006.  Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: Scientific rationale and study design.  Clin Genitourin Cancer 4:299-302."
"5118","PC081610","Ross RW, Beer TM, Jacobus S, et al.  2008.  A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone refractory prostate cancer who are refractory to docetaxel.  Cancer 112:521-526."
"5119","PC081610","Montgomery RB, Eisenberger MA, Rettig M, et al.  2012.  Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC).  J Clin Oncol 30(4665)."
"5120","PC081610","Montgomery RB, Joshua A, Hannah AL, et al.  2012.  A randomized, open-label, phase II study of MDV3100 alone or in combination with leuprolide and dutasteride as neoadjuvant therapy to prostatectomy in intermediate and high-risk prostate cancer.  J Clin Oncol 30:TPS4695.

"
"5121","PC081610","George DJ, Corn PG, Michaelson MD, et al.  2012.  Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA):  Updated results of a phase II study.  J Clin Oncol 30(4549)."
"5122","PC081613","Armstrong AJ, Netto GJ, Rudek MA, et al.  2010.  A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.  Clin Cancer Res 16(11):3057-3066.
"
"5123","PC081629","Yu EY, Duan F, Muzi M, et al.  2015.  Castration-resistant prostate cancer bone metastasis response measured by 18F-Fluoride PET after treatment with Dasatinib and correlation with progression-free survival: Results from American College of Radiology Imaging Network 6687.  J Nucl Med 56(3):354-360."
"5124","PC081629","McKay RR, Mamlouk K, Montgomery B, et al.  2014.  Treatment with Galeterone in an elderly man with castration-resistant prostate cancer: A case report.  Clin Genitourin Cancer S1558-7673(14)00289-4."
"5125","PC081629","Aggarwal RR, Beer TM, Weinberg VK, et al.  2014.  Intermittent chemotherapy as a platform for testing novel agents in patients with metastatic castration-resistant prostate cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel with prednisone with or without maintenance GM-CSF.  Clin Genitourin Cancer S1558-7673(14)00264-X."
"5126","PC081629","Courtney K, Manola J, Elfiky A, et al.  2014.  2014.  A phase I study of everolimus and docetaxel in patients with castration resistant prostate cancer.  Clin Genitourin Cancer, S1558-7673(14)00199-2."
"5127","PC081629","Ross RW, Galsky MD, Febbo P, et al.  2012.  Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer:  A prostate cancer clinical trials consortium trial.  Cancer 118(19):4777-4784."
"5128","PC081629","McKay RR, Zukotynski KA, Werner L, et al.  2014.  Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer.  Prostate Cancer Prostatic Dis 17(4):325-331."
"5129","PC081629","Mostaghel EA, Nelson PS, Lange P, et al.  2014.  Targeted androgen pathway suppression in localized prostate cancer: a pilot study.  Clin Oncol 32(3):229-237."
"5130","PC081629","Galsky MD, Xie W, Nakabayashi M, et al.  2013.  Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer.  Prostate Cancer Prostatic Dis 16(3):266-270."
"5131","PC081629","Scher HI, Beer TM, Higano CS, et al.  2010.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.  Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium.  Lancet 375(9724):1437-1446."
"5132","PC081629","Danila DC, Morris MJ, de Bono JS, et al.  2010.  Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.  J Clin Oncol 28(9):1496-1501."
"5133","PC081629","Taplin ME, Regan MM, Ko YJ, et al.  2009.  A phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.  Clin Cancer Res 15(22):7099-7105."
"5134","PC081629","Taplin ME, Montgomery B, Logothetis CJ, et al. 2014.  Intense androgen-deprivation therapy with abiraterone acetate plus Leuprolide Acetate in
patients with localized high-risk prostate cancer: Results of a randomized phase II neoadjuvant study.  J Clin Oncol 32(33):3705-3715."
"5135","PC081629","Chen E, Sowalsky AG, Gao S, et al.  2015.  Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.  Clin Cancer Res 21(6):1273-1280."
"5136","PC081633","Lin J, Zahurak M, Beer TM, et al.  2013.  A non-comparative randomized phase II study of 2 doses of ATN- 224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone naïve prostate cancer.  Urol Oncol 31(5):581-588."
"5137","PC081633","Basch EM, Bennett AV, Autio KA, et al.  2013.  Prevalence of pain and analgesic use in a contemporary cohort of men with metastatic prostate cancer using patient-reported outcomes.  J Oncol Pract 9(5):223-229."
"5138","PC081633","Slovin SF, Higano CS, Hamid O, et al.  2013.  Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase I/II study.  Ann Oncol 24(7):1813-1821."
"5139","PC081633","Beer TM, Smith DC, Hussain A, et al.  2012.  Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium.  Br J Cancer 107(5):808-983."
"5140","PC081633","Harzstark AL, Rosenberg JE, Weinberg VK, et al.  2011.  Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: A phase 2 study of the Department of Defense prostate cancer clinical trials consortium.  Cancer 117(11):2419-2425.

"
"5141","PC081633","Scher HI, Beer TM, Higano C, et al.  2010.  Antitumor activity of MDV3100 in a Phase 1-2 study of castration-resistant prostate cancer.  The Lancet 375(9724):1437-1446."
"5142","PC081633","Barnett CM, Flamiatos JF, and Beer TM.  2011.  Prolonged response to early docetaxel in a patient with biochemical relapse after primary therapy for prostate cancer and incomplete response to androgen suppression therapy.  Anticancer Res 31(3): 973-974."
"5143","PC081633","Taplin M, Regan M, Ko Y, et al.  2009.  Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer.  Clin Cancer Res 15(22):7099-7105."
"5144","PC081633","Rosenberg JE, Ryan CJ, Weinberg VK, et al.  2009.  Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration resistant prostate cancer previously treated with docetaxel-based therapy: A study of the department of defense prostate cancer clinical trials consortium.  J Clin Oncol 27(17):2772-2778."
"5145","PC081633","Basch EM, Somerfield MR, Beer TM, et al.  2007.  American society of clinical oncology endorsement of the cancer care Ontario practice guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.  J Clin Oncol 25(33):5313-5318."
"5146","PC081633","Scher HI, Halabi S, Tannock I, et al.  2008.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group.  J Clin Oncol 26(7):1148-1159."
"5147","PC081633","Ross RW, Beer TM, Jacobus S, et al.  2008.  A phase II study of carboplatin plus docetaxel in men with metastatic hormone refractory prostate cancer who are refractory to docetaxel.  Cancer 112(3):521-526."
"5148","PC081633","Tran C, Ouk S, Clegg NJ, et al.  2009.  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.  Science 324(5928):787-790."
"5149","PC081633","Morris MJ, Basch EM, Wilding G, et al.  2009.  Department of defense prostate cancer clinical trials consortium: A new instrument for prostate cancer clinical research.  Clin GU Cancer 7(1):51-57."
"5150","PC081633","Ryan CJ, Rosenthal M, Ng S, et al.  2013.  Targeted MET inhibition in castration-resistant prostate cancer: A randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone.  Clin Cancer Res 19(1):215-224."
"5151","PC081633","Beer TM, Ryan C, Alumkal J, et al.  2010.  A Phase II study of Paclitaxel Poliglumex (PPX) in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.  Anticancer Drugs 21(4):433-438."
"5152","PC081639","Corn PG, Song DY, Heath E, et al.  2013.  Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: Results from a multi-institutional phase 1 study.  Int J Radiat Oncol Biol Phys 28:S0360-3016(13)00177-6."
"5153","PC081639","Schweizer MT, Lin J, Blackford A, et al.  2013.  Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer.  Prostate Cancer and Prostatic Disease 16:357-361."
"5154","PC081639","Autio KA, Bennett AV, Jia X, et al.  2013.  Prevalence of pain and analgesic use in a contemporary cohort of men with metastatic prostate cancer using patient reported outcomes.  J Oncol Practice 9:223-229."
"5155","PC081639","Armstrong AJ, Haggman M, Stadler WM, et al.  2013.  Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.  Clin Cancer Res 19:6891-6901."
"5156","PC081639","Paller CJ, Olatoye D, Xie, S, et al.  2014.  The effect of the frequency and duration of prostate specific antigen (PSA) measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer.  Prostate Cancer Prostatic Dis 17:28-33."
"5157","PC081639","Paller CJ, Antonarakis ES, Eisenberger MA, et al.  2013.  Management of patients with biochemical recurrence after local therapy for prostate cancer.  Hematol Oncol Clin North Am 27:1205-1219."
"5158","PC081639","Antonarakis ES, Heath EI, Smith DC, et al.  2013.  Repurposing itraconazole as a treatment for advanced prostate cancer: A noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer.  Oncologist 18(2):163-73."
"5159","PC081639","Antonarakis ES, Heath EI, Posadas EM, et al.  2013.  A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.  Cancer Chemother Pharmacol 71(4):883-892."
"5160","PC081639","Freedland SJ, Carducci M, Kroeger N, et al.  2013.  A double blind, randomize neoadjuvant study of the tissue effects of POMx Pills in Men with prostate cancer prior to radical prostatectomy.  Cancer Prevent Res 6(10):1120-1127.

"
"5161","PC081639","Armstrong AJ, Netto GJ, Rudek MA, et al.  2010.  A pharmacodynamic study of rapamycin in men with intermediate to high risk localized prostate cancer.  Clin Cancer Res (in press)."
"5162","PC081639","Morris MJ, Basch EM, Wilding G, et al.  2009.  Department of Defense Prostate Cancer Clinical Trials Consortium:  A new instrument for prostate cancer clinical research.  Clin Genitourin Cancer 7(1):51-57.
"
"5163","PC081639","Keizman D, Zahurak M, Sinibaldi V, et al.  2010.  Lenalidomide in non-metastatic biochemically relapsed prostate cancer:  Results of a phase I/II double blinded randomized study.  Clin Cancer Res 16:5269-5276."
"5164","PC081639","Pili R, Haggman M, Stadler W, et al.  2011.  Phase II randomized double blind placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.  J Clin Oncol 29:4022-4028."
"5165","PC081639","Antonarakis ES, Zahurak ML, Lin J, et al.  2012.  Changes in PSA kinetics predict metastasis-free survival in men with PSA-recurrent prostate cancer treated with non-hormonal agents: Combined analysis of 4 phase II trials.  Cancer 118:1533-1542."
"5166","PC081639","Taplin ME, Regan MM, Ko YJ, et al.  2009.  Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.  Clin Cancer Res 15(22):7099-7105.

"
"5167","PC081639","Alva A, Slovin S, Daignault S, et al.  2010.  Phase II study of cilengitide in patients with non-metastatic castration resistant prostate cancer, NCI-6735.  A study by the DOD/PCF prostate cancer clinical trials consortium.  Invest New Drugs 30:749-757. "
"5168","PC081639","Danila DC, Morris MJ, deBono JS, et al.  2010.  Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.  J Clin Oncol 28:1496-1501."
"5169","PC081639","Rathkopf D, Liu G, Carducci MA, et al.  2011.  Phase I dose-escalation study of the novel anti-androgen BMS-641988 in patients with castration-resistant prostate cancer.  Clin Cancer Res 17:880-887. "
"5170","PC081639","Yu EY, Massard C, Gross ME. et al.  2011.  Once daily dasatinib: Expansion of a phase 2 study evaluating the safety and efficacy of dasatinib in patients with metastatic castration resistant prostate cancer.  Urology 77:1166-1171.

"
"5171","PC081639","Antonarakis E, Carducci M, Eisenberger M, et al.  2012.  Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: A PCCTC trial.  Cancer Chemot Pharmacol 69:763-771."
"5172","PC081639","Lin J, Zahurak M, Beer TM, et al.  2011.  A non-comparative randomized phase II study of two doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemical recurrent hormone-naïve prostate cancer.  Urol Oncol 31(5):581-588."
"5173","PC081639","Zabransky DJ, Smith HA, Thoburn CJ, et al.  2011.  Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.  Prostate 72:487-498."
"5174","PC081639","Morris M, Eisenberger MA, Pili R, et al.  2012.  A phase I/IIa study of AGS-PSCA for castration-resistant prostate cancer.  Ann Oncol 23:2714-2719. "
"5175","PC081640","Bradley DA, Daignault S, Ryan CJ, et al.  2011.  Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium.  Invest New Drugs 29(6):1432-1440."
"5176","PC081653","DeFord-Watts LM, Mintz A, and Kridel SJ.  2013.  The potential of 11C-acetate PET for monitoring the fatty acid synthesis pathway in tumors.  Curr Pharm Biotechnol 14(3):300-312."
"5177","PC081656","Hussain M, Smith MR, Sweeney C, et al.  2011.  Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.  J Clin Oncol 29:2011 (suppl; abstr 4516)."
"5178","PC081656","Antonarakis ES, Heath EI, Smith DC, et al.  2013.  Repurposing Itraconazole as a treatment for advanced prostate cancer: A noncomparative randomized Phase II trial in men with metastatic castration-resistant prostate cancer.  Oncologist 18(2):163-173."
"5179","PC081656","Corn PG, Song DY, Heath E, et al.  2013.  Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: Results from a multi-institutional phase 1 study.  Int J Radiat Oncol Biol Phys 86(3):540-545."
"5180","PC081656","Antonarakis ES, Heath EI, Posadas EM, et al.  2013.  A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.  Cancer Chemother Pharmacol 71(4):883-892."
"5181","PC081656","Antonarakis ES, Heath EI, Smith DC, et al.  2011.  A noncomparative randomized phase II study of two dose levels of itraconazole in men with metastatic castration¿resistant prostate cancer (mCRPC): A DOD/PCCTC trial.  J Clin Oncol 29:2011 (suppl; abstr 4532)."
"5182","PC081656","Najy AJ, Jung YS, Won JJ, et al.  2012.  Cediranib inhibits both the intraosseous growth of PDGF D¿positive prostate cancer cells and the associated bone reaction.  Prostate 72(12):1328-1338."
"5183","PC081656","Goodin S, Stein MN, Shih W, et al.  2012.  A phase II study of atorvastatin and celecoxib in patients with rising PSA following local therapy for prostate cancer (PC).  J Clin Oncol (suppl 5; abstr 89)."
"5184","PC081663","Singh AA, Jones LW, Antonelli JA, et al.  2013.  Association between exercise and primary incidence of prostate cancer: Does race matter?  Cancer 119(7):1338-1343."
"5185","PC081663","Bañez LL, Albisinni S, Freedland SJ, et al.  2012.  The impact of obesity on the predictive accuracy of PSA in men undergoing prostate biopsy.  World J Urol 80(1):162-167."
"5186","PC081663","Chu DI, De Nunzio C, Gerber L, et al.  2011.  Predictive value of digital rectal examination for prostate cancer detection is modified by obesity.  Prostate Cancer Prostatic Dis 14(4):346-353."
"5187","PC081663","Moreira DM, Banez LL, Presti Jr JC, et al.  2010.  Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the SEARCH database.  BJU Int 105(1):28-33."
"5188","PC081663","Banez LL, Loftis RM, Freedland SJ, et al.  2010.  The influence of hepatic function on prostate cancer outcomes after radical prostatectomy.  Prostate Cancer Prostatic Dis 13(2):173-177."
"5189","PC081663","Banez LL, Klink JC, Jayachandran J, et al.  2010.  Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy.  Cancer Epidemiol Biomarkers Prev 19(3):722-728."
"5190","PC081663","Lloyd JC, Banez LL, Aronson WJ, et al.  2010.  Estimated blood loss as a predictor of PSA recurrence after radical prostatectomy:  Results from the SEARCH database.  BJU Int 105(3):247-251."
"5191","PC081663","Jayachandran J, Banez LL, Aronson WJ, et al.  2009.  Obesity as a predictor of biochemical recurrence across black and white race: results from the SEARCH database.  Cancer 115(22):5263-5271."
"5192","PC081663","Banez LL, Sun L, Trock BJ, et al.  2009.  Body mass index and prostate specific antigen as a predictor of adverse pathology and biochemical recurrence following radical prostatectomy.  
J Urol 182(2):491-496.

"
"5193","PC081663","Antonelli JA, Jones LW, Banez LL, et al.  2009.  Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy.  J Urol 182(5):2226-2231.

"
"5194","PC081664","Tagawa ST, Hahn NM, Vaena DA, et al.  2011.  Radiolabeled anti-prostate specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) for nonmetastatic castration-resistant prostate cancer (CRPC): A randomized phase II trial.  J Clin Oncol 29:(suppl; abstrTPS193)."
"5195","PC081664","Akhtar NH, Pail O, Saran A, et al.  2012.   Prostate-specific membrane antigen-based therapeutics. Adv Urol 2012:973820."
"5196","PC081669","Chandler PD, Giovannucci EL, Scott JB, Bennett GG, et al. 2015. Effects of Vitamin D Supplementation on C-peptide and 25-hydroxyvitamin D Concentrations at 3 and 6 Months. Scientific Reports. 5:10411."
"5197","PC081669","Chandler PD, Scott JB, Drake BF, Ng K, et al. 2015. Impact of vitamin D supplementation on adiposity in African-Americans. Nutr Diabetes. 5:e164."
"5198","PC081669","Drake BF and Colditz GA.  2009.  Assessing cancer prevention studies:  A matter of time.  J Am Med Assoc 302(19):2152-2153."
"5199","PC081672","Aggarwal RR, Beer TM, Weinberg VK, et al.  2015.  Intermittent chemotherapy as a platform for testing novel agents in patients with metastatic castration-resistant prostate cancer:  A Department of Defense prostate cancer clinical trials consortium randomized Phase II trial of intermittent docetaxel with prednisone with or without maintenance GM-CSF.  Clin Genitourin Cancer 191-198."
"5200","PC081672","Kim W, Zhang L, Wilton JH, et al.  2014.  Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetatein castration-resistant prostate cancer and the predictive value of circulating androgens.  Clin Cancer Res 20(24) 6269-6276."
"5201","PC081672","Smith DC, Smith MR, Sweeney C, et al.  2013.  Cabozantinib in patients with advanced prostate cancer:  Results of a Phase II randomized discontinuation trial.  J Clin Oncol 31(4):412-419."
"5202","PC081686","Schayek H, Bentov I, Sun S, et al.  2010.  Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of insulin-like growth factor-I receptor gene.  Exp Cell Res. 316(9):1749-88."
"5203","PC081686","Molife LR, Attard G, Fong PC, et al.  2010.  Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).  Ann Oncol 21(1):109-113."
"5204","PC081686","Graff J, Smith DC, Neerukonda L, et al.  2008.  Phase II study of sagopilone (ZK-EPO) plus prednisone as first-line chemotherapy in patients with metastatic androgen-independent prostate cancer (AIPC).  ASCO Annual Meeting, Chicago, Illinois.  J Clin Oncol 26."
"5205","PC081686","Scher HI, Halabi S, Tannock I, et al.  2008.  Design and endpoints of Phase 2 trials for patients with progressive prostate cancer and castrate levels of testosterone.  Recommendation of the Prostate Cancer Trials Working Group (PCWG2).  J Clin Oncol 26(7):1159.

"
"5206","PC081686","Yu EY, Wilding G, Posadas M, et al.  2009.  Phase 2 study of dasatinib in patients with metastatic castration-resistant prostate cancer.  Clin Cancer Res 15(23):7421-7428."
"5207","PC081686","Lord JD, Hackman R, Moklebust A, et al.  2010.  Refractory colitis following anti-CTLA4 antibody therapy: Analysis of mucosal FOXP3+ T cells.  Dig Dis Sci. 55(5):1396-405."
"5208","PC081686","Yu EY, Massard C, Gross M, et al.  2011.  Once-daily dasatinib: Expansion of a phase 2 study evaluating the safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.  Urology 77(5):1166-1171."
"5209","PC081686","Scher HI, Beer TM, Higano CS, et al.  2010.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study.  Lancet 375(9724):1437-46."
"5210","PC081686","Basch E, Somerfield M, Beer T, et al.  2007.  No title given.  American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Non-hormonal Therapy for Men with Metastatic Hormone-refractory (Castration-resistant) Prostate Cancer.  J Clin Oncol 25(33):5313-5318.  [Oct 9 epub]."
"5211","PC081686","Dean JP, Sprenger CC, Wan J, et al.  2013.  Response of the Insulin-Like Growth Factor (IGF) system to IGF-1R inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: Effects of obesity and androgen deprivation.  J Clin Endocrinol 98(5):E820-E828.

"
"5212","PC081686","Morris MJ, Basch EM, Wilding G, et al.  2009.  Department of Defense prostate cancer clinical trial consortium: A new instrument for prostate cancer clinical research.  Clin Genitourin Cancer 7(1):51-57."
"5213","PC081686","Antonarakis ES, Heath El, Posadas EM, et al.  2013.  A phase 2 study of KX2-391, an oral inhibitor of SRC kinase and tubulin polymerization, in men with bone metastatic castration-resistant prostate cancer.  Cancer Chemother Pharmacol 71(4):883-892."
"5214","PC081686","Menon MP and Higano CS.  2013.  Enzalutamide, a second generation androgen receptor antagonist:  Development and clinical applications in prostate cancer.  Curr Oncol Rep 15(2):69-75."
"5215","PC081686","Scher HI, Fizazi K, Saad F, et al.  2012.  Increased survival with enzalutamide in prostate cancer after chemotherapy.  N Engl J Med 367(13):1187-1197."
"5216","PC081686","Ryan CJ, Smith MR, de Bono JS, et al.  2012.  Abiraterone in metastatic prostate cancer with no prior chemotherapy.   N Engl J Med 368(2):138-148.  "
"5217","PC081686","Slovin SF, Higano CS, Hamid O, et al.  2013.  Lpilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase 1/11 study.  Ann Oncol 24(7):1813-1821."
"5218","PC081686","Mulders PFA, Molina A, Marberger M, et al.  2014.  Efficacy and safety of abiraterone acetate in elderly (¿75 Yr) patient subgroup with metastatic castration-resistant prostate cancer post-docetaxel-based chemotherapy.  Eur Urol. 65(5):875-883."
"5219","PC081686","Higano CS, Beer TM, Yu EY, et al.  2011.  647 phase 1-2 study of MDV3100 in pre- and post-docetaxel advanced prostate cancer: Long-term efficacy results.  J Urol 185(4s): e262.  

"
"5220","PC081735","Hellenthal NJ, Parikh-Patel A, Bauer K, et al.  2010.  Men of higher socioeconomic status have improved outcomes after radical prostatectomy for localized prostate cancer.  Urology 76(6):1409-13.   

"
"5221","PC093019","Searle JS, Li B, Du W.  2010.  Targeting Rb mutant cancers by inactivating TSC2.  Oncotarget 1: 228-232.
"
"5222","PC093019","Danos AM and Du W.  2013.  Functional inactivation of Rb sensitizes cancer cells to TSC2 inactivation induced cell Death.  Cancer Lett 328(1):36-43.  "
"5223","PC093019","Li B, Gordon GM, Du CH, et al.  2010.  Specific killing of Rb mutant cancer cells by inactivating TSC2. 2010.  Cancer Cell 17:469--480.

"
"5224","PC093051","Puttamadappa SS, Jagadish K, Shekhtman A, et al.  2010.  Backbone dynamics of cyclotide MCoTI-I free and complexed with trypsin.  Angew Chem Int Ed 49(39):7030-7034."
"5225","PC093051","Jagadish K and Camarero JA.  2010.  Cyclotides, a promising molecular scaffold for peptide-based therapeutics.  Biopolymers 94(5):611-616."
"5226","PC093051","Jagadish K, Borra R, Lacey V, et al.  2013.  Expression of fluorescent cyclotides using protein trans-splicing for easy monitoring of cyclotide-protein interactions.  Angew Chem Int Ed 52(11):3037-3279."
"5227","PC093051","Austin J, Kimura RH, Woo Y-H, et al.  2010.  In-vivo biosynthesis of an Ala-scan library based on the cyclic peptide SFTI-1.  Amino Acids 38(5):1313-1322."
"5228","PC093051","Garcia E, Tai KP, Puttamadappa SS, et al.  2011.  Biosynthesis and antimicrobial evaluation of backbone-cyclized alpha-defensins.  Biochemistry 50(48):10508-10519."
"5229","PC093051","Gould A, Li Y, Aboye TL, et al.  2011.  Cyclotides, a novel ultrastable polypeptide scaffold for drug discovery.  Curr Pharm Des 17(38):4294-4307."
"5230","PC093051","Aboye TL and Camarero JA.  2012.  Biological synthesis of circular proteins.  J Biol Chem 287(32):27026-27032."
"5231","PC093051","Aboye TL, Li Y, Majumder S, et al.  2012.  Efficient one-pot cyclization/folding of Rhesus theta-defensin-1 (RTD-1).  Bioorg Med Chem Lett 22(8):2823-2826."
"5232","PC093051","Gould A, Li Y, Majumder S, et al.  2012.  Recombinant production of rhesus theta-defensin-1 (RTD-1) using a bacterial expression system.  Mol Biosyst 8(4):1359-1365."
"5233","PC093051","Contreras JJ, Elnagar AYO, Hamm-Alvarez S, et al.  2011.  Cellular uptake of cyclotide MCoTI-I follows multiple endocytic pathways.  J Control Release 115(2):134-143."
"5234","PC093051","Garcia AE and Camarero JA.  2010.  Biological activities of natural and engineered cyclotides, a novel molecular scaffold for peptide-based therapeutics.  Curr Mol Pharmacol 3(3):153-163."
"5235","PC093051","Berrade L, Garcia AE, and Camarero JA.  2010.  Protein microarrays: Novel developments and applications.  Pharm Res 28(7):1480-1499."
"5236","PC093051","Camarero JA.  2011.  Legume cyclotides shed new light on the genetic origin of knotted circular proteins.  Proc Natl Acad Sci USA 108(25):10025-10026.."
"5237","PC093051","Austin J, Wang W, Puttamadappa S, et al.  2009.  Biosynthesis and biological screening of a genetically-encoded library based on the cyclotide MCoTI-I.  Chem BioChem 10(16):2663-2670."
"5238","PC093124","Fu T, He Q, Sharma P.  2011.  The ICOS/ICOSL pathway is required for optimal anti-tumor responses mediated by anti-CTLA-4 therapy.  Cancer Res 71:5445-5454.

"
"5239","PC093124","Xiaozhou Fan,1 Sergio A. Quezada,3 Manuel A. Sepulveda,5,6
Padmanee Sharma,1,2,4 and James P. Allison1,4,5,6
Engagement of the ICOS pathway markedly
enhances efficacy of CTLA-4 blockade
in cancer immunotherapy
J. Exp. Med. 2014 Vol. 211 No. 4 715-725
www.jem.org/cgi/doi/10.1084/jem.20130590"
"5240","PC093132","Lee YC, Bilen MA, Yu G, et al.  2013.  Inhibition of cell adhesion by a cadherin-11 antibody thwarts bone metastasis.  Mol Cancer Res 11(11):1401-1411."
"5241","PC093132","Lee YC, Jin JK, Cheng CJ, et al.  2013.  Targeting constitutively activated beta1 integrin inhibits prostate cancer metastasis.  Mol Cancer Res 11(4):405-417.
"
"5242","PC093132","Gallick GE, Corn PG, Zurita AJ, et al.  2012.  Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.  Future Med Chem 4(1):107-119."
"5243","PC093132","Lee YC, Cheng CJ, Bilen MA, et al.  2011.  BMP4 promotes prostate tumor growth in bone through osteogenesis.  Cancer Res 71(15):5194-5203. "
"5244","PC093132","Huang CF, Lira C, Chu K, et al.  2010.  Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts.  Cancer Res 70(11):4580-4589."
"5245","PC093132","Lee YC, Cheng CJ, Huang M, et al.  2010.  Androgen depletion up-regulates cadherin-11 expression in prostate cancer.  J Pathol 221(1):68-76."
"5246","PC093215","Dao K-L, Sawant R, Hendricks JA, et al.  2012.   Design, synthesis, and initial biological evaluation of a steroidal anti-estrogen: doxorubicin bioconjugate for targeting estrogen receptor-positive breast cancer cells.  Bioconjug Chem 18;23:785-795."
"5247","PC093258","Reddy KR, Guan Y, Qin G, et al.  2011.  Combined treatment targeting HIF-1 and Stat3 is a potent strategy for prostate cancer therapy.  Prostate 71(16):1796-1809."
"5248","PC093258","Jing N.  2012.  Rational design of DNA anti-cancer agent that target signal transducer and activator of transcription (Stat3) for cancer therapy.  In: Cell Signalling and Molecular Targets in Cancer.  Springer Science LLC 167-190."
"5249","PC093283","Teesalu, T, Sugahara KN, and Ruoslahti E.  2012.  Mapping of vascular zip codes by phage display.  Methods Enymol 503:35-56."
"5250","PC093309","Otali D, He Q, Stockard CR, et al.  2013.  Preservation of immunorecognition by transferring cells from 10% neutral buffered formalin to 70% ethanol.  Biotech Histochem 88(3-4): 170-80."
"5251","PC093309","Grizzle WE.  2013. It is primarily the control of transcription and post-transcriptional processing that are critical to the development and progression of sporadic neoplasias.  Biotechnic and Histochemistry 88(7):361-364."
"5252","PC093309","Theodore SC, Davis M, Zhao F, et al.  2014.  MicroRNA profiling of novel African American and Caucasian prostate cancer cell lines reveals a reciprocal regulatory relationship of miR-152 and DNA methyltranferase-1.  Oncotarget Advance Publications 5(11):3512-3525."
"5253","PC093309","Kojima K, Bowersock GJ, Kojima C, et al.  2012.  Validation of a robust proteomic analysis carried out on FFPE tissues of the pancreas obtained from mouse and human. Proteomics 12(22):3393-3402. "
"5254","PC093309","Jones J, Grizzle W, Wang H, et al.  2013.  MicroRNAs that affect prostate cancer: emphasis on prostate cancer in African Americans.  Biotech Histochem 88(7):410-424."
"5255","PC093309","Auer QH, Mobley J, Ayers L, et al.  2014. The effects of frozen tissue storage conditions on the integrity of RNA and protein.  Biotech Histochem 89(7):518-528."
"5256","PC093309","Bledsoe MJ and Grizzle WE.  2013.  Use of human tissue in research: The current US regulatory, policy, and scientific landscape. Diagnostic Path 19(9):322-330.·"
"5257","PC093309","Zhang HG, Grizzle WE.  2014.  Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. Am J Pathol 184(1):28-41."
"5258","PC093309","Otali D, Fredenburgh J, Oelschlager DK, et al.  2016.  A standard tissue as a control for histochemical and immunohistochemical staining.  Biotech Histochem 91(5):309-326."
"5259","PC093309","Zhang HG and Grizzle WE.  2012.  The effects of exosomes and related vesicles on cancer development, progression and dissemination.  In: Emerging Concepts of Tumor Exosome-Mediated Cell-Cell Communication (Zhang HG, Ed.).  Springer Science 107-129."
"5260","PC093309","Grizzle WE, Srivastava S, and Manne U.  2011.  Translational pathology of neoplasia.  Cancer Biomark 9(1-6):7-20."
"5261","PC093309","Grizzle WE, Srivastava S, and Manne U.  2011.  The biology of incipient, pre-invasive or intraepithelial neoplasia.  Cancer Biomark 9 (1-6):21-39.  "
"5262","PC093309","Srivastava S and Grizzle WE.  2011.  Biomarkers and the genetics of early neoplastic lesions.  Cancer Biomark (9) (1-6):41-64. "
"5263","PC093309","Grizzle WE, Sexton KC, and Bell WC.  2013.  Human tissue biorepository.  In:  Molecular Genetic Pathology, Vol. 1, 2nd ed. (Cheng L, Zhang D, and Eble J, Eds.).  Springer Science+Business Media 483-497."
"5264","PC093309","McNally LR, Manne U, Grizzle WE.  2013.  Post-transcriptional processing of genetic information and its relation to cancer. Biotech Histochem 88(7):365-372."
"5265","PC093309P1","Grizzle WE.  2013.  It is primarily the control of transcription and post-transcriptional processing that are critical to the development and progression of sporadic neoplasias.  Biotech Histochem 88(7):361-364."
"5266","PC093309P1","Theodore SC, Davis M, Zhou F, et al.  2014.  MicroRNA profiling of novel African American and Caucasian prostate cancer cell lines reveals a reciprocal regulatory relationship of miR-152 and DNA methyltranferase-1.  Oncotarget Advance Publications 5(11):3512-3525."
"5267","PC093309P1","Auer QH, Mobley J, Ayers L, et al.  2014.  The effects of frozen tissue storage conditions on the integrity of RNA and protein.  Biotech Histochem 89(7):518-528."
"5268","PC093309P1","Zhang HG and Grizzle WE.  2014.  Exosomes: A novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions.  Am J Pathol 184(1):28-41."
"5269","PC093309P1","Jones J, Grizzle W, Wang H, et al.  2013.  MicroRNAs that affect prostate cancer: Emphasis on prostate cancer in African Americans.  Biotech Histochem 88(7):410-424."
"5270","PC093309P1","Otali D, He Q, Stockard CR, et al.  2013.  Preservation of immunorecognition by transferring cells from 10% neutral buffered formalin to 70% ethanol.  Biotech Histochem 88(3-4):170-180."
"5271","PC093309P1","Zhang HG and Grizzle WE.  2012.  The effects of exosomes and related vesicles on cancer development, progression and dissemination.  In: Emerging Concepts of Tumor Exosome-Mediated Cell-Cell Communication, (Zhang HG, Ed.), Springer Science, 107-129."
"5272","PC093309P1","Grizzle WE, Srivastava S, and Manne U.  2011.  Translational pathology of neoplasia.  Cancer Biomark 9(1-6):7-20."
"5273","PC093309P1","Grizzle WE, Srivastava S, and Manne U.  2011.  The biology of incipient, pre-invasive or intraepithelial neoplasia.  Cancer Biomark 9(1-6):21-39.

"
"5274","PC093309P1","Srivastava S and Grizzle WE.  2011.  Biomarkers and the genetics of early neoplastic lesions.  Cancer Biomark 9(1-6):41-64. "
"5275","PC093328","Long Q, Johnson BA, Osunkoya AO, et al.  2011.  Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy.  Am J Patho 179 (1):46-54. "
"5276","PC093350","Hsia DA, Tepper CG, Pomchampalli MR, et al.  2010.  KDM8, a H3Kme2 histone demethylase that acts in the cyclin A1 coding region to regulate cancer proliferation.  Proceedings of the National Academy of Sciences 107(21):9671-9676."
"5277","PC093350","Wang L-Y, Guo W, Kim K, et al.  2014.  Histone demethylases in prostate cancer.  In: Nuclear Signaling Pathways and Targeting Transcription in Cancer, Cancer Drug Discovery and Development 2014, (Kumar R, Ed) pp 373-397."
"5278","PC093372","Kumar A, White TA, MacKenzie AP, et al.  2011.  Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers.  Proc Natl Acad Sci U S A 108(41):17087-17092."
"5279","PC093372P1","Barbieri CE.  2012.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.  Nat Genet 44:685-689."
"5280","PC093372P1","Kumar A.  2011.  Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers.  Proc Natl Acad Sci U S A 108:17087-17092."
"5281","PC093372P1","Qu X, Randhawa G, Friedman C, et al.  2013.  A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.  PLoS One 8(9):e7467."
"5282","PC093408","Stephan MT and Irvine DJ.  2011.  Enhancing cell therapies from the outside in: Cell surface engineering using synthetic nanomaterials.  Nano Today 6(3):309-325."
"5283","PC093408","Stephan MT, Bak SPG, Stephan S, et al.  2012.  Synapse-directed delivery of immune-stimulants using T-cell-conjugated nanoparticles.  Biomaterials 33(23):5776-5787."
"5284","PC093408P1","Stephan MT, Bak SPG, Stephan S, et al.  Synapse-directed delivery of immune-stimulants using T-cell-conjugated nanoparticles.  Biomaterials 33:5776-5787."
"5285","PC093408P1","Bak SP, Barnkob MS, Bai A, et al.   2012.  Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells. J Immunol 189(4):1708-1716."
"5286","PC093408P1","Bak SP, Barnkob MS, Wittrup KD, et al.  2013.  CD8+ T-cell responses rapidly select for antigen-negative tumor cells in the prostate. Cancer Immunol Res 1(6):393-401."
"5287","PC093408P1","Stephan MT and Irvine DJ.  2011.  Enhancing cell therapies from the outside in:  Cell surface engineering using synthetic nanomaterials.  Nano Today 6:309-325."
"5288","PC093408P1","Zheng Y, Stephan MT, Gai SA, et al.  2013.  In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes.  J Control Release 172(2):426-435."
"5289","PC093408P2","Stephan MT, Stephan SB, Bak P, et al.  2012.  Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles.  Biomaterials 33:5776."
"5290","PC093408P2","Bak SP, Barnkob MS, Bai A, et al.  2012.  Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor tolerized CD8 T cells.  J Immunol 189:1708-1716. "
"5291","PC093444","Ronald S, Awate S, Rath A, et al.  2013.  Phenothiazine inhibitors of TLKs affect DSB repair and DDR recovery and potentiate tumor killing with radiomimetic therapy.  Genes Cancer 4(1-2):39-53."
"5292","PC093444","De Benedetti A.  2012.  The tousled-like kinases as guardians of genome integrity.  Review in ISRN Molecular Biology, Volume 2012, Article ID 627596. "
"5293","PC093444","Rath A, Hromas R, and De Benedetti A.  2014.  Fidelity of end joining in mammalian episomes and the impact of Metnase on joint processing.  BMC-Mol Biol 15:6."
"5294","PC093444","De Benedetti A.  2010.  Tousled kinase TLK1B mediates chromatin assembly in conjunction with Asf1 regardless of its kinase activity.  BMC Research Notes 3:68."
"5295","PC093444","Ronald S, Sunavala-Dossabhoy G, Adams L, et al.  2011.  The expression of tousled kinases in CaP cell lines and its relation to radiation response and DSB repair.  The Prostate 71(13):1367-1373."
"5296","PC093444","Kanikarla-Marie P, Ronald S, and De Benedetti A.  2011.  Nucleosome resection at a double-strand break during non-homologous ends joining in mammalian cells ¿ implications from repressive chromatin organization and the role of ARTEMIS.  BMC Research Notes 4:13.

"
"5297","PC093459","Minciacchi VR, You S, Spinelli C, et al.  2015.  Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived extracellular vesicles.  Oncotarget 6:11327-11341."
"5298","PC093459","Zhou B, An M, Freeman MR, et al.  2014.  Technologies and challenges in proteomic analysis of protein S-acylation.  J Proteomics Bioinform 7:256-263."
"5299","PC093480","Mediwala SN, Sun H, Szafran AT, et al.  201.  The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTENPI3K-AKT-dependent way.  Prostate 73(3):267-277."
"5300","PC093485","Peng Y, Jiang Y, Soylu FN, et al.  2012.  Registration of T2-weighted and diffusion-weighted MR images of the prostate: Comparison between manual and landmark-based methods.  Proc SPIE 8318-1H."
"5301","PC093485","Peng Y, Jiang Y, Yang C, et al.  2013.  Quantitative analysis of multi-parametric prostate MR images:  Differentiation between prostate cancer and normal tissue and correlation with Gleason score.  Radiology 267:787-796."
"5302","PC093485","Soylu N, Peng Y, Jiang Y, et al.  2013.  Seminal vesicle invasion in prostate cancer: Evaluation by multi-parametric MR imaging.  Radiology 267:797-806."
"5303","PC093485","Hansford B, Yousuf A, Peng Y, et al.  2014.  Revisiting the central gland anatomy via MR imaging: Does the central gland extend below the level of verumontanum?  J Magn Reson Imaging 39(1):167-171."
"5304","PC093485","Peng Y, Jiang Y, Antic T, et al.  2014.  Validation of quantitative analysis of multiparametric prostate MR images for prostate cancer detection and aggressiveness assessment: A cross-scanner robustness study.  Radiology 271(2):461-471."
"5305","PC093509","Cai C, He HH, and Chen S et al.  2011.  Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.  Cancer Cell 20(4):457-471."
"5306","PC093509","Qu X, Randhawa G, Friedman C, et al.  2013.  A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.  PLoS One 8(9):e74671."
"5307","PC093509","Mostaghel EA, Nelson PS, Lange P, et al.  2014.  Targeted androgen pathway suppression in localized prostate cancer: A pilot study.  J Clin Oncol 32(3):229-237."
"5308","PC093509","Yu Z, Chen S, Sowalsky AG, et al.  2014.  Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.  Clin Cancer Res 20(6):1590-1600."
"5309","PC093509","Hu R, Lu C, Mostaghel EA, et al.  2012.  Distinct transcriptional programsmediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.  Cancer Res 72(14):3457-3462.

"
"5310","PC093509","Bluemn EG and Nelson PS.  2012.  The androgen/androgen receptor axis in prostate cancer.  Curr Opin Oncol 24(3):251-257.

"
"5311","PC093509","Gao L, Schwartzman J, Gibbs A, et al.  2013.  Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation.  PLoS One 8(5):e63563."
"5312","PC093509","Chang KH, Li R, Kuri B, et al.  2013.  A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer.  Cell 154(5):1074-1084."
"5313","PC093509P1","Van Allen EM, Foye A, Wagle N, et al.  2013.  Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy.  Prostate Cancer Prostatic Dis 17(1):23-27."
"5314","PC093542","Jin F, Claessens F, and Fondell JD.  2012.  Regulation of androgen receptor-dependent transcription by coactivator MED1 is mediated through a newly discovered noncanonical binding motif.  J Biol Chem 287:858-870.

"
"5315","PC093542","Jin F, Irshad S, Yu W, et al.  2013.  ERK and AKT signaling pathways promote MED1 overexpression in prostate cancer cells in association with elevated proliferation and tumorigenicity.  Mol Cancer Res 11(7):736-747. "
"5316","PC093606","Stuart CH, Horita DA, Thomas MJ, et al.  2014.  Site-specific DNA¿doxorubicin conjugates display enhanced cytotoxicity to breast cancer cells. Bioconjug Chem 25(2):406-413."
"5317","PC093606","Ghosh S, Salsbury FR, Horita DA, et al.  2011.  Zn2+ selectively stabilizes FdU-substituted DNA through a unique major groove binding motif.  Nucl Acids Res 39(10):4490-4498."
"5318","PC093640","Danquah M, Fujiwara T, Mahato RI.  2010.  Self-assembling methoxypoly(ethylene glycol)-b-poly(carbonate-co-L-lactide) block copolymers for drug delivery.  Biomaterials 31:2358-2370."
"5319","PC093640","Danquah M, Zhang XA, and Mahato RI.  2011.  Extravasation of polymeric nanomedicines across tumor vasculature.  Adv Drug Delivery Review 63: 623-639."
"5320","PC093640","Li F and Mahato RI.  2014.  MicroRNAs and drug resistance in prostate cancers.  Mol Pharm 4:2539-52."
"5321","PC093640","Wen D, Chitkara D, Wu H, et al.  2014.  LHRH-conjugated micelles for targeted delivery of antiandrogen to treat advanced prostate cancer.  Pharm Res 31:2784-2795."
"5322","PC093640","Singh S, Chitkara D, Mehrazin R, et al.  2012.  Chemoresistance in prostate cancer cells is regulated by miRNAs and hedgehog pathway.  PLoS One 7(6):e40021."
"5323","PC093640","Li F, Danquah M, Singh S, et al.  2011.  Paclitaxel- and lapatinib-loaded lipopolymer micelles overcome multidrug resistance in prostate cancer.  Drug Deliv Transl Res 1:420-428.

"
"5324","PC093640","Danquah M, Fujiwara T, and Mahato RI.  2013.  Lactic acid- and carbonate-based crosslinked polymeric micelles for drug delivery.  J Polym Sci A Polym Chem 51:347-362."
"5325","PC093640","Danquah M, Duke III CB, Patil R, et al.  2012.  Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer.  Pharm Res 29:2079-2091."
"5326","PC093640","Singh S, Narang AS, and Mahato RI.  2011.  Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.  Pharm Res 28:2996-3015."
"5327","PC093640","Lu W, Li F, and Mahato RI.  2011.  Poly (ethylene glycol)-Block-Poly(2-methyl-2-benzoxycarbonylpropylene Carbonate) micelles for rapamycin delivery: In vitro characterization and biodistribution.  J Pharm Sci 100:2418-2429."
"5328","PC093640","Zhang X, and Mahato RI.  2011.  Targeting cell movement in cardiovascular and malignant diseases.  Adv Drug Delivery Review 63:555-557

"
"5329","PC093640","
Li F, Danquah M, and Mahato RI.  2010.  Synthesis and characterization of amphiphilic lipopolymers for micellar drug delivery.  Biomacromolecules 11:2610-2620.
"
"5330","PC093666","Hu S-H, Fang R-H, Chen Y-W, et al.  2014.  Photoresponsive protein-graphene-protein hybrid capsules with dual targeted heat-triggered drug delivery approach for enhanced tumor therapy.  Adv Func Mater 24(24):4144-4155."
"5331","PC093666","Hu S-H, Chen Y-W, Hung W-T, et al.  2012.  Quantum-dot-tagged reduced graphene oxide nanocomposites for bright fluorescence bioimaging and photothermal therapy monitored in situ. Adv Mater 24:1748-1754."
"5332","PC093666","Liu T, Choi H, Zhou R, et al.  2015.  Quantitative evaluation of the reticuloendothelial system function with dynamic MRI.  PLOS One 10(3):e0122323."
"5333","PC093666","Liu T, Choi H, Zhou R, et al.  2015.  RES blockade: A strategy for boosting efficiency of nanoparticle drug.  Nano Today 10:11-21."
"5334","PC093666","Chen Y-W, Chen P-J, Hu S-H, et al.  2014.  Near-infrared-triggered synergic photo-chemo-thermal therapy delivered by reduced graphene oxide/carbon/mesoporous silica nanocookies.  Adv Func Mater 24(4):451-459."
"5335","PC093666","Zhou R, Mazurchuk RV, Tamburlin JH, et al.  2010.  Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model.  J Pharmacol Exp Ther 332:479-488."
"5336","PC093666","Hu S-H, Liao B-J, Chiang C-S, et al.  2012.  Core-shell nanocapsules stabilized by single-component polymer and nanoparticles for magneto-chemotherapy-hyperthermia with multiple drugs.  Adv Mater 24:3627-3532."
"5337","PC093673","Cann GM, Gulzar ZG, Cooper S, et al.  2012.  mRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer.  PLoS-One 7(11):e49144."
"5338","PC093692","Arbini AA, Greco M, Yao JL, et al.  2011.  Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer.  Am J Pathol 178(5):2367-2376."
"5339","PC093692","Arbini AA, Guerra F, Greco M, et al.  2013.  Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2.  Oncogenesis 2:e82."
"5340","PC093692","Ro S, Ma H-Y, Park C, et al.  2013.  The mitochondrial genome encodes abundant small noncoding RNAs.  Cell Res 23(6):759-774."
"5341","PC093725","Keshari KR, Sriram R, Van Criekinge M, et al.  2013.  J Metabolic reprogramming and validation of hyperpolarized (13) C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor.  Prostate 73(11):1171-1181."
"5342","PC093725P1","Keshari KR, Sriram R, Van Criekinge M, et al.  2013.  Metabolic reprogramming and validation of hyperpolarized (13) C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor.  Prostate 73(11):1171-1181."
"5343","PC093725P2","Keshari KR, Sriram R, van Criekinge M, et al.  2013.  Metabolic reprogramming and validation of hyperpolarized 13C-lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor.  Prostate 73(11):1171-1181.  "
"5344","PC093757","Zhao H, Sun N, Young SR, et al.  2013.  Induced pluripotency of human prostatic epithelial cells.  PLoS One 8:e64503.

"
"5345","PC093768","Zhao H, Coram M, Nolley R, et al.  2012.  Transcript levels of androgen receptor splice variants, AR-V1 or AR-V7, do not predict recurrence in prostate cancer patients with indeterminate risk of progression.  J Urol 188:2158-2164. "
"5346","PC093768","Zhao H, Thong A, Nolley R, et al.  2013.  Patient derived tissue slice grafts accurately depict response of high-risk primary prostate cancer to androgen deprivation therapy.  J Transl Med 11:199."
"5347","PC093778","Tewari AK, Yardimci GG, Shibata Y, et al.  2012.  Chromatin accessibility reveals insights into androgen receptor activation and transcriptional specificity.  Genome Biol 13(10):R88."
"5348","PC093807","Gong Y, Scott E, Lu R, et al.  2013.  TIMP-1 promotes accumulation of cancer associated fibroblasts and cancer progression.  PLoS One 8(10):e77366."
"5349","PC093807","Murray LB, Ingar Y-K and Yu Q.  2012.  Merlin is a negative regulator of human melanoma growth.  PLOSOne 7:8-e43295."
"5350","PC093807","Stamenkovic I and Yu Q.  2010.  Merlin, a 'magic' linker between the extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival.  Curr Protein Pept Sci 11(6):471-484."
"5351","PC093850","Fiorentino M, Judson G, Penney K et al.  2010.  Immunohistochemical expression of BRCA1 and lethal prostate cancer.  Cancer Res 70:3136-3139."
"5352","PC093850","Sanchez A, Schoenfeld JD, Nguyen PL, et al. 2016. Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment. Prostate Cancer Prostatic Dis. 19(2):197-201."
"5353","PC093906","Khan N, Adhami VIM, Siddiqui IA, et al.  2012.  Oral administration of naturally occurring chitosan based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model.  The 103rd Annual Meeting of the American Association for Cancer Research, Chicago, Illinois, USA, Proc Amer Assoc Cancer Res 53:5438."
"5354","PC093918","Kannan K, Wang L, Wang J, et al.  2011.  Recurrent chimeric RNAs enriched in human prostate cancer identified by deep-sequencing.  Proc Natl Acad Sci USA 108:9172- 9177."
"5355","PC093918","Wu CC, Kannan K, Lin S, et al.  2013.  Identification of cancer fusion drivers using network fusion centrality.  Bioinformatics 29:1174-1181."
"5356","PC093932","Floryk D, Kurosaka S, Tanimoto R, et al.  2011.  Castration induced changes in mouse epididymal white adipose tissue.  Mol Cell Endocrin 15: 345(1-2):58-67.


"
"5357","PC093932","Karanika S, Karantanos T, Kurosaka S, et al.  2015.  GLIPR1-DTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.  Mol Cancer 14:122."
"5358","PC094003","Fang X, Gyabaah K, Nickkholgh, et al.  2015.  Novel in vivo model for combinatorial fluorescence labeling in mouse prostate. Prostate 75(9):988-1000. "
"5359","PC094008","Book Chapter:
Tajbakhsh J and Gertych A.  2012.  Three-dimensional quantitative DNA methylation imaging for chromatin texture analysis in pharmacoepigenomics and toxicoepigenomics  In: Epigenomics: From Chromatin Biology to Therapeutics (Appasani K, Ed.).  Cambridge, UK: Cambridge University Press 273-290.
"
"5360","PC094008","Tajbakhsh J.  2011.  DNA methylation topology: Potential of a chromatin landmark for epigenetic drug toxicology.  Epigenomics 3:761-770."
"5361","PC094008","Tajbakhsh J, Stefanovski D, Tang G, et al.  2015.  Dynamic heterogeneity of DNA methylation and hydroxymethylation in differentiating embryonic stem cell populations captured by single-cell high-content analysis.  Exp Cell Res 332:190-201."
"5362","PC094008","Tajbakhsh J (2013). Covisualization of methylcytosine, global DNA and protein biomarkers for in situ 3-D DNA
methylation phenotyping of stem cells. Methods Mol Biol. 1052:1-12."
"5363","PC094008","Tajbakhsh J and Wawrowsky K.  2015.  Using 3D high-content analysis and epigenetic phenotyping of cells in the characterization of human prostate tissue heterogeneity.  Single Cell Biol 4:1."
"5364","PC094008","Oh JH, Gertych A and Tajbakhsh J.  2013.  Nuclear DNA methylation and chromatin condensation phenotypes are distinct between normally proliferating/aging, rapidly growing/immortal, and senescent cells.  Oncotarget 4(3):474-493."
"5365","PC094008","Gertych A, Oh JH, Wawrowsky KA, et al.  2013.  3-D DNA methylation phenotypes correlate with cytotoxicity levels in prostate and liver cancer cell models.  BMC Pharmacol Toxicol 14(1):11."
"5366","PC094021","Armstrong AJ, Healy P, Halabi S, Vollmer R, Lark A, Kemeny G, et al.  2016.  Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer. Prostate Cancer Prostatic Dis 19(1):40-45."
"5367","PC094021","Bitting RL, Healy, Halabi S, et al.  2015.  Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration resistant prostate cancer.  Urol Oncol 33(3)e1-9."
"5368","PC094021","Bitting RL, Boominathan R, Rao C, et al.  2014.  Development of a method to isolate circulating tumor cells using mesenchymal-based capture.  Methods 64:129-136."
"5369","PC094021","Bitting RL, Boominathan R, Rao C, et al.  2013.  Development of a method to isolate circulating tumor cells using mesenchymal-based capture.  Methods 64(2):129-136."
"5370","PC094021","Armstrong AJ, Marengo MS, Oltean S, et al.  2011.  Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.  Mol Cancer Res 9(8):997-1007."
"5371","PC094021","Armstrong AJ, Freedland SJ and Garcia-Blanco M.  2011.  Epithelial-mesenchymal transition in prostate cancer: Providing new targets for therapy.  Asian J Androl 13(2):179-180."
"5372","PC094054","Salameh MA, Soares AS, Alloy A, et al.  2012.  Presence versus absence of hydrogen bond donor Tyr-39 influences interactions of cationic trypsin and mesotrypsin with protein protease inhibitors.  Protein Sci 21(8):1103-1112. "
"5373","PC094054","Hockla A, Miller E, Salameh MA, et al.  2012.  PRSS3/Mesotrypsin is a therapeutic target for metastatic prostate cancer.  Mol Cancer Res 10(12):1555-1566. "
"5374","PC094054","Radisky ES.  2013.  PRSS3/mesotrypsin in prostate cancer progression: implications for translational medicine.  Asian J Androl 15(4):439-440."
"5375","PC094054","Salameh MA, Soares AS, Hockla A, et al.  2011.  The P2' residue is a key determinant of mesotrypsin specificity: Engineering a high affinity inhibitor with anticancer activity.  Biochem J 440(1):95-105."
"5376","PC094054","Salameh MA, Soares AS, Navaneetham D, et al.  2010.  Determinants of affinity and proteolytic stability in interactions of Kunitz family protease inhibitors with mesotrypsin.  J Biol Chem 285(47):36884-36896."
"5377","PC094081","Chen M, Feurstein MA, Levina E, et al.  2010.  Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells.  Mol Cancer 9:89-101.  

"
"5378","PC094081","Li N, Truong S, Nouri M, et al. 2018. Non-canonical activation of hedgehog in prostate cancer cells mediated by the interaction of transcriptionally active androgen receptor proteins with Gli3. Oncogene. 37(17): 2313-2325. doi: 10.1038/s41388-017-0098-7."
"5379","PC094081","Li N, Chen M, Truong S, et al.  2014.  Determinants of Gli2 co-activation of wildtype and naturally truncated androgen receptors.  The Prostate 74:1400-1410."
"5380","PC094081","Levina E, Chen M, Carkner R, et al.  2012.  Paracrine Hedgehog increases the steroidogenic potential of prostate stromal cells in a Gli-dependent manner.  The Prostate 72:817-824."
"5381","PC094081","Chen M, Carkner R, and Buttyan R.  2011.  The hedgehog signaling paradigm in prostate cancer.  Exp Rev Metabol Endocrin 6:453-467.  "
"5382","PC094093","Rusmevichientong A and Chow SA.  2010.  Biology and pathophysiology of the new human retrovirus XMRV and its association with human disease.  Immunol Res 48:27-39."
"5383","PC094093","Rusmevichientong A, Das Gupta J, Elias PE, et al.  2011.  Analysis of single nucleotide polymorphisms in patient-derived retrovirus integration sites reveals possible contamination from cell lines acutely infected by xenotropic murine leukemia virus-related virus.  J Virol 85:12830-12834."
"5384","PC094122","Amatangelo MD, Goodyear S, Varma D, et al.  2012.  c-Myc expression and MEK1-induced Erk2 nuclear localization are required for TGF-beta induced epithelial-mesenchymal transition and invasion in prostate cancer.  Carcinogenesis 33(10):1965-1975."
"5385","PC094137","Scandiuzzi L, Ghosh K, Zang X.  2011.  T cell costimulation and coinhibition:  Genetics and disease.  Discov Med 12:119-128."
"5386","PC094137","Vigdorovich V, Ramagopal U, Lazar-Molnar E, et al.  2013.  Structure and T cell inhibition properties of B7 family member, B7-H3.  Structure 21:707-717."
"5387","PC094137","Barach YS, Lee JS, Zang X.  2011.  T cell coinhibition in prostate cancer: New immune evasion pathways and emerging therapeutics (Invited review).  Trends Mol Med 17:47-55.

"
"5388","PC094137","Zhao R, Chinai JM, Buhl S, et al.  2013.  HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function.  Proc Natl Acad Sci U S A 110(24):9879-9884. "
"5389","PC094151","Xie H, Hanai J, Ren JG, et al.  2014.  Targeting lactate dehydrogenase-A (LDH-A) inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor initiating cells.  Cell Metabolism 19(5):795-809."
"5390","PC094157","Park S, Soki F, McCauley L.  2011.  Roles of bone marrow cells in skeletal metastases: No longer bystanders.  Cancer Microenviron 4(3):237-246."
"5391","PC094157","Park S and McCauley L.  2012.  Nuclear localization of parathyroid hormone-related peptide confers resistance to anoikis in prostate cancer cells.  Endocrine-Related Cancer 19:1-12."
"5392","PC094157","Park SI, Liao J, Berry JE, et al.  2012.  Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis.  Cancer Research 72(10):2522-3252."
"5393","PC094159","Ellis L, Lehet K, Ramakrishnan S, et al.  2011.  Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression.  PLoS One 6(11):e27178."
"5394","PC094159","Ellis L, Lehet K, Ramakrishnan S. et al.  2012. Development of a castrate resistant transplant tumor model of prostate cancer.  Prostate 72(6):587-591."
"5395","PC094159","Ellis L, Ku SY, Ramakrishnan S,et al.  2013.  Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer.  Oncotarget 4(12):2225-2236."
"5396","PC094161","Laydner H, Huang SS, Heston WD, et al.  2013.  Robotic real-time near infrared targeted fluorescence imaging in a murine model of prostate cancer: a feasibility study.  Urology 81(2):451-456."
"5397","PC094163","Muller RL, Presti JC Jr, Aronson WJ, et al.  2012.  Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the SEARCH database.  Urology 79(5):1105-1110."
"5398","PC094193","Grisanzio C, Werner L, Takeda D, et al.  2012.  Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis.  Proc Natl Acad Sci U S A 109:11252-11257."
"5399","PC094193","Wang F, Gomez-Escudero A, Ramireddy RR, et al.  2013.  Electrostatic control of peptide side-chain reactivity using amphiphilic homopolymer-based supramolecular assemblies.  J Am Chem Soc 135(38):14179-14188."
"5400","PC094193","Curry SR, Schlackman JL, Hamilton TM, et al.  2011.  Perirectal swab surveillance for Clostridium difficile by use of selective broth preamplification and real-time PCR detection of tcdB.  J Clin Microbiol 49:3788-3793."
"5401","PC094193","Simons AL, Parsons AD, Foster KA, et al.  2009.  Inhibition of glutathione and thioredoxin metabolism enhances sensitivity to perifosine in head and neck cancer cells.  J Oncol 519563."
"5402","PC094195","Hoang DT, Augello MA, Lawrence YR, et al.  2012.  mTOR is a selective effector of the radiation response in androgen receptor-positive prostate cancer.  Endocr Relat Cancer 9:19(1):1-12."
"5403","PC094195","Comstock CES, Augello MA, Goodwin JF, et al.  2013.  Targeting cell cycle and hormone receptor pathways in cancer.  Oncogene 32:5481-5491."
"5404","PC094205","DePorter SM, Lui I, Mohan U, et al.  2013.  A Protein transduction domain with cell uptake and selectivity profiles that are controlled by multivalency effects.  Chem Biol 20:434-434."
"5405","PC094218","Mita P, Savas JN, Diouder N,et al.  2011.  Regulation of androgen receptor mediated transcription by RPB5 binding protein URI/RMP.  Mol Cell Bio 31(17):3639-3652."
"5406","PC094222","Mao YS, Zhang B, and Spector DL.  2011.  Nuclear body language¿biogenesis and function of nuclear bodies.  Trends in Genetics 27(8):295-306.  "
"5407","PC094222","Mao YS, Sunwoo H, Zhang B, et al.  2011.  Direct visualization of the co-transcriptional assembly of a nuclear body by noncoding RNAs.  Nat Cell Biol 13(1):95-101 PMCID: PMC3007124."
"5408","PC094231","White NM, Feng FY, and Maher CA.  2013.  Recurrent rearrangements in prostate cancer: Causes and therapeutic potential.  Curr Drug Targets 14:450-459."
"5409","PC094231","Brenner JC, Ateeq B, Li Y, et al.  2011.  Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.  Cancer Cell 19:664-678."
"5410","PC094246","Wang P, Heber D, and Henning SM.  2012.  Quercetin increased bioavailability and decreased methylation of green tea polyphenols in vitro and in vivo.  Food and Function 3:635-642.

"
"5411","PC094251","Wasserman NF and Nobrega MA.  2012.  Cis-Regulatory Variation and Cancer.  In:  Gene Regulatory Sequences and Human Disease.  (Ahituv N, Ed.).  12th Edition: Springer, New York.  195-216."
"5412","PC094251","Wasserman NF, Aneas I, and Nobrega MA.  2010.  An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer.  Genome Research 20(9):1191-1197."
"5413","PC094266","Sahoo D, Volkmer J-P, Chin R, et al.  2012.  Three differentiation states risk-stratify bladder cancer into distinct subtypes.  PNAS 109(6):2078-2083."
"5414","PC094266","Sahoo D.  2012.  The power of Boolean implication networks.  Front Physio 3:276."
"5415","PC094266","Sahoo D, Dalerba P, Kalisky T, et al.  2011.  High throughput single-cell analysis of colon tumors: Biological insights and clinical applications.  Nat Biotechnol 29(12):1120-1127."
"5416","PC094266","Ooi L, Sahoo D, Adorno M, et al.  2010.  Mir-125b expands hematopoietic stem cells and enriches for the lymphoid balanced and lymphoid biased HSC subsets.  PNAS 107(50):21505-21510."
"5417","PC094266","Sahoo D, Bhamre S, Tibshirani R, et al.  2010.  Gene expression changes induced by genistein in the prostate cancer cell line LNCaP.  The Open Prostate Cancer Journal 3:86-98."
"5418","PC094266","Tang C, Lee AS, Peter-Volkmer J, et al.  2011.  An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells.  Nature Biotechnol 29(9):829-834."
"5419","PC094270","Wu M, Shi L, Cimic A, et al.  2012.  Suppression of Tak1 kinase promotes prostate tumorigenesis.  Cancer Res 72(11):2833-2843."
"5420","PC094270","Ulkus L, Wu M, and Cramer SD.  2013.  Stem cell models for functional valication of prostate cancer.  In:  Stem Cells and Prostate Cancer (Kramer S, Ed.).  Springer New York 149-173."
"5421","PC094288","Dehghan E, Jain AK, Moradi M, et al.  2011.  Brachytherapy seed reconstruction with joint-encoded C-arm single-axis rotation and motion compensation.  Medical Image Analysis 15(5):760-771."
"5422","PC094288","Moradi M, Salcudean SE, Chang SD, et al.  2012.  Multiparametric MRI maps for detection and grading of dominant prostate tumors.  J Magn Reson Imaging 35(6):1403-1413."
"5423","PC094288","Lobo J, Moradi M, Chng N, et al.  2012.  Use of needle track detection to quantify the displacement of stranded seeds following prostate brachytherapy.  IEEE Transactions on Medical Imaging 31(3):738-748."
"5424","PC094288","Dehghan E, Jain AK, Moradi M, et al.  2011.  Brachytherapy seed reconstruction with joint-encoded C-arm single-axis rotation and motion compensation.  Medical Image Analysis 15(5):760-771."
"5425","PC094288","Mahdavi SS, Moradi M, Wen X, et al.  2011.  Evaluation of visualization of the prostate gland in vibroelastography images.  Medical Image Analysis 15(4):589-600."
"5426","PC094288","Lobo J, Moradi M, Chng N, et al.  2012.  Use of needle track detection to quantify the displacement of stranded seeds following prostate brachytherapy.  IEEE Transactions on Medical Imaging 31(3):738-748.

"
"5427","PC094290","Prensner JR, Chinnaiyan AM, and Srivastava S.  2012.  Systematic, evidence-based discovery of biomarkers at the NCI.  J Clin Exp Metastasis 29(7):645-652."
"5428","PC094290","Prensner JR, Iyer MK, Balbin OA, et al.  2011.  Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression.  Nat Biotechnol 29(8):742-749.

"
"5429","PC094290","Kim JH, Dhanasekaran SM, Prensner JR, et al.  2011.  Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer.  Genome Res 21(7):1028-4101.

"
"5430","PC094290","Wang XS, Shankar S, Dhanasekaran SM, et al.  2011.  Characterization of KRAS rearrangements in metastatic prostate cancer.  Cancer Discov 1(1):OF33-41."
"5431","PC094290","Cao Q, Mani RS, Ateeq B, et al.  2011.  Coordinated regulation of polycomb group complexes through microRNAs in cancer.  Cancer Cell 20(2):187-199."
"5432","PC094290","Prensner JR and Chinnaiyan AM.  2011.  Metabolism unhinged: IDH mutations in cancer.  Nat Med 17(3):291-293."
"5433","PC094290","Grasso CS, Wu YM, Robinson DR, et al.  2012.  The mutational landscape of lethal castrate resistant prostate cancer.  Nature 487(7406):239-243."
"5434","PC094290","Kalyana-Sundaram S, Kumar-Sinha C, Shankar S, et al.  2012.  Expressed pseudogenes in the transcriptional landscape of human cancers.  Cell 149(7):1622-1634."
"5435","PC094290","Prensner JR, Rubin MA, Wei JT, et al.  2012.  Beyond PSA: The next generation of prostate cancer biomarkers.  Sci Transl Med 4(127):127rv3."
"5436","PC094294","Kobayashi A, Okuda H, Xing F, et al.  2012.  Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone.  J Exp Med 209(3):639."
"5437","PC094297","Murphy AB, Kelley B, Nyame YA, et al.  2012.  Predictors of serum vitamin D levels in African American and European American Men in Chicago.  American J Men's Health 6(5):420-426."
"5438","PC094297","Murphy AB, Nyame Y, Martin IK, et al.  2014.  Vitamin D deficiency predicts prostate biopsy outcomes.  Clin Cancer Res 20(9):2289-2299. "
"5439","PC094297","Murphy AB, Akereyeni F, Nyame YA, et al.  2013.  Smoking and prostate cancer in a multi-ethnic sample.  The Prostate 73(14):1518-1528.  

"
"5440","PC094297","Batai K, Shah E, Murphy AB, et al.  2012.  Fine mapping of IL16 gene and prostate cancer risk in African Americans.  Cancer Epidemiol Biomarkers Prev 21(11):2059-2068."
"5441","PC094297","Murphy AB, Ukoli F, Freeman V, et al.  2012.  8q24 risk alleles in West African and Caribbean men.  Prostate 72(12):1366-1373."
"5442","PC094297","Batal K, Murphy AB, Nonn A, et al.  2016.  Vitamin D and immune response: Implications for prostate cancer in African Americans.  Frontier Immunology 7:53."
"5443","PC094302","Karthaus WR, Iaquinta PJ, Drost J, et al.  2014.  Identification of multipotent luminal progenitor cells in human prostate organoid cultures.  Cell 159(1):163-175."
"5444","PC094302","Ran L, Sirota I, Cao Z, et al.  2015.  Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth.  Cancer Dis 5(3):304-315."
"5445","PC094302","Wanjala J, Taylor BS, Chapinski C, et al.  2015.  Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling.  Mol Cancer Therapeutics 14(1):278-288."
"5446","PC094302","Chi P, Chen Y, Zhang L, et al.  2010.  ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.  Nature 467(7317):849-853. 8"
"5447","PC094302","Gao D, Vela I, Sboner A, et al.  Organoid cultures derived from patients with advanced prostate cancer.  Cell 159 (1):176-187."
"5448","PC094302","Chen Y, Chi P, Rockowitz S, et al.  2013.  ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.  Nat Med 19(8):1023-1029."
"5449","PC094304","Wilton JH, Titus MA, Efstathious E, et al.  2014.  Androgenic biomarker profiling in human matrices and cell culture samples using high-throughput electrospray tandem mass spectrometry.  Prostate 74(7):722-731."
"5450","PC094304","Maity SN, Titus MA, Gyftaki R, et al.  2016.  Targeting of CYP17A1 lyase by VT-464 inhibits adrenal and intratumoral androgen biosynthesis and tumor growth of castration resistant prostate cancer.  Sci Rep 6:35354."
"5451","PC094304","Titus MA, Li Y, Kozyreva OG, et al.  2014.  5alpha-reductase type 3 enzyme in benign and malignant prostate.  Prostate 74(3):235-249."
"5452","PC094304","Efstathiou E, Titus M, Wen S, et al.  2014.  Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.  Eur Urol S0302-2838(14)00415-1."
"5453","PC094304","Efstathiou E, Titus M, Tsavachidou D, et al.  2012.  Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.  J Clin Oncol 30:637."
"5454","PC094304","Titus MA, Zeithaml B, Kantor B, et al.  2012.  Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.  PLoS One 7:e30192."
"5455","PC094304","Mohler JL, Titus MA, and Wilson EM.  2011.  Potential prostate cancer drug target: Bioactivation of androstenediol by conversion to dihydrotestosterone.  Clin Cancer Res 17(18):5844-5849."
"5456","PC094309","Thomas R and Sharifi N.  2012.  SOD mimetics: A novel class of androgen receptor inhibitors that suppresses castration-resistant growth of prostate cancer.  Mol Cancer Ther 11(1):87-97."
"5457","PC094320","Wu B, Alrubaiee M, Cai W, et al.  2012.  Diffuse optical imaging using decomposition methods.  International J Optics, in press."
"5458","PC094320","Pu Y, Wang W, Xu M, et al.  2012.  Characterization and three-dimensional localization of cancerous prostate tissue using backscattering scanning polarization imaging and independent component analysis.  J Biomed Opt 17, 081419."
"5459","PC094320","Katz A, Xu M, Steiner JC, et al.  2013.  Influence of cations on aggregation rates in mg-montmorillonite.  Clays and Clay Minerals 61(1):1-10."
"5460","PC094320","Pu Y, Wang WB, Xu M, et al.  2011.  Near infrared photonic finger imager for prostate cancer screening.  Technol Cancer Res Treat 10(6):507-517.

"
"5461","PC094320","Xu M, Pu Y, and Wang WB.  2011.  Clean image synthesis and target numerical marching for optical imaging with backscattering light.  Biomed Opt Express 2(4):850-857."
"5462","PC094320","Xu M.  2011.  The scattering-phase theorem: Anomalous diffraction by forward-peaked scattering media.  Opt Express 19(22):21643-21651."
"5463","PC094320","Wu B, Alrubaiee M, Cai W, et al.  2012.  Diffuse optical imaging using decomposition methods.  International J Optics 185435."
"5464","PC094320","Pu Y, Wang W, Rubaiee M, et al.  2012.  Determination of optical coefficients and fractal dimensional parameters of cancerous and normal prostate tissues.  Appl Spectroscopy 66:828834.
"
"5465","PC094336","Izumi K, Fang L-Y, Mizokami A, et al.  2013.  Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation.  EMBO Mol Med 5:1383-1401."
"5466","PC094338","Yamada R, Kostova MB, Anchoori RK, et al.  2010.  Biological evaluation of paclitaxel-peptide conjugates as a model for MMP2-targeted drug delivery.  Cancer Biol Ther 9:192-203."
"5467","PC094338","Manning ML, Kostova MB, Williams SA, et al.  2012.  Trypsin-like proteolytic contamination of commercially available PSA purified from human seminal fluid.  Prostate 72:1233-1238."
"5468","PC094338","LeBeau AM, Kostova M, Craik CS, et al.  2010.  Prostate-specific antigen: An overlooked candidate for the targeted treatment and selective imaging of prostate cancer.  Biol Chem 391:333-343."
"5469","PC094371","Liu C and Tang DG.  2011.  MicroRNA regulation of cancer stem cells.  Cancer Res 15:71(18):5950-5954. 

"
"5470","PC094371","Liu C, Kelnar K, Liu B, et al.  2011.  The microRNA miR-34a inhibits PCa stem cells and metastasis by directly repressing CD44.  Nature Med 17:211-215."
"5471","PC094372","Spencer BA, Insel BJ, Hershman DL, et al.  2013.  Racial disparities in the use of palliative therapy for ureteral obstruction among elderly patients with advanced prostate cancer.  Support Care Cancer 21(5):1303-1311."
"5472","PC094373","Laurie MT, Bertout JA, Taylor SD, et al.  2013.  Simultaneous digital quantification and fluorescence-based size characterization of massively parallel sequencing libraries.  Biotechniques 55(2):61-67."
"5473","PC094375","Sottnik JL, Daignault-Newton S, Zhang X, et al.  2013.  Integrin alpha2beta 1 (alpha2beta1) promotes prostate cancer skeletal metastasis.  Clin Exp Metastasis 30(5):569-578."
"5474","PC094378","Tanner MJ, Welliver RC Jr, Chen M, et al.  2010.  Effects of androgen receptor and androgen on gene expression in prostate stromal fibroblasts and paracrine signaling to prostate cancer cells. PLoS One 6(1):e16027. "
"5475","PC094378","Chen M, Carkner R, and Buttyan R.  2011.  The Hedgehog/Gli signaling paradigm in prostate cancer.  Expert Rev Endocrinol Metab 6(3):453-467."
"5476","PC094378","Levina E, Chen M, Carkner R, et al.  2011.  Paracrine hedgehog increases the steroidogenic potential of prostate stromal cells in a Gli-dependent manner.  Prostate 72(8):817-824.  "
"5477","PC094378","Chen M, Feuerstein MA and Levina E.  2010.  Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells.  Mol Cancer 9:89."
"5478","PC094384","Kohli M, Qin R, Jimenez R et al.  2012.  Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer.  Adv Urol 2012:781459.

"
"5479","PC094384","Nyquist MD, and Dehm SM.  2013.  Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression.  Horm Cancer 4(2):61-69."
"5480","PC094384","Li Y, Chan SC, Brand LJ, et al.  2013.  Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.  Cancer Res 73(2):483-489."
"5481","PC094384","Brand LJ, and Dehm SM.  2013.  Androgen receptor gene rearrangements: New perspectives on prostate cancer progression.  Curr Drug Targets 14(4):441-449."
"5482","PC094384","Bohrer LR, Liu P, Zhong J et al.  2013.  FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants.  Prostate 73(10):1017-1027."
"5483","PC094384","Chan SC, Li Y, and Dehm SM.  2012.  Androgen receptor splice variants activate AR target genes and support aberrant prostate cancer cell growth independent of the canonical AR nuclear localization signal.  J Biol Chem 287(23):19736-19749."
"5484","PC094384","Li Y, Hwang TH, Oseth L, et al.  2012.  AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression.  Oncogene 31(45):4759-4767.

"
"5485","PC094384","Li Y, Alsagabi MD, Tewfik H, et al.  2011.  Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression.  Cancer Res 71(6):2108-2117."
"5486","PC094384","Li Y, Alsagabi M, Fan D, et al.  2011.  Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression.  Cancer Res. 20:2108-2117."
"5487","PC094384","Dehm SM, and Tindall DJ.  2011.  Alternatively spliced androgen receptor variants.  Endocrine Related Cancer 18:183-196."
"5488","PC094387","Darpolor MM, Yen YF, Chua MS, et al.  2011.  In vivo MRSI of hyperpolarized [1-(13)C] pyruvate metabolism in rat hepatocellular carcinoma.  NMR Biomed 24(5):506-513."
"5489","PC094393","Yang X, Guo Z, Sun F, et al.  2011.  Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells.  J Biol Chem 286(41):36152-36160."
"5490","PC094393","Linn DE, Yang X, Xie Y, et al.  2012.  Differential regulation of androgen receptor by PIM-1 kinases via phosphorylation-dependent recruitment of distinct ubiquitin E3 ligases.  J Biol Chem 287(27):22959-22968."
"5491","PC094396","Fields RJ, Cheng CJ, Quijano E, et al.  2012.  Surface modified poly(beta amino ester)-containing nanoparticles for plasmid DNA delivery.  J Control Release 164(1):41-48."
"5492","PC094400","Murthy S, Wu M, Bai U, et al.  2013.  Role of androgen receptor in progression of prostate cancer cells from G1 to S phase: Interaction with DNA replication machinery components.  PLoS One 8(2): e56692."
"5493","PC094400","Sivanandam A, Murthy S, Chinnakannu K, et al.  2011.  Calmodulin protects androgen receptor from calpain-mediated breakdown in prostate cancer cells.  J Cell Physiol 226:1889-1896."
"5494","PC094400","Zhou J, Richardson M, Reddy V, et al.  2013.  Structural and functional association of androgen receptor with telomeres in prostate cancer cells.  Aging 5 (1):3-17."
"5495","PC094414","Bhusari S, Yang B, Kueck J, et al.  2011.  Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer.  Prostate 71(15):1621-1630."
"5496","PC094418","Poch MA, Mehedint D, Green DJ, et al.  2013.  The association between calcium channel blocker use and prostate cancer outcome.  The Prostate 73:865-872."
"5497","PC094418","Schmidt LJ, Duncan K, Yadav N, et al.  2012.  RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.  Mol Endocrinol 26(5):716-735."
"5498","PC094418","Yadav N, and Heemers HV.  2012.  Androgen action in the prostate gland.  Minerva Urol Nefrol 64(1):35-49."
"5499","PC094418","Heemers HV, Schmidt LJ, Sun Z, et al.  2011.  Identification of a clinically relevant androgen-dependent gene signature in prostate cancer.  Cancer Res 71:1978-1988."
"5500","PC094418","Heemers HV.  2013.  Identification of a RhoA- and SRF-dependent mechanism of androgen action that is associated with prostate cancer progression.  Curr Drug Targets 14(4):481-489."
"5501","PC094418","Verone AR, Duncan K, Godoy K, et al.  2013.  Androgen-responsive serum response factor (SRF) target genes regulate prostate cancer cell migration.  Carcinogenesis 34(8):1737-1746."
"5502","PC094418","Heemers HV.  2013.  Editorial.  Androgen receptor and prostate cancer: New insights in an old target translate into novel therapeutic strategies.  Curr Drug Targets 14(4):399-400."
"5503","PC094418","Verone AR and Heemers HV.  2012.  Androgen receptor regulation of serum response factor signaling in prostate cancer.  In:  Androgen-Responsive Genes in Prostate Cancer (Wang Z, Ed.). Springer 257-273."
"5504","PC094418","Heemers HV.  2014.  Targeting androgen receptor action for prostate cancer treatment: Does the postreceptor level provide novel opportunities?  Int J Biol Sci 10(6):576-587."
"5505","PC094421","Kannan K, Wang L, Wang J, et al.  2011.  Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing.  Proc Natl Acad Sci U S A 108(22):9172-9177."
"5506","PC094421","Wang L, Wang S and Li W.  2012.  RseQC:  Quality control of RNA-seq experiments.  Bioinformatics 28:2184-2185."
"5507","PC094422","Huang V, Place RF, Portnoy V, et al.  2012.  Upregulation of cyclin B1 by miRNA and its implications in cancer.  Nucleic Acids Res 40(4):1695-707."
"5508","PC094423","Taioli E, Flores-Obando RE, and Agalliu I.  2011.  Multi-institutional prostate cancer study of genetic susceptibility in populations of African descent.  Carcinogenesis 32(9):1361-1365."
"5509","PC094435","Yuan C, Wang L, Zhou L, et al.  2014.  The function of FOXO1 in the late phases of the cell cycle is suppressed by PLK1-mediated phosphorylation.  Cell Cycle 13(5):807-819."
"5510","PC094439","Smith H, Cronk R, Lang J, et al.  2011.  Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer.  Cancer Research 71(21):6785-6795"
"5511","PC094439","Smith H and McNeel D.  2010.  The SSX family of cancer-testis antigens as target proteins for tumor therapy.  Clin Dev Immunol 150591."
"5512","PC094439","Smith H and McNeel D.  2011.  Vaccines targeting the cancer testis antigen SSX-2 elicit HLA-A2 epitope-specific CTL that lyse prostate cancer cells.  J Immunother 34(8):569-580."
"5513","PC094457","Swindall AF, Stanley J, and Yang ES.  2013.  PARP-1: Friend or foe of DNA damage and repair in tumorigenesis?  Cancers 5(3):943-958. "
"5514","PC094461","Pandey JP, Namboodiri AM, and Kistner-Griffin E.  2013.  IgG and FcgammaR genotypes and humoral immunity to mucin 1 in prostate cancer.  Hum Immunol 74(8):1030-1033."
"5515","PC094461","Pandey JP, and Namboodiri AM. 2014.  Genetic variants of IgG1 antibodies and Fc¿RIIIa receptors influence the magnitude of antibody-dependent cell-mediated cytotoxicity against prostate cancer cells.  OncoImmunology 3:e27317."
"5516","PC094461","Pandey JP, Kistner-Griffin E, Namboodiri AM, et al.  2013.  Suggestive evidence that Fc variants of IgG2 and Fc¿RIIa loci interact to contribute to the risk of prostate cancer. Hum Immunol 74:1656¿1658."
"5517","PC094461","Pandey JP.  2013.  Immunoglobulin GM allotypes as effect modifiers of cytomegalovirus-spurred neuroblastoma.  Cancer Epidemiol Biomarkers Prev 22:1927-1930."
"5518","PC094461","Pandey JP.  2012.  Immunoglobulin genes and immunity to herpes simplex virus type 1.  J Infect Dis 206:143-144."
"5519","PC094461","Pandey JP, Namboodiri AM, Ohue Y, et al.  2014.  Genetic variants of immunoglobulin ¿ and ¿ chains influence humoral immunity to the cancer-testis antigen XAGE-1b (GAGED2a) in patients with non-small cell lung cancer.  Clin Exp Immunol 176:78-83."
"5520","PC094461","Pandey JP, Namboodiri AM, and Kistner-Griffin E. 2013.  A genetic variant of Fc¿RIIIa is strongly associated with humoral immunity to cyclin B1 in African American patients with prostate cancer. Immunogenetics 65:91-96."
"5521","PC094461","Pandey JP.  2011.  Prognostic immune markers in non-small cell lung cancer.  Clin Cancer Res 17:7835."
"5522","PC094461","Pandey JP and Namboodiri AM.  2014.  Immunoglobulin GM and FcgammaRIIIa genotypes influence cytotoxicity of neuroblastoma cells.  J Neuroimmunol 270:95-97."
"5523","PC094461","Pandey JP, Kaur N, Costa S, et al.  2014.  Immunoglobulin genes implicated in glioma risk. OncoImmunology 3:e28609."
"5524","PC094467","van der Meer R, Song HY, Park S-H, et al.  2014.  RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition.  Clin Cancer Res 20:3211-3221."
"5525","PC094474","Ginzberg S, Uzzo RG, and Kutikov A.  2012.  The role of minimally invasive surgery in multifocal renal cell carcinoma.  Current Urology Reports 13:202. 

"
"5526","PC094474","Kutikov A, Egleston BL, Canter D, et al. 2012.   Competing risks of death in patients with localized renal cell carcinoma: A comorbidity based model.  J Urol 188(6):2077-2083."
"5527","PC094474","Makhov P, Golovine K, Kutikov A, et al.  2012.  Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells.  Mol Cancer Ther 11(7):1510-1517.

"
"5528","PC094474","Makhov P, Golovine KV, Kutikov AK, et al.  2011.  Reversal of epigenetic silencing of AP-2alpha results in increased zinc uptake in DU-145 and LNCaP prostate cancer cells.  Carcinogenesis 32(12):1773-1781."
"5529","PC094474","Golovine K, Makhov P, Teper E, et al.  2013.  Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells.  Prostate 73(1):23-30.

"
"5530","PC094474","Kutikov A, Rozenfeld B, Egleston BL, et al.  2012.  Academic ranking score: A publication-based reproducible metric of thought leadership in urology.  European Urology 61:435."
"5531","PC094474","Teper E, Makhov P, Golovine K, et al.  2012.  The effect of 5-aminolevulinic acid and its derivatives on protoporphyrin IX accumulation and apoptotic cell death in castrate-resistant prostate cancer cells.  Urology 80(6):1391.e1-7."
"5532","PC094474","Smaldone MC, Egleston BL, Uzzo RG, et al.  2012.  Does partial nephrectomy result in a durable overall survival benefit in the medicare population?  J Urol 188(6):2089-2094."
"5533","PC094474","Kutikov A, Smaldone MC, Egleston BL, et al.  2011.  Should partial nephrectomy be offered to all patients whenever technically feasible?  European Urology 61:732-734."
"5534","PC094474","Makhov P, Golovine K, Canter D, et al.  2012.  Co-administration of piperine and docetaxel results in improved anti-tumor efficacy via inhibition of CYP3A4 activity.  Prostate 72(6):661-667."
"5535","PC094474","Golovine K, Makhov P, Uzzo RG, et al.  2010.  Cadmium down-regulates expression of XIAP at the post-transcriptional level in prostate cancer cells through an NF-kappaB-independent, proteasome-mediated mechanism.  Mol Cancer 9:183."
"5536","PC094474","Kutikov A, Makhov P, Golovine K, et al.  2011.  Interleukin-6: A potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer.  Urology 78(4):968.e7-968.e11.
"
"5537","PC094474","Makhov P, Kutikov A, Golovine K, et al.  2011.  Docetaxel-mediated apoptosis in myeloid progenitor TF-1 cells is mitigated by zinc: Potential implications for prostate cancer therapy.  Prostate 71:1413-1419."
"5538","PC094474","Kutikov A, Piotrowski ZJ, Canter DJ, et al.  2011.  Routine adrenalectomy is unnecessary during surgery for large and/or upper pole renal tumors when the adrenal is radiographically normal.  J Urology 185:1198-1203."
"5539","PC094474","Kutikov A, Cooperberg MR, Paciorek AT, et al.  2012.  Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram.  Prostate Cancer Prostatic Dis 15(4):374-379."
"5540","PC094474","Kutikov A, Smaldone MC, Egleston BL, et al.  2011.  Anatomic features of enhancing renal masses predict malignant and high-grade pathology: A preoperative nomogram using the RENAL nephrometry score.  European Urology 60, 241."
"5541","PC094474","Kutikov A, Mallin K, Canter D, et al.  2011.  Effects of increased cross-sectional imaging on the diagnosis and prognosis of adrenocortical carcinoma: Analysis of the National Cancer Database.  J Urology 186:805-810."
"5542","PC094476","Menon J, Doebele RC, Gomes S, et al.  2012.  A novel interplay between Rap1 and PKA regulates induction of angiogenesis in prostate cancer.  PLoS One 7(11):e49893."
"5543","PC094496","Gormley AJ and Ghandehari H.  2009.  Evaluation of toxicity of nanostructures in biological systems.  In: Nanotoxicity: From In Vivo and In Vitro Models to Health Risks, (Sahu S, and Casciano D. Eds.), John Wiley & Sons Limited, West Sussex (pages 115-159)."
"5544","PC094496","Gormley AJ, Greish K, Ray A, et al.  2011.  Gold nanorod-mediated plasmonic photothermal therapy: A tool to enhance macromolecular delivery.  Int J Pharm 415(1-2):315-318."
"5545","PC094496","Gormley AJ, Larson N, Ray A, et al.  2012.  Guided delivery of polymer therapeutics using plasmonic photothermal therapy.  Nano Today 7:158-167."
"5546","PC094496","Gormley AJ, Malugin A, Ray A, et al.  2011.  Biological evaluation of RGDfK - gold nanorod conjugates for prostate cancer treatment.  J Drug Targeting 19:915-924."
"5547","PC094496","Gormley AJ, Larson N, Banisadr A, et al.  2013.  Plasmonic photothermal therapy increases the tumor mass penetration of HPMA copolymers.  Journal of Controlled Release 166(2):130-138."
"5548","PC094496","Gormley AJ, Larson N, Ray A, et al.  2011.  Guided delivery of polymer therapeutics using plasmonic photothermal therapy.  Nano Today 7:158-167."
"5549","PC094499","Sun D, Lee YS, Malholtra A, et al.  2011.  miR-99 family of microRNAs suppresses the expression of prostate specific antigen and prostate cancer cell proliferation.  Cancer Res 71(4):1313-1324."
"5550","PC094501","Austin RJ, Kuestner RE, Chang DK, et al.  2011.  SILAC compatible strain of Pichia pastoris for expression of isotopically labeled protein standards and quantitative proteomics.  J Proteome Res 10(11):5251-5259.  "
"5551","PC094501","Austin RJ, Smidansky HM, Holstein CA, et al.  2012.  Proteomic analysis of the androgen receptor via MS-compatible purification of biotinylated protein on streptavidin resin.  Proteomics 12(1):43-53."
"5552","PC094501","Austin R, et al.  2012.  IQcat: Multiplexed protein quantification by isoelectric QconCAT.  Proteomics 12(13):2078-2083."
"5553","PC094506","Subedi M, Minn I, Chen J, et al. 2016. Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands. Eur J Med Chem. 118: 208-218. doi: 10.1016/j.ejmech.2016.04.033."
"5554","PC094507","Olshavsky, Comstock C, et al.  2010.  Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene.  Cancer Res 70(10):3975-3984."
"5555","PC094507","Comstock C, Augello, et al.  2011.  Cyclin D1 is a selective modifier of androgen dependent signaling and androgen receptor function.  J Biol Chem 286(10):8117-8127."
"5556","PC094507","Comstock CE, Augello MA, Goodwin JF, et al.  2013.  Targeting cell cycle and hormone receptor pathways in cancer.  Oncogene 32(48):5481-5491."
"5557","PC094507","Balasubramaniam S, Comstock CE, Ertel A, et al.  2013.  Aberrant BAF57 signaling facilitates pro-metastatic phenotypes.  Clin Cancer Res 19(10):2657-2667."
"5558","PC094510","Bian J, Wang J, Han X, et al.  2013.  Optimization-based image reconstruction from sparse-view data in offset-detector CBCT.  Phys Med Biol 58(2). "
"5559","PC094510","Han X, Bian J, Kline TL, et al.  2012.  Optimization based reconstruction of sparse images from few-view projections.  Phys Med Biol 57(16). "
"5560","PC094510","Zhang Z, Han X, Bian J, et al.  2011.  Initial experience in image reconstruction from limited-angle C-arm CBCT data.  IEEE Nucl. Sci. Conf. Rec."
"5561","PC094510","Bian J, Wang J, Han X, et al.  2011.  Sparse-view image reconstruction from gated cardiac data.  IEEE Nucl. Sci. Conf. Rec."
"5562","PC094510","Bian J, Han X, Yang K, et al.  2012.  A preliminary investigation of reduced-view image reconstruction from low-dose breast CT data.  Proc. SPIE 8313, 831325."
"5563","PC094510","Bian J, Han X, Yang K, et al.  2011.  A preliminary study of image reconstruction from low-dose data in dedicated breast CT.  IEEE Nucl. Sci. Conf. Rec."
"5564","PC094510","Xia D, Xiao X, Bian J, et al.  2011.  Image Reconstruction from sparse data in synchrotron-radiation-based micro-tomography.  Review of Scientific Instruments 82(4):043706."
"5565","PC094510","Bian J, Wang J, Han X, et al.  2012.  A preliminary study of optimization-based image reconstruction from offset-detector CBCT.  Proceedings of the 2nd International Conference on Image Formation in X-ray Computed Tomography."
"5566","PC094510","Zhang Z, Bian J, Han X, et al.  2012.  Iterative image reconstruction with variable resolution in diagnostic CT.  Proceedings of the 2nd International Conference on Image Formation in X-ray Computed Tomography."
"5567","PC094510","Zhang Z, Han X, Bian J, et al.  2012.  Initial experience in constrained-TV-minimization image reconstruction from diagnostic-CT Data.  Proceedings of the 2nd International Conference on Image Formation in X-ray Computed Tomography."
"5568","PC094510","Han X, Shi S, Bian J, et al.  2011.  Feasibility study of low-dose intra-operative cone-beam CT for image-guided surgery.  Proc. SPIE, 7961, 79615P."
"5569","PC094510","Zhang Z, Bian J, Han X, et al.  2011.  Iterative image reconstruction with variable resolution in CT.  IEEE Nucl. Sci. Conf. Rec."
"5570","PC094510","Bian J, Siewerdsen JH, Han X, et al.  2010.  Evaluation of sparse-view reconstruction from flat-panel-detector cone-beam CT.  Phys Med Biol 55:6575-6599."
"5571","PC094510","Han X, Bian J, Eaker DR, et al.  2011.  Algorithm enabled low-dose micro-CT imaging.  IEEE Transactions on Medical Imaging 30(3):606-620."
"5572","PC094516","Berger MF, Lawrence MS, Demichelis F, et al.  2011.  The genomic complexity of primary human prostate cancer.  Nature 470(7333):214-220.

"
"5573","PC094516","Banerjee S, Oldridge D, Poptsova M, et al.  2011.  A computational framework discovers new copy number variants with functional importance.  PLoS One 6(3):e17539."
"5574","PC094516","Poptsova M, Banerjee S, Gokcumen O, et al.  2013.  Impact of constitutional copy number variants on biological pathway evolution.  BMC Evol Biol 13(1):19."
"5575","PC094516","Schaefer G, Mosquera JM, Ramoner R, et al.  2013.  Distinct ERG rearrangement prevalence in prostate cancer - higher frequency in young age and in low PSA prostate cancer.  Prostate Cancer Prostatic Dis 16(2):132-138."
"5576","PC094516","Baca SC, Prandi D, Lawrence MS et al.  2013.  Punctuated evolution of prostate cancer genomes.  Cell 153(3):666-677."
"5577","PC094516","Barbieri C, Baca SC, Lawrence MS, et al.  2012.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.  Nat Genet 44(6):685-689."
"5578","PC094516","Demichelis F, Setlur SR, Banerjee S, et al.  2012.  Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.  Proc Natl Acad Sci U S A. 109(17):6686-6691."
"5579","PC094541","Fleming IN, Kut C, Macura KJ, et al.  2012.  Ultrasound elastography as a tool for imaging guidance during prostatectomy: Initial experience.  Medical Science Monitor 18(11):CR635-642."
"5580","PC094557","Li Y, Tian L, Ligr M, et al.  2013.  Functional domains of androgen receptor coactivator  p44/Mep50/WDR77 and its Interaction with Smad1.  PloS One 8(5):e64663."
"5581","PC094560","Grabowska MM, DeGraff DJ, Yu X, et al.  2014.  Mouse models of prostate cancer: Picking the best model for the question.  Cancer Metastasis Rev 33(2-3):377-397."
"5582","PC094560","Jin RJ, Sterling JA, Edwards J, et al.  Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone.  PlosOne 8(4):e60983."
"5583","PC094560","Jin RJ, Yi A, Yull FE, et al.  2014.  NF-kappaB gene signature predicts prostate cancer progression. Cancer Res 74(10):2763-2772."
"5584","PC094562","Ma L and Chen W.  2010.  ZnS:Cu,Co water soluble afterglow nanoparticles - synthesis, luminescence and potential applications.  Nanotechnology  21: 385604."
"5585","PC094562","Generalov R, Kavaliauskiene S, Chen W, et al.  2011.  Entrapment in phospholipid vesicles quenches photoactivity of quantum dots.  Int J Nanomedicine 6:1875-1888."
"5586","PC094596","Comstock, CE, Augello, MA, et al. Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function.  J Biol Chem 286(10):8117-8127."
"5587","PC094596","Augello MA, Burd CJ, Birbe R, et al.  2013.  Convergence of oncogenic and nuclear receptor pathways promotes metastatic phenotypes.  J Clin Invest 123(1):493-508."
"5588","PC094599","Wang MT, Jiang H, Boral D, et al.  2013.  Cancer stem cells in resistance to cytotoxic drugs: Implications in chemotherapy.  In:  Molecular Mechanisms of Tumor Cell Resistance to chemotherapy Resistance to Targeted Anti-Cancer Therapeutics 1 (Bonavida, Ed.).  DOI: 10.1007/978-1-4614-7070-0_8.  Springer Science+Business Media New York."
"5589","PC094601","Bluemn EG, Spencer ES, Mecham B, et al.  2013.  PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality. Mol Cancer Res 11(6):568-578."
"5590","PC094601","Bluemn EG, and  Nelson PS.  2012.  The androgen/androgen receptor axis in prostate cancer.  Curr Opin Oncol 24(3):251-257."
"5591","PC094619","Tarapore P, Shu Y, Guo P, et al.  2011.  Application of Phi29 Motor pRNA for targeted therapeutic delivery of siRNA silencing metallothionein-IIA and survivin in ovarian cancers.  Mol Ther 19(2):386-394."
"5592","PC094619","Smithrud DB, Wang X, Tarapore P, et al.  2013.  Crown ether host-rotaxanes as cytotoxic agents.  ACS Med Chem Lett 4(1):27-31."
"5593","PC094628","An C, Beard WA, Chen D, et al.  2013.  Understanding the loss of function in a triple missense mutant of DNA polymerase beta found in prostate cancer.  Int J Oncol 43(4):1131-1140."
"5594","PC094628","An C, Chen D, and Makridakis NM.  2011.  Systematic biochemical analysis of somatic missense mutations in dna polymerase beta found in prostate cancer reveal alteration of enzymatic function.  Hum Mutat 32:415-423."
"5595","PC094628","Makridakis NM and Reichardt JKV.  2012.  Translesion DNA polymerases and cancer.  Frontiers in Genetics 3: e00174."
"5596","PC094637","Ting HJ, Yasmin-Karim S, Yan SJ, et al.  2012.  A positive feedback signaling loop between ATM and the vitamin D receptor is critical for cancer chemoprevention by vitamin D.  Cancer Res 72:958-968."
"5597","PC094637","Lin T-H, Lee SO, Niu Y, et al.  2013.  Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) lead to promotion versus suppression of prostate cancer metastasis.  J Biol Chem 288(27):19359-19369."
"5598","PC094637","Lee SO, Ma Z, Hey CR, et al.  2013.  New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non- stem/progenitor cells.  5(1):14-26."
"5599","PC094637","Xu D, Lin TH, Zhang C, et al.  2012.  The selective inhibitory effect of a synthetic tanshinone derivative on prostate cancer cells.  Prostate 72:803-813."
"5600","PC094637","Lin TH, Yeh S, and Chang C.  2012.  Tissue-specific knockout of androgen receptor in mice.  Methods Mol Biol 776:275-293"
"5601","PC094637","Xu D, Lin TH, Li S, et al.  2012.  Crypototanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells.  Cancer Lett 316:11-22."
"5602","PC094646","Seo J, Ren G, Liu H, et al.  2012.  In vivo biodistribution and small animal PET of 64Cu-labeled antimicrobial peptoids.  Bioconjugate Chem 23:1069-1079."
"5603","PC094646","Xu Y, Huang W, Gang R, et al.  2012.  A four-arm star-shaped poly(ethylene glycol) (StarPEG) platform for bombesin peptide delivery to gastrin-releasing peptide receptors in prostate cancer.  ACS Macro Letters 1:753-757."
"5604","PC094646","Persson M, Liu H, Madsen J, et al.  2013.  First (18)F-labeled ligand for PET imaging of uPAR: In vivo studies in human prostate cancer xenografts.  Nuclear Med Biol 40(5):618-624."
"5605","PC094680","Gomez CR, Knutson G, Bulur P, et al.  Age-dependent response of bone marrow cells to hyperbaric oxygen.  BMC Medicine DOI: 10.1007/s10522-012-9373-8."
"5606","PC094680","Nomellini V, Mahbub S, Gomez CR, et al.  2012.  Dysregulation of neutrophil CXCR2 and pulmonary endothelial icam-1 promotes age-related pulmonary inflammation.  Aging Dis 3:234-247."
"5607","PC094694","Xu G and Piao D.  2011.  Feasibility of rapid near-infrared diffuse optical tomography by swept-spectral-encoded sequential light delivery.  Proc SPIE 7896-78961W."
"5608","PC094694","Xu G, Piao D, and Dehghani H.  2011.  The utility of direct-current as compared to frequency domain measurement in spectrally-constrained diffuse optical tomography toward cancer imaging.  Technol Cancer Res Treat 10(5):403-416.

"
"5609","PC094694","Xu G, Piao D and Dehghani H.  2011.  Spectral a priori to spatial a posteriori in continuous-wave image reconstruction in near-infrared optical tomography.  Proc SPIE 7892-78920D."
"5610","PC094694","XU G and Piao D.  2013.  A geometric-differential-sensitivity based algorithm improves object depth-localization for diffuse optical tomography in a circular-array outward-imaging geometry.  Medical Physics 40(1):013101."
"5611","PC094694","Piao D, Zhang A, and Xu G.  2013.  Photon diffusion in a homogeneous medium bounded externally or internally by an infinitely long circular cylindrical applicator.  V. steady-state fluorescence.  Journal of the Optical Society of America, A, 30(4):791-805."
"5612","PC094694","Zhang A, Piao D, and Bunting CF.  2012.  Photon diffusion in a homogeneous medium bounded externally or internally by an infinitely long circular cylindrical applicator.  III.  Synthetic study of continuous-wave photon fluence rate along unique spiral-paths.  J Opt Soc Am A Opt Image Sci Vis: 29(4):545-558. "
"5613","PC094694","Zhang A and Piao D.  2012.  Photon diffusion in a homogeneous medium bounded externally or internally by an infinitely long circular cylindrical applicator.  IV.  Frequency-domain analysis.  J Opt Soc Am A Opt Image Sci Vis: 29(7):1445-1458."
"5614","PC094694","Piao D, Zhang A, Yao G, et al.  2011.  When is spiral straight?  Optics & Photonics News, 22(12):24.  Optics in 2011 special issue (peer-reviewed)."
"5615","PC094695","Podgorski I, Linebaugh BE Koblinski JE, et al.  2009.  Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis.  Am J Pathol 175 (3):1255-1269."
"5616","PC094695","Jedeszko C, Victor BC, Podgorski I. et al.  2009.  Hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ.  Cancer Res 69 (23):9148-9155."
"5617","PC094695","Trivedi ER, Harney AS, Olive MB, et al.  2010.  Chiral porphyrazines as near-infrared optical contrast agents: Tumor specific accumulation in vivo.  PNAS USA 107(4):1284-1288."
"5618","PC094715","Ozkumur E, Shah A, et al.  2013.  Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.  Sci Transl Med 5(179):179ra47.  
"
"5619","PC094715","Shah AM, Yu M, Nakamura Z, et al.  2012.  Biopolymer system for cell recovery from microfluidic cell capture devices.  Anal Chem 84(8):3682-3688.
"
"5620","PC094725","Prensner JR, Iyer MK, Balbin OA, et al.  2011.  Transcriptome sequencing identifies PCAT-1, a novel lincRNA implicated in prostate cancer progression.  Nat Biotechnol 29(8):742-749."
"5621","PC094725","Cao Q, Mani RS, Ateeq B, et al.  2011.  Coordinated regulation of Polycomb group complexes through microRNAs in cancer.  Cancer Cell 16:20(2):187-199."
"5622","PC094725","Ateeq B, Tomlins SA, Laxman B, et al.  2011.  Therapeutic targeting of SPINK1-positive prostate cancer.  Sci Transl Med 3:72ra17."
"5623","PC094754","Drake JM, Barnes JM, Madsen JM, et al.  2010.  ZEB1 coordinately regulates laminin-332 and beta4-integrin expression altering the invasive phenotype of prostate cancer cells.  J Biol Chem 285(44):33940-33948."
"5624","PC094767","Wilton JH, Titus MA, Efstathiou E, et al.  2014.  Androgenic biomarker profiling in human matrices and cell culture samples using high throughput, electrospray tandem mass spectrometry.  Prostate 74:722-731."
"5625","PC094786","Hurley P, Marchionni L, Simons B, et al. 2013.  Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. Proc Natl Acad Sci U S A. 109(37):14977-14982."
"5626","PC094786","Darshan M, Zheng Q, Fedor H L, et al.  2014.  Biobanking of derivatives from radical retropubic and robot¿ assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network.  Prostate 74(1):61-69."
"5627","PC094786","Antonarakis ES, Lu C, Wang H, et al.  2014.  AR-V7 and resistance to Enzalutamide and Abiraterone in prosate cancer.  New Eng J Med 371(11):1028-1238."
"5628","PC094797","Antonarakis ES, Lu C, Wang H, et al.  2014.  AR-V7 and resistance to Enzalutamide and Abiraterone in prostate cancer.  N Engl J Med 371(11):1028-1038."
"5629","PC094797","Hurley P, Marchionni L, Simons B, et al. 2013.  Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for  poor clinical outcome. Proc Natl Acad Sci U S A. 109(37):14977-14982."
"5630","PC094797S","Hurley P, Marchionni L, Simons B, et al. 2013.  Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for  poor clinical outcome. Proc Natl Acad Sci U S A. 109(37):14977-14982."
"5631","PC100093","Chen Z, Forman LW, Williams RM, et al.  2014.  Protein kinase C-delta inactivation inhibits the proliferation and survival of cancer stem cells in culture and in vivo.  BMC Cancer 14:90-98."
"5632","PC100093","Takashima A, English B, Chen Z, et al.  2014.  Protein kinase C delta is a therapeutic target in malignant melanoma with NRas mutation or BRaf inhibitor-resistance.  ACS Chem Biol 9(4):1003-1014."
"5633","PC100093","Takashima A and Faller DV.  2013.  Targeting the RAS oncogene.  Expert Opin Ther Targets 17(5):507-531."
"5634","PC100171","Prensner JR et al.  2011.  Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression.  Nat Biotechnol 29(8):742-749."
"5635","PC100171","Prensner JR, Chen W, Iyer MK, et al.  2014.  PCAT-1, a long noncoding RNA regulates BRCA2 and controls homologous recombination in cancer.  Cancer Res 74(6):1651-1660."
"5636","PC100171","Prensner JR, Iyer MK, Sahu A, et al.  2013.  The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex.  Nat Genet 45(11):1392-1398."
"5637","PC100211","Diamanduros A, Matheson J et al.  2013.  Mismatch repair proteins in recurrent prostate cancer.  Advances in Clin Chem 60:65-84."
"5638","PC100238","Thibodeau SN, French AJ, McDonnel SK, et al.  2015.  Identification of candidate genes for prostate cancer-risk SNPs utilizing a normal prostate tissue eQTL data set.  Nat Commun 6:8653."
"5639","PC100238","Larson NB, McDonnell S, French AJ, et al.  2015.  Comprehensively evaluating cis-regulatory variation in the human prostate transcriptome by using gene-level allele-specific expression.  Am Soc Hum Genet 96(6):869-882."
"5640","PC100266","Inoue M and Shinohara ML.  2011.  Intracellular osteopontin (iOPN) and immunity.  Immunol Res  49:160-172."
"5641","PC100266","Inoue M and Shinohara ML.  2015.  Cutting edge:  role of osteopontin and integrin in T cell mediated anti-inflammatory responses in endotoxemia.  J Immunol 194(12):5595-5598."
"5642","PC100266","Huang X, Yuan F, Liang M, et al.  2012. M-HIFU inhibits tumor growth, suppresses STAT3 activity and enhances tumor specific immunity in a transplant tumor model of prostate cancer.  PLoS One 7(7):e41632."
"5643","PC100310","Cho E, Montgomery RB, and Mostaghel EA. 2014.  Minireview: SLCO and ABC transporters: A role for steroid transport in prostate cancer progression. Endocrinology. 155(11):4124-32."
"5644","PC100310","Mostaghel EA. 2013.  Steroid hormone synthetic pathways in prostate cancer. Transl Androl Urol 2(3):212-227."
"5645","PC100310","Mostaghel EA, and Beyond T.  2014,  DHT - novel steroid derivatives capable of wild type androgen receptor activation. Int J Biol Sci 10(6):602-613."
"5646","PC100354","Schild R, Knuppel T, Konrad M, et al.  2012.  Double homozygous missense mutations in DACH1 and BMP4 in a patient with bilateral cystic renal dysplasia.  Nephrol Dial Transplant 28(1):227-232."
"5647","PC100354","Chen K, Wu K, Cai S, et al.  2013.  Dachshund binds p53 to block the growth of lung adenocarcinoma cells.  Cancer Res 73(11):3262-3274."
"5648","PC100354","Wu K, Chen K, Wang C, et al.  2014.  Cell fate factor DACH1 represses YB-1-mediated oncogenic transcription and translation.  Cancer Res 74(3):829-839."
"5649","PC100354","Chen K, Wu K, Wang L, et al.  2015.  The endogenous cell-fate factor dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a CXCL signaling module.  Cancer Res 75(10):1992-2004."
"5650","PC100354","Chen K, Wu K, Gormley M, et al.  2013.  Acetylation of the cell fate factor Dachshund determines p53 binding and signaling module in breast cancer.  Oncotarget 4(6):923-935."
"5651","PC100356","Wei H, Wei S, Gan B, et al.  2011.  Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis.  Genes Dev 25(14):1510-1527. "
"5652","PC100356","Zhang K, Li L, Qi Y, et al.  2012.  Hepatic suppression of Foxo1 and Foxo3 causes hypoglycemia and hyperlipidemia in mice.  Endocrinology 153(2):631-646. "
"5653","PC100356","Zhang Y, Gan B, Paik JH.  2011.  FoxO family members in cancer.  Cancer Biol Ther 12(4):253-259. "
"5654","PC100368","Gururajan M, Cavassani KA, Sievert M, et al.  2015.  SRC family kinase FYN promotes the neuroedeocrine phenotype and visceral metastasis in advanced prostate cancer.  Oncotarget 6(42):44072-44083."
"5655","PC100368","Jiang R, Lu Y-T, Ho H, et al.  2015.  A comparision of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer.  Oncotarget 6(42):44781-44793."
"5656","PC100374","Wagner EJ and Carpenter PB:  2012.  Translating the language of H3K36.  Nat Rev Mol Cell Biol 13(2):115-126."
"5657","PC100427","Billingsley KL, Park JM, Josan S, et al.  2014.  The feasibility of assessing branched-chain amino acid metabolism in cellular models of prostate cancer with hyperpolarized [1-(13)C]-ketoisocaproate.   Magn Reson Imaging 32(7):791-795."
"5658","PC100427","Billingsley KL, Josan S, Park JM, et al.  2014.  Hyperpolarized [1,4-(13)C]-diethylsuccinate: A potential DNP substrate for in vivo metabolic imaging.  NMR Biomed 27(3):356-362."
"5659","PC100427","Josan S, Hurd R, Billingsley K, et al.  2013.  Effects of isoflurane anesthesia on hyperpolarized (13)C metabolic measurements in rat brain.  Magn Reson Med 70(4):1117-1124."
"5660","PC100455","Drenkhahn SK, Jackson GA, Slusarz A, et al.  2013.  Inhibition of hedgehog/gli signaling by botanicals:  A review of compounds with potential hedgehog pathway inhibitory activities.  Curr Cancer Drug Targets 13(5):580-595."
"5661","PC100473","Hong H, Zhang Y, Nayak TR, et al.  2012.  Immuno-PET of tissue factor in pancreatic cancer.  J Nucl Med 53(11):1748-1754."
"5662","PC100473","Wang P, Yang Y, Hong H, et al.  2011.  Aptamers as therapeutics in cardiovascular diseases.  Current Med Chem 18:4169-4174."
"5663","PC100473","Hong H, Shi J, Yang Y, et al.  2011.  Cancer-targeted optical imaging with fluorescent zinc oxide nanowires.  Nano Letters 11:3744-3750."
"5664","PC100473","Xiao Y, Hong H, Javadi A, et al.  2012.  Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging.  Biomaterials 33(11):3071-3082."
"5665","PC100473","Zhang Y, Hong H, Engle JW, et al.  2012.  Positron emission tomography and optical imaging of tumor CD105 expression with a dual-labeled monoclonal antibody.  Mol Pharm 9(3):645-653.

"
"5666","PC100473","Hong H, Yang K, Zhang Y, et al.  2012.  In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene.  ACS Nano 6(3):2361-2370."
"5667","PC100473","Zhang Y, Jeon M, Rich LJ, et al.  2014.  Non-invasive, multimodal functional imaging of the intestine with frozen micellar naphthalocyanines.  Nat Nanotechnol 9(8):631-638."
"5668","PC100473","Chen F, Hong H, Zhang Y,  et al.  2013.  In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles.  ACS Nano 7(10):9027-9039."
"5669","PC100473","Nayak TR, Hong H, Zhang Y, et al.  2013.  Multimodality imaging of CXCR4 in cancer: current status towards clinical translation.  Curr Mol Med 13:1538-1548."
"5670","PC100473","Orbay H, Bean J, Zhang Y, et al.  2013.  Intraoperative targeted optical imaging: A guide towards tumor-free margins in cancer surgery.  Curr Pharm Biotechnol 14(8):733-742."
"5671","PC100473","Shi S, Chen F, and Cai W.  2013.  Biomedical applications of functionalized hollow mesoporous silica nanoparticles: Focusing on molecular imaging.  Nanomedicine 8:2027-2039."
"5672","PC100473","Yang K, Feng L, Hong H, et al.  2013.  Preparation and functionalization of graphene nanocomposites for biomedical applications.  Nat Protoc 8(12):2392-2403."
"5673","PC100473","Zhu Y, Hong H, Xu ZP, et al.  2013.  Quantum dot-based nanoprobes for in vivo targeted imaging.  Curr Mol Med 13:1549-1567."
"5674","PC100473","Chen F, Hong H, Goel S, et al.  2015.  In vivo tumor vasculature targeting of CuS@MSN based theranostic nanomedicine.  ACS Nano 9:3926-3934."
"5675","PC100473","Dougherty CA, Cai W, and Hong H.  2015.  Applications of aptamers in targeted imaging: State of the art.  Current Topics in Med Chem 15 1138-1152."
"5676","PC100473","Hong H, Zhang Y, Engle JW, et al.  2012.  In vivo targeting and positron emission tomography imaging of tumor vasculature with (66)Ga-labeled nano-graphene.  Biomaterials 33(16):4147-4156.

"
"5677","PC100473","Zhang Y, Nayak TR, Hong H, et al.  2012.  Graphene: A versatile nanoplatform for biomedical applications.  Nanoscale 4(13):3833-3842."
"5678","PC100473","Xiao Y, Hong H, Matson VZ, et al.  2012.  Gold nanorods conjugated with doxorubicin and cRGD for combined anticancer drug delivery and PET imaging. Theranostics 2(8):757-768."
"5679","PC100473","Zhang Y, Hong H, Severin GW, et al.  2012.  ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW.  Am J Transl Res 4(3):333-346."
"5680","PC100473","Hong H, Benink HA, Zhang Y, et al.  2011.  A novel reporter gene for positron emission tomography.  American Journal of Translational Research 3:392-403."
"5681","PC100473","Engle JW, Hong H, Zhang Y, et al.  2012.  Positron emission tomography imaging of tumor angiogenesis with a 66Ga-labeled monoclonal antibody.  Mol Pharm 9(5):1441-1448."
"5682","PC100473","Hong H, Zhang Y, Severin GW, et al.  2012.  Multimodality imaging of breast cancer experimental lung metastasis with bioluminescence and a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW.  Mol Pharm 4(1):32-42."
"5683","PC100473","Yang Y, Niu Y, Hong H, et al.  2012.  Radiolabeled gamma-AApeptides: A new class of tracers for positron emission tomography.  Chem Commun (Camb) 48(63):7850-7852."
"5684","PC100473","Chen F, Hong H, Shi S,  et al.  2014.  Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy.  Sci Rep 4:5080."
"5685","PC100473","Goel S, Chen F, Cai W.  2014.  Synthesis and biomedical applications of cupper sulfide nanoparticles: from sensors to theranostics. Small 10(4):631-645."
"5686","PC100473","Chen F, Ellison PA, Lewis CM, et al.  2013.  Chelator-free synthesis of a dual-modality PET/MRI agent.  Angew Chem Int Ed Engl 52(50):13319-13323."
"5687","PC100473","Orbay H, Hong H, Zhang Y, et al.  2013.  Positron emission tomography imaging of atherosclerosis.  Theranostics 3:894-902."
"5688","PC100473","Zhang Y, Nayak TR, Hong H, et al.  2013.  Biomedical applications of zinc oxide nanomaterials. Curr Mol Med 13:1633-1645."
"5689","PC100473","Guo J, Hong H, Chen G, et al.  2014.  Theranostic unimolecular micelles based on brush-shaped amphiphilic block copolymers for tumor-targeted drug delivery and positron emission tomography imaging.  ACS Applied Materials & Interfaces 6:21769-21779."
"5690","PC100473","Zhang Y, Hong H, Nayak TR, et al.  2013.  Imaging tumor angiogenesis in breast cancer experimental lung metastasis with positron emission tomography, near-infrared fluorescence, and bioluminescence. Angiogenesis 16(3):663-674."
"5691","PC100473","Chakravarty R, Goel S, Cai W.  2014.  Nanobody:  The 'magic bullet' for molecular imaging?  Theranostics 4(4):386-398."
"5692","PC100473","Chen F and Cai W.  2014.  Tumor vasculature targeting: A generally applicable approach for functionalized nanomaterials.  Small 10(10):1887-1893."
"5693","PC100473","Chakravarty R, Hong H, and Cai W.  2014.  Positron emission tomography image-guided drug delivery: Current status and future perspectives.  Mol Pharm 11(11):3777-3797."
"5694","PC100473","Chakravarty R, Valdovinos HF, Chen F, et al.  2014. Intrinsically germanium-69 labeled iron oxide nanoparticle: Synthesis and in vivo dual-modality PET/MR imaging.  Adv Mater 26(30):5119-5123."
"5695","PC100473","Hernandez R, Valdovinos HF, Yang Y,et al.  2014.  44Sc: An attractive isotope for peptide-based PET imaging.  Mol Pharm 11(8):2954-2961."
"5696","PC100473","Luo H, Hong H, Yang SP,  et al.  2014. Design and applications of bispecific heterodimers: Molecular imaging and beyond.  Mol Pharm 11(6):1750-1761."
"5697","PC100473","Orbay H, Hong H, Koch JM, et al.  2014.  Pravastatin stimulates angiogenesis in a murine hindlimb ischemia model: a positron emission tomography imaging study with 64Cu-NOTA-TRC105.  Am J Transl Res 6(1):54-63."
"5698","PC100473","Shi S, Hong H, Orbay H, et al.  2015.  ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragment.  European J Nuclear Med and Mol Imaging 42:1295-1303."
"5699","PC100473","Shi S, Orbay H, Yang Y, et al.  2015.  PET imaging of abdominal aortic aneurysm with 64Cu-labeled anti-CD105 antibody Fab fragment.  J Nuclear Med 56:927-932."
"5700","PC100473","Sun X, Cai W, and Chen X.  2015.  Positron emission tomography imaging using radiolabeled inorganic nanomaterials.  Accounts of Chem Res 48:286-294."
"5701","PC100473","Chen F, Goel S, Valdovinos HF, et al.  2015.  In vivo integrity and biological fate of chelator-free zirconium-89-labeled mesoporous silica nanoparticles.  ACS Nano 9:7950-7959."
"5702","PC100473","Zhang Y, Hong H, Engle JW, et al.  2011.  Positron emission tomography imaging of CD105 expression with a 64Cu-labeled antibody: NOTA is superior to DOTA.  PLoS ONE 6:e28005. "
"5703","PC100473","Yang Y, Zhang Y, Hong H, et al.  2011.  In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis.  European J Nuclear Med Mol Imag 38:2066-2076."
"5704","PC100473","Orbay H, Zhang Y, Valdovinos HF, et al.  2014.  Positron emission tomography imaging of CD105 expression in a rat myocardial infarction model with (64)Cu-NOTA-TRC105. Am  J Nucl Med Mol Imaging 4(1):1-9."
"5705","PC100473","England CG, Luo H, Cai W. et al.  2015.  HaloTag: A versatile platform for biomedical applications.  Bioconjugate Chem 26:975-986."
"5706","PC100473","Chakravarty R, Hong H, and Cai W.  2015.  Image-guided drug delivery with single-photon emission computed tomography: A review of literature.  Current Drug Targets 16:592-609."
"5707","PC100500","Guo CQ, Yi H, Yu X, et al.  2012.  In situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy of prostate cancer.  Mol Cancer Ther 11(11):2331-2341."
"5708","PC100500","Hedvat M, Emdad L, Das SK, et al.  2012.  Selected approaches for rational drug design and high throughput screening to identify anticancer molecules.  Anticancer Agents Med Chem 12(9):1143-1155."
"5709","PC100500","Yu X, Subjeck JR, and Wang XY.  2013.  Integrating a ¿danger¿ signal into cross-priming chaperone Grp170 to achieve therapeutic vaccination.  Expert Reviews on Vaccines 12(6):581-583."
"5710","PC100500","Bhatia S, Menezes ME, Das SK, et al.  2013.  Innovative approaches for enhancing cancer gene therapy.  Discov Med 15(84):309-317."
"5711","PC100500","Bhutia SK, Mukhopadhyay S, Sinha N, et al.  2013.  Autophagy: cancer¿s friend or foe?  Adv. Cancer Res 118:61-95."
"5712","PC100500","Guo C, Manjili MH, Subjeck JR, et al.  2013.  Therapeutic cancer vaccines: past, present and future.  Adv. Cancer Research 119:421-475."
"5713","PC100500","Wang H, Yu X, Guo C, et al.  2013.  Enhanced ER entry of tumor antigen is crucial for cross-presentation induced by dendritic cell-targeted vaccination.  J Immunology 191(12):6010-6021."
"5714","PC100500","Yu X, and Wang XY.  Engineering Grp170-based immune modulators for cancer immunotherapy.  Oncoimmunology  2(6): e24385."
"5715","PC100500","Yu X, Guo C, Yi H, et al.  2013.  A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity.  Cancer Research 73(7):2093-2103. "
"5716","PC100500","Yu X, Subjeck JR and Wang XY.  2013.  Integrating a danger signal into cross-priming chaperone Grp170 to achieve therapeutic vaccination. Expert Reviews on Vaccines 12(6):581-583."
"5717","PC100500","Wang XY and Subjeck JR.  2013.  High molecular weight stress proteins:  Identification, cloning and utilisation in cancer immunotherapy.  Int. J Hyperthermia 29(5):364-375."
"5718","PC100500","Azab BM, Dash R, Das SK, et al.  2014.  Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3-CTV).  J Cell Phys 229(1):34-43."
"5719","PC100500","Guo C, Buranych A, Sarkar D, et al.  2013.  The role of tumor-associated macrophages in tumor vascularization. Vascular Cell 5 (1):20-32."
"5720","PC100500","Kmieciak M, Payne KK, Rami F, et al.  2013.  IFN-gamma Ralpha is a key determinant of CD8+ T cell-mediated tumor elimination or tumor escape and relapse in FVB mouse.  Plos One 8(12):e82544."
"5721","PC100500","Menezes ME, Das SK, Emdad L, et al.  2014.  Genetically engineered mice as experimental tools to dissect the critical events in breast cancer.  Adv Cancer Res 121:331-382."
"5722","PC100500","Manjili MH, Scott A and Wang XY.  2014.  Evolution of our understanding of myeloid regulatory cells: from MDSCs to Mregs.  Front Immunol 5:303-305."
"5723","PC100500","Menezes ME, Bhatia S, Bhoopathi P, et al.  2014.  MDA-7/IL-24:  Multifunctional cancer killing cytokine.  Adv Exp Med Biol 818:127-153."
"5724","PC100500","Kegelman TP, Das SK, Emdad L, et al.  2014.  Targeting tumor invasion:  the roles of MDA- 9/Syntenin.  Expert Opin Ther Targets 15:1-16."
"5725","PC100500","Das SK, Menezes ME, Bhatia S, et al.  2015.  Gene therapies for cancer:  strategies, challenges and successes.  J Cell Physiology 230:259-271."
"5726","PC100500","Talukdar S, Emdad L, Das SK, et al.  2015.  Noninvasive approaches for detection and monitoring bladder cancer.  Expert Rev Anticancer Ther 15(3):283-294."
"5727","PC100500","Talukdar S, Emdad L, Das SK, et al.  2015.  Noninvasive approaches for detection and monitoring bladder cancer.  Expert Rev Anticancer Ther 15(3):283-294."
"5728","PC100500P1","Guo CQ, Yi H, Yu X, et al.  2012.  In situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy of prostate cancer.  Mol Cancer Ther 11(11):2331-2341."
"5729","PC100500P1","Hedvat M, Emdad L, Das SK, et al.  2012.  Selected approaches for rational drug design and high-throughput screening to identify anticancer molecules.  Anticancer Agents Med Chem 12(9):1143-1155."
"5730","PC100500P1","Guo C, Yi H, Yu X, et al.  2012.  In situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy of prostate cancer.  Mol Cancer Ther 11(11): 2331-2341."
"5731","PC100500P1","Das SK, Menezes ME, Bhatia S, et al.  2015.  Gene therapies for cancer: Strategies, challenges and successes.  J Cell Physiol 23):259-271."
"5732","PC100500P1","Y X, and Wang X-Y.  2013.  Engineering Grp170-based immune modulators for cancer immunotherapy.  Oncolmmunology 6:e24385."
"5733","PC100500P1","Guo C, Manjili M, Subjeck JR, et al.  2013.  Therapeutic cancer vaccines: Past, present, and future.  In: Advances in Cancer Research.  Elsevier, Volume 10:421-475."
"5734","PC100500P1","Bhutia SK, Mukhopadhyay S, Sinha N, et al.  2013.  Autophagy: cancer¿s friend or foe?  Adv Cancer Res 118:61-95."
"5735","PC100500P1","Yu X, Subjeck JR, and Wang XY.  2013.  Integrating a 'danger' signal into cross-priming chaperone Grp170 to achieve therapeutic vaccination.  Expert Rev Vaccines 12(6):581-583."
"5736","PC100500P1","Yu X, Guo C, Yi H, et al.  2013.  A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity.  Cancer Res 73(7):2093-2103. "
"5737","PC100500P1","Yu X and Wang XY.  2013.  Engineering Grp170-based immune modulators for cancer immunotherapy.  Oncoimmunology  2(6): e24385."
"5738","PC100500P1","Wang H, Yu X, Guo C, et al.  2013.  Enhanced ER entry of tumor antigen is crucial for cross-presentation induced by dendritic cell-targeted vaccination.  J Immun 191(12):6010-6021."
"5739","PC100500P1","Guo C, Manjili MH, Subjeck JR, et al.  2013.  Therapeutic cancer vaccines: Past, present and future.  Adv Cancer Res 119:421-475."
"5740","PC100500P1","Das SK, Sarkar S, Dash R, et al.  2012.  Cancer terminator viruses and approaches for enhancing therapeutic outcomes.  Adv Cancer Research 115:1-38."
"5741","PC100500P1","Thomas S, Quinn BA, Das SK, et al.  2013.  Targeting the Bcl-2 Family for Cancer Therapy.  Expert Opinion in Therapeutic Targets 17(1): 61-75."
"5742","PC100500P1","Hedvat M, Emdad L, Das SK, et al.  2012.  Selected approaches for rational drug design and high throughput screening to identify anti-cancer molecules.  Anticancer Agents in Medicinal Chemistry 212 (9):1143-1155."
"5743","PC100500P1","Sarkar S, Quinn BA, Shen XN, et al.  2015.  Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic.  Oncotarget 6:10712-10727."
"5744","PC100500P1","Das SK, Menezes ME, Bhatia S, et al.  2015.  Gene therapies for cancer: strategies, challenges and successes.  J Cell Physiology 230: 259-271."
"5745","PC100500P1","Kegelman TP, Das SK, Emdad L, et al.  2014.  Targeting tumor invasion: the roles of MDA- 9/Syntenin.  Expert Opin Ther Targets 15:1-16."
"5746","PC100500P1","Menezes ME, Bhatia S, Bhoopathi P, et al.  2014.  MDA-7/IL-24: Multifunctional cancer killing cytokine.  Adv Exp Med Biol 818: 127-153."
"5747","PC100500P1","Manjili MH, Scott A, and Wang XY.  2014.  Evolution of our understanding of myeloid regulatory cells: from MDSCs to Mregs.  Frontiers in Immunology 5:303-305."
"5748","PC100500P1","Yu X, Guo C, Yi H, et al.  2013.  A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity. Can Res 73(7):2093-2103."
"5749","PC100500P1","Sarkar S, Quinn BA, Shen X-N, et al.  2015.  Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic.  Oncotarget 6(13):10712-10727."
"5750","PC100500P1","Yu X, Subjeck JR, and Wang X-Y.  2014.  Integrating a 'danger' signal into molecular charperoning to improve vaccination against cancer.  Expert Review of Vaccines 12(6):581-583."
"5751","PC100500P1","Yu X, Guo C, Fisher PB et al.  Scavenger receptors: emerging roles in cancer biology and immunology.  In: Advances in Cancer Research.  Elsevier 128:310-345."
"5752","PC100500P1","Azab BM, Dash R, Das SK, et al.  2014.  Enhanced prostrate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus(Ad.5/3-CTV).  J Cell Physiol 229:34-43."
"5753","PC100500P1","Azab BM, Dash R, Das SK, et al.  2014.  Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5/3-CTV).  J Cell Physiology 229(1):34-43."
"5754","PC100500P1","Guo C, Buranych A, Sarkar D, et al.  2013.  The role of tumor-associated macrophages in tumor vascularization.  Vascular Cell 5(1):20-32."
"5755","PC100500P1","Guo C, Buranych A, Sarkar D, et al.  2013.  The role of tumor-associated macrophages in tumor vascularization.  Vascular Cell 5(1):20-32."
"5756","PC100500P1","Menezes ME, Das SK, Emdad L, et al.  2014.  Genetically engineered mice as experimental tools to dissect the critical events in breast cancer.  Adv Cancer Res 121:331-382."
"5757","PC100500P1","Bhatia S, Menezes ME, Das SK, et al.  2013.  Innovative approaches for enhancing cancer gene therapy.  Discov Med 15(84):309-317."
"5758","PC100502","Nadiminty N and Gao AC.  2012.  Mechanisms of persistent activation of the androgen receptor in CRPC: Recent advances and future perspectives.  World J Urol 30(3):287-295. "
"5759","PC100502","Zhu Y, Tummala R, Liu C, et al.  2012.  RhoGDI-alpha suppresses growth and survival of prostate cancer cells.  Prostate 72(4):392-398."
"5760","PC100502","Nadiminty N, Tummala R, Lou W, et al.  2012.  MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth.  PLoS One 7(3):e32832. "
"5761","PC100502","Liu C, Lou W, Zhu Y, et al.  2014.  Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.  Clin Cancer Res 20(12):3198-3210."
"5762","PC100502","Cui Y, Nadiminty N, Liu C, et al.  2014.  Upregulation of glucose metabolism by NF-kappaB2/p52 mediates enzalutamide resistance in castrationresistant prostate cancer cells.  Endocr Relat Cancer 21(3):435-442."
"5763","PC100502","Zhu Y, Liu C, Nadiminty N, et al.  2013.  Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer.  Mol Cancer Ther 12(9):1829-36."
"5764","PC100502","Tummala R, Nadiminty N, Lou W, et al.  2013.  Lin28 promotes the growth of prostate cancer cells and activates the androgen receptor.  Am J Pathol 183(1):288-295."
"5765","PC100502","Nadiminty N, Tummala R, Liu C, et al.  2013.  NFkappaB2/ p52 induces resistance to enzalutamide in prostate cancer: Role of androgen receptor and its variants.  Mol Cancer Ther 12(8):1629-1637."
"5766","PC100502","Liu C, Zhu Y, Lou W, et al.  2013.  Functional p53 determines docetaxel sensitivity in prostate cancer cells.  Prostate 73(4):418-427."
"5767","PC100502","Nadiminty N, Tummala R, Lou W, et al.  2012.  MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells.  J Biol Chem 287(2):1527-1537."
"5768","PC100502","Zhu Y, Liu C, Tummala R, et al.  2013.  RhoGDIalpha downregulates androgen receptor signaling in prostate cancer cells.  Prostate 73(15):1614-1622."
"5769","PC100502","Zhu Y, Liu C, Cui Y, et al.  2014.  Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST).  Prostate 74(11):1086-1094."
"5770","PC100502","Liu C, Lou W, Zhu Y, et al.  2015.  Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer.  Cancer Res 75(7):1413-1422."
"5771","PC100502","Nadiminty N, Tummala R, Liu C, et al.  2015.  NF-kappaB2/p52:c-Myc:hnRNPA1 pathway regulates expression of androgen receptor splice variants and enzalutamide sensitivity in prostate cancer.  Mol Cancer Ther 14(8):1884-1895."
"5772","PC100519","Yan L, Da Silva DM, et al.  2015.  Forced LIGHT expression in prostate tumors overcome Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes.  Prostate 75(3):280-291."
"5773","PC100550","Oh P, Testa JE, Borgstrom P, et al.  2014.  In vivo proteomic imaging analysis of caveolae reveals pumping system to penetrate solid tumors.  Nature Med 20:1062-1068."
"5774","PC100563","Basch E, Trentacosti AM, Burke LB, et al.  2014.  Pain palliation measurement in cancer clinical trials: The US food and drug administration perspective.  Cancer 120(5):761-767."
"5775","PC100563","Basch E, Autio KA, Smith MR, et al.  2015.  Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: Results from a phase 2 nonrandomized expansion cohort.  Eur Urol 67(2):310-318."
"5776","PC100570","Lo U, Yang D, and Hsieh JT.  2013.  The role of microRNAs in prostate cancer progression. Trans Androl Urol 2:228-241."
"5777","PC100606","Bramhecha Y, Guérard KP, Rouzbeh S, Scarlata E, Brimo F, Chevalier S, Hamel L, Dragomir A, Aprikian A, Lapointe J. Genomic Gain of 16p13.3 in Prostate Cancer Predicts Poor Clinical Outcome After Surgical Intervention. Mol Cancer Res. 2017 Oct 9. pii: molcanres.0270.2017. doi: 10.1158/1541-7786.MCR-17-0270. [Epub ahead of print]."
"5778","PC100613","Podder TK, Dicker AP, Hutapea P, et al.  2012.  A novel curvilinear approach for prostate seed implant.  Medical Physics 39(4):1887-1892."
"5779","PC100613","Datla NV, Konh B, Koo JJ, et al.  2014.  Polyacrylamide phantom for self-actuating needle-tissue interaction studies. Med Eng Phys  36(1):140-5."
"5780","PC100613","Joseph FO, Franz K, Luan Y, et al.  2014.  Delopment of a coordinated controller for robot-assisted shape memory alloy actuated needle for prostate brachytherapy. Conf Proc IEEE Eng Med Biol Soc 2014:357-60."
"5781","PC100613P1","Datla NV, Koo J, Choi D, et al.  2014.  Polyacrylamide phantom for needle-tissue interaction studies with active needles.  Med Eng Phys 36:140-145."
"5782","PC100613P1","Podder TK, Dicker AP, Hutapea P, et al.  2012.  A novel curvilinear approach for prostate seed implant.  Medical Physics 39(4):1887-1892."
"5783","PC100613P1","Joseph FM, Kumar M, Hutapea P, et al.  2015.  TU-AB-201-12: Effects of Tissue Interference On Electromagnetic Sensor and Ultrasound Imaging Sensing for Robot-Guided Needle Interventions. Med Phys 42(6):3596."
"5784","PC100613P1","Konh B, Datla NV and Hutapea P.  2014.  Analysis driven design optimization of SMA based steerable active needle.  ASME 13th Smart Materials, Adaptive Structures and Intelligent Systems (SMASIS), Newport, Rhode Island."
"5785","PC100613P1","Konh B, Honarvar M, and Hutapea P.  2015. Design optimization study of a shape memory alloy active needle for biomedical applications. Med Eng Phys 37(5):469-477."
"5786","PC100613P2","Joseph FM, Kumar Hutapea MP, et al.  2015.  Development of self-actuating flexible needle system for surgical procedures.  J Med Devices 9(2):1-2."
"5787","PC100613P2","Zhao YJ, Joseph FM, Franz K, et al.  2014.  Path planning for robot-assisted active flexible needle using improved rapidly-exploring random tree.  ASME/FDA 36th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Chicago, Illinois, pp. 380-383."
"5788","PC100613P2","Joseph FM, Kumar M, Franz K, et al.  2015.  Control of shape memory alloy actuated flexible needle using multimodal sensory feedbacks.  Journal of Automation and Control Engineering. 3(5):428-434."
"5789","PC100613P2","Zhao YJ, Kohn B, Honarwar M, et al.  2015.  3D motion planning for robot-assisted active flexible needle based on rapidly-exploring random trees.  J Automation Control Engineering 3(5):360-367."
"5790","PC100613P2","Joseph FM, Franz K, Luan Y, et al.  2014.  Development of a coordinated controller for robot-assisted shape memory alloy actuated needle for prostate brachytherapy.  36th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Chicago, Illinois, pp. 357-360."
"5791","PC100613P2","Podder TK, Dicker AP, Hutapea P, et al.  2012.  A novel curvilinear approach for prostate seed implant.  Medical Physics 39(4):1887-1892."
"5792","PC100663","Tessneer KL, Cai X, Pasula S, et al.  2013.  Epsin family of endocytic adaptor proteins as oncogenic regulators of cancer progression.  J Can Res Updates 2-3."
"5793","PC100663","Tessneer K, Pasula S, Cai X, et al.  2013.  Endocytic adaptor protein epsin is elevated in prostate cancer and required for cancer progression.  ISRN Oncol 420597:8."
"5794","PC100663","Liu X, Pasula S, Song H, et al.  2014.  Temporal and spatial regulation of epsin expression and VEGFR3 signaling are required for lymphatic valve formation and function.  Sci Signal 7:ra97."
"5795","PC100663","Pan Y, Yago T, Fu J, et al.  2014.  Podoplanin requires sialylated O- glycans for stable expression on lymphatic endothelial cells and for interaction with platelets.  Blood 124:3656-3665."
"5796","PC100663","Pasula S, Cai X, Dong Y, et al.  2012.  Endothelial epsin deficiency decreases tumor growth by enhancing VEGF signaling.  J Clin Invest 122(12):4424-4438."
"5797","PC100663","Tessneer KL, Pasula S, Cai X, et al.  2014.  Genetic reduction of VEGFR2 rescues aberrant angiogenesis caused by epsin deficiency.  Arterioscler Thromb Vasc Biol 34:331-337."
"5798","PC100700","Gsponer JR and Braun M.  2014.  Analysis of the ERG rearrangement and protein expression in the progression from hormone-naïve to castration-resistant prostate cancer.  Prostate Cancer Prostatic Dis 17:126-131."
"5799","PC100700","Sharad S and Ravindranath L.  2014.  Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer.  Epiginetics 9:918-927."
"5800","PC100700","Dobi A, Sreenath T, and Srivastava S.  2013.  Biological and clinical applications androgen-responsive genes in prostate cancer: Regulation function and clinical application.  In:  Chapter 19: Androgen-Dependent Oncogenic Activation of ETS Transcription Factors By Recurrent Gene Fusions in Prostate Cancer.  Springer Science and Business Media, New York, USA DOI 10.1007/978-1-4614-6182-1_19."
"5801","PC100704","Baena E, Shao Z, Linn DE, et al.  2013.  ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients.  Genes Dev 27(6):683-698."
"5802","PC100704","Linn DE, Bronson RT, Li Z. et al.  2015.  Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models. PLoS One 10(3):e0120628."
"5803","PC100729","Nagarajan R, Margolis D, Raman S, et al.  2012.  MR spectroscopic imaging and diffusion-weighted imaging of prostate cancer with Gleason scores.  J Magn Reson Imaging 36:697-703.  "
"5804","PC100729","McClure TD, Margolis DJ, Reiter RE, et al.  2012.  Use of MR imaging to determine preservation of the neurovascular bundles at robotic-assisted laparoscopic prostatectomy.  Radiology 262(3):874-883."
"5805","PC100729","Nagarajan R, Margolis D, Raman S, et al.  2011.  Correlation of Gleason scores with diffusion-weighted imaging findings of prostate cancer.  Advances in Urology 374805.

"
"5806","PC100729","Furuyama J, Wilson NE, Burns BL, et al.  2012.  Application of compressed sensing to multidimensional MR spectroscopic imaging in human prostate.  Magn Reson Med 67:1499-1505.  
"
"5807","PC100729","Nagarajan R, Iqbal Z, Burns B, et al.  2015.  Accelerated echo planar j-resolved spectroscopic imaging in prostate cancer: Nonlinear reconstruction using total variation and maximum entropy. NMR Biomed 28:1366-1373."
"5808","PC100761","Tavakoli I, Haile S, Watt K, et al.  2013.  An androgen receptor N-terminal domain antagonist for treating prostate cancer.  J Clin Invest 123(7):2948-2960."
"5809","PC100761","Myung JK, Banuelos CA, Fernandez JG, et al.  2013.  An androgen receptor N-terminal domain antagonist for treating prostate cancer.  J Clin Invest 123(7):2948-2960."
"5810","PC100761P1","Liu LL, Xie N, Sun S, et al.  2014.  Mechanisms of androgen receptor splicing in prostate cancer cells.  Oncogene 33(24):3140-3150."
"5811","PC100761P1","Cao B, Qi Y, Zhang G, et al.  2014.  Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.  Oncotarget 5(6):1646-1656."
"5812","PC100761P1","Sprenger CC and Plymate SR.  2014.  The link between androgen receptor splice variants and castration-resistant prostate cancer.  Horm Cancer 5(4):207-217."
"5813","PC100761P1","Liu G, Sprenger C, Sun S, et al.  2013.  AR variant AR(v567es) induces carcinogenesis in a novel transgenic mouse model of prostate cancer.  Neoplasia 15(9):1009-1017."
"5814","PC100761P1","Liu G, Sprenger C, Wu PJ, et al.  2015.   MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand. Oncotarget 6(1):288-304."
"5815","PC100761P1","Thadani-Mulero M, Portella L, Sun S, et al.  2014.  Androgen receptor splice variants determine taxane sensitivity in prostate cancer.  Cancer Res 74(8):2270-2282."
"5816","PC100806","Manning ML, Kostova M, Williams SA, et al.  2012.  Trypsin-like proteolytic contamination of commercially available PSA purified from human seminal fluid.  Prostate 72:1233-1238."
"5817","PC100806","Manning ML, Williams SA, Jelinek CA, et al.  2013.  Proteolysis of complement factors iC3b and C5 by the serine protease prostate-specific antigen (PSA) in prostatic fluid and seminal plasma.  Immunol 190(6):2567-2574."
"5818","PC100829","Yumoto K, Berry JE, Taichman RS, et al.  2014.  A novel method for monitoring tumor dormancy using fluorescent dye DiD.  Cytometry A 85(6):548-555."
"5819","PC100829","Yumoto K, Eber MR, Berry JE, et al.  2014.  Molecular pathways: niches in metastatic dormancy. Clin Cancer Res 20(13):3384-9."
"5820","PC100829","Mehta G, Shiozawa Y, and Taichman RS.  2014.   Hematopoietic stem cells and their niches.  In: Biomaterials and Regenerative Medicine, (Ma PX, Ed.).  Cambridge University Press, United Kingdom. 44-63."
"5821","PC100829","Shiozawa Y, Taichman RS, and Keller ET.  2013.  Detection and isolation of human disseminated tumor cells in the murine bone marrow stem cell niche.  In: Stem Cells Niche, Methods and Protocols.  Methods in Molecular Biology, (Turksen K, Ed.).  Springer Publishing. Vol 1035. Chapter 18."
"5822","PC100829","Jung Y, Kim JK, Shiozawa Y, et al.  2012.  CXCL16/CXCR6 signaling promotes prostate cancer metastasis by recruiting and converting mesenchymal stem cells into cancer-associated fibroblasts.  Nat Commun 4:1795."
"5823","PC100829","Kim JK, Jung Y, Wang J, et al.  2013.  TBK1 regulates prostate cancer dormancy through mTOR inhibition.  Neoplasia 15(9):1064-1074."
"5824","PC100829","Shiozawa Y, McGee S, Pienta M, et al.  2013.  Erythropoietin supports the survival of prostate cancer, but not growth and bone metastasis.  J Cell Biochem 114(11):2741-2478."
"5825","PC100829","Mishra A, Wang J, Shiozawa Y, et al.  2012.  Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.  Mol Cancer Res, 10(6):703-712."
"5826","PC100829","Jung Y, Wang J, Lee E, et al.  2014.  Annexin 2-CXCL12 interactions regulate prostate cancer growth in the bone marrow.  Mol Cancer Res 13(1):197-207."
"5827","PC100829","Taichman RS, Patel LR, Bedenis R, et al.  2013.  GAS6 receptor status is associated with dormancy and bone metastatic tumor formation.  PLoS One 8(4):e61873."
"5828","PC100869","Yokoyama NN, Shao S, Hoang BH, et al.  2014.  Wnt signaling in castration-resistant
prostate cancer: Implications for therapy. Am J Clin Exp Urol 2:27-44."
"5829","PC100869","Ji T, Guo Y, Kim K, et al.  2015.  Neuropilin-2 expression is inhibited by secreted Wnt antagonists and its down-regulation is associated with reduced tumor growth and metastasis in osteosarcoma.  Mol Cancer 14:86."
"5830","PC100869","Dellinger TH, Planutis K, Jandial DD, et al.  Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer.  Gynecol Oncol 126:259-267."
"5831","PC100869","Jandial DD, Blair CA, Zhang S, et al.  2014.  Molecular targeted approaches to cancer therapy and prevention using chalcones.  Curr Cancer Drug Targets 14:181-200."
"5832","PC100869","Lin CH, Guo Y, Ghaffar S, et al.  2013.  Dkk-3, a secreted wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcoma.  Sarcoma 147541."
"5833","PC100869","Lee C, Jia Z, Rahmatpanah F, et al.  2014.  Role of the adjacent stroma cells in prostate cancer development and progression: synergy between TGF-beta and IGF signaling.  Biomed Res Int 502093."
"5834","PC100888","Franson R, McCracken AN, Chen B, et al.  2013.  Design, synthesis, and antileukemic activity of stereochemically sefined constrained analogues of FTY720 (Gilenya).  ACS Med Chem Lett 4:969-973."
"5835","PC100914","Ge C, Zhao G, Li Y, et al.  201.  Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease.  Oncogene 35(3):366-376."
"5836","PC100931","Yu L, Tumati V, Tseng S-F, et al.  2013.  DAB2IP regulates autophagy in prostate cancer in response to combined treatment of radiation and a DNA-PKcs inhibitor.  Neoplasia 14:1203-1212.

"
"5837","PC100931","Tumati V, Mathur S, Song K, et al.  2013.  Development of a locally advanced orthotopic prostate tumor model in rats for assessment of combined modality therapy.  International Journal of Oncology 42:1613-1619."
"5838","PC100933","Balk SP.  2014.  Androgen receptor functions in prostate cancer development and progression.  Asian J Androl 16:561-564."
"5839","PC100933","Cai C, Wang H, and He HH, et al.  2013.  ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.  J Clin Invest 123:1109-1122."
"5840","PC100933","Yuan X, Cai C, Chen S, et al.  2014.  Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.  Oncogene 33:2815-2825."
"5841","PC100933","Wang H, Xu Y, Fang Z, et al.  2012.  Doxycycline regulated induction of AKT in murine prostate drives proliferation independently of p27 cyclin dependent kinase inhibitor downregulation.  PLoS ONE 7(7):e41330."
"5842","PC100950","Yu Z, Chen S, Sowalsky AG, et al.  2014.  Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.  Clin Cancer Res 20:1590-1600."
"5843","PC100950","Cai C and Balk SP.  2011.  Intratumoral androgen biosynthesis in prostate cancer\ pathogenesis and response to therapy.  Endocr Relat Cancer 18:R175-182."
"5844","PC100950","Yu Z, Cai C, Gao S, et al.  2014.  Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.  Clin Cancer Res 20:4075-4085."
"5845","PC100950","Sun T, Wang X, He HH, et al.  2013.  MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A.  Oncogene 33:2790-2800."
"5846","PC100950","Yuan X, Cai C, Chen S, et al.  2013.  Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.  Oncogene 33:2815-2825."
"5847","PC100950","Chen S, Gulla S, Cai C, et al.  2012.  Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation.  J Biol Chem 287:8571-8583."
"5848","PC100950","Shen HC, Shanmugasundaram K, Simon NI, et al.  2012.  In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer.  Mol Endocrinol 26:1836-1846."
"5849","PC100950","Xu K, Wu ZJ, Groner AC, et al.  2012.  EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.  Science 338:1465-1469."
"5850","PC100950","Yang M, Xie W, Mostaghel E, et al.  2011.  SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.  J Clin Oncol 29, 2565-2573.   Erratum in: J Clin Oncol.  2012 30(20):2572."
"5851","PC100950","Balk SP.  2014.  Androgen receptor functions in prostate cancer development and progression. Asian J Androl 16(4):561-564."
"5852","PC100950","Egan A, Dong Y, Zhang H, et al.  2014.  Castration-resistant prostate cancer: adaptive responses in the androgen axis.  Cancer Treat Rev 40:426-433."
"5853","PC100950","Mostaghel EA, Marck B, Plymate S, et al.  2011.  Resistance to CYP17A1 inhibition with abiraterone in castration resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants.  Clin Cancer Res 17(18):5913-5925."
"5854","PC100950","Cai C, He HH, Chen S, et al.  2011.  Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.  Cancer Cell 20:457-471.  "
"5855","PC100950","Cai C, Chen S, Ng P, et al.  2011.  Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.  Cancer Res 71:6503-6513."
"5856","PC100952","Brooks JD.  2012.  Translational genomics: The challenge of developing cancer diagnostic biomarkers.  Review, Genome Res 22:183-187."
"5857","PC100952","Brooks JD.  2013.  Managing localized prostate cancer in the era of prostate specific antigen testing.  Cancer 119:3906-3909."
"5858","PC100952","Hawley S, Fazil L, McKenney JK, et al.  2013.  Design and construction of a resource for the validation of candidate prognostic biomarkers: The Canary Prostate Cancer Tissue Microarray as a model.  Adv Anat Pathol 20(1):39-44."
"5859","PC100952","Chen Z, Gulzar ZG, St. Hill CA, et al.  2014.  Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP and MUC1 in human prostate cancers.  Prostate 74: 1059-1067."
"5860","PC100952","Brooks JD, Wei W, Hawley S,et al. 2015 Evaluation of ERG and SPINK1 by
Immunohistochemical Staining and Clinicopathological Outcomes in a
Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.  PLoS One 10(7):e0132343."
"5861","PC100952","Yan D, Wang P, Linden M, et al.  2012.  Statistical methods for analyzing tissue images-algorithmic scoring and co-training.  Ann Appl Stat 6(3):1280-1305."
"5862","PC100952P1","Troyer D, Jamaspishvili T, Wei W, et al.  2015.  A multicenter study shows PTEN deletion is strongly associated with seminal vesical involvement and extracapsular extension in localized prostate cancer.  The Prostate 75(11):1206-1215."
"5863","PC100952P1","Eminaga O, Wei W, Hawley SJ, et al.  2016.  Expression by immunohistochemistry is associated with adverse pathologic features in prostate cancer: A multi-institutional study.  PLoS One 11(11):e0165236."
"5864","PC100952P1","McKenny JK, Wei W, Hawley S, et al.  2016.  Histologic grading of prostatic adenocarcinoma can be further optimized: analysis of the relative prognostic strength of individual architectural patterns in 1275 patients from the Canary retrospective cohort.  Am. J. Surg. Pathol 40(11): 439-1456."
"5865","PC100952P1","Lotan TL, Wei W, Morais CL, et al.  2016.  PTEN loss as determined by clinical-grade immunohistochemistry assay is associated with worse recurrence-free survival in prostate cancer.  European Urology Focus 2(2):180-188."
"5866","PC100952P1","Brooks JD, Wei W, Pollack JR, et al.  2016.  Loss of expression of AZGP1 is associated with worse clinical outcomes in a multi-institutional radical prostatectomy cohort.  Prostate 76(15):1409-1419."
"5867","PC100952P1","Lotan TL, Wei W, Ludkovski O, et al.  2016.  Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.  Modern Path 29(8):904-914."
"5868","PC100952P1","Tretiakova MS, Wei W, Boyer HD, et al.  2016.  Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1,000 prostatectomies.  Prostate Can Prostatic Dis 19(3): 264-270."
"5869","PC100952P1","Chen Z, Gulzar ZG, St. Hill CA, et al.  2014.  Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP and MUC1 in human prostate cancers.  Prostate 74: 1059-1067."
"5870","PC100952P1","Brooks JD, Wei W, Hawley S, et al.  Evaluation of ERG and SPINK1 by immunohistochemical staining and clinicopathological outcomes in a multi-institutional radical prostatectomy cohort of 1067 patients.  PLOS One 10(7):e0132343."
"5871","PC100952P1","Troyer D, Jamaspishvili T, Wei W, et al.  2015.  A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.  Prostate 75(11):1206-1215."
"5872","PC100952P1","Chen Z, Gulzar ZG, St. Hill CA, et al.  2014.  Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP and MUC1 in human prostate cancers.  Prostate 74:1059-1067."
"5873","PC100952P1","Brooks JD.  2013.  Managing localized prostate cancer in the era of prostate specific antigen testing.  Cancer 119:3906-3909."
"5874","PC100952P1","Hawley S, Fazli L, McKenney JK, et al.  2013.  Design and construction of a resource for the validation of candidate prognostic biomarkers: The canary prostate cancer tissue microarray as a model.  Advances in Anatomic Pathology 20:39-44."
"5875","PC100958","Gulzar ZG, McKenney JK, Brooks JD. 2013. Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1.  Oncogene 32(1):70-77."
"5876","PC100962","Ottman R, Nguyen C, Lorch R, et al.  2014.  MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance.  Mol Cancer 13:1."
"5877","PC101008","Lu YT, Zhao L, Shen Q, et al.  2013.  NanoVelcro chip for CTC enumeration in prostate cancer patients.  Methods 64(2):144-152."
"5878","PC101008","Li Y, Liang C, and Huang J.  2014.  Serum lipid profiles and aggressive prostate cancer.  Asian J Androl 17(2):336."
"5879","PC101008","Stoyanova T, Cooper AR, Drake JM, et al.  2013.  Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells.  Proc Natl Acad Sci U S A 110(50):20111-20116.

"
"5880","PC101008","Le JD, Huang J, and Marks LS.  2014.  Targeted prostate biopsy: Value of multiparametric magnetic resonance imaging in detection of localized cancer. 16(4):522-529."
"5881","PC101008","Sun F, Chen HG, Li W, et al.  2014.  Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors.  J Biol Chem 289(3):1529-1539."
"5882","PC101008","Seiler D, Zheng J, Liu G, et al.  2013.  Enrichment of putative prostate cancer stem cells after androgen deprivation: Upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines.  Prostate 73(13):1378-1390.  "
"5883","PC101008","Schelling LA, Williamson SR, Zhang S, et al.  2013.  Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: The superiority of fluorescence in situ hybridization over ERG immunohistochemistry.  Hum Pathol 44(10):2227-2233. "
"5884","PC101008","Ren S, Wang F, Shen J, et al.  2013.  Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer.  Eur J Cancer 49(13):2949-2959. "
"5885","PC101008","Ren S, Liu Y, Xu W, et al.  2013.  Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer.  J Urol 190(6):2278-2287. "
"5886","PC101008","Gollapudi K, Galet C, Grogan T, et al.  2013.  Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy.  Am J Cancer Res 3(5):523-529.  "
"5887","PC101008","Drake JM, Graham NA, Lee JK, et al.  2013.  Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets.  Proc Natl Acad Sci U S A 110(49):E4762-4769."
"5888","PC101008","Chen R, Zeng X, Zhang R, et al.  2013.  Cav.3 channel alpha 1D protein is overexpressed and modulates androgen receptor transactivation in prostate cancers.  Urol Oncol S1078-1439(13)00243-3. "
"5889","PC101008","Hu JC, Chang E, Natarajan S, et al.  2014.  Targeted prostate biopsy to select men for active surveillance: Do the epstein criteria still apply?  J Urol 192(2):385-390."
"5890","PC101008","Chamie K, Sonn GA, Finley DS, et al.  2014.  The role of magnetic resonance imaging in delineating clinically significant prostate cancer.  Urology 83(2):369-375. "
"5891","PC101008","Lipianskaya J, Cohen A, Chen CJ, et al.  2014.  Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation.  Asian J Androl 16(4):541-544."
"5892","PC101008","Ding B, Sun Y, and Huang J.  2012.  Overexpression of SKI oncoprotein leads to p53 degradation through regulation of MDM2 protein sumoylation.  J Biol Chem 287:14621-14630."
"5893","PC101008","Tai S, Sun Y, Liu N, et al.  2012.  Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells.  Mol Cancer Therapeutics 11:1320-1331."
"5894","PC101008","Li Z, Chen CJ, Wang JK, et al.  2013.  Neuroendocrine differentiation of prostate cancer.  Asian J Androl 15:328-332."
"5895","PC101008","Drake JM and Huang J.  2014.  PIP5K1alpha inhibition as a therapeutic strategy for prostate cancer.  Proceedings of the National Academy of Sciences of the USA 111:12578-12579."
"5896","PC101008","Li Z, Sun Y, Chen X, et al.  2015.  p53 Mutation directs AURKA overexpression via miR-25 and FBXW7 in prostatic small cell neuroendocrine carcinoma.  Mol Cancer Res 13(3):584-591."
"5897","PC101008","Hu CD, Choo R, and Huang J.  2015.  Neuroendocrine differentiation in prostate cancer: A mechanism of radioresistance and treatment failure.  Front Oncol 5:90.  Review."
"5898","PC101008","Chen H, Sun Y, Wu C, et al.  2012.  Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.  Endocr Relat Cancer 19:321-331."
"5899","PC101008","Zong Y, Goldstein AS, and Huang J.  2013.  The molecular basis for ethnic variation and histological subtype differences in prostate cancer.  Sci China Life Sci 56(9):780-787.  "
"5900","PC101020","Baca SC, Prandi D, Lawrence MS, et al.  2013.  Punctuated Evolution of Prostate Cancer Genomes.  Cell 153(3):666-677."
"5901","PC101020","Demichelis F, Garraway LA and Rubin MA.  2013.  Molecular archeology: unearthing androgen-induced structural rearrangements in prostate cancer genomes.  Cancer Cell 23(2):133-135."
"5902","PC101020","Beltran H, Yelensky R, Frampton GM, et al.  2013.  Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity Eur Urol.  63(5):920-926."
"5903","PC101020","Khani F, Mosquera JM, Park K, et al.  2014.  Evidence for molecular differences in prostate cancer between African American and Caucasian men.  Clin Cancer Res 20(18):4925-4934."
"5904","PC101020","Barbieri CE, Baca SC, Lawrence MS, et al.  2012.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 44(6):685-689."
"5905","PC101020","Fontugne J, Lee D, Cantaloni C, et al.  2014.  Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment.  Cancer Epidemiol Biomarkers Prev 23(4):594-600."
"5906","PC101020","Blattner M, Lee D, O'Reilly C, et al.  2014.  SPOP mutations in prostate cancer across demographically diverse patient cohorts.  Neoplasia 16(1):14-20."
"5907","PC101020","Mosquera JM, Lin PC, and Rubin MA.  Genomics and epigenomics of prostate cancer.  In: Chapter 11 in Genitourinary Pathology, Practical Advances (Magi-Galluzzi C and Pryzybycin CG, Eds.).  Springer Science."
"5908","PC101020","Theurillat JP, Udeshi ND, Errington WJ, et al.  2014.  Prostate cancer.  Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer.  Science 346(6205):85-89."
"5909","PC101020","Barbieri C, Baca S, Lawrence M, et al.  2012.  Recurrent SPOP mutations define a distinct molecular subclass of prostate cancer.  Nat Genet 44(6):685-689."
"5910","PC101020P1","Baca SC, Prandi D, Lawrence MS, et al.  2013.  Punctuated evolution of prostate cancer genomes.  Cell 153(3):666-677."
"5911","PC101020P1","Barbieri C, Baca S, Lawrence M, et al.  2012.  Recurrent SPOP mutations define a distinct molecular subclass of prostate cancer.  Nat Genet 44(6):685-689."
"5912","PC101020P1","Theurillat JP, Udeshi ND, Errington WJ, et al.  2014.  Prostate cancer.  Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer.  Science 346(6205):85-89."
"5913","PC101020P2","Baca SC, Prandi D, Lawrence MS, et al.  2013.  Punctuated evolution of prostate cancer genomes.  Cell 153(3):666-677."
"5914","PC101020P2","Barbieri CE, Baca SC, Lawrence MS, et al.  2012.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.  Nat Genet 44(6):685-689.

"
"5915","PC101020P2","Demichelis F, Garray LA, Rubin MA.  2013.  Molecular archeology: unearthing androgen-induced structural rearrangements in prostate cancer genomes.  Cancer Cell 23(2):1333-135.  Preview."
"5916","PC101020P2","Romanel A, Lago S, Prandi D, et al.  2015.  ASEQ: fast allele-specific studies from nextgeneration sequencing data.  BMC Med Genomics 8(1):9."
"5917","PC101020P2","Carreira S, Romanel A, de Bono JS, et al.  2014.  Tumor clone dynamics in lethal prostate cancer.  Sci Transl Med 6: 254ra125."
"5918","PC101020P2","Prandi D, Baca SC, Romanel A, et al.  2014.  Unraveling the clonal hierarchy of somatic genomic aberrations.  Genome Biol 15(8):439."
"5919","PC101020P2","Blattner M, Lee D, O'Reilly C, et al.  2014.  SPOP mutations in prostate cancer across demographically diverse patient cohorts.  Neoplasia 16(1):14-20."
"5920","PC101070","Van Blarigan E, Kenfield SA, Yang M, et al. 2015.  Fat intake after prostate cancer diagnosis and mortality in the Physicians¿ Health Study.  Cancer Causes Control 26(8):1117-1126."
"5921","PC101070","Chavarro JE, et al.  2013.  Blood levels of saturated and monounsaturated fatty acids as markers of de novo lipogenesis and risk of prostate cancer.  Am J Epidemiol 178(8):1246-1255."
"5922","PC101070","Richman EL, et al.  2013.  Fat intake after diagnosis and risk of lethal prostate cancer and all-cause mortality.  JAMA Intern Med 173(14):1318-1326."
"5923","PC101070","Yang M, Kenfield SA, Van Blarigan EL, et al. 2015.  Dairy intake after prostate cancer diagnosis in relation to disease-specific and total mortality.  Int J Cancer 137(10):2462-2469."
"5924","PC101070","Crowe F, Appleby P, Travis R, et al.  2014.  Circulating fatty acids and prostate cancer risk: individual participant meta-analysis of prospective studies.  J Natl Cancer Inst 106(9) pii: dju240."
"5925","PC101096","Shepherd AJ and Mohapatra DP.  2012.  Tissue preparation and immunostaining of mouse sensory nerve fibers innervating skin and limb bones.  J Vis Exp 59:e3485."
"5926","PC101096","Mickl AD, Shepherd AJ, and Mohapatra DP.  2015.  Sensory TRP channels: The key transducers of nociception and pain.  In: Molecular and Cell Biology of Pain, Progress in Molecular Biology and Translational Science 131:73-118."
"5927","PC101096","Mickle AD, Shepherd AJ, Loo L, et al.  2015.  Induction of thermal and mechanical hypersensitivity by parathyroid hormone-related peptide (PTHrP) via upregulation of TRPV1 function and trafficking.  Pain 156(9):1620-1636."
"5928","PC101096","Mickle AD, Shepherd AJ, and Mohapatra DP.  2016.  Nociceptive TRP channels: Sensory detectors and transducers in multiple pain pathologies. Pharmaceuticals (Basel) 9(4). pii: E72."
"5929","PC101102","Katoh H, Zheng P, Liu Y, et al. 2013.  FOXP3:  Genetic and epigenetic implications for autoimmunity.  J Autoimmun 41:72-78."
"5930","PC101102","Wang L, Liu R, Ye P, et al.  2015.  Intracellular CD24 disrupts the ARF-NPM interaction and enables mutational and viral oncogene-mediated p53 inactivation.  Nat Commun 6:5909."
"5931","PC101141","Leen AM, Sukumaran S, Watanabe N, et al.  2014.  Reversal of tumor immune inhibition using a chimeric cytokine receptor.  Mol Ther 22(6):1211-1220."
"5932","PC101141","Bajgain P, Mucharla R, Wilson J, et al.  2014.  Optimizing the production of suspension cells using the G-Rex 'M' series.  Molecular Therapy - Methods & Clinical Development 1, Article number: 14015."
"5933","PC101141","Sanchez C, Chan R, Bajgain P, et al.  2013.  Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.  Prostate Cancer Prostatic Dis 16:123-131 S1."
"5934","PC101141","Anurathapan U, Leen AM, Brenner MK, et al.  2014.  Engineered T cells for cancer treatment.  Cytotherapy 16:713-733."
"5935","PC101141","Anurathapan U, Chan RC, Hindi HF, et al.  2014.  Kinetics of tumor destruction by chimeric antigen receptor-modified T cells.  Mol Ther 22:623-633."
"5936","PC101165","Mak TN, Sfanos KS, and Brüggemann H.  2013.  Draft genome sequences of two strains of Propionibacterium acnes isolated from radical prostatectomy specimens.  Genome Announcements 1(6):e01071-13."
"5937","PC101165","Mak TN, Yu S-H, De Marz, et al.  2013.  Multilocus sequence typing (MLST) analysis of propionibacterium acnes isolates from radical prostatectomy specimens.  Prostate 73(7):770-777."
"5938","PC101165","Sfanos K, Isaac, B, De Marz,  2013.  Infections and inflammation in prostate cancer.  American J Clinical and Experimental Urology 1(1):3-11."
"5939","PC101165","Sfanos KS, and De Marzo AM.  2012.  Prostate cancer and inflammation: The evidence.  Histopathology  60(1): 199-215."
"5940","PC101165","Sfanos K, Hempel H, and De Marzo A.  2014.  The role of inflammation in prostate cancer. In: Inflammation and Cancer: Springer Basel, (Aggarawal BB, Sung B, and Gupta SC, Eds).  pages 153-181."
"5941","PC101188","Ren S, Kang MR, Wang J, et al.  2013.  Targeted induction of endogenous NKX3-1 by small activating RNA inhibits prostate tumor growth.  Prostate 73(14):1591-1601. "
"5942","PC101212","Lupold SE, Johnson T, Chowdhury WH, et al.  2012.  A real time Metridia Luciferase based non-invasive reporter assay of mammalian cell viability and cytotoxicity via the beta-actin promoter and enhancer.  PLoS One 7(5):e36535."
"5943","PC101212","Wu P, Sokoll L, Kudrolli TA, et al.  2014.  A novel approach for detecting viable and tissue¿specific circulating tumor cells through an adenovirusbased reporter vector.  Prostate 74(13):1286¿1296."
"5944","PC101214","Hojfeldt JW, Cruz-Rodríguez O, Imaeda Y, et al.  2014.  Bifunctional ligands allow deliberate extrinsic reprogramming of the glucocorticoid receptor.  Mol Endocrinol 28(2):249-259."
"5945","PC101273","Tang K, Cai Y, Joshi S, et al.  2015.   Convergence of eicosanoid and integrin biology: 12-lipoxygenase seeks a partner. Mol Cancer 14:111."
"5946","PC101273","Lovey J, Nie D, Tovari J, et al.  2013.  Radiosensitivity of human prostate cancer cells can be modulated by inhibition of 12-lipoxygenase.  Cancer Lett 335(2):495-501. "
"5947","PC101349","Bowlby SC, Thomas MJ, D'Agostino Jr RB, et al.  2012.  Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells.  PloS One 7(6):e40195."
"5948","PC101369","Kobayashi A, Okuda H, Xing F, et al.  2011.  Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone.  J Exp Med 208(13):2641-2655."
"5949","PC101482","Bao B, Thakur A, Li Y, et al.  2012.  The immunological contribution of NF-kB within the tumor microenvironment: A potential protective role of zinc as an anti-tumor agent.  BBA Reviews on Cancer 1825:160-172.  "
"5950","PC101482","Bao B, Azmi A, Ali S, et al.  2012.  The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness.  Biochem Biophys Acta 1826(2):272-296.

"
"5951","PC101498","Anderson PD, McKissic SA, Logan M, et al.  2012.  Nkx3.1 and Myc cross-regulate shared target genes in mouse and human prostate tumorigenesis.  J Clin Invest 122(5):1907-1919."
"5952","PC101582","Jeter CR, Liu B, Liu X, et al.  2012.  NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation.  Oncogene 30:3833-3845."
"5953","PC101582","Tang DG.  2012.  Understanding cancer stem cell heterogeneity and plasticity.  Cell Res 22:457-472."
"5954","PC101582","Liu C, Kelner K, Vlassov AV, et al.  2012.  Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor suppressive functions of let-7.  Cancer Res 72(13):3393-3404."
"5955","PC101582","Qin J, Liu X, Laffin B, et al.  2012.  The PSA-/lo prostate cancer cells harbor self-renewing long-term tumor-propagating cells that resist castration.  Cell Stem Cell 10: 556-569."
"5956","PC101582","Yan H, Chen X, Zhang Q, et al.  2011.  Drug-tolerant cancer cells show reduced tumor-initiating capacity:  Depletion of CD44 cells and evidence for epigenetic mechanisms.  PLoS One 6:e24397. "
"5957","PC101584","Woloszynska-Read A, Johnson CD, and Trump DL.  2011.  Vitamin D and cancer: Clinical aspects.  Best Practice Res Clin Endo Met 25(4):605-615."
"5958","PC101699","Sharma V, Olweny O, Kapur P, et al.  2014.  Prostate cancer detection using combined auto-fluorescence and light reflectance spectroscopy: ex vivo study of human prostates.  Biomed Optics Exp 5(5): 1512-1529."
"5959","PC101699","LeBoulluec P, Liu H, and Yuan B.  2013.  A cost-efficient frequency-domain photoacoustic imaging system.   Am J Phys 81(9):712."
"5960","PC101749","Börnigen D, Tyekucheva S, Wang X, et al.  2016.  Computational Reconstruction of NF-B Pathway Interaction Mechanisms during Prostate Cancer. PLoS Comput Biol 12(4):e1004820."
"5961","PC101769","Lin DW, Newcome LF, Brown EC, et al.  2013.  Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: Results from a baseline analysis in the canary prostate active surveillance study.  Clin Cancer Res 19:2442-2450."
"5962","PC101769","Newcomb LF.  2016.  Outcomes of active surveillance for the management of clinically localized prostate cancer in the prospective, multi-institutional Canary PASS cohort.  Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.  J Urol 193:313-320."
"5963","PC101769","Cooperburg MR, Simko JP and Cowan JE.  2013.  Validation of a cell-cycle progression panel to improve risk-stratification in a contemporary prostatectomy cohort.  J Clin Oncol 31(11):1428-1434."
"5964","PC101819","Wang ZA, Mitrofanova A, Bergren SK, et al.  2013.  Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell of origin model for prostate cancer heterogeneity.  Nat Cell Biol 15(3): 274-283."
"5965","PC101832","
Hsieh AC and Ruggero D.  2010.  Targeting eukaryotic translation initiation facotr 4E (eIF4E) in cancer.  Clin Cancer Res 16(20):4914-4920. 
"
"5966","PC101832","Hsieh AC, Liu Y, Edlind MP, et al.  2012.  The translational landscape of oncogenic mTOR signaling controls cancer development and metastasis.  Nature 485(7396):55-61.  "
"5967","PC101832","Hsieh AC, Truitt ML, and Ruggero D.  2011.  Oncogenic AKTivation of translation as a therapeutic target.  Br J Cancer 105(3)."
"5968","PC101832","Kondrashov N, Pusic A, Stumpf CR, et al.  2011.  Ribosome mediated specificity of Hox mRNA translation and vertebrate tissue patterning.  Cell 145(3)."
"5969","PC101832","Hsieh AC, Costa M, Zollo O, et al.  2010.  Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBPeIF4E.  Cancer Cell 17(3):249-261."
"5970","PC101835","Isaac J, Tarapore P, Zhang X, et al.  2012. Site-specific S-nitrosylation of integrin alpha-6 increases the extent of prostate cancer cell migration by enhancing Integrin beta-1 association and weakening adhrence to Laminin-1.  Biochemistry 51(48):9689-9697."
"5971","PC101840","Gurusamy D, Gray JK, Pathrose P, et al.  2013.  Myeloid specific expression of Ron receptor kinase promotes prostate tumor growth.  Cancer Res 73(6):1-12."
"5972","PC101840","Marshall AM, McClaine RJ, Gurusamy D, et al.  2012.  Estrogen receptor alpha deletion enhances the metastatic phenotype of Ron overexpressing mammary tumors in mice.  Mol Cancer Res 11(1):2."
"5973","PC101840","Zhao H, Chen MS, Lo YH, et al.  2014.  The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer.  Oncogene 33(11):1429-1437."
"5974","PC101840","Vasiliauskas J, Nashu MA, Pathrose P, et al.  2014.  Hepatocyte growth factor-like protein is required for prostate tumor growth in the TRAMP mouse model.  Oncotarget 5(14):5547-5558."
"5975","PC101841","Zaorsky NG, Doyle LA, Hurwitz MD, et al.  2013.  Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?  Expert Rev Anticancer Ther 14(1):39-50."
"5976","PC101841","Zaorsky NG, Harrison A, Trabulsi E, et al.  2013.  Evolution of advanced technologies in prostate cancer radiotherapy.  Nat Rev Urol 10(10):565-579."
"5977","PC101841","Den RB, and Hurwitz M.  2014.  Prostate cancer, biochemical recurrence (elevated PSA) following radiation therapy.  In: The 5-Minute Urology Consult (The 5-Minute Consult Series), 3rd Edition (Gomella L, Ed.).  Lippincott Williams & Wilkins, New York."
"5978","PC101841","Zaorsky NG, Raj GV, Trabulsi EJ, et al.  2013.  The dilemma of a rising prostate-specific antigen level after local therapy: What are our options?  Semin Oncol 40(3):322-336."
"5979","PC101841","Den RB, Feng FY, Showalter TN, et al.  2014.  Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy.  Int J Radiat Oncol Biol Phys 89(5):1038-1046."
"5980","PC101841","Yamoah K, Eldredge-Hindy HB, Zaorsky NG, et al.  2014.  Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma.  Brachytherapy 13(5):456-464."
"5981","PC101841","Den RB, and Hurwitz M.  Prostate cancer, general considerations.  In: The 5-Minute Urology Consult (The 5-Minute Consult Series), 3rd Edition (Gomella L, Ed.).  Lippincott Williams & Wilkins, New York."
"5982","PC101841","Den RB, and Hurwitz M.  Testis, seminoma.  In: The 5-Minute Urology Consult (The 5-Minute Consult Series), 3rd Edition (Gomella L, Ed.).  Lippincott Williams & Wilkins, New York."
"5983","PC101841","Den RB, Nowak K, Buzurovic I, et al.  2012.  Implanted dosimeters identify radiation overdoses during IMRT for prostate cancer.  Int J Radiat Oncol Biol Phys 83(3):e371-6.

"
"5984","PC101841","Mishra MV, Shen X, Den RB, et al.  2013.  Patterns of care for elderly men diagnosed with favorable-risk prostate cancer from 2004 to 2008: A population-based analysis. Am J Clin Oncol 36(6):606-611."
"5985","PC101841","Zaorsky NG, Doyle LA, Yamoah K, et al.  2013.  High dose rate brachytherapy boost for prostate cancer: A systematic review.  Cancer Treat Rev 40(3):414-425."
"5986","PC101841","Goodwin JF, Schiewer MJ, Dean JL, et al.  2013.  A hormone-DNA repair circuit governs the response to genotoxic insult.  Cancer Discov 3(11):1254-1271."
"5987","PC101841","Zaorsky NG, Yamoah K, Thakur ML, et al.  2014.  A paradigm shift from anatomic to functional and molecular imaging in detection of recurrent prostate cancer.  Future Oncol 10(3):457-474."
"5988","PC101841","Den RB, Doyle LA, and Knudsen KE.  2014.  Practical guide to the use of radium-223 dichloride.  Can J Urol 21(2 Supp 1):70-76."
"5989","PC101841","Blumenfeld P, Pfeffer RM, Symon Z, et al.  2014.  The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress?  Br J Cancer 111(7):1305-1309."
"5990","PC101841","Ohri N, Shen X, Den RB, et al.  2012.  Salvage radiotherapy for prostate cancer: Finding a way forward using radiobiological modeling.  Cancer Biol Ther 13(14): 1449-1453."
"5991","PC101841","Zaorsky NG, Trabulsi EJ, Lin J, et al.  2013.  Multimodality therapy for patients with high-risk prostate cancer: Current status and future directions.  Semin Oncol 40(3):308-321."
"5992","PC101841","Zaorsky NG, Studenski MT, Dicker AP, et al.  2013.  Stereotactic body radiation therapy for prostate cancer: Is the technology ready to be the standard of care?  Cancer Treat Rev 39(3):212-218. "
"5993","PC101841","Zaorsky NG, Ohri N, Showalter TN, et al.  2013.  Systematic review of hypofractionated radiation therapy for prostate cancer.  Cancer Treat Rev 39(7):728-736."
"5994","PC101841","Buzurovic I, Showalter T, Studenski M, et al.  2013.  Commissioning and implementation of an implantable dosimeter for radiation therapy.  J Applied Clin Med Physics 14(2):1-19."
"5995","PC101841","Book Chapters
Den RB and Dicker AP.  2012.  Improving systemic disease:  The benefit of local therapy.  In: Signaling Pathways and Molecular Mediators in Metastasis (Fatatis A, Ed.).  Springer Science + Business Media (www.springer.com).  DOI 10.1007/978-94-007-2558-4.

"
"5996","PC101841","Augello MA, Den RB, and Knudsen KE.  2014.  AR function in promoting metastatic prostate cancer.  Cancer Metastasis Rev 33(2-3):399-411."
"5997","PC101909","Carroll V, Demoin D, Hoffman T, et al.  2012.  Chemistry in nuclear imaging and radiotherapy: Current and future directions.  Radiochimica Acta 100:653-667."
"5998","PC101913","Chornokur G, Han G, Tanner R, et al.  2013.  High grade prostate intraepithelial neoplasia (PIN) is a PSA-independent risk factor for prostate cancer in African American men: Results from a pilot study.  Cancer Letters 331(2):154-157."
"5999","PC101913","Chornokur G, Amankwah EK, Schildkraut JM, et al.  2013.  Global ovarian cancer health disparities.  Gyn Oncol 121(1):358-364."
"6000","PC101913","Chornokur G and Kumar NB.  2013.  Prostate cancer chemoprevention in men of African descent: Current state of the art and opportunities for future research.  Cancer Causes and Control 24(8):1465-1480."
"6001","PC101913","Kumar N and Chornokur G.  2012.  Molecular targeted therapies using botanicals for prostate cancer chemoprevention.  Transl Med S2: 005."
"6002","PC101913","Chornokur G, Amankwah EK, Davis SN, et al.  2013.  Variation in HNF1B and Obesity May Influence Prostate Cancer Risk in African American Men: A Pilot Study. Prostate Cancer. 2013:384594."
"6003","PC101917","Peek EM, Song W, Zhang H, et al.  2015.  Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.  Prostate 75(5):463-473."
"6004","PC101923","Azab B, Dash R, Das SK, et al.  2012.  Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells.  J Cell Physiol 227:2145-2153."
"6005","PC101923","Das SK, Sarkar S, Dash R, et al.  2012.  Cancer terminator viruses and approaches for enhancing therapeutic outcomes.  Adv Cancer Res 115:1-38."
"6006","PC101923","Sarkar S, Azab BM, Das SK, et al.  2013.  Chemoprevention gene therapy (CGT): Novel combinatorial approach for preventing and treating pancreatic cancer.  Curr Mol Med 13(7):1140-1159.

"
"6007","PC101923","Quinn BA, Dash R, Azab B, et al.  2011.  Targeting Mcl-1 for the therapy of cancer.  Expert Opinion Invest Drugs 20:1397-1411."
"6008","PC101923","Dash R, Azab B, Xhen X-N, et al.  2011.  Developing an effective gene therapy for prostate cancer: New technologies for potential to translate form the laboratory into the clinic.  Discov Med 11:46-56."
"6009","PC101923","Dash R, Azab B, Quinn BA, et al.  2011.  Apogossypol derivative Bl-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated cytotoxicity.  Proc Natl Acad Sci 108:8785-8790."
"6010","PC101928","Drake JM, et al.  2012.  Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.  Proceedings of the National Academy of Sciences 109(5):1643-1648."
"6011","PC101929","Wyhs N, Walker D, Giovinazzo H, et al.  2014. Time-Resolved Fluorescence Resonance Energy Transfer Assay for Discovery of Small-Molecule Inhibitors of Methyl-CpG Binding Domain Protein 2. J Biomol Screen 19(7):1060-1069."
"6012","PC101942","Lunardi A, Ala U, Epping MT, et al.  2013.  A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.  Nat Genet 45(7):747-755."
"6013","PC101942","Nardella C, Lunardi A, Patnaik A, et al.  2011.  The APL paradigm and the 'Co- Clinical Trial' Project.  Cancer Disc 1:108-116."
"6014","PC101942","Zadra G, Priolo C, Patnaik A, et al.  2010.  New strategies in prostate cancer:  targeting lipogenic pathways and the energy sensor AMPK.  Clin Can Res 16(13):3322-3328."
"6015","PC101942","Sturey R and Patnaik A. 2017. Neutrophils and anti-cancer immunity: a paradigm shift in cancer immunotherapy. Oncoscience 4(11-12): 164–165. doi: 10.18632/oncoscience.378."
"6016","PC101942","Gao S, Ye H, Gerrin S, et al. 2016. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Clin Cancer Res. 22(14): 3672-3682. doi: 10.1158/1078-0432.CCR-15-2309."
"6017","PC101942","Olson B, Li Y, Lin Y, Liu ET, Patnaik A. Mouse Models for Cancer Immunotherapy Research. Cancer Discov. 2018 Nov;8(11):1358-1365. doi: 10.1158/2159-8290.CD-18-0044. Epub 2018 Oct 11. Review. PubMed PMID: 30309862."
"6018","PC101942","Gonzalez-Billalabeitia E, Seitzer N, Song SJ, et al.  2014.  Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.  Cancer Disc 4(8):896-904."
"6019","PC101942","Fendt SM, Bell EL, Keibler MA, et al.  2013.  Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism.  Cancer Res 73:4429-4438."
"6020","PC101946","Ringer L, Sirajuddin P, Tricoli L, et al. 2014. The induction of the p53 tumor suppressor protein
bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells. Oncotarget 5(21):10678-10691."
"6021","PC101946","Beauchamp EM, Ringer L, Bulut G, et al.  2011.  Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway.  J Clin Invest 121(1):148-60."
"6022","PC101946","Ringer L, Sirajuddin P, Heckler M, et al.  2011.  VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells.  Cancer Biol Ther 12(9):818-826."
"6023","PC101949","Madigan AA, Sobek KM, Cummings JL, et al.  2012.  Activation of innate anti-viral immune response genes in symptomatic benign prostatic hyperplasia.  Genes Immun (7):566-572."
"6024","PC101951","Tinkum KL, Marpegan L, White LS, et al.  2011.  Bioluminescence imaging captures the expression and dynamics of endogenous p21 promoter activity in living mice and intact cells.  Mol Cell Biol 31 (18):3759-3772."
"6025","PC101951","Tinkum KL, White LS, Marpegan L, et al.  2013.  Forkhead box O1 (FOXO1) protein, but not p53, contributes to robust induction of p21 expression in fasted mice.  J Biol Chem 288(39):27999-8008."
"6026","PC101962","Beckham TH, Cheng JC, Lu P, et al.  2013.  Acid ceramidase induces sphingosine kinase 1/SIP receptor 2-mediated activation of oncogenic Akt signaling.  Oncogenesis 2:e49.  "
"6027","PC101962","Beckham TH, Cheng JC, Lu P, et al.   2013.  Acid ceramidase promotes nuclear export of PTEN through sphingosine 1-phosphate mediated Akt signaling.  PLoS One 8:e76593.  "
"6028","PC101962","Beckham TH, Cheng CJ, Lu P et al.  2013.  Acid ceramidase induces sphingosine kinase 1/S1P receptor 2 mediated activation of oncogenic Akt signaling.  Oncogenesis 2:e49."
"6029","PC101964","Rafii S, Kloss CC, Bulter JM, et al.  2013.  Human ESC-derived hemogenic endothelial cells undergo distinct waves of endothelial to hematopoietic transition.  Blood 121:770-780."
"6030","PC101964","Themeli M, Kloss CC, Ciriello G, et al.  2013.  Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy.  Nat Biotechnol 31(19):928-933."
"6031","PC101964","Kloss CC, Condomines M, Cartellieri M, et al.  2013.  Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells.  Nat Biotechnol 31:71-75."
"6032","PC101984","Kim C, Chang D, Petrisor D, et al.  2013.  Ultrasound probe and needle-guide calibration for robotic ultrasound scanning and needle targeting.  IEEE Trans Biomed Eng 60(6):1728-1734."
"6033","PC101984","Han M, Chang D, Kim C, et al.  2012.  Geometric evaluation of systematic transrectal ultrasound guided prostate biopsy.  J Urol 188(6):2404-2409."
"6034","PC101986","Lee G, Sparks R, Ali S, et al.  2014.  Co-occuring gland angularity in localized subgraphs: Predicting biochemical recurrence in intermediate-risk prostate cancer patients.  PLoS ONE 9(5):e97954."
"6035","PC101986","Sparks R and Madabhushi A.  2013.  Statistical shape model for manifold regularization: gleason grading of prostate histology.  Comput Vis Image Underst 117(9):1138-1146."
"6036","PC101986","Sparks R and Madabhushi A.  2013.  Explicit shape descriptors: Novel morphologic features for disease classification.  Med Imag Ana 17(8):997-1009."
"6037","PC101993","Nelson Q, Agarwal N, Stephenson R, et al.  2013.  A population-based analysis of clustering identifies a strong genetic contribution to lethal prostate cancer.  Front Genet 4:152."
"6038","PC101996","Wang S, Clark PA, Davis R. 2016. Sex steroid-induced DNA methylation changes and inflammation response in prostate cancer. Cytokine 86:110-8."
"6039","PC101996","Devaney JM, Wang S, Funda S, et al.  2013.  Identification of novel DNA-methylated genes that correlate with human prostate cancer and high-grade prostatic intraepithelial neoplasia.  Prostate Cancer Prostatic Dis 16(4):292-300."
"6040","PC101996","Devaney JM, Wang S, Furbert-Harris P, et al.  2015.  Genome-wide differentially methylated genes in prostate cancer tissues from African-American and Caucasian men. Epigenetics 10(4):319-328."
"6041","PC102004","Tien JC and Xu J.  2012.  Steroid receptor coactivatorC3 as a potential molecular target for cancer therapy.  Expert Opin Ther Targets 16(11):1085-1096."
"6042","PC102004","Walsh CA, Qin L, Tien JC, et al.  2012.  The function of steroid receptor coactivator C 1 in normal tissues and cancer.  Int J Biol Sci 8(4):470-485."
"6043","PC102029","Sordillo LA, Pu Y, Pratavieira S, et al.  2014.  Deep optical imaging of tissue using the second and third near-infrared spectral windows.  J Biomed Opt 19(5):056004-1-6."
"6044","PC102029","Shi L, Rodriguez-Contreras A, Budansky Y, et al.  2014.  Deep two-photon microscopic imaging through brain tissue using the second singlet state from fluorescent agent chlorophyll alpha in spinach leaf.  J Biomed Opt 19(6):066009-1-5."
"6045","PC102029","Jeyasingh, Pu Y, Wang WB, et al.  2012.  Stokes shift spectroscopy pilot study for cancerous and normal prostate tissues.  Appl Opt 51(16):3642-6349."
"6046","PC102029","Pu Y, Wang WB, Xu M, et al.  2011.  Near infrared photonic finger imager for prostate cancer screening.  Technol Cancer Res Treat 10:507-517."
"6047","PC102029","PuY, Wang WB, Yang Y, et al.  2012.  2012.  Stokes shift spectroscopy highlights differences of cancerous and normal human tissues.  Opt Lett 37(16):3360-3362."
"6048","PC102029","Pu Y, Wang W, AL-Rubaiee M, et al.  2012.  Determination of optical coefficients and fractal dimensional parameters of cancerous and normal prostate tissues.  Appl Spectrosc 66(7):828-834."
"6049","PC102029","Sun Y, Pu Y, Yang Y, et al.  2012.  Biomarkers spectral subspace for cancer detection.  J Biomed Opt 17(10):107005-1-9."
"6050","PC102029","Zhou Y, Liu C-H, Sun Y, et al.  2012.  Human brain cancer studied by resonance Raman spectroscopy.  J Biomed Opt 17(11)116021-1-7."
"6051","PC102029","Pu Y, Wang WB, Yang Y, et al.  2013.  Stokes shift spectroscopic analysis of multi-fluorophores for human cancer detection in breast and prostate tissues.  J Biomed Opt 18(1):017005-1-8."
"6052","PC102029","Pu Y, Tang R, Xue J, et al.  2014.  Synthesis of dye conjugates to visualize the cancer cells using fluorescence microscopy.  Appl Opt 53(11):2345-2351."
"6053","PC102029","Pu Y, Jagtap J, Pradhan A, et al.  2014.  Spatial frequency analysis for detecting early stage of cancer in human cervical tissues.  Technol Cancer Res Treat 13(5):421-425."
"6054","PC102029","Pu Y, Wang WB, Yang Y, et al.  2013.  Native fluorescence spectra of human cancerous and normal breast tissues analyzed with nonnegative constraint methods.  Appl Opt 52(6):1293-1301."
"6055","PC102029","PuY, Wang W, Dorshow RB, et al.  2013.  Review of ultrafast fluorescence polarization spectroscopy.  Appl Opt 52(5):917-929."
"6056","PC102029","Pu Y, Xue J, Wang W, et al.  2013.  Native fluorescence spectroscopy reveals spectral differences among prostate cancer cell lines with different risk levels.  J Biomed Opt 18(8):087002-1-5."
"6057","PC102029","Liu C-H, Zhou Y, Sun Y, et al.  2013.  Resonance Raman and Raman spectroscopy for breast cancer detection.  Technol Cancer Res Treat 12(4):371-382."
"6058","PC102029","Sordillo LA, Pu Y, Sordillo PP, et al.  2013.  Optical spectral fingerprints of tissues from patients with different breast cancer histologies using a novel fluorescence spectroscopic device.  Technol Cancer Res Treat 12(5):455-461."
"6059","PC102029","Pu Y, Shi L, Pratavieira S, et al.  2013.  Two-photon excitation microscopy using the second singlet state of fluorescent agents within the tissue optical window.  J Appl Phys 114(15):153102-1-4."
"6060","PC102029","Zhang L, Pu Y, Xue J, et al.  2014.  Tryptophan as the fingerprint for distinguishing aggressiveness among breast cancer cell lines using native fluorescence spectroscopy.  J Biomed Opt 19(3):037005-1-5."
"6061","PC102030","Ono M, Inkson CA, Sonn R, et al.  2013.  WISP1/CCN 4: A potential target for inhibiting prostate cancer growth and spread to bone.  PLoS One 8(8):e71709."
"6062","PC102033","Borysova ME, Mitchell O, Sultan DH, et al.  2012.  Racial and ethnic health disparities in incarcerated populations.  J Health Dispar Res Pract 5(2):92-100."
"6063","PC102033","Borysova ME, Sultan D, Chornokur G, et al.  2013.  Prostate cancer disparities throughout the Cancer Control Continuum.  Soc Sci 2(4): 247-269."
"6064","PC102033","Chornokur G, Dalton KJ, Borysova ME, et al.  2011.  Disparities at presentation, diagnosis, treatment and survival in African American men affected by prostate cancer.  Prostate 15:71(9):985-997. "
"6065","PC102033","Borysova ME, Mitchell O, Sultan DH, et al.  2013.  Racial and ethnic health disparities in incarcerated populations.  J Heath Dispar Res Pract 5(2):92-100."
"6066","PC102037","Murphy AB, Akereyeni F, Nyame YA, et al.  2013.  Smoking and prostate cancer in a multi-ethnic cohort.  Prostate 73(14):1518-1528."
"6067","PC102037","Murphy AB, Kelley B, Nyame YA, et al.  2012.  Predictors of serum vitamin D levels in African American and European American men in Chicago.  Am J Mens Health 6:420-426."
"6068","PC102056","Yang Y, Jia D, Kim H, et al.  2016.  Dysregulation of microRNA-212 promotes castration resistance via hnRNPH1-mediated regulation of AR and AR-V7: Implications for racial disparity of prostate cancer.  Clin Cancer Res 22(7):1744-1756."
"6069","PC102056","Abd Elmageed ZY, Yang Y, Thomas R, et al.  2014.  Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes. Stem Cells 32(4):983-997."
"6070","PC102056","Silberstein JL, Feibus AH, Maddox MM, et al.  2014.  Active surveillance of prostate cancer in African American men.  Urology 84(6):1255-1261."
"6071","PC102062","Preston MA, Batista JL, Wilson KM, et al.  2016.  Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.  J Clin Oncol 34(23):2705-2711."
"6072","PC102062","Gershman B, Zietman AL, Feldman AS, et al.  2013.  Transperineal template-guided prostate biopsy for patients with persistently elevated PSA and multiple prior negative biopsies.  Urol Oncol 31(7):1093-1097."
"6073","PC102062","Preston MA, Feldman AS, Coen JJ, et al.  2015.  Active surveillance for prostate cancer: Need for intervention and survival at 10 years.  Urol Oncol 33(9):383.e9-16."
"6074","PC102062","Ringer L, Sirajuddin P, Tricoli L, et al.  2014.  The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells.  Oncotarget 5(21):10678-10691."
"6075","PC102062","Pollock CB, McDonough S, Wang VS, et al.  2014.  Strigolactone analogues induce apoptosis through activation of p38 and the stress response pathway in cancer cell lines and in conditionally reprogrammed primary prostate cancer cells.  Oncotarget 5(6):1683-1698."
"6076","PC102068","Olson B, Jankowska-Gan E, Becker J, et al.  2012.  Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade.  Immunol J 189(12):5590-5601."
"6077","PC102068","Olson B and McNeel D.  2013.  Monitoring regulatory immune responses in tumor immunotherapy clinical trials.  Front Oncol 3:109."
"6078","PC102068","Olson B, Johnson L, and McNeel D.  2013.  The androgen receptor -- A biologically relevant vaccine target for the treatment of prostate cancer.  Cancer Immunol Immunother 62 (3):585-596."
"6079","PC102068","Bloom J, McNeel D, and Olson B.  2012.  Vaccination using peptides spanning the SYT-SSX tumor-specific translocation.  Expert Rev Vaccines 11 (12):1401-1404."
"6080","PC102068","Johnson L, Becker J, Dubovsky J, et al.  2012.  Prostate carcinoma in transgenic lewis rats -- A tumor model for evaluation of immunological treatments.  Chin Clin Oncol 2(1).

"
"6081","PC102068","McNeel D, Becker J, Johnson L, et al.  2012.  DNA vaccines for prostate cancer.  Curr Cancer Ther Rev 8(4):254-263."
"6082","PC102068","Olson B and McNeel D.  2012.  Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence.  Expert Rev Vaccines 11(11):1315-1317.

"
"6083","PC102071","Tewari AK, Yardimci GG, Shibata Y, et al.  2012.  Chromatin accessibility reveals insights into androgen receptor activation and transcriptional specificity.  Genome Biol 13(10):R88.

"
"6084","PC102072","Gurski LA, Xu X, Labrada LN, et al.  2012.  Hyaluronan (HA) interacting proteins RHAMM and hyaluronidase impact prostate cancer cell behavior and invadopodia formation in 3D HA-based hydrogels. PLoS One 7(11):e50075."
"6085","PC102080","Wang WLW and Tenniswood M.  2014.  Vitamin D, intermediary metabolism and prostate cancer tumor progression.  Front Physiol 5:183."
"6086","PC102080","Gaupel AC, Wang WLW, Mordan-McCombs S, et al.  Xenograft, transgenic and knockout models of prostate cancer.  In: Animal models for the study of human disease. (Conn M, Ed.).  Elsevier Group."
"6087","PC102080","Wang WL, Welsh J, and Tenniswood T.  2013.  J Vitamin D3 modulates lipid metabolism in prostate cancer through miRNA mediated regulation of PPARa.  J Steroid Biochem Mol Biol 136:247-251."
"6088","PC102080","Chatterjee N, Wang WL, Conklin T, et al.  2013.  Histone deacetylase inhibitors modulate miRNA and mRNA expression, block metaphase, and induce apoptosis in inflammatory breast cancer cells.  Cancer Biol Ther 14:658-671."
"6089","PC102080","Wang WLW, Chatterjee N, Chittur S, et al.  2011.  Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone mediated signaling on miRNA and mRNA expression in LNCaP cells.  Mol Cancer 10:58."
"6090","PC102086","Ishteiwy RA, Ward TM, Dykxhoorn DM, et al.  2012.  The microRNA-23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells.  PloS One 7(12):e52106."
"6091","PC102105","Pruitt FL, He Y, Franco OE, et al.  2013.  Cathepsin D acts as an essential mediator to promote malignancy of benign prostatic epithelium.  Prostate 73(5):476-488."
"6092","PC102106","Balbas MD, Evans MJ, Hosfield DJ, et al.  2013.  Overcoming mutation-based resistance to antiandrogens with rational drug design.  Elife 2:e00499."
"6093","PC102106","Arora VK, Schenkein E, Murali R, et al.  2013.  Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.  Cell 155(6):1309-1322."
"6094","PC102140","Winchester D, Ricks-Santi L, Mason T, et al.  2015.  SPINK1 Promoter Variants Are Associated with Prostate Cancer Predisposing Alterations in Benign Prostatic Hyperplasia Patients. Anticancer Res 35(7):3811-3819."
"6095","PC102144","Wu LY, Liu T, Hopkins M, et al.  2012.  Chemoaffinity capture of pre-targeted prostate cancer cells with magnetic beads.  Prostate 72(14):1532-1541.

"
"6096","PC102171","Kalyana-Sundaram S, Kumar-Sinha C, Shankar S, et al.  2012.  Expressed pseudogenes in the transcriptional landscape of human cancers.  Cell 22:149(7):1622-1634.  "
"6097","PC102171","Robinson DR, Wu YM, Kalyana-Sundaram S, et al.  2013.  Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing.  Nat Genet 45(2):180-185. "
"6098","PC102171","Lonigro RJ, Grasso CS, Robinson DR, et al.  2011.  Detection of somatic copy number alterations in cancer using targeted exome capture sequencing.  Neoplasia 13:1019-1025."
"6099","PC102171","Paulsen MT, Veloso A, Prasad J, et al.  2013.  Coordinated regulation of synthesis and stability of RNA during the acute TNF-induced proinflammatory response.  Proc Natl Acad Sci U S A 110:2240-2245."
"6100","PC102171","Wu YM, Su F, Kalyana-Sundaram S, et al.  2013.  Identification of targetable FGFR gene fusions in diverse cancers.  Cancer Discov 3 (6):636-647."
"6101","PC102171","Vlangos CN, Siuniak AN, Robinson D, et al.  2013.  Next-generation sequencing identifies the Danforth's short tail mouse mutation as a retrotransposon insertion affecting Ptf1a expression.  PLoS Genet 9(2):e1003205."
"6102","PC102171","Kim JH, Dhanasekaran SM, Prensner JR, et al.  2011.  Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer.  Genome Res 21:1028-1041."
"6103","PC102171","Roychowdhury S, Iyer MK, Robinson DR, et al.  2011.  Personalized oncology through integrative high-throughput sequencing: A pilot study.  Science Transl Med 3:111ra121."
"6104","PC102171","Cui Y, Niziolek PJ, MacDonald BT, et al.  2011.  Lrp5 functions in bone to regulate bone mass.  Nat Med 17:684-691."
"6105","PC102171","Sam LT, Lipson D, Raz T, et al.  2011.  A comparison of single molecule and amplification based sequencing of cancer transcriptomes.  PLoS One 6 e17305."
"6106","PC102171","Grasso CS, Wu Y-M, Robinson DR, et al.  2012.  The mutational landscape of lethal castrate resistant prosate cancer.  Nature 487(7406):239-243.  "
"6107","PC110064","Sanderson M, Fowke JH, Lipworth L, et al.  2013.  Diabetes and prostate cancer screening in black and white men. Cancer Causes Control 24(10):1893-9."
"6108","PC110065","Zacharias NM, McCullough CR, Wagner S, et al.  2016.  Towards real-time metabolic profiling of cancer with hyperpolarized succinate.  J Mol Imaging Dyn 6(1).4989923"
"6109","PC110065","Lee Y, Zacharias NM, Piwnica-Worms, et al.  2014.  Chemical reaction-induced multi-molecular polarized (CRIMP) 50:13030-13033."
"6110","PC110070","Odedina FT, Oluwayemisi AO, Pressey S, et al.  2014.  Development and assessment of an evidence-based prostate cancer intervention programme for black men: The W.O.R.D. on prostate cancer video.  Ecancermedicalscience 8:460."
"6111","PC110070","Chakraborty PK, Zhang Y, Coomes AS, et al.  2014.  G protein-coupled receptor kinase GRK5 phosphorylates moesin and regulates metastasis in prostate cancer.  Cancer Res 74(13):3489-3500."
"6112","PC110072","Sottnik JL, Dai J, Zhang H, et al.  2015.  Tumor-induced pressure in the bone microenvironment causes osteocytes to promote the growth of prostate cancer bone metastases. Cancer Res 75(11):2151-2158."
"6113","PC110072","Sottnik JL, Campbell B, et al.  2014.  Osteocytes serve as a progenitor cell of osteosarcoma.  J Cell Biochem 115(8) 1420-1429."
"6114","PC110080","Shui IM and Giovannucci E.  2013.  Vitamin D status and cancer incidence and mortality. In: Sunlight, Vitamin D and Skin Cancer (Reichrath J, Ed).  Second Edition, Springer, New York."
"6115","PC110080","Shui IM, Mondul AM, Lindström S, et al.  2015.  Breast and Prostate Cancer Cohort Consortium Group. Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer 121(12):1949-1956."
"6116","PC110080","Shui IM, Lindstrom S, Kibel AS et al. 2014.   Prostate Cancer (PCa) Risk Variants and Risk of Fatal PCa 11 in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Eur Urol 65(6):1069-75."
"6117","PC110106","Li Y, Lin T-Y, Luo Y, et al.  2014.  A smart and versatile theranostic nanomedicine platform based on nanoporphyrin.  Nat Commun 5:4712."
"6118","PC110106","Li Y, Xiao K, Zhu W, et al.  2013.  Stimuli-responsive cross-linked micelles for on-demand drug delivery against cancers.  Advanced Drug Delivery Reviews 66:58-73."
"6119","PC110106","Li Y, Budamagunta M, Juntao L, et al.  2012.  Probing of the assembly structure and dynamics within nanoparticles during interaction with blood proteins.  ACS Nano 6(11):9485-9495."
"6120","PC110126","Friedlander TW, Premasekharan G, and Paris PL.  2014.  Looking back to the future of circulating tumor cells.  Pharmacol Ther142(3):271-280."
"6121","PC110126","Anantharaman A, and Friedlander TW.  2015.  The double-edged sword of ADT: Emerging evidence of cardiovascular, pulmonary, and renal risks.  Oncology (Williston Park) 29(1):67-68."
"6122","PC110126","Anantharaman A and Friedlander TW.  2015.  A stepping stone toward personalized oncology: genomic analysis of circulating tumor cells to guide management of metastatic castration-resistant prostate cancer.  Eur Urol."
"6123","PC110126","Friedlander TW, Premasekharan G, and Paris PL.  2014.  Detection and characterization of invasive circulating tumor cells (iCTCs) derived from men with metastatic castration resistant prostate cancer (mCRPC).  Int J Cancer 134(10):2284-2293."
"6124","PC110126","Friedlander TW and Fong L.  2014.  The end of the beginning:  Circulating tumor cells as prognostic biomarkers in castration resistant prostate cancer.  J Clin Onco 32(11):1104-1116."
"6125","PC110126","Anantharaman A, and Friedlander TW.  2015.  Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review.  Urol Oncol, S1078-1439(15)00555-4."
"6126","PC110126","Friedlander TW, Fong L. 2014.  The end of the beginning: circulating tumor cells as a biomarker in castration-resistant prostate cancer.  J Clin Oncol 32(17):1863."
"6127","PC110174","Jiang W, Lumata L, Chen W, et al.  2015.  Hyperpolarized 15N probes as pH-sensitive MR imaging agents.  Sci Rep 5:9104."
"6128","PC110175","Jiang W, Lumata L, Chen W, et al.  2015.  Hyperpolarized 15N-pyridine derivatives as pH-sensitive MRI agents.  Sci Rep 5:9104."
"6129","PC110175","Niedbalski P, Parish C, Kiswandhi A, et al.  2017.  Influence of Dy3+ and Tb3+ doping on 13C dynamic nuclear polarization.  J Chem Phys 146:014303."
"6130","PC110175","Kiswandhi A. Niedbalski P, Parish C, et al.  2016.  Impact of Ho3+-doping on 13C dynamic nuclear polarization using trityl OX063 free radical.  Phys. Chem. Chem. Phys 18:21351-21359."
"6131","PC110259","Schurtz EA, Markes J, Newton MR, et al.  2013.  Novel use of the capio urethral anastomotic suturing device: A 50-case assessment.  Curr Urol 7:145-148."
"6132","PC110259","Sobhakumari A, Schickling BM, Love-Homan L, et al.  2013.  NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells.  Toxicol Appl Pharmacol 272(3):736-745."
"6133","PC110280","Kumar R, Korideck H, Ngwa W, et al.  2013.  Third generation gold nanoplatform optimized for radiation therapy.  Transl Cancer Res 2(4)."
"6134","PC110280","Ngwa W, Korideck H, Kassis AI, et al.  2012.   In vitro radiosensitization by gold nanoparticles during continuous low-dose-rate gamma irradiation with I-125 brachytherapy seeds.  Nanomedicine 9(1):25-27."
"6135","PC110305","Veltri RW, Zhu G, Lee G, et al.  2014.  Frontiers of Medical Imaging. Part 3: Emerging Methods and Medical Imaging Systems. Chapter 15: Histomorphometry of Digital Pathology: Case Study in Prostate Cancer (Chen CH, Ed.).  World Scientific Publishing, Singapore."
"6136","PC110305","Lee G, Sparks R, Ali S, et al.  2014.  Co-occurring gland angularity in localized subgraphs: predicting biochemical recurrence in intermediate-risk prostate cancer patients.  PLos ONE 9:5e97954."
"6137","PC110349","Singh P, Algotar AM and Bracamonte ER.  2013.  Prostate small cell carcinoma: diagnosis and management.  J Cancer Ther 4(3):804-810."
"6138","PC110349","Nagle RB, Algotar AM, Cortez CC, et al.  2013.  ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma.  Prostate 73(11):1233-1240."
"6139","PC110363","Moreira DF, Zhang Q, Hossain DMS, et al.  2015.  TLR9 signaling through NF-kappaB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells.  Oncotarget 6:17302-17313."
"6140","PC110363","Hossain DMS, Pal SK, Moreira DF, et al.  2015.  TLR9-targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate cancer patients. Clin Cancer Res 3145."
"6141","PC110363","Hossain DMS, Moreira D, Zhang Q, et al.  2016.  TLR9-targeted siRNA delivery in vivo.  Methods Mol Biol 1364:183-196."
"6142","PC110379","Zhang Z, Zhou N, Huang J, et al. 2016. Regulation of androgen receptor splice variant AR3 by PCGEM1. Oncotarget. 7(13): 15481–15491. doi: 10.18632/oncotarget.7139."
"6143","PC110389","Piert M, Montgomery J, Kunju LP, et al.  2016.  18F-choline PET/MRI: The additional value of PET for MRI-guided transrectal prostate biopsies.  J Nucl Med 57:1065-1070."
"6144","PC110389","Piert M, El Naqa I, Davenport MS, et al.  2016.  PET/MRI and prostate cancer.  Clin Transl Imaging 1-13."
"6145","PC110389","Piert M, Shankar P, Montgomery J, et al. 2018. Accuracy of tumor segmentation from multi-parametric prostate MRI and 18F-choline PET/CT for focal prostate cancer therapy applications. EJNMMI Res. 8(1): 23. doi: 10.1186/s13550-018-0377-5."
"6146","PC110389","Barnett C, Davenport MS, Montgomery JS, Kunju LP, Denton B, Piert M. 18F-choline PET/mpMRI for Detection of Significant Prostate Cancer: Part 2. Cost-Effectiveness Analysis. J Nucl Med. 2019 Jul 26. pii: jnumed.119.225771. doi: 10.2967/jnumed.119.225771. PMID: 31350321"
"6147","PC110389","Davenport MS, Montgomery JS, Kunju LP, Siddiqui J, Shanka PR, Rajendiran T, Shao X, Lee E, Barnett C, Denton B, Piert M. (18)F-choline PET/mpMRI for Detection of clinically significant prostate cancer: Part 1. Improved risk stratification for MRI-guided transrectal prostate biopsies. J Nucl Med. 2019 Aug 16. pii: jnumed.119.225789. doi: 10.2967/jnumed.119.225789. [Epub ahead of print] PubMed PMID: 31420496."
"6148","PC110393","Chua CW, Shibata M, Lei M, et al.  2014.  Single luminal epithelial progenitors can generate prostate organoids in culture.  Nat Cell Biol 16(10):951-961."
"6149","PC110403","Bicker KL. Sun J. Harrell M, et al.  2012.  Synthetic lectin arrays for the detection and discrimination of cancer associated glycans and cell lines.  Chem Sci  3:1147-1156."
"6150","PC110408","Westover D, Ling X, Lam H, et al.  2015.  FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.  Mol Cancer 14:92."
"6151","PC110408","Ling X, Liu XJ, Zhong K, et al.  2015.  FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human xenograft models.  Am J Transl Res 7(10):1765-1781."
"6152","PC110408","Zhao J, Ling X, Cao S, et al.  2014.  Antitumor activity of FL118, a survivin, Mcl-1, XIAP, cIAP2 selective inhibitor, is highly dependent on its primary structure and steric configuration.  Mol Pharm 11(2):457-467."
"6153","PC110408","Li F.  2014.  Anticancer drug FL118 is more than a survivin inhibitor: Where is the Achilles' heel of cancer?  Am J Cancer Res 4(3): 203-311."
"6154","PC110408","Li F.  2013.  Discovery of survivin inhibitors and beyond: FL118 as a proof of concept.  International Review of Cell Mol Biol 305:217-252."
"6155","PC110408","Ling X and Li F.  2013.  An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI).  American J Translational Res 3(2):139-154."
"6156","PC110408","Ling X, Cao S, Cheng Q, et al.  2012.  A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.  PLoS ONE 7:e45571."
"6157","PC110424","Talha Shekhani MT, Jayanthy A-S, Maddodi N, et al.  2013.  Cancer stem cells and tumor transdifferentiation: Implications for novel therapeutic strategies.  Am J Stem Cell 2(1):52-61."
"6158","PC110446","Mahajan K, Malla P, Lawrence HR, et al. 2017. ACK1/TNK2 Regulates Histone H4 Tyr88- phosphorylation and AR Gene Expression in Castration-Resistant Prostate Cancer. Cancer Cell. 31(6): 790-803.e8. doi: 10.1016/j.ccell.2017.05.003."
"6159","PC110451","Ford ME, Abraham LM, Harrison AL, et al.  2016.  Mentoring strategies and outcomes of two federally funded cancer research training programs for underrepresented students in the biomedical sciences.  J Canc Educ 31(2):228-235."
"6160","PC110451","Ford ME, Wei W, Burshell D, et al.  2015.  Evaluating the reliability of the attitudes to randomized trial questions (ARTQ) in a predominantly African American sample.  SpringerPlus 4:411."
"6161","PC110452","Bitting RL, Healy P, Halabi S, et al.  2015.  Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer. Urol Oncol 33(3):110.e1-9."
"6162","PC110468","Belair CD, Paikari A, Moltzahn  F, et al.  2015.  DGCR8 is essential for tumor progression following PTEN loss in the prostate.  EMBO Reports 16:1219-1232."
"6163","PC110481","Labbé RM, Holowatyj A, and Yang Z-Q.  Histone lysine demethylase (KDM) subfamily 4: Structures, functions and therapeutic potential.  Am J Transl Res 6:1-15."
"6164","PC110483","Garg R, Benedetti L, Abera M, et al.  2014.  Protein kinase C and cancer: What we know and what we don't.  Oncogene 33:5225-5237."
"6165","PC110483","Garg R, Blando JM, Perez CJ, et al. 2018. COX-2 mediates pro-tumorigenic effects of PKCe in prostate cancer. Oncogene 37: 4735-4749. doi: 10.1038/s41388-018-0318-9."
"6166","PC110487","An N, Xiong Y, LaRue AC, et al.  2015.  Activation of Pim kinases is sufficient to promote resistance to MET small-molecule inhibitors.  Cancer Res 75(24): 5318-5328."
"6167","PC110487","Warfel NA, Sainz AG, Song JH, et al. 2016. PIM kinase inhibitors kill hypoxic tumor cells by reducing Nrf2 signaling and increasing reactive oxygen species. Mol Cancer Ther 15(7): 1637-47."
"6168","PC110487","Warfel, NA, and Kraft, AS.  2015.  Pim kinase (and Akt) biology and signaling in tumors.  Pharmacol Ther. 151:41-49."
"6169","PC110487","Cen B, Mahajan S, Wang W, et al.  2013.  Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1.  Cancer Res 73(11):3402-1134."
"6170","PC110487","Cen B, Xiong Y, Song JH, et al.  2014.  The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling.  Mol Cell Biol 34(13):2517."
"6171","PC110487","Song J, An N, Chatterjee S, et al.  2015.  Deletion of Pim kinases elevates the cellular levels of reactive oxygen species and sensitizes to K-Ras-Induced cell killing.  Oncogene 34(28):3728-3736."
"6172","PC110511","Wu D, Sunkel B, Chen Z, et al.  2014.  Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer.  Nucleic Acids Res 42:3607-3622.  (NAR Breakthrough Article.)"
"6173","PC110511","Chen Z, Lan X, Thomas-Ahner JM, et al.  2015.  Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer.  EMBO J 34:502-516."
"6174","PC110511","Chen K, Chen Z, Wu D, et al.  2015.  Broad H3K4me3 is associated with increased transcriptional elongation and enhancer activity at tumor-suppressor genes.  Nat Genet 47:1149-1157."
"6175","PC110511","Sunkel B, Wu D, Chen Z, et al.  2016.  Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence.  Nucleic Acids Res 44(9):4105-4122."
"6176","PC110511","Chen Z, Lan X, Wu D, et al.  2015.  Ligand-dependent genomic function of the glucocorticoid receptor in triple-negative breast cancer.  Nat Commun 6:8323."
"6177","PC110511","Ye Z, Chen Z, Lan X, et al.  2014.  Computational analysis reveals a correlation of exon-skipping events with splicing, transcription and epigenetic factors.  Nucleic Acids Res 42:2856-2869."
"6178","PC110521","Gakhar G, Bande, NH, and Nanus DM.  2014.  In vitro method to observe E-selectin-mediated interactions between prostate circulating tumor cells derived from patients and human endothelial cells.  J Vis Exp 87, e51468. "
"6179","PC110521","Gakhar G, Navarro VN, Jurish M, et al.  2013.  Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow.  PloS ONE 8(12):e85143. "
"6180","PC110534","Zhang L, Wang J, Zhang Y, et al.  2016.  MNX1 is an androgen regulated oncogene that is upregulated in African-American prostate cancer.  Cancer Res 76(21):6290-6298."
"6181","PC110534","Khan AP, Rajendiran TM, Ateeq B, et al.  2013.  The role of sarcosine metabolism in prostate cancer progression.  Neoplasia 15(5):491-501."
"6182","PC110534","Kaushik AK, Vareed SK, Basu S, et al.  2014.  Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer.  J Proteome Res 13(2):1088-1100."
"6183","PC110534","Stossi F, Dandekar RD, Bolt MJ, et al.  2016.  High throughput microscopy identifies Bisphenol AP, a Bisphenol A Analog, as a novel AR down-regulator.  Oncotarget 7(13):16962-16974."
"6184","PC110534","Kaushik AK, Shojaie A, Panzitt K, et al.  2016.  Inhibition of hexosamine biosynthetic pathway promotes castration-resistant prostate cancer.  Nature Comm 7:11612."
"6185","PC110556","Stafforini DM.  2015.  Plasma PAF-AH (PLA2G7): Biochemical properties, association with LDLs and HDLs, and regulation of expression.  Enzymes 38:71-93."
"6186","PC110556","Stafforini, DM.  2015.  Diverse functions of plasma PAF-AH in tumorigenesis.  Enzymes 38:157-179."
"6187","PC110556","Samadi AK, Bilsland A, Georgakilas AG, et al.  A multi-targeted approach to suppress tumor-promoting inflammation.  Semin Cancer Biol 35 Suppl:S151-84."
"6188","PC110583","Roudier MP, Winters BR, Coleman I, et al.  2016.  Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.  Prostate 76(9):810-822."
"6189","PC110583","Miyamoto DT, Lee RJ, Stott SL, et al.  2012.  Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.  Cancer Discov 2:995-1003."
"6190","PC110583","Tin DT, Wittner BS, Ligorio M, et al.  2014.  Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells.  Cell Reports 8:1905-1918."
"6191","PC110583","Miyamoto DT, Sequist LV, and Lee RJ.  2014.  Circulating tumor cells - monitoring treatment response in prostate cancer.  Nature Rev Clin Oncol 11 (7):401-412."
"6192","PC110583","Saylor, P.J., Lee, R.J., Arora, K.S., Deshpande, V., Hu, R., Olivier, K., Meneely, E., Rivera,
M.N., Ting, D.T., Wu, C.L., Miyamoto, D.T. (2017) Branched chain RNA in situ hybridization for
androgen receptor splice variant AR-V7 as a prognostic biomarker for metastatic castrationsensitive
prostate cancer. Clinical Cancer Research, 23:363-369. PMID 27440270"
"6193","PC110583","Ozkumur E, Shah AM, Ciciliano JC, et al.  2013.  Inertial focusing for positive and negative sorting of rare circulating tumor cells.  Sci Transl Med 5:179ra47.

"
"6194","PC110596","Klukowska J, Davidi R, and Herman GT.  2013.  SNARK09 - A software package for the reconstruction of 2D images from 1D projections.  Comput Methods Programs Biomed 110:424-440."
"6195","PC110607","Nandana S and Chung L.  2014.  Prostate cancer progression and metastasis: Potential regulatory pathways for therapeutic targeting.  Am J Clin Exp Urol 2(2):92-101."
"6196","PC110608","Park SI, Lee C, Sadler WD, et al.  2013.  Parathyroid hormone-related protein drives a CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer growth.  Cancer Res 73(22):6574-6583."
"6197","PC110608","Cho SW, Soki FN, Koh AJ, et al.  2014.  Osteal macrophages support physiologic skeletal remodeling and anabolic actions of parathyroid hormone in bone.  Proc Natl Acad Sci U S A 111(4):1545-1550."
"6198","PC110609","Brennen WN, Denmeade SR, and Isaacs JT.  2013.  Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment.  Endocr Relat Cancer 20(5):R269-290."
"6199","PC110609","Brennen WN, Chen S, Denmeade SR, et al.  2013.  Quantification of mesenchymal stem cells MSCs at sites of human prostate cancer.  Oncotarget 4(1):106-117.

"
"6200","PC110626","Singh CK, George J, Nihal M, et al.  2014.  Novel downstream molecular targets of SIRT1 in melanoma: A quantitative proteomics approach.  Oncotarget 5(7):1987-1999."
"6201","PC110626","Singh CK, Ndiaye M, Nihal M, et al.  2014.  Methaneseleninic acid and gamma-tocopherol combination inhibits prostate tumor growth in vivo in a xenograft model.  Oncotarget 5(11):3651-3661."
"6202","PC110626","Singh CK, George J, and Ahmad N.  2013.  Resveratrol-based combinatorial strategies for cancer management.  Annals of the New York Academy of Sciences 1290:113-121."
"6203","PC110638","Stoyanova T, Goldstein AS, Cai H, et al.  2012.  Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via beta-catenin signaling.  Genes Dev 26(20):2271-2285. "
"6204","PC110638","Stoyanova T, Cooper AR, Drake JM, et al.  2013.  Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells.  Proc Natl Acad Sci U S A 110(50):20111-20116."
"6205","PC110650","Kasperzyk JL, Finn SP, Flavin RJ, et al.  2013.  Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer.  Cancer Epidemiol Biomarkers Prev 22(12):2354-2363."
"6206","PC110650","Margalit DN, Jordahl KM, Werner L, et al.  2015.  Germline variation in superoxide dismutase-2 (SOD2) and survival outcomes after radiation therapy for prostate cancer: results of a test and validation set analysis.  Clin Genitourin Cancer 13(4):370-377."
"6207","PC110650","Zadra G, Batista JL, and Loda M.  2015.  Dissecting the dual role of AMPK in cancer: from experimental to human studies.  Mol Cancer Res 13(7):1059-1072."
"6208","PC110699","Qi J, Tripathi M, Mishra R, et al.  2013.  The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity.  Cancer Cell 23(3)."
"6209","PC110722","Markovic S, Belz J, Kumar R, et al.  2016.  Near-infrared fluorescence imaging platform for quantifying in vivo nanoparticle diffusion from drug loaded implants.  International J Nanomedicine 11:1213."
"6210","PC110722","Kumar R, Belz J, Markovic S, et al.  2015.  Nanoparticles based 'smart' brachytherapy spacers for delivery of localized combined chemo-radiation therapy.  Int J Radiat Oncol Biol Phys 91(2):393-400."
"6211","PC110722","Ngwa W, Altunda Y, Korideck H, et al.  2014.  Radiation therapy biomaterials for response assessment and nodal detection (BRAND).  Int J Radiat Oncol Biol Phys 90(1):S856."
"6212","PC110722","Belz J, Kumar R, Makrigiorgos G, et al.  2016.  Docetaxel eluting brachytherapy spacers for local chemoradiation therapy in prostate cancer.  Medical Physics 43(6):3823-3823."
"6213","PC110722","Cormack R, Ngwa W, Tangutoori S, et al.  2014.  Optimal time release schedule of in-situ drug release during permanent prostate brachytherapy.  Med Phys 41:389."
"6214","PC110722","Kumar R, Belz J, Markovic S, et al.  2015.  Nanoparticle-based brachytherapy spacers for delivery of localized combined chemoradiation therapy. Int J Radiat Oncol Biol Phys 91(2):393-400."
"6215","PC110744","Kao C-J, Martiniez A, Shi X-B, et al.  2014.  miR-30 as a tumor suppressor connects EGF/Src singal to ERG and EMT.  Oncogene 33(19):2495-2503."
"6216","PC110784","Cao B, Qi Y, Yang Y, et al.  2014.  20(S)-protopanaxadiol inhibition of progression and growth of castration-resistance prosate cancer.  PLOS One 9(11):e111201."
"6217","PC110784","Cao B, Qi Y, Zhang G, et al.  2014.  Androgen receptor splice variants activating the full-length  receptor in mediating resistance to androgen-directed therapy. Oncotarget 5(6):1646-1656."
"6218","PC110858","Hansen A, Esakky P, Drury A, et al.  2014.  The aryl hydrocarbon receptor is important for proper seminiferous tubule architecture and sperm development.  Biol Reprod 90(1):8, 1-12."
"6219","PC110877","Wang H, He L, Ma F, et al.  2013.  SOX9 regulates low density lipoprotein receptor-related Protein 6 (LRP6) and T-cell Factor 4 (TCF4) expression and Wnt/B-catenin activation in breast cancer.  J Biol Chem 288(9):6478-6487."
"6220","PC110891","Schehr J, Schultz Z, Warrick JW, et al. 2016. Specificity in circulating tumor cell identification is required for accurate evaluation of programmed death-ligand 1.  PLOS One 11(7):e0159397."
"6221","PC110891","Sackmann EK, Casavant BP, Moussavi-Harami SF, et al.  2013.  Cell-based microfluidic assays in translational medicine.  In: Engineering in Translational Medicine (Cai W, Ed) Springer Publishing."
"6222","PC110891","Strotman L, O'Connell R, Casavant BP, et al.  2013.  Complete nucleic acid isolation using selective nucleic acid removal via exclusion (SNARE) for rare or precious samples.  Anal Chem 85(20):9764-9770."
"6223","PC110891","Héninger E, Krueger TE, and Lang JM.  2015.  Augmenting antitumor immune responses with epigenetic modifying agents.  Front Immunol 6:29."
"6224","PC110891","Kosoff D, Krueger T, and Lang JM.  2013.  Targeting epigenetic mechanisms for clinical translation: Enhancing the efficacy of tumor immunotherapies.  Immunotherapy 5(11):1243-1254."
"6225","PC110891","King J, Casavant BP, and Lang JM.  2013.  Rapid translation of circulating tumor cell biomarkers into clinical practice: technology development, clinical needs and regulatory requirements.  Lab Chip 14(1):24-31."
"6226","PC110891","Kosoff D, Casavant BP, and Lang JM.  2015.  Directing circulating tumor cell technologies into clinical practice: Clinical needs, technology development, and regulatory requirements.  In: Circulating Tumor Cells: Isolation and Analysis (Fan ZH, Ed.).  1st Edition, Wiley Publishing, Hoboken."
"6227","PC110902","Hurley PJ, Sundi D, Shinder B, et al.  2015.  Germline variants in asporin vary by race, modulate the tumor microenvironment, and are differentially associated with metastatic prostate cancer.  Clin Cancer Res 22(2):448-458."
"6228","PC110938","Ramteke A, Ting H, Agarwal C, et al.  2015.  Exosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junction molecules.  Mol Carcinog 54(7):554-565."
"6229","PC111002","Goldman DC, Alexeev V, Lash E, et al.  2015.  The triterpenoid RTA 408 is a Robust mitigator of hematopoietic acute radiation syndrome in mice.  Radiat Res 183:338-344."
"6230","PC111002","Alexeev V, Lash E, Aguillard A, et al.  2014.  Radiation protection of the gastrointestinal tract and growth inhibition of prostate cancer xenografts by a single compound.  Mol Cancer Ther 13:2968-2977."
"6231","PC111066","Marrache S, Pathak RK, Darley KL, et. al.  Nanocarriers for tracking and treating diseases.  Curr Med Chem 20(28);3500-3514."
"6232","PC111066","Pathtak RK, McNitt C, Popik VV, et al.  2014.  Copper-free click-chemistry platform to functionalize cisplatin prodrugs.  Chem. Eur J 20:6861-6865."
"6233","PC111066","Pathtak RK, Marrache S, Harn DA, et al.  2014.  Mito-DCA: A mitochondria targeted molecular scaffold for efficacious delivery of metabolic modulator dichloroacetate.  ASC Chem Biol 9:1178-1187."
"6234","PC111066","Wen R, Umeano AC, Francis L, et al.  2016.  Mitochondrion: A promising target for nanoparticle-based vaccine delivery systems. Vaccines (Basel) 4(2)."
"6235","PC111066","Pathak R K and Dhar S.  2015.  A nanoparticle cocktail: Temporal release of predefined drug combinations.  J Am Chem Soc 137:8324-8327."
"6236","PC111066","Pathak RK, Marrache S, Choi JH, et. al.  2014.  The prodrug Platin-A: Simultanenous release of cisplatin and aspirin.  Angew Chem 126:1-6."
"6237","PC111066","Kalathil AA, Kumar A, Banik B, et al.  2015.  New formulation of old aspirin for better delivery.  Chem Commun (Camb) 52(1):140-143."
"6238","PC111098","Tsouko E, Khan AS, White MA, et al.  2014.  Regulation of the pentose phosphate pathway by an androgen receptor mTRO-mediated mechanism and its role in prostate cancer growth.  Oncogenesis 3:e103."
"6239","PC111098","Tennakoon JB, Shi Y, Han JJ, et al.  2014.  Androgens regulate prostate cancer cell growth via an AMPK-PGC-1apha-mediated metabolic switch.  Oncogene 33(45):5251-5261."
"6240","PC111098","Popovics P, Frigo DE, Schally AV, et al.  2015.  Targeting the 5'-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer.  Expert Opin Ther Targets 19(5):617-632."
"6241","PC111100","Barnes JM, Nauseef JT, and Henry MD.  2012.  Resistance to fluid shear stress is a conserved biophysical property of malignant cells.  PLoS One 7(12):e50973."
"6242","PC111100","Chivukula VK, Krog B, Nauseef JT, et al.  2015.  Alterations in cancer cell mechanical properties after fluid shear stress exposure: A micropipette aspiration study.  Cell Health and Cytoskeleton 7:25-35."
"6243","PC111127","Vlaisavljevich E, Aydin O, Yuksel Y. et al.  2015.  The effects of ultrasound frequency on nanodroplet-mediated histotripsy.  Ultrasound in Med Biol 41(8):2135."
"6244","PC111127","Vlaisavljevich E, Durmaz YY, Maxwell MEH, et al.  2013.  Nanodroplet-mediated histotripsy for image-guided targeted ultrasound cell ablation.  Theranostics 3(11):802-815."
"6245","PC111127","Durmaz YY, Vlaisavljevich E, Xu Z, et al.  2014.  Development of nanodoplets for histotripsy-mediated cell ablation.  Mol Pharm 11(1):3864-3695."
"6246","PC111132","Ban F, Leblanc E, Li H, et al.  2014.  Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3).  J Med Chem 57(15):6867-6872."
"6247","PC111132","Lallous N, Volik SV, Awrey S, et al.  2016.  Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.  Genome Biol 17(1):10."
"6248","PC111132","Munuganti RSN, Hassona MDH, Leblanc E, et al.  2014.  Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer.  Chem Biol 21(11):1476-1485."
"6249","PC111175","Zhang G, Liu X, Li J, et al.  2015.  Androgen receptor splice variants circumvent ar blockade by microtubule-targeting agents.  Oncotarget 5."
"6250","PC111175","Cao B, Qi Y, Wang Y, et al.  2014.  20(S)-protopanaxadiol inhibition of progression and growth of castration-resistance prostate cancer.  PLOS One 9(11):e111201."
"6251","PC111175","Zhang H, Zhan Y, Xichun L, et al.  2013.  Splicing variants of androgen receptor in prostate cancer.  Am J Clin Exp Urol 1(1):18-24."
"6252","PC111175","Egan A, Dong Y, Zhang H, et al.  2013.  Castration-resistant prostate cancer: Adaptive responses in the androgen axis.  Cancer Treat Rev 40:426-433."
"6253","PC111175","Xu D, Zhan Y, Qi Y, et al.  2015.  Androgen receptor splice variants dimerize to transactivate target genes.  Cancer Res 75(17):3663-3671."
"6254","PC111175","Zhang G, Liu X, Li J, et al.  2015.  Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents.  Oncotarget 6(27):23358-23371."
"6255","PC111175","Tian Y, Zhao L, Wang Y, et al.  2016.  Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells.  Asian J Androl 18: 607-612."
"6256","PC111175","Cao B, Qi Y, Zhang GH, et al.  2014.  Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.  Oncotarget 5(6):1646-1656."
"6257","PC111190","Suarez CD, Deng X, and Hu CD.  2014.  Targeting CREB inhibits radiation-induced neuroendocrine differentiation and increases radiation-induced cell death in prostate cancer cells.  Am J Cancer Res 4:850-861."
"6258","PC111190","Deng X, Shao G, Zhang HT, et al.  2017.  Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.  Oncogene 36(9):1223-1231."
"6259","PC111190","Zhang H, Zeng L, Tao AW, et al.  2016.  The E3 ubiquitin ligase CHIP mediates ubiquitination and protesomal degradation of PRMT5.  Biochem Biophys Acta 1863:336-346."
"6260","PC111190","Hu CD, Choo R, and Huang J.  2015.  Neuroendocrine differentiation in prostate cancer: A mechanism of radioresistance and treatment failure.  Front Oncol 5:90."
"6261","PC111190","Zhang HT, Zhang D, Zha ZG, et al.  2014.  Transcriptional activation of PRMT5 by NF-Y is required for cell growth and negatively regulated by the PKC/c-Fos signaling in prostate cancer cells.  Biochim Biophys Acta 1839:1330-1340."
"6262","PC111230","Sorace AG, Warram JM, Mahoney M, et al.  2013.  Enhancement of adenovirus delivery after ultrasound-stimulated therapy in a cancer model.  Ultrasound Med Biol 39(12):2374-2381."
"6263","PC111230","Hoyt K, Mahoney M, Sorace AG.  2014.  Four-dimensional molecular ultrasound imaging of tumor angiogenesis in a preclinical animal model of prostate cancer.  IEEE International Ultrasonics Symposium Proceedings 1:1-4."
"6264","PC111233","Gustafson JL.  2015.  Small molecule-mediated degradation of the androgen receptor through hydrophobic tagging.  Angew Chem Int 54:9659-9662."
"6265","PC111233","Buckley DL, Raina K, Darricarrerre N, et al.  2015.  HaloPROTACS:  Use of small molecule protacs to induce degradation of halotag fusion proteins.  ACS Chem Biol 10(8):1831-1837"
"6266","PC111295","Hu WY, Xu L, Chen B, Ou S, Muzzarelli KM, Hu DP, Li Y, Yang Z, Vander Griend DJ, Prins GS, Qin Z. Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75. Prostate. 2019 Jul;79(10):1166-1179. doi: 10.1002/pros.23832. Epub 2019 May 28. PubMed PMID: 31135075."
"6267","PC111309","Kim J, Li S, Kasoji S, et al.  2015.  Phantom evaluation of stacked-type dualfrequency 1-3 composite transducers: a feasibility study on intracavitary acoustic angiography.  Ultrasonics 63:7-15."
"6268","PC111309","Martin KH, Lindsey B, Ma J, et al.  2014.  Dual-frequency transducers for contrast enhanced ultrasound imaging.  Sensors 14(11):20825-20842."
"6269","PC111314","Ramalinga M, Roy A, Srivastava A, et al.  2015.  MicroRNA-212 negatively regulates starvation induced autophagy in prostate cancer cells by inhibiting SIRT1 and is a modulator of angiogenesis and cellular senescence.  Oncotarget 6(33):34446-34457.  doi: 10.18632/oncotarget.5920."
"6270","PC111314","Srivastava A, Goldberger H, Dimtchev A, et al.  2013.  MicroRNA profiling in prostate cancer--the diagnostic potential of urinary miR-205 and miR-214.  PLoS One 8(10):e76994.  doi: 10.1371/journal.pone.0076994."
"6271","PC111314","Srivastava A, Goldberger H, Afzal Z, et al.  2015.  Detection of circulatory microRNAs in prostate cancer.  Methods Mol Biol 1238:523-538.  doi: 10.1007/978-1-4939-1804-1_27."
"6272","PC111314","Srivastava A, Goldberger H, Dimtchev A, et al.  2014.  Circulatory miR-628-5p is downregulated in prostate cancer patients.  Tumour Biol 35(5):4867-4873.  doi: 10.1007/s13277-014-1638-1."
"6273","PC111314","Roy A, Ramalinga M, Kim OJ, et al. 2017. Multiple roles of RARRES1 in prostate cancer: Autophagy induction and angiogenesis inhibition. Molecular players involved in the tumor suppressor role of RARRES1. PLoS One. 12(7): e0180344. doi: 10.1371/journal.pone.0180344."
"6274","PC111314P1","Roy A, Ramalinga M, Kim OJ, et al. 2017. Multiple roles of RARRES1 in prostate cancer: Autophagy induction and angiogenesis inhibition. Molecular players involved in the tumor suppressor role of RARRES1. PLoS One. 12(7). doi: 10.1371/journal.pone.0180344."
"6275","PC111318","LeBeau AM, Sevillano N, Markham K, et al.  2015.  Imaging active urokinase plasminogen activator in castration-resistant prostate cancer with an internalizing antagonistic human antibody.  Cancer Research 75(7):1225-1235."
"6276","PC111318","Lucas JM, Heinlein C, Kim T, et al.  2014.  The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.  Cancer Discov 4(11):1310-1325."
"6277","PC111318","Grove LM, Southern BD, Jin TH et al.  2014.  Urokinase-type plasminogen activator receptor 9uPAR) ligation induces a raft-localized integrin signaling switch that mediates the hypermotile phenotype of fibrotic fibroblasts.  J Biol Chem 289(18):12791-12804."
"6278","PC111331","Meaburn KJ, Agunloye O, Devine M, et al.  2016.  Tissue-of-origin specific gene repositioning in breast and prostate cancer.  Histochem Cell Biology 145(4):433-446."
"6279","PC111331","Leshner M, Devine M, Roloff GW, et al.  2016.  Locus-specific gene repositioning in prostate cancer.  Mol Biol Cell 27(2):236-246."
"6280","PC111399","Li S, Kennedy M, Payne S, et al.  2014.  Model of tumor dormancy/recurrence after short-term chemotherapy.  PLoS One 9(5):e98021."
"6281","PC111410","Parker MW, Linkugel AD, Goel HL, et al.  2015.  Structural basis for VEGF-C binding to neuropilin-2 and sequestration by a soluble slice form.  Structure 23:677-687."
"6282","PC111410","Goel HL, Chang C, Pursell B, et al.  2012.  VEGF/Neuropilin-2 regulation of Bmi-1 and repression of IGF-1R define a novel mechanism of aggressive prostate cancer.  Cancer Dis 2:906-921."
"6283","PC111410","Mercurio AM and Goel HL.  2013.  VEGF targets the tumor cell.  Nature Reviews Cancer 13:871-882."
"6284","PC111410","Mercurio AM, et al.  2012.  VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer.  Cancer Dis 2(10):906-921."
"6285","PC111410","Goel HL, Pursell B, Shultz LD, et al.  2016.  P-Rex1 promotes resistance to VEGF-targeted therapy in prostate cancer by mediating neuropilin signaling.  Cell Reports 14:2193-2208."
"6286","PC111467","Nguyen HG, Yang JC, Kung HJ, et al.  2014.  Targeting autophagy overcomes enzalutamide resistance in castrate resistant prostate cancer cells and improves therapeutic response in a xenograft model.  Oncogene 33(36):4521-4530."
"6287","PC111472","Wu JB, Lin T-P, Gallagher JD, et al.  2015.  Monoamine oxidase A inhibitor - near-infrared dye conjugate reduces prostate tumor growth.  J Am Chem Soc 137:2366-2374."
"6288","PC111472","Wu JB, Pan DF, Chung LWK.  2013.  Near-infrared fluorescence and nuclear imaging and targeting of prostate cancer.  Transl Androl Urol 2(3):254-264."
"6289","PC111472","Wu JB, Shao C, Li X, et al.  2014.  Near-infrared fluorescence imaging of cancer mediated by tumor hypoxia and HIF1alpha/OATPs signaling axis.  Biomaterials 35:8175-8185."
"6290","PC111472","Wu JB, Shao C, Li X, et al.  2014.  Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis.  J Clin Invest 124(7):2891-2908."
"6291","PC111472","Wu JB, Shi C, Chu GC, et al.  2015.  Near-infrared fluorescence heptamethine carbocyanine dyes mediate imaging and targeted drug delivery for brain tumor.  Biomaterials 67:1-10."
"6292","PC111503","Centenera MM, Raj GV, Knudsen KE, et al.  2013.  Ex vivo culture of human prostate tissue and drug development.  Nat Rev Urol 10(8):483-487."
"6293","PC111503","Daniel AR, Gaviglio AL, Knutson TP. Et al.  2015.  Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes.  Oncogene 34(4):506-515."
"6294","PC111503","Ravindranathan P, Lee TK, Yang L, et al.  2013.  Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer.  Nat Commun 4:1923."
"6295","PC111503","Grabowska MM, Elliott AD, DeGraff DJ, et al.  2014.  NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression.  Mol Endocrinol 28(6):949-964."
"6296","PC111503","Gonugunta VK, Miao L, Sareddy GR, et al.  2014.  The social network of PELP1 and its implications in breast and prostate cancer.  Endocr Relat Cancer 21(4):T79-86."
"6297","PC111503","Akram ON, Degraff DJ, Sheehan JH, et al.  2014.  Tailoring peptidomimetics for targeting protein-protein interactions.  Mol Cancer Res 12(7):967-978."
"6298","PC111510","Rahim S, Minas T, Hong S-H, et al.  2014.  A small molecule inhibitor of ETV1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model.  PLoS ONE 9(12):e114260."
"6299","PC111510P1","Roudier MP, Winters BR, Coleman I, et al.  2016.  Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.  Prostate 76(9):810-822."
"6300","PC111523","Sielski NL, Ihnatovych I, Hagen JJ, et al.  2014.  Tissue specific expression of myosin IC isoforms.  BMC Cell Biology 15:8."
"6301","PC111523","Simon DN, Domaradzki T, Hofmann WA, et al.  Lamin A tail modification by SUMO1 is disrupted by familial partial lipodystrophy-causing mutations.  Mol Biol Cell 24(3):342-350.
"
"6302","PC111523","Schwab RS, Ihantovych I, Yunus SZSA, et al.  2013.  Identification of signals that facilitate isoform specific nucleolar localization of myosin IC.  Exp Cell Res 319(8):1111-1123."
"6303","PC111523","Ihnatovych I, Sielski NL and Hofmann WA.  2014.  Selective expression of myosin IC isoform A in mouse and human cell lines and mouse prostate cancer tissues.  PLOS ONE 9(9):e108609."
"6304","PC111523","Karacosta LG, Kuroski LA, Hofmann WA, et al.  2016.  Nucleoporin 62 and Ca2+/Calmodulin dependent kinase Kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.  Prostate 76(3):294-306."
"6305","PC111594","Ganguly SS, Li X, and Miranti CK.  2014.  The host microenvironment influences prostate cancer invasion, system spread, bone colonization, and osteoblastic metastiasis.  Front Only 4:364-379."
"6306","PC111595","Bansal N, Davis S, Tereshchenko I, et al.  2014.  Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion.  Prostate 74(2):187-200."
"6307","PC111595P1","Bansal N, Bartucci M, Yusuff S, et al.  2016.  BMI-1 targeting interferes with patient-derived tumor-initiating cell survival and tumor growth in prostate cancer.  Clin Cancer Res 22(24):6176-6191."
"6308","PC111595P1","Bansal N, Davis S, Tereshchenko I, et al.  2014.  Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion.  Prostate 74(2):187-200."
"6309","PC111595P2","Bansal N, Davis S, Tereshchenko I, et al.  2014.  Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion.  Prostate 74(2):187-200."
"6310","PC111595P2","Bansal N, Bartucci M, Yusuff S, et al.  2016.  BMI-1 Targeting Interferes with patient-derived tumor-initiating cell survival and tumor growth in prostate cancer.  Clin Cancer Res 22(24):6176-6191."
"6311","PC111624","Daniels G, Gellert L, and Lee P.  2014.  TBLR1 as an AR coactivator selectively activates AR target genes to inhibit prostate cancer growth.  Endocrine Related Cancer 21(1):127-142."
"6312","PC111624","Li Y, Zhang DY, and Lee P.  2012.   Regulation of a novel androgen receptor target gene, the cyclin B1 gene, through androgen-dependent E2F family member switching.  Mol Cell Biol 32(13):2454-2466."
"6313","PC111624","Li Y, Tian L, and Lee P.  2013.  Functional domains of androgen receptor coactivator p44/Mep50/WDR77 and its interaction with Smad1.  PLoS One 8(5):e64663."
"6314","PC111624","Wu X, Gong S, Roy-Burman P, et al.  2013.  Current mouse and cell models in prostate cancer research.  Endocr Real Cancer 20(4):R155-70."
"6315","PC111624","Singh M, Jia R, and Lee P.  2014.  Stromal androgen receptor in prostate development and cancer.  Am J Pathol 184(10):2598-2607."
"6316","PC111624","Daniels G, Pei Z, Logan S, et al.  2015.  Androgen receptor phosphorylation in prostate cancer.  Am J Clin Exp Urol 2(1):62-70."
"6317","PC111624","Daniels G, Gellert L, and Lee P.  2014.  Decreased stromal estrogen receptor alpha and beta in prostate cancer.  American J Translational Res 6(2):140-146."
"6318","PC111667","Kaittanis C, Shaffer TM, Ogirala A, et al.  2014.  Environment-responsive nanophores for therapy and treatment monitoring via molecular MRI quenching.  Nature Communications 5:3384."
"6319","PC111703","Laberge RM, Sun Y, Orjalo AV, et al.  2015.  mTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation.  Nat Cell Biol 17:1049-1061."
"6320","PC111703","Chen F, Zhuang X, Lin L, et al.  2015.  New horizons in the tumor microenvironment biology: Challenges and opportunities.  BMC Med 13:45."
"6321","PC111703","Sun Y.  2015.  Translational horizons in the tumor microenvironment: Harnessing breakthroughs and targeting cures.  Med Res Rev 35:408-436."
"6322","PC111703","Chen F, Qi X, Qian M, et al.  2014.  Tackling the tumor microenvironment: What challenge does it pose to anticancer therapies?  Protein Cell 5:816-826."
"6323","PC111718","Bender RJ and Mac Gabhann F.  2015.  Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.  BMC Syst Biol 9:55."
"6324","PC111719","Escamilla J, Schokrpur S, Liu C, et al.  2015.  CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy.  Cancer Res 75(6):950-962."
"6325","PC111721","Kumar A, Mastren T, Wang B, et al.  2016.  Design of a small-molecule drug conjugate for prostate cancer targeted theranostics.  Bioconjugate Chem 27:1681-1689."
"6326","PC111721","Kumar A, Hao G, Liu L, et al.  2015.  Click-chemistry strategy for labeling antibodies with copper-64 via a cross-bridged tetraazamacrocyclic chelator scaffold.  Bioconjug Chem 26(4):782-789."
"6327","PC111721","Lo S-T, Kumar A, and Sun X.  2015.  Delivery and controlled release of therapeutics via dendrimer scaffolds.  In:  Nanoparticle Delivery of Biotherapeutics (Johnson V, Ed.).  Published by Future Science Group."
"6328","PC111721","Kumar A, Zhang S, Hao G, et al.  2015.  Molecular platform for design and synthesis of targeted dual-modality imaging probes.  Bioconjug Chem 26(3):549-558.  ACS Editor's Choice."
"6329","PC111721","Singh AN, Dakanali M, Hao G, et al.  2014.  Enantiopure bifunctional chelators for copper radiopharmaceuticals - Does chirality matter in radiotracer design?  Eur. J. Med. Chem 80:308-315."
"6330","PC111721","Hao G, Kumar A, Dobin T, et al.  2013.  A multivalent approach of imaging probe design to overcome an endogenous anion binding competition for noninvasive assessment of prostate specific membrane antigen.  Mol Pharm 10:2975-2985."
"6331","PC111721","Lo S-T, Kumar A, Hsieh J-T, et al.  2013.  Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry.  Mol Pharm 10:793-812."
"6332","PC111721","Kostiainen M, Maly J, da Costa CP, et al.  2013.  Synthesis of large dendrimers with the dimensions of small viruses.  J Am Chem Soc 135:4660-4663."
"6333","PC111721P1","Kostiainen M, Maly J, da Costa CP, et al.  2013.  Synthesis of large dendrimers with the dimensions of small viruses.  J Am Chem Soc 135:4660-4663."
"6334","PC111721P1","Lo S-T, Kumar A, Hsieh J-T, et al.  2013.  Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry.  Mol Pharm 10:793-812.

"
"6335","PC111721P1","Hao G, Kumar A, Dobin T, et al.  2013.  A multivalent approach of imaging probe design to overcome an endogenous anion binding competition for noninvasive assessment of prostate specific membrane antigen.  Mol Pharm 10:2975-2985."
"6336","PC111721P1","Liu HH, Tsai YS, Lai CL, et al.  2014.  Evolving avenue of personalized therapy for castration-resistant prostate cancer.  BIoMed 4:e7-15."
"6337","PC111721P1","Kumar A, Zhang S, Hao G, et al. 2015. Molecular Platform for Design and Synthesis of Targeted Dual-modality Imaging Probes.Bioconjug Chem. 26(3): 549-558. doi: 10.1021/acs.bioconjchem.5b00028."
"6338","PC111721P1","Lo ST, kumar A, and Sun X. 2015. Delivery and controlled release of therapeutics via dendrimer scaffolds. Nanoparticle Delivery of Biotherapeutics. 2(10): 14-28. doi: 10.4155/9781910420430."
"6339","PC111721P1","Singh AN, Dakanali M, Hao G, et al. 2014. Enantiopure bifunctional chelators for copper radiopharmaceuticals - Does chirality matter in radiotracer design. Eur J Med Chem. 80: 308-315. doi: 10.1016/j.ejmech.2014.04.071."
"6340","PC111721P1","Kumar A, Mastren T,Wang B, et al.  2016.  Design of small-molecule drug conjugates for prostate cancer targeted theranostics.  Bioconjug. Chem. 27:1681-1699."
"6341","PC111721P2","2017 Nanoparticle Effects on Human Platelets in Vitro:A Comparison between PAMAM and Triazine Dendrimers."
"6342","PC111721P2","2017 Facile synthesis of stable, water soluble, dendron-coated gold nanoparticles."
"6343","PC111721P2","Ramírez-Crescencio F, Enciso AE, Hasan M, et al.  2016.  Thermoregulated coacervation, metal-encapsulation and nanoparticle synthesis in novel Triazine dendrimers.  Molecules 21(5). pii: E599."
"6344","PC111721P2","Enciso AE, Garzoni M, Giovanni M, et al.  2015.  Influence of linker groups on the solubility of triazine dendrimers.  New J Chem 39:1247."
"6345","PC111721P2","Enciso AE, Ramirez-Crescencio F, Zeiser M, et al.  2015.  Accelerated synthesis of large generation triazine dendrimers using microwave assisted reactions: A 24-hour challenge. Polymer Chem 6(29):5219-5224."
"6346","PC111721P2","Lee C, Ji K, and Simanek EE.  2016.  Functionalization of a triazine dendrimer presenting four maleimides on the periphery and a DOTA group at the core.  Molecules 21(3). pii: E335."
"6347","PC111721P2","Ji K, Lee CS, Janesko BG, et al.  2015.  Triazine-substituted and Acyl Hydrazones:  Experiment and computation reveal a stability inversion at low pH.  Mol Pharm 12(8):2924-2927."
"6348","PC111721P2","Hao G, Kumar A, Dobin T, et al.  2013.  A multivalent approach of imaging probe design to overcome an endogenous anion binding competition for noninvasive assessment of prostate specific membrane antigen.  Mol Pharm 10:2975-2985."
"6349","PC111721P2","Lo S-T, Kumar A, Hsieh J-T, et al.  2013.  Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry.  Mol Pharm 10:793-812."
"6350","PC111721P2","Kostiainen M, Maly J, da Costa CP, et al.  2013.  Synthesis of large dendrimers with the dimensions of small viruses.  J Am Chem Soc 135:4660-4663."
"6351","PC111729","Kim W, Barron DA, Martin RS, et al.  RUNX1 is essential for mesenchymal stem cell proliferation and myofibroblast differentiation.  PNAS 111(46):16389-16394."
"6352","PC111750","Zitnay JL, Li Y, Qin Z, et al. 2017. Molecular level detection and localization of mechanical damage in collagen enabled by collagen hybridizing peptides. Nature Communication 8. doi: 10.1038/ncomms14913."
"6353","PC111750","Hwang J, Huang Y, Burwell TJ, et al. 2017. In situ imaging of tissue remodeling with collagen hybridizing peptides. ACS Nano 11(10): 9825-9835. doi: 10.1021/acsnano.7b03150."
"6354","PC111750","Li Y, San BH, Kessler JL, et al. 2015. Non-covalent photo-patterning of gelatin matrices using caged collagen mimetic peptides. Macromolecular Bioscience 15(1): 52-62. doi: 10.1002/mabi.201400436."
"6355","PC111750","Santos JL, Li Y, Culver HR, et al. 2014. Conducting polymer nanoparticles decorated with collagen mimetic peptides for collagen targeting. Chem Commun (Camb). 50(95): 15045-15048. doi: 10.1039/c4cc06056c."
"6356","PC111750","Bennink LL, Smith DJ, Foss CA, et al. 2017. High Serum Stability of Collagen Hybridizing Peptides and Their Fluorophore Conjugates. Molecular Pharmaceutics 14(6): 1906–1915. doi: 10.1021/acs.molpharmaceut.7b00009."
"6357","PC111750","Stahl PJ and Yu SM.  2012.  Encoding cell-instructive cues to PEG-based hydrogels via triple helical peptide assembly.  Soft Matter 8:10408."
"6358","PC111750","Li Y, San BH, Kessler JL, et al.  2015.  Non-covalent photopatterning of gelatin matrices using caged collagen mimetic peptides.  Macromolecular Bioscience 15:52-62."
"6359","PC111750","Santos JL, Li Y, Culver HS, et al.  2014.  Conducting polymer nanoparticles decorated with collagen mimetic peptides for collagen targeting.  Chem. Commun 50:15045-15048."
"6360","PC111750","Chan TR, Stahl PJ, Li Y, et al.  2015.  Collagen-gelatin mixtures as wound model, and substrates for VEGF-mimetic peptide binding and endothelial cell activation.  Acta Biomaterialia 15:164-172."
"6361","PC111750","Li Y and Yu SM.  2013.  Targeting and mimicking collagens via triple helical peptide assembly.  Curr Opin Chem Biol 17(6):968-975."
"6362","PC111750","Li Y, Foss CA, Pomper MG, et al.  2014.  Imaging denatured collagen strands in vivo and ex vivo via photo-triggered hybridization of caged collagen mimetic peptides.  J Vis Exp 31(83):e51052."
"6363","PC111750","Li Y, Foss CA, Summerfield DD, et al.  2012.  Targeting collagen strands by photo-triggered triple helix hybridization.  Proc Nat Acad Sci USA 109:14767.

"
"6364","PC111750","Li Y, Ho D, Meng H, et al.  2013.  Direct detection of collagenous proteins by fluorescently labeled collagen mimetic peptides.  Bioconj Chem 24:9."
"6365","PC111750","Hwang J, San BH, Turner NJ, et al. 2017. Molecular assessment of collagen denaturation in decellularized tissues using a collagen hybridizing peptide. Acta Biomaterialia 53: 268–278. doi: 10.1016/j.actbio.2017.01.079."
"6366","PC111750","Wahyudi H, Reynolds AA, Li Y, et al. 2016. Targeting collagen for diagnostic imaging and therapeutic delivery. J Control Release 240: 323-331. doi: 10.1016/j.jconrel.2016.01.007."
"6367","PC111750","San BH, Hwang J, Sampath S, et al. 2017. Self-assembled water-soluble nanofibers displaying collagen hybridizing peptides. J. Am. Chem. Soc. 139(46): 16640-16649. doi: 10.1021/jacs.7b07900."
"6368","PC111807","Liu W. 2016. DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer. Asian J Androl. 18(4): 533-542. doi: 10.4103/1008-682X.177120."
"6369","PC111807","Rodrigues LU, Rider L, Nieto C, et al. 2015. Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer. Cancer Res. 75(6): 1021–1034. doi:10.1158/0008-5472.CAN-14-1596."
"6370","PC111812","Phua KK, Leong KW, and Nair K.  2013.  Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format.  J Control Release 28;166(3):2270-2333."
"6371","PC111812","Phua KK, Staats HF, Leong KW, et al.  2014.  Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity.  Sci Rep 4:5128."
"6372","PC111812","Phua KK, Nair SK, and Leong KW.  2014.  Messenger RNA (mRNA) nanoparticle tumor vaccination.  Nanoscale 6(14):7715-7729."
"6373","PC111812","Lao YH, Phua KK, and Leong KW.  2015.  Aptamer nanomedicine for cancer therapeutics: Barriers and potential for translation.  ACS Nano 9(3):2235-2254."
"6374","PC111812","Phua KK, Boczkowski D, Dannull J, et al.  2014.  Whole blood cells loaded with messenger RNA as an anti-tumor vaccine.  Adv Healthc Mater 3(6):837-842."
"6375","PC111812P1","Phua KK, Boczkowski D, Dannull J, et al.  2014.  Whole blood cells loaded with messenger RNA as an anti-tumor vaccine.  Advanced Healthcare Materials 3(6):837-842."
"6376","PC111812P1","Lao YH, Phua KK, and Leong KW.  2015.  Aptamer nanomedicine for cancer therapeutics: Barriers and potential for translation.  ACS Nano 9(3):2235-2254."
"6377","PC111812P1","Phua, KK, Nair SK, Leong KW.  2014.  Messenger RNA (mRNA) nanoparticle tumor vaccination.  Nanoscale 6(14):7715-7729."
"6378","PC111812P1","Phua KK, Staats HF, Leong KW, et al.  2014.  Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity.  Scientific Reports 4:5128."
"6379","PC111812P1","Phua KK, Leong KW, Nair SK, et al.  2013.  Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format.  J Control Release 166(3):227-233."
"6380","PC111812P2","Phua KK, Nair SK, and Leong KW.  2014.  Messenger RNA (mRNA) nanoparticle tumor vaccination.  Nanoscale 6(14):7715-7729."
"6381","PC111812P2","Phua KK, Staats HF, Leong KW, et al.  2014.  Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity.  Scientific Reports 4:5128."
"6382","PC111812P2","Phua KK, Boczkowski D, Dannull J, et al.  2014.  Whole blood cells loaded with messenger RNA as an anti-tumor vaccine.  Advanced Healthcare Materials 3(6):837-842."
"6383","PC111812P2","Phua KK, Leong KW, and Nair SK.  2013.  Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format.  J Control Release 28:166(3):227-233."
"6384","PC111812P2","Lao YH, Phua KK, and Leong KW.  2015.  Aptamer nanomedicine for cancer therapeutics: Barriers and potential for translation.  ACS Nano 9(3):2235-2254."
"6385","PC111832","Wolfe T, Chatterjee D, Lee J, et al.  2015.  Targeted gold nanoparticles enhance sensitization of prostate tumors to megavoltage radiation therapy in vivo.  Nanomedicine 11(5):1277-1283."
"6386","PC111832","Reynoso FJ, Manohar N, Krishnan S, et al.  2014.  Design of a Yb-169 source optimized for gold nanoparticle-aided radiation therapy.  Med Phys 41(10):101709."
"6387","PC111832","Reynoso FJ, Munro Iii JJ and Cho SH. 2017. Technical Note: Monte Carlo calculations of the AAPM TG-43 brachytherapy dosimetry parameters for a new titanium encapsulated Yb-169 source. J Appl Clin Med Phys. 18(4): 193-199. doi: 10.1002/acm2.12111."
"6388","PC111860","Sheng Weng, Xiaoyun Xu, Jiasong Li, and Stephen T. C. Wong, 'Combining deep learning and coherent anti-Stokes Raman scattering imaging for automated differential diagnosis of lung cancer,' J Biomed Opt. 2017 Oct;22(10):1-10"
"6389","PC111867","Johnson KJ, Mitra S, Katoch P, et al.  2013.  Phosphorylation on Serines 279 and 282 of connexin43 regulates endocytosis and gap junction assembly in pancreatic cancer cells.  Mol Biol Cell 24:715-733."
"6390","PC111867","Katoch P, Mitra S, Ray A, et al.  2015.  The carboxyl tail of Connexin32 regulates gap junction assembly in human prostate and pancreatic cancer cells.  J Biol Chem 290:4647-4662."
"6391","PC111867","Kelsey L, Katoch P, Johnson, KE, et al.  2012.  Retinoids regulate the formation and degradation of gap junctions in androgen-responsive human prostate cancer cells.  PLoS ONE 7:e32846."
"6392","PC111867","Kelsey LS, Katoch P, Ray M, et al.  2014.  Vitamin D3 regulates the formation and degradation of gap junctions in androgen-responsive human prostate cancer cells.  PLoS One 9(9):e106437."
"6393","PC111867P1","Johnson KJ, Mitra S, Katoch P, et al.  2013.  Phosphorylation on Serines 279 and 282 of connexin43 regulates endocytosis and gap junction assembly in pancreatic cancer cells.  Mol Biol Cell 24:715-733."
"6394","PC111867P1","Kelsey L, Katoch P, Johnson, KE, et al.  2012.  Retinoids regulate the formation and degradation of gap junctions in androgen-responsive human prostate cancer cells.  PLoS ONE 7:e32846."
"6395","PC111867P1","Kelsey, LS; Katoch P, Ray Mitra S, et al.  2014 .  Vitamin D3 regulates the formation and degradation of gap junctions in androgen-responsive human prostate cancer cells.  PLoS ONE 9:e106437."
"6396","PC111867P1","Katoch P, Mitra S, Ray A, et al.  2015.  The carboxyl tail of connexin32 regulates gap junction assembly in human prostate and pancreatic cancer cells.  J Biol Chem 290:4647-4662."
"6397","PC111877","Mayers J, Wu C, Clish C, et al.  2014.  Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development.  Nature medicine 20(10): PMID: 25261994."
"6398","PC111877","Machiela MJ, Lindström S, Allen NE, et al.  2012.  Association of type 2 diabetes susceptibility variants with advanced prostate cancer risk in the breast and prostate cancer cohort consortium.  Am J Epidemiol 176(12):1121-1129."
"6399","PC111877","Song Y, Chavarro JE, Cao Y, et al.  2013.  Whole milk intake is associated with prostate cancer- specific mortality among U.S. male physicians.  J Nutr 143(2): PMID:23256145."
"6400","PC111877","Cao Y, Lindström S, Schumacher F, et al.  2014.  Insulin-like growth factor (IGF) pathway genetic polymorphisms, circulating IGF1 and IGFBP3 levels and prostate cancer survival.  JNCI 106(6): PMID: 24824313."
"6401","PC111969","Antonarakis ES, Lu C, Wang H, et al.  2014.  AR-V7 and resistance to Enzalutamide and Abiraterone in prostate cancer.  N Engl J Med 371(11):1028-1038."
"6402","PC111969","Nakazawa M, Lu C, Chen Y, et al.  2015.  Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.  Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 5:26(9):1859-1865."
"6403","PC111969","Antonarakis ES, Lu C, Luber B, et al.  2015.  Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer.  JAMA Oncology 1(5):582-591."
"6404","PC112000","Zhang A, Zhang J, Plymate S, et al.  2016.  Classical and non-classical roles for pre-receptor control of DHT metabolism in prostate cancer progression.  Horm Cancer 7:104-113."
"6405","PC112000","Mostaghel EA, Zhang A, and Plymate.  2016.  UDP-glucuronosyltransferase enzymes in prostate cancer progression: Is only androgen catabolism involved?  EAU 69:610-612."
"6406","PC112061","Joshu CE, Peskoe SB, Heaphy CM, et al. 2018. Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells. Prostate 78(3): 233-238. doi: 10.1002/pros.23462."
"6407","PC112061","Julin B, Shui I, Heaphy CM, et al.  2015.  Circulating leukocyte telomere length and risk of overall and aggressive prostate cancer.  Br J Cancer 112(4):769-776."
"6408","PC112061","Joshu CE, Peskoe SB, Heaphy CM, et al.  2015.  Prediagnostic obesity and physical inactivity are associated with shorter telomere length in prostate stromal cells.  Cancer Prev Res 8(8):737-742."
"6409","PC112093","Johnson LE, Brockstedt D, Leong M, et al. 2018. Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and Listeria vaccines elicits superior anti-tumor immunity dependent on CD4+ T cells elicited by DNA priming. Oncoimmunology 7(8): e1456603. doi: 10.1080/2162402X.2018.1456603."
"6410","PC120116","Yu Z, Chen S, Sowalsky AG, et al.  2014.  Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.  Clin Cancer Res. 20(6):1590-1600."
"6411","PC120116","Sowalsky A, Sager R, Schaefer R, et al.  2015.  Loss of wave1 gene defines a subtype of lethal prostate cancer.  Oncotarget 6:12383-12391."
"6412","PC120116","Sowalsky AG, Xia Z, Wang L, et al.  2015.  Whole transcriptome sequencing reveals extensive unspliced mrna in metastatic castration-resistant prostate cancer.  Mol Cancer Res 13(1):98-106."
"6413","PC120116","Chen E, Sowalsky AG, Gao S, et al.  2015.  Treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.  Clin Cancer Res 21(6):1273-1280."
"6414","PC120233","Simões RV, Veeraperumal S, Serganova IS, et al. 2017. Inhibition of prostate cancer proliferation by Deferiprone. NMR Biomed. 30(6). doi: 10.1002/nbm.3712."
"6415","PC120233","Leftin A, Zhao H, Turkekul M, et al. 2017. Iron Deposition is Associated with Differential Macrophage Infiltration and Therapeutic Response to Iron Chelation in Prostate Cancer. Scientific Reports. 7(1): 11632. doi. 10.1038/s41598-017-11899-2."
"6416","PC120241","Crowell PD, Fox JJ, Hashimoto T, Diaz JA, Navarro HI, Henry GH, Feldmar BA, Lowe MG, Garcia AJ, Wu YE, et al. Expansion of Luminal Progenitor Cells in the Aging Mouse and Human Prostate. Cell Rep. 2019 Aug 6;28(6):1499-1510.e6. doi: 10.1016/j.celrep.2019.07.007. PubMed PMID: 31390564; PubMed Central PMCID: PMC6710009."
"6417","PC120241","Crowell PD and Goldstein AS. 2017. Functional evidence that progenitor cells near sites of inflammation are precursors for aggressive prostate cancer. Mol Cell Oncol 4(2). doi: 10.1080/23723556.2017.1279723."
"6418","PC120387","Gao S, Ye H, Gerrin S, et al.  2016.  ErbB2 signaling increases androgen receptor expression in abiraterone-resistant Prostate Cancer.  Clin Cancer Res 22:3672-3682."
"6419","PC120387","Liu X, Han W, Gulla S, et al.  2016.  Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation.  Oncotarget 7:1754-1764."
"6420","PC120387","Yu Z, Cai C, Gao S, et al.  2014.  Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.  Clin Cancer Res 20:4075-4085."
"6421","PC120464","Kadakia KC, Tomlins SA, Sanghyi SK, et al.  2015.  Comprehensive serial molecular profiling of an 'N of 1' exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.  J Hematol Oncol 8:109."
"6422","PC120464","Hovelson DH, McDaniel AS, Cani AK, et al.  2015.  Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.  Neoplasia 17(4):385-399."
"6423","PC120466","Yang YA, and Yu J.  2015.  Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer.  Genes Dis 2(2):144-151."
"6424","PC120466","Yang YA, Kim J, and Yu J.  2014.  Influence of oncogenic transcription factors on chromatin conformation and implicaitons in prostate cancer.  Appl Clin Genet 7:81-91."
"6425","PC120466","Jin JH, Zhao JC, Wu L, et al.  2014.  Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program.  Nat Commun 5:3972."
"6426","PC120466","Yang YA, Zhao JC, Fong KW, et al. 2016.   FOXA1 potentiates lineage-specific enhancer activation through modulating TET1 expression and function.  Nucleic Acids Res 44(17):8153-8164."
"6427","PC120466","Yeqing Angela Yang , ung Kim, Jindan Yu , Influence of oncogenic transcription factors on chromatin conformation and implications
in prostate cancer .The Application of Clinical Genetics 2014:7 81–91"
"6428","PC120466","Xue XY, Yang YA, Zhang A, et al.  2016.  LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer.  Oncogene 35(21):2746-2755."
"6429","PC120481","Feng S, Wang J, Zhang Y, et al.  2015.  FGF23 promotes prostate cancer progression.  Oncotarget 6(19):17291-17301."
"6430","PC120489","Levenson AS, Kumar A, Zhang X.  2014.  MTA1 family proteins in prostate cancer: Biology, significance and therapeutic opportunities.  Cancer Metastasis Rev 33:929-942."
"6431","PC120489","Dhar S, Kumar A, Li K, et al.  2015.  Resveratrol regulates PTEN/Akt pathway through inhibition of MTA1/HDAC unit of the NuRD complex in prostate cancer.  BBA Molecular Cell Research 1853:265-275."
"6432","PC120489","Kumar A, Lin S-Y, Rimando AM, et al.  2014.  Plant-derived stilbenes inhibit androgen receptor expression in 22RV1 castrate-resistant prostate cancer cell line.  Journal of Medicinally Active Plants (JMAP) 3(1):1-8."
"6433","PC120489","Dhar S, Kumar A, Li K, et al.  2015.  Resveratrol regulates PTEN/Akt pathway through inhibition of MTA1/HDAC unit of the NuRD complex in prostate cancer.  BBA Mol Cell Res 1853:265-275."
"6434","PC120489","Dhar S, Kumar A, Rimando AM, et al.  2015.  Resveratrol and pterostilbene epigenetically restore PTEN expression by targeting oncomiRs of the miR-17 family in prostate cancer.  Oncotarget 6: 27214-27226."
"6435","PC120489","Kumar A, Dhar S, Rimando AM, et al.  2015.  Epigenetic potential of resveratrol and analogs in preclinical models of prostate cancer.  Ann N Y Acad Sci 1348(1):1-9."
"6436","PC120489","Kumar A, Lin S-Y, Rimando AM, et al.  2014.  Stilbenes inhibit androgen receptor expression in 22RV1 castrate-resistant prostate cancer cell line.  Journal of Medicinally Active Plants 3(1):1-8."
"6437","PC120512","Hu CD, Choo R, and Huang J.  2015.  Neuroendocrine differentiation in prostate cancer: A mechanism of radioresistance and treatment failure.  Front Oncol 5:90."
"6438","PC120512","Zhang HT, Zhang D, Zha ZG, et al.  2014.  Transcriptional activation of PRMT5 by NF-Y is required for cell growth and negatively regulated by the PKC/c-Fos signaling in prostate cancer cells.  Biochim Biophys Acta 1839:1330-1340."
"6439","PC120512","Suarez CD, Deng X, and Hu CD.  2014.   Targeting CREB inhibits radiation-induced neuroendocrine differentiation and increases radiation-induced cell death in prostate cancer cells.  Am J Cancer Res 4:850-861."
"6440","PC120512","Zhang H, Zeng L, Tao AW, et al.  2016.  The E3 ubiquitin ligase CHIP mediates  ubiquitination and proteosomal degradation of PRMT5.  Biochem Biophys Acta 1863:336-346."
"6441","PC120532","Rakow-Penner RA, White NS, Margolis DJA, et al.  2015.  Prostate diffusion imaging with distortion correction.  Magnetic Resonance Imaging 33(9):1178-1181."
"6442","PC120532","McCammack KC, Kane CJ, Parsons JK, et al.  2016.  In vivo prostate cancer detection and grading using restriction spectrum imaging-MRI.  Prostate Cancer Prostatic Dis 19:168-173."
"6443","PC120532","White NS, McDonald CR, Farid N, et al.  2014.  Diffusion-weighted imaging in cancer: physical foundations and applications of restriction spectrum imaging.  Cancer Res 74(17):4638-4652."
"6444","PC120532","Liss MA, White NS, Parsons JK, et al.  2015.  Restriction spectrum imaging cellularity index is associated with high grade prostate cancer on radical prostatectomy specimens.  Frontiers in Oncology 5:30."
"6445","PC120532","Yamin G, Schenker-Ahmed NM, Shabaik A, et al.  Voxel level radiologic-pathologic validation of restriction spectrum imaging cellularity index with gleason grade in prostate cancer.  Clin Cancer Res 22(11):2668-2674."
"6446","PC120532","Rakow-Penner RA, White NS, Parsons JK, et al.  2015.  Novel technique for characterizing prostate cancer utilizing MRI restriction spectrum imaging: proof of principle and initial clinical experience with extra-prostatic extension.  Prostate Cancer Prostatic Dis 18:81-85."
"6447","PC120577","Yu Z, Chen S, Sowalsky AG, et al.  2014.  Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.  Clin Cancer Res 20(6):1590-1600."
"6448","PC120577","Yu Z, Cai C, Gao S, et al.  2014.  Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.  Clin Cancer Res 20(15):4075-4085."
"6449","PC120587","Roberts JM, Martin RS, Piyarathna DB, et al. 2017.  Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG. Oncotarget. 8(27): 44447-44464. doi: 10.18632/oncotarget.17968."
"6450","PC120587","Kim JS, Roberts JM, Bingman WE, et al.  2014.  The prostate cancer TMPRSS2:ERG fusion synergizes with the Vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling.  Endocrinology 155(9):3262-3273."
"6451","PC120653","Ishiguro H, Izumi K, Kashiwagi E, et al.  2015.  Semenogelin I promotes prostate cancer cell growth via functioning as an androgen receptor coactivator and protecting against zinc cytotoxicity.  Am J Cancer Res 5(2):738-747."
"6452","PC120720","Ding Y, Li J, Xiao W, et al.  2015.  Microfluidic-enabled print-to-screen (P2S) platform for high-throughput screening of combinatorial chemotherapy.  Anal Chem 87(20):10166-10171."
"6453","PC120803","Morais CL, Han JS, Gordetsky J, et al.  2015.  Utility of PTEN and ERG immunostaining for distinguishing high grade PIN and intraductal carcinoma of the prostate on needle biopsy.  American J Surgical Path 39(2):169-178."
"6454","PC120803","Lotan TL, Wei W, Ludkovski O, et al.  2016.  Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison to PTEN FISH.  Modern Path 29(8):904-914."
"6455","PC120803","Morais CL Guedes LB, Hicks J, et al.  2016.  ERG and PTEN status of isolated high grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma.  Human Path 55:117-125."
"6456","PC120817","Rycaj K, Cho EJ, Liu X, et al.  2016.  Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSA-/lo castration-resistant cells.  Oncotarget 7(12):14220-14240."
"6457","PC120817","Rycaj K, and Tang DG.  2016.  Metastasis and metastatic cells: A historical perspective and current analysis.  In: Cancer Stem Cells: Targeting the Roots of Cancer, Seeds of Metastasis, and Sources of Therapy Resistance (Liu H, and Lathia JD, Eds).  Academic Press, Elsevier.  Pp317-340."
"6458","PC120817","Liu X, Chen X, Rycaj K, et al.  2015.  Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells.  Oncotarget 6(27):23959-23986."
"6459","PC120817","Gong S, Li Q, Jeter CR, et al.  2015.  Regulation of NANOG in cancer cells.  Mol Carcinog 54(9):679-687."
"6460","PC120817","Zhang D, Lin K, Lu Y, et al.  2017.  Developing a novel two-dimensional culture system to enrich human prostate luminal progenitors that can function as a cell of origin for prostate cancer.  Stem Cells Transl Med 6(3):748-760."
"6461","PC120817","Liu R, Liu C, Zhang D, et al.  2016.  miR-199a-3p targets stemness-related and mitogenic signaling pathways to suppress the expansion and tumorigenic capabilities of prostate cancer stem cells.  Oncotarget 7(35):56628-56642."
"6462","PC120817","Zhang D, Park D, Zhong Y, et al.  2016.  Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer.  Nat Commun 7:10798."
"6463","PC120817","Shi Y, Liu C, Liu X, et al. 2014. The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells. PLoS One. 9(3):e90022."
"6464","PC120817","Gong S, Li Q, Jeter CR, et al.  2015.  Regulation of NANOG in cancer cells.  Mol Carcinog 54(9):679-687."
"6465","PC120817","Liu X, Chen X, Rycaj K, et al.  2015.  Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells.  Oncotarget 6(27):23959-23986."
"6466","PC120817","Rycaj K and Tang DG.  2015.  Cell-of-origin of cancer versus cancer stem cells: Assays and interpretations.  Cancer Res 75(19):4003-4011."
"6467","PC120817","Li Q, Rycaj K, Chen X, et al.  2015.  Cancer stem cells and cell size: A causal link?  Semin Cancer Biol 35:191-199."
"6468","PC120817","Jeter CR, Yang T, Wang J, et al.  2015.  NANOG in cancer stem cells and tumor development: An update and outstanding questions.  Stem Cells 33(8):2381-2390."
"6469","PC120817","Deng Q and Tang DG.  2015.  Androgen receptor and prostate cancer stem cells: Biological mechanisms and clinical implications.  Endocr Relat Cancer 22(6):T209-T220."
"6470","PC120820","Liu C, Stonestrom AJ, Christian T, et al.  2016.  Molecular basis and consequences of the Cytochrome c-tRNA interaction.  J Biol Chem 291(19):10426-10436."
"6471","PC120820","Hou YM, and Yang X.  2013.  Regulation of cell death by transfer RNA.  Antioxid Redox Signal 19(6):583-594."
"6472","PC120857","Leo P, Lee G, Shih N, et al.  2016.  Evaluating stability of histomorphometric features across scanner and staining variations: prostate cancer diagnosis from whole slide images.  J Med Imaging (Bellingham). 3(4):047502 (PMID: 27803941)."
"6473","PC120857","Lee G, Romo-Bucheli DE and Madabhushi A.  2016.  Adaptive dimensionality reduction with semi-supervision (AdDReSS):  Classifying multi-attribute biomedical data.  PLoS One 11(7):e0159088."
"6474","PC120857","Lu C, Xu H, Xu J, et al.  2016.  Multi-pass adaptive voting for nuclei detection in histopathlogical images.  Sci Rep 6:33985."
"6475","PC120857","Xu J, Luo X, Wang G, et al.  A deep convolutional neural network for segmenting and classifying epithelial and stromal regions in histopathological images.  Neurocomputing 191:214-223."
"6476","PC120857","Penzias G, Janowczyk A, Singanamalli A, et al.  2016.  AutoStitcher:  An automated program for efficient and robust reconstruction of digitized whole histological sections from tissue fragments.  Nature Sci Rep 6:29906."
"6477","PC120857","Janowczyk A, Basavanhally A and Madabhushi A.  2016.  Stain normalization using sparse AutoEncoders (StaNoSA):  Application to digital pathology.  Comput Med Imaging Graph S0895-6111(16)30040-4."
"6478","PC120857","Sparks R and Madabhushi A.  2016.  Out-of-sample extrapolation utilizing semi-supervised manifold learning (OSE-SSL):  Content based image retrieval for histopathology images.  Nature Sci Rep 6:27306."
"6479","PC120857","Zhu G, Liu Z, Epstein JI, et al.  2015.  A novel quantitative multiplex tissue immunoblotting for biomarkers predicts a prostate cancer aggressive phenotype.  Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 24(12):1864-1872."
"6480","PC120857","Madabhushi A and Lee Ge.  2016.  Image analysis and machine learning in digital pathology: challenges and opportunities.  Med Image Anal S1361- 8415(16)30114-1."
"6481","PC120857","Bhargava R and Madabhushi A.  2016.  Emerging themes in image informatics and molecular analysis for digital pathology.  Annu Rev Biomed Eng 18:387-412 (PMID: 27420575)."
"6482","PC120857","Lee G, Veltri RW, Zhu G, et al.  2016.  Nuclear shape. architecture in benign fields predict biochemical recurrence in prostate cancer patients following radical prostatectomy:  Preliminary findings.  Eur Urol Focus doi:10.1016/j.euf.2016.05.009."
"6483","PC120857","Toth R, Feldman M Yu D, et al.  2014.  Histostitcher¿: An informatics software platform for reconstructing whole-mount prostate histology using the extensible imaging platform (XIP¿ ) framework,  Journal of Pathology Informatics 28;5:8."
"6484","PC120857","Rusu M, Bloch BN, Jaffe C, et al.  2014.  Prostatome: A combined anatomical and disease based MRI atlas of the prostate.  Medical Physics 41(7):072301."
"6485","PC120857","Ginsburg S, Bloch BN, Genega E, et al.  2015.  A novel PCA-VIP scheme for ranking MRI protocols and identifying computer extracted MRI measurements associated with central gland and peripheral zone prostate tumors.  Journal of Magnetic Resonance Imaging 41(5):1383-1393."
"6486","PC120857","Veltri RW and Christudass CS.  2014.  Nuclear morphometry, epigenetic changes, and clinical relevance in prostate cancer.  Adv Exp Med Biol 773:77-79."
"6487","PC120857","Tian Y, Choi CH, Li QK, et al.  2015.  Overexpression of periostin in stroma positively associated with aggressive prostate cancer:  A multi-institutional study.  PLoS One 10(3):e0121502."
"6488","PC120857","Sparks R, and Madabhushi A.  2015.  Statistical shape model for manifold regularization: gleason grading of prostate histology.  Computer Vision and Image Understanding Special Issue on Machine Learning in Medical Imaging, 117(9):1138-1146."
"6489","PC120857","Lee G, Ali S, Veltri R, et al.  2013.  Cell orientation entropy (COrE): Predicting biochemical recurrence from prostate cancer tissue microarrays.  Lect Note Comput Sc 8151:396-403."
"6490","PC120857","Ali S, Veltri R, Epstein JA, et al.  2013.  A cell cluster graph for prediction of biochemical recurrence in prostate cancer patients from tissue microarrays.  Proc Spie 8676."
"6491","PC120857","Verdone J, Princy P, Veltri RW, et al.  2015.  Epithelial-mesenchymal transition in prostate cancer is associated with quantifiable changes in nuclear structure.  Prostate 75(2):218-224."
"6492","PC120857","Kianercy A, Veltri R and Pienta K.  2014.  Critical transitions in a game theoretic model of tumour metabolism.  Interface Focus 4(4):20140014."
"6493","PC120857","Litjens G Toth R, van de Ven W, et al.  2014.  Evaluation of prostate segmentation algorithms for MRI: the PROMISE12 challenge.  Medical Image Analysis 18(2):359-373."
"6494","PC120857","Lee G, Sparks R, Ali S, et al.  2014.  Co-occurring gland tensors in localized subgraphs: predicting biochemical recurrence in intermediate-risk prostate cancer patients.   PLOS ONE, 9(5):e97954."
"6495","PC120857","Leo P, Lee G, Shih NNC, et al.  2016.  Evaluating stability of histomorphometric features across scanner and staining variations: prostate cancer diagnosis from whole slide images.  J Med Imaging Bellingham Wash 3(4):47502."
"6496","PC120857","Sparks R, and Madabhushi A.  2015.  Explicit shape descriptors: Novel morphologic features for histopathology classification medical image analysis.  Medical Image Analysis 7(8):997-1009."
"6497","PC120857","Janowczyk A and Madabhushi A.  2016.  Deep learning for digital pathology image analysis:  A comprehensive tutorial with selected use cases.  J Pathol Inform 7:29."
"6498","PC120857P1","Leo P, Lee G, Shih N, et al.  2016.  Evaluating stability of histomorphometric features across scanner and staining variations: prostate cancer diagnosis from whole slide images.  J Med Imaging (Bellingham) 3(4):047502 (PMID: 27803941)."
"6499","PC120857P1","Lu C, Xu H, Xu J, et al.  2016.  Multi-pass adaptive voting for nuclei detection in histopathlogical images.  Sci Rep 6:33985.  doi: 10.1038/srep33985 (PMID: 27694950)."
"6500","PC120857P1","Lee G, Sparks R, Ali S, et al.  2014.  Co-occurring gland tensors in localized subgraphs: predicting biochemical recurrence in intermediate-risk prostate cancer patients.   PLOS ONE, 9(5):e97954."
"6501","PC120857P1","Ginsburg S, Bloch BN, Genega E, et al.  2015.  A novel PCA-VIP scheme for ranking MRI protocols and identifying computer extracted MRI measurements associated with central gland and peripheral zone prostate tumors.  J Magn Reson Imaging 45(5):1383-1393."
"6502","PC120857P1","Rusu M, Bloch BN, Jaffe C, et al.  2014.  Prostatome: A combined anatomical and disease based MRI atlas of the prostate.  Medical Physics 41(7):072301."
"6503","PC120857P1","Toth R, Feldman M Yu D, et al.  2014.  Histostitcher¿: An informatics software platform for reconstructing whole-mount prostate histology using the extensible imaging platform (XIP) framework,  Journal of Pathology Informatics 28;5:8."
"6504","PC120857P1","Litjens G Toth R, van de Ven W, et al.  2014.  Evaluation of prostate segmentation algorithms for MRI: the PROMISE12 challenge.  Medical Image Analysis 18(2):359-373."
"6505","PC120857P1","Sparks R, and Madabhushi A.  2015.  Explicit shape descriptors: Novel morphologic features for histopathology classification medical image analysis.  Medical Image Analysis 7(8):997-1009."
"6506","PC120857P1","Sparks R, and Madabhushi A.  2015.  Statistical shape model for manifold regularization: gleason grading of prostate histology.  Computer Vision and Image Understanding Special Issue on Machine Learning in Medical Imaging, 117(9):1138-1146."
"6507","PC120857P1","Lee G, Romo-Bucheli DE and Madabhushi A.  2016.  Adaptive dimensionality reduction with semi-supervision (AdDReSS):  Classifying Multi-attribute Biomedical Data.  PLoS One 11(7):e0159088.  doi: 10.1371/journal.pone.0159088."
"6508","PC120857P1","Zhu G, Liu Z, Epstein JI, et al.  2015.  A novel quantitative multiplex tissue immunoblotting for biomarkers predicts a prostate cancer aggressive phenotype.  Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 24(12):1864-1872."
"6509","PC120857P1","Xu J, Luo X, Wang G, et al.  A deep convolutional neural network for segmenting and classifying epithelial and stromal regions in histopathological images.  Neurocomputing 191:214-223."
"6510","PC120857P1","Janowczyk A and Madabhushi A.  2016.  Deep learning for digital pathology image analysis:  A comprehensive tutorial with selected use cases.  J Pathol Inform 7:29.  doi: 10.4103/2153-3539.186902.  eCollection (PMID: 27563488)."
"6511","PC120857P1","Madabhushi A and Lee G.  2016.  Image analysis and machine learning in digital pathology: challenges and opportunities.  Med Image Anal S1361- 8415(16)30114-1.  doi: 10.1016/j.media.2016.06.037."
"6512","PC120857P1","Bhargava R and Madabhushi A.  2016.  Emerging themes in image informatics and molecular analysis for digital pathology.  Annu Rev Biomed Eng 18:387-412."
"6513","PC120857P1","Sparks R and Madabhushi A.  2016.  Out-of-sample extrapolation utilizing semi-supervised manifold learning (OSE-SSL):  Content based image retrieval for histopathology images.  Nature Sci Rep 6:27306."
"6514","PC120857P1","Janowczyk A, Basavanhally A and Madabhushi A.  2016.  Stain normalization using sparse autoencoders (StaNoSA):  Application to digital pathology.  Comput Med Imaging Graph S0895-6111(16)30040-4. doi: 10.1016/j.compmedimag..05.003."
"6515","PC120871","Wang W, Dong B, Ittmann MM, et al.  2016.  A versatile gene delivery system for efficient and tumor specific gene manipulation in vivo.  Discoveries 4;e58."
"6516","PC120872","Wang X, Yang Y, Jia H, et al.  2014.  Peptide decoration of nanovehicles to achieve active targeting and pathology-responsive cellular uptake for bone metastasis chemotherapy.  Biomater Sci 2:961-971."
"6517","PC120893","Moscat J, Richardson A, and Diaz-Meco M.T.  2015.  Nutrient stress revamps cancer cell metabolism.  Cell Res 25:537-538."
"6518","PC120893","Valencia T, Kim JY, Abu-Baker S, et al.  2014.  Metabolic reprogramming of stromal fibroblasts through p62-m TORC1 signaling promotes inflammation and tumorigenesis.  Cancer Cell 26(1):121-135."
"6519","PC120893P3","Moscat J, Richardson A, and Diaz-Meco M.T.  2015.  Nutrient stress revamps cancer cell metabolism.  Cell Res 25:537-538."
"6520","PC120893P3","Valencia T, Kim JY, Abu-Baker S, et al.  2014.  Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis.  Cancer Cell 26 121-135."
"6521","PC120893P3","Linares JF, Duran A, Reina-Campos M, et al.  2015.  Amino acid activation of mTORC1 by a PB1-domain-driven kinase complex cascade.  Cell Rep 12:1339-1352."
"6522","PC120946","Rogers HB, Anani T, Choi YS, et al.  2015.  Exploiting size-dependent drag and magnetic forces for size-specific separation of magnetic nanoparticles.  Intl J of Molecular Sciences 16:20001-20019."
"6523","PC121018","Reece AE, and Oakey J, et al.  2016.  Long-range forces affecting equilibrium inertial focusing behavior in straight high aspect ratio microfluidic channels.  Physics of Fluids 28:043303."
"6524","PC121018","Kaastrup K, Aguirre-Soto A, Wang C, et al.  2016.  UV-Vis/FT-NIR in-situ monitoring of visible-light induced polymerization of PEGDA hydrogels initiated by eosin/triethanolamine/O2.  Polymer Chem 7(3):592-602."
"6525","PC121018","Wong J, Kaastrup K, Aguirre-Soto A et al.  2015.  A quantitative analysis of peroxy- mediated cyclic regeneration of eosin in oxygen-rich photopolymerization conditions.  Polymer 69: 169-177."
"6526","PC121018","Hastrup K and Sikes HD.  2015.  Investigation of dendrimers functionalized with eosin as macrophotoinitiators for polymerization-based signal amplification reactions.  RSC Advances 5:15652-15659."
"6527","PC121018","McConnell JT, and Oakey J.  2016.  Observed and predicted particle dynamics driven by inertial flows within high aspect ratio microfluidic channels.  Microfluidics and Nanofluidics 20:22."
"6528","PC121018","Xia B, Liang Z Noren Z, et al.  2016.  Microfluidic single cell analysis.  Current Opinion in Biotechnology 40:90-96."
"6529","PC121018P1","Wong J and Sikes HD. 2016. The impact of continuous oxygen flux in a thin film photopolymerization reaction with peroxy-mediated regeneration of initiator.   Macromolecular Theory and Simulations. Volume 25, Issue 3 pages 229-237. DOI: 10.1002/mats.201500098"
"6530","PC121018P1","Kaastrup K and Sikes HD. 2015. Investigation of dendrimers functionalized with eosin as macrophotoinitiators for polymerization-based signal amplification reactions.  Royal Society of Chemistry Advances 5(20):15652-15659."
"6531","PC121018P1","Reece A, Kaastrup K, Sikes HD, et al. 2015. Staged inertial microfluidic focusing for complex fluid enrichment.  Royal Society of Chemistry Advances 5(66):53857-53864."
"6532","PC121018P1","Kaastrup K, Aguirre-Soto A, Wang C, et al. 2016. UV-Vis/FT-NIR in-situ monitoring of visible-light induced polymerization of PEGDA hydrogels initiated by eosin/triethanolamine/O2.  Polymer Chem 7:592-602."
"6533","PC121018P1","Wong J, Kaastrup K, Aguirre-Soto A et al.  2015.  A quantitative analysis of peroxy- mediated cyclic regeneration of eosin in oxygen-rich photopolymerization conditions.  Polymer 69:169-177."
"6534","PC121018P1","Kaastrup K and Sikes HD.  2015.  Investigation of dendrimers functionalized with eosin as macrophotoinitiators for polymerization-based signal amplification reactions.  RSC Advances 5:15652-15659."
"6535","PC121061","Brennen WN, Nguyen H, Dalrymple SL, et al.  2016.  Assessing angiogenic responses induced by primary human prostate stromal cells in a three-dimensional fibrin matrix assay. Oncotarget 7(44):71298-71308."
"6536","PC121061","Brennen WN, Kisteman LN, and Isaacs JT.  2016.  Rapid selection of mesenchymal stem and progenitor cells in primary prostate stromal cultures.  Prostate 76(6):552-564."
"6537","PC121061P1","Brennen WN, Kisteman LN, and Isaacs JT.  2016.  Rapid selection of mesenchymal stem and progenitor cells in primary prostate stromal cultures.  Prostate 76(6):552-564."
"6538","PC121086","Pollock CB, McDonough S, Want VS, et al.  2014.  Strigolactone analogues induce apoptosis through activation of p38 and the stress response pathway in cancer cell lines and in conditionally reprogrammed primary prostate cancer cells.  Oncotarget 5(6):1683-1698."
"6539","PC121086","Ringer L, Sirajuddin R, Tricoli L, et al.  2014.  The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells.  Oncotarget 5(21):10678-10691."
"6540","PC121086","Liu X, Krawczyk E, Suprynowicz FA, et al.  2017.  Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens.  Nat Protoc 12(2):439-451."
"6541","PC121086P1","Pollock CB, McDonough S, Wang VS, et al.  2014.  Strigolactone analogues induce apoptosis through activation of p38 and the stress response pathway in cancer cell lines and in conditionally reprogrammed primary prostate cancer cells.  Oncotarget 5(6):1683-1698."
"6542","PC121086P1","Ringer L, Sirajuddin P, Tricoli L, et al.  2014.  The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells.  Oncotarget 5(21):10678-10691."
"6543","PC121086P1","Liu X, Krawczyk E, Suprynowicz FA, et al.  2017.  Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens.  Nat Protoc 12(2):439-451."
"6544","PC121086P2","Ringer L, Sirajuddin R, Tricoli L, et al.  2014.  The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells.  Oncotarget 5(21):10678-10691."
"6545","PC121086P2","Liu X, Krawczyk E, Suprynowicz FA, et al.  2017.  Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens.  Nat Protoc 12(2):439-451."
"6546","PC121086P2","Pollock CB, McDonough S, Want VS, et al.  2014.  Strigolactone analogues induce apoptosis through activation of p38 and the stress response pathway in cancer cell lines and in conditionally reprogrammed primary prostate cancer cells.  Oncotarget 5(6):1683-1698."
"6547","PC121095","Chae YC, Vaira V, Caino MC, et al.  2016.  Mitochondrial Akt regulation of hypoxic tumor reprogramming.  Cancer Cell 30:257-272."
"6548","PC121095","Seo J H, Rivadeneira DB, Caino MC, et al.  2016.   The mitochondrial unfoldase-peptidase complex ClpXP controls bioenergetics stress and metastasis.  PLoS Biol 14(7):e1002507."
"6549","PC121095","Lisanti S, Tavecchio M, Chae YC, et al.  2014.  Deletion of the mitochondrial chaperone TRAP-1 uncovers global reprogramming of metabolic networks.  Cell Rep 8(3):671."
"6550","PC121095","Rivadeneira DB, Caino MC, Seo JH, et al.  2015.  Survivin promotes oxidative phosphorylation, subcellular mitochondrial repositioning, and tumor cell invasion.  Sci Signal 8(389):ra80."
"6551","PC121095","Trerotola M, Ganguly KK, Fazli L, et al.  2015.  Trop-2 is up-regulated in aggressive prostate cancer and interacts with alpha-5-beta-1 integrin.  Oncotarget 6:14318-14328."
"6552","PC121095","Caino MC, Ghosh JC, Chae YC, et al.  2015.  PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion.  Proc Natl Acad Sci USA 112:8638-8643."
"6553","PC121111","Picanço-Albuquerque CG, Morais CL, Carvalho FL, et al.  2016.  In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading.  Virchows Arch 468(5):607-617."
"6554","PC121111","Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, Danila D, Rathkopf D, Morris M, Slovin S, et al. Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00029. Epub 2017 May 31. PubMed PMID: 28825054; PubMed Central PMCID: PMC5558263."
"6555","PC121111","Torres A, Alshalalfa M, Tomlins SA, et al.  2017.  Comprehensive determination of prostate tumor ETS gene status in clinical samples using the CLIA decipher assay.  J Mol Diagn S1525-1578(17)30008-9."
"6556","PC121111","Guedes LB, Morais CL, Almutairi F, et al.  2016.  Analytic validation of RNA in situ hybridization (RISH) for AR and AR-V7 expression in human prostate cancer.  Clin Cancer Res 22(18):4651-4663."
"6557","PC121111","Lotan TL, Wei W, Ludkovski O, et al.  2016.  Analytic validation of a clinicalgrade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.  Mod Pathol 29(8):904-914."
"6558","PC121111","Guedes LB, Tosoian JJ, Hicks J, et al.  2017.  PTEN loss in Gleason Score 3 + 4 = 7 Prostate biopsies is associated with nonorgan confined disease at radical prostatectomy.  J Urol 197(4):1054-1059."
"6559","PC121111","Tosoian JJ, Almutairi F, Morais CL, et al.  2017.  Prevalence and prognostic significance of PTEN loss in African-American and European-American Men undergoing radical prostatectomy.  Eur Urol 71(5):697-700."
"6560","PC121111","Ahearn TU, Pettersson A, Ebot EM, et al.  2015.  A prospective investigation of PTEN loss and ERG expression in lethal prostate cancer.  J Natl Cancer Inst 108(2)."
"6561","PC121111","Lotan TL, Wei W, Morais CL, et al.  2016.  PTEN loss as determined by clinical-grade immunohistochemistry assay is associated with worse recurrence-free survival in prostate cancer.  Eur Urol Focus 2(2):180-188."
"6562","PC121152","Hu DG, Hickey TE, Irvine C, et al.  2014.  Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues.  Hormones & Cancer, 5(2):61-71."
"6563","PC121152","Chan SC, Selth LA, Li Y, et al.  2015.  Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies.  Nucleic Acids Res 43(12):5880-5897."
"6564","PC121152","Asim M, Massie CE, Orafidiya F, et al.  2015.  Choline kinase alpha is an androgen receptor chaperone and prostate cancer therapeutic target.  J Natl Cancer Inst 108(5).  pii: djv371."
"6565","PC121152","Sprenger C, Uo T, and Plymate S.  2015.  Androgen receptor splice variant V7 (AR-V7) in circulating tumor cells: A coming of age for AR splice variants?  Ann Oncol 26:1805-1807."
"6566","PC121152","Akram ON, Degraff DJ, Sheehan JH, et al.  2014.  Tailoring peptidomimetics for targeting protein-protein interactions.  Mol Cancer Res 12(7):967-978."
"6567","PC121152","Mostaghel EA, Plyamte SR, and Montgomery B.  2014.  Molecular pathways: Targeting resistance in the androgen receptor for therapeutic benefit.  Clin Cancer Res 20(4):791-798."
"6568","PC121152","Sprenger CC and Plymate SR.  2014.  The link between androgen receptor splice variants and castration resistant prostate cancer.  Horm Cancer 5(4):207-217."
"6569","PC121152","Selth LA, Das R, Townley SL, et al.  2017.  A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer.  Oncogene 36(1):24-34."
"6570","PC121152","Raj GV, Selth LA, Day TK, et al.  2015.  Evolution of androgen deprivation therapy.  Cancer Forum 39:189-194."
"6571","PC121152","Henzier C, Li Y, Yang R, et al.  2016.  Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer.  Nat Commun 7:13668."
"6572","PC121152","Uo T, Dvinge H, Sprenger CC, et al.  2017.  Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain.  Oncogene 36(10):1440-1450."
"6573","PC121152","Ferraldeschi R, Welti J, Powers MV, et al.  2016.  Second-Generation HSP90 inhibitor onalespib blocks mRNA splicing of androgen receptor Variant 7 in prostate cancer cells. Cancer Res 76(9):2731-2742."
"6574","PC121152","Montgomery RB, and Plymate SR.  2016.  AR-V7 Protein in circulating tumor cells-The decider for therapy?  JAMA Oncol 2(11):1450-1451."
"6575","PC121152","Welti J, Rodrigues DN, Sharp A, et al.  2016.  Analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice Variant-7 protein expression in metastatic castration-resistant prostate.  Eur Urol 70(4):599-608"
"6576","PC121152","Leach DA, Panagopoulos V, Nash C, et al.  2017.  Cell-lineage specificity and role of AP-1 in the prostate fibroblast androgen receptor cistrome.  Mol Cell Endocrinol 439:261-272."
"6577","PC121152","Schweizer MT, Plymate and SR.  2016.  Targeting constitutively active androgen receptor splice variants in castration resistant prostate cancer.  Expert Opin There Targets 20(8):903-906."
"6578","PC121152","Miao L, Yang L, Li R, Rodrigues DN, Crespo M, Hsieh JT, Tilley WD, de Bono J, Selth LA, Raj GV.
Disrupting Androgen Receptor Signaling Induces Snail-Mediated Epithelial-Mesenchymal Plasticity in
Prostate Cancer. Cancer Res. 2017 Jun 1;77(11):3101-3112. PMID:28302679"
"6579","PC121152","Uo T, Plymate SR, and Sprenger CC. 2017. Allosteric alterations in the androgen receptor and activity in prostate cancer. Endocr Relat Cancer. 24(9): R335-R348. doi: 10.1530/ERC-17-0108."
"6580","PC121152","Uo T, Plymate SR, and Sprenger CC. 2018. The potential of AR-V7 as a therapeutic target; Expert Opin Ther Targets. 22(3): 201-216. doi: 10.1080/14728222.2018.1439016."
"6581","PC121152","Welti J, Sharp A, and Yuan W. 2018. Targeting bromodomain and extra-terminal (BET) family proteins in castration resistant prostate cancer (CRPC). Clin Cancer Res. 24(13): 3149-3162. doi: 10.1158/1078-0432.CCR-17-3571. "
"6582","PC121152","Luo J, Attard G, Balk SP, et al. 2017. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol. 73(5): 715-723. doi: 10.1016/j.eururo.2017.11.038."
"6583","PC121152","Plymate SR, Sharp A, and de Bono JS. 2018. Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer: The Devil Is in the Detail. JAMA Oncol. doi: 10.1001/jamaoncol.2018.1615. [Epub ahead of print]."
"6584","PC121189","Yamoah K, Walker A, Whittemore A, et al.  2015.  African American race is a predictor of seminal vesicle invasion following radical prostatectomy.  Clin Genitourin Cancer 13(2):e65-72."
"6585","PC121189","Yamoah K, Deville C, Vapiwala N, et al.  2015.  African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men.  Urol Oncol 33(2):70e15-22."
"6586","PC121207","Coleman DJ, Van Hook K, King CJ, et al.  2016.  Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.  Oncotarget 7(26):40690-40703."
"6587","PC121207P1","Alumkal JJ, Heiser L, Beer TM, et al.  2014.  Identifying enzalutamide resistance mechanisms in men with castration-resistant prostate cancer.  J Clin Oncol 32:5s."
"6588","PC121207P1","Coleman DJ, Van Hook K, King CJ, et al.  2016.  Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.  Oncotarget 7(26):40690-40703."
"6589","PC121236","Jalloh M, Myers F, Cowan JE, et al.  2015.  Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics.  Eur Urol 67(3):451-457."
"6590","PC121236","Punnen S, Cowan JE, Chan JM, et al.  2015.  Long-term health-related quality of life after primary treatment for localized prostate cancer: Results from the CaPSURE Registry.  Eur Urol 68(4):600-608."
"6591","PC121236","Filippou P, Welty CJ, Cowan JE, et al.  2015.  Immediate versus delayed radical prostatectomy: Updated outcomes following active surveillance of prostate cancer.  Eur Urol 68(3):458-463."
"6592","PC121236","Hussein AA, Welty CJ, Ameli N, et al.  2015.  Untreated Gleason grade progression on serial biopsies during prostate cancer active surveillance: clinical course and pathological outcomes.  J Urol 194(1):85-90."
"6593","PC121236","Welty CJ, Cowan JE, Nguyen H, et al.  2015.  Extended follow-up and risk factors for disease reclassification from a large active surveillance cohort for localized prostate cancer.  J Urol 93(3):807-811."
"6594","PC121236","Cooperberg MR, and Carroll PR.  2015.  Trends in management for patients with localized prostate cancer. JAMA 314(1):80-82."
"6595","PC121236","Leapman MS, Ameli N, Shinohara K, et al.  2017.  Validity of the cancer of the prostate risk assessment score derived from targeted biopsy: Modeling evidence from ultrasound lesion-directed biopsy.  Clin Genitourin Cancer 15(1):93-99."
"6596","PC121236","Knudsen BS, Kim HL, Erho N, et al.  2016.  Application of a clinical whole-transcriptome assay for staging and prognosis of prostate cancer diagnosed in needle core biopsy specimens.  J Mol Diagn 18(3):395-406."
"6597","PC121236","Newcomb LF, Thompson IM Jr, Boyer HD, et al.  2016.  Canary prostate active surveillance study investigators. Outcomes of active surveillance for the management of clinically localized prostate cancer in the prospective, multiinstitutional Canary PASS cohort.  J Urol 195(2):313-320."
"6598","PC121236","Cedars BE, Washington SL 3rd, Cowan JE, Leapman M, Tenggara I, Chan JM, Cooperberg MR, Carroll PR. STABILITY OF A 17-GENE GENOMIC PROSTATE SCORE IN SERIAL TESTING OF MEN ON ACTIVE SURVEILLANCE FOR EARLY STAGE PROSTATE CANCER. J Urol. 2019 Apr 8:101097JU0000000000000271. doi: 10.1097/JU.0000000000000271.[Epub ahead of print] PubMed PMID: 30958742."
"6599","PC121236","Eltemamy MM, Leapman MS, Cowan JE, et al.  2016.  Serial anatomic prostate ultrasound imaging during prostate cancer active surveillance.  J Urol 196(3):727-733."
"6600","PC121236","Kenfield SA, Batista JL, Jahn JL, et al.  2016.  Development and application of a lifestyle score for prevention of lethal prostate cancer  J Natl Cancer Inst 108(3)."
"6601","PC121341","Puca L, Bareja R, Prandi D, Show R, Benelli M, Karthaus W, Siguoros M, Cyrta J, Sailer V, Kossai M, Pauli C, Gao D, Mosquera JM, Deonarine L, McNary TJ, Churakova Y, Cheung C, Rosati R, Gaudiano M, Chen X, Chen Y, Inghirami G, Grandori C, Sboner A, Demichelis F, Rubin M, Beltran H. Patient-derived models of neuroendocrine prostate cancer to explore novel therapeutic strategies. Nature Comm. 2018;9(1):2404. doi: 10.1038/s41467-018-04495-z."
"6602","PC121341","Beltran H.  2016.  Networking and matchmaking in prostate cancer.  Science Translational Med 8(353):353ec133."
"6603","PC121341","Gao D, Vela I, Sboner A, et al.  2014.  Organoid cultures derived from patients with advanced prostate cancer.  Cell 159(1):176-187."
"6604","PC121341","Terry S, Semprez F, Allory Y, et al.  2015.  CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities.  Oncotarget 6(14):11994-2008."
"6605","PC121341","Klimstra DS, Beltran H, Lilenbaum R, et al.  2015.  The spectrum of neuroendocrine tumors: Histologic classification, unique features and areas of overlap.  Am Soc Clin Oncol Educ Book 2015:92-103."
"6606","PC121341","Robinson D, Van Allen EM, Wu Y, et al.  2015.  Integrative clinical genomics of advanced prostate cancer.  Cell 161(5):1215-1228."
"6607","PC121341","Beltran H.  2014.  N-myc Oncogene: Maximizing its targets, regulation, and therapeutic potential.  Mol Cancer Res 12(6):815-822."
"6608","PC121341","Akamatsu S, Wyatt AW, Lin D, et al.  2015.  The placental gene PEG10 promotes progression of neuroendocrine prostate cancer.  Cell Rep 12(6):922-936."
"6609","PC121341","Attard G, and Beltran H.  2015.  Prioritising precision medicine for prostate cancer.  Ann Oncol 26(6):1041-1042."
"6610","PC121341","Beltran H, Eng K, Miguel J, et al.  2015.  A precision medicine trial for whole exome sequencing of metastatic cancer reveals biomarkers of treatment response.  JAMA Oncol 1(4):466-474."
"6611","PC121341","Beltran H and Demichelis R.  2015.  Intrapatient heterogeneity in prostate cancer: Clinical implications.  Nat Rev Urol 12:430-431."
"6612","PC121341","Gillessen S, Omlin A, Attard F, et al.  2015.  Management of patients with advanced prostate cancer: Highlights of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.  Ann Oncol 26(8):1589-1604."
"6613","PC121341","Epstein J, Amin M, and Beltran H.  In press.  Proposed morphologic classification of prostate cancer neuroendocrine differentiation.  Am J Surg Pathol 38(6):756-767."
"6614","PC121341","Park K, Chen Z, MacDonald T, et al.  2014.  Prostate cancer with paneth cell-like neuroendocrine differentiation has distinct histomorphology and harbors AURKA gene amplification.  Hum Pathol 45(10):2136-2143."
"6615","PC121341","Prandi D, Baca SC, Romanel A, et al.  2014.  Unraveling the clonal hierarchy of somatic genomic aberrations.  Genome Biol 15(8):439."
"6616","PC121341","Terry S and Beltran H.  2014.  The many faces of neuroendocrine differentiation in prostate cancer progression.  Front Oncol 4:60."
"6617","PC121341","Beltran H.  2016.  How to make a cocktail.  Science Translational Med 8(359):359ec158."
"6618","PC121341","Beltran H.  2016.  Synthetic lethality and beyond.  Science Translational Med 8(365):365ec182."
"6619","PC121341","Beltran H.  2016.  Cancer metastases: Are one and all the same?  Science Translational Med 8(333):333ec57."
"6620","PC121355","Mahajan K and Mahajan NP.  2015.  ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers.  Oncogene 34(32):4162-4167."
"6621","PC121355","Mahajan K and Mahajan NP.  2014.  AKT goes cycling.  Cancer Control  21:239-241."
"6622","PC121355","Lawrence HR, Mahajan K, Liu Y, et al.  2015.  Development of novel ACK1 inhibitors using a fragment based approach.  J Med Chem  58:2746-2763."
"6623","PC121382","Li, Z. et al. 2015. Conversion of abiraterone to D4A drives anti-tumor activity in prostate cancer. Nature Reviews Urology 523:347-351."
"6624","PC121382","Emamekhoo H, Li Z, and  Sharifi N. 2015.  Clinical significance of D4A in prostate cancer therapy with abiraterone. Cell Cycle 14(20):3213-3214."
"6625","PC121408","Liu JC, Parajuli S, Blackman E, et al.  2016.  High prevalence of discordant human papillomavirus and p16 oropharyngeal squamous cell carcinomas in an African American cohort. Head Neck 38(1):E867-72."
"6626","PC121415","Lumata L, Yang C, Ragavan M, et al.  2015.  Hyperpolarized 13C magnetic resonance and its use in metabolic assessment of cultured cells and perfused tissues.  Meth Enzymol 561:73-106."
"6627","PC121415","Niedbalski P, Parish C, Kiswandhi A, et al.  2017.  Influence of Dy3+ and Tb3+-doping on 13C dynamic nuclear polarization.  J Chem Physics 146:: 014303."
"6628","PC121415","Niedbalski P, Parish C, Kiswandhi A, et al.  2016.  13C dynamic nuclear polarization using isotopically-enriched 4-oxo-TEMPO free radicals.  Magnetic Resonance Chem 54:962-967."
"6629","PC121415","Kiswandhi A, Niedbalski P, Parish C, et al.  2016.  Impact of Ho3+-doping on 13C dynamic nuclear polarization using trityl OX063 free radical.  Phy Chem Chemical Physics 18:21351-21359."
"6630","PC121415","Kiswandhi A, Lama B, Niedbalski P, et al.  2016.  The effect of glassing solvent deuteration and Gd3+ doping on 13C DNP at 5 T.  RSC Advances 6: 38855-38860."
"6631","PC121424","Yokoyama NN, Shao S, Hoang BH, et al.  2014.  Wnt signaling in castration-resistant prostate cancer: implications for therapy.  Am J Clin Exp Urol 2(1):27-44."
"6632","PC121424","Yokoyama NN, Shao S, Hoang B, et al.  2014.  Wnt signaling in castration-resistant prostate cancer: Implications for therapy.  Am J Clin Exp Urol 2(1):27-44."
"6633","PC121430","Maund SL, Nolley R and Peehl D.  2014.  Optimization and comprehensive characterization of a faithful tissue culture model of the normal and malignant human prostate.  Lab Invest 94(2):208-221."
"6634","PC121446","Ross AE, Johnson MH, Yousefi K, et al. 2016. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. Eur Urol. 69(1): 157-165. doi: 10.1016/j.eururo.2015.05.042."
"6635","PC121468","VanderWeele DJ, Paner GP, Fleming GF, et al.  2015.  Sustained complete response to cytotoxic therapy and the PARP inhibitor veliparib in metastatic castration resistant prostate cancer - a case report.  Frontiers in Oncology 5:169."
"6636","PC121468","Gillard M, Tom W, Antic T, et al.  2015.  Next-gen tissue:  preservation of molecular and morphological fidelity in prostate tissue..  Am J of Transl Res 7(7):1227-1235."
"6637","PC121468","VanderWeele DJ, and Stadler WM.  2015.  The time for molecular phenotyping of metastatic castrate-resistant prostate cancer is now.  Clinical Advances in Hematology & Oncology 13(9):580."
"6638","PC121468","Lack J, Gillard M, Cam M, et al. 2017. Circulating tumor cells capture disease evolution in advanced prostate cancer.  J Translational Med 2017 Feb 23;15(1):44. doi: 10.1186/s12967-017-1138-3.15(1): 44."
"6639","PC121468","Gillard M, Lack J, Pontier A, et al. 2017. Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer. Eur Urol Focus. doi: 10.1016/j.euf.2017.12.003. [Epub ahead of print]."
"6640","PC121468","Packiam V, Patel SG, Pariser JJ, et al.  2015.  Contemporary population-based comparison of localized ductal adenocarcinoma and high-risk acinar adenocarcinoma of the prostate.  Urology 86(4):777-782."
"6641","PC121468","VanderWeele DJ, Brown CD, Taxy JB, et al.  2014.  Low-grade prostate cancer diverges early from high-grade and metastatic disease.  Cancer Sci 105(8):1079-1085."
"6642","PC121468","McCann S, Jiang Y, Fan X, et al.  2016.  Quantitative multi-parametric MRI Features and PTEN expression in prostate cancer: A pilot study.  AJR Am J Roentgenol 206(3):559-565."
"6643","PC121468","Reyes E, VanderWeele DJ, Duggan R, et al.  2014.  Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer.  J Transl Med 12(1):313."
"6644","PC121497","Soesbe TC, Ratnaker SJ, Milne M, et al.  2014.  Maximizing T2-exchange in Dy3+DOTA-(amide)x chelates: Fine-tuning the water molecule exchange rate for enhanced T2 contrast in MRI.  Magnetic Resonance in Medicine 71(3):1179-1185."
"6645","PC121517","Elzi DJ, Song M, Hakala K, et al.  2014.  Proteomic analysis of the EWS-Fli-1 interactome reveals the role of the lysosome in EWS-Fli-1 turnover.  J Proteome Res 8:3783-3791."
"6646","PC121522","Lin Y, Liu T, Wang W, et al.  2013.  The non-Gaussian nature of prostate motion based on real-time intra-fraction tracking.  Int J Radiat Oncol Biol Phys 87(2):363-369."
"6647","PC121522","Wang Y, Liu T, Rossi P, et al.  2013.  Influence of vascular comorbidities and race on erectile dysfunction after prostate cancer radiotherapy.  J Sex Med 10(8), 2108-2114."
"6648","PC121522","Yang X, Rossi P, Ogunleye T, et al.  2014.  Prostate CT segmentation method based on deformable registration in ultrasound-guided CT-based HDR prostate brachytherapy.  Medical Phys 41(11):111915."
"6649","PC121522","Yang X, Cheng G. Wu N, et al.  2014.  Automated segmentation of the parotid gland based on Atlas Registration and machine learning: A longitudinal MRI study.  In: Head-and-Neck Radiotherapy.  International J Rad Oncol Biol Physics 90(5):1225-1233."
"6650","PC121522","Lin Y, Liu T, Yang X, et al.  2013.  Respiratory-induced prostate motion using wavelet decomposition of the real-time electromagnetic tracking signal.  Int J Radiat Oncol Biol Phys 87(2):370-374."
"6651","PC121522","Yang X, Tridandapani S, Beitler J, et al.  2014.  Characterization of parotid-gland injury following head-and-neck radiotherapy.  Med Physics 41:022903."
"6652","PC121522","Gao Y, Tanenbaum A, Chen H, et al.  2013.  Development of automated skin segmentation in ultrasonic evaluation of skin toxicity in breast-cancer radiotherapy.  Ultrasound Med Biol 39(11):2166-2175."
"6653","PC121522","Yang X, Yoshida E, Cassidy R, et al.  2015.  Quantitiative ultrasonic Nakagami imaging of neck fibrosis after head and neck radition therapy.  International J Rad Oncol Bio Physics 92(2):407-414."
"6654","PC121522","Yang X, Beitler J, Tridandapani S, et al.  2014.  Quantitative ultrasound evaluation of acute and late parotid-gland injury in head-and-neck radiotherapy: Pilot study of sonographic features based on echo-histogram analysis.  Academic Radiology 21(10)."
"6655","PC121532","Bish R, Cuevas-Polo N, Cheng Z, et al.  2015.  Comprehensive protein interactome analysis of a key RNA Helicase: Detection of novel stress granule proteins.  Biomolecules 5(3):1441-1466."
"6656","PC121535","Hsieh CL, Botta G, Gao S, et al.  2015.  PLZF, a tumor suppressor genetically lost in metastatic castration resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy.  Cancer Res 75(10):1944-1948."
"6657","PC121535","Hsieh CL, Fei T, Chen Y, et al.  2014.  Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation.  Proc Natl Acad Sci U S A 111(20):7319-7324."
"6658","PC121543","Hsieh C-L, Botta G, Gao S, et al.  2015.  PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy.  Cancer Res 75(10):1945-1948."
"6659","PC121552","Shukla S, Zhang X, Niknafs YS, et al.  2016.  Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. Neoplasia 18(8):489-499."
"6660","PC121552","Iyer MK, Niknafs YS, Malik R, et al.  2015.  The landscape of long noncoding RNAs in the human transcriptome. Nat Genet 47(3):199-208."
"6661","PC121552","Malik R, Patel L, Prensner JR, et al.  2014.  The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer.  Mol Cancer Res 12(8):1081-1087."
"6662","PC121552","Prensner JR, Sahu A, Iyer MK, et al.  2014.  The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer.  Oncotarget 5(6):1434-1438."
"6663","PC121552","Niknafs YS, Han S, Ma T, et al.  2016.   The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nat Commun 7:12791."
"6664","PC121552","Prensner JR, Iyer MK, Sahu A, et al.  2013.  The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex.  Nat Genet 45(11):1392-1398."
"6665","PC121591","Dillon LW, Kumar P, Shibata Y, et al.  2015.  Production of extrachromosomal MicroDNAs is linked to mismatch repair pathways and transcriptional activity.  Cell Rep 11(11):1749-1759."
"6666","PC121591","Kumar P, Anaya J, Mudunuri SB, et al.  2014.  Meta-analysis of tRNA derived RNA fragments reveals that they are evolutionarily conserved and associate with AGO proteins to recognize specific RNA targets.  BMC Biol 12:78."
"6667","PC121591","Kumar P, Mudunuri SB, Anaya J, et al.  2015.  tRFdb: a database for transfer RNA fragments.  Nucleic Acids Res 43: D141-145."
"6668","PC121625","Ahmad M, Bazolova M, Xiang L, et al.  2014.  Order of magnitude sensitivity increase in X-ray fluorescence computed tomography (XFCT) imaging with an optimized spectro-spatial detector configuration: Theory and simulation.  IEEE Trans Med Imaging 33(5):1119-1128,"
"6669","PC121625","Xiang L, Ahmad M, Hu X, et al.  2014.  Label-free photoacoustic cell-tracking in real time.  X-Acoustics: Imaging and Sensing 1:18-22.  DeGruyter Publishing."
"6670","PC121645","Ingersoll MA, Lyons AS, Muniyan S, et al.  2015.  Novel imidazopyridine derivatives possess anti-tumor effect on human castration-resistant prostate cancer cells. PLoS ONE 10(6):e0131811."
"6671","PC121645","Muniyan S, Chou YW, Ingersoll MA, et al.  2014.  Antiproliferative activity of novel imidazopyridine derivatives on castration-resistant human prostate cancer cells.  Cancer Lett 353(1):59-67."
"6672","PC121647","Xu B, Guenther JF, Pociask DA, et al.  2014.  Promotion of lung tumor growth by interleukin-17.  Am J Physiol Lung Cell Mol Physiol 307(6):L497-508."
"6673","PC121647","Ren F, Fan M, Mei J, et al.  2014.  Interferon-¿ and celecoxib inhibit lung tumor growth through modulating M2/M1 macrophage ratio in the tumor microenvironment.  Drug Design Dev Ther 8:1527-1538."
"6674","PC121647","Lambrechts M, Nazari B, Dini A, et al.  2014.  Comparison of the cheese-wiring effects among three sutures used in rotator cuff repair.  Int J Shoulder Surg 8:81-85."
"6675","PC121647","Chen C, Zhang Q, Liu S, et al.  2014.  AZD5363 inhibits inflammatory synergy between interleukin-17 and insulin/insulin-like growth factor 1.  Front Oncol 4:343."
"6676","PC121647","Ge D, Dauchy RT, Liu S, et al.  2013.  Insulin and IGF1 enhance IL-17-induced chemokine expression through a GSK3B-dependent mechanism: A new target for melatonin¿s anti-inflammatory action.  J Pineal Res 55(4):377-387."
"6677","PC121647","Lambrechts M, O'Brien MJ, Savoie FH, et al.  2013.  Liposomal extended-release bupivacaine for postsurgical analgesia.  Patient Prefer Adherence 7:885-890.  (Invited Review Article, Peer-Reviewed)."
"6678","PC121647","Parajuli KR, Zhang Q, Liu S, and You Z.  2015.   Aminomethylphosphonic acid and methoxyacetic acid induce apoptosis in prostate cancer cells. Int J Mol Sci.16(5):11750-65."
"6679","PC121647","Ge D, Zhang QS, Zabaleta J, et al.  2014.  Doublecortin may play a role in defining chondrocyte phenotype.  Int J Mol Sci 15(4):6941-6960."
"6680","PC121647","Zhang Q, Liu S, Zhang Q, et al.  2014.  Interleukin-17 promotes development of castration-resistant prostate cancer potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment.  Prostate 74(8):869-879."
"6681","PC121647","Li Q, Liu L, Zhang Q, et al.  2014.  Interleukin-17 Indirectly promotes M2 macrophage differentiation through stimulation of COX-2/PGE2 pathway in the cancer cells.  Cancer Res Treat 46:297-306."
"6682","PC121647","Chen RY, Fan YM, Zhang Q, et al.  2015.  Estradiol inhibits Th17 cell differentiation through inhibition of RORgammaT transcription by recruiting the ERalpha/REA complex to estrogen response elements of the RORgammaT promoter.  J Immunol 194(8):4019-4028."
"6683","PC121647","Chen C, Zhang Q, Liu S, et al.  2015.  IL-17 and insulin/IGF1 enhance adhesion of prostate cancer cells to vascular endothelial cells through CD44-VCAM-1 interaction.  Prostate 75(8):883-895."
"6684","PC121655","Viswanath S, Toth R, Rusu M, et al.  2014.  Identifying quantitative in vivo multi-parametric MRI features for treatment related changes after laser interstitial thermal therapy of prostate cancer.  Neurocomputing 144:13-23."
"6685","PC121655","Antunes J, Viswanath S, Rusu M, et al.  2016.  Radiomics analysis on FLT-PET/MRI for characterization of early treatment response in renal cell carcinoma:  A proof-of-concept study.  Trans Oncol 9(2):155-162."
"6686","PC121655","Ginsburg SB, Rusu M, Kurhanewicz J, et al.  2014.  Computer extracted texture features on T2w MRI to predict biochemical recurrence following radiation therapy for prostate cancer.  SPIE Medical Imaging 9035:903509-903509-13."
"6687","PC121655","Rusu M, Bloch BN, Jaffe CC, et al.  2014.  Prostatome: a combined anatomical and disease based MRI atlas of the prostate.  Med Phys. 41(7):072301."
"6688","PC121655","Rusu M, Golden T, Wang H, et al.  2015.  Framework for 3D histologic reconstruction and fusion with in vivo MRI:  Preliminary results of characterizing pulmonary inflammation in a mouse model.  Med Phys 42:4822."
"6689","PC121655","Singanamalli A, Rusu M, Sparks RE, et al.  2016.  Identifying in vivo DCE MRI markers associated with microvessel architecture and Gleason grades of prostate cancer.  J Magn Reson Imaging 43(1):149-158."
"6690","PC121661","Lawrence HR, Mahajan K, Liu Y, et al.  2015.  Development of novel ACK1 inhibitors using a fragment based approach.  J Med Chem  58:2746-2763."
"6691","PC121661","Mahajan K and Mahajan NP.  2014.  AKT goes cycling.  Cancer Control 21(3):239-241."
"6692","PC121661","Mahajan K and Mahajan NP.  2015.  ACK1/TNK2 tyrosine kinase: Molecular signaling and evolving role in cancers.  Oncogene 34(32):4162-4167."
"6693","PC121667","Wang G, Lu X, Dey P, et al.  2016.  Targeting YAP-dependent MDSC infiltration impairs tumor progression.  Cancer Dis 6(1):80-95."
"6694","PC121671","Kissick HT, and Sanda MG.  2015.  The role of active vaccination in cancer immunotherapy: lessons from clinical trials.  Current Opinions in Immunology 35:15-22."
"6695","PC121671","Kissick HT, Sanda MG, Dunn LK, et al. 2013. Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer. Cancer Immunol Immunother. 62(12): 1831-1840. doi: 10.1007/s00262-013-1482-y."
"6696","PC121718","Bansal N, Johnson-Farley N, Wu LY, et al.  2015.  Darinaparsin inhibits prostate tumor Initiating cells and DU145 xenografts and is an inhibitor of hedgehog signaling.  Molecular Cancer Therapeutics 14(1):23-30."
"6697","PC121719","Goodwin JF, Schiewer MJ, Dean JL, et al.  2013.  A hormone-DNA repair circuit governs the response to genotoxic insult.  Cancer Discov 3(11):1254-1271."
"6698","PC121719","Comstock CE, Augello MA, Goodwin JF, et al.  2013.  Targeting cell cycle and hormone receptor pathways in cancer.  Oncogene 32(48):5481-5491."
"6699","PC121719","de Leeuw R, Berman-Booty LD, Schiewer MJ, et al. 2015. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin Cancer Res. 21(4):795-807."
"6700","PC121720","Kumar S, Chaudhary AK, Kumar R,  et al.  2016.  Combination therapy induces unfolded protein response and cytoskeletal rearrangement leading to mitochondrial apoptosis in prostate cancer. Mol Oncol 10(7):949-965."
"6701","PC121737","Movassaghian S, Xie Y, Hildebrandt C, et al.  2016.  Post-transcriptional regulation of the GASC1 oncogene with active tumor-targeted siRNA-nanoparticles.  Mol Pharm. 13:2605-2261."
"6702","PC121737","Yu, H, Jiang Y, Liu L, et al.  2017.  Integrative genomic and transcriptomic analysis for pinpointing recurrent alterations of plant homeodomain genes and their clinical significance in breast cancer.  Oncotarget 8(8):13099-13115."
"6703","PC121738","Guo W, Liu R, Bhardwaj G, et al.  2014.  Targeting Btk/Etk of prostate cancer cells by novel dual inhibitor.  Cell Death Disease 5:e1409."
"6704","PC121749","Mitcham T, Dextraze K, Taghavi H, et al.  2015.  Photoacoustic imaging drive by an interstitial irradiation source.  Photoacoustics 3(2):45-54."
"6705","PC121772","Diedrich D, Chkourko-Gusky H, and Podgorski I.  2015.  Adipose tissue dysfunction and its effects on tumor metabolism.  Special issue on adiposopathy in cancer and metabolic diseases: an endocrine approach.  Horm Mol Biol Clin Investig 21(1):17-41."
"6706","PC121837","Zhao H, Bauzon F, Bi E, et al.  Substituting threonine187 with alanine in p27Kip1 prevents pituitary tumorigenesis by two-hit loss of Rb1 and enhances humoral immunity in old age.  J Biol Chem 290:5797-5809."
"6707","PC121837","Zhao H, Bauzon F, Fu H et al.  2013.  Skp2 deletion unmasks a p27 safeguard that blocks tumorigenesis in the absence of pRb and p53 tumor suppressors.  Cancer Cell. 24(5):645-659."
"6708","PC121848","Zhang A, Zhao JC, Kim J, et al.  2015.  LncRNA HOTAIR enhances the androgen-receptor-mediated transcriptional program and drives castration-resistant prostate cancer.  Cell Rep 13(1):209-221."
"6709","PC121848","Yang YA, and Yu J.  2015.  Current perspectives of FOXA1 regulation of androgen receptor signaling and prostate cancer. Genes Dis 2(2):144-151."
"6710","PC121890","Mostaghel EA, and Lin DW.  2014.  Practical guide to the use of abiraterone in castration resistant prostate cancer. Can J Urol  21(2 Supp 1):57-63. Review."
"6711","PC121890","Mostaghel EA.  2014.   Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation. Int J Biol Sci 10(6):602-613."
"6712","PC121890","Mostaghel EA, and Lin DW.  2014.  Practical guide to the use of abiraterone in castration resistant prostate cancer. Can J Urol 21(2 Supp 1):57-63. Review."
"6713","PC121890","Mostaghel EA. 2014.  Abiraterone in the treatment of metastatic castration-resistant prostate cancer. Cancer Manag Res 6:39-51."
"6714","PC121915","Jiang P, Du W, and Yang X.  2013.  A critical role of glucose -6-phosphate dehydrogenase in TAp73-mediated cell proliferation.  Cell Cycle 12:3720-3726."
"6715","PC121915","Jiang P, Du W and Yang X.  2013.  p53 and regulation of tumor metabolism.  J Carcinog 12:21."
"6716","PC121924","Ngwa W, SAjo E, Ngoma T, et al.  2015.  Potential for information and communication technologies to catalyze global collaborations in radiation oncology.  Int J Radiat Oncol Biol Phys 91(2): 444-447."
"6717","PC121924","Odedina FT, Young ME, Pereira D, et al. 2017. Point of Prostate Cancer Diagnosis (PPCD) Experiences of Black Men: The Florida CaPCaS Study. Journal of Community and Supportive Oncology. JCSO 15(1): 10-19. doi. 10.12788/jcso.0323."
"6718","PC121924","Odedina FT, Young ME, Pereira D, et al. 2017. Needs of Black men at the Point of Prostate Cancer Diagnosis (PPCD): The Florida CaPCaS Study. International Journal of Cancer and Oncology. JCSO 4(1): 1-4."
"6719","PC121924","Gilbert LR. 2016. Photovoice: a Link between Research and Practice for Prostate Cancer Advocacy in Black Communities. J Racial Ethn Health Disparities. 4(3): 364-375. doi:10.1007/s40615-016-0237-9."
"6720","PC121924","Morrison BF, Aiken WD, Mayhew R, et al.  2017.  Prostate cancer knowledge, prevention, and screening behaviors in Jamaican Men.  J Cancer Educ 32(2):352-356."
"6721","PC121924","Ruktanonchai CW, Pindolia DK, Striley CW, et al.  2014.  Utilizing spatial statstics to identify cancer hot spots: A surveillance strategy to inform community-engaged outreach efforts.  Int J Health Geogr 13:39."
"6722","PC121963","Farran B, Dyson G, Craig D, et al. A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancer. Carcinogenesis. 2018 04; 39(4): 556-561. https://doi.org/10.1093/carcin/bgy025 PMID:29471417"
"6723","PC121963","Dyson G, Farran B, Bolton S, et al. The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer. American journal of cancer research. 2018; 8(10): 2088-2095. PMID:30416858"
"6724","PC121975","Olender J, Wang BD, Ching T, Garmire LX, Garofano K, Ji Y, Knox T, Latham P, Nguyen K, Rhim J, Lee NH. A Novel FGFR3 Splice Variant Preferentially Expressed in African American Prostate Cancer Drives Aggressive Phenotypes and Docetaxel Resistance. Mol Cancer Res. 2019 Jul 2. doi: 10.1158/1541-7786.MCR-19-0415. [Epub ahead of print] PubMed PMID: 31266816."
"6725","PC121975","Wang B-D, Ceniccola K, Yang Q, et al.  2015.  Identification and functional validation of reciprocal microRNA-mRNA pairings in African American prostate cancer disparities.  Clin Cancer Res 21(21):4970-4984."
"6726","PC121979","Farrell J, Young D, Chen Y, et al.  2014.  Predominance of ERG-negative high-grade prostate cancers in African American men.  Mol Clin Oncol 2(6):982-986."
"6727","PC130062","Tummala R, Lou W, Gao AC, et al. 2017. Quercetin targets hnRNPA1 to overcome enzalutamide resistance in prostate cancer.  Mol Cancer Ther: DOI: 10.1158/1535-7163.MCT-17-0030."
"6728","PC130062","Tummala R, Nadiminty N, Lou W, et al.  2016.  Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation.  Prostate 76(5):445-455."
"6729","PC130062","Nadiminty N, Tummala R, Liu C, et al.  2015.  NF-kB/p52: cmyc: hnRNPA1 pathway regulates expression of androgen receptor splice variants and enzalutamide sensitivity in prostate cancer. Mol Cancer Ther 14 (8):1884-1895."
"6730","PC130118","Chen RY, Fan YM, Zhang Q, et al.  2015.  Estradiol inhibits Th17 cell differentiation through inhibition of RORgammaT 22 transcription by recruiting the ERalpha/REA complex to estrogen response elements of the RORgammaT promoter.  J Immunol 194(8):4019-4028."
"6731","PC130118","Xu B, Guenther JF, Pociask DA, et al.  2014.  Promotion of lung tumor growth by interleukin-17.  Am J Physiol Lung Cell Mol Physio 307(6):L497-508."
"6732","PC130118","Cunningham D and You Z.  2015.  In vitro and in vivo model systems used in prostate cancer research.  J Biol Methods  2(1):e17."
"6733","PC130118","Chen C, Zhang Q, Liu S, et al.  2015.  IL-17 and insulin/IGF1 enhance adhesion of prostate cancer cells to vascular endothelial cells through CD44-VCAM-1 interaction.  Prostate 75(8):883-95."
"6734","PC130118","Manda KR, Tripathi P, Hsi AC, et al.  2016.  NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence.  Oncogene 35:3282-3292."
"6735","PC130118","Lu C, Chen F, Johnson KJ, et al.  2015.  Patterns and functional implications of rare germline variants across 12 cancer types.  Nat Comm 6:10086."
"6736","PC130118","Chen C, Zhang Q, Liu S, et al.  2014.  AZD5363 inhibits inflammatory synergy between interleukin-17 and insulin/insulin-like growth factor 1.  Front Oncol 4:343."
"6737","PC130118","Ge D, Zhang QS, Zabaleta J, et al.  2014.  Doublecortin may play a role in defining chondrocyte phenotype.  Int J Mol Sci 15(4):6941-6960."
"6738","PC130118","Ren F, Fan M, Mei J, et al.  2014.  Interferon-gamma and celecoxib inhibit lung tumor growth through modulating M2/M1 macrophage ratio in the tumor microenvironment.  Drug Des Devel Ther 8:1527-1538."
"6739","PC130188","Kechen Ban, Shu Feng, Longjiang Shao, and Michael Ittmann. 2017. RET Signaling in Prostate Cancer. Clinical Cancer Research 23(16):4885-4896."
"6740","PC130227","Zhang L, Yan S, Chen X, et al.  2015.  The Hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells.  Mol Cell Biol 25(8):1350-1362."
"6741","PC130259","Chu X, Guo X, Jiang Y, Yu H, Liu L, Shan W, Yang ZQ. Genotranscriptomic metaanalysis
of the CHD family chromatin remodelers in human cancers: initial evidence of an
oncogenic role for CHD7. Molecular Oncology 11 (2017) 1348–1360 Jun 26; PMID: 28649742"
"6742","PC130259","Movassaghian S, Xie Y, Hildebrandt C, et al.  2016.  Post-transcriptional regulation of the GASC1 oncogene with active tumor-targeted siRNA-nanoparticles.  Mol Pharm 13:2605-2621."
"6743","PC130265","Mirkheshti N, Park S, Song CS, et al.  2016.  Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer.  Oncotarget 7(38):62240-62254."
"6744","PC130265","Jiang S, Song CS, Chatterjee B. Stimulation of Prostate Cells by the Senescence Phenotype of Epithelial and stromal Cells: Implications for benign prostate hyperplasia. Faseb Bioadvances. Published: 15 March 2019. doi:10.1096/fba.2018-00084. FASEB.1:6, 353-363."
"6745","PC130321","Xie J, Owen T, Xia K, et al.  2015.  Zinc inhibits Hedgehog autoprocessing: linking zinc deficiency with Hedgehog activation.  J Biol Chem 290(18):11591-11600."
"6746","PC130321","Owen TS, Xie XJ, Laraway B, et al.  2015.  Active site targeting of hedgehog precursor protein with phenylarsine oxide.  Chembiochem 16:55-58."
"6747","PC130321","Owen TS, Ngoje G, Lageman TJ, et al.  2015.  Förster resonance energy transfer-based cholesterolysis assay identifies a novel hedgehog inhibitor.  Analytical Biochem, 488:1-5."
"6748","PC130321","Callahan BP, and Wang C.  2015.  Hedgehog cholesterolysis; specialized gatekeeper to oncogenic signaling.  Cancers 7:2037-2053."
"6749","PC130321","Li A, Yadav R, White JK,  et al. 2017. Illuminating cytochrome P450 binding: Ru(ii)-caged inhibitors of CYP17A1. Chem Commun (Camb). 53(26): 3673-3676. doi: 10.1039/c7cc01459g."
"6750","PC130321","Xie J, Owen T, Xia K, et al.  2016.  A single aspartate coordinates two catalytic steps in hedgehog autoprocessing.  J Am Chem Soc 138(34):10806-10809."
"6751","PC130321","Bordeau BM, Ciulla DA, and Callahan BP.  2016.  Hedgehog proteins consume steroidal CYP17A1 antagonists: Potential therapeutic significance in advanced prostate cancer.  ChemMedChem 11(18):1983-1986."
"6752","PC130355","Cooperberg MR, Brooks JD, Faino AV, et al. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. European urology. 2018 08; 74(2): 211-217. https://doi.org/10.1016/j.eururo.2018.01.017 PMID:29433975"
"6753","PC130355","Kearns JT, Faino AV, Newcomb LF, et al. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. European urology. 2018 05; 73(5): 706-712. https://doi.org/10.1016/j.eururo.2018.01.016 PMID:29433973"
"6754","PC130355","Lin DW, Newcomb LF, Brown MD, et al. 2017. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study . Eur Urol. 72(3): 448-454. doi: 10.1016/j.eururo.2016.11.017."
"6755","PC130359","Dai J, Hensel J, Wang N, et al.  2016.  Mouse models for studying prostate cancer bone metastasis.  BoneKEy Rep 5:777."
"6756","PC130359","Tsuzuki S, Park SH, Eber MR, et al.  2016,  Skeletal complications in cancer patients with bone metastases.  Int J Urol 23(10):825-832."
"6757","PC130359","Kast RE, Skuli N, Cos S, et al.  2017.  The ABC7 regimen: A new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy.  Breast Cancer (Dove Med Press) 9:495-514."
"6758","PC130359","Tsuzuki S, Park SH, Eber MR, et al. 2016. Skeletal complications in cancer patients with bone metastases. Int J Urol. 23(10): 825-832. doi: 10.1111/iju.13170."
"6759","PC130359","Zalucha JL, Jung Y, Joseph J, et al. 2015. The Role of Osteoclasts in Early Dissemination of Prostate Cancer Tumor Cells. J Cancer Stem Cell Res. 3:e1005. DOI: 10.14343/JCSCR.2015.3e1005."
"6760","PC130359","Shiozawa Y, Eber MR, Berry JE, et al. 2015. Bone marrow as a metastatic niche for disseminated tumor cells from solid tumors. Bonekey Rep. 4: 689. doi: 10.1038/bonekey.2015.57."
"6761","PC130359","Dai J, Hensel J, Wang N, et al. 2016. Mouse models for studying prostate cancer bone metastasis. Bonekey Rep. 5: 777. doi: 10.1038/bonekey.2016.4."
"6762","PC130359","Park SH, Keller ET, and Shiozawa Y. Bone marrow microenvironment as a regulator and therapeutic target for prostate cancer bone metastasis. Calcif Tissue Int. 102(2): 152-162. doi: 10.1007/s00223-017-0350-8."
"6763","PC130359","Miler SF, Thomas CY, and Shiozawa Y. 2016. Molecular involvement of the bone marrow microenvironment in bone metastasis. Introduction to Cancer Metastasis 14: 263-276. doi: 10.1016/B978-0-12-804003-4.00014-1."
"6764","PC130359","Sharma S, Xing F, Liu Y, et al. 2016. Secreted Protein Acidic and Rich in Cysteine (SPARC) Mediates Metastatic Dormancy of Prostate Cancer in Bone. J Biol Chem. 291(37): 19351-19363. doi: 10.1074/jbc.M116.737379."
"6765","PC130359","Park SH, Eber MR, Widner DB, et al. 2018. Role of the Bone Microenvironment in the Development of Painful Complications of Skeletal Metastases. Cancers (Basel). 10(5). doi: 10.3390/cancers10050141."
"6766","PC130359","Shiozawa Y, Berry JE, Eber MR, et al. 2016. The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer. Oncotarget. 7(27): 41217-41232. doi: 10.18632/oncotarget.9251."
"6767","PC130359","Park SH, Eber MR, Tsuzuki S, et al. 2017. Adeno-associated virus serotype rh10 is a useful gene transfer vector for sensory nerves that innervate bone in immunodeficient mice. Sci Rep. 7(1): 17428. doi: 10.1038/s41598-017-17393-z."
"6768","PC130359","Widner DB, Park SH, Eber MR, et al. 2018. Interactions Between Disseminated Tumor Cells and Bone Marrow Stromal Cells Regulate Tumor Dormancy. Curr Osteoporos Rep. 16(5): 596-602. doi: 10.1007/s11914-018-0471-7."
"6769","PC130359","Jones JD, Sinder BP, Paige D, Soki FN, Koh AJ, Thiele S, Shiozawa Y, Hofbauer LC, Daignault S, Roca H, McCauley LK. Trabectedin Reduces Skeletal Prostate Cancer Tumor Size in Association with Effects on M2 Macrophages and Efferocytosis. Neoplasia. 2019 Feb;21(2):172-184. doi: 10.1016/j.neo.2018.11.003. Epub 2018 Dec 31. PubMed PMID: 30591422; PubMed Central PMCID: PMC6314218."
"6770","PC130359","Shiozawa Y, Berry JE, Eber MR, Jung Y, Yumoto K, Cackowski FC, Yoon HJ, Parsana P, Mehra R, Wang J, et al. The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer. Oncotarget. 2016 Jul 5;7(27):41217-41232. doi: 10.18632/oncotarget.9251. Erratum in: Oncotarget. 2017 Jun 6;8(23 ):38075. PubMed PMID: 27172799; PubMed Central PMCID: PMC5173053."
"6771","PC130359","Park SH, Eber MR, Shiozawa Y. Models of Prostate Cancer Bone Metastasis. Methods Mol Biol. 2019;1914:295-308. doi: 10.1007/978-1-4939-8997-3_16. PubMed PMID: 30729472."
"6772","PC130359","Park SH, Eber MR, Tsuzuki S, Booker ME, Sunil AG, Widner DB, Parker RA, Peters CM, Shiozawa Y. Adeno-associated virus serotype rh10 is a useful gene transfer vector for sensory nerves that innervate bone in immunodeficient mice. Sci Rep. 2017 Dec 12;7(1):17428. doi: 10.1038/s41598-017-17393-z. PubMed PMID: 29233995; PubMed Central PMCID: PMC5727257."
"6773","PC130359","Cackowski FC, Eber MR, Rhee J, Decker AM, Yumoto K, Berry JE, Lee E, Shiozawa Y, Jung Y, Aguirre-Ghiso JA, Taichman RS. Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy. J Cell Biochem. 2017 Apr;118(4):891-902. doi: 10.1002/jcb.25768. Epub 2016 Nov 10. PubMed PMID: 27753136; PubMed Central PMCID: PMC5296338."
"6774","PC130382","Puplampu-Dove Y, Gefen T, Rajagopalan A, et al. 2017. Potentiating tumor immunity using aptamer targeted RNAi to render CD8+ T cells resistant to TGFbeta inhibition.  OncoImmunology http://dx.doi.org/10.1080/2162402X.2017.1349588.
"
"6775","PC130391","Nikhil K, Chang L, Viccaro K, Jacobsen M, McGuire C, Satapathy SR, Tandiary M, Broman MM, Cresswell G, He YJ, et al. Identification of LIMK2 as a therapeutic target in castration resistant prostate cancer. Cancer Lett. 2019 Apr 28;448:182-196. doi: 10.1016/j.canlet.2019.01.035. Epub 2019 Feb 1. PubMed PMID: 30716360."
"6776","PC130417","Nowak DG, Katsenelson KC, Watrud KE, Chen M, Mathew G, D'Andrea VD, Lee MF, Swamynathan MM, Casanova-Salas I, Jibilian MC, Buckholtz CL, Ambrico AJ, Pan CH, Wilkinson JE, Newton AC, Trotman LC. The PHLPP2 phosphatase is a druggable driver of prostate cancer progression. J Cell Biol. 2019 Jun 3;218(6):1943-1957. doi: 10.1083/jcb.201902048. Epub 2019 May 15. PubMed PMID: 31092557; PubMed Central PMCID: PMC6548123."
"6777","PC130417","Nowak DG, Cho H, Herzka T, et al. 2015. MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. Cancer Discov. 5(6): 636-651. doi: 10.1158/2159-8290.CD-14-1113."
"6778","PC130417","Naguib A, Mathew G, Reczek CR, et al. 2018. Mitochondrial Complex I Inhibitors Expose a Vulnerability for Selective Killing of Pten-Null Cells. Cell Reports. 23(1): 58-67. doi: 10.1016/j.celrep.2018.03.032."
"6779","PC130431","Behr SC, Aggarwal R, Van Brocklin HF, Flavell RR, Geo K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, et al. First-in-Human Phase I study of CTT1057, a Novel (18)F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer. J Nucl Med. 2018 Nov 21. pii: jnumed.118.220715. doi:10.2967/jnumed.118.220715. [Epub ahead of print] PubMed PMID: 30464040."
"6780","PC130479","McIlwain DM, Snider, BM, Zoetemelk M, et al.  2016.  Coordinated induction of cell survival signaling in the inflamed microenvironment of the prostate.  Prostate 76(8):722-734."
"6781","PC130479","McIlwain DW, Fishel ML, Wang L, et al. 2018. APE1/Ref-1 regulates prostate cancer cell proliferation via survivin protein expression. Oncotarget. 9(13): 10962–10977. doi:  10.18632/oncotarget.23493."
"6782","PC130483","Rycaj K, and Tang DG.  2016.  Metastasis and metastatic cells: A historical perspective and current analysis. In: Cancer Stem Cells: Targeting the Roots of Cancer, Seeds of Metastasis, and Sources of Therapy Resistance (Liu H, and Lathia JD, Eds).  Lathia. Academic Press, Elsevier.  Pp 317-340."
"6783","PC130483","Zhang D, Lin K, Lu Y, et al.  2017.  Developing a novel two-dimensional culture system to enrich human prostate luminal progenitors that can function as a cell of origin for prostate cancer.  Stem Cells Transl Med 6(3):748-760."
"6784","PC130483","Liu R, Liu C, Zhang D, et al.  2016.  miR-199a-3p targets stemness-related and mitogenic signaling pathways to suppress the expansion and tumorigenic capabilities of prostate cancer stem cells.  Oncotarget 7(35):56628-56642."
"6785","PC130483","Chen X, Li Q, Liu X, et al.  2016.  Defining a population of stem-like human prostate cancer cells that can generate and propagate castration-resistant prostate cancer.  Clin Cancer Res 22(17):4505-4516."
"6786","PC130483","Zhang D, Park D, Zhong Y, et al.  2016.  Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer.  Nat Commun 7:10798."
"6787","PC130483","Rycaj K, and Tang DG.  2015.  Cell-of-origin of cancer versus cancer stem cells:  Assays and interpretations.  Cancer Res 75(19): 4003-4011."
"6788","PC130483","Li Q, Deng Q, Chao HP, Liu X, Lu Y, Lin K, Liu B, Tang GW, Zhang D, Tracz A, et al. Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nat Commun. 2018 Sep 6;9(1):3600. doi: 10.1038/s41467-018-06067-7. PubMed PMID: 30190514; PubMed Central PMCID: PMC6127155."
"6789","PC130483","Li Q, Rycaj K, Chen X, et al.  2015.  Cancer stem cells and cell size: A causal link?  Semin Cancer Biol 35:191-199."
"6790","PC130483","Deng Q, and Tang DG.  2015.  Androgen receptor and prostate cancer stem cells: Biological mechanisms and clinical implications.  Endocr Relat cancer 22(6): T209-20."
"6791","PC130483","Gong S, Li Q, Jeter CR, et al.  2015.  Regulation of NANOG in cancer cells.  Mol Carcinog 54(9):679-687."
"6792","PC130483","Liu X, Chen X, Rycaj K, et al.  2015.  Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells.  Oncotarget  6(27): 23959-23986."
"6793","PC130483","Jeter CR, Yang T, Wang J, et al.  2015.  NANOG in Cancer stem cells and tumor development: An update and outstanding questions.  Stem Cells 33(8): 2381-2390."
"6794","PC130483","Rycaj K, Cho EJ, Liu X, et al.  2016.  Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSA-/lo castration-resistant cells.  Oncotarget 7(12):14220-14240."
"6795","PC130555","Dalal K, Che M, Que M et al. 2017. Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin Interactions.  Molecular Cancer Therapeutics. 16(10):2281-2291."
"6796","PC130555P1","Dalal K, Che M, Que M et al. 2017. Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin Interactions.  Molecular Cancer Therapeutics. 16(10):2281-2291."
"6797","PC130555P1","Dalal K, Munuganti R, Morin H, et al.  2016.  Drug-discovery Pipeline for Novel Inhibitors of the Androgen Receptor.  Meth. Mol. Biol. 1443:31-54."
"6798","PC130570","Liu X, Ledet E, Li D, et al.  2016.  A whole blood assay for AR-V7 and ARv567es in patients with prostate cancer.  J Urol 196:1758-1763."
"6799","PC130570","Xu D, Zhan Y, Qi Y, et al.  2015.  Androgen receptor splice variants dimerize to transactivate target genes.  Cancer Res 75:3663-71."
"6800","PC130570","Zhang G, Liu X, Li J, et al.  2015.  Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents.  Oncotarget 6:23358-71."
"6801","PC130587","Hannah Brechka, Raj R. Bhanvadia, Calvin VanOpstall, and Donald J. Vander Griend 
HOXB13 mutations and binding partners in prostate development and
cancer: Function, clinical significance, and future directions
Genes Dis. 2017 Jun; 4(2): 75–87."
"6802","PC130590","Xie X, Ross JL, Cowell JK, et al.  2015.  The promise of zebrafish as a chemical screening tool in cancer therapy.  Future Med Chem. 7(11):1395-405."
"6803","PC130594","Wu L, Yi B, Wei S, et al. Loss of FOXP3 and TSC1 Accelerates Prostate Cancer Progression through Synergistic Transcriptional and Posttranslational Regulation of c-MYC. Cancer research. 2019 Apr; 79(7): 1413-1425. https://doi.org/10.1158/0008-5472.CAN-18-2049 PMID:30733194"
"6804","PC130594","Wang Y, Li X, Liu W, Li B, Chen D, Hu F, Wang L, Liu XM, Cui R, Liu R. MicroRNA-1205, encoded on chromosome 8q24, targets EGLN3 to induce cell growth and contributes to risk of castration-resistant prostate cancer. Oncogene. 2019 Feb 26. doi: 10.1038/s41388-019-0760-3. [Epub ahead of print] PubMed PMID: 30808975."
"6805","PC130594","Zhang W, Yi B, Wang C, et al.  2016.  Silencing of CD24 Enhances the PRIMA-1-Induced restoration of Mutant p53 in prostate cancer cells.  Clin Cancer Res 22(10):2545-2554."
"6806","PC130594","Liu R, Liu C, Chen D, et al.  2015.  FOXP3 controls an miR-146/NF¿B negative feedback loop that inhibits apoptosis in breast cancer cells.  Cancer Res 75(8):1703-1713."
"6807","PC130594","Meredith LJ, Wang CM, Nascimento L, et al.  201.  The key regulator for language and speech development, FOXP2, is a novel substrate for SUMOylation.  J Cell Biochem 117(2):426-438."
"6808","PC130594","Liu R, Yi B, Wei S, et al.  2015.  FOXP3-microRNA-146-NF-¿B axis and therapy for precancerous lesions in prostate.  Cancer Res 75(8):1714-1724."
"6809","PC130594","Zhang Y, Li B, Zhang X, et al.  2017.  CD24 is a genetic modifier for risk and progression of prostate cancer.  Mol Carcinog 56(2):641-650."
"6810","PC130594","Etikala DM, Liu R, and Wang L.  2015.  FOXP3-microRNA-146-NF-kB as oncotarget.  Oncoscience 2(10):839-840."
"6811","PC130616","Frank SB, Schulz VV, and Miranti CK. 2017. A streamlined method for the design and cloning of shRNAs into an optimized Dox-inducible lentiviral vector. BMC Biotechnology 17. doi: 10.1186/s12896-017-0341-x."
"6812","PC130616","Frank SB, Berger PL, Ljungman M, et al. 2017. Human prostate luminal cell differentiation requires NOTCH3 induction by p38-MAPK and MYC. Journal of cell science 130(11): 1952-1964. doi: 10.1242/jcs.197152."
"6813","PC130616","Berger PL, Frank SB, Schulz VV, et al.  2014.  Transient induction of ING4 by MYC drives prostate epithelial cell differentiation and its disruption drives prostate tumorigenesis.  Cancer Res 74: 3357-3368."
"6814","PC130616","Berger PL, Winn ME, and Miranti CK.  2017.  Miz1, a Novel Target of ING4, Can Drive Prostate Luminal Epithelial Cell Differentiation. Prostate 77(1):49-59."
"6815","PC130641","Garg R, Blando JM, Perez CJ, Abba M, Benavides FJ, and Kazanietz, MG. Protein kinase C epsilon and
Pten loss cooperate for prostate tumorigenesis through the CXCL13-CXCR5 pathway. Cell Reports 19:375-388
(2017)."
"6816","PC130641","Garg R, Blando JM, Perez CJ, et al. 2018. COX-2 mediates pro-tumorigenic effects of PKCe in prostate cancer. Oncogene 37: 4735-4749. doi.10.1038/s41388-018-0318-9."
"6817","PC130641","Gutierrez-Uzquiza A, Lopez-Haber C, Jernigan DL, et al.  2015.  PKC is an essential mediator of prostate cancer bone metastasis.  Mol Cancer Res 13:1336-1346."
"6818","PC130699","Senft D, Qi J, Ronai ZA, et al. 2018. Ubiquitin ligases in oncogenic transformation and cancer therapy. Nat Rev Cancer. 18(2): 69-88. doi: 10.1038/nrc.2017.105."
"6819","PC130700","Yu X, Wang H, Li X, et al.  2016.  Activation of the MDA5-IPS1 viral sensing pathway induces cancer cell death and type I interferon-dependentantitumor immunity.  Cancer Res 76(8):2166-2176."
"6820","PC130700P1","Yu X, Wang H, Li X, et al.  2016.  Activation of the MDA5-IPS1 viral sensing pathway induces cancer cell death and type I interferon-dependentantitumor immunity.  Cancer Res 76(8):2166-2176."
"6821","PC130716","Larimer BM, Dubois F, Bloch E, et al. Specific. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2018 Oct; 59(10): 1538-1543. https://doi.org/10.2967/jnumed.118.208785 PMID:29853654"
"6822","PC130716P1","Larimer BM, Dubois F, Bloch E, et al. Specific. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2018 Oct; 59(10): 1538-1543. https://doi.org/10.2967/jnumed.118.208785 PMID:29853654"
"6823","PC130726","Harshman LC, Wang X, Nakabayashi M, et al.  2015.  Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer.  JAMA Oncol 1:495-504."
"6824","PC130726","Wang X, Harshman LC, Xie W, et al.  2016.  Association of SLCO2B1 genotypes with time to progression and overall survival in patients receiving androgen deprivation therapy for prostate cancer.  J Clin Oncol 34(4):352-359."
"6825","PC130736","Mukhopadhyay A, Hanold LE, Thayele Purayil H, Gisemba SA, Senadheera SN, Aldrich JV. Macrocyclic peptides decrease c-Myc protein levels and reduce prostate cancer cell growth. Cancer Biol Ther. 2017 Aug 3;18(8):571-583. doi: 10.1080/15384047.2017.1345384. Epub 2017 Jul 10. PubMed PMID: 28692379; PubMed Central PMCID: PMC5652972."
"6826","PC130870","Hafeez BB, Ganju A, Sikander M, Kashyap VK, Hafeez ZB, Chauhan N, Malik S, Massey AE, Tripathi
MK, Halaweish FT, Zafar N, Singh MM, Yallapu MM, Chauhan SC, Jaggi M. Chauhan SC.
Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of
Oncogenic ß-catenin Signaling and EMT Progression. Mol Cancer Ther. 2017 Oct;16(10):2267-2280."
"6827","PC130944","Wang D, Ding L, Wang L, et al.  2015.  LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer.  Oncotarget 6(38):41045-41055."
"6828","PC130944","Wu C, Jin X, Yang J, et al. 2016. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer. Oncotarget. 7(3): 3440-3452. doi: 10.18632/oncotarget.6497."
"6829","PC130964","Lee HJ, Li J, Vickman RE, Li J, Liu R, Durkes AC, Elzey BD, Yue S, Liu X, Ratliff TL, et al. Cholesterol Esterification Inhibition Suppresses Prostate Cancer Metastasis by Impairing the Wnt/ß-catenin Pathway. Molecular Cancer Research. 2018;16:974-985. doi: 10.1158/1541-7786.MCR-17-0665."
"6830","PC130964","Lee S-Y, Li J, Tai J-N, et al.  2015.  Avasimibe encapsulated in human serum albumin blocks cholesterol esterification for selective cancer treatment.  ACS Nano 3:2420-2432."
"6831","PC130991","Goldstein A, Valda Toro P, Lee J, et al. 2017. Detection fidelity of AR mutations in plasma derived cell-free DNA.  Oncotarget 8(9):15651-15662."
"6832","PC131008","Liu W, Almo SC, and Zang X.  2016.  Co-stimulate or co-inhibit regulatory T cells, which side to go?  Immunological Investigations 45:813-831."
"6833","PC131008","Janakiram M, Chinai JM, Zhao A, Sparano JA, Zang X. HHLA2 and TMIGD2: New
immunotherapeutic targets of the B7 and CD28 families. OncoImmunology, 4:
e1026534-­1-­ e1026534-­3, 2015"
"6834","PC131008","Zhao H, Bauzon F, Bi E, et al.  2015.  Substituting threonine187 with alanine in p27Kip1 prevents pituitary tumorigenesis by two-hit loss Of Rb1 and enhances humoral immunity in old age.  J Biol Chem 290:5797-5809."
"6835","PC131008","Chinai JM, Janakiram M, Chen F, et al.  2015.  New Immunotherapies targeting the PD-1 pathway.  Trends in Pharmacological Sciences 36:587-595."
"6836","PC131008","Assal A, Kaner J, Pendurti G, et al.  2015.  Emerging targets in cancer immunotherapy: Beyond CTLA-4 and PD-1.  Immunotherapy 7:1169-1186."
"6837","PC131008","Picarda E, Ohaegbulam KC, and Zang X.  2016.  Molecular pathways: Targeting B7-H3 (CD276) for human cancer immunotherapy.  Clin Can Res 22:3425-3431."
"6838","PC131008","Janakiram M, Chinai JM, Fineberg S, Fiser A, Montagna C, Medaverepu R, Castano E,
Jeon H, Ohaegbulam KC, Zhao R, Zhao A, Almo SC, Sparano JA, Zang X. Expression,
clinical significance, and receptor identification of the newest B7 family member HHLA2
protein. Clinical Cancer Research, 21:2359-­2366, 2015"
"6839","PC131008","Janakiram M, Pareek V, Cheng H, et al.  2016.  Immune checkpoint blockade in human cancer therapy: Lung cancer and hematopoietic malignancy.  Immunotherapy 8:809-819."
"6840","PC131008","Janakiram M, Shah UA, Liu W, et al.  2016.  The third group of B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x and B7- H3.  Immunol Rev 276(1):26-39."
"6841","PC131008","Kim C. Ohaegbulam, Weifeng Liu, Hyungjun Jeon, Steven C. Almo and Xingxing Zang Tumor-expressed immune checkpoint B7x promotes cancer progression and antigen-specific CD8 T cell exhaustion and suppressive innate immune cells Oncotarget, 2017, Vol. 8, (No. 47), pp: 82740-82753"
"6842","PC131008","Ohaegbulam KC, Assal A, Lázár-­Molnár E, Yao Y, Zang X. Human cancer
immunotherapy with antibodies to the PD-­1 and PD-­L1 pathway. Trends in Molecular
Medicine, 21:24-­33, 2015"
"6843","PC131036","Lu X, Horner JW, Paul E, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017 03; 543(7647): 728-732. https://doi.org/10.1038/nature21676 PMID:28321130"
"6844","PC131036","Wang G, Lu X, Dey P, et al.  2016.  Targeting YAP-dependent MDSC infiltration impairs tumor progression.  Cancer Discov 6:80-95."
"6845","PC131103","Lam HM, Ouyang B, Chen J, et al. 2014. Targeting GPR30 with G-1: a new therapeutic target for castration-resistant prostate cancer. Endocr Relat Cancer. 21(6): 903-914. doi: 10.1530/ERC-14-0402."
"6846","PC131242","Qi J, Dong Z, Liu J, Peery RC, Zhang S, Liu JY, Zhang JT. Effective Targeting of the Survivin Dimerization Interface with Small-Molecule Inhibitors. Cancer Res. 2016 Jan 15;76(2):453-62. doi: 10.1158/0008-5472.CAN-15-1874. Epub 2016 Jan 7. Erratum in: Cancer Res. 2018 Dec 15;78(24):6904. PubMed PMID: 26744521."
"6847","PC131242","Peery RC, Liu JY, Zhang JT. Targeting survivin for therapeutic discovery: past, present, and future promises. Drug Discov Today. 2017 Oct;22(10):1466-1477. doi: 10.1016/j.drudis.2017.05.009. Epub 2017 May 31. Review. PubMed PMID: 28577912."
"6848","PC131243","Long MD, Smiraglia DJ, and Campbell MJ.  2017.  The genomic impact of DNA CpG methylation on gene expression; relationships in prostate cancer.  Biomolecules 7(1). pii: E15."
"6849","PC131243","Long MD, Singh PK, Russell JR, Llimos G, Rosario S, Rizvi A, van den Berg PR, Kirk J, Sucheston-Campbell LE, Smiraglia DJ, et al. The miR-96 and RAR¿ signaling axis governs androgen signaling and prostate cancer progression. Oncogene. 2019 Jan;38(3):421-444. doi: 10.1038/s41388-018-0450-6. Epub 2018 Aug 17. PubMed PMID: 30120411; PubMed Central PMCID: PMC6336686."
"6850","PC131302","Roshan-Moniri M, Hsing M, Butler MS, et al.  2014.  Orphan nuclear receptors as drug targets for the treatment of prostate and breast cancers.  Cancer Treat Rev 40: 1137-1152."
"6851","PC131367","Vayalil PK and Landar A.  2015.  Mitochondrial oncobioenergetic index: A potential biomarker to predict progression from indolent to aggressive prostate cancer.  Oncotarget 6(40):43065-43080."
"6852","PC131378","Liang Y, Mafuvadze B, Aebi JD, et al.  2016.  Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells.  OncoTargets and Therapy 9:3223-3232."
"6853","PC131383","Drake JM and Huang J.  2014.  PIP5K1alpha inhibition as a therapeutic strategy for prostate cancer.  Proc Natl Acad Sci U S A 111(35):12578-12579."
"6854","PC131392","Yu EY, Duan F, Muzi M, et al.  2015.  Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: Results from ACRIN 6687.  J Nucl Med 56(3):354-360."
"6855","PC131392","Yu EY, Duan F, Muzi M, et al.  2015.  Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: Results from ACRIN 6687.  J Nucl Med 56(3):354-360."
"6856","PC131392","Evans CP, Higano CS, Keane T, et al.  2016.  The PREVAIL study: Primary outcomes by site and extent of baseline disease for enzalutamide-treated men with chemotherapy ynaïve metastatic castration-resistant prostate Cancer. Eur Urol 70(4):675-683."
"6857","PC131392","Pritchard CC, Mateo J, Walsh M., et al.  2016.  Inherited DNA repair mutations in men with metastatic prostate cancer.  N Engl J Med 375(5):443-453."
"6858","PC131392","McKay RR, Werner L, Mostaghel EA, et al.  2017.  A Phase II Trial of abiraterone combined with dutasteride for men with metastatic castration-resistant prostate cancer. Clin Cancer Res 23(4):935-945."
"6859","PC131392","Smith MR, Antonarakis ES, Ryan CJ, et al.  Phase 2 Study of the safety and antitumor activity of Apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort.  Eur Urol 70(6):963-970."
"6860","PC131392","Antonarakis EA, Kibel AS, Yu EY, et al.  2017.  Sequencing of sipuleucel-T and androgen deprivation therapy in men with hormone-sensitive biochemically-recurrent prostate cancer: A phase II randomized trial.  Clin Cancer Res 23(10):2451-2459."
"6861","PC131392","Penson DF, Armstrong AJ, Concepcion R, et al.  2016.  Enzalutamide versus Bicalutamide in castration-resistant prostate cancer: The STRIVE Trial.  J Clin Oncol 34(18):2098-2106."
"6862","PC131392","Graff JN, Higano CS, Hahn NM, et al.  2016.  Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors.  Cancer 122(16):2524-2533."
"6863","PC131392","Montgomery RB, Eisenberger MA, Rettig MB, et al.  2016.  Androgen receptor modulation optimized for response (ARMOR) Phase I and II Studies: Galeterone for the treatment of castration-resistant prostate cancer.  Clin Cancer Res 22(6):1356-1363"
"6864","PC131392","Scher HI, Morris MJ, Stadler WM, et al.  2016.  Trial design and objectives for castration resistant prostate cancer: Updated recommentations from the Prostate Cancer Clinical Trials Working Group 3.  J Clin Oncol 34(12):1402-1418"
"6865","PC131392","Graff JN, Baciarello G, Armstrong AJ, et al.  2016.  Efficacy and safety of enzalutamide in patients 75 hyears or older with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from PREVAIL.  Ann Oncol 27(2):286-294."
"6866","PC131392","Halabi S, Kelly WK, Ma H, et al.  2016.  Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer.  J Clin Oncol 34(14):1652-1659."
"6867","PC131392","Beer TM, Armstrong AJ, Rathkopf D, et al.  2017.  Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: Extended analysis of the Phase 3 PREVAIL Study.  Eur Urol 71(2):151-154."
"6868","PC131392","Aggarwal RR, Beer TM, Weinberg VK, et al.  2015.  Intermittent chemotherapy as a platform for testing novel agents in patients with metastatic castration-resistant prostate cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent docetaxel with prednisone with or without maintenance GM-CSF.  Clin Genitourin Cancer 13(3):e191-8."
"6869","PC131392","Hussain M, Rathkopf D, Liu G, et al.  2015.  A randomized non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC_1121B) plus mitozantrone and prednisone in men with metastatic docetaxel-pretreated castrationresistant prostate cancer.  Eur J Cancer 51(13):1714-1724."
"6870","PC131392","Higano CS, Berlin J, Gordon M, et al.  2015.  Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors.  Invest New Drugs 33(2):450-462."
"6871","PC131392","Penson DF, Armstrong AJ, Concepcion R, et al.  2016.  Enzalutamide versus bicalutamide in castration-resistant prostate cancer: The STRIVE Trial.  J Clin Oncol 34(18):2098-2106."
"6872","PC131392","Chi KN, Yu EY, Jacobs C, et al.  2016.  A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers.  Ann Oncol 27(6):1116-1122."
"6873","PC131448","Cunningham D and You Z.  2015.  In vitro and in vivo model systems used in prostate cancer research.  J Biol Methods 2(1):e17."
"6874","PC131522","Dogra V, Chinni B, Singh S, et al.  2016.  Photoacoustic imaging with an acoustic lens detects prostate cancer cells labeled with PSMA-targeting near-infrared dye-conjugates.  J Biomed Opt 21(6):66019."
"6875","PC131545","Yu Z, Cai C, Gao S, et al.  2014.  Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin Cancer Res  20(15):4075-85."
"6876","PC131545","Yu Z, Chen S, Sowalsky AG, et al.  2014.  Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res 20(6):1590-600."
"6877","PC131604","Yuan X, Cai C, Chen S, et al.  2014.  Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.  Oncogene 33(22):2815-2825."
"6878","PC131609","Barakat DJ, Zhang J, Barberi T, et al.  2015.  CCAAT/Enhancer binding protein beta controls androgen-deprivation-induced senescence in prostate cancer cells.  Oncogene 34(48):5912-5922."
"6879","PC131609","Barakat DJ, Mendonca J, Barberi T, et al.  2016.  C/EBPbeta regulates sensitivity to bortezomib in prostate cancer cells by inducing REDD1 and autophagosome-lysosome fusion.  Cancer Lett 375(1):152-161."
"6880","PC131680","Whiting N, Hu J, Shah J, et al.  2015.  Real-time MRI-guided catheter tracking using hyperpolarized silicon particles.  Sci Rep 5:12842."
"6881","PC131769","Wang G, Lu X, Dey P, et al.  1016.  Targeting YAP-dependent MDSC infiltration impairs tumor progression.  Cancer Discover 6(1):80-95."
"6882","PC131773","Huang FW, Mosquera JM, Garofalo A, Oh C, Baco M, Amin-Mansour A, Rabasha B, Bahl S, Mullane SA, Robinson BD, et al. Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. Cancer Discov. 2017 Sep;7(9):973 983. doi: 10.1158/2159-8290.CD-16-0960. Epub 2017 May 17. PubMed PMID: 28515055; PubMed Central PMCID: PMC5836784."
"6883","PC131800","Armstrong AJ, Saad F, Phung, et al. 2017. Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. Cancer. 123(12): 2303-2311. doi: 10.1002/cncr.30587."
"6884","PC131800","Smith MR.  Sweeney CJ, Corn PG, et al.  2014.  Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer:results of a phase II nonrandomized expansion study.  J Clin Oncol 32(30):3391-3399."
"6885","PC131800","Armstrong AJ, Halabi S, Healy P, et al.  2016.  A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.  Prostate Cancer Prostatic Dis 19(1):100-106."
"6886","PC131800","Penson DF, Armstrong AJ, Concepcion R, et al.  2016.  Enzalutamide Versus bicalutamide in castration-resistant prostate cancer: The STRIVE Trial.  J Clin Oncol 34:1-9."
"6887","PC131800","Scher HI, Morris MJ, Stadler WM, et al.  2016.  Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials Working Group (PCWG3). J Clin Oncol 34(12):1402-1418."
"6888","PC131800","Taplin ME, Armstrong AJ, Lin P, et al. 2017. Clinical Outcomes of Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer and Low Baseline PSA Treated with Enzalutamide vs Placebo. J Urol. 198(6): 1324-1332. doi: 10.1016/j.juro.2017.07.071."
"6889","PC131800","Ramalingam S, Humeniuk MS, Hu R, et al. 2017. Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer. Urol Oncol. 35(6): 418-424. doi: 10.1016/j.urolonc.2016.12.016."
"6890","PC131800","Armstrong AJ, Halabi S, Healy P, et al. 2017. Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. Eur J Cancer. 81: 228-236. doi: 10.1016/j.ejca.2017.02.030."
"6891","PC131800","Armstrong AJ, Humeniuk MS, Healy P, et al. 2017. Phase Ib Trial of Cabazitaxel and Tasquinimod in Men WithHeavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial. Prostate. 77(4): 385-395. doi: 10.1002/pros.23277."
"6892","PC131800","Gupta S, Li J, Kemeny G, et al. 2017. Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Menwith Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer. ClinCancer Res. 23(5): 1346-1357. doi: 10.1158/1078-0432.CCR-16-1211."
"6893","PC131800","Armstrong AJ, Kaboteh R, Carducci MA, et al.  2014.  Assessment of the bone scan index in a randomized placebo-controlled trial oftasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).  Urol Oncol 32(8):1308-16."
"6894","PC131802","Roca H, Jones JD, Purica MC, et al. 2018. Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. J Clin Invest. 128(1): 248-266. doi: 10.1172/JCI92466."
"6895","PC131802","Sinder BP, Zweifler L, Koh AJ, et al. 2017. Bone Mass is Compromised by the ChemotherapeuticTrabectedin via Effects on Osteoblasts and Macrophage Efferocytosis. J Bone Miner Res. 32(10): 2116-2127. doi: 10.1002/jbmr.3196."
"6896","PC131820","Cheng HH, Klemfuss N, Montgomery B, et al.  2016.  Pilot study of clinical targeted next generation sequencing for prostate cancer: Consequences for treatment and genetic counseling.  Prostate 76:1303-1311."
"6897","PC131820","Cowen (Shiovitz) S, Turner EH, Beightol MB, et al.  2016.  Frequent PIK3CA mutations in colorectal and endometrial tumors with 2 or more somatic mutations in mismatch repair genes.  Gastroenterology 151: 440-447."
"6898","PC131820","Salipante SJ, Scroggins SM, Hampel HL, et al.  2014.  Microsatellite instability detection by next generation sequencing.  Clin Chem 60 (9):1192-1199."
"6899","PC131820","Robinson D, Van Allen EM, Wu Y, et al.  2015.  Integrative clinical sequencing analysis of metastatic castration resistant prostate cancer reveals a high frequency of clinical actionability.  Cell 161:1215-1228."
"6900","PC131820","Pritchard CC, Morrissey C, Kumar A, et al.  2014.  Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer.  Nat Commun 5:4988."
"6901","PC131820","Hempelmann JA, Scroggins SM, Pritchard CC, et al.  2015.  MSIplus:  Integrated colorectal cancer molecular testing by next-generation sequencing.  J Mol Diagn 17(6):705-714."
"6902","PC131820","Hempelmann JA, Lockwood CM, Konnick EQ, Schweizer MT, Antonarakis ES, Lotan TL, Montgomery B, Nelson PS, Klemfuss N, Salipante SJ, et al. Microsatellite instability in prostate cancer by PCR or next-generation sequencing. J Immunother Cancer. 2018 Apr 17;6(1):29. doi: 10.1186/s40425-018-0341-y. PubMed PMID: 29665853; PubMed Central PMCID: PMC5904988."
"6903","PC131820","Cheng HH, Pritchard CC, Montgomery B, Lin DW, Nelson PS. Prostate Cancer Screening in a
New Era of Genetics. Clin Genitourin Cancer. (2017) Epub ahead of print. PMID: 28697982."
"6904","PC131820","Guedes LB, Antonarakis ES, Schweizer MT, Mirkheshti N, Almutairi F, Park JC, Glavaris S,
Hicks J, Eisenberger MA, De Marzo AM, Isaacs WB, Eshleman JR, Pritchard CC*, Lotan TL*
MSH2 Loss in Primary Prostate Cancer. (2017). Clin. Cancer Res. Epub ahead of print.
PMID:28790115"
"6905","PC131820","Van Allen EM, Robinson D, Morrissey C, et al.  2016.  A comparative assessment of clinical whole exome and transcrip-tome profiling across sequencing centers: Implications for precision cancer medicine.  Oncotarget 7(33):52888-52899."
"6906","PC131820","Pritchard CC, Mateo J, Walsh MF, et al.  2016.  Inherited DNA-Repair gene mutations in men with metastatic prostate cancer.  New England Journal of Medicine 375:443-453."
"6907","PC131820","Cheng HH, Pritchard CC, Boyd T, et al.  2016.  Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer. European J Urology 69:992-995."
"6908","PC131820","Mateo J, Boysen G, Barbieri CE, et al.  2017.  DNA repair in prostate cancer: Biology and clinical implications.  Eur Urol 71(3):417-425."
"6909","PC131833","Odedina FT, Reams RR, Kaninjing E, et al. 2018. Increasing the representation of minority students in the biomedical workforce: the ReTOOL program. J Cancer Educ. 1-7. doi: 10.1007/s13187-018-1344-6."
"6910","PC131841","Kozminski MA, Tomlins S, Cole A, Singhal U, Lu L, Skolarus TA, Palapattu GS, Montgomery JS, Weizer AZ, Mehra R, Hollenbeck BK, Miller DC, He C, Feng FY, Morgan TM. Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. Urol Oncol. 2016 Sep;34(9):415.e1-6. doi: 10.1016/j.urolonc.2016.03.019. Epub 2016 Apr 29. PubMed PMID: 27140065."
"6911","PC131841","Gogoi P, Sepehri S, Zhou Y, et al.  2016.  Development of an automated and sensitive microfluidic device for capturing and characterizing circulating tumor cells (CTCs) from clinical blood samples.  PLoS One 11(1): e0147400."
"6912","PC131841","Kozminski MA, Tomlins S, Cole A, et al.  2016.  Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy.  Urol Oncol 34(9):415.e1-6."
"6913","PC131841","Cole AI, Morgan TM, Spratt DE, Palapattu GS, He C, Tomlins SA, Weizer AZ, Feng FY, Wu A, Siddiqui J, Chinnaiyan AM, Montgomery JS, Kunju LP, Miller DC, Hollenbeck BK, Wei JT, Mehra R. Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. J Urol. 2016 Aug;196(2):405-11. doi: 10.1016/j.juro.2016.01.120. Epub 2016 Feb 23. PubMed PMID: 26920466."
"6914","PC131841","Jung Y, Cackowski FC, Yumoto K, Decker AM, Wang J, Kim JK, Lee E, Wang Y, Chung JS, Gursky AM, Krebsbach PH, Pienta KJ, Morgan TM, Taichman RS. CXCL12¿ Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes. Cancer Res. 2018 Apr 15;78(8):2026-2039. doi: 10.1158/0008-5472.CAN-17-2332. Epub 2018 Feb 5. PubMed PMID: 29431639; PubMed Central PMCID: PMC6324566."
"6915","PC131841","Morgan TM, Hawken SR, Ghani KR, Miller DC, Feng FY, Linsell SM, Salisz JA, Gao Y, Montie JE, Cher ML. Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomy. Prostate Cancer Prostatic Dis. 2016 Jun;19(2):216-21. doi: 10.1038/pcan.2016.9. Epub 2016 Mar 8. PubMed PMID: 26951715."
"6916","PC131841","Qiao Y, Feng FY, Wang Y, Cao X, Han S, Wilder-Romans K, Navone NM, Logothetis C, Taichman RS, Keller ET, Palapattu GS, Alva AS, Smith DC, Tomlins SA, Chinnaiyan AM, Morgan TM. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. Neoplasia. 2016 Jan;18(1):1-9. doi: 10.1016/j.neo.2015.11.009. PubMed PMID: 26806347; PubMed Central PMCID: PMC4735600."
"6917","PC131841","Kozminsky M, Fouladdel S, Chung JS, Wang Y, Smith DC, Alva A, Azizi E, Morgan T, Nagrath S. Detection of CTC Clusters and a Dedifferentiated RNA-Expression Survival Signature in Prostate Cancer. Adv Sci (Weinh). 2018 Nov 15;6(2):1801254. doi: 10.1002/advs.201801254. eCollection 2019 Jan 23. PubMed PMID: 30693182; PubMed Central PMCID: PMC6343066."
"6918","PC131841","Singhal U, Wang Y, Henderson J, et al. 2018. Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Mol Cancer Res. 16(4): 643-654. doi: 10.1158/1541-7786."
"6919","PC131841","Morgan TM, Hawken SR, Ghani KR, et al.  2016.  Variation in the use of postoperative radiotherapy among highrisk patients following radical prostatectomy.  Prostate Cancer Prostatic Dis 19(2):216-221."
"6920","PC131841","Qiao Y, Feng FY, Wang Y, et al.  2016.  Mechanistic support for combined MET and AR blockade in castration-resistant prostate cancer.  Neoplasia 18(1):1-9."
"6921","PC131841","Cole AI, Morgan TM, Spratt DE, et al.  2016.  Prognostic value of percent Gleason grade 4 at prostate biopsy on predicting prostatectomy pathology and recurrence.  J Urol 196:405-411."
"6922","PC131844","Farina NH, Zingiryan A, Vrolijk MA, et al. Nanoparticle-based targeted cancer strategies for non-invasive prostate cancer intervention. Journal of cellular physiology. 2018 Sep; 233(9): 6408-6417. https://doi.org/10.1002/jcp.26593 PMID:29663383"
"6923","PC131844","Zingiryan A, Farina NH, Finstad KH, et al.  2017.  Cover Image.  232:1. J Cell Physiol 232(1)."
"6924","PC131844","Balatti V, Nigita G, Veneziano D, et al. 2017. tsRNA signatures in cancer.  Proc Natl Acad Sci U S A. 114(30):8071-8076."
"6925","PC131844","Zingiryan A, Farina NH, Finstad KH, et al.  2017.  Dissection of individual prostate lobes in mouse models of prostate cancer to obtain high quality RNA.  J Cell Physiol 232(1):14-18."
"6926","PC131844","Farina NH, Zingiryan A, Akech JA, et al. A microRNA/Runx1/Runx2 network regulates prostate tumor progression from onset to adenocarcinoma in TRAMP mice. Oncotarget. 2016 Oct; 7(43): 70462-70474. https://doi.org/10.18632/oncotarget.11992 PMID:27634876"
"6927","PC131859","Zhu X, Xu Y, Solis LM, et al.  2015.  Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment.  Proc Natl Acad Sci U S A 112(25):7779-7784."
"6928","PC131859","Xu Y, Yang W, Shi J, et al.  2016.  Prohibitin 1 regulates tumor cell apoptosis via interaction with X-linked Inhibitor of Apoptosis Protein.  J Mol Cell Biol 8(3):282-285."
"6929","PC131859","Islam MA, Reesor EK, Xu Y, et al.  2015.  Biomaterials for mRNA delivery.  Biomater Sci 3(12):1519-1533."
"6930","PC131910","You S, Knudsen BS, Erho N, et al.  2016.  Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome.  Cancer Res 76(17):4948-4958."
"6931","PC131920","Oh Y, and Swierczewska M, et al.  2015. Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant Tumors. J Control Release 220(B):671-681."
"6932","PC131920","Swierczewska M, Han HS, Kim K, et al.  2016.  Polysaccharide-based nanoparticles for theranostic nanomedicine.  Adv Drug Deliv Rev 1:99(Pt A):70-84."
"6933","PC131927","Scher HI, Morris MJ, Stadler WM, et al.  2016.  Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the Prostate Cancer Clinical Trials Working Group 3.  J Clin Oncol 34(12):1402-1418."
"6934","PC131927","McKay RR, Werner L, Mostaghel EA, et al.  2017.  A phase II trial of abiraterone combined with dutasteride for men with metastatic castration-resistant prostate cancer.  Clin Cancer Res 23(4):935-945."
"6935","PC131927","Montgomery B, Tretiakova MS, Joshua AM, et al.  2017.  Neoadjuvant enzalutamide prior to prostatectomy.  Clin Cancer Res 23(9):2169-2176."
"6936","PC131930","Darshan M, Zheng Q, Fedor HL, et al. 2014. Biobanking of Derivatives From Radical Retropubic and Robot-Assisted Laparoscopic Prostatectomy Tissues as Part of the Prostate Cancer Biorepository Network. The Prostate 74(1): 61-69. doi: 10.1002/pros.22730."
"6937","PC131930","Baena-Del Valle JA, Zheng Q, Hicks JL, et al. 2017. Rapid Loss of RNA Detection by In Situ Hybridization in Stored Tissue Blocks and Preservation by Cold Storage of Unstained Slides. American journal of clinical pathology 148(5): 398-415. doi: 10.1093/ajcp/aqx094."
"6938","PC131930","Guedes LB, Morais CL, Fedor H, et al. 2018. Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate Cancer. Archives of pathology & laboratory medicine. doi: 10.5858/arpa.2018-0068-OA."
"6939","PC131930","Marrone MT, Joshu CE, Peskoe SB, et al. 2019. Adding the Team into T1 Translational Research: A Case Study of Multidisciplinary Team Science in the Evaluation of Biomarkers of Prostate Cancer Risk and Prognosis. Clinical chemistry 65(1): 189. doi: 10.1373/clinchem.2018.293365."
"6940","PC131930","Sfanos KS, Yegnasubramanian S, Nelson WG, Lotan TL, Kulac I, Hicks JL, Zheng Q, Bieberich CJ, Haffner MC, De Marzo AM. If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease. Asian J Urol. 2019 Jan;6(1):10-25. doi: 10.1016/j.ajur.2018.11.006. Epub 2018 Dec 12. Review. PubMed PMID: 30775245; PubMed Central PMCID: PMC6363603."
"6941","PC131930","Zhang L, Yang S, Chen X, et al.  2015.  The hippo pathway effector, yap, regulates motility, invasion and castration- resistant growth of prostate cancer cells.  Mol Cell Biol 35(8):1350-1362."
"6942","PC131930","Liang J, Li Y, Daniels G, et al.  2015.  LEF1 targeting EMT in prostate cancer invasion is mediated by miR-181a  Am J Cancer Res 5(3):1124-1132."
"6943","PC131930","Zheng Q, Peskoe SB, Ribas J, et al.  2014.  Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy.  Prostate 74(16):1655-1662"
"6944","PC131930","Di Mitri D, Toso A, Chen JJ, et al.  2014.  Tumour-infiltrating Gr-11 myeloid cells antagonize senescence in cancer nature.  515:134-137."
"6945","PC131930","Tian Y, Choi CH, Li QK, et al.  2015.  Overexpression of periostin in stroma positively associated with aggressive prostate cancer.  PLoS One 10(3):e0121502."
"6946","PC131930","Zhu G, Liu Z, Epstein JI, et al.  2015.  A novel quantitative multiplex tissue immunoblotting for biomarkers predicts a prostate cancer aggressive phenotype.  Cancer Epidemiol Biomarkers Prev 24(12):1864-1872."
"6947","PC131930","Zheng T, Pierre-Pierre N, Yan X, et al.  2015.  A gold nanoparticle-enabled blood test for early stage cancer detection and risk assessment.  ACS Appl Mater Interfaces 7(12):6819-6827."
"6948","PC131930P1","Baena-Del Valle JA, Zheng Q, Hicks JL, et al. 2017. Rapid Loss of RNA Detection by In Situ Hybridization in Stored Tissue Blocks and Preservation by Cold Storage of Unstained Slides. Am J Clin Pathol. 148(5): 398-415. doi: 10.1093/ajcp/aqx094."
"6949","PC131933","Thakur MK, Heilbrun LK, Sheng S, et al.  2016.  A randomized non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.  Invest New Drugs 34(1):112-118."
"6950","PC131933","Lin C, Bradshaw TJ, Perk TG, et al.  2016.  Repeatability of quantitative 18F-NaF PET: A multicenter study.  J Nucl Med, 57(12):1872-1879."
"6951","PC131933","Simoncic U, Perlman S, Liu G, et al.  2015.  Optimizing and 18F-NaF and 18F-FDG Cocktail for PET assessment of metastatic castration-resistant prostate cancer.  Nucl Med Commun 36(12):1174-1180."
"6952","PC131933","Scher HI, Morris MJ, Stadler WM, et al.  2016.  Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3.  J Clin Oncol 34(12):1402-1418."
"6953","PC131933","Smith MR, Antonarakis ES, Ryan CJ, et al.  2016.  Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen-receptor antagonist, in the high-risk non-metastatic castration-resistant prostate cancer cohort.  Eur Urol 70(6):963-970."
"6954","PC131933","Thakur MK, Heilbrun LK, Sheng S, et al.  2016.  A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.  Invest New Drugs 34(1):112-118."
"6955","PC131933","Coluru V, and McNeel DG.  2016.  B Lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines.  Oncotarget 7(42):67901-67918."
"6956","PC131933","Muzahir S, Jeraj R, Liu G, et al.  2015.  Differentiation of metastatic vs degenerative joint disease using semi-quantitative analysis with (18)F-NaF PET/CT in castrate resistant prostate cancer patients.  Am J Nucl Med Mol Imaging 5(2):162-168."
"6957","PC131933","Petrylak DP, Gandhi JG, Clark WR, et al.  2015.  Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.  Invest New Drugs 33(2):397-408."
"6958","PC131933","Hussain M, Rathkopf D, Liu G, et al.  2015.  A randomized non-comparative Phase II Trial of Cixutumumab (IMC-A12) or Ramucirumab (IMC-1121B) Plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.  Eur J Cancer 51(13):1714-1724."
"6959","PC131933","Kyriakopoulos CE, Heath EI, Eickhoff JC, et al.  2016.  A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer.  Invest New Drugs 34(2):225-230."
"6960","PC131933","Rekoske BT, Olson BM, and McNeel DG.  2016.  Antitumor vaccination of prostate cancer patients elicit PD-1/PD-L1 regulated antigen-specific immune response.  Oncoimmunology 5(6):e1165377."
"6961","PC131933","Shore ND, Antonarakis ES, Ryan CJ, et al.  2015.  Novel antiandrogen ARN-509 in high-risk non-metastatic castration-resistant prostate cancer.  J Urology 193(4):e1090."
"6962","PC131935","Saad F, Shore N, Van Poppel H, et al.  2015.  Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: Post hoc analysis of COU-AA-302.  Eur Urol 68(4): 570-577."
"6963","PC131935","Higano CS, Beer TM, Taplin ME, et al.  2015.  Long-term safety and antitumor activity in the Phase 1-2 study of enzalutamide in pre- and post-docetaxel castration-resistant prostate cancer.  Eur Urol 68(5): 795-801."
"6964","PC131935","Smith MR, Antonarakis ES, Ryan CJ, et al.  2016.  Phase 2 study of the safety and antitumor activity of apalutamide 1 (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort.  Eur Urol 70(6):963-970."
"6965","PC131935","Bryce AH, Alumkal JJ, Armstrong A, et al. 2017. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostatic Dis. 20(2): 221-227. doi: 10.1038/pcan.2016.71."
"6966","PC131935","Devlin N, Herdman M, Pavesi M, et al. 2017. Health-related quality of life effects of enzalutamide in patients with metastic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial. Health Qual Life Outcomes. 15(1): 130. doi: 10.1186/s12955-017-0704-y."
"6967","PC131935","Armstrong AJ, Halabi S, Healy P, et al. 2017. Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastic castration resistant prostate cancer. Eur J Cancer. 81: 228-236. doi: 10.1016/j.ejca.2017.02.030."
"6968","PC131935","Friedlander TW, Graff JN, Zejnullahu K, et al. 2017. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clin Genitourin Cancer. 15(6): 733-741.e1. doi: 10.1016/j.clgc.2017.05.026."
"6969","PC131935","Gillessen S, Attard G, Beer TM, et al. 2017. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol.73(2): 178-211. doi: 10.1016/j.eururo.2017.06.002."
"6970","PC131935","Devlin N, Herdman M, Pavesi M, et al.  2015.  Health-related quality of life (Hrqol) benefits of enzalutamide in patients with metastic castration-resistant prostate cancer (Mcrpc): An in-depth analysis of Eq-5d data from the prevail trial.  Value Health 18(7):A475."
"6971","PC131935","Graff JN, Higano CS, Hahn NM, et al.  2016.  Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors.  Cancer 122(16):2524-2533."
"6972","PC131935","Graff JN, Baciarello G, Armstrong AJ, et al.  2016.  Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from PREVAIL.  Ann Oncol 27(2):286-294."
"6973","PC131935","Graff JN, Thomas GV, Higano CS, et al.  2015.  Prolonged response to an IGF-1 receptor antibody in a patient with metastatic castration prostate cancer with neuroendocrine differentiation.  Cureus 7(12):e426."
"6974","PC131935","Beer TM, Armstrong AJ, Rathkopf D, et al.  2017.  Enzalutamide in men with chemotherapy- naive metastatic castration-resistant prostate cancer: Extended analysis of the Phase 3 PREVAI study.  Eur Urol 71(2):151-154."
"6975","PC131935","Beer TM, and Tombal B.  2014.  Enzalutamide in metastatic prostate cancer before chemotherapy.  N Engl J Med 371(18):1755-1756."
"6976","PC131935","Graff JN, Gordon MJ, and Beer TM.  2015.  Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer.  Expert Opin Pharmacother 16(5):749-754."
"6977","PC131935","Alumkal JJ, Slottke R, Schwartzman J, et al.  2015.  A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer.  Invest New Drugs 33(2):480-489."
"6978","PC131935","Courtney KD, Manola JB, Elfiky AA, et al.  2015.  A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.  Clin Genitourin Cancer 13(2):113-123."
"6979","PC131935","Aggarwal RR, Beer TM, Weinberg VK, et al.  2015.  Intermittent chemotherapy as a platform for testing novel agents in patients with metastatic castration-resistant prostate cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel with prednisone with or without maintenance GMCSF.  Clin Genitourin Cancer 13(3):e191-8."
"6980","PC131935","Loriot Y, Miller K, Sternberg CN, et al.  2015.  Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.  Lancet Oncol 16(5):509-521."
"6981","PC131935","Gillessen S, Omlin A, Attard G, et al.  2015.  Management of patients with advanced prostate cancer: Recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC).  Ann Oncol 26(8):1589-1604."
"6982","PC131935","Kimura G, Yonese J, Fukagai T, et al.  2016.  Enzalutamide in Japanese patients with chemotherapy-naive, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial.  Int J Urol 23(5):395-403."
"6983","PC131935","Evans CP, Higano CS, Keane T, et all.  2016.  The PREVAIL Study: Primary outcomes by site and extent of baseline disease for enzalutamide-treated men with chemotherapy-naive metastatic castration-resistant prostate cancer.  Eur Urol 70(4):675-683."
"6984","PC131954","Armstrong AJ, Halabi S, Healy P, et al.  2016.  A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.  Prostate Cancer Prostatic Dis 19(1):100-106."
"6985","PC131954","Teply BA, Wang H, Luber B, et al. 2018. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol. 19(1): 76-86. doi: 10.1016/S1470-2045(17)30906-3."
"6986","PC131954","Paller C, Zhou X, Heath E, et al. 2018. Muscadine grape skin extract in men with biochemically recurrent prostate cancer: A randomized, multicenter, placebo controlled clinical trial. Clin Cancer Res. 24(2): 306-315. doi: 10.1158/1078-0432.CCR-17-1100."
"6987","PC131954","Paller CJ, Rudek MA, Zhou XC, et al.  2015.  A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: safety, tolerability, and dose determination.  Prostate 75(14):1518-1525."
"6988","PC131954","Suzman DL, Zhou XC, Zahurak ML, et al.  2015.  Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with non-hormonal agents: Combined analysis of four phase-2 trials.  Prostate Cancer and Prostatic Diseases 18:49-55."
"6989","PC131954","Lin J, Zhan T, Duffy D, et al.  2014.  A pilot phase II study of digoxin in patients with recurrent prostate cancer as evident by rising PSA.  American Journal of Cancer Therapy and Pharmacology 2:21-32."
"6990","PC131954","Armstrong AJ, Kaboteh R, Carducci MA, et al.  2014.  Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).  Urol Oncol 32:1308-1316."
"6991","PC131954","Armstrong AJ, Haggman M, Stadler WM, et al.  2013.  Long term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.  Clin Cancer Res 19:6891-6901."
"6992","PC131954","Hussain M, Carducci MA, Slovin S, et al.  2014.  Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.  Invest New Drugs 32:904-912."
"6993","PC131954","Spreafico A, Chi KN, Sridhar SS, et al.  2014.  A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.  Invest New Drugs 32(5):1005-1016."
"6994","PC131955","Aggarwal RR, Beer TM, Weinberg VK, et al.  2015.  Intermittent chemotherapy as a platform for testing novel agents in patients with metastatic castration-resistant prostate cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of intermittent docetaxel with prednisone with or without maintenance GM-CSF.  Clinical Genitourinary Cancer 13(3):191-198."
"6995","PC131955","Aggarwal R, et al.  A Multicenter Phase I Study of cabazitaxel, mitxantrone, and prednisone, for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A Department of Defense prostate cancer clinical trials consortium study.  Urologic Oncol 35:149.e7-149.e13."
"6996","PC131955","Aggarwal R, Huang J, Alumkal J, et al. 2018. Clinical and Genomic Characterization of Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer: a Multi-Institutional Prospective Study. J Clin Oncol. 36(24): 2492-2503. doi: 10.1200/JCO.2017.77.6880."
"6997","PC131955","Friedlander TW, Graff JN, Zejnullahu K, et al. 2017. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clinical Genitourinary Cancer 15(6): 733-741.e1. doi: 10.1016/j.clgc.2017.05.026."
"6998","PC131956","Vaishampayan UN, Tehrani OS, Lawhorn-Crews JM, et al. 2017. A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [18F]FMAU-Positron Emission Tomography Imaging of Bone Metastases in Prostate Cancer. Mol Imaging Biol. 19(6): 810-816. doi: 10.1007/s11307-017-1057-y."
"6999","PC131956","Huang FW, Mosquera JM, Garofalo A, et al. 2017. Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. Cancer Discov. 7(9): 973-983. doi: 10.1158/2159-8290.CD-16-0960."
"7000","PC131956","McKay RR, Werner L, Fiorillo M, et al. 2016. Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer. Clin Genitourin Cancer. 15(4): 463-471. doi: 10.1016/j.clgc.2016.10.006."
"7001","PC131956","Conley-LaComb MK, Semaan L, Singareddy R, et al.  2016.  Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis.  Mol Cancer 15(1):68."
"7002","PC131956","Rosati R, Chen B, Patki M, et al.  2016.  Hybrid enzalutamide derivatives with histone deacetylase inhibitor activity decrease HSP90 and the androgen receptor levels and inhibit viability in enzalutamide resistant C4-2 prostate cancer cells.  Mol Pharmacol 90(3):225-237."
"7003","PC131956","Nakajima K, Heilbrun LK, Hogan V, et al.  2016.  Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I.  Oncotarget 7(50):82266-82272."
"7004","PC131956","Nakajima K, Heilbrun LK, Smith D, et al.  2017.  The influence of PSA autoantibodies in prostate cancer patients: a prospective clinical study-II.  Oncotarget 8(11):17643-17650."
"7005","PC131956","Hamel LM, Penner LA, Albrecht TL, et al.  2016.  Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer.  Cancer Control 23(4):327-337."
"7006","PC131956","McKay RR, Werner L, Fiorillo M, et al.  2016.  Efficacy of therapies after galeterone in patients with castration-resistant prostate cancer.  Clin Genitourin Cancer 15(4):463-471."
"7007","PC131956","Thakur MK and Vaishampayan U.  2016.  Multifaceted and personalized therapy of advanced prostate cancer.  Curr Opin Oncol 28:222-31."
"7008","PC131956","Cheng HH, Gulati R, Azad A, et al.  2015.  Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.  Prostate Cancer Prostatic Dis 18(2):122-127."
"7009","PC131956","Chinni S, Powell K, Louie S, et al.  2015.  ERG/AKR1C3/AR constitutes a feed-forward loop for AR signaling in prostate cancer cells.  Clin Cancer Res 21:2569-79."
"7010","PC131956","Nakajima K, Kho DH, Yanagawa T, et al.  2016.  Galectin-3 in bone tumor microenvironment: A beacon for individual skeletal metastasis management.  Cancer Metastasis Rev 35(2):333-346."
"7011","PC131956","Morgan TM, Hawken SR, Ghani KR, et al.  2016.  Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomy.  Prostate Cancer Prostatic Dis 19(2):216-221."
"7012","PC131956","Vaishampayan U.  2015.  Prostate cancer: Clinical implications of therapeutic sequence in mCRPC.  Nat Rev Urol 12:13-4."
"7013","PC131956","Robinson D, Van Allen EM, Wu YM, et al.  2015.  Integrative clinical genomics of advanced prostate cancer.  Cell 161(5):1215-28."
"7014","PC131956","Bernardo MM, Kaplun A, Dzinic SH, et al.  2015.  Maspin expression in prostate tumor cells averts stemness and stratifies drug sensitivity.  Cancer Res 75(18):3970-3979."
"7015","PC131956","Scher HI, Morris MJ, Stadler WM, et al.  2016.  Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3.  J Clin Oncol 34:1402-18."
"7016","PC131956","Kyriakopoulos CE, Heath EI, Eickhoff JC, et al.  2016.  A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer.  Invest New Drugs 34:225-30."
"7017","PC131956","Cho WJ, Oliveira DS, Najy AJ, et al.  2016.  Gene expression analysis of bone metastasis and circulating tumor cells from metastatic castrate-resistant prostate cancer patients.  J Transl Med 14:72."
"7018","PC131956","McKay RR, Zurita AJ, Werner L, et al.  2016.  A randomized phase II trial of short-course androgen deprivation therapy with or without bevacizumab for patients with recurrent prostate cancer after definitive local therapy.  J Clin Oncol 34(16):1913-1920."
"7019","PC131956","Vaishampayan U, Shevrin D, Stein M, et al.  2015.  Phase II trial of carboplatin, everolimus and prednisone in metastatic castrate resistant prostate cancer pretreated with docetaxel chemotherapy: A prostate cancer clinical trial consortium study.  Urology86:1206-11."
"7020","PC131956","Thakur MK, Heilbrun LK, Sheng S, et al.  2015.  A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.  Invest New Drugs 34:112-8."
"7021","PC131961","Antonarakis ES, Tagawa ST, Galletti G, et al. 2017. Randomized non-comparative phase II trial of early switch from docetaxel to cabazitaxel or vice versa, with integrated biomarker analysis, in men with chemotherapy-naïve metastatic castration-resistant prostate cancer. J Clin Oncol. 35(28): 3181-3188. doi: 10.1200/JCO.2017.72.4138."
"7022","PC131961","Beltran H, Oromendia C, Danila DC, et al. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Jan; 25(1): 43-51. https://doi.org/10.1158/1078-0432.CCR-18-1912 PMID:30232224"
"7023","PC131961","Tagawa ST, Antonarakis ES, Gjyrezi A, et al. Expression of AR-V7 and AR. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Mar; 25(6): 1880-1888. https://doi.org/10.1158/1078-0432.CCR-18-0320 PMID:30301829"
"7024","PC131967","Khan S, Hicks V, Colditz GA et al. 2017. The association of weight change in young adulthood and smoking status with risk of prostate cancer recurrence. Int J Cancer.  doi: 10.1002/ijc.31229"
"7025","PC131972","Freedman JA, Wang Y, Li X, et al. 2018. Single-nucleotide polymorphisms of stemness genes predicted to regulate RNA splicing, microRNA and oncogenic signaling are associated with prostate cancer survival. Carcinogenesis 39(7): 879-888. doi: 10.1093/carcin/bgy062."
"7026","PC131972","Wang Y, J.A. Freedman, X. Li, P.G. et al. Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. International Journal of Cancer. 2017;141(4):731-743. PMID: 28510291"
"7027","PC131985","Parsons TK, Pratt RN, Tang L, et al. 2018. An active and selective molecular mechanism mediating the uptake of sex steroids by prostate cancer cells. Molecular and cellular endocrinology 477: 121-131. doi: 10.1016/j.mce.2018.06.009."
"7028","PC131996","Eric T. Miller, Karim Chamie, Lorna Kwan et al. 2016. Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer.  Cancer Medicine."
"7029","PC132003","Wu Y, Yu H, Zheng S, et al. 2018. A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer. Prostate. 78(8): 607-615. doi: 10.1002/pros.23505."
"7030","PC132011","Hempel HA, Cuka NS, Kulac I, Barber JR, Cornish TC, Platz EA, De Marzo AM, Sfanos KS. Low Intratumoral Mast Cells Are Associated With a Higher Risk of Prostate Cancer Recurrence. Prostate. 2017 Mar;77(4):412-424. doi: 10.1002/pros.23280. Epub 2016 Nov 21. PubMed PMID: 27868214."
"7031","PC140068","Liu HY, Yu X, Liu H, et al.  2016.  Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer.  Sci. Rep. 6:30346."
"7032","PC140122","Rabacal W, Pabbisetty SK, Hoek KL, et al.  2016.  Transcription factor KLF2 regulates homeostatic NK cell proliferation and survival.  Proc Natl Acad Sci USA 113(19):5370-5375."
"7033","PC140122","Pabbisetty SK, Rabacal W, Volanakis EJ, et al.  2016.  Peripheral tolerance can be modified by altering KLF2-regulated Treg migration.  Proc Natl Acad Sci USA 113(32):E4662-E4670."
"7034","PC140124","Zahm CD, Colluru VT, and McNeel DG. 2017. Vaccination with high-affinity epitopes impairs antitumor efficacy by increasing PD-1 expression on CD8+ T cells.  Canc Imm Res 5:630-641."
"7035","PC140124","Gamat M and McNeel DG. 2017. Androgen deprivation and immunotherapy for the treatment of prostate cancer. Endocrine-related cancer 24(12): T297-T310. doi: 10.1530/ERC-17-0145."
"7036","PC140124","Zahm CD, Colluru VT, and McNeel DG. 2017. DNA vaccines for prostate cancer.  Pharmacol Ther 174:27-42."
"7037","PC140124","McNeel DG. 2016. TCR diversity - A universal cancer immunotherapy biomarker.  J ImmunoTherapy Cancer 4:69-72."
"7038","PC140136","Kargar S, Borisch EA, Froemming AT, Kawashima A, Mynderse LA, Stinson EG, Trzasko JD, Riederer SJ. Robust and efficient pharmacokinetic parameter non-linear least squares estimation for dynamic contrast enhanced MRI of the prostate. Magn Reson Imaging. 2018 May;48:50-61. doi: 10.1016/j.mri.2017.12.021. Epub 2017 Dec 24. PubMed PMID: 29278764; PubMed Central PMCID: PMC5889971."
"7039","PC140136","Riederer ST, Borisch EA, Froemming AT, et al.  2017.  Improved performance of prostate DCE-MRI using a 32-coil vs. 12-coil receiver array.  Magnetic Resonance Imaging 39:15-23."
"7040","PC140271","Meaburn KJ.  2016.  Spatial genome organization and its emerging role as a potential diagnosis tool.  Front Genet 7:134."
"7041","PC140271","Adriaens C, Serebryannyy LA, Feric M, et al. Blank spots on the map: some current questions on nuclear organization and genome architecture. Histochemistry and cell biology. 2018 Dec; 150(6): 579-592. https://doi.org/10.1007/s00418-018-1726-1 PMID:30238154"
"7042","PC140278","Wu JB, Yin L, Shi C, et al.  2017.  MAOA-dependent activation of sonic hedgehog-IL6-RANKL signaling network promotes prostate cancer metastasis by engaging tumor-stromal cell interactions.  Cancer Cell 31(3):368-382."
"7043","PC140278","Yin L, Li J, Liao CP, Jason Wu B. Monoamine Oxidase Deficiency Causes Prostate Atrophy and Reduces Prostate Progenitor Cell Activity. Stem Cells. 2018 Aug;36(8):1249-1258. doi: 10.1002/stem.2831. Epub 2018 Apr 22. PubMed PMID: 29637670."
"7044","PC140308","Zhang W, Yi B, Wang C, et al.  2016.  Silencing of CD24 enhances the PRIMA-1-induced restoration of mutant p53 in prostate cancer cells.  Clin Cancer Res 22(10):2545-2554."
"7045","PC140308","Zhang Y, Li B, Zhang X, et al.  2016.  CD24 is a genetic modifier for risk and progression of prostate cancer.  Mol Carcinog 56(2):641-650."
"7046","PC140318","Shi J, Kantoff PW, Wooster R, et al.  2017.  Cancer nanomedicine: Progress, challenges and opportunities.  Nat Rev Cancer 17(1):20-37."
"7047","PC140318","Xu X, Wu J, Liu S, et al. 2018. Redox-Responsive Nanoparticle-Mediated Systemic RNAi for Effective Cancer Therapy. Small 14(41). doi: 10.1002/smll.201802565."
"7048","PC140318","Zhu X, Tao W, Liu D, Wu J, Guo Z, Ji X, Bharwani Z, Zhao L, Zhao X, Farokhzad OC, Shi J. Surface De-PEGylation Controls Nanoparticle-Mediated siRNA Delivery In Vitro and In Vivo. Theranostics 2017; 7(7):1990-2002."
"7049","PC140318","Xu X, Wu J, Liu YL, et al.  2016.  Ultra pH-responsive and tumor-penetrating nanoplatform for targeted siRNA delivery with robust anti-cancer efficacy.  Angew Chem Int Ed 55(25):7091-7094."
"7050","PC140318P1","Markowski MC, Hubbard GK, Hicks JL, et al. 2018. Characterization of novel cell lines derived from a MYC-driven murine model of lethal metastatic adenocarcinoma of the prostate. The Prostate 78(13): 992-1000. doi: 10.1002/pros.23657."
"7051","PC140318P1","Xu X, Wu J, Liu YL, et al.  2016.  Ultra pH-responsive and tumor-penetrating nanoplatform for targeted siRNA delivery with robust anti-cancer efficacy.  Angew Chem Int 55(25):7091-7094."
"7052","PC140318P1","Zhu X, Tao W, Liu D, Wu J, Guo Z, Ji X, Bharwani Z, Zhao L, Zhao X, Farokhzad OC,
Shi J. Surface De-PEGylation Controls Nanoparticle-Mediated siRNA Delivery In Vitro
and In Vivo. Theranostics 2017; 7(7):1990-2002."
"7053","PC140318P1","Shi J, Kantoff PW, Wooster R, et al.  2017.  Cancer nanomedicine: Progress, challenges and opportunities.  Nat Rev Cancer 17(1):20-37."
"7054","PC140318P2","Zhu X, Tao W, Liu D, Wu J, Guo Z, Ji X, Bharwani Z, Zhao L, Zhao X, Farokhzad OC,
Shi J. Surface De-PEGylation Controls Nanoparticle-Mediated siRNA Delivery In Vitro
and In Vivo. Theranostics 2017; 7(7):1990-2002."
"7055","PC140318P2","Xu X, Wu J, Liu YL, et al.  2016.  Ultra pH-Responsive and tumor-penetrating nanoplatform for targeted siRNA delivery with robust anti-cancer efficacy.  Angew Chem Int Ed 55(25):7091-7094."
"7056","PC140318P2","Shi J, Kantoff PW, Wooster R, et al.  2017. Cancer nanomedicine: Progress, challenges and opportunities.  Nat Rev Cancer 17(1):20-37."
"7057","PC140318P2","Markowski MC, Hubbard GK, Hicks JL, et al. 2018. Characterization of novel cell lines derived from a MYC-driven murine model of lethal metastatic adenocarcinoma of the prostate. The Prostate 78(13): 992-1000. doi: 10.1002/pros.23657."
"7058","PC140319","Mohammad OS, Nyquist MD, Schweizer MT, et al. 2017. Supraphysiologic testosterone therapy in the treatment of prostate cancer: models, mechanisms and questions. Cancers 9(12): 166. doi:10.3390/cancers9120166."
"7059","PC140385","Bai S, Zhang BY, Dong Y. Impact of taxanes on androgen receptor signaling. Asian journal of andrology. 2019 May-Jun; 21(3): 249-252. https://doi.org/10.4103/aja.aja_37_18 PMID:29900882"
"7060","PC140408","McClinch K, Avelar RA, Callejas D,et al. 2018. Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer. Cancer research 78(8): 2065-2080. doi: 10.1158/0008-5472.CAN-17-0123."
"7061","PC140408P2","McClinch K, Avelar RA, Callejas D,et al. 2018. Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. Cancer research 78(8): 2065-2080. doi: 10.1158/0008-5472.CAN-17-0123."
"7062","PC140453","Kohli M, Ho Y, Hillman DW, et al. 2017. Androgen receptor variant AR-V9 is coexpressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance. Clinical Cancer Research 23(16): 4704-4715. doi: 10.1158/1078-0432.CCR-17-0017."
"7063","PC140453","Kohli M, Li J, Du M, Hillman DW, Dehm SM, Tan W, Carlson R, Campion MB, Wang L, Wang L, et al. Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients. Prostate Cancer Prostatic Dis. 2018 Sep;21(3):411-418. doi: 10.1038/s41391-018-0043-z. Epub 2018 Jun 1. PubMed PMID: 29858592."
"7064","PC140453","Wang L, Dehm SM, Hillman DW, et al. 2017. A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate–prednisone. Annals of Oncology 29(2): 352-360. doi: 10.1093/annonc/mdx689."
"7065","PC140453","Qin S, Liu D, Kohli M, et al. 2018. TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer. Clinical Pharmacology and Therapeutics 104(1): 201-210. doi: 10.1002/cpt.907."
"7066","PC140453P2","Qin S, Liu D, Kohli M, et al. 2018. TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer. Clinical Pharmacology and Therapeutics 104(1): 201-210. doi: 10.1002/cpt.907."
"7067","PC140453P2","Kohli M, Li J, Du M, Hillman DW, Dehm SM, Tan W, Carlson R, Campion MB, Wang L, Wang L, et al. Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients. Prostate Cancer Prostatic Dis. 2018 Sep;21(3):411-418. doi: 10.1038/s41391-018-0043-z. Epub 2018 Jun 1. PubMed PMID: 29858592."
"7068","PC140453P2","Wang L, Dehm SM, Hillman DW, et al. 2017. A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate–prednisone. Annals of Oncology 29(2): 352-360. doi: 10.1093/annonc/mdx689."
"7069","PC140453P2","Kohli M, Ho Y, Hillman DW, et al. 2017. Androgen receptor variant AR-V9 is co-expressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance. Clin. Cancer Res. 23(16): 4704-4715. doi: 10.1158/1078-0432.CCR-17-0017."
"7070","PC140478","Kim S, Yang X, Li Q, et al. 2017. Myristoylation of Src kinase mediates Src-induced and high-fat diet-accelerated prostate tumor progression in mice. The Journal of biological chemistry 292(45): 18422-18433. doi: 10.1074/jbc.M117.798827."
"7071","PC140478","Li Q, Alsaidan OA, Ma Y, et al. 2018. Pharmacologically targeting the myristoylation of the scaffold protein FRS2a inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression. The Journal of biological chemistry 293(17): 6434-6448. doi: 10.1074/jbc.RA117.000940."
"7072","PC140478","Kim S, Alsaidan OA, Goodwin O, et al. 2017. Blocking Myristoylation of Src Inhibits Its Kinase Activity and Suppresses Prostate Cancer Progression. Cancer research 77(24): 6950-6962. doi: 10.1158/0008-5472.CAN-17-0981."
"7073","PC140478","Yang X, Ma Y, Li N, et al. 2017. Development of a method for the determination of Acyl-CoA compounds by liquid chromatography mass spectrometry to probe the metabolism of fatty acids.  Analytical Chem 89(1):813-821."
"7074","PC140501","Ma F, Ye H, He HH, et al.  SOX9 drives WNT pathway activation in prostate cancer.  J Clin Invest.  126(5):1745-1758."
"7075","PC140519","Schweizer MT, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel
EA, Nelson PS, Yu EY, Montgomery B, True LD, Pritchard CC.
Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.
Oncotarget. 2016 Dec 13;7(50):82504-82510. doi: 10.18632/oncotarget.12697.
PMID: 27756888"
"7076","PC140519","Allen EM, Robinson D, Morrissey C, et al.  2016.  A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: Implications for precision cancer medicine.  Oncotarget 7(33):52888-52899."
"7077","PC140519","Kumar A, Coleman I, Morrissey C, et al.  2016.  Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.  Nat Med 22(4):369-378."
"7078","PC140560","Deep G, and Panigrahi GK.  2015.  Hypoxia-induced signaling promotes prostate cancerprogression: Exosomes role as messenger of hypoxic response in tumor microenvironment.  Critical Reviews in Oncogenesis 20(5-6):419-434."
"7079","PC140560","Deep G, Schlaepfer IR. Aberrant Lipid Metabolism Promotes Prostate Cancer: Role in Cell Survival under Hypoxia and Extracellular Vesicles Biogenesis. Int J Mol Sci. 2016 Jul 2;17(7). pii: E1061. doi: 10.3390/ijms17071061. Review. PubMed PMID: 27384557; PubMed Central PMCID: PMC4964437."
"7080","PC140570","Zhang M, Kobayashi N, Zettlitz KA, et al. 2019. Near-Infrared Dye-Labeled Anti-Prostate Stem Cell Antigen Minibody Enables Real-Time Fluorescence Imaging and Targeted Surgery in Translational Mouse Models. Clinical cancer research 25(1): 188-200. doi: 10.1158/1078-0432.CCR-18-1382."
"7081","PC140570P1","Zhang M, Kobayashi N, Zettlitz KA, Kono EA, Yamashiro JM, Tsai WK, Jiang ZK, Tran CP, Wang C, Guan J, Wu AM, Reiter RE. Near-Infrared Dye-Labeled Anti-Prostate Stem Cell Antigen Minibody Enables Real-Time Fluorescence Imaging and Targeted Surgery in Translational Mouse Models. Clin Cancer Res. 2019 Jan 1;25(1):188-200. doi: 10.1158/1078-0432.CCR-18-1382. Epub 2018 Oct 9. PubMed PMID: 30301826; PubMed Central PMCID: PMC6559730."
"7082","PC140570P1","Zettlitz KA, Waldmann CM, Tsai WK, Tavaré R, Collins J, Murphy JM, Wu AM. A dual-modality linker enables site-specific conjugation of antibody fragments for (18)F-immunoPET and fluorescence imaging. J Nucl Med. 2019 Mar 15. pii: jnumed.118.223560. doi: 10.2967/jnumed.118.223560. [Epub ahead of print] PubMed PMID: 30877181."
"7083","PC140570P1","Tsai WK, Zettlitz KA, Tavaré R, Kobayashi N, Reiter RE, Wu AM. Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody. Theranostics. 2018 Nov 12;8(21):5903-5914. doi: 10.7150/thno.27679. eCollection 2018. PubMed PMID: 30613270; PubMed Central PMCID: PMC6299441."
"7084","PC140570P1","Sonn GA, Behesnilian AS, Jiang ZK, Zettlitz KA, Lepin EJ, Bentolila LA, Knowles SM, Lawrence D, Wu AM, Reiter RE. Fluorescent Image-Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time. Clin Cancer Res. 2016 Mar 15;22(6):1403-12. doi: 10.1158/1078-0432.CCR-15-0503. Epub 2015 Oct 21. PubMed PMID: 26490315; PubMed Central PMCID: PMC4794340."
"7085","PC140571","Herbel C, Patsoukis N, Bardhan K, et al.  2016.  Clinical significance of T cell metabolic reprogramming in cancer.  Clin Transl Med 5(1):29."
"7086","PC140571P2","Herbel C, Patsoukis N, Bardhan K, et a;/  2016.  Clinical significance of T cell metabolic reprogramming in cancer.  Clin Transl Med 5(1):29."
"7087","PC140571P4","Korenchan DE, Flavell RR, Baligand C, et al. 2016. Dynamic nuclear polarization of biocompatible 13C-Enriched carbonates for In vivo pH imaging. Chem Commun (Camb) 52(14):3030-3033."
"7088","PC140574","Lee JH, Yang B, Lindahl AJ, et al. 2017. Identifying Dysregulated Epigenetic Enzyme Activity in Castrate-Resistant Prostate Cancer Development. ACS Chem Biol. 12(11): 2804-2814. doi: 10.1021/acschembio.6b01035."
"7089","PC140622","Birnbaum MD, Zhao N, Moorthy BT, Patel DM, Kryvenko ON, Heidman L, Kumar A, Morgan WM, Ban Y, Reis IM, et al. Reduced Arginyltransferase 1 is a driver and a potential prognostic indicator of prostate cancer metastasis. Oncogene. 2019 Feb;38(6):838-851. doi: 10.1038/s41388-018-0462-2. Epub 2018 Sep 3. PubMed PMID: 30177837; PubMed Central PMCID: PMC6368462."
"7090","PC140622","Birnbaum MD, Nemzow L, Kumar A, Gong F, Zhang F. A Rapid and Precise Mutation-Activated Fluorescence Reporter for Analyzing Acute Mutagenesis Frequency. Cell Chem Biol. 2018 Aug 16;25(8):1038-1049.e5. doi:10.1016/j.chembiol.2018.05.010. Epub 2018 Jun 14. PubMed PMID: 29909992."
"7091","PC140647","Wang Y, Dehigaspitiya DC, Levine PM, et al.  2016.  Multivalent peptoid conjugates which overcome enzalutamide resistance in prostate cancer cells.  Cancer Res 76(17):5124-5132."
"7092","PC140647P1","Wang Y, Dehigaspitiya DC, Levine PM, et al.  2016.  Multivalent peptoid conjugates which overcome enzalutamide resistance in prostate cancer cells.  Cancer Res 76(17):5124-5132."
"7093","PC140647P2","Wang Y, Dehigaspitiya DC, Levine PM, Profit AA, Haugbro M, Imberg-Kazdan K, Logan SK,
Kirshenbaum K, Garabedian MJ. Multivalent Peptoid Conjugates Which Overcome Enzalutamide
Resistance in Prostate Cancer Cells. Cancer Res. Cancer Res. 2016 Sep 1;76(17):5124-32. doi:
10.1158/0008-5472.CAN-16-0385. Epub 2016 Aug 3."
"7094","PC140665","Decker A, Jung Y, Cackowski C, et al. 2017. The role of hematopoietic stem cell niche in prostate cancer bone metastasis. J Bone Oncol. 5(3):117-120."
"7095","PC140665","Cackowski F, Eber MR, Rhee J, et al. 2017. Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy. Journal of cellular biochemistry 118(4): 891-902. doi: 10.1002/jcb.25768."
"7096","PC140665","Cackowski F, Eber MR, Rhee J, et al. 2017. Mer tyrosine kinase regulates disseminated prostate cancer cell dormancy.  J Cell Biochem. 118(4): 891–902. Published online 2016 Nov 10. doi:  10.1002/jcb.25768."
"7097","PC140665","Lee E, Wang J, Yumoto K, et al. 2016. DNMT1 participates in the primary prostate cancer metastasis by associating with epithelial-mesenchymal transition and cancer stem cells. Neoplasia 18(9): 553-566."
"7098","PC140665","Decker AM, Jung Y, Cackowski FC, et al. 2017. Sympathetic signaling reactivates quiescent disseminated prostate cancer cells in the bone marrow.  Mol Cancer Res. 15(12):1644-1655. doi: 10.1158/1541-7786.MCR-17-0132. Epub 2017 Aug 16."
"7099","PC140665","Decker AM, Cackowski FC, Jung Y, et al. 2017. Biochemical changes in the niche following tumor cell invasion.  J Cell Biochem. 118(8):1956-1964. doi: 10.1002/jcb.25843. Epub 2017 Apr 18."
"7100","PC140665","Jung Y, Decker AM, Wang J, et al.  2016.  Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow.  7(18):25698-25711."
"7101","PC140665","Yumoto K, Eber MR, Wang J, et al. 2016. Axl is required for TGF-beta-2-induced dormancy of prostate cancer cells in the bone marrow.  Sci Reports 6:36520."
"7102","PC140667","McIntire RK, Keith SW, Boamah M, et al. A Prostate Cancer Composite Score to Identify High Burden Neighborhoods. Preventive medicine. 2018 07; 112: 47-53. https://doi.org/10.1016/j.ypmed.2018.04.003 PMID:29625131"
"7103","PC140667","Zeigler-Johnson C, Keith S, McIntire R, et al. Racial and Ethnic Trends in Prostate Cancer Incidence and Mortality in Philadelphia, PA: an Observational Study. Journal of racial and ethnic health disparities. 2019 Apr; 6(2): 371-379. https://doi.org/10.1007/s40615-018-00534-z PMID:30520002"
"7104","PC140667P1","McIntire RK, Keith SW, Boamah M, et al. A Prostate Cancer Composite Score to Identify High Burden Neighborhoods. Preventive medicine. 2018 07; 112: 47-53. https://doi.org/10.1016/j.ypmed.2018.04.003 PMID:29625131"
"7105","PC140667P1","Zeigler-Johnson C, Keith S, McIntire R, et al. Racial and Ethnic Trends in Prostate Cancer Incidence and Mortality in Philadelphia, PA: an Observational Study. Journal of racial and ethnic health disparities. 2019 Apr; 6(2): 371-379. https://doi.org/10.1007/s40615-018-00534-z PMID:30520002"
"7106","PC140679","Zhu S, Zhao D, Li C, Li Q, Jiang W, Liu Q, Wang R, Fazli L, Li Y, Zhang L, et al. BMI1 is directly regulated by androgen receptor to promote castration-resistance in prostate cancer. Oncogene. 2019 Aug 28. doi: 10.1038/s41388-019-0966-4. [Epub ahead of print] PubMed PMID: 31462713."
"7107","PC140679","Liu Q, Li Q, Zhu S, et al. B lymphoma Moloney murine leukemia virus insertion region 1: An oncogenic mediator in prostate cancer. Asian journal of andrology. 2019 May-Jun; 21(3): 224-232. https://doi.org/10.4103/aja.aja_38_18 PMID:29862993"
"7108","PC140679","Zhu S, Zhao D, Yan L, et al. BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1. Nature communications. 2018 02; 9(1): 500. https://doi.org/10.1038/s41467-018-02863-3 PMID:29402932"
"7109","PC140690P2","Pollock JA, Wardell SE, Parent AA, et al.  2016.  Cyclobutane-core androgen receptor antagonists for treatment of enzalutamide-resistant prostate cancer.  Nature Chem Biol 12:795-801."
"7110","PC140699","Barros-Silva JD, Linn DE, Steiner I, Guo G, Ali A, Pakula H, Ashton G, Peset I, Brown M, Clarke NW, et al. Single-Cell Analysis Identifies LY6D as a Marker Linking Castration-Resistant Prostate Luminal Cells to Prostate Progenitors and Cancer. Cell Rep. 2018 Dec 18;25(12):3504-3518.e6. doi: 10.1016/j.celrep.2018.11.069. PubMed PMID: 30566873."
"7111","PC140703","Singh R, Karri D, Shen H, et al. 2018. TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis. J Clin Invest. 128(7): 3129-3143. doi: 10.1172/JCI96060."
"7112","PC140727","Jeong JH, Park SJ, Dickson SI, et al. 2017. A constitutive intrinsic inflammatory signaling circuit composed of miR-196b, Meis2, PPP3CC, and p65, drives prostate cancer castration resistance.  Mol Cell, 65(1):154-167."
"7113","PC140761","García-Hernández ML, Uribe-Uribe NO, Espinosa-González R, Kast WM, Khader SA, Rangel-Moreno
J. A Unique Cellular and Molecular Microenvironment is Present in Tertiary Lymphoid Organs of
Patients with Spontaneous Prostate Cancer Regression. Front Immunology. 2017 17; 8: 563."
"7114","PC140795","Jin J, Zhang L, Leng E, Metzger GJ, Koopmeiners JS. Detection of prostate cancer with multiparametric MRI utilizing the anatomic structure of the prostate. Stat Med. 2018 Sep 30;37(22):3214-3229. doi: 10.1002/sim.7810. Epub 2018 Jun 19. PubMed PMID: 29923345; PubMed Central PMCID: PMC6123293."
"7115","PC140795","Leng E, Spilseth B, Zhang L, Jin J, Koopmeiners JS, Metzger GJ. Development of a measure for evaluating lesion-wise performance of CAD algorithms in the context of mpMRI detection of prostate cancer. Med Phys. 2018 May;45(5):2076-2088. doi:10.1002/mp.12861. Epub 2018 Apr 16. PubMed PMID: 29542824."
"7116","PC140795P1","Jin J, Zhang L, Leng E, Metzger GJ, Koopmeiners JS. Detection of prostate cancer with multiparametric MRI utilizing the anatomic structure of the prostate. Stat Med. 2018 Sep 30;37(22):3214-3229. doi: 10.1002/sim.7810. Epub 2018 Jun 19. PubMed PMID: 29923345; PubMed Central PMCID: PMC6123293."
"7117","PC140795P1","Leng E, Spilseth B, Zhang L, Jin J, Koopmeiners JS, Metzger GJ. Development of a measure for evaluating lesion-wise performance of CAD algorithms in the context of mpMRI detection of prostate cancer. Med Phys. 2018 May;45(5):2076-2088. doi:10.1002/mp.12861. Epub 2018 Apr 16. PubMed PMID: 29542824."
"7118","PC140799","Carlson P, Dasgupta A, Grzelak CA, et al. Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy. Nature cell biology. 2019 02; 21(2): 238-250. https://doi.org/10.1038/s41556-018-0267-0 PMID:30664790"
"7119","PC140799","Hempelmann JA, Lockwood CM, Konnick EQ, et al. Microsatellite instability in prostate cancer by PCR or next-generation sequencing. Journal for immunotherapy of cancer. 2018 Apr; 6(1): 29. https://doi.org/10.1186/s40425-018-0341-y PMID:29665853"
"7120","PC140799","Chalfin HJ, Glavaris SA, Malihi PD, et al. Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. The Journal of urology. 2018 06; 199(6): 1494-1501. https://doi.org/10.1016/j.juro.2018.01.033 PMID:29339080"
"7121","PC140799","Hempelmann JA, Lockwood CM, Konnick EQ, Schweizer MT, Antonarakis ES, Lotan TL, Montgomery B, Nelson PS, Klemfuss N, Salipante SJ, et al. Microsatellite instability in prostate cancer by PCR or next-generation sequencing. J Immunother Cancer. 2018 Apr 17;6(1):29. doi: 10.1186/s40425-018-0341-y. PubMed PMID: 29665853; PubMed Central PMCID: PMC5904988."
"7122","PC140799","Sinha S and Nelson PS. 2017. The Path of Most Resistance: Transdifferentiation Underlies Exceptional Nonresponses to Androgen Receptor Pathway Inhibition in Prostate Cancer. Cancer discovery 7(7): 673-674. doi: 10.1158/2159-8290.CD-17-0481."
"7123","PC140799","Henzler C, Li Y, Yang R, et al. 2016. Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. Nature communications 7: 13668. doi: 10.1038/ncomms13668."
"7124","PC140799","Nguyen HM, Vessella RL, Morrissey C, et al. 2017. LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics. The Prostate 77(6): 654-671. doi: 10.1002/pros.23313."
"7125","PC140799","Sharp A, Coleman I, Yuan W, et al. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. The Journal of clinical investigation. 2019 Jan; 129(1): 192-208. https://doi.org/10.1172/JCI122819 PMID:30334814"
"7126","PC140799","Kumar A, Coleman I, Morrissey C, et al.  2016.  Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.  Nat Med 22(4):369-378."
"7127","PC140799","Schweizer MT, Cheng HH, Tretiakova MS, et al.  2016.  Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.  Oncotarget 7(50):82504-82510."
"7128","PC140804","Zhang J, Liu D, Li G, Staveley-O'Carroll KF, Graff JN, Li Z1, Wu JD. 2017. Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.Science Advances 3(5): e1602133"
"7129","PC140817","Xu H, Xu K, He HH, Zang C, Chen CH, Chen Y, Qin Q, Wang S, Wang C, Hu S, Li F, Long H, Brown M, Liu XS. Integrative Analysis Reveals the Transcriptional Collaboration between EZH2 and E2F1 in the Regulation of Cancer-Related Gene Expression. Mol Cancer Res. 2016 Feb;14(2):163-172. doi: 10.1158/1541-7786.MCR-15-0313. Epub 2015 Dec 9. PubMed PMID: 26659825; PubMed Central PMCID: PMC4828727."
"7130","PC140817","Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik NC, Göppert B, Ozgun F, van Royen ME, Houtsmuller AB, Vadhi R, Rao PK, Li L, Balk SP, Den RB, Trock BJ, Karnes RJ, Jenkins RB, Klein EA, Davicioni E, Gruhl FJ, Long HW, Liu XS, Cato ACB, Lack NA, Nelson PS, Plymate SR, Groner AC, Brown M. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cancer Cell. 2019 Mar 18;35(3):401-413.e6. doi: 10.1016/j.ccell.2019.01.008. Epub 2019 Feb 14. PubMed PMID: 30773341."
"7131","PC140817","Wang B, Wang M, Zhang W, Xiao T, Chen CH, Wu A, Wu F, Traugh N, Wang X, Li Z, Mei S, Cui Y, Shi S, Lipp JJ, Hinterndorfer M, Zuber J, Brown M, Li W, Liu XS. Integrative analysis of pooled CRISPR genetic screens using MAGeCKFlute. Nat Protoc. 2019 Mar;14(3):756-780. doi: 10.1038/s41596-018-0113-7. Epub 2019 Feb 1. PubMed PMID: 30710114."
"7132","PC140817","Chen CH, Xiao T, Xu H, Jiang P, Meyer CA, Li W, Brown M, Liu XS. Improved design and analysis of CRISPR knockout screens. Bioinformatics. 2018 Dec 1;34(23):4095-4101. doi: 10.1093/bioinformatics/bty450. PubMed PMID: 29868757; PubMed Central PMCID: PMC6247926."
"7133","PC140840","Xu J, Qiu Y. Current opinion and mechanistic interpretation of combination therapy for castration-resistant prostate cancer. Asian J Androl. 2019 May-Jun;21(3):270-278. doi: 10.4103/aja.aja_10_19. PubMed PMID: 30924449; PubMed Central PMCID: PMC6498727."
"7134","PC140863","Zhao J, Li X, Guo M, et al.  2016.  The common stress responsive transcription factor ATF3 binds genomic sites enriched with p300 and H3K27ac for transcriptional regulation.  BMC Genomics 17(1):335."
"7135","PC140863","Cui H, Li X, Han C, et al.  2016.  The stress responsive gene ATF3 mediates dichotomous UV responses by regulating Tip60 and p53.  J Biol Chem 291(20):10847-10857."
"7136","PC140924","Rao A, Teng YC, Schaef C, et al. 2018. An Analog Front End ASIC for Cardiac Electrical Impedance Tomography. IEEE transactions on biomedical circuits and systems 12(4): 729-738. doi: 10.1109/TBCAS.2018.2834412."
"7137","PC140924","Murphy EK, Skinner J, Martucci M, Rutkove SB, Halter RJ. Towards Electrical Impedance Tomography Coupled Ultrasound Imaging for Assessing Muscle Health. IEEE Trans Med Imaging. 2018 Dec 10. doi: 10.1109/TMI.2018.2886152. [Epub ahead of print] PubMed PMID: 30530320."
"7138","PC140924","Murphy EK, Wu X, Halter RJ. Fused-data transrectal EIT for prostate cancer imaging. Physiol Meas. 2018 May 25;39(5):054005. doi: 10.1088/1361-6579/aabf22. PubMed PMID: 29667932."
"7139","PC140924P1","Murphy E, Takhti M, Skinner J, Halter RJ, Odame K, “Signal-to-Noise Ratio Analysis of a Phase-Sensitive Voltmeter for Electrical Impedance Tomography,” IEEE Transactions on Biomedical Circuits and Systems, 11 (2): 360–369, 2017."
"7140","PC140924P1","Rao A, Teng YC, Schaef C, et al. 2018. An Analog Front End ASIC for Cardiac Electrical Impedance Tomography. IEEE transactions on biomedical circuits and systems 12(4): 729-738. doi: 10.1109/TBCAS.2018.2834412."
"7141","PC140952","Li L, Li L, Li W, et al. TAp73-induced phosphofructokinase-1 transcription promotes the Warburg effect and enhances cell proliferation. Nature communications. 2018 11; 9(1): 4683. https://doi.org/10.1038/s41467-018-07127-8 PMID:30409970"
"7142","PC140969","Rogers OC, Anthony L, Rosen DM, et al. 2018. PSA-selective activation of cytotoxic human serine proteases within the tumor microenvironment as a therapeutic strategy to target prostate cancer. Oncotarget. 9(32): 22436-22450. doi: 10.18632/oncotarget.25091."
"7143","PC141008","Heikinheimo M, Pihlajoki M, Schrade A, et al.  2015.  Testicular steroidogenic cells to the rescue.  Endocrinology 156(5):1616-1619."
"7144","PC141008","Pihlajoki M, Färkkilä A, Soini T, et al.  2016.  GATA factors in endocrine neoplasia.  Mol Cell Endocrinol 421:2-17."
"7145","PC141008","Schrade A, Kyrönlahti A, Akinrinade O, et al.  2015.  GATA4 is a key regulator of steroidogenesis and glycolysis in mouse Leydig cells.  Endocrinology 156(5):1860-1872."
"7146","PC141019","Lokhandwala PM, Riel SL, Haley L, et al. 2017. Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting. The Journal of Molecular Diagnostics 19(1): 115–125."
"7147","PC141019","Luo J. 2016. Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer. Asian Journal of Andrology 18(4): 580–585."
"7148","PC141019","Zhao P, Zhu Y, Cheng L, Luo J. Detection of androgen receptor (AR) and AR-V7 in small cell prostate carcinoma: Diagnostic and therapeutic implications. Asian J Urol. 2019 Jan;6(1):109-113. doi: 10.1016/j.ajur.2018.09.003. Epub 2018 Sep 28. PubMed PMID: 30775254; PubMed Central PMCID: PMC6363596."
"7149","PC141019","Antonarakis ES, Lu C, Brandon L, et al. 2017. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. J Clin Oncol 35(19):2149-2156."
"7150","PC141019","Sharp A, Coleman I, Yuan W, et al. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. The Journal of clinical investigation. 2019 Jan; 129(1): 192-208. https://doi.org/10.1172/JCI122819 PMID:30334814"
"7151","PC141019","Paschalis A, Sharp A, Welti JC, et al. Alternative splicing in prostate cancer. Nature reviews. Clinical oncology. 2018 11; 15(11): 663-675. https://doi.org/10.1038/s41571-018-0085-0 PMID:30135575"
"7152","PC141019","Luo J, Attard G, Balk SP,et al. 2018. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European urology 73(5): 715-723. doi: 10.1016/j.eururo.2017.11.038."
"7153","PC141019","Boudadi K, Suzman DL, Anagnostou V, et al. 2018. Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget 9(47): 28561-28571. doi: 10.18632/oncotarget.25564."
"7154","PC141019","Antonarakis ES, Armstrong AJ, Dehm SM, Luo J. Androgen receptor variant-driven prostate cancer:
clinical implications and therapeutic targeting. Prostate cancer and prostatic diseases. 2016;19(3):231-41.
Epub 2016/05/18. doi: 10.1038/pcan.2016.17. PubMed PMID: 27184811; PMCID: PMC5493501."
"7155","PC141019","Zhu Y, Sharp A, Anderson CM, et al. 2018. Novel junction-specific and quantifiable in situ detection of AR-V7 and its clinical correlates in metastatic castration-resistant prostate cancer. European urology 73(5): 727-735.  doi: 10.1016/j.eururo.2017.08.009."
"7156","PC141019","Sharp A, Welti JC, Lambros MBK, Dolling D, Rodrigues DN, Pope L, Aversa C, Figueiredo I, Fraser J, Ahmad Z, et al. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 Apr 27. pii: S0302-2838(19)30285-4. doi: 10.1016/j.eururo.2019.04.006. [Epub ahead of print] PubMed PMID: 31036442."
"7157","PC141019","Sharp A, Coleman I, Yuan W, et al. 2018. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. The Journal of Clinical Investigation 129(1): 192-208. doi: 10.1172/JCI122819."
"7158","PC141019","Paschalis A, Sharp A, Welti JC, et al. 2018 Alternative splicing in prostate cancer. Nature Rev. Clin Oncology (11): 663-675. doi: 10.1038/s41571-018-0085-0."
"7159","PC141019P1","Sharp A, Welti JC, Lambros MBK, Dolling D, Rodrigues DN, Pope L, Aversa C, Figueiredo I, Fraser J, Ahmad Z, et al. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 Apr 27. pii: S0302-2838(19)30285-4. doi: 10.1016/j.eururo.2019.04.006. [Epub ahead of print] PubMed PMID: 31036442."
"7160","PC141019P1","Sharp A, Porta N, Lambros MBK, Welti JC, Paschalis A, Raj GV, Plymate SP, de Bono JS. Dissecting Prognostic From Predictive Utility: Circulating AR-V7 Biomarker Testing for Advanced Prostate Cancer. J Clin Oncol. 2019 Aug 20;37(24):2182-2184. doi: 10.1200/JCO.19.01104. Epub 2019 Jul 2. PubMed PMID: 31265359."
"7161","PC141019P1","Zhu Y, Sharp A, Anderson CM, et al. 2018. Novel junction-specific and quantifiable in situ detection of AR-V7 and its clinical correlates in metastatic castration-resistant prostate cancer. European urology 73(5): 727-735.  doi: 10.1016/j.eururo.2017.08.009."
"7162","PC141019P2","Zhu Y, Sharp A, Anderson CM, et al. 2018. Novel junction-specific and quantifiable in situ detection of AR-V7 and its clinical correlates in metastatic castration-resistant prostate cancer. European urology 73(5): 727-735.  doi: 10.1016/j.eururo.2017.08.009."
"7163","PC141019P2","Uo T, Plymate SR, and Sprenger CC. 2018. The potential of AR-V7 as a therapeutic target. Expert opinion on therapeutic targets 22(3): 201-216. doi: 10.1080/14728222.2018.1439016."
"7164","PC141019P2","Plymate SR, Sharp A, and de Bono JS. 2018. Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer: The Devil Is in the Detail. JAMA oncology. doi: 10.1001/jamaoncol.2018.1615. [Epub ahead of print]."
"7165","PC141019P2","Paschalis A, Sharp A, Welti JC, et al. 2018 Alternative splicing in prostate cancer. Nature Rev. Clin Oncology (11): 663-675. doi: 10.1038/s41571-018-0085-0."
"7166","PC141019P2","Sharp A, Coleman I, Yuan W, et al. 2018. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. The Journal of Clinical Investigation 129(1): 192-208. doi: 10.1172/JCI122819."
"7167","PC141070","Kalina JL, Neilson DS, Comber AP, et al.  2017.  Immune modulation by androgen deprivation and radiation therapy: Implications for prostate cancer immunotherapy.  Cancers (Basel) 9(2): 13."
"7168","PC141083","Zhang Z, Zhou N, Huang J, et al.  2016.  Regulation of androgen receptor splice variant AR3 by PCGEM1.  Oncotarget 7(13):15481-15491."
"7169","PC141173","Gao S, Gao Y, He HH, Han D, Han W, Avery A, Macoska JA, Liu X, Chen S, Ma F, Chen S, Balk SP,
and Cai C. (2016) Androgen receptor tumor suppressor function mediated by recruitment of
Retinoblastoma Protein. Cell Reports. 17(4):966-76."
"7170","PC141173","Han W, Gao S, Barrett D, Ahmed M, Han D, Macoska JA, He HH, and Cai C. (2017) Reactivation of
androgen receptor-regulated lipid biosynthesis drives progression of castration-resistant prostate
cancer. Oncogene. [Published online]"
"7171","PC141230","Yin Y, Li R, Xu K, et al. 2017. Androgen receptor variants mediate DNA repair after prostate cancer irradiation.  Cancer Res 77(18):4745-4754."
"7172","PC141276","Sowalsky AG, Kissick HT, Gerrin SJ. et al. 2017. Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4. Clinical Cancer Research 23(14): 3823-3833. doi: 10.1158/1078-0432.CCR-16-2414."
"7173","PC141378","Hsieh AC, Nguyen HG, Wen L, et al.  2015.  Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors.  Sci Signal 8(403):ra116."
"7174","PC141378","Nguyen HG, Conn CS, Kye Y, et al. 2018. Development of a stress response therapy targeting aggressive prostate cancer. Science translational medicine 10(439): eaar2036. doi: 10.1126/scitranslmed.aar2036."
"7175","PC141416","Zheng J, Harris MR, Masci AM, et al.  2016.  The Ontology of biological and clinical statistics (OBCS) for standardized and reproducible statistical analysis.  J Biomed Semantics 7(1):53."
"7176","PC141416","Halabi S, Dutta S, Tangen CM, et al. Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Feb; 37(5): 403-410. https://doi.org/10.1200/JCO.18.01279 PMID:30576268"
"7177","PC141511","Cheong A, Zhang X, Cheung YY, et al.  2016.  DNA methylome changes by estradiol benzoate and bisphenol A links early-life environmental exposures to prostate cancer risk.  Epigenetics 11(9):674-689.  (Highlighted in NIEHS Environmental Factor)."
"7178","PC141527","Han, WT. *, Gao, S. *, Barrett, D., Ahmed, M., Han, D., Macoska, J., He, HH., Cai, C.
Reactivation of Androgen Receptor-Regulated Lipid Biosynthesis Drives the Progression of
Castration-Resistant Prostate Cancer. (2017) Oncogene. 2017.385"
"7179","PC141530","Bishop JL, Thaper D, Vahid S, et al.  2017.  The master neural transcription factor BRN2 is an androgen receptor suppressed driver of neuroendocrine differentiation in prostate cancer.  Cancer Dis 7(1):54-71."
"7180","PC141542","Bose R, Karthaus, WR, Armenia J, Abida W, Iaquinta PJ, Zhang Z, Wongvipat J, Wasmuth EV,
Shah N, Sullivan PS, Doran MG, Wang P, Patruno A, Zhao Y, International SU2C/PCF Prostate
Cancer Dream Team, Zheng D, Schultz N, Sawyers CL. ERF mutations reveal a balance of ETS
factors controlling prostate oncogenesis. Nature. 2017 June 29;546(7660):671-5."
"7181","PC141548","Ramalingam S, Ramamurthy VP, Njar VCO.  2017.  Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets.  J Steroid Biochem Mol Biol 166:16-27."
"7182","PC141559","Ingersoll MA, Miller DR, Martinez O, et al.  2016.  Statin derivatives as therapeutic agents for castration-resistant prostate cancer.  Cancer Lett 383(1):94-105."
"7183","PC141569","Hearn JWD, AbuAli G, Reichard CA, et al.  2016.  HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: A retrospective, multicohort study.  Lancet Oncology 17(10):1435-1444."
"7184","PC141569","Hearn JWD, Xie W, Nakabayashi M, Almassi N, Reichard CA, Pomerantz M,
Kantoff PW, Sharifi N: HSD3B1 Genotype and Response to Androgen
Deprivation Therapy for Biochemical Recurrence after Radiotherapy for
Localized Prostate Cancer. JAMA Oncology; doi:10.1001/jamaoncol.2017.3164.
Published online October 12, 2017."
"7185","PC141581","Chen X, Li Q, Liu X, Liu C, Liu R, Rycaj K, Zhang D, Liu B, Jeter C, Calhoun-Davis T, Lin K, Lu Y,
Chao HP, Shen J, Tang DG. Defining a population of stem-like human prostate cancer cells that can
generate and propagate castration-resistant prostate cancer. Clin Cancer Res. 2016; 22:4505-16."
"7186","PC141581","Rycaj K, Cho EJ, Liu X, Chao HP, Liu B, Li Q, Devkota AK, Zhang D, Chen X, Moore J, Dalby KN,
Tang DG. Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell
castration and identification"
"7187","PC141593","Liang P, Henning SM, Schokrpur S, et al.  2016.  Effect of dietary omega-3 fatty acids on tumor-associated macrophages and prostate cancer progression.  Prostate 76(14):1293-1302."
"7188","PC141599","Sano MB, Fan R, Hwang G, et al.  2016.  Production of spherical ablations using non-thermal irreversible electroporation.  J Vasc Interv Radiol 27(9):1432-1440.e3."
"7189","PC141607","Ku SY, Rosario S, Wang Y, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science (2017) 355, 78–83"
"7190","PC141612","Cook  LM, Araujo A, and Basanta D, et al.  2016.  Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer.  Sci Rep 6:29384."
"7191","PC141612","Araujo A, Cook LM, Lynch CC, et al. 2018. Size Matters: Metastatic Cluster Size and Stromal Recruitment in the Establishment of Successful Prostate Cancer to Bone Metastases. Bull Math Biol. 80(5): 1046-1058. doi: 10.1007/s11538-018-0416-4."
"7192","PC150040","Liu C, Armstrong CM, Lou W, Lombard A, Evans CP, Gao AC. Inhibition of AKR1C3 Activation
Overcomes Resistance to Abiraterone in Advanced Prostate Cancer. Mol Cancer Ther, 2017,16(1): 35-
44."
"7193","PC150040P1","Liu C, Armstrong CM, Lou W, Lombard A, Evans CP, Gao AC. Inhibition of AKR1C3 Activation
Overcomes Resistance to Abiraterone in Advanced Prostate Cancer. Mol Cancer Ther, 2017,16(1): 35-
44."
"7194","PC150065","Moses MA, Kim YS, Rivera-Marquez GM, et al. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer. Cancer research. 2018 Jul; 78(14): 4022-4035. https://doi.org/10.1158/0008-5472.CAN-17-3728 PMID:29764864"
"7195","PC150065","Shao H, Li X, Moses MA, et al. Exploration of Benzothiazole Rhodacyanines as Allosteric Inhibitors of Protein-Protein Interactions with Heat Shock Protein 70 (Hsp70). Journal of medicinal chemistry. 2018 Jul; 61(14): 6163-6177. https://doi.org/10.1021/acs.jmedchem.8b00583 PMID:29953808"
"7196","PC150065P1","Shao H, Li X, Moses MA, et al. Exploration of Benzothiazole Rhodacyanines as Allosteric Inhibitors of Protein-Protein Interactions with Heat Shock Protein 70 (Hsp70). Journal of medicinal chemistry. 2018 Jul; 61(14): 6163-6177. https://doi.org/10.1021/acs.jmedchem.8b00583 PMID:29953808"
"7197","PC150065P1","Moses MA, Kim YS, Rivera-Marquez GM, et al. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer. Cancer research. 2018 Jul; 78(14): 4022-4035. https://doi.org/10.1158/0008-5472.CAN-17-3728 PMID:29764864"
"7198","PC150109","Kozlowska AK, Florczak A, Smialek M, et al. 2017. Functionalized bioengineered spider silk spheres improve nuclease resistance and activity of oligonucleotide therapeutics providing a strategy for cancer treatment.  Acta Biomater 59:221-233."
"7199","PC150109","Kortylewski M and Moreira D. 2017. Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.  Cancer Immunol Immunother 66:979-988.  doi: 10.1007/s00262-017-1966-2. Epub 2017 Feb 18."
"7200","PC150109","Won H, Moreira D, Gao C, et al.  2017.  TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs.  J Leukoc Biol 102:423-436."
"7201","PC150123","Soekmadji C, Rockstroh A, Ramm GA, et al. 2017. Extracellular Vesicles in the Adaptive Process of Prostate Cancer during Inhibition of Androgen Receptor Signaling by Enzalutamide. Proteomics. 17(23-24). doi: 10.1002/pmic.201600427."
"7202","PC150123","Soekmadji C, An J, Rockstroh A, et al. Integrative pathway analysis on protein and miRNA allows investigation of the role of extracellular vesicles in mediating the adaptive response of prostate cancer cells to androgen deprivation. Journal of Extracellular Vesicles. 2018: 7(sup1):1461450. DOI: 10.1080/20013078.2018.1461450."
"7203","PC150123","Riches JD, Oleinikova I, Jovanovic L. The role of extracellular vesicles in advanced prostate cancer progression. The Australian Prostate Cancer Collaboration BioResource, Nelson CC, Russell PJ and Soekmadji C*. Journal of Extracellular Vesicles. 2017: 6(sup1): 1310414. DOI: 10.1080/20013078.2017.1310414"
"7204","PC150123","Soekmadji C, Corcoran NM, Oleinikova I, et al. 2017. Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer. Prostate. 77(14): 1416-1423. doi: 10.1002/pros.23403."
"7205","PC150123","Witwer KW, Soekmadji C, Hill AF, et al. 2017. Updating the MISEV minimal requirements for extracellular vesicle studies: building bridges to reproducibility. J Extracell Vesicles. 6(1): 1396823. doi: 10.1080/20013078.2017.1396823."
"7206","PC150144","Nissim L, Wu MR, Pery E, Binder-Nissim A, Suzuki HI, Stupp D, Wehrspaun C, Tabach Y, Sharp PA, Lu TK. Synthetic RNA-Based Immunomodulatory Gene Circuits for Cancer Immunotherapy. Cell. 2017 Nov 16;171(5):1138-1150.e15. doi: 10.1016/j.cell.2017.09.049. Epub 2017 Oct 19. PubMed PMID: 29056342; PubMed Central PMCID: PMC5986174."
"7207","PC150155","Xiao L, Tien JC, Vo J, et al. 2018. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer. Cancer research 78(20): 5731-5740. doi: 10.1158/0008-5472.CAN-18-0941."
"7208","PC150190","Zhang L, Zhao Z, Xu S, et al. 2017. Androgen suppresses protein kinase D1 expression through fibroblast growth factor receptor substrate 2 in prostate cancer cells. Oncotarget 8(8): 12800-12811. doi: 10.18632/oncotarget.14536."
"7209","PC150190","Roy A, Veroli MV, Prasad S, et al. 2018. Protein Kinase D2 Modulates Cell Cycle By Stabilizing Aurora A Kinase at Centrosomes. Molecular Cancer Research 16(11): 1785-1797. doi: 10.1158/1541-7786.MCR-18-0641."
"7210","PC150202","Barakat DJ, Suresh R, Barberi T, et al. 2018. Absence of myeloid Klf4 reduces prostate cancer growth with pro-atherosclerotic activation of tumor myeloid cells and infiltration of CD8 T cells. PLoS One 13(1): e0191188. doi: 10.1371/journal.pone.0191188."
"7211","PC150220","Han W, Gao S, Barrett D, et al. 2017. Reactivation of androgen receptor-regulated lipid biosynthesis drives progression of castration-resistant prostate cancer.  Oncogene. 2017 Oct 23. doi: 10.1038/onc.2017.385. [Epub ahead of print]"
"7212","PC150221","Richards KA, Liou JI, Cryns VL, et al. 2018. Metformin Use Is Associated with Improved Survival in Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy. J Urol. doi: 10.1016/j.juro.2018.06.031. [Epub ahead of print]."
"7213","PC150221P1","Damodaran S, Lang JM, Jarrard DF. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches. J Urol. 2019 May;201(5):876-885. doi: 10.1097/JU.0000000000000117. Review. PubMed PMID: 30747897."
"7214","PC150229","Liu C, CM A, Lou W, Lombard AP, Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP, Gao AC. Niclosamide and bicalutamide combination treatment overcomes enzalutamide and bicalutamide-resistant prostate cancer. Mol Cancer Ther.
2017;16(8):1521-1530 (PMID: 28500234, PMCID: PMC5544572)."
"7215","PC150246","Zhang Y, Pitchiaya S, Cieslik M, et al. 2018. Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. Nature genetics 50(6): 814-824. doi: 10.1038/s41588-018-0120-1."
"7216","PC150288","Li JN, Alyamani M, Zhang A, et al. 2017. Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. eLife 6:e20183. doi:  10.7554/eLife.20183."
"7217","PC150300P1","Hou C, Weidenbach S, Cano KE, et al. 2016. Structures of mithramycin analogues bound to DNA and implications for targeting transcription 6 factor FLI1.  Nucleic Acids Res 44:8990-9004."
"7218","PC150300P2","Hou C, Weidenbach S, Cano KE, et al. 2016. Structures of mithramycin analogues bound to DNA and implications for targeting transcription 6 factor FLI1.  Nucleic Acids Res 44:8990-9004."
"7219","PC150382","Park JW, Lee JK, Witte ON, et al. 2017. FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate.  Modern Pathology 30, 1262-1272 doi:10.1038/modpathol.2017.44."
"7220","PC150382P2","Park JW, Lee JK, Witte ON, et al. 2017. FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate. Mod Pathol. 30(9): 1262-1272. doi: 10.1038/modpathol.2017.44."
"7221","PC150382P2","Park JW, Lee JK, Witte ON, et al. 2017. FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate.  Mod Pathology 30: 1262-1272. doi: 10.1038/modpathol.2017.44. Epub 2017 Jun 16."
"7222","PC150382P2","Chen Z, Wu D, Thomas-Ahner JM, et al. 2018. Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13. Proc Natl Acad Sci U S A. 115(26): 6810-6815. doi: 10.1073/pnas.1718811115."
"7223","PC150410","San Martin et al. Tenascin-C and integrin alpha-9 mediate prostate cancer Interactions with bone.
2017. Cancer Res. (in press)."
"7224","PC150442","Govindi Samaranayake, Clara Troccoli, Mai Huynh, Rolando Lyles,
Karen Kage, Andrew Win, Vishalakshi Lakshmanan, Deukwoo
Kwon, Yuguang Ban, Steven Xi Chen, Enrique Rodriguez Zarco,
Merce Jorda, Kerry Burnstein and Priyamvada Rai*. Thioredoxin-1
protects against androgen receptor-induced redox vulnerability in
castration-resistant prostate cancer. Nature Communications,
accepted/in press (NCOMMS-17-04485B);"
"7225","PC150442P1","Govindi Samaranayake, Clara Troccoli, Mai Huynh, Rolando Lyles,
Karen Kage, Andrew Win, Vishalakshi Lakshmanan, Deukwoo
Kwon, Yuguang Ban, Steven Xi Chen, Enrique Rodriguez Zarco,
Merce Jorda, Kerry Burnstein and Priyamvada Rai*. Thioredoxin-1
protects against androgen receptor-induced redox vulnerability in
castration-resistant prostate cancer. Nature Communications,
accepted/in press (NCOMMS-17-04485B);"
"7226","PC150456","Bai S, Cao S, Jin L, Kobelski M, Schouest B, Wang X, Ungerleider N, Baddoo M, Zhang W, Corey E, et al. A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer. Oncogene. 2019 Jun;38(25):4977-4989. doi: 10.1038/s41388-019-0768-8. Epub 2019 Feb 28. PubMed PMID: 30820039; PubMed Central PMCID: PMC6586509."
"7227","PC150456","Nakhoul H, Lin Z, Wang X, Roberts C, Dong Y, Flemington E. High-Throughput Sequence Analysis of Peripheral T-Cell Lymphomas Indicates Subtype-Specific Viral Gene Expression Patterns and Immune Cell Microenvironments. mSphere. 2019 Jul 10;4(4). pii: e00248-19. doi: 10.1128/mSphere.00248-19. PubMed PMID: 31292228; PubMed Central PMCID: PMC6620372."
"7228","PC150456","Ungerleider N, Concha M, Lin Z, Roberts C, Wang X, Cao S, Baddoo M, Moss WN, Yu Y, Seddon M, et al. The Epstein Barr virus circRNAome. PLoS Pathog. 2018 Aug 6;14(8):e1007206. doi: 10.1371/journal.ppat.1007206. eCollection 2018 Aug. PubMed PMID: 30080890; PubMed Central PMCID: PMC6095625."
"7229","PC150456","Ungerleider NA, Jain V, Wang Y, Maness NJ, Blair RV, Alvarez X, Midkiff C, Kolson D, Bai S, Roberts C, et al. Comparative Analysis of Gammaherpesvirus Circular RNA Repertoires: Conserved and Unique Viral Circular RNAs. J Virol. 2019 Mar 5;93(6). pii: e01952-18. doi: 10.1128/JVI.01952-18. Print 2019 Mar 15. PubMed PMID: 30567979; PubMed Central PMCID: PMC6401440."
"7230","PC150456","Cao S, Ma T, Ungerleider N, Roberts C, Kobelski M, Jin L, Concha M, Wang X, Baddoo M, Nguyen HM, et al. Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer. Oncogene. 2019 Aug 13. doi: 10.1038/s41388-019-0947-7. [Epub ahead of print] PubMed PMID: 31409897."
"7231","PC150456","Bai S, Zhang BY, and Dong Y. 2018. Impact of Taxanes on Androgen Receptor Signaling. Asian Journal of Andrology 20: 1-4. doi: 10.4103/aja.aja_37_18."
"7232","PC150456","Cao S, Zhan Y, and Dong Y. 2016. Emerging data on androgen receptor splice variants in prostate cancer.  Endocrine-Related Cancer 23:T199-T210."
"7233","PC150456P1","Cao S, Ma T, Ungerleider N, Roberts C, Kobelski M, Jin L, Concha M, Wang X, Baddoo M, Nguyen HM, et al. Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer. Oncogene. 2019 Aug 13. doi: 10.1038/s41388-019-0947-7. [Epub ahead of print] PubMed PMID: 31409897."
"7234","PC150456P1","Cao S, Zhan Y, and Dong Y. 2016. Emerging data on androgen receptor splice variants in prostate cancer.  Endocrine-Related Cancer 2016 Dec;23(12):T199-T210. Epub 2016 Oct 4."
"7235","PC150557","Komura K, Yoshikawa Y, Shimamura T, et al. 2018. ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. The Journal of clinical investigation 128(7): 2979-2995. doi: 10.1172/JCI96769."
"7236","PC150635","Russo JW, Gao C, Bhasin SS, et al. 2018. Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer research 78(22): 6354-6362. doi: 10.1158/0008-5472.CAN-18-0687."
"7237","PC150635","Sowalsky AG, Ye H, Bhasin M, Van Allen EM, Loda M, Lis RT, Montaser-Kouhsari L, Calagua C, Ma F, Russo JW, et al. Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res. 2018 Aug 15;78(16):4716-4730. doi: 10.1158/0008-5472.CAN-18-0610. Epub 2018 Jun 19. PubMed PMID: 29921690; PubMed Central PMCID: PMC6095796."
"7238","PC150635P1","McKay RR, Montgomery B, Xie W, et al. 2018. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate cancer and prostatic diseases 21(3): 364-372. doi: 10.1038/s41391-017-0009-6."
"7239","PC150635P1","Russo JW, Gao C, Bhasin SS, et al. 2018. Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer research 78(22): 6354-6362. doi: 10.1158/0008-5472.CAN-18-0687."
"7240","PC150635P1","Ye H, Sowalsky AG. Molecular correlates of intermediate- and high-risk localized prostate cancer. Urol Oncol. 2018 Aug;36(8):368-374. doi: 10.1016/j.urolonc.2017.12.022. Epub 2018 Mar 2. Review. PubMed PMID: 30103901; PubMed Central PMCID: PMC6093287."
"7241","PC150635P1","Sowalsky AG, Ye H, Bhasin M, et al. 2018. Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer research 78(16): 4716-4730. doi: 10.1158/0008-5472.CAN-18-0610."
"7242","PC150635P1","Sowalsky AG, Ye H, Bhasin M, Van Allen EM, Loda M, Lis RT, Montaser-Kouhsari L, Calagua C, Ma F, Russo JW, et al. Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res. 2018 Aug 15;78(16):4716-4730. doi: 10.1158/0008-5472.CAN-18-0610. Epub 2018 Jun 19. PubMed PMID: 29921690; PubMed Central PMCID: PMC6095796."
"7243","PC150635P3","Sowalsky AG, Ye H, Bhasin M, Van Allen EM, Loda M, Lis RT, Montaser-Kouhsari L, Calagua C, Ma F, Russo JW, et al. Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res. 2018 Aug 15;78(16):4716-4730. doi: 10.1158/0008-5472.CAN-18-0610. Epub 2018 Jun 19. PubMed PMID: 29921690; PubMed Central PMCID: PMC6095796."
"7244","PC150635P3","Ye H, Sowalsky AG. Molecular correlates of intermediate- and high-risk localized prostate cancer. Urol Oncol. 2018 Aug;36(8):368-374. doi: 10.1016/j.urolonc.2017.12.022. Epub 2018 Mar 2. Review. PubMed PMID: 30103901; PubMed Central PMCID: PMC6093287."
"7245","PC150695","Kumari S, Senapati D, and Heemers HV. 2017. Rationale for the development of alternative forms of androgen deprivation therapy.  Endocr Relat Cancer 24(8):R275-R295."
"7246","PC150697","Deng X, Shao G, Zhang HT, et al. 2017. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.  Oncogene 36:1223-1231."
"7247","PC150704","Chen ZH, Yu YP, Tao J, et al. 2017. MAN2A1-FER fusion gene is expressed by human liver and other tumor types and has oncogenic activity in mice.  Gastroenterology 153(4):1120-1132.e15.  doi: 10.1053/j.gastro.2016.12.036."
"7248","PC150704","Chen ZH, Yu YP, Zuo ZH, et al.  2017.  Targeting genomic rearrangements in tumor cells through Cas9-mediated insertion of a suicide gene.  Nat Biotechnol 35(6):543-550."
"7249","PC150714","Zhang D, Jeter C, Gong S, et al. 2018. Histone 2B-GFP Label-Retaining Prostate Luminal Cells Possess Progenitor Cell Properties and Are Intrinsically Resistant to Castration. Stem Cell Reports 10(1): 228-242. doi:10.1016/j.stemcr.2017.11.016."
"7250","PC150714","Li Q, Deng Q, Chao HP, et al. 2018. Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nat Commun 9(1): 3600. doi: 10.1038/s41467-018-06067-7."
"7251","PC150714","Zhang D and Tang DG. 2018. “Splice” a way towards neuroendocrine prostate cancer. EBioMedicine 35: 12-13. doi: 10.1016/j.ebiom.2018.08.037."
"7252","PC150714","Rycaj K and Tang DG. 2017. Molecular determinants of prostate cancer metastasis. Oncotarget 8(50): 88211-88231. doi: 10.18632/oncotarget.21085."
"7253","PC150714","Li Q, Deng Q, Chao HP, et al. 2018. Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nat Commun. 9(1): 3600. doi: 10.1038/s41467-018-06067-7."
"7254","PC150752","Shi T, Quek S, Gao Y, et al. Multiplexed targeted mass spectrometry assays for prostate cancer-associated urinary proteins. Oncotarget 2017"
"7255","PC150752P1","Shi T, Quek S, Gao Y, et al. Multiplexed targeted mass spectrometry assays for prostate cancer-associated urinary proteins. Oncotarget 2017"
"7256","PC150752P1","Liu AY, Kanan AD, Radon TP, Shah S, Weeks ME, Foster JM, Sosabowski JK, Dumartin L, Crnogorac-Jurcevic T. AGR2, a unique tumor-associated antigen, is a promising candidate for antibody targeting. Oncotarget. 2019 Jul 2;10(42):4276-4289. doi: 10.18632/oncotarget.26945. eCollection 2019 Jul 2. PubMed PMID: 31303962; PubMed Central PMCID: PMC6611513."
"7257","PC150773","Aggarwal R, Behr S, Paris P, et al. 2017. Real time transferrin-based PET detects MYC-positive prostate cancer. Mol Cancer Res 15(9):1221-1229."
"7258","PC150773","Behr S, Aggarwal R, Seo Y, et al. 2016. A feasibility study showing 68Ga-Citrate PET detects prostate cancer. Mole Imag Biol 2016:18(6):946-951."
"7259","PC150797","Wu Y, Yu H, Zheng SL, et al. 2018. Germline mutations in PPFIBP2 are associated with lethal prostate cancer. The Prostate 78(16): 1222-1228. doi: 10.1002/pros.23697."
"7260","PC150797","Wu Y, Yu H, Zheng S, et al. 2018. A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer. The Prostate 78(8): 607-615. doi: 10.1002/pros.23505."
"7261","PC150797","Carter HB, Helfand B, Mamawala M, et al. 2018. Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. European urology. doi: 10.1016/j.eururo.2018.09.021. [Epub ahead of print]."
"7262","PC150797P1","Wu Y, Yu H, Zheng SL, et al. 2018. Germline mutations in PPFIBP2 are associated with lethal prostate cancer. The Prostate 78(16): 1222-1228. doi: 10.1002/pros.23697."
"7263","PC150797P1","Carter HB, Helfand B, Mamawala M, et al. 2018. Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. European urology. doi: 10.1016/j.eururo.2018.09.021. [Epub ahead of print]."
"7264","PC150797P1","Wu Y, Yu H, Zheng S, et al. 2018. A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer. The Prostate 78(8): 607-615. doi: 10.1002/pros.23505."
"7265","PC150797P2","Carter HB, Helfand B, Mamawala M, et al. 2018. Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. European urology. doi: 10.1016/j.eururo.2018.09.021. [Epub ahead of print]."
"7266","PC150797P2","Wu Y, Yu H, Zheng S, et al. 2018. A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer. The Prostate 78(8): 607-615. doi: 10.1002/pros.23505."
"7267","PC150797P2","Wu Y, Yu H, Zheng SL, et al. 2018. Germline mutations in PPFIBP2 are associated with lethal prostate cancer. The Prostate 78(16): 1222-1228. doi: 10.1002/pros.23697."
"7268","PC150836","Vagner T, Spinelli C, Minciacchi VR, Balaj L7, Zandian M, Conley A2, Zijlstra A, Freeman MR, Demichelis F, De S, et al. Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma.J Extracell Vesicles. 2018 Aug 7;7(1):1505403. doi: 10.1080/20013078.2018.1505403. PMID: 30108686 PMCID: PMC6084494"
"7269","PC150836","Minciacchi VR, Spinelli C, Reis-Sobreiro M, et al. 2017. MYC mediates large oncosome-induced fibroblast reprogramming in prostate cancer. Cancer Res. 77(14): 3961. doi: 10.1158/0008-5472.CAN-17-1493."
"7270","PC150847","Aggarwal R, Huang J, Alumkal JJ, et al. 2018. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. Journal of clinical oncology 36(24): 2492-2503. doi: 10.1200/JCO.2017.77.6880."
"7271","PC150847","Quigley DA, Dang HX, Zhao SG, et al. 2018. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell 174(3): 758-769. doi: 10.1016/j.cell.2018.06.039."
"7272","PC150932","Korenchan DE, Taglang C, von Morze C, et al. 2017. Dicarboxylic acids as pH sensors for hyperpolarized 13C magnetic resonance spectroscopic imaging.  Analyst 142(9):1429-1433. doi: 10.1039/c7an00076f."
"7273","PC150932","Korenchan DE, Flavell RR, Baligand C, et al. 2016. Dynamic nuclear polarization of biocompatible 13C-enriched carbonates for in vivo pH imaging.  Chem Commun (Camb) 52:3030-3033."
"7274","PC150933","Schweizer MT and Yu EY. 2017. AR-Signaling in Human Malignancies: Prostate Cancer and Beyond. Cancers 9(1): 7. doi: 10.3390/cancers9010007."
"7275","PC150933","Schweizer MT, Cheng HH, Tretiakova MS, et al. 2016. Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. Oncotarget 7(50): 82504-82510. doi: 10.18632/oncotarget.12697."
"7276","PC150933","Schweizer MT, Antonarakis ES, and Denmeade SR. 2017. Bipolar androgen therapy: a paradoxical approach for the treatment of castration-resistant prostate cancer. European urology 72(3): 323-325. doi: 10.1016/j.eururo.2017.03.022."
"7277","PC150933","Schweizer MT, Hancock ML, Getzenberg RH, et al. 2018. Hormone levels following surgical and medical castration: defining optimal androgen suppression. Asian journal of andrology 20(4): 405-406. doi: 10.4103/aja.aja_38_17."
"7278","PC150933","Teply BA, Wang H, Luber B, et al. 2018. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. The Lancet. Oncology 19(1): 76-86. doi: 10.1016/S1470-2045(17)30906-3."
"7279","PC150933","Mohammad OS, Nyquist MD, Schweizer MT, et al. 2017. Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions. Cancers 9(12). doi: 10.3390/cancers9120166."
"7280","PC150944","Jeong CH, Zhou C, and Flaws JA. 2017. Environmental Toxicants and Reproduction. In: Early Pregnancy, (Farquharson R abd Stephenson M, Eds.).  Second Edition, Cambridge University Press.  pp. 64-76."
"7281","PC150944","Jeong CH, Machek EJ, Shakeri M, et al. 2017. The impact of iodinated X-ray contrast agents on formation and toxicity of disinfection by-products in drinking water.  J Environ Sci. 58:173-182. https://doi.org/10.1016/j.jes.2017.03.032"
"7282","PC150959","Aytes A, Giacobbe A, Mitrofanova A, et al. NSD2 is a conserved driver of metastatic prostate cancer progression. Nature communications. 2018 12; 9(1): 5201. https://doi.org/10.1038/s41467-018-07511-4 PMID:30518758"
"7283","PC151032","Beebe-Dimmer J, Zuhlke K, Johnson A, et al. 2018. Rare germline mutations in African American men diagnosed with early-onset prostate cancer. The Prostate78(5): 321-326. doi: 10.1002/pros.23464."
"7284","PC151055","Nissim L, Wu MR, Pery E, et al. 2017. Synthetic RNA-based immunomodulatory gene circuits for cancerimmunotherapy. Cell 171(5): 1138-1150.e15. doi: 10.1016/j.cell.2017.09.049."
"7285","PC151068","Salami SS, Hovelson DH, Kaplan JB, Mathieu R, Udager AM, Curci NE, Lee M, Plouffe KR, de la Vega LL, Susani M, et al. Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight. 2018 Nov 2;3(21). pii: 123468. doi: 10.1172/jci.insight.123468. PubMed PMID: 30385730; PubMed Central PMCID: PMC6238741."
"7286","PC151068","Mahal BA, Alshalalfa M, Spratt DE, Davicioni E, Zhao SG, Feng FY, Rebbeck TR, Nguyen PL, Huang FW. Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores. Eur Urol. 2019 Jan 22. pii: S0302-2838(19)30011-9. doi: 10.1016/j.eururo.2019.01.010. [Epub ahead of print] PMID: 30683576."
"7287","PC151068","Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, Karnes RJ, Ross AE, Schaeffer EM, Rubin MA, Trock B, Klein EA, Den RB, Tomlins SA, Spratt DE, Davicioni E, Sboner A, Barbieri CE. Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00036. Epub 2018 Jul 24. PubMed PMID: 30761387; PubMed Central PMCID: PMC6370327."
"7288","PC151068","Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, et al. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 Oct 18;175(3):889. doi: 10.1016/j.cell.2018.10.019. PubMed PMID: 30340047."
"7289","PC151068","Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, Quigley DA, Dang HX, Barnard TJ, Mahal BA, et al. Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. Clin Cancer Res. 2018 Dec 20. doi: 10.1158/1078-0432.CCR-18-3121. Epub 2018 Dec 20. PubMed PMID: 30573691."
"7290","PC151074","Larimer BM, Phelan N, Wehrenberg-Klee E, et al. 2017. Phage display selection, in vitro characterization and correlative PET imaging of a novel HER3 peptide.  Mol Imaging Biol 77(9):2318-2327."
"7291","PC151082","Wang L, Failler M, Fu W, et al. 2018. A distal centriolar protein network controls organelle maturation and asymmetry. Nat Commun. 9(1): 3938. doi: 10.1038/s41467-018-06286-y."
"7292","PC151082","Wang L and Dynlacht BD. 2018. The regulation of cilium assembly and disassembly in development and disease. Development. 145(18). doi: 10.1242/dev.151407."
"7293","PC151085","Reon BJ, Takao RKB, Kiran M, et al. 2018. LINC00152 Promotes Invasion through a 3'-Hairpin Structure and Associates with Prognosis in Glioblastoma. Molecular cancer research 16(10): 1470-1482. doi: 10.1158/1541-7786.MCR-18-0322."
"7294","PC151085","Cichewicz MA, Kiran M, Przanowska RK, et al. 2018. MUNC, an eRNA upstream from the MYOD gene, induces a subgroup of myogenic transcripts in trans, independently of MyoD. Molecular and cellular biology. doi: 10.1128/MCB.00655-17. [Epub ahead of print]."
"7295","PC151085","Kuscu C, Kumar P, Kiran M, et al. 2018. tRNA fragments (tRFs) guide Ago to regulate gene expression post-transcriptionally in a Dicer-independent manner. RNA 24(8): 1093-1105. doi: 10.1261/rna.066126."
"7296","PC151085","Kiran M, Chatrath A, Tang X, et al. 2018. A Prognostic Signature for Lower Grade Gliomas Based on Expression of Long Non-Coding RNAs. Molecular Neurobiology 1-13. doi: 10.1007/s12035-018-1416-y."
"7297","PC151088","Shen MY, Chen JF, Luo CH, Lee S, Li CH, Yang YL, Tsai YH, Ho BC, Bao LR, Lee TJ, et al. Glycan Stimulation Enables Purification of Prostate Cancer Circulating Tumor Cells on PEDOT NanoVelcro Chips for RNA Biomarker Detection. Adv Healthc Mater. 2018 Feb;7(3). doi: 10.1002/adhm.201700701. Epub 2017 Sep 11. PubMed PMID: 28892262; PubMed Central PMCID: PMC5803304."
"7298","PC160018","Lee JK, Bangayan N, Chai T, et al. 2018. Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. PNAS 115(19): E4473–E4482. doi: 10.1073/pnas.1802354115."
"7299","PC160083","Colicino EG, Garrastegui AM, Freshour J, et al. 2018. Gravin regulates centrosome function through PLK1. Mol. Biol. Cell 29(5): 532-541. doi: 10.1091/mbc.E17-08-0524."
"7300","PC160083","Colicino EG, Garrastegui AM, Freshour J, Santra P, Post DE, Kotula L, Hehnly H. Gravin regulates centrosome function through PLK1. Mol Biol Cell. 2018 Mar 1;29(5):532-541. doi: 10.1091/mbc.E17-08-0524. Epub 2017 Dec 27. PubMed PMID: 29282278; PubMed Central PMCID: PMC6004580."
"7301","PC160083","Colicino EG, Stevens K, Curtis E, Rathbun L, Bates M, Manikas J, Amack J, Freshour J, Hehnly H. Chromosome misalignment is associated with PLK1 activity at cenexin-positive mitotic centrosomes. Mol Biol Cell. 2019 Jun 15;30(13):1598-1609. doi: 10.1091/mbc.E18-12-0817. Epub 2019 May 1. PubMed PMID: 31042116; PubMed Central PMCID: PMC6727634."
"7302","PC160209","Rosati R, Polin L, Ducker C, et al. 2018. Strategy for Tumor Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer. Clin Cancer Res. 1-14. doi: 10.1158/1078-0432.CCR-18-0982."
"7303","PC160209P1","Rosati R, Polin L, Ducker C, et al. 2018. Strategy for Tumor Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer. Clin Cancer Res. 1-14. doi: 10.1158/1078-0432.CCR-18-0982."
"7304","PC160264","Beltran H, Oromendia C, Danila DC, et al. 2019. A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration resistant and neuroendocrine prostate cancer: efficacy and biomarkers. Clin Cancer Res. 25(1): 43-51. doi: 10.1158/1078-0432.CCR-18-1912."
"7305","PC160264","Puca L, Bareja R, Prandi D, et al. 2018. Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun. 9(1): 2404. doi: 10.1038/s41467-018-04495-z."
"7306","PC160264P1","Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J, et al. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clin Cancer Res. 2019 Jan 1;25(1):43-51. doi: 10.1158/1078-0432.CCR-18-1912. Epub 2018 Sep 19. PubMed PMID: 30232224."
"7307","PC160264P1","Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M, et al. Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun. 2018 Jun 19;9(1):2404. doi: 10.1038/s41467-018-04495-z. PubMed PMID: 29921838."
"7308","PC160336","Kaur HB, Guedes LB, Lu J, et al. 2018. Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer. Modern Pathology 31(10): 1539-1552. doi: 10.1038/s41379-018-0083-x."
"7309","PC160353","Xiao J, Howard L, Wan J, et al. 2017. Low circulating levels of the mitochondrial peptide hormone SHLP2: novel biomarker for prostate cancer risk. Oncotarget. 8(55): 94900-94909. doi: 10.18632/oncotarget.20134."
"7310","PC160353","Yen K, Wan J, Mehta HH, et al. 2018. Humanin Prevents Age-Related Cognitive Decline in Mice and is Associated with Improved Cognitive Age in Humans. Nature Scientific Reports 8(1): 14212. doi: 10.1038/s41598-018-32616-7."
"7311","PC160371","Li X, Baek G, Ramanand S, et al. 2018. BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer. Cell Reports 22(3): 796–808. doi: 10.1016/j.celrep.2017.12.078."
"7312","PC160371","Welti J, Sharp A, Yuan W, et al. 2018. Targeting bromodomain and extra-terminal BET family proteins in castration resistant prostate cancer (CRPC). Clin Cancer Res 24(13): 3149-3162. doi: 10.1158/1078-0432.CCR-17-3571."
"7313","PC160371P1","Li X, Baek G, Ramanand SG, et al. 2018. BRD4 promotes DNA repair and mediates the formation of TMPRSS2-ERG gene rearrangements in prostate cancer. Cell Rep 22(3): 796-808. doi: 10.1016/j.celrep.2017.12.078."
"7314","PC160371P1","Welti J, Sharp A, Yuan W, et al. 2018. Targeting bromodomain and extra-terminal BET family proteins in castration resistant prostate cancer (CRPC). Clin Cancer Res 24(13): 3149-3162. doi: 10.1158/1078-0432.CCR-17-3571."
"7315","PC160371P2","Welti J, Sharp A, Yuan W, et al. 2018. Targeting bromodomain and extra-terminal BET family proteins in castration resistant prostate cancer (CRPC). Clin Cancer Res 24(13): 3149-3162. doi: 10.1158/1078-0432.CCR-17-3571."
"7316","PC160371P2","Li X, Baek G, Ramanand SG, et al. 2018. BRD4 promotes DNA repair and mediates the formation of TMPRSS2-ERG gene rearrangements in prostate cancer. Cell Rep 22(3): 796-808. doi: 10.1016/j.celrep.2017.12.078."
"7317","PC160398","Singh V, Jaiswal PK, Ghosh I, Koul HK, Yu X, De Benedetti A. Targeting the TLK1/NEK1 DDR axis with Thioridazine suppresses outgrowth of androgen independent prostate tumors. Int J Cancer. 2019 Aug 15;145(4):1055-1067. doi: 10.1002/ijc.32200. Epub 2019 Feb 25. PubMed PMID: 30737777; PubMed Central PMCID: PMC6617729."
"7318","PC160398","Singh V, Jaiswal PK, Ghosh I, Koul HK, Yu X, De Benedetti A. The TLK1-Nek1 axis promotes prostate cancer progression. Cancer Lett. 2019 Jul 1;453:131-141. doi: 10.1016/j.canlet.2019.03.041. Epub 2019 Mar 27. PubMed PMID: 30928383."
"7319","PC160398","Singh V, Connelly ZM, Shen X, et al. 2017. Identification of the proteome complement of humanTLK1 reveals it binds and phosphorylates NEK1 regulating its activity. Cell Cycle 16(10): 915-926. doi: 10.1080/15384101.2017.1314421."
"7320","PC160429","Wu YM, Cieslik M, Lonigro RJ, et al. 2018. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell 173(7): 1770-1782.e14. doi: 10.1016/j.cell.2018.04.034."
"7321","PC160429","Parolia A, Cieslik M, Chu SC, Xiao L, Ouchi T, Zhang Y, Wang X, Vats P, Cao X, Pitchiaya S, et al. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. Nature. 2019 Jul;571(7765):413-418. doi: 10.1038/s41586-019-1347-4. Epub 2019 Jun 26. PubMed PMID: 31243372; PubMed Central PMCID: PMC6661908."
"7322","PC160432","Abida W, Armenia J, Gopalan A, et al. 2017. Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations that May Affect Clinical Decision Making. JCO Precision Oncol. 1: 1-17. doi: 10.1200/PO.17.00029."
"7323","PC160432","Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, et al.Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncol. 2019 Apr 1;5(4):471-478. doi: 10.1001/jamaoncol.2018.5801. PubMed PMID: 30589920; PubMed Central PMCID: PMC6459218."
"7324","PC160455","Park SH, Eber MR, Tsuzuki S, et al. 2017. Adeno-associated virus serotype rh10 is a useful gene transfer vector for sensory nerves that innervate bone in immunodeficient mice. Scientific Reports 7: 17428. doi: 10.1038/s41598-017-17393-z."
"7325","PC160455P1","Park SH, Eber MR, Tsuzuki S, et al. 2017. Adeno-associated virus serotype rh10 is a useful gene transfer vector for sensory nerves that innervate bone in immunodeficient mice. Scientific Reports 7: 17428. doi: 10.1038/s41598-017-17393-z."
"7326","PC160531","Shapovalova M, Davydova J, Henzler C, Daniel M, Dehm SM, Warlick CA, LeBeau AM. Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer. Oncotarget. 2018 Nov 30;9(94):36693-36704. doi: 10.18632/oncotarget.26401. eCollection 2018 Nov 30. Erratum in: Oncotarget. 2019 Aug 06;10(47):4920. PubMed PMID: 30613352; PubMed Central PMCID: PMC6291171."
"7327","PC160610","Pawar A, Gollavilli PN, Wang S, et al. 2018. Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer. Cell Rep 22(9): 2236-2245. doi: 10.1016/j.celrep.2018.02.011."
"7328","PC160647","Naguib A, Mathew G, Reczek CR, et al. 2018. Mitochondrial Complex I Inhibitors Expose a Vulnerability for Selective Killing of Pten-Null Cells. Cell Rep. 23(1): 58-67. doi: 10.1016/j.celrep.2018.03.032."
"7329","PC160725","Parolia A, Cieslik M, Chu SC, Xiao L, Ouchi T, Zhang Y, Wang X, Vats P, Cao X, Pitchiaya S, et al. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. Nature. 2019 Jun 26. doi: 10.1038/s41586-019-1347-4. PMID: 31243372; PubMed Central PMCID: PMC6661908."
"7330","PC160839","Reddy V, Iskander A, Hwang C, Divine G, Menon M, Barrack ER, Reddy GP, Kim SH. Castration-resistant prostate cancer: Androgen receptor inactivation induces telomere DNA damage, and damage response inhibition leads to cell death. PLoS One. 2019 May 13;14(5):e0211090. doi: 10.1371/journal.pone.0211090. eCollection 2019. PubMed PMID: 31083651; PubMed Central PMCID: PMC6513077."
"7331","PC160946","Smith B, Agarwal P, Bhowmick NA. 2017. MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine. Endocr Relat Cancer. 24(5): R157-R172. doi: 10.1530/ERC-16-0525."
"7332","PC160955","Kregel S, Malik R, Asangani IA, Wilder-Romans K, Rajendiran T, Xiao L, Vo JN, Soni T, Cieslik M, Fernadez-Salas E, Zhou B, Cao X, Speers C, Wang S, Chinnaiyan AM. Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res. 2019 Mar 27. doi: 10.1158/1078-0432.CCR-18-3776. [Epub ahead of print] PubMed PMID: 30918020."
"7333","PC160970","Zhang Y, Pitchiaya S, Cieslik M, et al. 2018. Analysis of the androgen receptor–regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. Nature Genetics 50(6): 814-824. doi: 10.1038/s41588-018-0120-1."
"7334","PC160986","Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436. doi: 10.1073/pnas.1902651116. Epub 2019 May 6. PubMed PMID: 31061129; PubMed Central PMCID: PMC6561293."
"7335","PC160992","Hua JT, Ahmed M, Guo H, et al. 2018. Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19. Cell 174(3): 564-575.e18. doi: 10.1016/j.cell.2018.06.014."
"7336","PC160994","Augello MA, Liu D, Deonarine LD, Robinson BD, Huang D, Stelloo S, Blattner M, Doane AS, Wong EWP, Chen Y, et al. CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. Cancer Cell. 2019 Apr 15;35(4):603-617.e8. doi: 10.1016/j.ccell.2019.03.001. Epub 2019 Mar 28. PubMed PMID: 30930119; PubMed Central PMCID: PMC6467783."
"7337","PC161000","Taglang C , Korenchan DE , von Morze C , et al. 2018. Late-stage deuteration of 13C-enriched substrates for T1 prolongation in hyperpolarized 13C MRI. Chem Commun (Camb). 54(41): 5233-5236. doi: 10.1039/c8cc02246a."
"7338","PC161016","Madhav A, Andres A, Duong F, et al. 2018. Antagonizing CD105 enhances radiation sensitivity in prostate cancer. Oncogene 37(32): 4385–4397. doi: 10.1038/s41388-018-0278-0."
"7339","PC161018","Beer T, Miller K, Tombal B, et al. 2017. The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: exploratory analyses of AFFIRM and PREVAIL studies. Eur J Cancer. 87: 21-9.doi: 10.1016/j.ejca.2017.09.035."
"7340","PC161018","Armstrong A, Lin P, Higano C, et al. 2018. Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. Ann Oncol. 29(11): 2200-2207. doi: 10.1093/annonc/mdy406."
"7341","PC161018","Friedlander T, Graff J, Zejnullahu K, et al. 2017. High-dose abiraterone acetate in men with castration resistant prostate cancer. Clin Genitourin Cancer. 2017. 15(6): 733-41. doi: 10.1016/j.clgc.2017.05.026."
"7342","PC161018","Beer T, Hotte S, Saad F, et al. 2017. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomized, open-label, international, phase 3 trial. Lancet Oncol. 18(11): 1532-1542. doi: 10.1016/S1470-2045(17)30605-8."
"7343","PC161018","Alumkal J, Chowdhury S, Loriot Y, et al. 2017. Effect of visceral disease site on outcomes in patients with metastatic castration-resistant prostate cancer treated with enzalutamide in the PREVAIL trial. Clin Genitourin Cancer. 15(5): 610-617. doi: 10.1016/j.clgc.2017.02.007."
"7344","PC161018","Rathkopf D, Beer T, Loriot Y, et al. 2018. Radiographic progression-free survival as a clinically meaningful end point in metastatic castration-resistant prostate cancer: the PREVAIL randomized clinical trial. JAMA Oncol. 4(5): 694-701. doi: 10.1001/jamaoncol.2017.5808."
"7345","PC161019","Cheng HH. The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol. 2018 Mar 16. pii: S1078-1439(18)30070-X. doi: 10.1016/j.urolonc.2018.02.014. Epub 2018 Mar 17. Review. PubMed PMID: 29555412"
"7346","PC161019","Rathkopf DE, Beer TM, Loriot Y, Higano CS, Armstrong AJ, Sternberg CN, de Bono JS, Tombal B, Parli T, Bhattacharya S, et al. Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial. JAMA Oncol. 2018 May 1;4(5):694-701. PMID: 29522174."
"7347","PC161019","Hahn AW, Higano CS, Taplin ME, Ryan CJ, Agarwal N. Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment. Am Soc Clin Oncol Educ Book. 2018 May 23;38:363-371. doi: 10.1200/EDBK_200967. Review. PubMed PMID: 30231388."
"7348","PC161019","Alumkal JJ, Chowdhury S, Loriot Y, Sternberg CN, de Bono JS, Tombal B, Carles J, Flaig TW, Dorff TB, Phung,et al. Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. Clin Genitourin Cancer. 2017 Oct;15(5):610-617.e3. Epub 2017 Mar 3. PMID: 28344102."
"7349","PC161019","Rathkopf DE, Smith MR, Ryan CJ, Berry WR, Shore ND, Liu G, Higano CS, Alumkal JJ, Hauke R, Tutrone RF, et al. Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide. Ann Oncol. 2017 Sep 1;28(9):2264-2271. PMID: 28633425."
"7350","PC161019","Carlo MI, Giri VN, Paller CJ, Abida W, Alumkal JJ, Beer TM, Beltran H, George DJ, Heath EI, Higano CS, et al. Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00060. Epub 2018 Aug 16. PubMed PMID: 30761386."
"7351","PC161019","Mateo J, Cheng HH, Beltran H, Dolling D, Xu W, Pritchard CC, Mossop H, Rescigno P, Perez-Lopez R, Sailer V, et al. Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. Eur Urol. 2018 May;73(5):687-693. doi: 10.1016/j.eururo.2018.01.010. Epub 2018 Feb 8. PubMed PMID: 29429804."
"7352","PC161019","Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, Siddiqui J, Wu YM, Robinson D, Lonigro RJ, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018 Apr 1;36(10):991-999. doi: 10.1200/JCO.2017.75.7310. Epub 2017 Dec 20. PubMed PMID: 29261439"
"7353","PC161019","McKay RR, Montgomery B, Xie W, Zhang Z, Bubley GJ, Lin DW, Preston MA, Trinh QD, Chang P, Wagner AA, et al. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer Prostatic Dis. 2018 Sep;21(3):364-372. doi: 10.1038/s41391-017-0009-6. Epub 2017 Dec 20. PubMed PMID: 29263420."
"7354","PC161025","Kyriakopoulos C, Chen Y, Carducci M, et al. 2018. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 36(11): 1080-1087. doi: 10.1200/JCO.2017.75.3657."
"7355","PC161025","Olson B, Gamat M, Seliski J, et al. 2017. Prostate cancer cells express more androgen receptor (AR) following androgen deprivation, improving recognition by AR-specific T cells. Cancer Immunol Res. 5(12): 1074-1085. doi: 10.1158/2326-6066.CIR-16-0390."
"7356","PC161025","Wargowski E, Johnson L, Eickhoff J, et al. 2018. Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine. J Immunother Cancer. 6(1): 21. doi: 10.1186/s40425-018-0333-y."
"7357","PC161026","Armstrong AJ, Anand A, Edenbrandt L, et al. 2018. Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 4(7): 944-951. doi: 10.1001/jamaoncol.2018.1093."
"7358","PC161026","Koontz BF, Hoffman KE, Healy P, et al. 2018. Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer. Journal of Clinical Oncology 36: 11-11. doi: 10.1200/JCO.2018.36.6_suppl.11."
"7359","PC161026","Concepcion R, Armstrong AJ, Karsh LI, et al. 2018. Impact of enzalutamide (ENZA) vs. bicalutamide (BIC) on health-related quality of life (HRQoL) of patients (pts) with castration-resistant prostate cancer (CRPC): STRIVE study. Journal of Clinical Oncology 36: 234-234. doi: 10.1200/JCO.2018.36.6_suppl.234."
"7360","PC161031","Wu Y, Cieslik M, Lonigro R, et al. 2018. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell. 173(7): 1770-1782.e14. doi: 10.1016/j.cell.2018.04.034."
"7361","PC161031","Armstrong A, Antonarakis E, Taplin M, et al. 2018. Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. Ann Oncol. 29(1): 23-25. doi: 10.1093/annonc/mdx648."
"7362","PC161031","Ginsburg K, Auffenberg G, Qi J, et al. 2019. Risk of becoming lost to follow-up during active surveillance for prostate cancer. Eur Urol. 74(6): 704-707. doi: 10.1016/j.eururo.2018.08.010."
"7363","PC161031","Beebe-Dimmer J, Ruterbusch J, Bylsma L, et al. 2018. Patterns of bicalutamide use in prostate cancer treatment: a U.S. real-world analysis using the SEER-Medicare database. Adv Ther. 35(9): 1438-1451. doi: 10.1007/s12325-018-0738-5."
"7364","PC161031","Rodrigues N, Rescigno P, Liu D, et al. 2018. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 128(11): 5185. doi: 10.1172/JCI125184."
"7365","PC161031","Teslow E, Bao B, Dyson G, et al. 2018. Exogenous IL-6 induces mRNA splice variant MBD2_v2 to promote stemness in TP53 wild-type, African American PCa cells. Mol Oncol. 12(7): 1138-1152. doi: 10.1002/1878-0261.12316."
"7366","PC161031","Sbrissa D, Semaan L, Govindarajan B, et al. 2019. A novel cross-talk between CXCR4 and PI4KIIIa in prostate cancer cells. Oncogene. 38(3): 332-344. doi: 10.1038/s41388-018-0448-0."
"7367","PC161032","Armstrong AJ, Antonarakis ES, Taplin ME, et al. 2018. Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. Ann Oncol. 29(1): 23-25. doi: 10.1093/annonc/mdx648."
"7368","PC161032","Carlo MI, Giri VN, Paller CJ, et al. 2018. Evolving intersection between inherited cancer genetics and therapeutic clinical trials in prostate cancer: a white paper from the germline genetics working group of the prostate cancer clinical trials consortium. JCO Precision Oncology. doi: 10.1200/PO.18.00060. [Epub ahead of print]."
"7369","PC161032","Boudadi K, Suzman DL, Anagnostou V, et al. 2018. Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget. 9(47): 28561-28571. doi: 10.18632/oncotarget.25564."
"7370","PC170176","Barner LA, Glaser AK, True LD, Reder NP, Liu JTC. Solid immersion meniscus lens (SIMlens) for open-top light-sheet microscopy. Opt Lett. 2019 Sep 15;44(18):4451-4454. doi: 10.1364/OL.44.004451. PubMed PMID: 31517904."
"7371","PC170176","Glaser AK, Reder NP, Chen Y, Yin C, Wei L, Kang S, Barner LA, Xie W, McCarty EF, Mao C, et al. Multi-immersion open-top light-sheet microscope for high-throughput imaging of cleared tissues. Nat Commun. 2019 Jul 4;10(1):2781. doi: 10.1038/s41467-019-10534-0. PubMed PMID: 31273194; PubMed Central PMCID: PMC6609674."
"7372","PC171093","Stopsack KH, Whittaker CA, Gerke TA, Loda M, Kantoff PW, Mucci LA, Amon A. Aneuploidy drives lethal progression in prostate cancer. Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11390-11395. doi: 10.1073/pnas.1902645116. Epub 2019 May 13. PubMed PMID: 31085648; PubMed Central PMCID: PMC6561291."
"7373","PC171093","Khan NA, Stopsack KH, Allott EH, Gerke T, Giovannucci EL, Mucci LA, Kantoff PW. Intratumoral Sterol-27-Hydroxylase (CYP27A1) Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019 Jun;28(6):1052-1058. doi: 10.1158/1055-9965.EPI-18-1083. Epub 2019 Mar 13. PubMed PMID: 30867220; PubMed Central PMCID: PMC6548616."
"7374","PC970002","Mi Z, Kramer DL, Miller JT, Bergeron RJ, Bernacki R, Porter CW (1998): Human prostatic carcinoma cell lines display altered regulation of polyamine transport in response to polyamine analogs and inhibitors. Prostate 34:51-60."
"7375","PC970002","Vujcic S, Halmekyto M, Diegelman P, Gan G, Kramer DL, Janne J, Porter CW (2000): Effects of conditional overexpression of spermidine/spermine N1-acetyltransferase on polyamine pool dynamics, cell growth, and sensitivity to polyamine analogs. Journal of Biological Chemistry 275. 275:38319-28-38319-28."
"7376","PC970023","Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, and McConkey DJ.  2003.  Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts.  Mol Cancer Ther 2(9):835-43."
"7377","PC970023","Williams SA and McConkey DJ.  2003.  The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells.  Cancer Res 63(21):7338-44."
"7378","PC970029","Pinthus JH, Waks T, Malina V,  et al.  2004.  Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.  J. Clin. Invest. 114:1774-1781.
"
"7379","PC970068","Holleran JL, Miller CJ, Culp LA (2000): Tracking micrometastasis to multiple organs with lacZ-tagged CWR22R prostate carcinoma cells. Journal of Histochemistry and Cytochemistry 48. 48:643-51-643-51."
"7380","PC970068","Culp LA, Lin WC, Kleinman NR, Campero NM, Miller CJ, Holleran JL (1998): Tumor progression, micrometastasis, and genetic instability tracked with histochemical marker genes. Progress in Histochemistry and Cytochemistry 33. 33:XI-XV, 329-48-XI-XV, 329-48."
"7381","PC970072","Pang S (2000): Targeting and eradicating cancer cells by a prostate-specific vector carrying the diphtheria toxin A gene. Cancer Gene Ther 7:991-6."
"7382","PC970072","Yu D, Chen D, Chiu C, Razmazma B, Chow YH, Pang S (2001): Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther 8:628-35."
"7383","PC970073","Zaia A, Fraizer GC, Piantanelli L, Saunders GF (2001): Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1. Anticancer Res 21:1-10."
"7384","PC970073","Tanaka M, Fraizer GC, De La Cerda J, Cristiano RJ, Liebert M, Grossman HB (2001): Connexin 26 enhances the bystander effect in HSVtk/GCV gene therapy for human bladder cancer by adenovirus/PLL/DNA gene delivery. Gene Ther 8:139-48."
"7385","PC970075","Frost GI, Lustgarten J, Dudouet B, et al.  2005.  Novel syngeneic pseudo-orthotopic prostate cancer model: vascular, mitotic and apoptotic responses to castration.  Microvasc Res69(1-2):1-9."
"7386","PC970078","Balbay MD, Pettaway CA, Kuniyasu H, Inoue K, Ramirez E, Li E, Fidler IJ, Dinney CP (1999): Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Clinical Cancer Research 5:783-9."
"7387","PC970078","Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP (2000): Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clinical Cancer Research 6:2104-19."
"7388","PC970078","Kuniyasu H, Troncoso P, Johnston D, Bucana CD, Tahara E, Fidler IJ, Pettaway CA (2000): Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clinical Cancer Research 6. 6:2295-308-2295-308."
"7389","PC970087","Colletier PJ, Ashoori F, Cowen D, Meyn RE, Tofilon P, Meistrich ME, Pollack A (2000): Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation. International Journal of Radiation Oncology, Biology, Physics 48. 48:1507-12-1507-12."
"7390","PC970087","Pollack A, Smith LG, von Eschenbach AC (2000): External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. International Journal of Radiation Oncology, Biology, Physics 48. 48:507-12-507-12."
"7391","PC970087","Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, Starkschall G, Rosen I (2000): Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology 18. 18:3904-11-3904-11."
"7392","PC970087","Pollack A, Ashoori F, Sikes C, Joon DL, von Eschenbach AC, Zagars GK, Meistrich ML (2000): The early supra-additive apoptotic response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions. International Journal of Radiation Oncology, Biology, Physics 46:153-8."
"7393","PC970087","Khoo VS, Pollack A, Cowen D, Joon DL, Patel N, Terry NH, Zagars GK, von Eschenbach AC, Meistrich ML, Troncoso P (1999): Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate 41:166-72."
"7394","PC970087","Kelly J, Pollack A, Zagars GK (2000): Serum testosterone is not a correlate of prostate cancer lymph node involvement, but does predict biochemical failure for lymph node-positive disease. Urologic Oncology 5:78-84."
"7395","PC970087","Cowen D, Salem N, Ashoori F, Meyn R, Meistrich ML, Roth JA, Pollack A (2000): Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy. Clinical Cancer Research 6. 6:4402-8-4402-8."
"7396","PC970090","Lee LF, Guan J, Qiu Y, Kung HJ. 2011.  Neuropeptide-induced androgen independence in 
prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and
focal adhesion kinase. Mol Cell Biol 21(24):8385-8397."
"7397","PC970099","Tsihlias J, Zhang W, Bhattacharya N, Flanagan M, Klotz L, Slingerland J (2000): Involvement of p27Kip1 in G1 arrest by high dose 5 alpha-dihydrotestosterone in LNCaP human prostate cancer cells. Oncogene 19. 19:670-9-670-9."
"7398","PC970101","Phan D, Sui X, Chen DT, Najjar SM, Jenster G, Lin SH (2001): Androgen regulation of the cell-cell adhesion molecule-1 (Ceacam1) gene. Mol Cell Endocrinol 184:115-23."
"7399","PC970105","Hellberg CB. Burden-Gulley SM, Brady-Kalnay SM, et al. 2002. expression of the receptor protein tyrosine phosphatase, PTPmicro, restores E-cadherin-dependent adhesion in human prostate carcinoma cells. JBC 277:11165-11173."
"7400","PC970105","Mourton T, Hellberg C, Burden-Gulley S, et al. 2001. The protein tyrosine phosphatase, PTPmico, bind and recruits RACK1 to points of cell-cell contact, JBC 276:14896-14901."
"7401","PC970107","Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N, Hu M, Olive M, Martinez LA, Wood CG, Logothetis CJ, Karsenty G, Navone NM (2001): Prostate cancer cells induce osteoblast differentiation through a Cbfa1- dependent pathway. Cancer Res 61:5652-9."
"7402","PC970110","Liu G, Wilding G, Staab MJ, et al.  2003.  Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer.  Clin Cancer Res 9(11):4077-4083."
"7403","PC970110","Bailey HH, Ripple G, Bruskewitz R, et al. (1999): Phase I and Phase II trials of 1?-hydroxyvitamin D2 in patients with metastatic hormone-refractory prostate cancer. Clinical Cancer Research39."
"7404","PC970110","Bailey HH, Ripple G, Horvath D, et al. (2000): Phase I and Phase II trials of 1?-hydroxyvitamin D2 in patients with metastatic hormone-refractory prostate cancer. Clinical Cancer Research 6:112."
"7405","PC970111","Ly LH, Zhao XY, Holloway L, Feldman D (1999): Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 140:2071-6."
"7406","PC970111","Zhao XY, Peehl DM, Navone NM, et al.  2000.  1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 141(7):2548-2556."
"7407","PC970111","Zhao XY, Ly LH, Peehl DM, Feldman D (1999): Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 140:1205-12."
"7408","PC970111","Sung V, Feldman D.  2000. 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration.  Mol Cell Endocrinol 164(1-2):133-143."
"7409","PC970121","Fritz WA, Cotroneo MS, Wang J, et al. 2003. Dietary Diethylstilbestrol but Not Genistein Adversely Affects Rat Testicular Development. J Nutr 133(7):2287-2293."
"7410","PC970121","Lamartiniere CA, Cotroneo MS, Fritz WA, et al.2002. Genistein Chemoprevention: Timing and Mechanisms of Action in Murine Mammary and Prostate. J Nutr 132(3):552S-558S."
"7411","PC970121","Mentor-Marcel R, Lamartiniere CA, Eltoum IE, et al.  2001. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 61(18):6777-6782."
"7412","PC970121","Fritza WA, Wanga J, Eltoumb I-E. 2002. Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate. Mol Cell Endocrinol 186(1):89-99."
"7413","PC970121","Wanga J, Eltoumb I-E, Lamartiniere CA. 2002. Dietary genistein suppresses chemically induced prostate cancer in Lobund-Wistar rats. Cancer Lett 186(1):11-18."
"7414","PC970122","Honda T, Rounds BV, Bore L, Favaloro FG Jr, Gribble GW, Suh N, Wang Y, Spor MB (1999): Novel synthetic oleanane triterpenoids: a series of highly active inhibitors of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 9:3429-34."
"7415","PC970122","Honda T, Rounds BV, Bore L, Finlay HJ, Favaloro FG Jr, Suh N, Wang Y, Sporn MB, Gribble GW (2000): Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages. J Med Chem 43:4233-46."
"7416","PC970122","Wang Y, Porter WW, Suh N, Honda T, Gribble GW, Leesnitzer LM, Plunket KD, Mangelsdorf DJ, Blanchard SG, Willson TM, Sporn MB (2000): A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol Endocrinol 14:1550-6."
"7417","PC970122","Honda T, Gribble GW, Suh N, Finlay HJ, Rounds BV, Bore L, Favaloro FG Jr, Wang Y, Sporn MB (2000): Novel synthetic oleanane and ursane triterpenoids with various enone functionalities in ring A as inhibitors of nitric oxide production in mouse macrophages. J Med Chem 43:1866-77."
"7418","PC970122","Konopleva M, Tsao T, Ruvolo P, et al. 2002. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 99(1):326-35."
"7419","PC970131","Holt GE, Velders MP, Rudolf MP, et al. Critical dependence of the peptide delivery method on the efficacy of epitope focused immunotherapy. In: Peptide-based Cancer Vaccines. Eureka.com. 56-72pp."
"7420","PC970131","Yang D, Holt GE, Rudolf MP, et al. (2000): Peptide Vaccines. In: New Vaccine Technologies. Eureka.com. 214-226pp."
"7421","PC970131","Yang D HGRMea (2001): Peptide Vaccines. In: New Vaccine Technologies (Medical Intelligence Unit 26). Ellis RW, ed. Landes Bioscience."
"7422","PC970131","Holt GE VMRMea (2000): Critical dependence of the peptide delivery method on the efficacy of epitope focused immunotherapy. In: Peptide-Based Cancer Vaccines. Kast WM, ed. Landes Bioscience."
"7423","PC970137","Chen MW Vacherot F De La Taille A Gil-Diez-De-Medina S Shen R Friedman RA Burchardt M Chopin DK Buttyan R (2002): The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells. Oncogene 21:7861-7871."
"7424","PC970137","De La Taille A Rubin MA Chen MW Vacherot F De Medina SG Burchardt M Buttyan R Chopin D (2003): b-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells.  Clin. Cancer Res. 9:1801-1807."
"7425","PC970140","Varghese S, Newsome JT, Rabkin SD, McGeagh K, Mahoney D, Nielsen P, Todo T, Martuza RL (2001): Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum Gene Ther 12:999-1010."
"7426","PC970140","Jorgensen TJ, Katz S, Wittmack EK, Varghese S, Todo T, Rabkin SD, Martuza RL (2001): Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia 3:451-6."
"7427","PC970140","Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL (1999): Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 10:2237-43."
"7428","PC970146","Wallen E, Sellers RG, Peehl DM (2000): Brefeldin A induces p53-independent apoptosis in primary cultures of human prostatic cancer cells. J Urol 164:836-41."
"7429","PC970146","Sandhu C, Peehl DM, Slingerland J (2000): p16INK4A mediates cyclin dependent kinase 4 and 6 inhibition in senescent prostatic epithelial cells. Cancer Res 60:2616-22."
"7430","PC970146","Armstrong JS, Steinauer KK, Hornung B, Irish JM, Lecane P, Birrell GW, Peehl DM, Knox SJ (2002): Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. Cell Death Differ 9:252-263."
"7431","PC970149","Chen YQ, Hsieh JT, Yao F, Fang B, Pong RC, Cipriano SC, Krepulat F (1999): Induction of apoptosis and G2/M cell cycle arrest by DCC. Oncogene 18:2747-54."
"7432","PC970161","Edlund M, Miyamoto T, Sikes RA, Ogle R, Laurie GW, Farach-Carson MC, Otey CA, Zhau HE, Chung LW (2001): Integrin expression and usage by prostate cancer cell lines on laminin substrata. Cell Growth Differ 12:99-107."
"7433","PC970173","Butler JS, Loh SN.  2005.  Kinetic partitioning during folding of the p53 DNA binding domain.   J Mol Biol 350(5):906-918."
"7434","PC970173","Butler JS, Loh SN (2003): Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain. Biochemistry 42:2396-403."
"7435","PC970193","Curiel DT (1999): Strategies to adapt adenoviral vectors for targeted delivery. Annals of the New York Academy of Sciences 886. 886:158-71.:158-71."
"7436","PC970193","Curiel DT (2000): The development of conditionally replicative adenoviruses for cancer therapy. Clinical Cancer Research 6. 6:3395-9-3395-9."
"7437","PC970193","Dmitriev I, Kashentseva E, Rogers BE, Krasnykh V, Curiel DT (2000): Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. Journal of Virology 74. 74:6875-84-6875-84."
"7438","PC970193","Nicklin SA, Reynolds PN, Brosnan MJ, White SJ, Curiel DT, Dominiczak AF, Baker AH (2001): Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension 38. 38:65-70-65-70."
"7439","PC970193","Reynolds, P. N. and Curiel, D. T. (1999): Targeting and Integration. Cold Spring Harbor Laboratory Press."
"7440","PC970193","Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R (2001): A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clinical Cancer Research 7. 7:120-6-120-6."
"7441","PC970201","Siewerdsen JH and Jaffray DA.       (2000): Cone-beam CT with a flat-panel imager: Noise considerations for fully 3-D computed tomography SPIE Physics of Medical Imaging 3336: 546-554."
"7442","PC970201","Siewerdsen JH, Jaffray DA Edmundson GK et al. (2001): Flat-panel cone-beam CT: A novel imaging technology for image-guided procedures Proceedings of SPIE Medical Imaging: Image Display Visualization and Image-Guided Procedures."
"7443","PC970201","Siewerdsen JH, Jaffray DA (1999): A ghost story: spatio-temporal response characteristics of an indirect- detection flat-panel imager. Med Phys 26:1624-41."
"7444","PC970201","Siewerdsen JH, Jaffray DA (1999): Cone-beam computed tomography with a flat-panel imager: effects of image lag. Med Phys 26:2635-47."
"7445","PC970201","Siewerdsen JH, Jaffray DA (2000): Optimization of x-ray imaging geometry (with specific application to flat-panel cone-beam computed tomography). Med Phys 27:1903-14."
"7446","PC970201","Siewerdsen JH, Jaffray DA (2001): Cone-beam computed tomography with a flat-panel imager: magnitude and effects of x-ray scatter. Med Phys 28:220-31."
"7447","PC970201","Jaffray DA, Siewerdsen JH and Drake DG. (1999): Performance of a volumetric CT scanner based upon a flat-panel imager.  In Medical Imaging 1999: Physics of Medical Imaging, JM Boone and JT Dobbins III, editors.  Proceedings of Society of Photo-optical Instrumentation Engineers (SPIE) 3659: 204-214."
"7448","PC970201","Oldham M, Siewerdsen JH, Kumar S, Wong J, Jaffray DA (2003): Optical-CT gel-dosimetry I: Basic investigations. Med Phys.  30:623-634."
"7449","PC970201","Jaffray DA, Siewerdsen JH, Wong JW, Martinez AA (2002): Flat-panel cone-beam computed tomography for image-guided radiation therapy.  Int. Rad. Onc. Biol. Phys.  53:1337-1349."
"7450","PC970201","Jaffray DA, Siewerdsen JH (2000): Cone-beam computed tomography with a flat-panel imager: initial performance characterization. Med Phys 27:1311-23."
"7451","PC970201","Jaffray DA, Drake DG, Moreau M, Martinez AA, Wong JW (1999): A radiographic and tomographic imaging system integrated into a medical linear accelerator for localization of bone and soft-tissue targets. Int J Radiat Oncol Biol Phys 45:773-89."
"7452","PC970201","Jaffray DA and Siewerdsen JH . (2001): A volumetric cone-beam CT system based on a 41x41 cm2 flat-panel imager Proceedings of SPIE Medical Imaging: Physics of Medical Imaging. 4320: 800."
"7453","PC970201","Siewerdsen JH CIJD (2002): A framework for noise-power spectrum analysis of multidimensional images.   Med. Phys.  29:2655-2671."
"7454","PC970206","Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD (1999): Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18. 18:7389-94-7389-94."
"7455","PC970206","Palayoor ST, Tofilon PJ, Coleman CN. 2003. Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells. Clin Cancer Res 9(8):3150-7."
"7456","PC970218","Bates PJ, Kahlon JB, Thomas SD, Trent JO, Miller DM (1999): Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. Journal of Biological Chemistry 274:26369-77."
"7457","PC970218","Xu X, Hamhouyia F, Thomas SD, Burke TJ, Girvan AC, McGregor WG, Trent JO, Miller DM, Bates PJ (2001): Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides. J Biol Chem 276:43221-30."
"7458","PC970218","Dapic V, Bates PJ, Trent JO, Rodger A, Thomas SD, Miller DM (2002): Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications. Biochemistry 41:3676-85."
"7459","PC970218","Mi Y, Thomas SD, Xu X, et al. 2003.  Apoptosis in leukemia cells is accompanied by alterations in the levels and localization of nucleolin. J Biol Chem 278(10):8572-8579. 
"
"7460","PC970221","Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR (2000): Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Molecular and Cellular Biology 20:8969-82."
"7461","PC970221","Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, Sellers WR (1999): Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proceedings of the National Academy of Sciences of the United States of America 96:2110-5."
"7462","PC970221","McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR (1999): Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Research 59:4291-6."
"7463","PC970221","Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR (2000): Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 20:8969-82."
"7464","PC970221","Ramaswamy S, Nakamura N, Sansal I, Bergeron L, Sellers WR (2002): A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell 2:81-91."
"7465","PC970221","Vazquez F, Sellers WR (2000): The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochimica Et Biophysica Acta 1470:M21-35."
"7466","PC970221","Sellers WR (2001): PTEN review for the cancer encyclopedia. In: Encyclopedic Reference of Cancer. Schwab M, ed. Springer Verlag."
"7467","PC970221","Ramaswamy S and Sellers WR (2000): PTEN:  A prostate cancer tumor suppressor gene. The Prostate Journal 2."
"7468","PC970229","Smith-Jones PM, et. al. (1999): In Vivo evaluation of I-131 labeled monoclonal antibodies (Mab) specific for extracellular domain of prostate specific membrane antigen (PSMA). Journal of Nuclear Medicine 40:225p."
"7469","PC970229","Milowsky MI, Nanus DM, Kostakoglu L, et al.  2007.  Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumor.  J Clin Oncol 25(5):540-547.

"
"7470","PC970229","·Trabulsi EJ, Yao D, Kostakoglu L, et al.  2003.  Targeting metastatic prostate cancer with radiolabeled J591 monoclonal antibody (mAb) specific for the extracellular domain of prostate specific membrane antigen (PSMAEXT).  Proc AUA 167;395."
"7471","PC970229","·Vallabhajosula S, Smith-Jones PM, Navarro V, et al.  2004.  Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): Studies in nude mice.  The Prostate 58:145-155."
"7472","PC970229","·Yao D, Tabulsi EJ, Kostakoglu L, et al.  2002.  The utility of monoclonal antibodies in the imaging of prostate cancer.  Sem Urol Onc 20:211-218."
"7473","PC970229","·Nanus D, Milowsky MI, Kostakoglu L, et al.  2003.  Clincal use of monoclonal antibody HuJ591 in therapy: Targeting prostate specific membrane antigen.  J Urology 170:S84-S89."
"7474","PC970229","·Bander NH, Trabulsi E, Kostakoglu L, et al.  2003.  Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 in the extracellular domain of prostate-specific membrane antigen.  J Urology 170:1717-1721."
"7475","PC970229","·Bander NH, Nanus DM, Milowsky MI, et al.  2003.  Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen (PSMA).  Sem in Oncology 30:667-677."
"7476","PC970229","·Smith-Jones PM, Vallabhajosula S, Navarro V, et al.  2003.  Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: Preclinical studies in nude mice bearing LNCaP human prostate tumor.  J Nucl Med 44:610-617."
"7477","PC970229","Milowsky MI, Nanus DM, Kostakoglu L, et al.  2004.  Phase I trial of 90Y-Labeled anti-PSMA monoclonal antibody J591 for androgen-independent prostate cancer.  J Clin Oncol 22(13):2522-31."
"7478","PC970229","Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH (2000): In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Research 60. 60:5237-43-5237-43."
"7479","PC970229","Smith-Jones PM, et.al. (1999): Monoclonal antibodies (Mab) specific to extracellular domain of prostate specific membrane antigen (PSMA):  In vitro studies. Journal of Nuclear Medicine 40:226p."
"7480","PC970230","Chen LM, Hodge GB, Guarda LA, Welch JL, Greenberg NM, Chai KX (2001): Down-regulation of prostasin serine protease: a potential invasion suppressor in prostate cancer. Prostate 48:93-103."
"7481","PC970230","Narikiyo T, Kitamura K, Adachi M, Miyoshi T, Iwashita K, Shiraishi N, Nonoguchi H, Chen LM, Chai KX, Chao J, Tomita K (2002): Regulation of prostasin by aldosterone in the kidney. J Clin Invest 109:401-8."
"7482","PC970230","Chen LM, Chai KX (2002): Prostasin serine protease inhibits breast cancer invasiveness and is transcriptionally regulated by promoter DNA methylation. Int J Cancer 97:323-9."
"7483","PC970230","Chen LM, Skinner ML, Kauffman SW, Chao J, Chao L, Thaler CD, Chai KX (2001): Prostasin is a glycosylphosphatidylinositol-anchored active serine protease. J Biol Chem 276:21434-42."
"7484","PC970244","Zi X, Singh RP, Agarwal R (2000): Impairment of erbB1 receptor and fluid-phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells. Carcinogenesis 21. 21:2225-35-2225-35."
"7485","PC970244","Zi X, Grasso AW, Kung HJ, Agarwal R (1998): A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Research 58. 58:1920-9-1920-9."
"7486","PC970244","Sharma Y, Agarwal C, Singh AK, Agarwal R (2001): Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells. Molecular Carcinogenesis 30. 30:224-36-224-36."
"7487","PC970244","Bhatia N, Agarwal R (2001): Detrimental effect of cancer preventive phytochemicals silymarin, genistein and epigallocatechin 3-gallate on epigenetic events in human prostate carcinoma DU145 cells. Prostate 46. 46:98-107-98-107."
"7488","PC970244","Agarwal R (2000): Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochemical Pharmacology 60. 60:1051-9-1051-9."
"7489","PC970244","Agarwal C, Sharma Y, Agarwal R (2000): Anticarcinogenic effect of a polyphenolic fraction isolated from grape seeds in human prostate carcinoma DU145 cells: modulation of mitogenic signaling and cell-cycle regulators and induction of G1 arrest and apoptosis. Molecular Carcinogenesis 28. 28:129-38-129-38."
"7490","PC970244","Jiang C, Agarwal R, Lu J (2000): Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells. Biochemical and Biophysical Research Communications 276. 276:371-8-371-8."
"7491","PC970244","Zi X, Agarwal R (1999): Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proceedings Of The National Academy Of Sciences Of The United States Of America 96:7490-5."
"7492","PC970249","Sreenath T, Orosz A, Fujita K, Bieberich CJ (1999): Androgen-independent expression of hoxb-13 in the mouse prostate. Prostate 41:203-7."
"7493","PC970253","Miao H, Burnett E, Kinch M, et al.  Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol 2(2):62-69."
"7494","PC970253","Khan S, Koepke A, Jarad G, Schlessman K, Cleveland RP, Wang B, Konieczkowski M, Schelling JR (2001): Apoptosis and JNK activation are differentially regulated by Fas expression level in renal tubular epithelial cells. Kidney Int 60:65-76."
"7495","PC970253","Han DC, Shen TL, Miao H, Wang B, Guan JL (2002): EphB1 associates with Grb7 and regulates cell migration. J Biol Chem 277:45655-61."
"7496","PC970253","Jarad G, Wang B, Khan S, DeVore J, Miao H, Wu K, Nishimura SL, Wible BA, Konieczkowski M, Sedor JR, Schelling JR (2002): Fas activation induces renal tubular epithelial cell beta 8 integrin expression and function in the absence of apoptosis. J Biol Chem 277:47826-33."
"7497","PC970253","·Deroanne C, Vouret-Craviari V, Wang B, et al.  2003.  EphrinA1 inactivates integrin-mediated vascular smooth muscle cell spreading via the Rac/PAK pathway.  J. Cell Sci.      116:1367-1376."
"7498","PC970253","Miao H, Wei BR, Peehl DM, Li Q, Alexandrou T, Schelling JR, Rhim JS, Sedor JR, Burnett E, Wang B (2001): Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol 3:527-30."
"7499","PC970253","·Miao H, Nickel CH, Cantley LG, et al.  2003.  EphA kinase activation regulates HGF-induced epithelial branching morphogenesis.  J. Cell Biol. 162:1281-1292.

"
"7500","PC970253","·Myshkin E and Wang B.  2003.  Chemometrical classification of ephrin ligands and Eph kinases using GRID/CPCA approach.     J. Chem. Inf. Comput. Sci. 43:1004-1010."
"7501","PC970253","Zantek ND, Walker-Daniels J, Stewart J, Hansen RK, Robinson D, Miao H, Wang B, Kung HJ, Bissell MJ, Kinch MS (2001): MCF-10A-NeoST: a new cell system for studying cell-ECM and cell-cell interactions in breast cancer. Clin Cancer Res 7:3640-8."
"7502","PC970254","Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, Ren C, Wang J, Tahir SA, Thompson TC (2001): Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Research 61. 61:4386-92-4386-92."
"7503","PC970254","Thompson TC, Timme TL, Yang G, et al. (1999): Caveolin-1: a complex and provocative therapeutic target in prostyate cancer and potentially other malignancies.  Emerging Therapeutic Targets 3:337-346."
"7504","PC970254","Thompson T, Timme T, Li L, et al. Caveolin-1: A complex and provocative therapeutic target in prostate cancer and potentially other malignancies. Emerging Therapeutic Targets 3:337-346."
"7505","PC970259","Chen H, Toyooka S, Gazdar AF, Hsieh JT Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines.  J. Biol. Chem. 278:3121-3130 278:3121-3130."
"7506","PC970259","Zhou J, Hsieh JT (2001): The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2. J Biol Chem 276:27793-8."
"7507","PC970259","Chen H, Pong RC, Hsieh JT, et al.  2002. Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization.  Genomics 79(4):573-81."
"7508","PC970259","Wang Z, Tseng CP, Hsieh JT, et al.  2002. The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem. 277(15):12622-31."
"7509","PC970259","Zhou J, Scholes J, Hsieh JT (2003): Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer.  J. Biol. Chem.  278:6936-6941."
"7510","PC970259","Hsieh JT, Earley K, Pong RC, Wang Y, Van NT, Lin SH (1999): Structural analysis of the C-CAM1 molecule for its tumor suppression function in human prostate cancer. Prostate 41:31-8."
"7511","PC970259","Zhou J, Scholes J, Hsieh JT (2001): Signal transduction targets in androgen-independent prostate cancer. Cancer Metastasis Rev 20:351-62."
"7512","PC970260","Shappell SB, Keeney DS, Zhang J, Page R, Olson SJ, Brash AR (2001): 15-Lipoxygenase-2 expression in benign and neoplastic sebaceous glands and other cutaneous adnexa. Journal of Investigative Dermatology 117. 117:36-43-36-43."
"7513","PC970260","Jack GS, Brash AR, Olson SJ, Manning S, Coffey CS, Smith JA Jr, Shappell SB (2000): Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia. Human Pathology 31. 31:1146-54-1146-54."
"7514","PC970260","Brash AR, Jisaka M, Boeglin WE, Chang MS, Keeney DS, Nanney LB, Kasper S, Matusik RJ, Olson SJ, Shappell SB (1999): Investigation of a second 15S-lipoxygenase in humans and its expression in epithelial tissues. Advances in Experimental Medicine and Biology 469. 469:83-9.:83-9."
"7515","PC970260","Shappell SB, Boeglin WE, Olson SJ, Kasper S, Brash AR (1999): 15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. American Journal Of Pathology 155:235-45."
"7516","PC970260","Shappell SB, Gupta RA, Manning S, et al.  2001.  15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 61(2):497-503."
"7517","PC970260","Shappell SB, Manning S, Boeglin WE, et al.  2001.  Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia 3(4):287-303."
"7518","PC970263","Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS (2002): Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 62:1370-6."
"7519","PC970263","Steiner MS, Raghow S, Neubauer BL (2001): Selective estrogen receptor modulators for the chemoprevention of prostate cancer. Urology 57:68-72."
"7520","PC970263","Raghow S, Shapiro E, Steiner MS (1999): Immunohistochemical localization of transforming growth factor-alpha and transforming growth factor-beta during early human fetal prostate development. Journal of Urology 162. 162:509-13-509-13."
"7521","PC970263","Raghow S, Kuliyev E, Steakley M, Greenberg N, Steiner MS (2000): Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model. Cancer Research 60. 60:4093-7-4093-7."
"7522","PC970272","Thompson CJ, Tam NN, Joyce JM, Leav I, Ho SM (2002): Gene expression profiling of testosterone and estradiol-17 beta-induced prostatic dysplasia in Noble rats and response to the antiestrogen ICI 182,780. Endocrinology 143:2093-105."
"7523","PC970272","Mobley JA, L'Esperance JO, Wu M, et al. 2004. The novel estrogen 17alpha-20Z-21-[(4-amino)phenyl]-19-norpregna-1,3,5(10),20-tetraene-3,17beta-diol induces apoptosis in prostate cancer cell lines at nanomolar concentrations in vitro. Mol Cancer Ther 3:587-595."
"7524","PC970272","Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, Singh H, Ho SM (2001): Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 159:79-92."
"7525","PC970272","Lau KM, LaSpina M, Long J, Ho SM (2000): Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res 60:3175-82."
"7526","PC970272","Zhu X, Leav I, Leung YK, et al. 2004. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol 164:2003-2012."
"7527","PC970272","·Pais V, Leav I, Lau K-M, et al.  2003.  Estrogen receptor-b expression in human testicular germ cell tumors.  Clin. Cancer Research 9:4475-82
"
"7528","PC970272","·Murphy LC, Leygue E, Niu Y, et al.  2002.  Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer.  Brit. J. Cancer, 87:1411-1416.
"
"7529","PC970273","Leav I, Merk FB, Lee KF, Loda M, Mandoki M, McNeal JE, Ho SM (1999): Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. Am J Pathol 154:863-70."
"7530","PC970273","DeSalle LM, Latres E, Lin D, Graner E, Montagnoli A, Baker RT, Pagano M, Loda M (2001): The de-ubiquitinating enzyme Unp interacts with the retinoblastoma protein. Oncogene 20:5538-42."
"7531","PC970273","Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE (2000): Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 19:1288-96."
"7532","PC970273","McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR (1999): Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59:4291-6."
"7533","PC970273","Waltregny D, Leav I, Signoretti S, Soung P, Lin D, Merk F, Adams JY, Bhattacharya N, Cirenei N, Loda M (2001): Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol Endocrinol 15:765-82."
"7534","PC970273","Reiter RE, Sato I, Thomas G, Qian J, Gu Z, Watabe T, Loda M, Jenkins RB (2000): Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer 27:95-103."
"7535","PC970273","Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M (2000): Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 92:1918-25."
"7536","PC970273","Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M (2000): p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157:1769-75."
"7537","PC970273","Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB, Loda M, Reiter RE (1998): Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 159:941-5."
"7538","PC970274","Lee S, Furuya T, Kiyota T, et al.  2001.  De novo-designed peptide transforms Golgi-specific lipids into Golgi-like nanotubules. J Biol Chem 276(44):41224-41228."
"7539","PC970274","del Rio G, Castro-Obregon S, Rao R, Ellerby HM, Bredesen DE (2001): APAP, a sequence-pattern recognition approach identifies substance P as a potential apoptotic peptide. FEBS Lett 494:213-9."
"7540","PC970274","Arap W, Haedicke W, Bernasconi M, Kain R, Rajotte D, Krajewski S, Ellerby HM, Bredesen DE, Pasqualini R, Ruoslahti E (2002): Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci U S A 99:1527-31."
"7541","PC970274","Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, Bredesen DE, Pasqualini R (1999): Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5:1032-8."
"7542","PC970276","Kibel AS, Schutte M, Kern SE, Isaacs WB, Bova GS (1998): Identification of 12p as a region of frequent deletion in advanced prostate cancer. Cancer Research 58:5652-5."
"7543","PC970276","Kibel AS, Freije D, Isaacs WB, Bova GS (1999): Deletion mapping at 12p12-13 in metastatic prostate cancer. Genes Chromosomes Cancer 25:270-6."
"7544","PC970276","Kibel AS, Faith DA, Bova GS, Isaacs WB (2000): Loss of heterozygosity at 12P12-13 in primary and metastatic prostate adenocarcinoma. Journal of Urology 164. 164:192-6-192-6."
"7545","PC970278","Steadman DJ, Giuffrida D, and Gelmann EP.  2000.  DNA-binding sequence of the human prostate-specific homeodomain protein NKX3.1.  Nucleic Acids Res. 28:2389-2395.
"
"7546","PC970278","
.Gelmann EP, Steadman DJ, Ma J, et al.  2002.  Occurrence of NKX3.1 C154T polymorphism in men with and without prostate cancer and studies of its effect on protein function.  Cancer Res. 62:2654-2659.
"
"7547","PC970278","Bowen C, Bubendorf L, Voeller HJ, et al.  2000.  Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression.  Cancer Res. 60:6111-6115.
"
"7548","PC970278","Gelmann EP, Bowen C, and Bubendorf L.  2003.  Expression of NKX3.1 in normal and malignant tissues.  Prostate 55:111-117.
"
"7549","PC970278","Gelmann EP.  2003.  Searching for the gatekeeper of prostate cancer.  Crit. Rev. Oncol. Hematol. 46 Suppl:S11-20.
"
"7550","PC970286","Hyytinen ER, Frierson HF Jr, Boyd JC, Chung LW, Dong JT (1999): Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer. Genes Chromosomes Cancer 25:108-14."
"7551","PC970286","Dong JT, Boyd JC, Frierson HF Jr (2001): Loss of heterozygosity at 13q14 and 13q21 in high grade, high stage prostate cancer. Prostate 49:166-71."
"7552","PC970286","Chen C, Brabham WW, Stultz BG, Frierson HF Jr, Barrett JC, Sawyers CL, Isaacs JT, Dong JT (2001): Defining a common region of deletion at 13q21 in human cancers. Genes Chromosomes Cancer 31:333-44."
"7553","PC970286","Hyytinen ER, Frierson HF Jr, Sipe TW, Li CL, Degeorges A, Sikes RA, Chung LW, Dong JT (1999): Loss of heterozygosity and lack of mutations of the XPG/ERCC5 DNA repair gene at 13q33 in prostate cancer. Prostate 41:190-5."
"7554","PC970286","Dong JT, Chen C, Stultz BG, Isaacs JT, Frierson HF Jr (2000): Deletion at 13q21 is associated with aggressive prostate cancers. Cancer Res 60:3880-3."
"7555","PC970286","Dong JT, Li CL, Sipe TW, Frierson HF Jr (2001): Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients. Clin Cancer Res 7:304-8."
"7556","PC970288","Counsell RE LMPAea (2001): Synthesis and Evaluation of a Radioiodinated Phospholipid Ether Analog (NM-404) for Diagnostic Imaging of Prostate Cancer. In: Isotope Production and Applications in the 21st Century. Stevenson NR, ed. World Scientific Pub Co, Singapore. 163-166pp. "
"7557","PC970288","Counsell RE, Longino MA Pinchuk AN et al. (2000):  Synthesis and evaluation of a radioiodinated phospholipid ether analog (NM-404) for diagnostic imaging of prostate cancer  Isotope Production and Applications in the 21st Century, Proceedings of the 3rd International Conference on IsotopesVancouver, Canada 6 - 10 September 1999."
"7558","PC970288","Zasadny KR, Longino MA, Fisher SJ, et al. Predicted dosimetry for I-131 NM-404, a phospholipid ether agent for tumor imaging and possible therapy. Journal Of Nuclear Medicine 40:39."
"7559","PC970296","Grouse LH, Munson PJ, Nelson PS (2001): Sequence databases and microarrays as tools for identifying prostate cancer biomarkers. Urology 57:154-9."
"7560","PC970296","Li PE, Nelson PS (2001): Prostate cancer genomics. Curr Urol Rep 2:70-8."
"7561","PC970296","Nelson PS, Han D, Rochon Y, Corthals GL, Lin B, Monson A, Nguyen V, Franza BR, Plymate SR, Aebersold R, Hood L (2000): Comprehensive analyses of prostate gene expression: convergence of expressed sequence tag databases, transcript profiling and proteomics. Electrophoresis 21. 21:1823-31-1823-31."
"7562","PC970296","Liu AY, Nelson PS, van den Engh G, Hood L (2002): Human prostate epithelial cell-type cDNA libraries and prostate expression patterns. Prostate 50:92-103."
"7563","PC970296","Clegg N, Eroglu B, Ferguson C, Arnold H, Moorman A, Nelson PS (2002): Digital expression profiles of the prostate androgen-response program. J Steroid Biochem Mol Biol 80:13-23."
"7564","PC970300","Xu J (2000): Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics. American Journal of Human Genetics 66:945-57."
"7565","PC970300","Zhang JS, Wang L, Huang H, Nelson M, Smith DI (2001): Keratin 23 (K23), a novel acidic keratin, is highly induced by histone deacetylase inhibitors during differentiation of pancreatic cancer cells. Genes Chromosomes Cancer 30. 30:123-35-123-35."
"7566","PC970300","Xu J, Zheng SL, Chang B, Smith JR, Carpten JD, Stine OC, Isaacs SD, Wiley KE, Henning L, Ewing C, Bujnovszky P, Bleeker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB (2001): Linkage of prostate cancer susceptibility loci to chromosome 1. Human Genetics 108. 108:335-45-335-45."
"7567","PC970300","Potter SR, Miller MC, Mangold LA, Jones KA, Epstein JI, Veltri RW, Partin AW (1999): Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. Urology 54. 54:791-5-791-5."
"7568","PC970300","Veltri RW, Miller MC, Mangold LA, et al.  2002. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge. J Urol 168(1):100-104."
"7569","PC970300","Kawakami M, Staub J, Cliby W, Hartmann L, Smith DI, Shridhar V (1999): Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer. International Journal of Oncology 15. 15:715-20-715-20."
"7570","PC970302","Xie Y, Meier KE (2002): Assays for phospholipase D reaction products. Methods Enzymol 345:294-305."
"7571","PC970308","Huston AL, Justus BL, Falkenstein PL, et al.  2002. Optically stimulated luminescent glass optical fibre dosemeter. Radiat Prot Dosimetry 101(1-4):23-26."
"7572","PC970321","Snitkovsky S, Niederman TM, Mulligan RC, Young JA (2001): Targeting avian leukosis virus subgroup A vectors by using a TVA-VEGF bridge protein. J Virol 75:1571-5."
"7573","PC970321","Snitkovsky S, Niederman TM, Carter BS, Mulligan RC, Young JA (2000): A TVA-single-chain antibody fusion protein mediates specific targeting of a subgroup A avian leukosis virus vector to cells expressing a tumor- specific form of epidermal growth factor receptor. J Virol 74:9540-5."
"7574","PC970321","Boerger AL, Snitkovsky S, Young JA (1999): Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types. Proc Natl Acad Sci U S A 96:9867-72."
"7575","PC970321","Young JAT.   (in press). (2002): Targeting retrovirus vectors using molecular bridges. In: Vector Targeting for Therapeutic Gene Delivery. Curiel D and Douglas JT, ed.  Wiley Press."
"7576","PC970326","Elliott K, Ge K, Du W, Prendergast GC (2000): The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program. Oncogene 19:4669-84."
"7577","PC970326","Routhier EL, Burn TC, Abbaszade I, Summers M, Albright CF, Prendergast GC (2001): Human BIN3 complements the F-actin localization defects caused by loss of Hob3p, the fission yeast homolog of Rvs161p. Journal of Biological Chemistry 276. 276:21670-7-21670-7."
"7578","PC970326","Mao NC, Steingrimsson E, DuHadaway J, Wasserman W, Ruiz JC, Copeland NG, Jenkins NA, Prendergast GC (1999): The murine Bin1 gene functions early in myogenesis and defines a new region of synteny between mouse chromosome 18 and human chromosome 2. Genomics 56:51-8."
"7579","PC970326","Ge K, Minhas F, Duhadaway J, Mao NC, Wilson D, Buccafusca R, Sakamuro D, Nelson P, Malkowicz SB, Tomaszewski J, Prendergast GC (2000): Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma. International Journal Of Cancer 86:155-61."
"7580","PC970326","Ge K, Prendergast GC (2000): Bin2, a functionally nonredundant member of the BAR adaptor gene family. Genomics 67. 67:210-20-210-20."
"7581","PC970332","Smith DS, Krygiel J, Nease RF Jr, Sumner W 2nd, Catalona WJ (2002): Patient preferences for outcomes associated with surgical management of prostate cancer. J Urol 167:2117-22."
"7582","PC970333","Gala JL, Loric S, Guiot Y, Denmeade SR, Gady A, Brasseur F, Heusterspreute M, Eschwege P, De Nayer P, Van Cangh P, Tombal B (2000): Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value? Clinical Cancer Research 6. 6:4049-54-4049-54."
"7583","PC970333","Lapidus RG, Tiffany CW, Isaacs JT, Slusher BS (2000): Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate 45. 45:350-4-350-4."
"7584","PC970333","Tombal B, Weeraratna AT, Denmeade SR, Isaacs JT (2000): Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells. Prostate 43. 43:303-17-303-17."
"7585","PC970335","Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E, Bujnovszky P, Bova GS, Walsh P, Isaacs W, Schleutker J, Matikainen M, Tammela T, Visakorpi T, Kallioniemi OP, Berry R, Schaid D, French A, McDonnell S, Schroeder J, Blute M, Thibodeau S, Trent J, et al (1998): Evidence for a prostate cancer susceptibility locus on the X chromosome. Nature Genetics 20. 20:175-9-175-9."
"7586","PC970335","Xu J, Zheng SL, Isaacs WB, et al. 2002. Associations between hOGG1 sequence variants and prostate cancer susceptibility. Cancer Res 62:2253-2257."
"7587","PC970335","Xu J, Zheng SL, Isaacs WB, et al. 2002. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk.  Nat Genet 32:1-5."
"7588","PC970335","Xu J, Zheng SL, Isaacs WB, et al.  2003. Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Am. J. Hum.Genet. 72:208-212."
"7589","PC970335","Hawkins GA, Mychaleckyj JC, Isaacs WB,  et al. 2002. Germline sequence variants of the LZTS1 gene are associated with prostate cancer risk. Cancer Genet Cytogenet 137:1-7."
"7590","PC970335","Xu J, Zheng SL, Isaacs WB, et al. 2001. Linkage of prostate cancer susceptibility loci to chromosome 1. Hum Genet 108:335-345."
"7591","PC970335","Chang BL, Zheng SL, Isaacs WB, et al. 2002. Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. Cancer Res 62: 1784-1789."
"7592","PC970335","Chang B, Zheng SL, Isaacs WB, et al.2001. Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer. Int. J. Cancer 95:354-9."
"7593","PC970335","Zheng SL, Mychaleckyj JC, Isaacs WB, et al.  2003.  
Evaluation of DLC1 as a prostate cancer susceptibility gene: mutation screen and association study.  Mutat Res. 528(1-2):45-53. 

"
"7594","PC970335","Chang BL, Zheng SL, Isaacs WB, et al. 2002. Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk. Hum Genet. 110:122-129."
"7595","PC970335","Zheng SL Mychaleckyj JC Hawkins GA Isaacs SD Wiley KE Turner A Chang BL von Kap-Herr C Carpten JD Pettenati M Bleecker ER Walsh PC Trent JM Meyers DA Isaacs WB Xu J (2003): Evaluation of DLC1 as a prostate cancer susceptibility gene: mutation screen and association study. Mutat Res.  528:45-53."
"7596","PC970335","Xu J Zheng SL Komiya A Mychaleckyj JC Isaacs SD Hu JJ Sterling D Lange EM Hawkins GA Turner A Ewing CM Faith DA Johnson JR Suzuki H Bujnovszky P Wiley KE DeMarzo AM Bova GS Chang B Hall MC McCullough DL Partin AW Kassabian VS Carpten JD Bailey-Wilson JE Trent JM Ohar J Bleecker ER Walsh PC Isaacs WB Meyers DA (2002): Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk.   Nature Genet.  32:321-325."
"7597","PC970335","Ho GY Knapp M Freije D Nelson WG Smith JR Carpten JD Bailey-Wilson JE Beaty TH Petersen G Xu J Kamensky V Walsh PC Isaacs WB (2002): Transmission/disequilibrium tests of androgen receptor and glutathione S-transferase pi variants in prostate cancer families. Int. J. Cancer  98:938-942."
"7598","PC970335","Xu J, Zheng SL, Isaacs WB, et al. 2001. Linkage and association studies of prostate cancer susceptibiity: evidence for linkage at 8p22-23. Am. J. Hum. Genet. 69:341-350."
"7599","PC970344","Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL (2000): Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate"
"7600","PC970344","DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M, Hamper U, DeJong R, Detorie N, Rodriguez R, Haulk T, DeMarzo AM, Piantadosi S, Yu DC, Chen Y, Henderson DR, Carducci MA, Nelson WG, Simons JW (2001): A phase I trial of CV706, a replication-co"
"7601","PC970344","Chen Y, DeWeese T, Dilley J, Zhang Y, Li Y, Ramesh N, Lee J, Pennathur-Das R, Radzyminski J, Wypych J, Brignetti D, Scott S, Stephens J, Karpf DB, Henderson DR, Yu DC (2001): CV706, a prostate cancer-specific adenovirus variant, in combination with radiot"
"7602","PC970344","Zhong H, Agani F, Baccala AA, Laughner E, Rioseco-Camacho N, Isaacs WB, Simons JW, Semenza GL (1998): Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Res 58:5280-4."
"7603","PC970344","Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW (1999): Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59:5830-5."
"7604","PC970344","·Collis SJ, Swartz MJ, Nelson WG, et al.  2003.  Enhanced radiation and chemotherapy mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors.  Cancer Research 63:1550-1554."
"7605","PC970344","Collis SJ, Ketner GW, Hicks JL, Nelson WG, Demarzo AM, Deweese TL (2003): Expression of the DNA-PK binding protein E4-34K fails to confer radiation sensitivity to mammalian cells. Int J Radiat Biol 79:53-60."
"7606","PC970344","Zhong H, Hanrahan C, van der Poel H, Simons JW (2001): Hypoxia-inducible factor 1alpha and 1beta proteins share common signaling pathways in human prostate cancer cells. Biochem Biophys Res Commun 284:352-6."
"7607","PC970353","Rondinelli RH, Tricoli JV (1999): CLAR1, a novel gene that exhibits enhanced expression in advanced human prostate cancer. Clinical Cancer Research 5:1595-602."
"7608","PC970360","Gagliardi AR, Bittencourt MC Munn RK et al. (1998): Inhibition of renal carcinoma cell growth by diphenylureas, a unique group of antiangiogenic compounds 17th UICC International Cancer Congress."
"7609","PC970360","Gagliardi ART, Nickel P and Collins DC. (1998): Inhibition of prostate cancer cell growth by diphenylureas, a unique group of antiangiogenic compounds 17th UICC International Cancer Congress."
"7610","PC970360","Gagliardi AR, Collins DC and Nickel P. (1998): Diphenylureas are potent inhibitors of angiogenesis 17th UICC International Cancer Congress."
"7611","PC970360","Gagliardi AR, Kassack M, Kreimeyer A, Muller G, Nickel P, Collins DC (1998): Antiangiogenic and antiproliferative activity of suramin analogues. Cancer Chemother Pharmacol 41:117-24."
"7612","PC970366","Kochevar, J.G. Brody, J.R, Kadkol, S.S., Murphy, K.M., and Pasternack, G.R. Identification of a functional mutation in pp32r1(ANP32C). 2004. Human Mutation. 23(6):546-51."
"7613","PC970366","Brody, J.R., Kadkol, S.S., Hauer, M.C., Rajaii, F., Lee, J., and Pasternack, G.R.  2004.  pp32 reduction induces differentiation of TSU-Pr1 cells. Am J Pathol. 164:273-283."
"7614","PC970371","Langevin HM, Churchill DL, Fox JR, Badger GJ, Garra BS, Krag MH (2001): Biomechanical response to acupuncture needling in humans. J Appl Physiol 91:2471-8."
"7615","PC970371","Langevin HM, Churchill DL, Wu J, Badger GJ, Yandow JA, Fox JR, Krag MH (2002): Evidence of connective tissue involvement in acupuncture. FASEB J 16:872-4."
"7616","PC970372","Colorado PC, Torre A, Kamphaus G, Maeshima Y, Hopfer H, Takahashi K, Volk R, Zamborsky ED, Herman S, Sarkar PK, Ericksen MB, Dhanabal M, Simons M, Post M, Kufe DW, Weichselbaum RR, Sukhatme VP, Kalluri R (2000): Anti-angiogenic cues from vascular basement membrane collagen. Cancer Research 60:2520-6."
"7617","PC970372","Seetharam S, Staba MJ, Schumm LP, Schreiber K, Schreiber H, Kufe DW, Weichselbaum RR (1999): Enhanced eradication of local and distant tumors by genetically produced interleukin-12 and radiation. International Journal of Oncology 15:769-73."
"7618","PC970372","Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, Weichselbaum RR (1999): Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Research 59:3374-8."
"7619","PC970372","Gorski DH, Mauceri HJ, Salloum RM, Gately S, Hellman S, Beckett MA, Sukhatme VP, Soff GA, Kufe DW, Weichselbaum RR (1998): Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Research 58:5686-9."
"7620","PC970372","Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR (1998): Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394:287-91."
"7621","PC970372","Hari D, Beckett MA, Sukhatme VP, Dhanabal M, Nodzenski E, Lu H, Mauceri HJ, Kufe DW, Weichselbaum RR (2000): Angiostatin induces mitotic cell death of proliferating endothelial cells. Molecular Cell Biology Research Communications : MCBRC. 3:277-82."
"7622","PC970372","Hanna NN, Seetharam S, Mauceri HJ, Beckett MA, Jaskowiak NT, Salloum RM, Hari D, Dhanabal M, Ramchandran R, Kalluri R, Sukhatme VP, Kufe DW, Weichselbaum RR (2000): Antitumor interaction of short-course endostatin and ionizing radiation. Cancer Journal 6:287-93."
"7623","PC970380","Xue WM, Coetzee GA, Ross RK, Irvine R, Kolonel L, Henderson BE, Ingles SA (2001): Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort. Cancer Epidemiology, Biomarkers and Prevention 10. 10:575-9-575-9."
"7624","PC970386","Berlyn KA, Schultes B, Leveugle B, Noujaim AA, Alexander RB, Mann DL (2001): Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. Clin Immunol 101:276-83."
"7625","PC970386","Ponniah S, Arah I, Alexander RB (2000): PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate 44:49-54."
"7626","PC970395","Huang H, et al. (1998): Colocalization of the common fragile site, FRA7G, and the common region of deletion in prostate, breast and ovarian cancer. American Journal of Human Genetics 63:A395."
"7627","PC970395","Wang L, Darling J, Zhang JS, Huang H, Liu W, Smith DI (1999): Allele-specific late replication and fragility of the most active common fragile site, FRA3B. Human Molecular Genetics 8:431-7."
"7628","PC970395","Gemmill RM, West JD, Boldog F, Tanaka N, Robinson LJ, Smith DI, Li F, Drabkin HA (1998): The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8. Proceedings of the National Academy of Sciences of the United States of America 95:9572-7."
"7629","PC970395","Huang H, Qian J, Proffit J, Wilber K, Jenkins R, Smith DI (1998): FRA7G extends over a broad region: coincidence of human endogenous retroviral sequences (HERV-H) and small polydispersed circular DNAs (spcDNA) and fragile sites. Oncogene 16:2311-9."
"7630","PC970395","Jenkins RB, Qian J, Lee HK, Huang H, Hirasawa K, Bostwick DG, Proffitt J, Wilber K, Lieber MM, Liu W, Smith DI (1998): A molecular cytogenetic analysis of 7q31 in prostate cancer. Cancer Research 58:759-66."
"7631","PC970395","Krummel KA, Roberts LR, Kawakami M, Glover TW, Smith DI (2000): The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations. Genomics 69. 69:37-46-37-46."
"7632","PC970395","Huang H, Qian C, Jenkins RB, Smith DI (1998): Fish mapping of YAC clones at human chromosomal band 7q31.2: identification of YACS spanning FRA7G within the common region of LOH in breast and prostate cancer. Genes Chromosomes Cancer 21:152-9."
"7633","PC970395","Kawakami M, et al. (1998): Allele loss on 16q in high-grade invasive epithelial ovarian cancer. American Journal of Human Genetics 63:A400."
"7634","PC970395","Wang L, Darling J, Zhang JS, Liu W, Qian J, Bostwick D, Hartmann L, Jenkins R, Bardenhauer W, Schutte J, Opalka B, Smith DI (2000): Loss of expression of the DRR 1 gene at chromosomal segment 3p21.1 in renal cell carcinoma. Genes Chromosomes Cancer 27:1-10."
"7635","PC970395","Huang H, Reed CP, Zhang JS, Shridhar V, Wang L, Smith DI (1999): Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells. Cancer Research 59:2981-8."
"7636","PC970395","Smith DI, Huang H, Wang L (1998): Common fragile sites and cancer (Review). International Journal of Oncology 12:187-96."
"7637","PC970408","Foster KW, Frost AR, McKie-Bell P, Lin CY, Engler JA, Grizzle WE, Ruppert JM (2000): Increase of GKLF messenger RNA and protein expression during progression of breast cancer. Cancer Research 60. 60:6488-95-6488-95."
"7638","PC970408","Foster KW, Frost AR, McKie-Bell P, Lin CY, Engler JA, Grizzle WE, Ruppert JM (2000): Increase of GKLF messenger RNA and protein expression during progression of breast cancer. Cancer Res 60:6488-95."
"7639","PC970408","Foster KW, Ren S, Louro ID, Lobo-Ruppert SM, McKie-Bell P, Grizzle W, Hayes MR, Broker TR, Chow LT, Ruppert JM (1999): Oncogene expression cloning by retroviral transduction of adenovirus E1A-immortalized rat kidney RK3E cells: transformation of a host with epithelial features by c-MYC and the zinc finger protein GKLF. Cell Growth and Differentiation 10. 10:423-34-423-34."
"7640","PC970410","Huang X and C Lee (2003):  From TGF-b to cancer therapy. Current Drug Targets 4:243-250."
"7641","PC970410","Shah AH, Tabayoyong WB, Kundu SD, Kim SJ, Van Parijs L, Liu VC, Kwon E, Greenberg NM, Lee C. (2002): Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice. Cancer Research 62:7135-7138."
"7642","PC970410","Shah AH, Lee C (2000): TGF-beta-based immunotherapy for cancer: breaching the tumor firewall. Prostate 45:167-72."
"7643","PC970410","Matthews E, Yang T, Janulis L, Goodwin S, Kundu SD, Karpus WJ, Lee C (2000): Down-regulation of TGF-beta1 production restores immunogenicity in prostate cancer cells. Br J Cancer 83:519-25."
"7644","PC970410","Zhang Q1, Yang XJ, Kundu SD, et al.  2006.  Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle.  Mol Cancer Ther 5(7):1733-1743."
"7645","PC970410","Shah AH, Tabayoyong WB, Kimm SY, Kim SJ, Van Parijs L, Lee C (2002): Reconstitution of lethally irradiated adult mice with dominant negative TGF-beta type II receptor-transduced bone marrow leads to myeloid expansion and inflammatory disease. J Immunol 169:3485-91."
"7646","PC970412","Bruchovsky N, Klotz LH, Sadar M, Crook JM, Hoffart D, Godwin L, Warkentin M, Gleave ME, Goldenberg SL (2000): Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Mol Urol 4:191-9;discussion 201."
"7647","PC970412","Bruchovsky N GSMNaSM (2001): Evolving aspects of intermittent androgen blockage for prostate cancer:  Diagnosis and treatment of early tumor progression and maintenance of remission. In: Andrology in the 21st Century, Proceedings of the VIIth International Congress of Andrology. CHaMC Robaire B, ed. Medimond, Inc."
"7648","PC970412","Ueda T, Bruchovsky N, Sadar MD (2002): Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 277:7076-85."
"7649","PC970412","Sadar MD, Hussain M, Bruchovsky N (1999): Prostate cancer: molecular biology of early progression to androgen independence. Endocr Relat Cancer 6:487-502."
"7650","PC970412","Ueda T, Mawji NR, Bruchovsky N, Sadar MD (2002): Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 277:38087-94."
"7651","PC970414","Tamura K, Southwick EC, Kerns J, Rosi K, Carr BI, Wilcox C, Lazo JS (2000): Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue. Cancer Research 60:1317-25."
"7652","PC970414","Ducruet AP, Rice RL, Tamura K, Yokokawa F, Yokokawa S, Wipf P, Lazo JS (2000): Identification of new Cdc25 dual specificity phosphatase inhibitors in a targeted small molecule array. Bioorganic & Medicinal Chemistry 8:1451-66."
"7653","PC970414","Lazo JS, Wipf P (2000): Combinatorial chemistry and contemporary pharmacology. Journal Of  Pharmacology And Experimental Therapeutics 293:705-9."
"7654","PC970425","·Doxsey SJ.  2001.  Centrosomes as command centers for cellular control.  Nat. Cell Biol. 3:E105-8"
"7655","PC970425","Purohit A, Tynan SH, Vallee R, Doxsey SJ (1999): Direct interaction of pericentrin with cytoplasmic dynein light intermediate chain contributes to mitotic spindle organization. Journal of Cell Biology 147:481-92."
"7656","PC970425","·Doxsey SJ.  2001.  Re-evaluating centrosome function.  Nature Reviews in Molecular Biology 2:688-699."
"7657","PC970425","·Doxsey S.  2002.  Duplicating dangerously:  Linking centrosome duplication and aneuploidy.  Molecular Cell 10:1-2."
"7658","PC970425","·Pihan G, Zhou Y, Wallace J, et al.  2003.  Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas.  Cancer Research 63:1398-1404."
"7659","PC970425","·Doxsey SJ, et al.  2003.  A novel human protein of the maternal centriole is required for the final stages of cytokinesis and entry into S-phase.  Journal Cell Biology 161:535-545."
"7660","PC970425","·Doxsey SJ, et al.  2003.  Centrosome anchoring of PKC betaII controls microtubule organization, spindle function and cytokinesis.  Journal of Biochemistry 279:4829-39."
"7661","PC970425","·Pihan G, and Doxsey SJ.  2003.  Mutations an aneuploidy: Co-conspirators in cancer.  Cancer Cell 4:89-94."
"7662","PC970425","Pihan GA, Wallace J, Zhou Y, Doxsey SJ (2003): Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res 63:1398-404."
"7663","PC970425","Doxsey S (2002): Duplicating dangerously: linking centrosome duplication and aneuploidy. Mol Cell 10:439-40."
"7664","PC970425","Doxsey S (2001): Re-evaluating centrosome function. Nat Rev Mol Cell Biol 2:688-98."
"7665","PC970425","Doxsey SJ (2001): Centrosomes as command centres for cellular control. Nat Cell Biol 3:E105-8."
"7666","PC970425","Diviani D, Langeberg LK, Doxsey SJ, Scott JD (2000): Pericentrin anchors protein kinase A at the centrosome through a newly identified RII-binding domain. Current Biology 10. 10:417-20-417-20."
"7667","PC970425","Pihan GA, Purohit A, Wallace J, Knecht H, Woda B, Quesenberry P, Doxsey SJ (1998): Centrosome defects and genetic instability in malignant tumors. Cancer Research 58:3974-85."
"7668","PC970425","Doxsey S (1998): The centrosome--a tiny organelle with big potential [news; comment]. Nature Genetics 20:104-6."
"7669","PC970425","9:289-302."
"7670","PC970425","·Doxsey SJ, et al.  2001.  Centrosome defects can account for the cellular and genetic changes that accompany prostate cancer progression.  Cancer Research 61:2212-2219."
"7671","PC970430","Brooks JD, Goldberg MF, Nelson LA, Wu D, Nelson WG (2002): Identification of potential prostate cancer preventive agents through induction of quinone reductase in vitro. Cancer Epidemiol Biomarkers Prev 11:868-75."
"7672","PC970430","Higgins JP, Montgomery K, Wang L, Domanay E, Warnke RA, Brooks JD, van de Rijn M (2003): Expression of FKBP12 in benign and malignant vascular endothelium: an immunohistochemical study on conventional sections and tissue microarrays. Am J Surg Pathol 27:5"
"7673","PC970430","Shinghal R, Yemoto C, McNeal JE, Brooks JD (2003): Biochemical recurrence without PSA progression characterizes a subset of patients after radical prostatectomy. Prostate-specific antigen. Urology 61:380-5."
"7674","PC970430","Brooks JD, Paton VG, Vidanes G (2001): Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. Cancer Epidemiol Biomarkers Prev 10:949-54."
"7675","PC970430","Holterhus PM, Hiort O, Demeter J, Brown PO, Brooks JD (2003): Differential gene-expression patterns in genital fibroblasts of normal males and 46,XY females with androgen insensitivity syndrome: evidence for early programming involving the androgen recept"
"7676","PC970430","Lin X, Tascilar M, Lee WH, Vles WJ, Lee BH, Veeraswamy R, Asgari K, Freije D, van Rees B, Gage WR, Bova GS, Isaacs WB, Brooks JD, DeWeese TL, De Marzo AM, Nelson WG (2001): GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expressi"
"7677","PC970430","Brooks JD, Eggener SE, Chao WM (2002): Anatomy of the rectourethralis muscle. Eur Urol 41:94-100."
"7678","PC970430","Higgins JP, Shinghal R, Gill H, Reese JH, Terris M, Cohen RJ, Fero M, Pollack JR, van de Rijn M, Brooks JD (2003): Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol 162:925-32."
"7679","PC970430","DePrimo SE, Shinghal R, Vidanes G, Brooks JD (2001): Prevention of prostate cancer. Hematol Oncol Clin North Am 15:445-57."
"7680","PC970430","McNeal JE, Cohen RJ, Brooks JD (2001): Role of cytologic criteria in the histologic diagnosis of Gleason grade 1 prostatic adenocarcinoma. Hum Pathol 32:441-6."
"7681","PC970430","Williams ED, Brooks JD (2001): New molecular approaches for identifying novel targets, mechanisms, and biomarkers for prostate cancer chemopreventive agents. Urology 57:100-2."
"7682","PC970430","Brooks JD and Nelson WG   (2000): Chemoprevention of prostate cancer. In: Prostate Cancer: biology, genetics, and the new therapeutics. IWaSJ Chung L, ed. Humana Press Inc., Totowa, NJ, pp. 365-375."
"7683","PC970430","Brooks JD, Metter EJ, Chan DW, Sokoll LJ, Landis P, Nelson WG, Muller D, Andres R, Carter HB (2001): Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 166:2034-8."
"7684","PC970430","Tchou JC, Lin X, Freije D, Isaacs WB, Brooks JD, Rashid A, De Marzo AM, Kanai Y, Hirohashi S, Nelson WG (2000): GSTP1 CpG island DNA hypermethylation in hepatocellular carcinomas. Int J Oncol 16:663-76."
"7685","PC970430","Brooks JD, Marshall FF, Isaacs WB, Johns DR (1999): Absence of HinfI Restriction Abnormalities in Renal Oncocytoma Mitochondrial DNA. Mol Urol 3:1-3."
"7686","PC970430","Schwarze SR, DePrimo SE, Grabert LM, Fu VX, Brooks JD, Jarrard DF (2002): Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. J Biol Chem 277:14877-83."
"7687","PC970430","Vidanes GM, Paton V, Wallen E, Peehl DM, Navone N, Brooks JD (2002): Silencing of pi-class glutathione S-transferase in MDA PCa 2a and MDA PCa 2b cells. Prostate 51:225-30."
"7688","PC970430","DePrimo SE, Diehn M, Nelson JB, Reiter RE, Matese J, Fero M, Tibshirani R, Brown PO, Brooks JD (2002): Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol 3:RESEARCH0032."
"7689","PC970430","Brooks JD (2002): Microarray analysis in prostate cancer research. Curr Opin Urol 12:395-9."
"7690","PC970430","Shibata A, Garcia MI, Cheng I, Stamey TA, McNeal JE, Brooks JD, Henderson S, Yemoto CE, Peehl DM (2002): Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis. Prostate 52:269-78."
"7691","PC970430","Nelson WG, De Marzo AM, Deweese TL, Lin X, Brooks JD, Putzi MJ, Nelson CP, Groopman JD, Kensler TW (2001): Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann N Y Acad Sci 952:135-44."
"7692","PC970430","Nelson WG, De Marzo AM, DeWeese TL, and et al. (2001): Prostate Cancer: Principles and Practice."
"7693","PC970430","Brooks JD.  (2002): Campbell¿s Urology, 8th Edition."
"7694","PC970432","Li SL, Liang SJ, Guo N, Wu AM, Fujita-Yamaguchi Y (2000): Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth. Cancer Immunology, Immunotherapy 49. 49:243-52-243-52."
"7695","PC970432","Mineo R, Fichera E, Liang SJ, Fujita-Yamaguchi Y (2000): Promoter usage for insulin-like growth factor-II in cancerous and benign human breast, prostate, and bladder tissues, and confirmation of a 10th exon. Biochemical and Biophysical Research Communications 268. 268:886-92-886-92."
"7696","PC970432","Xu ZD, Oey L, Mohan S, Kawachi MH, Lee NS, Rossi JJ, Fujita-Yamaguchi Y (1999): Hammerhead ribozyme-mediated cleavage of the human insulin-like growth factor-II ribonucleic acid in vitro and in prostate cancer cells. Endocrinology 140:2134-44."
"7697","PC970432","Fichera E, Liang S, Xu Z, Guo N, Mineo R, Fujita-Yamaguchi Y (2000): A quantitative reverse transcription and polymerase chain reaction assay for human IGF-II allows direct comparison of IGF-II mRNA levels in cancerous breast, bladder, and prostate tissues. Growth Hormone & IGF Research 10. 10:61-70-61-70."
"7698","PC970433","Strom SS, Spitz MR, Yamamura Y, Babaian RJ, Scardino PT, Wei Q (2001): Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study. Prostate 47:269-75."
"7699","PC970437","Perambakam S, Xue BH, Sosman JA, Peace DJ (2002): Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer. Cancer Immunol Immunother 51:263-70."
"7700","PC970437","Medin JA, Liang S-B, Hou JW-S, et al.  2004.  Efficient transfer of PSA and PSAM cDNAs into DC generates antibody and T cell anti-tumor responses in vivo.  Cancer Gene Ther."
"7701","PC970437","Perambakam S, Xie H, Edassery S, et al. 2010.  Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue (PSA146-154).  Clin Dev Immunol 473453."
"7702","PC970452","McDonald AC, Jenkins FJ, Bunker CH, et al. 2011.  A case-cohort study of human herpesvirus 8 seropositivity and incident prostate cancer in Tobago.
Infect Agent Cancer 6:25."
"7703","PC970452","Shea PR, Ishwad CS, Bunker CH, et al.  2008.  
RNASEL and RNASEL-inhibitor variation and prostate cancer risk in Afro-Caribbeans.  Prostate 68(4):354-9"
"7704","PC970452","Bunker CH, Patrick AL, Miljkovic-Gacic I, et al.  2004. Prostate cancer screening parameters in a high-risk African-Caribbean population. Urology. 63(4):737-41.
"
"7705","PC970452","Hoffman LJ, Bunker CH, Pellett PE,, et al. 2004.  Elevated seroprevalence of human herpesvirus 8 among men with prostate cancer. J Infect Dis 189(1):15-20."
"7706","PC970452","Okobia MN, Zmuda JM, Ferrell RE, et al.  2011. Chromosome 8q24 variants are associated with prostate cancer risk in a high risk population of African ancestry. Prostate 71(10):1054 - 1063."
"7707","PC970452","Bunker CH, Zmuda JM, Patrick AL,et al.  2006. High bone density is associated with prostate cancer in older Afro-Caribbean men: Tobago prostate survey.
Cancer Causes Control.17(8):1083-9.
"
"7708","PC970452","Shea PR, Ferrell RE, Patrick AL, et al.  2002. ELAC2 and prostate cancer risk in Afro-Caribbeans of Tobago. Hum Genet 111(4-5):398-400."
"7709","PC970452","Bunker CH, McDonald AC, Evans RW,et al.  2007. A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk. Nutr Cancer.57(2):130-7.
"
"7710","PC970452","Miljkovic-Gacic I, Ferrell RE, Patrick AL, et al.  2005. 
Estimates of African, European and Native American ancestry in Afro-Caribbean men on the island of Tobago.
Hum Hered. 60(3):129-33."
"7711","PC970452","Bunker CH, Patrick AL, Konety BR, et al.  2002. High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. Cancer Epidemiol Biomarkers Prev.11(8):726-9.
"
"7712","PC970458","Guzey M, Takayama S, Reed JC. (2000): BAG-1L enhances trans-activation function of the vitamin D receptor. J. Biol. Chem.  275:40749-40756."
"7713","PC970458","Froesch BA, Takayama S, Reed JC. (1998): BAG-1L protein enhances androgen receptor function.  J. Biol. Chem.  1273:11660-11666."
"7714","PC970458","Briknarova K, Takayama S, Brive L, Havert ML, Knee DA, Velasco J, Homma S, Cabezas E, Stuart J, Hoyt DW, Satterthwait AC, Llinas M, Reed JC, Ely KR (2001): Structural analysis of BAG1 cochaperone and its interactions with Hsc70 heat shock protein. Nature Struct. Biol.  8:349-352."
"7715","PC970458","Knee DA, Froesch BA, Nuber U, Takayama S, Reed JC Structure-function analysis of Bag1 proteins. Effects on androgen receptor transcriptional activity. J. Biol. Chem. 276:12718-12724."
"7716","PC970458","Guzey M, Kitada S, Reed JC (2002): Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer. Mol. Cell Therap. 1:667-677."
"7717","PC970468","Chung BH, Mitchell SH, Zhang JS, Young CY (2001): Effects of docosahexaenoic acid and eicosapentaenoic acid on androgen- mediated cell growth and gene expression in LNCaP prostate cancer cells. Carcinogenesis 22:1201-6."
"7718","PC970468","Butler R, Mitchell SH, Tindall DJ, Young CY (2000): Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2. Cell Growth and Differentiation 11. 11:49-61-49-61."
"7719","PC970468","·Wang MH, Grossmann ME, and Young CYF.  2004.  Forced expression of heat-shock protein 70 increases the secretion of Hsp70 and provides protection against tumour growth.  British J Cancer Res 90:926-931."
"7720","PC970468","Donkena KV, Grossman ME, Celis E, Young CYF (2000): Tumor prevention and anti-tumor immunity with heat shock 70 induced by 15-deoxy?12,14-prostaglandin J2 in transgenic adenocarcinoma of the mouse prostate cancer cells. Cancer Research 60:4714-4718."
"7721","PC970468","Vanaja DK, Grossmann ME, Celis E, Young CY (2000): Tumor prevention and antitumor immunity with heat shock protein 70 induced by 15-deoxy-delta12,14-prostaglandin J2 in transgenic adenocarcinoma of mouse prostate cells. Cancer Res 60:4714-8."
"7722","PC970470","·Lara PN Jr, Kung H-J, Gumerlock PH, et al.  1999.  Molecular biology of prostate carcinogenesis.  Critical Reviews in Oncology/Hematology 32:197-208."
"7723","PC970479","Hong YK, Kim DH, Beletskii A, Lee C, Memili E, Strauss WM (2001): Development of two bacterial artificial chromosome shuttle vectors for a recombination-based cloning and regulated expression of large genes in mammalian cells. Anal Biochem 291:142-8."
"7724","PC970479","Memili E, Hong YK, Kim DH, Ontiveros SD, Strauss WM (2001): Murine Xist RNA isoforms are different at their 3' ends: a role for differential polyadenylation. Gene 266:131-7."
"7725","PC970479","Beletskii A, Hong YK, Pehrson J, Egholm M, Strauss WM (2001): PNA interference mapping demonstrates functional domains in the noncoding RNA Xist. Proc Natl Acad Sci U S A 98:9215-20."
"7726","PC970479","Kim DH, Hong YK, Egholm M, Strauss WM (2001): Non-disruptive PNA-FISH protocol for formalin-fixed and paraffin- embedded tissue sections. Biotechniques 31:472, 475-6."
"7727","PC970489","Gregory CW, Kim D, Ye P, D'Ercole AJ, Pretlow TG, Mohler JL, French FS (1999): Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft. Endocrinology 140. 140:2372-81-2372-81."
"7728","PC970489","Kim D, Gregory CW, Smith GJ, Mohler JL (1999): Immunohistochemical quantitation of androgen receptor expression using color video image analysis. Cytometry 35:2-10."
"7729","PC970489","Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL, French FS (1998): Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Research 58:5718-24."
"7730","PC970492","Waters DJ, Shen S, Cooley DM, Bostwick DG, Qian J, Combs GF Jr, Glickman LT, Oteham C, Schlittler D, Morris JS (2003): Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. J Natl Cancer Inst 95:237-41."
"7731","PC970492","Shen S, Cooley DM, Glickman LT, Glickman N, Waters DJ (2001): Reduction in DNA damage in brain and peripheral blood lymphocytes of elderly dogs after treatment with dehydroepiandrosterone (DHEA). Mutat Res 480-481:153-62."
"7732","PC970492","Bostwick DG, HB Burke, D Djakiew, et al., 2004.  Human prostate cancer risk factors.  Cancer 2004 101(10):2371-2490."
"7733","PC970492","Waters DJ, S Shen, LT Glickman, et al., 2005.  Prostate cancer risk and DNA damage:  Translational significance of selenium supplementation in a canine model.  Carcinogenesis 26(7):1256-1262."
"7734","PC970492","Bostwick DG, J Adolfsson, HB Burke, et al., 2005.  Report of the committee on epidemiology and statistical methods:  World Health Organization¿s 2004 International Consultation on Prostate Cancer.  Epidemiology and statistical methods in prediction of patient outcome.  Scand. J. Urol. Nephrol. 216:94-110."
"7735","PC970492","Waters DJ, EC Chiang, DM Cooley, et al., 2004.  Making sense of sex and supplements:  Differences in the anticarcinogenic effects of selenium in men and women.  Mutat. Res., 551(1-2):91-107."
"7736","PC970492","Waters DJ, Shen S, Glickman LT (2000): Life expectancy, antagonistic pleiotropy, and the testis of dogs and men. Prostate 43:272-7."
"7737","PC970493","Cohen-Jonathan E, Evans SM, Koch CJ, Muschel RJ, McKenna WG, Wu J, Bernhard EJ (2001): The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res 61:2289-93."
"7738","PC970499","Koeneman KS, Kao C, Ko SC, Yang L, Wada Y, Kallmes DF, Gillenwater JY, Zhau HE, Chung LW, Gardner TA (2000): Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J Urol 18:102-10."
"7739","PC970499","Jung C, Ou YC, Yeung F, Frierson HF Jr, Kao C (2001): Osteocalcin is incompletely spliced in non-osseous tissues. Gene 271:143-50."
"7740","PC970499","Lee SJ, Kim HS, Yu R, Lee K, Gardner TA, Jung C, Jeng MH, Yeung F, Cheng L, Kao C (2002): Novel prostate-specific promoter derived from PSA and PSMA enhancers. Mol Ther 6:415-21."
"7741","PC970501","Yu C, Liu B, Hu L (2000): A Simple One-Pot Procedure for the Direct Conversion of Alcohols to Azides via Phosphate Activation. Org Lett 2:1959-1961."
"7742","PC970501","Hu L, Liu B, Hacking DR (2000): 5'-[2-(2-Nitrophenyl)-2-methylpropionyl]-2'-deoxy-5-fluorouridine as a potential bioreductively activated prodrug of FUDR: synthesis, stability and reductive activation. Bioorg Med Chem Lett 10:797-800."
"7743","PC970502","Liu N, Gao F, Han Z, Xu X, Underhill CB, Zhang L (2001): Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells. Cancer Res 61:5207-14."
"7744","PC970506","Ashok BT, Kim E, Mittelman A, Tiwari RK (2001): Proteasome inhibitors differentially affect heat shock protein response in cancer cells. Int J Mol Med 8:385-90."
"7745","PC970506","Tiwari RK, Geliebter J, Garikapaty VP, Yedavelli SP, Chen S, Mittelman A (1999): Anti-tumor effects of PC-SPES, an herbal formulation in prostate cancer. Int J Oncol 14:713-9."
"7746","PC970506","Yedavelli SPK, Badithe A, Mittelman A, Tiwari RK (1999): Heat shock protein gp96: A novel tumor derived preventive and therapeutic agent. Journal of Immunotherapy 22:469."
"7747","PC970506","Yedavelli SP, Guo L, Daou ME, Srivastava PK, Mittelman A, Tiwari RK (1999): Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model. International Journal Of Molecular Medicine 4:243-8."
"7748","PC970506","Ashok BT, Chen Y Mittelman A et al. (2002): Single chain antibodies (scFv) isolated from phage display library as a tool to identify unique gp96 associated peptide antigens Proc. Amer. Assoc. Cancer Res."
"7749","PC970512","Wilbur DS, Hamlin DK Pathare PM et al. ( 2000 ): Evaluation of succinylated streptavidin as the radionuclide carrier in antibody pretargeting of prostate cancer. Isotope Production and Applications in the 21st Century, NR Stevenson, Editor. Proceedings of the Third International Conference on Isotopes, Vancouver, B.C., September 6-10, 1999, pp 167-169, World Scientific Publishing Co., River Edge, NJ."
"7750","PC970512","Wilbur, D. S., Hamlin, D. K., Pathare, P. M., and Buhler, K. R. Vessella R. L. (2000): Isotope Production and Applications in the 21st Century."
"7751","PC970512","Wilbur DS, Pathare PM, Hamlin DK, Stayton PS, To R, Klumb LA, Buhler KR, Vessella RL (1999): Development of new biotin/streptavidin reagents for pretargeting. Biomol Eng 16:113-8."
"7752","PC970515","Adams JY, Johnson M, Sato M, Berger F, Gambhir SS, Carey M, Iruela-Arispe ML, Wu L (2002): Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat Med 8:891-7."
"7753","PC970515","Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, Belldegrun A (2000): Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer Journal 6. 6:220-33-220-33."
"7754","PC970515","Zisman A, Ng CP, Pantuck AJ, Bonavida B, Belldegrun AS (2001): Actinomycin D and gemcitabine synergistically sensitize androgen- independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis. J Immunother 24:459-71."
"7755","PC970515","Patel BJ, Pantuck AJ, Zisman A, Tsui KH, Paik SH, Caliliw R, Sheriff S, Wu L, deKernion JB, Tso CL, Belldegrun AS (2000): CL1-GFP: an androgen independent metastatic tumor model for prostate cancer. Journal of Urology 164. 164:1420-5-1420-5."
"7756","PC970515","Ophoven, et al. (1999): Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) for treatment of prostate cancer:  first results and review of the literature. Prostate Cancer & Prostate Disease 2:227-233."
"7757","PC970515","Zhang L, Adams JY, Billick E, Ilagan R, Iyer M, Le K, Smallwood A, Gambhir SS, Carey M, Wu L (2002): Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer. Mol Ther 5:223-32."
"7758","PC970515","Pantuck AJ, Matherly J, Zisman A, Nguyen D, Berger F, Gambhir SS, Black ME, Belldegrun A, Wu L (2002): Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants. Hum Gene Ther 13:777-89."
"7759","PC970515","Wu L, Matherly J, Smallwood A, Adams JY, Billick E, Belldegrun A, Carey M (2001): Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Ther 8:1416-26."
"7760","PC970519","Simpson MA, Reiland J, Burger SR, Furcht LT, Spicer AP, Oegema TR Jr, McCarthy JB (2001): Hyaluronan synthase elevation in metastatic prostate carcinoma cells correlates with hyaluronan surface retention, a prerequisite for rapid adhesion to bone marrow endothelial cells. J Biol Chem 276:17949-57."
"7761","PC970519","Simpson MA, Wilson CM, Furcht LT, Spicer AP, Oegema TR Jr, McCarthy JB (2002): Manipulation of hyaluronan synthase expression in prostate adenocarcinoma cells alters pericellular matrix retention and adhesion to bone marrow endothelial cells. J Biol Chem 277:10050-7."
"7762","PC970519","Simpson MA, Wilson CM, McCarthy JB (2002): Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am J Pathol 161:849-57."
"7763","PC970522","Mellinghoff IK, Tran C, Sawyers CL (2002): Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res 62:5254-9."
"7764","PC970522","Chen CD, Sawyers CL (2002): NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 22:2862-70."
"7765","PC970522","Huang W, Shostak Y, Tarr P, Sawyers C, Carey M (1999): Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. Journal of Biological Chemistry 274. 274:25756-68-25756-68."
"7766","PC970522","Abreu-Martin MT, Chari A, Palladino AA, Craft NA, Sawyers CL (1999): Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Molecular and Cellular Biology 19:5143-54."
"7767","PC970522","Craft N, Shostak Y, Carey M, Sawyers CL (1999): A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Medicine 5:280-5."
"7768","PC970525","Ripple MO, et al. (1999): Androgen-induced oxidative stress in human LNCaP prostate cancer cells is associated with multiple mitochondrial modifications. Antioxidants and Redox Signaling 1:71-81."
"7769","PC970525","Ripple MO, Henry WF, Schwarze SR, Wilding G, Weindruch R (1999): Effect of antioxidants on androgen-induced AP-1 and NF-kappaB DNA-binding activity in prostate carcinoma cells. Journal of the National Cancer Institute 91:1227-32."
"7770","PC970526","Ahmed MM, Chendil D, Lele S, Venkatasubbarao K, Dey S, Ritter M, Rowland RG, Mohiuddin M (2001): Early growth response-1 gene: potential radiation response gene marker in prostate cancer. Am J Clin Oncol 24:500-5."
"7771","PC970528","Carlisle AJ, Prabhu VV, Elkahloun A, Hudson J, Trent JM, Linehan WM, Williams ED, Emmert-Buck MR, Liotta LA, Munson PJ, Krizman DB (2000): Development of a prostate cDNA microarray and statistical gene expression analysis package. Molecular Carcinogenesis 28. 28:12-22-12-22."
"7772","PC970530","Matthews, J. W., Harms, W. B., Bosch, W. R., and Purdy, J. A. (2000): Digital data exchange for multi-institutional clinical trials in 3D conformal radiotherapy and prostate brachytherapy. Proceedings of the XIIIth International Conference on the Use of Computers in Radiation Therapy."
"7773","PC970530","Bosch, W. R., Harms, W. B., Matthews, J. W., and Purdy, J. A. (2000): Database infrastructure for multi-institutional clinical trials in 3D conformal radiotherapy and prostate brachytherapy. Proceedings of the XIIIth International Conference on the Use of Computers in Radiation Therapy."
"7774","PC970533","Doukas DJ, Fetters MD, Coyne JC, McCullough LB (2000): How men view genetic testing for prostate cancer risk: findings from focus groups. Clinical Genetics 58. 58:169-76-169-76."
"7775","PC970533","Doukas DJ and Li Y.  2004.  Men's values-based factors on prostate cancer risk genetic testing: A telephone survey.  BMC Medical genetics.
"
"7776","PC970536","Sobrin L, Liu Z, Monroy DC, Solomon A, Selzer MG, Lokeshwar BL, Pflugfelder SC (2000): Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant. Invest Ophthalmol Vis Sci 41:1703-9."
"7777","PC970536","Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L (1999): Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23- dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev 8:241-8."
"7778","PC970536","Krishan A, Oppenheimer A, You W, Dubbin R, Sharma D, Lokeshwar BL (2000): Flow cytometric analysis of androgen receptor expression in human prostate tumors and benign tissues. Clin Cancer Res 6:1922-30."
"7779","PC970536","Lokeshwar BL (1999): MMP inhibition in prostate cancer. Ann N Y Acad Sci 878:271-89."
"7780","PC970536","Lokeshwar BL, Escatel E, Zhu B (2001): Cytotoxic activity and inhibition of tumor cell invasion by derivatives of a chemically modified tetracycline CMT-3 (COL-3). Curr Med Chem 8:271-9."
"7781","PC970536","Lokeshwar BL, Houston-Clark HL, Selzer MG, Block NL, Golub LM (1998): Potential application of a chemically modified non-antimicrobial tetracycline (CMT-3) against metastatic prostate cancer. Adv Dent Res 12:97-102."
"7782","PC970536","Lokeshwar VB, Rubinowicz D, Schroeder GL, Forgacs E, Minna JD, Block NL, Nadji M, Lokeshwar BL (2001): Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem 276:11922-32."
"7783","PC970536","Zhu B, Block NL, Lokeshwar BL (1999): Interaction between stromal cells and tumor cells induces chemoresistance and matrix metalloproteinase secretion. Ann N Y Acad Sci 878:642-6."
"7784","PC970536","Dandekar DS, VB Lokeshwar, E Cevallos-Arellano, et al., 2003. An orally active Amazonian plant extract (BIRM) inhibits prostate cancer growth and metastasis.  Cancer Chemother. Pharmacol. 52:59-66."
"7785","PC970536","Li DQ, TY Shang, HS Kim, et al., 2003.  Regulated expression of collagenases MMP-1, -8, and -13 and stromelysins MMP-3, -10, and -11 by human corneal epithelial cells.  Invest. Ophthalmol. Vis. Sci. 44:2928-2936."
"7786","PC970536","Solomon A, Rosenblatt M, Li DQ, Liu Z, Monroy D, Ji Z, Lokeshwar BL, Pflugfelder SC (2000): Doxycycline inhibition of interleukin-1 in the corneal epithelium. Invest Ophthalmol Vis Sci 41:2544-57."
"7787","PC970536","Zhu B, Block NL, Lokeshwar BL (1999): Interaction between stromal cells and tumor cells induces chemoresistance and matrix metalloproteinase secretion. Annals Of The New York Academy Of Sciences 878:642-6."
"7788","PC970536","Selzer MG, Zhu B, Block NL, Lokeshwar BL (1999): CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paraplegia in a rat model of prostate cancer. Annals Of The New York Academy Of Sciences 878:678-82."
"7789","PC970536","Lokeshwar BL (1999): MMP inhibition in prostate cancer. Annals Of The New York Academy Of Sciences 878:271-89."
"7790","PC970536","Lokeshwar BL, Selzer MG, Zhu BQ, Block NL, Golub LM (2002): Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int J Cancer 98:297-309."
"7791","PC970536","Selzer MG, Zhu B, Block NL, Lokeshwar BL (1999): CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paraplegia in a rat model of prostate cancer. Ann N Y Acad Sci 878:678-82."
"7792","PC970536","Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF (1998): Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25- hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 7:391-5."
"7793","PC970536","Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF (2000): The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25- dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clin Cancer Res 6:901-8."
"7794","PC970536","Afonso AA, Sobrin L, Monroy DC, Selzer M, Lokeshwar B, Pflugfelder SC (1999): Tear fluid gelatinase B activity correlates with IL-1alpha concentration and fluorescein clearance in ocular rosacea. Invest Ophthalmol Vis Sci 40:2506-12."
"7795","PC970537","Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N, Young P, Norton CR, Gridley T, Cardiff RD, Cunha GR, Abate-Shen C, Shen MM (1999): Roles for Nkx3.1 in prostate development and cancer. Genes and Development 13:966-77."
"7796","PC970537","Abate-Shen C, Shen MM (2000): Molecular genetics of prostate cancer. Genes and Development 14. 14:2410-34-2410-34."
"7797","PC970542","Giri D, Ittmann M (1999): Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Human Pathology 30. 30:419-24-419-24."
"7798","PC970542","Kwabi-Addo B, Thompson TC, Ittmann M (2000): Absence of PTEN/MMAC1 pseudogene in mice. DNA Cell Biol 19. 19:301-5-301-5."
"7799","PC970544","Meltzer D, Egleston B, Abdalla I (2001): Patterns of prostate cancer treatment by clinical stage and age. Am J Public Health 91:126-8."
"7800","PC970544","Meltzer D, Polonsky T (1998): Do Quality-Adjusted Life Years Reflect Patient Preferences?  Validation Using Revealed Preference for Intensive Treatment of Insulin-Dependent Diabetes Mellitus. Medical Decision Making 18:459."
"7801","PC970544","Meltzer D (2001): Addressing uncertainty in medical cost-effectiveness analysis implications of expected utility maximization for methods to perform sensitivity analysis and the use of cost-effectiveness analysis to set priorities for medical research. J Health Econ 20:109-29."
"7802","PC970544","Meltzer D (2001): Addressing uncertainty in medical cost-effectiveness analysis implications of expected utility maximization for methods to perform sensitivity analysis and the use of cost-effectiveness analysis to set priorities for medical research. Journal of Health Economics 20. 20:109-29-109-29."
"7803","PC970544","Meltzer D, Egleston B, Abdalla I (2001): Patterns of prostate cancer treatment by clinical stage and age. American Journal of Public Health 91. 91:126-8-126-8."
"7804","PC970544","Meltzer D, et al. (1998): Effect of Future Costs on the Cost-Effectiveness of Life Extension and Quality of Life Improvement Among the Elderly. Medical Decision Making 18:475."
"7805","PC970544","Meltzer D, Johannesson M On the role of theory in cost-effectiveness analysis:  A response to Garber, Russell and Weinstein. Medical Decision Making 19:383-384."
"7806","PC970544","Meltzer D and Johannesson M (1999): On the role of theory in cost-effectiveness analysis:  A response to Garber, Russell, and Weinstein. Medical Decision Making 19:383-384."
"7807","PC970544","Meltzer D, Johannesson M (1999): Inconsistencies in the 'societal perspective' on costs of the Panel on Cost-Effectiveness in Health and Medicine. Med Decis Making 19:371-7."
"7808","PC970551","Ruan W, Powell-Braxton L, Kopchick JJ, Kleinberg DL (1999): Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. Endocrinology 140:1984-9."
"7809","PC970559","Pidgeon GP, Tang K, Cai YL, Piasentin E, Honn KV (2003): Overexpression of platelet type 12-lipoxygenase promotes tumor cell survival by enhancing a Vbeta3 and Vbeta5 integrin expression.  Cancer Res.  63:4258-4267."
"7810","PC970559","Pidgeon GP, Tang K, Rice RL, Zacharek A, Li L, Taylor JD, Honn KV. (2003):  Overexpression of leukocyte type12-lipoxygenase promotes W256 tumor cell survival by enhancing aVbeta5 expression.  Intl. J. Cancer  105:459-471."
"7811","PC970559","Nie D, Tang K, Szekeres K, Li L, Honn KV (2000): Eicosanoid regulation of angiogenesis in human prostate carcinoma and its therapeutic implications. Annals of the New York Academy of Sciences 905:165-76."
"7812","PC970559","Nie D, Honn KV. (2002): Cyclooxygenase, lipoxygenase, and tumor angiogenesis. Cell Mol. Life Sci.  59:799-807.   "
"7813","PC970559","Szekeres CK, Trikha M, Nie D, Honn KV (2000): Eicosanoid 12(S)-HETE activates phosphatidylinositol 3-kinase. Biochem Biophys Res Commun 275:690-5."
"7814","PC970559","Nie D, Tang K, Diglio C, Honn KV (2000): Eicosanoid regulation of angiogenesis: role of endothelial arachidonate 12-lipoxygenase. Blood 95:2304-11."
"7815","PC970559","Tang K, Finley RL Jr, Nie D, Honn KV (2000): Identification of 12-lipoxygenase interaction with cellular proteins by yeast two-hybrid screening. Biochemistry 39:3185-91."
"7816","PC970559","Timar J, Raso E, Dome B, Li L, Grignon D, Nie D, Honn KV, Hagmann W (2000): Expression, subcellular localization and putative function of platelet- type 12-lipoxygenase in human prostate cancer cell lines of different metastatic potential. Int J Cancer 87:37-43."
"7817","PC970559","Nie D, Che M, Grignon D, Tang K, Honn KV (2001): Role of eicosanoids in prostate cancer progression. Cancer and Metastasis Review 20:195-206."
"7818","PC970562","Paris PL, Witte JS, Kupelian PA, Levin H, Klein EA, Catalona WJ, Casey G (2000): Identification and fine mapping of a region showing a high frequency of allelic imbalance on chromosome 16q23.2 that corresponds to a prostate cancer susceptibility locus. Cancer Research 60. 60:3645-9-3645-9."
"7819","PC970562","Loukola A, Chadha M, Penn SG, et al.  2004. Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2.  Eur J Hum Genet. 12(4):321-32.
"
"7820","PC970562","Cicek MS, Conti DV, Curran A, et al.  2004. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate 59(1):69-76.
"
"7821","PC970562","Plummer SJ, Conti DV, Paris PL, et al.  2003. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer.
Cancer Epidemiol Biomarkers Prev 12:(9):928-32.
"
"7822","PC970562","Neville PJ, Conti DV, Krumroy LM, Catalona WJ, Suarez BK, Witte JS, Casey G (2003): Prostate cancer aggressiveness locus on chromosome segment 19q12-q13.1 identified by linkage and allelic imbalance studies. Genes Chromosomes Cancer 36:332-9."
"7823","PC970562","Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, Klein EA, Catalona WJ, Nupponen N, Carpten JD, Trent JM, Silverman RH, Witte JS (2002): RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 32:581-3."
"7824","PC970562","Goddard KA, Witte JS, Suarez BK, Catalona WJ, Olson JM (2001): Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4. Am J Hum Genet 68:1197-206."
"7825","PC970562","Nelson KA, Witte JS (2002): Androgen receptor CAG repeats and prostate cancer. Am J Epidemiol 155:883-90."
"7826","PC970562","Klein EA, Kupelian PA, Witte JS (1998): Does a family history of prostate cancer result in more aggressive disease? Prostate Cancer Prostatic Dis 1:297-300."
"7827","PC970562","Kupelian PA, Klein EA, Witte JS (1999): Re: Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy. J Urol 161:1585-6."
"7828","PC970562","Suarez BK, Lin J, Witte JS, Conti DV, Resnick MI, Klein EA, Burmester JK, Vaske DA, Banerjee TK, Catalona WJ (2000): Replication linkage study for prostate cancer susceptibility genes. Prostate 45:106-14."
"7829","PC970562","Neville PJ, Conti DV, Paris PL, Levin H, Catalona WJ, Suarez BK, Witte JS, Casey G (2002): Prostate cancer aggressiveness locus on chromosome 7q32-q33 identified by linkage and allelic imbalance studies. Neoplasia 4:424-31."
"7830","PC970562","Kupelian PA, Klein EA, Witte JS, Kupelian VA, Suh JH (1997): Familial prostate cancer: a different disease? J Urol 158:2197-201."
"7831","PC970562","Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA, Casey G, Witte JS (1999): Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiology, Biomarkers and Prevention 8:901-5."
"7832","PC970562","Witte JS, Goddard KA, Conti DV, Elston RC, Lin J, Suarez BK, Broman KW, Burmester JK, Weber JL, Catalona WJ (2000): Genomewide scan for prostate cancer-aggressiveness loci. American Journal of Human Genetics 67. 67:92-9-92-9."
"7833","PC970562","Suarez BK, Lin J, Burmester JK, Broman KW, Weber JL, Banerjee TK, Goddard KA, Witte JS, Elston RC, Catalona WJ (2000): A genome screen of multiplex sibships with prostate cancer. American Journal of Human Genetics 66. 66:933-44-933-44."
"7834","PC970565","Qadan LR, Perez-Stable CM, Anderson C, D'Ippolito G, Herron A, Howard GA, Roos BA (2001): 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer. Biochem Biophys Res Commun 285:1259-66."
"7835","PC970565","Yang ES, Maiorino CA, Roos BA, Knight SR, Burnstein KL (2002): Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer. Mol Cell Endocrinol 186:69-79."
"7836","PC970565","Qadan LR, Perez-Stable CM, Schwall RH, Burnstein KL, Ostenson RC, Howard GA, Roos BA (2000): Hepatocyte growth factor and vitamin D cooperatively inhibit androgen- unresponsive prostate cancer cell lines. Endocrinology 141:2567-73."
"7837","PC970568","Borrelli MJ, Schoenherr DM, Wong A, Bernock LJ, Corry PM (2001): Heat-activated transgene expression from adenovirus vectors infected into human prostate cancer cells. Cancer Res 61:1113-21."
"7838","PC970570","Wiest J, Clark AM, Dai W (2001): Intron/exon organization and polymorphisms of the PLK3/PRK gene in human lung carcinoma cell lines. Genes Chromosomes Cancer 32:384-9."
"7839","PC970570","Xie SQ, Wu HY, Wang W, Kunick J, Thomas RO, Hollinigsworth RE, Cogswell J, Dai W.   2002.  Genotoxic stress-induced activiation of Plk3 is partly mediated by Chk2.  Cell Cycle , 1:424-429.
"
"7840","PC970570","Dai W, Liu T, Wang Q, Rao CV, Reddy BS (2002): Down-regulation of PLK3 gene expression by types and amount of dietary fat in rat colon tumors. Int J Oncol 20:121-6."
"7841","PC970570","Wang Q, Xie S, Chen J, Fukasawa K, Naik U, Traganos F, Darzynkiewicz Z, Jhanwar-Uniyal M, Dai W (2002): Cell cycle arrest and apoptosis induced by human Polo-like kinase 3 is mediated through perturbation of microtubule integrity. Mol Cell Biol 22:3450-9."
"7842","PC970570","Xie S, Wang Q, Wu H, Cogswell J, Lu L, Jhanwar-Uniyal M, Dai W (2001): Reactive oxygen species-induced phosphorylation of p53 on serine 20 is mediated in part by polo-like kinase-3. J Biol Chem 276:36194-9."
"7843","PC970570","Xie S, Wu H, Wang Q, Cogswell JP, Husain I, Conn C, Stambrook P, Jhanwar-Uniyal M, Dai W (2001): Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway. J Biol Chem 276:43305-12."
"7844","PC970575","Banyard J, Zetter BR (1998-1999): The role of cell motility in prostate cancer. Cancer Metastasis Rev 17:449-58."
"7845","PC970577","Elstner E, Campbell MJ, Munker R, Shintaku P, Binderup L, Heber D, Said J, Koeffler HP (1999): Novel 20-epi-vitamin D3 analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells. Prostate 40:141-9."
"7846","PC970578","McGuire TF, Trump DL, Johnson CS (2001): Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem 276:26365-73."
"7847","PC970578","Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS (1999): 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res 59:2644-9."
"7848","PC970579","Swanson C, Ross J, Jackson PK (2000): Nuclear accumulation of cyclin E/Cdk2 triggers a concentration-dependent switch for the destruction of p27Xic1. Proceedings of the National Academy of Sciences of the United States of America 97:7796-801."
"7849","PC970579","Regan-Reimann JD, Duong QV, Jackson PK (1999): Identification of novel F-box proteins in Xenopus laevis. Current Biology 9. 9:R762-3-R762-3."
"7850","PC970582","Sharma P, Schreiber-Agus N (1999): Mouse models of prostate cancer. Oncogene 18:5349-55."
"7851","PC970584","Deksukhum C, Ware JL, Ferreria-Gonzalez A, et al.  (2000): Detection of a novel truncated WT1 transcript in human neoplasia. Mol. Diagnosis 5:117-128."
"7852","PC970584","Ware JL (1998-1999): Growth factor network disruption in prostate cancer progression. Cancer and Metastasis Reviews 17. 17:443-7-443-7."
"7853","PC970584","Damon SE, Plymate SR, Carroll JM, Sprenger CC, Dechsukhum C, Ware JL, Roberts CT Jr (2001): Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. Endocrinology 142. 142:21-7-21-7."
"7854","PC970588","Gu Y, Lee HM, Roemer EJ, Musacchia L, Golub LM, Simon SR (2001): Inhibition of tumor cell invasiveness by chemically modified tetracyclines. Curr Med Chem 8:261-70."
"7855","PC970588","Zerler B RERHea (2000): Evaluation of the phototoxic potential of chemically modified tetracyclines with the 3T3 neutral red uptake phototoxicity test. In: Progress in the Reduction, Refinement and Replacement of Animal Experimentation. vZA-MHM Balls M, ed. Elsevier Science. 545-554pp."
"7856","PC970593","Donaldson L, Fordyce C, Gilliland F, Smith A, Feddersen R, Joste N, Moyzis R, Griffith J (1999): Association between outcome and telomere DNA content in prostate cancer. Journal of Urology 162:1788-92."
"7857","PC970595","Kunkel EJ, Bakker JR, Myers RE, Oyesanmi O, Gomella LG (2000): Biopsychosocial aspects of prostate cancer. Psychosomatics 41:85-94."
"7858","PC970595","Kunkel EJ, Myers RE, Lartey PL, Oyesanmi O (2000): Communicating effectively with the patient and family about treatment options for prostate cancer. Semin Urol Oncol 18:233-40."
"7859","PC970595","·Kunkel EJS, Meyer B, Daskalakis C, et al.  Behaviors used by men to protect themselves against prostate cancer.  Cancer Epidemiology Biomarkers and Prevention 13;78-86."
"7860","PC970595","Myers RE, Kunkel EJ (2000): Preparatory education for informed decision-making in prostate cancer early detection and treatment. Semin Urol Oncol 18:172-7."
"7861","PC970595","Myers RE (1999): African American men, prostate cancer early detection examination use, and informed decision-making. Semin Oncol 26:375-81."
"7862","PC970595","Liberatore MJ MRNRea (2003): Decision counseling for men considering prostate cancer screening. Computers & Operations Research 30:1421-1434."
"7863","PC970597","Cohen MB, Padarathsingh M, Hendrix MJ (2000): Experimental models of prostate cancer research. Am J Pathol 156:355-8."
"7864","PC970597","Languino LR aRW2 (2001): Integrins. In: The Liver: Biology and Pathobiology, 4/e . FBCaS Arias, ed. Lippincott Williams & Wilkins, 33:475-482."
"7865","PC970597","Fornaro M, Manes T, Languino LR (2001): Integrins and prostate cancer metastases. Cancer Metastasis Rev 20:321-31."
"7866","PC970597","Morales-Ruiz M, Fulton D, Sowa G, Languino LR, Fujio Y, Walsh K, Sessa WC (2000): Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt. Circ Res 86:892-6."
"7867","PC970597","Zheng DQ, Woodard AS, Tallini G, Languino LR (2000): Substrate specificity of alpha(v)beta(3) integrin-mediated cell migration and phosphatidylinositol 3-kinase/AKT pathway activation. J Biol Chem 275:24565-74."
"7868","PC970597","Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR (1999): Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 59:1655-64."
"7869","PC970597","Moro L, Fornaro M, Steger CA, Languino LR (2001): Regulation of MCP-3 and BRCA2 mRNA expression levels by beta(1) integrins. Exp Mol Pathol 70:239-47."
"7870","PC970597","Perlino E, Lovecchio M, Vacca RA, Fornaro M, Moro L, Ditonno P, Battaglia M, Selvaggi FP, Mastropasqua MG, Bufo P, Languino LR (2000): Regulation of mRNA and protein levels of beta1 integrin variants in human prostate carcinoma. Am J Pathol 157:1727-34."
"7871","PC970597","Fornaro M, Tallini G, Zheng DQ, Flanagan WM, Manzotti M, Languino LR (1999): p27(kip1) acts as a downstream effector of and is coexpressed with the beta1C integrin in prostatic adenocarcinoma. J Clin Invest 103:321-9."
"7872","PC970597","Fornaro M, Lovecchio M, Jose P, Zheng DQ, Moro L, Languino LR (2001): Epitope-specific antibodies to the beta(1C) integrin cytoplasmic domain variant. Exp Mol Pathol 70:275-80."
"7873","PC970597","Languino LR (2002): Cell adhesion:  The outside and inside story. Trends Cell Biol 12:539."
"7874","PC970597","Manzotti M, Dell'Orto P, Maisonneuve P, Fornaro M, Languino LR, Viale G (2000): Down-regulation of beta(1C) integrin in breast carcinomas correlates with high proliferative fraction, high histological grade, and larger size. Am J Pathol 156:169-74."
"7875","PC970601","Beheshti B, Park PC, Sweet JM, Trachtenberg J, Jewett MA, Squire JA (2001): Evidence of chromosomal instability in prostate cancer determined by spectral karyotyping (SKY) and interphase fish analysis. Neoplasia 3:62-9."
"7876","PC970601","Beheshti B, Karaskova J, Park PC, Squire JA, Beatty BG (2000): Identification of a high frequency of chromosomal rearrangements in the centromeric regions of prostate cancer cell lines by sequential giemsa banding and spectral karyotyping. Mol Diagn 5:23-32."
"7877","PC970601","Macoska JA, Beheshti B, Rhim JS, Hukku B, Lehr J, Pienta KJ, Squire JA (2000): Genetic characterization of immortalized human prostate epithelial cell cultures. Evidence for structural rearrangements of chromosome 8 and i(8q) chromosome formation in primary tumor-derived cells. Cancer Genet Cytogenet 120:50-7."
"7878","PC970601","Al-Maghrabi J, Vorobyova L, Toi A, Chapman W, Zielenska M, Squire JA (2002): Identification of numerical chromosomal changes detected by interphase fluorescence in situ hybridization in high-grade prostate intraepithelial neoplasia as a predictor of carcinoma. Arch Pathol Lab Med 126:165-9."
"7879","PC990004","McNeel DG, Nguyen LD and Disis ML. (2000):  Identification of potential CD4+ T helper epitopes derived from the protein sequence of prostatic acid phosphatase (PAP) Proc Amer Assn Cancer Res. 41:699."
"7880","PC990004","McNeel DG, Nguyen LD and Disis ML. (2000): T cells derived from patients with prostate cancer secrete IFN in response to stimulation with prostate cancer antigens Proc Amer Assn Cancer Res. 41:880."
"7881","PC990004","McNeel DG, Nguyen LD, Disis ML (2001): Identification of T helper epitopes from prostatic acid phosphatase. Cancer Res 61:5161-7."
"7882","PC990004","McNeel DG, Knutson KL and Disis ML. (2001):  Identification of PAP-specific MHC class I peptide epitopes by screening patients with prostate cancer by IFN ELISPOT Proc Amer Assn Cancer Res. 42:277."
"7883","PC990004","McNeel DG, Vessella R Lange PH et al. (1999): Antibody immunity to prostate cancer antigens can be detected in patients with prostate cancer Proc Amer Assn Cancer Res. 40:353."
"7884","PC990004","McNeel DG, Nguyen LD, Storer BE, Vessella R, Lange PH, Disis ML (2000): Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. J Urol 164:1825-9."
"7885","PC990004","McNeel DG, Disis ML (2000): Tumor vaccines for the management of prostate cancer. Arch Immunol Ther Exp (Warsz) 48:85-93."
"7886","PC990012","Ke N, Godzik A, Reed JC (2001): Bcl-B, a novel Bcl-2 family member that differentially binds and regulates Bax and Bak. J Biol Chem 276:12481-4."
"7887","PC990014","Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS (2001): Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 276:10767-74."
"7888","PC990016","Vazquez F, Ramaswamy S, Nakamura N, Sellers WR (2000): Phosphorylation of the PTEN tail regulates protein stability and function. Molecular And Cellular Biology 20:5010-8."
"7889","PC990016","Vazquez F, Sellers WR (2000): The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3- kinase signaling. Biochim Biophys Acta 1470:M21-35."
"7890","PC990016","Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR (2000): Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 20:8969-82."
"7891","PC990017","Bacich DJ, Ramadan E, O'Keefe DS, Bukhari N, Wegorzewska I, Ojeifo O, Olszewski R, Wrenn CC, Bzdega T, Wroblewska B, Heston WD, Neale JH (2002): Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate. J Neurochem 83:20-9."
"7892","PC990017","O¿Keefe DS BDaHW (2001): Prostate specific membrane antigen. In: Prostate Cancer: Biology, Genetics, and New Therapeutics. IWaSJ Chung LWK, ed. Humana Press Inc., Totowa, New Jersey. pp. 307-326pp."
"7893","PC990017","Uchida A, O'Keefe DS, Bacich DJ, Molloy PL, Heston WD (2001): In vivo suicide gene therapy model using a newly discovered prostate- specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy. Urology 58:132-9."
"7894","PC990017","Watt F, Martorana A, Brookes DE, Ho T, Kingsley E, O'Keefe DS, Russell PJ, Heston WD, Molloy PL (2001): A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. Genomics 73:243-54."
"7895","PC990017","Gong MC, Chang SS, Watt F, O'Keefe DS, Bacich DJ, Uchida A, Bander NH, Reuter VE, Gaudin PB, Molloy PL, Sadelian M, Heston WD (2000): Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy. Molecular Urology 4:217-22."
"7896","PC990017","O'Keefe DS, Bacich DJ, Heston WD. 2004.  Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene.  Prostate 58(2): 200-210."
"7897","PC990019","Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP (2001): Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 49:293-305."
"7898","PC990022","Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS (2000): Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 275:26333-42."
"7899","PC990022","Selvarajan S, Lund LR, Takeuchi T, Craik CS, Werb Z (2001): A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation. Nat Cell Biol 3:267-75."
"7900","PC990029","Pandori MW, Sano T (2000): Photoactivatable retroviral vectors: a strategy for targeted gene delivery. Gene Ther 7:1999-2006."
"7901","PC990029","Pandori MW, Hobson DA, Olejnik J, Krzymanska-Olejnik E, Rothschild KJ, Palmer AA, Phillips TJ, Sano T (2002): Photochemical control of the infectivity of adenoviral vectors using a novel photocleavable biotinylation reagent. Chem Biol 9:567-73."
"7902","PC990029","Pandori M, Hobson D, Sano T (2002): Adenovirus-microbead conjugates possess enhanced infectivity: a new strategy for localized gene delivery. Virology 299:204-12."
"7903","PC990031","Chen YR, Tan TH (2000): The c-Jun N-terminal kinase pathway and apoptotic signaling (review). International Journal of Oncology 16:651-62."
"7904","PC990031","Chen YR, Zhou G, Tan TH (1999): c-Jun N-terminal kinase mediates apoptotic signaling induced by N-(4-hydroxyphenyl)retinamide. Molecular Pharmacology 56:1271-9."
"7905","PC990031","Chen YR, Meyer CF, Ahmed B, Yao Z, Tan TH (1999): Caspase-mediated cleavage and functional changes of hematopoietic progenitor kinase 1 (HPK1). Oncogene 18:7370-7."
"7906","PC990031","Chen YR, Shrivastava A, Tan TH (2001): Down-regulation of the c-Jun N-terminal kinase (JNK) phosphatase M3/6 and activation of JNK by hydrogen peroxide and pyrrolidine dithiocarbamate. Oncogene 20:367-74."
"7907","PC990031","Chen YR, Han J, Kori R, Kong AN, Tan TH (2002): Phenylethyl isothiocyanate induces apoptotic signaling via suppressing phosphatase activity against c-Jun N-terminal kinase. J Biol Chem 277: 39334-42."
"7908","PC990037","Cinar B, Koeneman KS, Edlund M, Prins GS, Zhau HE, Chung LW (2001): Androgen receptor mediates the reduced tumor growth, enhanced androgen responsiveness, and selected target gene transactivation in a human prostate cancer cell line. Cancer Res 61:7310-7."
"7909","PC990037","Edlund M, Miyamoto T, Sikes RA, Ogle R, Laurie GW, Farach-Carson MC, Otey CA, Zhau HE, Chung LW (2001): Integrin expression and usage by prostate cancer cell lines on laminin substrata. Cell Growth Differ 12:99-107."
"7910","PC990038","Ge Zhou,1 Yoshihiro Hashimoto,1 Inseok Kwak,1 Sophia Y. Tsai,1,2 and Ming-Jer Tsai1.  2003.  Role of the Steroid Receptor Coactivator SRC-3 in Cell Growth. Mol Cell Biol. 23:7742¿7755."
"7911","PC990040","Naoya Masumori, Tania Z. Thomas, Pierre Chaurand, Tom Case, Manik Paul, Susan Kasper, Richard M. Caprioli, Taiji Tsukamoto, Scott B. Shappell and Robert J. Matusik.  2001. A Probasin-Large T Antigen Transgenic Mouse Line Develops Prostate Adenocarcinoma and Neuroendocrine Carcinoma with Metastatic Potential.  Cancer Research 61, 2239-2249"
"7912","PC990044","Steadman DJ, Giuffrida D, Gelmann EP (2000): DNA-binding sequence of the human prostate-specific homeodomain protein NKX3.1. Nucleic Acids Research 28:2389-95."
"7913","PC990045","Nava VE, Lacana E, Poulton S, Liu H, Sugiura M, Kono K, Milstien S, Kohama T, Spiegel S (2000): Functional characterization of human sphingosine kinase-1. FEBS Letters 473:81-4."
"7914","PC990045","Liu H, Sugiura M, Nava VE, Edsall LC, Kono K, Poulton S, Milstien S, Kohama T, Spiegel S (2000): Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. Journal Of Biological Chemistry 275:19513-20."
"7915","PC990045","Wang F, Van Brocklyn JR, Edsall L, Nava VE, Spiegel S (1999): Sphingosine-1-phosphate inhibits motility of human breast cancer cells independently of cell surface receptors. Cancer Research 59:6185-91."
"7916","PC990045","Nava VE, Cuvillier O, Edsall LC, Kimura K, Milstien S, Gelmann EP, Spiegel S (2000): Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Research 60:4468-74."
"7917","PC990045","Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, Rosenfeldt HM, Nava VE, Chae SS, Lee MJ, Liu CH, Hla T, Spiegel S, Proia RL (2000): Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 106:951-61."
"7918","PC990045","Olivera A, Kohama T, Edsall L, Nava V, Cuvillier O, Poulton S, Spiegel S (1999): Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. Journal Of Cell Biology 147:545-58."
"7919","PC990048","Chen CD, and Sawyers CL.  2002.  NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer.  Mol Cell Biol 22(8):2862-70."
"7920","PC990048","Chen CD, Welsbie DS, Tran C, et al.  2004.   Molecular determinants of resistance to antiandrogen therapy.  Nat Med 10(1):33-9."
"7921","PC990049","Sumitomo M, Shen R, Walburg M, Dai J, Geng Y, Navarro D, Boileau G, Papandreou CN, Giancotti FG, Knudsen B, Nanus DM (2000): Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J Clin Invest 106:1399-407."
"7922","PC990049","Shen R, Sumitomo M, Dai J, Hardy DO, Navarro D, Usmani B, Papandreou CN, Hersh LB, Shipp MA, Freedman LP, Nanus DM (2000): Identification and characterization of two androgen response regions in the human neutral endopeptidase gene. Mol Cell Endocrinol 170:131-42."
"7923","PC990049","Sumitomo M, Milowsky MI, Shen R, Navarro D, Dai J, Asano T, Hayakawa M, Nanus DM (2001): Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer Res 61:3294-8."
"7924","PC990049","Sumitomo M, Shen R, Goldberg JS, Dai J, Navarro D, Nanus DM (2000): Neutral endopeptidase promotes phorbol ester-induced apoptosis in prostate cancer cells by inhibiting neuropeptide-induced protein kinase C delta degradation. Cancer Res 60:6590-6."
"7925","PC990049","Dai J, Shen R, Sumitomo M, Goldberg JS, Geng Y, Navarro D, Xu S, Koutcher JA, Garzotto M, Powell CT, Nanus DM (2001): Tumor-suppressive effects of neutral endopeptidase in androgen- independent prostate cancer cells. Clin Cancer Res 7:1370-7."
"7926","PC990049","Shen R, Sumitomo M, Dai J, Harris A, Kaminetzky D, Gao M, Burnstein KL, Nanus DM (2000): Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. Endocrinology 141:1699-704."
"7927","PC991001","Gao JX, Zhang H, Bai XF, Wen J, Zheng X, Liu J, Zheng P, Liu Y (2002): Perinatal blockade of b7-1 and b7-2 inhibits clonal deletion of highly pathogenic autoreactive T cells. J Exp Med 195:959-71."
"7928","PC991001","Bai XF, Gao JX, Liu J, Wen J, Zheng P, Liu Y (2001): On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen. Cancer Res 61:6860-7."
"7929","PC991001","Bai XF, Liu JQ, Liu X, Guo Y, Cox K, Wen J, Zheng P, Liu Y (2000): The heat-stable antigen determines pathogenicity of self-reactive T cells in experimental autoimmune encephalomyelitis. J Clin Invest 105:1227-32."
"7930","PC991001","Bai XF, Bender J, Liu J, Zhang H, Wang Y, Li O, Du P, Zheng P, Liu Y (2001): Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens. J Immunol 167:3936-43."
"7931","PC991001","Liu X, Bai XF, Wen J, Gao JX, Liu J, Lu P, Wang Y, Zheng P, Liu Y (2001): B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8(+) T lymphocytes in vivo. J Exp Med 194:1339-48."
"7932","PC991001","Zheng P, Sarma S, Guo Y, Liu Y (1999): Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: lessons from recurrent tumors. Cancer Res 59:3461-7."
"7933","PC991001","Liu Y, Zheng P (2001): Is tumor expression of the major histocompatibility complex antigen required for T cell immune surveillance? Arch Immunol Ther Exp (Warsz) 49 Suppl 2:S61-4."
"7934","PC991001","Guo Y, Yang T, Liu X, Lu S, Wen J, Durbin JE, Liu Y, Zheng P (2002): Cis elements for transporter associated with antigen-processing-2 transcription: two new promoters and an essential role of the IFN response factor binding element in IFN-gamma-mediated activation of the transcription initiator. Int Immunol 14:189-200."
"7935","PC991001","May KF Jr, Chen L, Zheng P, Liu Y (2002): Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res 62:3459-65."
"7936","PC991001","Zheng X, Gao JX, Zhang H, Geiger TL, Liu Y, Zheng P (2002): Clonal deletion of simian virus 40 large T antigen-specific T cells in the transgenic adenocarcinoma of mouse prostate mice: an important role for clonal deletion in shaping the repertoire of T cells specific for antigens overexpressed in solid tumors. J Immunol 169:4761-9."
"7937","PC991001","Guilloux Y, Bai XF, Liu X, Zheng P, Liu Y (2001): Optimal induction of effector but not memory antitumor cytotoxic T lymphocytes involves direct antigen presentation by the tumor cells. Cancer Res 61:1107-12."
"7938","PC991011","Holaska JM, Black BE, Rastinejad F, Paschal BM (2002): Ca2+-dependent nuclear export mediated by calreticulin. Mol Cell Biol 22:6286-97."
"7939","PC991011","Devarakonda S, Harp JM, Kim Y, et al.  Structure of the heterodimeric ecdysone receptor DNA-binding complex. Embo J 22:5827-5840
"
"7940","PC991011","Black BE, Holaska JM, Rastinejad F, Paschal BM (2001): DNA binding domains in diverse nuclear receptors function as nuclear export signals. Curr Biol 11:1749-58."
"7941","PC991011","Mi LZ, Devarakonda S, Harp JM, Han Q, Pellicciari R, Willson TM, Khorasanizadeh S, Rastinejad F (2003): Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol Cell 11:1093-100."
"7942","PC991011","Orlowski M, Szyska M, Kowalska A, et al.  2004.  Plasticity of the ecdysone receptor DNA binding domain.  Mol Endocrinol 18(9):2166-84."
"7943","PC991018","Suzuki K, Alemany R, Yamamoto M, Curiel DT (2002): The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res 8:3348-59."
"7944","PC991018","Haviv YS, Takayama K, Glasgow JN, Blackwell JL, Wang M, Lei X, Curiel DT (2002): A model system for the design of armed replicating adenoviruses using p53 as a candidate transgene. Mol Cancer Ther 1:321-8."
"7945","PC991018","Reynolds PN and Curiel DT (1998): Strategies to adapt adenoviral vectors for gene therapy applications:  Targeting and integration. In: The Development of Human Gene Therapy. Friedmann T, ed. Cold Spring Harbor Laboratory Press."
"7946","PC991018","Bauerschmitz GJ, Lam JT, Kanerva A, Suzuki K, Nettelbeck DM, Dmitriev I, Krasnykh V, Mikheeva GV, Barnes MN, Alvarez RD, Dall P, Alemany R, Curiel DT, Hemminki A (2002): Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 62:1266-70."
"7947","PC991018","Reynolds, P. N. and Curiel, D. T. (1999): The Development of Human Gene Therapy. Cold Spring Harbor Laboratory Press."
"7948","PC991018","Dmitriev I, Kashentseva E, Rogers BE, Krasnykh V, Curiel DT (2000): Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol 74:6875-84."
"7949","PC991018","Haviv YS, Blackwell JL, Li H, Wang M, Lei X, Curiel DT (2001): Heat shock and heat shock protein 70i enhance the oncolytic effect of replicative adenovirus. Cancer Res 61:8361-5."
"7950","PC991018","Bauerschmitz GJ, Nettelbeck DM, Kanerva A, Baker AH, Hemminki A, Reynolds PN, Curiel DT (2002): The flt-1 promoter for transcriptional targeting of teratocarcinoma. Cancer Res 62:1271-4."
"7951","PC991018","Kruyt FA, Curiel DT (2002): Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther 13:485-95."
"7952","PC991018","Grill J, Lamfers ML, van Beusechem VW, Dirven CM, Pherai DS, Kater M, Van der Valk P, Vogels R, Vandertop WP, Pinedo HM, Curiel DT, Gerritsen WR (2002): The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro. Mol Ther 6:609-14."
"7953","PC991018","Gomez-Navarro J, Curiel DT (2000): Conditionally replicative adenoviral vectors for cancer gene therapy. Lancet Oncol 1:148-58."
"7954","PC991018","Douglas JT, Kim M, Sumerel LA, Carey DE, Curiel DT (2001): Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res 61:813-7."
"7955","PC991018","Curiel DT (2000): The development of conditionally replicative adenoviruses for cancer therapy. Clin Cancer Res 6:3395-9."
"7956","PC991018","Nicklin SA, Reynolds PN, Brosnan MJ, White SJ, Curiel DT, Dominiczak AF, Baker AH (2001): Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension 38:65-70."
"7957","PC991018","Alemany R, Balague C, Curiel DT (2000): Replicative adenoviruses for cancer therapy. Nat Biotechnol 18:723-7."
"7958","PC991018","Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R (2001): A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 7:120-6."
"7959","PC991018","Adachi Y, Reynolds PN, Yamamoto M, Wang M, Takayama K, Matsubara S, Muramatsu T, Curiel DT (2001): A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res 61:7882-8."
"7960","PC991036","Fan L, Pepicelli CV, Dibble CC, et al.  2004.  Hedgehog signaling promotes prostate xenograft tumor growth.  Endocrinol 145:3961-3970."
"7961","PC991036","Barnett DH, Huang HY, Wu XR, et al.  2002.  The human prostate expresses sonic hedgehog during fetal development.  J Urol 168:2206-2210."
"7962","PC991036","Bushman W.  2005.  Hedgehog signaling in growth and development.  Prostate Cancer: Novel Biology, Genetics and Therapy.

"
"7963","PC991038","Raikwar SP KCaGT (2002): Targeted adenoviral vectors II:  Transcriptional targeting. In: Adenoviral Vectors for Gene Therapy. Curiel D and Douglas JT, ed. Academic Press."
"7964","PC991038","Gardner TA, Sloan J, Raikwar SP, Kao C (2002): Prostate cancer gene therapy: past experiences and future promise. Cancer Metastasis Rev 21:137-45."
"7965","PC991038","Matsubara S, Wada Y, Gardner TA, Egawa M, Park MS, Hsieh CL, Zhau HE, Kao C, Kamidono S, Gillenwater JY, Chung LW (2001): A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 61:6012-9."
"7966","PC991052","Underhill CB, Zhang L (2000): Analysis of hyaluronan using biotinylated hyaluronan-binding proteins. Methods Mol Biol 137:441-7."
"7967","PC991052","Yang S Chen J Guo Z Xu XM Wang L Pei XF Yang J Underhill CB Zhang L (2003): Triptolide inhibits the growth and metastasis of solid tumors. Mol. Cancer Ther. 2:65-72."
"7968","PC991052","Hamada T, McLean WH, Ramsay M, Ashton GH, Nanda A, Jenkins T, Edelstein I, South AP, Bleck O, Wessagowit V, Mallipeddi R, Orchard GE, Wan H, Dopping-Hepenstal PJ, Mellerio JE, Whittock NV, Munro CS, van Steensel MA, Steijlen PM, Ni J, Zhang L, Hashimoto T, Eady RA, McGrath JA (2002): Lipoid proteinosis maps to 1q21 and is caused by mutations in the extracellular matrix protein 1 gene (ECM1). Hum Mol Genet 11:833-40."
"7969","PC991052","Liu N, Shao L, Xu X, Chen J, Song H, He Q, Lin Z, Zhang L, Underhill CB (2002): Hyaluronan metabolism in rat tail skin following blockage of the lymphatic circulation. Lymphology 35:15-22."
"7970","PC991052","Liu N, Lapcevich RK, Underhill CB, Han Z, Gao F, Swartz G, Plum SM, Zhang L, Gree SJ (2001): Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth. Cancer Res 61:1022-8."
"7971","PC991052","Chen Y, Xu X, Hong S, Chen J, Liu N, Underhill CB, Creswell K, Zhang L (2001): RGD-Tachyplesin inhibits tumor growth. Cancer Res 61:2434-8."
"7972","PC991052","Chen J, Xu X-M, Underhill CB, et al.  2005.  Tachyplesin activates the classical complement pathway to kill tumor cells.  Cancer Res 65:4614-4622."
"7973","PC991052","Xu X-M, Chen Y, Gao F, et al.  2003.  A peptide with three hyaluronan binding motifs inhibits tumor growth by inducing apoptosis.  Cancer Res 63:5685-5690."
"7974","PC991052","Liu N, Xu X-M, Chen J, et al.  2004.  A hyaluronan-binding peptide can inhibit tumor growth by interacting with Bcl-2.  Intl J Cancer 109:49-57."
"7975","PC991052","Grzywacz MJ, Yang JM, Hait WN. (2003): Effect of the multidrug resistance protein on the transport of the antiandrogen flutamide. Cancer Res.   63:2492-2498."
"7976","PC991052","Wang L Yu J Ni J Xu XM Wang J Ning H Pei XF Chen J Yang S Underhill CB Liu L Liekens J Merregaert J Zhang L. (2003): Extracellular matrix protein1 (ECM1) is over-expressed in malignant epithelial tumors. Cancer Letter, 200:57-67."
"7977","PC991066","Warrick C, Wutoh AK, Corria-McDow Z, Emekalam A.  2002. Prostate cancer education in the Washington, DC, area.  J Natl Med Assoc. 94(11):963-70.
"
"7978","PC991068","·Carraway RE, X Gui, and DE Cochrane, 2003.  Ca2+-channel blockers enhance neurotensin (NT) binding and inhibit NT induced inositol phosphate formation in prostate cancer PC3 cells.  J. Pharmacol. Exp. Therap.  307:640-50."
"7979","PC991068","Carraway RE, Hassan S, Cochrane DE, et al.  2004.  Polyphenolic antioxidants mimic the effects of 1,4-dihydropyridines on neurotensin receptor function in PC3 cells.  J Pharmacol Exp Ther 309(1):92-101."
"7980","PC991068","Hassan S, Dobner PR, and Carraway RE.  2004.  Involvement of MAP-kinase, PI3-kinase and EGF-receptor in the stimulatory effect of neurotensin on DNA synthesis in PC3 cells.  Regul Peptides 120:155-166."
"7981","PC991075","Chen F, Kamradt M, Mulcahy M, Byun Y, Xu H, McKay MJ, Cryns VL (2002): Caspase proteolysis of the cohesin component RAD21 promotes apoptosis. J Biol Chem 277:16775-81."
"7982","PC991085","Khaldoyanidi SK, Glinsky VV, Sikora L, Glinskii AB, Mossine VV, Quinn TP, Glinsky GV, Sriramarao P (2003): MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions. J Biol Chem 278:4127-34."
"7983","PC991085","·Glinsky VV, Glinsky GV, Glinskii OV, et al.  2003.  Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium.  Cancer Res. 63:3805-3811."
"7984","PC991087","Thomson AA (2001): Role of androgens and fibroblast growth factors in prostatic development. Reproduction 121. 121:187-95-187-95."
"7985","PC991087","Thomson AA, Timms BG, Barton L, Cunha GR, Grace OC (2002): The role of smooth muscle in regulating prostatic induction. Development 129:1905-12."
"7986","PC991089","Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT (2003): Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 54:249-57."
"7987","PC991089","Khan SR, Denmeade SR (2000): In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts. Prostate 45. 45:80-3-80-3."
"7988","PC991089","Jakobsen CM, Denmeade SR, Isaacs JT, Gady A, Olsen CE, Christensen SB (2001): Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. J Med Chem 44:4696-703."
"7989","PC991089","Tombal B, Denmeade SR, Isaacs JT (1999):  Assessment and validation of a microinjection method for kinetic analysis of [Ca2+]  in individual cells undergoing apoptosis. Cell Calcium 25:19-28."
"7990","PC991089","Denmeade SR, Lin XS, Tombal B, Isaacs JT (1999): Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells. Prostate 39:269-79."
"7991","PC991089","Tombal B, Weeraratna AT, Denmeade SR, Isaacs JT (2000): Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells. Prostate 43:303-17."
"7992","PC991089","Jackisch C, Hahm HA, Tombal B, McCloskey D, Butash K, Davidson NE, Denmeade SR (2000): Delayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast cancer cells. Clin Cancer Res 6:2844-50."
"7993","PC991089","Tombal B, Denmeade SR, Gillis JM, Isaacs JT (2002): A supramicromolar elevation of intracellular free calcium ([Ca(2+)](i)) is consistently required to induce the execution phase of apoptosis. Cell Death Differ 9:561-73."
"7994","PC991089","Mhaka A, Denmeade SR, Yao W, Isaacs JT, Khan SR (2002): A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer. Bioorg Med Chem Lett 12:2459-61."
"7995","PC991089","Denmeade SR, Lovgren J, Khan SR, Lilja H, Isaacs JT (2001): Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing. Prostate 48:122-6."
"7996","PC991089","Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT (2001): Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate 48:1-6."
"7997","PC991093","Ahonen TJ, Harkonen PL, Rui H, Nevalainen MT (2002): PRL signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro. Endocrinology 143:228-38."
"7998","PC991098","Suarez BK, Gerhard DS, Lin J, Haberer B, Nguyen L, Kesterson NK, Catalona WJ (2001): Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls. Cancer Res 61:4982-4."
"7999","PC991098","Culverhouse R, Lin J, Liu KY, Suarez BK (2001): Exploiting linkage disequilibrium in population isolates. Genet Epidemiol 21 Suppl 1:S429-34."
"8000","PC991103","Coard KCM and Freeman VL.  2004.  Gleason grading of prostate cancer: Level of concordance between pathologists at the University Hospital of the West Indies.  Am J Clin Pathol 122:373-376."
"8001","PC991103","Arap W, Haedicke W, Bernasconi M, Kain R, Rajotte D, Krajewski S, Ellerby HM, Bredesen DE, Pasqualini R, Ruoslahti E (2002): Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci U S A 99:1527-31."
"8002","PC991103","Freeman VL, Coard KCM, Wojcik E, and Durazo-Arvizu R. 2004.  Use of the Gleason system in international comparisons of prostatic adenocarcinomas in blacks.  Prostate 58(2):169-73."
"8003","PC991108","Selleck WA CSHWMMKAERCSHSJ (2003):  IFN-g  sensitization of prostate cancer cell to fas mediated death: a gene therapy approach. Mol. Ther. 7:185-192."
"8004","PC991108","Hall SJ, Canfield SE, Yan Y, Hassen W, Selleck WA, Chen SH (2002): A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer. Gene Ther 9:511-7."
"8005","PC991108","Sanford MA, Yan Y, Canfield SE, Hassan W, Selleck WA, Atkinson G, Chen SH, Hall SJ (2001): Independent contributions of GR-1+ leukocytes and Fas/FasL interactions to induce apoptosis following interleukin-12 gene therapy in a metastatic model of prostate "
"8006","PC991111","Lin DL, Whitney MC, Yao Z, Keller ET (2001): Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin. Cancer Res.  7:1773-1781."
"8007","PC991111","Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET (2001): Interleukin-6 and prostate cancer progression.  Cytokine and Growth Factor Reviews 12::33-40."
"8008","PC991111","Smith PC, Keller ET (2001): Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate  48:47-53."
"8009","PC991111","Keller ET. (2002): The role of osteoclastic activity in prostate cancer skeletal metastases.  Drugs Today  38:91-102."
"8010","PC991111","Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK (2002): Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone.  Cancer Res. 62:1832-1837."
"8011","PC991111","Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, Pienta KJ, Taichman RS (2001): Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastases Reviews  20:333-349."
"8012","PC991114","Han E, Phan D, Lo P, Poy MN, Behringer R, Najjar SM, Lin SH (2001): Differences in tissue-specific and embryonic expression of mouse Ceacam1 and Ceacam2 genes. Biochem J 355:417-23."
"8013","PC991122","Protozanova E, Demidov VV, Soldatenkov V, Chasovskikh S, Frank-Kamenetskii MD (2002): Tailoring the activity of restriction endonuclease PleI by PNA-induced DNA looping. EMBO Rep 3:956-61."
"8014","PC991122","Trofimova I, Dimtchev A, Jung M, Rosenthal D, Smulson M, Dritschilo A, Soldatenkov V (2002): Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase. Cancer Res 62:6879-83."
"8015","PC991122","Newman RE, Soldatenkov VA, Dritschilo A, Notario V (2002): Poly(ADP-ribose) polymerase turnover alterations do not contribute to PARP overexpression in Ewing's sarcoma cells. Oncol Rep 9:529-32."
"8016","PC991122","Soldatenkov VA, Trofimova IN, Rouzaut A, McDermott F, Dritschilo A, Notario V (2002): Differential regulation of the response to DNA damage in Ewing's sarcoma cells by ETS1 and EWS/FLI-1. Oncogene 21:2890-5."
"8017","PC991122","Soldatenkov VA, Chasovskikh S, Potaman VN, Trofimova I, Smulson ME, Dritschilo A (2002): Transcriptional repression by binding of poly(ADP-ribose) polymerase to promoter sequences. J Biol Chem 277:665-70."
"8018","PC991122","Soldatenkov VA, Smulson M (2000): Poly(ADP-ribose) polymerase in DNA damage-response pathway: implications for radiation oncology. International Journal of Cancer 90. 90:59-67-59-67."
"8019","PC991127","Sadar MD, Akopian VA, Beraldi E (2002): Characterization of a new in vivo hollow fiber model for the study of progression of prostate cancer to androgen independence. Mol Cancer Ther 1:629-37."
"8020","PC991139","Diefenbach MA, Dorsey J, Uzzo RG, Hanks GE, Greenberg RE, Horwitz E, Newton F, Engstrom PF (2002): Decision-making strategies for patients with localized prostate cancer. Semin Urol Oncol 20:55-62."
"8021","PC991139","Diefenbach MA, Hamrick N, Uzzo R, et al.  Clinical, demographic and psychosocial correlates of complementary and alternative medicine use by men diagnosed with localized prostate cancer.  J Urol;170(1):166-169."
"8022","PC991139","Diefenbach MA, Mohamed NE. 2007.  Regret of treatment decision and its association with disease-specific quality of life following prostate cancer treatment.  Cancer Invest 25(6):449-457."
"8023","PC991139","Mohamed NE, Bovbjerg DH, Montgomery GH, et al.  2012.  Pretreatment depressive symptoms and treatment modality predict post-treatment disease-specific quality of life among patients with localized prostate cancer.  Urol Oncol 30(6):804-812."
"8024","PC991140","·Rajasekaran SA, Anilkumar G, Oshima E, et al.  2003.  A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate specific membrane antigen.  Mol. Biol. Cell 14:4835-4845."
"8025","PC991140","·Anilkumar G, Rajasekaran SA, Wang S, et al.  2003.  Prostate specific membrane antigen association with filamin A modulates its internalization and NAALADase activity.  Cancer Res.    63:2645-2648."
"8026","PC991140","Christiansen JJ, Rajasekaran SA, Moy P, Butch A, Goodglick L, Gu Z, Reiter RE, Bander NH, Rajasekaran AK (2003): Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell line. Prostate 55:9-19."
"8027","PC991154","Buckley DL (2002): Uncertainty in the analysis of tracer kinetics using dynamic contrast- enhanced T1-weighted MRI. Magn Reson Med 47:601-6."
"8028","PC991154","Kershaw LE, Buckley DL.  2006.  Precision in Measurement of perfusion and microvascular permeability with T1-Weighted Dynamic Contrast-Enhanced MRI.  Mag Res Sci  56:986-992."
"8029","PC991154","Buckley DL, Roberts C, Parker GM, et al.  2004.  Prostate Cancer: Evaluation of Vascular Characteristics with dynamic contrast - enhanced T1-weighted MR Imaging- Initial Experience.  Radiology 233:709-715.
"
"8030","PC991154","Buckley DL (2002): Transcytolemmal water exchange and its affect on the determination of contrast agent concentration in vivo. Magn Reson Med 47:420-1."
"8031","PC991159","Logg CR, Logg A, Matusik RJ, Bochner BH, Kasahara N (2002): Tissue-specific transcriptional targeting of a replication-competent retroviral vector. J Virol 76:12783-91."
"8032","PC991163","Julian J and Carson DD.  2002.  Formation of MUC1 metabolic complex is conserved in tumor-derived and normal epithelial cells.  Biochem Biophys Res Commun 293:1183-1190."
"8033","PC991163","O'Connor JC, Julian J, Lim SD, et al.  2004.  MUC1 expression in human prostate cancer cell lines and primary tumors.  Prostate Cancer Prostatic Dis 2004 Oct 12 [Epub ahead of print].  

"
"8034","PC991165","Brown WM, EM Lange, H Chen, et al., 2004.  Hereditary prostate cancer in African American families:  Linkage analysis using markers that map to five candidate susceptibility loci.  British J. of Cancer 90:510-14."
"8035","PC991165","Xu J, Zheng SL, Chang B, Smith JR, Carpten JD, Stine OC, Isaacs SD, Wiley KE, Henning L, Ewing C, Bujnovszky P, Bleeker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB (2001): Linkage of prostate cancer susceptibility loci to chromosome 1. Human Genetics 108. 108:335-45-335-45."
"8036","PC991165","Xu J, Zheng SL, Carpten JD, Nupponen NN, Robbins CM, Mestre J, Moses TY, Faith DA, Kelly BD, Isaacs SD, Wiley KE, Ewing CM, Bujnovszky P, Chang B, Bailey-Wilson J, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB (2001): Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. American Journal of Human Genetics 68. 68:901-11-901-11."
"8037","PC991165","Zheng SL, Xu J, Isaacs SD, Wiley K, Chang B, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB (2001): Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families. Human Genetics 108. 108:430-5-430-5."
"8038","PC991165","Chang BL Zheng SL Isaacs SD Turner A Hawkins GA Wiley KE Bleecker ER Walsh PC Meyers DA Isaacs WB Xu J. (2003): Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk. Int. J. Cancer 106(3):375-8:375-8."
"8039","PC991165","Lindmark F, BA Jonsson, A Bergh, et al., 2004.  Analysis of the macrophage scavenger receptor 1 gene in Swedish hereditary and sporadic prostate cancer.  Prostate 59:132-40."
"8040","PC991165","Chang BL, SL Zheng, SD Isaacs, et al., 2004.  The polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer.  Cancer Res. 64:1997-9."
"8041","PC991165","Xu J, CD Langefeld, SL Zheng, et al., 2004.  Interaction effect of PTEN and CDKN1B chromosomal regions on prostate cancer linkage.  Hum. Gen. 115:255-62.

"
"8042","PC991165","Hawkins GA, BL Chang, SL Zheng, et al., 2004.  Mutational analysis of PinX1 in hereditary prostate cancer.  Prostate 60:298-302."
"8043","PC991165","Chang BL Zheng SL Isaacs SD Turner AR Bleecker ER Walsh PC Meyers DA Isaacs WB Xu J. (2003): Evaluation of SRD5A2 sequence variants insusceptibility to hereditary and sporadic prostate cancer.  The Prostate 56:37-44."
"8044","PC991165","Xu J Zheng SL Komiya A Mychaleckyj JC Isaacs SD Hu JJ Sterling D Lange EM Hawkins GA Turner A Ewing CM Faith DA Johnson JR Suzuki H Bujnovszky P Wiley KE DeMarzo AM Bova GS Chang B Hall MC McCullough DL Partin AW Kassabian VS Carpten JD Bailey-Wilson JE Trent JM Ohar J Bleecker ER Walsh PC Isaacs WB Meyers DA (2002): Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nature Genetics 32:321-325."
"8045","PC991165","Zheng SL Chang BL Faith DA Johnson JR Isaacs SD Hawkins GA Turner A Wiley KE Bleecker ER Walsh PC Meyers DA Isaacs WB Xu J. (2002): Sequence variants of a-Methylacyl-CoA Racemase are associated with prostate cancer risk. Cancer Research 62:6485-6488."
"8046","PC991165","Chang BL, Zheng SL, Isaacs SD, Turner A, Hawkins GA, Wiley KE, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J. (2003): Polymorphisms in the CYPIBI gene are associated with increased risk of prostate cancer. Journal of Cancer Research.  89:1524-1529."
"8047","PC991165","Xu J, Zheng SL, Turner A, Isaacs SD, Wiley KE, Hawkins GA, Chang BL, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB (2002): Associations between hOGG1 sequence variants and prostate cancer susceptibility. Cancer Res 62:2253-7."
"8048","PC991165","Zheng SL, Xu J, Isaacs SD, Wiley K, Chang B, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB (2001): Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families. Hum Genet 108:430-5."
"8049","PC991165","Chang B, Zheng SL, Isaacs SD, Wiley KE, Carpten JD, Hawkins GA, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB, Xu J (2001): Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer. Int J Cancer 95:354-9."
"8050","PC991165","Chang BL, Zheng SL, Hawkins GA, Isaacs SD, Wiley KE, Turner A, Carpten JD, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB, Xu J (2002): Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibilit"
"8051","PC991165","Chang BL, Zheng SL, Hawkins GA, Isaacs SD, Wiley KE, Turner A, Carpten JD, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB, Xu J (2002): Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cance"
"8052","PC991165","Ho GY, Knapp M, Freije D, Nelson WG, Smith JR, Carpten JD, Bailey-Wilson JE, Beaty TH, Petersen G, Xu J, Kamensky V, Walsh PC, Isaacs WB (2002): Transmission/disequilibrium tests of androgen receptor and glutathione S-transferase pi variants in prostate c"
"8053","PC991165","Xu J, Zheng SL, Hawkins GA, Faith DA, Kelly B, Isaacs SD, Wiley KE, Chang B, Ewing CM, Bujnovszky P, Carpten JD, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB (2001): Linkage and association studies of prostate cancer susceptibility: evidence for "
"8054","PC991165","Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, Faruque M, Moses T, Ewing C, Gillanders E, Hu P, Bujnovszky P, Makalowska I, Baffoe-Bonnie A, Faith D, Smith J, Stephan D, Wiley K, Brownstein M, Gildea D, Kelly B, Jenkins R, Hostetter G, Matikain"
"8055","PC991165","Hawkins GA, Mychaleckyj JC, Zheng SL, Faith DA, Kelly B, Isaacs SD, Wiley KE, Chang BL, Ewing CM, Bujnovszky P, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J (2002): Germline sequence variants of the LZTS1 gene are associated with prostate cancer risk. Cancer Genet Cytogenet 137:1-7."
"8056","PC991165","Zheng SL, JC Mychaleckyj, GA Kawkins, et al., 2003.  Evaluation of DLC1 as a prostate cancer susceptibility gene:  Mutation screen and association study.  Mut. Res. 528:42-53."
"8057","PC991165","Zheng SL, K Augustsson-Balter, BL Chang, et al., 2004.  Sequence variants of toll-like receptor 4 are associated with prostate cancer risk:  Results from the Cancer Prostate in Sweden Study. Cancer Res. 64:2918-22."
"8058","PC991165","Friedrichsen DM, JL Stanford, SD Isaacs, et al., 2004.  Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families.  PNAS 101:1939-44."
"8059","PC991165","Gillanders EM, J Xu, BL Chang, et al., 2004.  Combined genome-wide scan for prostate cancer susceptibility genes. JNCI, 96(16):1240-7."
"8060","PC991167","·Lin A and Karin M.  2003.  NF-kB in cancer: A marked target.  Seminars in Cancer Biology 13:107-114."
"8061","PC991167","Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M, Lin A (2001): Inhibition of JNK activation through NF-kappaB target genes. Nature 414:313-7."
"8062","PC991167","·Lin A.  2003.  Activation of the JNK signaling pathway: Breaking the brake of apoptosis.  BioEssays 24:17-24.    

"
"8063","PC991221","Lu L, Schulz H, Wolf DA (2002): The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells. BMC Cell Biol 3:22."
"8064","PC991256","Garcia-Bermejo ML, Leskow FC, Fujii T, Wang Q, Blumberg PM, Ohba M, Kuroki T, Han KC, Lee J, Marquez VE, Kazanietz MG (2002): Diacylglycerol (DAG)-lactones, a new class of protein kinase C (PKC) agonists, induce apoptosis in LNCaP prostate cancer cells by"
"8065","PC991256","Barry OP, Kazanietz MG (2001): Protein kinase C isozymes, novel phorbol ester receptors and cancer chemotherapy. Curr Pharm Des 7:1725-44."
"8066","PC991256","Eroles P WHLFea (2001): Protein kinase C and phorbol ester receptors in prostate carcinogenesis. Recent Res. Devel. Endocrinol 2:237-250."
"8067","PC991256","Gavrielides MV, Frijhoff AF, Conti CJ, et al.  2004.  Protein kinase C and prostate carcinogenesis: targeting the cell cycle and apoptosis mechanisms.  Current Drug Targets 5(5):431-43.  
"
"8068","PC991256","Fujii T, ML Garcia-Bermejo, JL Bernabo, et al., 2000.  Involvement of protein kinase C delta(PKCdelta)in phorbol ester-induced apoptosis in LNCaP prostate cancer cells.  Lack of proteolytic cleavage of PKCdelta.  J. Biol. Chem. 275:7574-82."
"8069","PC991256","Qiao L, L-Y Zhao, SB Rong, et al., 2001.  Rational design, synthesis, and biological evaluation of rigid pyrrolidone analogs as potential inhibitors of prostate cancer cell growth.  Bioorg. Med. Chem. Lett. 11:955-9."
"8070","PC991256","Kazanietz MG, MJ Caloca, ML Garcia-Bermejo, et al., 2000.  Pharmacology of the receptors for the phorbol ester tumor promoters:  Multiple receptors with different biochemical properties.  Biochem. Pharmacol. 60:1417-24."
"8071","PC991256","Yang C, and MG Kazanietz, 2003.  Divergence and complexities in DAG signaling:  Looking beyond PKC.  Trends Pharmacol. Sci. 24:602-8."
"8072","PC991256","Kazanietz MG.  2003.  Pharmacological probes for protein kinase C: An introduction.  Methods Mol Biol 233:389-395.

"
"8073","PC991256","Kazanietz MG, Lorenzo PS (2003): Phorbol esters as probes for the study of protein kinase C function. Methods Mol Biol 233:423-439."
"8074","PC991256","Tanaka Y, Gavrielides MV, Mitsuuchi Y, Fujii T, Kazanietz MG (2003): Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem.  278:33753-62."
"8075","PC991258","Chen TT, Brown EJ, Juang EJ, and Seaman WE.  2004.  Expression and activation of signal regulatory protein alpha; on astrocytomas.  Cancer Res 64:117-127."
"8076","PC991265","Zhang JC, Claffey K, Sakthivel R, Darzynkiewicz Z, Shaw DE, Leal J, Wang YC, Lu FM, McCrae KR (2000): Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. FASEB Journal 14. 14:2589-600-2589-600."
"8077","PC991265","Zhang JC, Qi X, Juarez J, Plunkett M, Donate F, Sakthivel R, Mazar AP, McCrae KR (2002): Inhibition of angiogenesis by two-chain high molecular weight kininogen (HKa) and kininogen-derived polypeptides. Can J Physiol Pharmacol 80:85-90."
"8078","PC991265","Juarez JC Guan X Shipulina NV Plunkett ML Parry GC Shaw DE Zhang JC Rabbani SA McCrae KR Mazar AP Morgan WT Donate F (2002): Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain. Cancer Res.  62:5344-5358."
"8079","PC991265","Zhang JC Donate F Qi X Ziats NP Juarez JC Mazar AP Pang YP McCrae KR (2002): The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Proc. Natl. Acad. Sci. USA 99:12224-12229."
"8080","PC991270","Gupta S, Stuffrein S, Plattner R, Tencati M, Gray C, Whang YE, Stanbridge EJ (2001): Role of phosphoinositide 3-kinase in the aggressive tumor growth of HT1080 human fibrosarcoma cells. Mol Cell Biol 21:5846-56."
"8081","PC991270","Yuan XJ, Whang YE (2002): PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene 21:319-27."
"8082","PC991270","Mayo MW, Madrid LV, Westerheide SD, Jones DR, Yuan XJ, Baldwin AS Jr, Whang YE (2002): PTEN blocks tumor necrosis factor-induced NF-kappa B-dependent transcription by inhibiting the transactivation potential of the p65 subunit. J Biol Chem 277:11116-25."
"8083","PC991270","Nan B, Snabboon T, Unni E, et al.  2003.  The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity.  J Mol Endocrinol 31(1):169-83."
"8084","PC991272","Turner MJ. Abdul-Alim CS, RA Willis, et al. 2001.  T-cell antigen discovery (T-CAD) assay: A novel technique for identifying T cell epitopes.  J Immunol Methods 256:107-119."
"8085","PC991274","Clegg N, Ferguson C, Nelson PS, et al. 2003. Molecular characterization of prostatic small-cell neuroendocrine carcinoma.  Prostate 55(1):55-64."
"8086","PC991274","Grouse LH, Munson PJ, Nelson PS (2001): Sequence databases and microarrays as tools for identifying prostate cancer biomarkers. Urology 57. 57:154-9-154-9."
"8087","PC991274","Lin B, White JT, Ferguson C, Wang S, Vessella R, Bumgarner R, True LD, Hood L, Nelson PS (2001): Prostate short-chain dehydrogenase reductase 1 (PSDR1): a new member of the short-chain steroid dehydrogenase/reductase family highly expressed in normal and neoplastic prostate epithelium. Cancer Research 61. 61:1611-8-1611-8."
"8088","PC991274","Nelson PS, Han D, Rochon Y, Corthals GL, Lin B, Monson A, Nguyen V, Franza BR, Plymate SR, Aebersold R, Hood L (2000): Comprehensive analyses of prostate gene expression: convergence of expressed sequence tag databases, transcript profiling and proteomics. Electrophoresis 21. 21:1823-31-1823-31."
"8089","PC991274","Nelson PS, Pritchard C, Abbott D, Clegg N (2002): The human (PEDB) and mouse (mPEDB) Prostate Expression Databases. Nucleic Acids Res 30:218-20."
"8090","PC991274","Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, Hood L, Lin B. (2002): The program of androgen-responsive genes in neoplastic prostate epithelium. Proc. Natl. Acad. Sci. USA  99:11890-11895."
"8091","PC991274","Lin B, White JT, Utleg AG, Wang S, Ferguson C, True LD, Vessella R, Hood L, Nelson PS (2003):  Isolation and characterization of human and mouse WDR19, a novel WD-repeat protein exhibiting androgen-regulated expression in prostate epithelium. Genomics 82:331-342."
"8092","PC991274","Clegg N, Eroglu B, Ferguson C, Arnold H, Moorman A, Nelson PS (2002): Digital expression profiles of the prostate androgen-response program.  J. Steroid. Biochem. Mol. Biol.  80:13-23."
"8093","PC991274","Liu AY, Nelson PS, van den Engh G, Hood L (2002): Human prostate epithelial cell-type cDNA libraries and prostate expression patterns.  Prostate  50:92-103."
"8094","PC991274","Nelson PS, Pritchard C, Abbott D, Clegg N. (2002): The human (PEDB) and mouse (mPEDB) prostate expression databases. Nucleic Acids Res. 30:218-220."
"8095","PC991274","Bonham M, Arnold H, Montgomery B, Nelson PS. (2002): Molecular effects of the herbal compound PC-SPES: identification of activity pathways in prostate carcinoma. Cancer Res.  62:3920-3924."
"8096","PC991274","Moore S, Pritchard C, Lin B, Ferguson C, Nelson PS (2002): Isolation and characterization of the murine prostate short-chain dehydrogenase/reductase 1 (Psdr 1) gene, a new member of the short-chain steroid dehydrogenase/reductase family. Gene  293:149-160."
"8097","PC991276","·Schulke N, Varlamova OA, Donovan GP, et al.  2003.  The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy.  PNAS 100:12590-12595."
"8098","PC991276","·Rajaskaran SA, Anilkumar G, Oshima E, et al.  2003.  A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate specific membrane antigen.  Mol. Biol. Cell. 14:4835-4845."
"8099","PC991276","·Ghosh A and Heston WDW.  2004. Tumor target prostate-specific membrane antigen (PSMA) and its regulation in prostate cancer.  J. Cell Biochem. 91:528-539."
"8100","PC991276","Ghosh A and Heston WDW (2003): Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen (PSMA).  The Prostate 57 :140-51."
"8101","PC991276","O'Keefe DS, Uchida A, Bacich DJ, Watt FB, Martorana A, Molloy PL, Heston WD (2000): Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate 45. 45:149-57-149-57."
"8102","PC991293","McEntee MF, Ziegler C, Reel D, et al.  2008. Dietary n-3 polyunsaturated fatty acids enhance hormone ablation therapy in androgen-dependent prostate cancer.
Am J Pathol173(1):229-241."
"8103","PC991307","Simon M, Lurie R, Dong X, et al. 2009.  Heeding Our Words: Complexities of Research Among Low-Literacy Populations. J Clin Oncol 27:1938-40.
"
"8104","PC991307","Kilbridge K, Fraser G, Krahn M, et al. 2009.  Lack of Comprehension of Common Prostate Cancer Terms in an Underserved Population.  J Clin Oncol 27:2015-21."
"8105","PC991308","·Van Brokhoven PN, Varella-Garcia M, Korch WU, et al.  2003. Molecular characterization of human prostate carcinoma cell lines.  Prostate 57:205-225."
"8106","PC991308","·Miller GJ, Miller HA, Van Bokhoven PN, et al.  2003.  Aberrant expression of HOXC genes accompanies the malignant phenotype of human prostate carcinoma.  Cancer Research 63:5879-5888."
"8107","PC991308","van Bokhoven A, Varella-Garcia M, Korch C, Miller GJ (2001): TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. Cancer Res 61:6340-4."
"8108","PC991308","·Van Brokhoven PN, Caires M, Di Maria A, et al.  2003.  Spectral karyotypic analysis of human prostate carcinoma cell lines.  Prostate 57:226-244.

"
"8109","PC991318","Chan ECY, Haynes MC, O'Donnell FT, et al.  2003.  CULTURAL SENSITIVITY AND INFORMED DECISION MAKING ABOUT PROSTATE CANCER SCREENING. J Community Health 28:393-405.
"
"8110","PC991333","·Salm SN, Takao T, Tsujimura A, et al. 2002. Differentiation and stromal-induced growth promotion of murine prostatic tumors. The Prostate 51:175-188.
"
"8111","PC991333","Takao T, Tsujimura A, Coetzee S, et al. 2003. Stromal/ epithelial interactions of murine prostatic cell lines in vivo:  A model for benign prostatic hyperplasia and the effect of doxazosin on tissue size.  The Prostate 54:17-24.
"
"8112","PC991333","Fu YM, Yu ZX, Li YQ, Ge X, Sanchez PJ, Fu X, Meadows GG (2003):  Specific amino acid dependency regulates invasiveness and viability of androgen-independent prostate cancer cells.  Nutr. Cancer  45:60-73."
"8113","PC991333","Salm SN, Takao T, Tsujimura A, Coetzee S, Moscatelli D, Wilson EL (2002): Differentiation and stromal-induced growth promotion of murine prostatic tumors. Prostate 51:175-88."
"8114","PC991334","Taneja S, MacGregor J, Markus S, Ha S, Mohr I (2001): Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc Natl Acad Sci U S A 98:8804-8."
"8115","PC991334","Mohr I.  2003.  Genetic metamorphosis of herpes simplex  virus-1 into a biological therapeutic for human cancer.  Expert. Opin. Biol. Ther. 3:113-125.
"
"8116","PC991334","Mohr I, Sternberg D, Ward S, et al.  2001.  An HSV-1 &#61543;34.5 second site suppressor mutant that exhibits enhanced growth in cultured gioblastoma cells is severely attenuated in animal. J Virol 75:5189-5196."
"8117","PC991353","Zhang Y, Yu J, Unni E, Shao TC, Nan B, Snabboon T, Kasper S, Andriani F, Denner L, Marcelli M. (2002): Monogene and polygene therapy for the treatment of experimental prostate cancers by use of apoptotic genes bax and bad driven by the prostate specific promoter ARR(2)PB.  Hum. Gene Ther.  13:2051-2064."
"8118","PC991353","Zhang Y, Nan B, Yu J, Snabboon T, Andriani F, Marcelli M. (2002): From castration-induced apoptosis of prostatic epithelium to the use of apoptotic genes in the treatment of prostate cancer. Ann. NY Acad. Sci.  963:191-203."
"8119","PC991353","Li X, Marani M, Marcelli M, et al. 2001.  Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer.  Cancer Res. 61(1):186-91."
"8120","PC991353","Andriani F, Nan B, Marcelli M, et al. 2001. Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells.
J Natl Cancer Inst. 93(17):1314-24. 
"
"8121","PC991359","Weier HU, Zitzelsberger HF, Hsieh HB, Sun MV, Wong M, Lersch RA, Yaswen P, Smida J, Kuschnick C, Clark OH (2001): Monitoring signal transduction in cancer: tyrosine kinase gene expression profiling. J Histochem Cytochem 49:673-4."
"8122","PC991359","Hsieh HB, Lersch RA, Callahan DE, Hayward S, Wong M, Clark OH, Weier HU (2001): Monitoring signal transduction in cancer: cDNA microarray for semiquantitative analysis. J Histochem Cytochem 49:1057-8."
"8123","PC991359","Lersch RA, Fung J, Hsieh HB, Smida J, Weier HU (2001): Monitoring signal transduction in cancer: from chips to fish. J Histochem Cytochem 49:925-6."
"8124","PC991359","·Weier HUG (2002): Quantitative DNA fiber mapping. In: FISH Technology. Rautenstrauss B and Liehr T, ed. Springer Verlag, Heidelberg."
"8125","PC991359","Weier HU, Greulich-Bode KM, Ito Y, Lersch RA, Fung J (2002): FISH in cancer diagnosis and prognostication: from cause to course of disease. Expert Rev Mol Diagn 2:109-19."
"8126","PC991364","He B, Lee LW, Minges JT, Wilson EM. 2002.  Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction. J Biol Chem 277(28):25631-9. Epub 2002 May 8.



"
"8127","PC991364","·Gregory CW, Fei X, Ponguta LA, et al.  2004.  Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer.  Journal Biological Chemistry 279:7119-7130."
"8128","PC991364","He B, Minges JT, Lee LW, Wilson EM. 2002.  The FXXLF motif mediates androgen receptor-specific interactions with coregulators. J Biol Chem 277(12):10226-35. Epub 2002 Jan 4

"
"8129","PC991364","·Mohler JL, Gregory CW, Ford OH, et al.  2004.  The androgen axis in recurrent prostate cancer.  Clinical Cancer Research 10:440-448."
"8130","PC991364","·He B and Wilson EM.  Electrostatic modulation in steroid receptor recruitment of the LXXLL and FXXLF motifs.  Molecular Cellular Biology 23:2135-2150."
"8131","PC991364","Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM (2001): A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61:4315-9."
"8132","PC991364","Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM (2001): Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61:2892-8."
"8133","PC991364","Gregory CW, He B, Wilson EM (2001): The putative androgen receptor-A form results from in vitro proteolysis. J Mol Endocrinol 27:309-19."
"8134","PC991371","·Cornell R, Rowley D, Wheeler H, et al.  2003.  Neuro-epithelial interactions in prostate cancer are enhanced in the presence of prostatic stroma.  Urology, The Gold Journal  61(4):870-875."
"8135","PC991371","Ayala GE, Wheeler TM, Shine HD, Schmelz M, Frolov A, Chakraborty S, Rowley D (2001): In vitro dorsal root ganglia and human prostate cell line interaction: redefining perineural invasion in prostate cancer. Prostate 49:213-23."
"8136","PC991371","Li, R., Wheeler, T., Dai, H., et al.  2003.  Neural cell adhesion molecule is up regulated in nerves with prostate cancer invasion.  Human Pathology.34:457-61."
"8137","PC991371","Ayala G, Dai H, Ittmann M, et. al  2004.  Growth and Survial Mechanisms Associated with Perineural Invasion in Prostate Cancer.  Cancer Res.  64:6082-91."
"8138","PC991386","Mitra A, Mulholland J, Nan A, et al.  Targeting tumor angiogenic vasculature using Polymer-RGD conjugates.  J Control Release 102:191-201.

"
"8139","PC991386","Mitra A, H Ghandehari, A Nan, et al.  Technetium-99m labeled N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers:  synthesis, characterization and in vivo biodistribution.  Pharm Res 21(7):1153-9."
"8140","PC991386","Line BR, Mitra A, Nan A, Ghandehari H. 2005. Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. J. Nucl. Med. 46:1552-1560."
"8141","PC991386","Mitra A, Nan A, Line BR, et al.  2006. 
Nanocarriers for nuclear imaging and radiotherapy of cancer. Curr Pharm Des 12(36):4729-4749.
"
"8142","PC991386","Mitra A, Nan A, Papadimitriou JC, Ghandehari H, Line BR. 2006. Polymer-peptide conjugates for angiogenesis targeted tumor radiotherapy. Nucl. Med. Biol. 33:43-52."
"8143","PC991395","Dingley KH UEVJea (2003): DNA isolation and sample preparation for quantitation of adduct levels by accelerator mass spectrometry. In: Molecular Toxicology Protocols. SG P Keohavong , ed."
"8144","PC991395","Dingley KH UEC-ZMea (2001): The effect of dietary supplements with chemopreventive potential on metabolism and DNA-adduct formation of the heterocyclic amine PhIP in rats. FASEB J 15:A618 ."
"8145","PC991395","West J TKaDK (2002): Phenylethylisothiocyanate (PEITC) both inhibits cytochrome P450 1A1/1A2 bioactivation and induces glucuronide detoxification of the carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Tox. Sci 66(1-S):LB23."
"8146","PC991395","Dingley K SEC-ZMeal (2002): Accelerator mass spectrometry: A tool for tracing environmentally relevant doses of 3H and 14C-labeled carcinogens. Tox. Sci. 66(1-S):883."
"8147","PC991395","West JA DKaTKW (2002): Phenylethylisothiocyanate (PEITC) reduces 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine (PhIP) DNA adduct formation by inhibition of cytochrome P450 dependent metabolism. Tox. Sci. 66(1-S):617."
"8148","PC991397","Knize MG, Kulp KS, Salmon CP, Keating GA, Felton JS (2002): Factors affecting human heterocyclic amine intake and the metabolism of PhIP. Mutat Res 506-507:153-62."
"8149","PC991397","Knize MG, Kulp KS, Malfatti MA, Salmon CP, Felton JS (2001): Liquid chromatography-tandem mass spectrometry method of urine analysis for determining human variation in carcinogen metabolism. J Chromatogr A 914:95-103."
"8150","PC991397","Felton JS, MG Knize, LM Bennett, et al., 2004.  Impact of environmental exposures on the mutagenicity/carcinogenicity of heterocyclic amines.  Toxicology 198:135-45.

"
"8151","PC991397","Kulp KS, MG Knize, N Fowler, et al., 2003.  PhIP metabolites in human urine after the consumption of well-cooked chicken.  J. Chromatogr. B 802:143-53."
"8152","PC991397","Felton JS, Knize MG, Salmon CP, Malfatti MA, Kulp KS (2002): Human exposure to heterocyclic amine food mutagens/carcinogens: relevance to breast cancer. Environ Mol Mutagen 39:112-8."
"8153","PC991404","Shurin MR, Tourkova IL, Hackstein H, and et al. (2003): The Cytokine Handbook.  4th Edition. 429-461."
"8154","PC991404","Pirtskhalaishvili G SGECTDSM (2001): TNF-a-mediated protection of dendritic cells from prostate cancer-induced cell death. Prostate Cancer and Prostatic Diseases  4:221-227."
"8155","PC991404","Tourkova IL, Yurkovetsky ZR, Shurin MR, Shurin GV (2001): Mechanisms of dendritic cell-induced T cell proliferation in the primary MLR assay. Immunol Lett 78:75-82."
"8156","PC991404","Shurin GV YZaSM (2002): Tumor-induced dendritic cell dysfunction. In: Mechanisms of Tumor Escape. Ochoa A, ed. Taylor & Francis."
"8157","PC991404","Shurin MR and Gabrilovich DI (2001): Regulation of dendritic cell system by tumor. Cancer Research, Therapy and Control 11:65-78."
"8158","PC991404","Pirtskhalaishvili G, Shurin MR Dendritic cells in the treatment of prostate cancer. Cancer Research Alert 1:89-91."
"8159","PC991404","Pirtskhalaishvili G, Shurin GV, Gambotto A, Esche C, Wahl M, Yurkovetsky ZR, Robbins PD, Shurin MR (2000): Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice. Journal of Immunology 165. 165:1956-64-1956-64."
"8160","PC991404","Pirtskhalaishvili G, Shurin GV, Esche C, Cai Q, Salup RR, Bykovskaia SN, Lotze MT, Shurin MR (2000): Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. British Journal of Cancer 83. 83:506-13-506-13."
"8161","PC991404","Aalamian M, Pirtskhalaishvili G, Nunez A, Esche C, Shurin GV, Huland E, Huland H, Shurin MR (2001): Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate 46:68-75."
"8162","PC991404","Shurin GV, Aalamian M, Pirtskhalaishvili G, Bykovskaia S, Huland E, Huland H, Shurin MR (2001): Human prostate cancer blocks the generation of dendritic cells from cd34+ hematopoietic progenitors. European Urology 39 Suppl 4. 39 Suppl 4:37-40.:37-40."
"8163","PC991404","Tourkova IL, Yamabe K, Foster B, et al.  2004.  Murine prostate cancer inhibits both in vivo and in vitro generation of dendritic cells from bone marrow precursors. Prostate 59(2):203-213."
"8164","PC991404","Aalamian M, Tourkova IL, Chatta GS, et al.  2003. Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen.  J Urol 170(5):2026-2030."
"8165","PC991404","Tourkova IL, Yurkovetsky ZR, Gambotto A, et al.  2002.  Increased function and survival of IL-15-transduced human dendritic cells are mediated by up-regulation of IL-15Ralpha and Bcl-2. J Leukoc Biol72(5):1037-1045."
"8166","PC991405","McBride WH, Iwamoto KS, Syljuasen R, Pervan M, Pajonk F (2003): The role of the ubiquitin/proteasome system in cellular responses to radiation. Oncogene 22:5755-73."
"8167","PC991405","Pajonk F, McBride WH (2001): The proteasome in cancer biology and treatment. Radiat Res 156:447-59."
"8168","PC991405","Pajonk F and McBride WH (2002): Survival of AIDS patients with primary central nervous system lymphoma may be improved by the radiosensitizing effects of highly active antiretroviral therapy. AIDS 16:1195-1196."
"8169","PC991405","Pajonk F, McBride WH (2001): Ionizing radiation affects 26s proteasome function and associated molecular responses, even at low doses. Radiotherapy and Oncology 59. 59:203-12-203-12."
"8170","PC991405","Pajonk F, Riess K, Sommer A, McBride WH (2002): N-acetyl-L-cysteine inhibits 26S proteasome function: implications for effects on NF-kappaB activation. Free Radic Biol Med 32:536-43."
"8171","PC991405","Pervan M, Pajonk F, Sun JR, Withers HR, McBride WH (2001): Molecular pathways that modify tumor radiation response. Am J Clin Oncol 24:481-5."
"8172","PC991405","McBride WH, Pervan M, Daigle JL, and et al (2003) The proteasome in cancer biology and therapy. Proceedings of the 7th International Meeting on Progress in Radio-Oncology ."
"8173","PC991405","McBride WH, Pajonk F, Chiang CS, Sun JR (2002): NF-kappa B, cytokines, proteasomes, and low-dose radiation exposure. Mil Med 167:66-7."
"8174","PC991405","Pajonk F HJRKSAMW (2002): The human immunodeficiency virus (HIV)-1 protease inhibitor Saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells.  Cancer Res.  62:62:5230-5235."
"8175","PC991429","Yang YA, Han WF, Morin PJ, Chrest FJ, Pizer ES (2002): Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3- kinase. Exp Cell Res 279:80-90."
"8176","PC991429","Yang YA, Morin PJ, Han WF, Chen T, Bornman DM, Gabrielson EW, Pizer ES (2003): Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res 282:132-7."
"8177","PC991429","Pizer ES, Pflug BR, Bova GS, Han WF, Udan MS, Nelson JB (2001): Increased fatty acid synthase as a therapeutic target in androgen- independent prostate cancer progression. Prostate 47:102-10."
"8178","PC991433","Vorwek P, Hohmann B, Oh Y, et al. 2002. Binding properties of insulin-like growth factor binding protein-3 (IGFBP-3), IGFBP-3 N- and C-terminal fragments, and members of the IGFBP superfamily measured using a biosensor.  Endocrinology 143:1677-1685."
"8179","PC991433","Twigg SM, Chen MM, Joly AH, Chakrapani SD, Tsubaki J, Kim HS, Oh Y, Rosenfeld RG (2001): Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a"
"8180","PC991433","Tsubaki J, Choi WK, Ingermann AR, Twigg SM, Kim HS, Rosenfeld RG, Oh Y (2001): Effects of sodium butyrate on expression of members of the IGF-binding protein superfamily in human mammary epithelial cells. J Endocrinol 169:97-110."
"8181","PC991433","Twigg SM, Joly AH, Chen MM, Tsubaki J, Kim HS, Hwa V, Oh Y, Rosenfeld RG (2002): Connective tissue growth factor/IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fib"
"8182","PC991433","Twigg SM, Chen MM, Joly AH, et al.  2001.  Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: A potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology 142:1760-1769."
"8183","PC991433","Rosenfeld RG, Hwa V. 2004. Toward a molecular basis for idiopathic short stature. J. Clin. Endocrinol. Metab. 89(3):1066-7."
"8184","PC991433","Kofoed EM, Hwa V, Little B, et al. 2003. Growth hormone insensitivity associated with a STAT5b mutation. N. Engl. J. Med. 349(12):1139-1147."
"8185","PC991433","Tsubaki J, Choi WK, Ingermann AR, Twigg SM, Kim HS, Rosenfeld RG, Oh Y (2001): Effects of sodium butyrate on expression of members of the IGF-binding protein superfamily in human mammary epithelial cells. Journal of Endocrinology 169. 169:97-110-97-110."
"8186","PC991433","Lopez-Bermejo A, Buckway CK, Devi GR, Hwa V, Plymate SR, Oh Y, Rosenfeld RG (2000): Characterization of insulin-like growth factor-binding protein-related proteins (IGFBP-rPs) 1, 2, and 3 in human prostate epithelial cells: potential roles for IGFBP-rP1 and 2 in senescence of the prostatic epithelium. Endocrinology 141. 141:4072-80-4072-80."
"8187","PC991433","Cohen P, Clemmons DR, Rosenfeld RG (2000): Does the GH-IGF axis play a role in cancer pathogenesis? Growth Hormone & IGF Research 10:297-305."
"8188","PC991433","Von HH, Hwa V, Rosenfeld RG, et al. 2002. Altered expression of low-affinity insulin-like growth factor binding protein related proteins in hepatoblastoma. Int J Mol Med 9:645-649.
"
"8189","PC991433","Lopez-Bermejo A, Khosravi J, Corless CL, et al. 2003. Generation of anti-insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1/MAC25) monoclonal antibodies and immunoassay: Quantification of IGFBP-rP1 in human serum and distribution in human fluids and tissues. J Clin Endocrinol Metab 88:3401-3408."
"8190","PC991433","Twigg SM, Joly AH, Chen MM, et al.  2002. Connective tissue growth factor/IGFBP-rP2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fibroblasts.  Endocrinology 143:1260-1269."
"8191","PC991438","Sheikh MS and Huang Y.  2004.  TRAIL death receptors, Bcl-2 protein family, and endoplasmic reticulum calcium pool.  Vitamin and Hormones (TRAIL, editor, Gerald Litwack) Academic Press. 67:169-187."
"8192","PC991438","Sheikh MS and Huang Y.  2004.  Death receptors as targets of cancer therapeutics.  Curr Cancer Drug Targets 4:97-100."
"8193","PC991438","He Q, Luo, X, Huang Y, et al.  2002.  Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells.  Oncogene 21:6032-6040."
"8194","PC991438","Huang Y, He Q, Hillman MJ, Rong R, Sheikh MS (2001): Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells. Cancer Res 61:6918-24."
"8195","PC991438","He Q, Lee DI, Rong R, Yu M, Luo X, Klein M, El-Deiry WS, Huang Y, Hussain A, Sheikh MS (2002): Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. Oncogene 21:2623-33."
"8196","PC991452","Abraham S, Zhang W, Greenberg N, Zhang M (2003): Maspin functions as tumor suppressor by increasing cell adhesion to extracellular matrix in prostate tumor cells. J Urol 169:1157-61."
"8197","PC991455","Kirschenbaum A, Liu X, Yao S, Levine AC (2001): The role of cyclooxygenase-2 in prostate cancer. Urology 58:127-31."
"8198","PC991455","Liu XH, Kirschenbaum A, Lu M, Yao S, Dosoretz A, Holland JF, Levine AC (2002): Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem 277:50081-6."
"8199","PC991460","Herman JG, Zhang H, Li Y-Q, et al. 2003.  Restriction of tyrosine and phenylalanine DU145 and PC-3 alters the expression of several genes involved in invasion and metastasis.  Proc Am Assoc Cancer Res 44(2nd ed.):1014."
"8200","PC991460","Fu Y-M, Zhang H, Li Y-Q, et al.  2003.  Specific amino acid restriction targets mitochondria of human solid tumor cells.  Proc Am Assoc Cancer Res 44(2nd ed.):1217."
"8201","PC991460","Fu Y-M, Ge X, Li Y-Q, et al.  2001.  Amino acid deprivation induces apoptosis of androgen-independent prostate cancer cells via activation of specific caspase and modulation of mitochondria.  Proc Am Assoc Cancer Res 42:441."
"8202","PC991460","Fu Y-M, Yu Z-X, Li YQ, et al.  2003.  Specific amino acid dependency regulates invasiveness and viability of androgen-independent prostate cancer cells.  Nutr Cancer 45:60-73."
"8203","PC991460","Roupe K, Teng SW, Fu X, et al.  2004.  Determination of piceatannol in rat serum and liver microsomes: Pharmacokinetics and phase 1 and II biotransformation.  Biochem Chromatog 18(8):486.

"
"8204","PC991460","Fu Y-M, Li YQ Zhang H et al. (2002): Specific amino acid dependency modulates expression of integrins and invasiveness in solid tumor cells Proc. Am. Assoc. Cancer Res."
"8205","PC991460","Meadows GG GXZHea (2002): Inhibition of invasion and metastasis during specific amino acid restriction associated with metastasis suppressor and other gene changes. In: Cancer Metastasis-Related Genes. Welch DR, ed. Kluwer Academic Publishers, Dordrecht"
"8206","PC991460","Redkar AA, Fu Y-M and Meadows GG. (2002): Resveratrol inhibits prostate cancer cell growth and enhances the effects of TPT and SN-38 at sublethal doses Proc. Am. Assoc. Cancer Res."
"8207","PC991460","Zhang H, Fu Y-M, Li Y-Q, and Meadows GG.  2003.  Deprivation of tyrosine and phenylalanine differentially modulates the gene expression of DU145 and PC-3 prostate cell lines.  Proc Am Assoc Cancer Res 44(2nd ed.):235."
"8208","PC991468","Kittles RA, Panguluri RK, Chen W, Massac A, Ahaghotu C, Jackson A, Ukoli F, Adams-Campbell L, Isaacs W, Dunston GM (2001): Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans. Cancer Epidemiol Biomarkers Prev 10:943-"
"8209","PC991468","·Kittles R and Wiliams R (2001): Genetics and cancer:  Challenges at the millennium. Journal of Registry Management 28:132-133."
"8210","PC991468","Panguluri R CWaKR (2002): SNP genotyping of candidate genes for complex disease using Pyrosequencing. American International Biotechnology Laboratory 20:30-34."
"8211","PC991468","Pfaff CL, Kittles RA, Shriver MD (2002): Adjusting for population structure in admixed populations. Genet Epidemiol 22:196-201."
"8212","PC991468","Kittles RA, Young D, Weinrich S, Hudson J, Argyropoulos G, Ukoli F, Adams-Campbell L, Dunston GM (2001): Extent of linkage disequilibrium between the androgen receptor gene CAG and GGC repeats in human populations: implications for prostate cancer risk. H"
"8213","PC991468","Kittles RA, Chen W, Panguluri RK, Ahaghotu C, Jackson A, Adebamowo CA, Griffin R, Williams T, Ukoli F, Adams-Campbell L, Kwagyan J, Isaacs W, Freeman V, Dunston GM (2002): CYP3A4-V and prostate cancer in African Americans: causal or confounding associatio"
"8214","PC991476","Bhatia-Gaur R Donjacour AA Sciavolino PJ Kim M Desai N Young P Norton CR GTCRCGA-SCSMM (1999): Roles for Nkx3.1 in prostate development and cancer. Genes Dev 13:966-977."
"8215","PC991476","Abate-Shen C and Shen MM (2002): Mouse models of prostate carcinogenesis. Trends Genet. 18:S1-S5."
"8216","PC991476","Abate-Shen C and Shen M. (2000): Molecular genetics of prostate cancer.  Genes Dev. 14:2410-2434."
"8217","PC991476","Abate-Shen C Banach-Petrosky WA Sun X Economides KD Desai N Gregg JP Borowsky AD Cardiff RD Shen MM (2003): Nkx3.1; Pten mutant mice develop invasive adenocarcinoma and lymph node metastases.  Cancer Res 63:3886-90."
"8218","PC991476","Abate-Shen C (2002): Deregulated homeobox gene expression in cancer: cause or consequence?  Nat Rev Cancer 2:777-785."
"8219","PC991476","Kim MJ Cardiff RD Desai N Banach-Petrosky WA Parsons R Shen MM Abate-Shen C. (2002): Cooperativity of Nkx3s.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Pro Natl Acad Sci USA 99:2884-2889."
"8220","PC991476","Kim MJ Bhatia-Gaur R Banach-Petrosky WA Desai N Wang Y Hayward SW Cunha GR Cardiff RD Shen MM Abate-Shen C (2002): Nkx3.1 Mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 62:2999-3004."
"8221","PC991476","Park JH Walls JE Galvez JJ Kim M Abate-Shen C Shen MM Cardiff RD. (2002):  Prostatic intraepithelial neoplasia in genetically engineered mice. Am J Pathol. 161:727-735."
"8222","PC991503","Politi K, Kljuic A, Szabolcs M, et al.  2004.  Designer' tumors in mice.  Oncogene 23(8):1558-1565.


"
"8223","PC991503","Li Z, Szabolcs M, Terwilliger JD, et al.  2006.  Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene.  Carcinogenesis 27(5):1054-1067. 




"
"8224","PC991505","Wang H, Huang ZQ, Xia L, Feng Q, Erdjument-Bromage H, Strahl BD, Briggs SD, Allis CD, Wong J, Tempst P, Zhang Y (2001): Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor. Science 293:853-7."
"8225","PC991505","Huang ZQ, Li J, Wong J (2002): AR possesses an intrinsic hormone-independent transcriptional activity. Mol Endocrinol 16:924-37."
"8226","PC991505","Lee KC, Li J, Cole PA, Wong J, Kraus WL. 2003, Transcriptional activation by thyroid hormone receptor-beta involves chromatin remodeling, histone acetylation,and synergeistic stimulation by p300 and steroid receptor coactivators. Mol endocrinol;17(5):908-922."
"8227","PC991505","Huang Z-Q, Li J, Sachs LM, cole PA, Wong J., 2003, A role for cofactor-cofactor and cofactor-histone interactions in targeting p300, SW!/SNF and mediator for transcription. EMBO J;22(9):2146-2155."
"8228","PC991507","Li W, Cavasotto CN, Cardozo T.  2005.  Androgen receptor mutations identified in prostate cancer and androgen insensitivity syndrome display aberrant ART-27 coactivator function.  Mol Endocrinol 19(9):2273-2282.
"
"8229","PC991507","Taneja SS, Ha S, Swenson NK, et al.  2004.  ART-27, an androgen receptor coactivator regulated in prostate development and cancer. J Biol Chem 279(14):13944-13952."
"8230","PC991507","Markus SM, Taneja SS, Logan SK, et al.  2002.  Identification and characterization of ART-27, a novel coactivator for the androgen receptor N terminus. Mol Biol Cell 13(2):670-682.
"
"8231","PC991513","Annes JP, Chen Y, Munger JS, Rifkin 2004. Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1. J Cell Biol 165(5):723-34.
"
"8232","PC991517","Wang X, Deng H, Basu I, Zhu L. 2004. Induction of androgen receptor-dependent apoptosis in prostate cancer cells by the retinoblastoma protein.
Cancer Res. 64(4):1377-85. 
"
"8233","PC991520","Govindarajan R, Zhao S, Song XH, Guo RJ, Wheelock M, Johnson KR, Mehta PP (2002): Impaired trafficking of connexins in androgen-independent human prostate cancer cell lines and its mitigation by alpha-catenin. J Biol Chem 277:50087-97."
"8234","PC991520","Habermann H, Chang WY, Birch L, Mehta P, Prins GS (2001): Developmental exposure to estrogens alters epithelial cell adhesion and gap junction proteins in the adult rat prostate. Endocrinology 142:359-69."
"8235","PC991526","Kim SJ, M Johnson, K Koterba, et al., 2003.  Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model.  Clin. Cancer Res. 9:5161-70."
"8236","PC991526","Davies MA, Kim SJ, Parikh NU, Dong Z, Bucana CD, Gallick GE (2002): Adenoviral-mediated Expression of MMAC/PTEN Inhibits Proliferation and Metastasis of Human Prostate Cancer Cells. Clin Cancer Res 8:1904-14."
"8237","PC991526","Boyd DD, Kim SJ, Wang H, Jones TR, Gallick GE (2003): A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis. Am. J. Pathol.  162:619-626."
"8238","PC991528","Lau YF, Zhang J (2000): Expression analysis of thirty one Y chromosome genes in human prostate cancer. Molecular Carcinogenesis 27. 27:308-21-308-21."
"8239","PC991528","Lau YF, Lau HW, Komuves LG (2003): Expression pattern of a gonadoblastoma candidate gene suggests a role of the Y chromosome in prostate cancer. Cytogenet Genome Res 101:250-60."
"8240","PC991528","Lau Y, Chou P, Iezzoni J, Alonzo J, Komuves L (2000): Expression of a candidate gene for the gonadoblastoma locus in gonadoblastoma and testicular seminoma. Cytogenet Cell Genet 91:160-4."
"8241","PC991538","Groszer M, Erickson R, Scripture-Adams DD, Lesche R, Trumpp A, Zack JA, Kornblum HI, Liu X, Wu H (2001): Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 294:2186-9."
"8242","PC991538","Freeman D, Lesche R, Kertesz N,et al. Genetic background controls tumor development in PTEN-deficient mice. Cancer Res 66(13):6492-6296."
"8243","PC991538","Dubey P, Wu H, Reiter RE, Witte ON (2001): Alternative pathways to prostate carcinoma activate prostate stem cell antigen expression. Cancer Research 61. 61:3256-61-3256-61."
"8244","PC991538","Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL (2001): Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 98:10314-9."
"8245","PC991538","Stiles B, Gilman V, Khanzenzon N, Lesche R, Li A, Qiao R, Liu X, Wu H (2002): Essential role of AKT-1/protein kinase B alpha in PTEN-controlled tumorigenesis. Mol Cell Biol 22:3842-51."
"8246","PC991538","Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H, Liu X, Wu H (2002): Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 32:148-9."
"8247","PC991539","Hovhannisyan RH, Carstens RP. 2005. A novel intronic cis element, ISE/ISS-3, regulates rat fibroblast growth factor receptor 2 splicing through activation of an upstream exon and repression of a downstream exon containing a noncanonical branch point sequence. Mol Cell Biol 25:250-63."
"8248","PC991539","Hovhannisyan RH, Warzecha CC, Carstens RP. 2006. Characterization of sequences and mechanisms through which ISE/ISS-3 regulates FGFR2 splicing. Nucleic Acids Res 34:373-85."
"8249","PC991539","Muh SJ, Hovhannisyan RH, Carstens RP (2002): A Non-sequence-specific double-stranded RNA structural element regulates splicing of two mutually exclusive exons of fibroblast growth factor receptor 2 (FGFR2). J Biol Chem 277:50143-54."
"8250","PC991544","Brubaker KD, Vessella RL, True LD, Thomas R, Corey E (2003): Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 18:222-30."
"8251","PC991544","Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL (2003): Zoledronic Acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 9:295-306."
"8252","PC991544","Pfitzenmaier J, Quinn JE, Odman AM, Zhang J, Keller ET, Vessella RL, Corey E. (2003): Characterization of C4-2 prostate cancer bone metastases and their response to castration.   J Bone Miner Res.  18:1882-8."
"8253","PC991548","Xu J, Dimitrov L, Chang BL, et al.  2005.  A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics.  Am J Hum Genet 77(2):219-229."
"8254","PC991548","Kotar K, Hamel N, Thiffault I, Foulkes WD (2003): The RNASEL 471delAAAG allele and prostate cancer in Ashkenazi Jewish men. J Med Genet 40:e22."
"8255","PC991548","Schaid DJ, McDonnell SK, Zarfas KE, et al.  2006.  Pooled genome linkage scan of aggressive prostate cancer: Results from the international consortium for prostate cancer genetics.  Human Genetics 120(4):471-485."
"8256","PC991548","Hope Q, Bullock S, Evans C, et al.  2005.  Macrophage scavenger receptor 1 999C>T(R293X) mutation and risk of prostate cancer.  The Cancer Research UK/British Association of Urological Surgeons¿ Section of Oncology Collaborators.  Cancer Epidemiol Biomarkers Prev 14:397-402."
"8257","PC991548","·Hamel N, Kotar K, and Foulkes WD.  2003.  Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.  BMC Medical Genetics 4:7."
"8258","PC991552","·Duguay D RFaMS (2003): Cadherin-mediated cell adhesion and tissue segregation: qualitative and quantitative determinants. Dev Biol. 253:309-23."
"8259","PC991552","Ryan PL FRKJSM (2001): Tissue spreading on implantable substrates is a competitive outcome of cell-cell vs. cell-substratum adhesivity.  PNAS  98:4323-4327."
"8260","PC991552","Robinson E KZSCaRF (2002): a5b1 integrin mediates strong tissue cohesion. a5b1 integrin mediates strong tissue cohesion 116:116(2):377-386."
"8261","PC991559","Zakowski SG, A Ramati, C Morton, et al., 2004.  Written emotional disclosure buffers the effects of social constraints on distress among cancer patients.  Health Psychology 23:555-563."
"8262","PC991559","Quartana, PJ, BJ Schmaus, and SG Zakowski.  Gender, neuroticism and emotional expressivity:  Effects on spousal constraints among individuals with cancer.  Journal of Consulting and Clinical Psychology."
"8263","PC991561","Chen Z, Nath R (2003): Biologically effective dose (BED) for interstitial seed implants containing a mixture of radionuclides with different half-lives. Int J Radiat Oncol Biol Phys 55:825-34."
"8264","PC991568","Hurwitz AA, Yanover P, Markowitz M, Allison JP, Kwon ED (2003): Prostate cancer: advances in immunotherapy. BioDrugs 17:131-8."
"8265","PC991568","Allison JP HAEAea (2000): CTAL-4 blockade in  tumor immunotherapy. In: Principles and Practice of the Biologic Therapy of Cancer, 3rd Edition . Rosenberg SA , ed. Lippincott Williams and Wilkins. 890-895pp. "
"8266","PC991568","Hurwitz AA, Kwon ED, van Elsas A (2000): Costimulatory wars: the tumor menace. Curr Opin Immunol 12:589-96."
"8267","PC991568","Yang D HGRMea (2001): Peptide vaccines from a technological perspective. In: New Vaccine Technologies. Ellis RW, ed. Landes Bioscience. 214-226pp. "
"8268","PC991568","Ellis TM, Moser MT, Le PT, Flanigan RC, Kwon ED (2001): Alterations in peripheral B cells and B cell progenitors following androgen ablation in mice. Int Immunol 13:553-8."
"8269","PC991568","Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, Ellis TM, Wojcik EM, Yang D, Flanigan RC, Waters WB, Kast WM, Kwon ED (2001): T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Aca"
"8270","PC991568","Yang D, Holt GE, Velders MP, Kwon ED, Kast WM (2001): Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate- specific cell-surface antigens highly expressed in prostate ca"
"8271","PC991568","Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP (2000): Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60:2444-8."
"8272","PC991568","Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI (2000): Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6:1755-66."
"8273","PC991568","Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM, Burg MB (1999): Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A 96:15074-9."
"8274","PC991568","Ellis RW (2000): New Vaccine Technologies. Landes Bioscience. <20 Page(s)>."
"8275","PC991568","Kruisbeck AM E (2001): Current Protocols in Immunology. John Wiley and Sons. <20 Page(s)>."
"8276","PC991571","Stewart DA, Cooper CR, Sikes RA, et al.  2004.  Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer.  Reprod Biol Endocrinol 2:2-14."
"8277","PC991571","Guo N, Ye JJ, Liang SJ, et al.  2003.  The role of insulin-like growth factor-II in cancer growth and progression evidenced by the use of ribozymes and prostate cancer progression models.  Growth Horm IGF Res 13:44-53."
"8278","PC991571","Sikes RA, Nicholson BE, Koeneman KS, et al.  2004.  Cellular interactions in the tropism of prostate cancer to bone.  Int J Cancer 110:497-503."
"8279","PC991571","Cooper CR, Sikes RA, Nicholson BE, et al.  2004.  Cancer cells homing to bone:  The significance of chemotaxis and cell adhesion.  Cancer Treat Res 118:291-309."
"8280","PC991571","Gregory CW, Degeorges A, and Sikes RA.  2001.  The role of the IGF axis in the development and progression of prostate cancer. Recent Research Developments in Cancer (SG Pandalai, H Mukhtar, and F Labrie, eds.).  Transworld Research Network, Kerala, India, 3(II):437-462."
"8281","PC991572","Jin F, Xie ZH, Kuo CJ, et al.  2005.  Co-target tumor and tumor endothelium effectively inhibits the growth of human prostate cancer by adenovirus-mediated antiangiogenesis and oncolysis combination therapy.  Cancer Gene Therapy 12:257-67.

"
"8282","PC991572","Sung SY, Chung LW (2002):  Prostate carcinoma-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. Differentiation 70:506-521."
"8283","PC991572","Chung LWK, Baseman A, Assikis V, et al. 2005. Molecular insights into prostate cancer progression: The missing link of tumor microenvironment.  J Urol 173:10-20.
"
"8284","PC991572","Chung LW, Baseman A, Assikis V, et al.  2005.  Molecular insights into prostate cancer progression: The missing link of tumor microenvironment.  J Urol 173:10-20."
"8285","PC991572","Jin F, Xie Z, Kuo CJ, et al.  2004.  Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer by adenovirus-mediated antiangiogenesis and oncolysis combination therapy.  Cancer Gene Ther  12:257-67."
"8286","PC992004","Wu L, Matherly J, Smallwood A, Adams JY, Billick E, Belldegrun A, Carey M (2001): Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Ther 8:1416-26."
"8287","PC992004","Weinzimer SA, Gibson TB, Collett-Solberg PF, Khare A, Liu B, Cohen P (2001): Transferrin is an insulin-like growth factor-binding protein-3 binding protein. Journal of Clinical Endocrinology and Metabolism 86. 86:1806-13-1806-13."
"8288","PC992004","Boyle BJ, Zhao XY, Cohen P, Feldman D (2001): Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. Journal of Urology 165:1319-24."
"8289","PC992004","Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, Cohen P (2000): Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. Journal of Biological Chemistry 275. 275:33607-13-33607-13."
"8290","PC992004","Grimberg A, Cohen P (2000): Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. Journal of Cellular Physiology 183. 183:1-9-1-9."
"8291","PC992004","Ngo TH BRTCCPAW (2002): Effect of diet and exercise on serum insulin, IGF-I, and IGFBP-1 levels and growth of LNCaP cells in vitro (United States).  Cancer Causes Control  13:929-935."
"8292","PC992004","Monzavi R and Cohen P (2002): IGFs and IGFBPs: Role in health and disease. Best Pract. Res. Clin. Endocrinol. Metab.  16:433-447."
"8293","PC992004","Lee KW CP (2002): Nuclear effects: Unexpected intracellular actions of insulin-like growth factor binding protein-3. J. Endocrinol.  175:33-40."
"8294","PC992004","Zhang L AJBEIRIMLKSAGSCMWL (2002): Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer. Mol. Ther.  5."
"8295","PC992004","Franklin SL FRJCP (2003): Rapid insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 on endothelial cell survival.  J. Clin. Endocrinol. Metab. 88:900-907."
"8296","PC992004","Moore MG WLFMPDCP (2003): Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells.  Int. J. Cancer 105:14-19."
"8297","PC992004","Rappaport R E (2002): In: Growth and Lactogenic Hormones. Elsevier Science B.V.  <20 Page(s)>."
"8298","PC992004","Lee HY, Chun KH, Liu B, Wiehle SA, Cristiano RJ, Hong WK, Cohen P, Kurie JM (2002): Insulin-like growth factor binding protein-3 inhibits the growth of non- small cell lung cancer. Cancer Res 62:3530-7."
"8299","PC992004","Mellinghoff IK, Tran C, Sawyers CL (2002): Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res 62:5254-9."
"8300","PC992004","Grimberg A, Liu B, Bannerman P, El-Deiry WS, Cohen P (2002): IGFBP-3 mediates p53-induced apoptosis during serum starvation. Int J Oncol 21:327-35."
"8301","PC992004","Rajah R, Lee KW, Cohen P (2002): Insulin-like growth factor binding protein-3 mediates tumor necrosis factor-alpha-induced apoptosis: role of Bcl-2 phosphorylation. Cell Growth Differ 13:163-71."
"8302","PC992004","Sperling MA, Saenger PH, Ray Hintz, Tom Wilson, Rose SR (2002): Growth hormone treatment and neoplasia-coincidence or consequence? J Clin Endocrinol Metab 87:5351-2."
"8303","PC992004","Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M (2001): In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I re"
"8304","PC992004","Jain A, Lam A, Vivanco I, Carey MF, Reiter RE (2002): Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene. Mol Endocrinol 16:2323-37."
"8305","PC992004","Rajah R, Khare A, Lee PD, Cohen P (1999): Insulin-like growth factor-binding protein-3 is partially responsible for high-serum-induced apoptosis in PC-3 prostate cancer cells. Journal of Endocrinology 163. 163:487-94-487-94."
"8306","PC992004","Adams JY, Johnson M, Sato M, Berger F, Gambhir SS, Carey M, Iruela-Arispe ML, Wu L (2002): Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat Med 8:891-7."
"8307","PC992004","Cohen P (2001): Clinical implications of the IGF-cancer connection. Growth Horm IGF Res 11:336-8."
"8308","PC992018","Park JJ, RA Irvine, et al., 2000.  Breast Cancer susceptibility gene1 (BRCA1) is a coactivator of the androgen receptor.  Cancer Res. 60 (21):5946-9."
"8309","PC992018","Jia L, Kim J, Shen H, Clark PE, Tilley WD, Coetzee GA (2003): Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Mol Cancer Res 1:385-92."
"8310","PC992018","Buchanan GN, M Greenberg, et al., 2001.  Collocation of androgen receptor gene mutations in prostate cancer.  Clin. Cancer Res. 7(5):1273-81."
"8311","PC992018","Chen CD, DS Welsbie, et al., 2004.  Molecular determinants of resistance to antiandrogen therapy.  Nat. Med. 10(1):33-9."
"8312","PC992018","Feldman BJ, and D Feldman, 2001.  The development of androgen-independent prostate cancer.  Nat. Rev. Cancer 1(1):34-45.

"
"8313","PC992018","Jia LC, CSY Choong, C Ricciardelli et al., 2004.  Androgen receptor signaling:  Mechanism of interleukin-6 inhibition.  Cancer Res. 64(7):2619-26."
"8314","PC992018","Kim J, L Jia, WD Tilley, and GA Coetzee, et al., 2003.  Dynamic methylation of histone H3 at lysine 4 in transcriptional regulation by the androgen receptor.  Nucleic Acids Res. 31(23):6741-7.

"
"8315","PC992018","Balk S, 2002.  Androgen receptor as a target in androgen-independent prostate cancer.  Urology 60(3):132-8."
"8316","PC992018","Buchanan G, Irvine RA, Coetzee GA, Tilley WD (2001): Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 20:207-23."
"8317","PC992018","Makridakis NM, and JKV Reichardt, 2004.  Molecular epidemiology of androgen-metabolic loci in prostate cancer:   Predisposition and progression.  J. Urol. 171:S25-9."
"8318","PC992022","Tu WH, Thomas TZ, Masumori N, et al.  2003.  The loss of TGF-beta signaling promotes prostate cancer metastasis. Neoplasia;5(3):267-277."
"8319","PC992041","Jessie BC, Sun CQ, Irons HR, Marshall FF, Wallace DC, Petros JA (2001): Accumulation of mitochondrial DNA deletions in the malignant prostate of patients of different ages. Exp Gerontol 37:169-74."
"8320","PC992041","Wu GJ, Wu MW, Wang SW, Liu Z, Qu P, Peng Q, Yang H, Varma VA, Sun QC, Petros JA, Lim SD, Amin MB (2001): Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and t"
"8321","PC992041","Arbiser JL, Petros J, Klafter R, Govindajaran B, McLaughlin ER, Brown LF, Cohen C, Moses M, Kilroy S, Arnold RS, Lambeth JD (2002): Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci U S A 99:715-20."
"8322","PC992041","Arnold RS, Shi J, Murad E, Whalen AM, Sun CQ, Polavarapu R, Parthasarathy S, Petros JA, Lambeth JD (2001): Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc Natl Acad Sci U S A 98:5550-5."
"8323","PC992041","Young AN, Amin MB, Moreno CS, Lim SD, Cohen C, Petros JA, Marshall FF, Neish AS (2001): Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 158:1639-51."
"8324","PC992041","Wu GJ, Varma VA, Wu MW, Wang SW, Qu P, Yang H, Petros JA, Lim SD, Amin MB (2001): Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues. Prostate 48:305-15."